
<html lang="en"     class="pb-page"  data-request-id="5c798a46-6f79-44e7-b313-8e308ed76bd4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01195;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure" /></meta><meta name="dc.Creator" content="Gang  Xing" /></meta><meta name="dc.Creator" content="Anthony Yiu-Ho  Woo" /></meta><meta name="dc.Creator" content="Li  Pan" /></meta><meta name="dc.Creator" content="Bin  Lin" /></meta><meta name="dc.Creator" content="Mao-Sheng  Cheng" /></meta><meta name="dc.Description" content="β2-Adrenoceptor (β2-AR) agonists are widely used as bronchodilators. The emerge of ultralong acting β2-agonists is an important breakthrough in pulmonary medicine. In this review, we will provide m..." /></meta><meta name="Description" content="β2-Adrenoceptor (β2-AR) agonists are widely used as bronchodilators. The emerge of ultralong acting β2-agonists is an important breakthrough in pulmonary medicine. In this review, we will provide m..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 19, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01195" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01195" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01195" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01195" /></link>
        
    
    

<title>Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01195" /></meta><meta property="og:title" content="Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0011.jpeg" /></meta><meta property="og:description" content="β2-Adrenoceptor (β2-AR) agonists are widely used as bronchodilators. The emerge of ultralong acting β2-agonists is an important breakthrough in pulmonary medicine. In this review, we will provide mechanistic insights into the application of β2-agonists in asthma, chronic obstructive pulmonary disease (COPD), and heart failure (HF). Recent studies in β-AR signal transduction have revealed opposing functions of the β1-AR and the β2-AR on cardiomyocyte survival. Thus, β2-agonists and β-blockers in combination may represent a novel strategy for HF management. Allosteric modulation and biased agonism at the β2-AR also provide a theoretical basis for developing drugs with novel mechanisms of action and pharmacological profiles. Overlap of COPD and HF presents a substantial clinical challenge but also a unique opportunity for evaluation of the cardiovascular safety of β2-agonists. Further basic and clinical research along these lines can help us develop better drugs and innovative strategies for the management of these difficult-to-treat diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01195"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01195">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01195&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01195&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01195&amp;href=/doi/10.1021/acs.jmedchem.0c01195" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15218-15242</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01192" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01282" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Advances in β<sub>2</sub>-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Gang Xing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Xing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</div><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Xing">Gang Xing</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anthony Yiu-Ho Woo</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anthony Yiu-Ho Woo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China</div></div><span class="conrtib-corresp"><strong>*</strong>A.Y.-H.W.: email, <a href="/cdn-cgi/l/email-protection#a3dacad6cbccd4cccce3d0dad3cbd68dc6c7d68dc0cd"><span class="__cf_email__" data-cfemail="047d6d716c6b736b6b44777d746c712a6160712a676a">[email protected]</span></a>, +86-024-23986375.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+Yiu-Ho++Woo">Anthony Yiu-Ho Woo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0662-698X" title="Orcid link">http://orcid.org/0000-0003-0662-698X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Pan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Pan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</div><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Pan">Li Pan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</div><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Lin">Bin Lin</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mao-Sheng Cheng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mao-Sheng Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</div><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</div></div><span class="conrtib-corresp"><strong>*</strong>M.-.C.: email, <a href="/cdn-cgi/l/email-protection#a3ced0c0cbc6cdc4e3d0dad3cbd68dc6c7d68dc0cd"><span class="__cf_email__" data-cfemail="412c322229242f260132383129346f2425346f222f">[email protected]</span></a>, +86-024-43520215.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mao-Sheng++Cheng">Mao-Sheng Cheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9073-4806" title="Orcid link">http://orcid.org/0000-0001-9073-4806</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01195&amp;href=/doi/10.1021%2Facs.jmedchem.0c01195" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15218–15242</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 19, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 July 2020</li><li><span class="item_label"><b>Published</b> online</span>19 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01195" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01195</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15218%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGang%2BXing%252C%2BAnthony%2BYiu-Ho%2BWoo%252C%2BLi%2BPan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01195%26title%3DRecent%2BAdvances%2Bin%2B%25CE%25B22-Agonists%2Bfor%2BTreatment%2Bof%2BChronic%2BRespiratory%2BDiseases%2Band%2BHeart%2BFailure%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15242%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01195"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">884</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01195" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Advances in β2-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Xing&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Yiu-Ho Woo&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Pan&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Mao-Sheng&quot;,&quot;last_name&quot;:&quot;Cheng&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15218-15242&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01195&quot;},&quot;abstract&quot;:&quot;β2-Adrenoceptor (β2-AR) agonists are widely used as bronchodilators. The emerge of ultralong acting β2-agonists is an important breakthrough in pulmonary medicine. In this review, we will provide mechanistic insights into the application of β2-agonists in asthma, chronic obstructive pulmonary disease (COPD), and heart failure (HF). Recent studies in β-AR signal transduction have revealed opposing functions of the β1-AR and the β2-AR on cardiomyocyte survival. Thus, β2-agonists and β-blockers in combination may represent a novel strategy for HF management. Allosteric modulation and biased agonism at the β2-AR also provide a theoretical basis for developing drugs with novel mechanisms of action and pharmacological profiles. Overlap of COPD and HF presents a substantial clinical challenge but also a unique opportunity for evaluation of the cardiovascular safety of β2-agonists. Further basic and clinical research along these lines can help us develop better drugs and innovative strategies for the management of th&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01195&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01195" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01195&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01195" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01195&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01195" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01195&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01195&amp;href=/doi/10.1021/acs.jmedchem.0c01195" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01195" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01195" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01195%26sid%3Dliteratum%253Aachs%26pmid%3D33213146%26genre%3Darticle%26aulast%3DXing%26date%3D2020%26atitle%3DRecent%2BAdvances%2Bin%2B%25CE%25B22-Agonists%2Bfor%2BTreatment%2Bof%2BChronic%2BRespiratory%2BDiseases%2Band%2BHeart%2BFailure%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15218%26epage%3D15242%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290969" title="Cell and molecular biology">Cell and molecular biology</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">β<sub>2</sub>-Adrenoceptor (β<sub>2</sub>-AR) agonists are widely used as bronchodilators. The emerge of ultralong acting β<sub>2</sub>-agonists is an important breakthrough in pulmonary medicine. In this review, we will provide mechanistic insights into the application of β<sub>2</sub>-agonists in asthma, chronic obstructive pulmonary disease (COPD), and heart failure (HF). Recent studies in β-AR signal transduction have revealed opposing functions of the β<sub>1</sub>-AR and the β<sub>2</sub>-AR on cardiomyocyte survival. Thus, β<sub>2</sub>-agonists and β-blockers in combination may represent a novel strategy for HF management. Allosteric modulation and biased agonism at the β<sub>2</sub>-AR also provide a theoretical basis for developing drugs with novel mechanisms of action and pharmacological profiles. Overlap of COPD and HF presents a substantial clinical challenge but also a unique opportunity for evaluation of the cardiovascular safety of β<sub>2</sub>-agonists. Further basic and clinical research along these lines can help us develop better drugs and innovative strategies for the management of these difficult-to-treat diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Vital body functions such as respiration and circulation are under the control of the autonomic nervous system made up of neurons, neurotransmitters, and receptors on target tissues. The cardiovascular system and the pulmonary system are responsive to sympathetic stimulations due to the presence of adrenoceptors (ARs) on effector cells. The myocardium and airway smooth muscles (ASMs) mainly express β-adrenoceptors (βARs), while vascular smooth muscles express both αARs and βARs. These receptors belong to the G protein-coupled receptors (GPCRs) superfamily and are traditional drug targets. βAR agonists and antagonists (blockers) are essential medicines widely used in the treatment of cardiovascular and pulmonary disorders.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">Heart failure (HF) is a condition in which the heart’s ability to pump blood is weakened such that the cardiac output cannot match with the metabolic demand of the body. HF may occur as an acute condition or chronic illness. Preexisting cardiovascular conditions such as ischemic heart disease, hypertension, and diabetes mellitus and advance in age are the most important risk factors for chronic HF. On the basis of the left ventricular ejection fraction (LVEF), chronic HF is classified into three types: that with reduced ejection fraction (HFrEF, LVEF < 40%), with preserved ejection fraction (HFpEF, LVEF ≥ 50%), and with midrange ejection fraction (HFmrEF, 40% ≤ LVEF ≤ 49%).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> According to the current statistics from the American Heart Association, about 6.2 million Americans over the age of 20 suffered from HF in 2013–2016, and an increment of 46% in prevalence will occur from 2012 to 2030, bringing the total number of affected people to >8 million.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> According to the data from the National Center for Health Statistics of the United States, 1 in 8 deaths in death certificates have mentioned HF among multiple causes.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition, the total cost of HF in the United States is estimated to increase from $30.7 billion in 2012 to $69.8 billion in 2030.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The mortality and hospitalization rates of patients with HF have reduced recently due to the application of guideline-recommended therapies, particularly the use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, cardiac resynchronization therapy, implantable cardioverter-defibrillators, and other treatments in patients with HFrEF.<a onclick="showRef(event, 'ref2 ref3 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref5">(2,3,5)</a> However, there are no specific treatment strategies to decrease mortality and hospitalization rates of patients with HFpEF due to an incomplete understanding of the pathophysiology and therapeutic targets and inadequacy in disease definition and classification.<a onclick="showRef(event, 'ref2 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref5 ref6">(2,5,6)</a> The 5-year mortality rate of HF remains high at 42.3%.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Asthma and chronic obstructive pulmonary disease (COPD) are the most common chronic respiratory diseases.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> According to the Global Initiative for Asthma (GINA) definition, asthma is a heterogeneous disease of the airway characterized by typical symptoms such as wheeze, shortness of breath, chest tightness, and cough.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The Global Burden of Disease (GBD) study group has found that about 272 million people had asthma in 2017 globally.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Asthma has a global prevalence ranging from <5% to ≥20% in adolescents and an estimate of 8.6% in adults.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> COPD is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The most common symptoms of COPD are shortness of breath and a cough that produces sputum. COPD affected the lives of more than 299 million people in 2017<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and is the fourth leading cause of death in the world.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Chronic respiratory diseases were the second leading causes of global disability-adjusted life-years (DALYs) in 2017.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Airflow obstruction, which is readily reversible spontaneously or with treatment in asthma but persistent and progressive in COPD, is a common underlying condition responsible for the cause of clinical symptoms in both diseases.<a onclick="showRef(event, 'ref8 ref10 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref8 ref10 ref13 ref14">(8,10,13,14)</a> In addition, inflammation of the airways contributes to the pathogenesis of both diseases.<a onclick="showRef(event, 'ref8 ref10 ref14'); return false;" href="javascript:void(0);" class="ref ref8 ref10 ref14">(8,10,14)</a> Thus, the use of bronchodilators (β<sub>2</sub>-agonists, muscarinic antagonists, and theophylline) to decrease airway resistance and anti-inflammatory drugs (corticosteroids, leukotriene (LT) receptor antagonist, and phosphodiesterase (PDE) 4 inhibitors) to treat chronic airway inflammation has become standard approaches in the treatment of asthma and COPD.<a onclick="showRef(event, 'ref8 ref10 ref15'); return false;" href="javascript:void(0);" class="ref ref8 ref10 ref15">(8,10,15)</a> Nevertheless, up to 17% of asthma patients have difficult-to-treat asthma.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, comorbidities are common among people with COPD and are associated with poorer prognosis.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> HF is a frequent and important comorbidity of COPD.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> HF can worsen COPD and vice versa.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Patients with severe asthma or severe exacerbation in COPD have a low responsiveness to inhaled reliever medications.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a></div><div class="NLM_p last">In the present review, we will highlight different aspects encompassing the pharmacology, mechanism of action, clinical usage, and research and development of β<sub>2</sub>-agonists and to a smaller extent β-blockers with respect to asthma, COPD, and HF, with a special emphasis on the use of β<sub>2</sub>-agonists and β-blockers in combination as a novel therapeutic strategy for HF and the application of the concept of functional selectivity in drug discovery.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Mechanisms of Action</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82754" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82754" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  βAR Signaling in Cardiac Physiology and HF</h3><div class="NLM_p">The β-adrenergic system plays a pivotal role in the regulation of myocardial function. Catecholamines released in response to sympathetic stimulation activate cardiac βARs to produce the classical positive chronotropic (change in heart rate), inotropic (change in contractile force), and lusitropic (change in relaxation rate) responses. Stimulation of the βARs activates the canonical stimulatory G proteins (G<sub>s</sub>)-adenylyl cyclase (AC)-cAMP-protein kinase A (PKA) signaling cascade. The PKA-dependent enhancement effect of β-adrenergic stimulation on cardiac excitation–contraction coupling has been well-documented.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In sinoatrial nodal cells and cardiomyocytes, the phosphorylation of PKA substrates, such as phospholamban (PLB), ryanodine receptor (RyR) 2, L-type Ca<sup>2+</sup> channel (LCC), T-type Ca<sup>2+</sup> channel, potassium channel <i>I</i><sub>Ks</sub> and funny channel enhances intracellular calcium ([Ca<sup>2+</sup>]<sub>i</sub>) dynamics, while the phosphorylation of cardiac troponin I (cTnI) and cardiac myosin-binding protein C (cMBP-C) reduces myofilament Ca<sup>2+</sup> sensitivity. Consequently, [Ca<sup>2+</sup>]<sub>i</sub> transient and contractility increase in cardiomyocytes and automaticity increases in sinoatrial nodal cells.</div><div class="NLM_p">The human heart expresses all of the three subtypes of the βAR with the β<sub>1</sub>AR being dominant. These βAR subtypes play an important role in the regulation of myocardial contractility, but they serve distinct functional roles in the heart as they display different signal transduction properties. For instance, while the β<sub>1</sub>AR couples only to G<sub>s</sub> proteins, the β<sub>2</sub>AR couples to both G<sub>s</sub> and inhibitory G proteins (G<sub>i</sub>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Thus, stimulation of the β<sub>2</sub>AR usually produces a maximal contractile response that is less than what could be attainable with β<sub>1</sub>-adrenergic stimulation. It is partly because the concomitant activated G<sub>i</sub> proteins counteract the effect of the activated G<sub>s</sub> proteins on cAMP synthesis. The distinct functional roles of the β<sub>1</sub>AR and the β<sub>2</sub>AR are also attributed to the different spatial distribution of the two receptor species on the surface of the myocardial membrane. β<sub>1</sub>ARs have an even distribution on the sarcolemma (plasma membrane of myocytes).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In contrast, β<sub>2</sub>ARs are localized mainly within signal complexes in caveolin 3-enriched subdomains of the sarcolemma including caveolae and T-tubules.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> Within these membrane compartments are a myriad of regulatory proteins for β-adrenergic signal transduction, including LCC,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> G<sub>i</sub>,<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> and PDEs, which restrict the diffusion of cAMP.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Because of the compartmentation of the β<sub>2</sub>AR-mediated cAMP signaling, unlike the global effect of the cardiac β<sub>1</sub>AR-stimulated cAMP/PKA signaling as described above, the β<sub>2</sub>AR-stimulated increase in cAMP is uncoupled from the phosphorylation of many cytosolic proteins including PLB, cTnI, and cMBP-C though β<sub>2</sub>-adrenergic stimulation remains capable of increasing the L-type Ca<sup>2+</sup> current (<i>I</i><sub>Ca,L</sub>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> As a result, the β<sub>2</sub>AR-stimulated cAMP signaling is uncoupled to [Ca<sup>2+</sup>]<sub>i</sub> dynamics and contractility in single ventricular myocytes<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> as well as <i>in vivo</i> hearts.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic diagrams of βAR signaling in the regulation of cardiac function in normal conditions and during HF. (A) βAR signaling in normal heart. Regulators are typed in blue. A black solid arrow represents activation in a stimulatory pathway. A blue solid arrow represents activation in a regulatory pathway. A blue dotted line with a blunt head represents inhibition. A blue solid line with round heads on both ends represents a tight binding. (1) β-agonists (β+) stimulate both the β<sub>1</sub>AR and the β<sub>2</sub>AR to produce a contractility enhancement effect via the canonical βAR-G<sub>s</sub>-AC-cAMP-PKA signaling cascade. (2) In heterologous desensitization, PKA-dependent phosphorylation of the β<sub>2</sub>AR causes the switching of the coupling preference of the receptor from G<sub>s</sub> to G<sub>i</sub>. The activated G<sub>i</sub> subsequently negates the effect of G<sub>s</sub> in promoting the activity of AC in synthesizing cAMP. (3) In homologous desensitization, the β<sub>1</sub>AR and the β<sub>2</sub>AR in their active conformations are prone to phosphorylation by GRK2, and phosphorylation of the C-terminus of the βARs greatly increases β-arrestin (βarr) recruitment. G<sub>s</sub> is uncoupled as its receptor binding sites is occupied by βarr. The βarr subsequently triggers receptor internalization. (4) The agonist-bound β<sub>1</sub>AR binds weakly with the βarr and does not readily internalize, but it activates unique βarr-dependent signalings either by forming a complex with the βarr or by activating the clathrin-coated structure-associated βarr after dissociating from it.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (5) When βarr is recruited to the β<sub>2</sub>AR on membrane surface, it brings along PDE4 in close association. The PDE4 degrades cAMP in the vicinity reducing PKA activity. The β<sub>2</sub>AR-mediated cAMP/PKA signaling is said to be compartmentalized. (6) The recruitment of PDE4 also affects the cAMP/PKA signaling mediated by a nearby β<sub>1</sub>AR, a process known as “offside” compartmentalization. (7) β<sub>2</sub>-Agonist can also stimulate the β<sub>2</sub>AR to produce a contractile response via direct activation of LCC assembled in a β<sub>2</sub>AR signal complex that also contains G<sub>s</sub>, AC, PKA, and the counterbalancing phosphatase PP2A.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (B) βAR signaling in the failing heart. The diagram has been simplified for clarity. A black dotted arrow represents impaired activation in a stimulatory pathway. The downward-pointed arrow next to the β<sub>1</sub>AR represents downregulation. The upward-pointed arrows next to GRK2 and G<sub>i</sub> represent upregulation. (1) The downregulation of the β<sub>1</sub>AR in HF leads to a substantial reduction of the β<sub>1</sub>AR-mediated response. (2) The upregulation of GRK2 in HF causes abnormal phosphorylation of the β<sub>2</sub>AR. This subsequently promotes a G<sub>i</sub>-biased β<sub>2</sub>AR signaling leading to the inhibition of both the β<sub>2</sub>AR-G<sub>s</sub> and the β<sub>1</sub>AR-G<sub>s</sub> signalings. (1 and 2) Persistent catecholamine stimulation of the βARs in HF leads to (homologous) desensitization of the receptors and temporary loss of responsiveness to further stimuli (see text for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The distinct signaling property of the β<sub>2</sub>AR makes it a key regulator to guard against excessive catecholamine stimulation of the heart. First, in a process known as heterologous desensitization, PKA-dependent phosphorylation of the β<sub>2</sub>AR, which can be the result of either β<sub>1</sub>- or β<sub>2</sub>-adrenergic stimulation, promotes the switching of G protein coupling preference of the β<sub>2</sub>AR from G<sub>s</sub> to G<sub>i</sub>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Second, β<sub>2</sub>-adrenergic stimulation-induced “offside” compartmentation, which involves GPCR kinase (GRK) 2-dependent recruitment of β-arrestin 1 and PDE4 to the C-terminus of the nearby β<sub>1</sub>AR, restricts β<sub>1</sub>AR signaling into submembrane microdomains in cardiomyocytes such that a normal β-adrenergic response beyond <i>I</i><sub>Ca,L</sub> increment is not elicited.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">β-Adrenergic dysfunction is an important pathophysiological mechanism of HF. A leading hallmark of this molecular change is a decreased responsiveness of the heart to catecholamines (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B), which leads to exercise intolerance of the affected person.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In HF, serum catecholamine levels are constantly high due to compensatory activation of the sympathetic nervous system.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Prolonged stimulation of cardiac βARs leads to receptor desensitization and downregulation, which are critically involved in myocardial dysfunction in HF.</div><div class="NLM_p">The mechanisms of desensitization involve phosphorylation of the activated βAR and recruitment of the adaptor protein β-arrestin. In the classical model of homologous desensitization, GRK2-dependent phosphorylation of the cytoplasmic domain of the β<sub>2</sub>AR facilitates recruitment of β-arrestin which terminates β<sub>2</sub>AR-G<sub>s</sub> signaling and triggers receptor internalization.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Other mechanisms distinct for the β<sub>2</sub>AR include phosphorylation-dependent enhancement of the β<sub>2</sub>AR-G<sub>i</sub> coupling<a onclick="showRef(event, 'ref32 ref37'); return false;" href="javascript:void(0);" class="ref ref32 ref37">(32,37)</a> and the formation of a β<sub>2</sub>AR/β-arrestin/PDE4D complex in the vicinity of membrane-associated PKA.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> Homologous desensitization of the β<sub>1</sub>AR appears to be less robust than that of the β<sub>2</sub>AR.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> It involves PKA or GRK phosphorylation of the β<sub>1</sub>AR,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and the two types of phosphorylation result in receptor endocytosis through different pathways.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The link of most of the above mechanisms to the pathogenesis of HF is not strong. In fact, some of them may even act as protective adaptations to guard against excessive catecholamine stimulation.</div><div class="NLM_p">On the other hand, evidence suggests that downregulation of the cardiac β<sub>1</sub>AR is a major cause of reduced responsiveness of the failing heart to catecholamine stimulation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> With a reduction of the expression of the β<sub>1</sub>AR by 50% and the unchanged expression levels of the β<sub>2</sub>AR during disease progression, the ratio of β<sub>1</sub>AR:β<sub>2</sub>AR on membrane surface drops from 4:1 in the normal condition to 3:2 in human HF.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">In addition, the failing human heart also has increased expression of GRK2 and G<sub>i</sub>,<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> which may be key mediators of the functional decline in HF. A recent study has suggested that phosphorylation of the β<sub>2</sub>AR by GRK2 promotes a β<sub>2</sub>AR-G<sub>i</sub> biased signaling in a pressure overload-induced HF model.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> This exaggerated β<sub>2</sub>AR-G<sub>i</sub> signaling uncouples G<sub>s</sub> proteins from both β<sub>1</sub>ARs and β<sub>2</sub>ARs and links GRK2 upregulation to HF. The cross-inhibition of the β<sub>1</sub>AR-G<sub>s</sub> signaling by the β<sub>2</sub>AR-G<sub>i</sub> signaling is HF-specific and not found under normal conditions, as evidenced by the resumption of the β-adrenergic responsiveness of myocardial contractile responses in whole animals and cells with experimental G<sub>i</sub> or GRK2 inhibition.<a onclick="showRef(event, 'ref37 ref47 ref48 ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref37 ref47 ref48 ref49 ref50 ref51 ref52">(37,47−52)</a> The mechanism of the cross-inhibition is far from clear but may be a function of increased expression of GRK2, G<sub>i</sub>, and Na<sup>+</sup>/Ca<sup>2+</sup>-exchanger,<a onclick="showRef(event, 'ref45 ref46 ref52'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref52">(45,46,52)</a> redistribution of β<sub>2</sub>ARs from T-tubules to the cell surface in HF,<a onclick="showRef(event, 'ref23 ref53'); return false;" href="javascript:void(0);" class="ref ref23 ref53">(23,53)</a> and β<sub>2</sub>AR-mediated “offside” compartmentalization of β<sub>1</sub>AR-signaling.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">The β<sub>1</sub>AR and the β<sub>2</sub>AR play opposing roles in cardiomyocyte survival and death (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Persistent β<sub>1</sub>-adrenergic stimulation is cardiotoxic and residual signal transduction capacity of the β<sub>1</sub>AR is sufficient to inflict harm on the failing heart.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Cellular and whole animal studies have revealed that long-term stimulation of the β<sub>1</sub>AR activates Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII), a key mediator of arrhythmias,<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> apoptosis,<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> and maladaptive cardiac remodeling.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> Furthermore, the important role of the CaMKII-δ9 splice variant in human HF has recently been substantiated by the fact that the δ9 isoform is the most abundant CaMKII-δ isoform expressed in the human heart and is involved in ubiquitin-conjugating enzyme E2T (UBE2T)-dependent DNA repair.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Its upregulation in various cellular injury models in neonatal rat cardiomyocytes and a pressure overload-induced cardiomyopathy model in mice promoted accumulation of DNA damage and genome instability. Myocardium from patients with hypertrophic cardiomyopathy had lower abundance of UBE2T compared with healthy controls, and human embryonic stem cell-derived cardiomyocytes overexpressed with CaMKII-δ9 also had reduced expression of UBE2T.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. A simplified scheme of cardiac βAR signaling and its modulation. The β<sub>2</sub>AR couples to both G<sub>s</sub> and G<sub>i</sub> while the β<sub>1</sub>AR couples only to G<sub>s</sub>. Stimulation of the βARs with catecholamines (CA) actives the G<sub>s</sub>-cAMP-PKA signaling (black arrows) and subsequently produces contractility enhancement. If stimulation of the β<sub>1</sub>AR is exaggerated as in the case of compensatory activation of the sympathetic nervous system during heart failure, the CaMKII pro-apoptotic pathway (red arrows) will be activated. As the disease progresses into decompensated heart failure, the loss of myocytes contributes to cardiac dysfunction. The loss of myocytes may be counteracted by activating the β<sub>2</sub>AR-G<sub>i</sub> antiapoptotic signaling (blue arrows) with a β<sub>2</sub>AR agonist (β<sub>2</sub>+) or by blocking the β<sub>1</sub>AR with a β<sub>1</sub>AR antagonist (β<sub>1</sub>– with a blue blocking sign). β<sub>2</sub>AR activation is complementary to β<sub>1</sub>AR blockade because it produces additional contractile support to the failing heart apart from its antiapoptotic effect (see text for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Multiple signal transduction pathways have been proposed to relay persistent β<sub>1</sub>-adrenergic stimulation to CaMKII activation. On the basis of data from cellular and genetic knockout mouse models, Mangmool and colleagues<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> have proposed a PKA-independent mechanism involving specific recruitment of β-arrestins to the C-terminus of the activated β<sub>1</sub>AR and interaction of cAMP with exchange protein directly activated by cAMP (EPAC), a guanine nucleotide exchange factor for the small GTPase Ras-related protein 1 (Rap1). In this mechanism, β-arrestin acts as a scaffold for the formation of a cardiotoxic β-arrestin-CaMKII-EPAC1 signal complex with the β<sub>1</sub>AR. However, recent evidence from a PKA inhibitor peptide transgenic mouse model suggests that EPAC can also mediate cardioprotective signals with β<sub>1</sub>-adrenergic stimulation<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> or the use of some antidiabetic drugs in HF.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Another mechanism to increase CaMKII activity in β<sub>1</sub>AR-stimulated cardiomyocytes is by raising [Ca<sup>2+</sup>]<sub>i</sub>, which stabilizes the Ca<sup>2+</sup>/calmodulin complexes.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> An increased [Ca<sup>2+</sup>]<sub>i</sub> could be due to increased <i>I</i><sub>Ca,L</sub><a onclick="showRef(event, 'ref58 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref58 ref67 ref68">(58,67,68)</a> or increases in sarcoplasmic reticulum (SR) Ca<sup>2+</sup> via PKA-mediated phosphorylation of PLB.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The resultant activation of CaMKII with increasing incidence of SR Ca<sup>2+</sup> leak can lead to cardiomyocyte death in HF as evidenced by studies on CaMKII-δ isoform transgenic and knockout mice.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> In addition, β<sub>1</sub>-adrenergic stimulation-induced cardiomyocyte death <i>in vitro</i> and <i>in vivo</i> has been shown to depend on crosstalk between the β<sub>1</sub>AR and the receptor for advanced glycation end-products (RAGE) pathway converging to a common downstream mediator CaMKII.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p">The deleterious effect of excessive β<sub>1</sub>-adrenergic stimulation in HF is well-established.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The use of β-blockers to block β<sub>1</sub>AR is now standard of care for patients suffering from HFrEF.<a onclick="showRef(event, 'ref2 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref5">(2,5)</a> Although β-blockers suppress contractility when treatment is initiated, their long-term use in HF can protect the human heart and restore its responsiveness to catecholamine stimulation.<a onclick="showRef(event, 'ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74">(72−74)</a> Recent experimental progress has also given hope on the translation of CaMKII inhibition into a treatment strategy for HF and related myocardial anomalies.<a onclick="showRef(event, 'ref75 ref76 ref77 ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref75 ref76 ref77 ref78 ref79">(75−79)</a></div><div class="NLM_p">In contrary to the cardiotoxic nature of the β<sub>1</sub>AR, the β<sub>2</sub>AR is a cardioprotective receptor.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Cardiac overexpression of the β<sub>2</sub>AR at 30-fold over the basal level has been shown to prevent maladaptive cardiac remodeling and improved cardiac function in a G<sub>αq</sub>-overexpressing mouse model of HF.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> On the other hand, deficiency of the β<sub>2</sub>AR increased isoproterenol-induced apoptosis of ventricular myocytes in mice<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> and animal death in a doxorubicin-induced cardiomyopathy model.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In consistent with these observations, HF patients carrying a loss-of-function Ile164 mutation in the <i>ADRB2</i> (β<sub>2</sub>AR) gene exhibited a higher mortality rate relative to patients without this mutation.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> Cardioprotection associated with the β<sub>2</sub>AR is often attributed to the ability of the receptor to elicit an antiapoptotic G<sub>i</sub>-G<sub>βγ</sub>-phosphatidylinositol 3-kinase (PI3K)-Akt signaling.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The importance of the β<sub>2</sub>AR-G<sub>i</sub> signaling in cardioprotection is further substantiated in our recent observational study involving hospitalized patients with chronic HF.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> We found that patients carrying the minor β<sub>2</sub>AR-Gly16 allele had increased risks of cardiovascular death in an allele dose-dependent manner and the increase in risks was associated with the inability of the β<sub>2</sub>AR-Gly16 variant to elicit a G<sub>i</sub> signaling. However, it should be noted that while the β<sub>2</sub>AR-G<sub>i</sub> signaling is cardioprotective and upregulated in HF to counteract the cardiotoxic β<sub>1</sub>AR-CaMKII signaling, the resultant salutary effect on cardiomyocyte survival comes at the expense of a compromised contractile reserve (or exercise capacity) as detailed above.<a onclick="showRef(event, 'ref37 ref87'); return false;" href="javascript:void(0);" class="ref ref37 ref87">(37,87)</a></div><div class="NLM_p">As opposed to the β<sub>1</sub>AR-G<sub>s</sub> signaling, the β<sub>2</sub>AR-G<sub>s</sub> signaling is neutral or cardioprotective rather than cardiotoxic. In fact, the beneficial effect of the G<sub>s</sub>-biased β<sub>2</sub>-agonist fenoterol has been repeatedly demonstrated in animal models of HF.<a onclick="showRef(event, 'ref88 ref89 ref90 ref91 ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90 ref91 ref92 ref93">(88−93)</a> It has been suggested that the activation of CaMKII is β<sub>1</sub>AR-specific because the engagement of β-arrestin with the C-terminus of β<sub>1</sub>AR results in a unique conformational shift of β-arrestin that allows for scaffolding of EPAC and CaMKII to form a stable complex, leading to the subsequent cAMP/EPAC-mediated activation of CaMKII. But the engagement with the C-terminus of β<sub>2</sub>AR results in a different conformation of β-arrestin that does not favor this complex formation.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> This explains why sustained β<sub>2</sub>-adrenergic stimulation does not induce cardiomyocyte death while sustained stimulation of the β<sub>1</sub>AR does. The cardioprotective mechanism of the β<sub>2</sub>AR-G<sub>s</sub> signaling is unclear but may be the result of engaging crosstalk with the tyrosine kinase receptor signaling leading to Akt phosphorylation<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> or provision of the needed contractile support to the failing heart.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div><div class="NLM_p last">The functional significance of the cardiac β<sub>3</sub>AR has also been revealed in recent years. As opposed to the β<sub>1</sub>AR and the β<sub>2</sub>AR, the β<sub>3</sub>AR couples to G<sub>i</sub> proteins and has been found to inhibit norepinephrine-induced cAMP synthesis in rat cardiomyocytes<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> and to produce a negative inotropic effect in human myocardial tissues.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> It is upregulated in HF in human<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> as well as pacing-induced HF in dogs<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and has been suggested to participate in the functional degradation of the failing heart.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a> However, mice with transgenic cardiac-specific expression of the human β<sub>3</sub>AR are protected from cardiac hypertrophy and fibrosis in response to isoproterenol or angiotensin II stimulation.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Therefore, there is no specific conclusion regarding the role of the β<sub>3</sub>AR in HF. β<sub>3</sub>AR agonists and antagonists are under investigation for HF and other conditions.<a onclick="showRef(event, 'ref101 ref102 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref103 ref104">(101−104)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Pathophysiology of Asthma and COPD, and Mechanisms of Drug Action</h3><div class="NLM_p">Asthma is a disease with a complicated and heterogeneous pathophysiology characterized by airway hyperresponsiveness, airway remodeling, and inflammation,<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> which collectively result in the dysfunction of ASMs. Airway inflammation is a leading cause of airway hyperresponsiveness and ASM hyperplasia.<a onclick="showRef(event, 'ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref106 ref107">(106,107)</a> Airway hyperresponsiveness is a symptom characterized as bronchospasm that could be triggered by allergens, air pollutants, and oxidative stress.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Airway remodeling that increases the ASM mass contributes to the risk of exacerbation.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p">Recent studies on the pathophysiology of asthma have substantially changed our understanding of the disease. It is now recognized that asthma is a group of disorders encompassing a collection of different disease subtypes (or phenotypes) with different underlying pathophysiological mechanisms that might be identified by corresponding biomarkers (or endotypes).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Earlier attempts in asthma phenotyping have resulted in different groupings based on clinical features with little regard for the underlying mechanisms.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Characterization of the endotypes, on the other hand, may provide important framework for research and development of personalized asthma treatment.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Research on asthma immunology in the past two decades has made tremendous progress in revealing the inflammatory processes involving various immune cells and cytokines that leads to asthma. On the basis of the current understanding of its pathophysiology and molecular features, asthma is categorized into two main endotypes, namely T2-high and T2-low, with T2 referring to T-helper type 2 (Th2)-driven inflammation or simply type 2 inflammation.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Reviews on this topic are available.<a onclick="showRef(event, 'ref109 ref110 ref112'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref112">(109,110,112)</a></div><div class="NLM_p">The majority of asthma cases, including early onset allergic asthma and late-onset eosinophilic asthma, fits into the T2-high asthma endotype that is mediated by type 2 cytokines, classically interleukins (IL)-4, IL-5, and IL-13. The characteristic features of the T2-immune response include atopy, allergy, type I hypersensitivity reactions, and eosinophilic inflammation.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> In a classical and simplified scheme of the interactions between inflammatory cells and mediators in T2-high asthma, pathogen/allergen-exposed dendritic cells promote naı̈ve CD4<sup>+</sup> T lymphocytes to differentiate into Th2 cells.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The activated Th2 cells produce IL-4, IL-5, and IL-13. These cytokines are also produced by group 2 innate lymphoid cells which express no antigen receptors for T or B lymphocytes.<a onclick="showRef(event, 'ref112 ref114'); return false;" href="javascript:void(0);" class="ref ref112 ref114">(112,114)</a> IL-4 generates more Th2 cells from naı̈ve T cells via an autocrine loop. It also causes class switching of B lymphocytes to produce IgE class antibodies which binds to FcεRI receptors on the surface of tissue mast cells and blood basophils.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> IL-5 is essential for the maturation, activation, and chemoattraction of eosinophils from the systemic circulation into inflamed tissues.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> IgE, mast cells, and eosinophils constitute an important defense line against parasitic infection,<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115,116)</a> but mast cells and eosinophils are also key effector cells in asthma. Allergen-sensitized mast cells degranulate to release multiple bronchoconstrictor factors, resulting in airway hyperresponsiveness. Eosinophils produces chemical mediators which promote persistent inflammation and airway remodeling. A well-recognized function of IL-13 is to drive the differentiation of airway epithelial cells into active goblet cells that produce mucins resulting in sputum formation. In addition, IL-13 also induces airway hyperresponsiveness and contributes to airway remodeling.<a onclick="showRef(event, 'ref112 ref117'); return false;" href="javascript:void(0);" class="ref ref112 ref117">(112,117)</a></div><div class="NLM_p">T2-low asthma is loosely defined as asthma in the absence of prominent T2-pathway signatures.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> More recent studies suggest that T2-low asthma may actually comprise different endotypes, which is currently an active area of research.<a onclick="showRef(event, 'ref110 ref112'); return false;" href="javascript:void(0);" class="ref ref110 ref112">(110,112)</a> T2-low asthma is typically associated with later age of onset, milder symptoms, obesity, smoking, and low responsiveness to corticosteroids as compared with T2-high asthma.<a onclick="showRef(event, 'ref109 ref118'); return false;" href="javascript:void(0);" class="ref ref109 ref118">(109,118)</a> The pathophysiology underlying T2-low asthma is less well-understood. In many cases of T2-low asthma, the levels of neutrophils rather than eosinophils are high. Neutrophilic asthma is usually associated with high levels of Th1 and Th17 cells.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Type 1 immunity (Th1-mediated) and type 3 immunity (Th17-mediated) are believed to play roles in the pathophysiology of T2-low asthma.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> By secreting IL-17 and IL-22 cytokines, Th17 cells mediate the recruitment and activation of neutrophils to elicit a cell-mediated immune response against extracellular microbes. Also, interferon-γ, the prototypical Th1 cytokine, activates macrophages to promote phagocytosis, oxidative burst, and the eradication of intracellular microbes, but under pathological conditions such as asthma, these mechanisms can induce inflammation and tissue damage.<a onclick="showRef(event, 'ref113 ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref113 ref118 ref119">(113,118,119)</a></div><div class="NLM_p">Proliferation of ASM cells (ASMCs) is the pathogenic basis of ASM hyperplasia and airway remodeling. Allergens facilitate the release of proinflammatory cytokines, CXC chemokines, and collapsins (known as semaphorins), and these factors subsequently enhance the proliferation and migration of ASMCs and increase collagen deposition.<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> Moreover, ASMCs themselves produce chemokines, cytokines, and growth factors.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Platelet-derived growth factor (PDGF) is one of the most potent factors that could markedly potentiate ASM contraction and remodeling.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The mechanism of its action involves enhancement of [Ca<sup>2+</sup>]<sub>i</sub> and mitochondrial biogenesis.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> It has been suggested that β<sub>2</sub>-agonists reverses PDGF-induced ASMC proliferation by modulating [Ca<sup>2+</sup>]<sub>i</sub> and mitochondrial fission/fusion.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Conversely, other studies have found that mast cells can blunt the ASM relaxant effect of β<sub>2</sub>-agonists by secreting growth factors (<i>e.g.</i>, transforming growth factor (TGF)-β1), which activate tyrosine kinase receptors leading to the phosphorylation of the tyrosine residues on the β<sub>2</sub>AR.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><div class="NLM_p">COPD is caused by a complex interaction among genes and environment. Smoking is the central environmental factor causing airway inflammation. The level of inflammation determines the severity of COPD.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The inflammatory immune response induced by tobacco smokes, bacteria, or viruses causes airway tissue injury and remodeling.<a onclick="showRef(event, 'ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref127 ref128 ref129">(127−129)</a> The resultant thickening of airway walls and/or narrowing of small airways impair ventilation and respiratory function. Activation of immune cells such as monocytes and T lymphocytes as well as neutrophilic infiltration and inflammation of the lungs marks the pathological distinction of COPD as compared to asthma.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The activated macrophages and T cells release chemokines and factors such as IL-8, CXCL2, and LTB<sub>4</sub>, which recruit neutrophils to the lungs, and the neutrophils generate enzymes such as myeloperoxidase, neutrophil elastase, and matrix metallopeptidases causing damage to alveoli.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a> Consequently, fibrosis (repair of the wound by replacement with connective tissues) leads to irreversibly narrowing of the airways. This process occurs early in COPD.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> In addition, proliferation of ASMCs also participates in the pathogenesis of COPD by increasing airway hyperresponsiveness and ASM mass.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> While inflammation is the common pathogenic mechanism for both asthma and COPD, the inflammatory cells and mediators involved are different. Asthma (primarily the T2-high endotype) is described as eosinophilic, while COPD is described as neutrophilic.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In addition, mast cells do not seem to play a significant role, while macrophages appear to play a major role in orchestrating the inflammatory response in COPD.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> The T lymphocytes involved are also different. Th1 and Type 1 cytotoxic T cells (Tc1) are activated in COPD, while Th2 cells are activated in asthma.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> These differences probably explain the low responsiveness of corticosteroids in COPD. However, specific differences are not fully clear, and severe asthma and COPD often exhibit similar inflammatory profiles where the distinctions among them become blurred.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></div><div class="NLM_p">Bronchodilators are commonly used for symptomatic treatment of asthma and COPD. Stimulation of the β<sub>2</sub>AR by β<sub>2</sub>-agonists or blockade of the M<sub>3</sub> receptor by muscarinic antagonists produces bronchodilation via ASM relaxation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Contraction and relaxation of ASMs are governed by the phosphorylation status of regulatory light chain of myosin (rMLC). Phosphorylation of rMLC by the myosin light chain kinase (MLCK) produces contraction, while dephosphorylation of rMLC by the myosin light chain phosphatase (MLCP) brings about relaxation.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> MLCK is a Ca<sup>2+</sup>/calmodulin-dependent kinase. Its activity is positively corelated with [Ca<sup>2+</sup>]<sub>i</sub>.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Stimulation of G<sub>q</sub>– coupled receptors such as M<sub>3</sub> receptors or histamine H<sub>1</sub> receptors in ASMCs activates the phospholipase C and inositol triphosphate (IP<sub>3</sub>) signaling pathway, triggering a sudden release of stored Ca<sup>2+</sup> via IP<sub>3</sub> receptors and RyRs on SR membranes and subsequently produces contraction.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> In contrast, stimulation of the G<sub>s</sub>-coupled β<sub>2</sub>AR activates PKA, increasing the phosphorylation of multiple downstream PKA substrates including IP<sub>3</sub> receptors, a number of sarcolemmal Ca<sup>2+</sup> channels, and proteins important for the regulation of MLCP activity.<a onclick="showRef(event, 'ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref137 ref138 ref139">(137−139)</a> This leads to reduced [Ca<sup>2+</sup>]<sub>i</sub>, [Ca<sup>2+</sup>]<sub>i</sub> dynamics, and Ca<sup>2+</sup> sensitivity resulting in the relaxation of ASMs.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Besides, studies have shown that β<sub>2</sub>-agonists inhibit PDGF-induced proliferation of ASMCs.<a onclick="showRef(event, 'ref124 ref140'); return false;" href="javascript:void(0);" class="ref ref124 ref140">(124,140)</a> The mechanism may involve attenuation of [Ca<sup>2+</sup>]<sub>i</sub> waves or PKA-dependent inhibition of ASMC migration.<a onclick="showRef(event, 'ref124 ref141'); return false;" href="javascript:void(0);" class="ref ref124 ref141">(124,141)</a> Other mechanisms of action of β<sub>2</sub>-agonists include anti-inflammation and inhibition of pro-fibrotic events.<a onclick="showRef(event, 'ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref142 ref143">(142,143)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Regulatory pathways of airway smooth muscle cell contraction and relaxation. Stimulation of M<sub>3</sub>R causes intracellular calcium level ([Ca<sup>2+</sup>]<sub>i</sub>) to rise via activation of the G<sub>q</sub>-PLC-IP<sub>3</sub> signaling pathway. The increase in [Ca<sup>2+</sup>]<sub>i</sub> activates MLCK, which phosphorylates rMLC. Increase in rMLC phosphorylation leads to muscle contraction. Stimulation of β<sub>2</sub>AR triggers the G<sub>s</sub>-AC-cAMP-PKA signaling cascade. PKA activation enhances the activity of MLCP which dephosphorylates rMLC. Decrease in rMLC phosphorylation leads to muscle relaxation. Bronchodilators including β<sub>2</sub>-agonists and muscarinic antagonists produce smooth muscle relaxation by acting on their respective receptors. Key: AC, adenylyl cyclase; Ach, acetylcholine; β<sub>2</sub>+, β<sub>2</sub>-agonist; β<sub>2</sub>AR, β<sub>2</sub>-adrenoceptor; cAMP, cyclic AMP; CICR, calcium-induced calcium release; DAG, diacylglycerol; IP<sub>3</sub>, inositol triphosphate; IP<sub>3</sub>R, IP<sub>3</sub> receptor; M–, muscarinic antagonist; M<sub>3</sub>R, M<sub>3</sub> receptor; MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase; +p, phosphorylation; −p, dephosphorylation; PI-4,5-P<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; PKA, cyclic AMP-dependent protein kinase; PLC, phospholipase C; rMLC, regulatory light chain of myosin; RyR, ryanodine receptor; SR, sarcoplasmic reticulum</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3.  β<sub>2</sub>-Agonists</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1.  Pharmacological Diversity of β<sub>2</sub>-Agonists</h3><div class="NLM_p">β<sub>2</sub>-Agonists vary in their pharmacological properties which affect their clinical performance. First of all, receptor subtype selectivity determines specificity of an agonist toward its target. According to a study about determination of the relative selectivity of different β-agonists at β<sub>1</sub>-, β<sub>2</sub>-, and β<sub>3</sub>-AR, the nonselective β-agonist isoproterenol (isoprenaline) had a 3.8-fold higher selectivity for the β<sub>2</sub>AR over the β<sub>1</sub>AR, while the β<sub>2</sub>-agonists salbutamol (albuterol) (<b>1</b>) and salmeterol (<b>2</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) had, respectively, a 21.4-fold and a 3388-fold higher selectivity for the β<sub>2</sub>AR over the β<sub>1</sub>AR.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> This suggests that β<sub>2</sub>-agonists can cross-activate the β<sub>1</sub>AR to some extent. In general, a β<sub>2</sub>-agonist with a high β<sub>2</sub>/β<sub>1</sub>-selectivity is desirable, as reduced activation of the β<sub>1</sub>AR lowers the risk of adverse cardiac effects such as tachycardia. Another important pharmacological characteristic of a β<sub>2</sub>-agonist is its efficacy, also called intrinsic activity. β<sub>2</sub>-Agonists may be categorized as full agonists or partial agonists based on the levels of their effects in functional assays. The maximum effect attainable from a full agonist is a full response, while the effect of a partial agonist is submaximal at full receptor occupancy. Clinical studies have shown that full β<sub>2</sub>-agonists display greater responses but also increased adverse effect profiles as compared with partial β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref145 ref146 ref147'); return false;" href="javascript:void(0);" class="ref ref145 ref146 ref147">(145−147)</a> In a head-to-head comparison between the full agonist formoterol (<b>3</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and the partial agonist salmeterol (<b>2</b>) in a double-blind, crossover, placebo-controlled design, salmeterol (<b>2</b>) showed a flatter dose–response curve on the relief of methacholine-induced bronchoconstriction as compared with formoterol (<b>3</b>), and it caused a significantly lower tremor score and a smaller drop in serum potassium than formoterol (<b>3</b>).<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Characterization of the β<sub>2</sub>/β<sub>1</sub>-selectivity and comparison of the intrinsic activities in bronchodilator and inotropic or chronotropic actions have become a common practice in preclinical testing of β<sub>2</sub>-agonists to gain an understanding of their safety margins.<a onclick="showRef(event, 'ref148 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref148 ref149 ref150">(148−150)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Chemical Structures and Pharmacological Properties of Selected β<sub>2</sub>-Agonists in Use Clinically</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0010.gif" alt="" id="gr10" /></img><div></div></div><div class="NLM_p">The potential of an agonist to trigger desensitization is also an important consideration. Continuous stimulation of the β<sub>2</sub>AR leads to homologous desensitization (see also <a class="ref internalNav" href="#sec2_1" aria-label="section 2.1">section 2.1</a>). Desensitization results in the loss of an effect after repeated dosing of a drug, also called tolerance or tachyphylaxis. The occurrence of tolerance is particularly relevant for agonist drugs used in the treatment of chronic diseases such as asthma and COPD.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Moreover, it has been long known that the effectiveness of β<sub>2</sub>-agonists in relieving bronchospasm can decrease over time.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Because a full β<sub>2</sub>-agonist could produce a clinically relevant bronchodilator response at a subsaturating concentration and at a lower receptor occupancy relative to a partial β<sub>2</sub>-agonist, it likely triggers fewer receptors into desensitization.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Therefore, the repeated use of a partial β<sub>2</sub>-agonist may have a higher chance of causing a loss of the bronchoprotective effect compared with that of a full β<sub>2</sub>-agonist. An early clinical study has shown that salmeterol (<b>2</b>) is a partial agonist while formoterol (<b>3</b>) is a full agonist.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Besides, recent biophysical studies have demonstrated that salmeterol (<b>2</b>) is less efficacious in inducing the active conformations of the β<sub>2</sub>AR for coupling to G<sub>s</sub> as compared with a full agonist.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a> Interestingly, both salmeterol (<b>2</b>) and formoterol (<b>3</b>) cause similar degrees of β<sub>2</sub>AR desensitization though via different mechanisms.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Formoterol (<b>3</b>) enhances receptor internalization.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> In contrast, receptor internalization is not a major contributor of salmeterol-induced desensitization.<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> Other studies have shown that salmeterol (<b>2</b>) stimulation causes GRK phosphorylation of the β<sub>2</sub>AR but has a little effect on recruitment of β-arrestins.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> On the contrary, salmeterol (<b>2</b>) operates a highly amplified PKA/PDE-mediated β<sub>2</sub>AR desensitization although it has a low efficacy in inducing cAMP accumulation.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Newer β<sub>2</sub>-agonists such as indacaterol (<b>4</b>) and olodaterol (<b>5</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) appear to induce less β<sub>2</sub>AR desensitization or tachyphylaxis as compared with the second-generation agents.<a onclick="showRef(event, 'ref148 ref158'); return false;" href="javascript:void(0);" class="ref ref148 ref158">(148,158)</a> It may be due in part to their full agonist status.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> In addition, combination with a corticosteroid has been shown to substantially reduce desensitization of the full β<sub>2</sub>-agonist formoterol (<b>3</b>) in cell assays.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> This finding correlates with the clinical superiority of the inhaled corticosteroid (ICS)/formoterol (<b>3</b>) combination compared with β<sub>2</sub>-agonist or ICS alone in the control of asthma (see <a class="ref internalNav" href="#sec3_3" aria-label="section 3.3">section 3.3</a>).</div><div class="NLM_p">As mentioned above, both receptor phosphorylation and β-arrestin recruitment play roles in receptor desensitization. Molecules involved in GPCR desensitization, including GRKs and β-arrestins, are also major players of functional selectivity, also called biased agonism. Functional selectivity describes a selectivity bias of the agonist-stimulated receptor signaling toward different pathways downstream of a single GPCR.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> It is now apparent that the β<sub>2</sub>AR can relay its signal through interacting with different cellular proteins. Some of them are membrane-bound, like receptors of a different family.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Others are cytosolic, such as G proteins, GRKs, and β-arrestins. Ligands preferentially directing receptor to mediate its signal via certain pathways at the expense of others, also known as biased ligands, have been described.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Moreover, biased ligands that induce a β-arrestin-biased signaling independent of G protein activation have also been described.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Carvedilol, a nonselective β-blocker, has been classified as a β-arrestin-biased β<sub>2</sub>-agonist under this definition.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Carvedilol was able to promote phosphorylation of the GRK sites on β<sub>2</sub>AR, recruitment of β-arrestins, β<sub>2</sub>AR internalization, and activation of extracellular signal-regulated kinase (ERK) while possessing an inverse efficacy in stimulating cAMP synthesis.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Apart from these “extreme” examples of functional selectivity, a bias toward preferential β-arrestin over G<sub>s</sub> signaling or vice versa is another possibility.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> On the basis of the idea that β<sub>2</sub>AR desensitization contributes to the loss of bronchoprotective effect,<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> it is expected that a β<sub>2</sub>-agonist with a signaling bias for G<sub>s</sub> over β-arrestin, such as salmeterol (<b>2</b>),<a onclick="showRef(event, 'ref154 ref164'); return false;" href="javascript:void(0);" class="ref ref154 ref164">(154,164)</a> would be preferred over one with a reversed bias due to a lower potential to induce receptor desensitization. Moreover, recent studies have suggested an important role of β-arrestins in signal transduction and as regulators of a multitude of pathophysiological processes including inflammation and apoptosis.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a> These concepts may have important implications in the development of bronchodilator β<sub>2</sub>-agonists.</div><div class="NLM_p last">Apart from the pharmacological properties mentioned above, the onset of action and the duration of action are obviously important parameters for a β<sub>2</sub>-agonist as detailed below.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2.  Development of β<sub>2</sub>-Agonists</h3><div class="NLM_p">β<sub>2</sub>-Agonists remain the first-line therapeutic agents for both asthma and COPD. Development of inhaled β<sub>2</sub>-agonists has been enormous over the past decades. The first-generation β<sub>2</sub>-agonist has a rapid onset of action and a short duration of action. Salbutamol (<b>1</b>), a prototypical short-acting β<sub>2</sub>-agonist (SABA), was first developed by Sir David Jack at Allen and Hanburys, a subsidiary of Glaxo (now GlaxoSmithKline), in the 1960s.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> It has a salicyl alcohol headgroup and a tertiary butyl tail in its molecule. It has a fair potency compared with isoproterenol but its selectivity for β<sub>2</sub>AR over β<sub>1</sub>AR is significantly higher.<a onclick="showRef(event, 'ref144 ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref144 ref168 ref169">(144,168,169)</a> Salbutamol (<b>1</b>) and other SABAs are commonly used to relieve acute bronchoconstriction in asthma and COPD.</div><div class="NLM_p">On the basis of the structure of salbutamol (<b>1</b>), Sir David Jack and colleagues set out on a long journey for the development of the first long-acting β<sub>2</sub>AR agonist (LABA), currently regarded as the second-generation agent. A long alkoxyaryl group was added to the tail of salbutamol (<b>1</b>) to increase lipophilicity, resulting in a compound with a duration of action of more than 12 h. Salmeterol (<b>2</b>) was finally launched in 1990.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Recent crystallographic data show that the long aryloxyalkyl tail of salmeterol (<b>2</b>) binds to the exosite sites of the β<sub>2</sub>AR by van der Waals and hydrophobic interactions.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> The position of the oxygen atom is important for fitting the long tail to the exosite sites by forming a hydrogen bond with the main chain amide group of the Phe193 residue.<a onclick="showRef(event, 'ref154 ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref154 ref170 ref171">(154,170,171)</a> Compared to salbutamol (<b>1</b>), salmeterol (<b>2</b>) has an increased selectivity for β<sub>2</sub>AR over β<sub>1</sub>AR,<a onclick="showRef(event, 'ref144 ref169'); return false;" href="javascript:void(0);" class="ref ref144 ref169">(144,169)</a> which contributes to a low cardiac toxicity. The second-generation β<sub>2</sub>AR agonists, such as salmeterol (<b>2</b>) and formoterol (<b>3</b>), are typically used in combination with an ICS for long-term treatment of asthma, or as monotherapy or in combination with a long-acting muscarinic antagonist (LAMA) and/or an ICS to treat COPD.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Formoterol (<b>3</b>) with two chiral centers in its molecules was first synthesized in its racemic form in the 1970s.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> The stereoisomers of formoterol (<b>3</b>) displayed different biological activities. The (<i>R</i>,<i>R</i>)-isomer was the most potent one among them in producing tracheobronchial muscle relaxation in isolated guinea pig trachea.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Formoterol (<b>3</b>) has an <i>N</i>-(5-(2-amino-1-hydroxyethyl)-2-hydroxyphenyl)formamide headgroup and an α-methyl-β-(4-methoxyphenyl)propane-amino tail group in its molecule. The 4-methoxyphenyl group contributes to an increased lipophilicity as compared with salbutamol (<b>1</b>). Formoterol (<b>3</b>) was found to have a rapid onset of action similar to salbutamol (<b>1</b>) and a 12 h duration of action.<a onclick="showRef(event, 'ref172 ref175 ref176'); return false;" href="javascript:void(0);" class="ref ref172 ref175 ref176">(172,175,176)</a> In 2001, formoterol fumarate was commercialized through a collaborative effort by Novartis and Schering-Plough (now Merck and Co.) for the treatment of COPD patients requiring long-term regular bronchodilator therapy. The drug is administered twice daily.</div><div class="NLM_p">Recently, a new class of third-generation agents known as ultra-LABAs with a duration of action of more than 24 h have emerged.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> These drugs including indacaterol (<b>4</b>),<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> olodaterol (<b>5</b>),<a onclick="showRef(event, 'ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref178 ref179">(178,179)</a> and vilanterol (<b>6</b>)<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> were marketed for the treatment of COPD.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Indacaterol (<b>4</b>) was the first ultra-LABA developed by Novartis as a once-daily inhaled bronchodilator.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> It was approved by the Food and Drug Administration (FDA) in 2011 and by the European Medicines Agency (EMA) in 2009. The indacaterol (<b>4</b>) molecule is composed of an 8-hydroxyquinolin-2(1<i>H</i>)-one headgroup and a symmetrically substituted indan moiety at its tail. In addition, the 5,6-diethylindan moiety, in particular, has an important contribution to form a long duration of action extending over 24 h and a rapid onset of action.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Ingo Konetzki et al. have synthesized a series of 6-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones as potent agonists of the human β<sub>2</sub>AR with a high β<sub>2</sub>/β<sub>1</sub>-selectivity.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> These compounds were assessed for application as inhaled once-daily long-acting bronchodilators. Olodaterol (<b>5</b>), also known as BI1744CL,<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> consists of a 6-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-one headgroup and a 2-(4-methoxyphenyl)ethan-1-amino tail with two germinal methyl groups at the α-carbon next to the amine (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The methoxy substituent at the terminal phenyl group plays a vital role in improving the duration of action of olodaterol (<b>5</b>) due to increased lipophilicity.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Structure–activity relationship (SAR) studies have revealed that the phenolic hydroxyl group at the <i>meta</i>-position of the 4<i>H</i>-benzo[1,4]oxazin-3-one head contributes to an increased β<sub>2</sub>/β<sub>1</sub>-selectivity relative to their <i>ortho</i>-hydroxyl counterparts.<a onclick="showRef(event, 'ref178 ref179'); return false;" href="javascript:void(0);" class="ref ref178 ref179">(178,179)</a> An <i>ortho</i>-hydroxyl derivative of the 4<i>H</i>-benzo[1,4]oxazin-3-one-containing compound named BI167107 (<b>7</b>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) is one of the LABAs discovered by Boehringer Ingelheim. BI167107 (<b>7</b>) binds strongly with the β<sub>2</sub>AR and has been used to support crystallization of the active state β<sub>2</sub>AR complexes and can be employed as a tool for the crystallization of other β-ARs.<a onclick="showRef(event, 'ref181 ref182'); return false;" href="javascript:void(0);" class="ref ref181 ref182">(181,182)</a> Procopiou et al. have identified an ultra-LABA, vilanterol (<b>6</b>), from analogues of salmeterol (<b>2</b>).<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Incorporation of an oxygen atom at the homobenzylic position of the terminal phenyl ring of salmeterol (<b>2</b>) with <i>ortho</i>-substitution of two chlorine atoms in it gives vilanterol (<b>6</b>). In docking simulations, the middle oxygen atom of vilanterol (<b>6</b>) formed a hydrogen bond with Asn318 whereby the benzylic ether oxygen formed two hydrogen bonds with Ser120 and Asn322, respectively. Vilanterol (<b>6</b>) had a high potency and a high β<sub>2</sub>/β<sub>1</sub>-selectivity similar to salmeterol (<b>2</b>) and exhibited a more rapid onset of action and very little washout on electrically stimulated isolated superfused guinea pig trachea. It was thus expected to have a long duration of action <i>in vivo</i>. Its metabolism by human liver microsomes was faster compared to salmeterol (<b>2</b>) and it had a very low oral bioavailability in rats. This pharmacokinetic profile is favorable for an inhaled bronchodilator.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of BI167107 (<b>7</b>), bedoradrine (<b>8</b>), abediterol (<b>9</b>), and trantinterol (<b>10</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A number of β<sub>2</sub>AR agonists are currently under clinical development. Bedoradrine (<b>8</b>), a new tetrahydronaphthalene derivative, is a novel, highly selective β<sub>2</sub>-agonists intended for the intravenous treatment of status asthmaticus.<a onclick="showRef(event, 'ref183 ref184 ref185'); return false;" href="javascript:void(0);" class="ref ref183 ref184 ref185">(183−185)</a> Clinical data show that in patients with acute exacerbation of asthma, bedoradrine (<b>8</b>) (1200 μg, one time, with monitoring hourly for 3 h) in the background of standard therapy did not significantly affect percentages of forced expiratory volume in 1 s (FEV<sub>1</sub>) at 3 h compared to placebo but was associated with significant improvement in dyspnea scores. The adverse effect profile of bedoradrine (<b>8</b>) was similar to that of other β<sub>2</sub>-agonists. Bedoradrine (<b>8</b>) may be used to manage symptoms in patients with acute exacerbation of asthma uncontrolled by inhaled β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Abediterol (<b>9</b>), a dual β<sub>2</sub>-agonists and muscarinic antagonist with an 8-hydroxyquinolin-2(1<i>H</i>)-one headgroup developed for asthma and COPD, exhibited an agonistic effect on the β<sub>2</sub>AR with an <i>E</i><sub>max</sub> of 91 ± 5% compared with isoproterenol in a cellular model overexpressing the human β<sub>2</sub>AR.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> The EC<sub>50</sub> value of abediterol (<b>9</b>) was 1.9 nM in isolated human bronchi. Its onset of action was similar to that of formoterol (<b>3</b>), and its duration of action was similar to that of indacaterol (<b>4</b>) in guinea pigs. In dogs, it produced more sustained bronchoprotective effect than salmeterol (<b>2</b>) and indacaterol (<b>4</b>) at doses without effects on heart rate.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> It had a long half-life of 36 h compared with 51 h for indacaterol (<b>4</b>), 47 h for olodaterol (<b>5</b>), and 18 h for vilanterol (<b>6</b>) in guinea pigs.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Abediterol (<b>9</b>) at 2.5, 5, and 10 μg once daily for 7 days significantly improved pulmonary function versus placebo in patients with stable and persistent asthma and exhibited a safety and tolerability profile compared with placebo.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> In patients with COPD, single-dose abediterol (<b>9</b>) at 2.5, 5, and 10 μg significantly improved trough FEV<sub>1</sub> compared with indacaterol (<b>4</b>), 150 μg. Incidence of adverse events was similar between the groups.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Trantinterol (<b>10</b>) with a nonclassical 2-amino-2-phenylethanol core structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) is a potential drug candidate for asthma.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> In a randomized, multicenter clinical study conducted in China, the treatment effects of trantinterol hydrochloride and procaterol hydrochloride in 223 eligible participants were compared.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> After a run-in period of 3 days, patients in the treatment group and the control group were given 50 μg of the tablet drugs twice daily for 10 days. The results showed that improvement in FEV<sub>1</sub> was significant and similar in both groups. There were also no significant differences between the groups in other parameters including days with rescue medication use, symptom score, lung function, vital signs, and adverse effects. The results demonstrate that the use of trantinterol hydrochloride tablets for asthma control is safe and effective.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Biological studies have shown that trantinterol (<b>10</b>) is a highly selective β<sub>2</sub>-agonist with strong tracheal relaxant activities in guinea pigs and rabbits.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Trantinterol (<b>10</b>) at 0.01 (equivalent to 50 μg or maximum recommended dose in human), 0.1, and 1 ng/mL did not cause significant inhibition of cytochrome P450 enzymes in human liver microsomes <i>in vitro</i>, demonstrating a low potential for drug–drug interactions.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a></div><div class="NLM_p">A number of novel β<sub>2</sub>-agonists have appeared in recent literature, but detailed information about their further development are hardly available. Procopiou et al. have synthesized a series of LABAs incorporating an arylsulfonamide group.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Compound <b>11</b> was identified as a candidate compound that possesses a high potency and a long duration of action. To search for new LABAs, chemists in Pfizer have designed and synthesized a series of saligenin analogues<a onclick="showRef(event, 'ref193 ref194'); return false;" href="javascript:void(0);" class="ref ref193 ref194">(193,194)</a> including compounds <b>11</b>, <b>12</b>, <b>13</b>, <b>14</b>, and <b>15</b>.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Compound <b>15</b> was found to have an effective duration of more than 24 h (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of compounds <b>11</b>– <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Roger et al. have described a series of catecholamine type compounds with high β<sub>2</sub>/β<sub>1</sub>-selectivity.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Compounds <b>16</b>, <b>17</b>, <b>18</b>, and <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) exhibited high potencies, with <i>K</i><sub>i</sub>β<sub>2</sub>AR values of 32, 25, 97, and 25–70 nM, respectively. Compounds <b>17</b> and <b>19</b> displayed excellent β<sub>2</sub>/β<sub>1</sub>-selectivity compared to compounds <b>16</b> and <b>18</b>. Liang et al. have discovered a group of β<sub>2</sub>-agonists from the natural product Rhizoma Curcumae.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Compounds <b>20</b> and <b>21</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) has agonistic actions on the β<sub>2</sub>AR, with EC<sub>50</sub> values of 23.82 and 5.925 μM, respectively. Compound <b>22</b> was found to have no activity. New compounds <b>23</b>, <b>24</b>, and <b>25</b> were isolated from purslane (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Their anti-inflammatory activities were evaluated in RAW 264.7 murine macrophages. All of the tested compounds exhibited potent anti-inflammatory activities, with EC<sub>50</sub> values ranging from 17.96 to 497.67 μM. Compounds <b>25</b> also showed agonistic effects on the β<sub>2</sub>AR in CHO-K1/G<sub>α15</sub> cell line, with EC<sub>50</sub> values of 87.86 nM. Compound <b>25</b> was suggested to be a dual functional agent exhibiting strong β<sub>2</sub>-agonistic and anti-inflammatory effects.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> On the basis of the 2-amino-2-phenylethanol scaffold, a series of compounds including trantinterol (<b>10</b>) analogues, compounds <b>26</b><a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> and <b>27</b>,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> have been designed and synthesized (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The structure of compound <b>26</b> was based on the 8-hydroxyquinolin-2(1<i>H</i>)-one head of indacaterol (<b>4</b>) and the ethanolamine core of trantinterol (<b>10</b>), and compound <b>27</b> was designed by bioisosteric replacement of the <i>ortho</i>-phenyl moieties on the 4-aminophenyl head of trantinterol (<b>10</b>). When tested under <i>in vitro</i> or organ bath assays, these compounds exhibited high potency and selectivity toward the β<sub>2</sub>AR.<a onclick="showRef(event, 'ref199 ref200'); return false;" href="javascript:void(0);" class="ref ref199 ref200">(199,200)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of compounds <b>16</b>–<b>27</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Conventional drug discovery at the β<sub>2</sub>AR have led to the development of ligands that bind almost exclusively to the receptor’s orthosteric site. However, in recent years, functionally active allosteric ligands which bind to sites other than the orthosteric sites have been discovered. It has been demonstrated by FDA approvals and clinical trials that GPCR allosteric modulation is a novel drug discovery strategy and broadens potentially useful small molecular species.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> For example, Lefkowitz lab reported the first negative allosteric modulator of β<sub>2</sub>AR compound <b>28</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) in 2017 through screening the DNA-encoded small-molecule libraries.<a onclick="showRef(event, 'ref202 ref203'); return false;" href="javascript:void(0);" class="ref ref202 ref203">(202,203)</a> It has been found that the <i>para</i>-formamidophenylalanine and the <i>meta</i>-bromobenzyl scaffold play vital roles in the activity of compound <b>28</b>.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> A positive allosteric modulator of β<sub>2</sub>AR compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) was also discovered in 2018.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Compound <b>29</b> exhibits low micromolar affinity for the β<sub>2</sub>AR allosteric site and can enhance the affinity of conventional β<sub>2</sub>AR agonists to bind on the orthosteric site, with the ability to coordinate downstream signal transduction proteins such as G proteins and β-arrestins to mediate downstream signal transduction. The Lefkowitz lab in cooperation with the Kobilka lab at Tsinghua University in China reported the crystal structure of an activate conformation of the β<sub>2</sub>AR bound with compound-6FA, a carboxylic acid derivative of compound <b>29</b>.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Allosteric ligands usually display greater receptor subtype selectivity than orthosteric ligands because allosteric sites may not face the same evolutionary pressure as do orthosteric sites and thus are more divergent across subtypes within a receptor family.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> This is exemplified by the fact that just 1 out of 15 amino acid residues constituting the ligand-binding pocket of the human β<sub>2</sub>AR is different from that of the human β<sub>1</sub>-AR,<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> whereas the allosteric site for compound-6FA binding lies within the intracellular loop (ICL)2 domain of the β<sub>2</sub>AR known to have low structural similarity compared with the ICL2 domain of the β<sub>1</sub>AR.<a onclick="showRef(event, 'ref206 ref208'); return false;" href="javascript:void(0);" class="ref ref206 ref208">(206,208)</a> Therefore, drugs targeting allosteric sites potentially have fewer adverse effects. Recently, Kobilka lab reported a newly developed allosteric modulator of the β<sub>2</sub>AR compound <b>30</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) as a negative allosteric modulator for agonists and positive allosteric modulator for inverse agonists.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Compound <b>30</b> binds to a different site compared with two other allosteric modulators, compounds <b>28</b> and <b>29</b>. The binding site of compound <b>30</b> locates on the lipid bilayer facing regions of transmembrane (TM)3 and TM5. Compound <b>28</b> binds to a pocket formed by the cytoplasmic ends of TMs 1, 2, 6, and 7.<a onclick="showRef(event, 'ref202 ref203'); return false;" href="javascript:void(0);" class="ref ref202 ref203">(202,203)</a> Compound <b>29</b> binds to the cytoplasmic ends of TMs 3 and 4.<a onclick="showRef(event, 'ref206 ref209'); return false;" href="javascript:void(0);" class="ref ref206 ref209">(206,209)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of compounds <b>28</b>–<b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.3.  Inhaled β<sub>2</sub>-Agonists: Clinical Practice and Development</h3><div class="NLM_p">Current algorithm in asthma treatment follows a stepwise approach.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> As-needed SABAs are commonly used as reliever medications in all steps. However, multiple studies have suggested that regular use of SABAs in the absence of anti-inflammatory treatment offers no benefit and could even worsen asthma control.<a onclick="showRef(event, 'ref210 ref211 ref212'); return false;" href="javascript:void(0);" class="ref ref210 ref211 ref212">(210−212)</a> Earlier asthma management guidelines still recommend SABA as reliever medication with regular low dose ICS only as an option in step 1 and regular low dose ICS with as-needed SABA in step 2. LABA can be added if symptoms remained uncontrolled in step 2.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> A fundamental change has been made on the 2019 and subsequent GINA recommendations, emphasizing the need to include an ICS whenever a SABA is used.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> With regard to the initial treatment in mild asthma, the preferred treatment is as-needed low dose ICS with formoterol (<b>3</b>) in step 1 and regular low dose ICS and as-needed SABA or as-needed low dose ICS with formoterol (<b>3</b>) in step 2.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This change is based on strong evidence that as-needed budesonide/formoterol (<b>3</b>) is superior to as-needed SABA alone and noninferior to regular budesonide in the control of mild asthma.<a onclick="showRef(event, 'ref215 ref216 ref217'); return false;" href="javascript:void(0);" class="ref ref215 ref216 ref217">(215−217)</a> Similarly, regular LABA is associated with increased risks of exacerbation and hospitalization in asthmatics,<a onclick="showRef(event, 'ref177 ref218'); return false;" href="javascript:void(0);" class="ref ref177 ref218">(177,218)</a> while regular LABA and ICS in combination (mometasone furoate/formoterol (<b>3</b>),<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> budesonide/formoterol (<b>3</b>),<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> and fluticasone propionate/salmeterol (<b>2</b>)<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a>) reduces side effects and the severity of the disease, particularly in patients with moderate or severe asthma. In addition, regular ICS/LABA produces more benefits in moderate-to-severe asthma as compared to ICS alone<a onclick="showRef(event, 'ref222 ref223'); return false;" href="javascript:void(0);" class="ref ref222 ref223">(222,223)</a> while having no significant effect on cardiovascular risks.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Therefore, ICS/LABA is the recommended initial treatment for patients with moderate-to-severe asthma to alleviate symptoms and to reduce the risk for exacerbation.<a onclick="showRef(event, 'ref8 ref213'); return false;" href="javascript:void(0);" class="ref ref8 ref213">(8,213)</a> Also, meta-analyses have shown that ICS/formoterol (<b>3</b>) used as single maintenance and reliever therapy is more effective than regular ICS with as-needed SABA in treating persistent asthma.<a onclick="showRef(event, 'ref225 ref226'); return false;" href="javascript:void(0);" class="ref ref225 ref226">(225,226)</a> The 2019 update of the GINA guideline recommends ICS/formoterol (<b>3</b>) as the preferred reliever across all steps of the asthma treatment algorithm.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a></div><div class="NLM_p">LABA either as monotherapy or in combination with ICS and/or LAMA in COPD management has a history of about 30 years. These bronchodilator medications are most commonly given on a regular basis to achieve symptom control.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The use of LABAs in COPD is not associated with changes in mortality and adverse effects.<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> An as-needed SABA alone or in combination with a short-acting muscarinic antagonist is recommended as the reliever medication in COPD, but the use of short-acting bronchodilators on a regular basis is not recommended.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Recent pharmaceutical research has resulted in the successful development of ultra-LABAs with a duration of action of more than 24 h and a fast action onset.<a onclick="showRef(event, 'ref175 ref179 ref180'); return false;" href="javascript:void(0);" class="ref ref175 ref179 ref180">(175,179,180)</a> Ultra-LABAs such as indacaterol (<b>4</b>) and olodaterol (<b>5</b>) improve lung function and symptoms and decrease the risk of exacerbation in COPD compared to LABAs,<a onclick="showRef(event, 'ref228 ref229'); return false;" href="javascript:void(0);" class="ref ref228 ref229">(228,229)</a> while having no significant effects on survival and risks of adverse events.<a onclick="showRef(event, 'ref230 ref231'); return false;" href="javascript:void(0);" class="ref ref230 ref231">(230,231)</a> Their use in a once-daily dosing regimen improves the compliance of COPD patients through decreasing the frequency of delivery.<a onclick="showRef(event, 'ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref231 ref232">(231,232)</a></div><div class="NLM_p">Up to now, ultra-LABAs are only indicated for maintenance treatment in patients with COPD. No specific guidance on their use in asthma has been provided as clinical trials are still ongoing. Published data about indacaterol (<b>4</b>) and olodaterol (<b>5</b>) only provide the evidence that they maintain effective relaxation for over 24 h in asthma, and there is no specific dose and dose frequency for olodaterol (<b>5</b>) or its combination with ICS.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> Recent studies have shown that the new combination mometasone furoate/indacaterol acetate, also known as QMF149, may be a potential therapeutic option for asthma.<a onclick="showRef(event, 'ref234 ref235'); return false;" href="javascript:void(0);" class="ref ref234 ref235">(234,235)</a> In addition, the efficacy of fluticasone furoate/vilanterol (<b>6</b>) in asthma has also being evaluated.<a onclick="showRef(event, 'ref236 ref237'); return false;" href="javascript:void(0);" class="ref ref236 ref237">(236,237)</a> The once-daily dosing regimen associated with the use of these agents is an advantage over the traditional ICS/LABA combination therapy as adherence is enhanced.</div><div class="NLM_p last">The medical community has a concern over the cardiovascular safety of inhaled β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> Tachycardia, tremor, and decrease in serum potassium are the most common side effects of extra-pulmonary β<sub>2</sub>-adrenergic stimulation.<a onclick="showRef(event, 'ref239 ref240'); return false;" href="javascript:void(0);" class="ref ref239 ref240">(239,240)</a> These side effects are usually mild and appear when inhaled β<sub>2</sub>-agonist treatment is first initiated. Most of them gradually subside when treatment is prolonged, indicating desensitization of the β<sub>2</sub>AR.<a onclick="showRef(event, 'ref241 ref242 ref243'); return false;" href="javascript:void(0);" class="ref ref241 ref242 ref243">(241−243)</a> Several reports have suggested that β<sub>2</sub>-agonists may increase the risks of arrhythmias, sudden cardiac death, myocardial infarction, and HF, particularly during initiation of treatment.<a onclick="showRef(event, 'ref241 ref244 ref245 ref246 ref247 ref248 ref249 ref250'); return false;" href="javascript:void(0);" class="ref ref241 ref244 ref245 ref246 ref247 ref248 ref249 ref250">(241,244−250)</a> Nevertheless, the increased risks are usually related to high dosage or underlying cardiovascular disease rather than the direct effect of the β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref145 ref245 ref246 ref247 ref249'); return false;" href="javascript:void(0);" class="ref ref145 ref245 ref246 ref247 ref249">(145,245−247,249)</a> The overall safety profile of β<sub>2</sub>-agonists is considered acceptable, but the cardiovascular risks of individual patients should be carefully assessed during clinical decision making.<a onclick="showRef(event, 'ref8 ref10 ref251'); return false;" href="javascript:void(0);" class="ref ref8 ref10 ref251">(8,10,251)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.4.  Application of β<sub>2</sub>-Agonists with Combination in Coexistent COPD and HF</h3><div class="NLM_p">COPD and HF often coexist, as they share common risk factors, for instance aging and cigarette smoking. Overlap of COPD and HF occurs in about 30% (with a range from 8% to 52%) of patients suffering from either of the diseases.<a onclick="showRef(event, 'ref252 ref253'); return false;" href="javascript:void(0);" class="ref ref252 ref253">(252,253)</a> β-Blockers and β<sub>2</sub>-agonists are the cornerstones of therapies for HF and COPD, respectively. As the actions of these two classes of drugs dramatically oppose each other, their use in patients with COPD-HF overlap has raised a number of concerns.</div><div class="NLM_p">LABAs have been suggested to increase the risk of cardiovascular adverse events.<a onclick="showRef(event, 'ref241 ref254'); return false;" href="javascript:void(0);" class="ref ref241 ref254">(241,254)</a> However, a recent meta-analysis has shown that LABAs are not associated with an overall increased risk of cardiovascular adverse events, and formoterol (<b>3</b>) and olodaterol (<b>5</b>) might even reduce the risks of some cardiovascular adverse events,<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> but LABAs might increase the risk of HF while reducing the incidence of hypertension.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> The outcomes can be interpreted as the fact that β<sub>2</sub>-agonists stimulate β<sub>2</sub>ARs in the cardiovascular system leading to vasodilation, an increase in heart rate, a reduction in serum potassium levels, and an increased risk of arrhythmias.<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> the overall safety profile of LABAs in patients with cardiovascular complications is considered acceptable. Nevertheless, caution is advised when using SABAs. As conclusive safety data about β<sub>2</sub>-agonists in patients with COPD and HF are still unavailable, it would be prudent to closely monitor patients when bronchodilator treatment is first initiated.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a></div><div class="NLM_p">The concern about bronchospasm caused by β-blockers is ungrounded, as the benefits of β-blockers in COPD-HF overlap have been clearly demonstrated. Studies have shown that cardioselective β-blockers, especially bisoprolol, produced no bronchospasm and exhibited benefits in reducing mortality and exacerbation in patients with coexistent COPD and HF.<a onclick="showRef(event, 'ref255 ref256 ref257 ref258'); return false;" href="javascript:void(0);" class="ref ref255 ref256 ref257 ref258">(255−258)</a> However, the long-term effects of β-blockers on pulmonary function remain uncertain.<a onclick="showRef(event, 'ref254'); return false;" href="javascript:void(0);" class="ref ref254">(254)</a> According to current guidelines, cardioselective β-blockers beginning at a low dose followed by up-titration to the target or maximum tolerated doses should be applied in HF patients with comorbid COPD.<a onclick="showRef(event, 'ref2 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref5">(2,5)</a> In addition, asthma is not an absolute contraindication for cardioselective β-blockers.<a onclick="showRef(event, 'ref2 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref5">(2,5)</a> Chronic administration of β-blockers has even been shown to reduce inflammatory changes related to airflow obstruction and airway hyperresponsiveness in mice.<a onclick="showRef(event, 'ref147 ref259'); return false;" href="javascript:void(0);" class="ref ref147 ref259">(147,259)</a></div><div class="NLM_p">Combination of LABA with LAMA or ICS may reduce adverse effects associated with the use of individual agents.<a onclick="showRef(event, 'ref260 ref261'); return false;" href="javascript:void(0);" class="ref ref260 ref261">(260,261)</a> A recent retrospective analysis has revealed that patients with coexistent COPD and HF using cardioselective β-blockers had the greatest reduction in mortality risk.<a onclick="showRef(event, 'ref262'); return false;" href="javascript:void(0);" class="ref ref262">(262)</a> ICS/LABA combinations, LAMAs, angiotensin receptor blockers, nonselective β-blockers, and statins were also associated with significant risk reduction, while SABAs, LABAs alone, and ICSs alone had minor effects. Unexpectedly, LABA/LAMA combinations have been found to be associated with a slightly higher cardiovascular risk as compared with LABAs alone and LAMAs alone which showed similar risks.<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a> In a more recent cohort study of COPD patients with a history of HF,<a onclick="showRef(event, 'ref264'); return false;" href="javascript:void(0);" class="ref ref264">(264)</a> the use of indacaterol (<b>4</b>)/glycopirronium, an ultra-LABA/LAMA combination, was associated with beneficial cardiovascular outcomes.</div><div class="NLM_p last">A possible cause of the cardiovascular adverse effects associated with the use of β<sub>2</sub>-agonists is off-target stimulation of the cardiac β<sub>1</sub>AR. As cardioselective β-blockers can ameliorate the cardiovascular adverse effects caused by inhaled β<sub>2</sub>-agonists while not causing bronchospasm, combining a β<sub>2</sub>-agonist with a selective β<sub>1</sub>-blocker has a good rationale for use in COPD-HF overlap.<a onclick="showRef(event, 'ref252'); return false;" href="javascript:void(0);" class="ref ref252">(252)</a> Future studies should focus on the analysis of the cardiovascular risks with different drug combinations.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.5.  β<sub>2</sub>-Agonists for HF Management: Research and Development</h3><div class="NLM_p">While the cardioprotective role of the β<sub>2</sub>AR is well-established (<a class="ref internalNav" href="#sec2_1" aria-label="section 2.1">section 2.1</a>), the usefulness of β<sub>2</sub>-agonists in cardiac conditions such as HF is still a matter of debate.<a onclick="showRef(event, 'ref265'); return false;" href="javascript:void(0);" class="ref ref265">(265)</a> When inhaled SABAs have just become widely available for asthma control, there was an increase in the reported cases of adverse events, sometimes including death, associated with the use of β<sub>2</sub>-agonists.<a onclick="showRef(event, 'ref247 ref248 ref249 ref250 ref266 ref267'); return false;" href="javascript:void(0);" class="ref ref247 ref248 ref249 ref250 ref266 ref267">(247−250,266,267)</a> Most of these adverse events can be attributed to overdosage, tolerance, or misuse such as the underusage of anti-inflammatory medications.<a onclick="showRef(event, 'ref210 ref268'); return false;" href="javascript:void(0);" class="ref ref210 ref268">(210,268)</a> However, the perception that β<sub>2</sub>-agonists increase the risks of HF, arrhythmias, and sudden cardiac death has since been formed among clinicians, while no definitive clinical evidence in favor of or contrary to this assumption has ever been provided.<a onclick="showRef(event, 'ref246 ref269 ref270 ref271 ref272 ref273'); return false;" href="javascript:void(0);" class="ref ref246 ref269 ref270 ref271 ref272 ref273">(246,269−273)</a></div><div class="NLM_p">On the other hand, experimental studies have repeatedly shown that β<sub>2</sub>-agonists alone or in combination with β-blockers produced benefits in various animal models of HF.<a onclick="showRef(event, 'ref88 ref89 ref90 ref91 ref92 ref274 ref275 ref276 ref277'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90 ref91 ref92 ref274 ref275 ref276 ref277">(88−92,274−277)</a> Xiao and colleagues have shown that a selective β<sub>2</sub>-agonist fenoterol preferentially stimulated the β<sub>2</sub>AR to couple to G<sub>s</sub> proteins, while most of the other β<sub>2</sub>-agonists such as salbutamol (<b>1</b>), procaterol, and zinterol stimulated the receptor to induce dual G<sub>s</sub> and G<sub>i</sub> signalings.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The other agonists did not produce a full contractile response in adult rat cardiomyocytes as did fenoterol, a full β<sub>2</sub>-agonist. But in cardiomyocytes in which the G<sub>i</sub> proteins had been inhibited by pertussis toxin (PTX), the contractile responses of these “partial” agonists were augmented to levels similar to a full response. In contrast, the contractile response of fenoterol was insensitive to treatment with PTX. In addition, fenoterol induced a full contractile response in cardiomyocytes isolated from heart failing spontaneously hypertensive rats while responsiveness to stimulation with zinterol was substantially reduced in these cells. These data suggest that fenoterol is a G<sub>s</sub>-biased β<sub>2</sub>-agonist with respect to G<sub>s</sub>/G<sub>i</sub> signaling and has a potential applicability in HF.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> A follow-up study in a myocardial infarction-induced rat cardiomyopathy model showed that short-term treatment with fenoterol for 3 months produced a strong cardioprotective effect as compared with metoprolol, a β-blocker, as exemplified in the reduction of cardiomyocyte apoptosis and infarct area expansion, and improvement in left ventricular function, cardiac remodeling, and hemodynamic indices.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> These protective effects, including improvement in cardiac structure and function and animal survival, gradually waned away when the treatment was continued for 12 months.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Interestingly, cotreatment of fenoterol with metoprolol greatly enhanced the cardioprotective effect and a synergistic action of the drugs was clearly evident.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> A possible interpretation of the results is that continuous treatment with a β<sub>2</sub>-agonist leads to β<sub>2</sub>AR desensitization and consequently the loss of protection, which can be effectively prevented by coadministration of a β-blocker. Similar synergistic actions of β<sub>2</sub>-agonists and β-blockers in improving cardiac structure and function in HF models have also been reported with other β<sub>2</sub>-agonist/β-blocker combinations such as indacaterol (<b>4</b>)/metoprolol and clenbuterol/metoprolol.<a onclick="showRef(event, 'ref276 ref277'); return false;" href="javascript:void(0);" class="ref ref276 ref277">(276,277)</a> In addition, a recent randomized, double-blinded, placebo-controlled trial has shown that salbutamol (<b>1</b>) improved pulmonary vascular reserve in HFpEF without worsening left heart congestion.<a onclick="showRef(event, 'ref278'); return false;" href="javascript:void(0);" class="ref ref278">(278)</a> Combination of mechanical and pharmacological therapy including the use of clenbuterol and β-blockers has also been successful in reversing severe HF in a few small-scaled clinical studies.<a onclick="showRef(event, 'ref279 ref280'); return false;" href="javascript:void(0);" class="ref ref279 ref280">(279,280)</a> Therefore, the usefulness of β<sub>2</sub>-agonists in HF is still an open question and likely be context-dependent. Confounding factors such as disease stages, comorbidities, and accompanying medications are anticipated to greatly affect treatment outcomes and should be taken into consideration during the study design.</div><div class="NLM_p">We have employed a medicinal chemistry approach to discover novel β<sub>2</sub>-agonists with potential applicability in HF and other cardiac conditions. On the basis of the scaffold of fenoterol, compounds containing a 5-(2-amino-1-hydroxyethyl)benzene-1,3-diol structure were designed and synthesized. Biological activities of these compounds were assessed by biophysical and cellular assays including contractility measurement in adult rat cardiomyocytes.<a onclick="showRef(event, 'ref281 ref282 ref283 ref284 ref285'); return false;" href="javascript:void(0);" class="ref ref281 ref282 ref283 ref284 ref285">(281−285)</a> (<i>R</i>,<i>R</i>)-Fenoterol (<b>31</b>) was found to be the most active stereoisomer of the parent compound fenoterol.<a onclick="showRef(event, 'ref282'); return false;" href="javascript:void(0);" class="ref ref282">(282)</a> SAR analyses revealed that the biological activities of these compounds depend on the presence of an (<i>R</i>) configuration on the first chiral carbon, whereas the stereochemistry of the second chiral center affects both activity and subtype selectivity.<a onclick="showRef(event, 'ref282 ref283'); return false;" href="javascript:void(0);" class="ref ref282 ref283">(282,283)</a> Fenoterol analogues with a terminal 1-naphthyl and/or a 4-methoxyphenyl moiety on the tail group, <i>i.e.</i>, compounds <b>32</b> and <b>33</b> exhibited comparable affinity and improved subtype selectivity relative to the parent compound either by engaging in hydrogen bond or π–π interactions with the β<sub>2</sub>AR.<a onclick="showRef(event, 'ref284'); return false;" href="javascript:void(0);" class="ref ref284">(284)</a> The presence of an ethyl group instead of a methyl group on the second chiral carbon, <i>i.e.</i>, compound <b>34</b> also contributes to improved subtype selectivity (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref285'); return false;" href="javascript:void(0);" class="ref ref285">(285)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of (<i>R</i>,<i>R</i>)-fenoterol (<b>31</b>) and compounds <b>32</b>–<b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recent studies have implicated the role of the β-arrestin-biased βAR signaling in cardioprotection which may serve as a mechanistic basis for the development of novel HF therapeutics.<a onclick="showRef(event, 'ref286'); return false;" href="javascript:void(0);" class="ref ref286">(286)</a> Noma and colleagues have initially described a cardioprotective β<sub>1</sub>AR signaling induced by carvedilol which is β-arrestin-dependent but G protein-independent, suggesting a possible new mechanism of the therapeutic action of carvedilol in treating HF.<a onclick="showRef(event, 'ref287'); return false;" href="javascript:void(0);" class="ref ref287">(287)</a> Later, Kim and group members discovered that the β-arrestin-biased β<sub>1</sub>AR signaling activated by carvedilol has a novel function of regulating micro-RNA (miR) biogenesis.<a onclick="showRef(event, 'ref288'); return false;" href="javascript:void(0);" class="ref ref288">(288)</a> They subsequently showed that the β<sub>2</sub>AR can also mediates carvedilol-activated β-arrestin-biased signaling, which causes the upregulation of several cardioprotective miRs.<a onclick="showRef(event, 'ref289'); return false;" href="javascript:void(0);" class="ref ref289">(289)</a> Meanwhile, Benovic and group members synthesized allosteric modulator peptides (pepducins) targeting the cytosolic portion of the β<sub>2</sub>AR, with an aim to produce a β-arrestin-biased signaling on a vacant receptor.<a onclick="showRef(event, 'ref290'); return false;" href="javascript:void(0);" class="ref ref290">(290)</a> One of the pepducins, ICL1–9, has the ability to induce β-arrestin-dependent and Ca<sup>2+</sup>-independent contractility in adult mouse cardiomyocytes.<a onclick="showRef(event, 'ref290'); return false;" href="javascript:void(0);" class="ref ref290">(290)</a> Tilley and group members subsequently showed that ICL1–9 protects cardiomyocytes both <i>in vitro</i> and <i>in vivo</i> in a β-arrestin- and β<sub>2</sub>AR-dependent manner.<a onclick="showRef(event, 'ref291'); return false;" href="javascript:void(0);" class="ref ref291">(291)</a></div><div class="NLM_p">Littmann et al. have attempted to discover β-arrestin-biased β<sub>2</sub>-agonists from some existing β<sub>2</sub>AR ligands, including fenoterol analogues, but could only find a few compounds with G<sub>s</sub>-biased agonism, and no compounds showed a significant selectivity bias toward β-arrestin.<a onclick="showRef(event, 'ref292'); return false;" href="javascript:void(0);" class="ref ref292">(292)</a> We have also synthesized and tested a number of compounds for agonist bias for β-arrestin versus G<sub>s</sub>/cAMP signaling using the HTRF cAMP assay and the PathHunter β-arrestin assay in β<sub>2</sub>AR-expressing cells.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> In this study, agonist biases of compounds were defined using an “unbiased β<sub>2</sub>-agonist”, isoproterenol, as a reference. We confirmed that salmeterol (<b>2</b>) is a G<sub>s</sub>-biased β<sub>2</sub>-agonist while fenoterol is unbiased.<a onclick="showRef(event, 'ref292'); return false;" href="javascript:void(0);" class="ref ref292">(292)</a> We also discovered that three new β<sub>2</sub>-agonists based on the 5-(1-amino-2-hydroxyethyl)-8-hydroxyquinolin-2(1<i>H</i>)-one scaffold,<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> compounds <b>35</b>–<b>37</b>, preferentially activated a β-arrestin-biased signaling (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> As a β-arrestin-biased β<sub>2</sub>-agonist may have an additional cardioprotective potential compared to a unbiased β<sub>2</sub>-agonist, its usefulness in HF and other cardiac conditions warrants further investigation. In view of their low potencies, these compounds are better to serve as templates for further optimization.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of compounds <b>35</b>–<b>37</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4.  Summary and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Asthma, COPD, and HF are difficult-to-treat diseases. Development of more effective treatment for these diseases is urgently needed. The use of β<sub>2</sub>-agonists in chronic respiratory diseases for symptomatic relief has a strong scientific basis and has already been widely applied. The development of ultra-LABAs and ICS/β<sub>2</sub>-agonist combination therapy are examples of important recent advances in pulmonary medicine. In the present review, we have provided deepened insights into the pathophysiology of asthma, COPD, and HF and the mechanisms of action, SARs, clinical uses, and potential applications of β<sub>2</sub>-agonists, with an aim to benefit development of β<sub>2</sub>-agonists with high potency, high selectivity, fast action onset, long duration of action, and low potential to induce receptor desensitization for bronchodilator therapy and potential cardiovascular applications. In addition, we have also given a detailed account on basic and translational studies that have provided a mechanistic framework and experimental evidence to support the use of β<sub>2</sub>-agonists in HF. Evaluation of the safety profiles of β<sub>2</sub>-agonists in different clinical settings are urgently needed to guide drug usage. In particular, association studies of the cardiovascular risks in COPD and HF overlap with β<sub>2</sub>-agonist/β-blocker combination therapy should be conducted to provide the needed foundation for further evaluation of the efficacy and safety of this drug combination. Furthermore, the advent of the concept of functional selectivity and allosteric modulation has innovated drug discovery with the discovery of novel pathways, mechanisms, and treatment strategies. Novel drugs from this class may include, for examples, G<sub>s</sub>-biased β<sub>2</sub>-agonist for the treatment of asthma and β-arrestin-biased β<sub>2</sub>-agonist for the treatment of HF. Future studies should focus on the design of β<sub>2</sub>-agonists with fewer side effects using innovative approaches such as structure–functional selectivity relationship analysis.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01195" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Yiu-Ho Woo</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0662-698X" title="Orcid link">http://orcid.org/0000-0003-0662-698X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2f56465a47405840406f5c565f475a014a4b5a014c41"><span class="__cf_email__" data-cfemail="2950405c41465e4646695a5059415c074c4d5c074a47">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mao-Sheng Cheng</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery of Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9073-4806" title="Orcid link">http://orcid.org/0000-0001-9073-4806</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#214c524249444f466152585149540f4445540f424f"><span class="__cf_email__" data-cfemail="026f71616a676c6542717b726a772c6766772c616c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Xing</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery of Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Pan</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery of Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Lin</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China</span>; 
    <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drug Design and Discovery of Ministry
of Education, Shenyang Pharmaceutical University, Shenyang 110016, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.Y.H.W and M.S.C. designed the study and planned the organization of the review. A.Y.H.W. and G.X. performed literature search and generated the initial draft. B.L., L. P., and M.S.C. critically reviewed the draft, provided inputs, and finalized the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Gang Xing</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Gang Xing</b> is currently a Ph.D. student in the School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, China. He received his bachelor’s degree in Pharmaceutical Engineering in 2016 and obtained his master’s degree in Medicinal Chemistry in 2019 from Shenyang Pharmaceutical University under the direction of Prof. Cheng. His research interests include rational drug design and organic synthesis.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Anthony Yiu-Ho Woo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Anthony Yiu-Ho Woo</b> is an associate professor at the School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, China. He obtained his B.S. (1993), M.Phil. (1998), and Ph.D. (2004) in Biochemistry from The Chinese University of Hong Kong, Hong Kong, China. His research interests include cardiovascular pharmacology and GPCR signal transduction.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Li Pan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Li Pan</b> is an associate professor at the School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, China. She is a member of Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University. She received her master’s degree in Medicinal Chemistry from Shenyang Pharmaceutical University (2009). Her research interests include R&D of β<sub>2</sub>-agonists and organic synthesis.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Bin Lin</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Bin Lin</b> is an associate professor at the School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, China. He studied Pharmaceutical Engineering for his B.S. in 2002 and Medicinal Chemistry for his M.S. in 2005 in Shenyang Pharmaceutical University. He then obtained his Ph.D. in Computational Biology in 2011 from Baylor College of Medicine in Houston, Texas, under the supervision of Prof. B. Montgomery Pettitt. He is a research scientist in the area of computer-aided drug discovery. His research interests include molecular modeling and its application in new drug R&D.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Mao-Sheng Cheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=bio5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mao-Sheng Cheng</b> is a Medicinal Chemistry professor at the School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, China. He obtained his M.S. under the supervision of Prof. Jianmin Shen in 1988 and his Ph.D. under the supervision of Prof. Zhizhong Ji in 2001 from Shenyang Pharmaceutical University. His research interests include rational drug design (β<sub>2</sub>-agonists, PAK inhibitors, carbonic anhydrase IV inhibitors, and H<sup>+</sup>,K<sup>+</sup>-ATPase inhibitors), total synthesis of bioactive natural products (steroidal saponins, triterpenoid saponins, and natural alkaloids), and the corresponding structural modification for drug discovery, and development and application of organic chemistry methods.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge financial support from the National Natural Science Foundation of China (grant no. 81872752 to M.S.C.) and The Ministry of Science and Technology of the People’s Republic of China “13th Five-Year” major new drug initiative (grant no. 2019ZX09739-004 to M.S.C.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">adenylyl cyclase</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">adrenoceptor</p></td></tr><tr><td class="NLM_term">ASM</td><td class="NLM_def"><p class="first last">airway smooth muscle</p></td></tr><tr><td class="NLM_term">ASMC</td><td class="NLM_def"><p class="first last">airway smooth muscle cell</p></td></tr><tr><td class="NLM_term">β<sub>2</sub>AR</td><td class="NLM_def"><p class="first last">β<sub>2</sub>-adrenoceptor</p></td></tr><tr><td class="NLM_term">[Ca<sup>2+</sup>]<sub>i</sub></td><td class="NLM_def"><p class="first last">intracellular calcium</p></td></tr><tr><td class="NLM_term">CaMKII</td><td class="NLM_def"><p class="first last">Ca<sup>2+</sup>/calmodulin-dependent protein kinase II</p></td></tr><tr><td class="NLM_term">cMBP-C</td><td class="NLM_def"><p class="first last">cardiac myosin-binding protein C</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">cTnI</td><td class="NLM_def"><p class="first last">cardiac troponin I</p></td></tr><tr><td class="NLM_term">DALYs</td><td class="NLM_def"><p class="first last">disability-adjusted life-years</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">EPAC</td><td class="NLM_def"><p class="first last">exchange protein directly activated by cAMP</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FEV<sub>1</sub></td><td class="NLM_def"><p class="first last">forced expiratory volume in 1 s</p></td></tr><tr><td class="NLM_term">GBD</td><td class="NLM_def"><p class="first last">global burden of disease</p></td></tr><tr><td class="NLM_term">G<sub>i</sub></td><td class="NLM_def"><p class="first last">inhibitory G protein</p></td></tr><tr><td class="NLM_term">GINA</td><td class="NLM_def"><p class="first last">Global Initiative for Asthma</p></td></tr><tr><td class="NLM_term">GOLD</td><td class="NLM_def"><p class="first last">Global Initiative for chronic obstructive lung disease</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">GRK</td><td class="NLM_def"><p class="first last">GPCR kinase</p></td></tr><tr><td class="NLM_term">G<sub>s</sub></td><td class="NLM_def"><p class="first last">stimulatory G protein</p></td></tr><tr><td class="NLM_term">HF</td><td class="NLM_def"><p class="first last">heart failure</p></td></tr><tr><td class="NLM_term">HFmrEF</td><td class="NLM_def"><p class="first last">heart failure with midrange ejection fraction</p></td></tr><tr><td class="NLM_term">HFpEF</td><td class="NLM_def"><p class="first last">heart failure with preserved ejection fraction</p></td></tr><tr><td class="NLM_term">HFrEF</td><td class="NLM_def"><p class="first last">heart failure with reduced ejection fraction</p></td></tr><tr><td class="NLM_term"><i>I</i><sub>Ca,L</sub></td><td class="NLM_def"><p class="first last">L-type Ca<sup>2+</sup> current</p></td></tr><tr><td class="NLM_term">ICL</td><td class="NLM_def"><p class="first last">intracellular loop</p></td></tr><tr><td class="NLM_term">ICS</td><td class="NLM_def"><p class="first last">inhaled corticosteroid</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IP<sub>3</sub></td><td class="NLM_def"><p class="first last">inositol triphosphate</p></td></tr><tr><td class="NLM_term">LABA</td><td class="NLM_def"><p class="first last">long-acting β<sub>2</sub>AR agonist</p></td></tr><tr><td class="NLM_term">LAMA</td><td class="NLM_def"><p class="first last">long-acting muscarinic antagonist</p></td></tr><tr><td class="NLM_term">LCC</td><td class="NLM_def"><p class="first last">L-type Ca<sup>2+</sup> channel</p></td></tr><tr><td class="NLM_term">LT</td><td class="NLM_def"><p class="first last">leukotriene</p></td></tr><tr><td class="NLM_term">LVEF</td><td class="NLM_def"><p class="first last">left ventricular ejection fraction</p></td></tr><tr><td class="NLM_term">miR</td><td class="NLM_def"><p class="first last">micro-RNA</p></td></tr><tr><td class="NLM_term">MLCK</td><td class="NLM_def"><p class="first last">myosin light chain kinase</p></td></tr><tr><td class="NLM_term">MLCP</td><td class="NLM_def"><p class="first last">myosin light chain phosphatase</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">PLB</td><td class="NLM_def"><p class="first last">phospholamban</p></td></tr><tr><td class="NLM_term">PTX</td><td class="NLM_def"><p class="first last">pertussis toxin</p></td></tr><tr><td class="NLM_term">RAGE</td><td class="NLM_def"><p class="first last">receptor for advanced glycation end-products</p></td></tr><tr><td class="NLM_term">Rap1</td><td class="NLM_def"><p class="first last">Ras-related protein 1</p></td></tr><tr><td class="NLM_term">RyR</td><td class="NLM_def"><p class="first last">ryanodine receptor</p></td></tr><tr><td class="NLM_term">SABA</td><td class="NLM_def"><p class="first last">short-acting β<sub>2</sub>AR agonist</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SR</td><td class="NLM_def"><p class="first last">sarcoplasmic reticulum</p></td></tr><tr><td class="NLM_term">T2</td><td class="NLM_def"><p class="first last">type 2</p></td></tr><tr><td class="NLM_term">Tc1</td><td class="NLM_def"><p class="first last">type 1 cytotoxic T cells</p></td></tr><tr><td class="NLM_term">TGF</td><td class="NLM_def"><p class="first last">transforming growth factor</p></td></tr><tr><td class="NLM_term">Th</td><td class="NLM_def"><p class="first last">T-helper cells</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane</p></td></tr><tr><td class="NLM_term">UBE2T</td><td class="NLM_def"><p class="first last">ubiquitin-conjugating enzyme E2T</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 292 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A brief history of G-protein coupled receptors (Nobel Lecture)</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6366</span>– <span class="NLM_lpage">6378</span>, <span class="refDoi"> DOI: 10.1002/anie.201301924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fanie.201301924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1SjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=6366-6378&author=R.+J.+Lefkowitz&title=A+brief+history+of+G-protein+coupled+receptors+%28Nobel+Lecture%29&doi=10.1002%2Fanie.201301924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A Brief History of G-Protein Coupled Receptors (Nobel Lecture)</span></div><div class="casAuthors">Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6366-6378</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review of studies made by the author and others in a form of Nobel lecture is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphWMsFzZ4fQrVg90H21EOLACvtfcHk0lhRmu0Tc12xAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1SjsLs%253D&md5=b83a3b0e790e24f6ff2ff5815786e358</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fanie.201301924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201301924%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520brief%2520history%2520of%2520G-protein%2520coupled%2520receptors%2520%2528Nobel%2520Lecture%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D6366%26epage%3D6378%26doi%3D10.1002%2Fanie.201301924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Juanatey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harjola, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowska, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nihoyannopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parissis, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieske, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruilope, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruschitzka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Meer, P.</span></span> <span> </span><span class="NLM_article-title">2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2200</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehw128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Feurheartj%2Fehw128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27206819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fhs1Srug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=2129-2200&author=P.+Ponikowskiauthor=A.+A.+Voorsauthor=S.+D.+Ankerauthor=H.+Buenoauthor=J.+Clelandauthor=A.+Coatsauthor=V.+Falkauthor=J.+R.+Gonz%C3%A1lez-Juanateyauthor=V.+P.+Harjolaauthor=E.+A.+Jankowskaauthor=M.+Jessupauthor=C.+Lindeauthor=P.+Nihoyannopoulosauthor=J.+T.+Parissisauthor=B.+Pieskeauthor=J.+P.+Rileyauthor=G.+Rosanoauthor=L.+M.+Ruilopeauthor=F.+Ruschitzkaauthor=F.+H.+Ruttenauthor=P.+van+der+Meer&title=2016+ESC+Guidelines+for+the+diagnosis+and+treatment+of+acute+and+chronic+heart+failure%3A+The+Task+Force+for+the+diagnosis+and+treatment+of+acute+and+chronic+heart+failure+of+the+European+Society+of+Cardiology+%28ESC%29+Developed+with+the+special+contribution+of+the+Heart+Failure+Association+%28HFA%29+of+the+ESC&doi=10.1093%2Feurheartj%2Fehw128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</span></div><div class="casAuthors">Ponikowski Piotr; Voors Adriaan A; Anker Stefan D; Bueno Hector; Cleland John G F; Coats Andrew J S; Falk Volkmar; Gonzalez-Juanatey Jose Ramon; Harjola Veli-Pekka; Jankowska Ewa A; Jessup Mariell; Linde Cecilia; Nihoyannopoulos Petros; Parissis John T; Pieske Burkert; Riley Jillian P; Rosano Giuseppe M C; Ruilope Luis M; Ruschitzka Frank; Rutten Frans H; van der Meer Peter</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2129-2200</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS0NiZ1KhBpP3jf77P2BG3fW6udTcc2ebXkjepbnKOw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fhs1Srug%253D%253D&md5=6d5c3d01ffc432870adea4fdc18697e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehw128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehw128%26sid%3Dliteratum%253Aachs%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DAnker%26aufirst%3DS.%2BD.%26aulast%3DBueno%26aufirst%3DH.%26aulast%3DCleland%26aufirst%3DJ.%26aulast%3DCoats%26aufirst%3DA.%26aulast%3DFalk%26aufirst%3DV.%26aulast%3DGonz%25C3%25A1lez-Juanatey%26aufirst%3DJ.%2BR.%26aulast%3DHarjola%26aufirst%3DV.%2BP.%26aulast%3DJankowska%26aufirst%3DE.%2BA.%26aulast%3DJessup%26aufirst%3DM.%26aulast%3DLinde%26aufirst%3DC.%26aulast%3DNihoyannopoulos%26aufirst%3DP.%26aulast%3DParissis%26aufirst%3DJ.%2BT.%26aulast%3DPieske%26aufirst%3DB.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DRosano%26aufirst%3DG.%26aulast%3DRuilope%26aufirst%3DL.%2BM.%26aulast%3DRuschitzka%26aufirst%3DF.%26aulast%3DRutten%26aufirst%3DF.%2BH.%26aulast%3Dvan%2Bder%2BMeer%26aufirst%3DP.%26atitle%3D2016%2520ESC%2520Guidelines%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520acute%2520and%2520chronic%2520heart%2520failure%253A%2520The%2520Task%2520Force%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520acute%2520and%2520chronic%2520heart%2520failure%2520of%2520the%2520European%2520Society%2520of%2520Cardiology%2520%2528ESC%2529%2520Developed%2520with%2520the%2520special%2520contribution%2520of%2520the%2520Heart%2520Failure%2520Association%2520%2528HFA%2529%2520of%2520the%2520ESC%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D2129%26epage%3D2200%26doi%3D10.1093%2Feurheartj%2Fehw128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Virani, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittencourt, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delling, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djousse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkind, M. S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissela, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackland, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loop, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutsey, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolino, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosamond, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, U. K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satou, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spartano, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirschwell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van-Wagner, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, C. W.</span></span> <span> </span><span class="NLM_article-title">Heart disease and stroke statistics-2020 update: A report from the American heart association</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">e139</span>– <span class="NLM_lpage">e596</span>, <span class="refDoi"> DOI: 10.1161/CIR.0000000000000757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIR.0000000000000757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31992061" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2020&pages=e139-e596&author=S.+S.+Viraniauthor=A.+Alonsoauthor=E.+J.+Benjaminauthor=M.+S.+Bittencourtauthor=C.+W.+Callawayauthor=A.+P.+Carsonauthor=A.+M.+Chamberlainauthor=A.+R.+Changauthor=S.+Chengauthor=F.+N.+Dellingauthor=L.+Djousseauthor=M.+S.+V.+Elkindauthor=J.+F.+Fergusonauthor=M.+Fornageauthor=S.+S.+Khanauthor=B.+M.+Kisselaauthor=K.+L.+Knutsonauthor=T.+W.+Kwanauthor=D.+T.+Lacklandauthor=T.+T.+Lewisauthor=J.+H.+Lichtmanauthor=C.+T.+Longeneckerauthor=M.+S.+Loopauthor=P.+L.+Lutseyauthor=S.+S.+Martinauthor=K.+Matsushitaauthor=A.+E.+Moranauthor=M.+E.+Mussolinoauthor=A.+M.+Perakauthor=W.+D.+Rosamondauthor=G.+A.+Rothauthor=U.+K.+A.+Sampsonauthor=G.+M.+Satouauthor=E.+B.+Schroederauthor=S.+H.+Shahauthor=C.+M.+Shayauthor=N.+L.+Spartanoauthor=A.+Stokesauthor=D.+L.+Tirschwellauthor=L.+B.+Van-Wagnerauthor=C.+W.+Tsao&title=Heart+disease+and+stroke+statistics-2020+update%3A+A+report+from+the+American+heart+association&doi=10.1161%2FCIR.0000000000000757"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1161%2FCIR.0000000000000757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIR.0000000000000757%26sid%3Dliteratum%253Aachs%26aulast%3DVirani%26aufirst%3DS.%2BS.%26aulast%3DAlonso%26aufirst%3DA.%26aulast%3DBenjamin%26aufirst%3DE.%2BJ.%26aulast%3DBittencourt%26aufirst%3DM.%2BS.%26aulast%3DCallaway%26aufirst%3DC.%2BW.%26aulast%3DCarson%26aufirst%3DA.%2BP.%26aulast%3DChamberlain%26aufirst%3DA.%2BM.%26aulast%3DChang%26aufirst%3DA.%2BR.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DDelling%26aufirst%3DF.%2BN.%26aulast%3DDjousse%26aufirst%3DL.%26aulast%3DElkind%26aufirst%3DM.%2BS.%2BV.%26aulast%3DFerguson%26aufirst%3DJ.%2BF.%26aulast%3DFornage%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DS.%2BS.%26aulast%3DKissela%26aufirst%3DB.%2BM.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DKwan%26aufirst%3DT.%2BW.%26aulast%3DLackland%26aufirst%3DD.%2BT.%26aulast%3DLewis%26aufirst%3DT.%2BT.%26aulast%3DLichtman%26aufirst%3DJ.%2BH.%26aulast%3DLongenecker%26aufirst%3DC.%2BT.%26aulast%3DLoop%26aufirst%3DM.%2BS.%26aulast%3DLutsey%26aufirst%3DP.%2BL.%26aulast%3DMartin%26aufirst%3DS.%2BS.%26aulast%3DMatsushita%26aufirst%3DK.%26aulast%3DMoran%26aufirst%3DA.%2BE.%26aulast%3DMussolino%26aufirst%3DM.%2BE.%26aulast%3DPerak%26aufirst%3DA.%2BM.%26aulast%3DRosamond%26aufirst%3DW.%2BD.%26aulast%3DRoth%26aufirst%3DG.%2BA.%26aulast%3DSampson%26aufirst%3DU.%2BK.%2BA.%26aulast%3DSatou%26aufirst%3DG.%2BM.%26aulast%3DSchroeder%26aufirst%3DE.%2BB.%26aulast%3DShah%26aufirst%3DS.%2BH.%26aulast%3DShay%26aufirst%3DC.%2BM.%26aulast%3DSpartano%26aufirst%3DN.%2BL.%26aulast%3DStokes%26aufirst%3DA.%26aulast%3DTirschwell%26aufirst%3DD.%2BL.%26aulast%3DVan-Wagner%26aufirst%3DL.%2BB.%26aulast%3DTsao%26aufirst%3DC.%2BW.%26atitle%3DHeart%2520disease%2520and%2520stroke%2520statistics-2020%2520update%253A%2520A%2520report%2520from%2520the%2520American%2520heart%2520association%26jtitle%3DCirculation%26date%3D2020%26volume%3D141%26spage%3De139%26epage%3De596%26doi%3D10.1161%2FCIR.0000000000000757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span> <i>National Vital Statistics System: Public Use Data File Documentation:
Mortality Multiple Cause-of-Death Micro-Data Files</i>. <span class="NLM_publisher-name">National Center for Health Statistics, Centers for Disease Control
and Prevention</span>, <span class="NLM_year">2017</span>; <a href="https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm" class="extLink">https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm</a> (accessed 2019-04-01).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+National+Vital+Statistics+System%3A+Public+Use+Data+File+Documentation%3A%0AMortality+Multiple+Cause-of-Death+Micro-Data+Files.+National+Center+for+Health+Statistics%2C+Centers+for+Disease+Control%0Aand+Prevention%2C+2017%3B+https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fnvss%2Fmortality_public_use_data.htm+%28accessed+2019-04-01%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNational%2520Vital%2520Statistics%2520System%253A%2520Public%2520Use%2520Data%2520File%2520Documentation%253A%250AMortality%2520Multiple%2520Cause-of-Death%2520Micro-Data%2520Files%26pub%3DNational%2520Center%2520for%2520Health%2520Statistics%252C%2520Centers%2520for%2520Disease%2520Control%250Aand%2520Prevention%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yancy, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozkurt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. E.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazner, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippatos, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonarow, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givertz, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenfeld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlake, C.</span></span> <span> </span><span class="NLM_article-title">2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">e137</span>– <span class="NLM_lpage">e161</span>, <span class="refDoi"> DOI: 10.1161/CIR.0000000000000509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIR.0000000000000509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28455343" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=e137-e161&author=C.+W.+Yancyauthor=M.+Jessupauthor=B.+Bozkurtauthor=J.+Butlerauthor=D.+E.+Caseyauthor=M.+M.+Colvinauthor=M.+H.+Draznerauthor=G.+S.+Filippatosauthor=G.+C.+Fonarowauthor=M.+M.+Givertzauthor=S.+M.+Hollenbergauthor=J.+Lindenfeldauthor=F.+A.+Masoudiauthor=P.+E.+McBrideauthor=P.+N.+Petersonauthor=L.+W.+Stevensonauthor=C.+Westlake&title=2017+ACC%2FAHA%2FHFSA+focused+update+of+the+2013+ACCF%2FAHA+guideline+for+the+management+of+heart+failure%3A+A+report+of+the+American+college+of+cardiology%2FAmerican+heart+association+task+force+on+clinical+practice+guidelines+and+the+heart+failure+society+of+America&doi=10.1161%2FCIR.0000000000000509"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1161%2FCIR.0000000000000509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIR.0000000000000509%26sid%3Dliteratum%253Aachs%26aulast%3DYancy%26aufirst%3DC.%2BW.%26aulast%3DJessup%26aufirst%3DM.%26aulast%3DBozkurt%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCasey%26aufirst%3DD.%2BE.%26aulast%3DColvin%26aufirst%3DM.%2BM.%26aulast%3DDrazner%26aufirst%3DM.%2BH.%26aulast%3DFilippatos%26aufirst%3DG.%2BS.%26aulast%3DFonarow%26aufirst%3DG.%2BC.%26aulast%3DGivertz%26aufirst%3DM.%2BM.%26aulast%3DHollenberg%26aufirst%3DS.%2BM.%26aulast%3DLindenfeld%26aufirst%3DJ.%26aulast%3DMasoudi%26aufirst%3DF.%2BA.%26aulast%3DMcBride%26aufirst%3DP.%2BE.%26aulast%3DPeterson%26aufirst%3DP.%2BN.%26aulast%3DStevenson%26aufirst%3DL.%2BW.%26aulast%3DWestlake%26aufirst%3DC.%26atitle%3D2017%2520ACC%252FAHA%252FHFSA%2520focused%2520update%2520of%2520the%25202013%2520ACCF%252FAHA%2520guideline%2520for%2520the%2520management%2520of%2520heart%2520failure%253A%2520A%2520report%2520of%2520the%2520American%2520college%2520of%2520cardiology%252FAmerican%2520heart%2520association%2520task%2520force%2520on%2520clinical%2520practice%2520guidelines%2520and%2520the%2520heart%2520failure%2520society%2520of%2520America%26jtitle%3DCirculation%26date%3D2017%26volume%3D136%26spage%3De137%26epage%3De161%26doi%3D10.1161%2FCIR.0000000000000509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonsu, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunmanakul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiyakunapruk, N.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatments for heart failure with preserved ejection fraction a systemic review and indirect comparison</span>. <i>Heart Failure Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1007/s10741-018-9679-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs10741-018-9679-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29411216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlantr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=147-156&author=K.+O.+Bonsuauthor=P.+Arunmanakulauthor=N.+Chaiyakunapruk&title=Pharmacological+treatments+for+heart+failure+with+preserved+ejection+fraction+a+systemic+review+and+indirect+comparison&doi=10.1007%2Fs10741-018-9679-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison</span></div><div class="casAuthors">Bonsu, Kwadwo Osei; Arunmanakul, Poukwan; Chaiyakunapruk, Nathorn</div><div class="citationInfo"><span class="NLM_cas:title">Heart Failure Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">HFREFC</span>;
        ISSN:<span class="NLM_cas:issn">1382-4147</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Pharmacol. interventions for heart failure with preserved ejection fraction (HFpEF) have failed to reduce mortality and hospitalization.  Evidence for mineralocorticoid antagonists (MRAs), β-adrenoceptor blockers (β-blockers), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs)-to reduce clin. outcomes in HFpEF remains unclear.  We conducted a systematic search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Clin. Trials.gov for randomized controlled trials (RCTs) assessing pharmacol. treatments in HFpEF diagnosed according the recommendations of the European Society of Cardiol. (ESC) 2016 guidelines from inception to August, 2017.  The study outcomes were mortality, hospitalization, changes in indexes of cardiac structure and function, biomarkers, and indexes of functional capacity-quality of life (QoL) assessment and 6-min walk distance test (6-MWD).  The random-effects models were used to est. pooled relative risks (RRs) for the binary outcomes and standardized mean differences for continuous outcomes, with 95% CI.  A network meta-anal. using a random-effects model was employed to est. the comparative efficacy of treatments.  We included data from 15 RCTs comprising 5930 patients.  There was no significant effect seen with all treatments compared with placebo and comparative efficacy of any two treatments on all outcomes assessed.  However, mineralocorticoid antagonist spironolactone demonstrated a trend towards reducing mortality compared with placebo (RR 0.92; 95% CI 0.79-1.08), sildenafil (0.14; 0.01-2.78), perindopril (0.87; 0.59-1.28), and eplerenone (0.91; 0.25-3.33).  Similar trends in treatment effect were obsd. with spironolactone on surrogate outcomes while eplerenone demonstrated a trend of superior effect in redn. of hospitalizations compared with all other drug treatment.  No drug treatment demonstrated statistically significant improvement in clin. and surrogate outcomes in HFpEF diagnosed according to the ESC 2016 guideline.  Spironolactone and eplerenone showed clin. relevant redn. in mortality and hospitalization resp. compared with other drug treatments.  Further trials with MRAs are warranted to confirm treatment effects in HFpEF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-JwbvfqUBgbVg90H21EOLACvtfcHk0lgy0vio9va53w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlantr4%253D&md5=67861d94c532f62068d84fc25765c68f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs10741-018-9679-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10741-018-9679-y%26sid%3Dliteratum%253Aachs%26aulast%3DBonsu%26aufirst%3DK.%2BO.%26aulast%3DArunmanakul%26aufirst%3DP.%26aulast%3DChaiyakunapruk%26aufirst%3DN.%26atitle%3DPharmacological%2520treatments%2520for%2520heart%2520failure%2520with%2520preserved%2520ejection%2520fraction%2520a%2520systemic%2520review%2520and%2520indirect%2520comparison%26jtitle%3DHeart%2520Failure%2520Rev.%26date%3D2018%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1007%2Fs10741-018-9679-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">GBD
2017 Disease and Injury Incidence and Prevalence Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases and injuries
for 195 countries and territories, 1990–2017: a systematic
analysis for the Global Burden of Disease Study 2017</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32279-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2818%2932279-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30496104" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1789-1858&author=GBD%0A2017+Disease+and+Injury+Incidence+and+Prevalence+Collaborators&title=Global%2C+regional%2C+and+national+incidence%2C%0Aprevalence%2C+and+years+lived+with+disability+for+354+diseases+and+injuries%0Afor+195+countries+and+territories%2C+1990%E2%80%932017%3A+a+systematic%0Aanalysis+for+the+Global+Burden+of+Disease+Study+2017&doi=10.1016%2FS0140-6736%2818%2932279-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932279-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932279-7%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520incidence%252C%250Aprevalence%252C%2520and%2520years%2520lived%2520with%2520disability%2520for%2520354%2520diseases%2520and%2520injuries%250Afor%2520195%2520countries%2520and%2520territories%252C%25201990%25E2%2580%25932017%253A%2520a%2520systematic%250Aanalysis%2520for%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202017%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1789%26epage%3D1858%26doi%3D10.1016%2FS0140-6736%2818%2932279-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span> <i>Global Strategy for Asthma Management and Prevention</i>; <span class="NLM_publisher-name">Global Initiative for Asthma</span>, <span class="NLM_year">2020</span>; <a href="http://www.ginasthma.org" class="extLink">www.ginasthma.org</a> (accessed
2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Strategy+for+Asthma+Management+and+Prevention%3B+Global+Initiative+for+Asthma%2C+2020%3B+www.ginasthma.org+%28accessed%0A2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Strategy%2520for%2520Asthma%2520Management%2520and%2520Prevention%26pub%3DGlobal%2520Initiative%2520for%2520Asthma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span> <i>The Global Asthma Report
2018</i>; <span class="NLM_publisher-name">Global Asthma
Network</span>: <span class="NLM_publisher-loc">Auckland, New Zealand</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+Global+Asthma+Report%0A2018%3B+Global+Asthma%0ANetwork%3A+Auckland%2C+New+Zealand%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Global%2520Asthma%2520Report%250A2018%26pub%3DGlobal%2520Asthma%250ANetwork%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span> <i>Global Strategy for the
Diagnosis, Management, and Prevention of
Chronic Obstructive Lung Disease (2020 Report)</i>; <span class="NLM_publisher-name">Global Initiative for Chronic Obstructive Lung Disease</span>, <span class="NLM_year">2020</span>; <a href="http://goldcopd.org/gold-reports" class="extLink">goldcopd.org/gold-reports</a> (accessed 2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Strategy+for+the%0ADiagnosis%2C+Management%2C+and+Prevention+of%0AChronic+Obstructive+Lung+Disease+%282020+Report%29%3B+Global+Initiative+for+Chronic+Obstructive+Lung+Disease%2C+2020%3B+goldcopd.org%2Fgold-reports+%28accessed+2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Strategy%2520for%2520the%250ADiagnosis%252C%2520Management%252C%2520and%2520Prevention%2520of%250AChronic%2520Obstructive%2520Lung%2520Disease%2520%25282020%2520Report%2529%26pub%3DGlobal%2520Initiative%2520for%2520Chronic%2520Obstructive%2520Lung%2520Disease%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">GBD
2017 Causes of Death Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national age-sex-specific mortality
for 282 causes of death in 195 countries and territories, 1980–2017:
a systematic analysis for the Global Burden of Disease Study 2017</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1788</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32203-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2818%2932203-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30496103" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1736-1788&author=GBD%0A2017+Causes+of+Death+Collaborators&title=Global%2C+regional%2C+and+national+age-sex-specific+mortality%0Afor+282+causes+of+death+in+195+countries+and+territories%2C+1980%E2%80%932017%3A%0Aa+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2017&doi=10.1016%2FS0140-6736%2818%2932203-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932203-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932203-7%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520age-sex-specific%2520mortality%250Afor%2520282%2520causes%2520of%2520death%2520in%2520195%2520countries%2520and%2520territories%252C%25201980%25E2%2580%25932017%253A%250Aa%2520systematic%2520analysis%2520for%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202017%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1736%26epage%3D1788%26doi%3D10.1016%2FS0140-6736%2818%2932203-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">GBD
2017 DALYs and HALE Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national disability-adjusted
life-years (DALYs) for 359 diseases and injuries and healthy life
expectancy (HALE) for 195 countries and territories, 1990–2017:
a systematic analysis for the Global Burden of Disease Study 2017</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1859</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32335-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2818%2932335-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30415748" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1859-1922&author=GBD%0A2017+DALYs+and+HALE+Collaborators&title=Global%2C+regional%2C+and+national+disability-adjusted%0Alife-years+%28DALYs%29+for+359+diseases+and+injuries+and+healthy+life%0Aexpectancy+%28HALE%29+for+195+countries+and+territories%2C+1990%E2%80%932017%3A%0Aa+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2017&doi=10.1016%2FS0140-6736%2818%2932335-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932335-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932335-3%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520disability-adjusted%250Alife-years%2520%2528DALYs%2529%2520for%2520359%2520diseases%2520and%2520injuries%2520and%2520healthy%2520life%250Aexpectancy%2520%2528HALE%2529%2520for%2520195%2520countries%2520and%2520territories%252C%25201990%25E2%2580%25932017%253A%250Aa%2520systematic%2520analysis%2520for%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202017%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1859%26epage%3D1922%26doi%3D10.1016%2FS0140-6736%2818%2932335-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span> <span> </span><span class="NLM_article-title">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)16900-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2804%2916900-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15325838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=709-721&author=J.+C.+Hogg&title=Pathophysiology+of+airflow+limitation+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2804%2916900-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg James C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9435</span>),
    <span class="NLM_cas:pages">709-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The airflow limitation that defines chronic obstructive pulmonary disease (COPD) is the result of a prolonged time constant for lung emptying, caused by increased resistance of the small conducting airways and increased compliance of the lung as a result of emphysematous destruction.  These lesions are associated with a chronic innate and adaptive inflammatory immune response of the host to a lifetime exposure to inhaled toxic gases and particles.  Processes contributing to obstruction in the small conducting airways include disruption of the epithelial barrier, interference with mucociliary clearance apparatus that results in accumulation of inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by inflammatory cells, and deposition of connective tissue in the airway wall.  This remodelling and repair thickens the airway walls, reduces lumen calibre, and restricts the normal increase in calibre produced by lung inflation.  Emphysematous lung destruction is associated with an infiltration of the same type of inflammatory cells found in the airways.  The centrilobular pattern of emphysematous destruction is most closely associated with cigarette smoking, and although it is initially focused on respiratory bronchioles, separate lesions coalesce to destroy large volumes of lung tissue.  The panacinar pattern of emphysema is characterised by a more even involvement of the acinus and is associated with alpha1 antitrypsin deficiency.  The technology needed to diagnose and quantitate the individual small airway and emphysema phenotypes present in people with COPD is being developed, and should prove helpful in the assessment of therapeutic interventions designed to modify the progress of either phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTicL3IkZ1Ezq91pGlMMoT5fW6udTcc2eah6ywbQW6LyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D&md5=020c93595544690ab6519a8d88cfb9ee</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2916900-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252916900-6%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26atitle%3DPathophysiology%2520of%2520airflow%2520limitation%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D709%26epage%3D721%26doi%3D10.1016%2FS0140-6736%2804%2916900-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puxeddu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">Airflow obstruction: is it asthma or is it COPD?</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3007</span>– <span class="NLM_lpage">3013</span>, <span class="refDoi"> DOI: 10.2147/COPD.S54927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S54927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27942210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2sjlvVyqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=3007-3013&author=P.+Roglianiauthor=J.+Oraauthor=E.+Puxedduauthor=M.+Cazzola&title=Airflow+obstruction%3A+is+it+asthma+or+is+it+COPD%3F&doi=10.2147%2FCOPD.S54927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Airflow obstruction: is it asthma or is it COPD?</span></div><div class="casAuthors">Rogliani Paola; Ora Josuel; Puxeddu Ermanno; Cazzola Mario</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3007-3013</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite the availability of guideline recommendations, diagnostic confusion between COPD and asthma appears common, and often it is very difficult to decide whether the obstruction is caused by asthma or COPD in a patient with airway obstruction.  However, there are well-defined features that help in differentiating asthma from COPD in the presence of fixed airflow obstruction.  Nonetheless, the presentations of asthma and COPD can converge and mimic each other, making it difficult to give these patients a diagnosis of either condition.  The association of asthma and COPD in the same patient has been designated mixed asthma-COPD phenotype or overlap syndrome.  However, since the absence of a clear definition and the inclusion of patients with different characteristics under this umbrella term, it may not facilitate treatment decisions, especially in the absence of clinical trials addressing this heterogeneous population.  We are realizing that neither asthma nor COPD are single diseases, but rather syndromes consisting of several endotypes and phenotypes, consequently comprising a spectrum of diseases that must be recognized and adequately treated with targeted therapy.  Therefore, we must treat patients by personalizing therapy on the basis of those treatable traits present in each subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaPlcGQH4dniCEBeYuoi7AfW6udTcc2eah6ywbQW6LyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjlvVyqsQ%253D%253D&md5=e513a3253f9c76723c84fa64e869df47</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S54927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S54927%26sid%3Dliteratum%253Aachs%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DOra%26aufirst%3DJ.%26aulast%3DPuxeddu%26aufirst%3DE.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DAirflow%2520obstruction%253A%2520is%2520it%2520asthma%2520or%2520is%2520it%2520COPD%253F%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2016%26volume%3D11%26spage%3D3007%26epage%3D3013%26doi%3D10.2147%2FCOPD.S54927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, I. P.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-agonists</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>237</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/164_2016_64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2F164_2016_64" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2016&pages=23-40&author=C.+K.+Billingtonauthor=R.+B.+Pennauthor=I.+P.+Hall&title=%CE%B22-agonists&doi=10.1007%2F164_2016_64"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2F164_2016_64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2016_64%26sid%3Dliteratum%253Aachs%26aulast%3DBillington%26aufirst%3DC.%2BK.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DHall%26aufirst%3DI.%2BP.%26atitle%3D%25CE%25B22-agonists%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2016%26volume%3D237%26spage%3D23%26epage%3D40%26doi%3D10.1007%2F164_2016_64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span> <span> </span><span class="NLM_article-title">Cardiac excitation contraction coupling</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1038/415198a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2F415198a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11805843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Whsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2002&pages=198-205&author=D.+M.+Bers&title=Cardiac+excitation+contraction+coupling&doi=10.1038%2F415198a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac excitation-contraction coupling</span></div><div class="casAuthors">Bers, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">6868</span>),
    <span class="NLM_cas:pages">198-205</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Of the ions involved in the intricate workings of the heart, calcium is considered perhaps the most important.  It is crucial to the very process that enables the chambers of the heart to contract and relax, a process called excitation-contraction coupling.  It is important to understand in quant. detail exactly how calcium is moved around the various organelles of the myocyte in order to bring about excitation-contraction coupling if we are to understand the basic physiol. of heart function.  Furthermore, spatial microdomains within the cell are important in localizing the mol. players that orchestrate cardiac function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKEixgvct9fbVg90H21EOLACvtfcHk0lgsvtG_qQIoKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Whsg%253D%253D&md5=3c60a38b02e263fb551dfdfe885cc5cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F415198a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F415198a%26sid%3Dliteratum%253Aachs%26aulast%3DBers%26aufirst%3DD.%2BM.%26atitle%3DCardiac%2520excitation%2520contraction%2520coupling%26jtitle%3DNature%26date%3D2002%26volume%3D415%26spage%3D198%26epage%3D205%26doi%3D10.1038%2F415198a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">Functional coupling of the beta2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7870040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2MXktVSlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1995&pages=322-329&author=R.+P.+Xiaoauthor=X.+Jiauthor=E.+G.+Lakatta&title=Functional+coupling+of+the+beta2-adrenoceptor+to+a+pertussis+toxin-sensitive+G+protein+in+cardiac+myocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes</span></div><div class="casAuthors">Xiao, Rui-Ping; Jl, Xiangwu; Lakatta, Edward G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-9</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Recently the authors demonstrated that the effects of β2-adrenoceptor (AR) stimulation to augment Ca2+ current (lCa), cytosolic Ca2+ (Cai) transients, and contractility in rat ventricular myocytes are largely dissocd. from its effect to increase cellular cAMP levels.  This result suggested that β2ARs might be coupled to signaling pathways other than the Gsa-mediated activation of adenylyl cyclase.  Here the authors show that pertussis toxin (PTX) pretreatment specifically potentiates the responses of rat heart cells to β2AR but not β1AR stimulation.  After PTX pretreatment, (1) the dose-response curve for the effects of the β2AR agonist zinterol on contraction amplitude is shifted leftward and upward (EC50 changed from about 1.0 μM to 70 nM), (2) in indo-1-loaded cells, the maximal effects of zinterol (10-5 M) on Cai transient and contraction amplitudes are addnl. increased 1.7- and 2.0- fold, resp., over those in control cells, and (3) the increase in ICa amplitude induced by the same zinterol concn. is potentiated by 2.5 fold.  Similar effects of PTX are obsd. when β2ARs are stimulated by isoproterenol in the presence of a selective β1AR blocker, CGP 20712A.  All effects of β2AR agonists in both PTX-treated and control cells are abolished by a selective β2AR blocker, ICI 118551.  In contrast, neither the baseline ICa, Cai transient, and contraction in the absence of βAR stimulation nor the β1AR-mediated augmentations of these parameters are significantly altered by PTX treatment.  These results demonstrate, for the first time, that the Gs-coupled β2AR can simultaneously activate a pathway that leads to functional inhibition in cardiac cells via a PTX-sensitive G protein.  The activation of more than one G protein during β2AR stimulation, leading to functionally opposite effects, may provide a mechanism to protect the heart from Ca2+ overload and arrhythmias during the response to stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJHIjdfXQwerVg90H21EOLACvtfcHk0lhf0OEjlxVBvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktVSlsLg%253D&md5=a952f2342854d8caa3c911c17d908ee5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DJi%26aufirst%3DX.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3DFunctional%2520coupling%2520of%2520the%2520beta2-adrenoceptor%2520to%2520a%2520pertussis%2520toxin-sensitive%2520G%2520protein%2520in%2520cardiac%2520myocytes%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D47%26spage%3D322%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eichel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jullié, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/ncb3307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fncb3307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26829388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=303-310&author=K.+Eichelauthor=D.+Julli%C3%A9author=M.+von+Zastrow&title=%CE%B2-Arrestin+drives+MAP+kinase+signalling+from+clathrin-coated+structures+after+GPCR+dissociation&doi=10.1038%2Fncb3307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The β -Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation</span></div><div class="casAuthors">Eichel, K.; Jullie, D.; von Zastrow, M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-310</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  β -Arrestins critically regulate G-protein-coupled receptor (GPCR) signalling, not only 'arresting' the G protein signal but also modulating endocytosis and initiating a discrete G-protein-independent signal through MAP kinase.  Despite enormous recent progress towards understanding biophys. aspects of arrestin function, arrestin cell biol. remains relatively poorly understood.  Two key tenets underlie the prevailing current view: β -arrestin accumulates in clathrin-coated structures (CCSs) exclusively in phys. complex with its activating GPCR, and MAP kinase activation requires endocytosis of formed GPCR-β -arrestin complexes.  We show here, using β 1-adrenergic receptors, that β -arrestin-2 (arrestin 3) accumulates robustly in CCSs after dissocg. from its activating GPCR and transduces the MAP kinase signal from CCSs.  Moreover, inhibiting subsequent endocytosis of CCSs enhances the clathrin- and β -arrestin-dependent MAP kinase signal.  These results demonstrate β -arrestin 'activation at a distance', after dissocg. from its activating GPCR, and signalling from CCSs.  We propose a β -arrestin signalling cycle that is catalytically activated by the GPCR and energetically coupled to the endocytic machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlrH9Sy0WTrVg90H21EOLACvtfcHk0lhf0OEjlxVBvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOrt7s%253D&md5=a9aef8c6cabc8e2d9fb7292139232969</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fncb3307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb3307%26sid%3Dliteratum%253Aachs%26aulast%3DEichel%26aufirst%3DK.%26aulast%3DJulli%25C3%25A9%26aufirst%3DD.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26atitle%3D%25CE%25B2-Arrestin%2520drives%2520MAP%2520kinase%2520signalling%2520from%2520clathrin-coated%2520structures%2520after%2520GPCR%2520dissociation%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2016%26volume%3D18%26spage%3D303%26epage%3D310%26doi%3D10.1038%2Fncb3307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davare, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdonin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peden, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hell, J. W.</span></span> <span> </span><span class="NLM_article-title">A beta2 adrenergic receptor signaling complex assembled with the Ca<sup>2+</sup> channel Cav1.2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1126/science.293.5527.98</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.293.5527.98" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11441182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFCntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=98-101&author=M.+A.+Davareauthor=V.+Avdoninauthor=D.+D.+Hallauthor=E.+M.+Pedenauthor=A.+Buretteauthor=R.+J.+Weinbergauthor=M.+C.+Horneauthor=T.+Hoshiauthor=J.+W.+Hell&title=A+beta2+adrenergic+receptor+signaling+complex+assembled+with+the+Ca2%2B+channel+Cav1.2&doi=10.1126%2Fscience.293.5527.98"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A β2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav 1.2</span></div><div class="casAuthors">Davare, Monika A.; Avdonin, Vladimir; Hall, Duane D.; Peden, Erik M.; Burette, Alain; Weinberg, Richard J.; Horne, Mary C.; Hoshi, Toshinori; Hell, Johannes W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5527</span>),
    <span class="NLM_cas:pages">98-101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The existence of a large no. of receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) raises the question of how a particular receptor selectively regulates specific targets.  The authors provide insight into this question by identifying a prototypical macromol. signaling complex.  The β2 adrenergic receptor was found to be directly assocd. with one of its ultimate effectors, the class C L-type calcium channel Cav1.2.  This complex also contained a G protein, an adenylyl cyclase, cAMP-dependent protein kinase, and the counterbalancing phosphatase PP2A.  The authors' electrophysiol. recordings from hippocampal neurons demonstrate highly localized signal transduction from the receptor to the channel.  The assembly of this signaling complex provides a mechanism that ensures specific and rapid signaling by a G protein-coupled receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AKYB09KiS7Vg90H21EOLACvtfcHk0lhf0OEjlxVBvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFCntLs%253D&md5=5d9e5f771833f8acaab9f571134255f9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.293.5527.98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.293.5527.98%26sid%3Dliteratum%253Aachs%26aulast%3DDavare%26aufirst%3DM.%2BA.%26aulast%3DAvdonin%26aufirst%3DV.%26aulast%3DHall%26aufirst%3DD.%2BD.%26aulast%3DPeden%26aufirst%3DE.%2BM.%26aulast%3DBurette%26aufirst%3DA.%26aulast%3DWeinberg%26aufirst%3DR.%2BJ.%26aulast%3DHorne%26aufirst%3DM.%2BC.%26aulast%3DHoshi%26aufirst%3DT.%26aulast%3DHell%26aufirst%3DJ.%2BW.%26atitle%3DA%2520beta2%2520adrenergic%2520receptor%2520signaling%2520complex%2520assembled%2520with%2520the%2520Ca2%252B%2520channel%2520Cav1.2%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D98%26epage%3D101%26doi%3D10.1126%2Fscience.293.5527.98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Head, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesman, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquhar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insel, P. A.</span></span> <span> </span><span class="NLM_article-title">G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">31036</span>– <span class="NLM_lpage">31044</span>, <span class="refDoi"> DOI: 10.1074/jbc.M502540200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M502540200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15961389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=31036-31044&author=B.+P.+Headauthor=H.+H.+Patelauthor=D.+M.+Rothauthor=N.+C.+Laiauthor=I.+R.+Niesmanauthor=M.+G.+Farquharauthor=P.+A.+Insel&title=G-protein-coupled+receptor+signaling+components+localize+in+both+sarcolemmal+and+intracellular+caveolin-3-associated+microdomains+in+adult+cardiac+myocytes&doi=10.1074%2Fjbc.M502540200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein-coupled Receptor Signaling Components Localize in Both Sarcolemmal and Intracellular Caveolin-3-associated Microdomains in Adult Cardiac Myocytes</span></div><div class="casAuthors">Head, Brian P.; Patel, Hemal H.; Roth, David M.; Lai, N. Chin; Niesman, Ingrid R.; Farquhar, Marilyn G.; Insel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">31036-31044</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">This study tests the hypothesis that G-protein-coupled receptor (GPCR) signaling components involved in the regulation of adenylyl cyclase (AC) localize with caveolin (Cav), a protein marker for caveolae, in both cell-surface and intracellular membrane regions.  Using sucrose d. fractionation of adult cardiac myocytes, we detected Cav-3 in both buoyant membrane fractions (BF) and heavy/non-buoyant fractions (HF); β2-adrenergic receptors (AR) in BF; and AC5/6, β1-AR, M4-muscarinic acetylcholine receptors (mAChR), μ-opioid receptors, and Gαs in both BF and HF.  In contrast, M2-mAChR, Gαi3, and Gαi2 were found only in HF.  Immunofluorescence microscopy showed co-localization of Cav-3 with AC5/6, Gαs, β2-AR, and μ-opioid receptors in both sarcolemmal and intracellular membranes, whereas M2-mAChR were detected only intracellularly.  Immunofluorescence of adult heart revealed a distribution of Cav-3 identical to that in isolated adult cardiac myocytes.  Upon immunoelectron microscopy, Cav-3 co-localized with AC5/6 and Gαs in sarcolemmal and intracellular vesicles, the latter closely allied with T-tubules.  Cav-3 immunoppts. possessed components that were necessary and sufficient for GPCR agonist-promoted stimulation and inhibition of cAMP formation.  The distribution of GPCR, G-proteins, and AC with Cav-3 in both sarcolemmal and intracellular T-tubule-assocd. regions indicates the existence of multiple Cav-3-localized cellular microdomains for signaling by hormones and drugs in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB0DBbj445ALVg90H21EOLACvtfcHk0lhf0OEjlxVBvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtLk%253D&md5=946a82263ff366d05d12979697206adb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M502540200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M502540200%26sid%3Dliteratum%253Aachs%26aulast%3DHead%26aufirst%3DB.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BH.%26aulast%3DRoth%26aufirst%3DD.%2BM.%26aulast%3DLai%26aufirst%3DN.%2BC.%26aulast%3DNiesman%26aufirst%3DI.%2BR.%26aulast%3DFarquhar%26aufirst%3DM.%2BG.%26aulast%3DInsel%26aufirst%3DP.%2BA.%26atitle%3DG-protein-coupled%2520receptor%2520signaling%2520components%2520localize%2520in%2520both%2520sarcolemmal%2520and%2520intracellular%2520caveolin-3-associated%2520microdomains%2520in%2520adult%2520cardiac%2520myocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D31036%26epage%3D31044%26doi%3D10.1074%2Fjbc.M502540200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parton, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, E.</span></span> <span> </span><span class="NLM_article-title">Caveolin-3 associates with developing T-tubules during muscle differentiation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1083/jcb.136.1.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1083%2Fjcb.136.1.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9008709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXltFKqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1997&pages=137-154&author=R.+G.+Partonauthor=M.+Wayauthor=N.+Zorziauthor=E.+Stang&title=Caveolin-3+associates+with+developing+T-tubules+during+muscle+differentiation&doi=10.1083%2Fjcb.136.1.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Caveolin-3 associates with developing T-tubules during muscle differentiation</span></div><div class="casAuthors">Parton, Robert G.; Way, Michael; Zorzi, Natasha; Stang, Espen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-154</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Caveolae, flask-shaped invaginations of the plasma membrane, are particularly abundant in muscle cells.  The authors recently cloned a muscle-specific caveolin, termed caveolin-3 (I), which was expressed in differentiated muscle cells.  Specific antibodies to I were generated and used to characterize the distribution of I in adult and differentiating muscle.  In fully differentiated skeletal muscle, I was shown to be assocd. exclusively with sarcolemmal caveolae.  The localization of I during differentiation of primary cultured muscle cells and development of mouse skeletal muscle in vivo suggested that I was transiently assocd. with an internal membrane system.  These elements were identified as developing transverse-(T)-tubules by double-labeling with antibodies to the α1 subunit of the dihydropyridine receptor in C2C12 cells.  Ultrastructural anal. of the I-labeled elements showed an assocn. of I with elaborate networks of interconnected caveolae, which penetrated the depths of the muscle fibers.  These elements, which formed regular reticular structures, were shown to be surface-connected by labeling with cholera toxin conjugates.  The results suggested that I transiently assocs. with T-tubules during development and may be involved in the early development of the T-tubule system in muscle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLMm-JI6lMHLVg90H21EOLACvtfcHk0lgas06_dGePOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltFKqtg%253D%253D&md5=4dfb4ef28487d98244aeba7e629882e5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.136.1.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.136.1.137%26sid%3Dliteratum%253Aachs%26aulast%3DParton%26aufirst%3DR.%2BG.%26aulast%3DWay%26aufirst%3DM.%26aulast%3DZorzi%26aufirst%3DN.%26aulast%3DStang%26aufirst%3DE.%26atitle%3DCaveolin-3%2520associates%2520with%2520developing%2520T-tubules%2520during%2520muscle%2520differentiation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1997%26volume%3D136%26spage%3D137%26epage%3D154%26doi%3D10.1083%2Fjcb.136.1.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rybin, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. F.</span></span> <span> </span><span class="NLM_article-title">Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">41447</span>– <span class="NLM_lpage">41457</span>, <span class="refDoi"> DOI: 10.1074/jbc.M006951200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M006951200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11006286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVKgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=41447-41457&author=V.+O.+Rybinauthor=X.+Xuauthor=M.+P.+Lisantiauthor=S.+F.+Steinberg&title=Differential+targeting+of+beta-adrenergic+receptor+subtypes+and+adenylyl+cyclase+to+cardiomyocyte+caveolae.+A+mechanism+to+functionally+regulate+the+cAMP+signaling+pathway&doi=10.1074%2Fjbc.M006951200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway</span></div><div class="casAuthors">Rybin, Vitalyi O.; Xu, Xiaohong; Lisanti, Michael P.; Steinberg, Susan F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">41447-41457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Differential modes for β1- and β2-adrenergic receptor (AR) regulation of adenylyl cyclase in cardiomyocytes is most consistent with spatial regulation in microdomains of the plasma membrane.  This study examines whether caveolae represent specialized subdomains that conc. and organize these moieties in cardiomyocytes.  Caveolae from quiescent rat ventricular cardiomyocytes are highly enriched in β2-ARs, Gαi, protein kinase A RIIα subunits, caveolin-3, and flotillins (caveolin functional homologs); β1-ARs, m2-muscarinic cholinergic receptors, Gαs, and cardiac types V/VI adenylyl cyclase distribute between caveolae and other cell fractions, whereas protein kinase A RIα subunits, G protein-coupled receptor kinase-2, and clathrin are largely excluded from caveolae.  Cell surface β2-ARs localize to caveolae in cardiomyocytes and cardiac fibroblasts (with markedly different β2-AR expression levels), indicating that the fidelity of β2-AR targeting to caveolae is maintained over a physiol. range of β2-AR expression.  In cardiomyocytes, agonist stimulation leads to a marked decline in the abundance of β2-ARs (but not β1-ARs) in caveolae.  Other studies show co-immunopptn. of cardiomyocytes adenylyl cyclase V/VI and caveolin-3, suggesting their in vivo assocn.  However, caveolin is not required for adenylyl cyclase targeting to low d. membranes, since adenylyl cyclase targets to low buoyant d. membrane fractions of HEK cells that lack prototypical caveolins.  Nevertheless, cholesterol depletion with cyclodextrin augments agonist-stimulated cAMP accumulation, indicating that caveolae function as neg. regulators of cAMP accumulation.  The inhibitory interaction between caveolae and the cAMP signaling pathway as well as domain-specific differences in the stoichiometry of individual elements in the β-AR signaling cascade represent important modifiers of cAMP-dependent signaling in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0e-oSmsZq77Vg90H21EOLACvtfcHk0lgas06_dGePOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVKgsg%253D%253D&md5=2d2f3e619a162c1e46ae3d0dab437027</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M006951200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M006951200%26sid%3Dliteratum%253Aachs%26aulast%3DRybin%26aufirst%3DV.%2BO.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26aulast%3DSteinberg%26aufirst%3DS.%2BF.%26atitle%3DDifferential%2520targeting%2520of%2520beta-adrenergic%2520receptor%2520subtypes%2520and%2520adenylyl%2520cyclase%2520to%2520cardiomyocyte%2520caveolae.%2520A%2520mechanism%2520to%2520functionally%2520regulate%2520the%2520cAMP%2520signaling%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D41447%26epage%3D41457%26doi%3D10.1074%2Fjbc.M006951200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miragoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korchev, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, J.</span></span> <span> </span><span class="NLM_article-title">Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">1653</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1126/science.1185988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.1185988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20185685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslaqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1653-1657&author=V.+O.+Nikolaevauthor=A.+Moshkovauthor=A.+R.+Lyonauthor=M.+Miragoliauthor=P.+Novakauthor=H.+Paurauthor=M.+J.+Lohseauthor=Y.+E.+Korchevauthor=S.+E.+Hardingauthor=J.+Gorelik&title=Beta2-adrenergic+receptor+redistribution+in+heart+failure+changes+cAMP+compartmentation&doi=10.1126%2Fscience.1185988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic Receptor Redistribution in Heart Failure Changes cAMP Compartmentation</span></div><div class="casAuthors">Nikolaev, Viacheslav O.; Moshkov, Alexey; Lyon, Alexander R.; Miragoli, Michele; Novak, Pavel; Paur, Helen; Lohse, Martin J.; Korchev, Yuri E.; Harding, Sian E.; Gorelik, Julia</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5973</span>),
    <span class="NLM_cas:pages">1653-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The β1- and β2-adrenergic receptors (βARs) on the surface of cardiomyocytes mediate distinct effects on cardiac function and the development of heart failure by regulating prodn. of the second messenger cyclic adenosine monophosphate (cAMP).  The spatial localization in cardiomyocytes of these βARs, which are coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins), and the functional implications of their localization have been unclear.  We combined nanoscale live-cell scanning ion conductance and fluorescence resonance energy transfer microscopy techniques and found that, in cardiomyocytes from healthy adult rats and mice, spatially confined β2AR-induced cAMP signals are localized exclusively to the deep transverse tubules, whereas functional β1ARs are distributed across the entire cell surface.  In cardiomyocytes derived from a rat model of chronic heart failure, β2ARs were redistributed from the transverse tubules to the cell crest, which led to diffuse receptor-mediated cAMP signaling.  Thus, the redistribution of β2ARs in heart failure changes compartmentation of cAMP and might contribute to the failing myocardial phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZlBG1csJ2sLVg90H21EOLACvtfcHk0lgas06_dGePOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslaqsLs%253D&md5=bb82007a88ac53cd8e830aafb5015bb7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.1185988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1185988%26sid%3Dliteratum%253Aachs%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DMoshkov%26aufirst%3DA.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DMiragoli%26aufirst%3DM.%26aulast%3DNovak%26aufirst%3DP.%26aulast%3DPaur%26aufirst%3DH.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DKorchev%26aufirst%3DY.%2BE.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26aulast%3DGorelik%26aufirst%3DJ.%26atitle%3DBeta2-adrenergic%2520receptor%2520redistribution%2520in%2520heart%2520failure%2520changes%2520cAMP%2520compartmentation%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D1653%26epage%3D1657%26doi%3D10.1126%2Fscience.1185988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balijepalli, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamp, T. J.</span></span> <span> </span><span class="NLM_article-title">Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">7500</span>– <span class="NLM_lpage">7505</span>, <span class="refDoi"> DOI: 10.1073/pnas.0503465103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.0503465103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16648270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslOrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=7500-7505&author=R.+C.+Balijepalliauthor=J.+D.+Foellauthor=D.+D.+Hallauthor=J.+W.+Hellauthor=T.+J.+Kamp&title=Localization+of+cardiac+L-type+Ca%282%2B%29+channels+to+a+caveolar+macromolecular+signaling+complex+is+required+for+beta%282%29-adrenergic+regulation&doi=10.1073%2Fpnas.0503465103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of cardiac L-type Ca2+ channels to a caveolar macromolecular signaling complex is required for β2-adrenergic regulation</span></div><div class="casAuthors">Balijepalli, Ravi C.; Foell, Jason D.; Hall, Duane D.; Hell, Johannes W.; Kamp, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7500-7505</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">L-type Ca2+ channels play a crit. role in regulating Ca2+-dependent signaling in cardiac myocytes, including excitation-contraction coupling; however, the subcellular localization of cardiac L-type Ca2+ channels and their regulation are incompletely understood.  Caveolae are specialized microdomains of the plasmalemma rich in signaling mols. and supported by the structural protein caveolin-3 in muscle.  Here we demonstrate that a subpopulation of L-type Ca2+ channels is localized to caveolae in ventricular myocytes as part of a macromol. signaling complex necessary for β2-adrenergic receptor (AR) regulation of ICa,L.  Immunofluorescence studies of isolated ventricular myocytes using confocal microscopy detected extensive colocalization of caveolin-3 and the major pore-forming subunit of the L-type Ca channel (Cav1.2).  Immunogold electron microscopy revealed that these proteins colocalize in caveolae.  Immunopptn. from ventricular myocytes using anti-Cav1.2 or anti-caveolin-3 followed by Western blot anal. showed that caveolin-3, Cav1.2, β2-AR (not β1-AR), G protein αs, adenylyl cyclase, protein kinase A, and protein phosphatase 2a are closely assocd.  To det. the functional impact of the caveolar-localized β2-AR/Cav1.2 signaling complex, β2-AR stimulation (salbutamol plus atenolol) of ICa,L was examd. in pertussis toxin-treated neonatal mouse ventricular myocytes.  The stimulation of ICa,L in response to β2-AR activation was eliminated by disruption of caveolae with 10 mM Me β-cyclodextrin or by small interfering RNA directed against caveolin-3, whereas β1-AR stimulation (norepinephrine plus prazosin) of ICa,L was not altered.  These findings demonstrate that subcellular localization of L-type Ca2+ channels to caveolar macromol. signaling complexes is essential for regulation of the channels by specific signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqndDJwYaXe4bVg90H21EOLACvtfcHk0ljFFnvF6v_XOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslOrtbs%253D&md5=37d91eb8a3220535c5f5f3abe8a4b95f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503465103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503465103%26sid%3Dliteratum%253Aachs%26aulast%3DBalijepalli%26aufirst%3DR.%2BC.%26aulast%3DFoell%26aufirst%3DJ.%2BD.%26aulast%3DHall%26aufirst%3DD.%2BD.%26aulast%3DHell%26aufirst%3DJ.%2BW.%26aulast%3DKamp%26aufirst%3DT.%2BJ.%26atitle%3DLocalization%2520of%2520cardiac%2520L-type%2520Ca%25282%252B%2529%2520channels%2520to%2520a%2520caveolar%2520macromolecular%2520signaling%2520complex%2520is%2520required%2520for%2520beta%25282%2529-adrenergic%2520regulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D7500%26epage%3D7505%26doi%3D10.1073%2Fpnas.0503465103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuschel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">22048</span>– <span class="NLM_lpage">22052</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.31.22048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.274.31.22048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10419531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXltVymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=22048-22052&author=M.+Kuschelauthor=Y.+Y.+Zhouauthor=H.+Chengauthor=S.+J.+Zhangauthor=Y.+Chenauthor=E.+G.+Lakattaauthor=R.+P.+Xiao&title=G%28i%29+protein-mediated+functional+compartmentalization+of+cardiac+beta%282%29-adrenergic+signaling&doi=10.1074%2Fjbc.274.31.22048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Gi protein-mediated functional compartmentalization of cardiac β2-adrenergic signaling</span></div><div class="casAuthors">Kuschel, Meike; Zhou, Ying-Ying; Cheng, Heping; Zhang, Sheng-Jun; Chen, Ye; Lakatta, Edward G.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">22048-22052</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In contrast to β1-adrenoreceptor (β1-AR) signaling, β2-AR stimulation in cardiomyocytes augments L-type Ca2+ current in a cAMP-dependent protein kinase (PKA)-dependent manner but fails to phosphorylate phospholamban, indicating that the β2-AR-induced cAMP/PKA signaling is highly localized.  Here we show that inhibition of Gi proteins with pertussis toxin (PTX) permits a full phospholamban phosphorylation and a de novo relaxant effect following β2-AR stimulation, converting the localized β2-AR signaling to a global signaling mode similar to that of β1-AR.  Thus, β2-AR-mediated Gi activation constricts the cAMP signaling to the sarcolemma.  PTX treatment did not significantly affect the β2-AR-stimulated PKA activation.  Similar to Gi inhibition, a protein phosphatase inhibitor, calyculin A (3 × 10-8 M), selectively enhanced the β2-AR but not β1-AR-mediated contractile response.  Furthermore, PTX and calyculin A treatment had a non-additive potentiating effect on the β2-AR-mediated pos. inotropic response.  These results suggest that the interaction of the β2-AR-coupled Gi and Gs signaling affects the local balance of protein kinase and phosphatase activities.  Thus, the addnl. coupling of β2-AR to Gi proteins is a key factor causing the compartmentalization of β2-AR-induced cAMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4cAlURu8g7Vg90H21EOLACvtfcHk0ljFFnvF6v_XOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVymtbY%253D&md5=f6a10edd2d57e42d24ee9bef8eb9d7bc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.31.22048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.31.22048%26sid%3Dliteratum%253Aachs%26aulast%3DKuschel%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DG%2528i%2529%2520protein-mediated%2520functional%2520compartmentalization%2520of%2520cardiac%2520beta%25282%2529-adrenergic%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D22048%26epage%3D22052%26doi%3D10.1074%2Fjbc.274.31.22048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen-Izu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izu, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuschel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2556</span>, <span class="refDoi"> DOI: 10.1016/S0006-3495(00)76495-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0006-3495%2800%2976495-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11053129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD3M%252FotFaltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=2547-2556&author=Y.+Chen-Izuauthor=R.+P.+Xiaoauthor=L.+T.+Izuauthor=H.+Chengauthor=M.+Kuschelauthor=H.+Spurgeonauthor=E.+G.+Lakatta&title=G%28i%29-dependent+localization+of+beta%282%29-adrenergic+receptor+signaling+to+L-type+Ca%282%2B%29+channels&doi=10.1016%2FS0006-3495%2800%2976495-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels</span></div><div class="casAuthors">Chen-Izu Y; Xiao R P; Izu L T; Cheng H; Kuschel M; Spurgeon H; Lakatta E G</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2547-56</span>
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    </div><div class="casAbstract">A plausible determinant of the specificity of receptor signaling is the cellular compartment over which the signal is broadcast.  In rat heart, stimulation of beta(1)-adrenergic receptor (beta(1)-AR), coupled to G(s)-protein, or beta(2)-AR, coupled to G(s)- and G(i)-proteins, both increase L-type Ca(2+) current, causing enhanced contractile strength.  But only beta(1)-AR stimulation increases the phosphorylation of phospholamban, troponin-I, and C-protein, causing accelerated muscle relaxation and reduced myofilament sensitivity to Ca(2+). beta(2)-AR stimulation does not affect any of these intracellular proteins.  We hypothesized that beta(2)-AR signaling might be localized to the cell membrane.  Thus we examined the spatial range and characteristics of beta(1)-AR and beta(2)-AR signaling on their common effector, L-type Ca(2+) channels.  Using the cell-attached patch-clamp technique, we show that stimulation of beta(1)-AR or beta(2)-AR in the patch membrane, by adding agonist into patch pipette, both activated the channels in the patch.  But when the agonist was applied to the membrane outside the patch pipette, only beta(1)-AR stimulation activated the channels.  Thus, beta(1)-AR signaling to the channels is diffusive through cytosol, whereas beta(2)-AR signaling is localized to the cell membrane.  Furthermore, activation of G(i) is essential to the localization of beta(2)-AR signaling because in pertussis toxin-treated cells, beta(2)-AR signaling becomes diffusive.  Our results suggest that the dual coupling of beta(2)-AR to both G(s)- and G(i)-proteins leads to a highly localized beta(2)-AR signaling pathway to modulate sarcolemmal L-type Ca(2+) channels in rat ventricular myocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1uNDJ76Sv1TAEfvC7EH1LfW6udTcc2ea7r7hhdvWPFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M%252FotFaltA%253D%253D&md5=e4a1c332312d4327e80e4a72203377ba</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0006-3495%2800%2976495-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3495%252800%252976495-2%26sid%3Dliteratum%253Aachs%26aulast%3DChen-Izu%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DIzu%26aufirst%3DL.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DKuschel%26aufirst%3DM.%26aulast%3DSpurgeon%26aufirst%3DH.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3DG%2528i%2529-dependent%2520localization%2520of%2520beta%25282%2529-adrenergic%2520receptor%2520signaling%2520to%2520L-type%2520Ca%25282%252B%2529%2520channels%26jtitle%3DBiophys.%2520J.%26date%3D2000%26volume%3D79%26spage%3D2547%26epage%3D2556%26doi%3D10.1016%2FS0006-3495%2800%2976495-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Gerges, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandecasteele, G.</span></span> <span> </span><span class="NLM_article-title">A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1088</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000218493.09370.8e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000218493.09370.8e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16556871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1Kltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=1081-1088&author=F.+Rochaisauthor=A.+Abi-Gergesauthor=K.+Hornerauthor=F.+Lefebvreauthor=D.+M.+Cooperauthor=M.+Contiauthor=R.+Fischmeisterauthor=G.+Vandecasteele&title=A+specific+pattern+of+phosphodiesterases+controls+the+cAMP+signals+generated+by+different+Gs-coupled+receptors+in+adult+rat+ventricular+myocytes&doi=10.1161%2F01.RES.0000218493.09370.8e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Specific Pattern of Phosphodiesterases Controls the cAMP Signals Generated by Different Gs-Coupled Receptors in Adult Rat Ventricular Myocytes</span></div><div class="casAuthors">Rochais, Francesca; Abi-Gerges, Aniella; Horner, Kathleen; Lefebvre, Florence; Cooper, Dermot M. F.; Conti, Marco; Fischmeister, Rodolphe; Vandecasteele, Gregoire</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1081-1088</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Compartmentation of cAMP is thought to generate the specificity of Gs-coupled receptor action in cardiac myocytes, with phosphodiesterases (PDEs) playing a major role in this process by preventing cAMP diffusion.  The authors tested this hypothesis in adult rat ventricular myocytes by characterizing PDEs involved in the regulation of cAMP signals and L-type Ca2+ current (ICa,L) on stimulation with β1-adrenergic receptors (β1-ARs), β2-ARs, glucagon receptors (Glu-Rs) and prostaglandin E1 receptors (PGE1-Rs).  All receptors but PGE1-R increased total cAMP, and inhibition of PDEs with 3-isobutyl-1-methylxanthine strongly potentiated these responses.  When monitored in single cells by high-affinity cyclic nucleotide-gated (CNG) channels, stimulation of β1-AR and Glu-R increased cAMP, whereas β2-AR and PGE1-R had no detectable effect.  Selective inhibition of PDE3 by cilostamide and PDE4 by Ro 20-1724 potentiated β1-AR cAMP signals, whereas Glu-R cAMP was augmented only by PD4 inhibition.  PGE1-R and β2-AR generated substantial cAMP increases only when PDE3 and PDE4 were blocked.  For all receptors except PGE1-R, the measurements of ICa,L closely matched the ones obtained with CNG channels.  Indeed, PDE3 and PDE4 controlled β1-AR and β2-AR regulation of ICa,L, whereas only PDE4 controlled Glu-R regulation of ICa,L thus demonstrating that receptor-PDE coupling has functional implications downstream of cAMP.  PGE1 had no effect on ICa,L even after blockade of PDE3 or PDE4, suggesting that other mechanisms prevent cAMP produced by PGE1 to diffuse to L-type Ca2+ channels.  These results identify specific functional coupling of individual PDE families to Gs-coupled receptors as a major mechanism enabling cardiac cells to generate heterogeneous cAMP signals in response to different hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBefD7Pnp9JrVg90H21EOLACvtfcHk0ljcZnyrQTzS9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1Kltro%253D&md5=8968ebfbaa9d384fa85e2d597fffb9e6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000218493.09370.8e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000218493.09370.8e%26sid%3Dliteratum%253Aachs%26aulast%3DRochais%26aufirst%3DF.%26aulast%3DAbi-Gerges%26aufirst%3DA.%26aulast%3DHorner%26aufirst%3DK.%26aulast%3DLefebvre%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DD.%2BM.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DVandecasteele%26aufirst%3DG.%26atitle%3DA%2520specific%2520pattern%2520of%2520phosphodiesterases%2520controls%2520the%2520cAMP%2520signals%2520generated%2520by%2520different%2520Gs-coupled%2520receptors%2520in%2520adult%2520rat%2520ventricular%2520myocytes%26jtitle%3DCirc.%2520Res.%26date%3D2006%26volume%3D98%26spage%3D1081%26epage%3D1088%26doi%3D10.1161%2F01.RES.0000218493.09370.8e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bünemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitteckert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, S.</span></span> <span> </span><span class="NLM_article-title">Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1084</span>– <span class="NLM_lpage">1091</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000250046.69918.d5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000250046.69918.d5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17038640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKgurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=1084-1091&author=V.+O.+Nikolaevauthor=M.+B%C3%BCnemannauthor=E.+Schmitteckertauthor=M.+J.+Lohseauthor=S.+Engelhardt&title=Cyclic+AMP+imaging+in+adult+cardiac+myocytes+reveals+far-reaching+beta1-adrenergic+but+locally+confined+beta2-adrenergic+receptor-mediated+signaling&doi=10.1161%2F01.RES.0000250046.69918.d5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching β1-adrenergic but locally confined β2-adrenergic receptor-mediated signaling</span></div><div class="casAuthors">Nikolaev, Viacheslav O.; Buenemann, Moritz; Schmitteckert, Eva; Lohse, Martin J.; Engelhardt, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1084-1091</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Both β1- and β2-adrenergic receptors (βARs) are known to differentially regulate cardiomyocyte contraction and growth.  The authors tested the hypothesis that these differences are attributable to spatial compartmentation of the second messenger cAMP.  Using a fluorescent resonance energy transfer (FRET)-based approach, the authors directly monitored the spatial and temporal distribution of cAMP in adult cardiomyocytes.  The authors developed a new cAMP-FRET sensor (termed HCN2-camps) based on a single cAMP binding domain of the hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2).  Its cytosolic distribution, high dynamic range, and sensitivity make HCN2-camps particularly well suited to monitor subcellular localization of cardiomyocyte cAMP.  The authors generated HCN2-camps transgenic mice and performed single-cell FRET imaging on freshly isolated cardiomyocytes.  Whole-cell superfusion with isoproterenol showed a moderate elevation of cAMP.  Application of various phosphodiesterase (PDE) inhibitors revealed stringent control of cAMP through PDE4 > PDE2 > PDE3.  The β1AR-mediated cAMP signals were entirely dependent on PDE4 activity, whereas β2AR-mediated cAMP was under control of multiple PDE isoforms.  β1AR subtype-specific stimulation yielded ≈2-fold greater cAMP responses compared with selective β2-subtype stimulation, even on treatment with the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) (ΔFRET, 17.3% [β1AR] vs. 8% [β2AR]).  Treatment with pertussis toxin to inactivate Gi did not affect cAMP prodn.  Localized β1AR stimulation generated a cAMP gradient propagating throughout the cell, whereas local β2AR stimulation did not elicit marked cAMP diffusion.  The authors' data reveal that in adult cardiac myocytes, β1ARs induce far-reaching cAMP signals, whereas β2AR-induced cAMP remains locally confined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM-iqaCHkBCrVg90H21EOLACvtfcHk0lgd918tRmfiww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKgurrF&md5=571cbbe298c3f8edce2ccc51f47665d2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000250046.69918.d5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000250046.69918.d5%26sid%3Dliteratum%253Aachs%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DB%25C3%25BCnemann%26aufirst%3DM.%26aulast%3DSchmitteckert%26aufirst%3DE.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DEngelhardt%26aufirst%3DS.%26atitle%3DCyclic%2520AMP%2520imaging%2520in%2520adult%2520cardiac%2520myocytes%2520reveals%2520far-reaching%2520beta1-adrenergic%2520but%2520locally%2520confined%2520beta2-adrenergic%2520receptor-mediated%2520signaling%26jtitle%3DCirc.%2520Res.%26date%3D2006%26volume%3D99%26spage%3D1084%26epage%3D1091%26doi%3D10.1161%2F01.RES.0000250046.69918.d5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altschuld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">Beta 2-adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca<sup>2+</sup> dynamics, contractility, or phospholamban phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">19151</span>– <span class="NLM_lpage">19156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8034672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2cXltVSmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=19151-19156&author=R.+P.+Xiaoauthor=C.+Hohlauthor=R.+Altschuldauthor=L.+Jonesauthor=B.+Livingstonauthor=B.+Zimanauthor=B.+Tantiniauthor=E.+G.+Lakatta&title=Beta+2-adrenergic+receptor-stimulated+increase+in+cAMP+in+rat+heart+cells+is+not+coupled+to+changes+in+Ca2%2B+dynamics%2C+contractility%2C+or+phospholamban+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation</span></div><div class="casAuthors">Xiao, Rui-Ping; Hohl, Charlene; Altschuld, Ruth; Jones, Larry; Livingston, Beth; Ziman, Bruce; Tantini, Benedetta; Lakatta, Edward G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">19151-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Previous studies have shown that both β1- and β2-adrenergic receptors (AR) are present in rat ventricular myocytes, but stimulation of these receptor subtypes elicites qual. different cellular responses.  In the present study, the biochem. mechanism underlying the distinct βAR subtype actions have been investigated.  Although both β1AR and β2AR stimulation increased total cellular cAMP in suspensions of rat ventricular myocytes to a similar extent, the max. elevation of the membrane bound cAMP by β2AR stimulation was only half of that induced by β1AR stimulation, suggesting that stimulation the βAR subtypes leads to different compartmentation of cAMP.  The effects of β1AR stimulation on Ca2+ transient (indexed by the transient increase in indo-1 fluorescence ratio after excitation) and contraction amplitude (measured via photodiode array) and their kinetics closely paralleled the increase in cAMP.  In contrast, the increases in both membrane bound and total cAMP content after β2AR stimulation were completely dissocd. from the effects of β2AR stimulation to increase the amplitudes of cytosolic Ca2+ transient and contraction.  Furthermore, β2AR stimulation did not phosphorylate phospholamban to the same extent as did β1AR stimulation.  This finding provides a mechanism for the failure of β2AR stimulation to accelerate the kinetics of the Ca2+i (cytosolic Ca2+) transient and contraction.  These results indicate that the effects of β2AR stimulation on Ca2+i transient and contraction are uncoupled from the cAMP prodn. and cAMP-dependent protein phosphorylation and indicate that, in addn. to coupling to adenylate cyclase, β2AR stimulation also activates other signal transduction pathway(s) to produce changes in cytosolic Ca2+ and contraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowZ1SnO0hVbrVg90H21EOLACvtfcHk0lgd918tRmfiww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltVSmsr0%253D&md5=87af1291b673256ea3059853fcb1aad1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DHohl%26aufirst%3DC.%26aulast%3DAltschuld%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DLivingston%26aufirst%3DB.%26aulast%3DZiman%26aufirst%3DB.%26aulast%3DTantini%26aufirst%3DB.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3DBeta%25202-adrenergic%2520receptor-stimulated%2520increase%2520in%2520cAMP%2520in%2520rat%2520heart%2520cells%2520is%2520not%2520coupled%2520to%2520changes%2520in%2520Ca2%252B%2520dynamics%252C%2520contractility%252C%2520or%2520phospholamban%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D19151%26epage%3D19156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanov, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altschuld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Localized cAMP-dependent signaling mediated β<sub>2</sub>-adrenregic modulation of cardiac excitation-contraction coupling</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">H1611</span>– <span class="NLM_lpage">H1618</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.1997.273.3.H1611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajpheart.1997.273.3.H1611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9321856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXmtlemsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1997&pages=H1611-H1618&author=Y.+Y.+Zhouauthor=H.+Chengauthor=K.+Y.+Bogdanovauthor=C.+Hohlauthor=R.+Altschuldauthor=E.+G.+Lakattaauthor=R.+P.+Xiao&title=Localized+cAMP-dependent+signaling+mediated+%CE%B22-adrenregic+modulation+of+cardiac+excitation-contraction+coupling&doi=10.1152%2Fajpheart.1997.273.3.H1611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Localized cAMP-dependent signaling mediates β2-adrenergic modulation of cardiac excitation-contraction coupling</span></div><div class="casAuthors">Zhou, Ying-Ying; Cheng, Heping; Bogdanov, Konstantin Y.; Hohl, Charlene; Altschhuld, Ruth; Lakatta, Edward G.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">H1611-H1618</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Recent studies have shown that β2-adrenergic receptor (β2-AR)-stimulated increases in the intracellular Ca2+ (Cai) treatment and contraction in cardiac myocytes are dissocd. from the increase in cAMP level and are not accompanied by an increase in phospholamban phosphorylation, an acceleration in relaxation, or a redn. in myofilament Ca2+ response.  Thus the authors hypothesized that the β2-AR modulation of cardiac excitation-contraction (EC) coupling may be mediated by either a cAMP-independent mechanism of a compartmentalized cAMP pathway.  To directly distinguish between these two possibilities, the responses of the L-type Ca2+ current (ICa), Cai transient, and contraction to β2-AR as well as to β1-AR stimulation were examd. in rat ventricular myocytes in the presence or absence of specific inhibitory cAMP analogs, Rp diastereomers of adenosine 3',5'-cyclic monophosphothionate (Rp-cAMPS) and 8-(4-chlorophenylthio)-cAMP (Rp-CPT-cAMPS).  As expected, the pos. inotropic effect induced by an adenylyl cyclase activator, forskolin (2 X 10-7 M), or a β1-AR agonist, norepinephrine (5 X 10-8 M) plus prazosin (10-6 M), was completely blocked by Rp-CPT-cAMPS.  More importantly, the responses of ICa, Cai transient, and contraction to β2-AR stimulation by zinterol (10-5 M) or isoproterenol plus a selective β1-AR antagonist, CGP-20712A, were also entirely abolished by Rp-cAMPS (in the patch-pipet soln.) or Rp-CPT-cAMPS (in the bath soln.).  In pertussis toxin-treated cells, although the response of cAMP was not altered, the β2-AR-stimulated increase in contraction amplitude was markedly enhanced and accompanied by a hastened relaxation, resulting in a tight assocn. between cAMP and contraction.  These results indicate that β2-AR modulation of cardiac excitation-contraction coupling requires cAMP.  The dissocn. of β2-AR-stimulated cAMP prodn. and regulation of myofilament and sarcoplasmic reticulum functions is attributable to a functional compartmentation of the cAMP-dependent signaling due to an activation of β2-AR-coupled Gi and/or G0.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFiPLmqOy77Vg90H21EOLACvtfcHk0lgd918tRmfiww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtlemsrk%253D&md5=38e7b92a3b0304fc1a96352171e0821d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.1997.273.3.H1611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.1997.273.3.H1611%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DBogdanov%26aufirst%3DK.%2BY.%26aulast%3DHohl%26aufirst%3DC.%26aulast%3DAltschuld%26aufirst%3DR.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DLocalized%2520cAMP-dependent%2520signaling%2520mediated%2520%25CE%25B22-adrenregic%2520modulation%2520of%2520cardiac%2520excitation-contraction%2520coupling%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1997%26volume%3D273%26spage%3DH1611%26epage%3DH1618%26doi%3D10.1152%2Fajpheart.1997.273.3.H1611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuschel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karczewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2458</span>– <span class="NLM_lpage">2465</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.99.18.2458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.99.18.2458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10318670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXjsFartrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=2458-2465&author=M.+Kuschelauthor=Y.+Y.+Zhouauthor=H.+A.+Spurgeonauthor=S.+Bartelauthor=P.+Karczewskiauthor=S.+J.+Zhangauthor=E.+G.+Krauseauthor=E.+G.+Lakattaauthor=R.+P.+Xiao&title=Beta2-adrenergic+cAMP+signaling+is+uncoupled+from+phosphorylation+of+cytoplasmic+proteins+in+canine+heart&doi=10.1161%2F01.CIR.99.18.2458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart</span></div><div class="casAuthors">Kuschel, Meike; Zhou, Ying-Ying; Spurgeon, Harold A.; Bartel, Sabine; Karczewski, Peter; Zhang, Sheng-Jun; Krause, Ernst-Georg; Lakatta, Edward G.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2458-2465</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent studies of β-adrenergic receptor (β-AR) subtype signaling in in vitro prepns. have raised doubts as to whether the cAMP/protein kinase A (PKA) signaling is activated in the same manner in response to β2-AR vs. β1-AR stimulation.  The present study compared, in the intact dog, the magnitude and characteristics of chronotropic, inotropic, and lusitropic effects of cAMP accumulation, PKA activation, and PKA-dependent phosphorylation of key effector proteins in response to β-AR subtype stimulation.  In addn., many of these parameters and L-type Ca2+ current (ICa) were also measured in single canine ventricular myocytes.  The results indicate that although the cAMP/PKA-dependent phosphorylation cascade activated by β1-AR stimulation could explain the resultant modulation of cardiac function, substantial β2-AR-mediated chronotropic, inotropic, and lusitropic responses occurred in the absence of PKA activation and phosphorylation of nonsarcolemmal proteins, including phospholamban, troponin I, C protein, and glycogen phosphorylase kinase.  However, in single canine myocytes, the authors found that β2-AR-stimulated increases in both ICa and contraction were abolished by PKA inhibition.  Thus, the β2-AR-directed cAMP/PKA signaling modulates sarcolemmal L-type Ca2+ channels but does not regulate PKA-dependent phosphorylation of cytoplasmic proteins.  These results indicate that the dissocn. of β2-AR signaling from cAMP regulatory systems is only apparent and that β2-AR-stimulated cAMP/PKA signaling is uncoupled from phosphorylation of nonsarcolemmal regulatory proteins involved in excitation-contraction coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqHyQtWkc6d7Vg90H21EOLACvtfcHk0ljNfUyE8r6tVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsFartrs%253D&md5=cfc6914b1028b00e3bf0ef1c655a0da7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.99.18.2458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.99.18.2458%26sid%3Dliteratum%253Aachs%26aulast%3DKuschel%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DSpurgeon%26aufirst%3DH.%2BA.%26aulast%3DBartel%26aufirst%3DS.%26aulast%3DKarczewski%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DKrause%26aufirst%3DE.%2BG.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DBeta2-adrenergic%2520cAMP%2520signaling%2520is%2520uncoupled%2520from%2520phosphorylation%2520of%2520cytoplasmic%2520proteins%2520in%2520canine%2520heart%26jtitle%3DCirculation%26date%3D1999%26volume%3D99%26spage%3D2458%26epage%3D2465%26doi%3D10.1161%2F01.CIR.99.18.2458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/36362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2F36362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9363896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Cru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=1997&pages=88-91&author=Y.+Daakaauthor=L.+M.+Luttrellauthor=R.+J.+Lefkowitz&title=Switching+of+the+coupling+of+the+beta2-adrenergic+receptor+to+different+G+proteins+by+protein+kinase+A&doi=10.1038%2F36362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A</span></div><div class="casAuthors">Daaka, Yehia; Luttrell, Louis M.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">6655</span>),
    <span class="NLM_cas:pages">88-91</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Many of the G-protein-coupled receptors for hormones that bind to the cell surface can signal to the interior of the cell through several different classes of G protein.  For example, although most of the actions of the prototype β2-adrenergic receptor are mediated through Gs proteins and the cyclic-AMP-dependent protein kinase (PKA) system, β-adrenergic receptors can also couple to Gi proteins.  Here the authors investigate the mechanism that controls the specificity of this coupling.  The authors show that in HEK293 cells, stimulation of mitogen-activated protein (MAP) kinase by the β2-adrenergic receptor is mediated by the βγ subunits of pertussis-toxin-sensitive G proteins through a pathway involving the non-receptor tyrosine kinase c-Src and the G protein Ras.  Activation of this pathway by the β2-adrenergic receptor requires that the receptor be phosphorylated by PKA because it is blocked by H-89, an inhibitor of PKA.  Addnl., a mutant of the receptor, which lacks the sites normally phosphorylated by PKA, can activate adenylyl cyclase, the enzyme that generates cAMP, but not MAP kinase.  The authors' results demonstrate that a mechanism previously shown to mediate uncoupling of the β2-adrenergic receptor from Gs and thus heterologous desensitization (PKA-mediated receptor phosphorylation), also serves to 'switch' coupling of this receptor from Gs to Gi and initiate a new set of signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQz1gYyUIrk7Vg90H21EOLACvtfcHk0ljNfUyE8r6tVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Cru7o%253D&md5=7d7ba63639514006ec2cfdbbd3a38e84</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2F36362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F36362%26sid%3Dliteratum%253Aachs%26aulast%3DDaaka%26aufirst%3DY.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSwitching%2520of%2520the%2520coupling%2520of%2520the%2520beta2-adrenergic%2520receptor%2520to%2520different%2520G%2520proteins%2520by%2520protein%2520kinase%2520A%26jtitle%3DNature%26date%3D1997%26volume%3D390%26spage%3D88%26epage%3D91%26doi%3D10.1038%2F36362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-Adrenergic stimulation compartmentalizes β<sub>1</sub> signaling into nanoscale local domains by targeting the C-terminus of β<sub>1</sub>-adrenoceptors</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.118.314322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.118.314322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30836825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlWmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=1350-1359&author=H.+Q.+Yangauthor=L.+P.+Wangauthor=Y.+Y.+Gongauthor=X.+X.+Fanauthor=S.+Y.+Zhuauthor=X.+T.+Wangauthor=Y.+P.+Wangauthor=L.+L.+Liauthor=X.+Xingauthor=X.+X.+Liuauthor=G.+S.+Jiauthor=T.+Houauthor=Y.+Zhangauthor=R.+P.+Xiaoauthor=S.+Q.+Wang&title=%CE%B22-Adrenergic+stimulation+compartmentalizes+%CE%B21+signaling+into+nanoscale+local+domains+by+targeting+the+C-terminus+of+%CE%B21-adrenoceptors&doi=10.1161%2FCIRCRESAHA.118.314322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic Stimulation Compartmentalizes β1 Signaling Into Nanoscale Local Domains by Targeting the C-Terminus of β1-Adrenoceptors</span></div><div class="casAuthors">Yang, Hua-Qian; Wang, Li-Peng; Gong, Yun-Yun; Fan, Xue-Xin; Zhu, Si-Yu; Wang, Xiao-Ting; Wang, Yu-Pu; Li, Lin-Lin; Xing, Xin; Liu, Xiao-Xiao; Ji, Guang-Shen; Hou, TingTing; Zhang, Yan; Xiao, Rui-Ping; Wang, Shi-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: βARs (β-adrenergic receptors) are prototypical GPCRs (G protein-coupled receptors) that play a pivotal role in sympathetic regulation.  In heart cells, β1AR signaling mediates a global response, including both L-type Ca channels in the sarcolemma/T tubules and RyRs (ryanodine receptors) in the SR (sarcoplasmic reticulum).  In contrast, β2AR mediates local signaling with little effect on the function of SR proteins.  Objective: To investigate the signaling relationship between β1ARs and β2ARs.  Method and results: Using whole-cell patch-clamp analyses combined with confocal Ca imaging, we found that the activation of compartmentalized β2AR signaling was able to convert the β1AR signaling from global to local mode, preventing β1ARs from phosphorylating RyRs that were only nanometers away from sarcolemma/T tubules.  This offside compartmentalization was eliminated by selective inhibition of β2AR, GRK2 (GPCR kinase-2), βarr1 (β-arrestin-1), and phosphodiesterase-4.  A knockin rat model harboring mutations of the last 3 serine residues of the β1AR C terminus, a component of the putative βarr1 binding site and GRK2 phosphorylation site, eliminated the offside compartmentalization conferred by β2AR activation.  Conclusions: β2AR stimulation compartmentalizes β1AR signaling into nanoscale local domains in a phosphodiesterase-4-dependent manner by targeting the C terminus of β1ARs.  This finding reveals a fundamental neg. feed-forward mechanism that serves to avoid the cytotoxicity of circulating catecholamine and to sharpen the transient β1AR response of sympathetic excitation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzLuSLVO3WrVg90H21EOLACvtfcHk0ljNfUyE8r6tVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlWmsLs%253D&md5=a18b47ba5aea5ab376dd881505a61496</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.118.314322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.118.314322%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%2BQ.%26aulast%3DWang%26aufirst%3DL.%2BP.%26aulast%3DGong%26aufirst%3DY.%2BY.%26aulast%3DFan%26aufirst%3DX.%2BX.%26aulast%3DZhu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DX.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%2BX.%26aulast%3DJi%26aufirst%3DG.%2BS.%26aulast%3DHou%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26atitle%3D%25CE%25B22-Adrenergic%2520stimulation%2520compartmentalizes%2520%25CE%25B21%2520signaling%2520into%2520nanoscale%2520local%2520domains%2520by%2520targeting%2520the%2520C-terminus%2520of%2520%25CE%25B21-adrenoceptors%26jtitle%3DCirc.%2520Res.%26date%3D2019%26volume%3D124%26spage%3D1350%26epage%3D1359%26doi%3D10.1161%2FCIRCRESAHA.118.314322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsburg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minobe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubicciotti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sageman, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingham, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, E. B.</span></span> <span> </span><span class="NLM_article-title">Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1056/NEJM198207223070401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJM198207223070401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=6283349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL38XkvV2qsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=1982&pages=205-211&author=M.+R.+Bristowauthor=R.+Ginsburgauthor=W.+Minobeauthor=R.+S.+Cubicciottiauthor=W.+S.+Sagemanauthor=K.+Lurieauthor=M.+E.+Billinghamauthor=D.+C.+Harrisonauthor=E.+B.+Stinson&title=Decreased+catecholamine+sensitivity+and+%CE%B2-adrenergic+receptor+density+in+failing+human+hearts&doi=10.1056%2FNEJM198207223070401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts</span></div><div class="casAuthors">Bristow, Michael R.; Ginsburg, Robert; Minobe, Wayne; Cubicciotti, Roger S.; Sageman, W. Scott; Lurie, Keith; Billingham, Margaret E.; Harrison, Donald C.; Stinson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-11</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">To identify the role of the myocardial β-adrenergic pathway in congestive heart failure, β-adrenergic receptor d., adenylate cyclase, and creatine kinase activities, muscle contraction in vitro, and myocardial contractile protein levels in the left ventricles of failing and normally functioning hearts from cardiac transplant recipients or prospective donors were examd.  Eleven failing left ventricles had a 50-56% redn. in β-receptor d., a 45% redn. in maximal isoproterenol-mediated adenylate cyclase stimulation, and a 54-73% redn. in maximal isoproterenol-stimulated muscle contraction, as compared with 6 normally functioning ventricles.  In contrast, cytoplasmic creatine kinase activity, adenylate cyclase activities stimulated by F- and by histamine, histamine-stimulated muscle contraction, and levels of contractile protein were not different in the 2 groups.  Apparently, in failing human hearts, a decrease in the β-receptor d. leads to subsensitivity of the β-adrenergic pathway and decreased β-agonist-stimulated muscle contraction.  Regulation of β-adrenergic receptors may be an important variable in cardiac failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOXb2sUUjylbVg90H21EOLACvtfcHk0ljNfUyE8r6tVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XkvV2qsrc%253D&md5=af0e3abceba888a5260bd1e9a2e07970</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJM198207223070401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198207223070401%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DM.%2BR.%26aulast%3DGinsburg%26aufirst%3DR.%26aulast%3DMinobe%26aufirst%3DW.%26aulast%3DCubicciotti%26aufirst%3DR.%2BS.%26aulast%3DSageman%26aufirst%3DW.%2BS.%26aulast%3DLurie%26aufirst%3DK.%26aulast%3DBillingham%26aufirst%3DM.%2BE.%26aulast%3DHarrison%26aufirst%3DD.%2BC.%26aulast%3DStinson%26aufirst%3DE.%2BB.%26atitle%3DDecreased%2520catecholamine%2520sensitivity%2520and%2520%25CE%25B2-adrenergic%2520receptor%2520density%2520in%2520failing%2520human%2520hearts%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1982%26volume%3D307%26spage%3D205%26epage%3D211%26doi%3D10.1056%2FNEJM198207223070401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, J. N.</span></span> <span> </span><span class="NLM_article-title">Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1659</span>– <span class="NLM_lpage">1666</span>, <span class="refDoi"> DOI: 10.1016/0002-9149(82)90243-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2F0002-9149%2882%2990243-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7044086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaL383gtlWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1982&pages=1659-1666&author=T.+B.+Levineauthor=G.+S.+Francisauthor=S.+R.+Goldsmithauthor=A.+B.+Simonauthor=J.+N.+Cohn&title=Activity+of+the+sympathetic+nervous+system+and+renin-angiotensin+system+assessed+by+plasma+hormone+levels+and+their+relation+to+hemodynamic+abnormalities+in+congestive+heart+failure&doi=10.1016%2F0002-9149%2882%2990243-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure</span></div><div class="casAuthors">Levine T B; Francis G S; Goldsmith S R; Simon A B; Cohn J N</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of cardiology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1659-66</span>
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFYKmwVGMZICnGiHuhFGv8fW6udTcc2eY0DDDZ9zq4Zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383gtlWjtA%253D%253D&md5=554885c33817dc4e5f0f15a92f9dfaae</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2882%2990243-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252882%252990243-0%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DT.%2BB.%26aulast%3DFrancis%26aufirst%3DG.%2BS.%26aulast%3DGoldsmith%26aufirst%3DS.%2BR.%26aulast%3DSimon%26aufirst%3DA.%2BB.%26aulast%3DCohn%26aufirst%3DJ.%2BN.%26atitle%3DActivity%2520of%2520the%2520sympathetic%2520nervous%2520system%2520and%2520renin-angiotensin%2520system%2520assessed%2520by%2520plasma%2520hormone%2520levels%2520and%2520their%2520relation%2520to%2520hemodynamic%2520abnormalities%2520in%2520congestive%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1982%26volume%3D49%26spage%3D1659%26epage%3D1666%26doi%3D10.1016%2F0002-9149%2882%2990243-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">18677</span>– <span class="NLM_lpage">18680</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.30.18677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.273.30.18677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9668034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1cXltFGrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=18677-18680&author=R.+J.+Lefkowitz&title=G+protein-coupled+receptors.+III.+New+roles+for+receptor+kinases+and+%CE%B2-arrestins+in+receptor+signaling+and+desensitization&doi=10.1074%2Fjbc.273.30.18677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors; III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization</span></div><div class="casAuthors">Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">18677-18680</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review, with 47 refs.  Of the many forms of GPCR regulation none has received as much attention as the process of receptor desensitization, i.e., the waning responsiveness of the receptors in the face of persistent stimulation.  Numerous mechanisms have been discovered, including those that operate at the transcriptional, translational, and protein levels.  The latter category in turn includes mechanisms that regulate the rate of degrdn. of the receptors.  Finally, there are mechanisms for the covalent modification of the receptors as well as for the regulation of their assocn. with other proteins and their subcellular localization.  This brief review is concerned with this last group of mechanisms, which appears to be most important with respect to the rapid (seconds-minutes as opposed to hours or days) control of receptor function.  Traditionally, receptor desensitization has been viewed as a process antithetical to receptor activation, one which terminates or attenuates receptor signaling.  Three families of regulatory mols. have been found to participate in desensitization of heptahelical receptors: second messenger-regulated kinases (e.g., PKA and PKC), GRKs (e.g. βARK, rhodopsin kinase), and the arrestins (visual and non-visual).  After briefly reviewing the well established paradigms for regulation of GPCRs by these three families of mols., I will attempt to demonstrate how newly acquired insights into the function of these receptor regulatory mols. are reshaping understanding of the classical dichotomy between receptor activation and desensitization.  The new information suggests that receptor signaling and desensitization are in reality two intimately linked aspects of receptor function and that mechanisms previously viewed as "desensitizing" with respect to one signaling pathway may be "activating" with respect to another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5m2AvH6IBA7Vg90H21EOLACvtfcHk0lgvQG_WS4nh7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFGrsrY%253D&md5=f22667077d638c9b682b2c1fcefaf36c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.30.18677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.30.18677%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DG%2520protein-coupled%2520receptors.%2520III.%2520New%2520roles%2520for%2520receptor%2520kinases%2520and%2520%25CE%25B2-arrestins%2520in%2520receptor%2520signaling%2520and%2520desensitization%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D18677%26epage%3D18680%26doi%3D10.1074%2Fjbc.273.30.18677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrashevskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuprun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, G. W.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Gi biased β<sub>2</sub>AR signaling links GRK2 upregulation to heart failure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.111.253260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.111.253260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22179058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2012&pages=265-274&author=W.+Zhuauthor=N.+Petrashevskayaauthor=S.+Renauthor=A.+Zhaoauthor=K.+Chakirauthor=E.+Gaoauthor=J.+K.+Chuprunauthor=Y.+Wangauthor=M.+Talanauthor=G.+W.+Dornauthor=E.+G.+Lakattaauthor=W.+J.+Kochauthor=A.+M.+Feldmanauthor=R.+P.+Xiao&title=Gi+biased+%CE%B22AR+signaling+links+GRK2+upregulation+to+heart+failure&doi=10.1161%2FCIRCRESAHA.111.253260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Gi-Biased β2AR Signaling Links GRK2 Upregulation to Heart Failure</span></div><div class="casAuthors">Zhu, Weizhong; Petrashevskaya, Natalia; Ren, Shuxun; Zhao, Aizhi; Chakir, Khalid; Gao, Erhe; Chuprun, J. Kurt; Wang, Yibin; Talan, Mark; Dorn, Gerald W., II; Lakatta, Edward G.; Koch, Walter J.; Feldman, Arthur M.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-274</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Phosphorylation of β2-adrenergic receptor (β2AR) by a family of serine/threonine kinases known as G protein-coupled receptor kinase (GRK) and protein kinase A (PKA) is a crit. determinant of cardiac function.  Upregulation of G protein-coupled receptor kinase 2 (GRK2) is a well-established causal factor of heart failure, but the underlying mechanism is poorly understood.  Objective: We sought to det. the relative contribution of PKA- and GRK-mediated phosphorylation of β2AR to the receptor coupling to Gi signaling that attenuates cardiac reserve and contributes to the pathogenesis of heart failure in response to pressure overload.  Methods and results: Overexpression of GRK2 led to a Gi-dependent decrease of contractile response to βAR stimulation in cultured mouse cardiomyocytes and in vivo.  Importantly, cardiac-specific transgenic overexpression of a mutant β2AR lacking PKA phosphorylation sites (PKA-TG) but not the wild-type β2AR (WT-TG) or a mutant β2AR lacking GRK sites (GRK-TG) led to exaggerated cardiac response to pressure overload, as manifested by markedly exacerbated cardiac maladaptive remodeling and failure and early mortality.  Furthermore, inhibition of Gi signaling with pertussis toxin restores cardiac function in heart failure assocd. with increased β2AR to Gi coupling induced by removing PKA phosphorylation of the receptor and in GRK2 transgenic mice, indicating that enhanced phosphorylation of β2AR by GRK and resultant increase in Gi-biased β2AR signaling play an important role in the development of heart failure.  Conclusions: Our data show that enhanced β2AR phosphorylation by GRK, in addn. to PKA, leads the receptor to Gi-biased signaling, which, in turn, contributes to the pathogenesis of heart failure, marking Gi-biased β2AR signaling as a primary event linking upregulation of GRK to cardiac maladaptive remodeling, failure and cardiodepression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT_CPZMWFFe7Vg90H21EOLACvtfcHk0lgvQG_WS4nh7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKrtrs%253D&md5=570f8da9fdfe282caa762dc79946f5c9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.111.253260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.111.253260%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DPetrashevskaya%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DA.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DChuprun%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTalan%26aufirst%3DM.%26aulast%3DDorn%26aufirst%3DG.%2BW.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DFeldman%26aufirst%3DA.%2BM.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DGi%2520biased%2520%25CE%25B22AR%2520signaling%2520links%2520GRK2%2520upregulation%2520to%2520heart%2520failure%26jtitle%3DCirc.%2520Res.%26date%3D2012%26volume%3D110%26spage%3D265%26epage%3D274%26doi%3D10.1161%2FCIRCRESAHA.111.253260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohout, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Targeting of cyclic AMP degradation to beta2-adrenergic receptors by beta-arrestins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1126/science.1074683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.1074683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12399592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFSntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=834-836&author=S.+J.+Perryauthor=G.+S.+Baillieauthor=T.+A.+Kohoutauthor=I.+McPheeauthor=M.+M.+Magieraauthor=K.+L.+Angauthor=W.+E.+Millerauthor=A.+J.+McLeanauthor=M.+Contiauthor=M.+D.+Houslayauthor=R.+J.+Lefkowitz&title=Targeting+of+cyclic+AMP+degradation+to+beta2-adrenergic+receptors+by+beta-arrestins&doi=10.1126%2Fscience.1074683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of cAMP degrdn. to β2-adrenergic receptors by β-arrestins</span></div><div class="casAuthors">Perry, Stephen J.; Baillie, George S.; Kohout, Trudy A.; McPhee, Ian; Magiera, Maria M.; Ang, Kok Long; Miller, William E.; McLean, Alison J.; Conti, Marco; Houslay, Miles D.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5594</span>),
    <span class="NLM_cas:pages">834-836</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Catecholamines signal through the β2-adrenergic receptor by promoting prodn. of the second messenger adenosine 3',5'-monophosphate (cAMP).  The magnitude of this signal is restricted by desensitization of the receptors through their binding to β-arrestins and by cAMP degrdn. by phosphodiesterase (PDE) enzymes.  The authors show that β-arrestins coordinate both processes by recruiting PDEs to activated β2-adrenergic receptors in the plasma membrane of mammalian cells.  In doing so, the β-arrestins limit activation of membrane-assocd. cAMP-activated protein kinase by simultaneously slowing the rate of cAMP prodn. through receptor desensitization and increasing the rate of its degrdn. at the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMGfeCRMNCbVg90H21EOLACvtfcHk0lgFyjgnS6i1Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFSntb0%253D&md5=34809e1b74aafc51dc61273a0ff5d590</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1074683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1074683%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DS.%2BJ.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DKohout%26aufirst%3DT.%2BA.%26aulast%3DMcPhee%26aufirst%3DI.%26aulast%3DMagiera%26aufirst%3DM.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BL.%26aulast%3DMiller%26aufirst%3DW.%2BE.%26aulast%3DMcLean%26aufirst%3DA.%2BJ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DTargeting%2520of%2520cyclic%2520AMP%2520degradation%2520to%2520beta2-adrenergic%2520receptors%2520by%2520beta-arrestins%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D834%26epage%3D836%26doi%3D10.1126%2Fscience.1074683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span> <span> </span><span class="NLM_article-title">Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">945</span>, <span class="refDoi"> DOI: 10.1073/pnas.262787199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.262787199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12552097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtF2gsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=940-945&author=G.+S.+Baillieauthor=A.+Soodauthor=I.+McPheeauthor=I.+Gallauthor=S.+J.+Perryauthor=R.+J.+Lefkowitzauthor=M.+D.+Houslay&title=Beta-arrestin-mediated+PDE4+cAMP+phosphodiesterase+recruitment+regulates+beta-adrenoceptor+switching+from+Gs+to+Gi&doi=10.1073%2Fpnas.262787199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi</span></div><div class="casAuthors">Baillie, George S.; Sood, Arvind; McPhee, Ian; Gall, Irene; Perry, Stephen J.; Lefkowitz, Robert J.; Houslay, Miles D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">940-945</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Phosphorylation of the β2 adrenoreceptor (β2AR) by cAMP-activated protein kinase A (PKA) switches its predominant coupling from stimulatory guanine nucleotide regulatory protein (Gs) to inhibitory guanine nucleotide regulatory protein (Gi).  β-Arrestins recruit the cAMP-degrading PDE4 phosphodiesterases to the β2AR, thus controlling PKA activity at the membrane.  Here we investigate a role for PDE4 recruitment in regulating G protein switching by the β2AR.  In human embryonic kidney 293 cells overexpressing a recombinant β2AR, stimulation with isoprenaline recruits β-arrestins 1 and 2 as well as both PDE4D3 and PDE4D5 to the receptor and stimulates receptor phosphorylation by PKA.  The PKA phosphorylation status of the β2AR is enhanced markedly when cells are treated with the selective PDE4-inhibitor rolipram or when they are transfected with a catalytically inactive PDE4D mutant (PDE4D5-D556A) that competitively inhibits isoprenaline-stimulated recruitment of native PDE4 to the β2AR.  Rolipram and PDE4D5-D556A also enhance β2AR-mediated activation of extra-cellular signal-regulated kinases ERK1/2.  This is consistent with a switch in coupling of the receptor from Gs to Gi, because the ERK1/2 activation is sensitive to both inhibitors of PKA (H89) and Gi (pertussis toxin).  In cardiac myocytes, the β2AR also switches from Gs to Gi coupling.  Treating primary cardiac myocytes with isoprenaline induces recruitment of PDE4D3 and PDE4D5 to membranes and activates ERK1/2.  Rolipram robustly enhances this activation in a manner sensitive to both pertussis toxin and H89.  Adenovirus-mediated expression of PDE4D5-D556A also potentiates ERK1/2 activation.  Thus, receptor-stimulated β-arrestin-mediated recruitment of PDE4 plays a central role in the regulation of G protein switching by the β2AR in a physiol. system, the cardiac myocyte.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5wepztukiHbVg90H21EOLACvtfcHk0lgFyjgnS6i1Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtF2gsLw%253D&md5=8bf5e4d9731ea7f1ad8347ae34fb249b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.262787199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.262787199%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DMcPhee%26aufirst%3DI.%26aulast%3DGall%26aufirst%3DI.%26aulast%3DPerry%26aufirst%3DS.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26atitle%3DBeta-arrestin-mediated%2520PDE4%2520cAMP%2520phosphodiesterase%2520recruitment%2520regulates%2520beta-adrenoceptor%2520switching%2520from%2520Gs%2520to%2520Gi%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D940%26epage%3D945%26doi%3D10.1073%2Fpnas.262787199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fsj.emboj.7601968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18188154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=384-893&author=W.+Richterauthor=P.+Dayauthor=R.+Agrawalauthor=M.+D.+Brussauthor=S.+Granierauthor=Y.+L.+Wangauthor=S.+G.+Rasmussenauthor=K.+Hornerauthor=P.+Wangauthor=T.+Leiauthor=A.+J.+Pattersonauthor=B.+Kobilkaauthor=M.+Conti&title=Signaling+from+beta1-+and+beta2-adrenergic+receptors+is+defined+by+differential+interactions+with+PDE4&doi=10.1038%2Fsj.emboj.7601968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling from β1- and β2-adrenergic receptors is defined by differential interactions with PDE4</span></div><div class="casAuthors">Richter, Wito; Day, Peter; Agrawal, Rani; Bruss, Matthew D.; Granier, Sebastien; Wang, Yvonne L.; Rasmussen, Soren G. F.; Horner, Kathleen; Wang, Ping; Lei, Tao; Patterson, Andrew J.; Kobilka, Brian; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">384-393</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">β1- And β2-adrenergic receptors (βARs) are highly homologous, yet they play clearly distinct roles in cardiac physiol. and pathol.  Myocyte contraction, for instance, is readily stimulated by β1AR but not β2AR signaling, and chronic stimulation of the two receptors has opposing effects on myocyte apoptosis and cell survival.  Differences in the assembly of macromol. signaling complexes may explain the distinct biol. outcomes.  Here, we demonstrate that β1AR forms a signaling complex with a cAMP-specific phosphodiesterase (PDE) in a manner inherently different from a β2AR/β-arrestin/PDE complex reported previously.  The β1AR binds a PDE variant, PDE4D8, in a direct manner, and occupancy of the receptor by an agonist causes dissocn. of this complex.  Conversely, agonist binding to the β2AR is a prerequisite for the recruitment of a complex consisting of β-arrestin and the PDE4D variant, PDE4D5, to the receptor.  We propose that the distinct modes of interaction with PDEs result in divergent cAMP signals in the vicinity of the two receptors, thus, providing an addnl. layer of complexity to enforce the specificity of β1- and β2-adrenoceptor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxpTjxgBWAd7Vg90H21EOLACvtfcHk0lgFyjgnS6i1Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKktb4%253D&md5=c50e0f4a704c4fe10b1b59a82fc23c6d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601968%26sid%3Dliteratum%253Aachs%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DP.%26aulast%3DAgrawal%26aufirst%3DR.%26aulast%3DBruss%26aufirst%3DM.%2BD.%26aulast%3DGranier%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BL.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DHorner%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLei%26aufirst%3DT.%26aulast%3DPatterson%26aufirst%3DA.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DSignaling%2520from%2520beta1-%2520and%2520beta2-adrenergic%2520receptors%2520is%2520defined%2520by%2520differential%2520interactions%2520with%2520PDE4%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D384%26epage%3D893%26doi%3D10.1038%2Fsj.emboj.7601968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, P. H.</span></span> <span> </span><span class="NLM_article-title">Resistance of the human beta1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining beta-subtype degradation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">39773</span>– <span class="NLM_lpage">39781</span>, <span class="refDoi"> DOI: 10.1074/jbc.M304482200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M304482200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12888573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFanu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=39773-39781&author=W.+Liangauthor=S.+Austinauthor=Q.+Hoangauthor=P.+H.+Fishman&title=Resistance+of+the+human+beta1-adrenergic+receptor+to+agonist-mediated+down-regulation.+Role+of+the+C+terminus+in+determining+beta-subtype+degradation&doi=10.1074%2Fjbc.M304482200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance of the human β1-adrenergic receptor to agonist-mediated down-regulation: Role of the C terminus in determining β-subtype degradation</span></div><div class="casAuthors">Liang, Wei; Austin, Steven; Hoang, Quang; Fishman, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">39773-39781</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Prolonged agonist stimulation results in down-regulation of most G protein-coupled receptors.  When the authors exposed baby hamster kidney cells stably expressing the human β1-adrenergic receptor (β1AR) to agonist over a 24-h period, they instead obsd. an increase of ∼30% in both β1AR binding activity and immune-detected receptors.  In contrast, β2AR expressed in these cells exhibited a decrease of ≥ 50%.  The authors detd. that the basal turnover rates of the two subtypes were similar (t1/2 ∼ 7 h) and that agonist stimulation increased β2AR but not β1AR turnover.  Blocking receptor trafficking to lysosomes with bafilomycin A1 had no effect on basal turnover of either subtype but blocked agonist-stimulated β2AR turnover.  As β1AR mRNA levels increased in agonist-stimulated cells, β1AR up-regulation appeared to result from increased synthesis with no change in degrdn.  To explore the basis for the subtype differences, the authors expressed chimeras in which the C termini had been exchanged.  Each chimera responded to persistent agonist stimulation based on the source of its C-tail; β1AR with a β2AR C-tail underwent down-regulation, and β2AR with a β1AR C-tail underwent up-regulation.  The C-tails had a corresponding effect on agonist-stimulated receptor phosphorylation and internalization with the order being β2AR > β1AR with β2AR C-tail > β2AR with a β1AR C-tail > β1AR.  As internalization may be a prerequisite for down-regulation, the authors addressed this possibility by co-expressing each subtype with arrestin-2.  Although β1AR internalization was increased to that of β2AR, down-regulation still did not occur.  Instead, β1AR accumulated inside the cells.  The authors conclude that in unstimulated cells, both subtypes appear to be turned over by the same mechanism.  Upon agonist stimulation, both subtypes are internalized, and β2AR but not β1AR undergoes lysosomal degrdn., the fate of each subtype being regulated by determinants in its C-tail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsq7OWI1bLLVg90H21EOLACvtfcHk0lhR_1uCm0al4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFanu7w%253D&md5=a85ad3e790fd9d9e012c040013780208</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M304482200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M304482200%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DAustin%26aufirst%3DS.%26aulast%3DHoang%26aufirst%3DQ.%26aulast%3DFishman%26aufirst%3DP.%2BH.%26atitle%3DResistance%2520of%2520the%2520human%2520beta1-adrenergic%2520receptor%2520to%2520agonist-mediated%2520down-regulation.%2520Role%2520of%2520the%2520C%2520terminus%2520in%2520determining%2520beta-subtype%2520degradation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D39773%26epage%3D39781%26doi%3D10.1074%2Fjbc.M304482200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liggett, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">17953</span>– <span class="NLM_lpage">17961</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.30.17953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.270.30.17953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7629102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Crurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=17953-17961&author=N.+J.+Freedmanauthor=S.+B.+Liggettauthor=D.+E.+Drachmanauthor=G.+Peiauthor=M.+G.+Caronauthor=R.+J.+Lefkowitz&title=Phosphorylation+and+desensitization+of+the+human+beta+1-adrenergic+receptor.+Involvement+of+G+protein-coupled+receptor+kinases+and+cAMP-dependent+protein+kinase&doi=10.1074%2Fjbc.270.30.17953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and desensitization of the human β1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase</span></div><div class="casAuthors">Freedman, Neil J.; Liggett, Stephen B.; Drachman, Douglas E.; Pei, Gang; Caron, Marc G.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">17953-61</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Persistent stimulation of the β1-adrenergic receptor (β1AR) engenders, within minutes, diminished responsiveness of the β1AR/adenylyl cyclase signal transduction system.  This desensitization remains incompletely defined mechanistically, however.  We therefore tested the hypothesis that agonist-induced desensitization of the B1AR (like that of the related β2AR) involves phosphorylation of the receptor itself, by cAMP-dependent protein kinase (PKA) and the β-adrenergic receptor kinase (βARK1) or other G protein-coupled receptor kinases (GRKs).  Both Chinese hamster fibroblast and 293 cells demonstrate receptor-specific desensitization of the β1AR within 3-5 min.  Both cell types also express βARK1 and the assocd. inhibitory proteins β-arrestin-1 and β-arrestin-2, as assessed by immunoblotting.  Agonist-induced β1AR desensitization in 293 cells correlates with a 2-fold increase in phosphorylation of the β1AR, detd. by immunopptn. of the β1 AR from cells metabolically labeled with 32Pi.  This agonist-induced β1AR phosphorylation derives approx. equally from PKA and GRK activity, as judged by intact cell studies with kinase inhibitors or dominant neg. βARK1 (K220R) mutant overexpression.  Desensitization, likewise, is reduced by only ∼50% when PKA is inhibited in the intact cells.  Overexpression of rhodopsin kinase, βARK1, βARK2, or GRK5 significantly increases agonist-induced β1AR phosphorylation and concomitantly decreases agonist-stimulated cellular cAMP prodn.  Furthermore, purified βARK1, βARK2, and GRK5 all demonstrate agonist-dependent phosphorylation of the β1AR.  Consistent with a GRK mechanism, receptor-specific desensitization of the β1AR was enhanced by overexpression of β-arrestin-1 and -2 in transfected 293 cells.  We conclude that rapid agonist-induced desensitization of the β1AR involves phosphorylation of the receptor by both PKA and at least βARK1 in intact cells.  Like the β2AR, the β1AR appears to bind either β-arrestin-1 or β-arrestin-2 and to react with rhodopsin kinase, βARK1, βARK2, and GRK5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj1459EiottrVg90H21EOLACvtfcHk0lhR_1uCm0al4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Crurg%253D&md5=8f390b45b77d1e1fb8ce817a53e38da1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.30.17953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.30.17953%26sid%3Dliteratum%253Aachs%26aulast%3DFreedman%26aufirst%3DN.%2BJ.%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26aulast%3DDrachman%26aufirst%3DD.%2BE.%26aulast%3DPei%26aufirst%3DG.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DPhosphorylation%2520and%2520desensitization%2520of%2520the%2520human%2520beta%25201-adrenergic%2520receptor.%2520Involvement%2520of%2520G%2520protein-coupled%2520receptor%2520kinases%2520and%2520cAMP-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D17953%26epage%3D17961%26doi%3D10.1074%2Fjbc.270.30.17953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rapacciuolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvarna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barki-Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">35403</span>– <span class="NLM_lpage">35411</span>, <span class="refDoi"> DOI: 10.1074/jbc.M305675200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M305675200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12821660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntVWqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=35403-35411&author=A.+Rapacciuoloauthor=S.+Suvarnaauthor=L.+Barki-Harringtonauthor=L.+M.+Luttrellauthor=M.+Congauthor=R.+J.+Lefkowitzauthor=H.+A.+Rockman&title=Protein+kinase+A+and+G+protein-coupled+receptor+kinase+phosphorylation+mediates+beta-1+adrenergic+receptor+endocytosis+through+different+pathways&doi=10.1074%2Fjbc.M305675200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates β-1 adrenergic receptor endocytosis through different pathways</span></div><div class="casAuthors">Rapacciuolo, Antonio; Suvarna, Shayela; Barki-Harrington, Liza; Luttrell, Louis M.; Cong, Mei; Lefkowitz, Robert J.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">35403-35411</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Agonist-induced phosphorylation of β-adrenergic receptors (βARs) by G protein-coupled receptor kinases (GRKs) results in their desensitization followed by internalization.  Whether protein kinase A (PKA)-mediated phosphorylation of βARs, particularly the β1AR subtype, can also trigger internalization is currently not known.  To test this, the authors cloned the mouse wild type β1AR (WTβ1AR) and created 3 mutants lacking, resp.: the putative PKA phosphorylation sites (PKA-β1AR), the putative GRK phosphorylation sites (GRK-β1AR), and both sets of phosphorylation sites (PKA-/GRK-β1AR).  Following agonist stimulation, both PKA-β1AR and GRK-β1AR mutants showed comparable increases in phosphorylation and desensitization.  Satg. concns. of agonist induced only 50% internalization of either mutant compared with wild type, suggesting that both PKA and GRK phosphorylation of the receptor contributed to receptor sequestration in an additive manner.  Moreover, in contrast to the WTβ1AR and PKA-β1AR, sequestration of the GRK-β1AR and PKA-/GRK-β1AR was independent of β-arrestin recruitment.  Importantly, clathrin inhibitors abolished agonist-dependent internalization for both the WTβ1AR and PKA-β1AR, whereas caveolae inhibitors prevented internalization only of the GRK-β1AR mutant.  Taken together, these data demonstrate that: PKA-mediated phosphorylation can trigger agonist-induced internalization of the β1AR and the pathway selected for β1AR internalization is primarily detd. by the kinase that phosphorylates the receptor, i.e.  PKA-mediated phosphorylation directs internalization via a caveolae pathway, whereas GRK-mediated phosphorylation directs it through clathrin-coated pits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRTtzcaLnd-bVg90H21EOLACvtfcHk0lhR_1uCm0al4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntVWqu7g%253D&md5=a1fb1e26c97da8e4358cd22cc6141c74</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M305675200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M305675200%26sid%3Dliteratum%253Aachs%26aulast%3DRapacciuolo%26aufirst%3DA.%26aulast%3DSuvarna%26aufirst%3DS.%26aulast%3DBarki-Harrington%26aufirst%3DL.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3DProtein%2520kinase%2520A%2520and%2520G%2520protein-coupled%2520receptor%2520kinase%2520phosphorylation%2520mediates%2520beta-1%2520adrenergic%2520receptor%2520endocytosis%2520through%2520different%2520pathways%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D35403%26epage%3D35411%26doi%3D10.1074%2Fjbc.M305675200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minobe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, R.</span></span> <span> </span><span class="NLM_article-title">β<sub>1</sub>- and β<sub>2</sub>-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=2564629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL1MXhslWisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1989&pages=295-303&author=M.+R.+Bristowauthor=R.+E.+Hershbergerauthor=J.+D.+Portauthor=W.+Minobeauthor=R.+Rasmussen&title=%CE%B21-+and+%CE%B22-adrenergic+receptor-mediated+adenylate+cyclase+stimulation+in+nonfailing+and+failing+human+ventricular+myocardium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">β1- and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium</span></div><div class="casAuthors">Bristow, Michael R.; Hershberger, Ray E.; Port, J. David; Minobe, Wayne; Rasmussen, Randy</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">295-303</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">In nonfailing human ventricular myocardium, β2-adrenergic receptors are coupled markedly more efficiently to adenylate cyclase than are β1-receptors.  Heart failure produces a loss in the amt. of adenylate cyclase stimulation than can be mediated by each subtype.  For β1-receptors, this is due to down-regulation and, for β2-receptors, the loss in activity is due to partial uncoupling.  In the human heart β1- and β2-receptors exhibit at least two fundamental differences; the β1-receptor selectively down-regulates in heart failure, whereas the β2-receptor is markedly more efficiently coupled to adenylate cyclase in nonfailing heart and then uncouples in response to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkC43CFuXZP7Vg90H21EOLACvtfcHk0ljb6eGRXrp08Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhslWisLw%253D&md5=13cc2cd664abbc24ce5e4a1aafd7ff5e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DM.%2BR.%26aulast%3DHershberger%26aufirst%3DR.%2BE.%26aulast%3DPort%26aufirst%3DJ.%2BD.%26aulast%3DMinobe%26aufirst%3DW.%26aulast%3DRasmussen%26aufirst%3DR.%26atitle%3D%25CE%25B21-%2520and%2520%25CE%25B22-adrenergic%2520receptor-mediated%2520adenylate%2520cyclase%2520stimulation%2520in%2520nonfailing%2520and%2520failing%2520human%2520ventricular%2520myocardium%26jtitle%3DMol.%2520Pharmacol.%26date%3D1989%26volume%3D35%26spage%3D295%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cates, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veazey, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baughman, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dop, C.</span></span> <span> </span><span class="NLM_article-title">Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1172/JCI113569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI113569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=2839545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL1cXkvFSlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1988&pages=189-197&author=A.+M.+Feldmanauthor=A.+E.+Catesauthor=W.+B.+Veazeyauthor=R.+E.+Hershbergerauthor=M.+R.+Bristowauthor=K.+L.+Baughmanauthor=W.+A.+Baumgartnerauthor=C.+Van+Dop&title=Increase+of+the+40%2C000-mol+wt+pertussis+toxin+substrate+%28G+protein%29+in+the+failing+human+heart&doi=10.1172%2FJCI113569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart</span></div><div class="casAuthors">Feldman, Arthur M.; Cates, Andree E.; Veazey, William B.; Hershberger, Ray; Bristow, Michael R.; Baughman, Kenneth L.; Baumgartner, William A.; Van Dop, Cornelis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-97</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">The activity of G proteins in failing human myocardium was measured.  The activity of a 40,000-mol wt pertussis toxin substrate (αG40) was increased by 36% in failing human hearts when compared with nonfailing controls.  There was no change in the level of the stimulatory regulatory subunit (Gs).  The increased activity in αG40 was assocd. with a 30% decrease in basal as well as 5'-guanylyl imidodiphosphate-stimulated adenylate cyclase activity.  The data suggest that increased αG40 activity is a new marker for failing myocardium and may account at least in part for the diminished responsiveness to β1-adrenergic agonists in the failing human heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocqubbOBjAebVg90H21EOLACvtfcHk0ljb6eGRXrp08Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXkvFSlsLs%253D&md5=eecfdd5f4654425dd033201f5d7ed8c7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1172%2FJCI113569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI113569%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DA.%2BM.%26aulast%3DCates%26aufirst%3DA.%2BE.%26aulast%3DVeazey%26aufirst%3DW.%2BB.%26aulast%3DHershberger%26aufirst%3DR.%2BE.%26aulast%3DBristow%26aufirst%3DM.%2BR.%26aulast%3DBaughman%26aufirst%3DK.%2BL.%26aulast%3DBaumgartner%26aufirst%3DW.%2BA.%26aulast%3DVan%2BDop%26aufirst%3DC.%26atitle%3DIncrease%2520of%2520the%252040%252C000-mol%2520wt%2520pertussis%2520toxin%2520substrate%2520%2528G%2520protein%2529%2520in%2520the%2520failing%2520human%2520heart%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1988%26volume%3D82%26spage%3D189%26epage%3D197%26doi%3D10.1172%2FJCI113569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ungerer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elce, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span> <span> </span><span class="NLM_article-title">Altered expression of β-adrenergic receptor kinase and β<sub>1</sub>-adrenergic receptors in the failing human heart</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.87.2.454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.87.2.454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8381058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK3s7ksFCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1993&pages=454-463&author=M.+Ungererauthor=M.+Bohmauthor=J.+S.+Elceauthor=E.+Erdmannauthor=M.+J.+Lohse&title=Altered+expression+of+%CE%B2-adrenergic+receptor+kinase+and+%CE%B21-adrenergic+receptors+in+the+failing+human+heart&doi=10.1161%2F01.CIR.87.2.454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart</span></div><div class="casAuthors">Ungerer M; Bohm M; Elce J S; Erdmann E; Lohse M J</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-63</span>
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    </div><div class="casAbstract">BACKGROUND:  In chronic heart failure, the positive inotropic effects of beta-adrenergic receptor agonists are greatly reduced, in part as a result of two alterations of the cardiac beta-adrenergic receptors: loss of their function (receptor uncoupling) and reduction of their number (downregulation).  In vitro studies have shown that a major mechanism leading to beta-adrenergic receptor uncoupling involves phosphorylation of the receptors by the specific beta-adrenergic receptor kinase (beta ARK).  METHODS AND RESULTS:  We have therefore investigated expression of beta ARK and beta-adrenergic receptors in samples from the left ventricles of patients with dilated cardiomyopathy or ischemic cardiomyopathy and from nonfailing control ventricles.  Contractile responses to beta-receptor stimulation were decreased in the failing hearts compared with control hearts, whereas those to forskolin and calcium remained unchanged.  The messenger RNA (mRNA) levels of beta ARK, beta 1- and beta 2-receptors, and of glyceraldehyde phosphate dehydrogenase and beta-actin as controls were measured by quantitative polymerase chain reactions.  In addition, beta ARK enzyme activity assays were performed, and the levels of beta 1- and beta 2-receptors were determined by radioligand binding. beta ARK mRNA levels were increased almost threefold in both forms of heart failure, and beta ARK activity was enhanced. beta 1-Receptor mRNA levels and beta 1-receptor numbers were decreased by approximately 50% in both failing groups, whereas these levels were unaltered for beta 2-receptors.  There were no differences between dilated and ischemic cardiomyopathy for any of these parameters.  CONCLUSIONS:  In addition to other alterations found in failing hearts, the diminished response to beta-receptor agonists appears to involve the combined effects of enhanced expression of beta ARK and reduced expression of beta 1-receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi9-nzhE6nCOdfST00W0BcfW6udTcc2eaQ8R-tUZRjw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7ksFCmug%253D%253D&md5=7e9bc7e5bc550d8cdf25096888552fb2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.87.2.454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.87.2.454%26sid%3Dliteratum%253Aachs%26aulast%3DUngerer%26aufirst%3DM.%26aulast%3DBohm%26aufirst%3DM.%26aulast%3DElce%26aufirst%3DJ.%2BS.%26aulast%3DErdmann%26aufirst%3DE.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26atitle%3DAltered%2520expression%2520of%2520%25CE%25B2-adrenergic%2520receptor%2520kinase%2520and%2520%25CE%25B21-adrenergic%2520receptors%2520in%2520the%2520failing%2520human%2520heart%26jtitle%3DCirculation%26date%3D1993%26volume%3D87%26spage%3D454%26epage%3D463%26doi%3D10.1161%2F01.CIR.87.2.454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span> <span> </span><span class="NLM_article-title">The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1992.tb14302.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.1992.tb14302.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1324064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK38XktVGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1992&pages=115-122&author=L.+A.+Brownauthor=S.+E.+Harding&title=The+effect+of+pertussis+toxin+on+%CE%B2-adrenoceptor+responses+in+isolated+cardiac+myocytes+from+noradrenaline-treated+guinea-pigs+and+patients+with+cardiac+failure&doi=10.1111%2Fj.1476-5381.1992.tb14302.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea pigs and patients with cardiac failure</span></div><div class="casAuthors">Brown, L. A.; Harding, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-22</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">A decreased responsiveness to the pos. inotropic effects of β-adrenoceptor agonists is a characteristic of human heart failure.  This study investigated the involvement of inhibitory guanine nucleotide- binding proteins (G-proteins) in this process using pertussis toxin treatment of isolated cardiac myocytes.  Myocytes isolated from failing human myocardium had a reduced max. contractile response to isoprenaline relative to that for maximally stimulating concns. of calcium, giving an isoprenaline/calcium ratio of 0.71.  This was lower than in myocytes from nonfailing myocardium, where the isoprenaline/calcium ratio was 1.16.  Responses to high calcium were unchanged.  Myocytes were treated with pertussis toxin for 3-5 h at 35°.  Successful inactivation of inhibitory G-proteins by pertussis toxin treatment was indicated by a loss of responsiveness to 10 μM adenosine (in the presence of submaximal isoprenaline).  Following pertussis toxin treatment of the myocytes from failing human heart the isoprenaline/calcium ratio increased to 1.43.  Pertussis toxin treatment had no effect upon the max. calcium contraction.  The isoprenaline/calcium ration in myocytes from non-failing human ventricle was not affected by the toxin treatment.  Apparently, increased inhibitory G-protein levels or activities contribute to β-adrenoceptor desensitization in human heart failure.  β-Adrenoceptor desensitization in human heart failure is thought to be secondary to raised noradrenaline levels in these patients.  Expts. were repeated on myocytes isolated from hearts of guinea-pigs which had been chronically infused with noradrenaline.  The isoprenaline/calcium ratio of these myocytes was reduced below that of myocytes from sham-operated animals (0.65 compared with 0.88).  Pertussis toxin treatment (2 h at 35°) increased the isoprenaline/calcium ratio to 1.02 in myocytes from noradrenaline-treated guinea-pigs.  This effect of pertussis toxin treatment was not seen in myocytes from sham-operated guinea pig hearts.  Incubation at 35° for similar periods in the absence of pertussis toxin also restored the isoprenaline/calcium ratio towards normal in the myocytes from both failing human and noradrenaline-treated guinea-pig hearts, although the effect was smaller than that produced by the toxin.  Myocytes kept at room temp. (22°) showed no such evidence of resensitization over periods up to 6 h.  Apparently, raised catecholamine levels result in increased inhibitory G-protein levels and functional β-adrenoceptor desensitization in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUR6C2OOHMy7Vg90H21EOLACvtfcHk0liB-k8IkCL-dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVGgsL0%253D&md5=ae3dc9b55d58fbbe7d4140152f3e8676</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1992.tb14302.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1992.tb14302.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DL.%2BA.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26atitle%3DThe%2520effect%2520of%2520pertussis%2520toxin%2520on%2520%25CE%25B2-adrenoceptor%2520responses%2520in%2520isolated%2520cardiac%2520myocytes%2520from%2520noradrenaline-treated%2520guinea-pigs%2520and%2520patients%2520with%2520cardiac%2520failure%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1992%26volume%3D106%26spage%3D115%26epage%3D122%26doi%3D10.1111%2Fj.1476-5381.1992.tb14302.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iaccarino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span> <span> </span><span class="NLM_article-title">Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">7000</span>– <span class="NLM_lpage">7005</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.12.7000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.95.12.7000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9618528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1cXjslyms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=7000-7005&author=H.+A.+Rockmanauthor=K.+R.+Chienauthor=D.+J.+Choiauthor=G.+Iaccarinoauthor=J.+J.+Hunterauthor=J.+Rossauthor=R.+J.+Lefkowitzauthor=W.+J.+Koch&title=Expression+of+a+beta-adrenergic+receptor+kinase+1+inhibitor+prevents+the+development+of+myocardial+failure+in+gene-targeted+mice&doi=10.1073%2Fpnas.95.12.7000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice</span></div><div class="casAuthors">Rockman, Howard A.; Chien, Kenneth R.; Choi, Dong-Ju; Iaccarino, Guido; Hunter, John J.; Ross, John, Jr.; Lefkowitz, Robert J.; Koch, Walter J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7000-7005</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Heart failure is accompanied by severely impaired β-adrenergic receptor (βAR) function, which includes loss of βAR d. and functional uncoupling of remaining receptors.  An important mechanism for the rapid desensitization of βAR function is agonist-stimulated receptor phosphorylation by the βAR kinase (βARK1), an enzyme known to be elevated in failing human heart tissue.  To investigate whether alterations in βAR function contribute to the development of myocardial failure, transgenic mice with cardiac-restricted overexpression of either a peptide inhibitor of βARK1 or the β2AR were mated into a genetic model of murine heart failure (MLP-/-).  In vivo cardiac function was assessed by echocardiog. and cardiac catheterization.  Both MLP-/- and MLP-/-/β2AR mice had enlarged left ventricular (LV) chambers with significantly reduced fractional shortening and mean velocity of circumferential fiber shortening.  In contrast, MLP-/-/βARKct mice had normal LV chamber size and function.  Basal LV contractility in the MLP-/-/βARKct mice, as measured by LV dP/dtmax, was increased significantly compared with the MLP-/- mice but less than controls.  Importantly, heightened βAR desensitization in the MLP-/- mice, measured in vivo (responsiveness to isoproterenol) and in vitro (isoproterenol-stimulated membrane adenylyl cyclase activity), was completely reversed with overexpression of the βARK1 inhibitor.  The authors report here the striking finding that overexpression of this inhibitor prevents the development of cardiomyopathy in this murine model of heart failure.  These findings implicate abnormal βAR-G protein coupling in the pathogenesis of the failing heart and point the way toward development of agents to inhibit βARK1 as a novel mode of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb_NLvvRJwjbVg90H21EOLACvtfcHk0liB-k8IkCL-dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjslyms7Y%253D&md5=a456743770d269ba225b206c7657fb6a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.12.7000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.12.7000%26sid%3Dliteratum%253Aachs%26aulast%3DRockman%26aufirst%3DH.%2BA.%26aulast%3DChien%26aufirst%3DK.%2BR.%26aulast%3DChoi%26aufirst%3DD.%2BJ.%26aulast%3DIaccarino%26aufirst%3DG.%26aulast%3DHunter%26aufirst%3DJ.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26atitle%3DExpression%2520of%2520a%2520beta-adrenergic%2520receptor%2520kinase%25201%2520inhibitor%2520prevents%2520the%2520development%2520of%2520myocardial%2520failure%2520in%2520gene-targeted%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D7000%26epage%3D7005%26doi%3D10.1073%2Fpnas.95.12.7000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kompa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R. J.</span></span> <span> </span><span class="NLM_article-title">Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1006/jmcc.1999.0951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1006%2Fjmcc.1999.0951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10371694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXjslOqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=1185-1201&author=A.+R.+Kompaauthor=X.+H.+Guauthor=B.+A.+Evansauthor=R.+J.+Summers&title=Desensitization+of+cardiac+beta-adrenoceptor+signaling+with+heart+failure+produced+by+myocardial+infarction+in+the+rat.+Evidence+for+the+role+of+Gi+but+not+Gs+or+phosphorylating+proteins&doi=10.1006%2Fjmcc.1999.0951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Desensitization of cardiac β-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins</span></div><div class="casAuthors">Kompa, Andrew R.; Gu, Xin-hua; Evans, Bronwyn A.; Summers, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1185-1201</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">This study examd. mechanisms of β-adrenergic (AR) desensitization in a myocardial infarction (MI) model of heart failure in the rat.  Inotropic responses to isoproterenol (non-selective β-AR agonist) and RO 363 (selective β1-AR agonist), in left atria and left papillary muscle, were reduced by up to 65%, while chronotropic responses in right atria were unaffected.  β1- And β2-AR d. did not change after MI, suggesting that changes in β-AR responsiveness are due to changes occurring downstream of the receptor.  Inotropic and chronotropic responses to forskolin were not altered in right and left atria and left papillary muscle after MI, suggesting changes at the level of the G-proteins.  Pertussis toxin treatment of animals restored inotropic responses to isoproterenol in left atria and left papillary muscle to levels seen in the sham group, indicating that inactivation of Gi-proteins improves inotropic function in MI rats, and that β-ARs couple to Gi in cardiac failure.  Expression of G-protein receptor kinase 2 (GRK2), β-arrestin1 and the regulatory subunits of cAMPdPK (RI α and RII α), showed no change after MI.  However the expression of Gi α2was significantly increased in left ventricle (sham 0.888±0.140, MI 1.759±0.352 P=0.026), right ventricle (sham 0.031±0.004, MI 0.037±0.002 P=0.006) and atria (sham 0.107±0.006, MI 0.138±0.006 P=0.004), with no changes obsd. in the expression of Gs α .  These results suggest that increases in Gi play an important role in the decreased β-AR responsiveness in the rat model of MI.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgQ-z4ZIZTrVg90H21EOLACvtfcHk0liB-k8IkCL-dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslOqtbg%253D&md5=3bdf4c9c7e8e50c16c1bda441148c139</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1006%2Fjmcc.1999.0951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmcc.1999.0951%26sid%3Dliteratum%253Aachs%26aulast%3DKompa%26aufirst%3DA.%2BR.%26aulast%3DGu%26aufirst%3DX.%2BH.%26aulast%3DEvans%26aufirst%3DB.%2BA.%26aulast%3DSummers%26aufirst%3DR.%2BJ.%26atitle%3DDesensitization%2520of%2520cardiac%2520beta-adrenoceptor%2520signaling%2520with%2520heart%2520failure%2520produced%2520by%2520myocardial%2520infarction%2520in%2520the%2520rat.%2520Evidence%2520for%2520the%2520role%2520of%2520Gi%2520but%2520not%2520Gs%2520or%2520phosphorylating%2520proteins%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D1999%26volume%3D31%26spage%3D1185%26epage%3D1201%26doi%3D10.1006%2Fjmcc.1999.0951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balijepalli, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haworth, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamp, T. J.</span></span> <span> </span><span class="NLM_article-title">Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of L-type Ca<sup>2+</sup> channels in canine heart failure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000181160.31851.05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000181160.31851.05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16100050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFGrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=566-573&author=J.+Q.+Heauthor=R.+C.+Balijepalliauthor=R.+A.+Haworthauthor=T.+J.+Kamp&title=Crosstalk+of+beta-adrenergic+receptor+subtypes+through+Gi+blunts+beta-adrenergic+stimulation+of+L-type+Ca2%2B+channels+in+canine+heart+failure&doi=10.1161%2F01.RES.0000181160.31851.05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalk of β-Adrenergic receptor subtypes through Gi blunts β-Adrenergic stimulation of L-Type Ca2+ Channels in canine heart failure</span></div><div class="casAuthors">He, Jia-Qiang; Balijepalli, Ravi C.; Haworth, Robert A.; Kamp, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">566-573</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The mechanisms underlying the blunted contractile response to β-adrenergic receptor (β-AR) stimulation in heart failure (HF) are incompletely understood, esp. with regard to β-AR subtype-specific regulation of L-type Ca2+ channels.  We evaluated the impact of HF induced by pacing tachycardia on β-AR regulation of L-type Ca2+ channels in a canine model.  To evaluate changes in the relative subcellular distribution of β-AR subtypes, left ventricular membranes enriched in surface sarcolemma and T-tubular sarcolemma were prepd.  Radioligand binding using [125I]cyanopindolol revealed that HF resulted in a comparable decrease in the d. of β1-ARs in both surface and T-tubule sarcolemma (55±4%, n=7, P<0.001; and 45±10%, n=7, P<0.01, resp.), but no significant change in β2-AR d. was obsd.  Whole-cell patch clamp studies demonstrated a markedly blunted increase in ICa,L in response to satg. concns. of the nonselective β-AR agonist isoproterenol (0.1 μmol/L) in failing myocytes compared with control (129±20%, n=11, vs. 332±35%, n=7; P<0.001).  Expts. testing β1-AR- and β2-AR-selective stimulation showed that the major component of the blunted response to nonselective β-AR stimulation in HF was caused by β2-AR activation, resulting in a pertussis toxin-sensitive, Gi-mediated inhibition of the β1-AR-induced increase in ICa,L.  In conclusion, canine HF results in the following: (1) a uniform redn. in β1-AR d. in surface and T-tubule membrane fractions without a change in β2-AR d.; and (2) the emergence of distinct Gi-coupling to β2-ARs resulting in accentuated antagonism of β1-AR-mediated stimulation of ICa,L.  These results have implications for optimizing the use of β-AR drugs in HF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI1j-jzJnjeLVg90H21EOLACvtfcHk0lgwIzys9_Z8Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFGrt7Y%253D&md5=ee0ff7fc69346f0fd5bc3fd74bf7a8f0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000181160.31851.05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000181160.31851.05%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%2BQ.%26aulast%3DBalijepalli%26aufirst%3DR.%2BC.%26aulast%3DHaworth%26aufirst%3DR.%2BA.%26aulast%3DKamp%26aufirst%3DT.%2BJ.%26atitle%3DCrosstalk%2520of%2520beta-adrenergic%2520receptor%2520subtypes%2520through%2520Gi%2520blunts%2520beta-adrenergic%2520stimulation%2520of%2520L-type%2520Ca2%252B%2520channels%2520in%2520canine%2520heart%2520failure%26jtitle%3DCirc.%2520Res.%26date%3D2005%26volume%3D97%26spage%3D566%26epage%3D573%26doi%3D10.1161%2F01.RES.0000181160.31851.05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Völkers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidenhammer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Wegner, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippe, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinks, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katus, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhart, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Most, P.</span></span> <span> </span><span class="NLM_article-title">The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.110.225201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.110.225201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21106943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FpsVKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=27-39&author=M.+V%C3%B6lkersauthor=C.+Weidenhammerauthor=N.+Herzogauthor=G.+Qiuauthor=K.+Spaichauthor=F.+V.+von+Wegnerauthor=K.+Peppelauthor=O.+J.+M%C3%BCllerauthor=S.+Schinkelauthor=J.+E.+Rabinowitzauthor=H.+J.+Hippeauthor=H.+Brinksauthor=H.+A.+Katusauthor=W.+J.+Kochauthor=A.+D.+Eckhartauthor=O.+Friedrichauthor=P.+Most&title=The+inotropic+peptide+%CE%B2ARKct+improves+%CE%B2AR+responsiveness+in+normal+and+failing+cardiomyocytes+through+G%28%CE%B2%CE%B3%29-mediated+L-type+calcium+current+disinhibition&doi=10.1161%2FCIRCRESAHA.110.225201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition</span></div><div class="casAuthors">Volkers Mirko; Weidenhammer Christian; Herzog Nicole; Qiu Gang; Spaich Kristin; Wegner Frederic V; Peppel Karsten; Muller Oliver J; Schinkel Stefanie; Rabinowitz Joseph E; Hippe Hans-Jorg; Brinks Henriette; Katus Hugo A; Koch Walter J; Eckhart Andrea D; Friedrich Oliver; Most Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Circulation research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  The G(βγ)-sequestering peptide β-adrenergic receptor kinase (βARK)ct derived from the G-protein-coupled receptor kinase (GRK)2 carboxyl terminus has emerged as a promising target for gene-based heart failure therapy.  Enhanced downstream cAMP signaling has been proposed as the underlying mechanism for increased β-adrenergic receptor (βAR) responsiveness.  However, molecular targets mediating improved cardiac contractile performance by βARKct and its impact on G(βγ)-mediated signaling have yet to be fully elucidated.  OBJECTIVE:  We sought to identify G(βγ)-regulated targets and signaling mechanisms conveying βARKct-mediated enhanced βAR responsiveness in normal (NC) and failing (FC) adult rat ventricular cardiomyocytes.  METHODS AND RESULTS:  Assessing viral-based βARKct gene delivery with electrophysiological techniques, analysis of contractile performance, subcellular Ca2(+) handling, and site-specific protein phosphorylation, we demonstrate that βARKct enhances the cardiac L-type Ca2(+) channel (LCC) current (I(Ca)) both in NCs and FCs on βAR stimulation.  Mechanistically, βARKct augments I(Ca) by preventing enhanced inhibitory interaction between the α1-LCC subunit (Cav1.2α) and liberated G(βγ) subunits downstream of activated βARs.  Despite improved βAR contractile responsiveness, βARKct neither increased nor restored cAMP-dependent protein kinase (PKA) and calmodulin-dependent kinase II signaling including unchanged protein kinase (PK)Cε, extracellular signal-regulated kinase (ERK)1/2, Akt, ERK5, and p38 activation both in NCs and FCs.  Accordingly, although βARKct significantly increases I(Ca) and Ca2(+) transients, being susceptible to suppression by recombinant G(βγ) protein and use-dependent LCC blocker, βARKct-expressing cardiomyocytes exhibit equal basal and βAR-stimulated sarcoplasmic reticulum Ca2(+) load, spontaneous diastolic Ca2(+) leakage, and survival rates and were less susceptible to field-stimulated Ca2(+) waves compared with controls.  CONCLUSION:  Our study identifies a G(βγ)-dependent signaling pathway attenuating cardiomyocyte I(Ca) on βAR as molecular target for the G(βγ)-sequestering peptide βARKct.  Targeted interruption of this inhibitory signaling pathway by βARKct confers improved βAR contractile responsiveness through increased I(Ca) without enhancing regular or restoring abnormal cAMP-signaling. βARKct-mediated improvement of I(Ca) rendered cardiomyocytes neither susceptible to βAR-induced damage nor arrhythmogenic sarcoplasmic reticulum Ca2(+) leakage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTejQxlDjErVXp3bfzSLaX5fW6udTcc2eYsWydVQYTtcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FpsVKjtQ%253D%253D&md5=116e2bc2e65138047f85f8ebeecad481</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.110.225201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.110.225201%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25B6lkers%26aufirst%3DM.%26aulast%3DWeidenhammer%26aufirst%3DC.%26aulast%3DHerzog%26aufirst%3DN.%26aulast%3DQiu%26aufirst%3DG.%26aulast%3DSpaich%26aufirst%3DK.%26aulast%3Dvon%2BWegner%26aufirst%3DF.%2BV.%26aulast%3DPeppel%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DO.%2BJ.%26aulast%3DSchinkel%26aufirst%3DS.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BE.%26aulast%3DHippe%26aufirst%3DH.%2BJ.%26aulast%3DBrinks%26aufirst%3DH.%26aulast%3DKatus%26aufirst%3DH.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DEckhart%26aufirst%3DA.%2BD.%26aulast%3DFriedrich%26aufirst%3DO.%26aulast%3DMost%26aufirst%3DP.%26atitle%3DThe%2520inotropic%2520peptide%2520%25CE%25B2ARKct%2520improves%2520%25CE%25B2AR%2520responsiveness%2520in%2520normal%2520and%2520failing%2520cardiomyocytes%2520through%2520G%2528%25CE%25B2%25CE%25B3%2529-mediated%2520L-type%2520calcium%2520current%2520disinhibition%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D108%26spage%3D27%26epage%3D39%26doi%3D10.1161%2FCIRCRESAHA.110.225201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span> <span> </span><span class="NLM_article-title">Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2003.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2003.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=14734046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=43-48&author=M.+Satoauthor=H.+Gongauthor=C.+M.+Terraccianoauthor=H.+Ranuauthor=S.+E.+Harding&title=Loss+of+beta-adrenoceptor+response+in+myocytes+overexpressing+the+Na%2B%2FCa%282%2B%29-exchanger&doi=10.1016%2Fj.yjmcc.2003.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of β-adrenoceptor response in myocytes overexpressing the Na+/Ca2+-exchanger</span></div><div class="casAuthors">Sato, Motoki; Gong, Haibin; Terracciano, Cesare M. N.; Ranu, Hardeep; Harding, Sian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-48</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Increased Na+/Ca2+-exchanger (NCX) and altered β-adrenoceptor (βAR) responses are obsd. in failing human heart.  To det. the possible interaction between these changes, we investigated the effect of NCX overexpression on responses to isoproterenol in adult rat ventricular myocytes.  Responses to isoproterenol were largely mediated through the β1AR in control myocytes.  Adenovirally-mediated overexpression of NCX, at levels, which did not alter basal contraction of myocytes, markedly depressed the isoproterenol concn.-response curve.  Responses to isoproterenol could be restored to normal by β2AR blockade, suggesting a β2AR-mediated inhibition of β1AR signaling.  Pertussis toxin normalized isoproterenol responses in NCX cells, indicating that β2AR effects were mediated by Gi.  Neg.-inotropic effects of high concns. of ICI 118,551, previously shown to be due to β2AR-Gi coupling, were increased in NCX cells.  We conclude that NCX upregulation can markedly alter the consequences of βAR stimulation and that this may contribute to the alterations in βAR response seen in failing human heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvGVuKScOYbVg90H21EOLACvtfcHk0lgwIzys9_Z8Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFOltg%253D%253D&md5=b6451d82195f583045539eec594abdd8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2003.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2003.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DTerracciano%26aufirst%3DC.%2BM.%26aulast%3DRanu%26aufirst%3DH.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26atitle%3DLoss%2520of%2520beta-adrenoceptor%2520response%2520in%2520myocytes%2520overexpressing%2520the%2520Na%252B%252FCa%25282%252B%2529-exchanger%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2004%26volume%3D36%26spage%3D43%26epage%3D48%26doi%3D10.1016%2Fj.yjmcc.2003.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schobesberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhargava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monszpart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, J.</span></span> <span> </span><span class="NLM_article-title">T-tubule remodelling disturbs localized β<sub>2</sub>-adrenergic signalling in rat ventricular myocytes during the progression of heart failure</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">782</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvx074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvx074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28505272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2nurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2017&pages=770-782&author=S.+Schobesbergerauthor=P.+Wrightauthor=S.+Tokarauthor=A.+Bhargavaauthor=C.+Mansfieldauthor=A.+V.+Glukhovauthor=C.+Pouletauthor=A.+Buzukauthor=A.+Monszpartauthor=M.+Sikkelauthor=S.+E.+Hardingauthor=V.+O.+Nikolaevauthor=A.+R.+Lyonauthor=J.+Gorelik&title=T-tubule+remodelling+disturbs+localized+%CE%B22-adrenergic+signalling+in+rat+ventricular+myocytes+during+the+progression+of+heart+failure&doi=10.1093%2Fcvr%2Fcvx074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">T-tubule remodelling disturbs localized β2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure</span></div><div class="casAuthors">Schobesberger, Sophie; Wright, Peter; Tokar, Sergiy; Bhargava, Anamika; Mansfield, Catherine; Glukhov, Alexey V.; Poulet, Claire; Buzuk, Andrey; Monszpart, Aron; Sikkel, Markus; Harding, Sian E.; Nikolaev, Viacheslav O.; Lyon, Alexander R.; Gorelik, Julia</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">770-782</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">1755-3245</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cardiomyocyte β2-adrenergic receptor (β2AR) cyclic adenosine monophosphate (cAMP) signalling is regulated by the receptors' subcellular location within transverse tubules (T-tubules), via interaction with structural and regulatory proteins, which form a signalosome.  In chronic heart failure (HF), β2ARs redistribute from T-tubules to the cell surface, which disrupts functional signalosomes and leads to diffuse cAMP signalling.  However, the functional consequences of structural changes upon β2AR-cAMP signalling during progression from hypertrophy to advanced HF are unknown.  Rat left ventricular myocytes were isolated at 4-, 8-, and 16-wk post-myocardial infarction (MI), β2ARs were stimulated either via whole-cell perfusion or locally through the nanopipette of the scanning ion conductance microscope.  CAMP release was measured via a Forster Resonance Energy Transfer-based sensor Epac2-camps.  Confocal imaging of di-8-ANNEPS-stained cells and immunoblotting were used to det. structural alterations.  At 4-wk post-MI, T-tubule regularity, d. and junctophilin-2 (JPH2) expression were significantly decreased.  The amplitude of local β2AR-mediated cAMP in T-tubules was reduced and cAMP diffused throughout the cytosol instead of being locally confined.  This was accompanied by partial caveolin-3 (Cav-3) dissocn. from the membrane.  At 8-wk post-MI, the β2AR-mediated cAMP response was obsd. at the T-tubules and the sarcolemma (crest).  Finally, at 16-wk post-MI, the whole cell β2AR-mediated cAMP signal was depressed due to adenylate cyclase dysfunction, while overall Cav-3 levels were significantly increased and a substantial portion of Cav-3 dissocd. into the cytosol.  Overexpression of JPH2 in failing cells in vitro or AAV9.SERCA2a gene therapy in vivo did not improve β2AR-mediated signal compartmentation or reduce cAMP diffusion.  Although changes in T-tubule structure and β2AR-mediated cAMP signalling are significant even at 4-wk post-MI, progression to the HF phenotype is not linear.  At 8-wk post-MI the loss of β2AR-mediated cAMP is temporarily reversed.  Complete disorganization of β2AR-mediated cAMP signalling due to changes in functional receptor localization and cellular structure occurs at 16-wk post-MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeNXbyJ0OhMrVg90H21EOLACvtfcHk0lhckE7vumggnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2nurnO&md5=8100107e853e60ca03f5ea4e18a0759a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvx074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvx074%26sid%3Dliteratum%253Aachs%26aulast%3DSchobesberger%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DP.%26aulast%3DTokar%26aufirst%3DS.%26aulast%3DBhargava%26aufirst%3DA.%26aulast%3DMansfield%26aufirst%3DC.%26aulast%3DGlukhov%26aufirst%3DA.%2BV.%26aulast%3DPoulet%26aufirst%3DC.%26aulast%3DBuzuk%26aufirst%3DA.%26aulast%3DMonszpart%26aufirst%3DA.%26aulast%3DSikkel%26aufirst%3DM.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DGorelik%26aufirst%3DJ.%26atitle%3DT-tubule%2520remodelling%2520disturbs%2520localized%2520%25CE%25B22-adrenergic%2520signalling%2520in%2520rat%2520ventricular%2520myocytes%2520during%2520the%2520progression%2520of%2520heart%2520failure%26jtitle%3DCardiovasc.%2520Res.%26date%3D2017%26volume%3D113%26spage%3D770%26epage%3D782%26doi%3D10.1093%2Fcvr%2Fcvx074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1073/pnas.98.4.1607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.98.4.1607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11171998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsVWjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1607-1612&author=W.+Z.+Zhuauthor=M.+Zhengauthor=W.+J.+Kochauthor=R.+J.+Lefkowitzauthor=B.+K.+Kobilkaauthor=R.+P.+Xiao&title=Dual+modulation+of+cell+survival+and+cell+death+by+beta%282%29-adrenergic+signaling+in+adult+mouse+cardiac+myocytes&doi=10.1073%2Fpnas.98.4.1607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes</span></div><div class="casAuthors">Zhu, Wei-Zhong; Zheng, Ming; Koch, Walter J.; Lefkowitz, Robert J.; Kobilka, Brian K.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1607-1612</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The goal of this study was to det. whether β1-adrenergic receptor (AR) and β2-AR differ in regulating cardiomyocyte survival and apoptosis and, if so, to explore underlying mechanisms.  One potential mechanism is that cardiac β2-AR can activate both Gs and Gi proteins, whereas cardiac β1-AR couples only to Gs.  To avoid complicated crosstalk between β-AR subtypes, the authors expressed β1-AR or β2-AR individually in adult β1/β2-AR double knockout mouse cardiac myocytes by using adenoviral gene transfer.  Stimulation of β1-AR, but not β2-AR, markedly induced myocyte apoptosis, as indicated by increased terminal deoxynucleotidyltransferase-mediated UTP end labeling or Hoechst staining pos. cells and DNA fragmentation.  In contrast, β2-AR (but not β1-AR) stimulation elevated the activity of Akt, a powerful survival signal; this effect was fully abolished by inhibiting Gi, Gβγ, or phosphoinositide 3-kinase (PI3K) with pertussis toxin, βARK-ct (a peptide inhibitor of Gβγ), or LY294002, resp.  This indicates that β2-AR activates Akt via a Gi-Gβγ-PI3K pathway.  More importantly, inhibition of the Gi-Gβγ-PI3K-Akt pathway converts β2-AR signaling from survival to apoptotic.  Thus, stimulation of a single class of receptors, β2-ARs, elicits concurrent apoptotic and survival signals in cardiac myocytes.  The survival effect appears to predominate and is mediated by the Gi-Gβγ-PI3K-Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG5FTscOMsI7Vg90H21EOLACvtfcHk0lhckE7vumggnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsVWjur0%253D&md5=96b8688ce8815fe9d4b41cc1a3840bde</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.98.4.1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.98.4.1607%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%2BZ.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DDual%2520modulation%2520of%2520cell%2520survival%2520and%2520cell%2520death%2520by%2520beta%25282%2529-adrenergic%2520signaling%2520in%2520adult%2520mouse%2520cardiac%2520myocytes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D1607%26epage%3D1612%26doi%3D10.1073%2Fpnas.98.4.1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1176</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.111.245092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.111.245092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22034480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=1176-1194&author=M.+R.+Bristow&title=Treatment+of+chronic+heart+failure+with+%CE%B2-adrenergic+receptor+antagonists%3A+a+convergence+of+receptor+pharmacology+and+clinical+cardiology&doi=10.1161%2FCIRCRESAHA.111.245092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Chronic Heart Failure With β-Adrenergic Receptor Antagonists: A Convergence of Receptor Pharmacology and Clinical Cardiology</span></div><div class="casAuthors">Bristow, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1176-1194</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Despite the absence of a systematic development plan, β-blockers have reached the top tier of medical therapies for chronic heart failure.  The successful outcome was due to the many dedicated investigators who produced, over a 30-yr period, increasing evidence that β-blocking agents should or actually did improve the natural history of dilated cardiomyopathies and heart failure.  It took 20 years for supportive evidence to become undeniable, at which time in 1993 the formidable drug development resources of large pharmaceutical companies were deployed into Phase 3 trials.  Success then came relatively quickly, and within 8 years multiple agents were on the market in the United States and Europe.  Importantly, there is ample room to improve antiadrenergic therapy, through novel approaches exploiting the nuances of receptor biol. and/or intracellular signaling, as well as through pharmacogenetic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKs1_r2M4hnrVg90H21EOLACvtfcHk0lhckE7vumggnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOnsLnI&md5=edada5b2073c4ef553c24e361b9b216b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.111.245092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.111.245092%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DM.%2BR.%26atitle%3DTreatment%2520of%2520chronic%2520heart%2520failure%2520with%2520%25CE%25B2-adrenergic%2520receptor%2520antagonists%253A%2520a%2520convergence%2520of%2520receptor%2520pharmacology%2520and%2520clinical%2520cardiology%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D109%26spage%3D1176%26epage%3D1194%26doi%3D10.1161%2FCIRCRESAHA.111.245092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temple, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzhura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trimble, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbran, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span> <span> </span><span class="NLM_article-title">Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000027583.73268.E7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.0000027583.73268.E7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12208807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=1288-1293&author=Y.+Wuauthor=J.+Templeauthor=R.+Zhangauthor=I.+Dzhuraauthor=W.+Zhangauthor=R.+Trimbleauthor=D.+M.+Rodenauthor=R.+Passierauthor=E.+N.+Olsonauthor=R.+J.+Colbranauthor=M.+E.+Anderson&title=Calmodulin+kinase+II+and+arrhythmias+in+a+mouse+model+of+cardiac+hypertrophy&doi=10.1161%2F01.CIR.0000027583.73268.E7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy</span></div><div class="casAuthors">Wu, Yuejin; Temple, Joel; Zhang, Rong; Dzhura, Igor; Zhang, Wei; Trimble, Robert; Roden, Dan M.; Passier, Robert; Olson, Eric N.; Colbran, Roger J.; Anderson, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1288-1293</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background - Calmodulin kinase (CaMK) II is linked to arrhythmia mechanisms in cellular models where repolarization is prolonged.  CaMKII upregulation and prolonged repolarization are general features of cardiomyopathy, but the role of CaMKII in arrhythmias in cardiomyopathy is unknown.  Methods and Results - We studied a mouse model of cardiac hypertrophy attributable to transgenic (TG) overexpression of a constitutively active form of CaMKIV that also has increased endogenous CaMKII activity.  ECG-telemetered TRG mice had significantly more arrhythmias than wild-type (WT) littermate controls at baseline, and arrhythmias were addnl. increased by isoproterenol.  Arrhythmias were significantly suppressed by an inhibitory agent targeting endogenous CaMKII.  TG mice had longer QT intervals and action potential durations than WT mice, and TG cardiomyocytes had frequent early after-depolarizations (EADs), a hypothesized mechanism for triggering arrhythmias.  EADs were absent in WT cells before and after isoproterenol, whereas EAD frequency was unaffected by isoproterenol in TG mice.  L-type Ca2+ channels (LTTCs) can activate EADs, and LTCC opening probability (Po) was significantly higher in TG than WT cardiomyocytes before and after isoproterenol.  A CaMKII inhibitory peptide equalized tG and LT LTCC Po and eliminated EADs, whereas a peptide antagonist of the Na+/Ca2+ exchanger current, also hypothesized to support EADs, was ineffective.  Conclusions - These findings support the hypothesis that CaMKII is a proarrhythmic signaling mol. in cardiac hypertrophy in vivo.  Cellular studies point to EADs as a triggering mechanism for arrhythmias but suggest that the increase in arrhythmias after β-adrenergic stimulation is independent of enhanced EAD frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbZkv-SIkS0bVg90H21EOLACvtfcHk0lh50krrin-XIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKks7g%253D&md5=0c70945ffbe2c9289e0d37c07ee30774</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000027583.73268.E7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000027583.73268.E7%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DTemple%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DDzhura%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTrimble%26aufirst%3DR.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DPassier%26aufirst%3DR.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26aulast%3DColbran%26aufirst%3DR.%2BJ.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26atitle%3DCalmodulin%2520kinase%2520II%2520and%2520arrhythmias%2520in%2520a%2520mouse%2520model%2520of%2520cardiac%2520hypertrophy%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D1288%26epage%3D1293%26doi%3D10.1161%2F01.CIR.0000027583.73268.E7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Oort, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Respress, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Almeida, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skapura, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrens, X. H.</span></span> <span> </span><span class="NLM_article-title">Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">2669</span>– <span class="NLM_lpage">2679</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.110.982298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCULATIONAHA.110.982298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21098440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2010&pages=2669-2679&author=R.+J.+van%0AOortauthor=M.+D.+McCauleyauthor=S.+S.+Dixitauthor=L.+Pereiraauthor=Y.+Yangauthor=J.+L.+Respressauthor=Q.+Wangauthor=A.+C.+De+Almeidaauthor=D.+G.+Skapuraauthor=M.+E.+Andersonauthor=D.+M.+Bersauthor=X.+H.+Wehrens&title=Ryanodine+receptor+phosphorylation+by+calcium%2Fcalmodulin-dependent+protein+kinase+II+promotes+life-threatening+ventricular+arrhythmias+in+mice+with+heart+failure&doi=10.1161%2FCIRCULATIONAHA.110.982298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure</span></div><div class="casAuthors">van Oort, Ralph J.; McCauley, Mark D.; Dixit, Sayali S.; Pereira, Laetitia; Yang, Yi; Respress, Jonathan L.; Wang, Qiongling; De Almeida, Angela C.; Skapura, Darlene G.; Anderson, Mark E.; Bers, Donald M.; Wehrens, Xander H. T.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2669-2679</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background-: Approx. half of patients with heart failure die suddenly as a result of ventricular arrhythmias.  Although abnormal Ca release from the sarcoplasmic reticulum through ryanodine receptors (RyR2) has been linked to arrhythmogenesis, the mol. mechanisms triggering release of arrhythmogenic Ca remain unknown.  We tested the hypothesis that increased RyR2 phosphorylation by Ca/calmodulin-dependent protein kinase II is both necessary and sufficient to promote lethal ventricular arrhythmias.  Methods and Results-: Mice in which the S2814 Ca/calmodulin-dependent protein kinase II site on RyR2 is constitutively activated (S2814D) develop pathol. sarcoplasmic reticulum Ca release events, resulting in reduced sarcoplasmic reticulum Ca load on confocal microscopy.  These Ca release events are assocd. with increased RyR2 open probability in lipid bilayer prepns.  At baseline, young S2814D mice have structurally and functionally normal hearts without arrhythmias; however, they develop sustained ventricular tachycardia and sudden cardiac death on catecholaminergic provocation by caffeine/epinephrine or programmed elec. stimulation.  Young S2814D mice have a significant predisposition to sudden arrhythmogenic death after transverse aortic constriction surgery.  Finally, genetic ablation of the Ca/calmodulin-dependent protein kinase II site on RyR2 (S2814A) protects mutant mice from pacing-induced arrhythmias vs. wild-type mice after transverse aortic constriction surgery.  Conclusions-: Our results suggest that Ca/calmodulin-dependent protein kinase II phosphorylation of RyR2 Ca release channels at S2814 plays an important role in arrhythmogenesis and sudden cardiac death in mice with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ndk-Ylj3vLVg90H21EOLACvtfcHk0lh50krrin-XIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbzN&md5=9e3c186fa919ecd088bfe50276398dff</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.110.982298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.110.982298%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BOort%26aufirst%3DR.%2BJ.%26aulast%3DMcCauley%26aufirst%3DM.%2BD.%26aulast%3DDixit%26aufirst%3DS.%2BS.%26aulast%3DPereira%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DRespress%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DDe%2BAlmeida%26aufirst%3DA.%2BC.%26aulast%3DSkapura%26aufirst%3DD.%2BG.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DBers%26aufirst%3DD.%2BM.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26atitle%3DRyanodine%2520receptor%2520phosphorylation%2520by%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520II%2520promotes%2520life-threatening%2520ventricular%2520arrhythmias%2520in%2520mice%2520with%2520heart%2520failure%26jtitle%3DCirculation%26date%3D2010%26volume%3D122%26spage%3D2669%26epage%3D2679%26doi%3D10.1161%2FCIRCULATIONAHA.110.982298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Linkage of β<sub>1</sub>-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca<sup>2+</sup>/calmodulin kinase II</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1172/JCI200316326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI200316326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12618516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=617-625&author=W.+Z.+Zhuauthor=S.+Q.+Wangauthor=K.+Chakirauthor=D.+Yangauthor=T.+Zhangauthor=J.+H.+Brownauthor=E.+Devicauthor=B.+K.+Kobilkaauthor=H.+Chengauthor=R.+P.+Xiao&title=Linkage+of+%CE%B21-adrenergic+stimulation+to+apoptotic+heart+cell+death+through+protein+kinase+A-independent+activation+of+Ca2%2B%2Fcalmodulin+kinase+II&doi=10.1172%2FJCI200316326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II</span></div><div class="casAuthors">Zhu, Wei-Zhong; Wang, Shi-Qiang; Chakir, Khalid; Yang, Dongmei; Zhang, Tong; Brown, Joan Heller; Devic, Eric; Kobilka, Brian K.; Cheng, Heping; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-625</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">β1-Adrenergic receptor (β1AR) stimulation activates the classic cAMP/protein kinase A (PKA) pathway to regulate vital cellular processes from the change of gene expression to the control of metab., muscle contraction, and cell apoptosis.  Here, we show that sustained β1AR stimulation promotes cardiac myocyte apoptosis by activation of Ca2+/calmodulin kinase II (CaMKII), independently of PKA signaling.  β1AR-induced apoptosis is resistant to inhibition of PKA by a specific peptide inhibitor, PKI14-22, or an inactive cAMP analog, Rp-8-CPT-cAMPS.  In contrast, the β1AR proapoptotic effect is assocd. with non-PKA-dependent increases in intracellular Ca2+ and CaMKII activity.  Blocking the L-type Ca2+ channel, buffering intracellular Ca2+, or inhibiting CaMKII activity fully protects cardiac myocytes against β1AR-induced apoptosis, and overexpressing a cardiac CaMKII isoform, CaMKII-δC, markedly exaggerates the β1AR apoptotic effect.  These findings indicate that CaMKII constitutes a novel PKA-independent linkage of β1AR stimulation to cardiomyocyte apoptosis that has been implicated in the overall process of chronic heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5HKXxjM5pzbVg90H21EOLACvtfcHk0lh50krrin-XIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFentbg%253D&md5=aba0137b0536977c5e06f261370c62ac</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1172%2FJCI200316326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200316326%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%2BZ.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DDevic%26aufirst%3DE.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DLinkage%2520of%2520%25CE%25B21-adrenergic%2520stimulation%2520to%2520apoptotic%2520heart%2520cell%2520death%2520through%2520protein%2520kinase%2520A-independent%2520activation%2520of%2520Ca2%252B%252Fcalmodulin%2520kinase%2520II%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D111%26spage%3D617%26epage%3D625%26doi%3D10.1172%2FJCI200316326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">10833</span>– <span class="NLM_lpage">10839</span>, <span class="refDoi"> DOI: 10.1074/jbc.M611507200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M611507200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17296607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1ShsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=10833-10839&author=W.+Zhuauthor=A.+Y.+Wooauthor=D.+Yangauthor=H.+Chengauthor=M.+T.+Crowauthor=R.+P.+Xiao&title=Activation+of+CaMKIIdeltaC+is+a+common+intermediate+of+diverse+death+stimuli-induced+heart+muscle+cell+apoptosis&doi=10.1074%2Fjbc.M611507200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of CaMKIIδC Is a Common Intermediate of Diverse Death Stimuli-induced Heart Muscle Cell Apoptosis</span></div><div class="casAuthors">Zhu, Weizhong; Woo, Anthony Yiu-Ho; Yang, Dongmei; Cheng, Heping; Crow, Michael T.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">10833-10839</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ca2+-calmodulin-dependent protein kinase II (CaMKII) is expressed in many mammalian cells, with the δ isoform predominantly expressed in cardiomyocytes.  Previous studies have shown that inhibition of CaMKII protects cardiomyocytes against β1-adrenergic receptor-mediated apoptosis.  However, it is unclear whether activation of CaMKII is sufficient to cause cardiomyocyte apoptosis and whether CaMKII signaling is important in heart muscle cell apoptosis mediated by other stimuli.  Here, we specifically enhanced or suppressed CaMKII activity using adenoviral gene transfer of constitutively active (CA-CaMKIIδC) or dominant neg. (DN-CaMKIIδC) mutants of CaMKIIδC in cultured adult rat cardiomyocytes.  Expression of CA-CaMKIIδC promoted cardiomyocyte apoptosis that was assocd. with increased mitochondrial cytochrome c release and attenuated by co-expression of Bcl-XL.  Importantly, isoform-specific suppression of CaMKIIδC with the DN-CaMKIIδC mutant similar to nonselective CaMKII inhibition by the pharmacol. inhibitors (KN-93 or AIP) not only prevented CA-CaMKIIδC-mediated apoptosis but also protected cells from multiple death-inducing stimuli.  Thus, activation of CaMKIIδC constitutes a common intermediate by which various death-inducing stimuli trigger cardiomyocyte apoptosis via the primary mitochondrial death pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc8rUDLtQ3xrVg90H21EOLACvtfcHk0livUOHfjp26xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1ShsLg%253D&md5=3868fab761d02b80447088469f99359d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M611507200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M611507200%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCrow%26aufirst%3DM.%2BT.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DActivation%2520of%2520CaMKIIdeltaC%2520is%2520a%2520common%2520intermediate%2520of%2520diverse%2520death%2520stimuli-induced%2520heart%2520muscle%2520cell%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D10833%26epage%3D10839%26doi%3D10.1074%2Fjbc.M611507200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Backs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvannaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1853</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1172/JCI27438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI27438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16767219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvV2ltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=1853-1864&author=J.+Backsauthor=K.+Songauthor=S.+Bezprozvannayaauthor=S.+Changauthor=E.+N.+Olson&title=CaM+kinase+II+selectively+signals+to+histone+deacetylase+4+during+cardiomyocyte+hypertrophy&doi=10.1172%2FJCI27438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy</span></div><div class="casAuthors">Backs, Johannes; Song, Kunhua; Bezprozvannaya, Svetlana; Chang, Shurong; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1853-1864</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Class IIa histone deacetylases (HDACs) regulate a variety of cellular processes, including cardiac growth, bone development, and specification of skeletal muscle fiber type.  Multiple serine/threonine kinases control the subcellular localization of these HDACs by phosphorylation of common serine residues, but whether certain class IIa HDACs respond selectively to specific kinases has not been detd.  Here we show that calcium/calmodulin-dependent kinase II (CaMKII) signals specifically to HDAC4 by binding to a unique docking site that is absent in other class IIa HDACs.  Phosphorylation of HDAC4 by CaMKII promotes nuclear export and prevents nuclear import of HDAC4, with consequent derepression of HDAC target genes.  In cardiomyocytes, CaMKII phosphorylation of HDAC4 results in hypertrophic growth, which can be blocked by a signal-resistant HDAC4 mutant.  These findings reveal a central role for HDAC4 in CaMKII signaling pathways and have implications for the control of gene expression by calcium signaling in a variety of cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLmEf11zn00bVg90H21EOLACvtfcHk0livUOHfjp26xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvV2ltbs%253D&md5=b6510a11e8f97c5506d37443e8324225</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1172%2FJCI27438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI27438%26sid%3Dliteratum%253Aachs%26aulast%3DBacks%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DBezprozvannaya%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DCaM%2520kinase%2520II%2520selectively%2520signals%2520to%2520histone%2520deacetylase%25204%2520during%2520cardiomyocyte%2520hypertrophy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D1853%26epage%3D1864%26doi%3D10.1172%2FJCI27438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Means, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller Brown, J.</span></span> <span> </span><span class="NLM_article-title">Requirement for Ca<sup>2+</sup>/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1172/JCI38022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI38022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19381018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFyrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=1230-1240&author=H.+Lingauthor=T.+Zhangauthor=L.+Pereiraauthor=C.+K.+Meansauthor=H.+Chengauthor=Y.+Guauthor=N.+D.+Daltonauthor=K.+L.+Petersonauthor=J.+Chenauthor=D.+Bersauthor=J.+Heller+Brown&title=Requirement+for+Ca2%2B%2Fcalmodulin-dependent+kinase+II+in+the+transition+from+pressure+overload-induced+cardiac+hypertrophy+to+heart+failure+in+mice&doi=10.1172%2FJCI38022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice</span></div><div class="casAuthors">Ling, Haiyun; Zhang, Tong; Pereira, Laetitia; Means, Christopher Kable; Cheng, Hongqiang; Gu, Yusu; Dalton, Nancy D.; Peterson, Kirk L.; Chen, Ju; Bers, Donald; Brown, Joan Heller</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1230-1240</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Ca2+/calmodulin-dependent kinase II (CaMKII) was implicated in cardiac hypertrophy and heart failure.  We generated mice in which the predominant cardiac isoform, CaMKIIδ, was genetically deleted (KO mice), and found that these mice showed no gross baseline changes in ventricular structure or function.  In WT and KO mice, transverse aortic constriction (TAC) induced comparable increases in relative heart wt., cell size, HDAC5 phosphorylation, and hypertrophic gene expression.  Strikingly, while KO mice showed preserved hypertrophy after 6-wk TAC, CaMKIIδ deficiency significantly ameliorated phenotypic changes assocd. with the transition to heart failure, such as chamber dilation, ventricular dysfunction, lung edema, cardiac fibrosis, and apoptosis.  The ratio of IP3R2 to ryanodine receptor 2 (RyR2) and the fraction of RyR2 phosphorylated at the CaMKII site increased significantly during development of heart failure in WT mice, but not KO mice, and this was assocd. with enhanced Ca2+ spark frequency only in WT mice.  We suggest that CaMKIIδ contributes to cardiac decompensation by enhancing RyR2-mediated sarcoplasmic reticulum Ca2+ leak and that attenuating CaMKIIδ activation can limit the progression to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruSwvKWOd4KrVg90H21EOLACvtfcHk0livUOHfjp26xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFyrsbY%253D&md5=758acb983b5e631ad5ccd30f5e7ace11</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1172%2FJCI38022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI38022%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DPereira%26aufirst%3DL.%26aulast%3DMeans%26aufirst%3DC.%2BK.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DN.%2BD.%26aulast%3DPeterson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBers%26aufirst%3DD.%26aulast%3DHeller%2BBrown%26aufirst%3DJ.%26atitle%3DRequirement%2520for%2520Ca2%252B%252Fcalmodulin-dependent%2520kinase%2520II%2520in%2520the%2520transition%2520from%2520pressure%2520overload-induced%2520cardiac%2520hypertrophy%2520to%2520heart%2520failure%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D1230%26epage%3D1240%26doi%3D10.1172%2FJCI38022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1038/s41556-019-0380-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41556-019-0380-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31481791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSiurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=1152-1163&author=M.+Zhangauthor=H.+Gaoauthor=D.+Liuauthor=X.+Zhongauthor=X.+Shiauthor=P.+Yuauthor=L.+Jinauthor=Y.+Liuauthor=Y.+Tangauthor=Y.+Songauthor=J.+Liuauthor=X.+Huauthor=C.+Y.+Liauthor=L.+Songauthor=J.+Qinauthor=F.+Wuauthor=F.+Lanauthor=Y.+Zhangauthor=R.+P.+Xiao&title=CaMKII-%CE%B49+promotes+cardiomyopathy+through+disrupting+UBE2T-dependent+DNA+repair&doi=10.1038%2Fs41556-019-0380-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair</span></div><div class="casAuthors">Zhang, Mao; Gao, Hua; Liu, Dairu; Zhong, Xiaoming; Shi, Xiaolu; Yu, Peng; Jin, Li; Liu, Yun; Tang, Yajie; Song, Yunhu; Liu, Jinghao; Hu, Xinli; Li, Chuan-Yun; Song, Lei; Qin, Jun; Wu, Fujian; Lan, Feng; Zhang, Yan; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1152-1163</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Ca2+/calmodulin-dependent kinase II (CaMKII) is a multifunctional serine/threonine kinase family, and its δ isoform is predominant in the heart.  Excessive CaMKII activation plays a pivotal role in the pathogenesis of severe heart conditions, including myocardial infarction, cardiomyopathy and heart failure.  However, the identity of CaMKII splice variants and the mechanism(s) underlying CaMKII-mediated cardiac pathol. remain elusive.  Here, we show that CaMKII-δ9, the most abundant CaMKII-δ splice variant in human heart, potently promotes cardiomyocyte death, cardiomyopathy and heart failure by disrupting cardiomyocyte genome stability.  Mechanistically, CaMKII-δ9, but not the previously well-studied CaMKII-δ2 and CaMKII-δ3, targets the ubiquitin-conjugating enzyme E2T (UBE2T) for phosphorylation and degrdn., disrupting UBE2T-dependent DNA repair and leading to the accumulation of DNA damage and genome instability.  These findings not only reveal a crucial role of CaMKII in the regulation of DNA repair, but also mark the CaMKII-δ9-UBE2T-DNA damage pathway as an important therapeutic target for cardiomyopathy and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8FdY8t-WWiLVg90H21EOLACvtfcHk0liT1W_3VVlVFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSiurvP&md5=706b3cd3e4d2ecc3b0c27c06e5bf6ffd</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fs41556-019-0380-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-019-0380-8%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DCaMKII-%25CE%25B49%2520promotes%2520cardiomyopathy%2520through%2520disrupting%2520UBE2T-dependent%2520DNA%2520repair%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2019%26volume%3D21%26spage%3D1152%26epage%3D1163%26doi%3D10.1038%2Fs41556-019-0380-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-dependent activation of Ca<sup>2+</sup>/calmodulin kinase II after β<sub>1</sub>-adrenergic receptor stimulation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1083/jcb.200911047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1083%2Fjcb.200911047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20421423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFyhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2010&pages=573-587&author=S.+Mangmoolauthor=A.+K.+Shuklaauthor=H.+A.+Rockman&title=%CE%B2-Arrestin-dependent+activation+of+Ca2%2B%2Fcalmodulin+kinase+II+after+%CE%B21-adrenergic+receptor+stimulation&doi=10.1083%2Fjcb.200911047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">β-arrestin-dependent activation of Ca2+/calmodulin kinase II after β1-adrenergic receptor stimulation</span></div><div class="casAuthors">Mangmool, Supachoke; Shukla, Arun K.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-587</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Ca2+/calmodulin kinase II (CaMKII) plays an important role in cardiac contractility and the development of heart failure.  Although stimulation of β1-adrenergic receptors (ARs) leads to an increase in CaMKII activity, the mol. mechanism by which β1-ARs activate CaMKII is not completely understood.  In this study, we show the requirement for the β1-AR regulatory protein β-arrestin as a scaffold for both CaMKII and Epac (exchange protein directly activated by cAMP).  Stimulation of β1-ARs induces the formation of a β-arrestin-CaMKII-Epac1 complex, allowing its recruitment to the plasma membrane, whereby interaction with cAMP leads to CaMKII activation.  β-Arrestin binding to the carboxyl-terminal tail of β1-ARs promotes a conformational change within β-arrestin that allows CaMKII and Epac to remain in a stable complex with the receptor.  The essential role for β-arrestin and identification of the mol. mechanism by which only β1-ARs and not β2-ARs activate CaMKII significantly advances our understanding of this important cellular pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpikMtLR2PhubVg90H21EOLACvtfcHk0liT1W_3VVlVFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFyhtbY%253D&md5=5f3320135032583ffc10f94cbbeb4c1f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200911047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200911047%26sid%3Dliteratum%253Aachs%26aulast%3DMangmool%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-Arrestin-dependent%2520activation%2520of%2520Ca2%252B%252Fcalmodulin%2520kinase%2520II%2520after%2520%25CE%25B21-adrenergic%2520receptor%2520stimulation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2010%26volume%3D189%26spage%3D573%26epage%3D587%26doi%3D10.1083%2Fjcb.200911047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarewich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunapuli, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.112.273896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.112.273896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23104882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=498-509&author=X.+Zhangauthor=C.+Szetoauthor=E.+Gaoauthor=M.+Tangauthor=J.+Jinauthor=Q.+Fuauthor=C.+Makarewichauthor=X.+Aiauthor=Y.+Liauthor=A.+Tangauthor=J.+Wangauthor=H.+Gaoauthor=F.+Wangauthor=X.+J.+Geauthor=S.+P.+Kunapuliauthor=L.+Zhouauthor=C.+Zengauthor=K.+Y.+Xiangauthor=X.+Chen&title=Cardiotoxic+and+cardioprotective+features+of+chronic+%CE%B2-adrenergic+signaling&doi=10.1161%2FCIRCRESAHA.112.273896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxic and Cardioprotective Features of Chronic β-Adrenergic Signaling</span></div><div class="casAuthors">Zhang, Xiaoying; Szeto, Christopher; Gao, Erhe; Tang, Mingxin; Jin, Jianguo; Fu, Qin; Makarewich, Catherine; Ai, Xiaojie; Li, Ying; Tang, Allen; Wang, Jenny; Gao, Hui; Wang, Fang; Ge, Xinyi Joy; Kunapuli, Satya P.; Zhou, Lin; Zeng, Chunyu; Xiang, Kevin Yang; Chen, Xiongwen</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">498-509</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: In the failing heart, persistent β-adrenergic receptor activation is thought to induce myocyte death by protein kinase A (PKA)-dependent and PKA-independent activation of calcium/calmodulin-dependent kinase II.  β-Adrenergic signaling pathways also are capable of activating cardioprotective mechanisms.  Objective: This study used a novel PKA inhibitor peptide to inhibit PKA activity to test the hypothesis that β-adrenergic receptor signaling causes cell death through PKA-dependent pathways and cardioprotection through PKA-independent pathways.  Methods and results: In PKA inhibitor peptide transgenic mice, chronic isoproterenol failed to induce cardiac hypertrophy, fibrosis, and myocyte apoptosis, and decreased cardiac function.  In cultured adult feline ventricular myocytes, PKA inhibition protected myocytes from death induced by β1-adrenergic receptor agonists by preventing cytosolic and sarcoplasmic reticulum Ca overload and calcium/calmodulin-dependent kinase II activation.  PKA inhibition revealed a cardioprotective role of β-adrenergic signaling via cAMP/exchange protein directly activated by cAMP/Rap1/Rac/extracellular signal-regulated kinase pathway.  Selective PKA inhibition causes protection in the heart after myocardial infarction that was superior to β-blocker therapy.  Conclusions: These results suggest that selective block of PKA could be a novel heart failure therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKU2AqOz86lbVg90H21EOLACvtfcHk0liT1W_3VVlVFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrs%253D&md5=5231fdb364db3537c8013aab4f71d73e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.112.273896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.112.273896%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSzeto%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DMakarewich%26aufirst%3DC.%26aulast%3DAi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DX.%2BJ.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DK.%2BY.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DCardiotoxic%2520and%2520cardioprotective%2520features%2520of%2520chronic%2520%25CE%25B2-adrenergic%2520signaling%26jtitle%3DCirc.%2520Res.%26date%3D2013%26volume%3D112%26spage%3D498%26epage%3D509%26doi%3D10.1161%2FCIRCRESAHA.112.273896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murohara, T.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/ras-related protein 1 axis</span>. <i>Circ.: Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e002081</span> <span class="refDoi"> DOI: 10.1161/CIRCHEARTFAILURE.115.002081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCHEARTFAILURE.115.002081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26721911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFyksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=M.+Aoyamaauthor=H.+Kawaseauthor=Y.+K.+Bandoauthor=A.+Monjiauthor=T.+Murohara&title=Dipeptidyl+peptidase+4+inhibition+alleviates+shortage+of+circulating+glucagon-like+peptide-1+in+heart+failure+and+mitigates+myocardial+remodeling+and+apoptosis+via+the+exchange+protein+directly+activated+by+cyclic+AMP+1%2Fras-related+protein+1+axis&doi=10.1161%2FCIRCHEARTFAILURE.115.002081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis</span></div><div class="casAuthors">Aoyama, Morihiko; Kawase, Haruya; Bando, Yasuko K.; Monji, Akio; Murohara, Toyoaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation: Heart Failure</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e002081</span>CODEN:
                <span class="NLM_cas:coden">CHFICM</span>;
        ISSN:<span class="NLM_cas:issn">1941-3289</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Ample evidence demonstrates cardiovascular protection by incretin-based therapy using dipeptidyl peptidase 4 inhibitor (DPP4i) and glucagon-like peptide-1 (GLP-1) under either diabetic or nondiabetic condition.  Their action on myocardium is mediated by the cAMP (cAMP) signal; however, the pathway remains uncertain.  This study was conducted to address the effect of DPP4i/GLP-1/cAMP axis on cardiac dysfunction and remodeling induced by pressure overload (thoracic aortic constriction [TAC]) independently of diabetes mellitus.  DPP4i (alogliptin, 10 mg/kg per day for 4 wk) prevented TAC-induced contractile dysfunction, remodeling, and apoptosis of myocardium in a GLP-1 receptor antagonist (exendin [9-39])-sensitive fashion.  In TAC, circulating level of GLP-1 (in pmol/L; 0.86±0.10 for TAC vs. 2.13±0.54 for sham control) unexpectedly declined and so did the myocardial cAMP concn. (in pmol/mg protein; 33.0±1.4 for TAC vs. 42.2±1.5 for sham).  Alogliptin restored the decline in the GLP-1/cAMP levels obsd. in TAC, thereby augmented cAMP signaling effectors (protein kinase A [PKA] and exchange protein directly activated by cAMP 1 [EPAC1]).  In vitro assay revealed distinct roles of PKA and EPAC1 in cardiac apoptosis.  EPAC1 promoted cardiomyocyte survival via concomitant increase in B cell lymphoma-2 (Bcl-2) expression and activation of small G protein Ras-related protein 1 (Rap1) in a cAMP dose-dependent and PKA-independent fashion.  DPP4i restores cardiac remodeling and apoptosis caused by the pathol. decline in circulating GLP-1 in response to pressure overload.  EPAC1 is essential for cardiomyocyte survival via the cAMP/Rap1 activation independently of PKA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbOpmz-ZLXr7Vg90H21EOLACvtfcHk0lh3ZLOwNGdzCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFyksr8%253D&md5=8715a3603d1b61207c7d79ce3b74b35c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1161%2FCIRCHEARTFAILURE.115.002081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCHEARTFAILURE.115.002081%26sid%3Dliteratum%253Aachs%26aulast%3DAoyama%26aufirst%3DM.%26aulast%3DKawase%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DY.%2BK.%26aulast%3DMonji%26aufirst%3DA.%26aulast%3DMurohara%26aufirst%3DT.%26atitle%3DDipeptidyl%2520peptidase%25204%2520inhibition%2520alleviates%2520shortage%2520of%2520circulating%2520glucagon-like%2520peptide-1%2520in%2520heart%2520failure%2520and%2520mitigates%2520myocardial%2520remodeling%2520and%2520apoptosis%2520via%2520the%2520exchange%2520protein%2520directly%2520activated%2520by%2520cyclic%2520AMP%25201%252Fras-related%2520protein%25201%2520axis%26jtitle%3DCirc.%253A%2520Heart%2520Failure%26date%3D2016%26volume%3D9%26doi%3D10.1161%2FCIRCHEARTFAILURE.115.002081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span> <span> </span><span class="NLM_article-title">CaMKII in myocardial hypertrophy and heart failure</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2011.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2011.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21276796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=468-473&author=M.+E.+Andersonauthor=J.+H.+Brownauthor=D.+M.+Bers&title=CaMKII+in+myocardial+hypertrophy+and+heart+failure&doi=10.1016%2Fj.yjmcc.2011.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKII in myocardial hypertrophy and heart failure</span></div><div class="casAuthors">Anderson, Mark E.; Brown, Joan Heller; Bers, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-473</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many signals have risen and fallen in the tide of investigation into mechanisms of myocardial hypertrophy and heart failure (HF).  In our opinion, the multifunctional Ca and calmodulin-dependent protein kinase II (CaMKII) has emerged as a mol. to watch, in part because a solid body of accumulated data essentially satisfy Koch's postulates, showing that the CaMKII pathway is a core mechanism for promoting myocardial hypertrophy and heart failure.  Multiple groups have now confirmed the following: (1) that CaMKII activity is increased in hypertrophied and failing myocardium from animal models and patients; (2) CaMKII overexpression causes myocardial hypertrophy and HF and (3) CaMKII inhibition (by drugs, inhibitory peptides and gene deletion) improves myocardial hypertrophy and HF.  Patients with myocardial disease die in equal proportion from HF and arrhythmias, and a major therapeutic obstacle is that drugs designed to enhance myocardial contraction promote arrhythmias.  In contrast, inhibiting the CaMKII pathway appears to reduce arrhythmias and improve myocardial responses to pathol. stimuli.  This brief paper will introduce the mol. physiol. of CaMKII and discuss the impact of CaMKII on ion channels, Ca handling proteins and transcription in myocardium.  This article is part of a special issue entitled "Key Signaling Mols. in Hypertrophy and Heart Failure".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvHcQrIQzdNrVg90H21EOLACvtfcHk0lh3ZLOwNGdzCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7rN&md5=1682cef22b50060e56ce32e682c64169</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DBers%26aufirst%3DD.%2BM.%26atitle%3DCaMKII%2520in%2520myocardial%2520hypertrophy%2520and%2520heart%2520failure%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2011%26volume%3D51%26spage%3D468%26epage%3D473%26doi%3D10.1016%2Fj.yjmcc.2011.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berretta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, S. R.</span></span> <span> </span><span class="NLM_article-title">Ca<sup>2+</sup> influx-induced sarcoplasmic reticulum Ca<sup>2+</sup> overload causes mitochondrial-dependent apoptosis in ventricular myocytes</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1017</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000189270.72915.D1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000189270.72915.D1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16210547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFOmtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=1009-1017&author=X.+Chenauthor=X.+Zhangauthor=H.+Kuboauthor=D.+M.+Harrisauthor=G.+D.+Millsauthor=J.+Moyerauthor=R.+Berrettaauthor=S.+T.+Pottsauthor=J.+D.+Marshauthor=S.+R.+Houser&title=Ca2%2B+influx-induced+sarcoplasmic+reticulum+Ca2%2B+overload+causes+mitochondrial-dependent+apoptosis+in+ventricular+myocytes&doi=10.1161%2F01.RES.0000189270.72915.D1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ Influx-Induced Sarcoplasmic Reticulum Ca2+ Overload Causes Mitochondrial-Dependent Apoptosis in Ventricular Myocytes</span></div><div class="casAuthors">Chen, Xiongwen; Zhang, Xiaoying; Kubo, Hajime; Harris, David M.; Mills, Geoffrey D.; Moyer, Jed; Berretta, Remus; Potts, Sabine Telemaque; Marsh, James D.; Houser, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Increases in Ca2+ influx through the L-type Ca2+ channel (LTCC, Cav1.2) augment sarcoplasmic reticulum (SR) Ca2+ loading and the amplitude of the cytosolic Ca2+ transient to enhance cardiac myocyte contractility.  Our hypothesis is that persistent increases in Ca2+ influx through the LTCC cause apoptosis if the excessive influx results in SR Ca2+ overload.  Feline ventricular myocytes (VMs) in primary culture were infected with either an adenovirus (Ad) contg. a rat Cav1.2 β2a subunit-green fluorescent protein (GFP) fusion gene (Adβ2a) to increase Ca2+ influx or with AdGFP as a control.  Significantly fewer β2a-VMs (21.4 ± 5.6%) than GFP-VMs (99.6 ± 1.7%) were viable at 96 h.  A fraction of β2a-VMs (20.8±1.8%) contracted spontaneously (SC-β2a-VMs), and viability was significantly correlated with the percentage of SC-β2a-VMs.  Higher percentages of apoptotic nuclei, DNA laddering, and cytochrome C release were detected in β2a-VMs.  This apoptosis was prevented with pan-caspase or caspase-3 or caspase-9 inhibitors.  L-type calcium current (ICa-L) d. was greater in β2a-VMs (23.4 ± 2.8 pA/pF) than in GFP-VMs (7.6 ± 1.6 pA/pF).  SC-β2a-VMs had higher diastolic intracellular Ca2+ (Indo-1 ratio: 1.1 ± 0.1 vs. 0.7 ± 0.03, P < 0.05) and systolic Ca2+ transients (1.89 ± 0.27 vs. 0.80 ± 0.08) than GFP-VMs.  Inhibitors of Ca2+ influx, SR Ca2+ uptake and release, mitochondrial Ca2+ uptake, mitochondrial permeation transition pore, calpain, and Bcl-2-assocd. X protein protected β2a-VMs from apoptosis.  These results show that persistent increases in Ca2+ influx through the ICa-L enhance contractility but lead to apoptosis through a mitochondrial death pathway if SR Ca2+ overload is induced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQHxYcIic1q7Vg90H21EOLACvtfcHk0lgaIdscsov1mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFOmtLvF&md5=04d7a6476ddd24fe4f9ae30094a270fb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000189270.72915.D1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000189270.72915.D1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKubo%26aufirst%3DH.%26aulast%3DHarris%26aufirst%3DD.%2BM.%26aulast%3DMills%26aufirst%3DG.%2BD.%26aulast%3DMoyer%26aufirst%3DJ.%26aulast%3DBerretta%26aufirst%3DR.%26aulast%3DPotts%26aufirst%3DS.%2BT.%26aulast%3DMarsh%26aufirst%3DJ.%2BD.%26aulast%3DHouser%26aufirst%3DS.%2BR.%26atitle%3DCa2%252B%2520influx-induced%2520sarcoplasmic%2520reticulum%2520Ca2%252B%2520overload%2520causes%2520mitochondrial-dependent%2520apoptosis%2520in%2520ventricular%2520myocytes%26jtitle%3DCirc.%2520Res.%26date%3D2005%26volume%3D97%26spage%3D1009%26epage%3D1017%26doi%3D10.1161%2F01.RES.0000189270.72915.D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berretta, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, S. R.</span></span> <span> </span><span class="NLM_article-title">β<sub>1</sub>-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways</span>. <i>Am. J. Physiol. Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">H322</span>– <span class="NLM_lpage">H331</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00392.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajpheart.00392.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20495143" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2010&pages=H322-H331&author=W.+Wangauthor=H.+Zhangauthor=H.+Gaoauthor=H.+Kuboauthor=R.+M.+Berrettaauthor=X.+Chenauthor=S.+R.+Houser&title=%CE%B21-Adrenergic+receptor+activation+induces+mouse+cardiac+myocyte+death+through+both+L-type+calcium+channel-dependent+and+-independent+pathways&doi=10.1152%2Fajpheart.00392.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00392.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00392.2010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DH.%26aulast%3DBerretta%26aufirst%3DR.%2BM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHouser%26aufirst%3DS.%2BR.%26atitle%3D%25CE%25B21-Adrenergic%2520receptor%2520activation%2520induces%2520mouse%2520cardiac%2520myocyte%2520death%2520through%2520both%2520L-type%2520calcium%2520channel-dependent%2520and%2520-independent%2520pathways%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2010%26volume%3D299%26spage%3DH322%26epage%3DH331%26doi%3D10.1152%2Fajpheart.00392.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span> <span> </span><span class="NLM_article-title">The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000069686.31472.C5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000069686.31472.C5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12676814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=912-919&author=T.+Zhangauthor=L.+S.+Maierauthor=N.+D.+Daltonauthor=S.+Miyamotoauthor=J.+Rossauthor=D.+M.+Bersauthor=J.+H.+Brown&title=The+deltaC+isoform+of+CaMKII+is+activated+in+cardiac+hypertrophy+and+induces+dilated+cardiomyopathy+and+heart+failure&doi=10.1161%2F01.RES.0000069686.31472.C5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The δC Isoform of CaMKII Is Activated in Cardiac Hypertrophy and Induces Dilated Cardiomyopathy and Heart Failure</span></div><div class="casAuthors">Zhang, Tong; Maier, Lars S.; Dalton, Nancy D.; Miyamoto, Shigeki; Ross, John; Bers, Donald M.; Brown, Joan Heller</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">912-919</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that transgenic (TG) expression of either Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) or CaMKIIδB, both of which localize to the nucleus, induces cardiac hypertrophy.  However, CaMKIV is not present in heart, and cardiomyocytes express not only the nuclear CaMKIIδB but also a cytoplasmic isoform, CaMKIIδC.  In the present study, we demonstrate that expression of the δC isoform of CaMKII is selectively increased and its phosphorylation elevated as early as 2 days and continuously for up to 7 days after pressure overload.  To det. whether enhanced activity of this cytoplasmic δC isoform of CaMKII can lead to phosphorylation of Ca2+ regulatory proteins and induce hypertrophy, we generated TG mice that expressed the δC isoform of CaMKII.  Immunocytochem. staining demonstrated that the expressed transgene is confined to the cytoplasm of cardiomyocytes isolated from these mice.  These mice develop a dilated cardiomyopathy with up to a 65% decrease in fractional shortening and die prematurely.  Isolated myocytes are enlarged and exhibit reduced contractility and altered Ca2+ handling.  Phosphorylation of the ryanodine receptor (RyR) at a CaMKII site is increased even before development of heart failure, and CaMKII is found assocd. with the RyR in immunoppts. from the CaMKII TG mice.  Phosphorylation of phospholamban is also increased specifically at the CaMKII but not at the PKA phosphorylation site.  These findings are the first to demonstrate that CaMKIIδC can mediate phosphorylation of Ca2+ regulatory proteins in vivo and provide evidence for the involvement of CaMKIIδC activation in the pathogenesis of dilated cardiomyopathy and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-nVcYxA4kbVg90H21EOLACvtfcHk0lgaIdscsov1mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7Y%253D&md5=00265204d17a421658d3361a5528fd8c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000069686.31472.C5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000069686.31472.C5%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DL.%2BS.%26aulast%3DDalton%26aufirst%3DN.%2BD.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DBers%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520deltaC%2520isoform%2520of%2520CaMKII%2520is%2520activated%2520in%2520cardiac%2520hypertrophy%2520and%2520induces%2520dilated%2520cardiomyopathy%2520and%2520heart%2520failure%26jtitle%3DCirc.%2520Res.%26date%3D2003%26volume%3D92%26spage%3D912%26epage%3D919%26doi%3D10.1161%2F01.RES.0000069686.31472.C5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willeford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Respress, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrens, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span> <span> </span><span class="NLM_article-title">CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca(2+) leak and the pathophysiological response to chronic β-adrenergic stimulation</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2015.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2015.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26080362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyiu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2015&pages=282-291&author=M.+Grimmauthor=H.+Lingauthor=A.+Willefordauthor=L.+Pereiraauthor=C.+B.+Grayauthor=J.+R.+Ericksonauthor=S.+Sarmaauthor=J.+L.+Respressauthor=X.+H.+Wehrensauthor=D.+M.+Bersauthor=J.+H.+Brown&title=CaMKII%CE%B4+mediates+%CE%B2-adrenergic+effects+on+RyR2+phosphorylation+and+SR+Ca%282%2B%29+leak+and+the+pathophysiological+response+to+chronic+%CE%B2-adrenergic+stimulation&doi=10.1016%2Fj.yjmcc.2015.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca2+ leak and the pathophysiological response to chronic β-adrenergic stimulation</span></div><div class="casAuthors">Grimm, Michael; Ling, Haiyun; Willeford, Andrew; Pereira, Laetitia; Gray, Charles B. B.; Erickson, Jeffrey R.; Sarma, Satyam; Respress, Jonathan L.; Wehrens, Xander H. T.; Bers, Donald M.; Brown, Joan Heller</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">282-291</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic activation of Ca2 +/calmodulin-dependent protein kinase II (CaMKII) has been implicated in the deleterious effects of β-adrenergic receptor (β-AR) signaling on the heart, in part, by enhancing RyR2-mediated sarcoplasmic reticulum (SR) Ca2 + leak.  We used CaMKIIδ knockout (CaMKIIδ-KO) mice and knock-in mice with an inactivated CaMKII site S2814 on the ryanodine receptor type 2 (S2814A) to investigate the involvement of these processes in β-AR signaling and cardiac remodeling.  Langendorff-perfused hearts from CaMKIIδ-KO mice showed inotropic and chronotropic responses to isoproterenol (ISO) that were similar to those of wild type (WT) mice; however, in CaMKIIδ-KO mice, CaMKII phosphorylation of phospholamban and RyR2 was decreased and isolated myocytes from CaMKIIδ-KO mice had reduced SR Ca2 + leak in response to isoproterenol (ISO).  Chronic catecholamine stress with ISO induced comparable increases in relative heart wt. and other measures of hypertrophy from day 9 through week 4 in WT and CaMKIIδ-KO mice, but the development of cardiac fibrosis was prevented in CaMKIIδ-KO animals.  A 4-wk challenge with ISO resulted in reduced cardiac function and pulmonary congestion in WT, but not in CaMKIIδ-KO or S2814A mice, implicating CaMKIIδ-dependent phosphorylation of RyR2-S2814 in the cardiomyopathy, independent of hypertrophy, induced by prolonged β-AR stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCx-_A00JgXLVg90H21EOLACvtfcHk0lgZprYeT0pP5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyiu7jF&md5=7b085abac5f2597cba08a99c11fd4f0f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2015.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2015.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DM.%26aulast%3DLing%26aufirst%3DH.%26aulast%3DWilleford%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DC.%2BB.%26aulast%3DErickson%26aufirst%3DJ.%2BR.%26aulast%3DSarma%26aufirst%3DS.%26aulast%3DRespress%26aufirst%3DJ.%2BL.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26aulast%3DBers%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26atitle%3DCaMKII%25CE%25B4%2520mediates%2520%25CE%25B2-adrenergic%2520effects%2520on%2520RyR2%2520phosphorylation%2520and%2520SR%2520Ca%25282%252B%2529%2520leak%2520and%2520the%2520pathophysiological%2520response%2520to%2520chronic%2520%25CE%25B2-adrenergic%2520stimulation%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2015%26volume%3D85%26spage%3D282%26epage%3D291%26doi%3D10.1016%2Fj.yjmcc.2015.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Interaction of beta1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e84969</span> <span class="refDoi"> DOI: 10.1172/jci.insight.84969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2Fjci.insight.84969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26966719" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&author=W.+Zhuauthor=S.+Tsangauthor=D.+M.+Broweauthor=A.+Y.+Wooauthor=Y.+Huangauthor=C.+Xuauthor=J.+F.+Liuauthor=F.+Lvauthor=Y.+Zhangauthor=R.+P.+Xiao&title=Interaction+of+beta1-adrenoceptor+with+RAGE+mediates+cardiomyopathy+via+CaMKII+signaling&doi=10.1172%2Fjci.insight.84969"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.84969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.84969%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTsang%26aufirst%3DS.%26aulast%3DBrowe%26aufirst%3DD.%2BM.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DInteraction%2520of%2520beta1-adrenoceptor%2520with%2520RAGE%2520mediates%2520cardiomyopathy%2520via%2520CaMKII%2520signaling%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26doi%3D10.1172%2Fjci.insight.84969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cigarroa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risser, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayburn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E. J.</span></span> <span> </span><span class="NLM_article-title">Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1016/0735-1097(94)00543-Y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2F0735-1097%2894%2900543-Y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7897129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2M3gsVyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1995&pages=1154-1161&author=S.+A.+Hallauthor=C.+G.+Cigarroaauthor=L.+Marcouxauthor=R.+C.+Risserauthor=P.+A.+Grayburnauthor=E.+J.+Eichhorn&title=Time+course+of+improvement+in+left+ventricular+function%2C+mass+and+geometry+in+patients+with+congestive+heart+failure+treated+with+beta-adrenergic+blockade&doi=10.1016%2F0735-1097%2894%2900543-Y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade</span></div><div class="casAuthors">Hall S A; Cigarroa C G; Marcoux L; Risser R C; Grayburn P A; Eichhorn E J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1154-61</span>
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    </div><div class="casAbstract">OBJECTIVES:  We examined the time course of ventricular functional improvement in patients with dilated cardiomyopathy who received beta-blockade and the long-term effects of beta-blockade on ventricular mass and geometry in these patients.  BACKGROUND:  Previous studies have shown that beta-adrenergic blocking agents when administered long term improve ventricular function in patients with heart failure.  However, the time course of improvement in ventricular function and the long-term effects of beta-blockade on ventricular mass and geometry are not known.  METHODS:  Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10).  At 3 months all patients on standard therapy were crossed over to metoprolol, and late echocardiograms were obtained after 18 +/- 5 (mean +/- SD) months of metoprolol therapy.  All echocardiograms were read in blinded manner.  RESULTS:  Patients treated with metoprolol had an initial decline (day 1 vs. day 0) in ventricular function (increase in end-systolic volume and decrease in ejection fraction).  Ventricular function improved between months 1 and 3 (p = 0.013, metoprolol vs. standard therapy).  Left ventricular mass regressed at 18 months (333 +/- 85 to 275 +/- 53 g, p = 0.011) but not at 3 months.  Left ventricular shape became less spherical and assumed a more normal elliptical shape by 18 months (major/minor axis ratio 1.5 +/- 0.2 to 1.7 +/- 0.2, p = 0.0001).  CONCLUSIONS:  Patients with heart failure treated with metoprolol do not demonstrate an improvement in systolic performance until after 1 month of therapy and may have a mild reduction in function initially.  Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression of left ventricular mass and improved ventricular geometry by 18 months.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStrLjIxZIbluRS7coPn-RtfW6udTcc2eZbgrjJxPne_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3gsVyhsA%253D%253D&md5=28451528476d691a59451c7920b26e4f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2F0735-1097%2894%2900543-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0735-1097%252894%252900543-Y%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DS.%2BA.%26aulast%3DCigarroa%26aufirst%3DC.%2BG.%26aulast%3DMarcoux%26aufirst%3DL.%26aulast%3DRisser%26aufirst%3DR.%2BC.%26aulast%3DGrayburn%26aufirst%3DP.%2BA.%26aulast%3DEichhorn%26aufirst%3DE.%2BJ.%26atitle%3DTime%2520course%2520of%2520improvement%2520in%2520left%2520ventricular%2520function%252C%2520mass%2520and%2520geometry%2520in%2520patients%2520with%2520congestive%2520heart%2520failure%2520treated%2520with%2520beta-adrenergic%2520blockade%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D1995%26volume%3D25%26spage%3D1154%26epage%3D1161%26doi%3D10.1016%2F0735-1097%2894%2900543-Y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mealy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrabee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span> <span> </span><span class="NLM_article-title">Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.94.11.2817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.94.11.2817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8941107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVShug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1996&pages=2817-2825&author=E.+M.+Gilbertauthor=W.+T.+Abrahamauthor=S.+Olsenauthor=B.+Hattlerauthor=M.+Whiteauthor=P.+Mealyauthor=P.+Larrabeeauthor=M.+R.+Bristow&title=Comparative+hemodynamic%2C+left+ventricular+functional%2C+and+antiadrenergic+effects+of+chronic+treatment+with+metoprolol+versus+carvedilol+in+the+failing+heart&doi=10.1161%2F01.CIR.94.11.2817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart</span></div><div class="casAuthors">Gilbert, Edward M.; Abraham, William T.; Olsen, Stephanie; Hattler, Brack; White, Michel; Mealy, Patrice; Larrabee, Patti; Bristow, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2817-2825</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">The basic pharmacol. of the third-generation β-blocking agent carvedilol differs considerably from second-generation compds. such as metoprolol.  Moreover, carvedilol may produce different, i.e., more favorable, clin. effects in chronic heart failure.  For these reasons, the authors compared the effects of carvedilol and metoprolol on adrenergic activity, receptor expression, degree of clin. β-blockade, hemodynamics, and left ventricular function in patients with mild or moderate chronic heart failure.  The effects of carvedilol vs. metoprolol were compared in two concurrent placebo-controlled trials with carvedilol or metoprolol that had common substudies focused on adrenergic, hemodynamic, and left ventricular functional measurements.  All subjects in the substudies had chronic heart failure resulting from idiopathic dilated cardiomyopathy.  Carvedilol at 50 to 100 mg/d produced redns. in exercise heart rate that were similar to metoprolol at 125 to 150 mg/d, indicating comparable degrees of β-blockade.  Compared with metoprolol, carvedilol was assocd. with greater improvement in New York Heart Assocn. functional class.  Although there were no significant differences in hemodynamic effects between the carvedilol and metoprolol active-treatment groups, carvedilol tended to produce relatively greater improvements in left ventricular ejection fraction, stroke vol., and stroke work compared with changes in the resp. placebo groups.  Carvedilol selectively lowered coronary sinus norepinephrine levels, an index of cardiac adrenergic activity, whereas metoprolol did not lower coronary sinus norepinephrine and actually increased central venous norepinephrine levels.  Finally, metoprolol was assocd. with an increase in cardiac β-receptor d., whereas carvedilol did not change cardiac β-receptor expression.  The third-generation β-blocking agent carvedilol has substantially different effects on left ventricular function, hemodynamics, adrenergic activity, and β-receptor expression than does the second-generation compd. metoprolol.  Some or all of these differences may explain the apparent differences in clin. results between the two compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo70WApcowSPrVg90H21EOLACvtfcHk0liD4fWHRfXGVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVShug%253D%253D&md5=733186f011680d86299fe8a4a35d7e4c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.94.11.2817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.94.11.2817%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DE.%2BM.%26aulast%3DAbraham%26aufirst%3DW.%2BT.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DHattler%26aufirst%3DB.%26aulast%3DWhite%26aufirst%3DM.%26aulast%3DMealy%26aufirst%3DP.%26aulast%3DLarrabee%26aufirst%3DP.%26aulast%3DBristow%26aufirst%3DM.%2BR.%26atitle%3DComparative%2520hemodynamic%252C%2520left%2520ventricular%2520functional%252C%2520and%2520antiadrenergic%2520effects%2520of%2520chronic%2520treatment%2520with%2520metoprolol%2520versus%2520carvedilol%2520in%2520the%2520failing%2520heart%26jtitle%3DCirculation%26date%3D1996%26volume%3D94%26spage%3D2817%26epage%3D2825%26doi%3D10.1161%2F01.CIR.94.11.2817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickenig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRosee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crivaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stäblein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuttke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, M.</span></span> <span> </span><span class="NLM_article-title">Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(01)01471-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0735-1097%2801%2901471-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11583862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVeksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2001&pages=939-946&author=C.+Maackauthor=T.+Elterauthor=G.+Nickenigauthor=K.+LaRoseeauthor=M.+Crivaroauthor=A.+St%C3%A4bleinauthor=H.+Wuttkeauthor=M.+B%C3%B6hm&title=Prospective+crossover+comparison+of+carvedilol+and+metoprolol+in+patients+with+chronic+heart+failure&doi=10.1016%2FS0735-1097%2801%2901471-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure</span></div><div class="casAuthors">Maack, Christoph; Elter, Thomas; Nickenig, Georg; LaRosee, Karl; Crivaro, Marina; Stablein, Alexander; Wuttke, Henrike; Bohm, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">939-946</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF).  Beta-blockers improve ventricular function and prolong survival in patients with HF.  It has recently been suggested that carvedilol has more pronounced effects on left ventricular ejection fraction (LVEF) compared with metoprolol.  It is uncertain whether a change from one beta-blocker to the other is safe and leads to any change of left ventricular function.  Forty-four patients with HF due to ischemic (n = 17) or idiopathic cardiomyopathy (n = 27) that had responded well to long-term treatment with either metoprolol (n = 20) or carvedilol (n = 24) were switched to an equiv. dose of the resp. other beta-blocker.  Before and six months after crossover of treatment, echocardiog., radionuclide ventriculog. and dobutamine stress echocardiog. were performed.  Six months after crossover of beta-blocker treatment, LVEF had further improved with both carvedilol and metoprolol (carvedilol: 32±3% to 36±4%; metoprolol: 27±4% to 30±5%; both p < 0.05 vs. baseline), without interindividual differences.  There were no changes in either New York Heart Assocn. functional class or any other hemodynamic parameters at rest.  Dobutamine stress echocardiog. revealed a more pronounced increase of heart rate after dobutamine infusion in metoprolol- compared with carvedilol-treated patients.  After dobutamine infusion, LVEF increased in the carvedilol- but not in the metoprolol-treated group.  When switching treatment from one beta-blocker to the other, improvement of LVEF in patients with HF is maintained.  Despite similar long-term effects on hemodynamics at rest, beta-adrenergic responsiveness is different in both treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWM6Qk1_MpjbVg90H21EOLACvtfcHk0liD4fWHRfXGVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVeksbw%253D&md5=b6d004aeb25e7cdecb0fcee025a56bc2</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2801%2901471-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252801%252901471-1%26sid%3Dliteratum%253Aachs%26aulast%3DMaack%26aufirst%3DC.%26aulast%3DElter%26aufirst%3DT.%26aulast%3DNickenig%26aufirst%3DG.%26aulast%3DLaRosee%26aufirst%3DK.%26aulast%3DCrivaro%26aufirst%3DM.%26aulast%3DSt%25C3%25A4blein%26aufirst%3DA.%26aulast%3DWuttke%26aufirst%3DH.%26aulast%3DB%25C3%25B6hm%26aufirst%3DM.%26atitle%3DProspective%2520crossover%2520comparison%2520of%2520carvedilol%2520and%2520metoprolol%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2001%26volume%3D38%26spage%3D939%26epage%3D946%26doi%3D10.1016%2FS0735-1097%2801%2901471-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation?</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1007/s00395-016-0582-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00395-016-0582-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27683175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2snht12ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=66-69&author=F.+Cuelloauthor=K.+Lorenz&title=Inhibition+of+cardiac+CaMKII+to+cure+heart+failure%3A+step+by+step+towards+translation%3F&doi=10.1007%2Fs00395-016-0582-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation?</span></div><div class="casAuthors">Cuello Friederike; Cuello Friederike; Lorenz Kristina; Lorenz Kristina; Lorenz Kristina</div><div class="citationInfo"><span class="NLM_cas:title">Basic research in cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWsQbBLvDmBC6Ufuk_1xoTfW6udTcc2eZ5CK3CVDm1ILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snht12ntg%253D%253D&md5=5d31bd6aacb23461719c498b87d6bd81</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs00395-016-0582-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-016-0582-1%26sid%3Dliteratum%253Aachs%26aulast%3DCuello%26aufirst%3DF.%26aulast%3DLorenz%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520cardiac%2520CaMKII%2520to%2520cure%2520heart%2520failure%253A%2520step%2520by%2520step%2520towards%2520translation%253F%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2016%26volume%3D111%26spage%3D66%26epage%3D69%26doi%3D10.1007%2Fs00395-016-0582-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwenger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybkova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L. S.</span></span> <span> </span><span class="NLM_article-title">Reduction of SR Ca<sup>2+</sup> leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1007/s00395-017-0637-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00395-017-0637-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28612156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC1cnotVKrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=45&author=S.+Neefauthor=C.+Mannauthor=A.+Zwengerauthor=N.+Dybkovaauthor=L.+S.+Maier&title=Reduction+of+SR+Ca2%2B+leak+and+arrhythmogenic+cellular+correlates+by+SMP-114%2C+a+novel+CaMKII+inhibitor+with+oral+bioavailability&doi=10.1007%2Fs00395-017-0637-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of SR Ca(2+) leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability</span></div><div class="casAuthors">Neef Stefan; Maier Lars S; Mann Christian; Zwenger Anne; Dybkova Nataliya</div><div class="citationInfo"><span class="NLM_cas:title">Basic research in cardiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sarcoplasmic reticulum (SR) Ca(2+) leak induced by Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is centrally involved in atrial and ventricular arrhythmogenesis as well as heart failure remodeling.  Consequently, treating SR Ca(2+) leak has been proposed as a novel therapeutic paradigm, but compounds for use in humans are lacking.  SMP-114 ("Rimacalib") is a novel, orally available CaMKII inhibitor developed for human use that has already entered clinical phase II trials to treat rheumatoid arthritis.  We speculated that SMP-114 might also be useful to treat cardiac SR Ca(2+) leak.  SMP-114 significantly reduces SR Ca(2+) leak (as assessed by Ca(2+) sparks) in human atrial (0.72 ± 0.33 sparks/100 μm/s vs. control 3.02 ± 0.91 sparks/100 μm/s) and failing left ventricular (0.78 ± 0.23 vs. 1.69 ± 0.27 sparks/100 μm/s) as well as in murine ventricular cardiomyocytes (0.30 ± 0.07 vs. 1.50 ± 0.28 sparks/100 μm/s).  Associated with lower SR Ca(2+) leak, we found that SMP-114 suppressed the occurrence of spontaneous arrhythmogenic spontaneous Ca(2+) release (0.356 ± 0.109 vs. 0.927 ± 0.216 events per 30 s stimulation cessation).  In consequence, post-rest potentiation of Ca(2+)-transient amplitude (measured using Fura-2) during the 30 s pause was improved by SMP-114 (52 ± 5 vs. 37 ± 4%).  Noteworthy, SMP-114 has these beneficial effects without negatively impairing global excitation-contraction coupling: neither systolic Ca(2+) release nor single cell contractility was compromised, and also SR Ca(2+) reuptake, in line with resulting cardiomyocyte relaxation, was not impaired by SMP-114 in our assays.  SMP-114 demonstrated potential to treat SR Ca(2+) leak and consequently proarrhythmogenic events in rodent as well as in human atrial cardiomyocytes and cardiomyocytes from patients with heart failure.  Further research is necessary towards clinical use in cardiac disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRra3kow31our0AGQpJZWpJfW6udTcc2eaSsukgXxCPjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnotVKrsw%253D%253D&md5=a53933be53a41f99df18771973c171b5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs00395-017-0637-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-017-0637-y%26sid%3Dliteratum%253Aachs%26aulast%3DNeef%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DC.%26aulast%3DZwenger%26aufirst%3DA.%26aulast%3DDybkova%26aufirst%3DN.%26aulast%3DMaier%26aufirst%3DL.%2BS.%26atitle%3DReduction%2520of%2520SR%2520Ca2%252B%2520leak%2520and%2520arrhythmogenic%2520cellular%2520correlates%2520by%2520SMP-114%252C%2520a%2520novel%2520CaMKII%2520inhibitor%2520with%2520oral%2520bioavailability%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2017%26volume%3D112%26spage%3D45%26doi%3D10.1007%2Fs00395-017-0637-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beauverger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozoux, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bégis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glénat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daveu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorchies, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauchet, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamarelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruniaux, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muslin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiak, P.</span></span> <span> </span><span class="NLM_article-title">Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvz097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvz097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=329-338&author=P.+Beauvergerauthor=M.+L.+Ozouxauthor=G.+B%C3%A9gisauthor=V.+Gl%C3%A9natauthor=V.+Briandauthor=M.+C.+Philippoauthor=C.+Daveuauthor=G.+Tavaresauthor=S.+Royauthor=A.+Corbierauthor=P.+Briandauthor=O.+Dorchiesauthor=A.+L.+Bauchetauthor=E.+Nicolaiauthor=O.+Duclosauthor=D.+Tamarelleauthor=M.+P.+Pruniauxauthor=A.+J.+Muslinauthor=P.+Janiak&title=Reversion+of+cardiac+dysfunction+by+a+novel+orally+available+calcium%2Fcalmodulin-dependent+protein+kinase+II+inhibitor%2C+RA306%2C+in+a+genetic+model+of+dilated+cardiomyopathy&doi=10.1093%2Fcvr%2Fcvz097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvz097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvz097%26sid%3Dliteratum%253Aachs%26aulast%3DBeauverger%26aufirst%3DP.%26aulast%3DOzoux%26aufirst%3DM.%2BL.%26aulast%3DB%25C3%25A9gis%26aufirst%3DG.%26aulast%3DGl%25C3%25A9nat%26aufirst%3DV.%26aulast%3DBriand%26aufirst%3DV.%26aulast%3DPhilippo%26aufirst%3DM.%2BC.%26aulast%3DDaveu%26aufirst%3DC.%26aulast%3DTavares%26aufirst%3DG.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DCorbier%26aufirst%3DA.%26aulast%3DBriand%26aufirst%3DP.%26aulast%3DDorchies%26aufirst%3DO.%26aulast%3DBauchet%26aufirst%3DA.%2BL.%26aulast%3DNicolai%26aufirst%3DE.%26aulast%3DDuclos%26aufirst%3DO.%26aulast%3DTamarelle%26aufirst%3DD.%26aulast%3DPruniaux%26aufirst%3DM.%2BP.%26aulast%3DMuslin%26aufirst%3DA.%2BJ.%26aulast%3DJaniak%26aufirst%3DP.%26atitle%3DReversion%2520of%2520cardiac%2520dysfunction%2520by%2520a%2520novel%2520orally%2520available%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520II%2520inhibitor%252C%2520RA306%252C%2520in%2520a%2520genetic%2520model%2520of%2520dilated%2520cardiomyopathy%26jtitle%3DCardiovasc.%2520Res.%26date%3D2019%26volume%3D116%26spage%3D329%26epage%3D338%26doi%3D10.1093%2Fcvr%2Fcvz097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mustroph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagemann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücht, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarnowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perbellini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schopka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zausig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sossalla, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span> <span> </span><span class="NLM_article-title">Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes</span>. <i>ESC Heart Fail</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1002/ehf2.12336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fehf2.12336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30117720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ptV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=642-648&author=J.+Mustrophauthor=O.+Wagemannauthor=C.+M.+L%C3%BCchtauthor=M.+Trumauthor=K.+P.+Hammerauthor=C.+M.+Sagauthor=S.+Lebekauthor=D.+Tarnowskiauthor=J.+Reindersauthor=F.+Perbelliniauthor=C.+Terraccianoauthor=C.+Schmidauthor=S.+Schopkaauthor=M.+Hilkerauthor=Y.+Zausigauthor=S.+Pabelauthor=S.+T.+Sossallaauthor=F.+Schwedaauthor=L.+S.+Maierauthor=S.+Wagner&title=Empagliflozin+reduces+Ca%2Fcalmodulin-dependent+kinase+II+activity+in+isolated+ventricular+cardiomyocytes&doi=10.1002%2Fehf2.12336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes</span></div><div class="casAuthors">Mustroph Julian; Wagemann Olivia; Lucht Charlotte M; Trum Maximilian; Hammer Karin P; Sag Can Martin; Lebek Simon; Tarnowski Daniel; Pabel Steffen; Sossalla Samuel T; Maier Lars S; Wagner Stefan; Reinders Jorg; Perbellini Filippo; Terracciano Cesare; Schmid Christof; Schopka Simon; Hilker Michael; Zausig York; Sossalla Samuel T; Schweda Frank</div><div class="citationInfo"><span class="NLM_cas:title">ESC heart failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">642-648</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  The EMPA-REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin.  Overexpression and Ca(2+) -dependent activation of Ca(2+) /calmodulin-dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfunction and arrhythmias.  We tested whether empagliflozin reduces CaMKII- activity and improves Ca(2+) -handling in human and murine ventricular myocytes.  METHODS AND RESULTS:  Myocytes from wild-type mice, mice with transverse aortic constriction (TAC) as a model of HF, and human failing ventricular myocytes were exposed to empagliflozin (1 μmol/L) or vehicle.  CaMKII activity was assessed by CaMKII-histone deacetylase pulldown assay.  Ca(2+) spark frequency (CaSpF) as a measure of sarcoplasmic reticulum (SR) Ca(2+) leak was investigated by confocal microscopy. [Na(+) ]i was measured using Na(+) /Ca(2+) -exchanger (NCX) currents (whole-cell patch clamp).  Compared with vehicle, 24 h empagliflozin exposure of murine myocytes reduced CaMKII activity (1.6 ± 0.7 vs. 4.2 ± 0.9, P < 0.05, n = 10 mice), and also CaMKII-dependent ryanodine receptor phosphorylation (0.8 ± 0.1 vs. 1.0 ± 0.1, P < 0.05, n = 11 mice), with similar results upon TAC.  In murine myocytes, empagliflozin reduced CaSpF (TAC: 1.7 ± 0.3 vs. 2.5 ± 0.4 1/100 μm(-1)  s(-1) , P < 0.05, n = 4 mice) but increased SR Ca(2+) load and Ca(2+) transient amplitude.  Importantly, empagliflozin also significantly reduced CaSpF in human failing ventricular myocytes (1 ± 0.2 vs. 3.3 ± 0.9, P < 0.05, n = 4 patients), while Ca(2+) transient amplitude was increased (F/F0 : 0.53 ± 0.05 vs. 0.36 ± 0.02, P < 0.05, n = 3 patients).  In contrast, 30 min exposure with empagliflozin did not affect CaMKII activity nor Ca(2+) -handling but significantly reduced [Na(+) ]i .  CONCLUSIONS:  We show for the first time that empagliflozin reduces CaMKII activity and CaMKII-dependent SR Ca(2+) leak.  Reduced Ca(2+) leak and improved Ca(2+) transients may contribute to the beneficial effects of empagliflozin in HF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNBuaIp3j4AUGy1nwu7K2mfW6udTcc2eaSsukgXxCPjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ptV2rsw%253D%253D&md5=41eb4f090c8de88a053ada619d49bc0f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fehf2.12336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fehf2.12336%26sid%3Dliteratum%253Aachs%26aulast%3DMustroph%26aufirst%3DJ.%26aulast%3DWagemann%26aufirst%3DO.%26aulast%3DL%25C3%25BCcht%26aufirst%3DC.%2BM.%26aulast%3DTrum%26aufirst%3DM.%26aulast%3DHammer%26aufirst%3DK.%2BP.%26aulast%3DSag%26aufirst%3DC.%2BM.%26aulast%3DLebek%26aufirst%3DS.%26aulast%3DTarnowski%26aufirst%3DD.%26aulast%3DReinders%26aufirst%3DJ.%26aulast%3DPerbellini%26aufirst%3DF.%26aulast%3DTerracciano%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DC.%26aulast%3DSchopka%26aufirst%3DS.%26aulast%3DHilker%26aufirst%3DM.%26aulast%3DZausig%26aufirst%3DY.%26aulast%3DPabel%26aufirst%3DS.%26aulast%3DSossalla%26aufirst%3DS.%2BT.%26aulast%3DSchweda%26aufirst%3DF.%26aulast%3DMaier%26aufirst%3DL.%2BS.%26aulast%3DWagner%26aufirst%3DS.%26atitle%3DEmpagliflozin%2520reduces%2520Ca%252Fcalmodulin-dependent%2520kinase%2520II%2520activity%2520in%2520isolated%2520ventricular%2520cardiomyocytes%26jtitle%3DESC%2520Heart%2520Fail%26date%3D2018%26volume%3D5%26spage%3D642%26epage%3D648%26doi%3D10.1002%2Fehf2.12336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 reduces ventricular arrhythmia activity and calcium sparks-mediated sarcoplasmic reticulum Ca leak in rats with heart failure</span>. <i>Int. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1536/ihj.19-327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1536%2Fihj.19-327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31956148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFWitbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=145-152&author=J.+Chenauthor=S.+Xuauthor=W.+Zhouauthor=L.+Wuauthor=L.+Wangauthor=W.+Li&title=Exendin-4+reduces+ventricular+arrhythmia+activity+and+calcium+sparks-mediated+sarcoplasmic+reticulum+Ca+leak+in+rats+with+heart+failure&doi=10.1536%2Fihj.19-327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 reduces ventricular arrhythmia activity and calcium sparks-mediated sarcoplasmic reticulum ca leak in rats with heart failure</span></div><div class="casAuthors">Chen, Jingjing; Xu, Shunen; Zhou, Wei; Wu, Lirong; Wang, Long; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">International Heart Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">IHJNAJ</span>;
        ISSN:<span class="NLM_cas:issn">1349-3299</span>.
    
            (<span class="NLM_cas:orgname">International Heart Journal Association</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the effect of exendin-4 (Ex-4) on ventricular arrhythmias and calcium sparks-mediated calcium leak in a myocardial infarction-heart failure model.  We studied the influence of exendin-4 on ventricular arrhythmogenesis in a rat myocardial infarction-heart failure model.  In vivo arrhythmia studies (ECG [ECG] telemetry studies), ex vivo arrhythmia studies calcium sparks tests.  ECG telemetry studies showed an antiarrhythmic effect of exendin-4 with redn. of spontaneous ventricular arrhythmias.  Exendin-4 abbreviated the APD90, which was longer in the heart failure model, and increase the APD alternans thresholds.  Exendin-4 also reduced the susceptibility to burst pacing-induced arrhythmia ex vivo.  Subcellular sarcoplasmic reticulum (SR) calcium leak characteristics were tested in four groups of rat cardiomyocytes.  Exendin-4 reduced calcium spark mass, spark frequency, and calcium leak, which may be due to reduced S2814-RyR2 and CaMK-II phosphorylation.  Co-administration of exendin 9-39 with exendin-4 partly abolished the above-mentioned effect of exendin-4.  These findings suggest that exendin-4 exerts an antiarrhythmic effect through decreasing SR calcium leak in spontaneous and burst pacing-induced ventricular arrhythmias, which may be due to reduced RyR2 phosphorylation and suppressed CaMK-II activity.  Exendin-4 may act as a novel antiarrhythmic strategy in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjB3FP8SNl17Vg90H21EOLACvtfcHk0lj4EYXVVlD4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFWitbbO&md5=cdfdc524e0ee2c6f7b9e57e97a367e73</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1536%2Fihj.19-327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1536%252Fihj.19-327%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DExendin-4%2520reduces%2520ventricular%2520arrhythmia%2520activity%2520and%2520calcium%2520sparks-mediated%2520sarcoplasmic%2520reticulum%2520Ca%2520leak%2520in%2520rats%2520with%2520heart%2520failure%26jtitle%3DInt.%2520Heart%2520J.%26date%3D2020%26volume%3D61%26spage%3D145%26epage%3D152%26doi%3D10.1536%2Fihj.19-327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, G. W.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepe, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liggett, S. B.</span></span> <span> </span><span class="NLM_article-title">Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">6400</span>– <span class="NLM_lpage">6405</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.11.6400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.96.11.6400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10339599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXksFKkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=6400-6405&author=G.+W.+Dornauthor=N.+M.+Tepeauthor=J.+N.+Lorenzauthor=W.+J.+Kochauthor=S.+B.+Liggett&title=Low-+and+high-level+transgenic+expression+of+beta2-adrenergic+receptors+differentially+affect+cardiac+hypertrophy+and+function+in+Galphaq-overexpressing+mice&doi=10.1073%2Fpnas.96.11.6400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice</span></div><div class="casAuthors">Dorn, Gerald W., II; Tepe, Nicole M.; Lorenz, John N.; Koch, Walter J.; Liggett, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6400-6405</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Transgenic overexpression of Gαq in the heart triggers events leading to a phenotype of eccentric hypertrophy, depressed ventricular function, marked expression of hypertrophy-assocd. genes, and depressed β-adrenergic receptor (βAR) function.  The role of βAR dysfunction in the development of this failure phenotype was delineated by transgenic coexpression of the carboxyl terminus of the βAR kinase (βARK), which acts to inhibit the kinase, or concomitant overexpression of the β2AR at low (≈30-fold, Gαq/β2ARL), moderate (≈140-fold, Gαq/β2ARM), and high (≈1,000-fold, Gαq/β2ARH) levels above background βAR d.  Expression of the βARK inhibitor had no effect on the phenotype, consistent with the lack of increased βARK levels in Gαq mice.  In marked contrast, Gαq/β2ARL mice displayed rescue of hypertrophy and resting ventricular function and decreased cardiac expression of atrial natriuretic factor and α-skeletal actin mRNA.  These effects occurred in the absence of any improvement in basal or agonist-stimulated adenylyl cyclase (AC) activities in crude cardiac membranes, although restoration of a compartmentalized β2AR/AC signal cannot be excluded.  Higher expression of receptors in Gαq/β2ARM mice resulted in salvage of AC activity, but hypertrophy, ventricular function, and expression of fetal genes were unaffected or worsened.  With ≈1,000-fold overexpression, the majority of Gαq/β2ARH mice died with cardiomegaly at 5 wk.  Thus, although it appears that excessive, uncontrolled, or generalized augmentation of βAR signaling is deleterious in heart failure, selective enhancement by overexpressing the β2AR subtype to limited levels restores not only ventricular function but also reverses cardiac hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgm5WNwYJkrVg90H21EOLACvtfcHk0lj4EYXVVlD4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksFKkt7g%253D&md5=01ad0a99c5d0e874294216df85e63838</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.11.6400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.11.6400%26sid%3Dliteratum%253Aachs%26aulast%3DDorn%26aufirst%3DG.%2BW.%26aulast%3DTepe%26aufirst%3DN.%2BM.%26aulast%3DLorenz%26aufirst%3DJ.%2BN.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26atitle%3DLow-%2520and%2520high-level%2520transgenic%2520expression%2520of%2520beta2-adrenergic%2520receptors%2520differentially%2520affect%2520cardiac%2520hypertrophy%2520and%2520function%2520in%2520Galphaq-overexpressing%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D6400%26epage%3D6405%26doi%3D10.1073%2Fpnas.96.11.6400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span> <span> </span><span class="NLM_article-title">Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart</span>. <i>Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1097/01.CCM.0000120049.43113.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1097%2F01.CCM.0000120049.43113.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15071399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD2c3gtVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=1041-1048&author=A.+J.+Pattersonauthor=W.+Zhuauthor=A.+Chowauthor=R.+Agrawalauthor=J.+Kosekauthor=R.+P.+Xiaoauthor=B.+Kobilka&title=Protecting+the+myocardium%3A+a+role+for+the+beta2+adrenergic+receptor+in+the+heart&doi=10.1097%2F01.CCM.0000120049.43113.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart</span></div><div class="casAuthors">Patterson Andrew J; Zhu Weizhong; Chow Amy; Agrawal Rani; Kosek Jon; Xiao Rui Ping; Kobilka Brian</div><div class="citationInfo"><span class="NLM_cas:title">Critical care medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1041-8</span>
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    </div><div class="casAbstract">OBJECTIVE:  The sympathetic nervous system enhances cardiac muscle function by activating beta adrenergic receptors (betaARs).  Recent studies suggest that chronic betaAR stimulation is detrimental, however, and that it may play a role in the clinical deterioration of patients with congestive heart failure.  To examine the impact of chronic beta1AR and beta2AR subtype stimulation individually, we studied the cardiovascular effects of catecholamine infusions in betaAR subtype knockout mice (beta1KO, beta2KO).  DESIGN:  Prospective, randomized, experimental study.  SETTING:  Animal research laboratory.  SUBJECTS:  beta1KO and beta2KO mice and wild-type controls.  INTERVENTIONS:  The animals were subjected to 2 wks of continuous infusion of the betaAR agonist isoproterenol.  Analyses of cardiac function and structure were performed during and 3 days after completion of the infusions.  Functional studies included graded exercise treadmill testing, in vivo assessments of left ventricular function using Mikro-Tip catheter transducers, right ventricular pressure measurements, and analyses of organ weight to body weight ratios.  Structural studies included heart weight measurements, assessments of myocyte ultrastructure using electron microscopy, and in situ terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick-end labeling staining to quantitate myocyte apoptosis.  MEASUREMENTS AND MAIN RESULTS:  We found that isoproterenol-treated beta2KO mice experienced greater mortality rates (p =.001, chi-square test using Fisher's exact method) and increased myocyte apoptosis at 3- and 7-day time points (p =.04 and p =.0007, respectively, two-way analysis of variance).  CONCLUSION:  The results of this study suggest that in vivo beta2AR activation is antiapoptotic and contributes to myocardial protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzob1NdxswGcNIRw0GKUoEfW6udTcc2ebw5q2-xHkFB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3gtVOqtQ%253D%253D&md5=b8c0bd09552830f3c76f5850c2d28242</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1097%2F01.CCM.0000120049.43113.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.CCM.0000120049.43113.90%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DA.%2BJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChow%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DR.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DKobilka%26aufirst%3DB.%26atitle%3DProtecting%2520the%2520myocardium%253A%2520a%2520role%2520for%2520the%2520beta2%2520adrenergic%2520receptor%2520in%2520the%2520heart%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2004%26volume%3D32%26spage%3D1041%26epage%3D1048%26doi%3D10.1097%2F01.CCM.0000120049.43113.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fajardo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes</span>. <i>Am. J. Physiol. Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">H2441</span>– <span class="NLM_lpage">H2449</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00005.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajpheart.00005.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16040722" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2005&pages=H2441-H2449&author=D.+Bernsteinauthor=G.+Fajardoauthor=M.+Zhaoauthor=T.+Urashimaauthor=J.+Powersauthor=G.+Berryauthor=B.+K.+Kobilka&title=Differential+cardioprotective%2Fcardiotoxic+effects+mediated+by+beta-adrenergic+receptor+subtypes&doi=10.1152%2Fajpheart.00005.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00005.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00005.2005%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DFajardo%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DUrashima%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DDifferential%2520cardioprotective%252Fcardiotoxic%2520effects%2520mediated%2520by%2520beta-adrenergic%2520receptor%2520subtypes%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2005%26volume%3D289%26spage%3DH2441%26epage%3DH2449%26doi%3D10.1152%2Fajpheart.00005.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liggett, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagoner, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoit, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, R. A.</span></span> <span> </span><span class="NLM_article-title">The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1534</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1172/JCI4059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI4059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9788966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1cXmvVygu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1534-1539&author=S.+B.+Liggettauthor=L.+E.+Wagonerauthor=L.+L.+Craftauthor=R.+W.+Hornungauthor=B.+D.+Hoitauthor=T.+C.+McIntoshauthor=R.+A.+Walsh&title=The+Ile164+beta2-adrenergic+receptor+polymorphism+adversely+affects+the+outcome+of+congestive+heart+failure&doi=10.1172%2FJCI4059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure</span></div><div class="casAuthors">Liggett, Stephen B.; Wagoner, Lynne E.; Craft, Laura L.; Hornung, Richard W.; Hoit, Brian D.; McIntosh, Tina C.; Walsh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1534-1539</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR), an important modulator of cardiac inotropy and chronotropy, has significant genetic heterogeneity in the population.  Because dysfunctional βARs play a role in the pathogenesis of the failing ventricle, we tested the hypothesis that β2AR polymorphisms alter the outcome of congestive heart failure.  259 Patients with NYHA functional class II-IV heart failure due to ischemic or dilated cardiomyopathy were genotyped and prospectively followed, with the endpoint defined as death or cardiac transplantation.  The allele frequencies between this group and those of 212 healthy controls also were compared and did not differ between the groups.  However, those with the Ile164 polymorphism displayed a striking difference in survival with a relative risk of death or cardiac transplant of 4.81 (P < 0.001) compared with those with the wild-type Thr at this position.  Age, race, gender, functional class, etiol., ejection fraction, and medication use did not differ between these individuals and those with the wild-type β2AR, and thus the β2AR genotype at position 164 was the only clear distinguishing feature between the two groups.  The 1-yr survival for Ile164 patients was 42% compared with 76% for patients harboring wild-type β2AR.  In contrast, polymorphisms at amino acid positions 16 (Arg or Gly) or 27 (Gln or Glu), which also alter receptor phenotype, did not appear to have an influence on the course of heart failure.  Taken together with cell-based and transgenic mouse results, this study establishes a paradigm whereby genetic variants of key signaling elements can have pathophysiol. consequences within the context of a disease.  Furthermore, patients with the Ile164 polymorphism and heart failure may be candidates for earlier aggressive intervention or cardiac transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj7-rqaxAguLVg90H21EOLACvtfcHk0lg69kWsrZwZjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvVygu7c%253D&md5=503988c4376a8da7f1750d664526fe9b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1172%2FJCI4059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI4059%26sid%3Dliteratum%253Aachs%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26aulast%3DWagoner%26aufirst%3DL.%2BE.%26aulast%3DCraft%26aufirst%3DL.%2BL.%26aulast%3DHornung%26aufirst%3DR.%2BW.%26aulast%3DHoit%26aufirst%3DB.%2BD.%26aulast%3DMcIntosh%26aufirst%3DT.%2BC.%26aulast%3DWalsh%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Ile164%2520beta2-adrenergic%2520receptor%2520polymorphism%2520adversely%2520affects%2520the%2520outcome%2520of%2520congestive%2520heart%2520failure%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1534%26epage%3D1539%26doi%3D10.1172%2FJCI4059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penicka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delrue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Durme, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goethals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijns, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartunek, J.</span></span> <span> </span><span class="NLM_article-title">Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy</span>. <i>Heart</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1136/hrt.2006.091959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fhrt.2006.091959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17569809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1KmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=856-861&author=E.+Barbatoauthor=M.+Penickaauthor=L.+Delrueauthor=F.+Van+Durmeauthor=B.+De+Bruyneauthor=M.+Goethalsauthor=W.+Wijnsauthor=M.+Vanderheydenauthor=J.+Bartunek&title=Thr164Ile+polymorphism+of+beta2-adrenergic+receptor+negatively+modulates+cardiac+contractility%3A+implications+for+prognosis+in+patients+with+idiopathic+dilated+cardiomyopathy&doi=10.1136%2Fhrt.2006.091959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Thr164Ile polymorphism of β2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy</span></div><div class="casAuthors">Barbato, Emanuele; Penicka, Martin; Delrue, Leen; Van Durme, Frederic; De Bruyne, Bernard; Goethals, Marc; Wijns, William; Vanderheyden, Marc; Bartunek, Jozef</div><div class="citationInfo"><span class="NLM_cas:title">Heart (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">856-861</span>CODEN:
                <span class="NLM_cas:coden">HEARFR</span>;
        ISSN:<span class="NLM_cas:issn">1355-6037</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: β2-adrenergic receptor Thr164Ile (threonine (Thr) is replaced by an isoleucine (Ile) at codon 164) polymorphism was postulated to contribute to lower exercise tolerance and poor prognosis in patients with congestive heart failure.  However, heart failure is assocd. with several abnormalities of β receptor signalling, and underlying mechanisms are not clear.  Objectives: To investigate whether Thr164Ile polymorphism neg. modulates myocardial contractile performance and is assocd. with adverse long-term prognosis of patients with congestive heart failure.  Methods: Among 55 subjects, cardiac contractile response to the β2-adrenergic receptor agonist terbutaline was assessed from the peak myocardial velocity of systolic shortening (Sm) in 18 subjects with the Ile-164 variant and 37 matched controls.  In total, 24 subjects had normal left ventricular (LV) function and 31 presented with congestive heart failure due to idiopathic dilated cardiomyopathy.  Results: In patients with normal LV function, peak terbutaline-induced increase (Δ) in Sm was lower in subjects with the Ile-164 variant than in controls (Δ33% (4%) vs Δ56% (4%), p<0.01).  In patients with heart failure, subjects with Ile-164 showed further severe redn. of β2-adrenergic-mediated increase in Sm as compared with controls with heart failure (Δ20% (5%) vs Δ39% (4%), p<0.05).  Patients with heart failure with Ile-164 showed a severely blunted force-frequency relationship in response to agonist stimulation.  At 2-years of follow-up, patients with heart failure with the Ile-164 variant showed higher incidence of adverse events than controls with heart failure (75% (6/8) vs 30% (7/23), p<0.05).  Conclusions: The β2-adrenergic Thr164Ile polymorphism directly modulates adrenergic-mediated cardiac responses in patients with normal and failing myocardium.  Furthermore, blunted β2 adrenergic-mediated myocardial contractile response in patients with Ile-164 variant seems to adversely modulate the course of congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-CRh2HSR68bVg90H21EOLACvtfcHk0lg69kWsrZwZjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1KmsLw%253D&md5=a2fc01693775a1e8b95865187fc1ede0</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1136%2Fhrt.2006.091959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fhrt.2006.091959%26sid%3Dliteratum%253Aachs%26aulast%3DBarbato%26aufirst%3DE.%26aulast%3DPenicka%26aufirst%3DM.%26aulast%3DDelrue%26aufirst%3DL.%26aulast%3DVan%2BDurme%26aufirst%3DF.%26aulast%3DDe%2BBruyne%26aufirst%3DB.%26aulast%3DGoethals%26aufirst%3DM.%26aulast%3DWijns%26aufirst%3DW.%26aulast%3DVanderheyden%26aufirst%3DM.%26aulast%3DBartunek%26aufirst%3DJ.%26atitle%3DThr164Ile%2520polymorphism%2520of%2520beta2-adrenergic%2520receptor%2520negatively%2520modulates%2520cardiac%2520contractility%253A%2520implications%2520for%2520prognosis%2520in%2520patients%2520with%2520idiopathic%2520dilated%2520cardiomyopathy%26jtitle%3DHeart%26date%3D2007%26volume%3D93%26spage%3D856%26epage%3D861%26doi%3D10.1136%2Fhrt.2006.091959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chesley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, M. T.</span></span> <span> </span><span class="NLM_article-title">The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1179</span>, <span class="refDoi"> DOI: 10.1161/01.RES.87.12.1172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.87.12.1172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11110775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslyntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2000&pages=1172-1179&author=A.+Chesleyauthor=M.+S.+Lundbergauthor=T.+Asaiauthor=R.+P.+Xiaoauthor=S.+Ohtaniauthor=E.+G.+Lakattaauthor=M.+T.+Crow&title=The+beta%282%29-adrenergic+receptor+delivers+an+antiapoptotic+signal+to+cardiac+myocytes+through+G%28i%29-dependent+coupling+to+phosphatidylinositol+3%E2%80%B2-kinase&doi=10.1161%2F01.RES.87.12.1172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3'-kinase</span></div><div class="casAuthors">Chesley, Alan; Lundberg, Martha S.; Asai, Toshinobu; Xiao, Rui-Ping; Ohtani, Seiji; Lakatta, Edward G.; Crow, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1172-1179</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent studies have shown that chronic β-adrenergic receptor (β-AR) stimulation alters cardiac myocyte survival in a receptor subtype-specific manner.  The authors examd. the effect of selective β1- and β2-AR subtype stimulation on apoptosis induced by hypoxia or H2O2 in rat neonatal cardiac myocytes.  Although neither β1- nor β2-AR stimulation had any significant effect on the basal level of apoptosis, selective β2-AR stimulation protected myocytes from apoptosis.  β2-AR stimulation markedly increased mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK) activation as well as phosphatidylinositol-3'-kinase (PI-3K) activity and Akt/protein kinase B phosphorylation.  β1-AR stimulation also markedly increased MAPK/ERK activation but only minimally activated PI-3K and Akt.  Pretreatment with pertussis toxin blocked β2-AR-mediated protection from apoptosis as well as the β2-AR-stimulated changes in MAPK/ERK, PI-3K, and Akt/protein kinase B.  The selective PI-3K inhibitor, LY 294002, also blocked β2-AR-mediated protection, whereas inhibition of MAPK/ERK activation at an inhibitor concn. that blocked agonist-induced activation but not the basal level of activation had no effect on β2-AR-mediated protection.  These findings demonstrate that β2-ARS activate a PI-3K-dependent, pertussis toxin-sensitive signaling pathway in cardiac myocytes that is required for protection from apoptosis-inducing stimuli often assocd. with ischemic stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMsvZU2hkzRrVg90H21EOLACvtfcHk0lhA-nkgYOO8Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslyntbY%253D&md5=db3e73951926ceb1ada3c490a6ab981c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1161%2F01.RES.87.12.1172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.87.12.1172%26sid%3Dliteratum%253Aachs%26aulast%3DChesley%26aufirst%3DA.%26aulast%3DLundberg%26aufirst%3DM.%2BS.%26aulast%3DAsai%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DOhtani%26aufirst%3DS.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DCrow%26aufirst%3DM.%2BT.%26atitle%3DThe%2520beta%25282%2529-adrenergic%2520receptor%2520delivers%2520an%2520antiapoptotic%2520signal%2520to%2520cardiac%2520myocytes%2520through%2520G%2528i%2529-dependent%2520coupling%2520to%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%26jtitle%3DCirc.%2520Res.%26date%3D2000%26volume%3D87%26spage%3D1172%26epage%3D1179%26doi%3D10.1161%2F01.RES.87.12.1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. W.</span></span> <span> </span><span class="NLM_article-title">ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure</span>. <i>Cell Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1038/s41421-018-0058-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41421-018-0058-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30374408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3cvks1ersA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=57-69&author=J.+Huangauthor=C.+Liauthor=Y.+Songauthor=X.+Fanauthor=L.+Youauthor=L.+Tanauthor=L.+Xiaoauthor=Q.+Liauthor=G.+Ruanauthor=S.+Huauthor=W.+Cuiauthor=Z.+Liauthor=L.+Niauthor=C.+Chenauthor=A.+Y.+Wooauthor=R.+P.+Xiaoauthor=D.+W.+Wang&title=ADRB2+polymorphism+Arg16Gly+modifies+the+natural+outcome+of+heart+failure+and+dictates+therapeutic+response+to+%CE%B2-blockers+in+patients+with+heart+failure&doi=10.1038%2Fs41421-018-0058-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure</span></div><div class="casAuthors">Huang Jin; Li Chenze; Tan Lun; Xiao Lei; Li Qing; Ruan Guoran; Hu Senlin; Li Zongzhe; Ni Li; Chen Chen; Wang Dao Wen; Huang Jin; Li Chenze; Chen Chen; Wang Dao Wen; Song Ying; Woo Anthony Yiu-Ho; Xiao Rui-Ping; Fan Xiaohan; You Ling; Cui Wei; Woo Anthony Yiu-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Cell discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn">2056-5968</span>.
    </div><div class="casAbstract">We sought to investigate the association of single nucleotide polymorphisms (SNPs) of the genes involved in βAR signaling with the response of patients to βAR blockers.  A total of 2403 hospitalized patients with chronic heart failure (HF) were enrolled in a multicenter observational study as the first cohort and followed up for a mean period of 20 months.  Genes for β1AR, β2AR, and the major cardiac G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 were analyzed to identify SNPs, and patients were stratified according to genotypes.  A second independent cohort enrolling 919 patients with chronic HF was applied to validate the observed associations.  The signaling properties of the key identified SNPs were assessed in vitro.  Our data showed that HF patients harboring the Gly16 allele in the gene for β2AR (ADRB2) had an increased risk of the composite end point relative to patients who were homozygous for Arg16.  Notably, these patients showed a beneficial response to βAR-blocker treatment in a G allele-dose-dependent manner, whereas Arg16 homozygotes had no response to βAR-blocker therapy.  This Arg16Gly genotype-dependent heterogeneity in clinical outcomes of HF was successfully validated in the second independent population.  Besides, the in vitro experiments revealed that G allele carriers were defective in β2AR-coupled inhibitory adenylate cyclase g (Gi) protein signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqb2LL6397p_9pSBfyDvp7fW6udTcc2ebxNgBpt4ioi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvks1ersA%253D%253D&md5=f3296538e181a91b898865f4fc5fb368</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fs41421-018-0058-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41421-018-0058-6%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DRuan%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DWang%26aufirst%3DD.%2BW.%26atitle%3DADRB2%2520polymorphism%2520Arg16Gly%2520modifies%2520the%2520natural%2520outcome%2520of%2520heart%2520failure%2520and%2520dictates%2520therapeutic%2520response%2520to%2520%25CE%25B2-blockers%2520in%2520patients%2520with%2520heart%2520failure%26jtitle%3DCell%2520Discovery%26date%3D2018%26volume%3D4%26spage%3D57%26epage%3D69%26doi%3D10.1038%2Fs41421-018-0058-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pharmthera.2005.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15979723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2005&pages=257-268&author=M.+Zhengauthor=W.+Zhuauthor=Q.+Hanauthor=R.+P.+Xiao&title=Emerging+concepts+and+therapeutic+implications+of+beta-adrenergic+receptor+subtype+signaling&doi=10.1016%2Fj.pharmthera.2005.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling</span></div><div class="casAuthors">Zheng, Ming; Zhu, Weizhong; Han, Qide; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-268</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review highlighting the distinct functionalities and signaling mechanisms of the 3 βAR subtypes in the heart and discussing how subtype-specific properties of βARs might affect the pathogenesis of congestive heart failure (CHF) and the therapeutic effectiveness of certain β-blockers in the treatment of congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdqLtg9deo2rVg90H21EOLACvtfcHk0lhA-nkgYOO8Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr7L&md5=6547f244c6d51273ce03c02b3a6ffa01</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DEmerging%2520concepts%2520and%2520therapeutic%2520implications%2520of%2520beta-adrenergic%2520receptor%2520subtype%2520signaling%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D108%26spage%3D257%26epage%3D268%26doi%3D10.1016%2Fj.pharmthera.2005.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdonin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balke, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span> <span> </span><span class="NLM_article-title">Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1633</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000087595.17277.73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.0000087595.17277.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12975249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsVKrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2003&pages=1633-1639&author=R.+P.+Xiaoauthor=S.+J.+Zhangauthor=K.+Chakirauthor=P.+Avdoninauthor=W.+Zhuauthor=R.+A.+Bondauthor=C.+W.+Balkeauthor=E.+G.+Lakattaauthor=H.+Cheng&title=Enhanced+G%28i%29+signaling+selectively+negates+beta2-adrenergic+receptor+%28AR%29-but+not+beta1-AR-mediated+positive+inotropic+effect+in+myocytes+from+failing+rat+hearts&doi=10.1161%2F01.CIR.0000087595.17277.73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Gi Signaling Selectively Negates β2-Adrenergic Receptor (AR)- but Not β1-AR-Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts</span></div><div class="casAuthors">Xiao, Rui-Ping; Zhang, Sheng-Jun; Chakir, Khalid; Avdonin, Pavel; Zhu, Weizhong; Bond, Richard A.; Balke, C. William; Lakatta, Edward G.; Cheng, Heping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1633-1639</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Myocardial contractile response to β1- and β2-adrenergic receptor (AR) stimulation is severely impaired in chronic heart failure, in which Gi signaling and the ratio of β2/β1 are often increased.  Because β2-AR but not β1-AR couples to Gs and Gi with the Gi coupling negating the Gs-mediated contractile response, the authors detd. whether the heart failure-assocd. augmentation of Gi signaling contributes differentially to the defects of these β-AR subtypes and, if so, whether inhibition of Gi or selective activation of β2-AR/Gs by ligands restores β2-AR contractile response in the failing heart.  Cardiomyocytes were isolated from 18- to 24-mo-old failing spontaneously hypertensive (SHR) or age-matched Wistar-Kyoto (WKY) rat hearts.  In SHR cardiomyocytes, either β-AR subtype-mediated inotropic effect was markedly diminished, whereas Gi proteins and the β2/β1 ratio were increased.  Disruption of Gi signaling by pertussis toxin (PTX) enabled β2- but not β1-AR to induce a full pos. inotropic response in SHR myocytes.  Furthermore, screening of a panel of β2-AR ligands revealed that the contractile response mediated by most β2-AR agonists, including zinterol, salbutamol, and procaterol, was potentiated by PTX, indicating concurrent Gs and Gi activation.  In contrast, fenoterol, another β2-AR agonist, induced a full pos. inotropic effect in SHR myocytes even in the absence of PTX.  We conclude that enhanced Gi signaling is selectively involved in the dysfunction of β2- but not β1-AR in failing SHR hearts and that disruption of Gi signaling by PTX or selective activation of β2-AR/Gs signaling by fenoterol restores the blunted β2-AR contractile response in the failing heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BQ8TPDdqR7Vg90H21EOLACvtfcHk0ljQ6ZhfeUVttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsVKrs78%253D&md5=9b7e777b4a1bd560ca8fd9614e267b87</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000087595.17277.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000087595.17277.73%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DAvdonin%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBond%26aufirst%3DR.%2BA.%26aulast%3DBalke%26aufirst%3DC.%2BW.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DCheng%26aufirst%3DH.%26atitle%3DEnhanced%2520G%2528i%2529%2520signaling%2520selectively%2520negates%2520beta2-adrenergic%2520receptor%2520%2528AR%2529-but%2520not%2520beta1-AR-mediated%2520positive%2520inotropic%2520effect%2520in%2520myocytes%2520from%2520failing%2520rat%2520hearts%26jtitle%3DCirculation%26date%3D2003%26volume%3D108%26spage%3D1633%26epage%3D1639%26doi%3D10.1161%2F01.CIR.0000087595.17277.73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span> <span> </span><span class="NLM_article-title">Beneficial effects of chronic pharmacological manipulation of β-adrenoceptor subtype signaling in rodent dilated ischemic cardiomyopathy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000139844.15045.F9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.0000139844.15045.F9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15313944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvV2gt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2004&pages=1083-1090&author=I.+Ahmetauthor=M.+Krawczykauthor=P.+Hellerauthor=C.+Moonauthor=E.+G.+Lakattaauthor=M.+I.+Talan&title=Beneficial+effects+of+chronic+pharmacological+manipulation+of+%CE%B2-adrenoceptor+subtype+signaling+in+rodent+dilated+ischemic+cardiomyopathy&doi=10.1161%2F01.CIR.0000139844.15045.F9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial Effects of Chronic Pharmacological Manipulation of β-Adrenoreceptor Subtype Signaling in Rodent Dilated Ischemic Cardiomyopathy</span></div><div class="casAuthors">Ahmet, Ismayil; Krawczyk, Melissa; Heller, Phillip; Moon, Chanil; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1083-1090</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background - Studies in isolated cardiac myocytes have demonstrated that signaling via specific β1-adrenergic receptor subtypes (β1ARs) promotes but that signaling via β2ARs protects from cell death.  We hypothesized that prolonged β2AR stimulation or β1AR blockade would each protect myocytes from death and thereby ameliorate cardiac remodeling in chronic heart failure.  Methods and Results - A large myocardial infarction (MI) induced in rats by coronary artery ligation resulted in a dilated cardiomyopathy (DCM) characterized by infarct expansion and a progressive increase in left ventricular (LV) end-diastolic vol., accompanied by a redn. in ejection fraction (EF), as assessed by repeated echocardiog.  Pressure-vol. anal. at 8 wk after ligation showed that diastolic stiffness (Eed) and arterial elastance (Ea) were increased, end-systolic elastance (Ees) was decreased, and arterioventricular (AV) coupling (Ea/Ees) had deteriorated.  Apoptosis was present in both peri-infarct and remote myocardium.  Chronic (6-wk) administration of the β2AR agonists fenoterol or zinterol, starting at 2 wk after MI, reduced the extent of LV dilation, infarct expansion, and EF decline.  The β1AR blocker metoprolol did not affect the former and preserved EF to a lesser extent than did the β2AR agonists.  At 8 wk after ligation, apoptosis was reduced by all drugs but to a greater extent by β2AR agonists than by the β1AR blocker.  Both β2AR agonists and the β1AR blocker improved AV coupling, the former mainly by reducing Ea and the latter mainly by increasing Ees.  Only the β2AR agonists reduced the Eed and the MI size by reducing infarct expansion.  Conclusions - These results provide proof of concept for the efficacy of chronic β2AR stimulation in this DCM model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJYqzYHWsIJrVg90H21EOLACvtfcHk0ljQ6ZhfeUVttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvV2gt7k%253D&md5=5cad698789a2e3433800aac01df4bafb</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000139844.15045.F9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000139844.15045.F9%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DHeller%26aufirst%3DP.%26aulast%3DMoon%26aufirst%3DC.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%2BI.%26atitle%3DBeneficial%2520effects%2520of%2520chronic%2520pharmacological%2520manipulation%2520of%2520%25CE%25B2-adrenoceptor%2520subtype%2520signaling%2520in%2520rodent%2520dilated%2520ischemic%2520cardiomyopathy%26jtitle%3DCirculation%26date%3D2004%26volume%3D110%26spage%3D1083%26epage%3D1090%26doi%3D10.1161%2F01.CIR.0000139844.15045.F9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological stimulation of β<sub>2</sub>-adrenergic receptors (β<sub>2</sub>AR) enhances therapeutic effectiveness of β<sub>1</sub>AR blockade in rodent dilated ischemic cardiomyopathy</span>. <i>Heart Failure Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1007/s10741-005-7543-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs10741-005-7543-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16583177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVKmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=289-296&author=I.+Ahmetauthor=E.+G.+Lakattaauthor=M.+Talan&title=Pharmacological+stimulation+of+%CE%B22-adrenergic+receptors+%28%CE%B22AR%29+enhances+therapeutic+effectiveness+of+%CE%B21AR+blockade+in+rodent+dilated+ischemic+cardiomyopathy&doi=10.1007%2Fs10741-005-7543-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Stimulation of β2-adrenergic Receptors (β2AR) Enhances Therapeutic Effectiveness of β1AR Blockade in Rodent Dilated Ischemic Cardiomyopathy</span></div><div class="casAuthors">Ahmet, Ismayil; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Heart Failure Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-296</span>CODEN:
                <span class="NLM_cas:coden">HFREFC</span>;
        ISSN:<span class="NLM_cas:issn">1382-4147</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: We have reported that β2 adrenoreceptor (β2AR) stimulation is anti-apoptotic, and has strong beneficial effect on cardiac remodeling in an exptl. model of post myocardial infarction chronic heart failure (CHF) in rats.  Here we investigate whether the addn. of chronic pharmacol. β2AR stimulation enhances the therapeutic effects of β1AR blockade on cardiac remodeling in the same model.  Methods and Results: Metoprolol, a β1AR blocker, given alone (β1) or in combination with β2AR agonist, fenoterol (β1β2) were administered to rats via drinking water for 6 wk, beginning 2 wk following permanent coronary ligation.  Progressive left ventricular (LV) remodeling of untreated animals, assessed by repeated echocardiog., occurred during the observation time, i.e., 42% and 25% increases in end-systolic and end-diastolic LV vols. resp., 27% fall in ejection fraction, and 35% infarct expansion.  Pressure-vol. loop analyses at 2d and 8th post infarction weeks showed continuous deterioration of systolic and diastolic functions and arterio-ventricular mismatch.  Histol. evaluation at the end of 8 wk revealed the MI expansion and hypertrophy of cardiomyocytes. β1β2 prevented LV remodeling, MI expansion and cardiomyocytes hypertrophy to a greater degree than β1, due, in large part, to a vasodilatory effect of β2AR stimulation and thus improvement of arterio-ventricular mismatch.  The abnormal diastolic performance improved only in β1β2. β1β2 treatment reduced myocardial apoptosis throughout myocardium, but β1 reduced apoptosis only in the areas remote from MI.  Conclusion: The therapeutic effects of chronic β1AR blockade on cardiac remodeling of heart failure are enhanced and extended when supplemented with β2AR stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqtXw6O8PwbbVg90H21EOLACvtfcHk0ljQ6ZhfeUVttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVKmt7g%253D&md5=ec29cc0c44a75a23cce1828d65e412fa</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs10741-005-7543-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10741-005-7543-3%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%26atitle%3DPharmacological%2520stimulation%2520of%2520%25CE%25B22-adrenergic%2520receptors%2520%2528%25CE%25B22AR%2529%2520enhances%2520therapeutic%2520effectiveness%2520of%2520%25CE%25B21AR%2520blockade%2520in%2520rodent%2520dilated%2520ischemic%2520cardiomyopathy%26jtitle%3DHeart%2520Failure%2520Rev.%26date%3D2005%26volume%3D10%26spage%3D289%26epage%3D296%26doi%3D10.1007%2Fs10741-005-7543-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poosala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span> <span> </span><span class="NLM_article-title">Cardioprotective and survival benefits of long-term combined therapy with β<sub>2</sub>AR agonist and β<sub>1</sub>AR blocker in dilated cardiomyopathy postmyocardial infarction</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.135335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.107.135335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18287209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=491-499&author=I.+Ahmetauthor=M.+Krawczykauthor=W.+Zhuauthor=A.+Y.+Wooauthor=C.+Morrellauthor=S.+Poosalaauthor=R.+P.+Xiaoauthor=E.+G.+Lakattaauthor=M.+I.+Talan&title=Cardioprotective+and+survival+benefits+of+long-term+combined+therapy+with+%CE%B22AR+agonist+and+%CE%B21AR+blocker+in+dilated+cardiomyopathy+postmyocardial+infarction&doi=10.1124%2Fjpet.107.135335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Cardioprotective and survival benefits of long-term combined therapy with β2 adrenoreceptor (AR) agonist and β1 AR blocker in dilated cardiomyopathy postmyocardial infarction</span></div><div class="casAuthors">Ahmet, Ismayil; Krawczyk, Melissa; Zhu, Weizhong; Woo, Anthony Yiu-Ho; Morrell, Christopher; Poosala, Suresh; Xiao, Riu-ping; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">491-499</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have reported therapeutic effectiveness of pharmacol. stimulation of β2 adrenoreceptors (ARs) to attenuate the cardiac remodeling and myocardial infarction (MI) expansion in a rat model of dilated cardiomyopathy (DCM) post-MI.  Furthermore, the combination of β2 AR stimulation with β1 AR blockade exceeded the therapeutic effectiveness of β1 AR blockade.  However, these studies were relatively short (6 wk).  In this study, in the same exptl. model, we compared different effects, including survival benefit, of combined therapy with the β1 AR blocker, metoprolol, plus the β2 AR agonist, fenoterol (β1- β2+), and either therapy alone (β1- or β2+) during the 1-yr study.  Therapy was started 2 wk after permanent ligation of the left coronary artery.  Cardiac remodeling, MI expansion, and left ventricular function were assessed by serial echocardiog. and compared with untreated animals (nT).  Sixty-seven percent mortality in nT was reduced to 33% in the β1- β2+ (p < 0.01).  Progressive cardiac remodeling obsd. in nT and β1- was significantly attenuated in β1- β2+ during the first 6 mo of treatment.  In β1- β2+, MI expansion was completely prevented, and functional decline was significantly attenuated during the entire year.  Myocardial apoptosis was significantly reduced in both β1- β2+ and β1-.  A redn. of cardiac β1 AR d. and decreases in chronotropic and contractile responses to β2 AR-specific stimulation in the absence of a redn. of β2 AR d. in nT were precluded in rats receiving combined therapy.  The results demonstrate the cardioprotective and survival benefit of long-term combination therapy of β2 AR agonists and β1 AR blockers in a model of DCM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsrdgZchcz6LVg90H21EOLACvtfcHk0lh5B3rmEPuLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsbc%253D&md5=02f84ec640112731bdcf2eddb3de1c60</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.135335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.135335%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DMorrell%26aufirst%3DC.%26aulast%3DPoosala%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%2BI.%26atitle%3DCardioprotective%2520and%2520survival%2520benefits%2520of%2520long-term%2520combined%2520therapy%2520with%2520%25CE%25B22AR%2520agonist%2520and%2520%25CE%25B21AR%2520blocker%2520in%2520dilated%2520cardiomyopathy%2520postmyocardial%2520infarction%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D491%26epage%3D499%26doi%3D10.1124%2Fjpet.107.135335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a combination of a β<sub>1</sub>-adrenoreceptor (AR) blocker and β<sub>2</sub>-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a β<sub>1</sub>-AR blocker plus angiotensin-converting enzyme inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.157107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.109.157107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19587314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GjtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=178-185&author=I.+Ahmetauthor=C.+Morrellauthor=E.+G.+Lakattaauthor=M.+I.+Talan&title=Therapeutic+efficacy+of+a+combination+of+a+%CE%B21-adrenoreceptor+%28AR%29+blocker+and+%CE%B22-AR+agonist+in+a+rat+model+of+postmyocardial+infarction+dilated+heart+failure+exceeds+that+of+a+%CE%B21-AR+blocker+plus+angiotensin-converting+enzyme+inhibitor&doi=10.1124%2Fjpet.109.157107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a combination of a β1-adrenoreceptor (AR) blocker and β2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a β1-AR blocker plus angiotensin-converting enzyme inhibitor</span></div><div class="casAuthors">Ahmet, Ismail; Morrell, Chris; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-185</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We had proposed previously a novel combination of β2-adrenoreceptor (AR) agonist and β1-AR blocker that in the rat model of postmyocardial infarction (MI) dilated cardiomyopathy exceeds the therapeutic effectiveness of either monotherapy.  In the present study, we compared that treatment with a combination of β1-AR blocker and angiotensin-converting enzyme inhibitor (ACEi), a current std. chronic heart failure (CHF) therapy.  Two weeks after coronary artery ligation, rats were divided into groups of similar av. MI size, measured by echocardiog., and the following 12-mo treatments were initiated: fenoterol (250 μg/kg/day), a β2-AR agonist, plus metoprolol (100 mg/kg/day), a β1-AR blocker (β1-β2+); metoprolol plus enalapril (20 mg/kg/day), an ACEi (β1-ACEi); and a combination of all three drugs (β1-β2 + ACEi).  These treatment groups were compared with each other and with nontreated (nT) and sham groups.  The 12-mo mortality was significantly reduced in all treatment groups (44% in β1-β2+, 56% in β1-β2 + ACEi, 59% in β1-ACEi vs. 81% in nT).  Bimonthly echocardiog. revealed significant attenuation of the left ventricular (LV) chamber remodeling, LV functional deterioration, and MI expansion in all three treatment groups, but effects were significantly more pronounced when treatment included a β2-AR agonist.  The results indicated that a combination of β1-AR blocker and β2-AR agonist is equipotent to a combination of β1-AR blocker and ACEi in the treatment of CHF in rats, with the respect to mortality, and exceeds the latter with respect to cardiac remodeling and MI expansion.  Thus, this novel therapeutic regimen for CHF warrants detailed clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraZxsoFKfX_bVg90H21EOLACvtfcHk0lh5B3rmEPuLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GjtL7L&md5=dd3c4059426975312797578fcd38f968</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.157107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.157107%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DMorrell%26aufirst%3DC.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%2BI.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520combination%2520of%2520a%2520%25CE%25B21-adrenoreceptor%2520%2528AR%2529%2520blocker%2520and%2520%25CE%25B22-AR%2520agonist%2520in%2520a%2520rat%2520model%2520of%2520postmyocardial%2520infarction%2520dilated%2520heart%2520failure%2520exceeds%2520that%2520of%2520a%2520%25CE%25B21-AR%2520blocker%2520plus%2520angiotensin-converting%2520enzyme%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D178%26epage%3D185%26doi%3D10.1124%2Fjpet.109.157107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimaano, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartunek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaselli, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, D. A.</span></span> <span> </span><span class="NLM_article-title">Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">100ra88</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3001909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscitranslmed.3001909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21918105" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=K.+Chakirauthor=C.+Depryauthor=V.+L.+Dimaanoauthor=W.+Z.+Zhuauthor=M.+Vanderheydenauthor=J.+Bartunekauthor=T.+P.+Abrahamauthor=G.+F.+Tomaselliauthor=S.+B.+Liuauthor=Y.+K.+Xiangauthor=M.+Zhangauthor=E.+Takimotoauthor=N.+Dulinauthor=R.+P.+Xiaoauthor=J.+Zhangauthor=D.+A.+Kass&title=Galphas-biased+beta2-adrenergic+receptor+signaling+from+restoring+synchronous+contraction+in+the+failing+heart&doi=10.1126%2Fscitranslmed.3001909"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001909%26sid%3Dliteratum%253Aachs%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DDepry%26aufirst%3DC.%26aulast%3DDimaano%26aufirst%3DV.%2BL.%26aulast%3DZhu%26aufirst%3DW.%2BZ.%26aulast%3DVanderheyden%26aufirst%3DM.%26aulast%3DBartunek%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DT.%2BP.%26aulast%3DTomaselli%26aufirst%3DG.%2BF.%26aulast%3DLiu%26aufirst%3DS.%2BB.%26aulast%3DXiang%26aufirst%3DY.%2BK.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DTakimoto%26aufirst%3DE.%26aulast%3DDulin%26aufirst%3DN.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKass%26aufirst%3DD.%2BA.%26atitle%3DGalphas-biased%2520beta2-adrenergic%2520receptor%2520signaling%2520from%2520restoring%2520synchronous%2520contraction%2520in%2520the%2520failing%2520heart%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26doi%3D10.1126%2Fscitranslmed.3001909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-adrenergic receptor-induced transactivation of EGFR and PDGFR via SRC kinase promotes rat cardiomyocytes survival</span>. <i>Cell Biol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1042/CBI20110162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1042%2FCBI20110162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21954875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFCitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=237-244&author=H.+Chenauthor=N.+Maauthor=J.+Xiaauthor=J.+Liuauthor=Z.+Xu&title=%CE%B22-adrenergic+receptor-induced+transactivation+of+EGFR+and+PDGFR+via+SRC+kinase+promotes+rat+cardiomyocytes+survival&doi=10.1042%2FCBI20110162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic receptor-induced transactivation of epidermal growth factor receptor and platelet-derived growth factor receptor via Src kinase promotes rat cardiomyocyte survival</span></div><div class="casAuthors">Chen, Hao; Ma, Ning; Xia, Jing; Liu, Jinfen; Xu, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-244</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1065-6995</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Chronic stimulation of the β-AR (adrenergic receptor) promotes apoptosis of cardiomyocytes, which is implicated in cardiac dysfunction. β1-AR and β2-AR are the main subtypes of β-AR that exert distinct effects on the survival of cardiomyocytes.  To clarify the physiol. roles of β1-AR and β2-AR in cardiomyocytes, the effects of β1-AR or β2-AR knockdown on the survival of H9c2 cardiomyocytes was investigated.  Knockdown of β2-AR, but not β1-AR, suppressed the phosphorylation of EGFR (epidermal growth factor receptor) and PDGFR (platelet-derived growth factor receptor) induced by ISO (isoprenaline).  The EGFR inhibitor, AG1478, attenuated ERK (extracellular-signal-regulated kinase) activation and partially decreased cell survival.  Pretreatment with AG1296, a PDGFR inhibitor, abolished ISO-induced Akt (also known as protein kinase B) phosphorylation and led to a decrease in cell viability.  In addn., the Src tyrosine kinase inhibitor, PP2, blocked ISO-mediated both Akt and ERK activation and heavily suppressed viability.  Accordingly, in primary neonatal rat cardiomyocytes, the β2-AR inhibitor, but not the β1-AR inhibitor, abrogated the transactivation of EGFR and PDGFR, which was resp. related to Akt and ERK activation.  The results show that β2-AR transactivates PDGFR and EGFR, thereby promoting survival of cardiomyocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPlITuhpg5CbVg90H21EOLACvtfcHk0lh5B3rmEPuLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFCitbw%253D&md5=d9fc659020204749f928f2f90163341c</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1042%2FCBI20110162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCBI20110162%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26atitle%3D%25CE%25B22-adrenergic%2520receptor-induced%2520transactivation%2520of%2520EGFR%2520and%2520PDGFR%2520via%2520SRC%2520kinase%2520promotes%2520rat%2520cardiomyocytes%2520survival%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2012%26volume%3D36%26spage%3D237%26epage%3D244%26doi%3D10.1042%2FCBI20110162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuenaes, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingvaldsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommundstad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-Adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00677.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2010.00677.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20412069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslyqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=116-129&author=J.+T.+Stuenaesauthor=A.+Bollingauthor=A.+Ingvaldsenauthor=C.+Rommundstadauthor=E.+Sudarauthor=F.+C.+Linauthor=Y.+C.+Laiauthor=J.+Jensen&title=%CE%B22-Adrenoceptor+stimulation+potentiates+insulin-stimulated+PKB+phosphorylation+in+rat+cardiomyocytes+via+cAMP+and+PKA&doi=10.1111%2Fj.1476-5381.2010.00677.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">β-Adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA</span></div><div class="casAuthors">Stuenaes, Jorid T.; Bolling, Astrid; Ingvaldsen, Ada; Rommundstad, Camilla; Sudar, Emina; Lin, Fang-Chin; Lai, Yu-Chiang; Jensen, Joergen</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Genetic approaches have documented protein kinase B (PKB) as a pivotal regulator of heart function.  Insulin strongly activates PKB, whereas adrenaline is not considered a major physiol. regulator of PKB in heart.  In skeletal muscles, however, adrenaline potentiates insulin-stimulated PKB activation without having effect in the absence of insulin.  The purpose of the present study was to investigate the interaction between insulin and β-adrenergic stimulation in regulation of PKB phosphorylation.  Cardiomyocytes were isolated from adult rats by collagenase, and incubated with insulin, isoprenaline, and other compds.  Protein phosphorylation was evaluated by Western blot and phospho-specific antibodies.  Isoprenaline increased insulin-stimulated PKB Ser473 and Thr308 phosphorylation more than threefold in cardiomyocytes.  Isoprenaline alone did not increase PKB phosphorylation.  Isoprenaline also increased insulin-stimulated GSK-3β Ser9 phosphorylation approx. twofold, supporting that PKB phosphorylation increased kinase activity.  Dobutamine (β1-agonist) increased insulin-stimulated PKB phosphorylation as effectively as isoprenaline (more than threefold), whereas salbutamol (β2-agonist) only potentiated insulin-stimulated PKB phosphorylation by approx. 80%.  Dobutamine, but not salbutamol, increased phospholamban Ser16 phosphorylation and glycogen phosphorylase activation (PKA-mediated effects).  Furthermore, the cAMP analog that activates PKA (dibutyryl-cAMP and N6-benzoyl-cAMP) increased insulin-stimulated PKB phosphorylation by more than threefold without effect alone.  The Epac-specific activator 8-(4-chlorophenylthio)-2'-O-methyl-cAMP (007) increased insulin-stimulated PKB phosphorylation by approx. 50%.  Db-cAMP and N6-benzoyl-cAMP, but not 007, increased phospholamban Ser16 phosphorylation.  β-adrenoceptors are strong regulators of PKB phosphorylation via cAMP and PKA when insulin is present.  We hypothesize that PKB mediates important signaling in the heart during β-adrenergic receptors stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrExtSiK0UwNrVg90H21EOLACvtfcHk0lj-ZBte30q2uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslyqtLs%253D&md5=9bafaa3c4a2265bcf4c95d6d17fe2d08</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00677.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00677.x%26sid%3Dliteratum%253Aachs%26aulast%3DStuenaes%26aufirst%3DJ.%2BT.%26aulast%3DBolling%26aufirst%3DA.%26aulast%3DIngvaldsen%26aufirst%3DA.%26aulast%3DRommundstad%26aufirst%3DC.%26aulast%3DSudar%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DF.%2BC.%26aulast%3DLai%26aufirst%3DY.%2BC.%26aulast%3DJensen%26aufirst%3DJ.%26atitle%3D%25CE%25B22-Adrenoceptor%2520stimulation%2520potentiates%2520insulin-stimulated%2520PKB%2520phosphorylation%2520in%2520rat%2520cardiomyocytes%2520via%2520cAMP%2520and%2520PKA%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D116%26epage%3D129%26doi%3D10.1111%2Fj.1476-5381.2010.00677.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickenson, J. M.</span></span> <span> </span><span class="NLM_article-title">Induction of beta3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">392</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.090597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.090597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16183708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=392-402&author=R.+Germackauthor=J.+M.+Dickenson&title=Induction+of+beta3-adrenergic+receptor+functional+expression+following+chronic+stimulation+with+noradrenaline+in+neonatal+rat+cardiomyocytes&doi=10.1124%2Fjpet.105.090597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of β3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes</span></div><div class="casAuthors">Germack, Renee; Dickenson, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">392-402</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study aimed to characterize β3-adrenergic receptors (ARs) in rat neonatal cardiomyocytes using the noradrenaline (NOR) properties to modulate the expression and function of the three β-ARs.  The authors assessed the effect of NOR (physiol. nonselective agonist), isoprenaline (ISO, β-nonselective agonist), dobutamine (DOB, β1-selective agonist), and procaterol (PROC, β2-selective agonist) on cAMP accumulation using cardiomyocytes untreated or treated with 100 μM NOR for 24 h.  The inhibition of forskolin-stimulated cAMP accumulation was detd. using NOR, isoprenaline, and the β3-selective agonists 4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxyacetic acid (BRL 37344) and 5-[-2-([-2-(3-chlorophenyl)-2-hydroxyethyl]amino)propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243).  The expts. were performed in the absence or presence of propranolol or 2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP 20712A) and/or 1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride (ICI 118551) to inhibit β1- and β2-AR stimulation and 1-(2-ethylphenoxy)-3-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino-(2S)-2-propanol hydrochloride (SR 59230A) (β3-selective antagonist).  In addn., the level of the three subtypes was detd. by reverse transcription polymerase chain reaction and Western blotting.  NOR pretreatment decreased the activation of cAMP induced by NOR, isoprenaline, and DOB, whereas PROC response was abolished.  The inhibition of NOR response by CGP 20712A or ICI 118551 demonstrated that β1- and β2-ARs are down-regulated and that β2-AR functional activity was also abolished in cardiomyocytes exposed to chronic stimulation.  β3-AR function was obsd. with NOR and ISO when β1-/β2-ARs were blocked and with both β3-selective agonists in NOR-treated cells only.  This response was completely inhibited by SR 59230A and involved Gi protein.  Furthermore, the results from functional studies agree well with those from expression expts.  In conclusion, these data provide strong evidence that β3-ARs are functionally upregulated and coupled to Gi protein in rat neonatal cardiomyocytes following chronic exposure to NOR when β1- and β2-ARs are down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmWhDan2vgLVg90H21EOLACvtfcHk0lj-ZBte30q2uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslCitA%253D%253D&md5=03a1b347f4d40b3a4ae9910d220a5cf0</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.090597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.090597%26sid%3Dliteratum%253Aachs%26aulast%3DGermack%26aufirst%3DR.%26aulast%3DDickenson%26aufirst%3DJ.%2BM.%26atitle%3DInduction%2520of%2520beta3-adrenergic%2520receptor%2520functional%2520expression%2520following%2520chronic%2520stimulation%2520with%2520noradrenaline%2520in%2520neonatal%2520rat%2520cardiomyocytes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D392%26epage%3D402%26doi%3D10.1124%2Fjpet.105.090597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavernier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpentier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Marec, H.</span></span> <span> </span><span class="NLM_article-title">Functional beta3-adrenoceptor in the human heart</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1172/JCI118823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI118823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8755668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK28XksFClt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1996&pages=556-562&author=C.+Gauthierauthor=G.+Tavernierauthor=F.+Charpentierauthor=D.+Langinauthor=H.+Le+Marec&title=Functional+beta3-adrenoceptor+in+the+human+heart&doi=10.1172%2FJCI118823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Functional β3-adrenoceptor in the human heart</span></div><div class="casAuthors">Gauthier, Chantal; Tavernier, Genevieve; Charpentier, Flavien; Langin, Dominique; Le Marec, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">556-562</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">β3-Adrenoceptors are involved in metab., gut relaxation, and vascular vasodilation.  However, their existence and role in the human heart have not been documented.  We investigated the effects of several β-adrenoceptor agonists and antagonists on the mech. properties of ventricular endomyocardial biopsies.  In the presence of nadolol, a β1 and β2-adrenoceptor antagonist, isoprenaline produced consistent neg. inotropic effects.  Similar neg. inotropic effects also resulted from the action of β3-adrenoceptor agonists with an order of potency: BRL 37344 > SR 58611 ≈ CL 316243 > CGP 12177.  The dose-response curve to BRL 37344-decreasing myocardial contractility was not modified by pretreatment with nadolol, but was shifted to the right by bupranolol, a nonselective β-adrenoceptor antagonist.  β3-Adrenoceptor agonists also induced a redn. in the amplitude and an acceleration in the repolarization phase of the human action potential.  β3-Adrenoceptor transcripts were detected in human ventricle by a polymerase chain reaction assay.  These results indicate that: (a) β3-adrenoceptors are present and functional in the human heart; and (b) these receptors are responsible for the unexpected neg. inotropic effects of catecholamines and may be involved in pathophysiol. mechanisms leading to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLi5eA29xcqbVg90H21EOLACvtfcHk0lj-ZBte30q2uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFClt7g%253D&md5=d471eb95964f32bcd4158e71b62b7134</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1172%2FJCI118823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI118823%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DC.%26aulast%3DTavernier%26aufirst%3DG.%26aulast%3DCharpentier%26aufirst%3DF.%26aulast%3DLangin%26aufirst%3DD.%26aulast%3DLe%2BMarec%26aufirst%3DH.%26atitle%3DFunctional%2520beta3-adrenoceptor%2520in%2520the%2520human%2520heart%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1996%26volume%3D98%26spage%3D556%26epage%3D562%26doi%3D10.1172%2FJCI118823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moniotte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobzik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trochu, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1655</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.103.12.1649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.103.12.1649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11273992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFWktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2001&pages=1649-1655&author=S.+Moniotteauthor=L.+Kobzikauthor=O.+Feronauthor=J.+N.+Trochuauthor=C.+Gauthierauthor=J.+L.+Balligand&title=Upregulation+of+beta%283%29-adrenoceptors+and+altered+contractile+response+to+inotropic+amines+in+human+failing+myocardium&doi=10.1161%2F01.CIR.103.12.1649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of β3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium</span></div><div class="casAuthors">Moniotte, Stephane; Kobzik, Lester; Feron, Olivier; Trochu, Jean-Noel; Gauthier, Chantal; Balligand, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1649-1655</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background-Contrary to β1- and β2-adrenoceptors, β3-adrenoceptors mediate a neg. inotropic effect in human ventricular muscle.  To assess their functional role in heart failure, our purpose was to compare the expression and contractile effect of β3-adrenoceptors in nonfailing and failing human hearts.  Methods and Results-We analyzed left ventricular samples from 29 failing (16 ischemic and 13 dilated cardiomyopathic) hearts (ejection fraction 18.6±2%) and 25 nonfailing (including 12 innervated) explanted hearts (ejection fraction 64.2±3%).  β3-Adrenoceptor proteins were identified by immunohistochem. in ventricular cardiomyocytes from nonfailing and failing hearts.  Contrary to β1-adrenoceptor mRNA, Western blot anal. of β3-adrenoceptor proteins showed a 2- to 3-fold increase in failing compared with nonfailing hearts.  A similar increase was obsd. for Gαi-2 proteins that couple β3-adrenoceptors to their neg. inotropic effect.  Contractile tension was measured in elec. stimulated myocardial samples ex vivo.  In failing hearts, the pos. inotropic effect of the nonspecific amine isoprenaline was reduced by 75% compared with that obsd. in nonfailing hearts.  By contrast, the neg. inotropic effect of β3-preferential agonists was only mildly reduced.  Conclusions-Opposite changes occur in β1- and β3-adrenoceptor abundance in the failing left ventricle, with an imbalance between their inotropic influences that may underlie the functional degrdn. of the human failing heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT34WD4d3hcbVg90H21EOLACvtfcHk0lhAYc-u3LWBUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFWktLk%253D&md5=6e2b01e291dc0f64d8ed1ed441a6395f</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.103.12.1649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.103.12.1649%26sid%3Dliteratum%253Aachs%26aulast%3DMoniotte%26aufirst%3DS.%26aulast%3DKobzik%26aufirst%3DL.%26aulast%3DFeron%26aufirst%3DO.%26aulast%3DTrochu%26aufirst%3DJ.%2BN.%26aulast%3DGauthier%26aufirst%3DC.%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DUpregulation%2520of%2520beta%25283%2529-adrenoceptors%2520and%2520altered%2520contractile%2520response%2520to%2520inotropic%2520amines%2520in%2520human%2520failing%2520myocardium%26jtitle%3DCirculation%26date%3D2001%26volume%3D103%26spage%3D1649%26epage%3D1655%26doi%3D10.1161%2F01.CIR.103.12.1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ukai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sane, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. P.</span></span> <span> </span><span class="NLM_article-title">Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1161/hh1901.098042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2Fhh1901.098042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11577025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFCgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2001&pages=599-606&author=H.+J.+Chengauthor=Z.+S.+Zhangauthor=K.+Onishiauthor=T.+Ukaiauthor=D.+C.+Saneauthor=C.+P.+Cheng&title=Upregulation+of+functional+beta%283%29-adrenergic+receptor+in+the+failing+canine+myocardium&doi=10.1161%2Fhh1901.098042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of functional β3-adrenergic receptor in the failing canine myocardium</span></div><div class="casAuthors">Cheng, Heng-Jie; Zhang, Zhu-Shan; Onishi, Katsuya; Ukai, Tomohiko; Sane, David C.; Cheng, Che-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">599-606</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Altered expression and functional responses to cardiac β3-adrenergic receptors (ARs) may contribute to progressive cardiac dysfunction in heart failure (CHF).  The authors compared myocyte β3-AR mRNA and protein levels and myocyte contractile, [Ca2+]i, transient, and Ca2+ current (lCaL) responses to BRL-37344 (BRL, 10-8 mol/L), a selective β3-AR agonist, in 9 instrumented dogs before and after pacing-induced CHF.  Myocytes were isolated from left ventricular myocardium biopsy tissues.  Using reverse transcription-polymerase chain reaction, the authors detected β3-AR mRNA from myocyte total RNA in each animal.  Using a cloned canine β3-AR cDNA probe and myocyte poly A+ RNA, the authors detected a single band about 3.4 kb in normal and CHF myocytes.  β3-AR protein was detected by Western blot.  β3-AR mRNA and protein levels were significantly greater in CHF myocytes than in normal myocytes.  Importantly, these changes were assocd. with enhanced β3-AR-mediated neg. modulation on myocyte contractile response and [Ca2+]i regulation.  Compared with normal myocytes, CHF myocytes had much greater decreases in the velocity of shortening and relengthening with BRL accompanied by larger redns. in the peak systolic [Ca2+]i transient and ICaL.  These responses were not modified by pretreating myocytes with metoprolol (a β1-AR antagonist) or nadolol (a β1- and β2-AR antagonist), but were nearly prevented by bupranolol or L-748,337 (β3-AR antagonists).  The authors conclude that in dogs with pacing-induced CHF β3-AR gene expression and protein levels are upregulated, and the functional response to β3-AR stimulation is increased.  This may contribute to progression of cardiac dysfunction in CHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2BR6yWZqzOrVg90H21EOLACvtfcHk0lhAYc-u3LWBUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFCgur4%253D&md5=e9a90a14a1e00d471d2e9faa6557d9d7</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1161%2Fhh1901.098042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhh1901.098042%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BS.%26aulast%3DOnishi%26aufirst%3DK.%26aulast%3DUkai%26aufirst%3DT.%26aulast%3DSane%26aufirst%3DD.%2BC.%26aulast%3DCheng%26aufirst%3DC.%2BP.%26atitle%3DUpregulation%2520of%2520functional%2520beta%25283%2529-adrenergic%2520receptor%2520in%2520the%2520failing%2520canine%2520myocardium%26jtitle%3DCirc.%2520Res.%26date%3D2001%26volume%3D89%26spage%3D599%26epage%3D606%26doi%3D10.1161%2Fhh1901.098042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois-Deruy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoury, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamelet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauloye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouleur, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jnaoui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götz, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herijgers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobysheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iaccarino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker-Kleiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavernier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dessy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Enhanced expression of β<sub>3</sub>-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.113.004940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCULATIONAHA.113.004940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24190960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ygsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=451-462&author=C.+Belgeauthor=J.+Hammondauthor=E.+Dubois-Deruyauthor=B.+Manouryauthor=J.+Hameletauthor=C.+Beauloyeauthor=A.+Marklauthor=A.+C.+Pouleurauthor=L.+Bertrandauthor=H.+Esfahaniauthor=K.+Jnaouiauthor=K.+R.+G%C3%B6tzauthor=V.+O.+Nikolaevauthor=A.+Vanderperauthor=P.+Herijgersauthor=I.+Lobyshevaauthor=G.+Iaccarinoauthor=D.+Hilfiker-Kleinerauthor=G.+Tavernierauthor=D.+Langinauthor=C.+Dessyauthor=J.+L.+Balligand&title=Enhanced+expression+of+%CE%B23-adrenoceptors+in+cardiac+myocytes+attenuates+neurohormone-induced+hypertrophic+remodeling+through+nitric+oxide+synthase&doi=10.1161%2FCIRCULATIONAHA.113.004940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Expression of β3-Adrenoceptors in Cardiac Myocytes Attenuates Neurohormone-Induced Hypertrophic Remodeling Through Nitric Oxide Synthase</span></div><div class="casAuthors">Belge, Catharina; Hammond, Joanna; Dubois-Deruy, Emilie; Manoury, Boris; Hamelet, Julien; Beauloye, Christophe; Markl, Andreas; Pouleur, Anne-Catherine; Bertrand, Luc; Esfahani, Hrag; Jnaoui, Karima; Goetz, Konrad R.; Nikolaev, Viacheslav O.; Vanderper, Annelies; Herijgers, Paul; Lobysheva, Irina; Iaccarino, Guido; Hilfiker-Kleiner, Denise; Tavernier, Genevieve; Langin, Dominique; Dessy, Chantal; Balligand, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">451-462</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: β1-2-adrenergic receptors (AR) are key regulators of cardiac contractility and remodeling in response to catecholamines.  β3-AR expression is enhanced in diseased human myocardium, but its impact on remodeling is unknown.  METHODS AND RESULTS-: Mice with cardiac myocyte-specific expression of human β3-AR (β3-TG) and wild-type (WT) littermates were used to compare myocardial remodeling in response to isoproterenol (Iso) or Angiotensin II (Ang II).  β3-TG and WT had similar morphometric and hemodynamic parameters at baseline. β3-AR colocalized with caveolin-3, endothelial nitric oxide synthase (NOS) and neuronal NOS in adult transgenic myocytes, which constitutively produced more cyclic GMP, detected with a new transgenic FRET sensor.  Iso and Ang II produced hypertrophy and fibrosis in WT mice, but not in β3-TG mice, which also had less re-expression of fetal genes and transforming growth factor β1.  Protection from Iso-induced hypertrophy was reversed by nonspecific NOS inhibition at low dose Iso, and by preferential neuronal NOS inhibition at high-dose Iso.  Adenoviral overexpression of β3-AR in isolated cardiac myocytes also increased NO prodn. and attenuated hypertrophy to Iso and phenylephrine.  Hypertrophy was restored on NOS or protein kinase G inhibition.  Mechanistically, β3-AR overexpression inhibited phenylephrine-induced nuclear factor of activated T-cell activation.  CONCLUSIONS-: Cardiac-specific overexpression of β3-AR does not affect cardiac morphol. at baseline but inhibits the hypertrophic response to neurohormonal stimulation in vivo and in vitro, through a NOS-mediated mechanism.  Activation of the cardiac β3-AR pathway may provide future therapeutic avenues for the modulation of hypertrophic remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWV_Jg3yXy0LVg90H21EOLACvtfcHk0lhAYc-u3LWBUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ygsLs%253D&md5=0beb0732eb470a95c3b9415c283bef0c</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.113.004940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.113.004940%26sid%3Dliteratum%253Aachs%26aulast%3DBelge%26aufirst%3DC.%26aulast%3DHammond%26aufirst%3DJ.%26aulast%3DDubois-Deruy%26aufirst%3DE.%26aulast%3DManoury%26aufirst%3DB.%26aulast%3DHamelet%26aufirst%3DJ.%26aulast%3DBeauloye%26aufirst%3DC.%26aulast%3DMarkl%26aufirst%3DA.%26aulast%3DPouleur%26aufirst%3DA.%2BC.%26aulast%3DBertrand%26aufirst%3DL.%26aulast%3DEsfahani%26aufirst%3DH.%26aulast%3DJnaoui%26aufirst%3DK.%26aulast%3DG%25C3%25B6tz%26aufirst%3DK.%2BR.%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DVanderper%26aufirst%3DA.%26aulast%3DHerijgers%26aufirst%3DP.%26aulast%3DLobysheva%26aufirst%3DI.%26aulast%3DIaccarino%26aufirst%3DG.%26aulast%3DHilfiker-Kleiner%26aufirst%3DD.%26aulast%3DTavernier%26aufirst%3DG.%26aulast%3DLangin%26aufirst%3DD.%26aulast%3DDessy%26aufirst%3DC.%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DEnhanced%2520expression%2520of%2520%25CE%25B23-adrenoceptors%2520in%2520cardiac%2520myocytes%2520attenuates%2520neurohormone-induced%2520hypertrophic%2520remodeling%2520through%2520nitric%2520oxide%2520synthase%26jtitle%3DCirculation%26date%3D2014%26volume%3D129%26spage%3D451%26epage%3D462%26doi%3D10.1161%2FCIRCULATIONAHA.113.004940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Cardiac salvage by tweaking with beta-3-adrenergic receptors</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvw056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvw056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27001422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVejsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=128-133&author=J.+L.+Balligand&title=Cardiac+salvage+by+tweaking+with+beta-3-adrenergic+receptors&doi=10.1093%2Fcvr%2Fcvw056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac salvage by tweaking with beta-3-adrenergic receptors</span></div><div class="casAuthors">Balligand, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">128-133</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Overstimulation of the orthosympathetic system leads to cardiovascular cell and tissue damage through prolonged activation of β-1-2 adrenergic receptors (BARs).  The more recent identification of the third isotype of BAR (B3AR) in cardiac myocytes and endothelial cells with a distinctive coupling and effect on cardiac function and remodelling introduced a new facet to this paradigm.  In particular, B3AR is up-regulated in cardiac disease and less prone to homologous desensitization, which may reinforce its influence on the diseased myocardium.  Mice with transgenic cardiac-specific expression of the human B3AR are protected from cardiac hypertrophy and fibrosis in response to neurohormonal stimulation.  B3AR has also been implicated in cardiac protection after ischemia-reperfusion and the benefits of exercise on the heart.  Many of these salvage mechanisms are mediated by B3AR coupling to nitric oxide synthase (eNOS and nNOS) and downstream cGMP/protein kinase G signalling.  Notably, B3AR exerts antioxidant protective effects on these and other signalling elements, which may subserve its protective properties in the setting of chronic heart failure.  Addnl. vasorelaxing properties and paracrine NO-mediated signalling by B3AR in endothelium, together with systemic metabolic effects on beige/brown fat complete the pleiotropic protective properties of this new therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt2SulFlUZ_rVg90H21EOLACvtfcHk0liFO1x2ZKvWZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVejsrzP&md5=43b2209d70c85e34032e53a2c7e791d5</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvw056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvw056%26sid%3Dliteratum%253Aachs%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DCardiac%2520salvage%2520by%2520tweaking%2520with%2520beta-3-adrenergic%2520receptors%26jtitle%3DCardiovasc.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D128%26epage%3D133%26doi%3D10.1093%2Fcvr%2Fcvw056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Beta3-adrenoceptors in the cardiovascular system</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(00)01562-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0165-6147%2800%2901562-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11121573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot12lt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=426-431&author=C.+Gauthierauthor=D.+Langinauthor=J.+L.+Balligand&title=Beta3-adrenoceptors+in+the+cardiovascular+system&doi=10.1016%2FS0165-6147%2800%2901562-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">β3-Adrenoceptors in the cardiovascular system</span></div><div class="casAuthors">Gauthier, C.; Langin, D.; Balligand, J.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">426-431</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 68 refs.  β-Adrenoceptors of the β1 and β2 subtypes classically mediate the effects of catecholamines on the contractility of cardiac muscle and the relaxation of vascular smooth muscle.  Since the mol. characterization of the β3-adrenoceptor in 1989, most studies of this adrenoceptor subtype have focused on its control of lipolysis in adipose tissues.  However, more recent studies have investigated the involvement of β3-adrenoceptors in the physiol. control of cardiac and vascular contractility.  In this article, the pharmacol. and mol. evidence that supports the functional role of β3-adrenoceptors in cardiovascular tissues of various species, including humans, will be discussed.  These data might provide new insights into the authors' understanding of the abnormal responsiveness of the cardiovascular system to catecholamines in heart failure and its treatment with β-adrenoceptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZjOtbwLaIhLVg90H21EOLACvtfcHk0liFO1x2ZKvWZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot12lt7k%253D&md5=a01bafbb05d0d19b492c7d8422900c54</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2800%2901562-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252800%252901562-5%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DC.%26aulast%3DLangin%26aufirst%3DD.%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DBeta3-adrenoceptors%2520in%2520the%2520cardiovascular%2520system%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2000%26volume%3D21%26spage%3D426%26epage%3D431%26doi%3D10.1016%2FS0165-6147%2800%2901562-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozec, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span> <span> </span><span class="NLM_article-title">Beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pharmthera.2005.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16480771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1Sks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2006&pages=652-673&author=B.+Rozecauthor=C.+Gauthier&title=Beta3-adrenoceptors+in+the+cardiovascular+system%3A+putative+roles+in+human+pathologies&doi=10.1016%2Fj.pharmthera.2005.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">β3-Adrenoceptors in the cardiovascular system: Putative roles in human pathologies</span></div><div class="casAuthors">Rozec, Bertrand; Gauthier, Chantal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">652-673</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The sympathetic nervous system is central for the neurohumoral regulation of the cardiovascular system and is largely involved in many cardiovascular diseases affecting millions of people around the world.  It is classically admitted that β-adrenoceptors (β-AR) of the β1 and β2 subtypes mediate the effects of catecholamines on the force of contraction of cardiac muscle, and on the relaxation of vascular smooth muscle.  However, the mol. characterization in 1989 of a third β-AR subtype, β3, and later its identification in human heart has changed the classically admitted paradigm on the regulation of heart function by the β-adrenergic system.  In blood vessels, β3-AR, like β1 and β2, produced a relaxation.  But at the present time, the physiol. role of β3-AR is not clearly identified.  Thus, the purpose of this review is to summarize the pharmacol. and mol. evidence supporting the functional roles of β3-AR in cardiovascular tissues of various species, including humans.  In addn., this review discusses the potential role of β3-AR in several cardiovascular diseases and emphasizes their putative involvement as new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYiwT4FS7gmrVg90H21EOLACvtfcHk0liFO1x2ZKvWZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1Sks7w%253D&md5=665db84e75259ca7c06d313b8dfb9422</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DRozec%26aufirst%3DB.%26aulast%3DGauthier%26aufirst%3DC.%26atitle%3DBeta3-adrenoceptors%2520in%2520the%2520cardiovascular%2520system%253A%2520putative%2520roles%2520in%2520human%2520pathologies%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D111%26spage%3D652%26epage%3D673%26doi%3D10.1016%2Fj.pharmthera.2005.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arioglu-Inan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayki-Mutlu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. C.</span></span> <span> </span><span class="NLM_article-title">Cardiac β<sub>3</sub>-adrenoceptors-A role in human pathophysiology?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2495</span>, <span class="refDoi"> DOI: 10.1111/bph.14635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fbph.14635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30801686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFylurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=2482-2495&author=E.+Arioglu-Inanauthor=G.+Kayki-Mutluauthor=M.+C.+Michel&title=Cardiac+%CE%B23-adrenoceptors-A+role+in+human+pathophysiology%3F&doi=10.1111%2Fbph.14635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac β3-adrenoceptors-A role in human pathophysiology?</span></div><div class="casAuthors">Arioglu-Inan, Ebru; Kayki-Mutlu, Gizem; Michel, Martin C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2482-2495</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  As β3-adrenoceptors were first demonstrated to be expressed in adipose tissue they have received much attention for their metabolic effects in obesity and diabetes.  After the existence of this subtype had been suggested to be present in the heart, studies focused on its role in cardiac function.  While the presence and functional role of β3-adrenoceptors in the heart has not uniformly been detected, there is a broad consensus that they become up-regulated in pathol. conditions assocd. with increased sympathetic activity such as heart failure and diabetes.  When detected, the β3-adrenceptor has been demonstrated to mediate neg. inotropic effects in an inhibitory G protein-dependent manner through the NO-cGMP-PKG signalling pathway.  Whether these neg. inotropic effects provide protection from the adverse effects induced by overstimulation of β1/β2-adrenoceptors or in themselves are potentially harmful is controversial, but ongoing clin. studies in patients with congestive heart failure are testing the hypothesis that β3-adrenceptor agonism has a beneficial effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeK1zGgpTTeLVg90H21EOLACvtfcHk0lhvDZc87ceyUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFylurg%253D&md5=b142c573f1d1af6d1db6529eab30b8d4</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1111%2Fbph.14635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14635%26sid%3Dliteratum%253Aachs%26aulast%3DArioglu-Inan%26aufirst%3DE.%26aulast%3DKayki-Mutlu%26aufirst%3DG.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DCardiac%2520%25CE%25B23-adrenoceptors-A%2520role%2520in%2520human%2520pathophysiology%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D2482%26epage%3D2495%26doi%3D10.1111%2Fbph.14635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötvall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akdis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacharier, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjermer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Custovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemanske, R. F.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardlaw, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, P. A.</span></span> <span> </span><span class="NLM_article-title">Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2010.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaci.2010.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21281866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3M7lslOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=355-360&author=J.+L%C3%B6tvallauthor=C.+A.+Akdisauthor=L.+B.+Bacharierauthor=L.+Bjermerauthor=T.+B.+Casaleauthor=A.+Custovicauthor=R.+F.+Lemanskeauthor=A.+J.+Wardlawauthor=S.+E.+Wenzelauthor=P.+A.+Greenberger&title=Asthma+endotypes%3A+a+new+approach+to+classification+of+disease+entities+within+the+asthma+syndrome&doi=10.1016%2Fj.jaci.2010.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome</span></div><div class="casAuthors">Lotvall Jan; Akdis Cezmi A; Bacharier Leonard B; Bjermer Leif; Casale Thomas B; Custovic Adnan; Lemanske Robert F Jr; Wardlaw Andrew J; Wenzel Sally E; Greenberger Paul A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">It is increasingly clear that asthma is a complex disease made up of number of disease variants with different underlying pathophysiologies.  Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of asthma and improving treatment and can explain the failure to identify consistent genetic and environmental correlations to asthma.  Here we describe a hypothesis whereby the asthma syndrome is divided into distinct disease entities with specific mechanisms, which we have called "asthma endotypes." An "endotype" is proposed to be a subtype of a condition defined by a distinct pathophysiological mechanism.  Criteria for defining asthma endotypes on the basis of their phenotypes and putative pathophysiology are suggested.  Using these criteria, we identify several proposed asthma endotypes and propose how these new definitions can be used in clinical study design and drug development to target existing and novel therapies to patients most likely to benefit.  This PRACTALL (PRACtical ALLergy) consensus report was produced by experts from the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLS-n5Q903mbxanA7vODO6fW6udTcc2eY5r-LZDMphlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7lslOntg%253D%253D&md5=4ae6fe65edea199280b1ab926d14f177</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2010.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2010.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tvall%26aufirst%3DJ.%26aulast%3DAkdis%26aufirst%3DC.%2BA.%26aulast%3DBacharier%26aufirst%3DL.%2BB.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DCasale%26aufirst%3DT.%2BB.%26aulast%3DCustovic%26aufirst%3DA.%26aulast%3DLemanske%26aufirst%3DR.%2BF.%26aulast%3DWardlaw%26aufirst%3DA.%2BJ.%26aulast%3DWenzel%26aufirst%3DS.%2BE.%26aulast%3DGreenberger%26aufirst%3DP.%2BA.%26atitle%3DAsthma%2520endotypes%253A%2520a%2520new%2520approach%2520to%2520classification%2520of%2520disease%2520entities%2520within%2520the%2520asthma%2520syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2011%26volume%3D127%26spage%3D355%26epage%3D360%26doi%3D10.1016%2Fj.jaci.2010.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girodet, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunon de
Lara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marthan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, P.</span></span> <span> </span><span class="NLM_article-title">Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pharmthera.2011.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21334378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsV2nu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=325-337&author=P.+O.+Girodetauthor=A.+Ozierauthor=I.+Baraauthor=J.+M.+Tunon+de%0ALaraauthor=R.+Marthanauthor=P.+Berger&title=Airway+remodeling+in+asthma%3A+new+mechanisms+and+potential+for+pharmacological+intervention&doi=10.1016%2Fj.pharmthera.2011.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Airway remodeling in asthma: New mechanisms and potential for pharmacological intervention</span></div><div class="casAuthors">Girodet, Pierre-Olivier; Ozier, Annaig; Bara, Imane; Tunon de Lara, Jose-Manuel; Marthan, Roger; Berger, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The chronic inflammatory response within the airways of asthmatics is assocd. with structural changes termed airway remodeling.  This remodeling process is a key feature of severe asthma.  The 5-10% of patients with a severe form of the disease account for the higher morbidity and health costs related to asthma.  Among the histopathol. characteristics of airway remodeling, recent reports indicate that the increased mass of airway smooth muscle (ASM) plays a crit. role.  ASM cell proliferation in severe asthma implicates a gallopamil-sensitive calcium influx and the activation of calcium-calmodulin kinase IV leading to enhanced mitochondrial biogenesis through the activation of various transcription factors (PGC-1α, NRF-1 and mt-TFA).  The altered expression and function of sarco/endoplasmic reticulum Ca2+ pump could play a role in ASM remodeling in moderate to severe asthma.  Addnl., aberrant communication between an injured airway epithelium and ASM could also contribute to disease severity.  Airway remodeling is insensitive to corticosteroids and anti-leukotrienes whereas the effect of monoclonal antibodies (the anti-IgE omalizumab, the anti-interleukin-5 mepolizumab or anti-tumor necrosis factor-alpha) remains to be investigated.  This review focuses on potential new therapeutic strategies targeting ASM cells, esp. Ca2+ and mitochondria-dependent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFl7SP_EuPWrVg90H21EOLACvtfcHk0lhvDZc87ceyUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsV2nu7g%253D&md5=46fce84291f66741fdbea6fe5629ba95</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DGirodet%26aufirst%3DP.%2BO.%26aulast%3DOzier%26aufirst%3DA.%26aulast%3DBara%26aufirst%3DI.%26aulast%3DTunon%2Bde%2BLara%26aufirst%3DJ.%2BM.%26aulast%3DMarthan%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DP.%26atitle%3DAirway%2520remodeling%2520in%2520asthma%253A%2520new%2520mechanisms%2520and%2520potential%2520for%2520pharmacological%2520intervention%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D130%26spage%3D325%26epage%3D337%26doi%3D10.1016%2Fj.pharmthera.2011.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Begueret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernejoux, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubuisson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marthan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunon-De-Lara, J. M.</span></span> <span> </span><span class="NLM_article-title">Inflammation of bronchial smooth muscle in allergic asthma</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1136/thx.2006.062141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.2006.062141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17189531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD28jltFWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=8-15&author=H.+Begueretauthor=P.+Bergerauthor=J.+M.+Vernejouxauthor=L.+Dubuissonauthor=R.+Marthanauthor=J.+M.+Tunon-De-Lara&title=Inflammation+of+bronchial+smooth+muscle+in+allergic+asthma&doi=10.1136%2Fthx.2006.062141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation of bronchial smooth muscle in allergic asthma</span></div><div class="casAuthors">Begueret H; Berger P; Vernejoux J M; Dubuisson L; Marthan R; Tunon-de-Lara J M</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-15</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Recent observations in asthma suggest that bronchial smooth muscle is infiltrated by inflammatory cells including mast cells.  Such an infiltration may contribute to airway remodelling that is partly due to an increase in smooth muscle mass.  Whether muscle increase is the result of smooth muscle cell hypertrophy remains controversial and has not been studied by ultrastructural analysis.  A morphometric analysis of airway smooth muscle (ASM) was undertaken in asthmatic patients using electron microscopy to examine the interactions between ASM cells and inflammatory cells.  METHODS:  ASM specimens were obtained from 14 asthmatic subjects and nine non-asthmatic controls undergoing fibreoptic endoscopy.  Inflammatory cell counts were assessed by immunohistochemistry, and ultrastructural parameters were measured using electron microscopy in a blinded fashion on smooth muscle cells and inflammatory cells.  RESULTS:  ASM from asthmatic patients was infiltrated by an increased number of mast cells and lymphocytes.  Smooth muscle cells and their basal lamina were thicker in asthmatic patients (9.5 (0.8) and 1.4 (0.2) microm) than in controls (6.7 (0.4) and 0.7 (0.1) microm).  In asthmatics the extracellular matrix was frequently organised in large amounts between ASM cells.  Myofibroblasts within smooth muscle bundles were only observed in asthmatics, some of them displaying a close contact with ASM cells.  CONCLUSION:  In asthma, airway myositis is characterised by a direct interaction between ASM cells and mast cells and lymphocytes.  Smooth muscle remodelling was present, including cell hypertrophy and abnormal extracellular matrix deposition moulding ASM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoKNTVX6jsazAEfvC7EH1LfW6udTcc2eb_fcj4PbxnQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jltFWmtg%253D%253D&md5=172600e5e647a35f4ffa3b4658152915</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.062141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.062141%26sid%3Dliteratum%253Aachs%26aulast%3DBegueret%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DP.%26aulast%3DVernejoux%26aufirst%3DJ.%2BM.%26aulast%3DDubuisson%26aufirst%3DL.%26aulast%3DMarthan%26aufirst%3DR.%26aulast%3DTunon-De-Lara%26aufirst%3DJ.%2BM.%26atitle%3DInflammation%2520of%2520bronchial%2520smooth%2520muscle%2520in%2520allergic%2520asthma%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26spage%3D8%26epage%3D15%26doi%3D10.1136%2Fthx.2006.062141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemiere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulet, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, P. M.</span></span> <span> </span><span class="NLM_article-title">Airway hyperresponsiveness in asthma: measurement and clinical relevance</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2016.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2016.11.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28163029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jt12iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=649-659&author=P.+Nairauthor=J.+G.+Martinauthor=D.+C.+Cockcroftauthor=M.+Dolovichauthor=C.+Lemiereauthor=L.+P.+Bouletauthor=P.+M.+O%E2%80%99Byrne&title=Airway+hyperresponsiveness+in+asthma%3A+measurement+and+clinical+relevance&doi=10.1016%2Fj.jaip.2016.11.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance</span></div><div class="casAuthors">Nair Parameswaran; Martin James G; Cockcroft Donald C; Dolovich Myrna; O'Byrne Paul M; Lemiere Catherine; Boulet Louis-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">649-659.e2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Airway hyperresponsiveness is a characteristic feature of asthma, and its measurement is an important tool in its diagnosis.  With a few caveats, methacholine bronchial provocation by a 2-minute tidal breathing method is highly sensitive; a negative test result (PC20 > 16 mg/mL, PD20 > 400 μg) rules out current asthma with reasonable certainty.  A PC20 value of less than 1 mg/mL/PD20 value of less than 25 μg is highly specific (ie, diagnostic) but quite insensitive for asthma.  For accurate interpretation of the test results, it is important to control and standardize technical factors that have an impact on nebulizer performance.  In addition to its utility to relate symptoms such as cough, wheeze, and shortness of breath to variable airflow obstruction (ie, to diagnose current asthma), the test is useful to make a number of other clinical assessments.  These include (1) evaluation of patients with occupational asthma, (2) evaluation of patients with exercise-induced respiratory symptoms, (3) evaluation of novel asthma medications, (4) evaluation of relative potency of inhaled bronchodilators, (5) as a biomarker to adjust anti-inflammatory therapy to improve clinical outcomes, and (6) in the evaluation of patients with severe asthma to rule out masqueraders such as laryngeal dysfunction.  The actual mechanism of altered smooth muscle behavior in asthma that is assessed by direct (eg, methacholine) or indirect (eg, allergen) bronchial provocation remains one of the most fundamental questions related to asthma that needs to be determined.  The test is underutilized in clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFNvKRYbkw8K_dlEzl_fBafW6udTcc2eb_fcj4PbxnQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jt12iug%253D%253D&md5=c8f7737e4ff4f555bfc13d6d462577af</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2016.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2016.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DJ.%2BG.%26aulast%3DCockcroft%26aufirst%3DD.%2BC.%26aulast%3DDolovich%26aufirst%3DM.%26aulast%3DLemiere%26aufirst%3DC.%26aulast%3DBoulet%26aufirst%3DL.%2BP.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26atitle%3DAirway%2520hyperresponsiveness%2520in%2520asthma%253A%2520measurement%2520and%2520clinical%2520relevance%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2017%26volume%3D5%26spage%3D649%26epage%3D659%26doi%3D10.1016%2Fj.jaip.2016.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S. E.</span></span> <span> </span><span class="NLM_article-title">Asthma phenotypes: the evolution from clinical to molecular approaches</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1038/nm.2678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnm.2678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22561835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFOqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=716-725&author=S.+E.+Wenzel&title=Asthma+phenotypes%3A+the+evolution+from+clinical+to+molecular+approaches&doi=10.1038%2Fnm.2678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma phenotypes: the evolution from clinical to molecular approaches</span></div><div class="casAuthors">Wenzel, Sally E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">716-725</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Although asthma was considered as a single disease for years, recent studies have increasingly focused on its heterogeneity.  The characterization of this heterogeneity has promoted the concept that asthma consists of multiple phenotypes or consistent groupings of characteristics.  Asthma phenotypes were initially focused on combinations of clin. characteristics, but they are now evolving to link biol. to phenotype, often through a statistically based process.  Ongoing studies of large-scale, molecularly and genetically focused and extensively clin. characterized cohorts of asthma should enhance our ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to asthma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMySJpATqXrVg90H21EOLACvtfcHk0lhsLgmv7q99eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFOqtbk%253D&md5=ce1354d6be255d65d1d1f40e0467cd59</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnm.2678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2678%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DS.%2BE.%26atitle%3DAsthma%2520phenotypes%253A%2520the%2520evolution%2520from%2520clinical%2520to%2520molecular%2520approaches%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D716%26epage%3D725%26doi%3D10.1038%2Fnm.2678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhlbrigge, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M.</span></span> <span> </span><span class="NLM_article-title">Precision medicine in asthma-using phenotypes to understand endotypes that lead us to new therapeutic options</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2019.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2019.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32037110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387gtVWqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=496-497&author=A.+L.+Fuhlbriggeauthor=M.+Castro&title=Precision+medicine+in+asthma-using+phenotypes+to+understand+endotypes+that+lead+us+to+new+therapeutic+options&doi=10.1016%2Fj.jaip.2019.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Precision Medicine in Asthma-Using Phenotypes to Understand Endotypes That Lead Us to New Therapeutic Options</span></div><div class="casAuthors">Fuhlbrigge Anne L; Castro Mario</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">496-497</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgQ7H1MpvaP4HWj6b1v8uTfW6udTcc2eb_fcj4PbxnQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387gtVWqsA%253D%253D&md5=c3bfe2c3c80e91f4697336b60c3a7128</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2019.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2019.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DFuhlbrigge%26aufirst%3DA.%2BL.%26aulast%3DCastro%26aufirst%3DM.%26atitle%3DPrecision%2520medicine%2520in%2520asthma-using%2520phenotypes%2520to%2520understand%2520endotypes%2520that%2520lead%2520us%2520to%2520new%2520therapeutic%2520options%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2020%26volume%3D8%26spage%3D496%26epage%3D497%26doi%3D10.1016%2Fj.jaip.2019.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwanger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koth, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arron, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span> <span> </span><span class="NLM_article-title">T-helper type 2-driven inflammation defines major subphenotypes of asthma</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1164/rccm.200903-0392OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Frccm.200903-0392OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19483109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOju7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=388-395&author=P.+G.+Woodruffauthor=B.+Modrekauthor=D.+F.+Choyauthor=G.+Jiaauthor=A.+R.+Abbasauthor=A.+Ellwangerauthor=L.+L.+Kothauthor=J.+R.+Arronauthor=J.+V.+Fahy&title=T-helper+type+2-driven+inflammation+defines+major+subphenotypes+of+asthma&doi=10.1164%2Frccm.200903-0392OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">T-helper type 2-driven inflammation defines major subphenotypes of asthma</span></div><div class="casAuthors">Woodruff, Prescott G.; Modrek, Barmak; Choy, David F.; Jia, Guiquan; Abbas, Alexander R.; Ellwanger, Almut; Arron, Joseph R.; Koth, Laura L.; Fahy, John V.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-395</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">T-helper type 2 (Th2) inflammation, mediated by IL-4, IL-5, and IL-13, is considered the central mol. mechanism underlying asthma, and Th2 cytokines are emerging therapeutic targets.  However, clin. studies increasingly suggest that asthma is heterogeneous.  To det. whether this clin. heterogeneity reflects heterogeneity in underlying mol. mechanisms related to Th2 inflammation.  Using microarray and polymerase chain reaction analyses of airway epithelial brushings from 42 patients with mild-to-moderate asthma and 28 healthy control subjects, we classified subjects with asthma based on high or low expression of IL-13-inducible genes.  We then validated this classification and investigated its clin. implications through analyses of cytokine expression in bronchial biopsies, markers of inflammation and remodeling, responsiveness to inhaled corticosteroids, and reproducibility on repeat examn.  Gene expression analyses identified two evenly sized and distinct subgroups, "Th2-high" and "Th2-low" asthma (the latter indistinguishable from control subjects).  These subgroups differed significantly in expression of IL-5 and IL-13 in bronchial biopsies and in airway hyperresponsiveness, serum IgE, blood and airway eosinophilia, subepithelial fibrosis, and airway mucin gene expression (all P < 0.03).  The lung function improvements expected with inhaled corticosteroids were restricted to Th2-high asthma, and Th2 markers were reproducible on repeat evaluation.  Asthma can be divided into at least two distinct mol. phenotypes defined by degree of Th2 inflammation.  Th2 cytokines are likely to be a relevant therapeutic target in only a subset of patients with asthma.  Furthermore, current models do not adequately explain non-Th2-driven asthma, which represents a significant proportion of patients and responds poorly to current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZSm0ro3vhkrVg90H21EOLACvtfcHk0lgomJ7YxEYcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOju7vI&md5=be044b3bf7e58373ffd1dc722811583e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1164%2Frccm.200903-0392OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200903-0392OC%26sid%3Dliteratum%253Aachs%26aulast%3DWoodruff%26aufirst%3DP.%2BG.%26aulast%3DModrek%26aufirst%3DB.%26aulast%3DChoy%26aufirst%3DD.%2BF.%26aulast%3DJia%26aufirst%3DG.%26aulast%3DAbbas%26aufirst%3DA.%2BR.%26aulast%3DEllwanger%26aufirst%3DA.%26aulast%3DKoth%26aufirst%3DL.%2BL.%26aulast%3DArron%26aufirst%3DJ.%2BR.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26atitle%3DT-helper%2520type%25202-driven%2520inflammation%2520defines%2520major%2520subphenotypes%2520of%2520asthma%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D388%26epage%3D395%26doi%3D10.1164%2Frccm.200903-0392OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptors in asthma therapy: pharmacology and drug action</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1124/pr.118.016899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fpr.118.016899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31767622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeqsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1-49&author=S.+G.+Wendellauthor=H.+Fanauthor=C.+Zhang&title=G+protein-coupled+receptors+in+asthma+therapy%3A+pharmacology+and+drug+action&doi=10.1124%2Fpr.118.016899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors in asthma therapy: pharmacology and drug actions</span></div><div class="casAuthors">Wendell, Stacy Gelhaus; Fan, Hao; Zhang, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-49</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Many asthma therapeutics target G protein-coupled receptors (GPCRs), which either enhance bronchodilation or prevent bronchoconstriction.  Short-acting and long-acting β2-agonists are widely used bronchodilators that signal through the activation of the β2-adrenergic receptor.  Short-acting and long-acting antagonists of muscarinic acetylcholine receptors are used to reduce bronchoconstriction by blocking the action of acetylcholine.  Leukotriene antagonists that block the signaling of cysteinyl leukotriene receptor 1 are used as an add-on therapy to reduce bronchoconstriction and inflammation induced by cysteinyl leukotrienes.  A no. of GPCR-targeting asthma drug candidates are also in different stages of development.  Among them, antagonists of prostaglandin D2 receptor 2 have advanced into phase III clin. trials.  Others, including antagonists of the adenosine A2B receptor and the histamine H4 receptor, are in early stages of clin. investigation.  In the past decade, significant research advancements in pharmacol., cell biol., structural biol., andmol. physiol. have greatly deepened our understanding of the therapeutic roles of GPCRs in asthma and drug action on these GPCRs.  This review summarizes our current understanding of GPCR signaling and pharmacol. in the context of asthma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEzWgQ2eNDlbVg90H21EOLACvtfcHk0lgomJ7YxEYcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeqsr%252FK&md5=38ed0347d973bdb94a02a63b03a640f5</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.016899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.016899%26sid%3Dliteratum%253Aachs%26aulast%3DWendell%26aufirst%3DS.%2BG.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DG%2520protein-coupled%2520receptors%2520in%2520asthma%2520therapy%253A%2520pharmacology%2520and%2520drug%2520action%26jtitle%3DPharmacol.%2520Rev.%26date%3D2020%26volume%3D72%26spage%3D1%26epage%3D49%26doi%3D10.1124%2Fpr.118.016899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1038/cmi.2010.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fcmi.2010.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20383174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFSmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=182-189&author=S.+Leungauthor=X.+Liuauthor=L.+Fangauthor=X.+Chenauthor=T.+Guoauthor=J.+Zhang&title=The+cytokine+milieu+in+the+interplay+of+pathogenic+Th1%2FTh17+cells+and+regulatory+T+cells+in+autoimmune+disease&doi=10.1038%2Fcmi.2010.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease</span></div><div class="casAuthors">Leung, Stewart; Liu, Xuebin; Fang, Lei; Chen, Xi; Guo, Taylor; Zhang, Jingwu</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">182-189</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  The propagation and regulation of an immune response is driven by a network of effector and regulatory T (Treg) cells.  The interplay of effector T and Treg cells dets. the direction of the immune response towards inflammation or its resoln. in an autoimmune disease setting.  In autoimmune diseases, this interplay shifts the balance in favor of the development of autoreactive effector T cells, resulting in inflammatory pathol.  The objective of an effective therapeutic approach for autoimmune disease is to restore this balance.  In this review, we describe the characteristics and development of pathogenic T helper 1 (Th1) and Th17 cells and the beneficial Treg cells in autoimmune diseases and the crucial roles of the cytokine milieu in influencing the balance of these T-cell subsets.  Given the importance of cytokines, we discuss current immunotherapeutic strategies using cytokine or cytokine receptor antibodies for the treatment of autoimmune diseases.  Cellular & Mol. Immunol. (2010) 7, 182-189; doi:10.1038/cmi.2010.22; published online 19 Apr. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV9rj_Z2r_lrVg90H21EOLACvtfcHk0lgomJ7YxEYcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFSmtbo%253D&md5=a6b3de6660b7d410fef0fb9c35d3faa9</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2010.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2010.22%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DThe%2520cytokine%2520milieu%2520in%2520the%2520interplay%2520of%2520pathogenic%2520Th1%252FTh17%2520cells%2520and%2520regulatory%2520T%2520cells%2520in%2520autoimmune%2520disease%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2010%26volume%3D7%26spage%3D182%26epage%3D189%26doi%3D10.1038%2Fcmi.2010.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coverstone, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibold, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M. C.</span></span> <span> </span><span class="NLM_article-title">Diagnosis and management of T2-high asthma</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2019.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2019.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32037108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387gtVWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=442-450&author=A.+M.+Coverstoneauthor=M.+A.+Seiboldauthor=M.+C.+Peters&title=Diagnosis+and+management+of+T2-high+asthma&doi=10.1016%2Fj.jaip.2019.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and Management of T2-High Asthma</span></div><div class="casAuthors">Coverstone Andrea M; Seibold Max A; Peters Michael C</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">442-450</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 2 (T2) inflammation plays a key role in the pathogenesis of asthma.  IL-4, IL-5, and IL-13, along with other inflammatory mediators, lead to increased cellular eosinophilic inflammation.  It is likely that around half of all patients with asthma have evidence of T2-high inflammation.  Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels, and airway gene expression markers are frequently used biomarkers of T2-high asthma.  Individuals with T2-high asthma tend to have several features of increased asthma severity, including reduced lung function and increased rates of asthma exacerbations, and T2-high patients demonstrate distinct pathologic features including increased airway remodeling and alterations in airway mucus production.  Several monoclonal antibodies are now available to treat individuals with T2-high asthma and these medications significantly reduce asthma exacerbation rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgQ7H1MpvaP9yzdcP07UmufW6udTcc2eZezJuvzurAZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387gtVWqsg%253D%253D&md5=8d3ac8cf7544b11293fdfb53651bd5e5</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2019.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2019.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DCoverstone%26aufirst%3DA.%2BM.%26aulast%3DSeibold%26aufirst%3DM.%2BA.%26aulast%3DPeters%26aufirst%3DM.%2BC.%26atitle%3DDiagnosis%2520and%2520management%2520of%2520T2-high%2520asthma%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2020%26volume%3D8%26spage%3D442%26epage%3D450%26doi%3D10.1016%2Fj.jaip.2019.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, E.</span></span> <span> </span><span class="NLM_article-title">Role of eosinophils in protective immunity against secondary nematode infections</span>. <i>Immunol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1080/25785826.2019.1697135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1080%2F25785826.2019.1697135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31794348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3MflvVKltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=148-155&author=K.+Yasudaauthor=E.+Kuroda&title=Role+of+eosinophils+in+protective+immunity+against+secondary+nematode+infections&doi=10.1080%2F25785826.2019.1697135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Role of eosinophils in protective immunity against secondary nematode infections</span></div><div class="casAuthors">Yasuda Koubun; Kuroda Etsushi</div><div class="citationInfo"><span class="NLM_cas:title">Immunological medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">148-155</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Infections with parasites, especially those involving nematodes that invade tissues, induce a strong Th2-type immune response, which increases immunoglobulin E and eosinophil levels in the blood and tissues.  Eosinophils are not effective against all possible helminth infections, but are known to be effective against nematode larvae.  In particular, when a host is re-infected by a species of nematode that it previously encountered, the activation of acquired immunity causes robust accumulation and activation of eosinophils that damages the nematode larvae.  Eosinophil production and activation processes are mainly induced by interleukin (IL)-5, which is produced by Th2 cells and group 2 innate lymphoid cells, and eosinophils have been shown to generally participate in host defense, inflammation, and immunomodulation.  Recently, several papers have reported host defense by non-antigen-specific immune activation, in which group 2 innate lymphoid cells and Th2 cells produce interleukin (IL)-5 and IL-13 in response to IL-33 stimulation.  This immune activation is produced by migrating larvae of a species that differs from the species previously encountered.  Eosinophils also play an important role in the eradication of migrating larvae.  Thus, eosinophils contribute to host defense in both antigen-specific and non-antigen-specific manners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpLfsw-fV3Jb0AGQpJZWpJfW6udTcc2eZezJuvzurAZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MflvVKltw%253D%253D&md5=60e89a4decc49f37101eff4322369719</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1080%2F25785826.2019.1697135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F25785826.2019.1697135%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DKuroda%26aufirst%3DE.%26atitle%3DRole%2520of%2520eosinophils%2520in%2520protective%2520immunity%2520against%2520secondary%2520nematode%2520infections%26jtitle%3DImmunol.%2520Med.%26date%3D2019%26volume%3D42%26spage%3D148%26epage%3D155%26doi%3D10.1080%2F25785826.2019.1697135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starkl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marichal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, S. J.</span></span> <span> </span><span class="NLM_article-title">IgE and mast cells in host defense against parasites and venoms</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1007/s00281-016-0565-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00281-016-0565-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27225312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1Wks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=581-603&author=K.+Mukaiauthor=M.+Tsaiauthor=P.+Starklauthor=T.+Marichalauthor=S.+J.+Galli&title=IgE+and+mast+cells+in+host+defense+against+parasites+and+venoms&doi=10.1007%2Fs00281-016-0565-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">IgE and mast cells in host defense against parasites and venoms</span></div><div class="casAuthors">Mukai, Kaori; Tsai, Mindy; Starkl, Philipp; Marichal, Thomas; Galli, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-603</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">IgE-dependent mast cell activation is a major effector mechanism underlying the pathol. assocd. with allergic disorders.  The most dramatic of these IgE-assocd. disorders is the fatal anaphylaxis which can occur in some people who have developed IgE antibodies to otherwise innocuous antigens, such as those contained in certain foods and medicines.  Why would such a highly "maladaptive" immune response develop in evolution and be retained to the present day.  Host defense against parasites has long been considered the only beneficial function that might be conferred by IgE and mast cells.  However, recent studies have provided evidence that, in addn. to participating in host resistance to certain parasites, mast cells and IgE are crit. components of innate (mast cells) and adaptive (mast cells and IgE) immune responses that can enhance host defense against the toxicity of certain arthropod and animal venoms, including enhancing the survival of mice injected with such venoms.  Yet, in some people, developing IgE antibodies to insect or snake venoms puts them at risk for having a potentially fatal anaphylactic reaction upon subsequent exposure to such venoms.  Delineating the mechanisms underlying beneficial vs. detrimental innate and adaptive immune responses assocd. with mast cell activation and IgE is likely to enhance our ability to identify potential therapeutic targets in such settings, not only for reducing the pathol. assocd. with allergic disorders but perhaps also for enhancing immune protection against pathogens and animal venoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_DsUxIO-PfbVg90H21EOLACvtfcHk0ljld72MjE_RQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1Wks7w%253D&md5=f9c7da89f29257c5cbce6fb651c6a32e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1007%2Fs00281-016-0565-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-016-0565-1%26sid%3Dliteratum%253Aachs%26aulast%3DMukai%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DStarkl%26aufirst%3DP.%26aulast%3DMarichal%26aufirst%3DT.%26aulast%3DGalli%26aufirst%3DS.%2BJ.%26atitle%3DIgE%2520and%2520mast%2520cells%2520in%2520host%2520defense%2520against%2520parasites%2520and%2520venoms%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2016%26volume%3D38%26spage%3D581%26epage%3D603%26doi%3D10.1007%2Fs00281-016-0565-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills-Karp, M.</span></span> <span> </span><span class="NLM_article-title">IL-4 and IL-13 signaling in allergic airway disease</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2015.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.cyto.2015.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26070934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsV2gtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=68-78&author=N.+Gourauthor=M.+Wills-Karp&title=IL-4+and+IL-13+signaling+in+allergic+airway+disease&doi=10.1016%2Fj.cyto.2015.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">IL-4 and IL-13 signaling in allergic airway disease</span></div><div class="casAuthors">Gour, Naina; Wills-Karp, Marsha</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-78</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aberrant prodn. of the prototypical type 2 cytokines, interleukin (IL)-4 and IL-13 has long been assocd. with the pathogenesis of allergic disorders.  Despite tremendous scientific inquiry, the similarities in their structure, and receptor usage have made it difficult to ascertain the distinct role that these two look-alike cytokines play in the onset and perpetuation of allergic inflammation.  However, recent discoveries of differences in receptor distribution, utilization/assembly and affinity between IL-4 and IL-13, along with the discovery of unique innate lymphoid 2 cells (ILC2) which preferentially produce IL-13, not IL-4, are beginning to shed light on these mysteries.  The purpose of this chapter is to review our current understanding of the distinct roles that IL-4 and IL-13 play in allergic inflammatory states and the utility of their modulation as potential therapeutic strategies for the treatment of allergic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLyxVXCbZzLVg90H21EOLACvtfcHk0ljld72MjE_RQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsV2gtL8%253D&md5=c5ea5d3c0debc413fb69fbad853bbe0d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2015.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2015.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DGour%26aufirst%3DN.%26aulast%3DWills-Karp%26aufirst%3DM.%26atitle%3DIL-4%2520and%2520IL-13%2520signaling%2520in%2520allergic%2520airway%2520disease%26jtitle%3DCytokine%26date%3D2015%26volume%3D75%26spage%3D68%26epage%3D78%26doi%3D10.1016%2Fj.cyto.2015.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipps, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holguin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, P. G.</span></span> <span> </span><span class="NLM_article-title">T2-“Low” asthma: overview and management strategies</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2019.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2019.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32037109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387gtVWqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=452-463&author=A.+M.+Fitzpatrickauthor=B.+E.+Chippsauthor=F.+Holguinauthor=P.+G.+Woodruff&title=T2-%E2%80%9CLow%E2%80%9D+asthma%3A+overview+and+management+strategies&doi=10.1016%2Fj.jaip.2019.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">T2-"Low" Asthma: Overview and Management Strategies</span></div><div class="casAuthors">Fitzpatrick Anne M; Chipps Bradley E; Holguin Fernando; Woodruff Prescott G</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">452-463</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the term "asthma" has been applied to all patients with airway lability and variable chest symptoms for centuries, phenotypes of asthma with distinct clinical and molecular features that may warrant different treatment approaches are well recognized.  Patients with type 2 (T2)-"high" asthma are characterized by upregulation of T2 immune pathways (ie, IL-4 and IL-13 gene sets) and eosinophilic airway inflammation, whereas these features are absent in patients with T2-"low" asthma and may contribute to poor responsiveness to corticosteroid treatment.  This review details definitions and clinical features of T2-"low" asthma, potential mechanisms and metabolic aspects, pediatric considerations, and potential treatment approaches.  Priority research questions for T2-"low" asthma are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgQ7H1MpvaP3thwrmtH4OBfW6udTcc2eYNQfCr_iM_Gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387gtVWqsw%253D%253D&md5=07da4bef4a0b9b05f6ea9f71e5adb6b5</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2019.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2019.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DFitzpatrick%26aufirst%3DA.%2BM.%26aulast%3DChipps%26aufirst%3DB.%2BE.%26aulast%3DHolguin%26aufirst%3DF.%26aulast%3DWoodruff%26aufirst%3DP.%2BG.%26atitle%3DT2-%25E2%2580%259CLow%25E2%2580%259D%2520asthma%253A%2520overview%2520and%2520management%2520strategies%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2020%26volume%3D8%26spage%3D452%26epage%3D463%26doi%3D10.1016%2Fj.jaip.2019.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, S.</span></span> <span> </span><span class="NLM_article-title">The 3 major types of innate and adaptive cell-mediated effector immunity</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaci.2014.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25528359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=626-635&author=F.+Annunziatoauthor=C.+Romagnaniauthor=S.+Romagnani&title=The+3+major+types+of+innate+and+adaptive+cell-mediated+effector+immunity&doi=10.1016%2Fj.jaci.2014.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">The 3 major types of innate and adaptive cell-mediated effector immunity</span></div><div class="casAuthors">Annunziato, Francesco; Romagnani, Chiara; Romagnani, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The immune system has tailored its effector functions to optimally respond to distinct species of microbes.  Based on emerging knowledge on the different effector T-cell and innate lymphoid cell (ILC) lineages, it is clear that the innate and adaptive immune systems converge into 3 major kinds of cell-mediated effector immunity, which we propose to categorize as type 1, type 2, and type 3.  Type 1 immunity consists of T-bet+ IFN-γ-producing group 1 ILCs (ILC1 and natural killer cells), CD8+ cytotoxic T cells (TC1), and CD4+ TH1 cells, which protect against intracellular microbes through activation of mononuclear phagocytes.  Type 2 immunity consists of GATA-3+ ILC2s, TC2 cells, and TH2 cells producing IL-4, IL-5, and IL-13, which induce mast cell, basophil, and eosinophil activation, as well as IgE antibody prodn., thus protecting against helminthes and venoms.  Type 3 immunity is mediated by retinoic acid-related orphan receptor γt+ ILC3s, TC17 cells, and TH17 cells producing IL-17, IL-22, or both, which activate mononuclear phagocytes but also recruit neutrophils and induce epithelial antimicrobial responses, thus protecting against extracellular bacteria and fungi.  On the other hand, type 1 and 3 immunity mediate autoimmune diseases, whereas type 2 responses can cause allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOlI4X4Np67Vg90H21EOLACvtfcHk0lhujFl4Duy6aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D&md5=16371c1d39a427d5ea96f9237e7b4d5a</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziato%26aufirst%3DF.%26aulast%3DRomagnani%26aufirst%3DC.%26aulast%3DRomagnani%26aufirst%3DS.%26atitle%3DThe%25203%2520major%2520types%2520of%2520innate%2520and%2520adaptive%2520cell-mediated%2520effector%2520immunity%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D135%26spage%3D626%26epage%3D635%26doi%3D10.1016%2Fj.jaci.2014.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeganeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movassagh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koziol-White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Alwan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. G.</span></span> <span> </span><span class="NLM_article-title">Emerging mediators of airway smooth muscle dysfunction in asthma</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pupt.2012.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22776693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2msr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=105-111&author=B.+Yeganehauthor=C.+Xiaauthor=H.+Movassaghauthor=C.+Koziol-Whiteauthor=Y.+Changauthor=L.+Al-Alwanauthor=J.+E.+Bourkeauthor=B.+G.+Oliver&title=Emerging+mediators+of+airway+smooth+muscle+dysfunction+in+asthma&doi=10.1016%2Fj.pupt.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging mediators of airway smooth muscle dysfunction in asthma</span></div><div class="casAuthors">Yeganeh, Behzad; Xia, Connie; Movassagh, Hesam; Koziol-White, Cynthia; Chang, Ying; Al-Alwan, Laila; Bourke, Jane E.; Oliver, Brian G. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-111</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phenotypic changes in airway smooth muscle are integral to the pathophysiol. changes that constitute asthma - namely inflammation, airway wall remodelling and bronchial hyperresponsiveness.  In vitro and in vivo studies have shown that the proliferative, secretory and contractile functions of airway smooth muscle are dysfunctional in asthma.  These functions can be modulated by various mediators whose levels are altered in asthma, derived from inflammatory cells or produced by airway smooth muscle itself.  In this review, we describe the emerging roles of the CXC chemokines (GROs, IP-10), Th17-derived cytokines (IL-17, IL-22) and semaphorins, as well as the influence of viral infection on airway smooth muscle function, with a view to identifying new opportunities for therapeutic intervention in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptXSeQfvX02bVg90H21EOLACvtfcHk0lhujFl4Duy6aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2msr%252FO&md5=e9f9e93985656dbaaf818230701e1bb9</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DYeganeh%26aufirst%3DB.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DMovassagh%26aufirst%3DH.%26aulast%3DKoziol-White%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DAl-Alwan%26aufirst%3DL.%26aulast%3DBourke%26aufirst%3DJ.%2BE.%26aulast%3DOliver%26aufirst%3DB.%2BG.%26atitle%3DEmerging%2520mediators%2520of%2520airway%2520smooth%2520muscle%2520dysfunction%2520in%2520asthma%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D105%26epage%3D111%26doi%3D10.1016%2Fj.pupt.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kardas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daszyńska-Kardas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brza̧kalska, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, M.</span></span> <span> </span><span class="NLM_article-title">Role of Platelet-Derived Growth Factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3389%2Ffphar.2020.00047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32116722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslyksbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=47&author=G.+Kardasauthor=A.+Daszy%C5%84ska-Kardasauthor=M.+Marynowskiauthor=O.+Brza%CC%A7kalskaauthor=P.+Kunaauthor=M.+Panek&title=Role+of+Platelet-Derived+Growth+Factor+%28PDGF%29+in+asthma+as+an+immunoregulatory+factor+mediating+airway+remodeling+and+possible+pharmacological+target&doi=10.3389%2Ffphar.2020.00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Platelet-Derived Growth Factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target</span></div><div class="casAuthors">Kardas, Grzegorz; Ska-Kardas, Agnieszka Daszyn; Marynowski, Mateusz; Brzakalska, Oliwia; Kuna, Piotr; Panek, Michal</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Asthma is a chronic and heterogenic disease of the respiratory system, one of the most common lung diseases worldwide.  Theunderlying pathologies, which are chronic inflammatory process and airway remodeling (AR), are mediated by numerous cells and cytokines.  Particularly interesting in this field is the platelet-derived growth factor (PDGF), one of the members of the human growth factor family.  In this article, the authors analyze the available data on the role of PDGF in asthma in exptl. models and in human research.  PDGF is expressed in airway by various cells contributing to asthma pathogenesis-mast cells, eosinophils, and airway epithelial cells.  Research confirms the thesis that this factor is also secreted by these cells in the course of asthma.  The main effects of PDGF on bronchi are the proliferation of airway smooth muscle (ASM) cells, migration of ASM cells into the epithelium and enhanced collagen synthesis by lung fibroblasts.  The importance of AR in asthma is well recognized and new therapies should also aim to manage it, possibly targeting PDGFRs.  Further studies on new and already existing drugs, mediating the PDGF signaling and related to asthma are necessary.  Several promising drugs from the tyrosine kinase inhibitors group, including nilotinib, imatinib masitinib, and sunitinib, are currently being clin. tested and other mols. are likely to emerge in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWdWoYGwflCrVg90H21EOLACvtfcHk0lg2xuRR6N9CIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslyksbvE&md5=0302627093d52b8b1fd5a2269734a423</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00047%26sid%3Dliteratum%253Aachs%26aulast%3DKardas%26aufirst%3DG.%26aulast%3DDaszy%25C5%2584ska-Kardas%26aufirst%3DA.%26aulast%3DMarynowski%26aufirst%3DM.%26aulast%3DBrza%25CC%25A7kalska%26aufirst%3DO.%26aulast%3DKuna%26aufirst%3DP.%26aulast%3DPanek%26aufirst%3DM.%26atitle%3DRole%2520of%2520Platelet-Derived%2520Growth%2520Factor%2520%2528PDGF%2529%2520in%2520asthma%2520as%2520an%2520immunoregulatory%2520factor%2520mediating%2520airway%2520remodeling%2520and%2520possible%2520pharmacological%2520target%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D47%26doi%3D10.3389%2Ffphar.2020.00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suganuma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span> <span> </span><span class="NLM_article-title">STIM1 regulates platelet-derived growth factor-induced migration and Ca<sup>2+</sup> influx in human airway smooth muscle cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e45056</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0045056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0045056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22984609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2jsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=N.+Suganumaauthor=S.+Itoauthor=H.+Asoauthor=M.+Kondoauthor=M.+Satoauthor=M.+Sokabeauthor=Y.+Hasegawa&title=STIM1+regulates+platelet-derived+growth+factor-induced+migration+and+Ca2%2B+influx+in+human+airway+smooth+muscle+cells&doi=10.1371%2Fjournal.pone.0045056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">STIM1 regulates platelet-derived growth factor-induced migration and Ca2+ influx in human airway smooth muscle cells</span></div><div class="casAuthors">Suganuma, Nobukazu; Ito, Satoru; Aso, Hiromichi; Kondo, Masashi; Sato, Mitsuo; Sokabe, Masahiro; Hasegawa, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e45056</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">It is suggested that migration of airway smooth muscle (ASM) cells plays an important role in the pathogenesis of airway remodeling in asthma.  Increases in intracellular Ca2+ concns. ([Ca2+]i) regulate most ASM cell functions related to asthma, such as contraction and proliferation.  Recently, STIM1 was identified as a sarcoplasmic reticulum (SR) Ca2+ sensor that activates Orai1, the Ca2+ channel responsible for store-operated Ca2+ entry (SOCE).  We investigated the role of STIM1 in [Ca2+]i and cell migration induced by platelet-derived growth factor (PDGF)-BB in human ASM cells.  Cell migration was assessed by a chemotaxis chamber assay.  Human ASM cells express STIM1, STIM2, and Orai1 mRNAs.  SOCE activated by thapsigargin, an inhibitor of SR Ca2+-ATPase, was significantly blocked by STIM1 siRNA and Orai1 siRNA but not by STIM2 siRNA.  PDGF-BB induced a transient increase in [Ca2+]i followed by sustained [Ca2+]ielevation.  Sustained increases in [Ca2+]i due to PDGF-BB were significantly inhibited by a Ca2+ chelating agent EGTA or by siRNA for STIM1 or Orai1.  The nos. of migrating cells were significantly increased by PDGF-BB treatment for 6 h.  Knockdown of STIM1 and Orai1 by siRNA transfection inhibited PDGF-induced cell migration.  Similarly, EGTA significantly inhibited PDGF-induced cell migration.  In contrast, transfection with siRNA for STIM2 did not inhibit the sustained elevation of [Ca2+]i or cell migration induced by PDGF-BB.  These results demonstrate that STIM1 and Orai1 are essential for PDGF-induced cell migration and Ca2+ influx in human ASM cells.  STIM1 could be an important mol. responsible for airway remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnKZDnzA5mKLVg90H21EOLACvtfcHk0lg2xuRR6N9CIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2jsbnM&md5=dbe4b1d8c495416516eabdd1b748ec26</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0045056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0045056%26sid%3Dliteratum%253Aachs%26aulast%3DSuganuma%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DAso%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSokabe%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DY.%26atitle%3DSTIM1%2520regulates%2520platelet-derived%2520growth%2520factor-induced%2520migration%2520and%2520Ca2%252B%2520influx%2520in%2520human%2520airway%2520smooth%2520muscle%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0045056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fayon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbé, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marthan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, P.</span></span> <span> </span><span class="NLM_article-title">An age-wise comparison of human airway smooth muscle proliferative capacity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0122446</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0122446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0122446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25798916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSjurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=M.+Fayonauthor=A.+Andrieuxauthor=I.+Baraauthor=M.+Rebolaauthor=A.+Labb%C3%A9author=R.+Marthanauthor=P.+Berger&title=An+age-wise+comparison+of+human+airway+smooth+muscle+proliferative+capacity&doi=10.1371%2Fjournal.pone.0122446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">An age-wise comparison of human airway smooth muscle proliferative capacity</span></div><div class="casAuthors">Fayon, Michael; Andrieux, Annick; Bara, Imane; Rebola, Muriel; Labbe, Andre; Marthan, Roger; Berger, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0122446/1-e0122446/13</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We compared the proliferation of neonatal and adult airway smooth muscle cells (ASMC) with no/moderate lung disease, in glucose- (energy prodn. by glycolysis) or glucose-free medium (ATP prodn. from mitochondrial oxidative phosphorylations only), in response to 10% fetal calf serum (FCS) and PDGF-AA.  In the presence of glucose, cell counts were significantly greater in neonatal vs. adult ASMC.  Similarly, neonatal ASMC DNA synthesis in 10% FCS and PDGF-AA, and [Ca2+]i responses in the presence of histamine were significantly enhanced vs. adults.  In glucose-free medium, cell proliferation was preserved in neonatal cells, unlike in adult cells, with concomitant increased porin (an indicator of mitochondrial activity) protein expression.  Compared to adults, stimulated neonatal human ASMC are in a rapid and robust proliferative phase and have the capacity to respond disproportionately under abnormal environmental conditions, through increased mitochondrial biogenesis and altered calcium homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKqo2FjteU5bVg90H21EOLACvtfcHk0lg2xuRR6N9CIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSjurfK&md5=bc093313045f83f0af92c0932d8bce05</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0122446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0122446%26sid%3Dliteratum%253Aachs%26aulast%3DFayon%26aufirst%3DM.%26aulast%3DAndrieux%26aufirst%3DA.%26aulast%3DBara%26aufirst%3DI.%26aulast%3DRebola%26aufirst%3DM.%26aulast%3DLabb%25C3%25A9%26aufirst%3DA.%26aulast%3DMarthan%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DP.%26atitle%3DAn%2520age-wise%2520comparison%2520of%2520human%2520airway%2520smooth%2520muscle%2520proliferative%2520capacity%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0122446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of mabuterol on proliferation of rat ASMCs induced by PDGF-BB via regulating [Ca<sup>2+</sup>]i and mitochondrial fission/fusion</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2019.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.cbi.2019.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31009640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVCntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2019&pages=63-72&author=Y.+Guauthor=X.+Yuauthor=X.+Liauthor=X.+Wangauthor=X.+Gaoauthor=M.+Wangauthor=S.+Wangauthor=X.+Liauthor=Y.+Zhang&title=Inhibitory+effect+of+mabuterol+on+proliferation+of+rat+ASMCs+induced+by+PDGF-BB+via+regulating+%5BCa2%2B%5Di+and+mitochondrial+fission%2Ffusion&doi=10.1016%2Fj.cbi.2019.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of mabuterol on proliferation of rat ASMCs induced by PDGF-BB via regulating [Ca2+]i and mitochondrial fission/fusion</span></div><div class="casAuthors">Gu, Yaru; Yu, Xitong; Li, Xiaoran; Wang, Xiaomin; Gao, Xiaoxiao; Wang, Miao; Wang, Siqi; Li, Xin; Zhang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">This study is aimed to investigate whether Mabuterol (Mab) inhibits proliferation of airway smooth muscle cells (ASMCs) induced by platelet-derived growth factor BB (PDGF-BB) and how far it is related to mitochondrial fission/fusion and intracellular calcium if it comes into play.  The inhibitory effect of Mab on S phase of ASM cell cycle induced by PDGF-BB was analyzed by flow cytometry (FCM).  Fluo-3/AM, Ca2+ fluorescent probe, was used to detect Ca2+ fluorescence intensity by inverted microscope and flow cytometry.  The gene expression of Drp-1 and Mfn-2 was obsd. with Real time PCR and the proteins of Drp-1, Mfn-2, PCNA and cyclin D1 were assessed by Western Blot.  Mab and Mdivi-1 both suppressed the proliferation induced by PDGF-BB.  The results from inverted microscope and flow cytometry showed that Mab inhibited [Ca2+]i in rat ASMCs induced by PDGF-BB.  Cell cycle concept map illustrated that Mab significantly controlled the S phase of ASM cell cycle induced by PDGF-BB.  As a consequence, Real time PCR and Western blot revealed the fact that Mab decreased the expression of Drp-1 mRNA and protein, and promoted the expression of Mfn-2 mRNA and protein.  These findings suggested that Mab placed restrictions on the proliferation of rat ASMCs induced by PDGF-BB and the mechanism might be assocd. with the intracellular calcium inhibited and the mitochondrial fission/fusion regulated by Mab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOW4mOhYfzZ7Vg90H21EOLACvtfcHk0lgXYQVf-gtYqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVCntrY%253D&md5=f5c26169076409d868a83ebf1a91074e</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2019.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2019.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DInhibitory%2520effect%2520of%2520mabuterol%2520on%2520proliferation%2520of%2520rat%2520ASMCs%2520induced%2520by%2520PDGF-BB%2520via%2520regulating%2520%255BCa2%252B%255Di%2520and%2520mitochondrial%2520fission%252Ffusion%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2019%26volume%3D307%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.cbi.2019.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chachi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzahrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koziol-White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biddle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagadood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrani, Y.</span></span> <span> </span><span class="NLM_article-title">Increased β<sub>2</sub>-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1111/cei.13191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fcei.13191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30069878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFygtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2018&pages=253-258&author=L.+Chachiauthor=A.+Alzahraniauthor=C.+Koziol-Whiteauthor=M.+Biddleauthor=R.+Bagadoodauthor=R.+A.+Panettieriauthor=P.+Braddingauthor=Y.+Amrani&title=Increased+%CE%B22-adrenoceptor+phosphorylation+in+airway+smooth+muscle+in+severe+asthma%3A+possible+role+of+mast+cell-derived+growth+factors&doi=10.1111%2Fcei.13191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors</span></div><div class="casAuthors">Chachi, L.; Alzahrani, A.; Koziol-White, C.; Biddle, M.; Bagadood, R.; Panettieri, R. A., Jr; Bradding, P.; Amrani, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-258</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate whether growth factors produced by activated human lung mast cells (HLMCs) impair β2-adrenoceptor (β2-AR) function in human airway smooth muscle (ASM) cells.  Protein array anal. confirmed the presence of various growth factors, including transforming growth factor (TGF)-β1, in the supernatants of high-affinity IgE receptor (FceRI)-activated HLMCs which, when applied to ASM cells, impaired albuterol-induced cyclic adenosine monophosphate (cAMP) prodn., an effect that was prevented following neutralization of TGF-β1.  This blunted β2-AR response was reproduced by treating ASM cells with TGF-β1 or fibroblast growth factor (FGF)-2, which induced β2-AR phosphorylation at tyrosine residues Tyr141 and Tyr350, and significantly reduced the maximal bronchorelaxant responses to isoproterenol in human precision cut lung slices (PCLS).  Finally, ASM cells isolated from severe asthmatics displayed constitutive elevated β2-AR phosphorylation at both Tyr141 and Tyr350 and a reduced relaxant response to albuterol.  This study shows for the first time that abnormal β2-AR phosphorylation/function in ASM cells that is induced rapidly by HLMC-derived growth factors, is present constitutively in cells from severe asthmatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWpczs6QMXB7Vg90H21EOLACvtfcHk0lgXYQVf-gtYqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFygtrvO&md5=a728fbeaa7fa32b984ae68c799ac91d8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1111%2Fcei.13191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.13191%26sid%3Dliteratum%253Aachs%26aulast%3DChachi%26aufirst%3DL.%26aulast%3DAlzahrani%26aufirst%3DA.%26aulast%3DKoziol-White%26aufirst%3DC.%26aulast%3DBiddle%26aufirst%3DM.%26aulast%3DBagadood%26aufirst%3DR.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26aulast%3DBradding%26aufirst%3DP.%26aulast%3DAmrani%26aufirst%3DY.%26atitle%3DIncreased%2520%25CE%25B22-adrenoceptor%2520phosphorylation%2520in%2520airway%2520smooth%2520muscle%2520in%2520severe%2520asthma%253A%2520possible%2520role%2520of%2520mast%2520cell-derived%2520growth%2520factors%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2018%26volume%3D194%26spage%3D253%26epage%3D258%26doi%3D10.1111%2Fcei.13191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdonas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raudoniute, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzauskaite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldonyte, R.</span></span> <span> </span><span class="NLM_article-title">Novel aspects of pathogenesis and regeneration mechanisms in COPD</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1013</span>, <span class="refDoi"> DOI: 10.2147/COPD.S82518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S82518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26082624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC287jtlOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=995-1013&author=E.+Bagdonasauthor=J.+Raudoniuteauthor=I.+Bruzauskaiteauthor=R.+Aldonyte&title=Novel+aspects+of+pathogenesis+and+regeneration+mechanisms+in+COPD&doi=10.2147%2FCOPD.S82518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Novel aspects of pathogenesis and regeneration mechanisms in COPD</span></div><div class="casAuthors">Bagdonas Edvardas; Raudoniute Jovile; Bruzauskaite Ieva; Aldonyte Ruta</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">995-1013</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD), a major cause of death and morbidity worldwide, is characterized by expiratory airflow limitation that is not fully reversible, deregulated chronic inflammation, and emphysematous destruction of the lungs.  Despite the fact that COPD is a steadily growing global healthcare problem, the conventional therapies remain palliative, and regenerative approaches for disease management are not available yet.  We aim to provide an overview of key reviews, experimental, and clinical studies addressing lung emphysema development and repair mechanisms published in the past decade.  Novel aspects discussed herein include integral revision of the literature focused on lung microflora changes in COPD, autoimmune component of the disease, and environmental risk factors other than cigarette smoke.  The time span of studies on COPD, including emphysema, chronic bronchitis, and asthmatic bronchitis, covers almost 200 years, and several crucial mechanisms of COPD pathogenesis are described and studied.  However, we still lack the holistic understanding of COPD development and the exact picture of the time-course and interplay of the events during stable, exacerbated, corticosteroid-treated COPD states, and transitions in-between.  Several generally recognized mechanisms will be discussed shortly herein, ie, unregulated inflammation, proteolysis/antiproteolysis imbalance, and destroyed repair mechanisms, while novel topics such as deviated microbiota, air pollutants-related damage, and autoimmune process within the lung tissue will be discussed more extensively.  Considerable influx of new data from the clinic, in vivo and in vitro studies stimulate to search for novel concise explanation and holistic understanding of COPD nowadays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcle58pui0BpyrDyM_m9cfW6udTcc2eauyBeY-SEfMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287jtlOlsg%253D%253D&md5=4d2ee72a1b2e76040284688435aaa355</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S82518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S82518%26sid%3Dliteratum%253Aachs%26aulast%3DBagdonas%26aufirst%3DE.%26aulast%3DRaudoniute%26aufirst%3DJ.%26aulast%3DBruzauskaite%26aufirst%3DI.%26aulast%3DAldonyte%26aufirst%3DR.%26atitle%3DNovel%2520aspects%2520of%2520pathogenesis%2520and%2520regeneration%2520mechanisms%2520in%2520COPD%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2015%26volume%3D10%26spage%3D995%26epage%3D1013%26doi%3D10.2147%2FCOPD.S82518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cançado, J. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">The pathology of small airways disease in COPD: historical aspects and future directions</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1186/s12931-019-1017-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2Fs12931-019-1017-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30832670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtlSgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=49-59&author=A.+Highamauthor=A.+M.+Quinnauthor=J.+E.+D.+Can%C3%A7adoauthor=D.+Singh&title=The+pathology+of+small+airways+disease+in+COPD%3A+historical+aspects+and+future+directions&doi=10.1186%2Fs12931-019-1017-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The pathology of small airways disease in COPD: historical aspects and future directions</span></div><div class="casAuthors">Higham Andrew; Singh Dave; Quinn Anne Marie; Cancado Jose Eduardo D; Singh Dave</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Small airways disease (SAD) is a cardinal feature of chronic obstructive pulmonary disease (COPD) first recognized in the nineteenth century.  The diverse histopathological features associated with SAD underpin the heterogeneous nature of COPD.  Our understanding of the key molecular mechanisms which drive the pathological changes are not complete.  In this article we will provide a historical overview of key histopathological studies which have helped shape our understanding of SAD and discuss the hallmark features of airway remodelling, mucous plugging and inflammation.  We focus on the relationship between SAD and emphysema, SAD in the early stages of COPD, and the mechanisms which cause SAD progression, including bacterial colonization and exacerbations.  We discuss the need to specifically target SAD to attenuate the progression of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0GsNW0WmBGEcLvDNbOD4DfW6udTcc2ebwcr5rFhPhobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtlSgsA%253D%253D&md5=95a3c9495699eddfb9743814ffc40c25</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2Fs12931-019-1017-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-019-1017-y%26sid%3Dliteratum%253Aachs%26aulast%3DHigham%26aufirst%3DA.%26aulast%3DQuinn%26aufirst%3DA.%2BM.%26aulast%3DCan%25C3%25A7ado%26aufirst%3DJ.%2BE.%2BD.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DThe%2520pathology%2520of%2520small%2520airways%2520disease%2520in%2520COPD%253A%2520historical%2520aspects%2520and%2520future%2520directions%26jtitle%3DRespir.%2520Res.%26date%3D2019%26volume%3D20%26spage%3D49%26epage%3D59%26doi%3D10.1186%2Fs12931-019-1017-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utokaparch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzatu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherniack, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciurba, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxson, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paré, P. D.</span></span> <span> </span><span class="NLM_article-title">The nature of small-airway obstruction in chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2645</span>– <span class="NLM_lpage">2653</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa032158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa032158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15215480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2645-2653&author=J.+C.+Hoggauthor=F.+Chuauthor=S.+Utokaparchauthor=R.+Woodsauthor=W.+M.+Elliottauthor=L.+Buzatuauthor=R.+M.+Cherniackauthor=R.+M.+Rogersauthor=F.+C.+Sciurbaauthor=H.+O.+Coxsonauthor=P.+D.+Par%C3%A9&title=The+nature+of+small-airway+obstruction+in+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa032158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The nature of small-airway obstruction in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg, James C.; Chu, Fanny; Utokaparch, Soraya; Woods, Ryan; Elliott, W. Mark; Buzatu, Liliana; Cherniack, Ruben M.; Rogers, Robert M.; Sciurba, Frank C.; Coxson, Harvey O.; Pare, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2645-2653</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major public health problem assocd. with long-term exposure to toxic gases and particles.  We examd. the evolution of the pathol. effects of airway obstruction in patients with COPD.  METHODS: The small airways were assessed in surgically resected lung tissue from 159 patients -39 with stage 0 (at risk), 39 with stage 1, 22 with stage 2, 16 with stage 3, and 43 with stage 4 (very severe) COPD, according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).  RESULTS: The progression of COPD was strongly assocd. with an increase in the vol. of tissue in the wall (P<0.001) and the accumulation of inflammatory mucous exudates in the lumen (P<0.001) of the small airways.  The percentage of the airways that contained polymorphonuclear neutrophils (P<0.001), macrophages (P<0.001), CD4 cells (P=0.02), CD8 cells (P=0.038), B cells (P<0.001), and lymphoid aggregates contg. follicles (P=0.003) and the abs. vol. of B cells (P=0.03) and CD8 cells (P=0.02) also increased as COPD progressed.  CONCLUSIONS: Progression of COPD is assocd. with the accumulation of inflammatory mucous exudates in the lumen and infiltration of the wall by innate and adaptive inflammatory immune cells that form lymphoid follicles.  These changes are coupled to a repair or remodeling process that thickens the walls of these airways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0FQMblvr8K7Vg90H21EOLACvtfcHk0lgcBoBmkUHigA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFGgur4%253D&md5=8445d6a31c9f1d8ccae5065a0dd04c65</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032158%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DUtokaparch%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DBuzatu%26aufirst%3DL.%26aulast%3DCherniack%26aufirst%3DR.%2BM.%26aulast%3DRogers%26aufirst%3DR.%2BM.%26aulast%3DSciurba%26aufirst%3DF.%2BC.%26aulast%3DCoxson%26aufirst%3DH.%2BO.%26aulast%3DPar%25C3%25A9%26aufirst%3DP.%2BD.%26atitle%3DThe%2520nature%2520of%2520small-airway%2520obstruction%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2645%26epage%3D2653%26doi%3D10.1056%2FNEJMoa032158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timens, W.</span></span> <span> </span><span class="NLM_article-title">The pathology of chronic obstructive pulmonary disease</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1146/annurev.pathol.4.110807.092145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1146%2Fannurev.pathol.4.110807.092145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18954287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=435-459&author=J.+C.+Hoggauthor=W.+Timens&title=The+pathology+of+chronic+obstructive+pulmonary+disease&doi=10.1146%2Fannurev.pathol.4.110807.092145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The pathology of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg, James C.; Timens, Wim</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">435-459</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The pathogenesis of chronic obstructive pulmonary disease (COPD) is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases.  Although tobacco smoking is the primary cause of this inhalation injury, many other environmental and occupational exposures contribute to the pathol. of COPD.  The immune inflammatory changes assocd. with COPD are linked to a tissue-repair and -remodeling process that increases mucus prodn. and causes emphysematous destruction of the gas-exchanging surface of the lung.  The common form of emphysema obsd. in smokers begins in the respiratory bronchioles near the thickened and narrowed small bronchioles that become the major site of obstruction in COPD.  The mechanism(s) that allow small airways to thicken in such close proximity to lung tissue undergoing emphysematous destruction remains a puzzle that needs to be solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUfxYoGB-w1bVg90H21EOLACvtfcHk0lgcBoBmkUHigA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ahsr0%253D&md5=e94a98c1e9426544621b833684ccb64c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.4.110807.092145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.4.110807.092145%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DTimens%26aufirst%3DW.%26atitle%3DThe%2520pathology%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2009%26volume%3D4%26spage%3D435%26epage%3D459%26doi%3D10.1146%2Fannurev.pathol.4.110807.092145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Immunology of asthma and chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nri2254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnri2254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18274560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=183-192&author=P.+J.+Barnes&title=Immunology+of+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnri2254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive airway diseases that involve chronic inflammation of the respiratory tract, but the type of inflammation is markedly different between these diseases, with different patterns of inflammatory cells and mediators being involved.  As described in this Review, these inflammatory profiles are largely detd. by the involvement of different immune cells, which orchestrate the recruitment and activation of inflammatory cells that drive the distinct patterns of structural changes in these diseases.  However, it is now becoming clear that the distinction between these diseases becomes blurred in patients with severe asthma, in asthmatic subjects who smoke and during acute exacerbations.  This has important implications for the development of new therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKkJK_5vmv57Vg90H21EOLACvtfcHk0lgF07jLHzk19Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D&md5=a1d09a214bbd87e31e0c714039077289</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnri2254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2254%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DImmunology%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D183%26epage%3D192%26doi%3D10.1038%2Fnri2254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Cellular and molecular mechanisms of asthma and COPD</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1541</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1042/CS20160487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1042%2FCS20160487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFalt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=1541-1558&author=P.+J.+Barnes&title=Cellular+and+molecular+mechanisms+of+asthma+and+COPD&doi=10.1042%2FCS20160487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and molecular mechanisms of asthma and COPD</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1541-1558</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Asthma and chronic obstructive pulmonary disease (COPD) both cause airway obstruction and are assocd. with chronic inflammation of the airways.  However, the nature and sites of the inflammation differ between these diseases, resulting in different pathol., clin. manifestations and response to therapy.  In this review, the inflammatory and cellular mechanisms of asthma and COPD are compared and the differences in inflammatory cells and profile of inflammatory mediators are highlighted.  These differences account for the differences in clin. manifestations of asthma and COPD and their response to therapy.  Although asthma and COPD are usually distinct, there are some patients who show an overlap of features, which may be explained by the coincidence of two common diseases or distinct phenotypes of each disease.  It is important to better understand the underlying cellular and mol. mechanisms of asthma and COPD in order to develop new treatments in areas of unmet need, such as severe asthma, curative therapy for asthma and effective anti-inflammatory treatments for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohVzYWx9UyhLVg90H21EOLACvtfcHk0lgF07jLHzk19Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFalt7zP&md5=000dc9977a91274d17101e8c6af816a9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1042%2FCS20160487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20160487%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DCellular%2520and%2520molecular%2520mechanisms%2520of%2520asthma%2520and%2520COPD%26jtitle%3DClin.%2520Sci.%26date%3D2017%26volume%3D131%26spage%3D1541%26epage%3D1558%26doi%3D10.1042%2FCS20160487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maarsingh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brook, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuidhof, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldenburger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timens, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurs, H.</span></span> <span> </span><span class="NLM_article-title">Small airway hyperresponsiveness in COPD: relationship between structure and function in lung slices</span>. <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">L537</span>– <span class="NLM_lpage">L546</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00325.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajplung.00325.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30628486" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2019&pages=L537-L546&author=H.+Maarsinghauthor=C.+M.+Bidanauthor=B.+S.+Brookauthor=A.+B.+Zuidhofauthor=C.+Elzingaauthor=M.+Smitauthor=A.+Oldenburgerauthor=R.+Gosensauthor=W.+Timensauthor=H.+Meurs&title=Small+airway+hyperresponsiveness+in+COPD%3A+relationship+between+structure+and+function+in+lung+slices&doi=10.1152%2Fajplung.00325.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00325.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00325.2018%26sid%3Dliteratum%253Aachs%26aulast%3DMaarsingh%26aufirst%3DH.%26aulast%3DBidan%26aufirst%3DC.%2BM.%26aulast%3DBrook%26aufirst%3DB.%2BS.%26aulast%3DZuidhof%26aufirst%3DA.%2BB.%26aulast%3DElzinga%26aufirst%3DC.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DOldenburger%26aufirst%3DA.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DTimens%26aufirst%3DW.%26aulast%3DMeurs%26aufirst%3DH.%26atitle%3DSmall%2520airway%2520hyperresponsiveness%2520in%2520COPD%253A%2520relationship%2520between%2520structure%2520and%2520function%2520in%2520lung%2520slices%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2019%26volume%3D316%26spage%3DL537%26epage%3DL546%26doi%3D10.1152%2Fajplung.00325.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Similarities and differences in inflammatory mechanisms of asthma and COPD</span>. <i>Breathe</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1183/20734735.026410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1183%2F20734735.026410" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=229-238&author=P.+J.+Barnes&title=Similarities+and+differences+in+inflammatory+mechanisms+of+asthma+and+COPD&doi=10.1183%2F20734735.026410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1183%2F20734735.026410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F20734735.026410%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DSimilarities%2520and%2520differences%2520in%2520inflammatory%2520mechanisms%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBreathe%26date%3D2011%26volume%3D7%26spage%3D229%26epage%3D238%26doi%3D10.1183%2F20734735.026410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, N. L.</span></span> <span> </span><span class="NLM_article-title">Airway smooth muscle</span>. <i>Lung</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1007/s004080000073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs004080000073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12040426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1ChtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2001&pages=333-373&author=N.+L.+Stephens&title=Airway+smooth+muscle&doi=10.1007%2Fs004080000073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Airway smooth muscle</span></div><div class="casAuthors">Stephens, N. L.</div><div class="citationInfo"><span class="NLM_cas:title">Lung</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">333-373</span>CODEN:
                <span class="NLM_cas:coden">LUNGD9</span>;
        ISSN:<span class="NLM_cas:issn">0341-2040</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag New York Inc.</span>)
        </div><div class="casAbstract">A review.  The greatest impetus to research in elucidating the fundamental biophysics and biochem. of airway smooth muscle (ASM) has undoubtedly been provided by the need to understand how these are altered in asthma.  Many of the biophys. and biochem. properties of this muscle have been reviewed before.  They resemble those of striated muscle; however, even though mech. properties are very similar, there are differences in biochem.  For example, in smooth muscle, calcium sensitive regulation of contraction is mediated by a calmodulin/myosin-light chain kinase/phosphatase system, not by the familiar troponin-tropomyosm system.  Thus, the mol. mechanisms to be investigated in understanding disorders of increased smooth muscle contraction, which occur in allergic bronchospasm, for example, may be quite different from those in striated muscle.  Much of the following material is based on studies of canine tracheal smooth muscle (TSM) because there is evidence that it serves as a model for ASM - at least with respect to contractility down to the sixth generation of airways.  Studies of isolated smooth muscle from smaller airways are few and are based mainly on studies of lung strips.  Since then, we have developed a bronchial smooth muscle prepn. (fifth generation) that allows precise study of those airways that are involved in allergic bronchospasm.  Considerable work has been carried out on ASM from a variety of animal models of asthma.  It should be pointed out that none of these reproduces the human disease exactly, and that they really should be identified as examples of nonspecific hyperreactivity.  Be that as it may, the nonspecificity found in human patients in vivo and in animals suggests that the primary cause of asthma may reside at the muscle cell level.  Whether it is the cell membrane, the excitation-contraction coupling app., or the contractile machinery that is primarily involved, is not yet known with certainty.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp14ppQxn5Y2rVg90H21EOLACvtfcHk0lgF07jLHzk19Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1ChtLg%253D&md5=6a3adc2ebcf0ec2047802ac6b6173d36</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs004080000073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004080000073%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DN.%2BL.%26atitle%3DAirway%2520smooth%2520muscle%26jtitle%3DLung%26date%3D2001%26volume%3D179%26spage%3D333%26epage%3D373%26doi%3D10.1007%2Fs004080000073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sommerville, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorne, D. J.</span></span> <span> </span><span class="NLM_article-title">Intracellular calcium and smooth muscle contraction</span>. <i>Cell Calcium</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/0143-4160(86)90038-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2F0143-4160%2886%2990038-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=3545487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL2sXotF2msQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1986&pages=353-364&author=L.+E.+Sommervilleauthor=D.+J.+Hartshorne&title=Intracellular+calcium+and+smooth+muscle+contraction&doi=10.1016%2F0143-4160%2886%2990038-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular calcium and smooth muscle contraction</span></div><div class="casAuthors">Sommerville, L. E.; Hartshorne, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Calcium</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">353-64</span>CODEN:
                <span class="NLM_cas:coden">CECADV</span>;
        ISSN:<span class="NLM_cas:issn">0143-4160</span>.
    </div><div class="casAbstract">A review, with 31 refs., on the regulation of intracellular Ca2+, its role in the contraction-relaxation cycle of smooth muscle, and a description of various Ca2+-dependent processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7iLzbGzdJE7Vg90H21EOLACvtfcHk0ljbyzfIJcMV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXotF2msQ%253D%253D&md5=5fef50d63d0176ea4de10b82dc9f255f</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2F0143-4160%2886%2990038-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0143-4160%252886%252990038-2%26sid%3Dliteratum%253Aachs%26aulast%3DSommerville%26aufirst%3DL.%2BE.%26aulast%3DHartshorne%26aufirst%3DD.%2BJ.%26atitle%3DIntracellular%2520calcium%2520and%2520smooth%2520muscle%2520contraction%26jtitle%3DCell%2520Calcium%26date%3D1986%26volume%3D7%26spage%3D353%26epage%3D364%26doi%3D10.1016%2F0143-4160%2886%2990038-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Microdomain elements of airway smooth muscle in calcium regulation and cell proliferation</span>. <i>J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.26402/jpp.2018.2.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.26402%2Fjpp.2018.2.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVylt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=151-163&author=C.+Zhaoauthor=A.+Y.+Wuauthor=X.+Yuauthor=Y.+Guauthor=Y.+Luauthor=X.+Songauthor=N.+Anauthor=Y.+Zhang&title=Microdomain+elements+of+airway+smooth+muscle+in+calcium+regulation+and+cell+proliferation&doi=10.26402%2Fjpp.2018.2.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Microdomain elements of airway smooth muscle in calcium regulation and cell proliferation</span></div><div class="casAuthors">Zhao, C.; Woo, A. Y.-H.; Yu, X.; Gu, Y.; Lu, Y.; Song, X.; An, N.; Zhang, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-163</span>CODEN:
                <span class="NLM_cas:coden">JPHPEI</span>;
        ISSN:<span class="NLM_cas:issn">0867-5910</span>.
    
            (<span class="NLM_cas:orgname">Polish Physiological Society</span>)
        </div><div class="casAbstract">Airway remodeling manifested by hyperplasia of airway smooth muscle cells (ASMCs) and other structural and functional changes is a pathol. condition in asthma not addressed by current treatment.  Ca2+ signaling is crucial for ASMC proliferation. lnositol-l,4,5-trisphosphate receptor (IP3R) and ryanodine receptor (RyR) mediate Ca2+ release from endoplasmic reticulum/sarcoplasmic reticulum (KR/SR).  Upon sensing the depletion of Ca2+ in ER/SR, stromal interaction mol. I (STIMI) aggregates and redistributes at the microdomain of ER/SR-plasma membrane (PM) and activates Orail a component of the store-operated Ca2+ (SOC) channels, to initiate Ca2+ influx.  The STIMI/Orail-mediated SOC entry is the main cause of a sustained intracellular calcium ([Ca2+]i) elevation, which is different from a transient rise of [Ca2+]i mediated by IP3R and RyR.  Extended-synaptotagmin 1 (E-Sytl) is recruited to the ER/SR-PM junction and anchors to the PM lipid phosphatidylinositol-4,5-bisphosphalc (PI(4,5)P2) in a SOC-dependent manner.  The subsequent strengthening of the ER/SR-PM connection by E-Sytl facilitates the phosphalidylinositol (PI) transfer protein, Nir2. to supplement PI, a PI(4,5)P2 substrate, for the generation of IP3 and the propagation of Ca2+ signaling.  Calcineurin and nuclear factor of activated T cells are the downstream signaling factors of elevated [Ca2+]i contributing to ASMC proliferation.  Mitochondrial Ca2+ uptake/efflux, mitochondrial fission/fusion and mitochondrial-ER/SR coupling also play important roles in modulating [Ca2+]i and ASMC proliferation.  Together, these pathways and mechanisms represent new therapeutic targets for airway remodeling.  The present review provides an overview of our current understanding of the mechanisms of ASMC proliferation involving Ca2+ and highlights potential directions to control airway remodeling in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdU1MqAH1E5LVg90H21EOLACvtfcHk0ljbyzfIJcMV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVylt7o%253D&md5=14eaedcbd4e28f3ad16405ca14252d52</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.26402%2Fjpp.2018.2.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.26402%252Fjpp.2018.2.01%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DA.%2BY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DAn%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMicrodomain%2520elements%2520of%2520airway%2520smooth%2520muscle%2520in%2520calcium%2520regulation%2520and%2520cell%2520proliferation%26jtitle%3DJ.%2520Physiol.%2520Pharmacol.%26date%3D2018%26volume%3D69%26spage%3D151%26epage%3D163%26doi%3D10.26402%2Fjpp.2018.2.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojo, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span> <span> </span><span class="NLM_article-title">cAMP regulation of airway smooth muscle function</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2012.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pupt.2012.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22634112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVaqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=112-120&author=C.+K.+Billingtonauthor=O.+O.+Ojoauthor=R.+B.+Pennauthor=S.+Ito&title=cAMP+regulation+of+airway+smooth+muscle+function&doi=10.1016%2Fj.pupt.2012.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP regulation of airway smooth muscle function</span></div><div class="casAuthors">Billington, Charlotte K.; Ojo, Oluwaseun O.; Penn, Raymond B.; Ito, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-120</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Agonists activating β2-adrenoceptors (β2ARs) on airway smooth muscle (ASM) are the drug of choice for rescue from acute bronchoconstriction in patients with both asthma and chronic obstructive pulmonary disease (COPD).  Moreover, the use of long-acting β-agonists combined with inhaled corticosteroids constitutes an important maintenance therapy for these diseases. β-Agonists are effective bronchodilators due primarily to their ability to antagonize ASM contraction.  The presumed cellular mechanism of action involves the generation of intracellular cAMP, which in turn can activate the effector mols. cAMP-dependent protein kinase (PKA) and Epac.  Other agents such as prostaglandin E2 and phosphodiesterase inhibitors that also increase intracellular cAMP levels in ASM, can also antagonize ASM contraction, and inhibit other ASM functions including proliferation and migration.  Therefore, β2ARs and cAMP are key players in combating the pathophysiol. of airway narrowing and remodeling.  However, limitations of β-agonist therapy due to drug tachyphylaxis related to β2AR desensitization, and recent findings regarding the manner in which β2ARs and cAMP signal, have raised new and interesting questions about these well-studied mols.  In this review we discuss current concepts regarding β2ARs and cAMP in the regulation of ASM cell functions and their therapeutic roles in asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq72EwTpkxB4bVg90H21EOLACvtfcHk0ljbyzfIJcMV2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVaqu70%253D&md5=8a236a8da936fe58e40231b5613910f1</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DBillington%26aufirst%3DC.%2BK.%26aulast%3DOjo%26aufirst%3DO.%2BO.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DIto%26aufirst%3DS.%26atitle%3DcAMP%2520regulation%2520of%2520airway%2520smooth%2520muscle%2520function%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D112%26epage%3D120%26doi%3D10.1016%2Fj.pupt.2012.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M. J.</span></span> <span> </span><span class="NLM_article-title">Airway smooth muscle relaxation results from a reduction in the frequency of Ca<sup>2+</sup> oscillations induced by a cAMP-mediated inhibition of the IP<sub>3</sub> receptor</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-7-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2F1465-9921-7-34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16504084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD283mtl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=34-53&author=Y.+Baiauthor=M.+J.+Sanderson&title=Airway+smooth+muscle+relaxation+results+from+a+reduction+in+the+frequency+of+Ca2%2B+oscillations+induced+by+a+cAMP-mediated+inhibition+of+the+IP3+receptor&doi=10.1186%2F1465-9921-7-34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Airway smooth muscle relaxation results from a reduction in the frequency of Ca2+ oscillations induced by a cAMP-mediated inhibition of the IP3 receptor</span></div><div class="casAuthors">Bai Yan; Sanderson Michael J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It has been shown that the contractile state of airway smooth muscle cells (SMCs) in response to agonists is determined by the frequency of Ca2+ oscillations occurring within the SMCs.  Therefore, we hypothesized that the relaxation of airway SMCs induced by agents that increase cAMP results from the down-regulation or slowing of the frequency of the Ca2+ oscillations.  METHODS:  The effects of isoproterenol (ISO), forskolin (FSK) and 8-bromo-cAMP on the relaxation and Ca2+ signaling of airway SMCs contracted with methacholine (MCh) was investigated in murine lung slices with phase-contrast and laser scanning microscopy.  RESULTS:  All three cAMP-elevating agents simultaneously induced a reduction in the frequency of Ca2+ oscillations within the SMCs and the relaxation of contracted airways.  The decrease in the Ca2+ oscillation frequency correlated with the extent of airway relaxation and was concentration-dependent.  The mechanism by which cAMP reduced the frequency of the Ca2+ oscillations was investigated.  Elevated cAMP did not affect the re-filling rate of the internal Ca2+ stores after emptying by repetitive exposure to 20 mM caffeine.  Neither did elevated cAMP limit the Ca2+ available to stimulate contraction because an elevation of intracellular Ca2+ concentration induced by exposure to a Ca2+ ionophore (ionomycin) or by photolysis of caged-Ca2+ did not reverse the effect of cAMP.  Similar results were obtained with iberiotoxin, a blocker of Ca2+-activated K+ channels, which would be expected to increase Ca2+ influx and contraction.  By contrast, the photolysis of caged-IP3 in the presence of agonist, to further elevate the intracellular IP3 concentration, reversed the slowing of the frequency of the Ca2+ oscillations and relaxation of the airway induced by FSK.  This result implied that the sensitivity of the IP3R to IP3 was reduced by FSK and this was supported by the reduced ability of IP3 to release Ca2+ in SMCs in the presence of FSK.  CONCLUSION:  These results indicate that the relaxant effect of cAMP-elevating agents on airway SMCs is achieved by decreasing the Ca2+ oscillation frequency by reducing internal Ca2+ release through IP3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS59KjxJhpCRpyrDyM_m9cfW6udTcc2ebOuOAEOeZhwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283mtl2gtA%253D%253D&md5=039321875eea8ddb9337d9a8c7d78ebf</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-7-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-7-34%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DY.%26aulast%3DSanderson%26aufirst%3DM.%2BJ.%26atitle%3DAirway%2520smooth%2520muscle%2520relaxation%2520results%2520from%2520a%2520reduction%2520in%2520the%2520frequency%2520of%2520Ca2%252B%2520oscillations%2520induced%2520by%2520a%2520cAMP-mediated%2520inhibition%2520of%2520the%2520IP3%2520receptor%26jtitle%3DRespir.%2520Res.%26date%3D2006%26volume%3D7%26spage%3D34%26epage%3D53%26doi%3D10.1186%2F1465-9921-7-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aburima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wraith, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raslan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magwenzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseem, K. M.</span></span> <span> </span><span class="NLM_article-title">cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3533</span>– <span class="NLM_lpage">3545</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-03-487850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1182%2Fblood-2013-03-487850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24100445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVehsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3533-3545&author=A.+Aburimaauthor=K.+S.+Wraithauthor=Z.+Raslanauthor=R.+Lawauthor=S.+Magwenziauthor=K.+M.+Naseem&title=cAMP+signaling+regulates+platelet+myosin+light+chain+%28MLC%29+phosphorylation+and+shape+change+through+targeting+the+RhoA-Rho+kinase-MLC+phosphatase+signaling+pathway&doi=10.1182%2Fblood-2013-03-487850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway</span></div><div class="casAuthors">Aburima, Ahmed; Wraith, Katie S.; Raslan, Zaher; Law, Robert; Magwenzi, Simbarashe; Naseem, Khalid M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3533-3545</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cyclic adenosine monophosphate (cAMP)-dependent signaling modulates platelet shape change through unknown mechanisms.  We examd. the effects of cAMP signaling on platelet contractile machinery.  Prostaglandin E1 (PGE1)-mediated inhibition of thrombin-stimulated shape change was accompanied by diminished phosphorylation of myosin light chain (MLC).  Since thrombin stimulates phospho-MLC through RhoA/Rho-assocd., coiled-coil contg. protein kinase (ROCK)-dependent inhibition of MLC phosphatase (MLCP), we examd. the effects of cAMP on this pathway.  Thrombin stimulated the membrane localization of RhoA and the formation of a signaling complex of RhoA/ROCK2/myosin phosphatase-targeting subunit 1 (MYPT1).  This resulted in ROCK-mediated phosphorylation of MYPT1 on threonine 853 (thr853), the disassocn. of the catalytic subunit protein phosphatase 1δ (PP1δ) from MYPT1 and inhibition of basal MLCP activity.  Treatment of platelets with PGE1 prevented thrombin-induced phospho-MYPT1-thr853 in a protein kinase A (PKA)-dependent manner.  Examn. of the mol. mechanisms revealed that PGE1 induced the phosphorylation of RhoA on serine188 through a pathway requiring cAMP and PKA.  This event inhibited the membrane relocalization of RhoA, prevented the assocn. of RhoA with ROCK2 and MYPT1, attenuated the dissocn. of PP1δ from MYPT1, and thereby restored basal MLCP activity leading to a decrease in phospho-MLC.  These data reveal a new mechanism by which the cAMP-PKA signaling pathway regulates platelet function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmssR0QJfsMLVg90H21EOLACvtfcHk0ljN2Bn_ADL0hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVehsr%252FJ&md5=b127548f10c62d5628bf61bd00a5bbe1</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-487850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-487850%26sid%3Dliteratum%253Aachs%26aulast%3DAburima%26aufirst%3DA.%26aulast%3DWraith%26aufirst%3DK.%2BS.%26aulast%3DRaslan%26aufirst%3DZ.%26aulast%3DLaw%26aufirst%3DR.%26aulast%3DMagwenzi%26aufirst%3DS.%26aulast%3DNaseem%26aufirst%3DK.%2BM.%26atitle%3DcAMP%2520signaling%2520regulates%2520platelet%2520myosin%2520light%2520chain%2520%2528MLC%2529%2520phosphorylation%2520and%2520shape%2520change%2520through%2520targeting%2520the%2520RhoA-Rho%2520kinase-MLC%2520phosphatase%2520signaling%2520pathway%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3533%26epage%3D3545%26doi%3D10.1182%2Fblood-2013-03-487850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dekkers, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehlic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaagsma, J.</span></span> <span> </span><span class="NLM_article-title">Glucocorticosteroids and β<sub>2</sub>-adrenoceptor agonists synergize to inhibit airway smooth muscle remodeling</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.195867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.112.195867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22685341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlShu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=780-787&author=B.+G.+Dekkersauthor=A.+Pehlicauthor=R.+Marianiauthor=I.+S.+Bosauthor=H.+Meursauthor=J.+Zaagsma&title=Glucocorticosteroids+and+%CE%B22-adrenoceptor+agonists+synergize+to+inhibit+airway+smooth+muscle+remodeling&doi=10.1124%2Fjpet.112.195867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Glucocorticosteroids and β2-adrenoceptor agonists synergize to inhibit airway smooth muscle remodeling</span></div><div class="casAuthors">Dekkers, Bart G. J.; Pehlic, Adnan; Mariani, Raissa; Bos, I. Sophie T.; Meurs, Herman; Zaagsma, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">780-787</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Airway remodeling, including increased airway smooth muscle (ASM) mass and contractility, contributes to increased airway narrowing in asthma.  Increased ASM mass may be caused by exposure to mitogens, including platelet-derived growth factor (PDGF) and collagen type I, which induce a proliferative, hypocontractile ASM phenotype.  In contrast, prolonged exposure to insulin induces a hypercontractile phenotype.  Glucocorticosteroids and β2-adrenoceptor agonists synergize to increase glucocorticosteroid receptor translocation in ASM cells; however, the impact of this synergism on phenotype modulation is unknown.  Using bovine tracheal smooth muscle, we investigated the effects of the glucocorticosteroids fluticasone (10 nM), budesonide (30 nM), and dexamethasone (0.1-1 μM) and the combination of low concns. of fluticasone (3-100 pM) and fenoterol (10 nM) on ASM phenotype switching in response to PDGF (10 ng/mL), collagen type I (50 μg/mL), and insulin (1 μM).  All glucocorticosteroids inhibited PDGF- and collagen I-induced proliferation and hypocontractility, with the effects of collagen I being less susceptible to glucocorticosteroid action.  At 100-fold lower concns., fluticasone (100 pM) synergized with fenoterol to prevent PDGF- and collagen I-induced phenotype switching.  This inhibition of ASM phenotype switching was assocd. with a normalization of the PDGF-induced decrease in the cell cycle inhibitors p21WAF1/CIP1 and p57KIP2.  At this concn., fluticasone also prevented the insulin-induced hypercontractile phenotype.  At even lower concns., fluticasone (3 pM) synergized with fenoterol to inhibit this phenotype switch.  Collectively, these findings indicate that glucocorticosteroids and β2-agonits synergistically inhibit ASM phenotype switching, which may contribute to the increased effectiveness of combined treatment with glucocorticosteroids and β2-agonists in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1DsS1aZCh4bVg90H21EOLACvtfcHk0ljN2Bn_ADL0hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlShu7vK&md5=ccd8591382e1a47dcdeff1e473421b10</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.195867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.195867%26sid%3Dliteratum%253Aachs%26aulast%3DDekkers%26aufirst%3DB.%2BG.%26aulast%3DPehlic%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DR.%26aulast%3DBos%26aufirst%3DI.%2BS.%26aulast%3DMeurs%26aufirst%3DH.%26aulast%3DZaagsma%26aufirst%3DJ.%26atitle%3DGlucocorticosteroids%2520and%2520%25CE%25B22-adrenoceptor%2520agonists%2520synergize%2520to%2520inhibit%2520airway%2520smooth%2520muscle%2520remodeling%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D780%26epage%3D787%26doi%3D10.1124%2Fjpet.112.195867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncharova, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krymskaya, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2011-0217OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1165%2Frcmb.2011-0217OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22210825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=48-54&author=E.+A.+Goncharovaauthor=D.+A.+Goncharovauthor=H.+Zhaoauthor=R.+B.+Pennauthor=V.+P.+Krymskayaauthor=R.+A.+Panettieri&title=%CE%B22-adrenergic+receptor+agonists+modulate+human+airway+smooth+muscle+cell+migration+via+vasodilator-stimulated+phosphoprotein&doi=10.1165%2Frcmb.2011-0217OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein</span></div><div class="casAuthors">Goncharova, Elena A.; Goncharov, Dmitry A.; Zhao, Hengjiang; Penn, Raymond B.; Krymskaya, Vera P.; Panettieri, Reynold A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-54</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Severe asthma manifests as airway remodeling and irreversible airway obstruction, in part because of the proliferation and migration of human airway smooth muscle (HASM) cells.  We previously reported that cyclic adenosine monophosphate-mobilizing agents, including β2-adrenergic receptor (β2AR) agonists, which are mainstay of asthma therapy, and prostaglandin E2 (PGE2), inhibit the migration of HASM cells, although the mechanism for this migration remains unknown.  Vasodilator-stimulated phosphoprotein (VASP), an anticapping protein, modulates the formation of actin stress fibers during cell motility, and is neg. regulated by protein kinase A (PKA)-specific inhibitory phosphorylation at serine 157 (Ser157).  Here, we show that treatment with β2AR agonists and PGE2 induces the PKA-dependent phosphorylation of VASP and inhibits the migration of HASM cells.  The stable expression of PKA inhibitory peptide and the small interfering (si) RNA-induced depletion of VASP abolish the inhibitory effects of albuterol and PGE2 on the migration of HASM cells.  Importantly, prolonged treatment with albuterol prevents the agonist-induced phosphorylation of VASP at Ser157, and reverses the inhibitory effects of albuterol and formoterol, but not PGE2, on the basal and PDGF-induced migration of HASM cells.  Collectively, our data demonstrate that β2AR agonists selectively inhibit the migration of HASM cells via a β2AR/PKA/VASP signaling pathway, and that prolonged treatment with albuterol abolishes the inhibitory effect of β-agonists on the phosphorylation of VASP and migration of HASM cells because of β2AR desensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTmlB6JvyB8bVg90H21EOLACvtfcHk0ljN2Bn_ADL0hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlWqtQ%253D%253D&md5=fb744bdc8cc4b0cb1784cb20abe7f89c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2011-0217OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2011-0217OC%26sid%3Dliteratum%253Aachs%26aulast%3DGoncharova%26aufirst%3DE.%2BA.%26aulast%3DGoncharov%26aufirst%3DD.%2BA.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DKrymskaya%26aufirst%3DV.%2BP.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26atitle%3D%25CE%25B22-adrenergic%2520receptor%2520agonists%2520modulate%2520human%2520airway%2520smooth%2520muscle%2520cell%2520migration%2520via%2520vasodilator-stimulated%2520phosphoprotein%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2012%26volume%3D46%26spage%3D48%26epage%3D54%26doi%3D10.1165%2Frcmb.2011-0217OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theron, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steel, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintinger, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, C.</span></span> <span> </span><span class="NLM_article-title">The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">105420</span>, <span class="refDoi"> DOI: 10.1155/2014/105420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1155%2F2014%2F105420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24733958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2cnjslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=105420&author=R.+Andersonauthor=A.+J.+Theronauthor=H.+C.+Steelauthor=C.+Durandtauthor=G.+R.+Tintingerauthor=C.+Feldman&title=The+beta-2-adrenoreceptor+agonists%2C+formoterol+and+indacaterol%2C+but+not+salbutamol%2C+effectively+suppress+the+reactivity+of+human+neutrophils+in+vitro&doi=10.1155%2F2014%2F105420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro</span></div><div class="casAuthors">Anderson Ronald; Steel Helen C; Durandt Chrisna; Tintinger Gregory R; Theron Annette J; Feldman Charles</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105420</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The clinical relevance of the anti-inflammatory properties of beta-2 agonists remains contentious possibly due to differences in their molecular structures and agonist activities.  The current study has compared the effects of 3 different categories of β 2-agonists, namely, salbutamol (short-acting), formoterol (long-acting) and indacaterol (ultra-long-acting), at concentrations of 1-1000 nM, with human blood neutrophils in vitro.  Neutrophils were activated with either N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP, 1 μM) or platelet-activating factor (PAF, 200 nM) in the absence and presence of the β 2-agonists followed by measurement of the generation of reactive oxygen species and leukotriene B4, release of elastase, and expression of the β 2-integrin, CR3, using a combination of chemiluminescence, ELISA, colorimetric, and flow cytometric procedures respectively.  These were correlated with alterations in the concentrations of intracellular cyclic-AMP and cytosolic Ca(2+).  At the concentrations tested, formoterol and indacaterol caused equivalent, significant (P < 0.05 at 1-10 nM) dose-related inhibition of all of the pro-inflammatory activities tested, while salbutamol was much less effective (P < 0.05 at 100 nM and higher).  Suppression of neutrophil reactivity was accompanied by elevations in intracellular cAMP and accelerated clearance of Ca(2+) from the cytosol of activated neutrophils.  These findings demonstrate that β 2-agonists vary with respect to their suppressive effects on activated neutrophils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNHMVjMpinWNenUz0lpNqnfW6udTcc2eZQZCaIgLs657ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnjslGgsQ%253D%253D&md5=a7d502e5ec575f849715ab02083f67e7</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1155%2F2014%2F105420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F105420%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DR.%26aulast%3DTheron%26aufirst%3DA.%2BJ.%26aulast%3DSteel%26aufirst%3DH.%2BC.%26aulast%3DDurandt%26aufirst%3DC.%26aulast%3DTintinger%26aufirst%3DG.%2BR.%26aulast%3DFeldman%26aufirst%3DC.%26atitle%3DThe%2520beta-2-adrenoreceptor%2520agonists%252C%2520formoterol%2520and%2520indacaterol%252C%2520but%2520not%2520salbutamol%252C%2520effectively%2520suppress%2520the%2520reactivity%2520of%2520human%2520neutrophils%2520in%2520vitro%26jtitle%3DMediators%2520Inflammation%26date%3D2014%26volume%3D2014%26spage%3D105420%26doi%3D10.1155%2F2014%2F105420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamyel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnken-Uhlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemann, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmedat, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller-Larsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racké, K.</span></span> <span> </span><span class="NLM_article-title">The β<sub>2</sub>-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1007/s00210-011-0655-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00210-011-0655-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21603974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2011&pages=133-145&author=F.+Lamyelauthor=M.+Warnken-Uhlichauthor=W.+K.+Seemannauthor=K.+Mohrauthor=E.+Kostenisauthor=A.+S.+Ahmedatauthor=M.+Smitauthor=R.+Gosensauthor=H.+Meursauthor=A.+Miller-Larssonauthor=K.+Rack%C3%A9&title=The+%CE%B22-subtype+of+adrenoceptors+mediates+inhibition+of+pro-fibrotic+events+in+human+lung+fibroblasts&doi=10.1007%2Fs00210-011-0655-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span></div><div class="casAuthors">Lamyel, F.; Warnken-Uhlich, M.; Seemann, W. K.; Mohr, K.; Kostenis, E.; Ahmedat, A. S.; Smit, M.; Gosens, R.; Meurs, H.; Miller-Larsson, A.; Racke, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fibrosis is part of airway remodelling obsd. in bronchial asthma and COPD.  Pro-fibrotic activity of lung fibroblasts may be suppressed by β-adrenoceptor activation.  We aimed, first, to characterize the expression pattern of β-adrenoceptor subtypes in human lung fibroblasts and, second, to probe β-adrenoceptor signaling with an emphasis on anti-fibrotic actions.  Using reverse transcription PCR, mRNA encoding β2-adrenoceptors was detected in MRC-5, HEL-299 and primary human lung fibroblasts, whereas transcripts for β1- and β3-adrenoceptors were not found.  Real-time measurement of dynamic mass redistribution in MRC-5 cells revealed β-agonist-induced Gs-signaling.  Proliferation of MRC-5 cells (detd. by [3H]-thymidine incorporation) was significantly inhibited by β-agonists including the β2-selective agonist formoterol (-logIC50, 10.2) and olodaterol (-logIC50, 10.6).  Formoterol's effect was insensitive to β1-antagonism (GCP 20712, 3 μM), but sensitive to β2-antagonism (ICI 118,551; apparent, pA 2, 9.6).  Collagen synthesis in MRC-5 cells (detd. by [3H]-proline incorporation) was inhibited by β-agonists including formoterol (-logIC50, 10.0) and olodaterol (-logIC50, 10.3) in a β2-blocker-sensitive manner. α-Smooth muscle actin, a marker of myo-fibroblast differentiation, was down-regulated at the mRNA and the protein level by about 50% following 24 and 48 h exposure to 1 nM formoterol, a maximally active concn.  In conclusion, human lung fibroblasts exclusively express β2-adrenoceptors and these mediate inhibition of various markers of pro-fibrotic cellular activity.  Under clin. conditions, anti-fibrotic actions may accompany the therapeutic effect of long-term β2-agonist treatment of bronchial asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrrxy9mSlR7Vg90H21EOLACvtfcHk0linAfkRihin_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D&md5=f72d9809b80589d1a5dc921d1dc09971</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs00210-011-0655-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-011-0655-5%26sid%3Dliteratum%253Aachs%26aulast%3DLamyel%26aufirst%3DF.%26aulast%3DWarnken-Uhlich%26aufirst%3DM.%26aulast%3DSeemann%26aufirst%3DW.%2BK.%26aulast%3DMohr%26aufirst%3DK.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DAhmedat%26aufirst%3DA.%2BS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DMeurs%26aufirst%3DH.%26aulast%3DMiller-Larsson%26aufirst%3DA.%26aulast%3DRack%25C3%25A9%26aufirst%3DK.%26atitle%3DThe%2520%25CE%25B22-subtype%2520of%2520adrenoceptors%2520mediates%2520inhibition%2520of%2520pro-fibrotic%2520events%2520in%2520human%2520lung%2520fibroblasts%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2011%26volume%3D384%26spage%3D133%26epage%3D145%26doi%3D10.1007%2Fs00210-011-0655-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. G.</span></span> <span> </span><span class="NLM_article-title">The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1048</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2010.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20590599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1048-1061&author=J.+G.+Baker&title=The+selectivity+of+beta-adrenoceptor+agonists+at+human+beta1-%2C+beta2-+and+beta3-adrenoceptors&doi=10.1111%2Fj.1476-5381.2010.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors</span></div><div class="casAuthors">Baker, Jillian G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1061</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).  Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.  In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.  This study examd. the affinity and intrinsic efficacy of β-adrenoceptor agonists at the three human β-adrenoceptors to det. whether the current agonists are subtype selective because of affinity or intrinsic efficacy.  Stable clonal CHO-K1 cell lines, transfected with either the human β1, β2 or β3-adrenoceptor, were used, and whole-cell [3H]-CGP 12177 radioligand binding and [3H]-cAMP accumulation were measured.  Several agonists were highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2-adrenoceptor over the β1 or β3), while others (e.g. isoprenaline) had little affinity-selectivity.  However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.  Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype-selective intrinsic efficacy.  Several ligands appeared to activate two agonist conformations of the β1- and β3-adrenoceptors.  There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.  Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopuUPn04Hp7LVg90H21EOLACvtfcHk0linAfkRihin_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D&md5=daff8f97b1dfc4732135d3aa79e7de0f</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520selectivity%2520of%2520beta-adrenoceptor%2520agonists%2520at%2520human%2520beta1-%252C%2520beta2-%2520and%2520beta3-adrenoceptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1048%26epage%3D1061%26doi%3D10.1111%2Fj.1476-5381.2010.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newhouse, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCallum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paré, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesic-Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molfino, N. A.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1378/chest.110.3.595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1378%2Fchest.110.3.595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8797398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXit1aksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=1996&pages=595-603&author=M.+T.+Newhouseauthor=K.+R.+Chapmanauthor=A.+L.+McCallumauthor=R.+T.+Abboudauthor=D.+M.+Bowieauthor=R.+V.+Hodderauthor=P.+D.+Par%C3%A9author=H.+Mesic-Fuchsauthor=N.+A.+Molfino&title=Cardiovascular+safety+of+high+doses+of+inhaled+fenoterol+and+albuterol+in+acute+severe+asthma&doi=10.1378%2Fchest.110.3.595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma</span></div><div class="casAuthors">Newhouse, Michael T.; Chapman, Kenneth R.; Mccallum, Andrew L.; Abboud, Raja T.; Bowie, Dennis M.; Hodder, Richard V.; Pare, Peter D.; Mesic-Fuchs, Hilda; Molfino, Nestor A.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-603</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">It has been suggested that overuse of fenoterol metered-dose inhalers (MDIs) may increase the risk of death from asthma due to cardiac arrhythmias.  Our primary objective was to compare the cardiovascular safety of fenoterol and albuterol MDIs when administered in maximal bronchodilating or maximal tolerated doses to an abs. max. of 16 puffs, for the emergency department (ED) treatment of acute severe asthma.  Asthmatic patients presenting to the ED with acute severe asthma (FEV1 less than 50% of predicted) were enrolled in a multicenter, randomized, double-blind, parallel-group study.  Following baseline measurements, (medical history, phys. examn., detn. of serum potassium and serum theophylline levels, oximetry, 12-lead ECG, and spirometry), each patient received 4 puffs of either fenoterol, 200 μg per puff, or albuterol, 100 μg per puff, 1 puff every 30 s via an MDI attached to a holding chamber.  Addnl. doses of inhaled β2-agonist were administered by dose titrn., 2 puffs every 10 min to a maximal cumulative dose of 16 puffs of albuterol or fenoterol, side effects were intolerable to the patient, or an FEV1 plateau (ie, <10% improvement for 2 consecutive doses) occurred.  ECG was recorded continuously via Holter monitor, and respiratory rate, BP, dyspnea (Borg scale), and FEV1 were assessed after each dose.  128 Patients were randomized to receive fenoterol and 129 to receive albuterol.  Overall, fenoterol increased FEV1 160 mL more than albuterol.  The mean (SEM) FEV1 increase from baseline was 0.75±0.06 L in the fenoterol group and 0.59±0.06 L in the albuterol group (p<0.03).  Both β2-agonists caused a decrease in serum potassium level that was significantly greater in the fenoterol (0.23±0.04 mmol/L) than in the salbutamol (0.06±0.03 mmol/L) group (p=0.0002).  There was also a greater increase in the Q-Tc interval in the fenoterol group, 0.011±0.003 s compared with 0.003±0.003 s in the albuterol group (p<0.05).  Differences in hypokalemia and Q-Tc prolongation assocd. with fenoterol and albuterol were significantly different only after 8 puffs of fenoterol had been given.  32 Patients exhibited ventricular premature beats, 14 in the fenoterol group and 18 in the albuterol group.  There were 34 patients with episodes of supraventricular premature beats, 17 in each group.  No episodes of sustained ventricular tachycardia were detected in either group.  In adequately oxygenated patients, using dose titrn. of fenoterol, in a formulation of 200 μg per puff by MDI valved holding chamber and mask, to a total dose of 3,200 μg and salbutamol (100 μg per puff) to a total dose of 1,600 μg over 90 min, showed cardiovascular safety in acute severe asthma.  This was evidenced by absence of cardiovascular mortality or clin. significant arrhythmias in either group.  The 100% greater dose of fenoterol improved FEV1 significantly more than salbutamol and was assocd. with a relatively small but significantly greater prolongation of the Q-Tc interval and decrease in serum potassium level.  This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYexc5KH5JHrVg90H21EOLACvtfcHk0lhMDheHMtuh1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1aksrk%253D&md5=f4be8fe2c00098efdb7f1eadb5450175</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1378%2Fchest.110.3.595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.110.3.595%26sid%3Dliteratum%253Aachs%26aulast%3DNewhouse%26aufirst%3DM.%2BT.%26aulast%3DChapman%26aufirst%3DK.%2BR.%26aulast%3DMcCallum%26aufirst%3DA.%2BL.%26aulast%3DAbboud%26aufirst%3DR.%2BT.%26aulast%3DBowie%26aufirst%3DD.%2BM.%26aulast%3DHodder%26aufirst%3DR.%2BV.%26aulast%3DPar%25C3%25A9%26aufirst%3DP.%2BD.%26aulast%3DMesic-Fuchs%26aufirst%3DH.%26aulast%3DMolfino%26aufirst%3DN.%2BA.%26atitle%3DCardiovascular%2520safety%2520of%2520high%2520doses%2520of%2520inhaled%2520fenoterol%2520and%2520albuterol%2520in%2520acute%2520severe%2520asthma%26jtitle%3DChest%26date%3D1996%26volume%3D110%26spage%3D595%26epage%3D603%26doi%3D10.1378%2Fchest.110.3.595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotvall, J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.160.1.9901063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm.160.1.9901063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10390407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1Mzit1akug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1999&pages=244-249&author=M.+Palmqvistauthor=T.+Ibsenauthor=A.+Mellenauthor=J.+Lotvall&title=Comparison+of+the+relative+efficacy+of+formoterol+and+salmeterol+in+asthmatic+patients&doi=10.1164%2Fajrccm.160.1.9901063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients</span></div><div class="casAuthors">Palmqvist M; Ibsen T; Mellen A; Lotvall J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">244-9</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a partial agonist on the beta2-receptor in comparison to formoterol.  In the present study we evaluated whether these pharmacological differences between salmeterol and formoterol also are applicable to asthmatic patients.  The protective effects by increasing cumulative doses of formoterol (12, 60, 120 micrograms) and salmeterol (50, 250, 500 micrograms) on methacholine-induced bronchoconstriction were evaluated in a double-blind, crossover, placebo-controlled design.  Patients were regularly treated with salbutamol 200 micrograms twice daily during the study period, to avoid variability in beta2-adrenoceptor tolerance.  S-potassium, heart rate corrected Q-T interval (Q-Tc), and tremor score were followed as measures of systemic effects.  Formoterol dose-dependently protected against methacholine responsiveness (4.6 doubling doses after 120 micrograms).  Salmeterol, however, showed a flatter dose-response curve, and a significantly weaker maximal protective effect (2.8 doubling doses after 250 micrograms).  Formoterol caused a significantly higher tremor score and a larger drop in S-potassium than salmeterol at the highest doses.  These data show that salmeterol is a partial agonist on the beta2-receptor in relation to formoterol in human airways in vivo.  Further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZ6w02B1-o54USrryheKE6fW6udTcc2eZCZFs2ZVjucLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1Mzit1akug%253D%253D&md5=105e03de4d8b2a6742a5d4f7f9796d02</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.160.1.9901063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.160.1.9901063%26sid%3Dliteratum%253Aachs%26aulast%3DPalmqvist%26aufirst%3DM.%26aulast%3DIbsen%26aufirst%3DT.%26aulast%3DMellen%26aufirst%3DA.%26aulast%3DLotvall%26aufirst%3DJ.%26atitle%3DComparison%2520of%2520the%2520relative%2520efficacy%2520of%2520formoterol%2520and%2520salmeterol%2520in%2520asthmatic%2520patients%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D160%26spage%3D244%26epage%3D249%26doi%3D10.1164%2Fajrccm.160.1.9901063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism</span>. <i>Curr. Opin. Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1097/MCP.0b013e328333def8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1097%2FMCP.0b013e328333def8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19887938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1MfhtFequw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1-5&author=N.+A.+Hananiaauthor=B.+F.+Dickeyauthor=R.+A.+Bond&title=Clinical+implications+of+the+intrinsic+efficacy+of+beta-adrenoceptor+drugs+in+asthma%3A+full%2C+partial+and+inverse+agonism&doi=10.1097%2FMCP.0b013e328333def8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism</span></div><div class="casAuthors">Hanania Nicola A; Dickey Burton F; Bond Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pulmonary medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  beta2-Adrenoceptor (AR) agonists are the most effective bronchodilators known, and play important roles in every step of asthma therapy.  Intrinsic efficacy is an important pharmacological property that differentiates the clinical effects and safety profile of beta2-AR agonists.  We review the role of beta2-AR agonist intrinsic efficacy in asthma treatment focusing on recent literature.  RECENT FINDINGS:  In acute asthma, a full agonist (high intrinsic efficacy) offers a clinical advantage over a partial agonist (low intrinsic efficacy) but with the potential of inducing dose-dependent adverse effects.  The chronic use of beta2-AR agonists may be associated with several adverse outcomes including loss of asthma control and even increased mortality.  Recently, the role of beta-AR inverse agonists (beta-blockers) which have a negative intrinsic efficacy was studied.  Whereas contraindicated in acute asthma, preliminary data suggest that the chronic use of these agents may be associated with attenuation of airway hyper-responsiveness in patients with mild asthma.  Studies in a murine model of asthma suggest that such effects may be related to decreased airway inflammation and mucous metaplasia.  SUMMARY:  Rational choice among beta2-AR agonists in acute and chronic asthma should be influenced by differences in intrinsic efficacy among these agents.  In acute severe asthma, a full agonist offers a clinical advantage over a partial agonist.  Whereas the use of inverse agonists in the treatment of asthma is still experimental and needs further exploration in future trials, preliminary studies suggest that their chronic use is well tolerated and is associated with decreased airway hyper-responsiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMmy4TEGSezKx48Rj5GnGofW6udTcc2ebM4KSXiFqvA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfhtFequw%253D%253D&md5=a64dcac78ab7e558289c996b64036c94</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e328333def8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e328333def8%26sid%3Dliteratum%253Aachs%26aulast%3DHanania%26aufirst%3DN.%2BA.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DBond%26aufirst%3DR.%2BA.%26atitle%3DClinical%2520implications%2520of%2520the%2520intrinsic%2520efficacy%2520of%2520beta-adrenoceptor%2520drugs%2520in%2520asthma%253A%2520full%252C%2520partial%2520and%2520inverse%2520agonism%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1%26epage%3D5%26doi%3D10.1097%2FMCP.0b013e328333def8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battram, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuenoud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton-Davies, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological characterization of 5-[(<i>R</i>)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1<i>H</i>-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.098251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.098251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16434564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=762-770&author=C.+Battramauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=M.+R.+Dowlingauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=J.+R.+Leighton-Daviesauthor=C.+A.+Lewisauthor=L.+McEvoyauthor=R.+J.+Turnerauthor=A.+Trifilieff&title=In+vitro+and+in+vivo+pharmacological+characterization+of+5-%5B%28R%29-2-%285%2C6-diethyl-indan-2-ylamino%29-1-hydroxy-ethyl%5D-8-hydroxy-1H-quinolin-2-one+%28indacaterol%29%2C+a+novel+inhaled+beta%282%29+adrenoceptor+agonist+with+a+24-h+duration+of+action&doi=10.1124%2Fjpet.105.098251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action</span></div><div class="casAuthors">Battram, Cliff; Charlton, Steven J.; Cuenoud, Bernard; Dowling, Mark R.; Fairhurst, Robin A.; Farr, David; Fozard, John R.; Leighton-Davies, Juliet R.; Lewis, Christine A.; McEvoy, Lorraine; Turner, Robert J.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-770</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Here, we describe the preclin. pharmacol. profile of indacaterol, a novel, chirally pure inhaled β2 adrenoceptor agonist, in comparison with marketed drugs.  Indacaterol is close to a full agonist at the human β2 adrenoceptor (Emax = 73±1% of the maximal effect of isoprenaline; pEC50 = 8.06±0.02), whereas salmeterol displays only partial efficacy (38±1%).  The functional selectivity profile of indacaterol over β1 human adrenoceptors is similar to that of formoterol, whereas its β3 adrenoceptor selectivity profile is similar to that of formoterol and salbutamol.  In isolated superfused guinea pig trachea, indacaterol has a fast onset of action (30±4 min) similar to formoterol and salbutamol, and a long duration of action (529±99 min) comparable with salmeterol.  In the conscious guinea pig, when given intratracheally as a dry powder, indacaterol inhibits 5-hydroxytryptamine-induced bronchoconstriction for at least 24 h, whereas salmeterol, formoterol, and salbutamol have durations of action of 12, 4, and 2 h, resp.  When given via nebulization to anesthetized rhesus monkeys, all of the compds. dose-dependently inhibit methacholine-induced bronchoconstriction, although indacaterol produces the most prolonged bronchoprotective effect and induces the lowest increase in heart rate for a similar degree of antibronchoconstrictor activity.  In conclusion, the preclin. profile of indacaterol suggests that this compd. has a superior duration of action compatible with once-daily dosing in human, together with a fast onset of action and an improved cardiovascular safety profile over marketed inhaled β2 adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNpFkEE8xZvbVg90H21EOLACvtfcHk0ljj8CuXaGtNOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D&md5=0ea4e459100f0d3971d8a7f89c5de059</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.098251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.098251%26sid%3Dliteratum%253Aachs%26aulast%3DBattram%26aufirst%3DC.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%2BR.%26aulast%3DLewis%26aufirst%3DC.%2BA.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DTurner%26aufirst%3DR.%2BJ.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%2520of%25205-%255B%2528R%2529-2-%25285%252C6-diethyl-indan-2-ylamino%2529-1-hydroxy-ethyl%255D-8-hydroxy-1H-quinolin-2-one%2520%2528indacaterol%2529%252C%2520a%2520novel%2520inhaled%2520beta%25282%2529%2520adrenoceptor%2520agonist%2520with%2520a%252024-h%2520duration%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D762%26epage%3D770%26doi%3D10.1124%2Fjpet.105.098251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist/β<sub>2</sub>-adrenoceptor agonist (MABA) molecule</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pupt.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28729041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=1-10&author=M.+Apariciauthor=C.+Carcasonaauthor=I.+Ramosauthor=J.+L.+Monteroauthor=J.+L.+Ortizauthor=J.+Cortijoauthor=C.+Puigauthor=D.+Vilellaauthor=C.+Doeauthor=A.+Gavald%C3%A0author=M.+Miralpeix&title=Pharmacological+preclinical+characterization+of+LAS190792%2C+a+novel+inhaled+bifunctional+muscarinic+receptor+antagonist%2F%CE%B22-adrenoceptor+agonist+%28MABA%29+molecule&doi=10.1016%2Fj.pupt.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule</span></div><div class="casAuthors">Aparici, Monica; Carcasona, Carla; Ramos, Israel; Montero, Jose Luis; Ortiz, Jose Luis; Cortijo, Julio; Puig, Carlos; Vilella, Dolors; Doe, Chris; Gavalda, Amadeu; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases.  This study investigated the pharmacol. profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol.  LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays).  It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compds. (pEC50 in spontaneous tone isolated trachea: 9.6).  The relaxant potency of LAS190792 in elec. stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol slightly higher than batefenterol (pIC50 of 8.3 vs. 7.9 in human tissue).  LAS190792 exhibits a sustained duration of action in isolated tissue longer than that of batefenterol.  Nebulized LAS190792 inhibits acetylcholine-induced bronchoconstriction in dog with minimal cardiac effects and sustained bronchodilation (t1/2: 13.3 h).  In conclusion, these studies suggest that LAS190792 is a dual-acting muscarinic antagonist β2-adrenoceptor agonist that has the potential to be a next generation bronchodilator with long-lasting effects and wide safety margin in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4xsgKu0EdJ7Vg90H21EOLACvtfcHk0ljj8CuXaGtNOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ&md5=c4199d8a8fccd880ff64bb6a07bd8a1d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DOrtiz%26aufirst%3DJ.%2BL.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520preclinical%2520characterization%2520of%2520LAS190792%252C%2520a%2520novel%2520inhaled%2520bifunctional%2520muscarinic%2520receptor%2520antagonist%252F%25CE%25B22-adrenoceptor%2520agonist%2520%2528MABA%2529%2520molecule%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.pupt.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Blanco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Alba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β<sub>2</sub>-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>770</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.11.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.ejphar.2015.11.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26656755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSrs73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=770&publication_year=2016&pages=61-69&author=M.+Apariciauthor=A.+Gavald%C3%A0author=I.+Ramosauthor=C.+Carcasonaauthor=R.+Otalauthor=J.+A.+Fern%C3%A1ndez-Blancoauthor=J.+L.+Monteroauthor=V.+M.+Garc%C3%ADaauthor=R.+L%C3%B3pezauthor=J.+De+Albaauthor=C.+Doeauthor=C.+Puigauthor=D.+Vilellaauthor=M.+Miralpeix&title=In+vitro+and+in+vivo+preclinical+profile+of+abediterol+%28LAS100977%29%2C+an+inhaled+long-acting+%CE%B22-adrenoceptor+agonist%2C+compared+with+indacaterol%2C+olodaterol+and+vilanterol&doi=10.1016%2Fj.ejphar.2015.11.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol</span></div><div class="casAuthors">Aparici, Monica; Gavalda, Amadeu; Ramos, Israel; Carcasona, Carla; Otal, Raquel; Fernandez-Blanco, Joan Antoni; Montero, Jose Luis; Garcia, Vicente Marco; Lopez, Rosa; De Alba, Jorge; Doe, Christopher; Puig, Carlos; Vilella, Dolors; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">770</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Abediterol is a novel long-acting β2-adrenoceptor agonist (LABA) currently in development for once-daily combination maintenance therapy of asthma and COPD.  This study investigated the preclin. profile of abediterol in terms of affinity, potency, selectivity, duration of action and cardiac effects in comparison to the marketed once-daily LABAs indacaterol, olodaterol and vilanterol.  Abediterol was the compd. with the highest in vitro potency for dog, guinea pig and human β2-adrenoceptors.  In elec. field stimulated guinea pig trachea, abediterol demonstrated 5-, 44- and 77-fold greater potency than olodaterol, indacaterol and vilanterol, resp.  In anesthetized guinea pigs, inhaled abediterol was also the most potent compd., with 5-20 times higher bronchoprotective potency than other once-daily LABAs against acetylcholine.  The bronchoprotective half-life of abediterol in guinea pigs was 36 h compared with 51 h for indacaterol, 47 h for olodaterol, and 18 h for vilanterol.  In anesthetized dogs, abediterol also inhibited acetylcholine-induced bronchoconstriction, with higher potency than olodaterol and vilanterol [ID40 (dose inhibiting bronchoconstriction by 40%) of 0.059 μg/kg, 0.180 μg/kg and 2.870 μg/kg, resp.].  In parallel, effects on heart rate in dogs were also measured.  Abediterol showed greater safety index (defined as the ratio of the maximal dose without effect on heart rate and the ID40) than olodaterol and vilanterol (10.5 vs. 4.9 and 2.4, resp.).  Taken together, these data suggest that abediterol offers potent bronchodilation and a sustained duration of action suited to once-daily dosing, plus a reduced potential for class-related cardiac side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagjLQjotrprVg90H21EOLACvtfcHk0lhxsbIcGBfnWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSrs73F&md5=7da502fd0f03f119d53e91b3f4b8849f</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.11.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.11.053%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez-Blanco%26aufirst%3DJ.%2BA.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DV.%2BM.%26aulast%3DL%25C3%25B3pez%26aufirst%3DR.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520preclinical%2520profile%2520of%2520abediterol%2520%2528LAS100977%2529%252C%2520an%2520inhaled%2520long-acting%2520%25CE%25B22-adrenoceptor%2520agonist%252C%2520compared%2520with%2520indacaterol%252C%2520olodaterol%2520and%2520vilanterol%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D770%26spage%3D61%26epage%3D69%26doi%3D10.1016%2Fj.ejphar.2015.11.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, R. J.</span></span> <span> </span><span class="NLM_article-title">Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis</span>. <i>Clin. Rev. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1385/CRIAI:31:2:279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1385%2FCRIAI%3A31%3A2%3A279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17085800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD28nltVantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=279-288&author=R.+J.+Hancox&title=Concluding+remarks%3A+can+we+explain+the+association+of+beta-agonists+with+asthma+mortality%3F+A+hypothesis&doi=10.1385%2FCRIAI%3A31%3A2%3A279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis</span></div><div class="casAuthors">Hancox Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical reviews in allergy & immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">279-88</span>
        ISSN:<span class="NLM_cas:issn">1080-0549</span>.
    </div><div class="casAbstract">Beta-agonists have clearly demonstrated benefits for the treatment of both acute and chronic asthma.  Therefore, it is perhaps surprising that many of the articles in this issue have focused on concerns about their safety.  Much of this concern can be traced back to the "beta-agonist controversy"--the association of high-dose isoprenaline and fenoterol inhalers with asthma mortality in the 1960s and 1970s.  Although a causal link was never proven, lingering doubts about the safety of beta-agonists remain.  It is unclear whether a similar adverse effect is responsible for recently reported association of long-acting beta-agonists with asthma deaths.  No mechanism for the beta-agonist controversy was established, but the evidence presented in this collection of articles points to a number of contributing factors.  I suggest that a combination of these effects provides a plausible mechanism for the association of frequent beta-agonist use with asthma mortality.  Rebound bronchoconstriction and bronchial hyperresponsiveness occur on withdrawal of regular beta-agonist treatment.  Regular use of fenoterol is associated with a reduction in morning peak flow suggesting that the overnight interval between doses is sufficient to allow rebound bronchoconstriction.  This has not been observed with terbutaline or salbutamol, although rebound phenomena do occur when these drugs are withdrawn for slightly longer periods.  Regular use of beta-agonists also leads to tolerance to their bronchoprotective and bronchodilator effects.  Tolerance becomes more apparent with worsening bronchoconstriction.  In severe asthma, this could result in a poor response to emergency treatment.  The combination of rebound deterioration of asthma and a poor response to beta-agonist treatment resulting from tolerance could explain the increased mortality associated with fenoterol and isoprenaline.  Both effects are probably caused by downregulation of beta-receptors which occurs with all beta-agonists.  Long-acing beta-agonists cause a similar degree of tolerance to short-acting beta-agonists, but avoid the problem of overnight withdrawal.  Long-acting beta-agonists have also been shown to improve asthma control when taken in combination with inhaled corticosteroids.  The clinical significance of tolerance in this context remains to be determined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVM2NArfZ8ZdHxxy173TfNfW6udTcc2eZMEq6A3fNgjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nltVantw%253D%253D&md5=75c7c2f008e49714b9e7991fbcdcf71c</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1385%2FCRIAI%3A31%3A2%3A279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCRIAI%253A31%253A2%253A279%26sid%3Dliteratum%253Aachs%26aulast%3DHancox%26aufirst%3DR.%2BJ.%26atitle%3DConcluding%2520remarks%253A%2520can%2520we%2520explain%2520the%2520association%2520of%2520beta-agonists%2520with%2520asthma%2520mortality%253F%2520A%2520hypothesis%26jtitle%3DClin.%2520Rev.%2520Allergy%2520Immunol.%26date%3D2006%26volume%3D31%26spage%3D279%26epage%3D288%26doi%3D10.1385%2FCRIAI%3A31%3A2%3A279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Agonist efficacy and receptor desensitization: from partial truths to a fuller picture</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00352.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2009.00352.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19719779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=165-168&author=S.+J.+Charlton&title=Agonist+efficacy+and+receptor+desensitization%3A+from+partial+truths+to+a+fuller+picture&doi=10.1111%2Fj.1476-5381.2009.00352.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist efficacy and receptor desensitization: from partial truths to a fuller picture</span></div><div class="casAuthors">Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-168</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It has been demonstrated that the degree of agonist-induced desensitization of the β2-adrenoceptor is related to agonist efficacy (strength of signaling), whereby high-efficacy agonists (e.g., formoterol) cause more phosphorylation and internalization of the receptor than low-efficacy agonists (e.g., salmeterol).  These early studies, however, used a protocol where agonists were matched for receptor occupancy rather than functional effect.  In this issue of the BJP, Duringer and colleagues have extended these studies to compare the ability of agonists to cause desensitization at equi-effective (cAMP signaling) concns. rather than equal occupancy.  Their data and conclusions are quite different from those previously described.  After prolonged exposure, all the agonists caused a similar degree of desensitization, whereas a pulse protocol uncovered a greater loss of responsiveness with the low-efficacy ligands.  This is consistent with the notion that high-efficacy agonists have 'spare receptors', and are therefore less sensitive to loss of receptors through desensitization.  It also reflects experience in the clinic, where both formoterol and salmeterol show a similar early decline in bronchoprotection, after which their effects remain stable.  These findings challenge the notion that high-efficacy ligands always cause more functional desensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc6mA_BbjssbVg90H21EOLACvtfcHk0lg877LBTMuiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu7fO&md5=c8fcca272d976d4893fcb9cc0621613c</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00352.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00352.x%26sid%3Dliteratum%253Aachs%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DAgonist%2520efficacy%2520and%2520receptor%2520desensitization%253A%2520from%2520partial%2520truths%2520to%2520a%2520fuller%2520picture%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D165%26epage%3D168%26doi%3D10.1111%2Fj.1476-5381.2009.00352.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregorio, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masureel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Aguilar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiasen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S. C.</span></span> <span> </span><span class="NLM_article-title">Single-molecule analysis of ligand efficacy in β<sub>2</sub>AR-G-protein activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>547</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1038/nature22354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature22354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28607487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=547&publication_year=2017&pages=68-73&author=G.+G.+Gregorioauthor=M.+Masureelauthor=D.+Hilgerauthor=D.+S.+Terryauthor=M.+Juetteauthor=H.+Zhaoauthor=Z.+Zhouauthor=J.+M.+Perez-Aguilarauthor=M.+Haugeauthor=S.+Mathiasenauthor=J.+A.+Javitchauthor=H.+Weinsteinauthor=B.+K.+Kobilkaauthor=S.+C.+Blanchard&title=Single-molecule+analysis+of+ligand+efficacy+in+%CE%B22AR-G-protein+activation&doi=10.1038%2Fnature22354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Single-molecule analysis of ligand efficacy in β2AR-G-protein activation</span></div><div class="casAuthors">Gregorio, G. Glenn; Masureel, Matthieu; Hilger, Daniel; Terry, Daniel S.; Juette, Manuel; Zhao, Hong; Zhou, Zhou; Perez-Aguilar, Jose Manuel; Hauge, Maria; Mathiasen, Signe; Javitch, Jonathan A.; Weinstein, Harel; Kobilka, Brian K.; Blanchard, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">547</span>
        (<span class="NLM_cas:issue">7661</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptor (GPCR)-mediated signal transduction is central to human physiol. and disease intervention, yet the mol. mechanisms responsible for ligand-dependent signaling responses remain poorly understood.  In class A GPCRs, receptor activation and G-protein coupling entail outward movements of transmembrane helix 6 (TM6).  Here, using single-mol. fluorescence resonance energy transfer imaging, we examine TM6 movements in the β2 adrenergic receptor (β2AR) upon exposure to orthosteric ligands with different efficacies, in the absence and presence of the Gs heterotrimer.  We show that partial and full agonists differentially affect TM6 motions to regulate the rate at which GDP-bound β2AR-Gs complexes are formed and the efficiency of nucleotide exchange leading to Gs activation.  These data also reveal transient nucleotide-bound β2AR-Gs species that are distinct from known structures, and provide single-mol. perspectives on the allosteric link between ligand- and nucleotide-binding pockets that shed new light on the G-protein activation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqox1l7GNlNIbVg90H21EOLACvtfcHk0lg877LBTMuiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb8%253D&md5=b7fc7f43e98bdf40611a7e7936b882af</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnature22354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22354%26sid%3Dliteratum%253Aachs%26aulast%3DGregorio%26aufirst%3DG.%2BG.%26aulast%3DMasureel%26aufirst%3DM.%26aulast%3DHilger%26aufirst%3DD.%26aulast%3DTerry%26aufirst%3DD.%2BS.%26aulast%3DJuette%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DPerez-Aguilar%26aufirst%3DJ.%2BM.%26aulast%3DHauge%26aufirst%3DM.%26aulast%3DMathiasen%26aufirst%3DS.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DBlanchard%26aufirst%3DS.%2BC.%26atitle%3DSingle-molecule%2520analysis%2520of%2520ligand%2520efficacy%2520in%2520%25CE%25B22AR-G-protein%2520activation%26jtitle%3DNature%26date%3D2017%26volume%3D547%26spage%3D68%26epage%3D73%26doi%3D10.1038%2Fnature22354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masureel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Westhuizen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mildorf, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structural insights into binding specificity, efficacy and bias of a β<sub>2</sub>AR partial agonist</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0145-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41589-018-0145-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30327561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCgsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1059-1066&author=M.+Masureelauthor=Y.+Zouauthor=L.+P.+Picardauthor=E.+van+der%0AWesthuizenauthor=J.+P.+Mahoneyauthor=J.+Rodriguesauthor=T.+J.+Mildorfauthor=R.+O.+Drorauthor=D.+E.+Shawauthor=M.+Bouvierauthor=E.+Pardonauthor=J.+Steyaertauthor=R.+K.+Sunaharaauthor=W.+I.+Weisauthor=C.+Zhangauthor=B.+K.+Kobilka&title=Structural+insights+into+binding+specificity%2C+efficacy+and+bias+of+a+%CE%B22AR+partial+agonist&doi=10.1038%2Fs41589-018-0145-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist</span></div><div class="casAuthors">Masureel, Matthieu; Zou, Yaozhong; Picard, Louis-Philippe; van der Westhuizen, Emma; Mahoney, Jacob P.; Rodrigues, Joao P. G. L. M.; Mildorf, Thomas J.; Dror, Ron O.; Shaw, David E.; Bouvier, Michel; Pardon, Els; Steyaert, Jan; Sunahara, Roger K.; Weis, William I.; Zhang, Cheng; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1059-1066</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Salmeterol is a partial agonist for the β2 adrenergic receptor (β2AR) and the first long-acting β2AR agonist to be widely used clin. for the treatment of asthma and chronic obstructive pulmonary disease.  Salmeterol's safety and mechanism of action have both been controversial.  To understand its unusual pharmacol. action and partial agonism, we obtained the crystal structure of salmeterol-bound β2AR in complex with an active-state-stabilizing nanobody.  The structure reveals the location of the salmeterol exosite, where sequence differences between β1AR and β2AR explain the high receptor-subtype selectivity.  A structural comparison with the β2AR bound to the full agonist epinephrine reveals differences in the hydrogen-bond network involving residues Ser2045.43 and Asn2936.55.  Mutagenesis and biophys. studies suggested that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G-protein activation and the limited β-arrestin recruitment for salmeterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7LnLZOttfbVg90H21EOLACvtfcHk0lg877LBTMuiJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCgsrzF&md5=6ab1b302fde86f7c68ca9b8b86f91ae4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0145-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0145-x%26sid%3Dliteratum%253Aachs%26aulast%3DMasureel%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DPicard%26aufirst%3DL.%2BP.%26aulast%3Dvan%2Bder%2BWesthuizen%26aufirst%3DE.%26aulast%3DMahoney%26aufirst%3DJ.%2BP.%26aulast%3DRodrigues%26aufirst%3DJ.%26aulast%3DMildorf%26aufirst%3DT.%2BJ.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructural%2520insights%2520into%2520binding%2520specificity%252C%2520efficacy%2520and%2520bias%2520of%2520a%2520%25CE%25B22AR%2520partial%2520agonist%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D1059%26epage%3D1066%26doi%3D10.1038%2Fs41589-018-0145-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurten, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainty, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.</span></span> <span> </span><span class="NLM_article-title">Formoterol and salmeterol induce a similar degree of β<sub>2</sub>-adrenoceptor tolerance in human small airways but via different mechanisms</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01257.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2011.01257.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21306583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslWqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=521-532&author=P.+R.+Cooperauthor=R.+C.+Kurtenauthor=J.+Zhangauthor=D.+J.+Nichollsauthor=I.+A.+Daintyauthor=R.+A.+Panettieri&title=Formoterol+and+salmeterol+induce+a+similar+degree+of+%CE%B22-adrenoceptor+tolerance+in+human+small+airways+but+via+different+mechanisms&doi=10.1111%2Fj.1476-5381.2011.01257.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms</span></div><div class="casAuthors">Cooper, P. R.; Kurten, R. C.; Zhang, J.; Nicholls, D. J.; Dainty, I. A.; Panettieri, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-532</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Steroids prevent and reverse salbutamol-induced β2-adrenoceptor tolerance in human small airways.  This study examines the effects of the long-acting β2 agonists (LABAs) formoterol and salmeterol, and the ability of budesonide to prevent desensitization.  Exptl. Approach Long-acting β2 agonists in the presence and absence of budesonide were incubated with human precision-cut lung slices contg. small airways.  Tolerance was deduced from measurements of reduced bronchodilator responses to isoprenaline and correlated with β2-adrenoceptor trafficking using a virally transduced, fluorescent-tagged receptor.  The ability of the LABAs to protect airways against muscarinic-induced contraction was also assessed.  Key Results Following a 12 h incubation, both formoterol and salmeterol attenuated isoprenaline-induced bronchodilation to a similar degree and these effects were not reversible by washing.  Pre-incubation with budesonide prevented the desensitization induced by formoterol, but not that induced by salmeterol.  Formoterol also protected the airways from carbachol-induced bronchoconstriction to a greater extent than salmeterol.  In the epithelial cells of small airways, incubation with formoterol promoted receptor internalization but this did not appear to occur following incubation with salmeterol.  Budesonide inhibited the formoterol-induced redn. in plasma membrane β2-adrenoceptor fluorescence.  Conclusions and Implications Although both formoterol and salmeterol attenuate isoprenaline-induced bronchodilation, they appear to induce β2-adrenoceptor tolerance via different mechanisms; formoterol, but not salmeterol, enhances receptor internalization.  Budesonide protection against β2-adrenoceptor tolerance was correlated with the retention of receptor fluorescence on the plasma membrane, thereby suggesting a mechanism by which steroids alter β2-adrenoceptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk0m7NQ1r6b7Vg90H21EOLACvtfcHk0li8HxkcrSFikA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslWqtL8%253D&md5=70b04822185c042933594e9225e2f5f5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01257.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01257.x%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DP.%2BR.%26aulast%3DKurten%26aufirst%3DR.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DDainty%26aufirst%3DI.%2BA.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26atitle%3DFormoterol%2520and%2520salmeterol%2520induce%2520a%2520similar%2520degree%2520of%2520%25CE%25B22-adrenoceptor%2520tolerance%2520in%2520human%2520small%2520airways%2520but%2520via%2520different%2520mechanisms%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D521%26epage%3D532%26doi%3D10.1111%2Fj.1476-5381.2011.01257.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godines, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span> <span> </span><span class="NLM_article-title">Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2006-0158OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1165%2Frcmb.2006-0158OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16980556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFWju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=254-261&author=R.+H.+Mooreauthor=E.+E.+Millmanauthor=V.+Godinesauthor=N.+A.+Hananiaauthor=T.+M.+Tranauthor=H.+Pengauthor=B.+F.+Dickeyauthor=B.+J.+Knollauthor=R.+B.+Clark&title=Salmeterol+stimulation+dissociates+beta2-adrenergic+receptor+phosphorylation+and+internalization&doi=10.1165%2Frcmb.2006-0158OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol stimulation dissociates β2-adrenergic receptor phosphorylation and internalization</span></div><div class="casAuthors">Moore, Robert H.; Millman, Ellen E.; Godines, Veronica; Hanania, Nicola A.; Tran, Tuan M.; Peng, Hui; Dickey, Burton F.; Knoll, Brian J.; Clark, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">254-261</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease.  It differs from other β-agonists in that it has a very low intrinsic efficacy, esp. when compared with the other available long-acting β-agonist, formoterol.  Receptor desensitization and down-regulation was described with the chronic use of β-agonists.  This effect may not be the same with all β-agonists and may be related to their stabilization of altered receptor states.  The extreme hydrophobicity and high-affinity quasi-irreversible binding of salmeterol have rendered studies examg. the mechanisms by which it mediates receptor desensitization, down-regulation, and internalization difficult.  We detd. the capacity of salmeterol to induce β2AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degrdn., and β-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies.  Despite stimulating GRK-mediated phosphorylation of Ser355, 356 after 30 min and 18 h to an extent similar to that obsd. with agonists of high intrinsic efficacy, such as epinephrine and formoterol, salmeterol did not induce significant β2AR internalization or degrdn. and was incapable of stimulating the translocation of enhanced green fluorescent protein-β-arrestin2 chimera (EGFP-β-arrestin2) to the cell surface.  Salmeterol-induced receptor endocytosis was rescued, at least in part, by the overexpression of EGFP-β-arrestin2.  Our data indicate that salmeterol binding induces an active receptor state that is unable to recruit β-arrestin or undergo significant endocytosis or degrdn. despite stimulating considerable GRK-site phosphorylation.  Defects in these components of salmeterol-induced receptor desensitization may be important determinants of its sustained bronchodilation with chronic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofK2ze86PqCbVg90H21EOLACvtfcHk0li8HxkcrSFikA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFWju70%253D&md5=6f2f2d3e21a928c1439bf9239291880a</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2006-0158OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2006-0158OC%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DR.%2BH.%26aulast%3DMillman%26aufirst%3DE.%2BE.%26aulast%3DGodines%26aufirst%3DV.%26aulast%3DHanania%26aufirst%3DN.%2BA.%26aulast%3DTran%26aufirst%3DT.%2BM.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DKnoll%26aufirst%3DB.%2BJ.%26aulast%3DClark%26aufirst%3DR.%2BB.%26atitle%3DSalmeterol%2520stimulation%2520dissociates%2520beta2-adrenergic%2520receptor%2520phosphorylation%2520and%2520internalization%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2007%26volume%3D36%26spage%3D254%26epage%3D261%26doi%3D10.1165%2Frcmb.2006-0158OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gimenez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baameur, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayttaden, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span> <span> </span><span class="NLM_article-title">Salmeterol efficacy and bias in the activation and kinase-mediated desensitization of β<sub>2</sub>-adrenergic receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1124/mol.114.096800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fmol.114.096800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25784721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=954-964&author=L.+E.+Gimenezauthor=F.+Baameurauthor=S.+J.+Vayttadenauthor=R.+B.+Clark&title=Salmeterol+efficacy+and+bias+in+the+activation+and+kinase-mediated+desensitization+of+%CE%B22-adrenergic+receptors&doi=10.1124%2Fmol.114.096800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol efficacy and bias in the activation and kinase-mediated desensitization of β2-adrenergic receptors</span></div><div class="casAuthors">Gimenez, Luis E.; Baameur, Faiza; Vayttaden, Sharat J.; Clark, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">954-964</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids.  Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the β2AR remains poorly understood.  In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-β2AR binding to arrestin and through kinetic studies of cAMP turnover.  First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to β2AR relative to isoproterenol.  The ratio of BRETISO/BRETSALM after 5-min stimulation was 20 and decreased to 5 after 35 min, reflecting a progressive decline in BRETISO and a stable BRETSALM.  Second, to assess salmeterol efficacy for functional desensitization, we examd. the kinetics of salmeterol-induced cAMP accumulation (0-30 min) in human airway smooth muscle cells in the presence and absence of phosphodiesterase inhibition.  Anal. of shaping of cAMP turnover for both agonists demonstrated significant salmeterol desensitization, although it was reduced relative to isoproterenol.  Using an isoproterenol rescue protocol after either short-term (10 min) or long-term (2 and 14 h) salmeterol pretreatments, we found that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent rescue by isoproterenol and addnl. isoproterenol-mediated desensitization.  Our findings reveal a complex efficacy for functional desensitization, demonstrating that although salmeterol shows weak efficacy for adenylyl cyclase activation and G protein-coupled receptor kinase/arrestin-mediated desensitization, it acts as a strong agonist in highly amplified protein kinase A-mediated events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH_8J6eA1wobVg90H21EOLACvtfcHk0li8HxkcrSFikA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wgtrs%253D&md5=f004d644d6ab5cd98e65b30c1f8c7764</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.096800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.096800%26sid%3Dliteratum%253Aachs%26aulast%3DGimenez%26aufirst%3DL.%2BE.%26aulast%3DBaameur%26aufirst%3DF.%26aulast%3DVayttaden%26aufirst%3DS.%2BJ.%26aulast%3DClark%26aufirst%3DR.%2BB.%26atitle%3DSalmeterol%2520efficacy%2520and%2520bias%2520in%2520the%2520activation%2520and%2520kinase-mediated%2520desensitization%2520of%2520%25CE%25B22-adrenergic%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D954%26epage%3D964%26doi%3D10.1124%2Fmol.114.096800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naline, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devillier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarosa, P.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub> agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings (Abstract)</span>. <i>Am. J. Respir. Crit. Care. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">A4443</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2010&pages=A4443&author=E.+Nalineauthor=A.+Ostermannauthor=P.+Devillierauthor=P.+Casarosa&title=%CE%B22+agonist+intrinsic+activity%3A+comparison+of+BI+1744+and+formoterol+in+different+functional+settings+%28Abstract%29&doi=10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443%26sid%3Dliteratum%253Aachs%26aulast%3DNaline%26aufirst%3DE.%26aulast%3DOstermann%26aufirst%3DA.%26aulast%3DDevillier%26aufirst%3DP.%26aulast%3DCasarosa%26aufirst%3DP.%26atitle%3D%25CE%25B22%2520agonist%2520intrinsic%2520activity%253A%2520comparison%2520of%2520BI%25201744%2520and%2520formoterol%2520in%2520different%2520functional%2520settings%2520%2528Abstract%2529%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care.%2520Med.%26date%3D2010%26volume%3D181%26spage%3DA4443%26doi%3D10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">β-Adrenergic receptor subtype signaling in heart: from bench to bedside</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1038/aps.2011.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Faps.2011.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22286918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1emt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=335-341&author=A.+Y.+Wooauthor=R.+P.+Xiao&title=%CE%B2-Adrenergic+receptor+subtype+signaling+in+heart%3A+from+bench+to+bedside&doi=10.1038%2Faps.2011.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">β-Adrenergic receptor subtype signaling in heart: From bench to bedside</span></div><div class="casAuthors">Woo, Anthony Yiu Ho; Xiao, Rui-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-341</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  β-Adrenergic receptor (βAR) stimulation by the sympathetic nervous system or circulating catecholamines is broadly involved in peripheral blood circulation, metabolic regulation, muscle contraction, and central neural activities.  In the heart, acute βAR stimulation serves as the most powerful means to regulate cardiac output in response to a fight-or-flight situation, whereas chronic βAR stimulation plays an important role in physiol. and pathol. cardiac remodeling.  There are three βAR subtypes, β1AR, β2AR and β3AR, in cardiac myocytes.  Over the past two decades, we systematically investigated the mol. and cellular mechanisms underlying the different even opposite functional roles of β1AR and β2AR subtypes in regulating cardiac structure and function, with keen interest in the development of novel therapies based on our discoveries.  We have made three major discoveries, including (1) dual coupling of β2AR to Gs and Gi proteins in cardiomyocytes, (2) cardioprotection by β2AR signaling in improving cardiac function and myocyte viability, and (3) PKA-independent, CaMKII-mediated β1AR apoptotic and maladaptive remodeling signaling in the heart.  Based on these discoveries and salutary effects of β1AR blockade on patients with heart failure, we envision that activation of β2AR in combination with clin. used β1AR blockade should provide a safer and more effective therapy for the treatment of heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_BfdUo0idFbVg90H21EOLACvtfcHk0ljlFstnQE5U-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1emt7c%253D&md5=5706be5ba5397bcede3e5ec0d3f41c9a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.201%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3D%25CE%25B2-Adrenergic%2520receptor%2520subtype%2520signaling%2520in%2520heart%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D335%26epage%3D341%26doi%3D10.1038%2Faps.2011.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapaidze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nivarthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devi, L. A.</span></span> <span> </span><span class="NLM_article-title">Oligomerization of opioid receptors with beta2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1073/pnas.98.1.343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.98.1.343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11134510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=343-348&author=B.+A.+Jordanauthor=N.+Trapaidzeauthor=I.+Gomesauthor=R.+Nivarthiauthor=L.+A.+Devi&title=Oligomerization+of+opioid+receptors+with+beta2-adrenergic+receptors%3A+a+role+in+trafficking+and+mitogen-activated+protein+kinase+activation&doi=10.1073%2Fpnas.98.1.343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Oligomerization of opioid receptors with β2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation</span></div><div class="casAuthors">Jordan, B. A.; Trapaidze, N.; Gomes, I.; Nivarthi, R.; Devi, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">343-348</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have recently joined the list of cell surface receptors that dimerize.  Dimerization has been shown to alter the ligand-binding, signaling, and trafficking properties of these receptors.  Recent studies have shown that GPCRs heterodimerize with closely related members, resulting in the modulation of their function.  In this study, the authors have attempted to det. whether members of GPCR superfamilies that couple to different families of G-proteins can assoc. and form oligomers.  The authors chose the β2 adrenergic receptor that couples to stimulatory G-proteins and δ & κ opioid receptors that couple to inhibitory G-proteins.  β2 And δ receptors undergo robust agonist-mediated endocytosis, whereas κ receptors do not.  The authors find that when coexpressed, β2 receptors can form heteromeric complexes with both δ and κ receptors.  This hetero-oligomerization does not significantly alter the ligand binding or coupling properties of the receptors.  However, it affects the trafficking properties of the receptors.  For example, the authors find that δ receptors, when coexpressed with β2 receptors, undergo isoproterenol-mediated endocytosis.  Conversely, β2 receptors in these cells undergo etorphine-mediated endocytosis.  However, β2 receptors, when coexpressed with κ receptors, undergo neither opioid- nor isoproterenol-mediated endocytosis.  Moreover, these cells exhibit a substantial decrease in the isoproterenol-induced phosphorylation of mitogen-activated protein kinases.  Taken together, these results provide direct evidence of heteromerization of GPCRs that couple to different types of G-proteins, which results in the modulation of receptor trafficking and signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5yHYduSV3bVg90H21EOLACvtfcHk0ljlFstnQE5U-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslOnsw%253D%253D&md5=84062a961d1d645ef48d3114435ff60a</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1073%2Fpnas.98.1.343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.98.1.343%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DB.%2BA.%26aulast%3DTrapaidze%26aufirst%3DN.%26aulast%3DGomes%26aufirst%3DI.%26aulast%3DNivarthi%26aufirst%3DR.%26aulast%3DDevi%26aufirst%3DL.%2BA.%26atitle%3DOligomerization%2520of%2520opioid%2520receptors%2520with%2520beta2-adrenergic%2520receptors%253A%2520a%2520role%2520in%2520trafficking%2520and%2520mitogen-activated%2520protein%2520kinase%2520activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D343%26epage%3D348%26doi%3D10.1073%2Fpnas.98.1.343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span> <span> </span><span class="NLM_article-title">Biased receptor signaling in drug discovery</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1124/pr.118.016790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fpr.118.016790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30914442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2gtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=267-315&author=T.+Kenakin&title=Biased+receptor+signaling+in+drug+discovery&doi=10.1124%2Fpr.118.016790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Biased receptor signaling in drug discovery</span></div><div class="casAuthors">Kenakin, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-315</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  A great deal of exptl. evidence suggests that ligands can stabilize different receptor active states that go on to interact with cellular signaling proteins to form a range of different complexes in varying quantities.  In pleiotropically linked receptor systems, this leads to selective activation of some signaling pathways at the expense of others (biased signaling).  This article summarizes the current knowledge about the complex components of receptor systems, the evidence that biased signaling is used in natural physiol. to fine-tune signaling, and the current thoughts on how this mechanism may be applied to the design of better drugs.  Although this is a fairly newly discovered phenomenon, theor. and exptl. data suggest that it is a ubiquitous behavior of ligands and receptors and to be expected.  Biased signaling is simple to detect in vitro and there are numerous methods to quantify the effect with scales that can be used to optimize this activity in structure-activity medicinal chem. studies.  At present, the major hurdle in the application of this mechanism to therapeutics is the translation of in vitro bias to in vivo effect; this is because of the numerous factors that can modify measures of bias in natural physiol. systems.  In spite of this, biased signaling still has the potential to justify revisiting of receptor targets previously thought to be intractable and also furnishes the means to pursue targets previously thought to be forbidden due to deleterious physiol. (as these may be eliminated through biased signaling).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomawYtBX53pbVg90H21EOLACvtfcHk0ljaEsPPqqTpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2gtL3E&md5=ddf8cb5adb1dc14783bfc82a308fc70d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.016790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.016790%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DBiased%2520receptor%2520signaling%2520in%2520drug%2520discovery%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D267%26epage%3D315%26doi%3D10.1124%2Fpr.118.016790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-biased ligands at seven-transmembrane receptors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.tips.2007.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17644195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=416-422&author=J.+D.+Violinauthor=R.+J.+Lefkowitz&title=%CE%B2-Arrestin-biased+ligands+at+seven-transmembrane+receptors&doi=10.1016%2Fj.tips.2007.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-biased ligands at seven-transmembrane receptors</span></div><div class="casAuthors">Violin, Jonathan D.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">416-422</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Seven-transmembrane receptors (7TMRs), the most common mol. targets of modern drug therapy, are critically regulated by β-arrestins, which both inhibit classic G-protein signaling and initiate distinct β-arrestin signaling.  The interplay of G-protein and β-arrestin signals largely dets. the cellular consequences of 7TMR-targeted drugs.  Until recently, a drug's efficacy for β-arrestin recruitment was believed to be proportional to its efficacy for G-protein activities.  This paradigm restricts 7TMR drug effects to a linear spectrum of responses, ranging from inhibition of all responses to stimulation of all responses.  However, it is now clear that 'biased ligands' can selectively activate G-protein or β-arrestin functions and thus elicit novel biol. effects from even well-studied 7TMRs.  Here, we discuss the current state of β-arrestin-biased ligand research and the prospects for β-arrestin bias as a therapeutic target.  Consideration of ligand bias might have profound influences on the way scientists approach 7TMR-targeted drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ODUMAQK-WrVg90H21EOLACvtfcHk0ljaEsPPqqTpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLc%253D&md5=3bd811aa19edfdc583e7e3c1266b4730</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3D%25CE%25B2-Arrestin-biased%2520ligands%2520at%2520seven-transmembrane%2520receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D416%26epage%3D422%26doi%3D10.1016%2Fj.tips.2007.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">16657</span>– <span class="NLM_lpage">16662</span>, <span class="refDoi"> DOI: 10.1073/pnas.0707936104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.0707936104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17925438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Wmu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=16657-16662&author=J.+W.+Wislerauthor=S.+M.+DeWireauthor=E.+J.+Whalenauthor=J.+D.+Violinauthor=M.+T.+Drakeauthor=S.+Ahnauthor=S.+K.+Shenoyauthor=R.+J.+Lefkowitz&title=A+unique+mechanism+of+beta-blocker+action%3A+carvedilol+stimulates+beta-arrestin+signaling&doi=10.1073%2Fpnas.0707936104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling</span></div><div class="casAuthors">Wisler, James W.; Dewire, Scott M.; Whalen, Erin J.; Violin, Jonatan D.; Drake, Matthew T.; Ahn, Seungkirl; Shenoy, Sudha K.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">16657-16662</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction.  More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition.  One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial.  Here, we report that among 16 clin. relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics.  We obsd. that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished by β-arrestin2 siRNA.  Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from Gs, is nonetheless able to stimulate β-arrestin-mediated signaling.  We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo93wOR8ANKWbVg90H21EOLACvtfcHk0ljaEsPPqqTpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Wmu7%252FJ&md5=cd03ae4a87363d9bca28b14dce173589</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0707936104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0707936104%26sid%3Dliteratum%253Aachs%26aulast%3DWisler%26aufirst%3DJ.%2BW.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDrake%26aufirst%3DM.%2BT.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520unique%2520mechanism%2520of%2520beta-blocker%2520action%253A%2520carvedilol%2520stimulates%2520beta-arrestin%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D16657%26epage%3D16662%26doi%3D10.1073%2Fpnas.0707936104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of β-arrestin-biased β<sub>2</sub>-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1095</span>– <span class="NLM_lpage">1105</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0200-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41401-018-0200-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30643208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFSns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=1095-1105&author=A.+Y.+Wooauthor=X.+Y.+Geauthor=L.+Panauthor=G.+Xingauthor=Y.+M.+Moauthor=R.+J.+Xingauthor=X.+R.+Liauthor=Y.+Y.+Zhangauthor=I.+W.+Wainerauthor=M.+S.+Chengauthor=R.+P.+Xiao&title=Discovery+of+%CE%B2-arrestin-biased+%CE%B22-adrenoceptor+agonists+from+2-amino-2-phenylethanol+derivatives&doi=10.1038%2Fs41401-018-0200-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives</span></div><div class="casAuthors">Woo, Anthony Yiu-Ho; Ge, Xin-yue; Pan, Li; Xing, Gang; Mo, Yong-mei; Xing, Rui-juan; Li, Xiao-ran; Zhang, Yu-yang; Wainer, Irving W.; Cheng, Mao-sheng; Xiao, Rui-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1095-1105</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In the present study, we evaluated agonist bias for compds. developed along a drug discovery project of β2-adrenoceptor agonists.  About 150 compds., including derivs. of fenoterol, 2-amino-1-phenylethanol and 2-amino-2-phenylethanol, were obtained or synthesized, and initially screened for their β-adrenoceptor-mediated activities in the guinea pig tracheal smooth muscle relaxation assay or the cardiomyocyte contractility assay.  Nineteen bioactive compds. were further assessed using both the HTRF cAMP assay and the PathHunter β-arrestin assay.  Their concn.-response data in stimulating cAMP synthesis and β-arrestin recruitment were applied to the Black-Leff operational model for ligand bias quantitation.  As a result, three compds. (L-2, L-4, and L-12) with the core structure of 5-(1-amino-2-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one were identified as a new series of β-arrestin-biased β2-adrenoceptor agonists, whereas salmeterol was found to be Gs-biased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_MkV43cL0qrVg90H21EOLACvtfcHk0ljaEsPPqqTpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFSns7k%253D&md5=be6a5c2ab300dce93cf24d237650e3a2</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0200-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0200-x%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DGe%26aufirst%3DX.%2BY.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DMo%26aufirst%3DY.%2BM.%26aulast%3DXing%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DX.%2BR.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DCheng%26aufirst%3DM.%2BS.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DDiscovery%2520of%2520%25CE%25B2-arrestin-biased%2520%25CE%25B22-adrenoceptor%2520agonists%2520from%25202-amino-2-phenylethanol%2520derivatives%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D1095%26epage%3D1105%26doi%3D10.1038%2Fs41401-018-0200-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span> <span> </span><span class="NLM_article-title">New perspectives regarding β(2)-adrenoceptor ligands in the treatment of asthma</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01178.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2010.01178.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21175591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=18-28&author=J.+K.+Walkerauthor=R.+B.+Pennauthor=N.+A.+Hananiaauthor=B.+F.+Dickeyauthor=R.+A.+Bond&title=New+perspectives+regarding+%CE%B2%282%29-adrenoceptor+ligands+in+the+treatment+of+asthma&doi=10.1111%2Fj.1476-5381.2010.01178.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives regarding β2-adrenoceptor ligands in the treatment of asthma</span></div><div class="casAuthors">Walker, J. K. L.; Penn, R. B.; Hanania, N. A.; Dickey, B. F.; Bond, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-28</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In the last 2 decades several significant changes were proposed in the receptor theory that describes how ligands can interact with G protein-coupled receptors (GPCRs).  Here we briefly summarize the evolution of receptor theory and detail recent prominent advances.  These include: (i) the existence of spontaneously active GPCRs that are capable of signaling even though they are unoccupied by any ligand; (ii) the discovery of ligands that can inactivate these spontaneously active receptors; (iii) the notion that a ligand may simultaneously activate more than one GPCR signaling pathway; and (iv) the notion that certain ligands may be able to preferentially direct receptor signaling to a specific pathway.  Because the data supporting these receptor theory ideas are derived primarily from studies using artificial expression systems, the physiol. relevance of these new paradigms remains in question.  As a potential example of how these new perspectives in receptor theory relate to drug actions and clin. outcomes, we discuss their relevance to the recent controversy regarding the chronic use of β2-adrenoceptor agonists in the treatment of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2HtWkdeFhLVg90H21EOLACvtfcHk0liMXUFYhiI6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7c%253D&md5=3de8d518f635a1d1557abfdd92282adf</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01178.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01178.x%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DJ.%2BK.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DHanania%26aufirst%3DN.%2BA.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DBond%26aufirst%3DR.%2BA.%26atitle%3DNew%2520perspectives%2520regarding%2520%25CE%25B2%25282%2529-adrenoceptor%2520ligands%2520in%2520the%2520treatment%2520of%2520asthma%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D18%26epage%3D28%26doi%3D10.1111%2Fj.1476-5381.2010.01178.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span> <span> </span><span class="NLM_article-title">Beta-arrestins and cell signaling</span>. <i>Annu. Rev. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1146/annurev.physiol.69.022405.154749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1146%2Fannurev.physiol.69.022405.154749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17305471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVaksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=483-510&author=S.+M.+DeWireauthor=S.+Ahnauthor=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Beta-arrestins+and+cell+signaling&doi=10.1146%2Fannurev.physiol.69.022405.154749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">β-arrestins and cell signaling</span></div><div class="casAuthors">DeWire, Scott M.; Ahn, Seungkirl; Lefkowitz, Robert J.; Shenoy, Sudha K.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">483-510</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Upon their discovery, β-arrestins 1 and 2 were named for their capacity to sterically hinder the G protein coupling of agonist-activated seven-transmembrane receptors, ultimately resulting in receptor desensitization.  Surprisingly, recent evidence shows that β-arrestins can also function to activate signaling cascades independently of G protein activation.  By serving as multiprotein scaffolds, the β-arrestins bring elements of specific signaling pathways into close proximity.  β-Arrestin regulation has been demonstrated for an ever-increasing no. of signaling mols., including MAP kinases ERK, JNK, and p38 as well as Akt, PI3 kinase, and RhoA.  In addn., investigators are discovering new roles for β-arrestins in nuclear functions.  Here, the authors review the signaling capacities of these versatile adapter mols. and discuss the possible implications for cellular processes such as chemotaxis and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeWSVCmd5eorVg90H21EOLACvtfcHk0liMXUFYhiI6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVaksLg%253D&md5=a49f06fb1de1e09593d89a8bbfa4c9f7</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1146%2Fannurev.physiol.69.022405.154749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.physiol.69.022405.154749%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DBeta-arrestins%2520and%2520cell%2520signaling%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2007%26volume%3D69%26spage%3D483%26epage%3D510%26doi%3D10.1146%2Fannurev.physiol.69.022405.154749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parameswaran, N.</span></span> <span> </span><span class="NLM_article-title">Multifaceted role of β-arrestins in inflammation and disease</span>. <i>Genes Immun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1038/gene.2015.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fgene.2015.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26378652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKkt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=499-513&author=D.+Sharmaauthor=N.+Parameswaran&title=Multifaceted+role+of+%CE%B2-arrestins+in+inflammation+and+disease&doi=10.1038%2Fgene.2015.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted role of β-arrestins in inflammation and disease</span></div><div class="casAuthors">Sharma, D.; Parameswaran, N.</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Immunity</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">499-513</span>CODEN:
                <span class="NLM_cas:coden">GEIMA2</span>;
        ISSN:<span class="NLM_cas:issn">1466-4879</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Arrestins are intracellular scaffolding proteins known to regulate a range of biochem. processes including G protein-coupled receptor (GPCR) desensitization, signal attenuation, receptor turnover and downstream signaling cascades.  Their roles in regulation of signaling network have lately been extended to receptors outside of the GPCR family, demonstrating their roles as important scaffolding proteins in various physiol. processes including proliferation, differentiation and apoptosis.  Recent studies have demonstrated a crit. role for arrestins in immunol. processes including key functions in inflammatory signaling pathways.  In this review, we provide a comprehensive anal. of the different functions of the arrestin family of proteins esp. related to immunity and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoooGvJJETlv7Vg90H21EOLACvtfcHk0liMXUFYhiI6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKkt7fO&md5=80d649be7dadb702defaf71e170af9b4</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fgene.2015.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgene.2015.37%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DD.%26aulast%3DParameswaran%26aufirst%3DN.%26atitle%3DMultifaceted%2520role%2520of%2520%25CE%25B2-arrestins%2520in%2520inflammation%2520and%2520disease%26jtitle%3DGenes%2520Immun.%26date%3D2015%26volume%3D16%26spage%3D499%26epage%3D513%26doi%3D10.1038%2Fgene.2015.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cullum, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, G. P.</span></span> <span> </span><span class="NLM_article-title">Salbutamol: a new, selective beta-adrenoceptive receptor stimulant</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1969.tb07975.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.1969.tb07975.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=5762037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaF1MXls1Slsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1969&pages=141-151&author=V.+A.+Cullumauthor=J.+B.+Farmerauthor=D.+Jackauthor=G.+P.+Levy&title=Salbutamol%3A+a+new%2C+selective+beta-adrenoceptive+receptor+stimulant&doi=10.1111%2Fj.1476-5381.1969.tb07975.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Salbutamol; an β-adrenoceptive receptor stimulant</span></div><div class="casAuthors">Cullum, Valerie A.; Farmer, John B.; Jack, David; Levy, G. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-51</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">Salbutamol is a β-adrenoceptive receptor stimulant.  Its pharmacol. actions are reduced or abolished by β-receptor antagonists.  In anesthetized animals, salbutamol, given i.v. was slightly less active than isoprenaline in preventing spasm of bronchial smooth muscle but was considerably less active as a cardiac stimulant and vasodepressor.  Its duration of action was about 2 to 3 times that of isoprenaline.  Salbutamol given by mouth or aerosol to conscious guinea pigs, greatly diminished bronchospasm caused by inhalation of acetylcholine.  By mouth, salbutamol was more active and had a longer duration than isoprenaline or orciprenaline without affecting heart rate.  By aerosol, salbutamol was approx. 10 times as active as isoprenaline and 100 times as active as orciprenaline.  Its duration of action was much longer than that of isoprenaline or orciprenaline.  Only isoprenaline produced an increase in heart rate by the aerosol route.  On isolated guinea pig trachea, salbutamol had about 1/10 the activity of isoprenaline and on isolated atria about 1/2000 the activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w5zQ-_X3cLVg90H21EOLACvtfcHk0lh1ThcN2XsJ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXls1Slsw%253D%253D&md5=5c012efa7d10ff3e73e1a45688df8706</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1969.tb07975.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1969.tb07975.x%26sid%3Dliteratum%253Aachs%26aulast%3DCullum%26aufirst%3DV.%2BA.%26aulast%3DFarmer%26aufirst%3DJ.%2BB.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DLevy%26aufirst%3DG.%2BP.%26atitle%3DSalbutamol%253A%2520a%2520new%252C%2520selective%2520beta-adrenoceptive%2520receptor%2520stimulant%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1969%26volume%3D35%26spage%3D141%26epage%3D151%26doi%3D10.1111%2Fj.1476-5381.1969.tb07975.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denyer, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunts, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nials, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, I. F.</span></span> <span> </span><span class="NLM_article-title">Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1991.tb12486.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.1991.tb12486.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1686740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK3MXmsVOrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1991&pages=665-671&author=D.+I.+Ballauthor=R.+T.+Brittainauthor=R.+A.+Colemanauthor=L.+H.+Denyerauthor=D.+Jackauthor=M.+Johnsonauthor=L.+H.+Luntsauthor=A.+T.+Nialsauthor=K.+E.+Sheldrickauthor=I.+F.+Skidmore&title=Salmeterol%2C+a+novel%2C+long-acting+beta+2-adrenoceptor+agonist%3A+characterization+of+pharmacological+activity+in+vitro+and+in+vivo&doi=10.1111%2Fj.1476-5381.1991.tb12486.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol, a novel, long-acting β2-adrenoceptor agonist:  characterization of pharmacological activity in vitro and in vivo</span></div><div class="casAuthors">Ball, D. I.; Brittain, R. T.; Coleman, R. A.; Denyer, L. H.; Jack, D.; Johnson, M.; Lunts, L. H. C.; Nials, A. T.; Sheldrick, K. E.; Skidmore, I. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">665-71</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">Salmeterol, a novel, long-acting β-adrenoceptor agonist, has been compared with isoprenaline and salbutamol for activity in vitro on a range of β-adrenoceptor contg. prepns. from lab. animals and man, and in vivo for bronchodilator activity in the conscious guinea-pig.  The results indicate that salmeterol is a potent and selective β2-adrenoceptor agonist with a remarkably long duration of action in isolated superfused airways smooth muscle.  It also causes persistent bronchodilation in vivo, in the guinea-pig, when administered by the inhaled route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreiLxM-Bl_PLVg90H21EOLACvtfcHk0lh1ThcN2XsJ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsVOrtr4%253D&md5=15b5a132eca52fc209a0724d2e1d52b2</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1991.tb12486.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1991.tb12486.x%26sid%3Dliteratum%253Aachs%26aulast%3DBall%26aufirst%3DD.%2BI.%26aulast%3DBrittain%26aufirst%3DR.%2BT.%26aulast%3DColeman%26aufirst%3DR.%2BA.%26aulast%3DDenyer%26aufirst%3DL.%2BH.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLunts%26aufirst%3DL.%2BH.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DSheldrick%26aufirst%3DK.%2BE.%26aulast%3DSkidmore%26aufirst%3DI.%2BF.%26atitle%3DSalmeterol%252C%2520a%2520novel%252C%2520long-acting%2520beta%25202-adrenoceptor%2520agonist%253A%2520characterization%2520of%2520pharmacological%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1991%26volume%3D104%26spage%3D665%26epage%3D671%26doi%3D10.1111%2Fj.1476-5381.1991.tb12486.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span> <span> </span><span class="NLM_article-title">Beta2-adrenoceptors: mechanisms of action of beta2-agonists</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1053/prrv.2000.0102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1053%2Fprrv.2000.0102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16263481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=57-62&author=M.+Johnson&title=Beta2-adrenoceptors%3A+mechanisms+of+action+of+beta2-agonists&doi=10.1053%2Fprrv.2000.0102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Beta2-adrenoceptors: mechanisms of action of beta2-agonists</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-62</span>
        ISSN:<span class="NLM_cas:issn">1526-0542</span>.
    </div><div class="casAbstract">The human beta2-adrenoceptor is a member of the 7 transmembrane family of receptors.  It is encoded by a gene on chromosome 5 and is widely distributed in the respiratory tract.  Following beta2-adrenoceptor activation, intracellular signalling is mainly produced by inducing cyclic AMP.  This produces airway relaxation through phosphorylation of muscle regulatory proteins and modification of cellular Ca2+concentrations.  Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in asthmatic patients.  Beta-adrenoceptor desensitisation is associated with beta2-agonist activation and differs depending on the cell type.  It is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described which appear to alter the behaviour of the receptor, including the degree of downregulation and response to beta2-agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUowsFMb9kLcvLc4ARHEmzfW6udTcc2eayI900VzAw2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D&md5=18b08b6aa45ab53a8bf757299ad12dfe</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1053%2Fprrv.2000.0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fprrv.2000.0102%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DBeta2-adrenoceptors%253A%2520mechanisms%2520of%2520action%2520of%2520beta2-agonists%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2001%26volume%3D2%26spage%3D57%26epage%3D62%26doi%3D10.1053%2Fprrv.2000.0102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.088914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.088914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16051698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=839-848&author=A.+A.+Carterauthor=S.+J.+Hill&title=Characterization+of+isoprenaline-+and+salmeterol-stimulated+interactions+between+beta2-adrenoceptors+and+beta-arrestin+2+using+beta-galactosidase+complementation+in+C2C12+cells&doi=10.1124%2Fjpet.105.088914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of isoprenaline- and salmeterol-stimulated interactions between β2-adrenoceptors and β-arrestin 2 using β-galactosidase complementation in C2C12 cells</span></div><div class="casAuthors">Carter, Alison A.; Hill, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">β-Arrestin is an adaptor protein that has been shown to couple G protein-coupled receptors (GPCRs) to clathrin-coated pits and target them for subsequent internalization.  More recently, β-arrestin 2 has also been shown to be involved in the activation of mitogen-activated protein kinase cascades by G protein-coupled receptors independently of G protein activation.  Direct interactions between proteins can be monitored using enzyme complementation between two inactive deletion mutants of β-galactosidase (β-gal; Δα and Δω).  In the present study, we have used fusion proteins of the human β2-adrenoceptor (C-terminal β-gal Δα) and β-arrestin 2 (β-gal Δω) to study directly the pharmacol. of this interaction in C2C12 cells expressing the β2-adrenoceptor-β-gal Δα fusion protein at low physiol. levels (38.2±2.7 fmol · mg protein-1).  Isoprenaline, noradrenaline, and adrenaline (-log EC50 = 5.9, 5.5, and 5.7, resp.) stimulated an assocn. between the β2-adrenoceptor and β-arrestin 2 at much higher concns. than required for activation of cAMP accumulation (-log EC50 = 7.6, 6.3, and 7.7, resp.).  This was sensitive to inhibition by the β2-adrenoceptor antagonists propranolol, timolol, and ICI 118551.  Both salbutamol and terbutaline behaved as partial agonists of β-gal complementation.  Furthermore, the long-acting β2-agonist salmeterol (-log KD for inhibition of [3H]CGP12177 binding = 8.7) behaved as an antagonist of isoprenaline-stimulated β2-adrenoceptor-arrestin 2 interactions (-log KD = 8.0), whereas acting as a full agonist of cAMP accumulation in the same cells (-log EC50 = 9.2).  These data suggest that salmeterol can discriminate between receptor-Gs protein and receptor-arrestin 2 complexes (in terms of efficacy and affinity) in a way that is favorable for its long duration of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqVIvFdANF7Vg90H21EOLACvtfcHk0liPsFsceiQANw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtrzP&md5=2277ec0be759013249d80a32efc3baa8</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.088914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.088914%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DA.%2BA.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26atitle%3DCharacterization%2520of%2520isoprenaline-%2520and%2520salmeterol-stimulated%2520interactions%2520between%2520beta2-adrenoceptors%2520and%2520beta-arrestin%25202%2520using%2520beta-galactosidase%2520complementation%2520in%2520C2C12%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D839%26epage%3D848%26doi%3D10.1124%2Fjpet.105.088914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facciolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>745</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.ejphar.2014.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25446566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVems7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=745&publication_year=2014&pages=135-143&author=M.+Cazzolaauthor=L.+Calzettaauthor=C.+P.+Pageauthor=P.+Roglianiauthor=F.+Faccioloauthor=A.+Gavald%C3%A0author=M.+G.+Matera&title=Pharmacological+characterization+of+the+interaction+between+aclidinium+bromide+and+formoterol+fumarate+on+human+isolated+bronchi&doi=10.1016%2Fj.ejphar.2014.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi</span></div><div class="casAuthors">Cazzola, Mario; Calzetta, Luigino; Page, Clive P.; Rogliani, Paola; Facciolo, Francesco; Gavalda, Amadeu; Matera, Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">745</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi.  The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM.  We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or elec. field stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles).  We analyzed the potential synergistic interaction between the compds. when administered in combination by using Bliss independence (BI) theory.  Both aclidinium bromide and formoterol fumarate completely relaxed segmental bronchi pre-contracted with acetylcholine (Emax: 97.5±2.6% and 96.4±1.1%; pEC50 8.5±0.1 and 8.8±0.1; resp.).  Formoterol fumarate, but not aclidinium bromide, abolished the contraction induced by acetylcholine in bronchioles (Emax: 68.1±4.5% and 99.0±5.6%; pEC50 7.9±0.3 and 8.4±0.3; resp.).  The BI anal. indicated synergistic interaction at low concns. in segmental bronchi (+18.4±2.7%; P<0.05 vs. expected effect) and from low to high concns. in bronchioles (+19.7±0.9%; P<0.05 vs. expected effect).  Low concns. of both drugs produced a synergistic relaxant interaction on isolated bronchi stimulated with EFS that was sustained for 6 h post-treatment (+55.1±9.4%; P<0.05 vs. expected effect).  These results suggest that combining aclidinium bromide plus formoterol fumarate provides synergistic benefit on ASM relaxation of both medium and small human airways, which may have major implications for the use of this combination in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Rc3myVw7grVg90H21EOLACvtfcHk0liPsFsceiQANw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVems7fP&md5=9502fcec7e9db43321db554ede010227</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DC.%2BP.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DFacciolo%26aufirst%3DF.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520the%2520interaction%2520between%2520aclidinium%2520bromide%2520and%2520formoterol%2520fumarate%2520on%2520human%2520isolated%2520bronchi%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D745%26spage%3D135%26epage%3D143%26doi%3D10.1016%2Fj.ejphar.2014.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span> <span> </span><span class="NLM_article-title">New beta-adrenoreceptor stimulants. Studies on 3-acylamino-4-hydroxy-alpha-(<i>N</i>-substitutedaminomethyl)benzyl alcohols</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1368</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1248/cpb.25.1368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1248%2Fcpb.25.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaE2sXlsFWku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1977&pages=1368-1377&author=K.+Muraseauthor=T.+Maseauthor=H.+Idaauthor=K.+Takahashiauthor=M.+Murakami&title=New+beta-adrenoreceptor+stimulants.+Studies+on+3-acylamino-4-hydroxy-alpha-%28N-substitutedaminomethyl%29benzyl+alcohols&doi=10.1248%2Fcpb.25.1368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">New β-adrenoreceptor stimulants.  Studies on 3-acylamino-4-hydroxy-α-(N-substituted aminomethyl)benzyl alcohols</span></div><div class="casAuthors">Murase, Kiyoshi; Mase, Toshiyasu; Ida, Hisashi; Takahashi, Kozo; Murakami, Masuo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1368-77</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">The 2-bromoacetophenone I was converted to eighteen α-(aminomethyl)benzyl alcs. II (R = H, Me, substituted methyl; R1 = CHMe2, CMe3, substituted phenethyl, substituted 3-phenylpropyl, substituted 3-cyclohexylpropyl), which showed bronchodilator activity.  Thus, I was treated with benzylamines, reduced (NaBH4), reduced (Fe-HCl), N-acylated, and deprotected to yield the II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9MdnjCjnJDbVg90H21EOLACvtfcHk0liPsFsceiQANw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXlsFWku7Y%253D&md5=f2290871cf292be610caf2f01486c1b3</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1248%2Fcpb.25.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.25.1368%26sid%3Dliteratum%253Aachs%26aulast%3DMurase%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DM.%26atitle%3DNew%2520beta-adrenoreceptor%2520stimulants.%2520Studies%2520on%25203-acylamino-4-hydroxy-alpha-%2528N-substitutedaminomethyl%2529benzyl%2520alcohols%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1977%26volume%3D25%26spage%3D1368%26epage%3D1377%26doi%3D10.1248%2Fcpb.25.1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span> <span> </span><span class="NLM_article-title">Absolute configurations of four isomers of 3-formamido-4-hydroxy-α-[[<i>N</i>-(<i>p</i>-methoxy-α-methylphenethyl)amino]methyl]benzyl alcohol, a potent β-adrenoreceptor stimulant</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1248/cpb.26.1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1248%2Fcpb.26.1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaE1cXltVOku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1978&pages=1123-1129&author=K.+Muraseauthor=T.+Maseauthor=H.+Idaauthor=K.+Takahashiauthor=M.+Murakami&title=Absolute+configurations+of+four+isomers+of+3-formamido-4-hydroxy-%CE%B1-%5B%5BN-%28p-methoxy-%CE%B1-methylphenethyl%29amino%5Dmethyl%5Dbenzyl+alcohol%2C+a+potent+%CE%B2-adrenoreceptor+stimulant&doi=10.1248%2Fcpb.26.1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Absolute configurations of four isomers of 3-formamido-4-hydroxy-α-[[N-(p-methoxy-α-methylphenethyl)amino]methyl]benzyl alcohol, a potent β-adrenoreceptor stimulant</span></div><div class="casAuthors">Murase, Kiyoshi; Mase, Toshiyasu; Ida, Hisashi; Takahashi, Kozo; Murakami, Masuo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1123-9</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">The configuration of 2 pairs of enantiomers of 3-formamido-4-hydroxy-α-[[N-(p-methoxy-α-methylphenethyl)amino]methyl]benzyl alc. were detd. by chem. correlation with those of N-(p-hydroxy-α-methylphenethyl)amine, whose configuration is known.  The bronchodilator activity of these compds. was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoViKC9EXgFM7Vg90H21EOLACvtfcHk0ljHGWO6TBxOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXltVOku7g%253D&md5=992c7ed48a46f4772bfb93fa641e03f2</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1248%2Fcpb.26.1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.26.1123%26sid%3Dliteratum%253Aachs%26aulast%3DMurase%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DM.%26atitle%3DAbsolute%2520configurations%2520of%2520four%2520isomers%2520of%25203-formamido-4-hydroxy-%25CE%25B1-%255B%255BN-%2528p-methoxy-%25CE%25B1-methylphenethyl%2529amino%255Dmethyl%255Dbenzyl%2520alcohol%252C%2520a%2520potent%2520%25CE%25B2-adrenoreceptor%2520stimulant%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1978%26volume%3D26%26spage%3D1123%26epage%3D1129%26doi%3D10.1248%2Fcpb.26.1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baur, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuenoud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeuillet-Ritzler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedaldi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, D.</span></span> <span> </span><span class="NLM_article-title">The Identification of indacaterol as an ultra-long-acting inhaled β<sub>2</sub>-adrenoceptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1021/jm100068m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100068m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3675-3684&author=F.+Baurauthor=D.+Beattieauthor=D.+Beerauthor=D.+Bentleyauthor=M.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=R.+Ernstauthor=R.+A.+Fairhurstauthor=B.+Fallerauthor=D.+Farrauthor=T.+Kellerauthor=J.+R.+Fozardauthor=J.+Fullertonauthor=S.+Garmanauthor=J.+Hattoauthor=C.+Haydenauthor=H.+Heauthor=C.+Howesauthor=D.+Janusauthor=Z.+Jiangauthor=C.+Lewisauthor=F.+Loeuillet-Ritzlerauthor=H.+Moserauthor=J.+Reillyauthor=A.+Stewardauthor=D.+Sykesauthor=L.+Tedaldiauthor=A.+Trifilieffauthor=M.+Tweedauthor=S.+Watsonauthor=E.+Wisslerauthor=D.+Wyss&title=The+Identification+of+indacaterol+as+an+ultra-long-acting+inhaled+%CE%B22-adrenoceptor+agonist&doi=10.1021%2Fjm100068m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist</span></div><div class="casAuthors">Baur, Francois; Beattie, David; Beer, David; Bentley, David; Bradley, Michelle; Bruce, Ian; Charlton, Steven J.; Cuenoud, Bernard; Ernst, Roland; Fairhurst, Robin A.; Faller, Bernard; Farr, David; Keller, Thomas; Fozard, John R.; Fullerton, Joe; Garman, Sheila; Hatto, Julia; Hayden, Claire; He, Handan; Howes, Colin; Janus, Diana; Jiang, Zhengjin; Lewis, Christine; Loeuillet-Ritzler, Frederique; Moser, Heinz; Reilly, John; Steward, Alan; Sykes, David; Tedaldi, Lauren; Trifilieff, Alexandre; Tweed, Morris; Watson, Simon; Wissler, Elke; Wyss, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3675-3684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of β2-adrenoceptor agonists have been prepd. and evaluated for their potential as inhaled ultralong-acting bronchodilators.  Detn. of their activities at the human β2-adrenoceptor receptor showed sym. substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clin. ref. β2-adrenoceptor agonists.  Further assessment with an in vitro superfused elec. stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses, which could be rationalized by considering the lipophilicity, potency, and intrinsic efficacy of the compds.  From these studies the 5,6-diethylindan analog indacaterol was shown to possess a unique profile of combining a rapid onset of action with a long duration of action.  Further in vivo profiling of indacaterol supported the long duration of action and a wide therapeutic index following administration to the lung, which led to the compd. being selected as a development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDXzKlPrfGY7Vg90H21EOLACvtfcHk0ljHGWO6TBxOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtbs%253D&md5=3aadd254472ad850897fe8a8b7297bab</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm100068m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100068m%26sid%3Dliteratum%253Aachs%26aulast%3DBaur%26aufirst%3DF.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DFullerton%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayden%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHowes%26aufirst%3DC.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DLoeuillet-Ritzler%26aufirst%3DF.%26aulast%3DMoser%26aufirst%3DH.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSteward%26aufirst%3DA.%26aulast%3DSykes%26aufirst%3DD.%26aulast%3DTedaldi%26aufirst%3DL.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DWissler%26aufirst%3DE.%26aulast%3DWyss%26aufirst%3DD.%26atitle%3DThe%2520Identification%2520of%2520indacaterol%2520as%2520an%2520ultra-long-acting%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3675%26epage%3D3684%26doi%3D10.1021%2Fjm100068m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontovnick, L.</span></span> <span> </span><span class="NLM_article-title">Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1164/ajrccm/142.5.1147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm%2F142.5.1147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1978619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK3MXnsV2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=1990&pages=1147-1152&author=J.+L.+Maloauthor=A.+Cartierauthor=C.+Trudeauauthor=H.+Ghezzoauthor=L.+Gontovnick&title=Formoterol%2C+a+new+inhaled+beta-2+adrenergic+agonist%2C+has+a+longer+blocking+effect+than+albuterol+on+hyperventilation-induced+bronchoconstriction&doi=10.1164%2Fajrccm%2F142.5.1147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction</span></div><div class="casAuthors">Malo, Jean Luc; Cartier, Andre; Trudeau, Carole; Ghezzo, Heberto; Gontovnick, Larry</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Respiratory Disease</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-52</span>CODEN:
                <span class="NLM_cas:coden">ARDSBL</span>;
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">The duration of effect of inhaled formoterol (24 μg) was compared with that of a placebo and that of inhaled albuterol (200 μg) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 °) on 4 study days.  On the control day, they were subjected to four hyperventilation tests to ensure functional stability.  On the 3 remaining days, after a first hyperventilation test, they inhaled placebo, albuterol, or formoterol in randomized, double-blind fashion.  The hyperventilation test was repeated 1, 4, and 8 h and, if the blocking effect was still present, 12 and 24 h after the drug had been administered.  The dose of hyperventilation of cold air causing a 20% fall in FEV1 (PD20) was interpolated on the dose-response curve.  The magnitude of the blocking effect at each time interval on each study day was assessed by comparing the changes in PD20 from baseline with the within-day variability of PD20 (standardized change in PD20).  The acute bronchodilator effect was not significantly different as assessed 15 min (21% for albuterol and 18% for formoterol) and 1 h (20% for albuterol and 18% for formoterol) after administering the medication.  The duration of the blocking effect was more prolonged for formoterol (8.0 h) than for albuterol (3.0 h).  Two subjects still demonstrated the presence of a blocking effect 4 h after inhaling albuterol, whereas 11 subjects did after formoterol.  After 12 h, three subjects still demonstrated the presence of a blocking effect after inhaled formoterol.  Apparently, the protection against bronchoconstriction induced by hyperventilation of unconditioned air in asthmatic subjects is significantly more prolonged after formoterol than after albuterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnEMo0rc9vqrVg90H21EOLACvtfcHk0ljHGWO6TBxOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXnsV2qtA%253D%253D&md5=c7ef2c88f10744f193f6f5c3852e2df4</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1164%2Fajrccm%2F142.5.1147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm%252F142.5.1147%26sid%3Dliteratum%253Aachs%26aulast%3DMalo%26aufirst%3DJ.%2BL.%26aulast%3DCartier%26aufirst%3DA.%26aulast%3DTrudeau%26aufirst%3DC.%26aulast%3DGhezzo%26aufirst%3DH.%26aulast%3DGontovnick%26aufirst%3DL.%26atitle%3DFormoterol%252C%2520a%2520new%2520inhaled%2520beta-2%2520adrenergic%2520agonist%252C%2520has%2520a%2520longer%2520blocking%2520effect%2520than%2520albuterol%2520on%2520hyperventilation-induced%2520bronchoconstriction%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1990%26volume%3D142%26spage%3D1147%26epage%3D1152%26doi%3D10.1164%2Fajrccm%2F142.5.1147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-adrenoceptor agonists: current and future direction</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01216.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2011.01216.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21232045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=4-17&author=M.+Cazzolaauthor=L.+Calzettaauthor=M.+G.+Matera&title=%CE%B22-adrenoceptor+agonists%3A+current+and+future+direction&doi=10.1111%2Fj.1476-5381.2011.01216.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">β2-adrenoceptor agonists: current and future direction</span></div><div class="casAuthors">Cazzola, Mario; Calzetta, Luigino; Matera, Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-17</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Despite the passionate debate over the use of β2-adrenoceptor agonists in the treatment of airway disorders, these agents are still central in the symptomatic management of asthma and COPD.  A variety of β2-adrenoceptor agonists with long half-lives, also called ultra long-acting β2-adrenoceptor agonists (ultra-LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF-610355) are currently under development with the hopes of achieving once-daily dosing.  It is likely that the once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clin. outcomes.  As combination therapy with an inhaled corticosteroid (ICS) and a LABA is important for treating patients suffering from asthma, and a combination with an inhaled long-acting antimuscarinic agent (LAMA) is important for treating COPD patients whose conditions are not sufficiently controlled by monotherapy with a β2-adrenoceptor agonist, some novel once-daily combinations of LABAs and ICSs or LAMAs are under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-1Esjz92QG7Vg90H21EOLACvtfcHk0lggRBFgSBYt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7Y%253D&md5=670b1493bcf250c56425e50732b00c33</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01216.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01216.x%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3D%25CE%25B22-adrenoceptor%2520agonists%253A%2520current%2520and%2520future%2520direction%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D4%26epage%3D17%26doi%3D10.1111%2Fj.1476-5381.2011.01216.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoenke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouyssou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konetzki, I.</span></span> <span> </span><span class="NLM_article-title">Use of 5-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones as β<sub>2</sub>-adrenoceptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6640</span>– <span class="NLM_lpage">6644</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19875286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6640-6644&author=C.+Hoenkeauthor=T.+Bouyssouauthor=C.+S.+Tautermannauthor=K.+Rudolfauthor=A.+Schnappauthor=I.+Konetzki&title=Use+of+5-hydroxy-4H-benzo%5B1%2C4%5Doxazin-3-ones+as+%CE%B22-adrenoceptor+agonists&doi=10.1016%2Fj.bmcl.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists</span></div><div class="casAuthors">Hoenke, Christoph; Bouyssou, Thierry; Tautermann, Christofer S.; Rudolf, Klaus; Schnapp, Andreas; Konetzki, Ingo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6640-6644</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel β2-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described.  Systematic chem. variations at the phenethylamine residue of these compds. lead to the discovery of compd. 6m as potent, full agonist of the β2-adrenoceptor with a high β1/β2-selectivity.  Mol. modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the β2-receptor as putative explanation for the high obsd. selectivity.  Further, compd. 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzC12KHZPa17Vg90H21EOLACvtfcHk0lggRBFgSBYt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLbJ&md5=0d7f9187ea8842e3986cf7e67ce05696</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DUse%2520of%25205-hydroxy-4H-benzo%255B1%252C4%255Doxazin-3-ones%2520as%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6640%26epage%3D6644%26doi%3D10.1016%2Fj.bmcl.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouyssou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Büttner, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konetzki, I.</span></span> <span> </span><span class="NLM_article-title">Discovery of olodaterol, a novel inhaled β<sub>2</sub>-adrenoceptor agonist with a 24 h bronchodilatory efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1410</span>– <span class="NLM_lpage">1414</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2009.12.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20096576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1410-1414&author=T.+Bouyssouauthor=C.+Hoenkeauthor=K.+Rudolfauthor=P.+Lustenbergerauthor=S.+Pestelauthor=P.+Siegerauthor=R.+Lotzauthor=C.+Heineauthor=F.+H.+B%C3%BCttnerauthor=A.+Schnappauthor=I.+Konetzki&title=Discovery+of+olodaterol%2C+a+novel+inhaled+%CE%B22-adrenoceptor+agonist+with+a+24+h+bronchodilatory+efficacy&doi=10.1016%2Fj.bmcl.2009.12.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy</span></div><div class="casAuthors">Bouyssou, Thierry; Hoenke, Christoph; Rudolf, Klaus; Lustenberger, Philipp; Pestel, Sabine; Sieger, Peter; Lotz, Ralf; Heine, Claudia; Buettner, Frank H.; Schnapp, Andreas; Konetzki, Ingo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1410-1414</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. 4p (I) was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity.  A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection.  The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects.  Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h.  In summary, the preclin. profile of compd. (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq_OHb0Lpw87Vg90H21EOLACvtfcHk0lggRBFgSBYt4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D&md5=4527e1e074c1ee33eccc2d9f3293bdef</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DC.%26aulast%3DB%25C3%25BCttner%26aufirst%3DF.%2BH.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DDiscovery%2520of%2520olodaterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520a%252024%2520h%2520bronchodilatory%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1410%26epage%3D1414%26doi%3D10.1016%2Fj.bmcl.2009.12.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggadike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchers, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li-Kwai-Cheung, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLay, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlin, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4522</span>– <span class="NLM_lpage">4530</span>, <span class="refDoi"> DOI: 10.1021/jm100326d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100326d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFKqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4522-4530&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+C.+Boxauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=A.+Emmonsauthor=A.+J.+Fordauthor=D.+S.+Holmesauthor=H.+Horsleyauthor=F.+Kerrauthor=A.+M.+Li-Kwai-Cheungauthor=B.+E.+Lookerauthor=I.+S.+Mannauthor=I.+M.+McLayauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=C.+E.+Smithauthor=P.+Tomlin&title=Synthesis+and+structure-activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+metabolic+inactivation%3A+an+antedrug+approach&doi=10.1021%2Fjm100326d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, Victoria J.; Bevan, Nicola J.; Biggadike, Keith; Box, Philip C.; Butchers, Peter R.; Coe, Diane M.; Conroy, Richard; Emmons, Amanda; Ford, Alison J.; Holmes, Duncan S.; Horsley, Helen; Kerr, Fern; Li-Kwai-Cheung, Anne-Marie; Looker, Brian E.; Mann, Inderjit S.; McLay, Iain M.; Morrison, Valerie S.; Mutch, Peter J.; Smith, Claire E.; Tomlin, Paula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4522-4530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of saligenin β2 adrenoceptor agonist antedrugs having high clearance were prepd. by reacting a protected saligenin oxazolidinone with protected hydroxyethoxyalkoxyalkyl bromides, followed by removal of the hydroxy-protecting group, alkylation, and final deprotection.  The compds. were screened for β2, β1, and β3 agonist activity in CHO cells.  The onset and duration of action in vitro of selected compds. were assessed on isolated superfused guinea pig trachea.  I had high potency, selectivity, fast onset, and long duration of action in vitro and was found to have long duration in vivo, low oral bioavailability in the rat, and to be rapidly metabolized.  Cryst. salts of I (vilanterol) were identified that had suitable properties for inhaled administration.  A proposed binding mode for I to the β2-receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSi1eD2OieFbVg90H21EOLACvtfcHk0lhYT_cWuAZxIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFKqt7o%253D&md5=3b59a1fdaba51d1688c14a3da96b4b4d</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fjm100326d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100326d%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DBox%26aufirst%3DP.%2BC.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEmmons%26aufirst%3DA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DHorsley%26aufirst%3DH.%26aulast%3DKerr%26aufirst%3DF.%26aulast%3DLi-Kwai-Cheung%26aufirst%3DA.%2BM.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMann%26aufirst%3DI.%2BS.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DTomlin%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520metabolic%2520inactivation%253A%2520an%2520antedrug%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4522%26epage%3D4530%26doi%3D10.1021%2Fjm100326d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarosa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devree, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konetzki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pautsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure of a nanobody-stabilized active state of the β<sub>2</sub> adrenoceptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1038/nature09648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature09648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21228869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=175-180&author=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=J.+J.+Fungauthor=E.+Pardonauthor=P.+Casarosaauthor=P.+S.+Chaeauthor=B.+T.+Devreeauthor=D.+M.+Rosenbaumauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=A.+Schnappauthor=I.+Konetzkiauthor=R.+K.+Sunaharaauthor=S.+H.+Gellmanauthor=A.+Pautschauthor=J.+Steyaertauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Structure+of+a+nanobody-stabilized+active+state+of+the+%CE%B22+adrenoceptor&doi=10.1038%2Fnature09648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a nanobody-stabilized active state of the β2 adrenoceptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Fung, Juan Jose; Pardon, Els; Casarosa, Paola; Chae, Pil Seok; DeVree, Brian T.; Rosenbaum, Daniel M.; Thian, Foon Sun; Kobilka, Tong Sun; Schnapp, Andreas; Konetzki, Ingo; Sunahara, Roger K.; Gellman, Samuel H.; Pautsch, Alexander; Steyaert, Jan; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviors in response to natural and synthetic ligands.  Recent crystal structures provide insights into inactive states of several GPCRs.  Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein.  We generated a camelid antibody fragment (nanobody) to the human β2 adrenergic receptor (β2AR) that exhibits G protein-like behavior, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex.  Comparison with the inactive β2AR structure reveals subtle changes in the binding pocket; however, these small changes are assocd. with an 11 Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those obsd. in opsin, an active form of rhodopsin.  This structure provides insights into the process of agonist binding and activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqITZxHz6Vi77Vg90H21EOLACvtfcHk0lhYT_cWuAZxIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D&md5=3a1d3bac6d92c9d54cf1ddd14d56ab8c</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnature09648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09648%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DFung%26aufirst%3DJ.%2BJ.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DPautsch%26aufirst%3DA.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520of%2520a%2520nanobody-stabilized%2520active%2520state%2520of%2520the%2520%25CE%25B22%2520adrenoceptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D175%26epage%3D180%26doi%3D10.1038%2Fnature09648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westfield, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi-Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleskie, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dosey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klink, B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penczek, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossiakoff, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, V. L.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiniotis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Visualization of arrestin recruitment by a G-protein-coupled receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1038/nature13430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature13430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25043026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGntb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2014&pages=218-222&author=A.+Shuklaauthor=G.+Westfieldauthor=K.+Xiaoauthor=R.+I.+Reisauthor=L.+Y.+Huangauthor=P.+Tripathi-Shuklaauthor=J.+Qianauthor=S.+Liauthor=A.+Blancauthor=A.+N.+Oleskieauthor=A.+M.+Doseyauthor=M.+Suauthor=C.+R.+Liangauthor=L.+L.+Guauthor=J.+M.+Shanauthor=X.+Chenauthor=R.+Hannaauthor=M.+Choiauthor=X.+J.+Yaoauthor=B.+U.+Klinkauthor=A.+W.+Kahsaiauthor=S.+S.+Sidhuauthor=S.+Koideauthor=P.+A.+Penczekauthor=A.+A.+Kossiakoffauthor=V.+L.+Woodsauthor=B.+K.+Kobilkaauthor=G.+Skiniotisauthor=R.+J.+Lefkowitz&title=Visualization+of+arrestin+recruitment+by+a+G-protein-coupled+receptor&doi=10.1038%2Fnature13430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Visualization of arrestin recruitment by a G-protein-coupled receptor</span></div><div class="casAuthors">Shukla, Arun K.; Westfield, Gerwin H.; Xiao, Kunhong; Reis, Rosana I.; Huang, Li-Yin; Tripathi-Shukla, Prachi; Qian, Jiang; Li, Sheng; Blanc, Adi; Oleskie, Austin N.; Dosey, Anne M.; Su, Min; Liang, Cui-Rong; Gu, Ling-Ling; Shan, Jin-Ming; Chen, Xin; Hanna, Rachel; Choi, Minjung; Yao, Xiao Jie; Klink, Bjoern U.; Kahsai, Alem W.; Sidhu, Sachdev S.; Koide, Shohei; Penczek, Pawel A.; Kossiakoff, Anthony A.; Woods Jr, Virgil L.; Kobilka, Brian K.; Skiniotis, Georgios; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">7513</span>),
    <span class="NLM_cas:pages">218-222</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are critically regulated by β-arrestins, which not only desensitize G-protein signaling but also initiate a G-protein-independent wave of signaling.  A recent surge of structural data on a no. of GPCRs, including the β2 adrenergic receptor (β2AR)-G-protein complex, has provided novel insights into the structural basis of receptor activation.  However, complementary information has been lacking on the recruitment of β-arrestins to activated GPCRs, primarily owing to challenges in obtaining stable receptor-β-arrestin complexes for structural studies.  Here the authors devised a strategy for forming and purifying a functional human β2AR-β-arrestin-1 complex that allowed the authors to visualize its architecture by single-particle neg.-stain electron microscopy and to characterize the interactions between β2AR and β-arrestin 1 using hydrogen-deuterium exchange mass spectrometry (HDX-MS) and chem. crosslinking.  Electron microscopy two-dimensional avs. and three-dimensional reconstructions reveal bimodal binding of β-arrestin 1 to the β2AR, involving two sep. sets of interactions, one with the phosphorylated C-terminus of the receptor and the other with its seven-transmembrane core.  Areas of reduced HDX together with identification of crosslinked residues suggest engagement of the finger loop of β-arrestin 1 with the seven-transmembrane core of the receptor.  In contrast, focal areas of raised HDX levels indicate regions of increased dynamics in both the N and C domains of β-arrestin 1 when coupled to the β2AR.  A mol. model of the β2AR-β-arrestin signaling complex was made by docking activated β-arrestin 1 and β2AR crystal structures into the electron microscopy map densities with constraints provided by HDX-MS and crosslinking, allowing the authors to obtain valuable insights into the overall architecture of a receptor-arrestin complex.  The dynamic and structural information presented here provides a framework for better understanding the basis of GPCR regulation by arrestins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGW0zJyKs9qbVg90H21EOLACvtfcHk0lh9jJxFqGOaUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGntb%252FO&md5=c88e93c104ccb4ed30a1687cd9a54aca</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fnature13430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13430%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DA.%26aulast%3DWestfield%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DK.%26aulast%3DReis%26aufirst%3DR.%2BI.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DTripathi-Shukla%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DBlanc%26aufirst%3DA.%26aulast%3DOleskie%26aufirst%3DA.%2BN.%26aulast%3DDosey%26aufirst%3DA.%2BM.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DC.%2BR.%26aulast%3DGu%26aufirst%3DL.%2BL.%26aulast%3DShan%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHanna%26aufirst%3DR.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DX.%2BJ.%26aulast%3DKlink%26aufirst%3DB.%2BU.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DSidhu%26aufirst%3DS.%2BS.%26aulast%3DKoide%26aufirst%3DS.%26aulast%3DPenczek%26aufirst%3DP.%2BA.%26aulast%3DKossiakoff%26aufirst%3DA.%2BA.%26aulast%3DWoods%26aufirst%3DV.%2BL.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DSkiniotis%26aufirst%3DG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DVisualization%2520of%2520arrestin%2520recruitment%2520by%2520a%2520G-protein-coupled%2520receptor%26jtitle%3DNature%26date%3D2014%26volume%3D512%26spage%3D218%26epage%3D222%26doi%3D10.1038%2Fnature13430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">House, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovato, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a new intravenous β<sub>2</sub>-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1273</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2015.08.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2015.08.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26324315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC287nvFGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2015&pages=1268-1273&author=S.+L.+Houseauthor=K.+Matsudaauthor=G.+O%E2%80%99Brienauthor=M.+Makhayauthor=Y.+Iwakiauthor=I.+Fergusonauthor=L.+M.+Lovatoauthor=L.+M.+Lewis&title=Efficacy+of+a+new+intravenous+%CE%B22-adrenergic+agonist+%28bedoradrine%2C+MN-221%29+for+patients+with+an+acute+exacerbation+of+asthma&doi=10.1016%2Fj.rmed.2015.08.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma</span></div><div class="casAuthors">House Stacey L; Matsuda Kazuko; O'Brien Geoffrey; Makhay Malath; Iwaki Yuichi; Ferguson Ian; Lewis Lawrence M; Lovato Luis M</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1268-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Many patients with acute exacerbation of asthma are non-responders to inhaled β-adrenergic agonists.  The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy.  METHODS:  Patients (N = 167) received standard therapy and were randomized to either bedoradrine (1200 μg) or placebo.  Safety and efficacy parameters were monitored hourly for 3 h, followed by a 24-h follow-up visit and an 8-day follow-up phone call.  Change in %FEV1 from baseline to Hour 3 was the primary outcome.  Secondary outcome measures included change in %FEV1 at 1 and 2 h, change in dyspnea score at 1, 2, and 3 h, treatment failure rate, defined as a combination of hospitalization on the index visit or return to the emergency department within 1 week, and safety monitoring.  RESULTS:  There was no significant difference in %FEV1 at 3 h between the 2 groups.  The dyspnea scores were significantly improved for patients treated with bedoradrine compared to placebo (AUC0-2 hP < 0.005, AUC0-3 hP < 0.05).  The safety profile for those treated with bedoradrine was consistent with the known mechanism of action of β-adrenergic agonists, and included both cardiovascular and metabolic effects.  CONCLUSIONS:  Intravenous bedoradrine, in addition to standard therapy, did not significantly increase %FEV1 at 3 h, but it was associated with significantly improved dyspnea scores.  TRIAL REGISTRATION:  Clinicaltrials.gov; study name: MN-221-CL-007, registration number: NCT00838591; www.clinical trials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjVe9fFhSfDxKDYG3bNImrfW6udTcc2ebXafG9NMqtrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nvFGhtQ%253D%253D&md5=a4c830e39b04b3997888c24ce7932f9d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2015.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2015.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DHouse%26aufirst%3DS.%2BL.%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DG.%26aulast%3DMakhay%26aufirst%3DM.%26aulast%3DIwaki%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DI.%26aulast%3DLovato%26aufirst%3DL.%2BM.%26aulast%3DLewis%26aufirst%3DL.%2BM.%26atitle%3DEfficacy%2520of%2520a%2520new%2520intravenous%2520%25CE%25B22-adrenergic%2520agonist%2520%2528bedoradrine%252C%2520MN-221%2529%2520for%2520patients%2520with%2520an%2520acute%2520exacerbation%2520of%2520asthma%26jtitle%3DRespir.%2520Med.%26date%3D2015%26volume%3D109%26spage%3D1268%26epage%3D1273%26doi%3D10.1016%2Fj.rmed.2015.08.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawarabayashi, T.</span></span> <span> </span><span class="NLM_article-title">Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant</span>. <i>J. Obstet. Gynaecol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1111/j.1447-0756.2008.01001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1447-0756.2008.01001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19527375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslOlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=405-413&author=Y.+Inoueauthor=T.+Yoshizatoauthor=T.+Kawarabayashi&title=Investigation+of+beta%282%29-adrenoceptor+subtype+selectivity+and+organ+specificity+for+bedoradrine+%28KUR-1246%29%2C+a+novel+tocolytic+beta-adrenergic+receptor+stimulant&doi=10.1111%2Fj.1447-0756.2008.01001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of β2-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant</span></div><div class="casAuthors">Inoue, Yoshihito; Yoshizato, Toshiyuki; Kawarabayashi, Tatsuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Obstetrics and Gynaecology Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">JOGRFD</span>;
        ISSN:<span class="NLM_cas:issn">1341-8076</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the beta-adrenergic receptor (β-AR) selectivity, organ specificity and efficacy of delaying the onset of spontaneous delivery of bedoradrine (KUR-1246), a novel uterine relaxant.  β-AR selectivity was evaluated in terms of the amt. of cyclic adenosine monophosphate produced by bedoradrine, ritodrine and isoprenaline in Chinese hamster ovary cells expressing human β1-, β2-AR or β3-AR.  Inhibition of contractions of the atrium, trachea and proximal colon by bedoradrine were compared with those of the uterus in pregnant rats using an organ bath method.  Finally, the delaying effect of bedoradrine on spontaneous labor was evaluated by an in vivo study using term pregnant rats.  EC50 values of bedoradrine for cyclic adenosine monophosphate prodn. in Chinese hamster ovary cells via β1-, β2- and β3-AR were 2400 ± 30, 2.9 ± 0.10 and 363 ± 3 nmol/L, resp., indicating that bedoradrine had 832- and 126-fold higher selectivity for β2-AR than for β1- and β3-AR.  EC50 values of bedoradrine for the uterus, atrium, trachea and proximal colon were 1.01 ± 0.27, 2300 ± 356, 1610 ± 299 and 219 ± 23.5 nmol/L, resp.  Thus, bedoradrine was 2280-, 1590- and 217-fold more specific for the uterus than for the atrium, trachea and proximal colon, resp.  Bedoradrine delayed the spontaneous delivery of 21-day-pregnant rats in a dose-dependent manner.  Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice because it has better selectivity for β2-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqVMqHhJGTjLVg90H21EOLACvtfcHk0lh9jJxFqGOaUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslOlsbY%253D&md5=409d9853d2ce96be232af88d5f2bcc94</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1111%2Fj.1447-0756.2008.01001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1447-0756.2008.01001.x%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DYoshizato%26aufirst%3DT.%26aulast%3DKawarabayashi%26aufirst%3DT.%26atitle%3DInvestigation%2520of%2520beta%25282%2529-adrenoceptor%2520subtype%2520selectivity%2520and%2520organ%2520specificity%2520for%2520bedoradrine%2520%2528KUR-1246%2529%252C%2520a%2520novel%2520tocolytic%2520beta-adrenergic%2520receptor%2520stimulant%26jtitle%3DJ.%2520Obstet.%2520Gynaecol.%2520Res.%26date%3D2009%26volume%3D35%26spage%3D405%26epage%3D413%26doi%3D10.1111%2Fj.1447-0756.2008.01001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion</span>. <i>J. Asthma</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1071</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.3109/02770903.2012.729631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3109%2F02770903.2012.729631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23094708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FnvVWhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=1071-1078&author=K.+Matsudaauthor=M.+Makhayauthor=K.+Johnsonauthor=Y.+Iwaki&title=Evaluation+of+bedoradrine+sulfate+%28MN-221%29%2C+a+novel%2C+highly+selective+beta2-adrenergic+receptor+agonist+for+the+treatment+of+asthma+via+intravenous+infusion&doi=10.3109%2F02770903.2012.729631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion</span></div><div class="casAuthors">Matsuda Kazuko; Makhay Malath; Johnson Kirk; Iwaki Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of asthma : official journal of the Association for the Care of Asthma</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1071-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The number of hospitalizations or deaths due to asthma, most of which result from acute exacerbations of asthma, has remained the same for the past 20 years.  MN-221 (bedoradrine sulfate) is a novel, highly selective beta2- (β2-) adrenergic agonist administered via intravenous (IV) infusion in development for the treatment for acute exacerbation of asthma.  OBJECTIVES:  Trial MN-221-CL-004 assessed the safety profile and preliminary efficacy of MN-221 in escalating doses in patients with stable mild-to-moderate asthma.  Study MN-221-CL-005 assessed the safety profile and preliminary efficacy of MN-221 in patients with stable moderate-to-severe asthma when given as a fixed dose over 1- or 2- hr infusion.  METHODS:  Two randomized, placebo-controlled clinical trials (n = 40) were performed to evaluate the pharmacokinetic (PK) and clinical effects of a novel, highly selective β2-agonist, MN-221, via IV infusion.  Safety evaluations included vital signs, adverse events (AEs), clinical laboratory parameters, and electrocardiogram results.  Efficacy evaluation included measurement of forced expiratory volume in 1 second (FEV) a1nd PK parameters were additionally monitored.  The study was reviewed and approved by the Institutional Review Board at each site.  RESULTS:  Adverse effects were mild or moderate and there were no serious AEs or deaths during the studies.  The most frequently reported AEs were tremor, hypokalemia, and headache.  There were no consistent dose-dependent effects of MN-221 on any safety parameters, with the exception of heart rate, which was not considered to be clinically significant and did not require any treatment.  Moderate hypokalemia occurred once in one subject in the MN-221-CL-004 study and twice in one subject in the MN-221-CL-005 study and were transient and returned to normal range following single oral potassium chloride treatments.  PK assessments indicated a linear response in MN-221 plasma concentrations for the doses evaluated.  Dose escalation results showed that mean changes in FEV1 from pre-infusion were significantly greater than placebo and an overall dose response was statistically significant (p < .0001).  Post-infusion FEV1 improvements appeared to plateau at the 30 μg/min dose level despite a higher peak plasma concentration at 60 μg/min.  Dose-rate escalation results demonstrated greater mean increases in change in FEV1 compared to the placebo group with the largest increase associated with the higher MN-221 dose rate and peak plasma concentration.  CONCLUSIONS:  The safety profile of MN-221 and evidence of dose- and plasma-concentration-related bronchodilation supports further clinical development and suggests the potential for clinical benefit without increased clinical risk, particularly for patients where inhaled or nebulized therapy is not adequate or possible.  Trial registry name and registration number:Name: MN-221-CL-005Number: NCT00679263.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcSwT0HwXjfpw7prLlxLOzfW6udTcc2eaJ1cOTPNpt4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FnvVWhtQ%253D%253D&md5=b6e6845b35ed81ffca47b671279e8016</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.3109%2F02770903.2012.729631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02770903.2012.729631%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DMakhay%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DIwaki%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520bedoradrine%2520sulfate%2520%2528MN-221%2529%252C%2520a%2520novel%252C%2520highly%2520selective%2520beta2-adrenergic%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520asthma%2520via%2520intravenous%2520infusion%26jtitle%3DJ.%2520Asthma%26date%3D2012%26volume%3D49%26spage%3D1071%26epage%3D1078%26doi%3D10.3109%2F02770903.2012.729631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Angelats, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viñals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Alba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beleta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.193284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.112.193284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22588259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=497-509&author=M.+Apariciauthor=M.+G%C3%B3mez-Angelatsauthor=D.+Vilellaauthor=R.+Otalauthor=C.+Carcasonaauthor=M.+Vi%C3%B1alsauthor=I.+Ramosauthor=A.+Gavald%C3%A0author=J.+De+Albaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=C.+Puigauthor=H.+Ryderauthor=J.+Beletaauthor=M.+Miralpeix&title=Pharmacological+characterization+of+abediterol%2C+a+novel+inhaled+%CE%B2%282%29-adrenoceptor+agonist+with+long+duration+of+action+and+a+favorable+safety+profile+in+preclinical+models&doi=10.1124%2Fjpet.112.193284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span></div><div class="casAuthors">Aparici, Monica; Gomez-Angelats, Mireia; Vilella, Dolors; Otal, Raquel; Carcasona, Carla; Vinals, Marisa; Ramos, Israel; Gavalda, Amadeu; De Alba, Jorge; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Puig, Carlos; Ryder, Hamish; Beleta, Jorge; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Abediterol is a novel potent, long-acting inhaled β2-adrenoceptor agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.  Abediterol shows subnanomolar affinity for the human β2-adrenoceptor and a functional selectivity over β1-adrenoceptors higher than that of formoterol and indacaterol in both a cellular model with overexpressed human receptors and isolated guinea pig tissue.  Abediterol is a full agonist at the human β2-adrenoceptor (Emax = 91 ± 5% of the maximal effect of isoprenaline).  The potency and onset of action that abediterol shows in isolated human bronchi (EC50 = 1.9 ± 0.4 nM; t1/2 onset = 7-10 min) is not significantly different from that of formoterol, but its duration of action (t1/2 ∼ 690 min) is similar to that of indacaterol.  Nebulized abediterol inhibits acetylcholine-induced bronchoconstriction in guinea pigs in a concn.-dependent manner, with higher potency and longer duration of action (t1/2 = 36 h) than salmeterol (t1/2 = 6 h) and formoterol (t1/2 = 4 h) and similar duration of action to indacaterol up to 48 h.  In dogs, the bronchoprotective effect of abediterol is more sustained than that of salmeterol and indacaterol at doses without effects on heart rate, thus showing a greater safety margin (defined as the ratio of dose increasing heart rate by 5% and dose inhibiting bronchospasm by 50%) than salmeterol, formoterol, and indacaterol (5.6 vs. 3.3, 2.2, and 0.3, resp.).  In conclusion, our results suggest that abediterol has a preclin. profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsT0Jt09WvbVg90H21EOLACvtfcHk0ljmJyZFa9K4Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK&md5=a102a6455f01c296d2beda412fa527c0</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.193284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.193284%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Angelats%26aufirst%3DM.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520abediterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B2%25282%2529-adrenoceptor%2520agonist%2520with%2520long%2520duration%2520of%2520action%2520and%2520a%2520favorable%2520safety%2520profile%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D497%26epage%3D509%26doi%3D10.1124%2Fjpet.112.193284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miquel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e00356</span> <span class="refDoi"> DOI: 10.1002/prp2.356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fprp2.356" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&author=J.+Beierauthor=R.+Fuhrauthor=B.+Seoaneauthor=E.+Massanaauthor=G.+de+Miquelauthor=H.+Pujolauthor=S.+Ruiz&title=Efficacy%2C+safety%2C+and+tolerability+of+once-daily+abediterol+in+patients+with+stable%2C+persistent+asthma%3A+a+Phase+II%2C+randomized%2C+7-day%2C+crossover+study&doi=10.1002%2Fprp2.356"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1002%2Fprp2.356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.356%26sid%3Dliteratum%253Aachs%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3DMassana%26aufirst%3DE.%26aulast%3Dde%2BMiquel%26aufirst%3DG.%26aulast%3DPujol%26aufirst%3DH.%26aulast%3DRuiz%26aufirst%3DS.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520once-daily%2520abediterol%2520in%2520patients%2520with%2520stable%252C%2520persistent%2520asthma%253A%2520a%2520Phase%2520II%252C%2520randomized%252C%25207-day%252C%2520crossover%2520study%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2017%26volume%3D5%26doi%3D10.1002%2Fprp2.356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astbury, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miquel, G.</span></span> <span> </span><span class="NLM_article-title">Abediterol, a novel long-acting β<sub>2</sub>-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD</span>. <i>BMC Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">102</span>, <span class="refDoi"> DOI: 10.1186/s12890-016-0266-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2Fs12890-016-0266-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27439370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkt1OgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=102&author=J.+Beierauthor=H.+Pujolauthor=B.+Seoaneauthor=E.+Jimenezauthor=C.+Astburyauthor=E.+Massanaauthor=S.+Ruizauthor=G.+de+Miquel&title=Abediterol%2C+a+novel+long-acting+%CE%B22-agonist%3A+bronchodilation%2C+safety%2C+tolerability+and+pharmacokinetic+results+from+a+single-dose%2C+dose-ranging%2C+active-comparator+study+in+patients+with+COPD&doi=10.1186%2Fs12890-016-0266-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD</span></div><div class="casAuthors">Beier, Jutta; Pujol, Helena; Seoane, Beatriz; Jimenez, Eulalia; Astbury, Carol; Massana, Eric; Ruiz, Sandrine; de Miquel, Gonzalo</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102/1-102/13</span>CODEN:
                <span class="NLM_cas:coden">BPMMBB</span>;
        ISSN:<span class="NLM_cas:issn">1471-2466</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent.  This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD.  Methods: Seventy patients (aged <40 years, Global initiative for chronic Obstructive Lung Disease Stage II/III) were randomised (1:1:1:1:1:1) to single doses of abediterol 0.625, 2.5, 5 or 10 μg, indacaterol 150 μg or placebo.  Spirometry was performed up to 36 h post-dose.  Pharmacokinetics were assessed in a subset of patients (N = 20).  Safety and tolerability were evaluated throughout the study.  Results: Abediterol (all doses) significantly improved change from baseline in trough forced expiratory vol. in 1 s (FEV1) compared with placebo (0.102, 0.203, 0.233 and 0.259 L for abediterol 0.625, 2.5, 5 and 10 μg, resp.; all p < 0.0001; primary endpoint).  Abediterol 2.5, 5 and 10 μg significantly improved trough FEV1 compared with indacaterol 150 μg (0.092, 0.122 and 0.148 L, resp.; all p < 0.0001).  Improvements in bronchodilation were maintained at all time points post-dose vs. placebo (all abediterol doses) and from 15 or 30 min post-dose vs. indacaterol 150 μg with abediterol 2.5, 5 and 10 μg (all p < 0.05).  Abediterol had low systemic exposure; incidence of treatment-emergent adverse events was similar between treatment groups.  Conclusions: All doses of abediterol (0.625-10 μg) provided clin. and statistically significant, dose-dependent improvements in bronchodilation vs. placebo, and abediterol 2.5, 5 and 10 μg gave significant improvements vs. indacaterol.  All doses of abediterol were safe and well tolerated in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppi04RHvhOi7Vg90H21EOLACvtfcHk0lgheXkXAehGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkt1OgsLk%253D&md5=212c479f94a86c177687661b09fcf5b6</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1186%2Fs12890-016-0266-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12890-016-0266-5%26sid%3Dliteratum%253Aachs%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DPujol%26aufirst%3DH.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DAstbury%26aufirst%3DC.%26aulast%3DMassana%26aufirst%3DE.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3Dde%2BMiquel%26aufirst%3DG.%26atitle%3DAbediterol%252C%2520a%2520novel%2520long-acting%2520%25CE%25B22-agonist%253A%2520bronchodilation%252C%2520safety%252C%2520tolerability%2520and%2520pharmacokinetic%2520results%2520from%2520a%2520single-dose%252C%2520dose-ranging%252C%2520active-comparator%2520study%2520in%2520patients%2520with%2520COPD%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2016%26volume%3D16%26spage%3D102%26doi%3D10.1186%2Fs12890-016-0266-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span> <span> </span><span class="NLM_article-title">Trachea relaxing effects and β<sub>2</sub>-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1248/bpb.26.323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1248%2Fbpb.26.323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12612441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=323-328&author=L.+L.+Ganauthor=M.+W.+Wangauthor=M.+S.+Chengauthor=L.+Pan&title=Trachea+relaxing+effects+and+%CE%B22-selectivity+of+SPFF%2C+a+newly+developed+bronchodilating+agent%2C+in+guinea+pigs+and+rabbits&doi=10.1248%2Fbpb.26.323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Trachea relaxing effects and β2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span></div><div class="casAuthors">Gan, Le-Ling; Wang, Min-Wei; Cheng, Mao-Sheng; Pan, Li</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">In this paper we evaluated the bronchodilator effects of SPFF [2-(4-amino-3-chloro-5-trifluomethyl-phenyl)- 2-tert-butylamino-ethanol chloride], a newly synthesized β2 adrenergic agonist in guinea pigs and rabbits, in comparison with other β2 adrenergic agonists, isoprenaline or salbutamol.  We studied in vitro the bronchodilator effects of SPFF and isoprenaline on isolated guinea pig trachea strips with or without the precontraction of bronchocontractors (acetylcholine and histamine).  The pos. chronotropic effects of SPFF and isoprenaline on isolated guinea pig left atria were also tested in vitro.  Potency values (pD2, pA2 or ED50) were detd. from the cumulative concn.-response curves.  The results showed that SPFF and isoprenaline dose-dependently relaxed the isolated guinea pig trachea strips and the pD2 values of both drugs were 7.66±0.68 and 8.79±0.19, resp.  Moreover, we confirmed that the bronchodilator effect of SPFF was due to the activation of β2 adrenoceptor because this effect was easily antagonized by ICI-118551 (pA2 8.90±0.01), a specific β2 adrenoceptor antagonist.  SPFF also dose-dependently relaxed the isolated guinea pig trachea strip precontraction with acetylcholine or histamine with ED50 values of 10.2±0.7 μM and 550±38.2 nM, resp.  Furthermore, the pos. chronotropic effect of SPFF on isolated guinea pig left atria (pD2 5.41±0.38) was much weaker than that of isoprenaline (pD2 8.75±0.24), which implied that SPFF was more selective to airway β2 adrenoceptor than isoprenaline; the β1/β2 selectivity assay also showed that SPFF was about 162 times more selective to β2 adrenoceptor than isoprenaline.  A radioligand binding expt. using guinea pig lung and cardiac ventricle as β2 and β1 adrenoceptor sources, resp., also demonstrated that SPFF possesses high affinity (27.3 nM) and selectivity (4.6 fold) to β2 adrenoceptors.  The protective effects of SPFF and salbutamol on bronchospasm induced by bronchoconstrictor aerosol in guinea pigs in vivo were investigated, and the Konzett and Rossler expt. in rabbits in vivo was also carried out.  SPFF significantly prolonged the latency time of histamine and acetylcholine induced asphyxiation collapse in guinea pigs: the ED50 value of SPFF i.g. was 0.32±0.05 mg·kg-1 in this expt.  Meanwhile, the ED50 values of salbutamol was 2.37±0.22, which meant that the bronchorelaxation effect of salbutamol was about 6 times less potent than that of SPFF.  The Konzett and Rossler expt. performed in anesthetized rabbit showed that intraduodenal administration of SPFF exerted action of longer duration than salbutamol.  From the results above we suggested that SPFF was a potent, long-acting bronchodilator with relatively higher β2 adrenoceptor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgmv60MqHPLVg90H21EOLACvtfcHk0lgheXkXAehGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D&md5=87227d7e445c13d7b74f1adf69cfaee9</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1248%2Fbpb.26.323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.26.323%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DM.%2BW.%26aulast%3DCheng%26aufirst%3DM.%2BS.%26aulast%3DPan%26aufirst%3DL.%26atitle%3DTrachea%2520relaxing%2520effects%2520and%2520%25CE%25B22-selectivity%2520of%2520SPFF%252C%2520a%2520newly%2520developed%2520bronchodilating%2520agent%252C%2520in%2520guinea%2520pigs%2520and%2520rabbits%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2003%26volume%3D26%26spage%3D323%26epage%3D328%26doi%3D10.1248%2Fbpb.26.323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span> <span> </span><span class="NLM_article-title">Randomized, multicenter clinical study of tratinterol hydrochloride tablets for the treatment of bronchial asthma</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1258</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2015.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.clinthera.2015.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25857594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsV2gtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2015&pages=1248-1258&author=L.+Kongauthor=J.+Liuauthor=G.+Guauthor=J.+Huoauthor=Z.+Maauthor=Y.+Shaoauthor=S.+Sunauthor=Y.+Yuanauthor=S.+Zhuauthor=C.+Yaoauthor=G.+Duauthor=M.+Chengauthor=J.+Kang&title=Randomized%2C+multicenter+clinical+study+of+tratinterol+hydrochloride+tablets+for+the+treatment+of+bronchial+asthma&doi=10.1016%2Fj.clinthera.2015.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, Multicenter Clinical Study of Tratinterol Hydrochloride Tablets for the Treatment of Bronchial Asthma</span></div><div class="casAuthors">Kong, Lingfei; Liu, Jiaming; Gu, Guozhong; Huo, Jianmin; Ma, Zhongsen; Shao, Yuxia; Sun, Shenghua; Yuan, Yuan; Zhu, Sainan; Yao, Chen; Du, Guijie; Cheng, Maosheng; Kang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1248-1258</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aim of this study was to det. the efficacy and safety profile of tratinterol hydrochloride tablets in the treatment of bronchial asthma.  This multicenter, randomized, double-blind clin. research study was completed at 6 centers in the People's Republic of China from March 2009 to June 2010, and a randomized trial of procaterol hydrochloride tablets produced by Otsuka Pharmaceutical Co Ltd was conducted.  The study was approved by the Medical Ethics Committee of the First Hospital of China Medical University.  The clin. trial registration no. is 2007L04263.  A total of 223 patients were selected for this study, with 112 patients in the treatment group and 111 in the control group.  The lung function of the 2 groups after treatment significantly increased in all (P < 0.05); however, there was no significant difference in the changes between the 2 groups (P > 0.05).  The occurrence of related adverse events at varying degrees in the control group was higher than in the treatment group.  It is safe and effective to use tratinterol hydrochloride tablets to treat bronchial asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTP1rG3e18jLVg90H21EOLACvtfcHk0lgheXkXAehGZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsV2gtLc%253D&md5=bdfd80da5133573e5d0ede9a30559c75</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2015.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2015.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DG.%26aulast%3DHuo%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DJ.%26atitle%3DRandomized%252C%2520multicenter%2520clinical%2520study%2520of%2520tratinterol%2520hydrochloride%2520tablets%2520for%2520the%2520treatment%2520of%2520bronchial%2520asthma%26jtitle%3DClin.%2520Ther.%26date%3D2015%26volume%3D37%26spage%3D1248%26epage%3D1258%26doi%3D10.1016%2Fj.clinthera.2015.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span> <span> </span><span class="NLM_article-title">Assessment of a novel β<sub>2</sub>-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2011.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.tiv.2011.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21466844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2ntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1033-1038&author=K.+Jiangauthor=K.+Liauthor=F.+Qinauthor=X.+Luauthor=F.+Li&title=Assessment+of+a+novel+%CE%B22-adrenoceptor+agonist%2C+trantinterol%2C+for+interference+with+human+liver+cytochrome+P450+enzymes+activities&doi=10.1016%2Fj.tiv.2011.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities</span></div><div class="casAuthors">Jiang, Kun; Li, Kunjie; Qin, Feng; Lu, Xiumei; Li, Famei</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1033-1038</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The effect of a novel β2-adrenoceptor agonist, trantinterol on the activities of cytochrome P 450 (CYP450) was investigated with human liver microsomes and human cryohepatocytes to assess the potential for drug-drug interactions.  The ability of trantinterol to inhibit CYP450 activities was evaluated in vitro in human liver microsomes.  Trantinterol did not inhibit CYP2C19, CYP2D6, and CYP3A4/5 (IC 50 > 100 μM).  It acted as a weak inhibitor of CYP1A2 and CYP2C9 with IC 50 of 70.8 and 81.9 μM, resp.  No time-dependent inhibitions were obsd. in the present research.  To evaluate CYP450 induction, human cryohepatocytes (n = 3) were used and treated once daily for 3 days with trantinterol (0.01, 0.1, and 1 ng/mL), after which CYP450 activities were measured.  At concn. of 0.01 ng/mL, which is close to the C max at maximal recommended doses (50 μg), trantinterol was about 8% as effective as omeprazole (CYP1A2 inducer) only with donor 2.  At concn. of 1 ng/mL, trantinterol was about 3.6% as effective as rifampin (CYP3A4/5 inducer).  These in vitro results indicated that, at pharmacol. relevant concns., trantinterol will not produce clin. significant CYP450 inhibition or induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6DwyZziP4hbVg90H21EOLACvtfcHk0lhlKZP5EYlA-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2ntLs%253D&md5=fec5958fc693ae3d54cbcd8e25f02c70</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2011.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2011.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26atitle%3DAssessment%2520of%2520a%2520novel%2520%25CE%25B22-adrenoceptor%2520agonist%252C%2520trantinterol%252C%2520for%2520interference%2520with%2520human%2520liver%2520cytochrome%2520P450%2520enzymes%2520activities%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2011%26volume%3D25%26spage%3D1033%26epage%3D1038%26doi%3D10.1016%2Fj.tiv.2011.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggadike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchers, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edney, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLay, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteith, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2280</span>– <span class="NLM_lpage">2288</span>, <span class="refDoi"> DOI: 10.1021/jm801016j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801016j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1GlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2280-2288&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=D.+D.+Edneyauthor=R.+N.+Fieldauthor=A.+J.+Fordauthor=S.+B.+Guntripauthor=B.+E.+Lookerauthor=I.+M.+McLayauthor=M.+J.+Monteithauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=S.+A.+Richardsauthor=R.+Sasseauthor=C.+E.+Smith&title=Synthesis+and+structure-activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+arylsulfonamide+groups&doi=10.1021%2Fjm801016j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, Victoria J.; Bevan, Nicola J.; Biggadike, Keith; Butchers, Peter R.; Coe, Diane M.; Conroy, Richard; Edney, Dean D.; Field, Rita N.; Ford, Alison J.; Guntrip, Stephen B.; Looker, Brian E.; McLay, Iain M.; Monteith, Michael J.; Morrison, Valerie S.; Mutch, Peter J.; Richards, Stephen A.; Sasse, Rosemary; Smith, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2280-2288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of saligenin alkoxyalkylphenylsulfonamide β2 adrenoceptor agonists were prepd. by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection.  The meta-substituted primary sulfonamide was more potent than the para- and the ortho-analogs.  Primary sulfonamides were more potent than the secondary and tertiary analogs.  The onset and duration of action in vitro of selected compds. was assessed on isolated superfused guinea pig trachea.  Sulfonamide I [X = (CH2)n, n = 4] had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus.  Furthermore, I was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation.  Cryst. salts of I were identified that had suitable properties for inhaled administration.  A proposed binding mode for I to the β2-receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-aSFpSwy7zrVg90H21EOLACvtfcHk0lhlKZP5EYlA-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1GlsL8%253D&md5=b057a3592d919da24d7211a23bf214fb</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fjm801016j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801016j%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEdney%26aufirst%3DD.%2BD.%26aulast%3DField%26aufirst%3DR.%2BN.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMonteith%26aufirst%3DM.%2BJ.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DRichards%26aufirst%3DS.%2BA.%26aulast%3DSasse%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520arylsulfonamide%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2280%26epage%3D2288%26doi%3D10.1021%2Fjm801016j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span> <span> </span><span class="NLM_article-title">The discovery of adamantyl-derived, inhaled, long acting beta2-adrenoreceptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2008.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18226900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlajtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1280-1283&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=K.+Jamesauthor=R.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=M.+Trevethickauthor=R.+Webster&title=The+discovery+of+adamantyl-derived%2C+inhaled%2C+long+acting+beta2-adrenoreceptor+agonists&doi=10.1016%2Fj.bmcl.2008.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of adamantyl-derived, inhaled, long acting β2-adrenoreceptor agonists</span></div><div class="casAuthors">Brown, Alan D.; Bunnage, Mark E.; Glossop, Paul A.; James, Kim; Jones, Rhys; Lane, Charlotte A. L.; Lewthwaite, Russell A.; Mantell, Simon; Perros-Huguet, Christelle; Price, David A.; Trevethick, Mike; Webster, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1280-1283</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design and profile of a series of adamantyl-contg. long acting β2-adrenoreceptor agonists are described.  An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacol. profile when assessed using a guinea pig trachea tissue model.  A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8PigIxSWqNrVg90H21EOLACvtfcHk0lhlKZP5EYlA-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlajtrc%253D&md5=b483e4c9001fd184c934ea6f863187db</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DTrevethick%26aufirst%3DM.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520adamantyl-derived%252C%2520inhaled%252C%2520long%2520acting%2520beta2-adrenoreceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1280%26epage%3D1283%26doi%3D10.1016%2Fj.bmcl.2008.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span> <span> </span><span class="NLM_article-title">The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6188</span>– <span class="NLM_lpage">6191</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2007.09.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17897826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6188-6191&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=M.+Holbrookauthor=R.+D.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=R.+Webster&title=The+discovery+of+indole-derived+long+acting+beta2-adrenoceptor+agonists+for+the+treatment+of+asthma+and+COPD&doi=10.1016%2Fj.bmcl.2007.09.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of indole-derived long acting β2-adrenoceptor agonists for the treatment of asthma and COPD</span></div><div class="casAuthors">Brown, Alan D.; Bunnage, Mark E.; Glossop, Paul A.; Holbrook, Mark; Jones, Rhys D.; Lane, Charlotte A. L.; Lewthwaite, Russell A.; Mantell, Simon; Perros-Huguet, Christelle; Price, David A.; Webster, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6188-6191</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design and profile of a series of indole contg. long acting β2-adrenoceptor agonists is described.  Evaluation of these analogs using an in vitro guinea pig trachea tissue model demonstrates that analogs such as I within this series have salmeterol-like duration of action with potential for long duration of action in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrci7Y0aY4eybVg90H21EOLACvtfcHk0lhAhsqi1RBWIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zN&md5=4ae7111899e82d2506f88152171eec10</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.031%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DHolbrook%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%2BD.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520indole-derived%2520long%2520acting%2520beta2-adrenoceptor%2520agonists%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6188%26epage%3D6191%26doi%3D10.1016%2Fj.bmcl.2007.09.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, F. J.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β<sub>2</sub>-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6640</span>– <span class="NLM_lpage">6652</span>, <span class="refDoi"> DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup</span></div><div class="casAuthors">Glossop, Paul A.; Lane, Charlotte A. L.; Price, David A.; Bunnage, Mark E.; Lewthwaite, Russell A.; James, Kim; Brown, Alan D.; Yeadon, Michael; Perros-Huguet, Christelle; Trevethick, Michael A.; Clarke, Nicholas P.; Webster, Robert; Jones, Rhys M.; Burrows, Jane L.; Feeder, Neil; Taylor, Stefan C. J.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6640-6652</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of potent and selective sulfonamide derived β2-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease.  Analogs from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state.  Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events.  Compd. 38 (PF-610355) is identified as a clin. candidate from this series, with in vivo duration of action studies confirming its potential for once-daily use in humans.  Compd. 38 is currently in advanced phase II clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGaBcfoYeu7Vg90H21EOLACvtfcHk0lhAhsqi1RBWIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ&md5=34cf266aa0f796ee5ec370369c726f6e</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R.</span>; <span class="NLM_string-name">Huebner, H.</span>; <span class="NLM_string-name">Shonberg, J.</span></span> <span> </span><span class="NLM_article-title">Beta-2 Selective Adrenergic Receptor Agonists</span>. WO Patent <span class="NLM_patent">2019112913</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+Sunahara&author=H.+Huebner&author=J.+Shonberg&title=Beta-2+Selective+Adrenergic+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSunahara%26aufirst%3DR.%26atitle%3DBeta-2%2520Selective%2520Adrenergic%2520Receptor%2520Agonists%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X. M.</span>; <span class="NLM_string-name">Zhou, W. J.</span>; <span class="NLM_string-name">Liu, Y. F.</span></span> <span> </span><span class="NLM_article-title">Beta2-Adrenergic Receptor Agonist in Rhizoma Curcumae and Application Thereof</span>. CN Patent <span class="NLM_patent">109806254</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.+M.+Liang&author=W.+J.+Zhou&author=Y.+F.+Liu&title=Beta2-Adrenergic+Receptor+Agonist+in+Rhizoma+Curcumae+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%2BM.%26atitle%3DBeta2-Adrenergic%2520Receptor%2520Agonist%2520in%2520Rhizoma%2520Curcumae%2520and%2520Application%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, L.</span>; <span class="NLM_string-name">Jin, T. Y.</span>; <span class="NLM_string-name">Shen, T.</span></span> <span> </span><span class="NLM_article-title">Beta2-AR Exciting and Anti-inflammatory Dual-function Alkaloid and Application Thereof</span>. CN Patent <span class="NLM_patent">107043371</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Xiang&author=T.+Y.+Jin&author=T.+Shen&title=Beta2-AR+Exciting+and+Anti-inflammatory+Dual-function+Alkaloid+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DL.%26atitle%3DBeta2-AR%2520Exciting%2520and%2520Anti-inflammatory%2520Dual-function%2520Alkaloid%2520and%2520Application%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of β<sub>2</sub>-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.ejmech.2018.04.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29751236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt12rs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2018&pages=424-435&author=X.+Geauthor=A.+Y.+Wooauthor=G.+Xingauthor=Y.+Luauthor=Y.+Moauthor=Y.+Zhaoauthor=Y.+Lanauthor=J.+Liauthor=H.+Yanauthor=L.+Panauthor=Y.+Zhangauthor=B.+Linauthor=M.+Cheng&title=Synthesis+and+biological+evaluation+of+%CE%B22-adrenoceptor+agonists+bearing+the+2-amino-2-phenylethanol+scaffold&doi=10.1016%2Fj.ejmech.2018.04.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of β2-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold</span></div><div class="casAuthors">Ge, Xinyue; Woo, Anthony Yiu-Ho; Xing, Gang; Lu, Yali; Mo, Yongmei; Zhao, Ying; Lan, Yi; Li, Jinyan; Yan, Haining; Pan, Li; Zhang, Yuyang; Lin, Bin; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">424-435</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new series of β-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold, compds. I [R = phenethyl, (1H-indol-3-yl)ethyl, 4-(4-phenylbutoxy)butyl, etc.] were synthesized.  Evaluation of the compds. using cell assays and an in-vitro guinea pig trachea relaxation assay showed that compd. I [R = 4-hydroxyphenethyl] had the best pharmacol. profile among all the evaluated compds.  The (S)-isomer of compd. I [R = 4-hydroxyphenethyl] was subsequently found to be the active enantiomer with a promising EC50 value of 1.26nM in stimulating β2-adrenoceptor-mediated cAMP accumulation and a substantially higher selectivity for the β2 than for the β1 subtype.  The putative binding mode of (S)-compd. I [R = 4-hydroxyphenethyl] revealed by mol. docking of the β2-adrenoceptor resembled that in agonist binding.  Taken together, these results showed that S isomer of compd. I [R = 4-hydroxyphenethyl] is a promising compd. worthy of further study for the development of β2-adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuxR7C_XJhsLVg90H21EOLACvtfcHk0lhCFwVHr89B_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt12rs7k%253D&md5=e78c694306c275618485681f0994479c</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DX.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520%25CE%25B22-adrenoceptor%2520agonists%2520bearing%2520the%25202-amino-2-phenylethanol%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D152%26spage%3D424%26epage%3D435%26doi%3D10.1016%2Fj.ejmech.2018.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel β<sub>2</sub>-adrenoceptor agonists</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bioorg.2018.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29751321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFCksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2018&pages=155-162&author=X.+Geauthor=Y.+Moauthor=G.+Xingauthor=L.+Jiauthor=H.+Zhaoauthor=J.+Chenauthor=B.+Heauthor=X.+Chenauthor=R.+Xingauthor=X.+Liauthor=Y.+Zhaoauthor=J.+Liauthor=H.+Yanauthor=A.+Y.+Wooauthor=Y.+Zhangauthor=B.+Linauthor=L.+Panauthor=M.+Cheng&title=Synthesis%2C+biological+evaluation+and+molecular+modeling+of+2-amino-2-phenylethanol+derivatives+as+novel+%CE%B22-adrenoceptor+agonists&doi=10.1016%2Fj.bioorg.2018.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel β2-adrenoceptor agonists</span></div><div class="casAuthors">Ge, Xinyue; Mo, Yongmei; Xing, Gang; Ji, Lei; Zhao, Haiyan; Chen, Jianfang; He, Bin; Chen, Xuyao; Xing, Ruijuan; Li, Xiaoqiang; Zhao, Ying; Li, Jinyan; Yan, Haining; Woo, Anthony Yiu-Ho; Zhang, Yuyang; Lin, Bin; Pan, Li; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-162</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of 2-amino-2-phenylethanol derivs. were developed as β2-adrenoceptor agonists.  Among them, 2-amino-3-fluoro-5-(2-hydroxy-1-(isopropylamino)ethyl)benzonitrile (compd. I) exhibited the highest activity (EC50 = 0.25 nM) in stimulating β2-adrenoceptor-mediated cellular cAMP prodn. with a 763.6-fold selectivity over the β1-adrenoceptor.  The (S)-isomer of I was subsequently found to be 8.5-fold more active than the (R)-isomer.  Mol. docking was performed to det. the putative binding modes of this new class of β2-adrenoceptor agonists.  Taken together, these data show that compd. I is a promising lead compd. worthy of further study for the development of β2-adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUyGy6gy6FTLVg90H21EOLACvtfcHk0lhCFwVHr89B_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFCksLo%253D&md5=ea0b1e2c81c2ef4f70abc61f0c0edc64</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520modeling%2520of%25202-amino-2-phenylethanol%2520derivatives%2520as%2520novel%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D79%26spage%3D155%26epage%3D162%26doi%3D10.1016%2Fj.bioorg.2018.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0lgKfeDGcCxNJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staus, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnaeve, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamerdin, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassoni, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavino, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husemoen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric “beta-blocker” isolated from a DNA-encoded small molecule library</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1708</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620645114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.1620645114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28130548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=1708-1713&author=S.+Ahnauthor=A.+W.+Kahsaiauthor=B.+Paniauthor=Q.+T.+Wangauthor=S.+Zhaoauthor=A.+L.+Wallauthor=R.+T.+Strachanauthor=D.+P.+Stausauthor=L.+M.+Winglerauthor=L.+D.+Sunauthor=J.+Sinnaeveauthor=M.+Choiauthor=T.+Choauthor=T.+T.+Xuauthor=G.+M.+Hansenauthor=M.+B.+Burnettauthor=J.+E.+Lamerdinauthor=D.+L.+Bassoniauthor=B.+J.+Gavinoauthor=G.+Husemoenauthor=E.+K.+Olsenauthor=T.+Franchauthor=S.+Costanziauthor=X.+Chenauthor=R.+J.+Lefkowitz&title=Allosteric+%E2%80%9Cbeta-blocker%E2%80%9D+isolated+from+a+DNA-encoded+small+molecule+library&doi=10.1073%2Fpnas.1620645114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library</span></div><div class="casAuthors">Ahn, Seungkirl; Kahsai, Alem W.; Pani, Biswaranjan; Wang, Qin-Ting; Zhao, Shuai; Wall, Alissa L.; Strachan, Ryan T.; Staus, Dean P.; Wingler, Laura M.; Sun, Lillian D.; Sinnaeve, Justine; Choi, Minjung; Cho, Ted; Xu, Thomas T.; Hansen, Gwenn M.; Burnett, Michael B.; Lamerdin, Jane E.; Bassoni, Daniel L.; Gavino, Bryant J.; Husemoen, Gitte; Olsen, Eva K.; Franch, Thomas; Costanzi, Stefano; Chen, Xin; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1708-1713</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR) has been a model system for understanding regulatory mechanisms of G-protein-coupled receptor (GPCR) actions and plays a significant role in cardiovascular and pulmonary diseases.  Because all known β-adrenergic receptor drugs target the orthosteric binding site of the receptor, we set out to isolate allosteric ligands for this receptor by panning DNA-encoded small-mol. libraries comprising 190 million distinct compds. against purified human β2AR.  Here, we report the discovery of a small-mol. neg. allosteric modulator (antagonist), compd. 15 [([4-((2S)-3-(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide], exhibiting a unique chemotype and low micromolar affinity for the β2AR.  Binding of 15 to the receptor cooperatively enhances orthosteric inverse agonist binding while neg. modulating binding of orthosteric agonists.  Studies with a specific antibody that binds to an intracellular region of the β2AR suggest that 15 binds in proximity to the G-protein binding site on the cytosolic surface of the β2AR.  In cell-signaling studies, 15 inhibits cAMP prodn. through the β2AR, but not that mediated by other Gs-coupled receptors.  Compd. 15 also similarly inhibits β-arrestin recruitment to the activated β2AR.  This study presents an allosteric small-mol. ligand for the β2AR and introduces a broadly applicable method for screening DNA-encoded small-mol. libraries against purified GPCR targets.  Importantly, such an approach could facilitate the discovery of GPCR drugs with tailored allosteric effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE5o7Ib4LtSrVg90H21EOLACvtfcHk0lgKfeDGcCxNJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kjsbs%253D&md5=c42863673c8b91fcb4a2c42c2b253ebc</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620645114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620645114%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%2BT.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DA.%2BL.%26aulast%3DStrachan%26aufirst%3DR.%2BT.%26aulast%3DStaus%26aufirst%3DD.%2BP.%26aulast%3DWingler%26aufirst%3DL.%2BM.%26aulast%3DSun%26aufirst%3DL.%2BD.%26aulast%3DSinnaeve%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DT.%2BT.%26aulast%3DHansen%26aufirst%3DG.%2BM.%26aulast%3DBurnett%26aufirst%3DM.%2BB.%26aulast%3DLamerdin%26aufirst%3DJ.%2BE.%26aulast%3DBassoni%26aufirst%3DD.%2BL.%26aulast%3DGavino%26aufirst%3DB.%2BJ.%26aulast%3DHusemoen%26aufirst%3DG.%26aulast%3DOlsen%26aufirst%3DE.%2BK.%26aulast%3DFranch%26aufirst%3DT.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DAllosteric%2520%25E2%2580%259Cbeta-blocker%25E2%2580%259D%2520isolated%2520from%2520a%2520DNA-encoded%2520small%2520molecule%2520library%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D1708%26epage%3D1713%26doi%3D10.1073%2Fpnas.1620645114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorraca, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Mechanism of intracellular allosteric β<sub>2</sub>AR antagonist revealed by X-ray crystal structure</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>548</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1038/nature23652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature23652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28813418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2017&pages=480-484&author=X.+Liuauthor=S.+Ahnauthor=A.+W.+Kahsaiauthor=K.+C.+Mengauthor=N.+R.+Latorracaauthor=B.+Paniauthor=A.+J.+Venkatakrishnanauthor=A.+Masoudiauthor=W.+I.+Weisauthor=R.+O.+Drorauthor=X.+Chenauthor=R.+J.+Lefkowitzauthor=B.+K.+Kobilka&title=Mechanism+of+intracellular+allosteric+%CE%B22AR+antagonist+revealed+by+X-ray+crystal+structure&doi=10.1038%2Fnature23652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure</span></div><div class="casAuthors">Liu, Xiangyu; Ahn, Seungkirl; Kahsai, Alem W.; Meng, Kai-Cheng; Latorraca, Naomi R.; Pani, Biswaranjan; Venkatakrishnan, A. J.; Masoudi, Ali; Weis, William I.; Dror, Ron O.; Chen, Xin; Lefkowitz, Robert J.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">7668</span>),
    <span class="NLM_cas:pages">480-484</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) pose challenges for drug discovery efforts because of the high degree of structural homol. in the orthosteric pocket, particularly for GPCRs within a single subfamily, such as the nine adrenergic receptors.  Allosteric ligands may bind to less-conserved regions of these receptors and therefore are more likely to be selective.  Unlike orthosteric ligands, which tonically activate or inhibit signaling, allosteric ligands modulate physiol. responses to hormones and neurotransmitters, and may therefore have fewer adverse effects.  The majority of GPCR crystal structures published to date were obtained with receptors bound to orthosteric antagonists, and only a few structures bound to allosteric ligands have been reported.  Cmpd-15 (4-((2S)-3-(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide) is an allosteric modulator of the β2 adrenergic receptor (β2AR) that was recently isolated from a DNA-encoded small-mol. library.  Orthosteric β-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in the world and Cmpd-15 is the first allosteric beta-blocker.  Cmpd-15 exhibits neg. cooperativity with agonists and pos. cooperativity with inverse agonists.  Here the authors present the structure of the β2AR bound to a polyethylene glycol-carboxylic acid deriv. (Cmpd-15PA) of this modulator.  Cmpd-15PA binds to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8.  A comparison of this structure with inactive- and active-state structures of the β2AR reveals the mechanism by which Cmpd-15 modulates agonist binding affinity and signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-_6yRhxeGLVg90H21EOLACvtfcHk0lgKfeDGcCxNJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvI&md5=6e2bf28f5dec63976158fb226c10817e</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fnature23652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23652%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DMeng%26aufirst%3DK.%2BC.%26aulast%3DLatorraca%26aufirst%3DN.%2BR.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DMasoudi%26aufirst%3DA.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DMechanism%2520of%2520intracellular%2520allosteric%2520%25CE%25B22AR%2520antagonist%2520revealed%2520by%2520X-ray%2520crystal%2520structure%26jtitle%3DNature%26date%3D2017%26volume%3D548%26spage%3D480%26epage%3D484%26doi%3D10.1038%2Fnature23652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β<sub>2</sub>-adrenergic receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2320</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmc.2018.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29588128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVCit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2320-2330&author=K.+Mengauthor=P.+Shimauthor=Q.+Wangauthor=S.+Zhaoauthor=T.+Guauthor=A.+W.+Kahsaiauthor=S.+Ahnauthor=X.+Chen&title=Design%2C+synthesis%2C+and+functional+assessment+of+Cmpd-15+derivatives+as+negative+allosteric+modulators+for+the+%CE%B22-adrenergic+receptor&doi=10.1016%2Fj.bmc.2018.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β2-adrenergic receptor</span></div><div class="casAuthors">Meng, Kaicheng; Shim, Paul; Wang, Qingtin; Zhao, Shuai; Gu, Ting; Kahsai, Alem W.; Ahn, Seungkirl; Chen, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2320-2330</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR), a G protein-coupled receptor, is an important therapeutic target.  We recently described Cmpd-15, the first small mol. neg. allosteric modulator (NAM) for the β2AR.  Herein we report in details the design, synthesis and structure-activity relationships (SAR) of seven Cmpd-15 derivs.  Furthermore, we provide in a dose-response paradigm, the details of the effects of these derivs. in modulating agonist-induced β2AR activities (G-protein-mediated cAMP prodn. and β-arrestin recruitment to the receptor) as well as the binding affinity of an orthosteric agonist in radio-ligand competition binding assay.  Our results show that some modifications, including removal of the formamide group in the para-formamido phenylalanine region and bromine in the meta-bromobenzyl methylbenzamide region caused dramatic redn. in the functional activity of Cmpd-15.  These SAR results provide valuable insights into the mechanism of action of the NAM Cmpd-15 as well as the basis for future development of more potent and selective modulators for the β2AR based on the chem. scaffold of Cmpd-15.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBC1jsMFZPQbVg90H21EOLACvtfcHk0litE75gHnAUng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVCit7Y%253D&md5=f6bf973f25925a6de055ae21cb1a646f</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DK.%26aulast%3DShim%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DT.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520functional%2520assessment%2520of%2520Cmpd-15%2520derivatives%2520as%2520negative%2520allosteric%2520modulators%2520for%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D2320%26epage%3D2330%26doi%3D10.1016%2Fj.bmc.2018.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husemoen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestergaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambarat, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simhal, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staus, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule positive allosteric modulators of the β<sub>2</sub>-adrenoceptor isolated from DNA-encoded libraries</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1124/mol.118.111948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fmol.118.111948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29769246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=850-861&author=S.+Ahnauthor=B.+Paniauthor=A.+W.+Kahsaiauthor=E.+K.+Olsenauthor=G.+Husemoenauthor=M.+Vestergaardauthor=L.+Jinauthor=S.+Zhaoauthor=L.+M.+Winglerauthor=P.+K.+Rambaratauthor=R.+K.+Simhalauthor=T.+T.+Xuauthor=L.+D.+Sunauthor=P.+J.+Shimauthor=D.+P.+Stausauthor=L.+Y.+Huangauthor=T.+Franchauthor=X.+Chenauthor=R.+J.+Lefkowitz&title=Small-molecule+positive+allosteric+modulators+of+the+%CE%B22-adrenoceptor+isolated+from+DNA-encoded+libraries&doi=10.1124%2Fmol.118.111948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule positive allosteric modulators of the β2-adrenoceptor isolated from DNA-encoded libraries</span></div><div class="casAuthors">Ahn, Seungkirl; Pani, Biswaranjan; Kahsai, Alem W.; Olsen, Eva K.; Husemoen, Gitte; Vestergaard, Mikkel; Jin, Lei; Zhao, Shuai; Wingler, Laura M.; Rambarat, Paula K.; Simhal, Rishabh K.; Xu, Thomas T.; Sun, Lillian D.; Shim, Paul J.; Staus, Dean P.; Huang, Li-Yin; Franch, Thomas; Chen, Xin; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">850-861</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Conventional drug discovery efforts at the β2-adrenoceptor (β2AR) have led to the development of ligands that bind almost exclusively to the receptor's hormone-binding orthosteric site.  However, targeting the largely unexplored and evolutionarily unique allosteric sites has potential for developing more specific drugs with fewer side effects than orthosteric ligands.  Using our recently developed approach for screening G protein-coupled receptors (GPCRs) with DNA-encoded small-mol. libraries, we have discovered and characterized the first β2AR smallmol. pos. allosteric modulators (PAMs)-compd. (Cmpd)-6 [(R)-N-(4-amino-1-(4-(tert-butyl)phenyl)-4-oxobutan- 2-yl)-5-(N-isopropyl-N-methylsulfamoyl)-2-((4-methoxyphenyl)- thio)benzamide] and its analogs.  We used purified human β2ARs, occupied by a high-affinity agonist, for the affinity-based screening of over 500 million distinct library compds., which yielded Cmpd-6.  It exhibits a low micro-molar affinity for the agonist-occupied β2AR and displays pos. cooperativity with orthosteric agonists, thereby enhancing their binding to the receptor and ability to stabilize its active state.  Cmpd-6 is cooperative with G protein and β-arrestin1 (a.k.a. arrestin2) to stabilize high-affinity, agonist-bound active states of the β2AR and potentiates downstream cAMP prodn. and receptor recruitment of β-arrestin2 (a.k.a. arrestin3).Cmpd-6 is specific for the β2AR compared with the closely related β1AR.  Structure- activity studies of select Cmpd-6 analogs defined the chem. groups that are crit. for its biol. activity.Wethus introduce the first smallmol. PAMs for the β2AR, which may serve as a lead mol. for the development of novel therapeutics.  The approach described in this work establishes a broadly applicable proof-of-concept strategy for affinity-based discovery of small-mol. allosteric compds. targeting unique conformational states of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoufq1o7mNfFLVg90H21EOLACvtfcHk0litE75gHnAUng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgsr7O&md5=b50b8775c33f7ebe34560295f8b80720</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1124%2Fmol.118.111948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.118.111948%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DOlsen%26aufirst%3DE.%2BK.%26aulast%3DHusemoen%26aufirst%3DG.%26aulast%3DVestergaard%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWingler%26aufirst%3DL.%2BM.%26aulast%3DRambarat%26aufirst%3DP.%2BK.%26aulast%3DSimhal%26aufirst%3DR.%2BK.%26aulast%3DXu%26aufirst%3DT.%2BT.%26aulast%3DSun%26aufirst%3DL.%2BD.%26aulast%3DShim%26aufirst%3DP.%2BJ.%26aulast%3DStaus%26aufirst%3DD.%2BP.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DFranch%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSmall-molecule%2520positive%2520allosteric%2520modulators%2520of%2520the%2520%25CE%25B22-adrenoceptor%2520isolated%2520from%2520DNA-encoded%2520libraries%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D94%26spage%3D850%26epage%3D861%26doi%3D10.1124%2Fmol.118.111948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staus, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simhal, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambarat, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span> <span> </span><span class="NLM_article-title">Mechanism of β<sub>2</sub>AR regulation by an intracellular positive allosteric modulator</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1126/science.aaw8981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.aaw8981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31249059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWjtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2019&pages=1283-1287&author=X.+Liuauthor=A.+Masoudiauthor=A.+W.+Kahsaiauthor=L.+Y.+Huangauthor=B.+Paniauthor=D.+P.+Stausauthor=P.+J.+Shimauthor=K.+Hirataauthor=R.+K.+Simhalauthor=A.+M.+Schwalbauthor=P.+K.+Rambaratauthor=S.+Ahnauthor=R.+J.+Lefkowitzauthor=B.+Kobilka&title=Mechanism+of+%CE%B22AR+regulation+by+an+intracellular+positive+allosteric+modulator&doi=10.1126%2Fscience.aaw8981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of β2AR regulation by an intracellular positive allosteric modulator</span></div><div class="casAuthors">Liu, Xiangyu; Masoudi, Ali; Kahsai, Alem W.; Huang, Li-Yin; Pani, Biswaranjan; Staus, Dean P.; Shim, Paul J.; Hirata, Kunio; Simhal, Rishabh K.; Schwalb, Allison M.; Rambarat, Paula K.; Ahn, Seungkirl; Lefkowitz, Robert J.; Kobilka, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">6447</span>),
    <span class="NLM_cas:pages">1283-1287</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Many drug discovery efforts focus on G protein-coupled receptors (GPCRs), a class of receptors that regulate many physiol. processes.  An exemplar is the β2-adrenergic receptor (β2AR), which is targeted by both blockers and agonists to treat cardiovascular and respiratory diseases.  Most GPCR drugs target the primary (orthosteric) ligand binding site, but binding at allosteric sites can modulate activation.  Because such allosteric sites are less conserved, they could possibly be targeted more specifically.  Liu et al. report the crystal structure of β2AR bound to both an orthosteric agonist and a pos. allosteric modulator that increases receptor activity.  The structure suggests why the modulator compd. is selective for β2AR over the closely related β1AR.  Furthermore, the structure reveals that the modulator acts by enhancing orthosteric agonist binding and stabilizing the active conformation of the receptor.  Science, this issue p.  1283.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqowDT5dSXkH7Vg90H21EOLACvtfcHk0litE75gHnAUng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWjtL3P&md5=17481f29b32a6bd0d10cc5bf7ca0ab61</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaw8981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaw8981%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMasoudi%26aufirst%3DA.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DStaus%26aufirst%3DD.%2BP.%26aulast%3DShim%26aufirst%3DP.%2BJ.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DSimhal%26aufirst%3DR.%2BK.%26aulast%3DSchwalb%26aufirst%3DA.%2BM.%26aulast%3DRambarat%26aufirst%3DP.%2BK.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%26atitle%3DMechanism%2520of%2520%25CE%25B22AR%2520regulation%2520by%2520an%2520intracellular%2520positive%2520allosteric%2520modulator%26jtitle%3DScience%26date%3D2019%26volume%3D364%26spage%3D1283%26epage%3D1287%26doi%3D10.1126%2Fscience.aaw8981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structural insights into adrenergic receptor function and pharmacology</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.tips.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21414670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFGrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=213-218&author=B.+K.+Kobilka&title=Structural+insights+into+adrenergic+receptor+function+and+pharmacology&doi=10.1016%2Fj.tips.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into adrenergic receptor function and pharmacology</span></div><div class="casAuthors">Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-218</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  It has been over 50 years since Sir James Black developed the first beta adrenergic receptor (βAR) blocker to treat heart disease.  At that time, the concept of cell surface receptors was relatively new and not widely accepted, and most of the tools currently used to characterize plasma membrane receptors had not been developed.  There has been remarkable progress in receptor biol. since then, including the development of radioligand binding assays, the biochem. characterization of receptors as discrete membrane proteins, and the cloning of the first G-protein-coupled receptors (GPCRs), which led to the identification of other members of the large family of GPCRs.  More recently, progress in GPCR structural biol. has led to insights into the three-dimensional structures of βARs in both active and inactive states.  Despite all of this progress, the process of developing a drug for a particular GPCR target has become more complex, time-consuming and expensive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovKQolsPC6q7Vg90H21EOLACvtfcHk0lgm-tCtywvNKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFGrurw%253D&md5=a7d646e99b0d10b850ae0e41eae2c6cf</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructural%2520insights%2520into%2520adrenergic%2520receptor%2520function%2520and%2520pharmacology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D213%26epage%3D218%26doi%3D10.1016%2Fj.tips.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehler, E. L.</span></span> <span> </span><span class="NLM_article-title">Probing the structural determinants for the function of intracellular loop 2 in structurally cognate G-protein-coupled receptors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">10691</span>– <span class="NLM_lpage">10701</span>, <span class="refDoi"> DOI: 10.1021/bi100580s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100580s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=10691-10701&author=J.+Shanauthor=H.+Weinsteinauthor=E.+L.+Mehler&title=Probing+the+structural+determinants+for+the+function+of+intracellular+loop+2+in+structurally+cognate+G-protein-coupled+receptors&doi=10.1021%2Fbi100580s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the structural determinants for function of intracellular loop 2 in structurally cognate G-protein-coupled receptors</span></div><div class="casAuthors">Shan, Jufang; Weinstein, Harel; Mehler, Ernest L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">10691-10701</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Intracellular loop 2 (IL2) in G-protein-coupled receptors (GPCRs) is functionally important, e.g., in binding to G-protein and β-arrestin.  Differences in secondary structure of IL2 in the crystal structures of the very similar β1- and β2-adrenergic receptors (β1AR and β2AR, resp.), i.e., an α-helix and an L-shaped strand, resp., emphasize the need to understand the structural basis for IL2 functionality.  We studied the properties of IL2 in the context of exptl. data using a Monte Carlo-based ab initio method.  The procedure was validated first by verifying that the IL2 structures in β1AR and β2AR crystals were correctly reproduced, even after conformational ensemble searches at >1200 K where most secondary structure had been lost.  We found that IL2 in β1AR and β2AR sampled each other's conformation but adopted different energetically preferred conformations, consistent with the crystal structures.  The results indicate a persistent contextual preference for the structure of IL2, which was conserved when the IL2 sequences were interchanged between the receptors.  We conclude that the protein environment, more than the IL2 sequence, regulates the IL2 structures.  We extended the approach to the mol. model of 5-HT2AR for which no crystal structure is available and found that IL2 is predominantly helical, similar to IL2 in β1AR.  Because the P3.57A mutation in IL2 had been shown to decrease β-arrestin binding and internalization, we predicted the effects of the mutation and found that it decreased the propensity of IL2 to form helix, identifying the helical IL2 as a component of the GPCR active form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4OS3Ex6lMibVg90H21EOLACvtfcHk0lgm-tCtywvNKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzN&md5=8a81ef781c97aa1d3885c4a81f68ca96</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fbi100580s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100580s%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DJ.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DMehler%26aufirst%3DE.%2BL.%26atitle%3DProbing%2520the%2520structural%2520determinants%2520for%2520the%2520function%2520of%2520intracellular%2520loop%25202%2520in%2520structurally%2520cognate%2520G-protein-coupled%2520receptors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D10691%26epage%3D10701%26doi%3D10.1021%2Fbi100580s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaindl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stößel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matt, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">An allosteric modulator binds to a conformational hub in the β<sub>2</sub> adrenergic receptor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1038/s41589-020-0549-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41589-020-0549-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32483378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGmtbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=749-755&author=X.+Liuauthor=J.+Kaindlauthor=M.+Korczynskaauthor=A.+St%C3%B6%C3%9Felauthor=D.+Denglerauthor=M.+Stanekauthor=H.+H%C3%BCbnerauthor=M.+J.+Clarkauthor=J.+Mahoneyauthor=R.+A.+Mattauthor=X.+Xuauthor=K.+Hirataauthor=B.+K.+Shoichetauthor=R.+K.+Sunaharaauthor=B.+K.+Kobilkaauthor=P.+Gmeiner&title=An+allosteric+modulator+binds+to+a+conformational+hub+in+the+%CE%B22+adrenergic+receptor&doi=10.1038%2Fs41589-020-0549-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric modulator binds to a conformational hub in the β2 adrenergic receptor</span></div><div class="casAuthors">Liu, Xiangyu; Kaindl, Jonas; Korczynska, Magdalena; Stossel, Anne; Dengler, Daniela; Stanek, Markus; Hubner, Harald; Clark, Mary J.; Mahoney, Jake; Matt, Rachel Ann; Xu, Xinyu; Hirata, Kunio; Shoichet, Brian K.; Sunahara, Roger K.; Kobilka, Brian K.; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">749-755</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Most drugs acting on G-protein-coupled receptors target the orthosteric binding pocket where the native hormone or neurotransmitter binds.  There is much interest in finding allosteric ligands for these targets because they modulate physiol. signaling and promise to be more selective than orthosteric ligands.  Here we describe a newly developed allosteric modulator of the β2-adrenergic receptor (β2AR), AS408, that binds to the membrane-facing surface of transmembrane segments 3 and 5, as revealed by X-ray crystallog.  AS408 disrupts a water-mediated polar network involving E1223.41 and the backbone carbonyls of V2065.45 and S2075.46.  The AS408 binding site is adjacent to a previously identified mol. switch for β2AR activation formed by I3.40, P5.50 and F6.44.  The structure reveals how AS408 stabilizes the inactive conformation of this switch, thereby acting as a neg. allosteric modulator for agonists and pos. allosteric modulator for inverse agonists. [graphic not available: see fulltext].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKv03WK0jgMrVg90H21EOLACvtfcHk0lgm-tCtywvNKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGmtbrE&md5=a53c31ae052c78d0b13cf3993c1f24f4</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1038%2Fs41589-020-0549-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-020-0549-2%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKaindl%26aufirst%3DJ.%26aulast%3DKorczynska%26aufirst%3DM.%26aulast%3DSt%25C3%25B6%25C3%259Fel%26aufirst%3DA.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DStanek%26aufirst%3DM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMahoney%26aufirst%3DJ.%26aulast%3DMatt%26aufirst%3DR.%2BA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DAn%2520allosteric%2520modulator%2520binds%2520to%2520a%2520conformational%2520hub%2520in%2520the%2520%25CE%25B22%2520adrenergic%2520receptor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26spage%3D749%26epage%3D755%26doi%3D10.1038%2Fs41589-020-0549-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suissa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habbick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockroft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNutt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buist, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, W. O.</span></span> <span> </span><span class="NLM_article-title">A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.149.3.8118625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm.149.3.8118625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8118625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2c7mtlCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=1994&pages=604-610&author=S.+Suissaauthor=P.+Ernstauthor=J.+F.+Boivinauthor=R.+I.+Horwitzauthor=B.+Habbickauthor=D.+Cockroftauthor=L.+Blaisauthor=M.+McNuttauthor=A.+S.+Buistauthor=W.+O.+Spitzer&title=A+cohort+analysis+of+excess+mortality+in+asthma+and+the+use+of+inhaled+beta-agonists&doi=10.1164%2Fajrccm.149.3.8118625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists</span></div><div class="casAuthors">Suissa S; Ernst P; Boivin J F; Horwitz R I; Habbick B; Cockroft D; Blais L; McNutt M; Buist A S; Spitzer W O</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">3 Pt 1</span>),
    <span class="NLM_cas:pages">604-10</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The association between the use of inhaled beta-agonists and the risk of death and near-death from asthma has previously been reported.  It was based on a nested case-control study of 129 cases and 655 control subjects selected from a cohort of 12,301 users of asthma drugs followed during the period 1980 through 1987.  In this paper we examine the question of asthma and non-asthma mortality using data from the entire cohort of 12,301 asthmatics.  There were 46 asthma and 134 non-asthma deaths in this cohort, for which there were 47,842 person-years of follow-up.  The overall rate of asthma death was 9.6 per 10,000 asthmatics per year.  This rate varied significantly according to the use of fenoterol, albuterol, or oral corticosteroids in the prior 12 months and the number of asthma hospitalizations in the prior 2 years.  The rate decreased significantly, by 0.6 asthma deaths per 10,000 asthmatics per year over the study period, after controlling for the effect of the four other risk factors.  It also increased significantly with the use of all beta-agonists, and more so for fenoterol than for albuterol, although this difference was partly explained by the dose inequivalence of the two drugs.  Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1.4 canisters (of 20,000 micrograms each) per month of inhaled beta-agonist, the recommended limit.  For non-asthma death, the overall rate of 28 deaths per 10,000 asthmatics per year was not related to the use of inhaled beta-agonists.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEB3OT4wgRIn6oPH0mYWL1fW6udTcc2eZ4ahmu8JvOAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7mtlCjtQ%253D%253D&md5=453201bfece5a719a3c4a27b33cf922e</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.149.3.8118625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.149.3.8118625%26sid%3Dliteratum%253Aachs%26aulast%3DSuissa%26aufirst%3DS.%26aulast%3DErnst%26aufirst%3DP.%26aulast%3DBoivin%26aufirst%3DJ.%2BF.%26aulast%3DHorwitz%26aufirst%3DR.%2BI.%26aulast%3DHabbick%26aufirst%3DB.%26aulast%3DCockroft%26aufirst%3DD.%26aulast%3DBlais%26aufirst%3DL.%26aulast%3DMcNutt%26aufirst%3DM.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DSpitzer%26aufirst%3DW.%2BO.%26atitle%3DA%2520cohort%2520analysis%2520of%2520excess%2520mortality%2520in%2520asthma%2520and%2520the%2520use%2520of%2520inhaled%2520beta-agonists%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1994%26volume%3D149%26spage%3D604%26epage%3D610%26doi%3D10.1164%2Fajrccm.149.3.8118625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, C.</span></span> <span> </span><span class="NLM_article-title">Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">S18</span>– <span class="NLM_lpage">S30</span>, <span class="refDoi"> DOI: 10.1016/S0091-6749(99)70270-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0091-6749%2899%2970270-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10452785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXmt12gurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=S18-S30&author=R.+Beasleyauthor=N.+Pearceauthor=J.+Craneauthor=C.+Burgess&title=Beta-agonists%3A+what+is+the+evidence+that+their+use+increases+the+risk+of+asthma+morbidity+and+mortality%3F&doi=10.1016%2FS0091-6749%2899%2970270-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">β-Agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?</span></div><div class="casAuthors">Beasley, Richard; Pearce, Neil; Crane, Julian; Burgess, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">S18-S30</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">A review with 112 refs.  In this article, studies that have examd. the effects on morbidity and mortality of β-agonist drugs are reviewed.  With regard to morbidity, there is considerable evidence that the regular use of β-agonist drugs as a class could potentially lead to worsening asthma control because of the effects on bronchial hyperresponsiveness, the development of tolerance and reduced protection against provoking stimuli, an increased allergen load, and masking of the symptoms of deteriorating asthma.  Despite these effects, the short-acting β-agonist drugs albuterol and terbutaline and the long-acting β-agonist drugs salmeterol and formoterol have, in general, not been assocd. with a significant worsening of asthma control or an increased frequency of severe attacks.  In contrast, there is evidence that the regular use of isoproterenol and fenoterol may lead to worsening asthma control.  With regard to deaths, available evidence indicates that the high-dose prepns. of isoproterenol and fenoterol are assocd. with increased mortality and were the major causes of the epidemics of asthma mortality obsd. in some countries.  The increased risk of death assocd. with isoproterenol and fenoterol is probably the result of both long-term effects with their regular use leading to worsening asthma control and acute effects resulting from their overuse in the situation of a life-threatening attack of asthma.  In contrast, the use of the short-acting β-agonists albuterol and terbutaline is not assocd. with an increased risk of mortality.  Although this lack of risk may also apply to formoterol and salmeterol, in the absence of sufficient studies specifically addressing the risk of death, this remains uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyyVEcerx0Z7Vg90H21EOLACvtfcHk0ling-mEGmm7DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt12gurg%253D&md5=004aec75f1c23740fbddb8478c148f7b</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2FS0091-6749%2899%2970270-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-6749%252899%252970270-8%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DPearce%26aufirst%3DN.%26aulast%3DCrane%26aufirst%3DJ.%26aulast%3DBurgess%26aufirst%3DC.%26atitle%3DBeta-agonists%253A%2520what%2520is%2520the%2520evidence%2520that%2520their%2520use%2520increases%2520the%2520risk%2520of%2520asthma%2520morbidity%2520and%2520mortality%253F%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1999%26volume%3D104%26spage%3DS18%26epage%3DS30%26doi%3D10.1016%2FS0091-6749%2899%2970270-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhamane, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, M.</span></span> <span> </span><span class="NLM_article-title">Short-acting β-agonist use and its ability to predict future asthma-related outcomes</span>. <i>Ann. Allergy, Asthma, Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/j.anai.2012.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.anai.2012.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23176877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=403-407&author=R.+H.+Stanfordauthor=M.+B.+Shahauthor=A.+O.+D%E2%80%99Souzaauthor=A.+D.+Dhamaneauthor=M.+Schatz&title=Short-acting+%CE%B2-agonist+use+and+its+ability+to+predict+future+asthma-related+outcomes&doi=10.1016%2Fj.anai.2012.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Short-acting β-agonist use and its ability to predict future asthma-related outcomes</span></div><div class="casAuthors">Stanford, Richard H.; Shah, Manan B.; D'Souza, Anna O.; Dhamane, Amol D.; Schatz, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Allergy, Asthma, & Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">403-407</span>CODEN:
                <span class="NLM_cas:coden">ALAIF6</span>;
        ISSN:<span class="NLM_cas:issn">1081-1206</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Short-acting β-agonist (SABA) use is well established in predicting asthma events in adults.  However, this predictive ability has yet to be established in a pediatric population together with an assessment of amt. of use.  To identify the no. of SABA canisters that best predicts future asthma-related exacerbations and the optimal length of time for measurement of SABA use in pediatric and adult asthma patients.  Asthma patients were identified from a Medicaid and a com. insured database (Jan. 1, 2004, through Dec. 31, 2005, and Jan. 1, 2004, through June 30, 2006, resp.).  Following the date of first asthma medication, an assessment period (3, 6, or 12 mo) was used to measure SABA use.  Asthma-related exacerbations were identified in the subsequent 12-mo period.  Receiver operating characteristic curve analyses and logistic regression were used to select the crit. values of SABA use and optimal assessment periods and to conduct incremental anal., resp.  A total of 33,793 Medicaid and 101,437 com. patients met the study criteria.  Use of 3 or more SABA canisters during 12 mo was identified in both pediatric Medicaid and com. populations to best predict an increased risk of an asthma-related exacerbation.  For adults, use of 2 or more SABA canisters was found as the crit. value with shorter optimal assessment periods of 3 and 6 mo.  Each addnl. SABA canister resulted in an 8% to 14% and 14% to 18% increase in risk of an asthma-related exacerbation in children and adults, resp.  The study identified crit. values of SABA use that predict future asthma events.  Each addnl. SABA canister predicted increases in exacerbation risk in children and adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRMZ0Bl_iTYLVg90H21EOLACvtfcHk0ling-mEGmm7DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqt7bO&md5=852546c4556c6b4b74c8c047a91565de</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2Fj.anai.2012.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.anai.2012.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DStanford%26aufirst%3DR.%2BH.%26aulast%3DShah%26aufirst%3DM.%2BB.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DA.%2BO.%26aulast%3DDhamane%26aufirst%3DA.%2BD.%26aulast%3DSchatz%26aufirst%3DM.%26atitle%3DShort-acting%2520%25CE%25B2-agonist%2520use%2520and%2520its%2520ability%2520to%2520predict%2520future%2520asthma-related%2520outcomes%26jtitle%3DAnn.%2520Allergy%252C%2520Asthma%252C%2520Immunol.%26date%3D2012%26volume%3D109%26spage%3D403%26epage%3D407%26doi%3D10.1016%2Fj.anai.2012.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span> <i>Pocket Guide for Asthma Management and Prevention
(for adults and
children older than 5 years), A Pocket Guide for Health Professionals</i>; <span class="NLM_publisher-name">Global Initiative for Asthma</span>, <span class="NLM_year">2018</span>; <a href="http://www.ginasthma.org" class="extLink">www.ginasthma.org</a> (accessed 2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pocket+Guide+for+Asthma+Management+and+Prevention%0A%28for+adults+and%0Achildren+older+than+5+years%29%2C+A+Pocket+Guide+for+Health+Professionals%3B+Global+Initiative+for+Asthma%2C+2018%3B+www.ginasthma.org+%28accessed+2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPocket%2520Guide%2520for%2520Asthma%2520Management%2520and%2520Prevention%250A%2528for%2520adults%2520and%250Achildren%2520older%2520than%25205%2520years%2529%252C%2520A%2520Pocket%2520Guide%2520for%2520Health%2520Professionals%26pub%3DGlobal%2520Initiative%2520for%2520Asthma%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span> <i>Global Strategy for Asthma
Management and Prevention</i>; <span class="NLM_publisher-name">Global Initiative
for Asthma</span>, <span class="NLM_year">2019</span> <a href="http://www.ginasthma.org" class="extLink">www.ginasthma.org</a> (accessed
2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Strategy+for+Asthma%0AManagement+and+Prevention%3B+Global+Initiative%0Afor+Asthma%2C+2019+www.ginasthma.org+%28accessed%0A2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Strategy%2520for%2520Asthma%250AManagement%2520and%2520Prevention%26pub%3DGlobal%2520Initiative%250Afor%2520Asthma%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddel, H. K.</span></span> <span> </span><span class="NLM_article-title">Inhaled combined budesonide-formoterol as needed in mild asthma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1865</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1715274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1715274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29768149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1865-1876&author=P.+M.+O%E2%80%99Byrneauthor=J.+M.+FitzGeraldauthor=E.+D.+Batemanauthor=P.+J.+Barnesauthor=N.+Zhongauthor=C.+Keenauthor=C.+Jorupauthor=R.+Lamarcaauthor=S.+Ivanovauthor=H.+K.+Reddel&title=Inhaled+combined+budesonide-formoterol+as+needed+in+mild+asthma&doi=10.1056%2FNEJMoa1715274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled combined budesonide-formoterol as needed in mild asthma</span></div><div class="casAuthors">O'Byrne, Paul M.; FitzGerald, J. Mark; Bateman, Eric D.; Barnes, Peter J.; Zhong, Nanshan; Keen, Christina; Jorup, Carin; Lamarca, Rosa; Ivanov, Stefan; Reddel, Helen K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1865-1876</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2-agonist may be an alternative to conventional treatment strategies. methods We conducted a 52-wk, double-blind trial involving patients 12 years of age or older with mild asthma.  Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed (budesonide-formoterol group), or twice-daily budesonide (200 μg) plus terbutaline used as needed (budesonide maintenance group).  The primary objective was to investigate the superiority of as-needed budesonide-formoterol to as-needed terbutaline with regard to electronically recorded weeks with well-controlled asthma. results A total of 3849 patients underwent randomization, and 3836 (1277 in the terbutaline group, 1277 in the budesonide-formoterol group, and 1282 in the budesonide maintenance group) were included in the full anal. and safety data sets.  With respect to the mean percentage of weeks with well-controlled asthma per patient, budesonide-formoterol was superior to terbutaline (34.4% vs. 31.1% of weeks; odds ratio, 1.14; 95% confidence interval [CI], 1.00 to 1.30; P = 0.046) but inferior to budesonide maintenance therapy (34.4% and 44.4%, resp.; odds ratio, 0.64; 95% CI, 0.57 to 0.73).  The annual rate of severe exacerbations was 0.20 with terbutaline, 0.07 with budesonide-formoterol, and 0.09 with budesonide maintenance therapy; the rate ratio was 0.36 (95% CI, 0.27 to 0.49) for budesonide-formoterol vs. terbutaline and 0.83 (95% CI, 0.59 to 1.16) for budesonide-formoterol vs. budesonide maintenance therapy.  The rate of adherence in the budesonide maintenance group was 78.9%.  The median metered daily dose of inhaled glucocorticoid in the budesonide-formoterol group (57 μg) was 17% of the dose in the budesonide maintenance group (340 μg). conclusions In patients with mild asthma, as-needed budesonide-formoterol provided superior asthma-symptom control to as-needed terbutaline, assessed according to electronically recorded weeks with well-controlled asthma, but was inferior to budesonide maintenance therapy.  Exacerbation rates with the two budesonide-contg. regimens were similar and were lower than the rate with terbutaline.  Budesonide-formoterol used as needed resulted in substantially lower glucocorticoid exposure than budesonide maintenance therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoikROAIrfIV7Vg90H21EOLACvtfcHk0lhcbg8pPgqeIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nN&md5=ae850bc200c13d178131a8c77fcc826e</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1715274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1715274%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26aulast%3DFitzGerald%26aufirst%3DJ.%2BM.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DKeen%26aufirst%3DC.%26aulast%3DJorup%26aufirst%3DC.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DIvanov%26aufirst%3DS.%26aulast%3DReddel%26aufirst%3DH.%2BK.%26atitle%3DInhaled%2520combined%2520budesonide-formoterol%2520as%2520needed%2520in%2520mild%2520asthma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1865%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1715274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwek-Posluszna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, J. M.</span></span> <span> </span><span class="NLM_article-title">As-needed budesonide-formoterol versus maintenance budesonide in mild asthma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1887</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1715275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1715275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29768147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1877-1887&author=E.+D.+Batemanauthor=H.+K.+Reddelauthor=P.+M.+O%E2%80%99Byrneauthor=P.+J.+Barnesauthor=N.+Zhongauthor=C.+Keenauthor=C.+Jorupauthor=R.+Lamarcaauthor=A.+Siwek-Poslusznaauthor=J.+M.+FitzGerald&title=As-needed+budesonide-formoterol+versus+maintenance+budesonide+in+mild+asthma&doi=10.1056%2FNEJMoa1715275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">As-needed budesonide-formoterol versus maintenance budesonide in mild asthma</span></div><div class="casAuthors">Bateman, Eric D.; Reddel, Helen K.; O'Byrne, Paul M.; Barnes, Peter J.; Zhong, Nanshan; Keen, Christina; Jorup, Carin; Lamarca, Rosa; Siwek-Posluszna, Agnieszka; FitzGerald, J. Mark</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1877-1887</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with mild asthma often rely on inhaled short-acting β2-agonists for symptom relief and have poor adherence to maintenance therapy.  Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk. methods We conducted a 52-wk, double-blind, multicenter trial involving patients 12 years of age or older who had mild asthma and were eligible for treatment with regular inhaled glucocorticoids.  Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 μg) plus terbutaline (0.5 mg) used as needed.  The primary anal. compared budesonide-formoterol used as needed with budesonide maintenance therapy with regard to the annualized rate of severe exacerbations, with a prespecified noninferiority limit of 1.2.  Symptoms were assessed according to scores on the Asthma Control Questionnaire-5 (ACQ-5) on a scale from 0 (no impairment) to 6 (max. impairment). results A total of 4215 patients underwent randomization, and 4176 (2089 in the budesonide-formoterol group and 2087 in the budesonide maintenance group) were included in the full anal. set.  Budesonide-formoterol used as needed was noninferior to budesonide maintenance therapy for severe exacerbations; the annualized rate of severe exacerbations was 0.11 (95% confidence interval [CI], 0.10 to 0.13) and 0.12 (95% CI, 0.10 to 0.14), resp. (rate ratio, 0.97; upper one-sided 95% confidence limit, 1.16).  The median daily metered dose of inhaled glucocorticoid was lower in the budesonide-formoterol group (66 μg) than in the budesonide maintenance group (267 μg).  The time to the first exacerbation was similar in the two groups (hazard ratio, 0.96; 95% CI, 0.78 to 1.17).  The change in ACQ-5 score showed a difference of 0.11 units (95% CI, 0.07 to 0.15) in favor of budesonide maintenance therapy. conclusions In patients with mild asthma, budesonide-formoterol used as needed was noninferior to twice-daily budesonide with respect to the rate of severe asthma exacerbations during 52 wk of treatment but was inferior in controlling symptoms.  Patients in the budesonide-formoterol group had approx. one quarter of the inhaled glucocorticoid exposure of those in the budesonide maintenance group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocos3eQcRO47Vg90H21EOLACvtfcHk0lhcbg8pPgqeIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nI&md5=fde52ddd8f99e016bc5ec497949dbee5</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1715275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1715275%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DReddel%26aufirst%3DH.%2BK.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DKeen%26aufirst%3DC.%26aulast%3DJorup%26aufirst%3DC.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DSiwek-Posluszna%26aufirst%3DA.%26aulast%3DFitzGerald%26aufirst%3DJ.%2BM.%26atitle%3DAs-needed%2520budesonide-formoterol%2520versus%2520maintenance%2520budesonide%2520in%2520mild%2520asthma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1877%26epage%3D1887%26doi%3D10.1056%2FNEJMoa1715275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braithwaite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebmeier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavord, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherall, M.</span></span> <span> </span><span class="NLM_article-title">Team controlled trial of budesonide-formoterol as needed for mild asthma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">2020</span>– <span class="NLM_lpage">2030</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1901963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31112386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3M7otFWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2020-2030&author=R.+Beasleyauthor=M.+Hollidayauthor=H.+K.+Reddelauthor=I.+Braithwaiteauthor=S.+Ebmeierauthor=R.+J.+Hancoxauthor=T.+Harrisonauthor=C.+Houghtonauthor=K.+Oldfieldauthor=A.+Papiauthor=I.+D.+Pavordauthor=M.+Williamsauthor=M.+Weatherall&title=Team+controlled+trial+of+budesonide-formoterol+as+needed+for+mild+asthma&doi=10.1056%2FNEJMoa1901963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma</span></div><div class="casAuthors">Beasley Richard; Holliday Mark; Reddel Helen K; Braithwaite Irene; Ebmeier Stefan; Hancox Robert J; Harrison Tim; Houghton Claire; Oldfield Karen; Papi Alberto; Pavord Ian D; Williams Mathew; Weatherall Mark</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2020-2030</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA.  The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.  METHODS:  We conducted a 52-week, randomized, open-label, parallel-group, controlled trial involving adults with mild asthma.  Patients were randomly assigned to one of three treatment groups: albuterol (100 μg, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 μg, one inhalation through a Turbuhaler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation through a Turbuhaler as needed) (budesonide-formoterol group).  Electronic monitoring of inhalers was used to measure medication use.  The primary outcome was the annualized rate of asthma exacerbations.  RESULTS:  The analysis included 668 of 675 patients who underwent randomization.  The annualized exacerbation rate in the budesonide-formoterol group was lower than that in the albuterol group (absolute rate, 0.195 vs. 0.400; relative rate, 0.49; 95% confidence interval [CI], 0.33 to 0.72; P<0.001) and did not differ significantly from the rate in the budesonide maintenance group (absolute rate, 0.195 in the budesonide-formoterol group vs. 0.175 in the budesonide maintenance group; relative rate, 1.12; 95% CI, 0.70 to 1.79; P = 0.65).  The number of severe exacerbations was lower in the budesonide-formoterol group than in both the albuterol group (9 vs. 23; relative risk, 0.40; 95% CI, 0.18 to 0.86) and the budesonide maintenance group (9 vs. 21; relative risk, 0.44; 95% CI, 0.20 to 0.96).  The mean (±SD) dose of inhaled budesonide was 107±109 μg per day in the budesonide-formoterol group and 222±113 μg per day in the budesonide maintenance group.  The incidence and type of adverse events reported were consistent with those in previous trials and with reports in clinical use.  CONCLUSIONS:  In an open-label trial involving adults with mild asthma, budesonide-formoterol used as needed was superior to albuterol used as needed for the prevention of asthma exacerbations. (Funded by AstraZeneca and the Health Research Council of New Zealand; Novel START Australian New Zealand Clinical Trials Registry number, ACTRN12615000999538.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEFz8wTkOF4Px2phytoz6_fW6udTcc2eZ59JZI0WwG8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7otFWrtQ%253D%253D&md5=9ce5c6e56d5952700f7fce528d3ac212</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901963%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DHolliday%26aufirst%3DM.%26aulast%3DReddel%26aufirst%3DH.%2BK.%26aulast%3DBraithwaite%26aufirst%3DI.%26aulast%3DEbmeier%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DR.%2BJ.%26aulast%3DHarrison%26aufirst%3DT.%26aulast%3DHoughton%26aufirst%3DC.%26aulast%3DOldfield%26aufirst%3DK.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DPavord%26aufirst%3DI.%2BD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWeatherall%26aufirst%3DM.%26atitle%3DTeam%2520controlled%2520trial%2520of%2520budesonide-formoterol%2520as%2520needed%2520for%2520mild%2520asthma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D2020%26epage%3D2030%26doi%3D10.1056%2FNEJMoa1901963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinchilli, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemanske, R. F.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorkness, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauger, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szefler, S. J.</span></span> <span> </span><span class="NLM_article-title">Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">2583</span>– <span class="NLM_lpage">2593</span>, <span class="refDoi"> DOI: 10.1001/jama.285.20.2583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1001%2Fjama.285.20.2583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11368732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlCisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2001&pages=2583-2593&author=S.+C.+Lazarusauthor=H.+A.+Bousheyauthor=J.+V.+Fahyauthor=V.+M.+Chinchilliauthor=R.+F.+Lemanskeauthor=C.+A.+Sorknessauthor=M.+Kraftauthor=J.+E.+Fishauthor=S.+P.+Petersauthor=T.+Craigauthor=J.+M.+Drazenauthor=J.+G.+Fordauthor=E.+Israelauthor=R.+J.+Martinauthor=E.+A.+Maugerauthor=S.+A.+Nachmanauthor=J.+D.+Spahnauthor=S.+J.+Szefler&title=Long-acting+beta2-agonist+monotherapy+vs+continued+therapy+with+inhaled+corticosteroids+in+patients+with+persistent+asthma%3A+a+randomized+controlled+trial&doi=10.1001%2Fjama.285.20.2583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial</span></div><div class="casAuthors">Lazarus, Stephen C.; Boushey, Homer A.; Fahy, John V.; Chinchilli, Vernon M.; Lemanske, Robert F., Jr.; Sorkness, Christine A.; Kraft, Monica; Fish, James E.; Peters, Stephen P.; Craig, Timothy; Drazen, Jeffrey M.; Ford, Jean G.; Israel, Elliot; Martin, Richard J.; Mauger, Elizabeth A.; Nachman, Sami A.; Spahn, Joseph D.; Szefler, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2583-2593</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Long-acting β2-agonists are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs).  No evidence exists, however, to support their use as monotherapy in adults with persistent asthma.  Objective: To examine the effectiveness of salmeterol xinafoate, a long-acting β2-agonist, as replacement therapy in patients whose asthma is well controlled by low-dose triamcinolone acetonide, an ICS.  Design and Setting: A 28-wk, randomized, blinded, placebo-controlled, parallel group trial conducted at 6 National Institutes of Health-sponsored, university-based ambulatory care centers from Feb. 1997 to Jan. 1999.  Participants: One hundred sixty-four patients aged 12 through 65 yr with persistent asthma that was well controlled during a 6-wk run-in period of treatment with inhaled triamcinolone (400 μg twice per day).  Interventions: Patients were randomly assigned to continue triamcinolone therapy (400 μg twice per day; n=54) or switch to salmeterol (42 μg twice per day; n=54) or to placebo (n=56) for 16 wk, after which all patients received placebo for an addnl. 6-wk run-out period.  Main Outcome Measures: Change in morning and evening peak expiratory flow (PEF), forced expiratory vol. in 1 s (FEV1), self-assessed asthma symptom scores, rescue albuterol use, asthma-specific quality-of-life scores, treatment failure, asthma exacerbation, bronchial reactivity, and markers of airway inflammation, compared among the 3 treatment groups.  Results: During the 16-wk randomized treatment period, no significant differences between the salmeterol and triamcinolone groups were obsd. for conventional outcomes of clin. studies of asthma therapy-morning PEF, evening PEF, asthma symptom scores, rescue albuterol sulfate use, or quality of life.  Both active treatments were superior to placebo.  However, the salmeterol group had more treatment failures than the triamcinolone group (13/54 [24%] vs. 3/54 [6%]; P=.004), as well as more asthma exacerbations (11/54 [20%] vs. 4/54 [7%]; P=.04), greater increases in median (interquartile range) sputum eosinophils (2.4% [0.0% to 10.6%] vs -0.1% [-0.7% to 0.3%]; P<.001), eosinophil cationic protein (71 [-2 to 430] U/L vs -4 [-31 to 56] U/L; P=.005), and tryptase (3.1 [2.1 to 7.6] ng/mL vs. 0.0 [0.0 to 0.7] ng/mL; P<.001).  The duration of benefit when patients were switched from active treatment to placebo after 22 wk of randomized treatment was not significantly longer in the triamcinolone group than in the salmeterol group.  Conclusion: Patients with persistent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monotherapy without risk of clin. significant loss of asthma control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_y8kjAsnsarVg90H21EOLACvtfcHk0lh0meZYyttLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlCisr4%253D&md5=25fe79bc91f34a6edb2f245a78abfaec</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1001%2Fjama.285.20.2583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.285.20.2583%26sid%3Dliteratum%253Aachs%26aulast%3DLazarus%26aufirst%3DS.%2BC.%26aulast%3DBoushey%26aufirst%3DH.%2BA.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26aulast%3DChinchilli%26aufirst%3DV.%2BM.%26aulast%3DLemanske%26aufirst%3DR.%2BF.%26aulast%3DSorkness%26aufirst%3DC.%2BA.%26aulast%3DKraft%26aufirst%3DM.%26aulast%3DFish%26aufirst%3DJ.%2BE.%26aulast%3DPeters%26aufirst%3DS.%2BP.%26aulast%3DCraig%26aufirst%3DT.%26aulast%3DDrazen%26aufirst%3DJ.%2BM.%26aulast%3DFord%26aufirst%3DJ.%2BG.%26aulast%3DIsrael%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DR.%2BJ.%26aulast%3DMauger%26aufirst%3DE.%2BA.%26aulast%3DNachman%26aufirst%3DS.%2BA.%26aulast%3DSpahn%26aufirst%3DJ.%2BD.%26aulast%3DSzefler%26aufirst%3DS.%2BJ.%26atitle%3DLong-acting%2520beta2-agonist%2520monotherapy%2520vs%2520continued%2520therapy%2520with%2520inhaled%2520corticosteroids%2520in%2520patients%2520with%2520persistent%2520asthma%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJAMA%26date%3D2001%26volume%3D285%26spage%3D2583%26epage%3D2593%26doi%3D10.1001%2Fjama.285.20.2583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agache, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, R. A.</span></span> <span> </span><span class="NLM_article-title">SPIRO, Investigators. Serious asthma events with Mometasone furoate plus formoterol compared with Mometasone furoate</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2018.10.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaci.2018.10.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30537475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2019&pages=1395-1402&author=C.+Weinsteinauthor=N.+Ryanauthor=T.+Shekarauthor=D.+Gatesauthor=S.+J.+Laneauthor=I.+Agacheauthor=R.+A.+Nathan&title=SPIRO%2C+Investigators.+Serious+asthma+events+with+Mometasone+furoate+plus+formoterol+compared+with+Mometasone+furoate&doi=10.1016%2Fj.jaci.2018.10.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate</span></div><div class="casAuthors">Weinstein, Cindy L. J.; Ryan, Nicholas; Shekar, Tulin; Gates, Davis; Lane, Stephen J.; Agache, Ioana; Nathan, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1395-1402</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The safety of long-acting β-agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.  We sought to det. whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes (SAOs) compared with mometasone furoate alone.  This clin. trial is registered as NCT01471340.  We conducted a 26-wk, randomized, double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of SAOs (adjudicated hospitalization, intubation, or death) compared with mometasone furoate alone.  The key efficacy end point was asthma exacerbation (composite of hospitalization of ≥24 h, emergency department visits of <24 h requiring systemic corticosteroids, or use of systemic corticosteroids for ≥3 consecutive days).  Among 11,729 patients (mometasone furoate-formoterol, n = 5,868; mometasone furoate, n = 5,861), a total of 81 SAOs, all asthma-related hospitalizations, were obsd. in 71 patients: 45 events from 39 patients receiving mometasone furoate-formoterol and 36 events from 32 patients receiving mometasone furoate.  The hazard ratio for the first SAO in the mometasone furoate-formoterol vs. mometasone furoate group was 1.22 (95% CI, 0.76-1.94; P = .411).  Asthma exacerbation occurred in 1,487 patients: 708 receiving mometasone furoate-formoterol and 779 receiving mometasone furoate.  The hazard ratio for the first asthma exacerbation in the mometasone furoate-formoterol vs. mometasone furoate group was 0.89 (95% CI, 0.80-0.98; P = .021).  The addn. of formoterol to mometasone furoate maintenance therapy did not increase the risk of serious asthma-related events and reduced the risk of asthma exacerbation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQaUZZeKYErVg90H21EOLACvtfcHk0lh0meZYyttLJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrt78%253D&md5=b2e9b2460c4e1bb51a563367666d25db</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2018.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2018.10.065%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DC.%26aulast%3DRyan%26aufirst%3DN.%26aulast%3DShekar%26aufirst%3DT.%26aulast%3DGates%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DS.%2BJ.%26aulast%3DAgache%26aufirst%3DI.%26aulast%3DNathan%26aufirst%3DR.%2BA.%26atitle%3DSPIRO%252C%2520Investigators.%2520Serious%2520asthma%2520events%2520with%2520Mometasone%2520furoate%2520plus%2520formoterol%2520compared%2520with%2520Mometasone%2520furoate%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2019%26volume%3D143%26spage%3D1395%26epage%3D1402%26doi%3D10.1016%2Fj.jaci.2018.10.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sears, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radner, F.</span></span> <span> </span><span class="NLM_article-title">Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1968</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2009.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2009.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19815402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1MjkvVSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=1960-1968&author=M.+R.+Searsauthor=F.+Radner&title=Safety+of+budesonide%2Fformoterol+maintenance+and+reliever+therapy+in+asthma+trials&doi=10.1016%2Fj.rmed.2009.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials</span></div><div class="casAuthors">Sears Malcolm R; Radner Finn</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1960-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The safety of long-acting beta(2)-agonists (LABAs) in asthma is debated.  This study examined the safety of the inhaled corticosteroid (ICS)/LABA combination budesonide/formoterol dry powder inhaler used as maintenance and reliever therapy versus combination treatments based on guideline recommendations.  METHODS:  Safety data from six double-blind, randomised clinical trials (RCTs) in asthma where budesonide/formoterol was used as maintenance and reliever therapy for at least 6 months were reviewed (N=14 346).  All-cause mortality and asthma-related serious adverse events (SAEs) (co-primary endpoints), overall and cardiac SAEs, and discontinuations due to adverse events (DAEs) were assessed.  Estimated Mantel-Haenszel (MH) relative risks (RR) with this regimen versus comparators were calculated.  RESULTS:  There was no increase in all-cause mortality with budesonide/formoterol maintenance and reliever therapy (four deaths [0.07%] versus nine [0.10%]; pooled MH RR 0.70, 95% confidence interval [CI] 0.21-2.30).  Asthma-related SAEs were reduced with budesonide/formoterol maintenance and reliever therapy: 41 (0.73%) versus 121 (1.38%); pooled MH RR 0.59, 95% CI 0.42-0.85.  All-cause and asthma-related DAEs were also reduced with budesonide/formoterol maintenance and reliever therapy: pooled MH RR 0.60 (95% CI 0.46-0.79) and 0.43 (0.28-0.68), respectively.  Overall and cardiac-related SAEs were comparable between treatment groups: pooled MH RR 0.96 (95% CI 0.82-1.14) and 1.26 (0.72-2.22), respectively.  CONCLUSION:  Budesonide/formoterol dry powder inhaler maintenance and reliever therapy was well tolerated in RCTs versus fixed-dose alternatives and not associated with increased risk of death or cardiac-related SAEs and DAEs, and asthma-related SAEs and DAEs were significantly reduced.  Given the limitations of RCTs, particularly exclusion of patients with co-morbidities, ongoing surveillance is appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQugFsuSveOoDDnmmyUf5qOfW6udTcc2eY3SWoP6xI-p7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjkvVSmsw%253D%253D&md5=2cc2bb75b9a4e8d28518a9b49bc60744</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2009.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2009.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DSears%26aufirst%3DM.%2BR.%26aulast%3DRadner%26aufirst%3DF.%26atitle%3DSafety%2520of%2520budesonide%252Fformoterol%2520maintenance%2520and%2520reliever%2520therapy%2520in%2520asthma%2520trials%26jtitle%3DRespir.%2520Med.%26date%3D2009%26volume%3D103%26spage%3D1960%26epage%3D1968%26doi%3D10.1016%2Fj.rmed.2009.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weatherall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijesinghe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span> <span> </span><span class="NLM_article-title">Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1136/thx.2009.116608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.2009.116608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20029037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1MfktVelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=39-43&author=M.+Weatherallauthor=M.+Wijesingheauthor=K.+Perrinauthor=M.+Harwoodauthor=R.+Beasley&title=Meta-analysis+of+the+risk+of+mortality+with+salmeterol+and+the+effect+of+concomitant+inhaled+corticosteroid+therapy&doi=10.1136%2Fthx.2009.116608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy</span></div><div class="casAuthors">Weatherall M; Wijesinghe M; Perrin K; Harwood M; Beasley R</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There is concern that long-acting beta agonist (LABA) drugs may increase the risk of asthma mortality.  METHODS:  A meta-analysis was conducted of asthma deaths in randomised controlled clinical trials from the GlaxoSmithKline database that compared salmeterol with a non-LABA comparator treatment in asthma.  The Peto one-step method was used to determine the risk overall (all studies) and in derived datasets based on inhaled corticosteroid (ICS) use.  RESULTS:  There were 35 asthma deaths in 215 studies with 106,575 subjects.  Two studies (SMART and SNS) contributed 30/35 (86%) asthma deaths, the overall findings largely reflecting the characteristics of these studies.  The odds ratio for risk of asthma mortality with salmeterol was 2.7 (95% CI 1.4 to 5.3).  In 54 placebo controlled studies the risk of death from asthma in patients not prescribed ICS was 7.3 (95% CI 1.8 to 29.4).  In 127 studies in which patients were prescribed ICS, the risk of asthma death was 2.1 (95% CI 0.6 to 7.9).  In 63 studies in which patients were randomised to receive the combination salmeterol/fluticasone propionate inhaler or ICS, there were no asthma deaths among 22,600 patients.  CONCLUSIONS:  Salmeterol monotherapy in asthma increases the risk of asthma mortality and this risk is reduced with concomitant ICS therapy.  There is no evidence that combination salmeterol/fluticasone propionate therapy is associated with an increased risk of asthma mortality, although this interpretation is limited by the low statistical power of available studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFULdOEbw9x0ewzGPswiWOfW6udTcc2eY3SWoP6xI-p7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfktVelsg%253D%253D&md5=6be085a51b7c458c89db5103d67050b2</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1136%2Fthx.2009.116608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2009.116608%26sid%3Dliteratum%253Aachs%26aulast%3DWeatherall%26aufirst%3DM.%26aulast%3DWijesinghe%26aufirst%3DM.%26aulast%3DPerrin%26aufirst%3DK.%26aulast%3DHarwood%26aufirst%3DM.%26aulast%3DBeasley%26aufirst%3DR.%26atitle%3DMeta-analysis%2520of%2520the%2520risk%2520of%2520mortality%2520with%2520salmeterol%2520and%2520the%2520effect%2520of%2520concomitant%2520inhaled%2520corticosteroid%2520therapy%26jtitle%3DThorax%26date%3D2010%26volume%3D65%26spage%3D39%26epage%3D43%26doi%3D10.1136%2Fthx.2009.116608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stempel, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphiou, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeakey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prazma, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buaron, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascoe, S. J.</span></span> <span> </span><span class="NLM_article-title">AUSTRI, Investigators. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1511049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1511049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26949137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOltLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1822-1830&author=D.+A.+Stempelauthor=I.+H.+Raphiouauthor=K.+M.+Kralauthor=A.+M.+Yeakeyauthor=A.+H.+Emmettauthor=C.+M.+Prazmaauthor=K.+S.+Buaronauthor=S.+J.+Pascoe&title=AUSTRI%2C+Investigators.+Serious+asthma+events+with+fluticasone+plus+salmeterol+versus+fluticasone+alone&doi=10.1056%2FNEJMoa1511049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Serious asthma events with fluticasone plus salmeterol versus fluticasone alone</span></div><div class="casAuthors">Stempel, David A.; Raphiou, Ibrahim H.; Kral, Kenneth M.; Yeakey, Anne M.; Emmett, Amanda H.; Prazma, Charlene M.; Buaron, Kathleen S.; Pascoe, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1822-1830</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated.  In two large clin. trials, investigators found a potential risk of serious asthma-related events assocd. with LABAs.  This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.  METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 wk.  All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month.  Patients were excluded from the trial if they had a history of lifethreatening or unstable asthma.  The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization).  Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0.  The efficacy end point was the first severe asthma exacerbation.  RESULTS Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group.  The hazard ratio for a serious asthmarelated event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P = 0.003).  There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthmarelated intubation.  The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).  CONCLUSIONS Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone.  Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdtYh9KG12rVg90H21EOLACvtfcHk0ljiU_u0e1WTdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOltLbI&md5=2cea1dab41cda2e30c7ac9730a376422</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1511049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1511049%26sid%3Dliteratum%253Aachs%26aulast%3DStempel%26aufirst%3DD.%2BA.%26aulast%3DRaphiou%26aufirst%3DI.%2BH.%26aulast%3DKral%26aufirst%3DK.%2BM.%26aulast%3DYeakey%26aufirst%3DA.%2BM.%26aulast%3DEmmett%26aufirst%3DA.%2BH.%26aulast%3DPrazma%26aufirst%3DC.%2BM.%26aulast%3DBuaron%26aufirst%3DK.%2BS.%26aulast%3DPascoe%26aufirst%3DS.%2BJ.%26atitle%3DAUSTRI%252C%2520Investigators.%2520Serious%2520asthma%2520events%2520with%2520fluticasone%2520plus%2520salmeterol%2520versus%2520fluticasone%2520alone%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1822%26epage%3D1830%26doi%3D10.1056%2FNEJMoa1511049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleecker, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canonica, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fjallbrant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, U. J.</span></span> <span> </span><span class="NLM_article-title">Serious asthma events with budesonide plus formoterol vs. budesonide alone</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1511190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1511190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27579635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=850-860&author=S.+P.+Petersauthor=E.+R.+Bleeckerauthor=G.+W.+Canonicaauthor=Y.+B.+Parkauthor=R.+Ramirezauthor=S.+Hollisauthor=H.+Fjallbrantauthor=C.+Jorupauthor=U.+J.+Martin&title=Serious+asthma+events+with+budesonide+plus+formoterol+vs.+budesonide+alone&doi=10.1056%2FNEJMoa1511190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Serious asthma events with budesonide plus formoterol vs. budesonide alone</span></div><div class="casAuthors">Peters, Stephen P.; Bleecker, Eugene R.; Canonica, Giorgio W.; Park, Yong B.; Ramirez, Ricardo; Hollis, Sally; Fjallbrant, Harald; Jorup, Carin; Martin, Ubaldo J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Concerns remain about the safety of adding long-acting β2-agonists to inhaled glucocorticoids for the treatment of asthma.  In a postmarketing safety study mandated by the Food and Drug Administration, we evaluated whether the addn. of formoterol to budesonide maintenance therapy increased the risk of serious asthma-related events in patients with asthma.  METHODS: In this multicenter, double-blind, 26-wk study, we randomly assigned patients, 12 years of age or older, who had persistent asthma, were receiving daily asthma medication, and had had one to four asthma exacerbations in the previous year to receive budesonide-formoterol or budesonide alone.  Patients with a history of life-threatening asthma were excluded.  The primary end point was the first serious asthma-related event (a composite of adjudicated death, intubation, and hospitalization), as assessed in a time-to-event anal.  The noninferiority of budesonide-formoterol to budesonide was defined as an upper limit of the 95% confidence interval for the risk of the primary safety end point of less than 2.0.  The primary efficacy end point was the first asthma exacerbation, as assessed in a time-to-event anal.  RESULTS: A total of 11,693 patients underwent randomization, of whom 5846 were assigned to receive budesonide-formoterol and 5847 to receive budesonide.  A serious asthma-related event occurred in 43 patients who were receiving budesonide-formoterol and in 40 patients who were receiving budesonide (hazard ratio, 1.07; 95% confidence interval [CI], 0.70 to 1.65); budesonide-formoterol was shown to be noninferior to budesonide alone.  There were two asthma-related deaths, both in the budesonide-formoterol group; one of these patients had undergone an asthma-related intubation.  The risk of an asthma exacerbation was 16.5% lower with budesonide-formoterol than with budesonide (hazard ratio, 0.84; 95% CI, 0.74 to 0.94; P = 0.002).  CONCLUSIONS: Among adolescents and adults with predominantly moderate-to-severe asthma, treatment with budesonide-formoterol was assocd. with a lower risk of asthma exacerbations than budesonide and a similar risk of serious asthma-related events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgH7g0WIHhpLVg90H21EOLACvtfcHk0liRVQJJqNq7-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks73O&md5=bcc44d41a30ddb02a9b4d8b9ff172bd9</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1511190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1511190%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%2BP.%26aulast%3DBleecker%26aufirst%3DE.%2BR.%26aulast%3DCanonica%26aufirst%3DG.%2BW.%26aulast%3DPark%26aufirst%3DY.%2BB.%26aulast%3DRamirez%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DFjallbrant%26aufirst%3DH.%26aulast%3DJorup%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DU.%2BJ.%26atitle%3DSerious%2520asthma%2520events%2520with%2520budesonide%2520plus%2520formoterol%2520vs.%2520budesonide%2520alone%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D850%26epage%3D860%26doi%3D10.1056%2FNEJMoa1511190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iftikhar, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imtiaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brett, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrol, D. J.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of long acting beta agonist-inhaled corticosteroid combination products in adult patients with asthma: a systematic review</span>. <i>Lung</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1007/s00408-013-9525-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00408-013-9525-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24153452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFChsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=47-54&author=I.+H.+Iftikharauthor=M.+Imtiazauthor=A.+S.+Brettauthor=D.+J.+Amrol&title=Cardiovascular+safety+of+long+acting+beta+agonist-inhaled+corticosteroid+combination+products+in+adult+patients+with+asthma%3A+a+systematic+review&doi=10.1007%2Fs00408-013-9525-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular Safety of Long Acting Beta Agonist-Inhaled Corticosteroid Combination Products in Adult Patients with Asthma: A Systematic Review</span></div><div class="casAuthors">Iftikhar, Imran H.; Imtiaz, Muhammad; Brett, Allan S.; Amrol, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Lung</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">LUNGD9</span>;
        ISSN:<span class="NLM_cas:issn">0341-2040</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Introduction Long-acting beta agonists and inhaled corticosteroids combination products (LABA-ICS) are widely used in the treatment of asthma.  However, there appears to be little data on their cardiovascular safety.  The purpose of this study was to conduct a systematic review of the available studies and trials on the cardiovascular safety of LABA-ICS in adults with asthma.  Methods Two independent reviewers screened citations from PubMed and National Clin. Trials registry to identify studies and trials on the cardiovascular effects of LABA-ICS in patients with asthma.  Results A total of 15 studies (with 17 cohorts on LABA-ICS to compare with a comparator or placebo) with 5,440 total study participants met the inclusion criteria.  Two studies on budesonide-formoterol and one on fluticasone-salmeterol reported treatment emergent cardiovascular adverse events, all of which were dysrhythmias.  For comparison, the pooled est. of the Peto odds ratio (0.72; 95 % confidence interval [CI] 0.17-3; p = 0.65) and the summary risk ratio (0.77; 95 % CI 0.26-2.3; p = 0.64) indicated a nonsignificant difference between LABA-ICS and comparator/placebo groups.  Conclusions Our systematic review found that few studies and trials reported treatment emergent cardiovascular adverse events with LABA-ICS.  However, the Peto odds ratio and risk ratio for these outcomes was statistically nonsignificant.  This suggests that LABA-ICS products may have a safe cardiovascular profile in asthma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRcznxY-xJ-bVg90H21EOLACvtfcHk0liRVQJJqNq7-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFChsbk%253D&md5=cdc9962c341f1b101fd0a0c98e16c6e9</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1007%2Fs00408-013-9525-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-013-9525-x%26sid%3Dliteratum%253Aachs%26aulast%3DIftikhar%26aufirst%3DI.%2BH.%26aulast%3DImtiaz%26aufirst%3DM.%26aulast%3DBrett%26aufirst%3DA.%2BS.%26aulast%3DAmrol%26aufirst%3DD.%2BJ.%26atitle%3DCardiovascular%2520safety%2520of%2520long%2520acting%2520beta%2520agonist-inhaled%2520corticosteroid%2520combination%2520products%2520in%2520adult%2520patients%2520with%2520asthma%253A%2520a%2520systematic%2520review%26jtitle%3DLung%26date%3D2014%26volume%3D192%26spage%3D47%26epage%3D54%26doi%3D10.1007%2Fs00408-013-9525-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Maltzahn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naya, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T.</span></span> <span> </span><span class="NLM_article-title">Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2009.02320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1742-1241.2009.02320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20456215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2010&pages=619-627&author=S.+J.+Edwardsauthor=R.+von+Maltzahnauthor=I.+P.+Nayaauthor=T.+Harrison&title=Budesonide%2Fformoterol+for+maintenance+and+reliever+therapy+of+asthma%3A+a+meta+analysis+of+randomised+controlled+trials&doi=10.1111%2Fj.1742-1241.2009.02320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomized controlled trials</span></div><div class="casAuthors">Edwards, S. J.; von Maltzahn, R.; Naya, I. P.; Harrison, T.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">619-627</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To compare the effectiveness of budesonide/formoterol (Symbicort) for Maintenance and Reliever Therapy (Symbicort SMART) Turbuhaler with twice daily inhaled corticosteroid (ICS) treatment, alone or in combination with a long-acting β2-agonist (LABA).  Meta anal. of randomized controlled trials (RCTs) using a fixed effects model.  RCTs were included if the comparator with budesonide/formoterol for maintenance and relief had the equiv., or up to fourfold higher, maintenance dose of ICS.  The primary outcome was the incidence of severe exacerbation (oral glucocorticosteroid treatment for ≥ 3 days, emergency visit and/or hospitalization).  Of the seven RCTs available six met the inclusion criteria.  Risk of severe exacerbations was significantly reduced: 41% vs. higher-dose budesonide alone [relative risk (RR) 0.59, 95% confidence interval (95% CI): 0.51-0.68, p < 0.00001]; 43% vs. equiv. dose budesonide/formoterol as maintenance twice daily (RR 0.57, 95% CI: 0.49-0.66, p < 0.00001); 24% vs. higher-dose salmeterol/fluticasone twice daily (RR 0.76, 95% CI: 0.64-0.90, p = 0.002); and 26% vs. higher-dose budesonide/formoterol twice daily (RR 0.74, 95% CI: 0.58-0.96, p = 0.02).  Significant heterogeneity was not detected in the primary analyses (p > 0.1).  Secondary analyses also demonstrated that budesonide/formoterol for maintenance and relief reduced the most severe exacerbations, resulting in less hospitalizations/accident and emergency visits than higher-dose budesonide, equiv. dose budesonide/formoterol and higher-dose salmeterol/fluticasone twice daily.  Budesonide/formoterol for maintenance and relief is significantly more effective at reducing severe exacerbations than higher-dose ICS alone, or in combination with a LABA.  This has important implications for treating uncontrolled patients at steps 2 and 3 of the joint BTS/SIGN guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzWH0iEN2dDLVg90H21EOLACvtfcHk0liRVQJJqNq7-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVertbg%253D&md5=50ff7372227b5a985639eed52ec43fd7</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2009.02320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2009.02320.x%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DS.%2BJ.%26aulast%3Dvon%2BMaltzahn%26aufirst%3DR.%26aulast%3DNaya%26aufirst%3DI.%2BP.%26aulast%3DHarrison%26aufirst%3DT.%26atitle%3DBudesonide%252Fformoterol%2520for%2520maintenance%2520and%2520reliever%2520therapy%2520of%2520asthma%253A%2520a%2520meta%2520analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2010%26volume%3D64%26spage%3D619%26epage%3D627%26doi%3D10.1111%2Fj.1742-1241.2009.02320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobieraj, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeda, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. L.</span></span> <span> </span><span class="NLM_article-title">Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1001/jama.2018.2769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1001%2Fjama.2018.2769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29554195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFKjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2018&pages=1485-1496&author=D.+M.+Sobierajauthor=E.+R.+Weedaauthor=E.+Nguyenauthor=C.+I.+Colemanauthor=C.+M.+Whiteauthor=S.+C.+Lazarusauthor=K.+V.+Blakeauthor=J.+E.+Langauthor=W.+L.+Baker&title=Association+of+inhaled+corticosteroids+and+long-acting+%CE%B2-agonists+as+controller+and+quick+relief+therapy+with+exacerbations+and+symptom+control+in+persistent+asthma%3A+A+systematic+review+and+meta-analysis&doi=10.1001%2Fjama.2018.2769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis</span></div><div class="casAuthors">Sobieraj, Diana M.; Weeda, Erin R.; Nguyen, Elaine; Coleman, Craig I.; White, C. Michael; Lazarus, Stephen C.; Blake, Kathryn V.; Lang, Jason E.; Baker, William L.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1485-1496</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma.  Objective To conduct a systematic review and meta-anal. of the effects of SMART in patients with persistent asthma.  Data Sources and Study Selection The databases of MEDLINE via OVID, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched from database inception through August 2016 and updated through Nov. 28, 2017.  Two reviewers selected randomized clin. trials or observational studies evaluating SMART vs inhaled corticosteroids with or without a LABA used as the controller therapy and short-acting β-agonists as the relief therapy for patients aged 5 years or older with persistent asthma and reporting on an outcome of interest.  Data Extn. and Synthesis Meta-analyses were conducted using a random-effects model to calc. risk ratios (RRs), risk differences (RDs), and mean differences with corresponding 95% CIs.  Citation screening, data abstraction, risk assessment, and strength of evidence grading were completed by 2 independent reviewers.  Main Outcomes and Measures Asthma exacerbations.  Results The analyses included 16 randomized clin. trials (N = 22748 patients), 15 of which evaluated SMART as a combination therapy with budesonide and formoterol in a dry-powder inhaler.  Among patients aged 12 years or older (n = 22524; mean age, 42 years; 14634 [65%] were female), SMART was assocd. with a reduced risk of asthma exacerbations compared with the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.68 [95% CI, 0.58 to 0.80]; RD, -6.4% [95% CI, -10.2% to -2.6%]) and a higher dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.77 [95% CI, 0.60 to 0.98]; RD, -2.8% [95% CI, -5.2% to -0.3%]).  Similar results were seen when SMART was compared with inhaled corticosteroids alone as the controller therapy.  Among patients aged 4 to 11 years (n = 341; median age, 8 [range, 4-11] years; 69 [31%] were female), SMART was assocd. with a reduced risk of asthma exacerbations compared with a higher dose of inhaled corticosteroids as the controller therapy (RR, 0.55 [95% CI, 0.32 to 0.94]; RD, -12.0% [95% CI, -22.5% to -1.5%]) or the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.38 [95% CI, 0.23 to 0.63]; RD, -23.2% [95% CI, -33.6% to -12.1%]).  Conclusions and Relevance In this meta-anal. of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was assocd. with a lower risk of asthma exacerbations.  Evidence for patients aged 4 to 11 years was limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWucPj8fg0pbVg90H21EOLACvtfcHk0lhDFaRr9FdufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFKjtL8%253D&md5=0b9e5aaa1ddd1f222f7b872071cb6ef0</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1001%2Fjama.2018.2769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2018.2769%26sid%3Dliteratum%253Aachs%26aulast%3DSobieraj%26aufirst%3DD.%2BM.%26aulast%3DWeeda%26aufirst%3DE.%2BR.%26aulast%3DNguyen%26aufirst%3DE.%26aulast%3DColeman%26aufirst%3DC.%2BI.%26aulast%3DWhite%26aufirst%3DC.%2BM.%26aulast%3DLazarus%26aufirst%3DS.%2BC.%26aulast%3DBlake%26aufirst%3DK.%2BV.%26aulast%3DLang%26aufirst%3DJ.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BL.%26atitle%3DAssociation%2520of%2520inhaled%2520corticosteroids%2520and%2520long-acting%2520%25CE%25B2-agonists%2520as%2520controller%2520and%2520quick%2520relief%2520therapy%2520with%2520exacerbations%2520and%2520symptom%2520control%2520in%2520persistent%2520asthma%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DJAMA%26date%3D2018%26volume%3D319%26spage%3D1485%26epage%3D1496%26doi%3D10.1001%2Fjama.2018.2769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kew, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavergames, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J. A. E.</span></span> <span> </span><span class="NLM_article-title">Long-acting beta2-agonists for chronic obstructive pulmonary disease</span>. <i>Cochrane. Db. Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">CD001104</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD010177.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2F14651858.CD010177.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=CD001104&author=K.+M.+Kewauthor=C.+Mavergamesauthor=J.+A.+E.+Walters&title=Long-acting+beta2-agonists+for+chronic+obstructive+pulmonary+disease&doi=10.1002%2F14651858.CD010177.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD010177.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD010177.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DKew%26aufirst%3DK.%2BM.%26aulast%3DMavergames%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DJ.%2BA.%2BE.%26atitle%3DLong-acting%2520beta2-agonists%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane.%2520Db.%2520Syst.%2520Rev.%26date%3D2013%26volume%3D3%26spage%3DCD001104%26doi%3D10.1002%2F14651858.CD010177.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonikov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleasdale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1136/thx.2009.125435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.2009.125435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20522841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3cvks1ensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=473-479&author=R.+Dahlauthor=K.+F.+Chungauthor=R.+Buhlauthor=H.+Magnussenauthor=V.+Nonikovauthor=D.+Jackauthor=P.+Bleasdaleauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramer&title=Efficacy+of+a+new+once-daily+long-acting+inhaled+beta2-agonist+indacaterol+versus+twice-daily+formoterol+in+COPD&doi=10.1136%2Fthx.2009.125435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD</span></div><div class="casAuthors">Dahl Ronald; Chung Kian Fan; Buhl Roland; Magnussen Helgo; Nonikov Vladimir; Jack Damon; Bleasdale Patricia; Owen Roger; Higgins Mark; Kramer Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">473-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Indacaterol is a long-acting inhaled beta(2)-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD).  In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action.  This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year.  METHODS:  Patients with moderate to severe COPD were randomised to receive once-daily indacaterol 300 microg (n=437) or 600 microg (n=428), twice-daily formoterol 12 microg (n=435) or placebo (n=432) for 52 weeks in a double-blind double-dummy parallel group study.  The primary efficacy variable was forced expiratory volume in 1 s (FEV(1)) measured 24 h postdose after 12 weeks (indacaterol vs placebo).  Other outcomes included dyspnoea (transition dyspnoea index, TDI), use of as-needed salbutamol, symptom-based measures recorded on diary cards, exacerbations, health status (St George's Respiratory Questionnaire), BODE index (body mass index, obstruction, dyspnoea, exercise), safety and tolerability.  RESULTS:  Indacaterol increased 24 h postdose FEV(1) after 12 weeks by 170 ml (both doses) versus placebo and by 100 ml versus formoterol (all p<0.001).  These significant differences were maintained at 52 weeks.  Symptomatic outcomes were improved compared with placebo with all active treatments, and indacaterol was more effective than formoterol in improving TDI score and reducing the need for as-needed salbutamol.  Indacaterol was well tolerated and had a good overall safety profile, including minimal impact on QTc interval and systemic beta(2)-mediated events.  CONCLUSIONS:  Once-daily indacaterol is an effective 24 h bronchodilator that improves symptoms and health status and confers clinical improvements over a twice-daily 12 h LABA as a treatment for patients with moderate to severe COPD.  TRIAL REGISTRATION NUMBER:  NCT 00393458.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSW_IgXNgeCDUE-swuRqsHfW6udTcc2eYR7P_JxguxQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvks1ensg%253D%253D&md5=e20b65f2a8c271ac399904f6ad65e38d</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1136%2Fthx.2009.125435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2009.125435%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DNonikov%26aufirst%3DV.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DBleasdale%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26atitle%3DEfficacy%2520of%2520a%2520new%2520once-daily%2520long-acting%2520inhaled%2520beta2-agonist%2520indacaterol%2520versus%2520twice-daily%2520formoterol%2520in%2520COPD%26jtitle%3DThorax%26date%3D2010%26volume%3D65%26spage%3D473%26epage%3D479%26doi%3D10.1136%2Fthx.2009.125435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzichini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korducki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Salvo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paggiaro, P.</span></span> <span> </span><span class="NLM_article-title">Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.2147/COPD.S62502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S62502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25045258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yjtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=697-714&author=A.+Kochauthor=E.+Pizzichiniauthor=A.+Hamiltonauthor=L.+Hartauthor=L.+Korduckiauthor=M.+C.+De+Salvoauthor=P.+Paggiaro&title=Lung+function+efficacy+and+symptomatic+benefit+of+olodaterol+once+daily+delivered+via+Respimat%C2%AE+versus+placebo+and+formoterol+twice+daily+in+patients+with+GOLD+2%E2%80%934+COPD%3A+results+from+two+replicate+48-week+studies&doi=10.2147%2FCOPD.S62502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies</span></div><div class="casAuthors">Koch, Andrea; Pizzichini, Emilio; Hamilton, Alan; Hart, Lorna; Korducki, Lawrence; De Salvo, Maria Cristina; Paggiaro, Pierluigi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">697-714, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat vs. placebo and formoterol over 48 wk in patients with moderate to very severe chronic obstructive pulmonary disease receiving usual-care background therapy.  Patients received once-daily olodaterol 5 or 10 μg, twice-daily formoterol 12 μg, or placebo.  Co-primary end points were forced expiratory vol. in 1 s (FEV1) area under the curve from 0-3 h response, FEV1 trough response, and Mahler transition dyspnea index total score after 24 wk; secondary end points included St George's Respiratory Questionnaire.  Overall, 904 (Study 1222.13) and 934 (Study 1222.14) patients received treatment.  Olodaterol significantly improved FEV1 area under the curve from 0-3 h vs. placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and FEV1 trough responses vs. placebo (0.053-0.085 L; P<0.01), as did formoterol.  Primary anal. revealed no significant difference in transition dyspnea index focal score for any active treatment vs. placebo.  Post hoc anal. using pattern mixt. modeling (accounting for discontinuations) demonstrated statistical significance for olodaterol vs. placebo.  St George's Respiratory Questionnaire total score was significantly improved with olodaterol, but not formoterol, vs. placebo.  No safety signals were identified from adverse-event or other safety data.  Once-daily olodaterol 5 μg and 10 μg is efficacious in patients with moderate to very severe chronic obstructive pulmonary disease on usual-care maintenance therapy, with a satisfactory safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSeMaO_9_CM7Vg90H21EOLACvtfcHk0lhDFaRr9FdufA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yjtbrJ&md5=99c19c78088850263c442a017508dbbc</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S62502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S62502%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DPizzichini%26aufirst%3DE.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DHart%26aufirst%3DL.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DDe%2BSalvo%26aufirst%3DM.%2BC.%26aulast%3DPaggiaro%26aufirst%3DP.%26atitle%3DLung%2520function%2520efficacy%2520and%2520symptomatic%2520benefit%2520of%2520olodaterol%2520once%2520daily%2520delivered%2520via%2520Respimat%25C2%25AE%2520versus%2520placebo%2520and%2520formoterol%2520twice%2520daily%2520in%2520patients%2520with%2520GOLD%25202%25E2%2580%25934%2520COPD%253A%2520results%2520from%2520two%2520replicate%252048-week%2520studies%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2014%26volume%3D9%26spage%3D697%26epage%3D714%26doi%3D10.2147%2FCOPD.S62502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGarvey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewoehner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korducki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bothner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, G. T.</span></span> <span> </span><span class="NLM_article-title">One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: Results of a pre-specified pooled analysis</span>. <i>COPD</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.3109/15412555.2014.991864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3109%2F15412555.2014.991864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25692310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2MrmsVWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=484-493&author=L.+McGarveyauthor=D.+Niewoehnerauthor=S.+Magderauthor=P.+Sachsauthor=K.+Tetzlaffauthor=A.+Hamiltonauthor=L.+Korduckiauthor=U.+Bothnerauthor=C.+Vogelmeierauthor=A.+Kochauthor=G.+T.+Ferguson&title=One-year+safety+of+olodaterol+once+daily+via+Respimat%C2%AE+in+patients+with+GOLD+2%E2%80%934+chronic+obstructive+pulmonary+disease%3A+Results+of+a+pre-specified+pooled+analysis&doi=10.3109%2F15412555.2014.991864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis</span></div><div class="casAuthors">McGarvey Lorcan; Niewoehner Dennis; Magder Sheldon; Sachs Paul; Tetzlaff Kay; Bothner Ulrich; Tetzlaff Kay; Hamilton Alan; Korducki Lawrence; Vogelmeier Claus; Koch Andrea; Ferguson Gary T</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">484-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies.  This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2-4) chronic obstructive pulmonary disease (COPD).  The studies compared olodaterol (5 or 10 μg) QD via Respimat®, formoterol 12 μg twice daily (BID) via Aerolizer® (1222.13 and 1222.14), and placebo for 48 weeks.  Patients continued receiving background maintenance therapy, with ∼60% receiving concomitant cardiovascular therapy and 25% having a history of concomitant cardiac disease.  Pre-specified analyses of pooled data assessed the adverse events (AEs) and serious AEs in the whole population, and in subgroups with cardiac disease, along with in-depth electrocardiogram and Holter monitoring.  In total, 3104 patients were included in the safety analysis: 876 received olodaterol 5 μg, 883 received olodaterol 10 μg, 885 received placebos, and 460 received formoterol 12 μg BID.  Overall incidence of on-treatment AEs (71.2%), serious AEs (16.1%), and deaths (1.7%) were balanced across treatment groups.  Respiratory and cardiovascular AEs, including major adverse cardiac events, were reported at similar frequencies in placebo and active treatment groups.  The safety profiles of both olodaterol 5 μg (marketed and registered dose) and 10 μg QD delivered via Respimat® are comparable to placebo and formoterol BID in this population, with no safety signals identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPzdDD_1opdjDnmmyUf5qOfW6udTcc2eY1q5SW2-j1ibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrmsVWitw%253D%253D&md5=80568c046bb23f134c9edbc3a1be6d80</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.3109%2F15412555.2014.991864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15412555.2014.991864%26sid%3Dliteratum%253Aachs%26aulast%3DMcGarvey%26aufirst%3DL.%26aulast%3DNiewoehner%26aufirst%3DD.%26aulast%3DMagder%26aufirst%3DS.%26aulast%3DSachs%26aufirst%3DP.%26aulast%3DTetzlaff%26aufirst%3DK.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DBothner%26aufirst%3DU.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26atitle%3DOne-year%2520safety%2520of%2520olodaterol%2520once%2520daily%2520via%2520Respimat%25C2%25AE%2520in%2520patients%2520with%2520GOLD%25202%25E2%2580%25934%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520Results%2520of%2520a%2520pre-specified%2520pooled%2520analysis%26jtitle%3DCOPD%26date%3D2015%26volume%3D12%26spage%3D484%26epage%3D493%26doi%3D10.3109%2F15412555.2014.991864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metaxas, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balis, E.</span></span> <span> </span><span class="NLM_article-title">The safety of indacaterol for the treatment of COPD</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1080/14740338.2018.1472233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1080%2F14740338.2018.1472233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29741108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFCmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=637-642&author=E.+I.+Metaxasauthor=E.+Balis&title=The+safety+of+indacaterol+for+the+treatment+of+COPD&doi=10.1080%2F14740338.2018.1472233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">The safety of indacaterol for the treatment of COPD</span></div><div class="casAuthors">Metaxas, Evgenios I.; Balis, Evangelos</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">637-642</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Bronchodilators, namely long-acting inhaled β2-agonists and long-acting muscarinic antagonists, are the first-line medications for chronic obstructive pulmonary disease (COPD).  The safety of these medicines is of great concern since COPD patients usually have other co-morbidities such as cardio- and cerebrovascular diseases.: In this review we present information about the safety and the use of indacaterol in COPD.  Indacaterol is the first once-daily, long-acting inhaled β2-agonist approved for COPD.  We provide data about its mechanism of action as well as, pharmacodynamics and pharmacokynetics.  Moreover, we present the available literature data focused on the the safety of indacaterol.  Data from post-marketing studies are presented and also data from comparative reviews and meta-anal.: Indacaterol's safety is very favorable since in controlled trials it was similar to placebo.  Nevertheless, physicians must be alerted to use indacaterol only according to its approved indications They must be aware of the possible adverse events since side effects may appear when the medicine is used for a prolonged period of time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xzs1hpJbXrVg90H21EOLACvtfcHk0ljdq7JN0FrGWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFCmtr8%253D&md5=9d43f051c3a28d8f3019a8e9d417df87</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1080%2F14740338.2018.1472233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2018.1472233%26sid%3Dliteratum%253Aachs%26aulast%3DMetaxas%26aufirst%3DE.%2BI.%26aulast%3DBalis%26aufirst%3DE.%26atitle%3DThe%2520safety%2520of%2520indacaterol%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2018%26volume%3D17%26spage%3D637%26epage%3D642%26doi%3D10.1080%2F14740338.2018.1472233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melani, A. S.</span></span> <span> </span><span class="NLM_article-title">Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1611</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1518431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1080%2F14656566.2018.1518431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30311516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1603-1611&author=A.+S.+Melani&title=Olodaterol+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+narrative+review&doi=10.1080%2F14656566.2018.1518431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review</span></div><div class="casAuthors">Melani, Andrea S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1603-1611</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management.  Olodaterol 5 μg, a long-acting β2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy.: This article reviews the several trials that have assessed olodaterol as a COPD therapy.  It covers safety and tolerability data and provides the reader with an expert opinion on its use as a treatment for COPD.: Olodaterol improves lung function for 24 h and reduces rescue medication use.  It may also improve dyspnea, exercise tolerance, and health-related quality of life.  It is well tolerated with an acceptable cardiovascular and respiratory adverse event profile.  There is some evidence that olodaterol, as well as other LABAs, can reduce exacerbation frequency, but not FEV1 decline and death.  LABAs alone are indicated in group A/B COPD subjects.  Olodaterol and indacaterol are administered once-daily and may offer an adherence advantage over other LABAs with more frequent dosing schedules.  Co-administration of an olodaterol/tiotropium fixed dose combination in a single inhaler device is recommended as step-up in group A/B COPD subjects not sufficiently treated by olodaterol alone or as initial therapy in those with severe exertional dyspnea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroTyoaAt_l2LVg90H21EOLACvtfcHk0ljdq7JN0FrGWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWiurrM&md5=efbf7235b6be6130d17bddc2e4f283d8</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1518431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1518431%26sid%3Dliteratum%253Aachs%26aulast%3DMelani%26aufirst%3DA.%2BS.%26atitle%3DOlodaterol%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520narrative%2520review%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D1603%26epage%3D1611%26doi%3D10.1080%2F14656566.2018.1518431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">Ultra-LABAs for the treatment of asthma</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2019.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2019.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31425937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvpt1yrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=47-52&author=M.+Cazzolaauthor=P.+Roglianiauthor=M.+G.+Matera&title=Ultra-LABAs+for+the+treatment+of+asthma&doi=10.1016%2Fj.rmed.2019.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Ultra-LABAs for the treatment of asthma</span></div><div class="casAuthors">Cazzola Mario; Rogliani Paola; Matera Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The term ultra-LABA indicates once-daily β2-AR agonists (abediterol, indacaterol, olodaterol and vilanterol) that are single enantiomers of the (R)-configuration.  All have a near full-agonist profile at human β2-AR.  They can be prescribed in asthmatics only when associated with an with ICS, although further confirmations need to clarify what really these agents add if used in association to ICS and in what asthmatic patients this association may have more value.  They are also under development in triple inhalers that include an ultra-LABA, a LAMA and an ICS.  The once-daily posology might increase adherence in long-term treatment of asthma but superiority to twice-daily LABAs has not yet been fully demonstrated.  In any case, still no ultra-LABA can be recommended as preferred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTC0N4vCAp6RFwe7cAcrfPfW6udTcc2eZKtxQ4knJFtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvpt1yrtw%253D%253D&md5=e529d4d908bcbf44c1247eb8afbe1d94</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2019.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2019.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DUltra-LABAs%2520for%2520the%2520treatment%2520of%2520asthma%26jtitle%3DRespir.%2520Med.%26date%3D2019%26volume%3D156%26spage%3D47%26epage%3D52%26doi%3D10.1016%2Fj.rmed.2019.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hederer, B. M.</span></span> <span> </span><span class="NLM_article-title">Effect of once-daily indacaterol maleate/Mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial</span>. <i>BMJ. Open</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e006131</span> <span class="refDoi"> DOI: 10.1136/bmjopen-2014-006131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fbmjopen-2014-006131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25649209" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=R.+W.+Beasleyauthor=J.+F.+Donohueauthor=R.+Mehtaauthor=H.+S.+Nelsonauthor=M.+Clayauthor=A.+Motonauthor=H.+J.+Kimauthor=B.+M.+Hederer&title=Effect+of+once-daily+indacaterol+maleate%2FMometasone+furoate+on+exacerbation+risk+in+adolescent+and+adult+asthma%3A+a+double-blind+randomised+controlled+trial&doi=10.1136%2Fbmjopen-2014-006131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1136%2Fbmjopen-2014-006131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmjopen-2014-006131%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%2BW.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DH.%2BS.%26aulast%3DClay%26aufirst%3DM.%26aulast%3DMoton%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DHederer%26aufirst%3DB.%2BM.%26atitle%3DEffect%2520of%2520once-daily%2520indacaterol%2520maleate%252FMometasone%2520furoate%2520on%2520exacerbation%2520risk%2520in%2520adolescent%2520and%2520adult%2520asthma%253A%2520a%2520double-blind%2520randomised%2520controlled%2520trial%26jtitle%3DBMJ.%2520Open%26date%3D2015%26volume%3D5%26doi%3D10.1136%2Fbmjopen-2014-006131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kornmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucsi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolosa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satlin, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/Mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">105809</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2019.105809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2019.105809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32056721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387hvFOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2020&pages=105809&author=O.+Kornmannauthor=J.+Mucsiauthor=N.+Kolosaauthor=L.+Bandelliauthor=B.+Senauthor=L.+C.+Satlinauthor=P.+D%E2%80%99Andrea&title=Efficacy+and+safety+of+inhaled+once-daily+low-dose+indacaterol+acetate%2FMometasone+furoate+in+patients+with+inadequately+controlled+asthma%3A+Phase+III+randomised+QUARTZ+study+findings&doi=10.1016%2Fj.rmed.2019.105809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings</span></div><div class="casAuthors">Kornmann Oliver; Mucsi Janos; Kolosa Nadezda; Bandelli Lorraine; Satlin Lisa C; D'Andrea Peter; Sen Biswajit</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105809</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Global initiative for asthma (GINA) 2019 recommends adding a long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma.  Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients.  OBJECTIVE:  This phase III QUARTZ was a multicentre, randomised, double-blind, double-dummy and parallel-group study to assess the efficacy and safety of low-dose IND/MF 150/80 μg once daily (o.d.) versus MF 200 μg o.d. in adult and adolescent patients with inadequately controlled asthma.  METHODS:  Eligible patients (n = 802) were randomised (1:1) to receive either low-dose IND/MF 150/80 μg o.d. via Breezhaler® or MF 200 μg o.d. via Twisthaler® for 12 weeks.  Primary endpoint was trough forced expiratory volume in 1 s (FEV1) and key secondary endpoint was Asthma Control Questionnaire (ACQ-7) treatment difference after 12-week treatment.  Other secondary endpoints included ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, evaluated over 12-week treatment.  Safety was also assessed including serious asthma outcomes.  RESULTS:  Low-dose IND/MF significantly improved trough FEV1 (least squares mean treatment difference [LSMTD]: 0.182 L; p < 0.001) and ACQ-7 (LSMTD: -0.218; p < 0.001) versus MF at Week 12.  Improvements in all other secondary endpoints favoured low-dose IND/MF.  Safety was comparable.  CONCLUSION:  These results support the use of low-dose IND/MF 150/80 μg o.d. as a potential therapy for adult and adolescent patients with inadequately controlled asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl2FEczvBfOXp3bfzSLaX5fW6udTcc2eZKtxQ4knJFtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387hvFOmuw%253D%253D&md5=2a3bbf84f20315b661d940f8b8b3136d</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2019.105809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2019.105809%26sid%3Dliteratum%253Aachs%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DMucsi%26aufirst%3DJ.%26aulast%3DKolosa%26aufirst%3DN.%26aulast%3DBandelli%26aufirst%3DL.%26aulast%3DSen%26aufirst%3DB.%26aulast%3DSatlin%26aufirst%3DL.%2BC.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520inhaled%2520once-daily%2520low-dose%2520indacaterol%2520acetate%252FMometasone%2520furoate%2520in%2520patients%2520with%2520inadequately%2520controlled%2520asthma%253A%2520Phase%2520III%2520randomised%2520QUARTZ%2520study%2520findings%26jtitle%3DRespir.%2520Med.%26date%3D2020%26volume%3D161%26spage%3D105809%26doi%3D10.1016%2Fj.rmed.2019.105809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, S.</span></span> <span> </span><span class="NLM_article-title">Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2014.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2014.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25524507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2MzosVGrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2015&pages=44-53&author=J.+Linauthor=J.+Kangauthor=S.+H.+Leeauthor=C.+Wangauthor=X.+Zhouauthor=J.+Crawfordauthor=L.+Jacquesauthor=S.+Stone&title=Fluticasone+furoate%2Fvilanterol+200%2F25+mcg+in+Asian+asthma+patients%3A+a+randomized+trial&doi=10.1016%2Fj.rmed.2014.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial</span></div><div class="casAuthors">Lin Jiangtao; Kang Jian; Lee Sang Haak; Wang Changzheng; Zhou Xiangdong; Crawford Jodie; Jacques Loretta; Stone Sally</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study investigated the efficacy and safety of the inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) combination fluticasone furoate (FF)/vilanterol (VI) in Asian asthma patients.  METHODS:  A 12-week, double-blind, double-dummy, active-comparator, parallel-group, multicenter study. 309 Asian asthma patients (≥12 years, uncontrolled with high-strength ICS or mid-dose ICS/LABA) were randomized (1:1) and included in the intent-to-treat population; 155 received once-daily FF/VI 200/25 mcg and 154 received twice-daily fluticasone propionate (FP) 500 mcg.  The primary endpoint was change from baseline in daily evening peak expiratory flow (PEF) averaged over 12 weeks.  Secondary endpoints were mean change from baseline in % rescue-free 24-h periods, daily morning PEF, % symptom-free 24-h periods, and overall Asthma Quality of Life Questionnaire score.  Safety assessments were performed.  RESULTS:  For change from baseline in daily evening PEF, the adjusted mean treatment difference for FF/VI versus FP of 28.5 L/min (95% confidence interval [CI]: 20.1, 36.9) was clinically and statistically significant (p < 0.001).  For change from baseline in % rescue-free 24-h periods, the adjusted mean treatment difference (1.0%; 95% CI: -7.3, 9.2) was not statistically significant (p = 0.821).  Statistical significance could not be inferred for the remaining endpoints due to the statistical hierarchy employed.  Incidence of on-treatment adverse events was similar with FF/VI (26%; 3% treatment-related; n = 1 serious) and FP (27%; 3% treatment-related; n = 2 serious); none were fatal.  No further safety concerns were identified.  CONCLUSIONS:  FF/VI improved evening PEF over 12 weeks versus FP in Asian patients, with a similar safety profile.  The results are generally consistent with a global study comparing the same treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRz0GQkGQIPXENoizSOkG_FfW6udTcc2eZKtxQ4knJFtbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzosVGrug%253D%253D&md5=8c9a93fc2860a761d5dddf89f4d77860</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2014.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2014.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DCrawford%26aufirst%3DJ.%26aulast%3DJacques%26aufirst%3DL.%26aulast%3DStone%26aufirst%3DS.%26atitle%3DFluticasone%2520furoate%252Fvilanterol%2520200%252F25%2520mcg%2520in%2520Asian%2520asthma%2520patients%253A%2520a%2520randomized%2520trial%26jtitle%3DRespir.%2520Med.%26date%3D2015%26volume%3D109%26spage%3D44%26epage%3D53%26doi%3D10.1016%2Fj.rmed.2014.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devillier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boye, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachgo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grouin, J. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β<sub>2</sub>-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2018.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2018.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30053956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3c7islCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2018&pages=111-120&author=P.+Devillierauthor=M.+Humbertauthor=A.+Boyeauthor=W.+Zachgoauthor=L.+Jacquesauthor=C.+Nunnauthor=S.+Westauthor=A.+Nichollsauthor=Z.+Antounauthor=L.+Spinuauthor=J.+M.+Grouin&title=Efficacy+and+safety+of+once-daily+fluticasone+furoate%2Fvilanterol+%28FF%2FVI%29+versus+twice-daily+inhaled+corticosteroids%2Flong-acting+%CE%B22-agonists+%28ICS%2FLABA%29+in+patients+with+uncontrolled+asthma%3A+An+open-label%2C+randomized%2C+controlled+trial&doi=10.1016%2Fj.rmed.2018.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial</span></div><div class="casAuthors">Devillier Philippe; Humbert Marc; Boye Alain; Zachgo Wolfgang; Jacques Loretta; Nunn Carol; West Sarah; Nicholls Andy; Antoun Zeina; Spinu Luminita; Grouin Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-120</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A variety of different fixed-dose combinations of inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) are available for the treatment of asthma.  The aim of this 24-week, open-label, multicenter, Phase IIIb randomized controlled trial was to evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI; 100/25 or 200/25 μg) compared with twice-daily fixed combinations of ICS/LABA (fluticasone propionate/salmeterol [FP/S] and budesonide/formoterol [BUD/F]) as maintenance therapy in patients with uncontrolled asthma treated with ICS alone.  METHODS:  Adult patients with documented physician-diagnosed asthma ≥1 year with an Asthma Control Test (ACT) score ≥15 and < 20 were included.  The primary study endpoint was change from baseline in ACT total score at Week 12.  RESULTS:  Overall, 423 patients were randomized to receive study medication in France and Germany.  The least-squares mean change (standard error) in ACT total score at Week 12 was 3.6 units with FF/VI and 2.8 with usual ICS/LABA, giving a treatment difference of 0.8 (95% confidence interval 0.1, 1.5; p = 0.033).  Non-inferiority of FF/VI to usual ICS/LABA was confirmed at Weeks 6, 18 and 24.  The observed safety profile for FF/VI in this study was in line with previous experience with FF/VI.  CONCLUSIONS:  These findings suggest that, in a tightly controlled randomized controlled trial setting, once-daily FF/VI provides similar asthma control over 24 weeks to usual, twice-daily ICS/LABA in patients with asthma that is uncontrolled on ICS alone.  FF/VI was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvXcj8_Toz3e-MdeMhXAHkfW6udTcc2ebUP7gUmoEcTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7islCktg%253D%253D&md5=f9751b062d629f25decd0aa65a35d3b7</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2018.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DDevillier%26aufirst%3DP.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DBoye%26aufirst%3DA.%26aulast%3DZachgo%26aufirst%3DW.%26aulast%3DJacques%26aufirst%3DL.%26aulast%3DNunn%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DNicholls%26aufirst%3DA.%26aulast%3DAntoun%26aufirst%3DZ.%26aulast%3DSpinu%26aufirst%3DL.%26aulast%3DGrouin%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520fluticasone%2520furoate%252Fvilanterol%2520%2528FF%252FVI%2529%2520versus%2520twice-daily%2520inhaled%2520corticosteroids%252Flong-acting%2520%25CE%25B22-agonists%2520%2528ICS%252FLABA%2529%2520in%2520patients%2520with%2520uncontrolled%2520asthma%253A%2520An%2520open-label%252C%2520randomized%252C%2520controlled%2520trial%26jtitle%3DRespir.%2520Med.%26date%3D2018%26volume%3D141%26spage%3D111%26epage%3D120%26doi%3D10.1016%2Fj.rmed.2018.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donner, C. F.</span></span> <span> </span><span class="NLM_article-title">Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1610</span>, <span class="refDoi"> DOI: 10.2165/00003495-200565120-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2165%2F00003495-200565120-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16060696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1595-1610&author=M.+Cazzolaauthor=M.+G.+Materaauthor=C.+F.+Donner&title=Inhaled+beta2-adrenoceptor+agonists%3A+cardiovascular+safety+in+patients+with+obstructive+lung+disease&doi=10.2165%2F00003495-200565120-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease</span></div><div class="casAuthors">Cazzola, Mario; Matera, Maria G.; Donner, Claudio F.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1595-1610</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Although large surveys have documented the favorable safety profile of β2-adrenoceptor agonists (β2-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality.  The coexistence of β1- and β2-adrenoceptors in the heart clearly indicates that β2-agonists do have some effect on the heart, even when they are highly selective.  It should also be taken into account that the β2-agonists utilized in clin. practice have differing selectivities and potencies.  β2-Agonist use has, in effect, been assocd. with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death.  Moreover, patients who have either asthma or chronic obstructive pulmonary disease may be at increased risk of cardiovascular complications because these diseases amplify the impact of these agents on the heart and, unfortunately, are a confounding factor when the impact of β2-agonists on the heart is evaluated.  Whatever the case may be, this effect is of particular concern for those patients with underlying cardiac conditions.  Therefore, β2-agonists must always be used with caution in patients with cardiopathies because these agents may ppt. the concomitant cardiac disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVXEAr6uqOorVg90H21EOLACvtfcHk0lg3u8_7cmadLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtr%252FI&md5=fa894b87f871cb31b93be5b0c22d348f</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.2165%2F00003495-200565120-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200565120-00001%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DDonner%26aufirst%3DC.%2BF.%26atitle%3DInhaled%2520beta2-adrenoceptor%2520agonists%253A%2520cardiovascular%2520safety%2520in%2520patients%2520with%2520obstructive%2520lung%2520disease%26jtitle%3DDrugs%26date%3D2005%26volume%3D65%26spage%3D1595%26epage%3D1610%26doi%3D10.2165%2F00003495-200565120-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grove, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipworth, B. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1136/thx.51.1.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.51.1.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8658370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK283msVCjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1996&pages=54-58&author=A.+Groveauthor=B.+J.+Lipworth&title=Evaluation+of+the+beta+2+adrenoceptor+agonist%2Fantagonist+activity+of+formoterol+and+salmeterol&doi=10.1136%2Fthx.51.1.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol</span></div><div class="casAuthors">Grove A; Lipworth B J</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-8</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Salmeterol and formoterol have a lower intrinsic activity at beta 2 receptors than isoprenaline in human bronchus in vitro.  The aim of the present study was to evaluate in vivo the beta 2 agonist/antagonist activity of salmeterol and formoterol at rest with low endogenous adrenergic tone, on exercise with raised endogenous adrenergic tone, and in the presence of fenoterol, an exogenous full beta 2 receptor agonist.  METHODS:  Eight normal subjects were randomised to receive single doses of placebo, salmeterol 300 micrograms, formoterol 72 micrograms, or propranolol 80 mg at weekly intervals. beta 2 adrenoceptor responses were evaluated at rest, at peak exercise, and after treatment with fenoterol 2.4 mg.  RESULTS:  At rest salmeterol and formoterol exhibited equivalent beta 2 agonist activity with regard to decrease in serum potassium levels and increase in finger tremor, with propranolol having no effect.  Salmeterol and formoterol, like propranolol, potentiated the hyperkalaemic delta response to exercise compared with placebo, consistent with beta 2 antagonism: (mean difference and 95% confidence interval (CI) compared with placebo) salmeterol 0.20 (0.02 to 0.38) mmol/l, formoterol 0.17 (0.00 to 0.34) mmol/l, propranolol 0.45 (0.08 to 0.82) mmol/l.  Propranolol blunted the heart rate delta response to exercise, consistent with beta 1 blockade, whilst salmeterol and formoterol had no effect.  Salmeterol and formoterol, like propranolol, attenuated the hypokalaemic, tremor, and heart rate delta responses to fenoterol compared with placebo, in keeping with beta 2 blockade: potassium, salmeterol 0.18 (0.0 to 0.36) mmol/l, formoterol 0.17 (-0.03 to 0.37) mmol/l, propranolol 0.80 (0.54 to 1.06) mmol/l; tremor, salmeterol -0.69 (-1.26 to -0.12) log units, formoterol -0.71 (-1.53 to 0.11) log units, propranolol -0.85 (-1.66 to -0.04) log units; heart rate, salmeterol -6 (-13 to 1) beats/min, formoterol -10 (-19 to -1) beats/min, propranolol -18 (-29 to -7) beats/min.  CONCLUSIONS:  At rest with low endogenous adrenergic tone salmeterol and formoterol showed equivalent beta 2 mediated agonist activity in terms of serum potassium and finger tremor responses.  In the presence of raised endogenous adrenergic tone at peak exercise and in the presence of fenoterol (an exogenous full beta 2 receptor agonist), salmeterol and formoterol, like propranolol, exhibited beta 2 receptor antagonism as evidenced by their attenuation of beta 2 receptor mediated responses.  The degree of beta 2 blockade with formoterol and salmeterol was comparable but less than with propranolol.  The relevance of these findings at extrapulmonary beta 2 receptors with regard to airway beta 2 responses remains unclear and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdfzygottJpeRS7coPn-RtfW6udTcc2ebUP7gUmoEcTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283msVCjtA%253D%253D&md5=08e09a99435f754540436344fb60fe81</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1136%2Fthx.51.1.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.51.1.54%26sid%3Dliteratum%253Aachs%26aulast%3DGrove%26aufirst%3DA.%26aulast%3DLipworth%26aufirst%3DB.%2BJ.%26atitle%3DEvaluation%2520of%2520the%2520beta%25202%2520adrenoceptor%2520agonist%252Fantagonist%2520activity%2520of%2520formoterol%2520and%2520salmeterol%26jtitle%3DThorax%26date%3D1996%26volume%3D51%26spage%3D54%26epage%3D58%26doi%3D10.1136%2Fthx.51.1.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grove, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarlane, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipworth, B. J.</span></span> <span> </span><span class="NLM_article-title">Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1136/thx.50.2.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.50.2.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7701450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2M3hsF2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=134-138&author=A.+Groveauthor=L.+C.+McFarlaneauthor=B.+J.+Lipworth&title=Expression+of+the+beta+2+adrenoceptor+partial+agonist%2Fantagonist+activity+of+salbutamol+in+states+of+low+and+high+adrenergic+tone&doi=10.1136%2Fthx.50.2.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone</span></div><div class="casAuthors">Grove A; McFarlane L C; Lipworth B J</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-8</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Salbutamol exhibits partial agonist/antagonist activity at airway beta 2 receptors in vitro in that it attenuates the bronchorelaxant effect of the full agonist isoprenaline.  The aim of the present study was to characterise the partial beta 2 agonist/antagonist activity of salbutamol in vivo during supine rest and exercise, in states of low and high adrenergic tone.  METHODS:  Eight normal subjects were randomised to receive single oral doses of salbutamol 2 mg, 4 mg, 8 mg (S2, S4, S8), placebo (PL), or propranolol 80 mg (PR).  The beta 2 adrenoceptor responses were evaluated after supine rest and subsequently in response to maximal exercise.  RESULTS:  Salbutamol demonstrated a dose-related increase in resting heart rate and tremor and a fall in serum potassium level consistent with beta 2 agonism.  On exercise, the hyperkalaemic response was augmented by propranolol compared with placebo consistent with beta 2 blockade: mean difference for delta response (95% CI) PR v PL was 0.60 (0.02 to 1.27) mmol/l.  This effect also occurred with salbutamol in a dose-related fashion: S8 v PL 0.33 (0.01 to 0.71) mmol/l, S8 v S2 0.31 (-0.02 to 0.61) mmol/l.  Whilst propranolol blunted exercise heart rate in keeping with beta 1 blockade, salbutamol had no effect.  Exercise produced an increase in lymphocyte beta 2 receptor binding density (Bmax) which was not affected by salbutamol.  Plasma levels of adrenaline and noradrenaline at peak exercise were also unaltered by salbutamol in comparison with placebo.  CONCLUSIONS:  In a state of low adrenergic tone at rest salbutamol produces effects consistent with beta 2 agonism.  In contrast, in a state of increased adrenergic tone during exercise salbutamol produced beta 2 selective antagonism as evidenced by its effects on exercise-induced hyperkalaemia (beta 2) but not on exercise-induced tachycardia (beta 1).  The effects of salbutamol on beta 2 receptor density do not explain its effects on exercise-induced hyperkalaemia since upregulation rather than downregulation was observed.  This in vivo phenomenon of partial beta 2 agonist/antagonist activity of salbutamol may be of relevance in the setting of acute asthma if adrenergic tone is increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL8_xqzNejzlUIs6wFK5xJfW6udTcc2ea-RRCuNsUynrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3hsF2kug%253D%253D&md5=dfaa8d601a1176e09d477b93c8af0b10</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1136%2Fthx.50.2.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.50.2.134%26sid%3Dliteratum%253Aachs%26aulast%3DGrove%26aufirst%3DA.%26aulast%3DMcFarlane%26aufirst%3DL.%2BC.%26aulast%3DLipworth%26aufirst%3DB.%2BJ.%26atitle%3DExpression%2520of%2520the%2520beta%25202%2520adrenoceptor%2520partial%2520agonist%252Fantagonist%2520activity%2520of%2520salbutamol%2520in%2520states%2520of%2520low%2520and%2520high%2520adrenergic%2520tone%26jtitle%3DThorax%26date%3D1995%26volume%3D50%26spage%3D134%26epage%3D138%26doi%3D10.1136%2Fthx.50.2.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salpeter, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormiston, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salpeter, E. E.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2309</span>– <span class="NLM_lpage">2321</span>, <span class="refDoi"> DOI: 10.1378/chest.125.6.2309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1378%2Fchest.125.6.2309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15189956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslanurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2004&pages=2309-2321&author=S.+R.+Salpeterauthor=T.+M.+Ormistonauthor=E.+E.+Salpeter&title=Cardiovascular+effects+of+beta-agonists+in+patients+with+asthma+and+COPD%3A+a+meta-analysis&doi=10.1378%2Fchest.125.6.2309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of β-agonists in patients with asthma and COPD: A meta-analysis</span></div><div class="casAuthors">Salpeter, Shelley R.; Ormiston, Thomas M.; Salpeter, Edwin E.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2309-2321</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">β-Adrenergic agonists exert physiol. effects that are the opposite of those of β-blockers.  β-Blockers are known to reduce morbidity and mortality in patients with cardiac disease.  β2-Agonist use in patients with obstructive airway disease has been assocd. with an increased risk for myocardial infarction, congestive heart failure, cardiac arrest, and acute cardiac death.  The aim of this study was to assess the cardiovascular safety of β2-agonist use in patients with obstructive airway disease, defined as asthma or COPD.  This was a meta-anal. of randomized placebo-controlled trials of β2-agonist treatment in patients with obstructive airway disease was performed, to evaluate the short-term effect on heart rate and potassium concns., and the long-term effect on adverse cardiovascular events.  Longer duration trials were included in the anal. if they reported at least one adverse event.  Adverse events included sinus and ventricular tachycardia, syncope, atrial fibrillation, congestive heart failure, myocardial infarction, cardiac arrest, or sudden death.  Thirteen single-dose trials and 20 longer duration trials were included in the study.  A single dose of β2-agonist increased the heart rate by 9.12 beats/min (95% confidence interval [CI], 5.32 to 12.92) and reduced the potassium concn. by 0.36 mmol/L (95% CI, 0.18 to 0.54), compared to placebo.  For trials lasting from 3 days to 1 yr, β2-agonist treatment significantly increased the risk for a cardiovascular event (relative risk [RR], 2.54; 95% CI, 1.59 to 4.05) compared to placebo.  The RR for sinus tachycardia alone was 3.06 (95% CI, 1.70 to 5.50), and for all other events it was 1.66 (95% CI, 0.76 to 3.6).  β2-Agonist use in patients with obstructive airway disease increases the risk for adverse cardiovascular events.  The initiation of treatment increases heart rate and reduces potassium concns. compared to placebo.  It could be through these mechanisms, and other effects of β-adrenergic stimulation, that β2-agonists may ppt. ischemia, congestive heart failure, arrhythmias, and sudden death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTACBJGKU-5rVg90H21EOLACvtfcHk0ljw6q3kpHdniQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslanurY%253D&md5=12a2319a8b72dfdfd44afa8c9fbe6fe8</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1378%2Fchest.125.6.2309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.125.6.2309%26sid%3Dliteratum%253Aachs%26aulast%3DSalpeter%26aufirst%3DS.%2BR.%26aulast%3DOrmiston%26aufirst%3DT.%2BM.%26aulast%3DSalpeter%26aufirst%3DE.%2BE.%26atitle%3DCardiovascular%2520effects%2520of%2520beta-agonists%2520in%2520patients%2520with%2520asthma%2520and%2520COPD%253A%2520a%2520meta-analysis%26jtitle%3DChest%26date%3D2004%26volume%3D125%26spage%3D2309%26epage%3D2321%26doi%3D10.1378%2Fchest.125.6.2309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croxford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzavara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanbrook, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upshur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stukel, T. A.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease</span>. <i>JAMA. Int. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1185</span>, <span class="refDoi"> DOI: 10.1001/jamainternmed.2013.1016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1001%2Fjamainternmed.2013.1016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23689820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3snlt1Cmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2013&pages=1175-1185&author=A.+Gershonauthor=R.+Croxfordauthor=A.+Calzavaraauthor=T.+Toauthor=M.+B.+Stanbrookauthor=R.+Upshurauthor=T.+A.+Stukel&title=Cardiovascular+safety+of+inhaled+long-acting+bronchodilators+in+individuals+with+chronic+obstructive+pulmonary+disease&doi=10.1001%2Fjamainternmed.2013.1016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Gershon Andrea; Croxford Ruth; Calzavara Andrew; To Teresa; Stanbrook Matthew B; Upshur Ross; Stukel Therese A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1175-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Chronic obstructive pulmonary disease (COPD) is a common and deadly disease.  Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes.  When choosing between the medications, patients and physicians would benefit from knowing which has the least risk.  OBJECTIVE:  To assess the association of these classes of medications with the risk of hospitalizations and emergency department visits for cardiovascular events.  DESIGN:  We conducted a nested case-control analysis of a retrospective cohort study.  We compared the risk of events between patients newly prescribed inhaled long-acting β-agonists and anticholinergics, after matching and adjusting for prognostic factors.  SETTING:  Health care databases from Ontario, the largest province of Canada, with a multicultural population of approximately 13 million.  PARTICIPANTS:  All individuals 66 years or older meeting a validated case definition of COPD, based on health administrative data, and treated for COPD from September 1, 2003, through March 31, 2009.  EXPOSURE:  New use of an inhaled long-acting β-agonist or long-acting anticholinergic.  MAIN OUTCOME AND MEASURES:  An emergency department visit or a hospitalization for a cardiovascular event.  RESULTS:  Of 191 005 eligible patients, 53 532 (28.0%) had a hospitalization or an emergency department visit for a cardiovascular event.  Newly prescribed long-acting inhaled β-agonists and anticholinergics were associated with a higher risk of an event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 [95% CI, 1.12-1.52; P < .001] and 1.14 [1.01-1.28; P = .03]).  We found no significant difference in events between the 2 medications (adjusted odds ratio of long-acting inhaled β-agonists compared with anticholinergics, 1.15 [95% CI, 0.95-1.38; P = .16]).  CONCLUSIONS AND RELEVANCE:  Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events.  Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsLI4Tm6tClnELvajU9pjPfW6udTcc2ea-RRCuNsUynrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snlt1Cmug%253D%253D&md5=51badbd39c783da3428d7b374d50fd06</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2013.1016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2013.1016%26sid%3Dliteratum%253Aachs%26aulast%3DGershon%26aufirst%3DA.%26aulast%3DCroxford%26aufirst%3DR.%26aulast%3DCalzavara%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DT.%26aulast%3DStanbrook%26aufirst%3DM.%2BB.%26aulast%3DUpshur%26aufirst%3DR.%26aulast%3DStukel%26aufirst%3DT.%2BA.%26atitle%3DCardiovascular%2520safety%2520of%2520inhaled%2520long-acting%2520bronchodilators%2520in%2520individuals%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJAMA.%2520Int.%2520Med.%26date%3D2013%26volume%3D173%26spage%3D1175%26epage%3D1185%26doi%3D10.1001%2Fjamainternmed.2013.1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipworth, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, D. G.</span></span> <span> </span><span class="NLM_article-title">Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">586</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1164/ajrccm/140.3.586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm%2F140.3.586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=2782734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaL1MzptFWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1989&pages=586-592&author=B.+J.+Lipworthauthor=A.+D.+Struthersauthor=D.+G.+McDevitt&title=Tachyphylaxis+to+systemic+but+not+to+airway+responses+during+prolonged+therapy+with+high+dose+inhaled+salbutamol+in+asthmatics&doi=10.1164%2Fajrccm%2F140.3.586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics</span></div><div class="casAuthors">Lipworth B J; Struthers A D; McDevitt D G</div><div class="citationInfo"><span class="NLM_cas:title">The American review of respiratory disease</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">586-92</span>
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses.  The purpose of the present study was to investigate whether tachyphylaxis occurs during prolonged treatment with high dose inhaled salbutamol.  Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design.  During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes.  At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).  Treatment had no significant effect on baseline values.  There were dose-dependent increases in FEV1 and FEF25-75 (p less than 0.001), and pretreatment with HDS did not displace the DRC to the right.  DRC for HR (p less than 0.001), K (p less than 0.001), and Glu (p less than 0.005) were attenuated after treatment with HDS compared with PI.  There were also differences between HDS and LDS for HR (p less than 0.001) and Glu (p less than 0.05) responses.  Frequency and severity of subjective adverse effects were also reduced after HDS: tremor (p less than 0.001), palpitations (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW3quDKyShfJVVjGoY74BafW6udTcc2eYy0EfNA0qcl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1MzptFWnsg%253D%253D&md5=b989ef6e14876814673f697742b0aa86</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1164%2Fajrccm%2F140.3.586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm%252F140.3.586%26sid%3Dliteratum%253Aachs%26aulast%3DLipworth%26aufirst%3DB.%2BJ.%26aulast%3DStruthers%26aufirst%3DA.%2BD.%26aulast%3DMcDevitt%26aufirst%3DD.%2BG.%26atitle%3DTachyphylaxis%2520to%2520systemic%2520but%2520not%2520to%2520airway%2520responses%2520during%2520prolonged%2520therapy%2520with%2520high%2520dose%2520inhaled%2520salbutamol%2520in%2520asthmatics%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1989%26volume%3D140%26spage%3D586%26epage%3D592%26doi%3D10.1164%2Fajrccm%2F140.3.586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiks, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Localio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmeier, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. G.</span></span> <span> </span><span class="NLM_article-title">Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1002/pds.4562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fpds.4562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29806185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yjtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=815-822&author=A.+S.+Czajaauthor=M.+E.+Rossauthor=W.+Liuauthor=A.+G.+Fiksauthor=R.+Localioauthor=R.+C.+Wassermanauthor=R.+W.+Grundmeierauthor=W.+G.+Adams&title=Electronic+health+record+%28EHR%29+based+postmarketing+surveillance+of+adverse+events+associated+with+pediatric+off-label+medication+use%3A+A+case+study+of+short-acting+beta-2+agonists+and+arrhythmias&doi=10.1002%2Fpds.4562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias</span></div><div class="casAuthors">Czaja, Angela S.; Ross, Michelle E.; Liu, Weiwei; Fiks, Alexander G.; Localio, Russell; Wasserman, Richard C.; Grundmeier, Robert W.; Adams, William G.; for the Comparative Effectiveness Research through Collaborative Electronic Reporting Consortium</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-822</span>CODEN:
                <span class="NLM_cas:coden">PDSAEA</span>;
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Use electronic health record (EHR) data to (1) est. the risk of arrhythmia assocd. with inhaled short-acting beta-2 agonists (SABA) in pediatric patients and (2) det. whether risk varied by on-label vs. off-label prescribing.  Retrospective cohort study of 335 041 children =18 years using EHR primary care data from 2 pediatric health systems (2011-2013).  A series of monthly pseudotrials were created, using propensity score methodol. to balance baseline characteristics between SABA-exposed (identified by prescription) and SABA-unexposed children.  Assocn. between SABA and subsequent arrhythmia for each health system was estd. through pooled logistic regression with sep. ests. for children initiating under and over 4 years old (off-label and on-label, resp.).  Eleven percent of the cohort received a SABA prescription, 57% occurred under the age of 4 years (off-label).  During the follow-up period, there were 283 first arrhythmia events, most commonly atrial tachyarrhythmias and premature ventricular/atrial contractions.  In 1 health system, adjusted risk for arrhythmia was increased among exposed children (OR 1.89, 95% CI 1.31-2.73) without evidence of interaction between label status and risk.  The abs. adjusted rate difference was 3.6/10 000 person-years of SABA exposure.  The assocn. between SABA exposure and arrhythmias was less strong in the second system (OR 1.26, 95% CI 0.30-5.33).  Using EHR data, we could est. the risk of a rare event assocd. with medication use and det. difference in risk related to on-label vs. off-label status.  These findings support the value of EHR-based data for postmarketing drug studies in the pediatric population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpmxC9v_NcmLVg90H21EOLACvtfcHk0libWOzPbu7Zrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yjtr3K&md5=fed2fab3464483fde08c8cef013fc55a</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1002%2Fpds.4562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.4562%26sid%3Dliteratum%253Aachs%26aulast%3DCzaja%26aufirst%3DA.%2BS.%26aulast%3DRoss%26aufirst%3DM.%2BE.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DFiks%26aufirst%3DA.%2BG.%26aulast%3DLocalio%26aufirst%3DR.%26aulast%3DWasserman%26aufirst%3DR.%2BC.%26aulast%3DGrundmeier%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DW.%2BG.%26atitle%3DElectronic%2520health%2520record%2520%2528EHR%2529%2520based%2520postmarketing%2520surveillance%2520of%2520adverse%2520events%2520associated%2520with%2520pediatric%2520off-label%2520medication%2520use%253A%2520A%2520case%2520study%2520of%2520short-acting%2520beta-2%2520agonists%2520and%2520arrhythmias%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2018%26volume%3D27%26spage%3D815%26epage%3D822%26doi%3D10.1002%2Fpds.4562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warnier, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blom, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdowksi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souverein, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoes, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H. L.</span></span> <span> </span><span class="NLM_article-title">Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e65638</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0065638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0065638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23755262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFKhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+J.+Warnierauthor=M.+T.+Blomauthor=A.+Bardaiauthor=J.+Berdowksiauthor=P.+C.+Souvereinauthor=A.+W.+Hoesauthor=F.+H.+Ruttenauthor=A.+de+Boerauthor=R.+W.+Kosterauthor=M.+L.+De+Bruinauthor=H.+L.+Tan&title=Increased+risk+of+sudden+cardiac+arrest+in+obstructive+pulmonary+disease%3A+a+case-control+study&doi=10.1371%2Fjournal.pone.0065638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study</span></div><div class="casAuthors">Warnier, Miriam Jacoba; Blom, Marieke Tabo; Bardai, Abdennasser; Berdowksi, Jocelyn; Souverein, Patrick Cyriel; Hoes, Arno Wilhelmus; Rutten, Frans Hendrik; de Boer, Anthonius; Koster, Rudolph Willem; De Bruin, Marie Louise; Tan, Han Liong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e65638</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: We aimed to det. whether (1) patients with obstructive pulmonary disease (OPD) have an increased risk of sudden cardiac arrest (SCA) due to ventricular tachycardia or fibrillation (VT/VF), and (2) the SCA risk is mediated by cardiovascular risk-profile and/or respiratory drug use.  Methods: A community-based case-control study was performed, with 1310 cases of SCA of the ARREST study and 5793 age, sex and SCA-date matched non-SCA controls from the PHARMO database.  Only incident SCA cases, age older than 40 years, that resulted from unequivocal cardiac causes with electro-cardiog. documentation of VT/VF were included.  Conditional logistic regression anal. was used to assess the assocn. between SCA and OPD.  Pre-specified subgroup analyses were performed regarding age, sex, cardiovascular risk-profile, disease severity and current use of respiratory drugs.  Results: A higher risk of SCA was obsd. in patients with OPD (n = 190 cases [15%], 622 controls [11%]) than in those without OPD (OR adjusted for cardiovascular risk-profile 1.4 [1.2-1.6]).  In OPD patients with a high cardiovascular risk-profile (OR 3.5 [2.7-4.4]) a higher risk of SCA was obsd. than in those with a low cardiovascular risk-profile (OR: 1.3 [0.9-1.9]).  The obsd. SCA risk was highest among OPD patients who received short-acting β2-adrenoreceptor agonists (SABA) or anticholinergics (AC) at the time of SCA (SABA OR: 3.9 [1.7-8.8], AC OR: 2.7 [1.5-4.8] compared to those without OPD).  Conclusions: OPD is assocd. with an increased obsd. risk of SCA.  The most increased risk was obsd. in patients with a high cardiovascular risk-profile, and in those who received SABA and, possibly, those who received AC at the time of SCA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLwFXsCsIhRLVg90H21EOLACvtfcHk0libWOzPbu7Zrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFKhtbs%253D&md5=0ffba9b00b7d96bc26220b3d422f2bea</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0065638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0065638%26sid%3Dliteratum%253Aachs%26aulast%3DWarnier%26aufirst%3DM.%2BJ.%26aulast%3DBlom%26aufirst%3DM.%2BT.%26aulast%3DBardai%26aufirst%3DA.%26aulast%3DBerdowksi%26aufirst%3DJ.%26aulast%3DSouverein%26aufirst%3DP.%2BC.%26aulast%3DHoes%26aufirst%3DA.%2BW.%26aulast%3DRutten%26aufirst%3DF.%2BH.%26aulast%3Dde%2BBoer%26aufirst%3DA.%26aulast%3DKoster%26aufirst%3DR.%2BW.%26aulast%3DDe%2BBruin%26aufirst%3DM.%2BL.%26aulast%3DTan%26aufirst%3DH.%2BL.%26atitle%3DIncreased%2520risk%2520of%2520sudden%2520cardiac%2520arrest%2520in%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520case-control%2520study%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0065638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouwels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klungel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leufkens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Staa, T.</span></span> <span> </span><span class="NLM_article-title">Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2007.03077.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1365-2125.2007.03077.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18279472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Cgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=580-586&author=F.+de+Vriesauthor=S.+Pouwelsauthor=M.+Brackeauthor=J.+W.+Lammersauthor=O.+Klungelauthor=H.+Leufkensauthor=T.+van+Staa&title=Use+of+beta2+agonists+and+risk+of+acute+myocardial+infarction+in+patients+with+hypertension&doi=10.1111%2Fj.1365-2125.2007.03077.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Use of β2 agonists and risk of acute myocardial infarction in patients with hypertension</span></div><div class="casAuthors">de Vries, Frank; Pouwels, Sander; Bracke, Madelon; Lammers, Jan-Willem; Klungel, Olaf; Leufkens, Hubert; van Staa, Tjeerd</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">580-586</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">AIM: Observational retrospective studies of the assocn. between use of β2 agonists and the risk of acute myocardial infarction (MI) have demonstrated conflicting results, particularly among first-time users.  The aim of this study was to examine the assocn. between β2 agonist use and first nonfatal acute MI.  METHODS: We conducted a case-control study (2476 cases) nested in a cohort of antihypertensive drug users in the Dutch PHARMO RLS database.  PHARMO RLS consists of drug dispensing linked to the national hospitalizations register.  Each case of nonfatal acute MI was matched with up to 12 control patients by gender, age and region.  Drug and disease history and the severity of the underlying respiratory disease were adjusted for.  RESULTS: Risk of acute MI was increased in current β2 agonist users [crude odds ratio (OR) 1.36, 95% confidence interval (CI) 1.15, 1.61].  However, this excess risk was reduced after adjustment for severity of asthma and chronic obstructive pulmonary disease (adjusted OR 1.18, 95% CI 0.93, 1.49).  The risk was highest in patients with ischemic heart disease and low cumulative dose of β2 agonists (adjusted OR 2.47, 95% CI 1.60, 3.82).  CONCLUSION: Most users of β2 agonists did not have an increased risk of acute MI.  Only patients with ischemic heart disease with low cumulative exposure to β2 agonists had an increased risk of acute MI.  It is likely that this increased risk was related to latent cardiovascular disease rather than to the direct effects of β2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB7p3aDcMwBbVg90H21EOLACvtfcHk0ljAf3N32rt1qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Cgsbs%253D&md5=e9a9df243c1b4f6b3f0c0f64460140b6</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2007.03077.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2007.03077.x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVries%26aufirst%3DF.%26aulast%3DPouwels%26aufirst%3DS.%26aulast%3DBracke%26aufirst%3DM.%26aulast%3DLammers%26aufirst%3DJ.%2BW.%26aulast%3DKlungel%26aufirst%3DO.%26aulast%3DLeufkens%26aufirst%3DH.%26aulast%3Dvan%2BStaa%26aufirst%3DT.%26atitle%3DUse%2520of%2520beta2%2520agonists%2520and%2520risk%2520of%2520acute%2520myocardial%2520infarction%2520in%2520patients%2520with%2520hypertension%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D65%26spage%3D580%26epage%3D586%26doi%3D10.1111%2Fj.1365-2125.2007.03077.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thottathil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zareba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. L.</span></span> <span> </span><span class="NLM_article-title">International Long QT Syndrome Investigative Group Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2008.05.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.amjcard.2008.05.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18805113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFektrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=871-874&author=P.+Thottathilauthor=J.+Acharyaauthor=A.+J.+Mossauthor=C.+Jonsauthor=S.+McNittauthor=I.+Goldenbergauthor=W.+Zarebaauthor=E.+Kaufmanauthor=M.+Qiauthor=J.+L.+Robinson&title=International+Long+QT+Syndrome+Investigative+Group+Risk+of+cardiac+events+in+patients+with+asthma+and+long-QT+syndrome+treated+with+beta%282%29+agonists&doi=10.1016%2Fj.amjcard.2008.05.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of Cardiac Events in Patients With Asthma and Long-QT Syndrome Treated With Beta2 Agonists</span></div><div class="casAuthors">Thottathil, Princy; Acharya, Jay; Moss, Arthur J.; Jons, Christian; McNitt, Scott; Goldenberg, Ilan; Zareba, Wojciech; Kaufman, Elizabeth; Qi, Ming; Robinson, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">871-874</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The clin. course and risk factors assocd. with β2-agonist therapy for asthma have not been investigated previously in patients with the long-QT syndrome (LQTS).  The risk of a first LQTS-related cardiac event due to β2-agonist therapy was examd. in 3,287 patients enrolled in the International LQTS Registry with QTc ≥450 ms.  The Cox proportional hazards model was used to assess the independent contribution of clin. factors for first cardiac events (syncope, aborted cardiac arrest, or sudden death) from birth through age 40.  Time-dependent β2-agonist therapy for asthma was assocd. with an increased risk for cardiac events (hazard ratio [HR] = 2.00, 95% confidence interval 1.26 to 3.15, p = 0.003) after adjustment for relevant covariates including time-dependent β-blocker use, gender, QTc, and history of asthma.  This risk was augmented within the first year after the initiation of β2-agonist therapy (HR = 3.53, p = 0.006).  The combined use of β2-agonist therapy and anti-inflammatory steroids was assocd. with an elevated risk for cardiac events (HR = 3.66, p <0.01); β-blocker therapy was assocd. with a redn. in cardiac events in those using β2 agonists (HR = 0.14, p = 0.05).  In conclusion, β2-agonist therapy was assocd. with an increased risk for cardiac events in patients with asthma with LQTS, and this risk was diminished in patients receiving β blockers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEO9G66YprrVg90H21EOLACvtfcHk0ljAf3N32rt1qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFektrjL&md5=ec100c7cccd7921bc4171ecc7cba23e6</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2008.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2008.05.029%26sid%3Dliteratum%253Aachs%26aulast%3DThottathil%26aufirst%3DP.%26aulast%3DAcharya%26aufirst%3DJ.%26aulast%3DMoss%26aufirst%3DA.%2BJ.%26aulast%3DJons%26aufirst%3DC.%26aulast%3DMcNitt%26aufirst%3DS.%26aulast%3DGoldenberg%26aufirst%3DI.%26aulast%3DZareba%26aufirst%3DW.%26aulast%3DKaufman%26aufirst%3DE.%26aulast%3DQi%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DJ.%2BL.%26atitle%3DInternational%2520Long%2520QT%2520Syndrome%2520Investigative%2520Group%2520Risk%2520of%2520cardiac%2520events%2520in%2520patients%2520with%2520asthma%2520and%2520long-QT%2520syndrome%2520treated%2520with%2520beta%25282%2529%2520agonists%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2008%26volume%3D102%26spage%3D871%26epage%3D874%26doi%3D10.1016%2Fj.amjcard.2008.05.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, J. W.</span></span> <span> </span><span class="NLM_article-title">Can oral beta2 agonists cause heart failure?</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)79750-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2805%2979750-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9798578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1M%252Fht12hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=1998&pages=1081-1082&author=J.+W.+Jenne&title=Can+oral+beta2+agonists+cause+heart+failure%3F&doi=10.1016%2FS0140-6736%2805%2979750-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Can oral beta2 agonists cause heart failure?</span></div><div class="casAuthors">Jenne J W</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">9134</span>),
    <span class="NLM_cas:pages">1081-2</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmOZZGvZAIlK2q3xNe7a7QfW6udTcc2ebKSxpunv2bJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252Fht12hsA%253D%253D&md5=bf46c30ad2a060ced3f246349bbce627</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2979750-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252979750-6%26sid%3Dliteratum%253Aachs%26aulast%3DJenne%26aufirst%3DJ.%2BW.%26atitle%3DCan%2520oral%2520beta2%2520agonists%2520cause%2520heart%2520failure%253F%26jtitle%3DLancet%26date%3D1998%26volume%3D352%26spage%3D1081%26epage%3D1082%26doi%3D10.1016%2FS0140-6736%2805%2979750-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemaitre, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siscovick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Psaty, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunathan, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitsel, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinmann, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span> <span> </span><span class="NLM_article-title">Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1016/S0002-9343(02)01384-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0002-9343%2802%2901384-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12517359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVWh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2002&pages=711-716&author=R.+N.+Lemaitreauthor=D.+S.+Siscovickauthor=B.+M.+Psatyauthor=R.+M.+Pearceauthor=T.+E.+Raghunathanauthor=E.+A.+Whitselauthor=S.+A.+Weinmannauthor=G.+D.+Andersonauthor=D.+Lin&title=Inhaled+beta-2+adrenergic+receptor+agonists+and+primary+cardiac+arrest&doi=10.1016%2FS0002-9343%2802%2901384-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest</span></div><div class="casAuthors">Lemaitre, Rozenn N.; Siscovick, David S.; Psaty, Bruce M.; Pearce, Rachel M.; Raghunathan, Trivellore E.; Whitsel, Eric A.; Weinmann, Sheila A.; Anderson, Gail D.; Lin, Danyu</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">We sought to investigate if short-acting, inhaled β2-adrenergic receptor agonists were assocd. with higher risk of primary cardiac arrest in patients with asthma or chronic obstructive pulmonary disease (COPD).  We conducted a population-based study involving 454 patients enrolled in a health maintenance organization, aged 40 to 79 yr, who had asthma or COPD and who experienced primary cardiac arrest during 1980 to 1994.  We randomly selected 586 controls from strata of enrollees, defined by age, sex, calendar year, and prior heart disease.  Medication use was assessed from computerized pharmacy data, and risk factors from medical record review.  Use of inhaled β-agonists was assocd. with a twofold increased risk of primary cardiac arrest (odds ratio [OR] = 1.9; 95% confidence interval [CI]: 1.1 to 3.3) among patients with asthma, but not among those with COPD (OR = 1.3; 95% CI: 0.6 to 2.7), after adjustment for risk factors.  This assocn. was obsd. only with use of two or more canisters of metered-dose, inhaled β-agonists for 3 mo, and when inhaled steroids were not used.  These results support current guidelines recommending inhaled steroids as first-line asthma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqtIblsNz9-rVg90H21EOLACvtfcHk0liKwI6t3JS8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVWh&md5=bbc1f7add31a50438001f0c7e203b098</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2FS0002-9343%2802%2901384-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9343%252802%252901384-0%26sid%3Dliteratum%253Aachs%26aulast%3DLemaitre%26aufirst%3DR.%2BN.%26aulast%3DSiscovick%26aufirst%3DD.%2BS.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DPearce%26aufirst%3DR.%2BM.%26aulast%3DRaghunathan%26aufirst%3DT.%2BE.%26aulast%3DWhitsel%26aufirst%3DE.%2BA.%26aulast%3DWeinmann%26aufirst%3DS.%2BA.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DLin%26aufirst%3DD.%26atitle%3DInhaled%2520beta-2%2520adrenergic%2520receptor%2520agonists%2520and%2520primary%2520cardiac%2520arrest%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2002%26volume%3D113%26spage%3D711%26epage%3D716%26doi%3D10.1016%2FS0002-9343%2802%2901384-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warnier, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kors, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoes, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, M. L.</span></span> <span> </span><span class="NLM_article-title">Cardiac arrhythmias in adult patients with asthma</span>. <i>J. Asthma</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.3109/02770903.2012.724132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3109%2F02770903.2012.724132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23013453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FgtlCjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=942-946&author=M.+J.+Warnierauthor=F.+H.+Ruttenauthor=J.+A.+Korsauthor=J.+W.+Lammersauthor=A.+de+Boerauthor=A.+W.+Hoesauthor=M.+L.+de+Bruin&title=Cardiac+arrhythmias+in+adult+patients+with+asthma&doi=10.3109%2F02770903.2012.724132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac arrhythmias in adult patients with asthma</span></div><div class="casAuthors">Warnier Miriam J; Rutten Frans H; Kors Jan A; Lammers Jan Willem J; de Boer Anthonius; Hoes Arno W; de Bruin Marie L</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of asthma : official journal of the Association for the Care of Asthma</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The pathogenesis of cardiac arrhythmias in asthma patients has not been fully elucidated.  Adverse drug effects, particularly those of β2-mimetics, may play a role.  The aim of this study was to determine whether asthma is associated with the risk of cardiac arrhythmias and electrocardiographic characteristics of arrhythmogenicity (ECG) and to explore the role of β2-mimetics.  METHODS:  A cross-sectional study was conducted among 158 adult patients with a diagnosis of asthma and 6303 participants without asthma from the cohort of the Utrecht Health Project-an ongoing, longitudinal, primary care-based study.  All patients underwent extensive examinations, including resting 12-lead electrocardiogram (ECG) and pulmonary function tests.  The primary outcome was "any arrhythmia on the ECG" (including tachycardia, bradycardia, premature ventricular contraction (PVC), and atrial fibrillation or flutter).  Secondary outcomes were tachycardia, bradycardia, PVC, atrial fibrillation or flutter, mean heart rate, mean corrected QT (QTc) interval length, and prolonged QTc interval.  RESULTS:  Tachycardia and PVCs were more prevalent in patients with asthma (3% and 4%, respectively) than those without asthma (0.6%, p < .001; 2%, p = .03, respectively).  The prevalence of QTc interval prolongation was similar in participants with (2%) and without asthma (3%, odds ratio [OR]: 0.6 and 95% confidence interval [95% CI]: 0.2-2.0).  In 74 asthma patients, who received β2-mimetics, tachycardia and PVCs were more common (OR: 12.4 [95% CI: 4.7-32.8] and 3.7 [95% CI: 1.3-10.5], respectively).  CONCLUSIONS:  The adult patients with asthma more commonly show tachycardia and PVCs on the ECG than those without asthma.  The patients with asthma received β2-mimetics; the risk of tachycardia and PVCs is even more pronounced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPSOrd7VZ0PZagfuraLLzSfW6udTcc2ebwGunIt3XjLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FgtlCjsw%253D%253D&md5=08ee6eef1a338fe0d653e9f176d9493e</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.3109%2F02770903.2012.724132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02770903.2012.724132%26sid%3Dliteratum%253Aachs%26aulast%3DWarnier%26aufirst%3DM.%2BJ.%26aulast%3DRutten%26aufirst%3DF.%2BH.%26aulast%3DKors%26aufirst%3DJ.%2BA.%26aulast%3DLammers%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BBoer%26aufirst%3DA.%26aulast%3DHoes%26aufirst%3DA.%2BW.%26aulast%3Dde%2BBruin%26aufirst%3DM.%2BL.%26atitle%3DCardiac%2520arrhythmias%2520in%2520adult%2520patients%2520with%2520asthma%26jtitle%3DJ.%2520Asthma%26date%3D2012%26volume%3D49%26spage%3D942%26epage%3D946%26doi%3D10.3109%2F02770903.2012.724132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, W.</span></span> <span> </span><span class="NLM_article-title">Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.2147/COPD.S198288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S198288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31114181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGksrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=799-808&author=C.+Liauthor=W.+Chengauthor=J.+Guoauthor=W.+Guan&title=Relationship+of+inhaled+long-acting+bronchodilators+with+cardiovascular+outcomes+among+patients+with+stable+COPD%3A+a+meta-analysis+and+systematic+review+of+43+randomized+trials&doi=10.2147%2FCOPD.S198288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials</span></div><div class="casAuthors">Li, Chenxi; Cheng, Wenke; Guo, Jin; Guan, Wei</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">799-808</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease (COPD).  Although previous studies have supported inhaled long-acting bronchodilators (ILABs) for overall cardiovascular safety, the risk of specific cardiovascular outcomes such as arrhythmia, heart failure and stroke is still unknown.  Materials and methods: We systematically searched from PubMed, the Embase database and the Cochrane Library for published studies on ILABs and COPD, from its inception to Nov. 10, 2018, with no language restrictions.  The RRs and corresponding 95% CIs were pooled to evaluate ILAB/placebo.  Results: Finally, 43 randomized controlled trials were included.  Compared with placebo, ILABs do not increase the risk of overall and specific cardiovascular adverse events (AEs); on the contrary, they can reduce the incidence of hypertension (RR 0.73, 95% CI 0.55-0.98; I219.9%; P= 0.221).  However, when stratified according to the specific agents of ILABs, olodaterol might reduce the risk of overall cardiovascular adverse events (OCAEs) (RR 0.65, 95% CI 0.49-0.88;I227.5%; P= 0.000), and the protective effect of lowing blood pressure disappeared.  Similarly, the use of inhaled LABA might increase the risk of cardiac failure (RR 1.71, 95% CI 1.04-2.84;I20%; P= 0.538), but this risk disappeared when stratified according to the specific agents of LABA.  Besides, formoterol might decrease the risk of cardiac ischemia (RR 0.53, 95% CI 0.32-0.91; I20%; P= 0.676).  Conclusions: Overall, the use of ILABs was not assocd. with overall cardiovascular AEs in patients with stable COPD.  When stratified according to the specific agents of LABA, olodaterol might reduce the risk of OCAE; and formoterol might decrease the risk of cardiac ischemia.  LABA might reduce the incidence of hypertension, but might increase the risk of heart failure.  Therefore, COPD patients with a history of heart failure should use it with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdd357FBOMGbVg90H21EOLACvtfcHk0liKwI6t3JS8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGksrjJ&md5=2223f750c874a5bc4555cbf699947c14</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S198288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S198288%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DW.%26atitle%3DRelationship%2520of%2520inhaled%2520long-acting%2520bronchodilators%2520with%2520cardiovascular%2520outcomes%2520among%2520patients%2520with%2520stable%2520COPD%253A%2520a%2520meta-analysis%2520and%2520systematic%2520review%2520of%252043%2520randomized%2520trials%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2019%26volume%3D14%26spage%3D799%26epage%3D808%26doi%3D10.2147%2FCOPD.S198288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canepa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, G.</span></span> <span> </span><span class="NLM_article-title">Pulmonary and cardiac drugs: clinically relevant interactions</span>. <i>Herz</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1007/s00059-019-4834-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00059-019-4834-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31297545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3MzmsFGnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=517-521&author=H.+Olschewskiauthor=M.+Canepaauthor=G.+Kovacs&title=Pulmonary+and+cardiac+drugs%3A+clinically+relevant+interactions&doi=10.1007%2Fs00059-019-4834-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary and cardiac drugs: clinically relevant interactions</span></div><div class="casAuthors">Olschewski H; Kovacs G; Canepa M</div><div class="citationInfo"><span class="NLM_cas:title">Herz</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">517-521</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic heart and lung diseases are very common in the elderly population.  The combination of chronic heart failure and chronic obstructive pulmonary disease (COPD) is also common and, according to current guidelines, these patients should be treated for both diseases.  In patients with heart failure, beta-blockers are very important drugs because their use is associated with significantly improved morbidity and mortality.  These beneficial effects were documented in patients with and without COPD, although theoretically there is a risk for bronchoconstriction, particularly with non-beta1 selective blockers.  In COPD patients, long-acting sympathomimetics (LABA) improve lung function, dyspnea, and quality of life and their combination with a beta-blocker makes sense from a pharmacological and a clinical point of view, because any potential arrhythmogenic effects of the LABA will be ameliorated by the beta-blocker.  Inhaled tiotropium, a long-acting muscarinic antagonist (LAMA), has been extensively investigated and no safety concerns were reported in terms of cardiac adverse effects.  The same applies for the other approved LAMA preparations and LAMA-LABA combinations.  Severe COPD causes air-trapping with increasing pressures in the thorax, leading to limitations in blood return into the thorax from the periphery of the body.  This causes a decrease in stroke volume and cardiac index and is associated with dyspnea.  All these adverse effects can be ameliorated by potent anti-obstructive therapy as recently shown by means of a LABA-LAMA combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1kRjIWrnkV_xQvRxYU81tfW6udTcc2ebwGunIt3XjLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzmsFGnuw%253D%253D&md5=d4e83a7439ab1ecfae51bdbe1b297c15</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1007%2Fs00059-019-4834-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00059-019-4834-3%26sid%3Dliteratum%253Aachs%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DCanepa%26aufirst%3DM.%26aulast%3DKovacs%26aufirst%3DG.%26atitle%3DPulmonary%2520and%2520cardiac%2520drugs%253A%2520clinically%2520relevant%2520interactions%26jtitle%3DHerz%26date%3D2019%26volume%3D44%26spage%3D517%26epage%3D521%26doi%3D10.1007%2Fs00059-019-4834-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhund, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span> <span> </span><span class="NLM_article-title">Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1093/eurjhf/hfn013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Feurjhf%2Fhfn013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19168510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FpsFGjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=130-139&author=N.+M.+Hawkinsauthor=M.+C.+Petrieauthor=P.+S.+Jhundauthor=G.+W.+Chalmersauthor=F.+G.+Dunnauthor=J.+J.+McMurray&title=Heart+failure+and+chronic+obstructive+pulmonary+disease%3A+diagnostic+pitfalls+and+epidemiology&doi=10.1093%2Feurjhf%2Fhfn013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology</span></div><div class="casAuthors">Hawkins Nathaniel Mark; Petrie Mark C; Jhund Pardeep S; Chalmers George W; Dunn Francis G; McMurray John J V</div><div class="citationInfo"><span class="NLM_cas:title">European journal of heart failure</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-9</span>
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    </div><div class="casAbstract">Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are global epidemics incurring significant morbidity and mortality.  The combination presents many diagnostic challenges.  Clinical symptoms and signs frequently overlap.  Evaluation of cardiac and pulmonary function is often problematic and occasionally misleading.  Echocardiography and pulmonary function tests should be performed in every patient.  Careful interpretation is required to avoid misdiagnosis and inappropriate treatment.  Airflow obstruction, in particular, must be demonstrated when clinically euvolaemic.  Very high and very low concentrations of natriuretic peptides have high positive and negative predictive values for diagnosing HF in those with both conditions.  Intermediate values are less informative.  Both conditions are systemic disorders with overlapping pathophysiological processes.  In patients with HF, COPD is consistently an independent predictor of death and hospitalization.  However, the impact on ischaemic and arrhythmic events is unknown.  Greater collaboration is required between cardiologists and pulmonologists to better identify and manage concurrent HF and COPD.  The resulting symptomatic and prognostic benefits outweigh those attainable by treating either condition alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgpJDHp8VZjtXdcedVHT5tfW6udTcc2eb8wONRnIqwM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FpsFGjtA%253D%253D&md5=2a3f91a114e394485b7d0e1499fcbba0</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfn013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfn013%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DN.%2BM.%26aulast%3DPetrie%26aufirst%3DM.%2BC.%26aulast%3DJhund%26aufirst%3DP.%2BS.%26aulast%3DChalmers%26aufirst%3DG.%2BW.%26aulast%3DDunn%26aufirst%3DF.%2BG.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26atitle%3DHeart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520diagnostic%2520pitfalls%2520and%2520epidemiology%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2009%26volume%3D11%26spage%3D130%26epage%3D139%26doi%3D10.1093%2Feurjhf%2Fhfn013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhund, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span> <span> </span><span class="NLM_article-title">Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2011.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jacc.2011.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21596228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1yjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2011&pages=2127-2138&author=N.+M.+Hawkinsauthor=M.+C.+Petrieauthor=M.+R.+Macdonaldauthor=P.+S.+Jhundauthor=L.+M.+Fabbriauthor=J.+Wikstrandauthor=J.+J.+McMurray&title=Heart+failure+and+chronic+obstructive+pulmonary+disease+the+quandary+of+Beta-blockers+and+Beta-agonists&doi=10.1016%2Fj.jacc.2011.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Heart failure and chronic obstructive pulmonary disease: The quandary of beta-blockers and beta-antagonists</span></div><div class="casAuthors">Hawkins, Nathaniel M.; Petrie, Mark C.; MacDonald, Michael R.; Jhund, Pardeep S.; Fabbri, Leonardo M.; Wikstrand, John; McMurray, John J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2127-2138</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The combination of heart failure and chronic obstructive pulmonary disease presents many therapeutic challenges.  The cornerstones of therapy are beta-blockers and beta-agonists, resp.  Their pharmacol. effects are diametrically opposed, and each is purported to adversely affect the alternative condition.  The tolerability of beta-blockade in patients with mild and fixed airflow obstruction likely extends to those with more severe disease.  However, the evidence is rudimentary.  The long-term influence of beta-blockade on pulmonary function, symptoms, and quality of life is unclear.  Low-dose Initiation and gradual up-titrn. of cardioselective beta-blockers is currently recommended.  Robust clin. trials are needed to provide the answers that may finally allay physicians' mistrust of beta-blockers in patients with chronic obstructive pulmonary disease.  Beta-agonists are assocd. with incident heart failure in patients with pulmonary disease and with increased mortality and hospitalization In those with existing heart failure.  These purported adverse effects require further Investigation.  In the meantime, clinicians should consider carefully the etiol. of dyspnea and obtain objective evidence of airflow obstruction before prescribing beta-agonists to patients with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrdoZS5Xtv4bVg90H21EOLACvtfcHk0lhuNM7hSZaDFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1yjsLY%253D&md5=f654f84e3c9736760ef231ad0973e0bd</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2011.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2011.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DN.%2BM.%26aulast%3DPetrie%26aufirst%3DM.%2BC.%26aulast%3DMacdonald%26aufirst%3DM.%2BR.%26aulast%3DJhund%26aufirst%3DP.%2BS.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DWikstrand%26aufirst%3DJ.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26atitle%3DHeart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520the%2520quandary%2520of%2520Beta-blockers%2520and%2520Beta-agonists%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2011%26volume%3D57%26spage%3D2127%26epage%3D2138%26doi%3D10.1016%2Fj.jacc.2011.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, W.</span></span> <span> </span><span class="NLM_article-title">Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.2147/COPD.S79942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S79942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25784798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnls1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=515-523&author=Y.+Kubotaauthor=K.+Asaiauthor=E.+Furuseauthor=S.+Nakamuraauthor=K.+Muraiauthor=Y.+T.+Tsukadaauthor=W.+Shimizu&title=Impact+of+%CE%B2-blocker+selectivity+on+long-term+outcomes+in+congestive+heart+failure+patients+with+chronic+obstructive+pulmonary+disease&doi=10.2147%2FCOPD.S79942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Kubota Yoshiaki; Asai Kuniya; Furuse Erito; Nakamura Shunichi; Murai Koji; Tsukada Yayoi Tetsuou; Shimizu Wataru</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">515-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is present in approximately one-third of all congestive heart failure (CHF) patients, and is a key cause of underprescription and underdosing of β-blockers, largely owing to concerns about precipitating respiratory deterioration.  For these reasons, the aim of this study was to evaluate the impact of β-blockers on the long-term outcomes in CHF patients with COPD.  In addition, we compared the effects of two different β-blockers, carvedilol and bisoprolol.  METHODS:  The study was a retrospective, non-randomized, single center trial.  Acute decompensated HF patients with COPD were classified according to the oral drug used at discharge into β-blocker (n=86; carvedilol [n=52] or bisoprolol [n=34]) and non-β-blocker groups (n=46).  The primary endpoint was all-cause mortality between the β-blocker and non-β-blocker groups during a mean clinical follow-up of 33.9 months.  The secondary endpoints were the differences in all-cause mortality and the hospitalization rates for CHF and/or COPD exacerbation between patients receiving carvedilol and bisoprolol.  RESULTS:  The mortality rate was higher in patients without β-blockers compared with those taking β-blockers (log-rank P=0.039), and univariate analyses revealed that the use of β-blockers was the only factor significantly correlated with the mortality rate (hazard ratio: 0.41; 95% confidence interval: 0.17-0.99; P=0.047).  Moreover, the rate of CHF and/or COPD exacerbation was higher in patients treated with carvedilol compared with bisoprolol (log-rank P=0.033).  In the multivariate analysis, only a past history of COPD exacerbation significantly increased the risk of re-hospitalization due to CHF and/or COPD exacerbation (adjusted hazard ratio: 3.11; 95% confidence interval: 1.47-6.61; P=0.003).  CONCLUSION:  These findings support the recommendations to use β-blockers in HF patients with COPD.  Importantly, bisoprolol reduced the incidence of CHF and/or COPD exacerbation compared with carvedilol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvDoMDseirLGLFM_lbR1VmfW6udTcc2eb8wONRnIqwM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnls1Wguw%253D%253D&md5=8f868868e9b5287a7b33afc30ec7df11</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S79942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S79942%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DK.%26aulast%3DFuruse%26aufirst%3DE.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DMurai%26aufirst%3DK.%26aulast%3DTsukada%26aufirst%3DY.%2BT.%26aulast%3DShimizu%26aufirst%3DW.%26atitle%3DImpact%2520of%2520%25CE%25B2-blocker%2520selectivity%2520on%2520long-term%2520outcomes%2520in%2520congestive%2520heart%2520failure%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2015%26volume%3D10%26spage%3D515%26epage%3D523%26doi%3D10.2147%2FCOPD.S79942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puente-Maestu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-González, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Márquez-Martín, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcos-Rodriguez, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Hermosa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malo de Molina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobradillo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcázar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Conde, G.</span></span> <span> </span><span class="NLM_article-title">GEMEPOC, Group. Multicentric study on the beta-blocker use and relation with exacerbations in COPD</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2014.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2014.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24635914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2crktlWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=737-744&author=L.+Puente-Maestuauthor=M.+Calleauthor=A.+Ortega-Gonz%C3%A1lezauthor=A.+Fusterauthor=C.+Gonz%C3%A1lezauthor=E.+M%C3%A1rquez-Mart%C3%ADnauthor=P.+J.+Marcos-Rodriguezauthor=C.+Caleroauthor=J.+L.+Rodr%C3%ADguez-Hermosaauthor=R.+Malo+de+Molinaauthor=M.+Aburtoauthor=P.+Sobradilloauthor=B.+Alc%C3%A1zarauthor=G.+Tirado-Conde&title=GEMEPOC%2C+Group.+Multicentric+study+on+the+beta-blocker+use+and+relation+with+exacerbations+in+COPD&doi=10.1016%2Fj.rmed.2014.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Multicentric study on the beta-blocker use and relation with exacerbations in COPD</span></div><div class="casAuthors">Puente-Maestu Luis; Calle Myriam; Rodriguez-Hermosa Juan Luis; Ortega-Gonzalez Angel; Fuster Antonia; Gonzalez Cruz; Marquez-Martin Eduardo; Marcos-Rodriguez Pedro Jorge; Calero Carmen; Malo de Molina Rosa; Aburto Myriam; Sobradillo Patricia; Alcazar Bernardino; Tirado-Conde Gema</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">737-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart failure (CHF) or coronary artery disease (CAD).  In spite of the recommendation to use beta-blockers (BB) they are likely under-prescribed to patients with concurrent COPD and heart diseases.  To find out the prevalence of use of BB, 256 COPD patients were consecutively recruited by pulmonary physicians from 14 hospitals in 7 regions of Spain in their outpatient offices if they had a diagnosis of COPD, were not on long-term oxygen therapy, had CHF or CAD, and met the criteria for BB treatment.  In patients with indication 58% (95%CI, 52-64%) of the COPD patients and 97% of the non-COPD patients were on BB (p < 0.001).  In patients with COPD, several factors were independently related to at least one visit to the emergency room in the previous year such as use of BB, adjusted OR = 0.27 (95% CI 0.15-0.50), GOLD stage D, OR = 2.52 (1.40-4.53), baseline heart rate >70, OR 2.19 (1.24-3.86) use of long-acting beta2-agonists OR = 2.18 (1.29-3.68), previous episodes of left ventricular failure OR 2.27 (1.19-4.33) and diabetes, OR = 1.82 (1.08-3.38).  We conclude that, according to what is recommended by current guidelines, BB are still under-prescribed in COPD patients.  COPD patients with CHF or CAD using BB suffer fewer exacerbations and visits to the ER.  GOLD stage, use of long-acting beta2-agonists, baseline heart rate and comorbidities are also risk factors for exacerbations in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyATmu1Y79DPx2phytoz6_fW6udTcc2eYg8YSGX5jxH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crktlWjtQ%253D%253D&md5=82f92c3e93a6e2fc4645bb0e6374b43b</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2014.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2014.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DPuente-Maestu%26aufirst%3DL.%26aulast%3DCalle%26aufirst%3DM.%26aulast%3DOrtega-Gonz%25C3%25A1lez%26aufirst%3DA.%26aulast%3DFuster%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DC.%26aulast%3DM%25C3%25A1rquez-Mart%25C3%25ADn%26aufirst%3DE.%26aulast%3DMarcos-Rodriguez%26aufirst%3DP.%2BJ.%26aulast%3DCalero%26aufirst%3DC.%26aulast%3DRodr%25C3%25ADguez-Hermosa%26aufirst%3DJ.%2BL.%26aulast%3DMalo%2Bde%2BMolina%26aufirst%3DR.%26aulast%3DAburto%26aufirst%3DM.%26aulast%3DSobradillo%26aufirst%3DP.%26aulast%3DAlc%25C3%25A1zar%26aufirst%3DB.%26aulast%3DTirado-Conde%26aufirst%3DG.%26atitle%3DGEMEPOC%252C%2520Group.%2520Multicentric%2520study%2520on%2520the%2520beta-blocker%2520use%2520and%2520relation%2520with%2520exacerbations%2520in%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2014%26volume%3D108%26spage%3D737%26epage%3D744%26doi%3D10.1016%2Fj.rmed.2014.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span> <span> </span><span class="NLM_article-title">The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2573</span>– <span class="NLM_lpage">2581</span>, <span class="refDoi"> DOI: 10.2147/COPD.S141694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S141694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28894360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGhs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2573-2581&author=K.+M.+Liaoauthor=T.+Y.+Linauthor=Y.+B.+Huangauthor=C.+C.+Kuoauthor=C.+Y.+Chen&title=The+evaluation+of+%CE%B2-adrenoceptor+blocking+agents+in+patients+with+COPD+and+congestive+heart+failure%3A+a+nationwide+study&doi=10.2147%2FCOPD.S141694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study</span></div><div class="casAuthors">Liao, Kuang-Ming; Lin, Tien-Yu; Huang, Yaw-Bin; Kuo, Chen-Chun; Chen, Chung-Yu</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2573-2581</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Objective: β-Blockers are safe and improve survival in patients with both congestive heart failure (CHF) and COPD.  However, the superiority of different types of β-blockers is still unclear among patients with CHF and COPD.  The assocn. between β-blockers and CHF exacerbation as well as COPD exacerbation remains unclear.  The objective of this study was to compare the outcome of different β-blockers in patients with concurrent CHF and COPD.  Patients and methods: We used the National Health Insurance Research Database in Taiwan to conduct a retrospective cohort study.  The inclusion criteria for CHF were patients who were < 20 years old and were diagnosed with CHF between Jan. 1, 2005 and Dec. 31, 2012.  COPD patients included those who had outpatient visit claims $ 2 times within 365 days or 1 claim for hospitalization with a COPD diagnosis.  A time-dependent Cox proportional hazards regression model was applied to evaluate the effectiveness of β-blockers in the study population.  Results: We identified 1,872 patients with concurrent CHF and COPD.  Only high-dose bisoprolol significantly reduced the risk of death and slightly decreased the hospitalization rate due to CHF exacerbation (death: adjusted hazard ratio [aHR] = 0.51, 95% confidence interval [CI] = 0.29-0.89; hospitalization rate due to CHF exacerbation: aHR = 0.48, 95% CI = 0.23-1.00).  No assocn. was obsd. between β-blocker use and COPD exacerbation.  Conclusion: In patients with concurrent CHF and COPD, β-blockers reduced mortality, CHF exacerbation, and the need for hospitalization.  Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKdmQgYj1G_bVg90H21EOLACvtfcHk0ljhuyaFs5Yx6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGhs7w%253D&md5=1b156213d2f929145447050a3ca02aec</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S141694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S141694%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DK.%2BM.%26aulast%3DLin%26aufirst%3DT.%2BY.%26aulast%3DHuang%26aufirst%3DY.%2BB.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BY.%26atitle%3DThe%2520evaluation%2520of%2520%25CE%25B2-adrenoceptor%2520blocking%2520agents%2520in%2520patients%2520with%2520COPD%2520and%2520congestive%2520heart%2520failure%253A%2520a%2520nationwide%2520study%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2017%26volume%3D12%26spage%3D2573%26epage%3D2581%26doi%3D10.2147%2FCOPD.S141694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perng, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. J.</span></span> <span> </span><span class="NLM_article-title">Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>95</i></span>, <span class="NLM_elocation-id">e2427</span> <span class="refDoi"> DOI: 10.1097/MD.0000000000002427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1097%2FMD.0000000000002427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26844454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2016&author=V.+Y.+Suauthor=Y.+S.+Changauthor=Y.+W.+Huauthor=M.+H.+Hungauthor=S.+M.+Ouauthor=F.+Y.+Leeauthor=K.+T.+Chouauthor=K.+Y.+Yangauthor=D.+W.+Perngauthor=T.+J.+Chenauthor=C.+J.+Liu&title=Carvedilol%2C+bisoprolol%2C+and+metoprolol+use+in+patients+with+coexistent+heart+failure+and+chronic+obstructive+pulmonary+disease&doi=10.1097%2FMD.0000000000002427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Su, Vincent Yi-Fong; Chang, Yu-Sheng; Hu, Yu-Wen; Hung, Man-Hsin; Ou, Shuo-Ming; Lee, Fa-Yauh; Chou, Kun-Ta; Yang, Kuang-Yao; Perng, Diahn-Warng; Chen, Tzeng-Ji; Liu, Chia-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e2427</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Beta (β)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs.  We aimed to evaluate the survival effects of β-blockers in patients with coexistent HF and COPD.  Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study.  Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled.  Doses of the 3 β-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extd.  The primary endpoint was cumulative survival.  Patients were followed until Dec. 31, 2009.  The study included 11,558 subjects, with a mean follow-up period of 4.07 years.  After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)=0.76, 95% confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95% CI=0.26-0.63, P<0.001] compared with nonusers, whereas no survival difference was obsd. for carvedilol or metoprolol.  Compared with patients with HF alone, this special HF+COPD cohort received significantly fewer targeted β-blockers (108.8 vs 137.3 defined daily doses (DDDs)/person-year, P<0.001) and bisoprolol (57.9 vs 70.8DDDs/person-year, P<0.001).  In patients with coexisting HF and COPD, this study demonstrated a dose-response survival benefit of bisoprolol use, but not of carvedilol or metoprolol use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHbBhP3bWqfrVg90H21EOLACvtfcHk0ljhuyaFs5Yx6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWrtrY%253D&md5=3e17c450681e50493e9263fdd85c4a74</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1097%2FMD.0000000000002427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0000000000002427%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DV.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DHu%26aufirst%3DY.%2BW.%26aulast%3DHung%26aufirst%3DM.%2BH.%26aulast%3DOu%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChou%26aufirst%3DK.%2BT.%26aulast%3DYang%26aufirst%3DK.%2BY.%26aulast%3DPerng%26aufirst%3DD.%2BW.%26aulast%3DChen%26aufirst%3DT.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%2BJ.%26atitle%3DCarvedilol%252C%2520bisoprolol%252C%2520and%2520metoprolol%2520use%2520in%2520patients%2520with%2520coexistent%2520heart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DMedicine%26date%3D2016%26volume%3D95%26doi%3D10.1097%2FMD.0000000000002427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoluabi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieske, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammar-Aouchiche, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesimer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuvim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span> <span> </span><span class="NLM_article-title">Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2007-0279RC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1165%2Frcmb.2007-0279RC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18096872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFejtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=256-262&author=L.+P.+Nguyenauthor=O.+Omoluabiauthor=S.+Parraauthor=J.+M.+Frieskeauthor=C.+Clementauthor=Z.+Ammar-Aouchicheauthor=S.+B.+Hoauthor=C.+Ehreauthor=M.+Kesimerauthor=B.+J.+Knollauthor=M.+J.+Tuvimauthor=B.+F.+Dickeyauthor=R.+A.+Bond&title=Chronic+exposure+to+beta-blockers+attenuates+inflammation+and+mucin+content+in+a+murine+asthma+model&doi=10.1165%2Frcmb.2007-0279RC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model</span></div><div class="casAuthors">Nguyen, Long P.; Omoluabi, Ozozoma; Parra, Sergio; Frieske, Joanna M.; Clement, Cecilia; Ammar-Aouchiche, Zoulikha; Ho, Samuel B.; Ehre, Camille; Kesimer, Mehmet; Knoll, Brian J.; Tuvim, Michael J.; Dickey, Burton F.; Bond, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-262</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Single-dose administration of β-adrenoceptor agonists produces bronchodilation and inhibits airway hyperresponsiveness (AHR), and is the std. treatment for the acute relief of asthma.  However, chronic repetitive administration of β-adrenoceptor agonists may increase AHR, airway inflammation, and risk of death.  Based upon the paradigm shift that occurred with the use of β-blockers in congestive heart failure, we previously detd. that chronic administration of β-blockers decreased AHR in a murine model of asthma.  To elucidate the mechanisms for the beneficial effects of β-blockers, we examd. the effects of chronic administration of several β-adrenoceptor ligands in a murine model of allergic asthma.  Administration of β-blockers resulted in a redn. in total cell counts, eosinophils, and the cytokines IL-13, IL-10, IL-5, and TGF-β1 in bronchoalveolar lavage, and attenuated epithelial mucin content and morphol. changes.  The differences in mucin content also occurred if the β-blockers were administered only during the ovalbumin challenge phase, but administration of β-blockers for 7 days was not as effective as administration for 28 days.  These results indicate that in a murine model of asthma, chronic administration of β-blockers reduces inflammation and mucous metaplasia, cardinal features of asthma that may contribute to airflow obstruction and AHR.  Similar to heart failure, our results provide a second disease model in which beta-blockers producing an acutely detrimental effect may provide a therapeutically beneficial effect with chronic administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-NIQ8z1s2E7Vg90H21EOLACvtfcHk0lgZIaj0c9o7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFejtLg%253D&md5=0de7cd6897989d8a2154a3b7a6bfcc62</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2007-0279RC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2007-0279RC%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BP.%26aulast%3DOmoluabi%26aufirst%3DO.%26aulast%3DParra%26aufirst%3DS.%26aulast%3DFrieske%26aufirst%3DJ.%2BM.%26aulast%3DClement%26aufirst%3DC.%26aulast%3DAmmar-Aouchiche%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DS.%2BB.%26aulast%3DEhre%26aufirst%3DC.%26aulast%3DKesimer%26aufirst%3DM.%26aulast%3DKnoll%26aufirst%3DB.%2BJ.%26aulast%3DTuvim%26aufirst%3DM.%2BJ.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DBond%26aufirst%3DR.%2BA.%26atitle%3DChronic%2520exposure%2520to%2520beta-blockers%2520attenuates%2520inflammation%2520and%2520mucin%2520content%2520in%2520a%2520murine%2520asthma%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2008%26volume%3D38%26spage%3D256%26epage%3D262%26doi%3D10.1165%2Frcmb.2007-0279RC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">Safety considerations with dual bronchodilator therapy in COPD: An update</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1007/s40264-016-0402-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs40264-016-0402-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26924197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFemsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=501-508&author=M.+G.+Materaauthor=P.+Roglianiauthor=L.+Calzettaauthor=M.+Cazzola&title=Safety+considerations+with+dual+bronchodilator+therapy+in+COPD%3A+An+update&doi=10.1007%2Fs40264-016-0402-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update</span></div><div class="casAuthors">Matera, Maria Gabriella; Rogliani, Paola; Calzetta, Luigino; Cazzola, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">501-508</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Combining a long-acting β2-agonist (LABA) with a long-acting anti-muscarinic agent (LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have major implications for the use of LABA/LAMA combinations in the treatment of chronic obstructive pulmonary disease (COPD).  There are four different approved LAMA/LABA fixed-dose combinations (FDCs)-glycopyrronium/indacaterol, umeclidinium/vilanterol, tiotropium/olodaterol, and aclidinium/formoterol-and another, glycopyrronium/formoterol, that is still under clin. development.  Many pivotal trials have shown that all of these FDCs are more effective than monotherapies in inducing bronchodilation and do not amplify the possible adverse events (AEs) that are characteristic of LAMAs and LABAs when used as monotherapy.  Unfortunately, these clin. trials have included a very small and highly selected fraction of the COPD patient population.  Therefore, it is questionable whether such data can be extrapolated to a larger, 'real-life' population of patients with COPD, esp. given that COPD patients with co-morbidities are often excluded from clin. trials, COPD is a major risk factor for most cardiovascular diseases, and both LAMAs and LABAs have a high potential to impact cardiac activities.  All clin. trials have been conducted under widely varying conditions and, consequently, AE rates of a drug obsd. in a clin. trial cannot be directly compared with rates in the clin. trials of another drug and may not reflect the rates obsd. in practice.  Head-to-head studies comparing the different LAMA/LABA FDCs that will include the true patients that we meet in our everyday practice are absolutely essential if we wish to make a therapeutic choice that is not purely empirical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi6JckVyKkn7Vg90H21EOLACvtfcHk0lgZIaj0c9o7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFemsLY%253D&md5=065ba0fee9b13218e1f7e70f95644377</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1007%2Fs40264-016-0402-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-016-0402-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DSafety%2520considerations%2520with%2520dual%2520bronchodilator%2520therapy%2520in%2520COPD%253A%2520An%2520update%26jtitle%3DDrug%2520Saf.%26date%3D2016%26volume%3D39%26spage%3D501%26epage%3D508%26doi%3D10.1007%2Fs40264-016-0402-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mentz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiuzat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenfeld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, C. M.</span></span> <span> </span><span class="NLM_article-title">Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2012.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.cardfail.2012.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22555273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1yhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=413-422&author=R.+J.+Mentzauthor=M.+Fiuzatauthor=M.+Kraftauthor=J.+Lindenfeldauthor=C.+M.+O%E2%80%99Connor&title=Bronchodilators+in+heart+failure+patients+with+COPD%3A+is+it+time+for+a+clinical+trial%3F&doi=10.1016%2Fj.cardfail.2012.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial?</span></div><div class="casAuthors">Mentz, Robert J.; Fiuzat, Mona; Kraft, Monica; Lindenfeld, Joann; O'Connor, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Chronic heart failure (HF) and chronic obstructive pulmonary disease (COPD) commonly coexist, and patients with both diseases fare worse than those with either disease alone.  Several factors may contribute to worse outcomes, including an increased burden of care related to greater disease complexity, an overlap of symptoms resulting in misapplication of therapy, and the adverse effects of treatment for one disease on the symptoms and outcomes related to the other.  For example, there are conflicting data about the cardiovascular risks of bronchodilators in HF patients who may experience worse outcomes with inhaled beta-2 agonists via arrhythmogenesis, ischemia, and/or attenuation of beta-blocker benefits.  In contrast, the long-acting anticholinergic class of bronchodilators has a more reassuring safety profile.  Anticholinergic bronchodilators may be the preferred first-line agents for COPD patients with comorbid HF, yet data supporting these recommendations are limited.  Therapeutic trials in COPD patients have generally excluded patients with significant HF and vice-versa.  This paper reviews bronchodilator therapy in HF and proposes a randomized trial designed to enroll patients with significant COPD and HF to det. the risks and/or benefits of adding a long-acting beta-2 agonist to patients currently taking a long-acting anticholinergic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRfLGmY4wkbVg90H21EOLACvtfcHk0lgZIaj0c9o7Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1yhsLs%253D&md5=74fb04c6a7a7517e5eefd9d97df38380</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2012.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2012.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DMentz%26aufirst%3DR.%2BJ.%26aulast%3DFiuzat%26aufirst%3DM.%26aulast%3DKraft%26aufirst%3DM.%26aulast%3DLindenfeld%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DC.%2BM.%26atitle%3DBronchodilators%2520in%2520heart%2520failure%2520patients%2520with%2520COPD%253A%2520is%2520it%2520time%2520for%2520a%2520clinical%2520trial%253F%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2012%26volume%3D18%26spage%3D413%26epage%3D422%26doi%3D10.1016%2Fj.cardfail.2012.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perng, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. Y.</span></span> <span> </span><span class="NLM_article-title">Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap</span>. <i>Aging</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3650</span>– <span class="NLM_lpage">3667</span>, <span class="refDoi"> DOI: 10.18632/aging.102004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.18632%2Faging.102004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31175265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1egu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=3650-3667&author=V.+Y.+Suauthor=Y.+H.+Yangauthor=D.+W.+Perngauthor=Y.+H.+Tsaiauthor=K.+T.+Chouauthor=K.+C.+Suauthor=W.+J.+Suauthor=P.+C.+Chenauthor=K.+Y.+Yang&title=Real-world+effectiveness+of+medications+on+survival+in+patients+with+COPD-heart+failure+overlap&doi=10.18632%2Faging.102004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap</span></div><div class="casAuthors">Su, Vincent Yi-Fong; Yang, Yao-Hsu; Perng, Diahn-Warng; Tsai, Ying-Huang; Chou, Kun-Ta; Su, Kang-Cheng; Su, Wei-Juin; Chen, Pau-Chung; Yang, Kuang-Yao</div><div class="citationInfo"><span class="NLM_cas:title">Aging</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3650-3667</span>CODEN:
                <span class="NLM_cas:coden">AGINCN</span>;
        ISSN:<span class="NLM_cas:issn">1945-4589</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">The appropriate treatment for patients with coexistent chronic obstructive pulmonary disease (COPD) and heart failure (HF) remains unclear.  Data from the Taiwan National Health Insurance Research Database was used for this retrospective cohort study.  Patients diagnosed with both diseases between 1997 and 2012 were enrolled as the COPD-heart failure overlap cohort.  Patients were categorized as non-users and users of specific COPD and HF medications.  Medication prescriptions in each 3-mo and 1-yr period served as time-dependent covariates.  The primary endpoint was cumulative survival.  The validation study confirmed the accuracy of definitions of COPD (94.0% sensitivity) and HF (96.3% sensitivity).  The study included 275,436 patients with COPD-heart failure overlap, with a mean follow-up period of 9.32 years.  The COPD-heart failure overlap cohort had more medical service use and higher mortality than did the COPD alone cohort.  Use of inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, long-acting muscarinic antagonist (LAMA), angiotensin receptor blockers (ARBs), β blockers, aldosterone antagonists, and statins reduced mortality risk compared with non-use.  Sensitivity and subgroup analyses confirmed the consistency and robustness of results.  ICS/LABA combinations, LAMA, ARBs, β blockers, aldosterone antagonists, and statins use was assocd. with a lower mortality risk in patients with COPD-heart failure overlap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaqdt2Xy-QOLVg90H21EOLACvtfcHk0lhcRamTuLIunw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1egu7o%253D&md5=822c27f20bff228b901686736b9b07b8</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.18632%2Faging.102004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Faging.102004%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DV.%2BY.%26aulast%3DYang%26aufirst%3DY.%2BH.%26aulast%3DPerng%26aufirst%3DD.%2BW.%26aulast%3DTsai%26aufirst%3DY.%2BH.%26aulast%3DChou%26aufirst%3DK.%2BT.%26aulast%3DSu%26aufirst%3DK.%2BC.%26aulast%3DSu%26aufirst%3DW.%2BJ.%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DYang%26aufirst%3DK.%2BY.%26atitle%3DReal-world%2520effectiveness%2520of%2520medications%2520on%2520survival%2520in%2520patients%2520with%2520COPD-heart%2520failure%2520overlap%26jtitle%3DAging%26date%3D2019%26volume%3D11%26spage%3D3650%26epage%3D3667%26doi%3D10.18632%2Faging.102004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. S.</span></span> <span> </span><span class="NLM_article-title">Comparative cardiovascular and cerebrovascular safety of inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: A population-based cohort study</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1002/phar.1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fphar.1684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26799347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=26-37&author=Y.+H.+Dongauthor=C.+H.+Changauthor=J.+J.+Gagneauthor=C.+L.+Hsuauthor=M.+S.+Lai&title=Comparative+cardiovascular+and+cerebrovascular+safety+of+inhaled+long-acting+bronchodilators+in+patients+with+chronic+obstructive+pulmonary+disease%3A+A+population-based+cohort+study&doi=10.1002%2Fphar.1684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study</span></div><div class="casAuthors">Dong, Yaa-Hui; Chang, Chia-Hsuin; Gagne, Joshua J.; Hsu, Chia-Lin; Lai, Mei-Shu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-37</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Study Objective : Inhaled long-acting bronchodilators are commonly used as maintenance therapy in chronic obstructive pulmonary disease (COPD).  We compared the risk of cardiovascular and cerebrovascular events among patients with COPD treated with inhaled long-acting bronchodilator monotherapy and combination therapy.  Design : Retrospective cohort study.  Settings : A population-based health care database from Taiwan.  Patients : Individuals with COPD who initiated long-acting muscarinic antagonists (LAMAs) alone, long-acting β-2 agonists (LABA) alone, and LABA and LAMA in combination between 2001 and 2010.  Measurements and Main Results : We used Cox regression models to compare a composite cardiovascular outcome, defined as hospitalization for acute myocardial infarction, congestive heart failure, and cerebrovascular diseases among the three treatment groups, adjusting for potential confounders.  Among a cohort of 3458 study-eligible patients, we identified 505 composite cardiovascular events during 10,590 patient-years of follow-up.  In the primary anal. which considered first exposure carried forward, LABA alone and LAMA alone were assocd. with similar risks of the composite outcome (hazard ratio [HR] 1.09; 95% confidence interval [CI] 0.87-1.37).  The HR comparing LABA and LAMA in combination with LAMA alone was 1.13 (95% CI 0.60-2.13) and to LABA alone was 1.03 (95% CI 0.55-1.92).  The secondary anal. in which we allowed patients to reenter the cohort upon treatment change yielded similar results, but with slightly higher HRs comparing LABA and LAMA in combination with LAMA alone (HR 1.26, 95% CI 0.74-2.15) and to LABA alone (HR 1.31, 95% CI 0.80-2.13).  Conclusions : Our results suggest similar cardiovascular and cerebrovascular safety of LABA and LAMA when agents are used alone.  Addnl. studies are needed to rule out potential risk assocd. with inhaled long-acting bronchodilator combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgoX9k0vml1bVg90H21EOLACvtfcHk0lhcRamTuLIunw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOkurk%253D&md5=92474b5b0afb3a57d22a77ffa122b500</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1002%2Fphar.1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1684%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%2BH.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DGagne%26aufirst%3DJ.%2BJ.%26aulast%3DHsu%26aufirst%3DC.%2BL.%26aulast%3DLai%26aufirst%3DM.%2BS.%26atitle%3DComparative%2520cardiovascular%2520and%2520cerebrovascular%2520safety%2520of%2520inhaled%2520long-acting%2520bronchodilators%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520A%2520population-based%2520cohort%2520study%26jtitle%3DPharmacotherapy%26date%3D2016%26volume%3D36%26spage%3D26%26epage%3D37%26doi%3D10.1002%2Fphar.1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosentino, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landolfo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentivenga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinardi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposti, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miceli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghi, C.</span></span> <span> </span><span class="NLM_article-title">Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study</span>. <i>BMC Cardiovasc. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12872-018-0986-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2Fs12872-018-0986-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30651063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3cjit1Sitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=20-26&author=E.+R.+Cosentinoauthor=M.+Landolfoauthor=C.+Bentivengaauthor=L.+Spinardiauthor=D.+D.+Espostiauthor=A.+F.+Ciceroauthor=R.+Miceliauthor=V.+Buiauthor=E.+Berardiauthor=C.+Borghi&title=Morbidity+and+mortality+in+a+population+of+patients+affected+by+heart+failure+and+chronic+obstructive+pulmonary+disease%3A+an+observational+study&doi=10.1186%2Fs12872-018-0986-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study</span></div><div class="casAuthors">Cosentino Eugenio Roberto; Landolfo Matteo; Bentivenga Crescenzio; Spinardi Luca; Esposti Daniela Degli; Cicero Arrigo Francesco; Miceli Rinaldo; Bui Virna; Borghi Claudio; Berardi Emanuela</div><div class="citationInfo"><span class="NLM_cas:title">BMC cardiovascular disorders</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) and heart failure (HF) often coexist.  Moreover, elderly patients suffering from HF have a higher incidence of COPD, which further complicates their clinical condition.  Indacaterol/glycopirronium has shown benefits in the treatment of COPD, with few cardiologic adverse effects.  We evaluated the safety and efficacy of this therapy in patients with history of HF.  METHODS:  We enrolled 56 patients with a history of HF (New York Heart Association [NYHA] classes II and III) and stable COPD.  We evaluated blood samples, clinical assessment, echocardiograms and basal spirometry at baseline and after 6 months of therapy with indacaterol/glycopirronium.  In addition, the number of re-hospitalizations during the treatment period was evaluated.  RESULTS:  The treatment was well tolerated.  Brain natriuretic peptide (BNP) levels were significantly reduced compared with baseline (p < 0.001) after 6 months of treatment, and a higher percentage of patients improved their clinical status compared with baseline (p < 0.001).  Minor changes were noted in the hemodynamic and metabolic parameters.  Significant improvements in the echocardiographic parameters were noted in HF with reduced ejection fraction (HFrEF) patients.  All respiratory parameters (forced expiratory volume in 1 s [FEV1], FEV1/forced vital capacity [FVC] ratio and COPD Assessment Test [CAT] scores) improved significantly (p < 0.001).  No hospitalizations owing to HF or COPD exacerbation occurred.  One patient died of respiratory failure.  CONCLUSION:  Indacaterol/glycopirronium was well-tolerated and effective in the treatment of COPD in this cohort of patients with a history of HF.  Further studies are needed to clarify whether this compound can have a direct role in improving overall cardiovascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxAmj6DAngMUkUaC_kzhvyfW6udTcc2eaElfQvYr7eUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjit1Sitg%253D%253D&md5=9b7bc83c15be6c371b04f6af611fc068</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1186%2Fs12872-018-0986-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12872-018-0986-y%26sid%3Dliteratum%253Aachs%26aulast%3DCosentino%26aufirst%3DE.%2BR.%26aulast%3DLandolfo%26aufirst%3DM.%26aulast%3DBentivenga%26aufirst%3DC.%26aulast%3DSpinardi%26aufirst%3DL.%26aulast%3DEsposti%26aufirst%3DD.%2BD.%26aulast%3DCicero%26aufirst%3DA.%2BF.%26aulast%3DMiceli%26aufirst%3DR.%26aulast%3DBui%26aufirst%3DV.%26aulast%3DBerardi%26aufirst%3DE.%26aulast%3DBorghi%26aufirst%3DC.%26atitle%3DMorbidity%2520and%2520mortality%2520in%2520a%2520population%2520of%2520patients%2520affected%2520by%2520heart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520an%2520observational%2520study%26jtitle%3DBMC%2520Cardiovasc.%2520Disord.%26date%3D2019%26volume%3D19%26spage%3D20%26epage%3D26%26doi%3D10.1186%2Fs12872-018-0986-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub> AR agonists in treatment of chronic heart failure: long path to translation</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2010.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2010.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20888833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=529-533&author=M.+I.+Talanauthor=I.+Ahmetauthor=R.+P.+Xiaoauthor=E.+G.+Lakatta&title=%CE%B22+AR+agonists+in+treatment+of+chronic+heart+failure%3A+long+path+to+translation&doi=10.1016%2Fj.yjmcc.2010.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">β2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation</span></div><div class="casAuthors">Talan, Mark I.; Ahmet, Ismayil; Xiao, Riu-Ping; Lakatta, Edward G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-533</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The main clin. manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling.  Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration assocd. with dilated cardiomyopathy (DCM).  Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β1 AR activates the proapoptotic signaling pathways, while selective stimulation of β2 AR is antiapoptotic, but its precise mechanisms remain to be elucidated.  Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β2 AR agonist, fenoterol, in combination with a β1 AR blocker, metoprolol, is more effective than β1 AR blocker alone and as effective as β1 AR blocker with ACE inhibitor with respect to survival and cardiac remodeling.  This combined regimen of β2 AR agonists and a β1 AR blocker might be considered for clin. testing as alternative or adjunct therapy to currently acceptable CHF arsenal.  This article is part of a special issue entitled "Key Signaling Mols. in Hypertrophy and Heart Failure".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiDT4tTRCfEbVg90H21EOLACvtfcHk0lju8diD6CZ5vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7vE&md5=5f5c41410ca15d031d9bdb81e7332262</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2010.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2010.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTalan%26aufirst%3DM.%2BI.%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3D%25CE%25B22%2520AR%2520agonists%2520in%2520treatment%2520of%2520chronic%2520heart%2520failure%253A%2520long%2520path%2520to%2520translation%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2011%26volume%3D51%26spage%3D529%26epage%3D533%26doi%3D10.1016%2Fj.yjmcc.2010.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R.</span></span> <span> </span><span class="NLM_article-title">Fenoterol and asthma mortality</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(89)92768-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2889%2992768-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1989&pages=1196-1197&author=N.+Pearceauthor=J.+Craneauthor=C.+Burgessauthor=R.+Beasleyauthor=R.+Jackson&title=Fenoterol+and+asthma+mortality&doi=10.1016%2FS0140-6736%2889%2992768-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2889%2992768-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252889%252992768-2%26sid%3Dliteratum%253Aachs%26aulast%3DPearce%26aufirst%3DN.%26aulast%3DCrane%26aufirst%3DJ.%26aulast%3DBurgess%26aufirst%3DC.%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DR.%26atitle%3DFenoterol%2520and%2520asthma%2520mortality%26jtitle%3DLancet%26date%3D1989%26volume%3D333%26spage%3D1196%26epage%3D1197%26doi%3D10.1016%2FS0140-6736%2889%2992768-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, R. D.</span></span> <span> </span><span class="NLM_article-title">Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1136/thx.53.7.558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.53.7.558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9797754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1M%252FhsVCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=558-562&author=R.+M.+Martinauthor=N.+R.+Dunnauthor=S.+N.+Freemantleauthor=R.+D.+Mann&title=Risk+of+non-fatal+cardiac+failure+and+ischaemic+heart+disease+with+long+acting+beta+2+agonists&doi=10.1136%2Fthx.53.7.558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists</span></div><div class="casAuthors">Martin R M; Dunn N R; Freemantle S N; Mann R D</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">558-62</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  The long term safety of beta agonists, particularly in patients with heart disease, has not been fully established.  METHODS:  This study accessed the results of three cohort studies involving: 12,294 patients receiving at least one prescription for nedocromil between November 1986 and September 1988; 15,407 patients prescribed salmeterol between December 1990 and May 1991; and 8098 patients prescribed bambuterol between February 1993 and December 1995.  Details of all dispensed prescriptions for these drugs prescribed by general practitioners in England soon after their launch were provided in confidence by the Prescription Pricing Authority.  Questionnaires were sent to the prescriber asking for details of events occurring after the first prescription (prescription event monitoring).  Rates and relative risks of non-fatal cardiac failure and ischaemic heart disease were calculated, comparing bambuterol and salmeterol with the reference drug nedocromil.  RESULTS:  The age and sex adjusted relative risk of non-fatal cardiac failure associated with bambuterol was 3.41 (95% confidence limits (CL) 1.99 to 5.86) when compared with nedocromil.  When salmeterol was compared with nedocromil the adjusted relative risk of non-fatal cardiac failure was 1.10 (95% CL 0.63 to 1.91).  The adjusted relative risk of non-fatal ischaemic heart disease was 1.23 (95% CL 0.73 to 2.08) and 1.07 (95% CL 0.69 to 1.66) for bambuterol and salmeterol, compared with nedocromil, respectively.  However, in the first month of exposure the adjusted relative risk of non-fatal ischaemic heart disease was 3.95 (95% CL 1.38 to 11.31) when bambuterol was compared with nedocromil.  CONCLUSIONS:  Caution should be exercised when prescribing long acting oral beta agonists to patients at risk of cardiac failure.  More definitive evidence would come from prospective randomised trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjVN-vZ51Twgwxfk_AGB-EfW6udTcc2ebXNsc0va6K0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FhsVCrug%253D%253D&md5=7a256ae746cee0c6f11a9ca0f593f0c7</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1136%2Fthx.53.7.558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.53.7.558%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BM.%26aulast%3DDunn%26aufirst%3DN.%2BR.%26aulast%3DFreemantle%26aufirst%3DS.%2BN.%26aulast%3DMann%26aufirst%3DR.%2BD.%26atitle%3DRisk%2520of%2520non-fatal%2520cardiac%2520failure%2520and%2520ischaemic%2520heart%2520disease%2520with%2520long%2520acting%2520beta%25202%2520agonists%26jtitle%3DThorax%26date%3D1998%26volume%3D53%26spage%3D558%26epage%3D562%26doi%3D10.1136%2Fthx.53.7.558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushey, H. A.</span></span> <span> </span><span class="NLM_article-title">Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma</span>. <i>Clin. Chest. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8565410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK287lslCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=715-733&author=J.+V.+Fahyauthor=H.+A.+Boushey&title=Controversies+involving+inhaled+beta-agonists+and+inhaled+corticosteroids+in+the+treatment+of+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma</span></div><div class="casAuthors">Fahy J V; Boushey H A</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">715-33</span>
        ISSN:<span class="NLM_cas:issn">0272-5231</span>.
    </div><div class="casAbstract">Controversy over the use of inhaled beta-agonists has dated almost from their introduction as a treatment for asthma.  Their effectiveness as bronchodilators is not disputed, but there is concern that they may worsen asthma control if used regularly and that excessive use may increase the risk of death from asthma.  Five years after the report from Sears and colleagues suggested that regular use of fenoterol worsens asthma control, we do not have definitive corroborative evidence that this effect of fenoterol is real or is shared by other members of the beta-agonist class.  It also remains disputed whether the documented association between excessive beta-agonist use and death from asthma is a causal or a spurious association.  Undisputed is the fact that excessive beta-agonist use by asthmatics indicates an increased risk of death from asthma and so indicates a need for clinicians to advise anti-inflammatory medications for these patients.  Happily, although there are legitimate concerns about the possible implications of the development of tolerance to the non-bronchodilating effects of beta-agonists, there is currently little evidence that treatment with conventional doses of the beta-agonists currently available in the United States, including salmeterol, is harmful to asthmatic patients.  The controversies over the use of inhaled corticosteroids revolve around the issue of whether the clinical benefit easily demonstrated with their short-term use is justified in the face of their possible long-term systemic toxicity.  Unsettled questions about their therapeutic use include whether dose dependence can be shown for the clinical benefits of inhaled corticosteroids, whether delay in initiating inhaled corticosteroid treatment reduces the benefit that can be achieved, and whether the benefits of even prolonged therapy are short-lasting.  The great unsettled question about their toxicity is whether systemic absorption of inhaled corticosteroids increases the risk of long-term systemic complications, like osteoporosis, cataracts, and growth inhibition.  Current evidence suggests that significant risk of such toxicity is not likely to be associated with the long-term use of the equivalent of 800 micrograms/d of beclomethasone in adults and 400 micrograms/d in children.  If higher doses are used to obtain greater clinical benefit, the answers to these questions may determine the place of new inhaled corticosteroids with high local potency and little systemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTz8BS3SeIq1LGbPKh4T9eAfW6udTcc2ebXNsc0va6K0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287lslCisA%253D%253D&md5=33bb168c325b079f87693448da308b1d</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26aulast%3DBoushey%26aufirst%3DH.%2BA.%26atitle%3DControversies%2520involving%2520inhaled%2520beta-agonists%2520and%2520inhaled%2520corticosteroids%2520in%2520the%2520treatment%2520of%2520asthma%26jtitle%3DClin.%2520Chest.%2520Med.%26date%3D1995%26volume%3D16%26spage%3D715%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottosson, A.</span></span> <span> </span><span class="NLM_article-title">Beta2 agonists and heart failure</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1709</span>– <span class="NLM_lpage">1710</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)61488-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2805%2961488-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9853469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1M%252FmvVemug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=1998&pages=1709-1710&author=B.+Lindmarkauthor=A.+Ottosson&title=Beta2+agonists+and+heart+failure&doi=10.1016%2FS0140-6736%2805%2961488-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Beta2 agonists and heart failure</span></div><div class="casAuthors">Lindmark B; Ottosson A</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">9141</span>),
    <span class="NLM_cas:pages">1709-10</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx90Qz_NU9YSjiVMCqkKxVfW6udTcc2eZ3FpngzF4CZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FmvVemug%253D%253D&md5=6094e9e876ce6308fd8b6ba81ee0d05c</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2961488-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252961488-2%26sid%3Dliteratum%253Aachs%26aulast%3DLindmark%26aufirst%3DB.%26aulast%3DOttosson%26aufirst%3DA.%26atitle%3DBeta2%2520agonists%2520and%2520heart%2520failure%26jtitle%3DLancet%26date%3D1998%26volume%3D352%26spage%3D1709%26epage%3D1710%26doi%3D10.1016%2FS0140-6736%2805%2961488-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, E. H.</span></span> <span> </span><span class="NLM_article-title">Adverse effects of beta-agonists: are they clinically relevant?</span>. <i>Am. J. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1007/BF03256657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2FBF03256657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=14719995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsVymtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=287-297&author=M.+J.+Abramsonauthor=J.+Waltersauthor=E.+H.+Walters&title=Adverse+effects+of+beta-agonists%3A+are+they+clinically+relevant%3F&doi=10.1007%2FBF03256657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of β-agonists: Are they clinically relevant?</span></div><div class="casAuthors">Abramson, Michael J.; Walters, Julia; Walters, E. Haydn</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">AJRMAG</span>;
        ISSN:<span class="NLM_cas:issn">1175-6365</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled β2-adrenoceptor agonists (β2-agonists) are the most commonly used asthma medications in many Western countries.  Minor adverse effects such as palpitations, tremor, headache and metabolic effects are predictable and dose related.  Time series studies suggested an assocn. between the relatively nonselective β-agonist fenoterol and asthma deaths.  Three case-control studies confirmed that among patients prescribed fenoterol, the risk of death was significantly elevated even after controlling for the severity of asthma.  The Saskatchewan study not only found an increased risk of death among patients dispensed fenoterol, but also suggested this might be a class effect of β2-agonists.  However, in subsequent studies, the long-acting β2-agonist salmeterol was not assocd. with increased asthma mortality.  In a case-control study blood albuterol (salbutamol) concns. were found to be 2.5 times higher among patients who died of asthma compared with controls.  It is speculated that such toxic concns. could cause tachyarrhythmias under conditions of hypoxia and hypokalemia.  The risk of asthma exacerbations and near-fatal attacks may also be increased among patients dispensed fenoterol, but this assocn. may be largely due to confounding by severity.  Although salmeterol does not appear to increase the risk of near-fatal attacks, there is a consistent assocn. with the use of nebulized β2-agonists.  Nebulized and oral β2-agonists are also assocd. with an increased risk of cardiovascular death, ischemic heart disease and cardiac failure.  Caution should be exercised when first prescribing a β-agonist for patients with cardiovascular disease.  A potential mechanism for adverse effects with regular use of β2-agonists is tachyphylaxis.  Tachyphylaxis to the bronchodilator effects of long-acting β2-agonists can occur, but has been consistently demonstrated only for formoterol (eformoterol) a full agonist, rather than salmeterol, a partial agonist.  Tachyphylaxis to protection against induced bronchospasm occurs with both full and partial β2-agonists, and probably within a matter of days at most.  Underlying airway responsiveness to directly acting bronchoconstricting agents is not increased when the bronchodilator effect of the regular β2-agonist has been allowed to wear off, although there may be an increase in responsiveness to indirectly acting agents.  While there has been speculation that underlying airway inflammation in asthma may be made worse by regular use of short-acting β2-agonists, in contradistinction, a no. of studies have shown that long-acting β2-agonists have pos. anti-inflammatory effects.  An Australian Cochrane Airways Group systematic review of the randomized, controlled trials of short-acting β-agonists found only minimal and clin. unimportant differences between regular use and use as needed.  Regular short-acting treatment was better than placebo.  However, a subsequent systematic review has found that regular use of long-acting β-agonists had significant advantages over regular use of short-acting β-agonists.  More studies and data are needed on the regular use of β2-agonists in patients not taking inhaled corticosteroids, and in potentially vulnerable groups, such as the elderly and those with particular genotypes for the β-receptor, who might be more prone to adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzI8kxaal7vbVg90H21EOLACvtfcHk0lgvAmcW4mH9hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsVymtrs%253D&md5=3608930880ae780a5dfe226ceab816af</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1007%2FBF03256657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03256657%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DM.%2BJ.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DE.%2BH.%26atitle%3DAdverse%2520effects%2520of%2520beta-agonists%253A%2520are%2520they%2520clinically%2520relevant%253F%26jtitle%3DAm.%2520J.%2520Respir.%2520Med.%26date%3D2003%26volume%3D2%26spage%3D287%26epage%3D297%26doi%3D10.1007%2FBF03256657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClintock, D. E.</span></span> <span> </span><span class="NLM_article-title">Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?</span>. <i>J. Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.jemermed.2007.11.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jemermed.2007.11.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18572345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3M7mvVaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=135-145&author=C.+A.+Maakauthor=J.+A.+Tabasauthor=D.+E.+McClintock&title=Should+acute+treatment+with+inhaled+beta+agonists+be+withheld+from+patients+with+dyspnea+who+may+have+heart+failure%3F&doi=10.1016%2Fj.jemermed.2007.11.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?</span></div><div class="casAuthors">Maak Carley Ann; Tabas Jeffrey A; McClintock Dana E</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of emergency medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-45</span>
        ISSN:<span class="NLM_cas:issn">0736-4679</span>.
    </div><div class="casAbstract">In patients with dyspnea, prehospital and emergency providers make therapeutic decisions before a diagnosis is established.  Inhaled beta-2 agonists are frontline treatment for patients with dyspnea due to asthma or chronic obstructive pulmonary disease (COPD) exacerbations.  However, these agents have been associated with increased adverse events when administered chronically to heart failure patients.  Our goal was to determine the safety and efficacy of acute administration of inhaled beta-2 agonists to patients with heart failure.  MEDLINE and EMBASE searches were performed using the terms "beta agonists," "albuterol," "congestive heart failure," and "pulmonary edema." Bibliographies of relevant articles were searched.  Only studies addressing acute effects of beta-2 agonists were included for analysis.  Twenty-four studies comprising 434 patients were identified that addressed the acute delivery of beta-2 agonists in subjects with heart failure--five studies with inhaled administration and 19 with systemic administration.  No study directly evaluated the effects of inhaled beta-2 agonists to patients with acutely decompensated heart failure.  Treatment of heart failure patients with beta-2 agonists resulted in transient improvements in pulmonary function and cardiovascular hemodynamics.  Only one investigation reported an association between beta-2 agonist use and an increase in malignant dysrhythmias.  Investigations in animal models of heart failure and acute lung injury demonstrated resolution of pulmonary edema with beta agonist administration.  There is insufficient evidence to suggest that acute treatment with inhaled beta-2 agonists should be avoided in patients with dyspnea who may have heart failure.  Based on small studies and indirect evidence, administration of beta-2 agonists to patients with heart failure seems to improve pulmonary function, cardiovascular hemodynamics, and resorption of pulmonary edema.  Although an increase in adverse effects with the use of beta-2 agonists cannot be ruled out based on these data, there was no evidence of an increase in clinically significant dysrhythmias, especially when administered by inhalation.  Based on these findings, further study should focus on the clinical outcomes of patients with acutely decompensated heart failure who are treated with inhaled beta-2 agonist therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfNcJfxKztMczK395ZObgVfW6udTcc2eZ3FpngzF4CZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7mvVaqsg%253D%253D&md5=3c3bd536608c090eaee3c7ce8573bff4</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1016%2Fj.jemermed.2007.11.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jemermed.2007.11.056%26sid%3Dliteratum%253Aachs%26aulast%3DMaak%26aufirst%3DC.%2BA.%26aulast%3DTabas%26aufirst%3DJ.%2BA.%26aulast%3DMcClintock%26aufirst%3DD.%2BE.%26atitle%3DShould%2520acute%2520treatment%2520with%2520inhaled%2520beta%2520agonists%2520be%2520withheld%2520from%2520patients%2520with%2520dyspnea%2520who%2520may%2520have%2520heart%2520failure%253F%26jtitle%3DJ.%2520Emerg.%2520Med.%26date%3D2011%26volume%3D40%26spage%3D135%26epage%3D145%26doi%3D10.1016%2Fj.jemermed.2007.11.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermingham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawkins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samsudin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, M.</span></span> <span> </span><span class="NLM_article-title">Are beta2-agonists responsible for increased mortality in heart failure?</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1093/eurjhf/hfr063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Feurjhf%2Fhfr063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21791542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Ohsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=885-891&author=M.+Berminghamauthor=E.+O%E2%80%99Callaghanauthor=I.+Dawkinsauthor=S.+Miwaauthor=S.+Samsudinauthor=K.+McDonaldauthor=M.+Ledwidge&title=Are+beta2-agonists+responsible+for+increased+mortality+in+heart+failure%3F&doi=10.1093%2Feurjhf%2Fhfr063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Are beta2-agonists responsible for increased mortality in heart failure?</span></div><div class="casAuthors">Bermingham, Margaret; O'Callaghan, Eleanor; Dawkins, Ian; Miwa, Saki; Samsudin, Shazzarina; McDonald, Kenneth; Ledwidge, Mark</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-891</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Previous large-scale, retrospective studies have shown increased mortality in heart failure (HF) patients using β2-agonists (B2As).  We further examd. the relationship between B2A use and mortality in a well-characterized population by adjusting for natriuretic peptide levels as a measure of HF severity.  This was a retrospective cohort study of patients attending an HF Disease Management Program with mean follow-up of 2.9 ± 2.4 years.  Chart review confirmed B2A use, dose and duration of use, and documented pulmonary function evaluation.  The primary endpoint was the effect of B2A use compared with no B2A use on mortality using unadjusted and adjusted Kaplan-Meier survival curves.  Data were available for 1294 patients (age 70.6 ± 11.5 years) of whom 64% were male and 22.2% were taking B2As. β2-Agonist users were older, more likely to be male, to have smoked, to have chronic obstructive pulmonary disease (COPD) and asthma, and less likely to take beta-blockers.  Multivariable assocs. of mortality included: B-type natriuretic peptide (BNP), coronary artery disease, age, and beta-blocker use.  Unadjusted mortality rates for B2A users were found to be significantly higher than non-B2A users [hazard ratio (HR) 1.304, 95% confidence interval (CI) 1.030-1.652, P= 0.028].  However, when adjusted for age, sex, medication, co-morbidity, smoking, COPD, and BNP differences, overall mortality rates were similar [HR 1.043, 95% CI (0.771-1.412), P= 0.783].  Unlike previous reports, this retrospective evaluation of B2A therapy in HF patients shows no relationship with long-term mortality when adjusted for population differences including BNP.  Large, prospective studies are required to define the risk/benefit ratio of B2As in patients with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQYtePql13bVg90H21EOLACvtfcHk0ljgOaQ9rFqxhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Ohsbg%253D&md5=ee091530fb41e80ca20370504b7bddea</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfr063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfr063%26sid%3Dliteratum%253Aachs%26aulast%3DBermingham%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DE.%26aulast%3DDawkins%26aufirst%3DI.%26aulast%3DMiwa%26aufirst%3DS.%26aulast%3DSamsudin%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DK.%26aulast%3DLedwidge%26aufirst%3DM.%26atitle%3DAre%2520beta2-agonists%2520responsible%2520for%2520increased%2520mortality%2520in%2520heart%2520failure%253F%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2011%26volume%3D13%26spage%3D885%26epage%3D891%26doi%3D10.1093%2Feurjhf%2Fhfr063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sears, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. R.</span></span> <span> </span><span class="NLM_article-title">The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.2165/00002018-199411040-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2165%2F00002018-199411040-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7848546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2M7ltFWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1994&pages=259-283&author=M.+R.+Searsauthor=D.+R.+Taylor&title=The+beta+2-agonist+controversy.+Observations%2C+explanations+and+relationship+to+asthma+epidemiology&doi=10.2165%2F00002018-199411040-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology</span></div><div class="casAuthors">Sears M R; Taylor D R</div><div class="citationInfo"><span class="NLM_cas:title">Drug safety</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-83</span>
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    </div><div class="casAbstract">Links between frequent use of inhaled beta 2-agonists and morbidity and mortality from asthma appear probable.  Two mortality epidemics followed the marketing of potent inhaled adrenergic agents.  Case-control studies in New Zealand linked mortality with prescription of fenoterol, especially in severe asthma.  A Saskatchewan case-control study confirmed an association of mortality with fenoterol, and also with frequent use of salbutamol (albuterol).  Cardiac effects of beta 2-agonists do not cause mortality, but frequent use of these agents may increase the chronic severity of asthma, hence increasing the number of asthmatic patients at risk of death in an acute attack.  Frequent use of beta 2-agonists may reduce lung function, increasing airway responsiveness, and impair control of asthma, despite use of inhaled corticosteroids.  Mechanisms for this effect may include tachyphylaxis to nonbronchodilator effects, increased responsiveness to allergen, interaction with corticosteroid receptors, altered mucociliary function, differential effects of enantiomers, and masking of symptoms by beta 2-agonist use.  The withdrawal of fenoterol from New Zealand in 1990 was associated with a substantial decline in morbidity and mortality.  Overall, the evidence suggests that frequent use of inhaled beta 2-agonists has a deleterious effect on the control of asthma.  Epidemics of mortality are explained by an increase in chronic severity of asthma following introduction of more potent beta 2-agonists.  While beta 2-agonists remain essential for relief of breakthrough symptoms, long term use, particularly with high doses of potent agents, appears to be detrimental.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj0afGi4QZEHwOGIfWJ7-GfW6udTcc2eZl7goBwtrxPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ltFWkuw%253D%253D&md5=c07fab0121f18ac42e7215ee63eb2963</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.2165%2F00002018-199411040-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-199411040-00005%26sid%3Dliteratum%253Aachs%26aulast%3DSears%26aufirst%3DM.%2BR.%26aulast%3DTaylor%26aufirst%3DD.%2BR.%26atitle%3DThe%2520beta%25202-agonist%2520controversy.%2520Observations%252C%2520explanations%2520and%2520relationship%2520to%2520asthma%2520epidemiology%26jtitle%3DDrug%2520Saf.%26date%3D1994%26volume%3D11%26spage%3D259%26epage%3D283%26doi%3D10.2165%2F00002018-199411040-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xydas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kherani, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutrie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.099432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.099432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16421285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=553-561&author=S.+Xydasauthor=A.+R.+Kheraniauthor=J.+S.+Changauthor=S.+Klotzauthor=I.+Hayauthor=C.+J.+Mutrieauthor=G.+W.+Mossauthor=A.+Guauthor=A.+R.+Schulmanauthor=D.+Gaoauthor=D.+Huauthor=E.+X.+Wuauthor=C.+Weiauthor=M.+C.+Ozauthor=J.+Wang&title=Beta%282%29-Adrenergic+stimulation+attenuates+left+ventricular+remodeling%2C+decreases+apoptosis%2C+and+improves+calcium+homeostasis+in+a+rodent+model+of+ischemic+cardiomyopathy&doi=10.1124%2Fjpet.105.099432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy</span></div><div class="casAuthors">Xydas, Steve; Kherani, Aftab R.; Chang, Jonathan S.; Klotz, Stefan; Hay, Ilan; Mutrie, Christopher J.; Moss, Garrett W.; Gu, Anguo; Schulman, Allison R.; Gao, Daqing; Hu, Debora; Wu, Ed X.; Wei, Chiming; Oz, Mehmet C.; Wang, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">553-561</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The benefit of the β2-adrenergic agonist, clenbuterol, in left ventricular assist device patients with dilated cardiomyopathy has been reported, but its effect on ischemic heart failure (HF) is unknown.  We investigated whether clenbuterol improves left ventricular remodeling, myocardial apoptosis and has synergy with a β1 antagonist, metoprolol, in a model of ischemic HF.  Rats were randomized to: (1) HF only; (2) HF + clenbuterol; (3) HF + metoprolol; (4) HF + clenbuterol + metoprolol; and (5) rats with sham surgery.  HF was induced by left anterior descending artery (LAD) artery ligation and confirmed by decreased left ventricular fractional shortening, decreased max. left ventricular dP/dt (dP/dtmax), and elevated left ventricular end-diastolic pressure (LVEDP) compared with sham rats (p < 0.01).  After 9 wk of oral therapy, echocardiog., hemodynamic, and ex vivo end-diastolic pressure-vol. relation (EDPVR) measurements were obtained.  Immunohistochem. was performed for myocardial apoptosis and DNA damage markers.  Levels of calcium-handling proteins were assessed by Western blot anal.  Clenbuterol-treated HF rats had increased wt. gain and heart wts. vs. HF rats (p < 0.05).  EDPVR curves revealed a leftward shift in clenbuterol rats vs. metoprolol and HF rats (p < 0.05).  The metoprolol-treated group had a lower LVEDP and higher dP/dtmax vs. the HF group (p < 0.05).  Clenbuterol and metoprolol groups had decreased myocardial apoptosis and DNA damage markers and increased DNA repair markers vs. HF rats (all p < 0.01).  Protein levels of the ryanodine receptor and sarcoplasmic reticulum calcium-ATPase were improved in clenbuterol-, metoprolol-, and clenbuterol + metoprolol-treated groups vs. HF rats.  However, as a combination therapy, there were no synergistic effects of clenbuterol + metoprolol treatment.  We conclude that clenbuterol ameliorates EDPVR, apoptosis, and calcium homeostasis but does not have synergy with metoprolol in our model of ischemic HF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvFyOEGr-NYbVg90H21EOLACvtfcHk0ljgOaQ9rFqxhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamtLc%253D&md5=0a9616c9347b3f44b6e48c22dde284f1</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.099432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.099432%26sid%3Dliteratum%253Aachs%26aulast%3DXydas%26aufirst%3DS.%26aulast%3DKherani%26aufirst%3DA.%2BR.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DKlotz%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DI.%26aulast%3DMutrie%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DG.%2BW.%26aulast%3DGu%26aufirst%3DA.%26aulast%3DSchulman%26aufirst%3DA.%2BR.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DE.%2BX.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DOz%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DBeta%25282%2529-Adrenergic%2520stimulation%2520attenuates%2520left%2520ventricular%2520remodeling%252C%2520decreases%2520apoptosis%252C%2520and%2520improves%2520calcium%2520homeostasis%2520in%2520a%2520rodent%2520model%2520of%2520ischemic%2520cardiomyopathy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D553%26epage%3D561%26doi%3D10.1124%2Fjpet.105.099432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soppa, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felkin, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlecka, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youssef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C. M.</span></span> <span> </span><span class="NLM_article-title">Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvm106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvm106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18178572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=695-706&author=G.+K.+Soppaauthor=J.+Leeauthor=M.+A.+Staggauthor=L.+E.+Felkinauthor=P.+J.+Bartonauthor=U.+Siedleckaauthor=S.+Youssefauthor=M.+H.+Yacoubauthor=C.+M.+Terracciano&title=Role+and+possible+mechanisms+of+clenbuterol+in+enhancing+reverse+remodelling+during+mechanical+unloading+in+murine+heart+failure&doi=10.1093%2Fcvr%2Fcvm106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure</span></div><div class="casAuthors">Soppa, Gopal K. R.; Lee, Joon; Stagg, Mark A.; Felkin, Leanne E.; Barton, Paul J. R.; Siedlecka, Urszula; Youssef, Samuel; Yacoub, Magdi H.; Terracciano, Cesare M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">695-706</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Combined left ventricular assist device (LVAD) and pharmacol. therapy was proposed to favor myocardial recovery in patients with end-stage heart failure (HF).  Clenbuterol (Clen), a β2-adrenoceptor (β2-AR) agonist, was used as a part of this strategy.  In this study, we investigated the direct effects of clenbuterol on unloaded myocardium in HF.  Left coronary artery ligation or sham operation was performed in male Lewis rats.  After 4-6 wk, heterotopic abdominal transplantation of the failing hearts into normal recipients was performed to induce LV unloading (UN).  Recipient rats were treated with saline (Sal) or clenbuterol (2 mg/kg/day) via osmotic minipumps (HF + UN + Sal or HF + UN + Clen) for 7 days.  Non-transplanted HF animals were treated with Sal (Sham + Sal, HF + Sal) or clenbuterol (HF + Clen).  LV myocytes were isolated and studied using optical, fluorescence, and electrophysiol. techniques.  Clenbuterol treatment improved in vivo LV function measured with echocardiog. (LVEF (%): HF 35.9 ± 2 [16], HF + Clen 52.1 ± 1.4 [16]; P < 0.001; mean ± SEM [n]).  In combination with unloading, clenbuterol increased sarcomere shortening (amplitude (μm): HF + UN + Clen 0.1 ± 0.01 [50], HF + UN + Sal 0.07 ± 0.01 [38]; P < 0.001) by normalizing the depressed myofilament sensitivity to Ca2+ (slope of the linear relationship between Ca2+ transient and sarcomere shortening hysteresis loop during relaxation (μm/ratio unit): HF + UN + Clen 2.13 ± 0.2 [52], HF + UN + Sal 1.42 ± 0.13 [38]; P < 0.05).  Clenbuterol treatment of failing rat hearts, alone or in combination with mech. unloading, improves LV function at the whole-heart and cellular levels by affecting cell morphol., excitation-contraction coupling, and myofilament sensitivity to Ca.  This study supports the use of this drug in the strategy to enhance recovery in HF patients treated with LVADs and also begins to elucidate some of the possible cellular mechanisms responsible for the improvement in LV function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJTdOA2hkIrVg90H21EOLACvtfcHk0lgmXHduCRHMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvVaisro%253D&md5=c461f570994565ea289b2bb3a44745f4</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvm106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvm106%26sid%3Dliteratum%253Aachs%26aulast%3DSoppa%26aufirst%3DG.%2BK.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DStagg%26aufirst%3DM.%2BA.%26aulast%3DFelkin%26aufirst%3DL.%2BE.%26aulast%3DBarton%26aufirst%3DP.%2BJ.%26aulast%3DSiedlecka%26aufirst%3DU.%26aulast%3DYoussef%26aufirst%3DS.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26aulast%3DTerracciano%26aufirst%3DC.%2BM.%26atitle%3DRole%2520and%2520possible%2520mechanisms%2520of%2520clenbuterol%2520in%2520enhancing%2520reverse%2520remodelling%2520during%2520mechanical%2520unloading%2520in%2520murine%2520heart%2520failure%26jtitle%3DCardiovasc.%2520Res.%26date%3D2008%26volume%3D77%26spage%3D695%26epage%3D706%26doi%3D10.1093%2Fcvr%2Fcvm106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donniacuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gritti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martuscelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafaniello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">Effects of chronic treatment with the new ultra-long-acting β<sub>2</sub>-adrenoceptor agonist indacaterol alone or in combination with the β<sub>1</sub>-adrenoceptor blocker metoprolol on cardiac remodelling</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">3627</span>– <span class="NLM_lpage">3637</span>, <span class="refDoi"> DOI: 10.1111/bph.13148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fbph.13148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25825265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=3627-3637&author=B.+Rinaldiauthor=M.+Donniacuoauthor=L.+Sodanoauthor=G.+Grittiauthor=E.+Martuscelliauthor=A.+Orlandiauthor=C.+Rafanielloauthor=F.+Rossiauthor=L.+Calzettaauthor=A.+Capuanoauthor=M.+G.+Matera&title=Effects+of+chronic+treatment+with+the+new+ultra-long-acting+%CE%B22-adrenoceptor+agonist+indacaterol+alone+or+in+combination+with+the+%CE%B21-adrenoceptor+blocker+metoprolol+on+cardiac+remodelling&doi=10.1111%2Fbph.13148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling</span></div><div class="casAuthors">Rinaldi, Barbara; Donniacuo, Maria; Sodano, Loredana; Gritti, Giulia; Martuscelli, Eugenio; Orlandi, Augusto; Rafaniello, Concetta; Rossi, Francesco; Calzetta, Luigino; Capuano, Annalisa; Matera, Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3627-3637</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2-adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1-adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF).  Exptl. Approach : We investigated the effects of indacaterol and metoprolol, administered alone or in combination, on myocardial histol., β-adrenoceptor-mediated pathways, markers of remodelling and haemodynamic parameters in a rat model of HF.  Five groups of rats were assessed: sham-operated rats; HF rats; HF + indacaterol 0.3 mg·kg-1·day-1; HF + metoprolol 100 mg·kg-1·day-1; HF + metoprolol + indacaterol.  All pharmacol. treatments continued for 15 wk.  Key Results : Treatment with either indacaterol or metoprolol significantly reduced the infarct size in HF rats.  However, the combination of indacaterol and metoprolol reduced the infarct size even further, reduced both BP and heart rate, reversed the decrease in ejection fraction, normalized left ventricular systolic and diastolic internal diams., normalized the decreased β1 adrenoceptor mRNA expression as well as cardiac cAMP levels and reduced cardiac GPCR kinase 2 expression, compared with the untreated HF group.  Conclusion and Implications : The results of our study demonstrated an additive interaction between indacaterol and metoprolol in normalizing and reversing cardiac remodelling in our exptl. model of HF.  The translation of these findings to clin. practice might be of interest, as this combination of drugs could be safer and more effective in patients suffering from HF and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE1FPXeSofzrVg90H21EOLACvtfcHk0lgmXHduCRHMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurvP&md5=7a37f5752178bba96642432e43c25145</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1111%2Fbph.13148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13148%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi%26aufirst%3DB.%26aulast%3DDonniacuo%26aufirst%3DM.%26aulast%3DSodano%26aufirst%3DL.%26aulast%3DGritti%26aufirst%3DG.%26aulast%3DMartuscelli%26aufirst%3DE.%26aulast%3DOrlandi%26aufirst%3DA.%26aulast%3DRafaniello%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DF.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DCapuano%26aufirst%3DA.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DEffects%2520of%2520chronic%2520treatment%2520with%2520the%2520new%2520ultra-long-acting%2520%25CE%25B22-adrenoceptor%2520agonist%2520indacaterol%2520alone%2520or%2520in%2520combination%2520with%2520the%2520%25CE%25B21-adrenoceptor%2520blocker%2520metoprolol%2520on%2520cardiac%2520remodelling%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D3627%26epage%3D3637%26doi%3D10.1111%2Fbph.13148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navaratnarajah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlecka, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doorn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soppa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukadia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C. M.</span></span> <span> </span><span class="NLM_article-title">Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e92909</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0092909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0092909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25268495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKisb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+Navaratnarajahauthor=U.+Siedleckaauthor=M.+Ibrahimauthor=C.+van+Doornauthor=G.+Soppaauthor=A.+Gandhiauthor=A.+Shahauthor=P.+Kukadiaauthor=M.+H.+Yacoubauthor=C.+M.+Terracciano&title=Impact+of+combined+clenbuterol+and+metoprolol+therapy+on+reverse+remodelling+during+mechanical+unloading&doi=10.1371%2Fjournal.pone.0092909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading</span></div><div class="casAuthors">Navaratnarajah, Manoraj; Siedlecka, Urszula; Ibrahim, Michael; van Doorn, Carin; Soppa, Gopal; Gandhi, Ajay; Shah, Adarsh; Kukadia, Punam; Yacoub, Magdi H.; Terracciano, Cesare M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e92909/1-e92909/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Clenbuterol (Cl), a β2 agonist, is assocd. with enhanced myocardial recovery during left ventricular assist device (LVAD) support, and exerts beneficial remodelling effects during mech. unloading (MU) in rodent heart failure (HF).  However, the specific effects of combined Cl+β1 blockade during MU are unknown.  Methods and Results: We studied the chronic effects 4 wk of β2-adrenoceptor (AR) stimulation via Cl 2 mg/kg/day alone, and in combination with β1-AR blockade using metoprolol Met, 250 mg/kg/day, on whole heart/cell structure, function and excitation-contraction (EC) coupling in failing induced by left coronary artery (LCA) ligation, and unloaded induced by heterotopic abdominal heart transplantation (HATx) failing rat hearts.  Combined Cl+Met therapy displayed favorable effects in HF: Met enhanced Cl's improvement in ejection fraction (EF) while preventing Cl-induced hypertrophy and tachycardia.  During MU combined therapy was less beneficial than either mono-therapy.  Met, not Cl, prevented MU-induced myocardial atrophy, with increased atrophy occurring during combined therapy.  MU-induced recovery of Ca2+ transient amplitude, speed of Ca2+ release and sarcoplasmic reticulum Ca2+ content was enhanced equally by Cl or Met mono-therapy, but these benefits, together with Cl's enhancement of sarcomeric contraction speed, and MU-induced recovery of Ca2+ spark frequency, disappeared during combined therapy.  Conclusions: Combined Cl+Met therapy shows superior functional effects to mono-therapy in rodent HF, but appears inferior to either mono-therapy in enhancing MU-induced recovery of EC coupling.  These results suggest that combined β2-AR simulation+β1-AR blockade therapy is likely to be a safe and beneficial therapeutic HF strategy, but is not as effective as mono-therapy in enhancing myocardial recovery during LVAD support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8nJUR-yYfKrVg90H21EOLACvtfcHk0lgmXHduCRHMZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKisb%252FO&md5=f759bc3c1fd013caba89e3ae6c772d8a</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0092909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0092909%26sid%3Dliteratum%253Aachs%26aulast%3DNavaratnarajah%26aufirst%3DM.%26aulast%3DSiedlecka%26aufirst%3DU.%26aulast%3DIbrahim%26aufirst%3DM.%26aulast%3Dvan%2BDoorn%26aufirst%3DC.%26aulast%3DSoppa%26aufirst%3DG.%26aulast%3DGandhi%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DKukadia%26aufirst%3DP.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26aulast%3DTerracciano%26aufirst%3DC.%2BM.%26atitle%3DImpact%2520of%2520combined%2520clenbuterol%2520and%2520metoprolol%2520therapy%2520on%2520reverse%2520remodelling%2520during%2520mechanical%2520unloading%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0092909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref278"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref278'); return false;" data-citation="" class="refNumLink">278</a></strong><div class="NLM_citation" id="cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, Y. N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obokata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koepp, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbe, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlaug, B. A.</span></span> <span> </span><span class="NLM_article-title">The β-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.118.313832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.118.313832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30582447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=306-314&author=Y.+N.+V.+Reddyauthor=M.+Obokataauthor=K.+E.+Koeppauthor=A.+C.+Egbeauthor=B.+Wileyauthor=B.+A.+Borlaug&title=The+%CE%B2-adrenergic+agonist+albuterol+improves+pulmonary+vascular+reserve+in+heart+failure+with+preserved+ejection+fraction&doi=10.1161%2FCIRCRESAHA.118.313832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial</span></div><div class="casAuthors">Reddy, Yogesh N. V.; Obokata, Masaru; Koepp, Katlyn E.; Egbe, Alexander C.; Wiley, Brandon; Borlaug, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-314</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction (HFpEF).  Interventions that enhance pulmonary vasodilation might be beneficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion.  I.v. β-agonists reduce pulmonary vascular resistance but are not suitable for chronic use.  Objective: We hypothesized that the inhaled β-adrenergic agonist albuterol would improve pulmonary vasodilation during exercise in patients with HFpEF, without increasing left heart filling pressures.  Methods and results: We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjects with HFpEF using high-fidelity micromanometer catheters and expired gas anal.  The primary end point was pulmonary vascular resistance during exercise.  Subjects with HFpEF (n=30) underwent resting and exercise hemodynamic assessment and were then randomized 1:1 to inhaled, nebulized albuterol or placebo.  Rest and exercise hemodynamic testing was then repeated.  Albuterol improved the primary end point of exercise pulmonary vascular resistance as compared with placebo (-0.6±0.5 vs. +0.1±0.7 WU; P=0.003).  Albuterol enhanced cardiac output reserve and right ventricular pulmonary artery coupling, reduced right atrial and pulmonary artery pressures, improved pulmonary artery compliance, and enhanced left ventricular transmural distending pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures.  Conclusions: Albuterol improves pulmonary vascular reserve in patients with HFpEF without worsening left heart congestion.  Further study is warranted to evaluate the chronic efficacy of β-agonists in HFpEF and other forms of pulmonary hypertension.  Clin. trial registration: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT02885636.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTq9INpvOF7rVg90H21EOLACvtfcHk0lipgvx6gHxzyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVagtrk%253D&md5=db1df4e7fd23405bb3319fc830aa563c</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.118.313832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.118.313832%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DY.%2BN.%2BV.%26aulast%3DObokata%26aufirst%3DM.%26aulast%3DKoepp%26aufirst%3DK.%2BE.%26aulast%3DEgbe%26aufirst%3DA.%2BC.%26aulast%3DWiley%26aufirst%3DB.%26aulast%3DBorlaug%26aufirst%3DB.%2BA.%26atitle%3DThe%2520%25CE%25B2-adrenergic%2520agonist%2520albuterol%2520improves%2520pulmonary%2520vascular%2520reserve%2520in%2520heart%2520failure%2520with%2520preserved%2520ejection%2520fraction%26jtitle%3DCirc.%2520Res.%26date%3D2019%26volume%3D124%26spage%3D306%26epage%3D314%26doi%3D10.1161%2FCIRCRESAHA.118.313832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref279"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref279'); return false;" data-citation="" class="refNumLink">279</a></strong><div class="NLM_citation" id="cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birks, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tansley, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaghani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span> <span> </span><span class="NLM_article-title">Left ventricular assist device and drug therapy for the reversal of heart failure</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1873</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa053063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa053063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17079761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKjurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1873-1884&author=E.+J.+Birksauthor=P.+D.+Tansleyauthor=J.+Hardyauthor=R.+S.+Georgeauthor=C.+T.+Bowlesauthor=M.+Burkeauthor=N.+R.+Bannerauthor=A.+Khaghaniauthor=M.+H.+Yacoub&title=Left+ventricular+assist+device+and+drug+therapy+for+the+reversal+of+heart+failure&doi=10.1056%2FNEJMoa053063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Left ventricular assist device and drug therapy for the reversal of heart failure</span></div><div class="casAuthors">Birks, Emma J.; Tansley, Patrick D.; Hardy, James; George, Robert S.; Bowles, Christopher T.; Burke, Margaret; Banner, Nicholas R.; Khaghani, Asghar; Yacoub, Magdi H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1873-1884</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In patients with severe heart failure, prolonged unloading of the myocardium with the use of a left ventricular assist device has been reported to lead to myocardial recovery in small nos. of patients for varying periods of time.  Increasing the frequency and durability of myocardial recovery could reduce or postpone the need for subsequent heart transplantation.  We enrolled 15 patients with severe heart failure due to nonischemic cardiomyopathy and with no histol. evidence of active myocarditis.  All had markedly reduced cardiac output and were receiving inotropes.  The patients underwent implantation of left ventricular assist devices and were treated with lisinopril, carvedilol, spironolactone, and losartan to enhance reverse remodeling.  Once regression of left ventricular enlargement had been achieved, the β2-adrenergic-receptor agonist clenbuterol was administered to prevent myocardial atrophy.  Eleven of the 15 patients had sufficient myocardial recovery to undergo explantation of the left ventricular assist device a mean (±SD) of 320±186 days after implantation of the device.  On patient died of intractable arrhythmias 24 h after explantation; another died of carcinoma of the lung 27 mo after explantation.  The cumulative rate of freedom from recurrent heart failure among the surviving patients was 100% and 88.9% 1 and 4 years after explantation, resp.  The quality of life as assessed by the Minnesota Living with Heart Failure Questionnaire score at 3 years was nearly normal.  Fifty-nine months after explantation, the mean left ventricular ejection fraction was 64 ± 12%, the mean left ventricular end-diastolic diam. was 59.4 ± 12.1 mm, the mean left ventricular end-systolic diam. was 42.5 ± 13.2 mm, and the mean maximal oxygen uptake with exercise was 26.3 ± 6.0 mL per kg of body wt. per min.  In this single-center study, we found that sustained reversal of severe heart failure secondary to nonischemic cardiomyopathy could be achieved in selected patients with the use of a left ventricular assist device and a specific pharmacol. regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYG88vSSSsTLVg90H21EOLACvtfcHk0lipgvx6gHxzyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKjurfJ&md5=a5a8a6489d6727dfe1011ab12367bd5f</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa053063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa053063%26sid%3Dliteratum%253Aachs%26aulast%3DBirks%26aufirst%3DE.%2BJ.%26aulast%3DTansley%26aufirst%3DP.%2BD.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BS.%26aulast%3DBowles%26aufirst%3DC.%2BT.%26aulast%3DBurke%26aufirst%3DM.%26aulast%3DBanner%26aufirst%3DN.%2BR.%26aulast%3DKhaghani%26aufirst%3DA.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26atitle%3DLeft%2520ventricular%2520assist%2520device%2520and%2520drug%2520therapy%2520for%2520the%2520reversal%2520of%2520heart%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1873%26epage%3D1884%26doi%3D10.1056%2FNEJMoa053063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref280"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref280'); return false;" data-citation="" class="refNumLink">280</a></strong><div class="NLM_citation" id="cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birks, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahrami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyfus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaghani, A.</span></span> <span> </span><span class="NLM_article-title">Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.109.933960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCULATIONAHA.109.933960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21242487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=381-390&author=E.+J.+Birksauthor=R.+S.+Georgeauthor=M.+Hedgerauthor=T.+Bahramiauthor=P.+Wiltonauthor=C.+T.+Bowlesauthor=C.+Webbauthor=R.+Bougardauthor=M.+Amraniauthor=M.+H.+Yacoubauthor=G.+Dreyfusauthor=A.+Khaghani&title=Reversal+of+severe+heart+failure+with+a+continuous-flow+left+ventricular+assist+device+and+pharmacological+therapy%3A+a+prospective+study&doi=10.1161%2FCIRCULATIONAHA.109.933960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy: A Prospective Study</span></div><div class="casAuthors">Birks, Emma J.; George, Robert S.; Hedger, Mike; Bahrami, Toufan; Wilton, Penny; Bowles, Christopher T.; Webb, Carole; Bougard, Robert; Amrani, Mohammed; Yacoub, Magdi H.; Dreyfus, Gilles; Khaghani, Asghar</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-390</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We have previously shown that a specific combination of drug therapy and left ventricular assist device unloading results in significant myocardial recovery, sufficient to allow pump removal, in two thirds of patients with dilated cardiomyopathy receiving a Heartmate I pulsatile device.  However, this protocol has not been used with nonpulsatile devices.  We report the results of a prospective study of 20 patients who received a combination of angiotensin-converting enzymes, β-blockers, angiotensin II inhibitors, and aldosterone antagonists followed by the β2-agonist clenbuterol and were regularly tested (echocardiograms, exercise tests, catheterizations) with the pump at low speed.  Before left ventricular assist device insertion, patient age was 35.2 ± 12.6 years (16 male patients), patients were on 2.0 ± 0.9 inotropes, 7 (35%) had an intra-aortic balloon pump, 2 were hemofiltered, 2 were ventilated, 3 had a prior Levitronix device, and 1 had extracorporeal membrane oxygenation.  Cardiac index was 1.39 ± 0.43 L/min-1/m-2, pulmonary capillary wedge pressure was 31.5 ± 5.7 mm Hg, and heart failure history was 3.4 ± 3.5 years.  One patient was lost to follow-up and died after 240 days of support.  Of the remaining 19 patients, 12 (63.2%) were explanted after 286 ± 97 days.  8 Had symptomatic heart failure for ≤6 mo and 4 for >6 mo (48 to 132 mo).  Before explantation, at low flow for 15 min, ejection fraction was 70 ± 7%, left ventricular end-diastolic diam. was 48.6 ± 5.7 mm, left ventricular end-systolic diam. was 32.3 ± 5.7 mm, mVO2 was 21.6 ± 4 mL/kg-1/min-1, pulmonary capillary wedge pressure was 5.9 ± 4.6 mm Hg, and cardiac index was 3.6 ± 0.6 L/min-1/m-2.  Estd. survival without heart failure recurrence was 83.3% at 1 and 3 years.  After a 430.7 ± 337.1-day follow-up, surviving explants had an ejection fraction of 58.1 ± 13.8%, left ventricular end-diastolic diam. of 59.0 ± 9.3 mm, left ventricular end-systolic diam. of 42.0 ± 10.7 mm, and mVO2 of 22.6 ± 5.3 mL/kg-1/min-1.  Reversal of end-stage heart failure secondary to nonischemic cardiomyopathy can be achieved in a substantial proportion of patients with nonpulsatile flow through the use of a combination of mech. and pharmacol. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8zpEU_f3KtLVg90H21EOLACvtfcHk0lipgvx6gHxzyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSqtb8%253D&md5=b6bcfeb3b6ae77275f1702dfde8c5f60</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.109.933960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.109.933960%26sid%3Dliteratum%253Aachs%26aulast%3DBirks%26aufirst%3DE.%2BJ.%26aulast%3DGeorge%26aufirst%3DR.%2BS.%26aulast%3DHedger%26aufirst%3DM.%26aulast%3DBahrami%26aufirst%3DT.%26aulast%3DWilton%26aufirst%3DP.%26aulast%3DBowles%26aufirst%3DC.%2BT.%26aulast%3DWebb%26aufirst%3DC.%26aulast%3DBougard%26aufirst%3DR.%26aulast%3DAmrani%26aufirst%3DM.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26aulast%3DDreyfus%26aufirst%3DG.%26aulast%3DKhaghani%26aufirst%3DA.%26atitle%3DReversal%2520of%2520severe%2520heart%2520failure%2520with%2520a%2520continuous-flow%2520left%2520ventricular%2520assist%2520device%2520and%2520pharmacological%2520therapy%253A%2520a%2520prospective%2520study%26jtitle%3DCirculation%26date%3D2011%26volume%3D123%26spage%3D381%26epage%3D390%26doi%3D10.1161%2FCIRCULATIONAHA.109.933960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref281"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref281'); return false;" data-citation="" class="refNumLink">281</a></strong><div class="NLM_citation" id="cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berzetei-Gurske, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozocas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abernethy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2903</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.1021/jm070030d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070030d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1yktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2903-2915&author=K.+Jozwiakauthor=C.+Khalidauthor=M.+J.+Tangaauthor=I.+Berzetei-Gurskeauthor=L.+Jimenezauthor=J.+A.+Kozocasauthor=A.+Wooauthor=W.+Zhuauthor=R.+P.+Xiaoauthor=D.+R.+Abernethyauthor=I.+W.+Wainer&title=Comparative+molecular+field+analysis+of+the+binding+of+the+stereoisomers+of+fenoterol+and+fenoterol+derivatives+to+the+beta2+adrenergic+receptor&doi=10.1021%2Fjm070030d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Molecular Field Analysis of the Binding of the Stereoisomers of Fenoterol and Fenoterol Derivatives to the β2 Adrenergic Receptor</span></div><div class="casAuthors">Jozwiak, Krzysztof; Khalid, Chakir; Tanga, Mary J.; Berzetei-Gurske, Ilona; Jimenez, Lucita; Kozocas, Joseph A.; Woo, Anthony; Zhu, Weizhong; Xiao, Rui-Ping; Abernethy, Darrell R.; Wainer, Irving W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2903-2915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereoisomers of fenoterol and six fenoterol derivs. have been synthesized and their binding affinities for the β2 adrenergic receptor (Kiβ2-AR), the subtype selectivity relative to the β1-AR (Kiβ1-AR/Kiβ2-AR) and their functional activities were detd.  Of the 26 compds. synthesized in the study, submicromolar binding affinities were obsd. for (R,R)-fenoterol, the (R,R)-isomer of the p-methoxy, and (R,R)- and (R,S)-isomers of 1-naphthyl derivs. and all of these compds. were active at submicromolar concns. in cardiomyocyte contractility tests.  The Kiβ1-AR/Kiβ2-AR ratios were >40 for (R,R)-fenoterol and the (R,R)-p-methoxy and (R,S)-1-naphthyl derivs. and 14 for the (R,R)-1-naphthyl deriv.  The binding data was analyzed using comparative mol. field anal. (CoMFA), and the resulting model indicated that the fenoterol derivs. interacted with two sep. binding sites and one steric restricted site on the pseudo-receptor and that the chirality of the second stereogenic center affected Kiβ2 and subtype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvfopNTVaQLVg90H21EOLACvtfcHk0lj2-gzpahstvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1yktL4%253D&md5=592e198e4cd90179f12f7a638e740fbe</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1021%2Fjm070030d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070030d%26sid%3Dliteratum%253Aachs%26aulast%3DJozwiak%26aufirst%3DK.%26aulast%3DKhalid%26aufirst%3DC.%26aulast%3DTanga%26aufirst%3DM.%2BJ.%26aulast%3DBerzetei-Gurske%26aufirst%3DI.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DKozocas%26aufirst%3DJ.%2BA.%26aulast%3DWoo%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DAbernethy%26aufirst%3DD.%2BR.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DComparative%2520molecular%2520field%2520analysis%2520of%2520the%2520binding%2520of%2520the%2520stereoisomers%2520of%2520fenoterol%2520and%2520fenoterol%2520derivatives%2520to%2520the%2520beta2%2520adrenergic%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2903%26epage%3D2915%26doi%3D10.1021%2Fjm070030d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref282"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref282'); return false;" data-citation="" class="refNumLink">282</a></strong><div class="NLM_citation" id="cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beigi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abernethy, D. R.</span></span> <span> </span><span class="NLM_article-title">Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol</span>. <i>Chirality</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1002/chir.20317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fchir.20317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16917835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFenurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=822-827&author=F.+Beigiauthor=C.+Bertucciauthor=W.+Zhuauthor=K.+Chakirauthor=I.+W.+Wainerauthor=R.+P.+Xiaoauthor=D.+R.+Abernethy&title=Enantioselective+separation+and+online+affinity+chromatographic+characterization+of+R%2CR-+and+S%2CS-fenoterol&doi=10.1002%2Fchir.20317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol</span></div><div class="casAuthors">Beigi, Farideh; Bertucci, Carlo; Zhu, Weizhong; Chakir, Khalid; Wainer, Irving W.; Xiao, Rui-Ping; Abernethy, Darrell R.</div><div class="citationInfo"><span class="NLM_cas:title">Chirality</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">822-827</span>CODEN:
                <span class="NLM_cas:coden">CHRLEP</span>;
        ISSN:<span class="NLM_cas:issn">0899-0042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Rac-fenoterol is a β2-adrenoceptor agonist (β2-AR) used in the treatment of asthma.  It has 2 chiral centers and is marketed as a racemic mixt. of R,R'- and S,S'-fenoterol (R-F and S-F).  Here we report the sepn. of the R-F and S-F enantiomers and the evaluation of their binding to and activation of the β2-AR.  R-F and S-F were sepd. from the enantiomeric mixt. by chiral chromatog. and abs. configuration detd. by CD.  β2-AR binding was evaluated using frontal affinity chromatog. with a stationary phase contg. immobilized membranes from HEK-293 cells that express human β2-AR and std. membrane binding studies using the same membranes.  The effect of R-F and S-F on cardiomyocyte contractility was also investigated using freshly isolated adult rat cardiomyocytes.  Chiral chromatog. of rac-fenoterol yielded sepd. peaks with an enantioselectivity factor of 1.21.  The less retained peak was assigned the abs. configuration of S-F and the more retained peak R-F.  Frontal chromatog. using membrane-bound β2-AR as the stationary phase and rac-3H-fenoterol as a marker ligand showed that addn. of increasing concns. of R-F to the mobile phase produced concn.-dependent decreases in rac-3H-fenoterol retention, while similar addn. of S-F produced no change in rac-3H-fenoterol retention.  The calcd. dissocn. const. of R-F was 472 nM and the no. of available binding sites 176 pmol/column, which was consistent with the results from the membrane binding study 460 nM (R-F) and 109,000 nM (S-F).  In the cardiomyocytes, R-F increased max. contractile response from 265% to 306% of resting cell length and reduced EC50 from -7.0 to -7.1 log[M], while S-F had no significant effect.  Previous studies have shown that rac-fenoterol acts as an apparent β2-AR/Gs selective agonist and fully restores diminished β2-AR contractile response in cardiomyocytes from failing hearts of spontaneously hypertensive rats (SHR).  Here we report the sepn. of the enantiomers of rac-fenoterol and that R-F is the active component of rac-fenoterol.  Further evaluation of R-F will det. if it has enhanced selectivity and specificity for β2-AR/Gs activation and if it can be used in the treatment of congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0_YQuoc6id7Vg90H21EOLACvtfcHk0lj2-gzpahstvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFenurfL&md5=5aeb8818ee644cddb1f5fff740c70529</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1002%2Fchir.20317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchir.20317%26sid%3Dliteratum%253Aachs%26aulast%3DBeigi%26aufirst%3DF.%26aulast%3DBertucci%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DAbernethy%26aufirst%3DD.%2BR.%26atitle%3DEnantioselective%2520separation%2520and%2520online%2520affinity%2520chromatographic%2520characterization%2520of%2520R%252CR-%2520and%2520S%252CS-fenoterol%26jtitle%3DChirality%26date%3D2006%26volume%3D18%26spage%3D822%26epage%3D827%26doi%3D10.1002%2Fchir.20317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref283"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref283'); return false;" data-citation="" class="refNumLink">283</a></strong><div class="NLM_citation" id="cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plazinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span> <span> </span><span class="NLM_article-title">Molecular interactions between fenoterol stereoisomers and derivatives and the β<sub>2</sub>-adrenergic receptor binding site studied by docking and molecular dynamics simulations</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4919</span>– <span class="NLM_lpage">4930</span>, <span class="refDoi"> DOI: 10.1007/s00894-013-1981-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00894-013-1981-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24043542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOktrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4919-4930&author=A.+Plazinskaauthor=M.+Kolinskiauthor=I.+W.+Wainerauthor=K.+Jozwiak&title=Molecular+interactions+between+fenoterol+stereoisomers+and+derivatives+and+the+%CE%B22-adrenergic+receptor+binding+site+studied+by+docking+and+molecular+dynamics+simulations&doi=10.1007%2Fs00894-013-1981-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular interactions between fenoterol stereoisomers and derivatives and the β2-adrenergic receptor binding site studied by docking and molecular dynamics simulations</span></div><div class="casAuthors">Plazinska, Anita; Kolinski, Michal; Wainer, Irving W.; Jozwiak, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4919-4930</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The β2 adrenergic receptor (β2-AR) has become a model system for studying the ligand recognition process and mechanism of the G protein coupled receptors activation.  In the present study stereoisomers of fenoterol and some of its derivs. (N = 94 mols.) were used as mol. probes to identify differences in stereo-recognition interactions between β2-AR and structurally similar agonists.  The present study aimed at detg. the 3D mol. models of the fenoterol deriv.-β2-AR complexes.  Mol. models of β2-AR have been developed by using the crystal structure of the human β2-AR T4 lysozyme fusion protein with bound (S)-carazolol (PDB ID: 2RH1) and more recently reported structure of a nanobody-stabilized active state of the β2-AR with the bound full agonist BI-167107 (PDB ID: 3P0G).  The docking procedure allowed us to study the similarities and differences in the recognition binding site(s) for tested ligands.  The agonist mols. occupied the same binding region, between TM III, TM V, TM VI and TM VII.  The residues identified by us during docking procedure (Ser203, Ser207, Asp113, Lys305, Asn312, Tyr308, Asp192) were exptl. indicated in functional and biophys. studies as being very important for the agonist-receptor interactions.  Moreover, the addnl. space, an extension of the orthosteric pocket, was identified and described.  Furthermore, the mol. dynamics simulations were used to study the mol. mechanism of interaction between ligands ((R,R')- and (S,S')-fenoterol) and β2-AR.  Our research offers new insights into the ligand stereoselective interaction with one of the most important GPCR member.  This study may also facilitate the design of improved selective medications, which can be used to treat, prevent and control heart failure symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-6xhaMGVD6rVg90H21EOLACvtfcHk0lj2-gzpahstvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOktrbL&md5=bb3cf560cbe53be858f605e9d47b6f32</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1007%2Fs00894-013-1981-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-013-1981-y%26sid%3Dliteratum%253Aachs%26aulast%3DPlazinska%26aufirst%3DA.%26aulast%3DKolinski%26aufirst%3DM.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DJozwiak%26aufirst%3DK.%26atitle%3DMolecular%2520interactions%2520between%2520fenoterol%2520stereoisomers%2520and%2520derivatives%2520and%2520the%2520%25CE%25B22-adrenergic%2520receptor%2520binding%2520site%2520studied%2520by%2520docking%2520and%2520molecular%2520dynamics%2520simulations%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D4919%26epage%3D4930%26doi%3D10.1007%2Fs00894-013-1981-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref284"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref284'); return false;" data-citation="" class="refNumLink">284</a></strong><div class="NLM_citation" id="cit284"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozocas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plazinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.11.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmc.2009.11.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20036561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1yquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=728-736&author=K.+Jozwiakauthor=A.+Y.+Wooauthor=M.+J.+Tangaauthor=L.+Tollauthor=L.+Jimenezauthor=J.+A.+Kozocasauthor=A.+Plazinskaauthor=R.+P.+Xiaoauthor=I.+W.+Wainer&title=Comparative+molecular+field+analysis+of+fenoterol+derivatives%3A+A+platform+towards+highly+selective+and+effective+beta%282%29-adrenergic+receptor+agonists&doi=10.1016%2Fj.bmc.2009.11.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit284R"><div class="casContent"><span class="casTitleNuber">284</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists</span></div><div class="casAuthors">Jozwiak, Krzysztof; Woo, Anthony Yiu-Ho; Tanga, Mary J.; Toll, Lawrence; Jimenez, Lucita; Kozocas, Joseph A.; Plazinska, Anita; Xiao, Rui-Ping; Wainer, Irving W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">728-736</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of the study was to use a previously developed CoMFA model to design a series of new structures of high selectivity and efficacy towards the β2-adrenergic receptor.  Out of 21 computationally designed structures 6 compds. were synthesized and characterized for β2-AR binding affinities, subtype selectivities and functional activities.  The best compd. was found to be (R,R)-4-methoxy-1-naphthylfenoterol (I) with K iβ2-AR = 0.28 μm, K iβ1-AR/K iβ2-AR = 573, EC50cAMP = 3.9 nm, EC50cardio = 16 nm.  The CoMFA model appeared to be an effective predictor of the cardiomocyte contractility of the studied compds. which are targeted for use in congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn5_GNVS8ftLVg90H21EOLACvtfcHk0liEDD-YzFPA0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1yquw%253D%253D&md5=76b1252884c8e6f73e13d8fe44ddd0d1</span></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.11.062%26sid%3Dliteratum%253Aachs%26aulast%3DJozwiak%26aufirst%3DK.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DTanga%26aufirst%3DM.%2BJ.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DKozocas%26aufirst%3DJ.%2BA.%26aulast%3DPlazinska%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DComparative%2520molecular%2520field%2520analysis%2520of%2520fenoterol%2520derivatives%253A%2520A%2520platform%2520towards%2520highly%2520selective%2520and%2520effective%2520beta%25282%2529-adrenergic%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D728%26epage%3D736%26doi%3D10.1016%2Fj.bmc.2009.11.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref285"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref285'); return false;" data-citation="" class="refNumLink">285</a></strong><div class="NLM_citation" id="cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plazinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span> <span> </span><span class="NLM_article-title">Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β<sub>2</sub>-adrenergic receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmc.2013.11.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24326276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=234-246&author=A.+Plazinskaauthor=K.+Pajakauthor=E.+Rutkowskaauthor=L.+Jimenezauthor=J.+Kozocasauthor=G.+Koolpeauthor=M.+Tangaauthor=L.+Tollauthor=I.+W.+Wainerauthor=K.+Jozwiak&title=Comparative+molecular+field+analysis+of+fenoterol+derivatives+interacting+with+an+agonist-stabilized+form+of+the+%CE%B22-adrenergic+receptor&doi=10.1016%2Fj.bmc.2013.11.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β2-adrenergic receptor</span></div><div class="casAuthors">Plazinska, Anita; Pajak, Karolina; Rutkowska, Ewelina; Jimenez, Lucita; Kozocas, Joseph; Koolpe, Gary; Tanga, Mary; Toll, Lawrence; Wainer, Irving W.; Jozwiak, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-246</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2-AR) agonist [3H]-(R,R')-methoxyfenoterol was employed as the marker ligand in displacement studies measuring the binding affinities (Ki values) of the stereoisomers of a series of 4'-methoxyfenoterol analogs in which the length of the alkyl substituent at α' position was varied from 0 to 3 carbon atoms.  The binding affinities of the compds. were addnl. detd. using the inverse agonist [3H]-CGP-12177 as the marker ligand and the ability of the compds. to stimulate cAMP accumulation, measured as EC50 values, were detd. in HEK293 cells expressing the β2-AR.  The data indicate that the highest binding affinities and functional activities were produced by Me and Et substituents at the α' position.  The results also indicate that the Ki values obtained using [3H]-(R,R')-methoxyfenoterol as the marker ligand modeled the EC50 values obtained from cAMP stimulation better than the data obtained using [3H]-CGP-12177 as the marker ligand.  The data from this study was combined with data from previous studies and processed using the Comparative Mol. Field Anal. approach to produce a CoMFA model reflecting the binding to the β2-AR conformation probed by [3H]-(R,R')-4'-methoxyfenoterol.  The CoMFA model of the agonist-stabilized β2-AR suggests that the binding of the fenoterol analogs to an agonist-stabilized conformation of the β2-AR is governed to a greater extend by steric effects than binding to the [3H]-CGP-12177-stabilized conformation(s) in which electrostatic interactions play a more predominate role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9MLvvJg7wibVg90H21EOLACvtfcHk0liEDD-YzFPA0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtbrM&md5=c1e879cea178fce6e8a355415762937b</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DPlazinska%26aufirst%3DA.%26aulast%3DPajak%26aufirst%3DK.%26aulast%3DRutkowska%26aufirst%3DE.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DKozocas%26aufirst%3DJ.%26aulast%3DKoolpe%26aufirst%3DG.%26aulast%3DTanga%26aufirst%3DM.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DJozwiak%26aufirst%3DK.%26atitle%3DComparative%2520molecular%2520field%2520analysis%2520of%2520fenoterol%2520derivatives%2520interacting%2520with%2520an%2520agonist-stabilized%2520form%2520of%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D234%26epage%3D246%26doi%3D10.1016%2Fj.bmc.2013.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref286"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref286'); return false;" data-citation="" class="refNumLink">286</a></strong><div class="NLM_citation" id="cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">Beta-arrestin-mediated signaling in the heart</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1725</span>– <span class="NLM_lpage">1729</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-08-0734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1253%2Fcircj.CJ-08-0734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18838825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWltrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2008&pages=1725-1729&author=P.+A.+Patelauthor=D.+G.+Tilleyauthor=H.+A.+Rockman&title=Beta-arrestin-mediated+signaling+in+the+heart&doi=10.1253%2Fcircj.CJ-08-0734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">Beta-arrestin-mediated signaling in the heart</span></div><div class="casAuthors">Patel, Priyesh A.; Tilley, Douglas G.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1725-1729</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">A review.  Beta-arrestin is a multifunctional adapter protein well known for its role in G-protein-coupled receptor (GPCR) desensitization.  Exciting new evidence indicates that β-arrestin is also a signaling mol. capable of initiating its own G-protein-independent signaling at GPCRs.  One of the best-studied β-arrestin signaling pathways is the one involving β-arrestin-dependent activation of a mitogen-activated protein kinase cascade, the extracellular regulated kinase (ERK).  ERK signaling, which is classically activated by agonist stimulation of the epidermal growth factor receptor (EGFR), can be activated by a no. of GPCRs in a β-arrestin-dependent manner.  Recent work in animal models of heart failure suggests that β-arrestin-dependent activation of EGFR/ERK signaling by the β-1-adrenergic receptor, and possibly the angiotensin II Type 1A receptor, are cardioprotective.  Hence, a new model of signaling at cardiac GPCRs has emerged and implicates classical G-protein-mediated signaling with promoting harmful remodeling in heart failure, while concurrently linking β-arrestin-dependent, G-protein-independent signaling with cardioprotective effects.  Based on this paradigm, a new class of drugs could be identified, termed "biased ligands", which simultaneously block harmful G-protein signaling, while also promoting cardioprotective β-arrestin-dependent signaling, leading to a potential breakthrough in the treatment of chronic cardiac disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiYFy2SSoVrVg90H21EOLACvtfcHk0liEDD-YzFPA0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWltrnE&md5=bf09d9169bf26cba22d2234198a24033</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-08-0734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-08-0734%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BA.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3DBeta-arrestin-mediated%2520signaling%2520in%2520the%2520heart%26jtitle%3DCirc.%2520J.%26date%3D2008%26volume%3D72%26spage%3D1725%26epage%3D1729%26doi%3D10.1253%2Fcircj.CJ-08-0734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref287"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref287'); return false;" data-citation="" class="refNumLink">287</a></strong><div class="NLM_citation" id="cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naga Prasad, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barki-Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Corvoisier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-mediated β<sub>1</sub>-adrenergic receptor transactivation of the EGFR confers cardioprotection</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2445</span>– <span class="NLM_lpage">2458</span>, <span class="refDoi"> DOI: 10.1172/JCI31901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI31901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17786238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCms7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2445-2458&author=T.+Nomaauthor=A.+Lemaireauthor=S.+V.+Naga+Prasadauthor=L.+Barki-Harringtonauthor=D.+G.+Tilleyauthor=J.+Chenauthor=P.+Le+Corvoisierauthor=J.+D.+Violinauthor=H.+Weiauthor=R.+J.+Lefkowitzauthor=H.+A.+Rockman&title=%CE%B2-arrestin-mediated+%CE%B21-adrenergic+receptor+transactivation+of+the+EGFR+confers+cardioprotection&doi=10.1172%2FJCI31901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection</span></div><div class="casAuthors">Noma, Takahisa; Lemaire, Anthony; Prasad, Sathyamangla V. Naga; Barki-Harrington, Liza; Tilley, Douglas G.; Chen, Juhsien; Le Corvoisier, Philippe; Violin, Jonathan D.; Wei, Huijun; Lefkowitz, Robert J.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2445-2458</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Deleterious effects on the heart from chronic stimulation of β-adrenergic receptors (βARs), members of the 7 transmembrane receptor family, have classically been shown to result from Gs-dependent adenylyl cyclase activation.  Here, we identify a new signaling mechanism using both in vitro and in vivo systems whereby β-arrestins mediate β1AR signaling to the EGFR.  This β-arrestin-dependent transactivation of the EGFR, which is independent of G protein activation, requires the G protein-coupled receptor kinases 5 and 6.  In mice undergoing chronic sympathetic stimulation, this novel signaling pathway is shown to promote activation of cardioprotective pathways that counteract the effects of catecholamine toxicity.  These findings suggest that drugs that act as classical antagonists for G protein signaling, but also stimulate signaling via β-arrestin-mediated cytoprotective pathways, would represent a novel class of agents that could be developed for multiple members of the 7 transmembrane receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvSYQwqS-dwbVg90H21EOLACvtfcHk0ljq__LQR3y3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCms7vP&md5=721bdd41511d9cf6836d86bdd7bf64da</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1172%2FJCI31901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31901%26sid%3Dliteratum%253Aachs%26aulast%3DNoma%26aufirst%3DT.%26aulast%3DLemaire%26aufirst%3DA.%26aulast%3DNaga%2BPrasad%26aufirst%3DS.%2BV.%26aulast%3DBarki-Harrington%26aufirst%3DL.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLe%2BCorvoisier%26aufirst%3DP.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-arrestin-mediated%2520%25CE%25B21-adrenergic%2520receptor%2520transactivation%2520of%2520the%2520EGFR%2520confers%2520cardioprotection%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D2445%26epage%3D2458%26doi%3D10.1172%2FJCI31901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref288"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref288'); return false;" data-citation="" class="refNumLink">288</a></strong><div class="NLM_citation" id="cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynham, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pironti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-arrestin1-biased β<sub>1</sub>-adrenergic receptor signaling regulates microRNA processing</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.114.302766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.114.302766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24334028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=833-844&author=I.+M.+Kimauthor=Y.+Wangauthor=K.+M.+Parkauthor=Y.+Tangauthor=J.+P.+Teohauthor=J.+Vinsonauthor=C.+J.+Traynhamauthor=G.+Pirontiauthor=L.+Maoauthor=H.+Suauthor=J.+A.+Johnsonauthor=W.+J.+Kochauthor=H.+A.+Rockman&title=%CE%B2-arrestin1-biased+%CE%B21-adrenergic+receptor+signaling+regulates+microRNA+processing&doi=10.1161%2FCIRCRESAHA.114.302766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit288R"><div class="casContent"><span class="casTitleNuber">288</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin1-Biased β1-Adrenergic Receptor Signaling Regulates MicroRNA Processing</span></div><div class="casAuthors">Kim, Il-man; Wang, Yongchao; Park, Kyoung-mi; Tang, Yaoping; Teoh, Jian-peng; Vinson, Joseph; Traynham, Christopher J.; Pironti, Gianluigi; Mao, Lan; Su, Huabo; Johnson, John A.; Koch, Walter J.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: MicroRNAs (miRs) are small, noncoding RNAs that function to post-transcriptionally regulate gene expression.  First transcribed as long primary miR transcripts (pri-miRs), they are enzymically processed in the nucleus by Drosha into hairpin intermediate miRs (pre-miRs) and further processed in the cytoplasm by Dicer into mature miRs where they regulate cellular processes after activation by a variety of signals such as those stimulated by β-adrenergic receptors (βARs).  Initially discovered to desensitize βAR signaling, β-arrestins are now appreciated to transduce multiple effector pathways independent of G-protein-mediated second messenger accumulation, a concept known as biased signaling.  We previously showed that the β-arrestin-biased βAR agonist, carvedilol, activates cellular pathways in the heart.  Objective: Here, we tested whether carvedilol could activate β-arrestin-mediated miR maturation, thereby providing a novel potential mechanism for its cardioprotective effects.  Methods and results: In human cells and mouse hearts, carvedilol upregulates a subset of mature and pre-miRs, but not their pri-miRs, in β1AR-, G-protein-coupled receptor kinase 5/6-, and β-arrestin1-dependent manner.  Mechanistically, β-arrestin1 regulates miR processing by forming a nuclear complex with hnRNPA1 and Drosha on pri-miRs.  Conclusions: Our findings indicate a novel function for β1AR-mediated β-arrestin1 signaling activated by carvedilol in miR biogenesis, which may be linked, in part, to its mechanism for cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohMPKnya33VrVg90H21EOLACvtfcHk0ljq__LQR3y3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSiu7g%253D&md5=a2025fbbc31d0e0b609639e4b57b1b46</span></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.114.302766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.114.302766%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DK.%2BM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DVinson%26aufirst%3DJ.%26aulast%3DTraynham%26aufirst%3DC.%2BJ.%26aulast%3DPironti%26aufirst%3DG.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-arrestin1-biased%2520%25CE%25B21-adrenergic%2520receptor%2520signaling%2520regulates%2520microRNA%2520processing%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D114%26spage%3D833%26epage%3D844%26doi%3D10.1161%2FCIRCRESAHA.114.302766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref289"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref289'); return false;" data-citation="" class="refNumLink">289</a></strong><div class="NLM_citation" id="cit289"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aonuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2018.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2018.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29627294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=225-236&author=J.+P.+Teohauthor=A.+S.+Bayoumiauthor=T.+Aonumaauthor=Y.+Xuauthor=J.+A.+Johnsonauthor=H.+Suauthor=N.+L.+Weintraubauthor=Y.+Tangauthor=I.+M.+Kim&title=%CE%B2-arrestin-biased+agonism+of+%CE%B2-adrenergic+receptor+regulates+Dicer-mediated+microRNA+maturation+to+promote+cardioprotective+signaling&doi=10.1016%2Fj.yjmcc.2018.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling</span></div><div class="casAuthors">Teoh, Jian-Peng; Bayoumi, Ahmed S.; Aonuma, Tatsuya; Xu, Yanyan; Johnson, John A.; Su, Huabo; Weintraub, Neal L.; Tang, Yaoliang; Kim, Il-Man</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-236</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">MicroRNAs (miRs) are small, non-coding RNAs that function to post-transcriptionally regulate target genes.  First transcribed as primary miR transcripts (pri-miRs), they are enzymically processed by Drosha into premature miRs (pre-miRs) and further cleaved by Dicer into mature miRs.  Initially discovered to desensitize β-adrenergic receptor (βAR) signaling, β-arrestins are now well-appreciated to modulate multiple pathways independent of G protein signaling, a concept known as biased signaling.  Using the β-arrestin-biased βAR ligand carvedilol, we previously showed that β-arrestin1 (not β-arrestin2)-biased β1AR (not β2AR) cardioprotective signaling stimulates Drosha-mediated processing of six miRs by forming a multi-protein nuclear complex, which includes β-arrestin1, the Drosha microprocessor complex and a single-stranded RNA binding protein hnRNPA1.  Here, we investigate whether β-arrestin-mediated βAR signaling induced by carvedilol could regulate Dicer-mediated miR maturation in the cytoplasm and whether this novel mechanism promotes cardioprotective signaling.  In mouse hearts, carvedilol indeed upregulates three mature miRs, but not their pre-miRs and pri-miRs, in a β-arrestin 1- or 2-dependent manner.  Interestingly, carvedilol-mediated activation of miR-466g or miR-532-5p, and miR-674 is dependent on β2ARs and β1ARs, resp.  Mechanistically, β-arrestin 1 or 2 regulates maturation of three newly identified βAR/β-arrestin-responsive miRs (β-miRs) by assocg. with the Dicer maturation RNase III enzyme on three pre-miRs of β-miRs.  Myocardial cell approaches uncover that despite their distinct roles in different cell types, β-miRs act as gatekeepers of cardiac cell functions by repressing deleterious targets.  Our findings indicate a novel role for βAR-mediated β-arrestin signaling activated by carvedilol in Dicer-mediated miR maturation, which may be linked to its protective mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Fs7pDRFpCLVg90H21EOLACvtfcHk0ljq__LQR3y3dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslOisr8%253D&md5=22b9cdc76d97176d2f2a4c287302cabe</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2018.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2018.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DBayoumi%26aufirst%3DA.%2BS.%26aulast%3DAonuma%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DWeintraub%26aufirst%3DN.%2BL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DI.%2BM.%26atitle%3D%25CE%25B2-arrestin-biased%2520agonism%2520of%2520%25CE%25B2-adrenergic%2520receptor%2520regulates%2520Dicer-mediated%2520microRNA%2520maturation%2520to%2520promote%2520cardioprotective%2520signaling%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2018%26volume%3D118%26spage%3D225%26epage%3D236%26doi%3D10.1016%2Fj.yjmcc.2018.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref290"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref290'); return false;" data-citation="" class="refNumLink">290</a></strong><div class="NLM_citation" id="cit290"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynham, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benovic, J. L.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-biased signaling through the β<sub>2</sub>-adrenergic receptor promotes cardiomyocyte contraction</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E4107</span>– <span class="NLM_lpage">E4116</span>, <span class="refDoi"> DOI: 10.1073/pnas.1606267113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.1606267113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27354517" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E4107-E4116&author=R.+Carrauthor=J.+Schillingauthor=J.+Songauthor=R.+L.+Carterauthor=Y.+Duauthor=S.+M.+Yooauthor=C.+J.+Traynhamauthor=W.+J.+Kochauthor=J.+Y.+Cheungauthor=D.+G.+Tilleyauthor=J.+L.+Benovic&title=%CE%B2-arrestin-biased+signaling+through+the+%CE%B22-adrenergic+receptor+promotes+cardiomyocyte+contraction&doi=10.1073%2Fpnas.1606267113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1606267113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1606267113%26sid%3Dliteratum%253Aachs%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DSchilling%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DR.%2BL.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DYoo%26aufirst%3DS.%2BM.%26aulast%3DTraynham%26aufirst%3DC.%2BJ.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26atitle%3D%25CE%25B2-arrestin-biased%2520signaling%2520through%2520the%2520%25CE%25B22-adrenergic%2520receptor%2520promotes%2520cardiomyocyte%2520contraction%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE4107%26epage%3DE4116%26doi%3D10.1073%2Fpnas.1606267113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref291"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref291'); return false;" data-citation="" class="refNumLink">291</a></strong><div class="NLM_citation" id="cit291"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grisanti, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lucia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benovic, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span> <span> </span><span class="NLM_article-title">Pepducin-mediated cardioprotection via β-arrestin-biased β<sub>2</sub>-adrenergic receptor-specific signaling</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4664</span>– <span class="NLM_lpage">4678</span>, <span class="refDoi"> DOI: 10.7150/thno.26619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.7150%2Fthno.26619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30279730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1egtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=4664-4678&author=L.+A.+Grisantiauthor=T.+P.+Thomasauthor=R.+L.+Carterauthor=C.+de+Luciaauthor=E.+Gaoauthor=W.+J.+Kochauthor=J.+L.+Benovicauthor=D.+G.+Tilley&title=Pepducin-mediated+cardioprotection+via+%CE%B2-arrestin-biased+%CE%B22-adrenergic+receptor-specific+signaling&doi=10.7150%2Fthno.26619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling</span></div><div class="casAuthors">Grisanti, Laurel A.; Thomas, Toby P.; Carter, Rhonda L.; de Lucia, Claudio; Gao, Erhe; Koch, Walter J.; Benovic, Jeffrey L.; Tilley, Douglas G.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4664-4678</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Reperfusion as a therapeutic intervention for acute myocardial infarction-induced cardiac injury itself induces further cardiomyocyte death. β-arrestin (βarr)-biased β-adrenergic receptor (βAR) activation promotes survival signaling responses in vitro; thus, we hypothesize that this pathway can mitigate cardiomyocyte death at the time of reperfusion to better preserve function.  However, a lack of efficacious βarr-biased orthosteric small mols. has prevented investigation into whether this pathway relays protection against ischemic injury in vivo.  We recently demonstrated that the pepducin ICL1-9, a small lipidated peptide fragment designed from the first intracellular loop of β2AR, allosterically engaged pro-survival signaling cascades in a βarr-dependent manner in vitro.  Thus, in this study we tested whether ICL1-9 relays cardioprotection against ischemia/reperfusion (I/R)-induced injury in vivo.  Methods: Wild-type (WT) C57BL/6, β2AR knockout (KO), βarr1KO and βarr2KO mice received intracardiac injections of either ICL1-9 or a scrambled control pepducin (Scr) at the time of ischemia (30 min) followed by reperfusion for either 24 h, to assess infarct size and cardiomyocyte death, or 4 wk, to monitor the impact of ICL1-9 on long-term cardiac structure and function.  Neonatal rat ventricular myocytes (NRVM) were used to assess the impact of ICL1-9 vs. Scr pepducin on cardiomyocyte survival and mitochondrial superoxide formation in response to either serum deprivation or hypoxia/reoxygenation (H/R) in vitro and to investigate the assocd. mechanism(s).  Results: Intramyocardial injection of ICL1-9 at the time of I/R reduced infarct size, cardiomyocyte death and improved cardiac function in a β2AR- and βarr-dependent manner, which led to improved contractile function early and less fibrotic remodeling over time.  Mechanistically, ICL1-9 attenuated mitochondrial superoxide prodn. and promoted cardiomyocyte survival in a RhoA/ROCK-dependent manner.  RhoA activation could be detected in cardiomyocytes and whole heart up to 24 h post-treatment, demonstrating the stability of ICL1-9 effects on βarr-dependent β2AR signaling.  Conclusion: Pepducin-based allosteric modulation of βarr-dependent β2AR signaling represents a novel therapeutic approach to reduce reperfusion-induced cardiac injury and relay long-term cardiac remodeling benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxBwJQYSCJrVg90H21EOLACvtfcHk0lj-Krp1g31TDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1egtbg%253D&md5=b86c36731becdcc3f4fc5c2e053b87ef</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.7150%2Fthno.26619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.26619%26sid%3Dliteratum%253Aachs%26aulast%3DGrisanti%26aufirst%3DL.%2BA.%26aulast%3DThomas%26aufirst%3DT.%2BP.%26aulast%3DCarter%26aufirst%3DR.%2BL.%26aulast%3Dde%2BLucia%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26atitle%3DPepducin-mediated%2520cardioprotection%2520via%2520%25CE%25B2-arrestin-biased%2520%25CE%25B22-adrenergic%2520receptor-specific%2520signaling%26jtitle%3DTheranostics%26date%3D2018%26volume%3D8%26spage%3D4664%26epage%3D4678%26doi%3D10.7150%2Fthno.26619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref292"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref292'); return false;" data-citation="" class="refNumLink">292</a></strong><div class="NLM_citation" id="cit292"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Littmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göttle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinartz, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kälble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span> <span> </span><span class="NLM_article-title">Recruitment of β-arrestin 1 and 2 to the β<sub>2</sub>-adrenoceptor: analysis of 65 ligands</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.227959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.115.227959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26306764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=183-190&author=T.+Littmannauthor=M.+G%C3%B6ttleauthor=M.+T.+Reinartzauthor=S.+K%C3%A4lbleauthor=I.+W.+Wainerauthor=T.+Ozawaauthor=R.+Seifert&title=Recruitment+of+%CE%B2-arrestin+1+and+2+to+the+%CE%B22-adrenoceptor%3A+analysis+of+65+ligands&doi=10.1124%2Fjpet.115.227959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands</span></div><div class="casAuthors">Littmann, Timo; Goettle, Martin; Reinartz, Michael T.; Kaelble, Solveig; Wainer, Irving W.; Ozawa, Takeaki; Seifert, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Beyond canonical signaling via Gαs and cAMP, the concept of functional selectivity at β2-adrenoceptors (β2ARs) describes the ability of adrenergic drugs to stabilize ligand-specific receptor conformations to initiate further signaling cascades comprising addnl. G-protein classes or β-arrestins (βarr).  A set of 65 adrenergic ligands including 40 agonists and 25 antagonists in either racemic or enantiopure forms was used for βarr recruitment expts. based on a split-luciferase assay in a cellular system expressing β2AR.  Many agonists showed only (weak) partial agonism regarding βarr recruitment.  Potencies and/or efficacies increased depending on the no. of chirality centers in (R) configuration; no (S)-configured distomer was more effective at inducing βarr recruitment other than the eutomer. βarr2 was recruited more effectively than βarr1.  The anal. of antagonists revealed no significant effects on βarr recruitment.  Several agonists showed preference for activation of Gαs GTPase relative to βarr recruitment, and no βarr-biased ligand was identified.  In conclusion: (1) agonists show strong bias for Gαs activation relative to βarr recruitment; (2) agonists recruit βarr1 and βarr2 with subtle differences; and (3) there is no evidence for βarr recruitment by antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBFkWzU6mIbbVg90H21EOLACvtfcHk0lgzB_AtNE-OFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsrs%253D&md5=3eb8449a84369867dad25f211b6b6b90</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227959%26sid%3Dliteratum%253Aachs%26aulast%3DLittmann%26aufirst%3DT.%26aulast%3DG%25C3%25B6ttle%26aufirst%3DM.%26aulast%3DReinartz%26aufirst%3DM.%2BT.%26aulast%3DK%25C3%25A4lble%26aufirst%3DS.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DSeifert%26aufirst%3DR.%26atitle%3DRecruitment%2520of%2520%25CE%25B2-arrestin%25201%2520and%25202%2520to%2520the%2520%25CE%25B22-adrenoceptor%253A%2520analysis%2520of%252065%2520ligands%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D183%26epage%3D190%26doi%3D10.1124%2Fjpet.115.227959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277'],'ref278':['cit278'],'ref279':['cit279'],'ref280':['cit280'],'ref281':['cit281'],'ref282':['cit282'],'ref283':['cit283'],'ref284':['cit284'],'ref285':['cit285'],'ref286':['cit286'],'ref287':['cit287'],'ref288':['cit288'],'ref289':['cit289'],'ref290':['cit290'],'ref291':['cit291'],'ref292':['cit292']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mario  Cazzola</span>, <span class="hlFld-ContribAuthor ">Paola  Rogliani</span>, <span class="hlFld-ContribAuthor ">Maria Gabriella  Matera</span>. </span><span class="cited-content_cbyCitation_article-title">The Future of Bronchodilators in COPD and Asthma. </span><span class="cited-content_cbyCitation_journal-name">Archivos de Bronconeumología</span><span> <strong>2021,</strong> <em>72 </em><a href="https://doi.org/10.1016/j.arbres.2021.06.005" title="DOI URL">https://doi.org/10.1016/j.arbres.2021.06.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.arbres.2021.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.arbres.2021.06.005%26sid%3Dliteratum%253Aachs%26jtitle%3DArchivos%2520de%2520Bronconeumolog%25C3%25ADa%26atitle%3DThe%252BFuture%252Bof%252BBronchodilators%252Bin%252BCOPD%252Band%252BAsthma%26aulast%3DCazzola%26aufirst%3DMario%26date%3D2021%26volume%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic diagrams of βAR signaling in the regulation of cardiac function in normal conditions and during HF. (A) βAR signaling in normal heart. Regulators are typed in blue. A black solid arrow represents activation in a stimulatory pathway. A blue solid arrow represents activation in a regulatory pathway. A blue dotted line with a blunt head represents inhibition. A blue solid line with round heads on both ends represents a tight binding. (1) β-agonists (β+) stimulate both the β<sub>1</sub>AR and the β<sub>2</sub>AR to produce a contractility enhancement effect via the canonical βAR-G<sub>s</sub>-AC-cAMP-PKA signaling cascade. (2) In heterologous desensitization, PKA-dependent phosphorylation of the β<sub>2</sub>AR causes the switching of the coupling preference of the receptor from G<sub>s</sub> to G<sub>i</sub>. The activated G<sub>i</sub> subsequently negates the effect of G<sub>s</sub> in promoting the activity of AC in synthesizing cAMP. (3) In homologous desensitization, the β<sub>1</sub>AR and the β<sub>2</sub>AR in their active conformations are prone to phosphorylation by GRK2, and phosphorylation of the C-terminus of the βARs greatly increases β-arrestin (βarr) recruitment. G<sub>s</sub> is uncoupled as its receptor binding sites is occupied by βarr. The βarr subsequently triggers receptor internalization. (4) The agonist-bound β<sub>1</sub>AR binds weakly with the βarr and does not readily internalize, but it activates unique βarr-dependent signalings either by forming a complex with the βarr or by activating the clathrin-coated structure-associated βarr after dissociating from it.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (5) When βarr is recruited to the β<sub>2</sub>AR on membrane surface, it brings along PDE4 in close association. The PDE4 degrades cAMP in the vicinity reducing PKA activity. The β<sub>2</sub>AR-mediated cAMP/PKA signaling is said to be compartmentalized. (6) The recruitment of PDE4 also affects the cAMP/PKA signaling mediated by a nearby β<sub>1</sub>AR, a process known as “offside” compartmentalization. (7) β<sub>2</sub>-Agonist can also stimulate the β<sub>2</sub>AR to produce a contractile response via direct activation of LCC assembled in a β<sub>2</sub>AR signal complex that also contains G<sub>s</sub>, AC, PKA, and the counterbalancing phosphatase PP2A.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (B) βAR signaling in the failing heart. The diagram has been simplified for clarity. A black dotted arrow represents impaired activation in a stimulatory pathway. The downward-pointed arrow next to the β<sub>1</sub>AR represents downregulation. The upward-pointed arrows next to GRK2 and G<sub>i</sub> represent upregulation. (1) The downregulation of the β<sub>1</sub>AR in HF leads to a substantial reduction of the β<sub>1</sub>AR-mediated response. (2) The upregulation of GRK2 in HF causes abnormal phosphorylation of the β<sub>2</sub>AR. This subsequently promotes a G<sub>i</sub>-biased β<sub>2</sub>AR signaling leading to the inhibition of both the β<sub>2</sub>AR-G<sub>s</sub> and the β<sub>1</sub>AR-G<sub>s</sub> signalings. (1 and 2) Persistent catecholamine stimulation of the βARs in HF leads to (homologous) desensitization of the receptors and temporary loss of responsiveness to further stimuli (see text for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. A simplified scheme of cardiac βAR signaling and its modulation. The β<sub>2</sub>AR couples to both G<sub>s</sub> and G<sub>i</sub> while the β<sub>1</sub>AR couples only to G<sub>s</sub>. Stimulation of the βARs with catecholamines (CA) actives the G<sub>s</sub>-cAMP-PKA signaling (black arrows) and subsequently produces contractility enhancement. If stimulation of the β<sub>1</sub>AR is exaggerated as in the case of compensatory activation of the sympathetic nervous system during heart failure, the CaMKII pro-apoptotic pathway (red arrows) will be activated. As the disease progresses into decompensated heart failure, the loss of myocytes contributes to cardiac dysfunction. The loss of myocytes may be counteracted by activating the β<sub>2</sub>AR-G<sub>i</sub> antiapoptotic signaling (blue arrows) with a β<sub>2</sub>AR agonist (β<sub>2</sub>+) or by blocking the β<sub>1</sub>AR with a β<sub>1</sub>AR antagonist (β<sub>1</sub>– with a blue blocking sign). β<sub>2</sub>AR activation is complementary to β<sub>1</sub>AR blockade because it produces additional contractile support to the failing heart apart from its antiapoptotic effect (see text for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Regulatory pathways of airway smooth muscle cell contraction and relaxation. Stimulation of M<sub>3</sub>R causes intracellular calcium level ([Ca<sup>2+</sup>]<sub>i</sub>) to rise via activation of the G<sub>q</sub>-PLC-IP<sub>3</sub> signaling pathway. The increase in [Ca<sup>2+</sup>]<sub>i</sub> activates MLCK, which phosphorylates rMLC. Increase in rMLC phosphorylation leads to muscle contraction. Stimulation of β<sub>2</sub>AR triggers the G<sub>s</sub>-AC-cAMP-PKA signaling cascade. PKA activation enhances the activity of MLCP which dephosphorylates rMLC. Decrease in rMLC phosphorylation leads to muscle relaxation. Bronchodilators including β<sub>2</sub>-agonists and muscarinic antagonists produce smooth muscle relaxation by acting on their respective receptors. Key: AC, adenylyl cyclase; Ach, acetylcholine; β<sub>2</sub>+, β<sub>2</sub>-agonist; β<sub>2</sub>AR, β<sub>2</sub>-adrenoceptor; cAMP, cyclic AMP; CICR, calcium-induced calcium release; DAG, diacylglycerol; IP<sub>3</sub>, inositol triphosphate; IP<sub>3</sub>R, IP<sub>3</sub> receptor; M–, muscarinic antagonist; M<sub>3</sub>R, M<sub>3</sub> receptor; MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase; +p, phosphorylation; −p, dephosphorylation; PI-4,5-P<sub>2</sub>, phosphatidylinositol 4,5-bisphosphate; PKA, cyclic AMP-dependent protein kinase; PLC, phospholipase C; rMLC, regulatory light chain of myosin; RyR, ryanodine receptor; SR, sarcoplasmic reticulum</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of BI167107 (<b>7</b>), bedoradrine (<b>8</b>), abediterol (<b>9</b>), and trantinterol (<b>10</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of compounds <b>11</b>– <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of compounds <b>16</b>–<b>27</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chemical structures of compounds <b>28</b>–<b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of (<i>R</i>,<i>R</i>)-fenoterol (<b>31</b>) and compounds <b>32</b>–<b>34</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/medium/jm0c01195_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of compounds <b>35</b>–<b>37</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01195/20201218/images/large/jm0c01195_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01195&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 292 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A brief history of G-protein coupled receptors (Nobel Lecture)</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6366</span>– <span class="NLM_lpage">6378</span>, <span class="refDoi"> DOI: 10.1002/anie.201301924</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fanie.201301924" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1SjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=6366-6378&author=R.+J.+Lefkowitz&title=A+brief+history+of+G-protein+coupled+receptors+%28Nobel+Lecture%29&doi=10.1002%2Fanie.201301924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">A Brief History of G-Protein Coupled Receptors (Nobel Lecture)</span></div><div class="casAuthors">Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6366-6378</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review of studies made by the author and others in a form of Nobel lecture is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphWMsFzZ4fQrVg90H21EOLACvtfcHk0liORLHAxDAYoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1SjsLs%253D&md5=b83a3b0e790e24f6ff2ff5815786e358</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fanie.201301924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201301924%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520brief%2520history%2520of%2520G-protein%2520coupled%2520receptors%2520%2528Nobel%2520Lecture%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D6366%26epage%3D6378%26doi%3D10.1002%2Fanie.201301924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anker, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Juanatey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harjola, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowska, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nihoyannopoulos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parissis, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieske, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruilope, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruschitzka, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Meer, P.</span></span> <span> </span><span class="NLM_article-title">2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2200</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehw128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Feurheartj%2Fehw128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27206819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fhs1Srug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=2129-2200&author=P.+Ponikowskiauthor=A.+A.+Voorsauthor=S.+D.+Ankerauthor=H.+Buenoauthor=J.+Clelandauthor=A.+Coatsauthor=V.+Falkauthor=J.+R.+Gonz%C3%A1lez-Juanateyauthor=V.+P.+Harjolaauthor=E.+A.+Jankowskaauthor=M.+Jessupauthor=C.+Lindeauthor=P.+Nihoyannopoulosauthor=J.+T.+Parissisauthor=B.+Pieskeauthor=J.+P.+Rileyauthor=G.+Rosanoauthor=L.+M.+Ruilopeauthor=F.+Ruschitzkaauthor=F.+H.+Ruttenauthor=P.+van+der+Meer&title=2016+ESC+Guidelines+for+the+diagnosis+and+treatment+of+acute+and+chronic+heart+failure%3A+The+Task+Force+for+the+diagnosis+and+treatment+of+acute+and+chronic+heart+failure+of+the+European+Society+of+Cardiology+%28ESC%29+Developed+with+the+special+contribution+of+the+Heart+Failure+Association+%28HFA%29+of+the+ESC&doi=10.1093%2Feurheartj%2Fehw128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</span></div><div class="casAuthors">Ponikowski Piotr; Voors Adriaan A; Anker Stefan D; Bueno Hector; Cleland John G F; Coats Andrew J S; Falk Volkmar; Gonzalez-Juanatey Jose Ramon; Harjola Veli-Pekka; Jankowska Ewa A; Jessup Mariell; Linde Cecilia; Nihoyannopoulos Petros; Parissis John T; Pieske Burkert; Riley Jillian P; Rosano Giuseppe M C; Ruilope Luis M; Ruschitzka Frank; Rutten Frans H; van der Meer Peter</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2129-2200</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS0NiZ1KhBpP3jf77P2BG3fW6udTcc2eas0TkM3l9b37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fhs1Srug%253D%253D&md5=6d5c3d01ffc432870adea4fdc18697e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehw128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehw128%26sid%3Dliteratum%253Aachs%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DAnker%26aufirst%3DS.%2BD.%26aulast%3DBueno%26aufirst%3DH.%26aulast%3DCleland%26aufirst%3DJ.%26aulast%3DCoats%26aufirst%3DA.%26aulast%3DFalk%26aufirst%3DV.%26aulast%3DGonz%25C3%25A1lez-Juanatey%26aufirst%3DJ.%2BR.%26aulast%3DHarjola%26aufirst%3DV.%2BP.%26aulast%3DJankowska%26aufirst%3DE.%2BA.%26aulast%3DJessup%26aufirst%3DM.%26aulast%3DLinde%26aufirst%3DC.%26aulast%3DNihoyannopoulos%26aufirst%3DP.%26aulast%3DParissis%26aufirst%3DJ.%2BT.%26aulast%3DPieske%26aufirst%3DB.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DRosano%26aufirst%3DG.%26aulast%3DRuilope%26aufirst%3DL.%2BM.%26aulast%3DRuschitzka%26aufirst%3DF.%26aulast%3DRutten%26aufirst%3DF.%2BH.%26aulast%3Dvan%2Bder%2BMeer%26aufirst%3DP.%26atitle%3D2016%2520ESC%2520Guidelines%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520acute%2520and%2520chronic%2520heart%2520failure%253A%2520The%2520Task%2520Force%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520acute%2520and%2520chronic%2520heart%2520failure%2520of%2520the%2520European%2520Society%2520of%2520Cardiology%2520%2528ESC%2529%2520Developed%2520with%2520the%2520special%2520contribution%2520of%2520the%2520Heart%2520Failure%2520Association%2520%2528HFA%2529%2520of%2520the%2520ESC%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D2129%26epage%3D2200%26doi%3D10.1093%2Feurheartj%2Fehw128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Virani, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittencourt, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaway, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delling, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djousse, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkind, M. S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissela, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knutson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackland, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loop, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutsey, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mussolino, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosamond, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, U. K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satou, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spartano, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirschwell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van-Wagner, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, C. W.</span></span> <span> </span><span class="NLM_article-title">Heart disease and stroke statistics-2020 update: A report from the American heart association</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">e139</span>– <span class="NLM_lpage">e596</span>, <span class="refDoi"> DOI: 10.1161/CIR.0000000000000757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIR.0000000000000757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31992061" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2020&pages=e139-e596&author=S.+S.+Viraniauthor=A.+Alonsoauthor=E.+J.+Benjaminauthor=M.+S.+Bittencourtauthor=C.+W.+Callawayauthor=A.+P.+Carsonauthor=A.+M.+Chamberlainauthor=A.+R.+Changauthor=S.+Chengauthor=F.+N.+Dellingauthor=L.+Djousseauthor=M.+S.+V.+Elkindauthor=J.+F.+Fergusonauthor=M.+Fornageauthor=S.+S.+Khanauthor=B.+M.+Kisselaauthor=K.+L.+Knutsonauthor=T.+W.+Kwanauthor=D.+T.+Lacklandauthor=T.+T.+Lewisauthor=J.+H.+Lichtmanauthor=C.+T.+Longeneckerauthor=M.+S.+Loopauthor=P.+L.+Lutseyauthor=S.+S.+Martinauthor=K.+Matsushitaauthor=A.+E.+Moranauthor=M.+E.+Mussolinoauthor=A.+M.+Perakauthor=W.+D.+Rosamondauthor=G.+A.+Rothauthor=U.+K.+A.+Sampsonauthor=G.+M.+Satouauthor=E.+B.+Schroederauthor=S.+H.+Shahauthor=C.+M.+Shayauthor=N.+L.+Spartanoauthor=A.+Stokesauthor=D.+L.+Tirschwellauthor=L.+B.+Van-Wagnerauthor=C.+W.+Tsao&title=Heart+disease+and+stroke+statistics-2020+update%3A+A+report+from+the+American+heart+association&doi=10.1161%2FCIR.0000000000000757"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1161%2FCIR.0000000000000757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIR.0000000000000757%26sid%3Dliteratum%253Aachs%26aulast%3DVirani%26aufirst%3DS.%2BS.%26aulast%3DAlonso%26aufirst%3DA.%26aulast%3DBenjamin%26aufirst%3DE.%2BJ.%26aulast%3DBittencourt%26aufirst%3DM.%2BS.%26aulast%3DCallaway%26aufirst%3DC.%2BW.%26aulast%3DCarson%26aufirst%3DA.%2BP.%26aulast%3DChamberlain%26aufirst%3DA.%2BM.%26aulast%3DChang%26aufirst%3DA.%2BR.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DDelling%26aufirst%3DF.%2BN.%26aulast%3DDjousse%26aufirst%3DL.%26aulast%3DElkind%26aufirst%3DM.%2BS.%2BV.%26aulast%3DFerguson%26aufirst%3DJ.%2BF.%26aulast%3DFornage%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DS.%2BS.%26aulast%3DKissela%26aufirst%3DB.%2BM.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26aulast%3DKwan%26aufirst%3DT.%2BW.%26aulast%3DLackland%26aufirst%3DD.%2BT.%26aulast%3DLewis%26aufirst%3DT.%2BT.%26aulast%3DLichtman%26aufirst%3DJ.%2BH.%26aulast%3DLongenecker%26aufirst%3DC.%2BT.%26aulast%3DLoop%26aufirst%3DM.%2BS.%26aulast%3DLutsey%26aufirst%3DP.%2BL.%26aulast%3DMartin%26aufirst%3DS.%2BS.%26aulast%3DMatsushita%26aufirst%3DK.%26aulast%3DMoran%26aufirst%3DA.%2BE.%26aulast%3DMussolino%26aufirst%3DM.%2BE.%26aulast%3DPerak%26aufirst%3DA.%2BM.%26aulast%3DRosamond%26aufirst%3DW.%2BD.%26aulast%3DRoth%26aufirst%3DG.%2BA.%26aulast%3DSampson%26aufirst%3DU.%2BK.%2BA.%26aulast%3DSatou%26aufirst%3DG.%2BM.%26aulast%3DSchroeder%26aufirst%3DE.%2BB.%26aulast%3DShah%26aufirst%3DS.%2BH.%26aulast%3DShay%26aufirst%3DC.%2BM.%26aulast%3DSpartano%26aufirst%3DN.%2BL.%26aulast%3DStokes%26aufirst%3DA.%26aulast%3DTirschwell%26aufirst%3DD.%2BL.%26aulast%3DVan-Wagner%26aufirst%3DL.%2BB.%26aulast%3DTsao%26aufirst%3DC.%2BW.%26atitle%3DHeart%2520disease%2520and%2520stroke%2520statistics-2020%2520update%253A%2520A%2520report%2520from%2520the%2520American%2520heart%2520association%26jtitle%3DCirculation%26date%3D2020%26volume%3D141%26spage%3De139%26epage%3De596%26doi%3D10.1161%2FCIR.0000000000000757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span> <i>National Vital Statistics System: Public Use Data File Documentation:
Mortality Multiple Cause-of-Death Micro-Data Files</i>. <span class="NLM_publisher-name">National Center for Health Statistics, Centers for Disease Control
and Prevention</span>, <span class="NLM_year">2017</span>; <a href="https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm" class="extLink">https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm</a> (accessed 2019-04-01).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+National+Vital+Statistics+System%3A+Public+Use+Data+File+Documentation%3A%0AMortality+Multiple+Cause-of-Death+Micro-Data+Files.+National+Center+for+Health+Statistics%2C+Centers+for+Disease+Control%0Aand+Prevention%2C+2017%3B+https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fnvss%2Fmortality_public_use_data.htm+%28accessed+2019-04-01%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DNational%2520Vital%2520Statistics%2520System%253A%2520Public%2520Use%2520Data%2520File%2520Documentation%253A%250AMortality%2520Multiple%2520Cause-of-Death%2520Micro-Data%2520Files%26pub%3DNational%2520Center%2520for%2520Health%2520Statistics%252C%2520Centers%2520for%2520Disease%2520Control%250Aand%2520Prevention%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yancy, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozkurt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. E.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazner, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filippatos, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonarow, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givertz, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenfeld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlake, C.</span></span> <span> </span><span class="NLM_article-title">2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">e137</span>– <span class="NLM_lpage">e161</span>, <span class="refDoi"> DOI: 10.1161/CIR.0000000000000509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIR.0000000000000509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28455343" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2017&pages=e137-e161&author=C.+W.+Yancyauthor=M.+Jessupauthor=B.+Bozkurtauthor=J.+Butlerauthor=D.+E.+Caseyauthor=M.+M.+Colvinauthor=M.+H.+Draznerauthor=G.+S.+Filippatosauthor=G.+C.+Fonarowauthor=M.+M.+Givertzauthor=S.+M.+Hollenbergauthor=J.+Lindenfeldauthor=F.+A.+Masoudiauthor=P.+E.+McBrideauthor=P.+N.+Petersonauthor=L.+W.+Stevensonauthor=C.+Westlake&title=2017+ACC%2FAHA%2FHFSA+focused+update+of+the+2013+ACCF%2FAHA+guideline+for+the+management+of+heart+failure%3A+A+report+of+the+American+college+of+cardiology%2FAmerican+heart+association+task+force+on+clinical+practice+guidelines+and+the+heart+failure+society+of+America&doi=10.1161%2FCIR.0000000000000509"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1161%2FCIR.0000000000000509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIR.0000000000000509%26sid%3Dliteratum%253Aachs%26aulast%3DYancy%26aufirst%3DC.%2BW.%26aulast%3DJessup%26aufirst%3DM.%26aulast%3DBozkurt%26aufirst%3DB.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DCasey%26aufirst%3DD.%2BE.%26aulast%3DColvin%26aufirst%3DM.%2BM.%26aulast%3DDrazner%26aufirst%3DM.%2BH.%26aulast%3DFilippatos%26aufirst%3DG.%2BS.%26aulast%3DFonarow%26aufirst%3DG.%2BC.%26aulast%3DGivertz%26aufirst%3DM.%2BM.%26aulast%3DHollenberg%26aufirst%3DS.%2BM.%26aulast%3DLindenfeld%26aufirst%3DJ.%26aulast%3DMasoudi%26aufirst%3DF.%2BA.%26aulast%3DMcBride%26aufirst%3DP.%2BE.%26aulast%3DPeterson%26aufirst%3DP.%2BN.%26aulast%3DStevenson%26aufirst%3DL.%2BW.%26aulast%3DWestlake%26aufirst%3DC.%26atitle%3D2017%2520ACC%252FAHA%252FHFSA%2520focused%2520update%2520of%2520the%25202013%2520ACCF%252FAHA%2520guideline%2520for%2520the%2520management%2520of%2520heart%2520failure%253A%2520A%2520report%2520of%2520the%2520American%2520college%2520of%2520cardiology%252FAmerican%2520heart%2520association%2520task%2520force%2520on%2520clinical%2520practice%2520guidelines%2520and%2520the%2520heart%2520failure%2520society%2520of%2520America%26jtitle%3DCirculation%26date%3D2017%26volume%3D136%26spage%3De137%26epage%3De161%26doi%3D10.1161%2FCIR.0000000000000509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonsu, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunmanakul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiyakunapruk, N.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatments for heart failure with preserved ejection fraction a systemic review and indirect comparison</span>. <i>Heart Failure Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1007/s10741-018-9679-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs10741-018-9679-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29411216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlantr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=147-156&author=K.+O.+Bonsuauthor=P.+Arunmanakulauthor=N.+Chaiyakunapruk&title=Pharmacological+treatments+for+heart+failure+with+preserved+ejection+fraction+a+systemic+review+and+indirect+comparison&doi=10.1007%2Fs10741-018-9679-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison</span></div><div class="casAuthors">Bonsu, Kwadwo Osei; Arunmanakul, Poukwan; Chaiyakunapruk, Nathorn</div><div class="citationInfo"><span class="NLM_cas:title">Heart Failure Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">HFREFC</span>;
        ISSN:<span class="NLM_cas:issn">1382-4147</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Pharmacol. interventions for heart failure with preserved ejection fraction (HFpEF) have failed to reduce mortality and hospitalization.  Evidence for mineralocorticoid antagonists (MRAs), β-adrenoceptor blockers (β-blockers), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs)-to reduce clin. outcomes in HFpEF remains unclear.  We conducted a systematic search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Clin. Trials.gov for randomized controlled trials (RCTs) assessing pharmacol. treatments in HFpEF diagnosed according the recommendations of the European Society of Cardiol. (ESC) 2016 guidelines from inception to August, 2017.  The study outcomes were mortality, hospitalization, changes in indexes of cardiac structure and function, biomarkers, and indexes of functional capacity-quality of life (QoL) assessment and 6-min walk distance test (6-MWD).  The random-effects models were used to est. pooled relative risks (RRs) for the binary outcomes and standardized mean differences for continuous outcomes, with 95% CI.  A network meta-anal. using a random-effects model was employed to est. the comparative efficacy of treatments.  We included data from 15 RCTs comprising 5930 patients.  There was no significant effect seen with all treatments compared with placebo and comparative efficacy of any two treatments on all outcomes assessed.  However, mineralocorticoid antagonist spironolactone demonstrated a trend towards reducing mortality compared with placebo (RR 0.92; 95% CI 0.79-1.08), sildenafil (0.14; 0.01-2.78), perindopril (0.87; 0.59-1.28), and eplerenone (0.91; 0.25-3.33).  Similar trends in treatment effect were obsd. with spironolactone on surrogate outcomes while eplerenone demonstrated a trend of superior effect in redn. of hospitalizations compared with all other drug treatment.  No drug treatment demonstrated statistically significant improvement in clin. and surrogate outcomes in HFpEF diagnosed according to the ESC 2016 guideline.  Spironolactone and eplerenone showed clin. relevant redn. in mortality and hospitalization resp. compared with other drug treatments.  Further trials with MRAs are warranted to confirm treatment effects in HFpEF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-JwbvfqUBgbVg90H21EOLACvtfcHk0lhdSIg3uyQa7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlantr4%253D&md5=67861d94c532f62068d84fc25765c68f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs10741-018-9679-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10741-018-9679-y%26sid%3Dliteratum%253Aachs%26aulast%3DBonsu%26aufirst%3DK.%2BO.%26aulast%3DArunmanakul%26aufirst%3DP.%26aulast%3DChaiyakunapruk%26aufirst%3DN.%26atitle%3DPharmacological%2520treatments%2520for%2520heart%2520failure%2520with%2520preserved%2520ejection%2520fraction%2520a%2520systemic%2520review%2520and%2520indirect%2520comparison%26jtitle%3DHeart%2520Failure%2520Rev.%26date%3D2018%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1007%2Fs10741-018-9679-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">GBD
2017 Disease and Injury Incidence and Prevalence Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases and injuries
for 195 countries and territories, 1990–2017: a systematic
analysis for the Global Burden of Disease Study 2017</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1858</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32279-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2818%2932279-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30496104" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1789-1858&author=GBD%0A2017+Disease+and+Injury+Incidence+and+Prevalence+Collaborators&title=Global%2C+regional%2C+and+national+incidence%2C%0Aprevalence%2C+and+years+lived+with+disability+for+354+diseases+and+injuries%0Afor+195+countries+and+territories%2C+1990%E2%80%932017%3A+a+systematic%0Aanalysis+for+the+Global+Burden+of+Disease+Study+2017&doi=10.1016%2FS0140-6736%2818%2932279-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932279-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932279-7%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520incidence%252C%250Aprevalence%252C%2520and%2520years%2520lived%2520with%2520disability%2520for%2520354%2520diseases%2520and%2520injuries%250Afor%2520195%2520countries%2520and%2520territories%252C%25201990%25E2%2580%25932017%253A%2520a%2520systematic%250Aanalysis%2520for%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202017%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1789%26epage%3D1858%26doi%3D10.1016%2FS0140-6736%2818%2932279-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span> <i>Global Strategy for Asthma Management and Prevention</i>; <span class="NLM_publisher-name">Global Initiative for Asthma</span>, <span class="NLM_year">2020</span>; <a href="http://www.ginasthma.org" class="extLink">www.ginasthma.org</a> (accessed
2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Strategy+for+Asthma+Management+and+Prevention%3B+Global+Initiative+for+Asthma%2C+2020%3B+www.ginasthma.org+%28accessed%0A2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Strategy%2520for%2520Asthma%2520Management%2520and%2520Prevention%26pub%3DGlobal%2520Initiative%2520for%2520Asthma%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span> <i>The Global Asthma Report
2018</i>; <span class="NLM_publisher-name">Global Asthma
Network</span>: <span class="NLM_publisher-loc">Auckland, New Zealand</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+Global+Asthma+Report%0A2018%3B+Global+Asthma%0ANetwork%3A+Auckland%2C+New+Zealand%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Global%2520Asthma%2520Report%250A2018%26pub%3DGlobal%2520Asthma%250ANetwork%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span> <i>Global Strategy for the
Diagnosis, Management, and Prevention of
Chronic Obstructive Lung Disease (2020 Report)</i>; <span class="NLM_publisher-name">Global Initiative for Chronic Obstructive Lung Disease</span>, <span class="NLM_year">2020</span>; <a href="http://goldcopd.org/gold-reports" class="extLink">goldcopd.org/gold-reports</a> (accessed 2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Strategy+for+the%0ADiagnosis%2C+Management%2C+and+Prevention+of%0AChronic+Obstructive+Lung+Disease+%282020+Report%29%3B+Global+Initiative+for+Chronic+Obstructive+Lung+Disease%2C+2020%3B+goldcopd.org%2Fgold-reports+%28accessed+2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Strategy%2520for%2520the%250ADiagnosis%252C%2520Management%252C%2520and%2520Prevention%2520of%250AChronic%2520Obstructive%2520Lung%2520Disease%2520%25282020%2520Report%2529%26pub%3DGlobal%2520Initiative%2520for%2520Chronic%2520Obstructive%2520Lung%2520Disease%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">GBD
2017 Causes of Death Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national age-sex-specific mortality
for 282 causes of death in 195 countries and territories, 1980–2017:
a systematic analysis for the Global Burden of Disease Study 2017</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1736</span>– <span class="NLM_lpage">1788</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32203-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2818%2932203-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30496103" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1736-1788&author=GBD%0A2017+Causes+of+Death+Collaborators&title=Global%2C+regional%2C+and+national+age-sex-specific+mortality%0Afor+282+causes+of+death+in+195+countries+and+territories%2C+1980%E2%80%932017%3A%0Aa+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2017&doi=10.1016%2FS0140-6736%2818%2932203-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932203-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932203-7%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520age-sex-specific%2520mortality%250Afor%2520282%2520causes%2520of%2520death%2520in%2520195%2520countries%2520and%2520territories%252C%25201980%25E2%2580%25932017%253A%250Aa%2520systematic%2520analysis%2520for%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202017%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1736%26epage%3D1788%26doi%3D10.1016%2FS0140-6736%2818%2932203-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">GBD
2017 DALYs and HALE Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national disability-adjusted
life-years (DALYs) for 359 diseases and injuries and healthy life
expectancy (HALE) for 195 countries and territories, 1990–2017:
a systematic analysis for the Global Burden of Disease Study 2017</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1859</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)32335-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2818%2932335-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30415748" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1859-1922&author=GBD%0A2017+DALYs+and+HALE+Collaborators&title=Global%2C+regional%2C+and+national+disability-adjusted%0Alife-years+%28DALYs%29+for+359+diseases+and+injuries+and+healthy+life%0Aexpectancy+%28HALE%29+for+195+countries+and+territories%2C+1990%E2%80%932017%3A%0Aa+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2017&doi=10.1016%2FS0140-6736%2818%2932335-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2932335-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252932335-3%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520disability-adjusted%250Alife-years%2520%2528DALYs%2529%2520for%2520359%2520diseases%2520and%2520injuries%2520and%2520healthy%2520life%250Aexpectancy%2520%2528HALE%2529%2520for%2520195%2520countries%2520and%2520territories%252C%25201990%25E2%2580%25932017%253A%250Aa%2520systematic%2520analysis%2520for%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202017%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1859%26epage%3D1922%26doi%3D10.1016%2FS0140-6736%2818%2932335-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span> <span> </span><span class="NLM_article-title">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)16900-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2804%2916900-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15325838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=709-721&author=J.+C.+Hogg&title=Pathophysiology+of+airflow+limitation+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2804%2916900-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg James C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9435</span>),
    <span class="NLM_cas:pages">709-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The airflow limitation that defines chronic obstructive pulmonary disease (COPD) is the result of a prolonged time constant for lung emptying, caused by increased resistance of the small conducting airways and increased compliance of the lung as a result of emphysematous destruction.  These lesions are associated with a chronic innate and adaptive inflammatory immune response of the host to a lifetime exposure to inhaled toxic gases and particles.  Processes contributing to obstruction in the small conducting airways include disruption of the epithelial barrier, interference with mucociliary clearance apparatus that results in accumulation of inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by inflammatory cells, and deposition of connective tissue in the airway wall.  This remodelling and repair thickens the airway walls, reduces lumen calibre, and restricts the normal increase in calibre produced by lung inflation.  Emphysematous lung destruction is associated with an infiltration of the same type of inflammatory cells found in the airways.  The centrilobular pattern of emphysematous destruction is most closely associated with cigarette smoking, and although it is initially focused on respiratory bronchioles, separate lesions coalesce to destroy large volumes of lung tissue.  The panacinar pattern of emphysema is characterised by a more even involvement of the acinus and is associated with alpha1 antitrypsin deficiency.  The technology needed to diagnose and quantitate the individual small airway and emphysema phenotypes present in people with COPD is being developed, and should prove helpful in the assessment of therapeutic interventions designed to modify the progress of either phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTicL3IkZ1Ezq91pGlMMoT5fW6udTcc2ea1KL5RdzYVGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D&md5=020c93595544690ab6519a8d88cfb9ee</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2916900-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252916900-6%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26atitle%3DPathophysiology%2520of%2520airflow%2520limitation%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D709%26epage%3D721%26doi%3D10.1016%2FS0140-6736%2804%2916900-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ora, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puxeddu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">Airflow obstruction: is it asthma or is it COPD?</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3007</span>– <span class="NLM_lpage">3013</span>, <span class="refDoi"> DOI: 10.2147/COPD.S54927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S54927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27942210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2sjlvVyqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=3007-3013&author=P.+Roglianiauthor=J.+Oraauthor=E.+Puxedduauthor=M.+Cazzola&title=Airflow+obstruction%3A+is+it+asthma+or+is+it+COPD%3F&doi=10.2147%2FCOPD.S54927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Airflow obstruction: is it asthma or is it COPD?</span></div><div class="casAuthors">Rogliani Paola; Ora Josuel; Puxeddu Ermanno; Cazzola Mario</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3007-3013</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite the availability of guideline recommendations, diagnostic confusion between COPD and asthma appears common, and often it is very difficult to decide whether the obstruction is caused by asthma or COPD in a patient with airway obstruction.  However, there are well-defined features that help in differentiating asthma from COPD in the presence of fixed airflow obstruction.  Nonetheless, the presentations of asthma and COPD can converge and mimic each other, making it difficult to give these patients a diagnosis of either condition.  The association of asthma and COPD in the same patient has been designated mixed asthma-COPD phenotype or overlap syndrome.  However, since the absence of a clear definition and the inclusion of patients with different characteristics under this umbrella term, it may not facilitate treatment decisions, especially in the absence of clinical trials addressing this heterogeneous population.  We are realizing that neither asthma nor COPD are single diseases, but rather syndromes consisting of several endotypes and phenotypes, consequently comprising a spectrum of diseases that must be recognized and adequately treated with targeted therapy.  Therefore, we must treat patients by personalizing therapy on the basis of those treatable traits present in each subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRaPlcGQH4dniCEBeYuoi7AfW6udTcc2eaubLo1dC2uybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjlvVyqsQ%253D%253D&md5=e513a3253f9c76723c84fa64e869df47</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S54927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S54927%26sid%3Dliteratum%253Aachs%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DOra%26aufirst%3DJ.%26aulast%3DPuxeddu%26aufirst%3DE.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DAirflow%2520obstruction%253A%2520is%2520it%2520asthma%2520or%2520is%2520it%2520COPD%253F%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2016%26volume%3D11%26spage%3D3007%26epage%3D3013%26doi%3D10.2147%2FCOPD.S54927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, I. P.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-agonists</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>237</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1007/164_2016_64</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2F164_2016_64" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2016&pages=23-40&author=C.+K.+Billingtonauthor=R.+B.+Pennauthor=I.+P.+Hall&title=%CE%B22-agonists&doi=10.1007%2F164_2016_64"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2F164_2016_64&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2016_64%26sid%3Dliteratum%253Aachs%26aulast%3DBillington%26aufirst%3DC.%2BK.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DHall%26aufirst%3DI.%2BP.%26atitle%3D%25CE%25B22-agonists%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2016%26volume%3D237%26spage%3D23%26epage%3D40%26doi%3D10.1007%2F164_2016_64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span> <span> </span><span class="NLM_article-title">Cardiac excitation contraction coupling</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1038/415198a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2F415198a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11805843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Whsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2002&pages=198-205&author=D.+M.+Bers&title=Cardiac+excitation+contraction+coupling&doi=10.1038%2F415198a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac excitation-contraction coupling</span></div><div class="casAuthors">Bers, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">6868</span>),
    <span class="NLM_cas:pages">198-205</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Of the ions involved in the intricate workings of the heart, calcium is considered perhaps the most important.  It is crucial to the very process that enables the chambers of the heart to contract and relax, a process called excitation-contraction coupling.  It is important to understand in quant. detail exactly how calcium is moved around the various organelles of the myocyte in order to bring about excitation-contraction coupling if we are to understand the basic physiol. of heart function.  Furthermore, spatial microdomains within the cell are important in localizing the mol. players that orchestrate cardiac function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKEixgvct9fbVg90H21EOLACvtfcHk0ljLYuBmh_uqOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Whsg%253D%253D&md5=3c60a38b02e263fb551dfdfe885cc5cd</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F415198a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F415198a%26sid%3Dliteratum%253Aachs%26aulast%3DBers%26aufirst%3DD.%2BM.%26atitle%3DCardiac%2520excitation%2520contraction%2520coupling%26jtitle%3DNature%26date%3D2002%26volume%3D415%26spage%3D198%26epage%3D205%26doi%3D10.1038%2F415198a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">Functional coupling of the beta2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">329</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7870040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2MXktVSlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1995&pages=322-329&author=R.+P.+Xiaoauthor=X.+Jiauthor=E.+G.+Lakatta&title=Functional+coupling+of+the+beta2-adrenoceptor+to+a+pertussis+toxin-sensitive+G+protein+in+cardiac+myocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes</span></div><div class="casAuthors">Xiao, Rui-Ping; Jl, Xiangwu; Lakatta, Edward G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">322-9</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Recently the authors demonstrated that the effects of β2-adrenoceptor (AR) stimulation to augment Ca2+ current (lCa), cytosolic Ca2+ (Cai) transients, and contractility in rat ventricular myocytes are largely dissocd. from its effect to increase cellular cAMP levels.  This result suggested that β2ARs might be coupled to signaling pathways other than the Gsa-mediated activation of adenylyl cyclase.  Here the authors show that pertussis toxin (PTX) pretreatment specifically potentiates the responses of rat heart cells to β2AR but not β1AR stimulation.  After PTX pretreatment, (1) the dose-response curve for the effects of the β2AR agonist zinterol on contraction amplitude is shifted leftward and upward (EC50 changed from about 1.0 μM to 70 nM), (2) in indo-1-loaded cells, the maximal effects of zinterol (10-5 M) on Cai transient and contraction amplitudes are addnl. increased 1.7- and 2.0- fold, resp., over those in control cells, and (3) the increase in ICa amplitude induced by the same zinterol concn. is potentiated by 2.5 fold.  Similar effects of PTX are obsd. when β2ARs are stimulated by isoproterenol in the presence of a selective β1AR blocker, CGP 20712A.  All effects of β2AR agonists in both PTX-treated and control cells are abolished by a selective β2AR blocker, ICI 118551.  In contrast, neither the baseline ICa, Cai transient, and contraction in the absence of βAR stimulation nor the β1AR-mediated augmentations of these parameters are significantly altered by PTX treatment.  These results demonstrate, for the first time, that the Gs-coupled β2AR can simultaneously activate a pathway that leads to functional inhibition in cardiac cells via a PTX-sensitive G protein.  The activation of more than one G protein during β2AR stimulation, leading to functionally opposite effects, may provide a mechanism to protect the heart from Ca2+ overload and arrhythmias during the response to stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJHIjdfXQwerVg90H21EOLACvtfcHk0ljLYuBmh_uqOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXktVSlsLg%253D&md5=a952f2342854d8caa3c911c17d908ee5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DJi%26aufirst%3DX.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3DFunctional%2520coupling%2520of%2520the%2520beta2-adrenoceptor%2520to%2520a%2520pertussis%2520toxin-sensitive%2520G%2520protein%2520in%2520cardiac%2520myocytes%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D47%26spage%3D322%26epage%3D329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eichel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jullié, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/ncb3307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fncb3307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26829388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=303-310&author=K.+Eichelauthor=D.+Julli%C3%A9author=M.+von+Zastrow&title=%CE%B2-Arrestin+drives+MAP+kinase+signalling+from+clathrin-coated+structures+after+GPCR+dissociation&doi=10.1038%2Fncb3307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The β -Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation</span></div><div class="casAuthors">Eichel, K.; Jullie, D.; von Zastrow, M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-310</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  β -Arrestins critically regulate G-protein-coupled receptor (GPCR) signalling, not only 'arresting' the G protein signal but also modulating endocytosis and initiating a discrete G-protein-independent signal through MAP kinase.  Despite enormous recent progress towards understanding biophys. aspects of arrestin function, arrestin cell biol. remains relatively poorly understood.  Two key tenets underlie the prevailing current view: β -arrestin accumulates in clathrin-coated structures (CCSs) exclusively in phys. complex with its activating GPCR, and MAP kinase activation requires endocytosis of formed GPCR-β -arrestin complexes.  We show here, using β 1-adrenergic receptors, that β -arrestin-2 (arrestin 3) accumulates robustly in CCSs after dissocg. from its activating GPCR and transduces the MAP kinase signal from CCSs.  Moreover, inhibiting subsequent endocytosis of CCSs enhances the clathrin- and β -arrestin-dependent MAP kinase signal.  These results demonstrate β -arrestin 'activation at a distance', after dissocg. from its activating GPCR, and signalling from CCSs.  We propose a β -arrestin signalling cycle that is catalytically activated by the GPCR and energetically coupled to the endocytic machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlrH9Sy0WTrVg90H21EOLACvtfcHk0li9r1xV11DvRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOrt7s%253D&md5=a9aef8c6cabc8e2d9fb7292139232969</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fncb3307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb3307%26sid%3Dliteratum%253Aachs%26aulast%3DEichel%26aufirst%3DK.%26aulast%3DJulli%25C3%25A9%26aufirst%3DD.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26atitle%3D%25CE%25B2-Arrestin%2520drives%2520MAP%2520kinase%2520signalling%2520from%2520clathrin-coated%2520structures%2520after%2520GPCR%2520dissociation%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2016%26volume%3D18%26spage%3D303%26epage%3D310%26doi%3D10.1038%2Fncb3307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davare, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdonin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peden, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burette, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hell, J. W.</span></span> <span> </span><span class="NLM_article-title">A beta2 adrenergic receptor signaling complex assembled with the Ca<sup>2+</sup> channel Cav1.2</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1126/science.293.5527.98</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.293.5527.98" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11441182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFCntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=98-101&author=M.+A.+Davareauthor=V.+Avdoninauthor=D.+D.+Hallauthor=E.+M.+Pedenauthor=A.+Buretteauthor=R.+J.+Weinbergauthor=M.+C.+Horneauthor=T.+Hoshiauthor=J.+W.+Hell&title=A+beta2+adrenergic+receptor+signaling+complex+assembled+with+the+Ca2%2B+channel+Cav1.2&doi=10.1126%2Fscience.293.5527.98"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A β2 adrenergic receptor signaling complex assembled with the Ca2+ channel Cav 1.2</span></div><div class="casAuthors">Davare, Monika A.; Avdonin, Vladimir; Hall, Duane D.; Peden, Erik M.; Burette, Alain; Weinberg, Richard J.; Horne, Mary C.; Hoshi, Toshinori; Hell, Johannes W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5527</span>),
    <span class="NLM_cas:pages">98-101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The existence of a large no. of receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) raises the question of how a particular receptor selectively regulates specific targets.  The authors provide insight into this question by identifying a prototypical macromol. signaling complex.  The β2 adrenergic receptor was found to be directly assocd. with one of its ultimate effectors, the class C L-type calcium channel Cav1.2.  This complex also contained a G protein, an adenylyl cyclase, cAMP-dependent protein kinase, and the counterbalancing phosphatase PP2A.  The authors' electrophysiol. recordings from hippocampal neurons demonstrate highly localized signal transduction from the receptor to the channel.  The assembly of this signaling complex provides a mechanism that ensures specific and rapid signaling by a G protein-coupled receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4AKYB09KiS7Vg90H21EOLACvtfcHk0li9r1xV11DvRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFCntLs%253D&md5=5d9e5f771833f8acaab9f571134255f9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.293.5527.98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.293.5527.98%26sid%3Dliteratum%253Aachs%26aulast%3DDavare%26aufirst%3DM.%2BA.%26aulast%3DAvdonin%26aufirst%3DV.%26aulast%3DHall%26aufirst%3DD.%2BD.%26aulast%3DPeden%26aufirst%3DE.%2BM.%26aulast%3DBurette%26aufirst%3DA.%26aulast%3DWeinberg%26aufirst%3DR.%2BJ.%26aulast%3DHorne%26aufirst%3DM.%2BC.%26aulast%3DHoshi%26aufirst%3DT.%26aulast%3DHell%26aufirst%3DJ.%2BW.%26atitle%3DA%2520beta2%2520adrenergic%2520receptor%2520signaling%2520complex%2520assembled%2520with%2520the%2520Ca2%252B%2520channel%2520Cav1.2%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D98%26epage%3D101%26doi%3D10.1126%2Fscience.293.5527.98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Head, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesman, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farquhar, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insel, P. A.</span></span> <span> </span><span class="NLM_article-title">G-protein-coupled receptor signaling components localize in both sarcolemmal and intracellular caveolin-3-associated microdomains in adult cardiac myocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">31036</span>– <span class="NLM_lpage">31044</span>, <span class="refDoi"> DOI: 10.1074/jbc.M502540200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M502540200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15961389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=31036-31044&author=B.+P.+Headauthor=H.+H.+Patelauthor=D.+M.+Rothauthor=N.+C.+Laiauthor=I.+R.+Niesmanauthor=M.+G.+Farquharauthor=P.+A.+Insel&title=G-protein-coupled+receptor+signaling+components+localize+in+both+sarcolemmal+and+intracellular+caveolin-3-associated+microdomains+in+adult+cardiac+myocytes&doi=10.1074%2Fjbc.M502540200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">G-protein-coupled Receptor Signaling Components Localize in Both Sarcolemmal and Intracellular Caveolin-3-associated Microdomains in Adult Cardiac Myocytes</span></div><div class="casAuthors">Head, Brian P.; Patel, Hemal H.; Roth, David M.; Lai, N. Chin; Niesman, Ingrid R.; Farquhar, Marilyn G.; Insel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">31036-31044</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">This study tests the hypothesis that G-protein-coupled receptor (GPCR) signaling components involved in the regulation of adenylyl cyclase (AC) localize with caveolin (Cav), a protein marker for caveolae, in both cell-surface and intracellular membrane regions.  Using sucrose d. fractionation of adult cardiac myocytes, we detected Cav-3 in both buoyant membrane fractions (BF) and heavy/non-buoyant fractions (HF); β2-adrenergic receptors (AR) in BF; and AC5/6, β1-AR, M4-muscarinic acetylcholine receptors (mAChR), μ-opioid receptors, and Gαs in both BF and HF.  In contrast, M2-mAChR, Gαi3, and Gαi2 were found only in HF.  Immunofluorescence microscopy showed co-localization of Cav-3 with AC5/6, Gαs, β2-AR, and μ-opioid receptors in both sarcolemmal and intracellular membranes, whereas M2-mAChR were detected only intracellularly.  Immunofluorescence of adult heart revealed a distribution of Cav-3 identical to that in isolated adult cardiac myocytes.  Upon immunoelectron microscopy, Cav-3 co-localized with AC5/6 and Gαs in sarcolemmal and intracellular vesicles, the latter closely allied with T-tubules.  Cav-3 immunoppts. possessed components that were necessary and sufficient for GPCR agonist-promoted stimulation and inhibition of cAMP formation.  The distribution of GPCR, G-proteins, and AC with Cav-3 in both sarcolemmal and intracellular T-tubule-assocd. regions indicates the existence of multiple Cav-3-localized cellular microdomains for signaling by hormones and drugs in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB0DBbj445ALVg90H21EOLACvtfcHk0li9r1xV11DvRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsVCmtLk%253D&md5=946a82263ff366d05d12979697206adb</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M502540200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M502540200%26sid%3Dliteratum%253Aachs%26aulast%3DHead%26aufirst%3DB.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BH.%26aulast%3DRoth%26aufirst%3DD.%2BM.%26aulast%3DLai%26aufirst%3DN.%2BC.%26aulast%3DNiesman%26aufirst%3DI.%2BR.%26aulast%3DFarquhar%26aufirst%3DM.%2BG.%26aulast%3DInsel%26aufirst%3DP.%2BA.%26atitle%3DG-protein-coupled%2520receptor%2520signaling%2520components%2520localize%2520in%2520both%2520sarcolemmal%2520and%2520intracellular%2520caveolin-3-associated%2520microdomains%2520in%2520adult%2520cardiac%2520myocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D31036%26epage%3D31044%26doi%3D10.1074%2Fjbc.M502540200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parton, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, E.</span></span> <span> </span><span class="NLM_article-title">Caveolin-3 associates with developing T-tubules during muscle differentiation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1083/jcb.136.1.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1083%2Fjcb.136.1.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9008709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXltFKqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1997&pages=137-154&author=R.+G.+Partonauthor=M.+Wayauthor=N.+Zorziauthor=E.+Stang&title=Caveolin-3+associates+with+developing+T-tubules+during+muscle+differentiation&doi=10.1083%2Fjcb.136.1.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Caveolin-3 associates with developing T-tubules during muscle differentiation</span></div><div class="casAuthors">Parton, Robert G.; Way, Michael; Zorzi, Natasha; Stang, Espen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-154</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Caveolae, flask-shaped invaginations of the plasma membrane, are particularly abundant in muscle cells.  The authors recently cloned a muscle-specific caveolin, termed caveolin-3 (I), which was expressed in differentiated muscle cells.  Specific antibodies to I were generated and used to characterize the distribution of I in adult and differentiating muscle.  In fully differentiated skeletal muscle, I was shown to be assocd. exclusively with sarcolemmal caveolae.  The localization of I during differentiation of primary cultured muscle cells and development of mouse skeletal muscle in vivo suggested that I was transiently assocd. with an internal membrane system.  These elements were identified as developing transverse-(T)-tubules by double-labeling with antibodies to the α1 subunit of the dihydropyridine receptor in C2C12 cells.  Ultrastructural anal. of the I-labeled elements showed an assocn. of I with elaborate networks of interconnected caveolae, which penetrated the depths of the muscle fibers.  These elements, which formed regular reticular structures, were shown to be surface-connected by labeling with cholera toxin conjugates.  The results suggested that I transiently assocs. with T-tubules during development and may be involved in the early development of the T-tubule system in muscle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLMm-JI6lMHLVg90H21EOLACvtfcHk0ljoIYYg83vr7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltFKqtg%253D%253D&md5=4dfb4ef28487d98244aeba7e629882e5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.136.1.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.136.1.137%26sid%3Dliteratum%253Aachs%26aulast%3DParton%26aufirst%3DR.%2BG.%26aulast%3DWay%26aufirst%3DM.%26aulast%3DZorzi%26aufirst%3DN.%26aulast%3DStang%26aufirst%3DE.%26atitle%3DCaveolin-3%2520associates%2520with%2520developing%2520T-tubules%2520during%2520muscle%2520differentiation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1997%26volume%3D136%26spage%3D137%26epage%3D154%26doi%3D10.1083%2Fjcb.136.1.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rybin, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. F.</span></span> <span> </span><span class="NLM_article-title">Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">41447</span>– <span class="NLM_lpage">41457</span>, <span class="refDoi"> DOI: 10.1074/jbc.M006951200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M006951200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11006286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVKgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=41447-41457&author=V.+O.+Rybinauthor=X.+Xuauthor=M.+P.+Lisantiauthor=S.+F.+Steinberg&title=Differential+targeting+of+beta-adrenergic+receptor+subtypes+and+adenylyl+cyclase+to+cardiomyocyte+caveolae.+A+mechanism+to+functionally+regulate+the+cAMP+signaling+pathway&doi=10.1074%2Fjbc.M006951200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Differential targeting of β-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway</span></div><div class="casAuthors">Rybin, Vitalyi O.; Xu, Xiaohong; Lisanti, Michael P.; Steinberg, Susan F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">41447-41457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Differential modes for β1- and β2-adrenergic receptor (AR) regulation of adenylyl cyclase in cardiomyocytes is most consistent with spatial regulation in microdomains of the plasma membrane.  This study examines whether caveolae represent specialized subdomains that conc. and organize these moieties in cardiomyocytes.  Caveolae from quiescent rat ventricular cardiomyocytes are highly enriched in β2-ARs, Gαi, protein kinase A RIIα subunits, caveolin-3, and flotillins (caveolin functional homologs); β1-ARs, m2-muscarinic cholinergic receptors, Gαs, and cardiac types V/VI adenylyl cyclase distribute between caveolae and other cell fractions, whereas protein kinase A RIα subunits, G protein-coupled receptor kinase-2, and clathrin are largely excluded from caveolae.  Cell surface β2-ARs localize to caveolae in cardiomyocytes and cardiac fibroblasts (with markedly different β2-AR expression levels), indicating that the fidelity of β2-AR targeting to caveolae is maintained over a physiol. range of β2-AR expression.  In cardiomyocytes, agonist stimulation leads to a marked decline in the abundance of β2-ARs (but not β1-ARs) in caveolae.  Other studies show co-immunopptn. of cardiomyocytes adenylyl cyclase V/VI and caveolin-3, suggesting their in vivo assocn.  However, caveolin is not required for adenylyl cyclase targeting to low d. membranes, since adenylyl cyclase targets to low buoyant d. membrane fractions of HEK cells that lack prototypical caveolins.  Nevertheless, cholesterol depletion with cyclodextrin augments agonist-stimulated cAMP accumulation, indicating that caveolae function as neg. regulators of cAMP accumulation.  The inhibitory interaction between caveolae and the cAMP signaling pathway as well as domain-specific differences in the stoichiometry of individual elements in the β-AR signaling cascade represent important modifiers of cAMP-dependent signaling in the heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0e-oSmsZq77Vg90H21EOLACvtfcHk0ljoIYYg83vr7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVKgsg%253D%253D&md5=2d2f3e619a162c1e46ae3d0dab437027</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M006951200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M006951200%26sid%3Dliteratum%253Aachs%26aulast%3DRybin%26aufirst%3DV.%2BO.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26aulast%3DSteinberg%26aufirst%3DS.%2BF.%26atitle%3DDifferential%2520targeting%2520of%2520beta-adrenergic%2520receptor%2520subtypes%2520and%2520adenylyl%2520cyclase%2520to%2520cardiomyocyte%2520caveolae.%2520A%2520mechanism%2520to%2520functionally%2520regulate%2520the%2520cAMP%2520signaling%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D41447%26epage%3D41457%26doi%3D10.1074%2Fjbc.M006951200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moshkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miragoli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korchev, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, J.</span></span> <span> </span><span class="NLM_article-title">Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">1653</span>– <span class="NLM_lpage">1657</span>, <span class="refDoi"> DOI: 10.1126/science.1185988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.1185988" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20185685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslaqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1653-1657&author=V.+O.+Nikolaevauthor=A.+Moshkovauthor=A.+R.+Lyonauthor=M.+Miragoliauthor=P.+Novakauthor=H.+Paurauthor=M.+J.+Lohseauthor=Y.+E.+Korchevauthor=S.+E.+Hardingauthor=J.+Gorelik&title=Beta2-adrenergic+receptor+redistribution+in+heart+failure+changes+cAMP+compartmentation&doi=10.1126%2Fscience.1185988"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic Receptor Redistribution in Heart Failure Changes cAMP Compartmentation</span></div><div class="casAuthors">Nikolaev, Viacheslav O.; Moshkov, Alexey; Lyon, Alexander R.; Miragoli, Michele; Novak, Pavel; Paur, Helen; Lohse, Martin J.; Korchev, Yuri E.; Harding, Sian E.; Gorelik, Julia</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5973</span>),
    <span class="NLM_cas:pages">1653-1657</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The β1- and β2-adrenergic receptors (βARs) on the surface of cardiomyocytes mediate distinct effects on cardiac function and the development of heart failure by regulating prodn. of the second messenger cyclic adenosine monophosphate (cAMP).  The spatial localization in cardiomyocytes of these βARs, which are coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins), and the functional implications of their localization have been unclear.  We combined nanoscale live-cell scanning ion conductance and fluorescence resonance energy transfer microscopy techniques and found that, in cardiomyocytes from healthy adult rats and mice, spatially confined β2AR-induced cAMP signals are localized exclusively to the deep transverse tubules, whereas functional β1ARs are distributed across the entire cell surface.  In cardiomyocytes derived from a rat model of chronic heart failure, β2ARs were redistributed from the transverse tubules to the cell crest, which led to diffuse receptor-mediated cAMP signaling.  Thus, the redistribution of β2ARs in heart failure changes compartmentation of cAMP and might contribute to the failing myocardial phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZlBG1csJ2sLVg90H21EOLACvtfcHk0ljoIYYg83vr7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslaqsLs%253D&md5=bb82007a88ac53cd8e830aafb5015bb7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.1185988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1185988%26sid%3Dliteratum%253Aachs%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DMoshkov%26aufirst%3DA.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DMiragoli%26aufirst%3DM.%26aulast%3DNovak%26aufirst%3DP.%26aulast%3DPaur%26aufirst%3DH.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DKorchev%26aufirst%3DY.%2BE.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26aulast%3DGorelik%26aufirst%3DJ.%26atitle%3DBeta2-adrenergic%2520receptor%2520redistribution%2520in%2520heart%2520failure%2520changes%2520cAMP%2520compartmentation%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D1653%26epage%3D1657%26doi%3D10.1126%2Fscience.1185988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balijepalli, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hell, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamp, T. J.</span></span> <span> </span><span class="NLM_article-title">Localization of cardiac L-type Ca(2+) channels to a caveolar macromolecular signaling complex is required for beta(2)-adrenergic regulation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">7500</span>– <span class="NLM_lpage">7505</span>, <span class="refDoi"> DOI: 10.1073/pnas.0503465103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.0503465103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16648270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XkslOrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=7500-7505&author=R.+C.+Balijepalliauthor=J.+D.+Foellauthor=D.+D.+Hallauthor=J.+W.+Hellauthor=T.+J.+Kamp&title=Localization+of+cardiac+L-type+Ca%282%2B%29+channels+to+a+caveolar+macromolecular+signaling+complex+is+required+for+beta%282%29-adrenergic+regulation&doi=10.1073%2Fpnas.0503465103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Localization of cardiac L-type Ca2+ channels to a caveolar macromolecular signaling complex is required for β2-adrenergic regulation</span></div><div class="casAuthors">Balijepalli, Ravi C.; Foell, Jason D.; Hall, Duane D.; Hell, Johannes W.; Kamp, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7500-7505</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">L-type Ca2+ channels play a crit. role in regulating Ca2+-dependent signaling in cardiac myocytes, including excitation-contraction coupling; however, the subcellular localization of cardiac L-type Ca2+ channels and their regulation are incompletely understood.  Caveolae are specialized microdomains of the plasmalemma rich in signaling mols. and supported by the structural protein caveolin-3 in muscle.  Here we demonstrate that a subpopulation of L-type Ca2+ channels is localized to caveolae in ventricular myocytes as part of a macromol. signaling complex necessary for β2-adrenergic receptor (AR) regulation of ICa,L.  Immunofluorescence studies of isolated ventricular myocytes using confocal microscopy detected extensive colocalization of caveolin-3 and the major pore-forming subunit of the L-type Ca channel (Cav1.2).  Immunogold electron microscopy revealed that these proteins colocalize in caveolae.  Immunopptn. from ventricular myocytes using anti-Cav1.2 or anti-caveolin-3 followed by Western blot anal. showed that caveolin-3, Cav1.2, β2-AR (not β1-AR), G protein αs, adenylyl cyclase, protein kinase A, and protein phosphatase 2a are closely assocd.  To det. the functional impact of the caveolar-localized β2-AR/Cav1.2 signaling complex, β2-AR stimulation (salbutamol plus atenolol) of ICa,L was examd. in pertussis toxin-treated neonatal mouse ventricular myocytes.  The stimulation of ICa,L in response to β2-AR activation was eliminated by disruption of caveolae with 10 mM Me β-cyclodextrin or by small interfering RNA directed against caveolin-3, whereas β1-AR stimulation (norepinephrine plus prazosin) of ICa,L was not altered.  These findings demonstrate that subcellular localization of L-type Ca2+ channels to caveolar macromol. signaling complexes is essential for regulation of the channels by specific signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqndDJwYaXe4bVg90H21EOLACvtfcHk0lh9CkwYBu6hYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkslOrtbs%253D&md5=37d91eb8a3220535c5f5f3abe8a4b95f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503465103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503465103%26sid%3Dliteratum%253Aachs%26aulast%3DBalijepalli%26aufirst%3DR.%2BC.%26aulast%3DFoell%26aufirst%3DJ.%2BD.%26aulast%3DHall%26aufirst%3DD.%2BD.%26aulast%3DHell%26aufirst%3DJ.%2BW.%26aulast%3DKamp%26aufirst%3DT.%2BJ.%26atitle%3DLocalization%2520of%2520cardiac%2520L-type%2520Ca%25282%252B%2529%2520channels%2520to%2520a%2520caveolar%2520macromolecular%2520signaling%2520complex%2520is%2520required%2520for%2520beta%25282%2529-adrenergic%2520regulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D7500%26epage%3D7505%26doi%3D10.1073%2Fpnas.0503465103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuschel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>274</i></span>,  <span class="NLM_fpage">22048</span>– <span class="NLM_lpage">22052</span>, <span class="refDoi"> DOI: 10.1074/jbc.274.31.22048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.274.31.22048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10419531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXltVymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=22048-22052&author=M.+Kuschelauthor=Y.+Y.+Zhouauthor=H.+Chengauthor=S.+J.+Zhangauthor=Y.+Chenauthor=E.+G.+Lakattaauthor=R.+P.+Xiao&title=G%28i%29+protein-mediated+functional+compartmentalization+of+cardiac+beta%282%29-adrenergic+signaling&doi=10.1074%2Fjbc.274.31.22048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Gi protein-mediated functional compartmentalization of cardiac β2-adrenergic signaling</span></div><div class="casAuthors">Kuschel, Meike; Zhou, Ying-Ying; Cheng, Heping; Zhang, Sheng-Jun; Chen, Ye; Lakatta, Edward G.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">274</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">22048-22052</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In contrast to β1-adrenoreceptor (β1-AR) signaling, β2-AR stimulation in cardiomyocytes augments L-type Ca2+ current in a cAMP-dependent protein kinase (PKA)-dependent manner but fails to phosphorylate phospholamban, indicating that the β2-AR-induced cAMP/PKA signaling is highly localized.  Here we show that inhibition of Gi proteins with pertussis toxin (PTX) permits a full phospholamban phosphorylation and a de novo relaxant effect following β2-AR stimulation, converting the localized β2-AR signaling to a global signaling mode similar to that of β1-AR.  Thus, β2-AR-mediated Gi activation constricts the cAMP signaling to the sarcolemma.  PTX treatment did not significantly affect the β2-AR-stimulated PKA activation.  Similar to Gi inhibition, a protein phosphatase inhibitor, calyculin A (3 × 10-8 M), selectively enhanced the β2-AR but not β1-AR-mediated contractile response.  Furthermore, PTX and calyculin A treatment had a non-additive potentiating effect on the β2-AR-mediated pos. inotropic response.  These results suggest that the interaction of the β2-AR-coupled Gi and Gs signaling affects the local balance of protein kinase and phosphatase activities.  Thus, the addnl. coupling of β2-AR to Gi proteins is a key factor causing the compartmentalization of β2-AR-induced cAMP signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp4cAlURu8g7Vg90H21EOLACvtfcHk0lh9CkwYBu6hYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVymtbY%253D&md5=f6a10edd2d57e42d24ee9bef8eb9d7bc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.274.31.22048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.274.31.22048%26sid%3Dliteratum%253Aachs%26aulast%3DKuschel%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DG%2528i%2529%2520protein-mediated%2520functional%2520compartmentalization%2520of%2520cardiac%2520beta%25282%2529-adrenergic%2520signaling%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D22048%26epage%3D22052%26doi%3D10.1074%2Fjbc.274.31.22048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen-Izu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izu, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuschel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2556</span>, <span class="refDoi"> DOI: 10.1016/S0006-3495(00)76495-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0006-3495%2800%2976495-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11053129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD3M%252FotFaltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=2547-2556&author=Y.+Chen-Izuauthor=R.+P.+Xiaoauthor=L.+T.+Izuauthor=H.+Chengauthor=M.+Kuschelauthor=H.+Spurgeonauthor=E.+G.+Lakatta&title=G%28i%29-dependent+localization+of+beta%282%29-adrenergic+receptor+signaling+to+L-type+Ca%282%2B%29+channels&doi=10.1016%2FS0006-3495%2800%2976495-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">G(i)-dependent localization of beta(2)-adrenergic receptor signaling to L-type Ca(2+) channels</span></div><div class="casAuthors">Chen-Izu Y; Xiao R P; Izu L T; Cheng H; Kuschel M; Spurgeon H; Lakatta E G</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical journal</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2547-56</span>
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    </div><div class="casAbstract">A plausible determinant of the specificity of receptor signaling is the cellular compartment over which the signal is broadcast.  In rat heart, stimulation of beta(1)-adrenergic receptor (beta(1)-AR), coupled to G(s)-protein, or beta(2)-AR, coupled to G(s)- and G(i)-proteins, both increase L-type Ca(2+) current, causing enhanced contractile strength.  But only beta(1)-AR stimulation increases the phosphorylation of phospholamban, troponin-I, and C-protein, causing accelerated muscle relaxation and reduced myofilament sensitivity to Ca(2+). beta(2)-AR stimulation does not affect any of these intracellular proteins.  We hypothesized that beta(2)-AR signaling might be localized to the cell membrane.  Thus we examined the spatial range and characteristics of beta(1)-AR and beta(2)-AR signaling on their common effector, L-type Ca(2+) channels.  Using the cell-attached patch-clamp technique, we show that stimulation of beta(1)-AR or beta(2)-AR in the patch membrane, by adding agonist into patch pipette, both activated the channels in the patch.  But when the agonist was applied to the membrane outside the patch pipette, only beta(1)-AR stimulation activated the channels.  Thus, beta(1)-AR signaling to the channels is diffusive through cytosol, whereas beta(2)-AR signaling is localized to the cell membrane.  Furthermore, activation of G(i) is essential to the localization of beta(2)-AR signaling because in pertussis toxin-treated cells, beta(2)-AR signaling becomes diffusive.  Our results suggest that the dual coupling of beta(2)-AR to both G(s)- and G(i)-proteins leads to a highly localized beta(2)-AR signaling pathway to modulate sarcolemmal L-type Ca(2+) channels in rat ventricular myocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1uNDJ76Sv1TAEfvC7EH1LfW6udTcc2eYaGAaSEvTmhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M%252FotFaltA%253D%253D&md5=e4a1c332312d4327e80e4a72203377ba</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0006-3495%2800%2976495-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3495%252800%252976495-2%26sid%3Dliteratum%253Aachs%26aulast%3DChen-Izu%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DIzu%26aufirst%3DL.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DKuschel%26aufirst%3DM.%26aulast%3DSpurgeon%26aufirst%3DH.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3DG%2528i%2529-dependent%2520localization%2520of%2520beta%25282%2529-adrenergic%2520receptor%2520signaling%2520to%2520L-type%2520Ca%25282%252B%2529%2520channels%26jtitle%3DBiophys.%2520J.%26date%3D2000%26volume%3D79%26spage%3D2547%26epage%3D2556%26doi%3D10.1016%2FS0006-3495%2800%2976495-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Gerges, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandecasteele, G.</span></span> <span> </span><span class="NLM_article-title">A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1088</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000218493.09370.8e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000218493.09370.8e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16556871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1Kltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=1081-1088&author=F.+Rochaisauthor=A.+Abi-Gergesauthor=K.+Hornerauthor=F.+Lefebvreauthor=D.+M.+Cooperauthor=M.+Contiauthor=R.+Fischmeisterauthor=G.+Vandecasteele&title=A+specific+pattern+of+phosphodiesterases+controls+the+cAMP+signals+generated+by+different+Gs-coupled+receptors+in+adult+rat+ventricular+myocytes&doi=10.1161%2F01.RES.0000218493.09370.8e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Specific Pattern of Phosphodiesterases Controls the cAMP Signals Generated by Different Gs-Coupled Receptors in Adult Rat Ventricular Myocytes</span></div><div class="casAuthors">Rochais, Francesca; Abi-Gerges, Aniella; Horner, Kathleen; Lefebvre, Florence; Cooper, Dermot M. F.; Conti, Marco; Fischmeister, Rodolphe; Vandecasteele, Gregoire</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1081-1088</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Compartmentation of cAMP is thought to generate the specificity of Gs-coupled receptor action in cardiac myocytes, with phosphodiesterases (PDEs) playing a major role in this process by preventing cAMP diffusion.  The authors tested this hypothesis in adult rat ventricular myocytes by characterizing PDEs involved in the regulation of cAMP signals and L-type Ca2+ current (ICa,L) on stimulation with β1-adrenergic receptors (β1-ARs), β2-ARs, glucagon receptors (Glu-Rs) and prostaglandin E1 receptors (PGE1-Rs).  All receptors but PGE1-R increased total cAMP, and inhibition of PDEs with 3-isobutyl-1-methylxanthine strongly potentiated these responses.  When monitored in single cells by high-affinity cyclic nucleotide-gated (CNG) channels, stimulation of β1-AR and Glu-R increased cAMP, whereas β2-AR and PGE1-R had no detectable effect.  Selective inhibition of PDE3 by cilostamide and PDE4 by Ro 20-1724 potentiated β1-AR cAMP signals, whereas Glu-R cAMP was augmented only by PD4 inhibition.  PGE1-R and β2-AR generated substantial cAMP increases only when PDE3 and PDE4 were blocked.  For all receptors except PGE1-R, the measurements of ICa,L closely matched the ones obtained with CNG channels.  Indeed, PDE3 and PDE4 controlled β1-AR and β2-AR regulation of ICa,L, whereas only PDE4 controlled Glu-R regulation of ICa,L thus demonstrating that receptor-PDE coupling has functional implications downstream of cAMP.  PGE1 had no effect on ICa,L even after blockade of PDE3 or PDE4, suggesting that other mechanisms prevent cAMP produced by PGE1 to diffuse to L-type Ca2+ channels.  These results identify specific functional coupling of individual PDE families to Gs-coupled receptors as a major mechanism enabling cardiac cells to generate heterogeneous cAMP signals in response to different hormones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBefD7Pnp9JrVg90H21EOLACvtfcHk0li0PBD2vDoXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1Kltro%253D&md5=8968ebfbaa9d384fa85e2d597fffb9e6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000218493.09370.8e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000218493.09370.8e%26sid%3Dliteratum%253Aachs%26aulast%3DRochais%26aufirst%3DF.%26aulast%3DAbi-Gerges%26aufirst%3DA.%26aulast%3DHorner%26aufirst%3DK.%26aulast%3DLefebvre%26aufirst%3DF.%26aulast%3DCooper%26aufirst%3DD.%2BM.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DVandecasteele%26aufirst%3DG.%26atitle%3DA%2520specific%2520pattern%2520of%2520phosphodiesterases%2520controls%2520the%2520cAMP%2520signals%2520generated%2520by%2520different%2520Gs-coupled%2520receptors%2520in%2520adult%2520rat%2520ventricular%2520myocytes%26jtitle%3DCirc.%2520Res.%26date%3D2006%26volume%3D98%26spage%3D1081%26epage%3D1088%26doi%3D10.1161%2F01.RES.0000218493.09370.8e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bünemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitteckert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, S.</span></span> <span> </span><span class="NLM_article-title">Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1084</span>– <span class="NLM_lpage">1091</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000250046.69918.d5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000250046.69918.d5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17038640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKgurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2006&pages=1084-1091&author=V.+O.+Nikolaevauthor=M.+B%C3%BCnemannauthor=E.+Schmitteckertauthor=M.+J.+Lohseauthor=S.+Engelhardt&title=Cyclic+AMP+imaging+in+adult+cardiac+myocytes+reveals+far-reaching+beta1-adrenergic+but+locally+confined+beta2-adrenergic+receptor-mediated+signaling&doi=10.1161%2F01.RES.0000250046.69918.d5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching β1-adrenergic but locally confined β2-adrenergic receptor-mediated signaling</span></div><div class="casAuthors">Nikolaev, Viacheslav O.; Buenemann, Moritz; Schmitteckert, Eva; Lohse, Martin J.; Engelhardt, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1084-1091</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Both β1- and β2-adrenergic receptors (βARs) are known to differentially regulate cardiomyocyte contraction and growth.  The authors tested the hypothesis that these differences are attributable to spatial compartmentation of the second messenger cAMP.  Using a fluorescent resonance energy transfer (FRET)-based approach, the authors directly monitored the spatial and temporal distribution of cAMP in adult cardiomyocytes.  The authors developed a new cAMP-FRET sensor (termed HCN2-camps) based on a single cAMP binding domain of the hyperpolarization activated cyclic nucleotide-gated potassium channel 2 (HCN2).  Its cytosolic distribution, high dynamic range, and sensitivity make HCN2-camps particularly well suited to monitor subcellular localization of cardiomyocyte cAMP.  The authors generated HCN2-camps transgenic mice and performed single-cell FRET imaging on freshly isolated cardiomyocytes.  Whole-cell superfusion with isoproterenol showed a moderate elevation of cAMP.  Application of various phosphodiesterase (PDE) inhibitors revealed stringent control of cAMP through PDE4 > PDE2 > PDE3.  The β1AR-mediated cAMP signals were entirely dependent on PDE4 activity, whereas β2AR-mediated cAMP was under control of multiple PDE isoforms.  β1AR subtype-specific stimulation yielded ≈2-fold greater cAMP responses compared with selective β2-subtype stimulation, even on treatment with the nonselective PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) (ΔFRET, 17.3% [β1AR] vs. 8% [β2AR]).  Treatment with pertussis toxin to inactivate Gi did not affect cAMP prodn.  Localized β1AR stimulation generated a cAMP gradient propagating throughout the cell, whereas local β2AR stimulation did not elicit marked cAMP diffusion.  The authors' data reveal that in adult cardiac myocytes, β1ARs induce far-reaching cAMP signals, whereas β2AR-induced cAMP remains locally confined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM-iqaCHkBCrVg90H21EOLACvtfcHk0li0PBD2vDoXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKgurrF&md5=571cbbe298c3f8edce2ccc51f47665d2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000250046.69918.d5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000250046.69918.d5%26sid%3Dliteratum%253Aachs%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DB%25C3%25BCnemann%26aufirst%3DM.%26aulast%3DSchmitteckert%26aufirst%3DE.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DEngelhardt%26aufirst%3DS.%26atitle%3DCyclic%2520AMP%2520imaging%2520in%2520adult%2520cardiac%2520myocytes%2520reveals%2520far-reaching%2520beta1-adrenergic%2520but%2520locally%2520confined%2520beta2-adrenergic%2520receptor-mediated%2520signaling%26jtitle%3DCirc.%2520Res.%26date%3D2006%26volume%3D99%26spage%3D1084%26epage%3D1091%26doi%3D10.1161%2F01.RES.0000250046.69918.d5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altschuld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">Beta 2-adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca<sup>2+</sup> dynamics, contractility, or phospholamban phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">19151</span>– <span class="NLM_lpage">19156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8034672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2cXltVSmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=19151-19156&author=R.+P.+Xiaoauthor=C.+Hohlauthor=R.+Altschuldauthor=L.+Jonesauthor=B.+Livingstonauthor=B.+Zimanauthor=B.+Tantiniauthor=E.+G.+Lakatta&title=Beta+2-adrenergic+receptor-stimulated+increase+in+cAMP+in+rat+heart+cells+is+not+coupled+to+changes+in+Ca2%2B+dynamics%2C+contractility%2C+or+phospholamban+phosphorylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation</span></div><div class="casAuthors">Xiao, Rui-Ping; Hohl, Charlene; Altschuld, Ruth; Jones, Larry; Livingston, Beth; Ziman, Bruce; Tantini, Benedetta; Lakatta, Edward G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">19151-6</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Previous studies have shown that both β1- and β2-adrenergic receptors (AR) are present in rat ventricular myocytes, but stimulation of these receptor subtypes elicites qual. different cellular responses.  In the present study, the biochem. mechanism underlying the distinct βAR subtype actions have been investigated.  Although both β1AR and β2AR stimulation increased total cellular cAMP in suspensions of rat ventricular myocytes to a similar extent, the max. elevation of the membrane bound cAMP by β2AR stimulation was only half of that induced by β1AR stimulation, suggesting that stimulation the βAR subtypes leads to different compartmentation of cAMP.  The effects of β1AR stimulation on Ca2+ transient (indexed by the transient increase in indo-1 fluorescence ratio after excitation) and contraction amplitude (measured via photodiode array) and their kinetics closely paralleled the increase in cAMP.  In contrast, the increases in both membrane bound and total cAMP content after β2AR stimulation were completely dissocd. from the effects of β2AR stimulation to increase the amplitudes of cytosolic Ca2+ transient and contraction.  Furthermore, β2AR stimulation did not phosphorylate phospholamban to the same extent as did β1AR stimulation.  This finding provides a mechanism for the failure of β2AR stimulation to accelerate the kinetics of the Ca2+i (cytosolic Ca2+) transient and contraction.  These results indicate that the effects of β2AR stimulation on Ca2+i transient and contraction are uncoupled from the cAMP prodn. and cAMP-dependent protein phosphorylation and indicate that, in addn. to coupling to adenylate cyclase, β2AR stimulation also activates other signal transduction pathway(s) to produce changes in cytosolic Ca2+ and contraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowZ1SnO0hVbrVg90H21EOLACvtfcHk0li0PBD2vDoXfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltVSmsr0%253D&md5=87af1291b673256ea3059853fcb1aad1</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DHohl%26aufirst%3DC.%26aulast%3DAltschuld%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DLivingston%26aufirst%3DB.%26aulast%3DZiman%26aufirst%3DB.%26aulast%3DTantini%26aufirst%3DB.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3DBeta%25202-adrenergic%2520receptor-stimulated%2520increase%2520in%2520cAMP%2520in%2520rat%2520heart%2520cells%2520is%2520not%2520coupled%2520to%2520changes%2520in%2520Ca2%252B%2520dynamics%252C%2520contractility%252C%2520or%2520phospholamban%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D19151%26epage%3D19156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanov, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohl, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altschuld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Localized cAMP-dependent signaling mediated β<sub>2</sub>-adrenregic modulation of cardiac excitation-contraction coupling</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">H1611</span>– <span class="NLM_lpage">H1618</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.1997.273.3.H1611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajpheart.1997.273.3.H1611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9321856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXmtlemsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1997&pages=H1611-H1618&author=Y.+Y.+Zhouauthor=H.+Chengauthor=K.+Y.+Bogdanovauthor=C.+Hohlauthor=R.+Altschuldauthor=E.+G.+Lakattaauthor=R.+P.+Xiao&title=Localized+cAMP-dependent+signaling+mediated+%CE%B22-adrenregic+modulation+of+cardiac+excitation-contraction+coupling&doi=10.1152%2Fajpheart.1997.273.3.H1611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Localized cAMP-dependent signaling mediates β2-adrenergic modulation of cardiac excitation-contraction coupling</span></div><div class="casAuthors">Zhou, Ying-Ying; Cheng, Heping; Bogdanov, Konstantin Y.; Hohl, Charlene; Altschhuld, Ruth; Lakatta, Edward G.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">H1611-H1618</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Recent studies have shown that β2-adrenergic receptor (β2-AR)-stimulated increases in the intracellular Ca2+ (Cai) treatment and contraction in cardiac myocytes are dissocd. from the increase in cAMP level and are not accompanied by an increase in phospholamban phosphorylation, an acceleration in relaxation, or a redn. in myofilament Ca2+ response.  Thus the authors hypothesized that the β2-AR modulation of cardiac excitation-contraction (EC) coupling may be mediated by either a cAMP-independent mechanism of a compartmentalized cAMP pathway.  To directly distinguish between these two possibilities, the responses of the L-type Ca2+ current (ICa), Cai transient, and contraction to β2-AR as well as to β1-AR stimulation were examd. in rat ventricular myocytes in the presence or absence of specific inhibitory cAMP analogs, Rp diastereomers of adenosine 3',5'-cyclic monophosphothionate (Rp-cAMPS) and 8-(4-chlorophenylthio)-cAMP (Rp-CPT-cAMPS).  As expected, the pos. inotropic effect induced by an adenylyl cyclase activator, forskolin (2 X 10-7 M), or a β1-AR agonist, norepinephrine (5 X 10-8 M) plus prazosin (10-6 M), was completely blocked by Rp-CPT-cAMPS.  More importantly, the responses of ICa, Cai transient, and contraction to β2-AR stimulation by zinterol (10-5 M) or isoproterenol plus a selective β1-AR antagonist, CGP-20712A, were also entirely abolished by Rp-cAMPS (in the patch-pipet soln.) or Rp-CPT-cAMPS (in the bath soln.).  In pertussis toxin-treated cells, although the response of cAMP was not altered, the β2-AR-stimulated increase in contraction amplitude was markedly enhanced and accompanied by a hastened relaxation, resulting in a tight assocn. between cAMP and contraction.  These results indicate that β2-AR modulation of cardiac excitation-contraction coupling requires cAMP.  The dissocn. of β2-AR-stimulated cAMP prodn. and regulation of myofilament and sarcoplasmic reticulum functions is attributable to a functional compartmentation of the cAMP-dependent signaling due to an activation of β2-AR-coupled Gi and/or G0.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFiPLmqOy77Vg90H21EOLACvtfcHk0ljI2y_veUlmHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmtlemsrk%253D&md5=38e7b92a3b0304fc1a96352171e0821d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.1997.273.3.H1611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.1997.273.3.H1611%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DBogdanov%26aufirst%3DK.%2BY.%26aulast%3DHohl%26aufirst%3DC.%26aulast%3DAltschuld%26aufirst%3DR.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DLocalized%2520cAMP-dependent%2520signaling%2520mediated%2520%25CE%25B22-adrenregic%2520modulation%2520of%2520cardiac%2520excitation-contraction%2520coupling%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1997%26volume%3D273%26spage%3DH1611%26epage%3DH1618%26doi%3D10.1152%2Fajpheart.1997.273.3.H1611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuschel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karczewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Beta2-adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2458</span>– <span class="NLM_lpage">2465</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.99.18.2458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.99.18.2458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10318670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXjsFartrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=2458-2465&author=M.+Kuschelauthor=Y.+Y.+Zhouauthor=H.+A.+Spurgeonauthor=S.+Bartelauthor=P.+Karczewskiauthor=S.+J.+Zhangauthor=E.+G.+Krauseauthor=E.+G.+Lakattaauthor=R.+P.+Xiao&title=Beta2-adrenergic+cAMP+signaling+is+uncoupled+from+phosphorylation+of+cytoplasmic+proteins+in+canine+heart&doi=10.1161%2F01.CIR.99.18.2458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart</span></div><div class="casAuthors">Kuschel, Meike; Zhou, Ying-Ying; Spurgeon, Harold A.; Bartel, Sabine; Karczewski, Peter; Zhang, Sheng-Jun; Krause, Ernst-Georg; Lakatta, Edward G.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2458-2465</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent studies of β-adrenergic receptor (β-AR) subtype signaling in in vitro prepns. have raised doubts as to whether the cAMP/protein kinase A (PKA) signaling is activated in the same manner in response to β2-AR vs. β1-AR stimulation.  The present study compared, in the intact dog, the magnitude and characteristics of chronotropic, inotropic, and lusitropic effects of cAMP accumulation, PKA activation, and PKA-dependent phosphorylation of key effector proteins in response to β-AR subtype stimulation.  In addn., many of these parameters and L-type Ca2+ current (ICa) were also measured in single canine ventricular myocytes.  The results indicate that although the cAMP/PKA-dependent phosphorylation cascade activated by β1-AR stimulation could explain the resultant modulation of cardiac function, substantial β2-AR-mediated chronotropic, inotropic, and lusitropic responses occurred in the absence of PKA activation and phosphorylation of nonsarcolemmal proteins, including phospholamban, troponin I, C protein, and glycogen phosphorylase kinase.  However, in single canine myocytes, the authors found that β2-AR-stimulated increases in both ICa and contraction were abolished by PKA inhibition.  Thus, the β2-AR-directed cAMP/PKA signaling modulates sarcolemmal L-type Ca2+ channels but does not regulate PKA-dependent phosphorylation of cytoplasmic proteins.  These results indicate that the dissocn. of β2-AR signaling from cAMP regulatory systems is only apparent and that β2-AR-stimulated cAMP/PKA signaling is uncoupled from phosphorylation of nonsarcolemmal regulatory proteins involved in excitation-contraction coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqHyQtWkc6d7Vg90H21EOLACvtfcHk0ljI2y_veUlmHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjsFartrs%253D&md5=cfc6914b1028b00e3bf0ef1c655a0da7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.99.18.2458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.99.18.2458%26sid%3Dliteratum%253Aachs%26aulast%3DKuschel%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DSpurgeon%26aufirst%3DH.%2BA.%26aulast%3DBartel%26aufirst%3DS.%26aulast%3DKarczewski%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DKrause%26aufirst%3DE.%2BG.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DBeta2-adrenergic%2520cAMP%2520signaling%2520is%2520uncoupled%2520from%2520phosphorylation%2520of%2520cytoplasmic%2520proteins%2520in%2520canine%2520heart%26jtitle%3DCirculation%26date%3D1999%26volume%3D99%26spage%3D2458%26epage%3D2465%26doi%3D10.1161%2F01.CIR.99.18.2458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1038/36362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2F36362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9363896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Cru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=1997&pages=88-91&author=Y.+Daakaauthor=L.+M.+Luttrellauthor=R.+J.+Lefkowitz&title=Switching+of+the+coupling+of+the+beta2-adrenergic+receptor+to+different+G+proteins+by+protein+kinase+A&doi=10.1038%2F36362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A</span></div><div class="casAuthors">Daaka, Yehia; Luttrell, Louis M.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">6655</span>),
    <span class="NLM_cas:pages">88-91</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Many of the G-protein-coupled receptors for hormones that bind to the cell surface can signal to the interior of the cell through several different classes of G protein.  For example, although most of the actions of the prototype β2-adrenergic receptor are mediated through Gs proteins and the cyclic-AMP-dependent protein kinase (PKA) system, β-adrenergic receptors can also couple to Gi proteins.  Here the authors investigate the mechanism that controls the specificity of this coupling.  The authors show that in HEK293 cells, stimulation of mitogen-activated protein (MAP) kinase by the β2-adrenergic receptor is mediated by the βγ subunits of pertussis-toxin-sensitive G proteins through a pathway involving the non-receptor tyrosine kinase c-Src and the G protein Ras.  Activation of this pathway by the β2-adrenergic receptor requires that the receptor be phosphorylated by PKA because it is blocked by H-89, an inhibitor of PKA.  Addnl., a mutant of the receptor, which lacks the sites normally phosphorylated by PKA, can activate adenylyl cyclase, the enzyme that generates cAMP, but not MAP kinase.  The authors' results demonstrate that a mechanism previously shown to mediate uncoupling of the β2-adrenergic receptor from Gs and thus heterologous desensitization (PKA-mediated receptor phosphorylation), also serves to 'switch' coupling of this receptor from Gs to Gi and initiate a new set of signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQz1gYyUIrk7Vg90H21EOLACvtfcHk0ljI2y_veUlmHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Cru7o%253D&md5=7d7ba63639514006ec2cfdbbd3a38e84</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2F36362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F36362%26sid%3Dliteratum%253Aachs%26aulast%3DDaaka%26aufirst%3DY.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSwitching%2520of%2520the%2520coupling%2520of%2520the%2520beta2-adrenergic%2520receptor%2520to%2520different%2520G%2520proteins%2520by%2520protein%2520kinase%2520A%26jtitle%3DNature%26date%3D1997%26volume%3D390%26spage%3D88%26epage%3D91%26doi%3D10.1038%2F36362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-Adrenergic stimulation compartmentalizes β<sub>1</sub> signaling into nanoscale local domains by targeting the C-terminus of β<sub>1</sub>-adrenoceptors</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1359</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.118.314322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.118.314322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30836825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlWmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=1350-1359&author=H.+Q.+Yangauthor=L.+P.+Wangauthor=Y.+Y.+Gongauthor=X.+X.+Fanauthor=S.+Y.+Zhuauthor=X.+T.+Wangauthor=Y.+P.+Wangauthor=L.+L.+Liauthor=X.+Xingauthor=X.+X.+Liuauthor=G.+S.+Jiauthor=T.+Houauthor=Y.+Zhangauthor=R.+P.+Xiaoauthor=S.+Q.+Wang&title=%CE%B22-Adrenergic+stimulation+compartmentalizes+%CE%B21+signaling+into+nanoscale+local+domains+by+targeting+the+C-terminus+of+%CE%B21-adrenoceptors&doi=10.1161%2FCIRCRESAHA.118.314322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic Stimulation Compartmentalizes β1 Signaling Into Nanoscale Local Domains by Targeting the C-Terminus of β1-Adrenoceptors</span></div><div class="casAuthors">Yang, Hua-Qian; Wang, Li-Peng; Gong, Yun-Yun; Fan, Xue-Xin; Zhu, Si-Yu; Wang, Xiao-Ting; Wang, Yu-Pu; Li, Lin-Lin; Xing, Xin; Liu, Xiao-Xiao; Ji, Guang-Shen; Hou, TingTing; Zhang, Yan; Xiao, Rui-Ping; Wang, Shi-Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: βARs (β-adrenergic receptors) are prototypical GPCRs (G protein-coupled receptors) that play a pivotal role in sympathetic regulation.  In heart cells, β1AR signaling mediates a global response, including both L-type Ca channels in the sarcolemma/T tubules and RyRs (ryanodine receptors) in the SR (sarcoplasmic reticulum).  In contrast, β2AR mediates local signaling with little effect on the function of SR proteins.  Objective: To investigate the signaling relationship between β1ARs and β2ARs.  Method and results: Using whole-cell patch-clamp analyses combined with confocal Ca imaging, we found that the activation of compartmentalized β2AR signaling was able to convert the β1AR signaling from global to local mode, preventing β1ARs from phosphorylating RyRs that were only nanometers away from sarcolemma/T tubules.  This offside compartmentalization was eliminated by selective inhibition of β2AR, GRK2 (GPCR kinase-2), βarr1 (β-arrestin-1), and phosphodiesterase-4.  A knockin rat model harboring mutations of the last 3 serine residues of the β1AR C terminus, a component of the putative βarr1 binding site and GRK2 phosphorylation site, eliminated the offside compartmentalization conferred by β2AR activation.  Conclusions: β2AR stimulation compartmentalizes β1AR signaling into nanoscale local domains in a phosphodiesterase-4-dependent manner by targeting the C terminus of β1ARs.  This finding reveals a fundamental neg. feed-forward mechanism that serves to avoid the cytotoxicity of circulating catecholamine and to sharpen the transient β1AR response of sympathetic excitation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzLuSLVO3WrVg90H21EOLACvtfcHk0lg2b028cK0__Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlWmsLs%253D&md5=a18b47ba5aea5ab376dd881505a61496</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.118.314322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.118.314322%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%2BQ.%26aulast%3DWang%26aufirst%3DL.%2BP.%26aulast%3DGong%26aufirst%3DY.%2BY.%26aulast%3DFan%26aufirst%3DX.%2BX.%26aulast%3DZhu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DX.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DLi%26aufirst%3DL.%2BL.%26aulast%3DXing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%2BX.%26aulast%3DJi%26aufirst%3DG.%2BS.%26aulast%3DHou%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26atitle%3D%25CE%25B22-Adrenergic%2520stimulation%2520compartmentalizes%2520%25CE%25B21%2520signaling%2520into%2520nanoscale%2520local%2520domains%2520by%2520targeting%2520the%2520C-terminus%2520of%2520%25CE%25B21-adrenoceptors%26jtitle%3DCirc.%2520Res.%26date%3D2019%26volume%3D124%26spage%3D1350%26epage%3D1359%26doi%3D10.1161%2FCIRCRESAHA.118.314322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsburg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minobe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubicciotti, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sageman, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingham, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, E. B.</span></span> <span> </span><span class="NLM_article-title">Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1056/NEJM198207223070401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJM198207223070401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=6283349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL38XkvV2qsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=1982&pages=205-211&author=M.+R.+Bristowauthor=R.+Ginsburgauthor=W.+Minobeauthor=R.+S.+Cubicciottiauthor=W.+S.+Sagemanauthor=K.+Lurieauthor=M.+E.+Billinghamauthor=D.+C.+Harrisonauthor=E.+B.+Stinson&title=Decreased+catecholamine+sensitivity+and+%CE%B2-adrenergic+receptor+density+in+failing+human+hearts&doi=10.1056%2FNEJM198207223070401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts</span></div><div class="casAuthors">Bristow, Michael R.; Ginsburg, Robert; Minobe, Wayne; Cubicciotti, Roger S.; Sageman, W. Scott; Lurie, Keith; Billingham, Margaret E.; Harrison, Donald C.; Stinson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-11</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">To identify the role of the myocardial β-adrenergic pathway in congestive heart failure, β-adrenergic receptor d., adenylate cyclase, and creatine kinase activities, muscle contraction in vitro, and myocardial contractile protein levels in the left ventricles of failing and normally functioning hearts from cardiac transplant recipients or prospective donors were examd.  Eleven failing left ventricles had a 50-56% redn. in β-receptor d., a 45% redn. in maximal isoproterenol-mediated adenylate cyclase stimulation, and a 54-73% redn. in maximal isoproterenol-stimulated muscle contraction, as compared with 6 normally functioning ventricles.  In contrast, cytoplasmic creatine kinase activity, adenylate cyclase activities stimulated by F- and by histamine, histamine-stimulated muscle contraction, and levels of contractile protein were not different in the 2 groups.  Apparently, in failing human hearts, a decrease in the β-receptor d. leads to subsensitivity of the β-adrenergic pathway and decreased β-agonist-stimulated muscle contraction.  Regulation of β-adrenergic receptors may be an important variable in cardiac failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOXb2sUUjylbVg90H21EOLACvtfcHk0lg2b028cK0__Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XkvV2qsrc%253D&md5=af0e3abceba888a5260bd1e9a2e07970</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJM198207223070401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198207223070401%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DM.%2BR.%26aulast%3DGinsburg%26aufirst%3DR.%26aulast%3DMinobe%26aufirst%3DW.%26aulast%3DCubicciotti%26aufirst%3DR.%2BS.%26aulast%3DSageman%26aufirst%3DW.%2BS.%26aulast%3DLurie%26aufirst%3DK.%26aulast%3DBillingham%26aufirst%3DM.%2BE.%26aulast%3DHarrison%26aufirst%3DD.%2BC.%26aulast%3DStinson%26aufirst%3DE.%2BB.%26atitle%3DDecreased%2520catecholamine%2520sensitivity%2520and%2520%25CE%25B2-adrenergic%2520receptor%2520density%2520in%2520failing%2520human%2520hearts%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1982%26volume%3D307%26spage%3D205%26epage%3D211%26doi%3D10.1056%2FNEJM198207223070401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levine, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, J. N.</span></span> <span> </span><span class="NLM_article-title">Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1659</span>– <span class="NLM_lpage">1666</span>, <span class="refDoi"> DOI: 10.1016/0002-9149(82)90243-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2F0002-9149%2882%2990243-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7044086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaL383gtlWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1982&pages=1659-1666&author=T.+B.+Levineauthor=G.+S.+Francisauthor=S.+R.+Goldsmithauthor=A.+B.+Simonauthor=J.+N.+Cohn&title=Activity+of+the+sympathetic+nervous+system+and+renin-angiotensin+system+assessed+by+plasma+hormone+levels+and+their+relation+to+hemodynamic+abnormalities+in+congestive+heart+failure&doi=10.1016%2F0002-9149%2882%2990243-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure</span></div><div class="casAuthors">Levine T B; Francis G S; Goldsmith S R; Simon A B; Cohn J N</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of cardiology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1659-66</span>
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFYKmwVGMZICnGiHuhFGv8fW6udTcc2ebzGJ3G-eVa-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383gtlWjtA%253D%253D&md5=554885c33817dc4e5f0f15a92f9dfaae</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2F0002-9149%2882%2990243-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0002-9149%252882%252990243-0%26sid%3Dliteratum%253Aachs%26aulast%3DLevine%26aufirst%3DT.%2BB.%26aulast%3DFrancis%26aufirst%3DG.%2BS.%26aulast%3DGoldsmith%26aufirst%3DS.%2BR.%26aulast%3DSimon%26aufirst%3DA.%2BB.%26aulast%3DCohn%26aufirst%3DJ.%2BN.%26atitle%3DActivity%2520of%2520the%2520sympathetic%2520nervous%2520system%2520and%2520renin-angiotensin%2520system%2520assessed%2520by%2520plasma%2520hormone%2520levels%2520and%2520their%2520relation%2520to%2520hemodynamic%2520abnormalities%2520in%2520congestive%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D1982%26volume%3D49%26spage%3D1659%26epage%3D1666%26doi%3D10.1016%2F0002-9149%2882%2990243-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">18677</span>– <span class="NLM_lpage">18680</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.30.18677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.273.30.18677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9668034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1cXltFGrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=18677-18680&author=R.+J.+Lefkowitz&title=G+protein-coupled+receptors.+III.+New+roles+for+receptor+kinases+and+%CE%B2-arrestins+in+receptor+signaling+and+desensitization&doi=10.1074%2Fjbc.273.30.18677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors; III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization</span></div><div class="casAuthors">Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">18677-18680</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review, with 47 refs.  Of the many forms of GPCR regulation none has received as much attention as the process of receptor desensitization, i.e., the waning responsiveness of the receptors in the face of persistent stimulation.  Numerous mechanisms have been discovered, including those that operate at the transcriptional, translational, and protein levels.  The latter category in turn includes mechanisms that regulate the rate of degrdn. of the receptors.  Finally, there are mechanisms for the covalent modification of the receptors as well as for the regulation of their assocn. with other proteins and their subcellular localization.  This brief review is concerned with this last group of mechanisms, which appears to be most important with respect to the rapid (seconds-minutes as opposed to hours or days) control of receptor function.  Traditionally, receptor desensitization has been viewed as a process antithetical to receptor activation, one which terminates or attenuates receptor signaling.  Three families of regulatory mols. have been found to participate in desensitization of heptahelical receptors: second messenger-regulated kinases (e.g., PKA and PKC), GRKs (e.g. βARK, rhodopsin kinase), and the arrestins (visual and non-visual).  After briefly reviewing the well established paradigms for regulation of GPCRs by these three families of mols., I will attempt to demonstrate how newly acquired insights into the function of these receptor regulatory mols. are reshaping understanding of the classical dichotomy between receptor activation and desensitization.  The new information suggests that receptor signaling and desensitization are in reality two intimately linked aspects of receptor function and that mechanisms previously viewed as "desensitizing" with respect to one signaling pathway may be "activating" with respect to another.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5m2AvH6IBA7Vg90H21EOLACvtfcHk0lj6Esxc9KjEHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltFGrsrY%253D&md5=f22667077d638c9b682b2c1fcefaf36c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.30.18677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.30.18677%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DG%2520protein-coupled%2520receptors.%2520III.%2520New%2520roles%2520for%2520receptor%2520kinases%2520and%2520%25CE%25B2-arrestins%2520in%2520receptor%2520signaling%2520and%2520desensitization%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26spage%3D18677%26epage%3D18680%26doi%3D10.1074%2Fjbc.273.30.18677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrashevskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuprun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, G. W.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Gi biased β<sub>2</sub>AR signaling links GRK2 upregulation to heart failure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.111.253260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.111.253260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22179058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVKrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2012&pages=265-274&author=W.+Zhuauthor=N.+Petrashevskayaauthor=S.+Renauthor=A.+Zhaoauthor=K.+Chakirauthor=E.+Gaoauthor=J.+K.+Chuprunauthor=Y.+Wangauthor=M.+Talanauthor=G.+W.+Dornauthor=E.+G.+Lakattaauthor=W.+J.+Kochauthor=A.+M.+Feldmanauthor=R.+P.+Xiao&title=Gi+biased+%CE%B22AR+signaling+links+GRK2+upregulation+to+heart+failure&doi=10.1161%2FCIRCRESAHA.111.253260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Gi-Biased β2AR Signaling Links GRK2 Upregulation to Heart Failure</span></div><div class="casAuthors">Zhu, Weizhong; Petrashevskaya, Natalia; Ren, Shuxun; Zhao, Aizhi; Chakir, Khalid; Gao, Erhe; Chuprun, J. Kurt; Wang, Yibin; Talan, Mark; Dorn, Gerald W., II; Lakatta, Edward G.; Koch, Walter J.; Feldman, Arthur M.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-274</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Phosphorylation of β2-adrenergic receptor (β2AR) by a family of serine/threonine kinases known as G protein-coupled receptor kinase (GRK) and protein kinase A (PKA) is a crit. determinant of cardiac function.  Upregulation of G protein-coupled receptor kinase 2 (GRK2) is a well-established causal factor of heart failure, but the underlying mechanism is poorly understood.  Objective: We sought to det. the relative contribution of PKA- and GRK-mediated phosphorylation of β2AR to the receptor coupling to Gi signaling that attenuates cardiac reserve and contributes to the pathogenesis of heart failure in response to pressure overload.  Methods and results: Overexpression of GRK2 led to a Gi-dependent decrease of contractile response to βAR stimulation in cultured mouse cardiomyocytes and in vivo.  Importantly, cardiac-specific transgenic overexpression of a mutant β2AR lacking PKA phosphorylation sites (PKA-TG) but not the wild-type β2AR (WT-TG) or a mutant β2AR lacking GRK sites (GRK-TG) led to exaggerated cardiac response to pressure overload, as manifested by markedly exacerbated cardiac maladaptive remodeling and failure and early mortality.  Furthermore, inhibition of Gi signaling with pertussis toxin restores cardiac function in heart failure assocd. with increased β2AR to Gi coupling induced by removing PKA phosphorylation of the receptor and in GRK2 transgenic mice, indicating that enhanced phosphorylation of β2AR by GRK and resultant increase in Gi-biased β2AR signaling play an important role in the development of heart failure.  Conclusions: Our data show that enhanced β2AR phosphorylation by GRK, in addn. to PKA, leads the receptor to Gi-biased signaling, which, in turn, contributes to the pathogenesis of heart failure, marking Gi-biased β2AR signaling as a primary event linking upregulation of GRK to cardiac maladaptive remodeling, failure and cardiodepression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT_CPZMWFFe7Vg90H21EOLACvtfcHk0lj6Esxc9KjEHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVKrtrs%253D&md5=570f8da9fdfe282caa762dc79946f5c9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.111.253260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.111.253260%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DPetrashevskaya%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DA.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DChuprun%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTalan%26aufirst%3DM.%26aulast%3DDorn%26aufirst%3DG.%2BW.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DFeldman%26aufirst%3DA.%2BM.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DGi%2520biased%2520%25CE%25B22AR%2520signaling%2520links%2520GRK2%2520upregulation%2520to%2520heart%2520failure%26jtitle%3DCirc.%2520Res.%26date%3D2012%26volume%3D110%26spage%3D265%26epage%3D274%26doi%3D10.1161%2FCIRCRESAHA.111.253260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohout, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Targeting of cyclic AMP degradation to beta2-adrenergic receptors by beta-arrestins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1126/science.1074683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.1074683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12399592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFSntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=834-836&author=S.+J.+Perryauthor=G.+S.+Baillieauthor=T.+A.+Kohoutauthor=I.+McPheeauthor=M.+M.+Magieraauthor=K.+L.+Angauthor=W.+E.+Millerauthor=A.+J.+McLeanauthor=M.+Contiauthor=M.+D.+Houslayauthor=R.+J.+Lefkowitz&title=Targeting+of+cyclic+AMP+degradation+to+beta2-adrenergic+receptors+by+beta-arrestins&doi=10.1126%2Fscience.1074683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of cAMP degrdn. to β2-adrenergic receptors by β-arrestins</span></div><div class="casAuthors">Perry, Stephen J.; Baillie, George S.; Kohout, Trudy A.; McPhee, Ian; Magiera, Maria M.; Ang, Kok Long; Miller, William E.; McLean, Alison J.; Conti, Marco; Houslay, Miles D.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5594</span>),
    <span class="NLM_cas:pages">834-836</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Catecholamines signal through the β2-adrenergic receptor by promoting prodn. of the second messenger adenosine 3',5'-monophosphate (cAMP).  The magnitude of this signal is restricted by desensitization of the receptors through their binding to β-arrestins and by cAMP degrdn. by phosphodiesterase (PDE) enzymes.  The authors show that β-arrestins coordinate both processes by recruiting PDEs to activated β2-adrenergic receptors in the plasma membrane of mammalian cells.  In doing so, the β-arrestins limit activation of membrane-assocd. cAMP-activated protein kinase by simultaneously slowing the rate of cAMP prodn. through receptor desensitization and increasing the rate of its degrdn. at the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMGfeCRMNCbVg90H21EOLACvtfcHk0lj6Esxc9KjEHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFSntb0%253D&md5=34809e1b74aafc51dc61273a0ff5d590</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscience.1074683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1074683%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DS.%2BJ.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DKohout%26aufirst%3DT.%2BA.%26aulast%3DMcPhee%26aufirst%3DI.%26aulast%3DMagiera%26aufirst%3DM.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BL.%26aulast%3DMiller%26aufirst%3DW.%2BE.%26aulast%3DMcLean%26aufirst%3DA.%2BJ.%26aulast%3DConti%26aufirst%3DM.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DTargeting%2520of%2520cyclic%2520AMP%2520degradation%2520to%2520beta2-adrenergic%2520receptors%2520by%2520beta-arrestins%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D834%26epage%3D836%26doi%3D10.1126%2Fscience.1074683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gall, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houslay, M. D.</span></span> <span> </span><span class="NLM_article-title">Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">940</span>– <span class="NLM_lpage">945</span>, <span class="refDoi"> DOI: 10.1073/pnas.262787199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.262787199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12552097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtF2gsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=940-945&author=G.+S.+Baillieauthor=A.+Soodauthor=I.+McPheeauthor=I.+Gallauthor=S.+J.+Perryauthor=R.+J.+Lefkowitzauthor=M.+D.+Houslay&title=Beta-arrestin-mediated+PDE4+cAMP+phosphodiesterase+recruitment+regulates+beta-adrenoceptor+switching+from+Gs+to+Gi&doi=10.1073%2Fpnas.262787199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi</span></div><div class="casAuthors">Baillie, George S.; Sood, Arvind; McPhee, Ian; Gall, Irene; Perry, Stephen J.; Lefkowitz, Robert J.; Houslay, Miles D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">940-945</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Phosphorylation of the β2 adrenoreceptor (β2AR) by cAMP-activated protein kinase A (PKA) switches its predominant coupling from stimulatory guanine nucleotide regulatory protein (Gs) to inhibitory guanine nucleotide regulatory protein (Gi).  β-Arrestins recruit the cAMP-degrading PDE4 phosphodiesterases to the β2AR, thus controlling PKA activity at the membrane.  Here we investigate a role for PDE4 recruitment in regulating G protein switching by the β2AR.  In human embryonic kidney 293 cells overexpressing a recombinant β2AR, stimulation with isoprenaline recruits β-arrestins 1 and 2 as well as both PDE4D3 and PDE4D5 to the receptor and stimulates receptor phosphorylation by PKA.  The PKA phosphorylation status of the β2AR is enhanced markedly when cells are treated with the selective PDE4-inhibitor rolipram or when they are transfected with a catalytically inactive PDE4D mutant (PDE4D5-D556A) that competitively inhibits isoprenaline-stimulated recruitment of native PDE4 to the β2AR.  Rolipram and PDE4D5-D556A also enhance β2AR-mediated activation of extra-cellular signal-regulated kinases ERK1/2.  This is consistent with a switch in coupling of the receptor from Gs to Gi, because the ERK1/2 activation is sensitive to both inhibitors of PKA (H89) and Gi (pertussis toxin).  In cardiac myocytes, the β2AR also switches from Gs to Gi coupling.  Treating primary cardiac myocytes with isoprenaline induces recruitment of PDE4D3 and PDE4D5 to membranes and activates ERK1/2.  Rolipram robustly enhances this activation in a manner sensitive to both pertussis toxin and H89.  Adenovirus-mediated expression of PDE4D5-D556A also potentiates ERK1/2 activation.  Thus, receptor-stimulated β-arrestin-mediated recruitment of PDE4 plays a central role in the regulation of G protein switching by the β2AR in a physiol. system, the cardiac myocyte.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5wepztukiHbVg90H21EOLACvtfcHk0lh9DomZyEMQpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtF2gsLw%253D&md5=8bf5e4d9731ea7f1ad8347ae34fb249b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.262787199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.262787199%26sid%3Dliteratum%253Aachs%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DMcPhee%26aufirst%3DI.%26aulast%3DGall%26aufirst%3DI.%26aulast%3DPerry%26aufirst%3DS.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26atitle%3DBeta-arrestin-mediated%2520PDE4%2520cAMP%2520phosphodiesterase%2520recruitment%2520regulates%2520beta-adrenoceptor%2520switching%2520from%2520Gs%2520to%2520Gi%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D940%26epage%3D945%26doi%3D10.1073%2Fpnas.262787199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richter, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruss, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fsj.emboj.7601968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18188154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=384-893&author=W.+Richterauthor=P.+Dayauthor=R.+Agrawalauthor=M.+D.+Brussauthor=S.+Granierauthor=Y.+L.+Wangauthor=S.+G.+Rasmussenauthor=K.+Hornerauthor=P.+Wangauthor=T.+Leiauthor=A.+J.+Pattersonauthor=B.+Kobilkaauthor=M.+Conti&title=Signaling+from+beta1-+and+beta2-adrenergic+receptors+is+defined+by+differential+interactions+with+PDE4&doi=10.1038%2Fsj.emboj.7601968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Signaling from β1- and β2-adrenergic receptors is defined by differential interactions with PDE4</span></div><div class="casAuthors">Richter, Wito; Day, Peter; Agrawal, Rani; Bruss, Matthew D.; Granier, Sebastien; Wang, Yvonne L.; Rasmussen, Soren G. F.; Horner, Kathleen; Wang, Ping; Lei, Tao; Patterson, Andrew J.; Kobilka, Brian; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">384-393</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">β1- And β2-adrenergic receptors (βARs) are highly homologous, yet they play clearly distinct roles in cardiac physiol. and pathol.  Myocyte contraction, for instance, is readily stimulated by β1AR but not β2AR signaling, and chronic stimulation of the two receptors has opposing effects on myocyte apoptosis and cell survival.  Differences in the assembly of macromol. signaling complexes may explain the distinct biol. outcomes.  Here, we demonstrate that β1AR forms a signaling complex with a cAMP-specific phosphodiesterase (PDE) in a manner inherently different from a β2AR/β-arrestin/PDE complex reported previously.  The β1AR binds a PDE variant, PDE4D8, in a direct manner, and occupancy of the receptor by an agonist causes dissocn. of this complex.  Conversely, agonist binding to the β2AR is a prerequisite for the recruitment of a complex consisting of β-arrestin and the PDE4D variant, PDE4D5, to the receptor.  We propose that the distinct modes of interaction with PDEs result in divergent cAMP signals in the vicinity of the two receptors, thus, providing an addnl. layer of complexity to enforce the specificity of β1- and β2-adrenoceptor signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxpTjxgBWAd7Vg90H21EOLACvtfcHk0lh9DomZyEMQpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKktb4%253D&md5=c50e0f4a704c4fe10b1b59a82fc23c6d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601968%26sid%3Dliteratum%253Aachs%26aulast%3DRichter%26aufirst%3DW.%26aulast%3DDay%26aufirst%3DP.%26aulast%3DAgrawal%26aufirst%3DR.%26aulast%3DBruss%26aufirst%3DM.%2BD.%26aulast%3DGranier%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BL.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DHorner%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLei%26aufirst%3DT.%26aulast%3DPatterson%26aufirst%3DA.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DSignaling%2520from%2520beta1-%2520and%2520beta2-adrenergic%2520receptors%2520is%2520defined%2520by%2520differential%2520interactions%2520with%2520PDE4%26jtitle%3DEMBO%2520J.%26date%3D2008%26volume%3D27%26spage%3D384%26epage%3D893%26doi%3D10.1038%2Fsj.emboj.7601968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, P. H.</span></span> <span> </span><span class="NLM_article-title">Resistance of the human beta1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining beta-subtype degradation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">39773</span>– <span class="NLM_lpage">39781</span>, <span class="refDoi"> DOI: 10.1074/jbc.M304482200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M304482200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12888573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvFanu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=39773-39781&author=W.+Liangauthor=S.+Austinauthor=Q.+Hoangauthor=P.+H.+Fishman&title=Resistance+of+the+human+beta1-adrenergic+receptor+to+agonist-mediated+down-regulation.+Role+of+the+C+terminus+in+determining+beta-subtype+degradation&doi=10.1074%2Fjbc.M304482200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance of the human β1-adrenergic receptor to agonist-mediated down-regulation: Role of the C terminus in determining β-subtype degradation</span></div><div class="casAuthors">Liang, Wei; Austin, Steven; Hoang, Quang; Fishman, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">39773-39781</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Prolonged agonist stimulation results in down-regulation of most G protein-coupled receptors.  When the authors exposed baby hamster kidney cells stably expressing the human β1-adrenergic receptor (β1AR) to agonist over a 24-h period, they instead obsd. an increase of ∼30% in both β1AR binding activity and immune-detected receptors.  In contrast, β2AR expressed in these cells exhibited a decrease of ≥ 50%.  The authors detd. that the basal turnover rates of the two subtypes were similar (t1/2 ∼ 7 h) and that agonist stimulation increased β2AR but not β1AR turnover.  Blocking receptor trafficking to lysosomes with bafilomycin A1 had no effect on basal turnover of either subtype but blocked agonist-stimulated β2AR turnover.  As β1AR mRNA levels increased in agonist-stimulated cells, β1AR up-regulation appeared to result from increased synthesis with no change in degrdn.  To explore the basis for the subtype differences, the authors expressed chimeras in which the C termini had been exchanged.  Each chimera responded to persistent agonist stimulation based on the source of its C-tail; β1AR with a β2AR C-tail underwent down-regulation, and β2AR with a β1AR C-tail underwent up-regulation.  The C-tails had a corresponding effect on agonist-stimulated receptor phosphorylation and internalization with the order being β2AR > β1AR with β2AR C-tail > β2AR with a β1AR C-tail > β1AR.  As internalization may be a prerequisite for down-regulation, the authors addressed this possibility by co-expressing each subtype with arrestin-2.  Although β1AR internalization was increased to that of β2AR, down-regulation still did not occur.  Instead, β1AR accumulated inside the cells.  The authors conclude that in unstimulated cells, both subtypes appear to be turned over by the same mechanism.  Upon agonist stimulation, both subtypes are internalized, and β2AR but not β1AR undergoes lysosomal degrdn., the fate of each subtype being regulated by determinants in its C-tail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsq7OWI1bLLVg90H21EOLACvtfcHk0lh9DomZyEMQpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvFanu7w%253D&md5=a85ad3e790fd9d9e012c040013780208</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M304482200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M304482200%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DAustin%26aufirst%3DS.%26aulast%3DHoang%26aufirst%3DQ.%26aulast%3DFishman%26aufirst%3DP.%2BH.%26atitle%3DResistance%2520of%2520the%2520human%2520beta1-adrenergic%2520receptor%2520to%2520agonist-mediated%2520down-regulation.%2520Role%2520of%2520the%2520C%2520terminus%2520in%2520determining%2520beta-subtype%2520degradation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D39773%26epage%3D39781%26doi%3D10.1074%2Fjbc.M304482200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liggett, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drachman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">17953</span>– <span class="NLM_lpage">17961</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.30.17953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.270.30.17953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7629102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2MXnt1Crurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=17953-17961&author=N.+J.+Freedmanauthor=S.+B.+Liggettauthor=D.+E.+Drachmanauthor=G.+Peiauthor=M.+G.+Caronauthor=R.+J.+Lefkowitz&title=Phosphorylation+and+desensitization+of+the+human+beta+1-adrenergic+receptor.+Involvement+of+G+protein-coupled+receptor+kinases+and+cAMP-dependent+protein+kinase&doi=10.1074%2Fjbc.270.30.17953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and desensitization of the human β1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase</span></div><div class="casAuthors">Freedman, Neil J.; Liggett, Stephen B.; Drachman, Douglas E.; Pei, Gang; Caron, Marc G.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">17953-61</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Persistent stimulation of the β1-adrenergic receptor (β1AR) engenders, within minutes, diminished responsiveness of the β1AR/adenylyl cyclase signal transduction system.  This desensitization remains incompletely defined mechanistically, however.  We therefore tested the hypothesis that agonist-induced desensitization of the B1AR (like that of the related β2AR) involves phosphorylation of the receptor itself, by cAMP-dependent protein kinase (PKA) and the β-adrenergic receptor kinase (βARK1) or other G protein-coupled receptor kinases (GRKs).  Both Chinese hamster fibroblast and 293 cells demonstrate receptor-specific desensitization of the β1AR within 3-5 min.  Both cell types also express βARK1 and the assocd. inhibitory proteins β-arrestin-1 and β-arrestin-2, as assessed by immunoblotting.  Agonist-induced β1AR desensitization in 293 cells correlates with a 2-fold increase in phosphorylation of the β1AR, detd. by immunopptn. of the β1 AR from cells metabolically labeled with 32Pi.  This agonist-induced β1AR phosphorylation derives approx. equally from PKA and GRK activity, as judged by intact cell studies with kinase inhibitors or dominant neg. βARK1 (K220R) mutant overexpression.  Desensitization, likewise, is reduced by only ∼50% when PKA is inhibited in the intact cells.  Overexpression of rhodopsin kinase, βARK1, βARK2, or GRK5 significantly increases agonist-induced β1AR phosphorylation and concomitantly decreases agonist-stimulated cellular cAMP prodn.  Furthermore, purified βARK1, βARK2, and GRK5 all demonstrate agonist-dependent phosphorylation of the β1AR.  Consistent with a GRK mechanism, receptor-specific desensitization of the β1AR was enhanced by overexpression of β-arrestin-1 and -2 in transfected 293 cells.  We conclude that rapid agonist-induced desensitization of the β1AR involves phosphorylation of the receptor by both PKA and at least βARK1 in intact cells.  Like the β2AR, the β1AR appears to bind either β-arrestin-1 or β-arrestin-2 and to react with rhodopsin kinase, βARK1, βARK2, and GRK5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj1459EiottrVg90H21EOLACvtfcHk0lgr5Ov3igeqJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnt1Crurg%253D&md5=8f390b45b77d1e1fb8ce817a53e38da1</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.30.17953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.30.17953%26sid%3Dliteratum%253Aachs%26aulast%3DFreedman%26aufirst%3DN.%2BJ.%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26aulast%3DDrachman%26aufirst%3DD.%2BE.%26aulast%3DPei%26aufirst%3DG.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DPhosphorylation%2520and%2520desensitization%2520of%2520the%2520human%2520beta%25201-adrenergic%2520receptor.%2520Involvement%2520of%2520G%2520protein-coupled%2520receptor%2520kinases%2520and%2520cAMP-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D17953%26epage%3D17961%26doi%3D10.1074%2Fjbc.270.30.17953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rapacciuolo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvarna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barki-Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttrell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">35403</span>– <span class="NLM_lpage">35411</span>, <span class="refDoi"> DOI: 10.1074/jbc.M305675200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M305675200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12821660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXntVWqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=35403-35411&author=A.+Rapacciuoloauthor=S.+Suvarnaauthor=L.+Barki-Harringtonauthor=L.+M.+Luttrellauthor=M.+Congauthor=R.+J.+Lefkowitzauthor=H.+A.+Rockman&title=Protein+kinase+A+and+G+protein-coupled+receptor+kinase+phosphorylation+mediates+beta-1+adrenergic+receptor+endocytosis+through+different+pathways&doi=10.1074%2Fjbc.M305675200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates β-1 adrenergic receptor endocytosis through different pathways</span></div><div class="casAuthors">Rapacciuolo, Antonio; Suvarna, Shayela; Barki-Harrington, Liza; Luttrell, Louis M.; Cong, Mei; Lefkowitz, Robert J.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">35403-35411</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Agonist-induced phosphorylation of β-adrenergic receptors (βARs) by G protein-coupled receptor kinases (GRKs) results in their desensitization followed by internalization.  Whether protein kinase A (PKA)-mediated phosphorylation of βARs, particularly the β1AR subtype, can also trigger internalization is currently not known.  To test this, the authors cloned the mouse wild type β1AR (WTβ1AR) and created 3 mutants lacking, resp.: the putative PKA phosphorylation sites (PKA-β1AR), the putative GRK phosphorylation sites (GRK-β1AR), and both sets of phosphorylation sites (PKA-/GRK-β1AR).  Following agonist stimulation, both PKA-β1AR and GRK-β1AR mutants showed comparable increases in phosphorylation and desensitization.  Satg. concns. of agonist induced only 50% internalization of either mutant compared with wild type, suggesting that both PKA and GRK phosphorylation of the receptor contributed to receptor sequestration in an additive manner.  Moreover, in contrast to the WTβ1AR and PKA-β1AR, sequestration of the GRK-β1AR and PKA-/GRK-β1AR was independent of β-arrestin recruitment.  Importantly, clathrin inhibitors abolished agonist-dependent internalization for both the WTβ1AR and PKA-β1AR, whereas caveolae inhibitors prevented internalization only of the GRK-β1AR mutant.  Taken together, these data demonstrate that: PKA-mediated phosphorylation can trigger agonist-induced internalization of the β1AR and the pathway selected for β1AR internalization is primarily detd. by the kinase that phosphorylates the receptor, i.e.  PKA-mediated phosphorylation directs internalization via a caveolae pathway, whereas GRK-mediated phosphorylation directs it through clathrin-coated pits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRTtzcaLnd-bVg90H21EOLACvtfcHk0lgr5Ov3igeqJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXntVWqu7g%253D&md5=a1fb1e26c97da8e4358cd22cc6141c74</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M305675200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M305675200%26sid%3Dliteratum%253Aachs%26aulast%3DRapacciuolo%26aufirst%3DA.%26aulast%3DSuvarna%26aufirst%3DS.%26aulast%3DBarki-Harrington%26aufirst%3DL.%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3DProtein%2520kinase%2520A%2520and%2520G%2520protein-coupled%2520receptor%2520kinase%2520phosphorylation%2520mediates%2520beta-1%2520adrenergic%2520receptor%2520endocytosis%2520through%2520different%2520pathways%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D35403%26epage%3D35411%26doi%3D10.1074%2Fjbc.M305675200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minobe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, R.</span></span> <span> </span><span class="NLM_article-title">β<sub>1</sub>- and β<sub>2</sub>-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=2564629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL1MXhslWisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1989&pages=295-303&author=M.+R.+Bristowauthor=R.+E.+Hershbergerauthor=J.+D.+Portauthor=W.+Minobeauthor=R.+Rasmussen&title=%CE%B21-+and+%CE%B22-adrenergic+receptor-mediated+adenylate+cyclase+stimulation+in+nonfailing+and+failing+human+ventricular+myocardium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">β1- and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium</span></div><div class="casAuthors">Bristow, Michael R.; Hershberger, Ray E.; Port, J. David; Minobe, Wayne; Rasmussen, Randy</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">295-303</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">In nonfailing human ventricular myocardium, β2-adrenergic receptors are coupled markedly more efficiently to adenylate cyclase than are β1-receptors.  Heart failure produces a loss in the amt. of adenylate cyclase stimulation than can be mediated by each subtype.  For β1-receptors, this is due to down-regulation and, for β2-receptors, the loss in activity is due to partial uncoupling.  In the human heart β1- and β2-receptors exhibit at least two fundamental differences; the β1-receptor selectively down-regulates in heart failure, whereas the β2-receptor is markedly more efficiently coupled to adenylate cyclase in nonfailing heart and then uncouples in response to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkC43CFuXZP7Vg90H21EOLACvtfcHk0lgr5Ov3igeqJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhslWisLw%253D&md5=13cc2cd664abbc24ce5e4a1aafd7ff5e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DM.%2BR.%26aulast%3DHershberger%26aufirst%3DR.%2BE.%26aulast%3DPort%26aufirst%3DJ.%2BD.%26aulast%3DMinobe%26aufirst%3DW.%26aulast%3DRasmussen%26aufirst%3DR.%26atitle%3D%25CE%25B21-%2520and%2520%25CE%25B22-adrenergic%2520receptor-mediated%2520adenylate%2520cyclase%2520stimulation%2520in%2520nonfailing%2520and%2520failing%2520human%2520ventricular%2520myocardium%26jtitle%3DMol.%2520Pharmacol.%26date%3D1989%26volume%3D35%26spage%3D295%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cates, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veazey, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baughman, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgartner, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dop, C.</span></span> <span> </span><span class="NLM_article-title">Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1172/JCI113569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI113569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=2839545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL1cXkvFSlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1988&pages=189-197&author=A.+M.+Feldmanauthor=A.+E.+Catesauthor=W.+B.+Veazeyauthor=R.+E.+Hershbergerauthor=M.+R.+Bristowauthor=K.+L.+Baughmanauthor=W.+A.+Baumgartnerauthor=C.+Van+Dop&title=Increase+of+the+40%2C000-mol+wt+pertussis+toxin+substrate+%28G+protein%29+in+the+failing+human+heart&doi=10.1172%2FJCI113569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart</span></div><div class="casAuthors">Feldman, Arthur M.; Cates, Andree E.; Veazey, William B.; Hershberger, Ray; Bristow, Michael R.; Baughman, Kenneth L.; Baumgartner, William A.; Van Dop, Cornelis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-97</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">The activity of G proteins in failing human myocardium was measured.  The activity of a 40,000-mol wt pertussis toxin substrate (αG40) was increased by 36% in failing human hearts when compared with nonfailing controls.  There was no change in the level of the stimulatory regulatory subunit (Gs).  The increased activity in αG40 was assocd. with a 30% decrease in basal as well as 5'-guanylyl imidodiphosphate-stimulated adenylate cyclase activity.  The data suggest that increased αG40 activity is a new marker for failing myocardium and may account at least in part for the diminished responsiveness to β1-adrenergic agonists in the failing human heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocqubbOBjAebVg90H21EOLACvtfcHk0lgBtpq9cxFbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXkvFSlsLs%253D&md5=eecfdd5f4654425dd033201f5d7ed8c7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1172%2FJCI113569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI113569%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DA.%2BM.%26aulast%3DCates%26aufirst%3DA.%2BE.%26aulast%3DVeazey%26aufirst%3DW.%2BB.%26aulast%3DHershberger%26aufirst%3DR.%2BE.%26aulast%3DBristow%26aufirst%3DM.%2BR.%26aulast%3DBaughman%26aufirst%3DK.%2BL.%26aulast%3DBaumgartner%26aufirst%3DW.%2BA.%26aulast%3DVan%2BDop%26aufirst%3DC.%26atitle%3DIncrease%2520of%2520the%252040%252C000-mol%2520wt%2520pertussis%2520toxin%2520substrate%2520%2528G%2520protein%2529%2520in%2520the%2520failing%2520human%2520heart%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1988%26volume%3D82%26spage%3D189%26epage%3D197%26doi%3D10.1172%2FJCI113569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ungerer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elce, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span> <span> </span><span class="NLM_article-title">Altered expression of β-adrenergic receptor kinase and β<sub>1</sub>-adrenergic receptors in the failing human heart</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.87.2.454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.87.2.454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8381058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK3s7ksFCmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1993&pages=454-463&author=M.+Ungererauthor=M.+Bohmauthor=J.+S.+Elceauthor=E.+Erdmannauthor=M.+J.+Lohse&title=Altered+expression+of+%CE%B2-adrenergic+receptor+kinase+and+%CE%B21-adrenergic+receptors+in+the+failing+human+heart&doi=10.1161%2F01.CIR.87.2.454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart</span></div><div class="casAuthors">Ungerer M; Bohm M; Elce J S; Erdmann E; Lohse M J</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">454-63</span>
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    </div><div class="casAbstract">BACKGROUND:  In chronic heart failure, the positive inotropic effects of beta-adrenergic receptor agonists are greatly reduced, in part as a result of two alterations of the cardiac beta-adrenergic receptors: loss of their function (receptor uncoupling) and reduction of their number (downregulation).  In vitro studies have shown that a major mechanism leading to beta-adrenergic receptor uncoupling involves phosphorylation of the receptors by the specific beta-adrenergic receptor kinase (beta ARK).  METHODS AND RESULTS:  We have therefore investigated expression of beta ARK and beta-adrenergic receptors in samples from the left ventricles of patients with dilated cardiomyopathy or ischemic cardiomyopathy and from nonfailing control ventricles.  Contractile responses to beta-receptor stimulation were decreased in the failing hearts compared with control hearts, whereas those to forskolin and calcium remained unchanged.  The messenger RNA (mRNA) levels of beta ARK, beta 1- and beta 2-receptors, and of glyceraldehyde phosphate dehydrogenase and beta-actin as controls were measured by quantitative polymerase chain reactions.  In addition, beta ARK enzyme activity assays were performed, and the levels of beta 1- and beta 2-receptors were determined by radioligand binding. beta ARK mRNA levels were increased almost threefold in both forms of heart failure, and beta ARK activity was enhanced. beta 1-Receptor mRNA levels and beta 1-receptor numbers were decreased by approximately 50% in both failing groups, whereas these levels were unaltered for beta 2-receptors.  There were no differences between dilated and ischemic cardiomyopathy for any of these parameters.  CONCLUSIONS:  In addition to other alterations found in failing hearts, the diminished response to beta-receptor agonists appears to involve the combined effects of enhanced expression of beta ARK and reduced expression of beta 1-receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi9-nzhE6nCOdfST00W0BcfW6udTcc2eYbax_O7Dt26rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7ksFCmug%253D%253D&md5=7e9bc7e5bc550d8cdf25096888552fb2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.87.2.454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.87.2.454%26sid%3Dliteratum%253Aachs%26aulast%3DUngerer%26aufirst%3DM.%26aulast%3DBohm%26aufirst%3DM.%26aulast%3DElce%26aufirst%3DJ.%2BS.%26aulast%3DErdmann%26aufirst%3DE.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26atitle%3DAltered%2520expression%2520of%2520%25CE%25B2-adrenergic%2520receptor%2520kinase%2520and%2520%25CE%25B21-adrenergic%2520receptors%2520in%2520the%2520failing%2520human%2520heart%26jtitle%3DCirculation%26date%3D1993%26volume%3D87%26spage%3D454%26epage%3D463%26doi%3D10.1161%2F01.CIR.87.2.454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span> <span> </span><span class="NLM_article-title">The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1992.tb14302.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.1992.tb14302.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1324064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK38XktVGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=1992&pages=115-122&author=L.+A.+Brownauthor=S.+E.+Harding&title=The+effect+of+pertussis+toxin+on+%CE%B2-adrenoceptor+responses+in+isolated+cardiac+myocytes+from+noradrenaline-treated+guinea-pigs+and+patients+with+cardiac+failure&doi=10.1111%2Fj.1476-5381.1992.tb14302.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea pigs and patients with cardiac failure</span></div><div class="casAuthors">Brown, L. A.; Harding, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-22</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">A decreased responsiveness to the pos. inotropic effects of β-adrenoceptor agonists is a characteristic of human heart failure.  This study investigated the involvement of inhibitory guanine nucleotide- binding proteins (G-proteins) in this process using pertussis toxin treatment of isolated cardiac myocytes.  Myocytes isolated from failing human myocardium had a reduced max. contractile response to isoprenaline relative to that for maximally stimulating concns. of calcium, giving an isoprenaline/calcium ratio of 0.71.  This was lower than in myocytes from nonfailing myocardium, where the isoprenaline/calcium ratio was 1.16.  Responses to high calcium were unchanged.  Myocytes were treated with pertussis toxin for 3-5 h at 35°.  Successful inactivation of inhibitory G-proteins by pertussis toxin treatment was indicated by a loss of responsiveness to 10 μM adenosine (in the presence of submaximal isoprenaline).  Following pertussis toxin treatment of the myocytes from failing human heart the isoprenaline/calcium ratio increased to 1.43.  Pertussis toxin treatment had no effect upon the max. calcium contraction.  The isoprenaline/calcium ration in myocytes from non-failing human ventricle was not affected by the toxin treatment.  Apparently, increased inhibitory G-protein levels or activities contribute to β-adrenoceptor desensitization in human heart failure.  β-Adrenoceptor desensitization in human heart failure is thought to be secondary to raised noradrenaline levels in these patients.  Expts. were repeated on myocytes isolated from hearts of guinea-pigs which had been chronically infused with noradrenaline.  The isoprenaline/calcium ratio of these myocytes was reduced below that of myocytes from sham-operated animals (0.65 compared with 0.88).  Pertussis toxin treatment (2 h at 35°) increased the isoprenaline/calcium ratio to 1.02 in myocytes from noradrenaline-treated guinea-pigs.  This effect of pertussis toxin treatment was not seen in myocytes from sham-operated guinea pig hearts.  Incubation at 35° for similar periods in the absence of pertussis toxin also restored the isoprenaline/calcium ratio towards normal in the myocytes from both failing human and noradrenaline-treated guinea-pig hearts, although the effect was smaller than that produced by the toxin.  Myocytes kept at room temp. (22°) showed no such evidence of resensitization over periods up to 6 h.  Apparently, raised catecholamine levels result in increased inhibitory G-protein levels and functional β-adrenoceptor desensitization in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUR6C2OOHMy7Vg90H21EOLACvtfcHk0lgBtpq9cxFbLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XktVGgsL0%253D&md5=ae3dc9b55d58fbbe7d4140152f3e8676</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1992.tb14302.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1992.tb14302.x%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DL.%2BA.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26atitle%3DThe%2520effect%2520of%2520pertussis%2520toxin%2520on%2520%25CE%25B2-adrenoceptor%2520responses%2520in%2520isolated%2520cardiac%2520myocytes%2520from%2520noradrenaline-treated%2520guinea-pigs%2520and%2520patients%2520with%2520cardiac%2520failure%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1992%26volume%3D106%26spage%3D115%26epage%3D122%26doi%3D10.1111%2Fj.1476-5381.1992.tb14302.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iaccarino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span> <span> </span><span class="NLM_article-title">Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">7000</span>– <span class="NLM_lpage">7005</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.12.7000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.95.12.7000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9618528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1cXjslyms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=7000-7005&author=H.+A.+Rockmanauthor=K.+R.+Chienauthor=D.+J.+Choiauthor=G.+Iaccarinoauthor=J.+J.+Hunterauthor=J.+Rossauthor=R.+J.+Lefkowitzauthor=W.+J.+Koch&title=Expression+of+a+beta-adrenergic+receptor+kinase+1+inhibitor+prevents+the+development+of+myocardial+failure+in+gene-targeted+mice&doi=10.1073%2Fpnas.95.12.7000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice</span></div><div class="casAuthors">Rockman, Howard A.; Chien, Kenneth R.; Choi, Dong-Ju; Iaccarino, Guido; Hunter, John J.; Ross, John, Jr.; Lefkowitz, Robert J.; Koch, Walter J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7000-7005</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Heart failure is accompanied by severely impaired β-adrenergic receptor (βAR) function, which includes loss of βAR d. and functional uncoupling of remaining receptors.  An important mechanism for the rapid desensitization of βAR function is agonist-stimulated receptor phosphorylation by the βAR kinase (βARK1), an enzyme known to be elevated in failing human heart tissue.  To investigate whether alterations in βAR function contribute to the development of myocardial failure, transgenic mice with cardiac-restricted overexpression of either a peptide inhibitor of βARK1 or the β2AR were mated into a genetic model of murine heart failure (MLP-/-).  In vivo cardiac function was assessed by echocardiog. and cardiac catheterization.  Both MLP-/- and MLP-/-/β2AR mice had enlarged left ventricular (LV) chambers with significantly reduced fractional shortening and mean velocity of circumferential fiber shortening.  In contrast, MLP-/-/βARKct mice had normal LV chamber size and function.  Basal LV contractility in the MLP-/-/βARKct mice, as measured by LV dP/dtmax, was increased significantly compared with the MLP-/- mice but less than controls.  Importantly, heightened βAR desensitization in the MLP-/- mice, measured in vivo (responsiveness to isoproterenol) and in vitro (isoproterenol-stimulated membrane adenylyl cyclase activity), was completely reversed with overexpression of the βARK1 inhibitor.  The authors report here the striking finding that overexpression of this inhibitor prevents the development of cardiomyopathy in this murine model of heart failure.  These findings implicate abnormal βAR-G protein coupling in the pathogenesis of the failing heart and point the way toward development of agents to inhibit βARK1 as a novel mode of therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb_NLvvRJwjbVg90H21EOLACvtfcHk0lizDSAIdPp-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjslyms7Y%253D&md5=a456743770d269ba225b206c7657fb6a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.12.7000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.12.7000%26sid%3Dliteratum%253Aachs%26aulast%3DRockman%26aufirst%3DH.%2BA.%26aulast%3DChien%26aufirst%3DK.%2BR.%26aulast%3DChoi%26aufirst%3DD.%2BJ.%26aulast%3DIaccarino%26aufirst%3DG.%26aulast%3DHunter%26aufirst%3DJ.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26atitle%3DExpression%2520of%2520a%2520beta-adrenergic%2520receptor%2520kinase%25201%2520inhibitor%2520prevents%2520the%2520development%2520of%2520myocardial%2520failure%2520in%2520gene-targeted%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D7000%26epage%3D7005%26doi%3D10.1073%2Fpnas.95.12.7000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kompa, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R. J.</span></span> <span> </span><span class="NLM_article-title">Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1006/jmcc.1999.0951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1006%2Fjmcc.1999.0951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10371694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXjslOqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1999&pages=1185-1201&author=A.+R.+Kompaauthor=X.+H.+Guauthor=B.+A.+Evansauthor=R.+J.+Summers&title=Desensitization+of+cardiac+beta-adrenoceptor+signaling+with+heart+failure+produced+by+myocardial+infarction+in+the+rat.+Evidence+for+the+role+of+Gi+but+not+Gs+or+phosphorylating+proteins&doi=10.1006%2Fjmcc.1999.0951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Desensitization of cardiac β-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins</span></div><div class="casAuthors">Kompa, Andrew R.; Gu, Xin-hua; Evans, Bronwyn A.; Summers, Roger J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1185-1201</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">This study examd. mechanisms of β-adrenergic (AR) desensitization in a myocardial infarction (MI) model of heart failure in the rat.  Inotropic responses to isoproterenol (non-selective β-AR agonist) and RO 363 (selective β1-AR agonist), in left atria and left papillary muscle, were reduced by up to 65%, while chronotropic responses in right atria were unaffected.  β1- And β2-AR d. did not change after MI, suggesting that changes in β-AR responsiveness are due to changes occurring downstream of the receptor.  Inotropic and chronotropic responses to forskolin were not altered in right and left atria and left papillary muscle after MI, suggesting changes at the level of the G-proteins.  Pertussis toxin treatment of animals restored inotropic responses to isoproterenol in left atria and left papillary muscle to levels seen in the sham group, indicating that inactivation of Gi-proteins improves inotropic function in MI rats, and that β-ARs couple to Gi in cardiac failure.  Expression of G-protein receptor kinase 2 (GRK2), β-arrestin1 and the regulatory subunits of cAMPdPK (RI α and RII α), showed no change after MI.  However the expression of Gi α2was significantly increased in left ventricle (sham 0.888±0.140, MI 1.759±0.352 P=0.026), right ventricle (sham 0.031±0.004, MI 0.037±0.002 P=0.006) and atria (sham 0.107±0.006, MI 0.138±0.006 P=0.004), with no changes obsd. in the expression of Gs α .  These results suggest that increases in Gi play an important role in the decreased β-AR responsiveness in the rat model of MI.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRgQ-z4ZIZTrVg90H21EOLACvtfcHk0lizDSAIdPp-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslOqtbg%253D&md5=3bdf4c9c7e8e50c16c1bda441148c139</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1006%2Fjmcc.1999.0951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmcc.1999.0951%26sid%3Dliteratum%253Aachs%26aulast%3DKompa%26aufirst%3DA.%2BR.%26aulast%3DGu%26aufirst%3DX.%2BH.%26aulast%3DEvans%26aufirst%3DB.%2BA.%26aulast%3DSummers%26aufirst%3DR.%2BJ.%26atitle%3DDesensitization%2520of%2520cardiac%2520beta-adrenoceptor%2520signaling%2520with%2520heart%2520failure%2520produced%2520by%2520myocardial%2520infarction%2520in%2520the%2520rat.%2520Evidence%2520for%2520the%2520role%2520of%2520Gi%2520but%2520not%2520Gs%2520or%2520phosphorylating%2520proteins%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D1999%26volume%3D31%26spage%3D1185%26epage%3D1201%26doi%3D10.1006%2Fjmcc.1999.0951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balijepalli, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haworth, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamp, T. J.</span></span> <span> </span><span class="NLM_article-title">Crosstalk of beta-adrenergic receptor subtypes through Gi blunts beta-adrenergic stimulation of L-type Ca<sup>2+</sup> channels in canine heart failure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000181160.31851.05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000181160.31851.05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16100050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFGrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=566-573&author=J.+Q.+Heauthor=R.+C.+Balijepalliauthor=R.+A.+Haworthauthor=T.+J.+Kamp&title=Crosstalk+of+beta-adrenergic+receptor+subtypes+through+Gi+blunts+beta-adrenergic+stimulation+of+L-type+Ca2%2B+channels+in+canine+heart+failure&doi=10.1161%2F01.RES.0000181160.31851.05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalk of β-Adrenergic receptor subtypes through Gi blunts β-Adrenergic stimulation of L-Type Ca2+ Channels in canine heart failure</span></div><div class="casAuthors">He, Jia-Qiang; Balijepalli, Ravi C.; Haworth, Robert A.; Kamp, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">566-573</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The mechanisms underlying the blunted contractile response to β-adrenergic receptor (β-AR) stimulation in heart failure (HF) are incompletely understood, esp. with regard to β-AR subtype-specific regulation of L-type Ca2+ channels.  We evaluated the impact of HF induced by pacing tachycardia on β-AR regulation of L-type Ca2+ channels in a canine model.  To evaluate changes in the relative subcellular distribution of β-AR subtypes, left ventricular membranes enriched in surface sarcolemma and T-tubular sarcolemma were prepd.  Radioligand binding using [125I]cyanopindolol revealed that HF resulted in a comparable decrease in the d. of β1-ARs in both surface and T-tubule sarcolemma (55±4%, n=7, P<0.001; and 45±10%, n=7, P<0.01, resp.), but no significant change in β2-AR d. was obsd.  Whole-cell patch clamp studies demonstrated a markedly blunted increase in ICa,L in response to satg. concns. of the nonselective β-AR agonist isoproterenol (0.1 μmol/L) in failing myocytes compared with control (129±20%, n=11, vs. 332±35%, n=7; P<0.001).  Expts. testing β1-AR- and β2-AR-selective stimulation showed that the major component of the blunted response to nonselective β-AR stimulation in HF was caused by β2-AR activation, resulting in a pertussis toxin-sensitive, Gi-mediated inhibition of the β1-AR-induced increase in ICa,L.  In conclusion, canine HF results in the following: (1) a uniform redn. in β1-AR d. in surface and T-tubule membrane fractions without a change in β2-AR d.; and (2) the emergence of distinct Gi-coupling to β2-ARs resulting in accentuated antagonism of β1-AR-mediated stimulation of ICa,L.  These results have implications for optimizing the use of β-AR drugs in HF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI1j-jzJnjeLVg90H21EOLACvtfcHk0lg7alLEtLV7gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFGrt7Y%253D&md5=ee0ff7fc69346f0fd5bc3fd74bf7a8f0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000181160.31851.05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000181160.31851.05%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DJ.%2BQ.%26aulast%3DBalijepalli%26aufirst%3DR.%2BC.%26aulast%3DHaworth%26aufirst%3DR.%2BA.%26aulast%3DKamp%26aufirst%3DT.%2BJ.%26atitle%3DCrosstalk%2520of%2520beta-adrenergic%2520receptor%2520subtypes%2520through%2520Gi%2520blunts%2520beta-adrenergic%2520stimulation%2520of%2520L-type%2520Ca2%252B%2520channels%2520in%2520canine%2520heart%2520failure%26jtitle%3DCirc.%2520Res.%26date%3D2005%26volume%3D97%26spage%3D566%26epage%3D573%26doi%3D10.1161%2F01.RES.0000181160.31851.05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Völkers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weidenhammer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Wegner, F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peppel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippe, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinks, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katus, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhart, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Most, P.</span></span> <span> </span><span class="NLM_article-title">The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.110.225201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.110.225201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21106943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FpsVKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=27-39&author=M.+V%C3%B6lkersauthor=C.+Weidenhammerauthor=N.+Herzogauthor=G.+Qiuauthor=K.+Spaichauthor=F.+V.+von+Wegnerauthor=K.+Peppelauthor=O.+J.+M%C3%BCllerauthor=S.+Schinkelauthor=J.+E.+Rabinowitzauthor=H.+J.+Hippeauthor=H.+Brinksauthor=H.+A.+Katusauthor=W.+J.+Kochauthor=A.+D.+Eckhartauthor=O.+Friedrichauthor=P.+Most&title=The+inotropic+peptide+%CE%B2ARKct+improves+%CE%B2AR+responsiveness+in+normal+and+failing+cardiomyocytes+through+G%28%CE%B2%CE%B3%29-mediated+L-type+calcium+current+disinhibition&doi=10.1161%2FCIRCRESAHA.110.225201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition</span></div><div class="casAuthors">Volkers Mirko; Weidenhammer Christian; Herzog Nicole; Qiu Gang; Spaich Kristin; Wegner Frederic V; Peppel Karsten; Muller Oliver J; Schinkel Stefanie; Rabinowitz Joseph E; Hippe Hans-Jorg; Brinks Henriette; Katus Hugo A; Koch Walter J; Eckhart Andrea D; Friedrich Oliver; Most Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Circulation research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  The G(βγ)-sequestering peptide β-adrenergic receptor kinase (βARK)ct derived from the G-protein-coupled receptor kinase (GRK)2 carboxyl terminus has emerged as a promising target for gene-based heart failure therapy.  Enhanced downstream cAMP signaling has been proposed as the underlying mechanism for increased β-adrenergic receptor (βAR) responsiveness.  However, molecular targets mediating improved cardiac contractile performance by βARKct and its impact on G(βγ)-mediated signaling have yet to be fully elucidated.  OBJECTIVE:  We sought to identify G(βγ)-regulated targets and signaling mechanisms conveying βARKct-mediated enhanced βAR responsiveness in normal (NC) and failing (FC) adult rat ventricular cardiomyocytes.  METHODS AND RESULTS:  Assessing viral-based βARKct gene delivery with electrophysiological techniques, analysis of contractile performance, subcellular Ca2(+) handling, and site-specific protein phosphorylation, we demonstrate that βARKct enhances the cardiac L-type Ca2(+) channel (LCC) current (I(Ca)) both in NCs and FCs on βAR stimulation.  Mechanistically, βARKct augments I(Ca) by preventing enhanced inhibitory interaction between the α1-LCC subunit (Cav1.2α) and liberated G(βγ) subunits downstream of activated βARs.  Despite improved βAR contractile responsiveness, βARKct neither increased nor restored cAMP-dependent protein kinase (PKA) and calmodulin-dependent kinase II signaling including unchanged protein kinase (PK)Cε, extracellular signal-regulated kinase (ERK)1/2, Akt, ERK5, and p38 activation both in NCs and FCs.  Accordingly, although βARKct significantly increases I(Ca) and Ca2(+) transients, being susceptible to suppression by recombinant G(βγ) protein and use-dependent LCC blocker, βARKct-expressing cardiomyocytes exhibit equal basal and βAR-stimulated sarcoplasmic reticulum Ca2(+) load, spontaneous diastolic Ca2(+) leakage, and survival rates and were less susceptible to field-stimulated Ca2(+) waves compared with controls.  CONCLUSION:  Our study identifies a G(βγ)-dependent signaling pathway attenuating cardiomyocyte I(Ca) on βAR as molecular target for the G(βγ)-sequestering peptide βARKct.  Targeted interruption of this inhibitory signaling pathway by βARKct confers improved βAR contractile responsiveness through increased I(Ca) without enhancing regular or restoring abnormal cAMP-signaling. βARKct-mediated improvement of I(Ca) rendered cardiomyocytes neither susceptible to βAR-induced damage nor arrhythmogenic sarcoplasmic reticulum Ca2(+) leakage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTejQxlDjErVXp3bfzSLaX5fW6udTcc2eYGWt3HWLBU5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FpsVKjtQ%253D%253D&md5=116e2bc2e65138047f85f8ebeecad481</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.110.225201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.110.225201%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25B6lkers%26aufirst%3DM.%26aulast%3DWeidenhammer%26aufirst%3DC.%26aulast%3DHerzog%26aufirst%3DN.%26aulast%3DQiu%26aufirst%3DG.%26aulast%3DSpaich%26aufirst%3DK.%26aulast%3Dvon%2BWegner%26aufirst%3DF.%2BV.%26aulast%3DPeppel%26aufirst%3DK.%26aulast%3DM%25C3%25BCller%26aufirst%3DO.%2BJ.%26aulast%3DSchinkel%26aufirst%3DS.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BE.%26aulast%3DHippe%26aufirst%3DH.%2BJ.%26aulast%3DBrinks%26aufirst%3DH.%26aulast%3DKatus%26aufirst%3DH.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DEckhart%26aufirst%3DA.%2BD.%26aulast%3DFriedrich%26aufirst%3DO.%26aulast%3DMost%26aufirst%3DP.%26atitle%3DThe%2520inotropic%2520peptide%2520%25CE%25B2ARKct%2520improves%2520%25CE%25B2AR%2520responsiveness%2520in%2520normal%2520and%2520failing%2520cardiomyocytes%2520through%2520G%2528%25CE%25B2%25CE%25B3%2529-mediated%2520L-type%2520calcium%2520current%2520disinhibition%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D108%26spage%3D27%26epage%3D39%26doi%3D10.1161%2FCIRCRESAHA.110.225201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span> <span> </span><span class="NLM_article-title">Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2003.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2003.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=14734046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=43-48&author=M.+Satoauthor=H.+Gongauthor=C.+M.+Terraccianoauthor=H.+Ranuauthor=S.+E.+Harding&title=Loss+of+beta-adrenoceptor+response+in+myocytes+overexpressing+the+Na%2B%2FCa%282%2B%29-exchanger&doi=10.1016%2Fj.yjmcc.2003.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of β-adrenoceptor response in myocytes overexpressing the Na+/Ca2+-exchanger</span></div><div class="casAuthors">Sato, Motoki; Gong, Haibin; Terracciano, Cesare M. N.; Ranu, Hardeep; Harding, Sian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-48</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Increased Na+/Ca2+-exchanger (NCX) and altered β-adrenoceptor (βAR) responses are obsd. in failing human heart.  To det. the possible interaction between these changes, we investigated the effect of NCX overexpression on responses to isoproterenol in adult rat ventricular myocytes.  Responses to isoproterenol were largely mediated through the β1AR in control myocytes.  Adenovirally-mediated overexpression of NCX, at levels, which did not alter basal contraction of myocytes, markedly depressed the isoproterenol concn.-response curve.  Responses to isoproterenol could be restored to normal by β2AR blockade, suggesting a β2AR-mediated inhibition of β1AR signaling.  Pertussis toxin normalized isoproterenol responses in NCX cells, indicating that β2AR effects were mediated by Gi.  Neg.-inotropic effects of high concns. of ICI 118,551, previously shown to be due to β2AR-Gi coupling, were increased in NCX cells.  We conclude that NCX upregulation can markedly alter the consequences of βAR stimulation and that this may contribute to the alterations in βAR response seen in failing human heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvGVuKScOYbVg90H21EOLACvtfcHk0lg7alLEtLV7gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFOltg%253D%253D&md5=b6451d82195f583045539eec594abdd8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2003.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2003.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DTerracciano%26aufirst%3DC.%2BM.%26aulast%3DRanu%26aufirst%3DH.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26atitle%3DLoss%2520of%2520beta-adrenoceptor%2520response%2520in%2520myocytes%2520overexpressing%2520the%2520Na%252B%252FCa%25282%252B%2529-exchanger%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2004%26volume%3D36%26spage%3D43%26epage%3D48%26doi%3D10.1016%2Fj.yjmcc.2003.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schobesberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhargava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monszpart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelik, J.</span></span> <span> </span><span class="NLM_article-title">T-tubule remodelling disturbs localized β<sub>2</sub>-adrenergic signalling in rat ventricular myocytes during the progression of heart failure</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">782</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvx074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvx074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28505272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2nurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2017&pages=770-782&author=S.+Schobesbergerauthor=P.+Wrightauthor=S.+Tokarauthor=A.+Bhargavaauthor=C.+Mansfieldauthor=A.+V.+Glukhovauthor=C.+Pouletauthor=A.+Buzukauthor=A.+Monszpartauthor=M.+Sikkelauthor=S.+E.+Hardingauthor=V.+O.+Nikolaevauthor=A.+R.+Lyonauthor=J.+Gorelik&title=T-tubule+remodelling+disturbs+localized+%CE%B22-adrenergic+signalling+in+rat+ventricular+myocytes+during+the+progression+of+heart+failure&doi=10.1093%2Fcvr%2Fcvx074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">T-tubule remodelling disturbs localized β2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure</span></div><div class="casAuthors">Schobesberger, Sophie; Wright, Peter; Tokar, Sergiy; Bhargava, Anamika; Mansfield, Catherine; Glukhov, Alexey V.; Poulet, Claire; Buzuk, Andrey; Monszpart, Aron; Sikkel, Markus; Harding, Sian E.; Nikolaev, Viacheslav O.; Lyon, Alexander R.; Gorelik, Julia</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">770-782</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">1755-3245</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cardiomyocyte β2-adrenergic receptor (β2AR) cyclic adenosine monophosphate (cAMP) signalling is regulated by the receptors' subcellular location within transverse tubules (T-tubules), via interaction with structural and regulatory proteins, which form a signalosome.  In chronic heart failure (HF), β2ARs redistribute from T-tubules to the cell surface, which disrupts functional signalosomes and leads to diffuse cAMP signalling.  However, the functional consequences of structural changes upon β2AR-cAMP signalling during progression from hypertrophy to advanced HF are unknown.  Rat left ventricular myocytes were isolated at 4-, 8-, and 16-wk post-myocardial infarction (MI), β2ARs were stimulated either via whole-cell perfusion or locally through the nanopipette of the scanning ion conductance microscope.  CAMP release was measured via a Forster Resonance Energy Transfer-based sensor Epac2-camps.  Confocal imaging of di-8-ANNEPS-stained cells and immunoblotting were used to det. structural alterations.  At 4-wk post-MI, T-tubule regularity, d. and junctophilin-2 (JPH2) expression were significantly decreased.  The amplitude of local β2AR-mediated cAMP in T-tubules was reduced and cAMP diffused throughout the cytosol instead of being locally confined.  This was accompanied by partial caveolin-3 (Cav-3) dissocn. from the membrane.  At 8-wk post-MI, the β2AR-mediated cAMP response was obsd. at the T-tubules and the sarcolemma (crest).  Finally, at 16-wk post-MI, the whole cell β2AR-mediated cAMP signal was depressed due to adenylate cyclase dysfunction, while overall Cav-3 levels were significantly increased and a substantial portion of Cav-3 dissocd. into the cytosol.  Overexpression of JPH2 in failing cells in vitro or AAV9.SERCA2a gene therapy in vivo did not improve β2AR-mediated signal compartmentation or reduce cAMP diffusion.  Although changes in T-tubule structure and β2AR-mediated cAMP signalling are significant even at 4-wk post-MI, progression to the HF phenotype is not linear.  At 8-wk post-MI the loss of β2AR-mediated cAMP is temporarily reversed.  Complete disorganization of β2AR-mediated cAMP signalling due to changes in functional receptor localization and cellular structure occurs at 16-wk post-MI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeNXbyJ0OhMrVg90H21EOLACvtfcHk0li3KzVQnvxiWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2nurnO&md5=8100107e853e60ca03f5ea4e18a0759a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvx074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvx074%26sid%3Dliteratum%253Aachs%26aulast%3DSchobesberger%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DP.%26aulast%3DTokar%26aufirst%3DS.%26aulast%3DBhargava%26aufirst%3DA.%26aulast%3DMansfield%26aufirst%3DC.%26aulast%3DGlukhov%26aufirst%3DA.%2BV.%26aulast%3DPoulet%26aufirst%3DC.%26aulast%3DBuzuk%26aufirst%3DA.%26aulast%3DMonszpart%26aufirst%3DA.%26aulast%3DSikkel%26aufirst%3DM.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DGorelik%26aufirst%3DJ.%26atitle%3DT-tubule%2520remodelling%2520disturbs%2520localized%2520%25CE%25B22-adrenergic%2520signalling%2520in%2520rat%2520ventricular%2520myocytes%2520during%2520the%2520progression%2520of%2520heart%2520failure%26jtitle%3DCardiovasc.%2520Res.%26date%3D2017%26volume%3D113%26spage%3D770%26epage%3D782%26doi%3D10.1093%2Fcvr%2Fcvx074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1607</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1073/pnas.98.4.1607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.98.4.1607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11171998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsVWjur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1607-1612&author=W.+Z.+Zhuauthor=M.+Zhengauthor=W.+J.+Kochauthor=R.+J.+Lefkowitzauthor=B.+K.+Kobilkaauthor=R.+P.+Xiao&title=Dual+modulation+of+cell+survival+and+cell+death+by+beta%282%29-adrenergic+signaling+in+adult+mouse+cardiac+myocytes&doi=10.1073%2Fpnas.98.4.1607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes</span></div><div class="casAuthors">Zhu, Wei-Zhong; Zheng, Ming; Koch, Walter J.; Lefkowitz, Robert J.; Kobilka, Brian K.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1607-1612</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The goal of this study was to det. whether β1-adrenergic receptor (AR) and β2-AR differ in regulating cardiomyocyte survival and apoptosis and, if so, to explore underlying mechanisms.  One potential mechanism is that cardiac β2-AR can activate both Gs and Gi proteins, whereas cardiac β1-AR couples only to Gs.  To avoid complicated crosstalk between β-AR subtypes, the authors expressed β1-AR or β2-AR individually in adult β1/β2-AR double knockout mouse cardiac myocytes by using adenoviral gene transfer.  Stimulation of β1-AR, but not β2-AR, markedly induced myocyte apoptosis, as indicated by increased terminal deoxynucleotidyltransferase-mediated UTP end labeling or Hoechst staining pos. cells and DNA fragmentation.  In contrast, β2-AR (but not β1-AR) stimulation elevated the activity of Akt, a powerful survival signal; this effect was fully abolished by inhibiting Gi, Gβγ, or phosphoinositide 3-kinase (PI3K) with pertussis toxin, βARK-ct (a peptide inhibitor of Gβγ), or LY294002, resp.  This indicates that β2-AR activates Akt via a Gi-Gβγ-PI3K pathway.  More importantly, inhibition of the Gi-Gβγ-PI3K-Akt pathway converts β2-AR signaling from survival to apoptotic.  Thus, stimulation of a single class of receptors, β2-ARs, elicits concurrent apoptotic and survival signals in cardiac myocytes.  The survival effect appears to predominate and is mediated by the Gi-Gβγ-PI3K-Akt signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG5FTscOMsI7Vg90H21EOLACvtfcHk0li3KzVQnvxiWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsVWjur0%253D&md5=96b8688ce8815fe9d4b41cc1a3840bde</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.98.4.1607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.98.4.1607%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%2BZ.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DDual%2520modulation%2520of%2520cell%2520survival%2520and%2520cell%2520death%2520by%2520beta%25282%2529-adrenergic%2520signaling%2520in%2520adult%2520mouse%2520cardiac%2520myocytes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D1607%26epage%3D1612%26doi%3D10.1073%2Fpnas.98.4.1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span> <span> </span><span class="NLM_article-title">Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1176</span>– <span class="NLM_lpage">1194</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.111.245092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.111.245092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22034480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=1176-1194&author=M.+R.+Bristow&title=Treatment+of+chronic+heart+failure+with+%CE%B2-adrenergic+receptor+antagonists%3A+a+convergence+of+receptor+pharmacology+and+clinical+cardiology&doi=10.1161%2FCIRCRESAHA.111.245092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Chronic Heart Failure With β-Adrenergic Receptor Antagonists: A Convergence of Receptor Pharmacology and Clinical Cardiology</span></div><div class="casAuthors">Bristow, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1176-1194</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Despite the absence of a systematic development plan, β-blockers have reached the top tier of medical therapies for chronic heart failure.  The successful outcome was due to the many dedicated investigators who produced, over a 30-yr period, increasing evidence that β-blocking agents should or actually did improve the natural history of dilated cardiomyopathies and heart failure.  It took 20 years for supportive evidence to become undeniable, at which time in 1993 the formidable drug development resources of large pharmaceutical companies were deployed into Phase 3 trials.  Success then came relatively quickly, and within 8 years multiple agents were on the market in the United States and Europe.  Importantly, there is ample room to improve antiadrenergic therapy, through novel approaches exploiting the nuances of receptor biol. and/or intracellular signaling, as well as through pharmacogenetic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKs1_r2M4hnrVg90H21EOLACvtfcHk0li3KzVQnvxiWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOnsLnI&md5=edada5b2073c4ef553c24e361b9b216b</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.111.245092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.111.245092%26sid%3Dliteratum%253Aachs%26aulast%3DBristow%26aufirst%3DM.%2BR.%26atitle%3DTreatment%2520of%2520chronic%2520heart%2520failure%2520with%2520%25CE%25B2-adrenergic%2520receptor%2520antagonists%253A%2520a%2520convergence%2520of%2520receptor%2520pharmacology%2520and%2520clinical%2520cardiology%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D109%26spage%3D1176%26epage%3D1194%26doi%3D10.1161%2FCIRCRESAHA.111.245092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temple, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzhura, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trimble, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roden, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbran, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span> <span> </span><span class="NLM_article-title">Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000027583.73268.E7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.0000027583.73268.E7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12208807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=1288-1293&author=Y.+Wuauthor=J.+Templeauthor=R.+Zhangauthor=I.+Dzhuraauthor=W.+Zhangauthor=R.+Trimbleauthor=D.+M.+Rodenauthor=R.+Passierauthor=E.+N.+Olsonauthor=R.+J.+Colbranauthor=M.+E.+Anderson&title=Calmodulin+kinase+II+and+arrhythmias+in+a+mouse+model+of+cardiac+hypertrophy&doi=10.1161%2F01.CIR.0000027583.73268.E7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy</span></div><div class="casAuthors">Wu, Yuejin; Temple, Joel; Zhang, Rong; Dzhura, Igor; Zhang, Wei; Trimble, Robert; Roden, Dan M.; Passier, Robert; Olson, Eric N.; Colbran, Roger J.; Anderson, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1288-1293</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background - Calmodulin kinase (CaMK) II is linked to arrhythmia mechanisms in cellular models where repolarization is prolonged.  CaMKII upregulation and prolonged repolarization are general features of cardiomyopathy, but the role of CaMKII in arrhythmias in cardiomyopathy is unknown.  Methods and Results - We studied a mouse model of cardiac hypertrophy attributable to transgenic (TG) overexpression of a constitutively active form of CaMKIV that also has increased endogenous CaMKII activity.  ECG-telemetered TRG mice had significantly more arrhythmias than wild-type (WT) littermate controls at baseline, and arrhythmias were addnl. increased by isoproterenol.  Arrhythmias were significantly suppressed by an inhibitory agent targeting endogenous CaMKII.  TG mice had longer QT intervals and action potential durations than WT mice, and TG cardiomyocytes had frequent early after-depolarizations (EADs), a hypothesized mechanism for triggering arrhythmias.  EADs were absent in WT cells before and after isoproterenol, whereas EAD frequency was unaffected by isoproterenol in TG mice.  L-type Ca2+ channels (LTTCs) can activate EADs, and LTCC opening probability (Po) was significantly higher in TG than WT cardiomyocytes before and after isoproterenol.  A CaMKII inhibitory peptide equalized tG and LT LTCC Po and eliminated EADs, whereas a peptide antagonist of the Na+/Ca2+ exchanger current, also hypothesized to support EADs, was ineffective.  Conclusions - These findings support the hypothesis that CaMKII is a proarrhythmic signaling mol. in cardiac hypertrophy in vivo.  Cellular studies point to EADs as a triggering mechanism for arrhythmias but suggest that the increase in arrhythmias after β-adrenergic stimulation is independent of enhanced EAD frequency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbZkv-SIkS0bVg90H21EOLACvtfcHk0lgBh3vQUyZ1Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKks7g%253D&md5=0c70945ffbe2c9289e0d37c07ee30774</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000027583.73268.E7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000027583.73268.E7%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DTemple%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DDzhura%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DTrimble%26aufirst%3DR.%26aulast%3DRoden%26aufirst%3DD.%2BM.%26aulast%3DPassier%26aufirst%3DR.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26aulast%3DColbran%26aufirst%3DR.%2BJ.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26atitle%3DCalmodulin%2520kinase%2520II%2520and%2520arrhythmias%2520in%2520a%2520mouse%2520model%2520of%2520cardiac%2520hypertrophy%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D1288%26epage%3D1293%26doi%3D10.1161%2F01.CIR.0000027583.73268.E7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Oort, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixit, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Respress, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Almeida, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skapura, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrens, X. H.</span></span> <span> </span><span class="NLM_article-title">Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">2669</span>– <span class="NLM_lpage">2679</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.110.982298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCULATIONAHA.110.982298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21098440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2010&pages=2669-2679&author=R.+J.+van%0AOortauthor=M.+D.+McCauleyauthor=S.+S.+Dixitauthor=L.+Pereiraauthor=Y.+Yangauthor=J.+L.+Respressauthor=Q.+Wangauthor=A.+C.+De+Almeidaauthor=D.+G.+Skapuraauthor=M.+E.+Andersonauthor=D.+M.+Bersauthor=X.+H.+Wehrens&title=Ryanodine+receptor+phosphorylation+by+calcium%2Fcalmodulin-dependent+protein+kinase+II+promotes+life-threatening+ventricular+arrhythmias+in+mice+with+heart+failure&doi=10.1161%2FCIRCULATIONAHA.110.982298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure</span></div><div class="casAuthors">van Oort, Ralph J.; McCauley, Mark D.; Dixit, Sayali S.; Pereira, Laetitia; Yang, Yi; Respress, Jonathan L.; Wang, Qiongling; De Almeida, Angela C.; Skapura, Darlene G.; Anderson, Mark E.; Bers, Donald M.; Wehrens, Xander H. T.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2669-2679</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background-: Approx. half of patients with heart failure die suddenly as a result of ventricular arrhythmias.  Although abnormal Ca release from the sarcoplasmic reticulum through ryanodine receptors (RyR2) has been linked to arrhythmogenesis, the mol. mechanisms triggering release of arrhythmogenic Ca remain unknown.  We tested the hypothesis that increased RyR2 phosphorylation by Ca/calmodulin-dependent protein kinase II is both necessary and sufficient to promote lethal ventricular arrhythmias.  Methods and Results-: Mice in which the S2814 Ca/calmodulin-dependent protein kinase II site on RyR2 is constitutively activated (S2814D) develop pathol. sarcoplasmic reticulum Ca release events, resulting in reduced sarcoplasmic reticulum Ca load on confocal microscopy.  These Ca release events are assocd. with increased RyR2 open probability in lipid bilayer prepns.  At baseline, young S2814D mice have structurally and functionally normal hearts without arrhythmias; however, they develop sustained ventricular tachycardia and sudden cardiac death on catecholaminergic provocation by caffeine/epinephrine or programmed elec. stimulation.  Young S2814D mice have a significant predisposition to sudden arrhythmogenic death after transverse aortic constriction surgery.  Finally, genetic ablation of the Ca/calmodulin-dependent protein kinase II site on RyR2 (S2814A) protects mutant mice from pacing-induced arrhythmias vs. wild-type mice after transverse aortic constriction surgery.  Conclusions-: Our results suggest that Ca/calmodulin-dependent protein kinase II phosphorylation of RyR2 Ca release channels at S2814 plays an important role in arrhythmogenesis and sudden cardiac death in mice with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ndk-Ylj3vLVg90H21EOLACvtfcHk0lgBh3vQUyZ1Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtbzN&md5=9e3c186fa919ecd088bfe50276398dff</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.110.982298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.110.982298%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BOort%26aufirst%3DR.%2BJ.%26aulast%3DMcCauley%26aufirst%3DM.%2BD.%26aulast%3DDixit%26aufirst%3DS.%2BS.%26aulast%3DPereira%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DRespress%26aufirst%3DJ.%2BL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DDe%2BAlmeida%26aufirst%3DA.%2BC.%26aulast%3DSkapura%26aufirst%3DD.%2BG.%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DBers%26aufirst%3DD.%2BM.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26atitle%3DRyanodine%2520receptor%2520phosphorylation%2520by%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520II%2520promotes%2520life-threatening%2520ventricular%2520arrhythmias%2520in%2520mice%2520with%2520heart%2520failure%26jtitle%3DCirculation%26date%3D2010%26volume%3D122%26spage%3D2669%26epage%3D2679%26doi%3D10.1161%2FCIRCULATIONAHA.110.982298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Linkage of β<sub>1</sub>-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca<sup>2+</sup>/calmodulin kinase II</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1172/JCI200316326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI200316326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12618516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=617-625&author=W.+Z.+Zhuauthor=S.+Q.+Wangauthor=K.+Chakirauthor=D.+Yangauthor=T.+Zhangauthor=J.+H.+Brownauthor=E.+Devicauthor=B.+K.+Kobilkaauthor=H.+Chengauthor=R.+P.+Xiao&title=Linkage+of+%CE%B21-adrenergic+stimulation+to+apoptotic+heart+cell+death+through+protein+kinase+A-independent+activation+of+Ca2%2B%2Fcalmodulin+kinase+II&doi=10.1172%2FJCI200316326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II</span></div><div class="casAuthors">Zhu, Wei-Zhong; Wang, Shi-Qiang; Chakir, Khalid; Yang, Dongmei; Zhang, Tong; Brown, Joan Heller; Devic, Eric; Kobilka, Brian K.; Cheng, Heping; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">617-625</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">β1-Adrenergic receptor (β1AR) stimulation activates the classic cAMP/protein kinase A (PKA) pathway to regulate vital cellular processes from the change of gene expression to the control of metab., muscle contraction, and cell apoptosis.  Here, we show that sustained β1AR stimulation promotes cardiac myocyte apoptosis by activation of Ca2+/calmodulin kinase II (CaMKII), independently of PKA signaling.  β1AR-induced apoptosis is resistant to inhibition of PKA by a specific peptide inhibitor, PKI14-22, or an inactive cAMP analog, Rp-8-CPT-cAMPS.  In contrast, the β1AR proapoptotic effect is assocd. with non-PKA-dependent increases in intracellular Ca2+ and CaMKII activity.  Blocking the L-type Ca2+ channel, buffering intracellular Ca2+, or inhibiting CaMKII activity fully protects cardiac myocytes against β1AR-induced apoptosis, and overexpressing a cardiac CaMKII isoform, CaMKII-δC, markedly exaggerates the β1AR apoptotic effect.  These findings indicate that CaMKII constitutes a novel PKA-independent linkage of β1AR stimulation to cardiomyocyte apoptosis that has been implicated in the overall process of chronic heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5HKXxjM5pzbVg90H21EOLACvtfcHk0ljeKZMtdZOAEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFentbg%253D&md5=aba0137b0536977c5e06f261370c62ac</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1172%2FJCI200316326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200316326%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%2BZ.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DDevic%26aufirst%3DE.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DLinkage%2520of%2520%25CE%25B21-adrenergic%2520stimulation%2520to%2520apoptotic%2520heart%2520cell%2520death%2520through%2520protein%2520kinase%2520A-independent%2520activation%2520of%2520Ca2%252B%252Fcalmodulin%2520kinase%2520II%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D111%26spage%3D617%26epage%3D625%26doi%3D10.1172%2FJCI200316326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">10833</span>– <span class="NLM_lpage">10839</span>, <span class="refDoi"> DOI: 10.1074/jbc.M611507200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1074%2Fjbc.M611507200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17296607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1ShsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=10833-10839&author=W.+Zhuauthor=A.+Y.+Wooauthor=D.+Yangauthor=H.+Chengauthor=M.+T.+Crowauthor=R.+P.+Xiao&title=Activation+of+CaMKIIdeltaC+is+a+common+intermediate+of+diverse+death+stimuli-induced+heart+muscle+cell+apoptosis&doi=10.1074%2Fjbc.M611507200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of CaMKIIδC Is a Common Intermediate of Diverse Death Stimuli-induced Heart Muscle Cell Apoptosis</span></div><div class="casAuthors">Zhu, Weizhong; Woo, Anthony Yiu-Ho; Yang, Dongmei; Cheng, Heping; Crow, Michael T.; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">10833-10839</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Ca2+-calmodulin-dependent protein kinase II (CaMKII) is expressed in many mammalian cells, with the δ isoform predominantly expressed in cardiomyocytes.  Previous studies have shown that inhibition of CaMKII protects cardiomyocytes against β1-adrenergic receptor-mediated apoptosis.  However, it is unclear whether activation of CaMKII is sufficient to cause cardiomyocyte apoptosis and whether CaMKII signaling is important in heart muscle cell apoptosis mediated by other stimuli.  Here, we specifically enhanced or suppressed CaMKII activity using adenoviral gene transfer of constitutively active (CA-CaMKIIδC) or dominant neg. (DN-CaMKIIδC) mutants of CaMKIIδC in cultured adult rat cardiomyocytes.  Expression of CA-CaMKIIδC promoted cardiomyocyte apoptosis that was assocd. with increased mitochondrial cytochrome c release and attenuated by co-expression of Bcl-XL.  Importantly, isoform-specific suppression of CaMKIIδC with the DN-CaMKIIδC mutant similar to nonselective CaMKII inhibition by the pharmacol. inhibitors (KN-93 or AIP) not only prevented CA-CaMKIIδC-mediated apoptosis but also protected cells from multiple death-inducing stimuli.  Thus, activation of CaMKIIδC constitutes a common intermediate by which various death-inducing stimuli trigger cardiomyocyte apoptosis via the primary mitochondrial death pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc8rUDLtQ3xrVg90H21EOLACvtfcHk0ljeKZMtdZOAEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1ShsLg%253D&md5=3868fab761d02b80447088469f99359d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M611507200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M611507200%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCrow%26aufirst%3DM.%2BT.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DActivation%2520of%2520CaMKIIdeltaC%2520is%2520a%2520common%2520intermediate%2520of%2520diverse%2520death%2520stimuli-induced%2520heart%2520muscle%2520cell%2520apoptosis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D10833%26epage%3D10839%26doi%3D10.1074%2Fjbc.M611507200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Backs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvannaya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. N.</span></span> <span> </span><span class="NLM_article-title">CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">1853</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1172/JCI27438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI27438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16767219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvV2ltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=1853-1864&author=J.+Backsauthor=K.+Songauthor=S.+Bezprozvannayaauthor=S.+Changauthor=E.+N.+Olson&title=CaM+kinase+II+selectively+signals+to+histone+deacetylase+4+during+cardiomyocyte+hypertrophy&doi=10.1172%2FJCI27438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy</span></div><div class="casAuthors">Backs, Johannes; Song, Kunhua; Bezprozvannaya, Svetlana; Chang, Shurong; Olson, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1853-1864</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Class IIa histone deacetylases (HDACs) regulate a variety of cellular processes, including cardiac growth, bone development, and specification of skeletal muscle fiber type.  Multiple serine/threonine kinases control the subcellular localization of these HDACs by phosphorylation of common serine residues, but whether certain class IIa HDACs respond selectively to specific kinases has not been detd.  Here we show that calcium/calmodulin-dependent kinase II (CaMKII) signals specifically to HDAC4 by binding to a unique docking site that is absent in other class IIa HDACs.  Phosphorylation of HDAC4 by CaMKII promotes nuclear export and prevents nuclear import of HDAC4, with consequent derepression of HDAC target genes.  In cardiomyocytes, CaMKII phosphorylation of HDAC4 results in hypertrophic growth, which can be blocked by a signal-resistant HDAC4 mutant.  These findings reveal a central role for HDAC4 in CaMKII signaling pathways and have implications for the control of gene expression by calcium signaling in a variety of cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLmEf11zn00bVg90H21EOLACvtfcHk0ljeKZMtdZOAEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvV2ltbs%253D&md5=b6510a11e8f97c5506d37443e8324225</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1172%2FJCI27438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI27438%26sid%3Dliteratum%253Aachs%26aulast%3DBacks%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DBezprozvannaya%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DOlson%26aufirst%3DE.%2BN.%26atitle%3DCaM%2520kinase%2520II%2520selectively%2520signals%2520to%2520histone%2520deacetylase%25204%2520during%2520cardiomyocyte%2520hypertrophy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D1853%26epage%3D1864%26doi%3D10.1172%2FJCI27438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Means, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller Brown, J.</span></span> <span> </span><span class="NLM_article-title">Requirement for Ca<sup>2+</sup>/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1172/JCI38022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI38022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19381018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFyrsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=1230-1240&author=H.+Lingauthor=T.+Zhangauthor=L.+Pereiraauthor=C.+K.+Meansauthor=H.+Chengauthor=Y.+Guauthor=N.+D.+Daltonauthor=K.+L.+Petersonauthor=J.+Chenauthor=D.+Bersauthor=J.+Heller+Brown&title=Requirement+for+Ca2%2B%2Fcalmodulin-dependent+kinase+II+in+the+transition+from+pressure+overload-induced+cardiac+hypertrophy+to+heart+failure+in+mice&doi=10.1172%2FJCI38022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice</span></div><div class="casAuthors">Ling, Haiyun; Zhang, Tong; Pereira, Laetitia; Means, Christopher Kable; Cheng, Hongqiang; Gu, Yusu; Dalton, Nancy D.; Peterson, Kirk L.; Chen, Ju; Bers, Donald; Brown, Joan Heller</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1230-1240</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Ca2+/calmodulin-dependent kinase II (CaMKII) was implicated in cardiac hypertrophy and heart failure.  We generated mice in which the predominant cardiac isoform, CaMKIIδ, was genetically deleted (KO mice), and found that these mice showed no gross baseline changes in ventricular structure or function.  In WT and KO mice, transverse aortic constriction (TAC) induced comparable increases in relative heart wt., cell size, HDAC5 phosphorylation, and hypertrophic gene expression.  Strikingly, while KO mice showed preserved hypertrophy after 6-wk TAC, CaMKIIδ deficiency significantly ameliorated phenotypic changes assocd. with the transition to heart failure, such as chamber dilation, ventricular dysfunction, lung edema, cardiac fibrosis, and apoptosis.  The ratio of IP3R2 to ryanodine receptor 2 (RyR2) and the fraction of RyR2 phosphorylated at the CaMKII site increased significantly during development of heart failure in WT mice, but not KO mice, and this was assocd. with enhanced Ca2+ spark frequency only in WT mice.  We suggest that CaMKIIδ contributes to cardiac decompensation by enhancing RyR2-mediated sarcoplasmic reticulum Ca2+ leak and that attenuating CaMKIIδ activation can limit the progression to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruSwvKWOd4KrVg90H21EOLACvtfcHk0liSNqqY6KmtOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFyrsbY%253D&md5=758acb983b5e631ad5ccd30f5e7ace11</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1172%2FJCI38022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI38022%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DPereira%26aufirst%3DL.%26aulast%3DMeans%26aufirst%3DC.%2BK.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DDalton%26aufirst%3DN.%2BD.%26aulast%3DPeterson%26aufirst%3DK.%2BL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBers%26aufirst%3DD.%26aulast%3DHeller%2BBrown%26aufirst%3DJ.%26atitle%3DRequirement%2520for%2520Ca2%252B%252Fcalmodulin-dependent%2520kinase%2520II%2520in%2520the%2520transition%2520from%2520pressure%2520overload-induced%2520cardiac%2520hypertrophy%2520to%2520heart%2520failure%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D1230%26epage%3D1240%26doi%3D10.1172%2FJCI38022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1152</span>– <span class="NLM_lpage">1163</span>, <span class="refDoi"> DOI: 10.1038/s41556-019-0380-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41556-019-0380-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31481791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSiurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=1152-1163&author=M.+Zhangauthor=H.+Gaoauthor=D.+Liuauthor=X.+Zhongauthor=X.+Shiauthor=P.+Yuauthor=L.+Jinauthor=Y.+Liuauthor=Y.+Tangauthor=Y.+Songauthor=J.+Liuauthor=X.+Huauthor=C.+Y.+Liauthor=L.+Songauthor=J.+Qinauthor=F.+Wuauthor=F.+Lanauthor=Y.+Zhangauthor=R.+P.+Xiao&title=CaMKII-%CE%B49+promotes+cardiomyopathy+through+disrupting+UBE2T-dependent+DNA+repair&doi=10.1038%2Fs41556-019-0380-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKII-δ9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair</span></div><div class="casAuthors">Zhang, Mao; Gao, Hua; Liu, Dairu; Zhong, Xiaoming; Shi, Xiaolu; Yu, Peng; Jin, Li; Liu, Yun; Tang, Yajie; Song, Yunhu; Liu, Jinghao; Hu, Xinli; Li, Chuan-Yun; Song, Lei; Qin, Jun; Wu, Fujian; Lan, Feng; Zhang, Yan; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1152-1163</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Ca2+/calmodulin-dependent kinase II (CaMKII) is a multifunctional serine/threonine kinase family, and its δ isoform is predominant in the heart.  Excessive CaMKII activation plays a pivotal role in the pathogenesis of severe heart conditions, including myocardial infarction, cardiomyopathy and heart failure.  However, the identity of CaMKII splice variants and the mechanism(s) underlying CaMKII-mediated cardiac pathol. remain elusive.  Here, we show that CaMKII-δ9, the most abundant CaMKII-δ splice variant in human heart, potently promotes cardiomyocyte death, cardiomyopathy and heart failure by disrupting cardiomyocyte genome stability.  Mechanistically, CaMKII-δ9, but not the previously well-studied CaMKII-δ2 and CaMKII-δ3, targets the ubiquitin-conjugating enzyme E2T (UBE2T) for phosphorylation and degrdn., disrupting UBE2T-dependent DNA repair and leading to the accumulation of DNA damage and genome instability.  These findings not only reveal a crucial role of CaMKII in the regulation of DNA repair, but also mark the CaMKII-δ9-UBE2T-DNA damage pathway as an important therapeutic target for cardiomyopathy and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8FdY8t-WWiLVg90H21EOLACvtfcHk0liSNqqY6KmtOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSiurvP&md5=706b3cd3e4d2ecc3b0c27c06e5bf6ffd</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fs41556-019-0380-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41556-019-0380-8%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DCaMKII-%25CE%25B49%2520promotes%2520cardiomyopathy%2520through%2520disrupting%2520UBE2T-dependent%2520DNA%2520repair%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2019%26volume%3D21%26spage%3D1152%26epage%3D1163%26doi%3D10.1038%2Fs41556-019-0380-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangmool, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-dependent activation of Ca<sup>2+</sup>/calmodulin kinase II after β<sub>1</sub>-adrenergic receptor stimulation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1083/jcb.200911047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1083%2Fjcb.200911047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20421423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFyhtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2010&pages=573-587&author=S.+Mangmoolauthor=A.+K.+Shuklaauthor=H.+A.+Rockman&title=%CE%B2-Arrestin-dependent+activation+of+Ca2%2B%2Fcalmodulin+kinase+II+after+%CE%B21-adrenergic+receptor+stimulation&doi=10.1083%2Fjcb.200911047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">β-arrestin-dependent activation of Ca2+/calmodulin kinase II after β1-adrenergic receptor stimulation</span></div><div class="casAuthors">Mangmool, Supachoke; Shukla, Arun K.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-587</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Ca2+/calmodulin kinase II (CaMKII) plays an important role in cardiac contractility and the development of heart failure.  Although stimulation of β1-adrenergic receptors (ARs) leads to an increase in CaMKII activity, the mol. mechanism by which β1-ARs activate CaMKII is not completely understood.  In this study, we show the requirement for the β1-AR regulatory protein β-arrestin as a scaffold for both CaMKII and Epac (exchange protein directly activated by cAMP).  Stimulation of β1-ARs induces the formation of a β-arrestin-CaMKII-Epac1 complex, allowing its recruitment to the plasma membrane, whereby interaction with cAMP leads to CaMKII activation.  β-Arrestin binding to the carboxyl-terminal tail of β1-ARs promotes a conformational change within β-arrestin that allows CaMKII and Epac to remain in a stable complex with the receptor.  The essential role for β-arrestin and identification of the mol. mechanism by which only β1-ARs and not β2-ARs activate CaMKII significantly advances our understanding of this important cellular pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpikMtLR2PhubVg90H21EOLACvtfcHk0liSNqqY6KmtOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFyhtbY%253D&md5=5f3320135032583ffc10f94cbbeb4c1f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200911047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200911047%26sid%3Dliteratum%253Aachs%26aulast%3DMangmool%26aufirst%3DS.%26aulast%3DShukla%26aufirst%3DA.%2BK.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-Arrestin-dependent%2520activation%2520of%2520Ca2%252B%252Fcalmodulin%2520kinase%2520II%2520after%2520%25CE%25B21-adrenergic%2520receptor%2520stimulation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2010%26volume%3D189%26spage%3D573%26epage%3D587%26doi%3D10.1083%2Fjcb.200911047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarewich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunapuli, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.112.273896</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.112.273896" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23104882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=498-509&author=X.+Zhangauthor=C.+Szetoauthor=E.+Gaoauthor=M.+Tangauthor=J.+Jinauthor=Q.+Fuauthor=C.+Makarewichauthor=X.+Aiauthor=Y.+Liauthor=A.+Tangauthor=J.+Wangauthor=H.+Gaoauthor=F.+Wangauthor=X.+J.+Geauthor=S.+P.+Kunapuliauthor=L.+Zhouauthor=C.+Zengauthor=K.+Y.+Xiangauthor=X.+Chen&title=Cardiotoxic+and+cardioprotective+features+of+chronic+%CE%B2-adrenergic+signaling&doi=10.1161%2FCIRCRESAHA.112.273896"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiotoxic and Cardioprotective Features of Chronic β-Adrenergic Signaling</span></div><div class="casAuthors">Zhang, Xiaoying; Szeto, Christopher; Gao, Erhe; Tang, Mingxin; Jin, Jianguo; Fu, Qin; Makarewich, Catherine; Ai, Xiaojie; Li, Ying; Tang, Allen; Wang, Jenny; Gao, Hui; Wang, Fang; Ge, Xinyi Joy; Kunapuli, Satya P.; Zhou, Lin; Zeng, Chunyu; Xiang, Kevin Yang; Chen, Xiongwen</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">498-509</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: In the failing heart, persistent β-adrenergic receptor activation is thought to induce myocyte death by protein kinase A (PKA)-dependent and PKA-independent activation of calcium/calmodulin-dependent kinase II.  β-Adrenergic signaling pathways also are capable of activating cardioprotective mechanisms.  Objective: This study used a novel PKA inhibitor peptide to inhibit PKA activity to test the hypothesis that β-adrenergic receptor signaling causes cell death through PKA-dependent pathways and cardioprotection through PKA-independent pathways.  Methods and results: In PKA inhibitor peptide transgenic mice, chronic isoproterenol failed to induce cardiac hypertrophy, fibrosis, and myocyte apoptosis, and decreased cardiac function.  In cultured adult feline ventricular myocytes, PKA inhibition protected myocytes from death induced by β1-adrenergic receptor agonists by preventing cytosolic and sarcoplasmic reticulum Ca overload and calcium/calmodulin-dependent kinase II activation.  PKA inhibition revealed a cardioprotective role of β-adrenergic signaling via cAMP/exchange protein directly activated by cAMP/Rap1/Rac/extracellular signal-regulated kinase pathway.  Selective PKA inhibition causes protection in the heart after myocardial infarction that was superior to β-blocker therapy.  Conclusions: These results suggest that selective block of PKA could be a novel heart failure therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKU2AqOz86lbVg90H21EOLACvtfcHk0lhnqLLc6SiKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrs%253D&md5=5231fdb364db3537c8013aab4f71d73e</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.112.273896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.112.273896%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSzeto%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DMakarewich%26aufirst%3DC.%26aulast%3DAi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DX.%2BJ.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DK.%2BY.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DCardiotoxic%2520and%2520cardioprotective%2520features%2520of%2520chronic%2520%25CE%25B2-adrenergic%2520signaling%26jtitle%3DCirc.%2520Res.%26date%3D2013%26volume%3D112%26spage%3D498%26epage%3D509%26doi%3D10.1161%2FCIRCRESAHA.112.273896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murohara, T.</span></span> <span> </span><span class="NLM_article-title">Dipeptidyl peptidase 4 inhibition alleviates shortage of circulating glucagon-like peptide-1 in heart failure and mitigates myocardial remodeling and apoptosis via the exchange protein directly activated by cyclic AMP 1/ras-related protein 1 axis</span>. <i>Circ.: Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e002081</span> <span class="refDoi"> DOI: 10.1161/CIRCHEARTFAILURE.115.002081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCHEARTFAILURE.115.002081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26721911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFyksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=M.+Aoyamaauthor=H.+Kawaseauthor=Y.+K.+Bandoauthor=A.+Monjiauthor=T.+Murohara&title=Dipeptidyl+peptidase+4+inhibition+alleviates+shortage+of+circulating+glucagon-like+peptide-1+in+heart+failure+and+mitigates+myocardial+remodeling+and+apoptosis+via+the+exchange+protein+directly+activated+by+cyclic+AMP+1%2Fras-related+protein+1+axis&doi=10.1161%2FCIRCHEARTFAILURE.115.002081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis</span></div><div class="casAuthors">Aoyama, Morihiko; Kawase, Haruya; Bando, Yasuko K.; Monji, Akio; Murohara, Toyoaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation: Heart Failure</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e002081</span>CODEN:
                <span class="NLM_cas:coden">CHFICM</span>;
        ISSN:<span class="NLM_cas:issn">1941-3289</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Ample evidence demonstrates cardiovascular protection by incretin-based therapy using dipeptidyl peptidase 4 inhibitor (DPP4i) and glucagon-like peptide-1 (GLP-1) under either diabetic or nondiabetic condition.  Their action on myocardium is mediated by the cAMP (cAMP) signal; however, the pathway remains uncertain.  This study was conducted to address the effect of DPP4i/GLP-1/cAMP axis on cardiac dysfunction and remodeling induced by pressure overload (thoracic aortic constriction [TAC]) independently of diabetes mellitus.  DPP4i (alogliptin, 10 mg/kg per day for 4 wk) prevented TAC-induced contractile dysfunction, remodeling, and apoptosis of myocardium in a GLP-1 receptor antagonist (exendin [9-39])-sensitive fashion.  In TAC, circulating level of GLP-1 (in pmol/L; 0.86±0.10 for TAC vs. 2.13±0.54 for sham control) unexpectedly declined and so did the myocardial cAMP concn. (in pmol/mg protein; 33.0±1.4 for TAC vs. 42.2±1.5 for sham).  Alogliptin restored the decline in the GLP-1/cAMP levels obsd. in TAC, thereby augmented cAMP signaling effectors (protein kinase A [PKA] and exchange protein directly activated by cAMP 1 [EPAC1]).  In vitro assay revealed distinct roles of PKA and EPAC1 in cardiac apoptosis.  EPAC1 promoted cardiomyocyte survival via concomitant increase in B cell lymphoma-2 (Bcl-2) expression and activation of small G protein Ras-related protein 1 (Rap1) in a cAMP dose-dependent and PKA-independent fashion.  DPP4i restores cardiac remodeling and apoptosis caused by the pathol. decline in circulating GLP-1 in response to pressure overload.  EPAC1 is essential for cardiomyocyte survival via the cAMP/Rap1 activation independently of PKA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbOpmz-ZLXr7Vg90H21EOLACvtfcHk0lhnqLLc6SiKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFyksr8%253D&md5=8715a3603d1b61207c7d79ce3b74b35c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1161%2FCIRCHEARTFAILURE.115.002081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCHEARTFAILURE.115.002081%26sid%3Dliteratum%253Aachs%26aulast%3DAoyama%26aufirst%3DM.%26aulast%3DKawase%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DY.%2BK.%26aulast%3DMonji%26aufirst%3DA.%26aulast%3DMurohara%26aufirst%3DT.%26atitle%3DDipeptidyl%2520peptidase%25204%2520inhibition%2520alleviates%2520shortage%2520of%2520circulating%2520glucagon-like%2520peptide-1%2520in%2520heart%2520failure%2520and%2520mitigates%2520myocardial%2520remodeling%2520and%2520apoptosis%2520via%2520the%2520exchange%2520protein%2520directly%2520activated%2520by%2520cyclic%2520AMP%25201%252Fras-related%2520protein%25201%2520axis%26jtitle%3DCirc.%253A%2520Heart%2520Failure%26date%3D2016%26volume%3D9%26doi%3D10.1161%2FCIRCHEARTFAILURE.115.002081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span> <span> </span><span class="NLM_article-title">CaMKII in myocardial hypertrophy and heart failure</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">468</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2011.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2011.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21276796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=468-473&author=M.+E.+Andersonauthor=J.+H.+Brownauthor=D.+M.+Bers&title=CaMKII+in+myocardial+hypertrophy+and+heart+failure&doi=10.1016%2Fj.yjmcc.2011.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKII in myocardial hypertrophy and heart failure</span></div><div class="casAuthors">Anderson, Mark E.; Brown, Joan Heller; Bers, Donald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">468-473</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many signals have risen and fallen in the tide of investigation into mechanisms of myocardial hypertrophy and heart failure (HF).  In our opinion, the multifunctional Ca and calmodulin-dependent protein kinase II (CaMKII) has emerged as a mol. to watch, in part because a solid body of accumulated data essentially satisfy Koch's postulates, showing that the CaMKII pathway is a core mechanism for promoting myocardial hypertrophy and heart failure.  Multiple groups have now confirmed the following: (1) that CaMKII activity is increased in hypertrophied and failing myocardium from animal models and patients; (2) CaMKII overexpression causes myocardial hypertrophy and HF and (3) CaMKII inhibition (by drugs, inhibitory peptides and gene deletion) improves myocardial hypertrophy and HF.  Patients with myocardial disease die in equal proportion from HF and arrhythmias, and a major therapeutic obstacle is that drugs designed to enhance myocardial contraction promote arrhythmias.  In contrast, inhibiting the CaMKII pathway appears to reduce arrhythmias and improve myocardial responses to pathol. stimuli.  This brief paper will introduce the mol. physiol. of CaMKII and discuss the impact of CaMKII on ion channels, Ca handling proteins and transcription in myocardium.  This article is part of a special issue entitled "Key Signaling Mols. in Hypertrophy and Heart Failure".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvHcQrIQzdNrVg90H21EOLACvtfcHk0lhnqLLc6SiKGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7rN&md5=1682cef22b50060e56ce32e682c64169</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DBers%26aufirst%3DD.%2BM.%26atitle%3DCaMKII%2520in%2520myocardial%2520hypertrophy%2520and%2520heart%2520failure%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2011%26volume%3D51%26spage%3D468%26epage%3D473%26doi%3D10.1016%2Fj.yjmcc.2011.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berretta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, S. R.</span></span> <span> </span><span class="NLM_article-title">Ca<sup>2+</sup> influx-induced sarcoplasmic reticulum Ca<sup>2+</sup> overload causes mitochondrial-dependent apoptosis in ventricular myocytes</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1017</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000189270.72915.D1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000189270.72915.D1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16210547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFOmtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2005&pages=1009-1017&author=X.+Chenauthor=X.+Zhangauthor=H.+Kuboauthor=D.+M.+Harrisauthor=G.+D.+Millsauthor=J.+Moyerauthor=R.+Berrettaauthor=S.+T.+Pottsauthor=J.+D.+Marshauthor=S.+R.+Houser&title=Ca2%2B+influx-induced+sarcoplasmic+reticulum+Ca2%2B+overload+causes+mitochondrial-dependent+apoptosis+in+ventricular+myocytes&doi=10.1161%2F01.RES.0000189270.72915.D1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Ca2+ Influx-Induced Sarcoplasmic Reticulum Ca2+ Overload Causes Mitochondrial-Dependent Apoptosis in Ventricular Myocytes</span></div><div class="casAuthors">Chen, Xiongwen; Zhang, Xiaoying; Kubo, Hajime; Harris, David M.; Mills, Geoffrey D.; Moyer, Jed; Berretta, Remus; Potts, Sabine Telemaque; Marsh, James D.; Houser, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Increases in Ca2+ influx through the L-type Ca2+ channel (LTCC, Cav1.2) augment sarcoplasmic reticulum (SR) Ca2+ loading and the amplitude of the cytosolic Ca2+ transient to enhance cardiac myocyte contractility.  Our hypothesis is that persistent increases in Ca2+ influx through the LTCC cause apoptosis if the excessive influx results in SR Ca2+ overload.  Feline ventricular myocytes (VMs) in primary culture were infected with either an adenovirus (Ad) contg. a rat Cav1.2 β2a subunit-green fluorescent protein (GFP) fusion gene (Adβ2a) to increase Ca2+ influx or with AdGFP as a control.  Significantly fewer β2a-VMs (21.4 ± 5.6%) than GFP-VMs (99.6 ± 1.7%) were viable at 96 h.  A fraction of β2a-VMs (20.8±1.8%) contracted spontaneously (SC-β2a-VMs), and viability was significantly correlated with the percentage of SC-β2a-VMs.  Higher percentages of apoptotic nuclei, DNA laddering, and cytochrome C release were detected in β2a-VMs.  This apoptosis was prevented with pan-caspase or caspase-3 or caspase-9 inhibitors.  L-type calcium current (ICa-L) d. was greater in β2a-VMs (23.4 ± 2.8 pA/pF) than in GFP-VMs (7.6 ± 1.6 pA/pF).  SC-β2a-VMs had higher diastolic intracellular Ca2+ (Indo-1 ratio: 1.1 ± 0.1 vs. 0.7 ± 0.03, P < 0.05) and systolic Ca2+ transients (1.89 ± 0.27 vs. 0.80 ± 0.08) than GFP-VMs.  Inhibitors of Ca2+ influx, SR Ca2+ uptake and release, mitochondrial Ca2+ uptake, mitochondrial permeation transition pore, calpain, and Bcl-2-assocd. X protein protected β2a-VMs from apoptosis.  These results show that persistent increases in Ca2+ influx through the ICa-L enhance contractility but lead to apoptosis through a mitochondrial death pathway if SR Ca2+ overload is induced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQHxYcIic1q7Vg90H21EOLACvtfcHk0liPRzOsxGHYsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFOmtLvF&md5=04d7a6476ddd24fe4f9ae30094a270fb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000189270.72915.D1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000189270.72915.D1%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKubo%26aufirst%3DH.%26aulast%3DHarris%26aufirst%3DD.%2BM.%26aulast%3DMills%26aufirst%3DG.%2BD.%26aulast%3DMoyer%26aufirst%3DJ.%26aulast%3DBerretta%26aufirst%3DR.%26aulast%3DPotts%26aufirst%3DS.%2BT.%26aulast%3DMarsh%26aufirst%3DJ.%2BD.%26aulast%3DHouser%26aufirst%3DS.%2BR.%26atitle%3DCa2%252B%2520influx-induced%2520sarcoplasmic%2520reticulum%2520Ca2%252B%2520overload%2520causes%2520mitochondrial-dependent%2520apoptosis%2520in%2520ventricular%2520myocytes%26jtitle%3DCirc.%2520Res.%26date%3D2005%26volume%3D97%26spage%3D1009%26epage%3D1017%26doi%3D10.1161%2F01.RES.0000189270.72915.D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berretta, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houser, S. R.</span></span> <span> </span><span class="NLM_article-title">β<sub>1</sub>-Adrenergic receptor activation induces mouse cardiac myocyte death through both L-type calcium channel-dependent and -independent pathways</span>. <i>Am. J. Physiol. Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">H322</span>– <span class="NLM_lpage">H331</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00392.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajpheart.00392.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20495143" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2010&pages=H322-H331&author=W.+Wangauthor=H.+Zhangauthor=H.+Gaoauthor=H.+Kuboauthor=R.+M.+Berrettaauthor=X.+Chenauthor=S.+R.+Houser&title=%CE%B21-Adrenergic+receptor+activation+induces+mouse+cardiac+myocyte+death+through+both+L-type+calcium+channel-dependent+and+-independent+pathways&doi=10.1152%2Fajpheart.00392.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00392.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00392.2010%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DH.%26aulast%3DBerretta%26aufirst%3DR.%2BM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHouser%26aufirst%3DS.%2BR.%26atitle%3D%25CE%25B21-Adrenergic%2520receptor%2520activation%2520induces%2520mouse%2520cardiac%2520myocyte%2520death%2520through%2520both%2520L-type%2520calcium%2520channel-dependent%2520and%2520-independent%2520pathways%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2010%26volume%3D299%26spage%3DH322%26epage%3DH331%26doi%3D10.1152%2Fajpheart.00392.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span> <span> </span><span class="NLM_article-title">The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000069686.31472.C5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.0000069686.31472.C5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12676814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=912-919&author=T.+Zhangauthor=L.+S.+Maierauthor=N.+D.+Daltonauthor=S.+Miyamotoauthor=J.+Rossauthor=D.+M.+Bersauthor=J.+H.+Brown&title=The+deltaC+isoform+of+CaMKII+is+activated+in+cardiac+hypertrophy+and+induces+dilated+cardiomyopathy+and+heart+failure&doi=10.1161%2F01.RES.0000069686.31472.C5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The δC Isoform of CaMKII Is Activated in Cardiac Hypertrophy and Induces Dilated Cardiomyopathy and Heart Failure</span></div><div class="casAuthors">Zhang, Tong; Maier, Lars S.; Dalton, Nancy D.; Miyamoto, Shigeki; Ross, John; Bers, Donald M.; Brown, Joan Heller</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">912-919</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent studies have demonstrated that transgenic (TG) expression of either Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) or CaMKIIδB, both of which localize to the nucleus, induces cardiac hypertrophy.  However, CaMKIV is not present in heart, and cardiomyocytes express not only the nuclear CaMKIIδB but also a cytoplasmic isoform, CaMKIIδC.  In the present study, we demonstrate that expression of the δC isoform of CaMKII is selectively increased and its phosphorylation elevated as early as 2 days and continuously for up to 7 days after pressure overload.  To det. whether enhanced activity of this cytoplasmic δC isoform of CaMKII can lead to phosphorylation of Ca2+ regulatory proteins and induce hypertrophy, we generated TG mice that expressed the δC isoform of CaMKII.  Immunocytochem. staining demonstrated that the expressed transgene is confined to the cytoplasm of cardiomyocytes isolated from these mice.  These mice develop a dilated cardiomyopathy with up to a 65% decrease in fractional shortening and die prematurely.  Isolated myocytes are enlarged and exhibit reduced contractility and altered Ca2+ handling.  Phosphorylation of the ryanodine receptor (RyR) at a CaMKII site is increased even before development of heart failure, and CaMKII is found assocd. with the RyR in immunoppts. from the CaMKII TG mice.  Phosphorylation of phospholamban is also increased specifically at the CaMKII but not at the PKA phosphorylation site.  These findings are the first to demonstrate that CaMKIIδC can mediate phosphorylation of Ca2+ regulatory proteins in vivo and provide evidence for the involvement of CaMKIIδC activation in the pathogenesis of dilated cardiomyopathy and heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB-nVcYxA4kbVg90H21EOLACvtfcHk0liPRzOsxGHYsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtFWqu7Y%253D&md5=00265204d17a421658d3361a5528fd8c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000069686.31472.C5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000069686.31472.C5%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DMaier%26aufirst%3DL.%2BS.%26aulast%3DDalton%26aufirst%3DN.%2BD.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DBers%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26atitle%3DThe%2520deltaC%2520isoform%2520of%2520CaMKII%2520is%2520activated%2520in%2520cardiac%2520hypertrophy%2520and%2520induces%2520dilated%2520cardiomyopathy%2520and%2520heart%2520failure%26jtitle%3DCirc.%2520Res.%26date%3D2003%26volume%3D92%26spage%3D912%26epage%3D919%26doi%3D10.1161%2F01.RES.0000069686.31472.C5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willeford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Respress, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrens, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span> <span> </span><span class="NLM_article-title">CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca(2+) leak and the pathophysiological response to chronic β-adrenergic stimulation</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2015.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2015.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26080362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVyiu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2015&pages=282-291&author=M.+Grimmauthor=H.+Lingauthor=A.+Willefordauthor=L.+Pereiraauthor=C.+B.+Grayauthor=J.+R.+Ericksonauthor=S.+Sarmaauthor=J.+L.+Respressauthor=X.+H.+Wehrensauthor=D.+M.+Bersauthor=J.+H.+Brown&title=CaMKII%CE%B4+mediates+%CE%B2-adrenergic+effects+on+RyR2+phosphorylation+and+SR+Ca%282%2B%29+leak+and+the+pathophysiological+response+to+chronic+%CE%B2-adrenergic+stimulation&doi=10.1016%2Fj.yjmcc.2015.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca2+ leak and the pathophysiological response to chronic β-adrenergic stimulation</span></div><div class="casAuthors">Grimm, Michael; Ling, Haiyun; Willeford, Andrew; Pereira, Laetitia; Gray, Charles B. B.; Erickson, Jeffrey R.; Sarma, Satyam; Respress, Jonathan L.; Wehrens, Xander H. T.; Bers, Donald M.; Brown, Joan Heller</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">282-291</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic activation of Ca2 +/calmodulin-dependent protein kinase II (CaMKII) has been implicated in the deleterious effects of β-adrenergic receptor (β-AR) signaling on the heart, in part, by enhancing RyR2-mediated sarcoplasmic reticulum (SR) Ca2 + leak.  We used CaMKIIδ knockout (CaMKIIδ-KO) mice and knock-in mice with an inactivated CaMKII site S2814 on the ryanodine receptor type 2 (S2814A) to investigate the involvement of these processes in β-AR signaling and cardiac remodeling.  Langendorff-perfused hearts from CaMKIIδ-KO mice showed inotropic and chronotropic responses to isoproterenol (ISO) that were similar to those of wild type (WT) mice; however, in CaMKIIδ-KO mice, CaMKII phosphorylation of phospholamban and RyR2 was decreased and isolated myocytes from CaMKIIδ-KO mice had reduced SR Ca2 + leak in response to isoproterenol (ISO).  Chronic catecholamine stress with ISO induced comparable increases in relative heart wt. and other measures of hypertrophy from day 9 through week 4 in WT and CaMKIIδ-KO mice, but the development of cardiac fibrosis was prevented in CaMKIIδ-KO animals.  A 4-wk challenge with ISO resulted in reduced cardiac function and pulmonary congestion in WT, but not in CaMKIIδ-KO or S2814A mice, implicating CaMKIIδ-dependent phosphorylation of RyR2-S2814 in the cardiomyopathy, independent of hypertrophy, induced by prolonged β-AR stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCx-_A00JgXLVg90H21EOLACvtfcHk0liPRzOsxGHYsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVyiu7jF&md5=7b085abac5f2597cba08a99c11fd4f0f</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2015.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2015.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DGrimm%26aufirst%3DM.%26aulast%3DLing%26aufirst%3DH.%26aulast%3DWilleford%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DC.%2BB.%26aulast%3DErickson%26aufirst%3DJ.%2BR.%26aulast%3DSarma%26aufirst%3DS.%26aulast%3DRespress%26aufirst%3DJ.%2BL.%26aulast%3DWehrens%26aufirst%3DX.%2BH.%26aulast%3DBers%26aufirst%3DD.%2BM.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26atitle%3DCaMKII%25CE%25B4%2520mediates%2520%25CE%25B2-adrenergic%2520effects%2520on%2520RyR2%2520phosphorylation%2520and%2520SR%2520Ca%25282%252B%2529%2520leak%2520and%2520the%2520pathophysiological%2520response%2520to%2520chronic%2520%25CE%25B2-adrenergic%2520stimulation%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2015%26volume%3D85%26spage%3D282%26epage%3D291%26doi%3D10.1016%2Fj.yjmcc.2015.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Interaction of beta1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>, <span class="NLM_elocation-id">e84969</span> <span class="refDoi"> DOI: 10.1172/jci.insight.84969</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2Fjci.insight.84969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26966719" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&author=W.+Zhuauthor=S.+Tsangauthor=D.+M.+Broweauthor=A.+Y.+Wooauthor=Y.+Huangauthor=C.+Xuauthor=J.+F.+Liuauthor=F.+Lvauthor=Y.+Zhangauthor=R.+P.+Xiao&title=Interaction+of+beta1-adrenoceptor+with+RAGE+mediates+cardiomyopathy+via+CaMKII+signaling&doi=10.1172%2Fjci.insight.84969"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.84969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.84969%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTsang%26aufirst%3DS.%26aulast%3DBrowe%26aufirst%3DD.%2BM.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DInteraction%2520of%2520beta1-adrenoceptor%2520with%2520RAGE%2520mediates%2520cardiomyopathy%2520via%2520CaMKII%2520signaling%26jtitle%3DJCI%2520Insight%26date%3D2016%26volume%3D1%26doi%3D10.1172%2Fjci.insight.84969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cigarroa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risser, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayburn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E. J.</span></span> <span> </span><span class="NLM_article-title">Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1016/0735-1097(94)00543-Y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2F0735-1097%2894%2900543-Y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7897129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2M3gsVyhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1995&pages=1154-1161&author=S.+A.+Hallauthor=C.+G.+Cigarroaauthor=L.+Marcouxauthor=R.+C.+Risserauthor=P.+A.+Grayburnauthor=E.+J.+Eichhorn&title=Time+course+of+improvement+in+left+ventricular+function%2C+mass+and+geometry+in+patients+with+congestive+heart+failure+treated+with+beta-adrenergic+blockade&doi=10.1016%2F0735-1097%2894%2900543-Y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade</span></div><div class="casAuthors">Hall S A; Cigarroa C G; Marcoux L; Risser R C; Grayburn P A; Eichhorn E J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1154-61</span>
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    </div><div class="casAbstract">OBJECTIVES:  We examined the time course of ventricular functional improvement in patients with dilated cardiomyopathy who received beta-blockade and the long-term effects of beta-blockade on ventricular mass and geometry in these patients.  BACKGROUND:  Previous studies have shown that beta-adrenergic blocking agents when administered long term improve ventricular function in patients with heart failure.  However, the time course of improvement in ventricular function and the long-term effects of beta-blockade on ventricular mass and geometry are not known.  METHODS:  Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10).  At 3 months all patients on standard therapy were crossed over to metoprolol, and late echocardiograms were obtained after 18 +/- 5 (mean +/- SD) months of metoprolol therapy.  All echocardiograms were read in blinded manner.  RESULTS:  Patients treated with metoprolol had an initial decline (day 1 vs. day 0) in ventricular function (increase in end-systolic volume and decrease in ejection fraction).  Ventricular function improved between months 1 and 3 (p = 0.013, metoprolol vs. standard therapy).  Left ventricular mass regressed at 18 months (333 +/- 85 to 275 +/- 53 g, p = 0.011) but not at 3 months.  Left ventricular shape became less spherical and assumed a more normal elliptical shape by 18 months (major/minor axis ratio 1.5 +/- 0.2 to 1.7 +/- 0.2, p = 0.0001).  CONCLUSIONS:  Patients with heart failure treated with metoprolol do not demonstrate an improvement in systolic performance until after 1 month of therapy and may have a mild reduction in function initially.  Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression of left ventricular mass and improved ventricular geometry by 18 months.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStrLjIxZIbluRS7coPn-RtfW6udTcc2eZGbrKyev4QE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3gsVyhsA%253D%253D&md5=28451528476d691a59451c7920b26e4f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2F0735-1097%2894%2900543-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0735-1097%252894%252900543-Y%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DS.%2BA.%26aulast%3DCigarroa%26aufirst%3DC.%2BG.%26aulast%3DMarcoux%26aufirst%3DL.%26aulast%3DRisser%26aufirst%3DR.%2BC.%26aulast%3DGrayburn%26aufirst%3DP.%2BA.%26aulast%3DEichhorn%26aufirst%3DE.%2BJ.%26atitle%3DTime%2520course%2520of%2520improvement%2520in%2520left%2520ventricular%2520function%252C%2520mass%2520and%2520geometry%2520in%2520patients%2520with%2520congestive%2520heart%2520failure%2520treated%2520with%2520beta-adrenergic%2520blockade%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D1995%26volume%3D25%26spage%3D1154%26epage%3D1161%26doi%3D10.1016%2F0735-1097%2894%2900543-Y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mealy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larrabee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, M. R.</span></span> <span> </span><span class="NLM_article-title">Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.94.11.2817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.94.11.2817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8941107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXlsVShug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1996&pages=2817-2825&author=E.+M.+Gilbertauthor=W.+T.+Abrahamauthor=S.+Olsenauthor=B.+Hattlerauthor=M.+Whiteauthor=P.+Mealyauthor=P.+Larrabeeauthor=M.+R.+Bristow&title=Comparative+hemodynamic%2C+left+ventricular+functional%2C+and+antiadrenergic+effects+of+chronic+treatment+with+metoprolol+versus+carvedilol+in+the+failing+heart&doi=10.1161%2F01.CIR.94.11.2817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart</span></div><div class="casAuthors">Gilbert, Edward M.; Abraham, William T.; Olsen, Stephanie; Hattler, Brack; White, Michel; Mealy, Patrice; Larrabee, Patti; Bristow, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2817-2825</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">American Heart Association</span>)
        </div><div class="casAbstract">The basic pharmacol. of the third-generation β-blocking agent carvedilol differs considerably from second-generation compds. such as metoprolol.  Moreover, carvedilol may produce different, i.e., more favorable, clin. effects in chronic heart failure.  For these reasons, the authors compared the effects of carvedilol and metoprolol on adrenergic activity, receptor expression, degree of clin. β-blockade, hemodynamics, and left ventricular function in patients with mild or moderate chronic heart failure.  The effects of carvedilol vs. metoprolol were compared in two concurrent placebo-controlled trials with carvedilol or metoprolol that had common substudies focused on adrenergic, hemodynamic, and left ventricular functional measurements.  All subjects in the substudies had chronic heart failure resulting from idiopathic dilated cardiomyopathy.  Carvedilol at 50 to 100 mg/d produced redns. in exercise heart rate that were similar to metoprolol at 125 to 150 mg/d, indicating comparable degrees of β-blockade.  Compared with metoprolol, carvedilol was assocd. with greater improvement in New York Heart Assocn. functional class.  Although there were no significant differences in hemodynamic effects between the carvedilol and metoprolol active-treatment groups, carvedilol tended to produce relatively greater improvements in left ventricular ejection fraction, stroke vol., and stroke work compared with changes in the resp. placebo groups.  Carvedilol selectively lowered coronary sinus norepinephrine levels, an index of cardiac adrenergic activity, whereas metoprolol did not lower coronary sinus norepinephrine and actually increased central venous norepinephrine levels.  Finally, metoprolol was assocd. with an increase in cardiac β-receptor d., whereas carvedilol did not change cardiac β-receptor expression.  The third-generation β-blocking agent carvedilol has substantially different effects on left ventricular function, hemodynamics, adrenergic activity, and β-receptor expression than does the second-generation compd. metoprolol.  Some or all of these differences may explain the apparent differences in clin. results between the two compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo70WApcowSPrVg90H21EOLACvtfcHk0lg2RPB1Y8m2IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlsVShug%253D%253D&md5=733186f011680d86299fe8a4a35d7e4c</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.94.11.2817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.94.11.2817%26sid%3Dliteratum%253Aachs%26aulast%3DGilbert%26aufirst%3DE.%2BM.%26aulast%3DAbraham%26aufirst%3DW.%2BT.%26aulast%3DOlsen%26aufirst%3DS.%26aulast%3DHattler%26aufirst%3DB.%26aulast%3DWhite%26aufirst%3DM.%26aulast%3DMealy%26aufirst%3DP.%26aulast%3DLarrabee%26aufirst%3DP.%26aulast%3DBristow%26aufirst%3DM.%2BR.%26atitle%3DComparative%2520hemodynamic%252C%2520left%2520ventricular%2520functional%252C%2520and%2520antiadrenergic%2520effects%2520of%2520chronic%2520treatment%2520with%2520metoprolol%2520versus%2520carvedilol%2520in%2520the%2520failing%2520heart%26jtitle%3DCirculation%26date%3D1996%26volume%3D94%26spage%3D2817%26epage%3D2825%26doi%3D10.1161%2F01.CIR.94.11.2817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickenig, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRosee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crivaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stäblein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuttke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, M.</span></span> <span> </span><span class="NLM_article-title">Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(01)01471-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0735-1097%2801%2901471-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11583862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVeksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2001&pages=939-946&author=C.+Maackauthor=T.+Elterauthor=G.+Nickenigauthor=K.+LaRoseeauthor=M.+Crivaroauthor=A.+St%C3%A4bleinauthor=H.+Wuttkeauthor=M.+B%C3%B6hm&title=Prospective+crossover+comparison+of+carvedilol+and+metoprolol+in+patients+with+chronic+heart+failure&doi=10.1016%2FS0735-1097%2801%2901471-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure</span></div><div class="casAuthors">Maack, Christoph; Elter, Thomas; Nickenig, Georg; LaRosee, Karl; Crivaro, Marina; Stablein, Alexander; Wuttke, Henrike; Bohm, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">939-946</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF).  Beta-blockers improve ventricular function and prolong survival in patients with HF.  It has recently been suggested that carvedilol has more pronounced effects on left ventricular ejection fraction (LVEF) compared with metoprolol.  It is uncertain whether a change from one beta-blocker to the other is safe and leads to any change of left ventricular function.  Forty-four patients with HF due to ischemic (n = 17) or idiopathic cardiomyopathy (n = 27) that had responded well to long-term treatment with either metoprolol (n = 20) or carvedilol (n = 24) were switched to an equiv. dose of the resp. other beta-blocker.  Before and six months after crossover of treatment, echocardiog., radionuclide ventriculog. and dobutamine stress echocardiog. were performed.  Six months after crossover of beta-blocker treatment, LVEF had further improved with both carvedilol and metoprolol (carvedilol: 32±3% to 36±4%; metoprolol: 27±4% to 30±5%; both p < 0.05 vs. baseline), without interindividual differences.  There were no changes in either New York Heart Assocn. functional class or any other hemodynamic parameters at rest.  Dobutamine stress echocardiog. revealed a more pronounced increase of heart rate after dobutamine infusion in metoprolol- compared with carvedilol-treated patients.  After dobutamine infusion, LVEF increased in the carvedilol- but not in the metoprolol-treated group.  When switching treatment from one beta-blocker to the other, improvement of LVEF in patients with HF is maintained.  Despite similar long-term effects on hemodynamics at rest, beta-adrenergic responsiveness is different in both treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWM6Qk1_MpjbVg90H21EOLACvtfcHk0ljpScZMsbXabg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVeksbw%253D&md5=b6d004aeb25e7cdecb0fcee025a56bc2</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2801%2901471-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252801%252901471-1%26sid%3Dliteratum%253Aachs%26aulast%3DMaack%26aufirst%3DC.%26aulast%3DElter%26aufirst%3DT.%26aulast%3DNickenig%26aufirst%3DG.%26aulast%3DLaRosee%26aufirst%3DK.%26aulast%3DCrivaro%26aufirst%3DM.%26aulast%3DSt%25C3%25A4blein%26aufirst%3DA.%26aulast%3DWuttke%26aufirst%3DH.%26aulast%3DB%25C3%25B6hm%26aufirst%3DM.%26atitle%3DProspective%2520crossover%2520comparison%2520of%2520carvedilol%2520and%2520metoprolol%2520in%2520patients%2520with%2520chronic%2520heart%2520failure%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2001%26volume%3D38%26spage%3D939%26epage%3D946%26doi%3D10.1016%2FS0735-1097%2801%2901471-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation?</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1007/s00395-016-0582-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00395-016-0582-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27683175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2snht12ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=66-69&author=F.+Cuelloauthor=K.+Lorenz&title=Inhibition+of+cardiac+CaMKII+to+cure+heart+failure%3A+step+by+step+towards+translation%3F&doi=10.1007%2Fs00395-016-0582-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation?</span></div><div class="casAuthors">Cuello Friederike; Cuello Friederike; Lorenz Kristina; Lorenz Kristina; Lorenz Kristina</div><div class="citationInfo"><span class="NLM_cas:title">Basic research in cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWsQbBLvDmBC6Ufuk_1xoTfW6udTcc2ebIWEpL8ePr8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snht12ntg%253D%253D&md5=5d31bd6aacb23461719c498b87d6bd81</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs00395-016-0582-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-016-0582-1%26sid%3Dliteratum%253Aachs%26aulast%3DCuello%26aufirst%3DF.%26aulast%3DLorenz%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520cardiac%2520CaMKII%2520to%2520cure%2520heart%2520failure%253A%2520step%2520by%2520step%2520towards%2520translation%253F%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2016%26volume%3D111%26spage%3D66%26epage%3D69%26doi%3D10.1007%2Fs00395-016-0582-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwenger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dybkova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L. S.</span></span> <span> </span><span class="NLM_article-title">Reduction of SR Ca<sup>2+</sup> leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability</span>. <i>Basic Res. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1007/s00395-017-0637-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00395-017-0637-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28612156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC1cnotVKrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=45&author=S.+Neefauthor=C.+Mannauthor=A.+Zwengerauthor=N.+Dybkovaauthor=L.+S.+Maier&title=Reduction+of+SR+Ca2%2B+leak+and+arrhythmogenic+cellular+correlates+by+SMP-114%2C+a+novel+CaMKII+inhibitor+with+oral+bioavailability&doi=10.1007%2Fs00395-017-0637-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of SR Ca(2+) leak and arrhythmogenic cellular correlates by SMP-114, a novel CaMKII inhibitor with oral bioavailability</span></div><div class="casAuthors">Neef Stefan; Maier Lars S; Mann Christian; Zwenger Anne; Dybkova Nataliya</div><div class="citationInfo"><span class="NLM_cas:title">Basic research in cardiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sarcoplasmic reticulum (SR) Ca(2+) leak induced by Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) is centrally involved in atrial and ventricular arrhythmogenesis as well as heart failure remodeling.  Consequently, treating SR Ca(2+) leak has been proposed as a novel therapeutic paradigm, but compounds for use in humans are lacking.  SMP-114 ("Rimacalib") is a novel, orally available CaMKII inhibitor developed for human use that has already entered clinical phase II trials to treat rheumatoid arthritis.  We speculated that SMP-114 might also be useful to treat cardiac SR Ca(2+) leak.  SMP-114 significantly reduces SR Ca(2+) leak (as assessed by Ca(2+) sparks) in human atrial (0.72 ± 0.33 sparks/100 μm/s vs. control 3.02 ± 0.91 sparks/100 μm/s) and failing left ventricular (0.78 ± 0.23 vs. 1.69 ± 0.27 sparks/100 μm/s) as well as in murine ventricular cardiomyocytes (0.30 ± 0.07 vs. 1.50 ± 0.28 sparks/100 μm/s).  Associated with lower SR Ca(2+) leak, we found that SMP-114 suppressed the occurrence of spontaneous arrhythmogenic spontaneous Ca(2+) release (0.356 ± 0.109 vs. 0.927 ± 0.216 events per 30 s stimulation cessation).  In consequence, post-rest potentiation of Ca(2+)-transient amplitude (measured using Fura-2) during the 30 s pause was improved by SMP-114 (52 ± 5 vs. 37 ± 4%).  Noteworthy, SMP-114 has these beneficial effects without negatively impairing global excitation-contraction coupling: neither systolic Ca(2+) release nor single cell contractility was compromised, and also SR Ca(2+) reuptake, in line with resulting cardiomyocyte relaxation, was not impaired by SMP-114 in our assays.  SMP-114 demonstrated potential to treat SR Ca(2+) leak and consequently proarrhythmogenic events in rodent as well as in human atrial cardiomyocytes and cardiomyocytes from patients with heart failure.  Further research is necessary towards clinical use in cardiac disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRra3kow31our0AGQpJZWpJfW6udTcc2ebIWEpL8ePr8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnotVKrsw%253D%253D&md5=a53933be53a41f99df18771973c171b5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs00395-017-0637-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00395-017-0637-y%26sid%3Dliteratum%253Aachs%26aulast%3DNeef%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DC.%26aulast%3DZwenger%26aufirst%3DA.%26aulast%3DDybkova%26aufirst%3DN.%26aulast%3DMaier%26aufirst%3DL.%2BS.%26atitle%3DReduction%2520of%2520SR%2520Ca2%252B%2520leak%2520and%2520arrhythmogenic%2520cellular%2520correlates%2520by%2520SMP-114%252C%2520a%2520novel%2520CaMKII%2520inhibitor%2520with%2520oral%2520bioavailability%26jtitle%3DBasic%2520Res.%2520Cardiol.%26date%3D2017%26volume%3D112%26spage%3D45%26doi%3D10.1007%2Fs00395-017-0637-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beauverger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozoux, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bégis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glénat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daveu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorchies, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauchet, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamarelle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruniaux, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muslin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janiak, P.</span></span> <span> </span><span class="NLM_article-title">Reversion of cardiac dysfunction by a novel orally available calcium/calmodulin-dependent protein kinase II inhibitor, RA306, in a genetic model of dilated cardiomyopathy</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvz097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvz097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=329-338&author=P.+Beauvergerauthor=M.+L.+Ozouxauthor=G.+B%C3%A9gisauthor=V.+Gl%C3%A9natauthor=V.+Briandauthor=M.+C.+Philippoauthor=C.+Daveuauthor=G.+Tavaresauthor=S.+Royauthor=A.+Corbierauthor=P.+Briandauthor=O.+Dorchiesauthor=A.+L.+Bauchetauthor=E.+Nicolaiauthor=O.+Duclosauthor=D.+Tamarelleauthor=M.+P.+Pruniauxauthor=A.+J.+Muslinauthor=P.+Janiak&title=Reversion+of+cardiac+dysfunction+by+a+novel+orally+available+calcium%2Fcalmodulin-dependent+protein+kinase+II+inhibitor%2C+RA306%2C+in+a+genetic+model+of+dilated+cardiomyopathy&doi=10.1093%2Fcvr%2Fcvz097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvz097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvz097%26sid%3Dliteratum%253Aachs%26aulast%3DBeauverger%26aufirst%3DP.%26aulast%3DOzoux%26aufirst%3DM.%2BL.%26aulast%3DB%25C3%25A9gis%26aufirst%3DG.%26aulast%3DGl%25C3%25A9nat%26aufirst%3DV.%26aulast%3DBriand%26aufirst%3DV.%26aulast%3DPhilippo%26aufirst%3DM.%2BC.%26aulast%3DDaveu%26aufirst%3DC.%26aulast%3DTavares%26aufirst%3DG.%26aulast%3DRoy%26aufirst%3DS.%26aulast%3DCorbier%26aufirst%3DA.%26aulast%3DBriand%26aufirst%3DP.%26aulast%3DDorchies%26aufirst%3DO.%26aulast%3DBauchet%26aufirst%3DA.%2BL.%26aulast%3DNicolai%26aufirst%3DE.%26aulast%3DDuclos%26aufirst%3DO.%26aulast%3DTamarelle%26aufirst%3DD.%26aulast%3DPruniaux%26aufirst%3DM.%2BP.%26aulast%3DMuslin%26aufirst%3DA.%2BJ.%26aulast%3DJaniak%26aufirst%3DP.%26atitle%3DReversion%2520of%2520cardiac%2520dysfunction%2520by%2520a%2520novel%2520orally%2520available%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520II%2520inhibitor%252C%2520RA306%252C%2520in%2520a%2520genetic%2520model%2520of%2520dilated%2520cardiomyopathy%26jtitle%3DCardiovasc.%2520Res.%26date%3D2019%26volume%3D116%26spage%3D329%26epage%3D338%26doi%3D10.1093%2Fcvr%2Fcvz097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mustroph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagemann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lücht, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammer, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sag, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarnowski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perbellini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schopka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zausig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sossalla, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span> <span> </span><span class="NLM_article-title">Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes</span>. <i>ESC Heart Fail</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">642</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1002/ehf2.12336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fehf2.12336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30117720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ptV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=642-648&author=J.+Mustrophauthor=O.+Wagemannauthor=C.+M.+L%C3%BCchtauthor=M.+Trumauthor=K.+P.+Hammerauthor=C.+M.+Sagauthor=S.+Lebekauthor=D.+Tarnowskiauthor=J.+Reindersauthor=F.+Perbelliniauthor=C.+Terraccianoauthor=C.+Schmidauthor=S.+Schopkaauthor=M.+Hilkerauthor=Y.+Zausigauthor=S.+Pabelauthor=S.+T.+Sossallaauthor=F.+Schwedaauthor=L.+S.+Maierauthor=S.+Wagner&title=Empagliflozin+reduces+Ca%2Fcalmodulin-dependent+kinase+II+activity+in+isolated+ventricular+cardiomyocytes&doi=10.1002%2Fehf2.12336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes</span></div><div class="casAuthors">Mustroph Julian; Wagemann Olivia; Lucht Charlotte M; Trum Maximilian; Hammer Karin P; Sag Can Martin; Lebek Simon; Tarnowski Daniel; Pabel Steffen; Sossalla Samuel T; Maier Lars S; Wagner Stefan; Reinders Jorg; Perbellini Filippo; Terracciano Cesare; Schmid Christof; Schopka Simon; Hilker Michael; Zausig York; Sossalla Samuel T; Schweda Frank</div><div class="citationInfo"><span class="NLM_cas:title">ESC heart failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">642-648</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  The EMPA-REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin.  Overexpression and Ca(2+) -dependent activation of Ca(2+) /calmodulin-dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfunction and arrhythmias.  We tested whether empagliflozin reduces CaMKII- activity and improves Ca(2+) -handling in human and murine ventricular myocytes.  METHODS AND RESULTS:  Myocytes from wild-type mice, mice with transverse aortic constriction (TAC) as a model of HF, and human failing ventricular myocytes were exposed to empagliflozin (1 μmol/L) or vehicle.  CaMKII activity was assessed by CaMKII-histone deacetylase pulldown assay.  Ca(2+) spark frequency (CaSpF) as a measure of sarcoplasmic reticulum (SR) Ca(2+) leak was investigated by confocal microscopy. [Na(+) ]i was measured using Na(+) /Ca(2+) -exchanger (NCX) currents (whole-cell patch clamp).  Compared with vehicle, 24 h empagliflozin exposure of murine myocytes reduced CaMKII activity (1.6 ± 0.7 vs. 4.2 ± 0.9, P < 0.05, n = 10 mice), and also CaMKII-dependent ryanodine receptor phosphorylation (0.8 ± 0.1 vs. 1.0 ± 0.1, P < 0.05, n = 11 mice), with similar results upon TAC.  In murine myocytes, empagliflozin reduced CaSpF (TAC: 1.7 ± 0.3 vs. 2.5 ± 0.4 1/100 μm(-1)  s(-1) , P < 0.05, n = 4 mice) but increased SR Ca(2+) load and Ca(2+) transient amplitude.  Importantly, empagliflozin also significantly reduced CaSpF in human failing ventricular myocytes (1 ± 0.2 vs. 3.3 ± 0.9, P < 0.05, n = 4 patients), while Ca(2+) transient amplitude was increased (F/F0 : 0.53 ± 0.05 vs. 0.36 ± 0.02, P < 0.05, n = 3 patients).  In contrast, 30 min exposure with empagliflozin did not affect CaMKII activity nor Ca(2+) -handling but significantly reduced [Na(+) ]i .  CONCLUSIONS:  We show for the first time that empagliflozin reduces CaMKII activity and CaMKII-dependent SR Ca(2+) leak.  Reduced Ca(2+) leak and improved Ca(2+) transients may contribute to the beneficial effects of empagliflozin in HF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRNBuaIp3j4AUGy1nwu7K2mfW6udTcc2eYU3cXxceRxXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ptV2rsw%253D%253D&md5=41eb4f090c8de88a053ada619d49bc0f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fehf2.12336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fehf2.12336%26sid%3Dliteratum%253Aachs%26aulast%3DMustroph%26aufirst%3DJ.%26aulast%3DWagemann%26aufirst%3DO.%26aulast%3DL%25C3%25BCcht%26aufirst%3DC.%2BM.%26aulast%3DTrum%26aufirst%3DM.%26aulast%3DHammer%26aufirst%3DK.%2BP.%26aulast%3DSag%26aufirst%3DC.%2BM.%26aulast%3DLebek%26aufirst%3DS.%26aulast%3DTarnowski%26aufirst%3DD.%26aulast%3DReinders%26aufirst%3DJ.%26aulast%3DPerbellini%26aufirst%3DF.%26aulast%3DTerracciano%26aufirst%3DC.%26aulast%3DSchmid%26aufirst%3DC.%26aulast%3DSchopka%26aufirst%3DS.%26aulast%3DHilker%26aufirst%3DM.%26aulast%3DZausig%26aufirst%3DY.%26aulast%3DPabel%26aufirst%3DS.%26aulast%3DSossalla%26aufirst%3DS.%2BT.%26aulast%3DSchweda%26aufirst%3DF.%26aulast%3DMaier%26aufirst%3DL.%2BS.%26aulast%3DWagner%26aufirst%3DS.%26atitle%3DEmpagliflozin%2520reduces%2520Ca%252Fcalmodulin-dependent%2520kinase%2520II%2520activity%2520in%2520isolated%2520ventricular%2520cardiomyocytes%26jtitle%3DESC%2520Heart%2520Fail%26date%3D2018%26volume%3D5%26spage%3D642%26epage%3D648%26doi%3D10.1002%2Fehf2.12336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 reduces ventricular arrhythmia activity and calcium sparks-mediated sarcoplasmic reticulum Ca leak in rats with heart failure</span>. <i>Int. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1536/ihj.19-327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1536%2Fihj.19-327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31956148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFWitbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=145-152&author=J.+Chenauthor=S.+Xuauthor=W.+Zhouauthor=L.+Wuauthor=L.+Wangauthor=W.+Li&title=Exendin-4+reduces+ventricular+arrhythmia+activity+and+calcium+sparks-mediated+sarcoplasmic+reticulum+Ca+leak+in+rats+with+heart+failure&doi=10.1536%2Fihj.19-327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 reduces ventricular arrhythmia activity and calcium sparks-mediated sarcoplasmic reticulum ca leak in rats with heart failure</span></div><div class="casAuthors">Chen, Jingjing; Xu, Shunen; Zhou, Wei; Wu, Lirong; Wang, Long; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">International Heart Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-152</span>CODEN:
                <span class="NLM_cas:coden">IHJNAJ</span>;
        ISSN:<span class="NLM_cas:issn">1349-3299</span>.
    
            (<span class="NLM_cas:orgname">International Heart Journal Association</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the effect of exendin-4 (Ex-4) on ventricular arrhythmias and calcium sparks-mediated calcium leak in a myocardial infarction-heart failure model.  We studied the influence of exendin-4 on ventricular arrhythmogenesis in a rat myocardial infarction-heart failure model.  In vivo arrhythmia studies (ECG [ECG] telemetry studies), ex vivo arrhythmia studies calcium sparks tests.  ECG telemetry studies showed an antiarrhythmic effect of exendin-4 with redn. of spontaneous ventricular arrhythmias.  Exendin-4 abbreviated the APD90, which was longer in the heart failure model, and increase the APD alternans thresholds.  Exendin-4 also reduced the susceptibility to burst pacing-induced arrhythmia ex vivo.  Subcellular sarcoplasmic reticulum (SR) calcium leak characteristics were tested in four groups of rat cardiomyocytes.  Exendin-4 reduced calcium spark mass, spark frequency, and calcium leak, which may be due to reduced S2814-RyR2 and CaMK-II phosphorylation.  Co-administration of exendin 9-39 with exendin-4 partly abolished the above-mentioned effect of exendin-4.  These findings suggest that exendin-4 exerts an antiarrhythmic effect through decreasing SR calcium leak in spontaneous and burst pacing-induced ventricular arrhythmias, which may be due to reduced RyR2 phosphorylation and suppressed CaMK-II activity.  Exendin-4 may act as a novel antiarrhythmic strategy in heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjB3FP8SNl17Vg90H21EOLACvtfcHk0ljVAyvrQEy_dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFWitbbO&md5=cdfdc524e0ee2c6f7b9e57e97a367e73</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1536%2Fihj.19-327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1536%252Fihj.19-327%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DExendin-4%2520reduces%2520ventricular%2520arrhythmia%2520activity%2520and%2520calcium%2520sparks-mediated%2520sarcoplasmic%2520reticulum%2520Ca%2520leak%2520in%2520rats%2520with%2520heart%2520failure%26jtitle%3DInt.%2520Heart%2520J.%26date%3D2020%26volume%3D61%26spage%3D145%26epage%3D152%26doi%3D10.1536%2Fihj.19-327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorn, G. W.,  2nd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepe, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liggett, S. B.</span></span> <span> </span><span class="NLM_article-title">Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">6400</span>– <span class="NLM_lpage">6405</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.11.6400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.96.11.6400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10339599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXksFKkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=6400-6405&author=G.+W.+Dornauthor=N.+M.+Tepeauthor=J.+N.+Lorenzauthor=W.+J.+Kochauthor=S.+B.+Liggett&title=Low-+and+high-level+transgenic+expression+of+beta2-adrenergic+receptors+differentially+affect+cardiac+hypertrophy+and+function+in+Galphaq-overexpressing+mice&doi=10.1073%2Fpnas.96.11.6400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice</span></div><div class="casAuthors">Dorn, Gerald W., II; Tepe, Nicole M.; Lorenz, John N.; Koch, Walter J.; Liggett, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">6400-6405</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Transgenic overexpression of Gαq in the heart triggers events leading to a phenotype of eccentric hypertrophy, depressed ventricular function, marked expression of hypertrophy-assocd. genes, and depressed β-adrenergic receptor (βAR) function.  The role of βAR dysfunction in the development of this failure phenotype was delineated by transgenic coexpression of the carboxyl terminus of the βAR kinase (βARK), which acts to inhibit the kinase, or concomitant overexpression of the β2AR at low (≈30-fold, Gαq/β2ARL), moderate (≈140-fold, Gαq/β2ARM), and high (≈1,000-fold, Gαq/β2ARH) levels above background βAR d.  Expression of the βARK inhibitor had no effect on the phenotype, consistent with the lack of increased βARK levels in Gαq mice.  In marked contrast, Gαq/β2ARL mice displayed rescue of hypertrophy and resting ventricular function and decreased cardiac expression of atrial natriuretic factor and α-skeletal actin mRNA.  These effects occurred in the absence of any improvement in basal or agonist-stimulated adenylyl cyclase (AC) activities in crude cardiac membranes, although restoration of a compartmentalized β2AR/AC signal cannot be excluded.  Higher expression of receptors in Gαq/β2ARM mice resulted in salvage of AC activity, but hypertrophy, ventricular function, and expression of fetal genes were unaffected or worsened.  With ≈1,000-fold overexpression, the majority of Gαq/β2ARH mice died with cardiomegaly at 5 wk.  Thus, although it appears that excessive, uncontrolled, or generalized augmentation of βAR signaling is deleterious in heart failure, selective enhancement by overexpressing the β2AR subtype to limited levels restores not only ventricular function but also reverses cardiac hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXgm5WNwYJkrVg90H21EOLACvtfcHk0ljVAyvrQEy_dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksFKkt7g%253D&md5=01ad0a99c5d0e874294216df85e63838</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.11.6400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.11.6400%26sid%3Dliteratum%253Aachs%26aulast%3DDorn%26aufirst%3DG.%2BW.%26aulast%3DTepe%26aufirst%3DN.%2BM.%26aulast%3DLorenz%26aufirst%3DJ.%2BN.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26atitle%3DLow-%2520and%2520high-level%2520transgenic%2520expression%2520of%2520beta2-adrenergic%2520receptors%2520differentially%2520affect%2520cardiac%2520hypertrophy%2520and%2520function%2520in%2520Galphaq-overexpressing%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D6400%26epage%3D6405%26doi%3D10.1073%2Fpnas.96.11.6400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span> <span> </span><span class="NLM_article-title">Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart</span>. <i>Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1041</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1097/01.CCM.0000120049.43113.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1097%2F01.CCM.0000120049.43113.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15071399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD2c3gtVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=1041-1048&author=A.+J.+Pattersonauthor=W.+Zhuauthor=A.+Chowauthor=R.+Agrawalauthor=J.+Kosekauthor=R.+P.+Xiaoauthor=B.+Kobilka&title=Protecting+the+myocardium%3A+a+role+for+the+beta2+adrenergic+receptor+in+the+heart&doi=10.1097%2F01.CCM.0000120049.43113.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart</span></div><div class="casAuthors">Patterson Andrew J; Zhu Weizhong; Chow Amy; Agrawal Rani; Kosek Jon; Xiao Rui Ping; Kobilka Brian</div><div class="citationInfo"><span class="NLM_cas:title">Critical care medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1041-8</span>
        ISSN:<span class="NLM_cas:issn">0090-3493</span>.
    </div><div class="casAbstract">OBJECTIVE:  The sympathetic nervous system enhances cardiac muscle function by activating beta adrenergic receptors (betaARs).  Recent studies suggest that chronic betaAR stimulation is detrimental, however, and that it may play a role in the clinical deterioration of patients with congestive heart failure.  To examine the impact of chronic beta1AR and beta2AR subtype stimulation individually, we studied the cardiovascular effects of catecholamine infusions in betaAR subtype knockout mice (beta1KO, beta2KO).  DESIGN:  Prospective, randomized, experimental study.  SETTING:  Animal research laboratory.  SUBJECTS:  beta1KO and beta2KO mice and wild-type controls.  INTERVENTIONS:  The animals were subjected to 2 wks of continuous infusion of the betaAR agonist isoproterenol.  Analyses of cardiac function and structure were performed during and 3 days after completion of the infusions.  Functional studies included graded exercise treadmill testing, in vivo assessments of left ventricular function using Mikro-Tip catheter transducers, right ventricular pressure measurements, and analyses of organ weight to body weight ratios.  Structural studies included heart weight measurements, assessments of myocyte ultrastructure using electron microscopy, and in situ terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick-end labeling staining to quantitate myocyte apoptosis.  MEASUREMENTS AND MAIN RESULTS:  We found that isoproterenol-treated beta2KO mice experienced greater mortality rates (p =.001, chi-square test using Fisher's exact method) and increased myocyte apoptosis at 3- and 7-day time points (p =.04 and p =.0007, respectively, two-way analysis of variance).  CONCLUSION:  The results of this study suggest that in vivo beta2AR activation is antiapoptotic and contributes to myocardial protection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzob1NdxswGcNIRw0GKUoEfW6udTcc2eZpwRD2OVGROLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3gtVOqtQ%253D%253D&md5=b8c0bd09552830f3c76f5850c2d28242</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1097%2F01.CCM.0000120049.43113.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.CCM.0000120049.43113.90%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DA.%2BJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChow%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DR.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DKobilka%26aufirst%3DB.%26atitle%3DProtecting%2520the%2520myocardium%253A%2520a%2520role%2520for%2520the%2520beta2%2520adrenergic%2520receptor%2520in%2520the%2520heart%26jtitle%3DCrit.%2520Care%2520Med.%26date%3D2004%26volume%3D32%26spage%3D1041%26epage%3D1048%26doi%3D10.1097%2F01.CCM.0000120049.43113.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fajardo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes</span>. <i>Am. J. Physiol. Heart Circ. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">H2441</span>– <span class="NLM_lpage">H2449</span>, <span class="refDoi"> DOI: 10.1152/ajpheart.00005.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajpheart.00005.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16040722" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2005&pages=H2441-H2449&author=D.+Bernsteinauthor=G.+Fajardoauthor=M.+Zhaoauthor=T.+Urashimaauthor=J.+Powersauthor=G.+Berryauthor=B.+K.+Kobilka&title=Differential+cardioprotective%2Fcardiotoxic+effects+mediated+by+beta-adrenergic+receptor+subtypes&doi=10.1152%2Fajpheart.00005.2005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.00005.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.00005.2005%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DFajardo%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DUrashima%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DBerry%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DDifferential%2520cardioprotective%252Fcardiotoxic%2520effects%2520mediated%2520by%2520beta-adrenergic%2520receptor%2520subtypes%26jtitle%3DAm.%2520J.%2520Physiol.%2520Heart%2520Circ.%2520Physiol.%26date%3D2005%26volume%3D289%26spage%3DH2441%26epage%3DH2449%26doi%3D10.1152%2Fajpheart.00005.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liggett, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagoner, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornung, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoit, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, R. A.</span></span> <span> </span><span class="NLM_article-title">The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1534</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1172/JCI4059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI4059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9788966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1cXmvVygu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1534-1539&author=S.+B.+Liggettauthor=L.+E.+Wagonerauthor=L.+L.+Craftauthor=R.+W.+Hornungauthor=B.+D.+Hoitauthor=T.+C.+McIntoshauthor=R.+A.+Walsh&title=The+Ile164+beta2-adrenergic+receptor+polymorphism+adversely+affects+the+outcome+of+congestive+heart+failure&doi=10.1172%2FJCI4059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure</span></div><div class="casAuthors">Liggett, Stephen B.; Wagoner, Lynne E.; Craft, Laura L.; Hornung, Richard W.; Hoit, Brian D.; McIntosh, Tina C.; Walsh, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1534-1539</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR), an important modulator of cardiac inotropy and chronotropy, has significant genetic heterogeneity in the population.  Because dysfunctional βARs play a role in the pathogenesis of the failing ventricle, we tested the hypothesis that β2AR polymorphisms alter the outcome of congestive heart failure.  259 Patients with NYHA functional class II-IV heart failure due to ischemic or dilated cardiomyopathy were genotyped and prospectively followed, with the endpoint defined as death or cardiac transplantation.  The allele frequencies between this group and those of 212 healthy controls also were compared and did not differ between the groups.  However, those with the Ile164 polymorphism displayed a striking difference in survival with a relative risk of death or cardiac transplant of 4.81 (P < 0.001) compared with those with the wild-type Thr at this position.  Age, race, gender, functional class, etiol., ejection fraction, and medication use did not differ between these individuals and those with the wild-type β2AR, and thus the β2AR genotype at position 164 was the only clear distinguishing feature between the two groups.  The 1-yr survival for Ile164 patients was 42% compared with 76% for patients harboring wild-type β2AR.  In contrast, polymorphisms at amino acid positions 16 (Arg or Gly) or 27 (Gln or Glu), which also alter receptor phenotype, did not appear to have an influence on the course of heart failure.  Taken together with cell-based and transgenic mouse results, this study establishes a paradigm whereby genetic variants of key signaling elements can have pathophysiol. consequences within the context of a disease.  Furthermore, patients with the Ile164 polymorphism and heart failure may be candidates for earlier aggressive intervention or cardiac transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj7-rqaxAguLVg90H21EOLACvtfcHk0lhOJTJYhGB7OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvVygu7c%253D&md5=503988c4376a8da7f1750d664526fe9b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1172%2FJCI4059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI4059%26sid%3Dliteratum%253Aachs%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26aulast%3DWagoner%26aufirst%3DL.%2BE.%26aulast%3DCraft%26aufirst%3DL.%2BL.%26aulast%3DHornung%26aufirst%3DR.%2BW.%26aulast%3DHoit%26aufirst%3DB.%2BD.%26aulast%3DMcIntosh%26aufirst%3DT.%2BC.%26aulast%3DWalsh%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Ile164%2520beta2-adrenergic%2520receptor%2520polymorphism%2520adversely%2520affects%2520the%2520outcome%2520of%2520congestive%2520heart%2520failure%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1534%26epage%3D1539%26doi%3D10.1172%2FJCI4059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penicka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delrue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Durme, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goethals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijns, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartunek, J.</span></span> <span> </span><span class="NLM_article-title">Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy</span>. <i>Heart</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1136/hrt.2006.091959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fhrt.2006.091959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17569809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXot1KmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2007&pages=856-861&author=E.+Barbatoauthor=M.+Penickaauthor=L.+Delrueauthor=F.+Van+Durmeauthor=B.+De+Bruyneauthor=M.+Goethalsauthor=W.+Wijnsauthor=M.+Vanderheydenauthor=J.+Bartunek&title=Thr164Ile+polymorphism+of+beta2-adrenergic+receptor+negatively+modulates+cardiac+contractility%3A+implications+for+prognosis+in+patients+with+idiopathic+dilated+cardiomyopathy&doi=10.1136%2Fhrt.2006.091959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Thr164Ile polymorphism of β2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy</span></div><div class="casAuthors">Barbato, Emanuele; Penicka, Martin; Delrue, Leen; Van Durme, Frederic; De Bruyne, Bernard; Goethals, Marc; Wijns, William; Vanderheyden, Marc; Bartunek, Jozef</div><div class="citationInfo"><span class="NLM_cas:title">Heart (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">856-861</span>CODEN:
                <span class="NLM_cas:coden">HEARFR</span>;
        ISSN:<span class="NLM_cas:issn">1355-6037</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background: β2-adrenergic receptor Thr164Ile (threonine (Thr) is replaced by an isoleucine (Ile) at codon 164) polymorphism was postulated to contribute to lower exercise tolerance and poor prognosis in patients with congestive heart failure.  However, heart failure is assocd. with several abnormalities of β receptor signalling, and underlying mechanisms are not clear.  Objectives: To investigate whether Thr164Ile polymorphism neg. modulates myocardial contractile performance and is assocd. with adverse long-term prognosis of patients with congestive heart failure.  Methods: Among 55 subjects, cardiac contractile response to the β2-adrenergic receptor agonist terbutaline was assessed from the peak myocardial velocity of systolic shortening (Sm) in 18 subjects with the Ile-164 variant and 37 matched controls.  In total, 24 subjects had normal left ventricular (LV) function and 31 presented with congestive heart failure due to idiopathic dilated cardiomyopathy.  Results: In patients with normal LV function, peak terbutaline-induced increase (Δ) in Sm was lower in subjects with the Ile-164 variant than in controls (Δ33% (4%) vs Δ56% (4%), p<0.01).  In patients with heart failure, subjects with Ile-164 showed further severe redn. of β2-adrenergic-mediated increase in Sm as compared with controls with heart failure (Δ20% (5%) vs Δ39% (4%), p<0.05).  Patients with heart failure with Ile-164 showed a severely blunted force-frequency relationship in response to agonist stimulation.  At 2-years of follow-up, patients with heart failure with the Ile-164 variant showed higher incidence of adverse events than controls with heart failure (75% (6/8) vs 30% (7/23), p<0.05).  Conclusions: The β2-adrenergic Thr164Ile polymorphism directly modulates adrenergic-mediated cardiac responses in patients with normal and failing myocardium.  Furthermore, blunted β2 adrenergic-mediated myocardial contractile response in patients with Ile-164 variant seems to adversely modulate the course of congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-CRh2HSR68bVg90H21EOLACvtfcHk0lgbuyy70aKC3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXot1KmsLw%253D&md5=a2fc01693775a1e8b95865187fc1ede0</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1136%2Fhrt.2006.091959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fhrt.2006.091959%26sid%3Dliteratum%253Aachs%26aulast%3DBarbato%26aufirst%3DE.%26aulast%3DPenicka%26aufirst%3DM.%26aulast%3DDelrue%26aufirst%3DL.%26aulast%3DVan%2BDurme%26aufirst%3DF.%26aulast%3DDe%2BBruyne%26aufirst%3DB.%26aulast%3DGoethals%26aufirst%3DM.%26aulast%3DWijns%26aufirst%3DW.%26aulast%3DVanderheyden%26aufirst%3DM.%26aulast%3DBartunek%26aufirst%3DJ.%26atitle%3DThr164Ile%2520polymorphism%2520of%2520beta2-adrenergic%2520receptor%2520negatively%2520modulates%2520cardiac%2520contractility%253A%2520implications%2520for%2520prognosis%2520in%2520patients%2520with%2520idiopathic%2520dilated%2520cardiomyopathy%26jtitle%3DHeart%26date%3D2007%26volume%3D93%26spage%3D856%26epage%3D861%26doi%3D10.1136%2Fhrt.2006.091959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chesley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, M. T.</span></span> <span> </span><span class="NLM_article-title">The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1179</span>, <span class="refDoi"> DOI: 10.1161/01.RES.87.12.1172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.RES.87.12.1172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11110775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslyntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2000&pages=1172-1179&author=A.+Chesleyauthor=M.+S.+Lundbergauthor=T.+Asaiauthor=R.+P.+Xiaoauthor=S.+Ohtaniauthor=E.+G.+Lakattaauthor=M.+T.+Crow&title=The+beta%282%29-adrenergic+receptor+delivers+an+antiapoptotic+signal+to+cardiac+myocytes+through+G%28i%29-dependent+coupling+to+phosphatidylinositol+3%E2%80%B2-kinase&doi=10.1161%2F01.RES.87.12.1172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3'-kinase</span></div><div class="casAuthors">Chesley, Alan; Lundberg, Martha S.; Asai, Toshinobu; Xiao, Rui-Ping; Ohtani, Seiji; Lakatta, Edward G.; Crow, Michael T.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1172-1179</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Recent studies have shown that chronic β-adrenergic receptor (β-AR) stimulation alters cardiac myocyte survival in a receptor subtype-specific manner.  The authors examd. the effect of selective β1- and β2-AR subtype stimulation on apoptosis induced by hypoxia or H2O2 in rat neonatal cardiac myocytes.  Although neither β1- nor β2-AR stimulation had any significant effect on the basal level of apoptosis, selective β2-AR stimulation protected myocytes from apoptosis.  β2-AR stimulation markedly increased mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK) activation as well as phosphatidylinositol-3'-kinase (PI-3K) activity and Akt/protein kinase B phosphorylation.  β1-AR stimulation also markedly increased MAPK/ERK activation but only minimally activated PI-3K and Akt.  Pretreatment with pertussis toxin blocked β2-AR-mediated protection from apoptosis as well as the β2-AR-stimulated changes in MAPK/ERK, PI-3K, and Akt/protein kinase B.  The selective PI-3K inhibitor, LY 294002, also blocked β2-AR-mediated protection, whereas inhibition of MAPK/ERK activation at an inhibitor concn. that blocked agonist-induced activation but not the basal level of activation had no effect on β2-AR-mediated protection.  These findings demonstrate that β2-ARS activate a PI-3K-dependent, pertussis toxin-sensitive signaling pathway in cardiac myocytes that is required for protection from apoptosis-inducing stimuli often assocd. with ischemic stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMsvZU2hkzRrVg90H21EOLACvtfcHk0lgbuyy70aKC3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslyntbY%253D&md5=db3e73951926ceb1ada3c490a6ab981c</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1161%2F01.RES.87.12.1172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.87.12.1172%26sid%3Dliteratum%253Aachs%26aulast%3DChesley%26aufirst%3DA.%26aulast%3DLundberg%26aufirst%3DM.%2BS.%26aulast%3DAsai%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DOhtani%26aufirst%3DS.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DCrow%26aufirst%3DM.%2BT.%26atitle%3DThe%2520beta%25282%2529-adrenergic%2520receptor%2520delivers%2520an%2520antiapoptotic%2520signal%2520to%2520cardiac%2520myocytes%2520through%2520G%2528i%2529-dependent%2520coupling%2520to%2520phosphatidylinositol%25203%25E2%2580%25B2-kinase%26jtitle%3DCirc.%2520Res.%26date%3D2000%26volume%3D87%26spage%3D1172%26epage%3D1179%26doi%3D10.1161%2F01.RES.87.12.1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. W.</span></span> <span> </span><span class="NLM_article-title">ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure</span>. <i>Cell Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1038/s41421-018-0058-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41421-018-0058-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30374408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3cvks1ersA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=57-69&author=J.+Huangauthor=C.+Liauthor=Y.+Songauthor=X.+Fanauthor=L.+Youauthor=L.+Tanauthor=L.+Xiaoauthor=Q.+Liauthor=G.+Ruanauthor=S.+Huauthor=W.+Cuiauthor=Z.+Liauthor=L.+Niauthor=C.+Chenauthor=A.+Y.+Wooauthor=R.+P.+Xiaoauthor=D.+W.+Wang&title=ADRB2+polymorphism+Arg16Gly+modifies+the+natural+outcome+of+heart+failure+and+dictates+therapeutic+response+to+%CE%B2-blockers+in+patients+with+heart+failure&doi=10.1038%2Fs41421-018-0058-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure</span></div><div class="casAuthors">Huang Jin; Li Chenze; Tan Lun; Xiao Lei; Li Qing; Ruan Guoran; Hu Senlin; Li Zongzhe; Ni Li; Chen Chen; Wang Dao Wen; Huang Jin; Li Chenze; Chen Chen; Wang Dao Wen; Song Ying; Woo Anthony Yiu-Ho; Xiao Rui-Ping; Fan Xiaohan; You Ling; Cui Wei; Woo Anthony Yiu-Ho</div><div class="citationInfo"><span class="NLM_cas:title">Cell discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn">2056-5968</span>.
    </div><div class="casAbstract">We sought to investigate the association of single nucleotide polymorphisms (SNPs) of the genes involved in βAR signaling with the response of patients to βAR blockers.  A total of 2403 hospitalized patients with chronic heart failure (HF) were enrolled in a multicenter observational study as the first cohort and followed up for a mean period of 20 months.  Genes for β1AR, β2AR, and the major cardiac G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 were analyzed to identify SNPs, and patients were stratified according to genotypes.  A second independent cohort enrolling 919 patients with chronic HF was applied to validate the observed associations.  The signaling properties of the key identified SNPs were assessed in vitro.  Our data showed that HF patients harboring the Gly16 allele in the gene for β2AR (ADRB2) had an increased risk of the composite end point relative to patients who were homozygous for Arg16.  Notably, these patients showed a beneficial response to βAR-blocker treatment in a G allele-dose-dependent manner, whereas Arg16 homozygotes had no response to βAR-blocker therapy.  This Arg16Gly genotype-dependent heterogeneity in clinical outcomes of HF was successfully validated in the second independent population.  Besides, the in vitro experiments revealed that G allele carriers were defective in β2AR-coupled inhibitory adenylate cyclase g (Gi) protein signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqb2LL6397p_9pSBfyDvp7fW6udTcc2eZJM0GeDmEiULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvks1ersA%253D%253D&md5=f3296538e181a91b898865f4fc5fb368</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fs41421-018-0058-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41421-018-0058-6%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DRuan%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DWang%26aufirst%3DD.%2BW.%26atitle%3DADRB2%2520polymorphism%2520Arg16Gly%2520modifies%2520the%2520natural%2520outcome%2520of%2520heart%2520failure%2520and%2520dictates%2520therapeutic%2520response%2520to%2520%25CE%25B2-blockers%2520in%2520patients%2520with%2520heart%2520failure%26jtitle%3DCell%2520Discovery%26date%3D2018%26volume%3D4%26spage%3D57%26epage%3D69%26doi%3D10.1038%2Fs41421-018-0058-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pharmthera.2005.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15979723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2005&pages=257-268&author=M.+Zhengauthor=W.+Zhuauthor=Q.+Hanauthor=R.+P.+Xiao&title=Emerging+concepts+and+therapeutic+implications+of+beta-adrenergic+receptor+subtype+signaling&doi=10.1016%2Fj.pharmthera.2005.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling</span></div><div class="casAuthors">Zheng, Ming; Zhu, Weizhong; Han, Qide; Xiao, Rui-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-268</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review highlighting the distinct functionalities and signaling mechanisms of the 3 βAR subtypes in the heart and discussing how subtype-specific properties of βARs might affect the pathogenesis of congestive heart failure (CHF) and the therapeutic effectiveness of certain β-blockers in the treatment of congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdqLtg9deo2rVg90H21EOLACvtfcHk0lhMFoppnIWcgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Olsr7L&md5=6547f244c6d51273ce03c02b3a6ffa01</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DEmerging%2520concepts%2520and%2520therapeutic%2520implications%2520of%2520beta-adrenergic%2520receptor%2520subtype%2520signaling%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D108%26spage%3D257%26epage%3D268%26doi%3D10.1016%2Fj.pharmthera.2005.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avdonin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balke, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span> <span> </span><span class="NLM_article-title">Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">1633</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000087595.17277.73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.0000087595.17277.73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12975249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsVKrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2003&pages=1633-1639&author=R.+P.+Xiaoauthor=S.+J.+Zhangauthor=K.+Chakirauthor=P.+Avdoninauthor=W.+Zhuauthor=R.+A.+Bondauthor=C.+W.+Balkeauthor=E.+G.+Lakattaauthor=H.+Cheng&title=Enhanced+G%28i%29+signaling+selectively+negates+beta2-adrenergic+receptor+%28AR%29-but+not+beta1-AR-mediated+positive+inotropic+effect+in+myocytes+from+failing+rat+hearts&doi=10.1161%2F01.CIR.0000087595.17277.73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Gi Signaling Selectively Negates β2-Adrenergic Receptor (AR)- but Not β1-AR-Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts</span></div><div class="casAuthors">Xiao, Rui-Ping; Zhang, Sheng-Jun; Chakir, Khalid; Avdonin, Pavel; Zhu, Weizhong; Bond, Richard A.; Balke, C. William; Lakatta, Edward G.; Cheng, Heping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1633-1639</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Myocardial contractile response to β1- and β2-adrenergic receptor (AR) stimulation is severely impaired in chronic heart failure, in which Gi signaling and the ratio of β2/β1 are often increased.  Because β2-AR but not β1-AR couples to Gs and Gi with the Gi coupling negating the Gs-mediated contractile response, the authors detd. whether the heart failure-assocd. augmentation of Gi signaling contributes differentially to the defects of these β-AR subtypes and, if so, whether inhibition of Gi or selective activation of β2-AR/Gs by ligands restores β2-AR contractile response in the failing heart.  Cardiomyocytes were isolated from 18- to 24-mo-old failing spontaneously hypertensive (SHR) or age-matched Wistar-Kyoto (WKY) rat hearts.  In SHR cardiomyocytes, either β-AR subtype-mediated inotropic effect was markedly diminished, whereas Gi proteins and the β2/β1 ratio were increased.  Disruption of Gi signaling by pertussis toxin (PTX) enabled β2- but not β1-AR to induce a full pos. inotropic response in SHR myocytes.  Furthermore, screening of a panel of β2-AR ligands revealed that the contractile response mediated by most β2-AR agonists, including zinterol, salbutamol, and procaterol, was potentiated by PTX, indicating concurrent Gs and Gi activation.  In contrast, fenoterol, another β2-AR agonist, induced a full pos. inotropic effect in SHR myocytes even in the absence of PTX.  We conclude that enhanced Gi signaling is selectively involved in the dysfunction of β2- but not β1-AR in failing SHR hearts and that disruption of Gi signaling by PTX or selective activation of β2-AR/Gs signaling by fenoterol restores the blunted β2-AR contractile response in the failing heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BQ8TPDdqR7Vg90H21EOLACvtfcHk0lhMFoppnIWcgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsVKrs78%253D&md5=9b7e777b4a1bd560ca8fd9614e267b87</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000087595.17277.73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000087595.17277.73%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DZhang%26aufirst%3DS.%2BJ.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DAvdonin%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBond%26aufirst%3DR.%2BA.%26aulast%3DBalke%26aufirst%3DC.%2BW.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DCheng%26aufirst%3DH.%26atitle%3DEnhanced%2520G%2528i%2529%2520signaling%2520selectively%2520negates%2520beta2-adrenergic%2520receptor%2520%2528AR%2529-but%2520not%2520beta1-AR-mediated%2520positive%2520inotropic%2520effect%2520in%2520myocytes%2520from%2520failing%2520rat%2520hearts%26jtitle%3DCirculation%26date%3D2003%26volume%3D108%26spage%3D1633%26epage%3D1639%26doi%3D10.1161%2F01.CIR.0000087595.17277.73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span> <span> </span><span class="NLM_article-title">Beneficial effects of chronic pharmacological manipulation of β-adrenoceptor subtype signaling in rodent dilated ischemic cardiomyopathy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000139844.15045.F9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.0000139844.15045.F9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15313944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvV2gt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2004&pages=1083-1090&author=I.+Ahmetauthor=M.+Krawczykauthor=P.+Hellerauthor=C.+Moonauthor=E.+G.+Lakattaauthor=M.+I.+Talan&title=Beneficial+effects+of+chronic+pharmacological+manipulation+of+%CE%B2-adrenoceptor+subtype+signaling+in+rodent+dilated+ischemic+cardiomyopathy&doi=10.1161%2F01.CIR.0000139844.15045.F9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Beneficial Effects of Chronic Pharmacological Manipulation of β-Adrenoreceptor Subtype Signaling in Rodent Dilated Ischemic Cardiomyopathy</span></div><div class="casAuthors">Ahmet, Ismayil; Krawczyk, Melissa; Heller, Phillip; Moon, Chanil; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1083-1090</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background - Studies in isolated cardiac myocytes have demonstrated that signaling via specific β1-adrenergic receptor subtypes (β1ARs) promotes but that signaling via β2ARs protects from cell death.  We hypothesized that prolonged β2AR stimulation or β1AR blockade would each protect myocytes from death and thereby ameliorate cardiac remodeling in chronic heart failure.  Methods and Results - A large myocardial infarction (MI) induced in rats by coronary artery ligation resulted in a dilated cardiomyopathy (DCM) characterized by infarct expansion and a progressive increase in left ventricular (LV) end-diastolic vol., accompanied by a redn. in ejection fraction (EF), as assessed by repeated echocardiog.  Pressure-vol. anal. at 8 wk after ligation showed that diastolic stiffness (Eed) and arterial elastance (Ea) were increased, end-systolic elastance (Ees) was decreased, and arterioventricular (AV) coupling (Ea/Ees) had deteriorated.  Apoptosis was present in both peri-infarct and remote myocardium.  Chronic (6-wk) administration of the β2AR agonists fenoterol or zinterol, starting at 2 wk after MI, reduced the extent of LV dilation, infarct expansion, and EF decline.  The β1AR blocker metoprolol did not affect the former and preserved EF to a lesser extent than did the β2AR agonists.  At 8 wk after ligation, apoptosis was reduced by all drugs but to a greater extent by β2AR agonists than by the β1AR blocker.  Both β2AR agonists and the β1AR blocker improved AV coupling, the former mainly by reducing Ea and the latter mainly by increasing Ees.  Only the β2AR agonists reduced the Eed and the MI size by reducing infarct expansion.  Conclusions - These results provide proof of concept for the efficacy of chronic β2AR stimulation in this DCM model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJYqzYHWsIJrVg90H21EOLACvtfcHk0lhMFoppnIWcgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvV2gt7k%253D&md5=5cad698789a2e3433800aac01df4bafb</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000139844.15045.F9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000139844.15045.F9%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DHeller%26aufirst%3DP.%26aulast%3DMoon%26aufirst%3DC.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%2BI.%26atitle%3DBeneficial%2520effects%2520of%2520chronic%2520pharmacological%2520manipulation%2520of%2520%25CE%25B2-adrenoceptor%2520subtype%2520signaling%2520in%2520rodent%2520dilated%2520ischemic%2520cardiomyopathy%26jtitle%3DCirculation%26date%3D2004%26volume%3D110%26spage%3D1083%26epage%3D1090%26doi%3D10.1161%2F01.CIR.0000139844.15045.F9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological stimulation of β<sub>2</sub>-adrenergic receptors (β<sub>2</sub>AR) enhances therapeutic effectiveness of β<sub>1</sub>AR blockade in rodent dilated ischemic cardiomyopathy</span>. <i>Heart Failure Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1007/s10741-005-7543-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs10741-005-7543-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16583177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVKmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=289-296&author=I.+Ahmetauthor=E.+G.+Lakattaauthor=M.+Talan&title=Pharmacological+stimulation+of+%CE%B22-adrenergic+receptors+%28%CE%B22AR%29+enhances+therapeutic+effectiveness+of+%CE%B21AR+blockade+in+rodent+dilated+ischemic+cardiomyopathy&doi=10.1007%2Fs10741-005-7543-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Stimulation of β2-adrenergic Receptors (β2AR) Enhances Therapeutic Effectiveness of β1AR Blockade in Rodent Dilated Ischemic Cardiomyopathy</span></div><div class="casAuthors">Ahmet, Ismayil; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Heart Failure Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-296</span>CODEN:
                <span class="NLM_cas:coden">HFREFC</span>;
        ISSN:<span class="NLM_cas:issn">1382-4147</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: We have reported that β2 adrenoreceptor (β2AR) stimulation is anti-apoptotic, and has strong beneficial effect on cardiac remodeling in an exptl. model of post myocardial infarction chronic heart failure (CHF) in rats.  Here we investigate whether the addn. of chronic pharmacol. β2AR stimulation enhances the therapeutic effects of β1AR blockade on cardiac remodeling in the same model.  Methods and Results: Metoprolol, a β1AR blocker, given alone (β1) or in combination with β2AR agonist, fenoterol (β1β2) were administered to rats via drinking water for 6 wk, beginning 2 wk following permanent coronary ligation.  Progressive left ventricular (LV) remodeling of untreated animals, assessed by repeated echocardiog., occurred during the observation time, i.e., 42% and 25% increases in end-systolic and end-diastolic LV vols. resp., 27% fall in ejection fraction, and 35% infarct expansion.  Pressure-vol. loop analyses at 2d and 8th post infarction weeks showed continuous deterioration of systolic and diastolic functions and arterio-ventricular mismatch.  Histol. evaluation at the end of 8 wk revealed the MI expansion and hypertrophy of cardiomyocytes. β1β2 prevented LV remodeling, MI expansion and cardiomyocytes hypertrophy to a greater degree than β1, due, in large part, to a vasodilatory effect of β2AR stimulation and thus improvement of arterio-ventricular mismatch.  The abnormal diastolic performance improved only in β1β2. β1β2 treatment reduced myocardial apoptosis throughout myocardium, but β1 reduced apoptosis only in the areas remote from MI.  Conclusion: The therapeutic effects of chronic β1AR blockade on cardiac remodeling of heart failure are enhanced and extended when supplemented with β2AR stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqtXw6O8PwbbVg90H21EOLACvtfcHk0liJnbbqco-T1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVKmt7g%253D&md5=ec29cc0c44a75a23cce1828d65e412fa</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1007%2Fs10741-005-7543-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10741-005-7543-3%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%26atitle%3DPharmacological%2520stimulation%2520of%2520%25CE%25B22-adrenergic%2520receptors%2520%2528%25CE%25B22AR%2529%2520enhances%2520therapeutic%2520effectiveness%2520of%2520%25CE%25B21AR%2520blockade%2520in%2520rodent%2520dilated%2520ischemic%2520cardiomyopathy%26jtitle%3DHeart%2520Failure%2520Rev.%26date%3D2005%26volume%3D10%26spage%3D289%26epage%3D296%26doi%3D10.1007%2Fs10741-005-7543-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poosala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span> <span> </span><span class="NLM_article-title">Cardioprotective and survival benefits of long-term combined therapy with β<sub>2</sub>AR agonist and β<sub>1</sub>AR blocker in dilated cardiomyopathy postmyocardial infarction</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.135335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.107.135335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18287209" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=491-499&author=I.+Ahmetauthor=M.+Krawczykauthor=W.+Zhuauthor=A.+Y.+Wooauthor=C.+Morrellauthor=S.+Poosalaauthor=R.+P.+Xiaoauthor=E.+G.+Lakattaauthor=M.+I.+Talan&title=Cardioprotective+and+survival+benefits+of+long-term+combined+therapy+with+%CE%B22AR+agonist+and+%CE%B21AR+blocker+in+dilated+cardiomyopathy+postmyocardial+infarction&doi=10.1124%2Fjpet.107.135335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Cardioprotective and survival benefits of long-term combined therapy with β2 adrenoreceptor (AR) agonist and β1 AR blocker in dilated cardiomyopathy postmyocardial infarction</span></div><div class="casAuthors">Ahmet, Ismayil; Krawczyk, Melissa; Zhu, Weizhong; Woo, Anthony Yiu-Ho; Morrell, Christopher; Poosala, Suresh; Xiao, Riu-ping; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">491-499</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We have reported therapeutic effectiveness of pharmacol. stimulation of β2 adrenoreceptors (ARs) to attenuate the cardiac remodeling and myocardial infarction (MI) expansion in a rat model of dilated cardiomyopathy (DCM) post-MI.  Furthermore, the combination of β2 AR stimulation with β1 AR blockade exceeded the therapeutic effectiveness of β1 AR blockade.  However, these studies were relatively short (6 wk).  In this study, in the same exptl. model, we compared different effects, including survival benefit, of combined therapy with the β1 AR blocker, metoprolol, plus the β2 AR agonist, fenoterol (β1- β2+), and either therapy alone (β1- or β2+) during the 1-yr study.  Therapy was started 2 wk after permanent ligation of the left coronary artery.  Cardiac remodeling, MI expansion, and left ventricular function were assessed by serial echocardiog. and compared with untreated animals (nT).  Sixty-seven percent mortality in nT was reduced to 33% in the β1- β2+ (p < 0.01).  Progressive cardiac remodeling obsd. in nT and β1- was significantly attenuated in β1- β2+ during the first 6 mo of treatment.  In β1- β2+, MI expansion was completely prevented, and functional decline was significantly attenuated during the entire year.  Myocardial apoptosis was significantly reduced in both β1- β2+ and β1-.  A redn. of cardiac β1 AR d. and decreases in chronotropic and contractile responses to β2 AR-specific stimulation in the absence of a redn. of β2 AR d. in nT were precluded in rats receiving combined therapy.  The results demonstrate the cardioprotective and survival benefit of long-term combination therapy of β2 AR agonists and β1 AR blockers in a model of DCM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsrdgZchcz6LVg90H21EOLACvtfcHk0liJnbbqco-T1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjsbc%253D&md5=02f84ec640112731bdcf2eddb3de1c60</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.135335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.135335%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DMorrell%26aufirst%3DC.%26aulast%3DPoosala%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%2BI.%26atitle%3DCardioprotective%2520and%2520survival%2520benefits%2520of%2520long-term%2520combined%2520therapy%2520with%2520%25CE%25B22AR%2520agonist%2520and%2520%25CE%25B21AR%2520blocker%2520in%2520dilated%2520cardiomyopathy%2520postmyocardial%2520infarction%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D491%26epage%3D499%26doi%3D10.1124%2Fjpet.107.135335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span> <span> </span><span class="NLM_article-title">Therapeutic efficacy of a combination of a β<sub>1</sub>-adrenoreceptor (AR) blocker and β<sub>2</sub>-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a β<sub>1</sub>-AR blocker plus angiotensin-converting enzyme inhibitor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.157107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.109.157107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19587314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GjtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=178-185&author=I.+Ahmetauthor=C.+Morrellauthor=E.+G.+Lakattaauthor=M.+I.+Talan&title=Therapeutic+efficacy+of+a+combination+of+a+%CE%B21-adrenoreceptor+%28AR%29+blocker+and+%CE%B22-AR+agonist+in+a+rat+model+of+postmyocardial+infarction+dilated+heart+failure+exceeds+that+of+a+%CE%B21-AR+blocker+plus+angiotensin-converting+enzyme+inhibitor&doi=10.1124%2Fjpet.109.157107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of a combination of a β1-adrenoreceptor (AR) blocker and β2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a β1-AR blocker plus angiotensin-converting enzyme inhibitor</span></div><div class="casAuthors">Ahmet, Ismail; Morrell, Chris; Lakatta, Edward G.; Talan, Mark I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-185</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We had proposed previously a novel combination of β2-adrenoreceptor (AR) agonist and β1-AR blocker that in the rat model of postmyocardial infarction (MI) dilated cardiomyopathy exceeds the therapeutic effectiveness of either monotherapy.  In the present study, we compared that treatment with a combination of β1-AR blocker and angiotensin-converting enzyme inhibitor (ACEi), a current std. chronic heart failure (CHF) therapy.  Two weeks after coronary artery ligation, rats were divided into groups of similar av. MI size, measured by echocardiog., and the following 12-mo treatments were initiated: fenoterol (250 μg/kg/day), a β2-AR agonist, plus metoprolol (100 mg/kg/day), a β1-AR blocker (β1-β2+); metoprolol plus enalapril (20 mg/kg/day), an ACEi (β1-ACEi); and a combination of all three drugs (β1-β2 + ACEi).  These treatment groups were compared with each other and with nontreated (nT) and sham groups.  The 12-mo mortality was significantly reduced in all treatment groups (44% in β1-β2+, 56% in β1-β2 + ACEi, 59% in β1-ACEi vs. 81% in nT).  Bimonthly echocardiog. revealed significant attenuation of the left ventricular (LV) chamber remodeling, LV functional deterioration, and MI expansion in all three treatment groups, but effects were significantly more pronounced when treatment included a β2-AR agonist.  The results indicated that a combination of β1-AR blocker and β2-AR agonist is equipotent to a combination of β1-AR blocker and ACEi in the treatment of CHF in rats, with the respect to mortality, and exceeds the latter with respect to cardiac remodeling and MI expansion.  Thus, this novel therapeutic regimen for CHF warrants detailed clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraZxsoFKfX_bVg90H21EOLACvtfcHk0liJnbbqco-T1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GjtL7L&md5=dd3c4059426975312797578fcd38f968</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.157107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.157107%26sid%3Dliteratum%253Aachs%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DMorrell%26aufirst%3DC.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26aulast%3DTalan%26aufirst%3DM.%2BI.%26atitle%3DTherapeutic%2520efficacy%2520of%2520a%2520combination%2520of%2520a%2520%25CE%25B21-adrenoreceptor%2520%2528AR%2529%2520blocker%2520and%2520%25CE%25B22-AR%2520agonist%2520in%2520a%2520rat%2520model%2520of%2520postmyocardial%2520infarction%2520dilated%2520heart%2520failure%2520exceeds%2520that%2520of%2520a%2520%25CE%25B21-AR%2520blocker%2520plus%2520angiotensin-converting%2520enzyme%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D178%26epage%3D185%26doi%3D10.1124%2Fjpet.109.157107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimaano, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartunek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaselli, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, D. A.</span></span> <span> </span><span class="NLM_article-title">Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">100ra88</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3001909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscitranslmed.3001909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21918105" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=K.+Chakirauthor=C.+Depryauthor=V.+L.+Dimaanoauthor=W.+Z.+Zhuauthor=M.+Vanderheydenauthor=J.+Bartunekauthor=T.+P.+Abrahamauthor=G.+F.+Tomaselliauthor=S.+B.+Liuauthor=Y.+K.+Xiangauthor=M.+Zhangauthor=E.+Takimotoauthor=N.+Dulinauthor=R.+P.+Xiaoauthor=J.+Zhangauthor=D.+A.+Kass&title=Galphas-biased+beta2-adrenergic+receptor+signaling+from+restoring+synchronous+contraction+in+the+failing+heart&doi=10.1126%2Fscitranslmed.3001909"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3001909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3001909%26sid%3Dliteratum%253Aachs%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DDepry%26aufirst%3DC.%26aulast%3DDimaano%26aufirst%3DV.%2BL.%26aulast%3DZhu%26aufirst%3DW.%2BZ.%26aulast%3DVanderheyden%26aufirst%3DM.%26aulast%3DBartunek%26aufirst%3DJ.%26aulast%3DAbraham%26aufirst%3DT.%2BP.%26aulast%3DTomaselli%26aufirst%3DG.%2BF.%26aulast%3DLiu%26aufirst%3DS.%2BB.%26aulast%3DXiang%26aufirst%3DY.%2BK.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DTakimoto%26aufirst%3DE.%26aulast%3DDulin%26aufirst%3DN.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKass%26aufirst%3DD.%2BA.%26atitle%3DGalphas-biased%2520beta2-adrenergic%2520receptor%2520signaling%2520from%2520restoring%2520synchronous%2520contraction%2520in%2520the%2520failing%2520heart%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26doi%3D10.1126%2Fscitranslmed.3001909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-adrenergic receptor-induced transactivation of EGFR and PDGFR via SRC kinase promotes rat cardiomyocytes survival</span>. <i>Cell Biol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1042/CBI20110162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1042%2FCBI20110162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21954875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFCitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=237-244&author=H.+Chenauthor=N.+Maauthor=J.+Xiaauthor=J.+Liuauthor=Z.+Xu&title=%CE%B22-adrenergic+receptor-induced+transactivation+of+EGFR+and+PDGFR+via+SRC+kinase+promotes+rat+cardiomyocytes+survival&doi=10.1042%2FCBI20110162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic receptor-induced transactivation of epidermal growth factor receptor and platelet-derived growth factor receptor via Src kinase promotes rat cardiomyocyte survival</span></div><div class="casAuthors">Chen, Hao; Ma, Ning; Xia, Jing; Liu, Jinfen; Xu, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Biology International</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">237-244</span>CODEN:
                <span class="NLM_cas:coden">CBIIEV</span>;
        ISSN:<span class="NLM_cas:issn">1065-6995</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Chronic stimulation of the β-AR (adrenergic receptor) promotes apoptosis of cardiomyocytes, which is implicated in cardiac dysfunction. β1-AR and β2-AR are the main subtypes of β-AR that exert distinct effects on the survival of cardiomyocytes.  To clarify the physiol. roles of β1-AR and β2-AR in cardiomyocytes, the effects of β1-AR or β2-AR knockdown on the survival of H9c2 cardiomyocytes was investigated.  Knockdown of β2-AR, but not β1-AR, suppressed the phosphorylation of EGFR (epidermal growth factor receptor) and PDGFR (platelet-derived growth factor receptor) induced by ISO (isoprenaline).  The EGFR inhibitor, AG1478, attenuated ERK (extracellular-signal-regulated kinase) activation and partially decreased cell survival.  Pretreatment with AG1296, a PDGFR inhibitor, abolished ISO-induced Akt (also known as protein kinase B) phosphorylation and led to a decrease in cell viability.  In addn., the Src tyrosine kinase inhibitor, PP2, blocked ISO-mediated both Akt and ERK activation and heavily suppressed viability.  Accordingly, in primary neonatal rat cardiomyocytes, the β2-AR inhibitor, but not the β1-AR inhibitor, abrogated the transactivation of EGFR and PDGFR, which was resp. related to Akt and ERK activation.  The results show that β2-AR transactivates PDGFR and EGFR, thereby promoting survival of cardiomyocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPlITuhpg5CbVg90H21EOLACvtfcHk0lgJKoYroL7nCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFCitbw%253D&md5=d9fc659020204749f928f2f90163341c</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1042%2FCBI20110162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCBI20110162%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26atitle%3D%25CE%25B22-adrenergic%2520receptor-induced%2520transactivation%2520of%2520EGFR%2520and%2520PDGFR%2520via%2520SRC%2520kinase%2520promotes%2520rat%2520cardiomyocytes%2520survival%26jtitle%3DCell%2520Biol.%2520Int.%26date%3D2012%26volume%3D36%26spage%3D237%26epage%3D244%26doi%3D10.1042%2FCBI20110162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stuenaes, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingvaldsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommundstad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-Adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00677.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2010.00677.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20412069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslyqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=116-129&author=J.+T.+Stuenaesauthor=A.+Bollingauthor=A.+Ingvaldsenauthor=C.+Rommundstadauthor=E.+Sudarauthor=F.+C.+Linauthor=Y.+C.+Laiauthor=J.+Jensen&title=%CE%B22-Adrenoceptor+stimulation+potentiates+insulin-stimulated+PKB+phosphorylation+in+rat+cardiomyocytes+via+cAMP+and+PKA&doi=10.1111%2Fj.1476-5381.2010.00677.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">β-Adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA</span></div><div class="casAuthors">Stuenaes, Jorid T.; Bolling, Astrid; Ingvaldsen, Ada; Rommundstad, Camilla; Sudar, Emina; Lin, Fang-Chin; Lai, Yu-Chiang; Jensen, Joergen</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-129</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Genetic approaches have documented protein kinase B (PKB) as a pivotal regulator of heart function.  Insulin strongly activates PKB, whereas adrenaline is not considered a major physiol. regulator of PKB in heart.  In skeletal muscles, however, adrenaline potentiates insulin-stimulated PKB activation without having effect in the absence of insulin.  The purpose of the present study was to investigate the interaction between insulin and β-adrenergic stimulation in regulation of PKB phosphorylation.  Cardiomyocytes were isolated from adult rats by collagenase, and incubated with insulin, isoprenaline, and other compds.  Protein phosphorylation was evaluated by Western blot and phospho-specific antibodies.  Isoprenaline increased insulin-stimulated PKB Ser473 and Thr308 phosphorylation more than threefold in cardiomyocytes.  Isoprenaline alone did not increase PKB phosphorylation.  Isoprenaline also increased insulin-stimulated GSK-3β Ser9 phosphorylation approx. twofold, supporting that PKB phosphorylation increased kinase activity.  Dobutamine (β1-agonist) increased insulin-stimulated PKB phosphorylation as effectively as isoprenaline (more than threefold), whereas salbutamol (β2-agonist) only potentiated insulin-stimulated PKB phosphorylation by approx. 80%.  Dobutamine, but not salbutamol, increased phospholamban Ser16 phosphorylation and glycogen phosphorylase activation (PKA-mediated effects).  Furthermore, the cAMP analog that activates PKA (dibutyryl-cAMP and N6-benzoyl-cAMP) increased insulin-stimulated PKB phosphorylation by more than threefold without effect alone.  The Epac-specific activator 8-(4-chlorophenylthio)-2'-O-methyl-cAMP (007) increased insulin-stimulated PKB phosphorylation by approx. 50%.  Db-cAMP and N6-benzoyl-cAMP, but not 007, increased phospholamban Ser16 phosphorylation.  β-adrenoceptors are strong regulators of PKB phosphorylation via cAMP and PKA when insulin is present.  We hypothesize that PKB mediates important signaling in the heart during β-adrenergic receptors stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrExtSiK0UwNrVg90H21EOLACvtfcHk0lgJKoYroL7nCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslyqtLs%253D&md5=9bafaa3c4a2265bcf4c95d6d17fe2d08</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00677.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00677.x%26sid%3Dliteratum%253Aachs%26aulast%3DStuenaes%26aufirst%3DJ.%2BT.%26aulast%3DBolling%26aufirst%3DA.%26aulast%3DIngvaldsen%26aufirst%3DA.%26aulast%3DRommundstad%26aufirst%3DC.%26aulast%3DSudar%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DF.%2BC.%26aulast%3DLai%26aufirst%3DY.%2BC.%26aulast%3DJensen%26aufirst%3DJ.%26atitle%3D%25CE%25B22-Adrenoceptor%2520stimulation%2520potentiates%2520insulin-stimulated%2520PKB%2520phosphorylation%2520in%2520rat%2520cardiomyocytes%2520via%2520cAMP%2520and%2520PKA%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D116%26epage%3D129%26doi%3D10.1111%2Fj.1476-5381.2010.00677.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Germack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickenson, J. M.</span></span> <span> </span><span class="NLM_article-title">Induction of beta3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">392</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.090597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.090597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16183708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=392-402&author=R.+Germackauthor=J.+M.+Dickenson&title=Induction+of+beta3-adrenergic+receptor+functional+expression+following+chronic+stimulation+with+noradrenaline+in+neonatal+rat+cardiomyocytes&doi=10.1124%2Fjpet.105.090597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of β3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes</span></div><div class="casAuthors">Germack, Renee; Dickenson, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">392-402</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study aimed to characterize β3-adrenergic receptors (ARs) in rat neonatal cardiomyocytes using the noradrenaline (NOR) properties to modulate the expression and function of the three β-ARs.  The authors assessed the effect of NOR (physiol. nonselective agonist), isoprenaline (ISO, β-nonselective agonist), dobutamine (DOB, β1-selective agonist), and procaterol (PROC, β2-selective agonist) on cAMP accumulation using cardiomyocytes untreated or treated with 100 μM NOR for 24 h.  The inhibition of forskolin-stimulated cAMP accumulation was detd. using NOR, isoprenaline, and the β3-selective agonists 4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxyacetic acid (BRL 37344) and 5-[-2-([-2-(3-chlorophenyl)-2-hydroxyethyl]amino)propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243).  The expts. were performed in the absence or presence of propranolol or 2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP 20712A) and/or 1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride (ICI 118551) to inhibit β1- and β2-AR stimulation and 1-(2-ethylphenoxy)-3-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino-(2S)-2-propanol hydrochloride (SR 59230A) (β3-selective antagonist).  In addn., the level of the three subtypes was detd. by reverse transcription polymerase chain reaction and Western blotting.  NOR pretreatment decreased the activation of cAMP induced by NOR, isoprenaline, and DOB, whereas PROC response was abolished.  The inhibition of NOR response by CGP 20712A or ICI 118551 demonstrated that β1- and β2-ARs are down-regulated and that β2-AR functional activity was also abolished in cardiomyocytes exposed to chronic stimulation.  β3-AR function was obsd. with NOR and ISO when β1-/β2-ARs were blocked and with both β3-selective agonists in NOR-treated cells only.  This response was completely inhibited by SR 59230A and involved Gi protein.  Furthermore, the results from functional studies agree well with those from expression expts.  In conclusion, these data provide strong evidence that β3-ARs are functionally upregulated and coupled to Gi protein in rat neonatal cardiomyocytes following chronic exposure to NOR when β1- and β2-ARs are down-regulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmWhDan2vgLVg90H21EOLACvtfcHk0lgJKoYroL7nCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslCitA%253D%253D&md5=03a1b347f4d40b3a4ae9910d220a5cf0</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.090597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.090597%26sid%3Dliteratum%253Aachs%26aulast%3DGermack%26aufirst%3DR.%26aulast%3DDickenson%26aufirst%3DJ.%2BM.%26atitle%3DInduction%2520of%2520beta3-adrenergic%2520receptor%2520functional%2520expression%2520following%2520chronic%2520stimulation%2520with%2520noradrenaline%2520in%2520neonatal%2520rat%2520cardiomyocytes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D392%26epage%3D402%26doi%3D10.1124%2Fjpet.105.090597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavernier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpentier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Marec, H.</span></span> <span> </span><span class="NLM_article-title">Functional beta3-adrenoceptor in the human heart</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1172/JCI118823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI118823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8755668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK28XksFClt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1996&pages=556-562&author=C.+Gauthierauthor=G.+Tavernierauthor=F.+Charpentierauthor=D.+Langinauthor=H.+Le+Marec&title=Functional+beta3-adrenoceptor+in+the+human+heart&doi=10.1172%2FJCI118823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Functional β3-adrenoceptor in the human heart</span></div><div class="casAuthors">Gauthier, Chantal; Tavernier, Genevieve; Charpentier, Flavien; Langin, Dominique; Le Marec, Herve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">556-562</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">β3-Adrenoceptors are involved in metab., gut relaxation, and vascular vasodilation.  However, their existence and role in the human heart have not been documented.  We investigated the effects of several β-adrenoceptor agonists and antagonists on the mech. properties of ventricular endomyocardial biopsies.  In the presence of nadolol, a β1 and β2-adrenoceptor antagonist, isoprenaline produced consistent neg. inotropic effects.  Similar neg. inotropic effects also resulted from the action of β3-adrenoceptor agonists with an order of potency: BRL 37344 > SR 58611 ≈ CL 316243 > CGP 12177.  The dose-response curve to BRL 37344-decreasing myocardial contractility was not modified by pretreatment with nadolol, but was shifted to the right by bupranolol, a nonselective β-adrenoceptor antagonist.  β3-Adrenoceptor agonists also induced a redn. in the amplitude and an acceleration in the repolarization phase of the human action potential.  β3-Adrenoceptor transcripts were detected in human ventricle by a polymerase chain reaction assay.  These results indicate that: (a) β3-adrenoceptors are present and functional in the human heart; and (b) these receptors are responsible for the unexpected neg. inotropic effects of catecholamines and may be involved in pathophysiol. mechanisms leading to heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLi5eA29xcqbVg90H21EOLACvtfcHk0liVnn6lM5-8pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFClt7g%253D&md5=d471eb95964f32bcd4158e71b62b7134</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1172%2FJCI118823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI118823%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DC.%26aulast%3DTavernier%26aufirst%3DG.%26aulast%3DCharpentier%26aufirst%3DF.%26aulast%3DLangin%26aufirst%3DD.%26aulast%3DLe%2BMarec%26aufirst%3DH.%26atitle%3DFunctional%2520beta3-adrenoceptor%2520in%2520the%2520human%2520heart%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1996%26volume%3D98%26spage%3D556%26epage%3D562%26doi%3D10.1172%2FJCI118823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moniotte, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobzik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trochu, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1655</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.103.12.1649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2F01.CIR.103.12.1649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11273992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFWktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2001&pages=1649-1655&author=S.+Moniotteauthor=L.+Kobzikauthor=O.+Feronauthor=J.+N.+Trochuauthor=C.+Gauthierauthor=J.+L.+Balligand&title=Upregulation+of+beta%283%29-adrenoceptors+and+altered+contractile+response+to+inotropic+amines+in+human+failing+myocardium&doi=10.1161%2F01.CIR.103.12.1649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of β3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium</span></div><div class="casAuthors">Moniotte, Stephane; Kobzik, Lester; Feron, Olivier; Trochu, Jean-Noel; Gauthier, Chantal; Balligand, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1649-1655</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background-Contrary to β1- and β2-adrenoceptors, β3-adrenoceptors mediate a neg. inotropic effect in human ventricular muscle.  To assess their functional role in heart failure, our purpose was to compare the expression and contractile effect of β3-adrenoceptors in nonfailing and failing human hearts.  Methods and Results-We analyzed left ventricular samples from 29 failing (16 ischemic and 13 dilated cardiomyopathic) hearts (ejection fraction 18.6±2%) and 25 nonfailing (including 12 innervated) explanted hearts (ejection fraction 64.2±3%).  β3-Adrenoceptor proteins were identified by immunohistochem. in ventricular cardiomyocytes from nonfailing and failing hearts.  Contrary to β1-adrenoceptor mRNA, Western blot anal. of β3-adrenoceptor proteins showed a 2- to 3-fold increase in failing compared with nonfailing hearts.  A similar increase was obsd. for Gαi-2 proteins that couple β3-adrenoceptors to their neg. inotropic effect.  Contractile tension was measured in elec. stimulated myocardial samples ex vivo.  In failing hearts, the pos. inotropic effect of the nonspecific amine isoprenaline was reduced by 75% compared with that obsd. in nonfailing hearts.  By contrast, the neg. inotropic effect of β3-preferential agonists was only mildly reduced.  Conclusions-Opposite changes occur in β1- and β3-adrenoceptor abundance in the failing left ventricle, with an imbalance between their inotropic influences that may underlie the functional degrdn. of the human failing heart.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT34WD4d3hcbVg90H21EOLACvtfcHk0liVnn6lM5-8pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFWktLk%253D&md5=6e2b01e291dc0f64d8ed1ed441a6395f</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.103.12.1649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.103.12.1649%26sid%3Dliteratum%253Aachs%26aulast%3DMoniotte%26aufirst%3DS.%26aulast%3DKobzik%26aufirst%3DL.%26aulast%3DFeron%26aufirst%3DO.%26aulast%3DTrochu%26aufirst%3DJ.%2BN.%26aulast%3DGauthier%26aufirst%3DC.%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DUpregulation%2520of%2520beta%25283%2529-adrenoceptors%2520and%2520altered%2520contractile%2520response%2520to%2520inotropic%2520amines%2520in%2520human%2520failing%2520myocardium%26jtitle%3DCirculation%26date%3D2001%26volume%3D103%26spage%3D1649%26epage%3D1655%26doi%3D10.1161%2F01.CIR.103.12.1649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ukai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sane, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. P.</span></span> <span> </span><span class="NLM_article-title">Upregulation of functional beta(3)-adrenergic receptor in the failing canine myocardium</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">599</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1161/hh1901.098042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2Fhh1901.098042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11577025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFCgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2001&pages=599-606&author=H.+J.+Chengauthor=Z.+S.+Zhangauthor=K.+Onishiauthor=T.+Ukaiauthor=D.+C.+Saneauthor=C.+P.+Cheng&title=Upregulation+of+functional+beta%283%29-adrenergic+receptor+in+the+failing+canine+myocardium&doi=10.1161%2Fhh1901.098042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of functional β3-adrenergic receptor in the failing canine myocardium</span></div><div class="casAuthors">Cheng, Heng-Jie; Zhang, Zhu-Shan; Onishi, Katsuya; Ukai, Tomohiko; Sane, David C.; Cheng, Che-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">599-606</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Altered expression and functional responses to cardiac β3-adrenergic receptors (ARs) may contribute to progressive cardiac dysfunction in heart failure (CHF).  The authors compared myocyte β3-AR mRNA and protein levels and myocyte contractile, [Ca2+]i, transient, and Ca2+ current (lCaL) responses to BRL-37344 (BRL, 10-8 mol/L), a selective β3-AR agonist, in 9 instrumented dogs before and after pacing-induced CHF.  Myocytes were isolated from left ventricular myocardium biopsy tissues.  Using reverse transcription-polymerase chain reaction, the authors detected β3-AR mRNA from myocyte total RNA in each animal.  Using a cloned canine β3-AR cDNA probe and myocyte poly A+ RNA, the authors detected a single band about 3.4 kb in normal and CHF myocytes.  β3-AR protein was detected by Western blot.  β3-AR mRNA and protein levels were significantly greater in CHF myocytes than in normal myocytes.  Importantly, these changes were assocd. with enhanced β3-AR-mediated neg. modulation on myocyte contractile response and [Ca2+]i regulation.  Compared with normal myocytes, CHF myocytes had much greater decreases in the velocity of shortening and relengthening with BRL accompanied by larger redns. in the peak systolic [Ca2+]i transient and ICaL.  These responses were not modified by pretreating myocytes with metoprolol (a β1-AR antagonist) or nadolol (a β1- and β2-AR antagonist), but were nearly prevented by bupranolol or L-748,337 (β3-AR antagonists).  The authors conclude that in dogs with pacing-induced CHF β3-AR gene expression and protein levels are upregulated, and the functional response to β3-AR stimulation is increased.  This may contribute to progression of cardiac dysfunction in CHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2BR6yWZqzOrVg90H21EOLACvtfcHk0liVnn6lM5-8pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFCgur4%253D&md5=e9a90a14a1e00d471d2e9faa6557d9d7</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1161%2Fhh1901.098042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhh1901.098042%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%2BJ.%26aulast%3DZhang%26aufirst%3DZ.%2BS.%26aulast%3DOnishi%26aufirst%3DK.%26aulast%3DUkai%26aufirst%3DT.%26aulast%3DSane%26aufirst%3DD.%2BC.%26aulast%3DCheng%26aufirst%3DC.%2BP.%26atitle%3DUpregulation%2520of%2520functional%2520beta%25283%2529-adrenergic%2520receptor%2520in%2520the%2520failing%2520canine%2520myocardium%26jtitle%3DCirc.%2520Res.%26date%3D2001%26volume%3D89%26spage%3D599%26epage%3D606%26doi%3D10.1161%2Fhh1901.098042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois-Deruy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoury, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamelet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauloye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouleur, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esfahani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jnaoui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götz, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaev, V. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herijgers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobysheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iaccarino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker-Kleiner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavernier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dessy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Enhanced expression of β<sub>3</sub>-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.113.004940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCULATIONAHA.113.004940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24190960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ygsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=451-462&author=C.+Belgeauthor=J.+Hammondauthor=E.+Dubois-Deruyauthor=B.+Manouryauthor=J.+Hameletauthor=C.+Beauloyeauthor=A.+Marklauthor=A.+C.+Pouleurauthor=L.+Bertrandauthor=H.+Esfahaniauthor=K.+Jnaouiauthor=K.+R.+G%C3%B6tzauthor=V.+O.+Nikolaevauthor=A.+Vanderperauthor=P.+Herijgersauthor=I.+Lobyshevaauthor=G.+Iaccarinoauthor=D.+Hilfiker-Kleinerauthor=G.+Tavernierauthor=D.+Langinauthor=C.+Dessyauthor=J.+L.+Balligand&title=Enhanced+expression+of+%CE%B23-adrenoceptors+in+cardiac+myocytes+attenuates+neurohormone-induced+hypertrophic+remodeling+through+nitric+oxide+synthase&doi=10.1161%2FCIRCULATIONAHA.113.004940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Expression of β3-Adrenoceptors in Cardiac Myocytes Attenuates Neurohormone-Induced Hypertrophic Remodeling Through Nitric Oxide Synthase</span></div><div class="casAuthors">Belge, Catharina; Hammond, Joanna; Dubois-Deruy, Emilie; Manoury, Boris; Hamelet, Julien; Beauloye, Christophe; Markl, Andreas; Pouleur, Anne-Catherine; Bertrand, Luc; Esfahani, Hrag; Jnaoui, Karima; Goetz, Konrad R.; Nikolaev, Viacheslav O.; Vanderper, Annelies; Herijgers, Paul; Lobysheva, Irina; Iaccarino, Guido; Hilfiker-Kleiner, Denise; Tavernier, Genevieve; Langin, Dominique; Dessy, Chantal; Balligand, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">451-462</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: β1-2-adrenergic receptors (AR) are key regulators of cardiac contractility and remodeling in response to catecholamines.  β3-AR expression is enhanced in diseased human myocardium, but its impact on remodeling is unknown.  METHODS AND RESULTS-: Mice with cardiac myocyte-specific expression of human β3-AR (β3-TG) and wild-type (WT) littermates were used to compare myocardial remodeling in response to isoproterenol (Iso) or Angiotensin II (Ang II).  β3-TG and WT had similar morphometric and hemodynamic parameters at baseline. β3-AR colocalized with caveolin-3, endothelial nitric oxide synthase (NOS) and neuronal NOS in adult transgenic myocytes, which constitutively produced more cyclic GMP, detected with a new transgenic FRET sensor.  Iso and Ang II produced hypertrophy and fibrosis in WT mice, but not in β3-TG mice, which also had less re-expression of fetal genes and transforming growth factor β1.  Protection from Iso-induced hypertrophy was reversed by nonspecific NOS inhibition at low dose Iso, and by preferential neuronal NOS inhibition at high-dose Iso.  Adenoviral overexpression of β3-AR in isolated cardiac myocytes also increased NO prodn. and attenuated hypertrophy to Iso and phenylephrine.  Hypertrophy was restored on NOS or protein kinase G inhibition.  Mechanistically, β3-AR overexpression inhibited phenylephrine-induced nuclear factor of activated T-cell activation.  CONCLUSIONS-: Cardiac-specific overexpression of β3-AR does not affect cardiac morphol. at baseline but inhibits the hypertrophic response to neurohormonal stimulation in vivo and in vitro, through a NOS-mediated mechanism.  Activation of the cardiac β3-AR pathway may provide future therapeutic avenues for the modulation of hypertrophic remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWV_Jg3yXy0LVg90H21EOLACvtfcHk0liApmWzCi1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ygsLs%253D&md5=0beb0732eb470a95c3b9415c283bef0c</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.113.004940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.113.004940%26sid%3Dliteratum%253Aachs%26aulast%3DBelge%26aufirst%3DC.%26aulast%3DHammond%26aufirst%3DJ.%26aulast%3DDubois-Deruy%26aufirst%3DE.%26aulast%3DManoury%26aufirst%3DB.%26aulast%3DHamelet%26aufirst%3DJ.%26aulast%3DBeauloye%26aufirst%3DC.%26aulast%3DMarkl%26aufirst%3DA.%26aulast%3DPouleur%26aufirst%3DA.%2BC.%26aulast%3DBertrand%26aufirst%3DL.%26aulast%3DEsfahani%26aufirst%3DH.%26aulast%3DJnaoui%26aufirst%3DK.%26aulast%3DG%25C3%25B6tz%26aufirst%3DK.%2BR.%26aulast%3DNikolaev%26aufirst%3DV.%2BO.%26aulast%3DVanderper%26aufirst%3DA.%26aulast%3DHerijgers%26aufirst%3DP.%26aulast%3DLobysheva%26aufirst%3DI.%26aulast%3DIaccarino%26aufirst%3DG.%26aulast%3DHilfiker-Kleiner%26aufirst%3DD.%26aulast%3DTavernier%26aufirst%3DG.%26aulast%3DLangin%26aufirst%3DD.%26aulast%3DDessy%26aufirst%3DC.%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DEnhanced%2520expression%2520of%2520%25CE%25B23-adrenoceptors%2520in%2520cardiac%2520myocytes%2520attenuates%2520neurohormone-induced%2520hypertrophic%2520remodeling%2520through%2520nitric%2520oxide%2520synthase%26jtitle%3DCirculation%26date%3D2014%26volume%3D129%26spage%3D451%26epage%3D462%26doi%3D10.1161%2FCIRCULATIONAHA.113.004940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Cardiac salvage by tweaking with beta-3-adrenergic receptors</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvw056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvw056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27001422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVejsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=128-133&author=J.+L.+Balligand&title=Cardiac+salvage+by+tweaking+with+beta-3-adrenergic+receptors&doi=10.1093%2Fcvr%2Fcvw056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac salvage by tweaking with beta-3-adrenergic receptors</span></div><div class="casAuthors">Balligand, Jean-Luc</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">128-133</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Overstimulation of the orthosympathetic system leads to cardiovascular cell and tissue damage through prolonged activation of β-1-2 adrenergic receptors (BARs).  The more recent identification of the third isotype of BAR (B3AR) in cardiac myocytes and endothelial cells with a distinctive coupling and effect on cardiac function and remodelling introduced a new facet to this paradigm.  In particular, B3AR is up-regulated in cardiac disease and less prone to homologous desensitization, which may reinforce its influence on the diseased myocardium.  Mice with transgenic cardiac-specific expression of the human B3AR are protected from cardiac hypertrophy and fibrosis in response to neurohormonal stimulation.  B3AR has also been implicated in cardiac protection after ischemia-reperfusion and the benefits of exercise on the heart.  Many of these salvage mechanisms are mediated by B3AR coupling to nitric oxide synthase (eNOS and nNOS) and downstream cGMP/protein kinase G signalling.  Notably, B3AR exerts antioxidant protective effects on these and other signalling elements, which may subserve its protective properties in the setting of chronic heart failure.  Addnl. vasorelaxing properties and paracrine NO-mediated signalling by B3AR in endothelium, together with systemic metabolic effects on beige/brown fat complete the pleiotropic protective properties of this new therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt2SulFlUZ_rVg90H21EOLACvtfcHk0liApmWzCi1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVejsrzP&md5=43b2209d70c85e34032e53a2c7e791d5</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvw056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvw056%26sid%3Dliteratum%253Aachs%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DCardiac%2520salvage%2520by%2520tweaking%2520with%2520beta-3-adrenergic%2520receptors%26jtitle%3DCardiovasc.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D128%26epage%3D133%26doi%3D10.1093%2Fcvr%2Fcvw056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balligand, J. L.</span></span> <span> </span><span class="NLM_article-title">Beta3-adrenoceptors in the cardiovascular system</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(00)01562-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0165-6147%2800%2901562-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11121573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot12lt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=426-431&author=C.+Gauthierauthor=D.+Langinauthor=J.+L.+Balligand&title=Beta3-adrenoceptors+in+the+cardiovascular+system&doi=10.1016%2FS0165-6147%2800%2901562-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">β3-Adrenoceptors in the cardiovascular system</span></div><div class="casAuthors">Gauthier, C.; Langin, D.; Balligand, J.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">426-431</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 68 refs.  β-Adrenoceptors of the β1 and β2 subtypes classically mediate the effects of catecholamines on the contractility of cardiac muscle and the relaxation of vascular smooth muscle.  Since the mol. characterization of the β3-adrenoceptor in 1989, most studies of this adrenoceptor subtype have focused on its control of lipolysis in adipose tissues.  However, more recent studies have investigated the involvement of β3-adrenoceptors in the physiol. control of cardiac and vascular contractility.  In this article, the pharmacol. and mol. evidence that supports the functional role of β3-adrenoceptors in cardiovascular tissues of various species, including humans, will be discussed.  These data might provide new insights into the authors' understanding of the abnormal responsiveness of the cardiovascular system to catecholamines in heart failure and its treatment with β-adrenoceptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZjOtbwLaIhLVg90H21EOLACvtfcHk0liApmWzCi1gQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot12lt7k%253D&md5=a01bafbb05d0d19b492c7d8422900c54</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2800%2901562-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252800%252901562-5%26sid%3Dliteratum%253Aachs%26aulast%3DGauthier%26aufirst%3DC.%26aulast%3DLangin%26aufirst%3DD.%26aulast%3DBalligand%26aufirst%3DJ.%2BL.%26atitle%3DBeta3-adrenoceptors%2520in%2520the%2520cardiovascular%2520system%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2000%26volume%3D21%26spage%3D426%26epage%3D431%26doi%3D10.1016%2FS0165-6147%2800%2901562-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozec, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, C.</span></span> <span> </span><span class="NLM_article-title">Beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pharmthera.2005.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16480771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1Sks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2006&pages=652-673&author=B.+Rozecauthor=C.+Gauthier&title=Beta3-adrenoceptors+in+the+cardiovascular+system%3A+putative+roles+in+human+pathologies&doi=10.1016%2Fj.pharmthera.2005.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">β3-Adrenoceptors in the cardiovascular system: Putative roles in human pathologies</span></div><div class="casAuthors">Rozec, Bertrand; Gauthier, Chantal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">652-673</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The sympathetic nervous system is central for the neurohumoral regulation of the cardiovascular system and is largely involved in many cardiovascular diseases affecting millions of people around the world.  It is classically admitted that β-adrenoceptors (β-AR) of the β1 and β2 subtypes mediate the effects of catecholamines on the force of contraction of cardiac muscle, and on the relaxation of vascular smooth muscle.  However, the mol. characterization in 1989 of a third β-AR subtype, β3, and later its identification in human heart has changed the classically admitted paradigm on the regulation of heart function by the β-adrenergic system.  In blood vessels, β3-AR, like β1 and β2, produced a relaxation.  But at the present time, the physiol. role of β3-AR is not clearly identified.  Thus, the purpose of this review is to summarize the pharmacol. and mol. evidence supporting the functional roles of β3-AR in cardiovascular tissues of various species, including humans.  In addn., this review discusses the potential role of β3-AR in several cardiovascular diseases and emphasizes their putative involvement as new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYiwT4FS7gmrVg90H21EOLACvtfcHk0lgrVAcSUu2PMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1Sks7w%253D&md5=665db84e75259ca7c06d313b8dfb9422</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DRozec%26aufirst%3DB.%26aulast%3DGauthier%26aufirst%3DC.%26atitle%3DBeta3-adrenoceptors%2520in%2520the%2520cardiovascular%2520system%253A%2520putative%2520roles%2520in%2520human%2520pathologies%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D111%26spage%3D652%26epage%3D673%26doi%3D10.1016%2Fj.pharmthera.2005.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arioglu-Inan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayki-Mutlu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. C.</span></span> <span> </span><span class="NLM_article-title">Cardiac β<sub>3</sub>-adrenoceptors-A role in human pathophysiology?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2495</span>, <span class="refDoi"> DOI: 10.1111/bph.14635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fbph.14635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30801686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFylurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=2482-2495&author=E.+Arioglu-Inanauthor=G.+Kayki-Mutluauthor=M.+C.+Michel&title=Cardiac+%CE%B23-adrenoceptors-A+role+in+human+pathophysiology%3F&doi=10.1111%2Fbph.14635"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac β3-adrenoceptors-A role in human pathophysiology?</span></div><div class="casAuthors">Arioglu-Inan, Ebru; Kayki-Mutlu, Gizem; Michel, Martin C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2482-2495</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  As β3-adrenoceptors were first demonstrated to be expressed in adipose tissue they have received much attention for their metabolic effects in obesity and diabetes.  After the existence of this subtype had been suggested to be present in the heart, studies focused on its role in cardiac function.  While the presence and functional role of β3-adrenoceptors in the heart has not uniformly been detected, there is a broad consensus that they become up-regulated in pathol. conditions assocd. with increased sympathetic activity such as heart failure and diabetes.  When detected, the β3-adrenceptor has been demonstrated to mediate neg. inotropic effects in an inhibitory G protein-dependent manner through the NO-cGMP-PKG signalling pathway.  Whether these neg. inotropic effects provide protection from the adverse effects induced by overstimulation of β1/β2-adrenoceptors or in themselves are potentially harmful is controversial, but ongoing clin. studies in patients with congestive heart failure are testing the hypothesis that β3-adrenceptor agonism has a beneficial effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeK1zGgpTTeLVg90H21EOLACvtfcHk0lgrVAcSUu2PMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFylurg%253D&md5=b142c573f1d1af6d1db6529eab30b8d4</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1111%2Fbph.14635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14635%26sid%3Dliteratum%253Aachs%26aulast%3DArioglu-Inan%26aufirst%3DE.%26aulast%3DKayki-Mutlu%26aufirst%3DG.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DCardiac%2520%25CE%25B23-adrenoceptors-A%2520role%2520in%2520human%2520pathophysiology%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D2482%26epage%3D2495%26doi%3D10.1111%2Fbph.14635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lötvall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akdis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacharier, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjermer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casale, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Custovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemanske, R. F.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardlaw, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, P. A.</span></span> <span> </span><span class="NLM_article-title">Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2010.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaci.2010.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21281866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3M7lslOntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=355-360&author=J.+L%C3%B6tvallauthor=C.+A.+Akdisauthor=L.+B.+Bacharierauthor=L.+Bjermerauthor=T.+B.+Casaleauthor=A.+Custovicauthor=R.+F.+Lemanskeauthor=A.+J.+Wardlawauthor=S.+E.+Wenzelauthor=P.+A.+Greenberger&title=Asthma+endotypes%3A+a+new+approach+to+classification+of+disease+entities+within+the+asthma+syndrome&doi=10.1016%2Fj.jaci.2010.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome</span></div><div class="casAuthors">Lotvall Jan; Akdis Cezmi A; Bacharier Leonard B; Bjermer Leif; Casale Thomas B; Custovic Adnan; Lemanske Robert F Jr; Wardlaw Andrew J; Wenzel Sally E; Greenberger Paul A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of allergy and clinical immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">It is increasingly clear that asthma is a complex disease made up of number of disease variants with different underlying pathophysiologies.  Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of asthma and improving treatment and can explain the failure to identify consistent genetic and environmental correlations to asthma.  Here we describe a hypothesis whereby the asthma syndrome is divided into distinct disease entities with specific mechanisms, which we have called "asthma endotypes." An "endotype" is proposed to be a subtype of a condition defined by a distinct pathophysiological mechanism.  Criteria for defining asthma endotypes on the basis of their phenotypes and putative pathophysiology are suggested.  Using these criteria, we identify several proposed asthma endotypes and propose how these new definitions can be used in clinical study design and drug development to target existing and novel therapies to patients most likely to benefit.  This PRACTALL (PRACtical ALLergy) consensus report was produced by experts from the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLS-n5Q903mbxanA7vODO6fW6udTcc2ea1c_bIcl39lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7lslOntg%253D%253D&md5=4ae6fe65edea199280b1ab926d14f177</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2010.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2010.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6tvall%26aufirst%3DJ.%26aulast%3DAkdis%26aufirst%3DC.%2BA.%26aulast%3DBacharier%26aufirst%3DL.%2BB.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DCasale%26aufirst%3DT.%2BB.%26aulast%3DCustovic%26aufirst%3DA.%26aulast%3DLemanske%26aufirst%3DR.%2BF.%26aulast%3DWardlaw%26aufirst%3DA.%2BJ.%26aulast%3DWenzel%26aufirst%3DS.%2BE.%26aulast%3DGreenberger%26aufirst%3DP.%2BA.%26atitle%3DAsthma%2520endotypes%253A%2520a%2520new%2520approach%2520to%2520classification%2520of%2520disease%2520entities%2520within%2520the%2520asthma%2520syndrome%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2011%26volume%3D127%26spage%3D355%26epage%3D360%26doi%3D10.1016%2Fj.jaci.2010.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girodet, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunon de
Lara, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marthan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, P.</span></span> <span> </span><span class="NLM_article-title">Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2011.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pharmthera.2011.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21334378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsV2nu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=325-337&author=P.+O.+Girodetauthor=A.+Ozierauthor=I.+Baraauthor=J.+M.+Tunon+de%0ALaraauthor=R.+Marthanauthor=P.+Berger&title=Airway+remodeling+in+asthma%3A+new+mechanisms+and+potential+for+pharmacological+intervention&doi=10.1016%2Fj.pharmthera.2011.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Airway remodeling in asthma: New mechanisms and potential for pharmacological intervention</span></div><div class="casAuthors">Girodet, Pierre-Olivier; Ozier, Annaig; Bara, Imane; Tunon de Lara, Jose-Manuel; Marthan, Roger; Berger, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-337</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The chronic inflammatory response within the airways of asthmatics is assocd. with structural changes termed airway remodeling.  This remodeling process is a key feature of severe asthma.  The 5-10% of patients with a severe form of the disease account for the higher morbidity and health costs related to asthma.  Among the histopathol. characteristics of airway remodeling, recent reports indicate that the increased mass of airway smooth muscle (ASM) plays a crit. role.  ASM cell proliferation in severe asthma implicates a gallopamil-sensitive calcium influx and the activation of calcium-calmodulin kinase IV leading to enhanced mitochondrial biogenesis through the activation of various transcription factors (PGC-1α, NRF-1 and mt-TFA).  The altered expression and function of sarco/endoplasmic reticulum Ca2+ pump could play a role in ASM remodeling in moderate to severe asthma.  Addnl., aberrant communication between an injured airway epithelium and ASM could also contribute to disease severity.  Airway remodeling is insensitive to corticosteroids and anti-leukotrienes whereas the effect of monoclonal antibodies (the anti-IgE omalizumab, the anti-interleukin-5 mepolizumab or anti-tumor necrosis factor-alpha) remains to be investigated.  This review focuses on potential new therapeutic strategies targeting ASM cells, esp. Ca2+ and mitochondria-dependent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFl7SP_EuPWrVg90H21EOLACvtfcHk0ljZ8fD_Sp2VOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsV2nu7g%253D&md5=46fce84291f66741fdbea6fe5629ba95</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DGirodet%26aufirst%3DP.%2BO.%26aulast%3DOzier%26aufirst%3DA.%26aulast%3DBara%26aufirst%3DI.%26aulast%3DTunon%2Bde%2BLara%26aufirst%3DJ.%2BM.%26aulast%3DMarthan%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DP.%26atitle%3DAirway%2520remodeling%2520in%2520asthma%253A%2520new%2520mechanisms%2520and%2520potential%2520for%2520pharmacological%2520intervention%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D130%26spage%3D325%26epage%3D337%26doi%3D10.1016%2Fj.pharmthera.2011.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Begueret, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernejoux, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubuisson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marthan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunon-De-Lara, J. M.</span></span> <span> </span><span class="NLM_article-title">Inflammation of bronchial smooth muscle in allergic asthma</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1136/thx.2006.062141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.2006.062141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17189531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD28jltFWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=8-15&author=H.+Begueretauthor=P.+Bergerauthor=J.+M.+Vernejouxauthor=L.+Dubuissonauthor=R.+Marthanauthor=J.+M.+Tunon-De-Lara&title=Inflammation+of+bronchial+smooth+muscle+in+allergic+asthma&doi=10.1136%2Fthx.2006.062141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation of bronchial smooth muscle in allergic asthma</span></div><div class="casAuthors">Begueret H; Berger P; Vernejoux J M; Dubuisson L; Marthan R; Tunon-de-Lara J M</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-15</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Recent observations in asthma suggest that bronchial smooth muscle is infiltrated by inflammatory cells including mast cells.  Such an infiltration may contribute to airway remodelling that is partly due to an increase in smooth muscle mass.  Whether muscle increase is the result of smooth muscle cell hypertrophy remains controversial and has not been studied by ultrastructural analysis.  A morphometric analysis of airway smooth muscle (ASM) was undertaken in asthmatic patients using electron microscopy to examine the interactions between ASM cells and inflammatory cells.  METHODS:  ASM specimens were obtained from 14 asthmatic subjects and nine non-asthmatic controls undergoing fibreoptic endoscopy.  Inflammatory cell counts were assessed by immunohistochemistry, and ultrastructural parameters were measured using electron microscopy in a blinded fashion on smooth muscle cells and inflammatory cells.  RESULTS:  ASM from asthmatic patients was infiltrated by an increased number of mast cells and lymphocytes.  Smooth muscle cells and their basal lamina were thicker in asthmatic patients (9.5 (0.8) and 1.4 (0.2) microm) than in controls (6.7 (0.4) and 0.7 (0.1) microm).  In asthmatics the extracellular matrix was frequently organised in large amounts between ASM cells.  Myofibroblasts within smooth muscle bundles were only observed in asthmatics, some of them displaying a close contact with ASM cells.  CONCLUSION:  In asthma, airway myositis is characterised by a direct interaction between ASM cells and mast cells and lymphocytes.  Smooth muscle remodelling was present, including cell hypertrophy and abnormal extracellular matrix deposition moulding ASM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoKNTVX6jsazAEfvC7EH1LfW6udTcc2ebBQYwSexdM_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jltFWmtg%253D%253D&md5=172600e5e647a35f4ffa3b4658152915</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.062141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.062141%26sid%3Dliteratum%253Aachs%26aulast%3DBegueret%26aufirst%3DH.%26aulast%3DBerger%26aufirst%3DP.%26aulast%3DVernejoux%26aufirst%3DJ.%2BM.%26aulast%3DDubuisson%26aufirst%3DL.%26aulast%3DMarthan%26aufirst%3DR.%26aulast%3DTunon-De-Lara%26aufirst%3DJ.%2BM.%26atitle%3DInflammation%2520of%2520bronchial%2520smooth%2520muscle%2520in%2520allergic%2520asthma%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26spage%3D8%26epage%3D15%26doi%3D10.1136%2Fthx.2006.062141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockcroft, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolovich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemiere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulet, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, P. M.</span></span> <span> </span><span class="NLM_article-title">Airway hyperresponsiveness in asthma: measurement and clinical relevance</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2016.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2016.11.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28163029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC1c3jt12iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=649-659&author=P.+Nairauthor=J.+G.+Martinauthor=D.+C.+Cockcroftauthor=M.+Dolovichauthor=C.+Lemiereauthor=L.+P.+Bouletauthor=P.+M.+O%E2%80%99Byrne&title=Airway+hyperresponsiveness+in+asthma%3A+measurement+and+clinical+relevance&doi=10.1016%2Fj.jaip.2016.11.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance</span></div><div class="casAuthors">Nair Parameswaran; Martin James G; Cockcroft Donald C; Dolovich Myrna; O'Byrne Paul M; Lemiere Catherine; Boulet Louis-Philippe</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">649-659.e2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Airway hyperresponsiveness is a characteristic feature of asthma, and its measurement is an important tool in its diagnosis.  With a few caveats, methacholine bronchial provocation by a 2-minute tidal breathing method is highly sensitive; a negative test result (PC20 > 16 mg/mL, PD20 > 400 μg) rules out current asthma with reasonable certainty.  A PC20 value of less than 1 mg/mL/PD20 value of less than 25 μg is highly specific (ie, diagnostic) but quite insensitive for asthma.  For accurate interpretation of the test results, it is important to control and standardize technical factors that have an impact on nebulizer performance.  In addition to its utility to relate symptoms such as cough, wheeze, and shortness of breath to variable airflow obstruction (ie, to diagnose current asthma), the test is useful to make a number of other clinical assessments.  These include (1) evaluation of patients with occupational asthma, (2) evaluation of patients with exercise-induced respiratory symptoms, (3) evaluation of novel asthma medications, (4) evaluation of relative potency of inhaled bronchodilators, (5) as a biomarker to adjust anti-inflammatory therapy to improve clinical outcomes, and (6) in the evaluation of patients with severe asthma to rule out masqueraders such as laryngeal dysfunction.  The actual mechanism of altered smooth muscle behavior in asthma that is assessed by direct (eg, methacholine) or indirect (eg, allergen) bronchial provocation remains one of the most fundamental questions related to asthma that needs to be determined.  The test is underutilized in clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFNvKRYbkw8K_dlEzl_fBafW6udTcc2ebBQYwSexdM_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3jt12iug%253D%253D&md5=c8f7737e4ff4f555bfc13d6d462577af</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2016.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2016.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DJ.%2BG.%26aulast%3DCockcroft%26aufirst%3DD.%2BC.%26aulast%3DDolovich%26aufirst%3DM.%26aulast%3DLemiere%26aufirst%3DC.%26aulast%3DBoulet%26aufirst%3DL.%2BP.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26atitle%3DAirway%2520hyperresponsiveness%2520in%2520asthma%253A%2520measurement%2520and%2520clinical%2520relevance%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2017%26volume%3D5%26spage%3D649%26epage%3D659%26doi%3D10.1016%2Fj.jaip.2016.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, S. E.</span></span> <span> </span><span class="NLM_article-title">Asthma phenotypes: the evolution from clinical to molecular approaches</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1038/nm.2678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnm.2678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22561835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFOqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=716-725&author=S.+E.+Wenzel&title=Asthma+phenotypes%3A+the+evolution+from+clinical+to+molecular+approaches&doi=10.1038%2Fnm.2678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma phenotypes: the evolution from clinical to molecular approaches</span></div><div class="casAuthors">Wenzel, Sally E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">716-725</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Although asthma was considered as a single disease for years, recent studies have increasingly focused on its heterogeneity.  The characterization of this heterogeneity has promoted the concept that asthma consists of multiple phenotypes or consistent groupings of characteristics.  Asthma phenotypes were initially focused on combinations of clin. characteristics, but they are now evolving to link biol. to phenotype, often through a statistically based process.  Ongoing studies of large-scale, molecularly and genetically focused and extensively clin. characterized cohorts of asthma should enhance our ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to asthma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkMySJpATqXrVg90H21EOLACvtfcHk0lgruA8cT9Q2dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFOqtbk%253D&md5=ce1354d6be255d65d1d1f40e0467cd59</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnm.2678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2678%26sid%3Dliteratum%253Aachs%26aulast%3DWenzel%26aufirst%3DS.%2BE.%26atitle%3DAsthma%2520phenotypes%253A%2520the%2520evolution%2520from%2520clinical%2520to%2520molecular%2520approaches%26jtitle%3DNat.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D716%26epage%3D725%26doi%3D10.1038%2Fnm.2678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuhlbrigge, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, M.</span></span> <span> </span><span class="NLM_article-title">Precision medicine in asthma-using phenotypes to understand endotypes that lead us to new therapeutic options</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2019.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2019.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32037110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387gtVWqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=496-497&author=A.+L.+Fuhlbriggeauthor=M.+Castro&title=Precision+medicine+in+asthma-using+phenotypes+to+understand+endotypes+that+lead+us+to+new+therapeutic+options&doi=10.1016%2Fj.jaip.2019.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Precision Medicine in Asthma-Using Phenotypes to Understand Endotypes That Lead Us to New Therapeutic Options</span></div><div class="casAuthors">Fuhlbrigge Anne L; Castro Mario</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">496-497</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgQ7H1MpvaP4HWj6b1v8uTfW6udTcc2eZEr9ZH-R4itLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387gtVWqsA%253D%253D&md5=c3bfe2c3c80e91f4697336b60c3a7128</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2019.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2019.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DFuhlbrigge%26aufirst%3DA.%2BL.%26aulast%3DCastro%26aufirst%3DM.%26atitle%3DPrecision%2520medicine%2520in%2520asthma-using%2520phenotypes%2520to%2520understand%2520endotypes%2520that%2520lead%2520us%2520to%2520new%2520therapeutic%2520options%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2020%26volume%3D8%26spage%3D496%26epage%3D497%26doi%3D10.1016%2Fj.jaip.2019.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellwanger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koth, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arron, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span> <span> </span><span class="NLM_article-title">T-helper type 2-driven inflammation defines major subphenotypes of asthma</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1164/rccm.200903-0392OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Frccm.200903-0392OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19483109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOju7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2009&pages=388-395&author=P.+G.+Woodruffauthor=B.+Modrekauthor=D.+F.+Choyauthor=G.+Jiaauthor=A.+R.+Abbasauthor=A.+Ellwangerauthor=L.+L.+Kothauthor=J.+R.+Arronauthor=J.+V.+Fahy&title=T-helper+type+2-driven+inflammation+defines+major+subphenotypes+of+asthma&doi=10.1164%2Frccm.200903-0392OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">T-helper type 2-driven inflammation defines major subphenotypes of asthma</span></div><div class="casAuthors">Woodruff, Prescott G.; Modrek, Barmak; Choy, David F.; Jia, Guiquan; Abbas, Alexander R.; Ellwanger, Almut; Arron, Joseph R.; Koth, Laura L.; Fahy, John V.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">388-395</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">T-helper type 2 (Th2) inflammation, mediated by IL-4, IL-5, and IL-13, is considered the central mol. mechanism underlying asthma, and Th2 cytokines are emerging therapeutic targets.  However, clin. studies increasingly suggest that asthma is heterogeneous.  To det. whether this clin. heterogeneity reflects heterogeneity in underlying mol. mechanisms related to Th2 inflammation.  Using microarray and polymerase chain reaction analyses of airway epithelial brushings from 42 patients with mild-to-moderate asthma and 28 healthy control subjects, we classified subjects with asthma based on high or low expression of IL-13-inducible genes.  We then validated this classification and investigated its clin. implications through analyses of cytokine expression in bronchial biopsies, markers of inflammation and remodeling, responsiveness to inhaled corticosteroids, and reproducibility on repeat examn.  Gene expression analyses identified two evenly sized and distinct subgroups, "Th2-high" and "Th2-low" asthma (the latter indistinguishable from control subjects).  These subgroups differed significantly in expression of IL-5 and IL-13 in bronchial biopsies and in airway hyperresponsiveness, serum IgE, blood and airway eosinophilia, subepithelial fibrosis, and airway mucin gene expression (all P < 0.03).  The lung function improvements expected with inhaled corticosteroids were restricted to Th2-high asthma, and Th2 markers were reproducible on repeat evaluation.  Asthma can be divided into at least two distinct mol. phenotypes defined by degree of Th2 inflammation.  Th2 cytokines are likely to be a relevant therapeutic target in only a subset of patients with asthma.  Furthermore, current models do not adequately explain non-Th2-driven asthma, which represents a significant proportion of patients and responds poorly to current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZSm0ro3vhkrVg90H21EOLACvtfcHk0lgruA8cT9Q2dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOju7vI&md5=be044b3bf7e58373ffd1dc722811583e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1164%2Frccm.200903-0392OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200903-0392OC%26sid%3Dliteratum%253Aachs%26aulast%3DWoodruff%26aufirst%3DP.%2BG.%26aulast%3DModrek%26aufirst%3DB.%26aulast%3DChoy%26aufirst%3DD.%2BF.%26aulast%3DJia%26aufirst%3DG.%26aulast%3DAbbas%26aufirst%3DA.%2BR.%26aulast%3DEllwanger%26aufirst%3DA.%26aulast%3DKoth%26aufirst%3DL.%2BL.%26aulast%3DArron%26aufirst%3DJ.%2BR.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26atitle%3DT-helper%2520type%25202-driven%2520inflammation%2520defines%2520major%2520subphenotypes%2520of%2520asthma%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D180%26spage%3D388%26epage%3D395%26doi%3D10.1164%2Frccm.200903-0392OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendell, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptors in asthma therapy: pharmacology and drug action</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1124/pr.118.016899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fpr.118.016899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31767622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeqsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1-49&author=S.+G.+Wendellauthor=H.+Fanauthor=C.+Zhang&title=G+protein-coupled+receptors+in+asthma+therapy%3A+pharmacology+and+drug+action&doi=10.1124%2Fpr.118.016899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors in asthma therapy: pharmacology and drug actions</span></div><div class="casAuthors">Wendell, Stacy Gelhaus; Fan, Hao; Zhang, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-49</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Many asthma therapeutics target G protein-coupled receptors (GPCRs), which either enhance bronchodilation or prevent bronchoconstriction.  Short-acting and long-acting β2-agonists are widely used bronchodilators that signal through the activation of the β2-adrenergic receptor.  Short-acting and long-acting antagonists of muscarinic acetylcholine receptors are used to reduce bronchoconstriction by blocking the action of acetylcholine.  Leukotriene antagonists that block the signaling of cysteinyl leukotriene receptor 1 are used as an add-on therapy to reduce bronchoconstriction and inflammation induced by cysteinyl leukotrienes.  A no. of GPCR-targeting asthma drug candidates are also in different stages of development.  Among them, antagonists of prostaglandin D2 receptor 2 have advanced into phase III clin. trials.  Others, including antagonists of the adenosine A2B receptor and the histamine H4 receptor, are in early stages of clin. investigation.  In the past decade, significant research advancements in pharmacol., cell biol., structural biol., andmol. physiol. have greatly deepened our understanding of the therapeutic roles of GPCRs in asthma and drug action on these GPCRs.  This review summarizes our current understanding of GPCR signaling and pharmacol. in the context of asthma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEzWgQ2eNDlbVg90H21EOLACvtfcHk0lgruA8cT9Q2dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeqsr%252FK&md5=38ed0347d973bdb94a02a63b03a640f5</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.016899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.016899%26sid%3Dliteratum%253Aachs%26aulast%3DWendell%26aufirst%3DS.%2BG.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DG%2520protein-coupled%2520receptors%2520in%2520asthma%2520therapy%253A%2520pharmacology%2520and%2520drug%2520action%26jtitle%3DPharmacol.%2520Rev.%26date%3D2020%26volume%3D72%26spage%3D1%26epage%3D49%26doi%3D10.1124%2Fpr.118.016899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease</span>. <i>Cell. Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1038/cmi.2010.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fcmi.2010.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20383174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFSmtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=182-189&author=S.+Leungauthor=X.+Liuauthor=L.+Fangauthor=X.+Chenauthor=T.+Guoauthor=J.+Zhang&title=The+cytokine+milieu+in+the+interplay+of+pathogenic+Th1%2FTh17+cells+and+regulatory+T+cells+in+autoimmune+disease&doi=10.1038%2Fcmi.2010.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease</span></div><div class="casAuthors">Leung, Stewart; Liu, Xuebin; Fang, Lei; Chen, Xi; Guo, Taylor; Zhang, Jingwu</div><div class="citationInfo"><span class="NLM_cas:title">Cellular & Molecular Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">182-189</span>CODEN:
                <span class="NLM_cas:coden">CMIEAO</span>;
        ISSN:<span class="NLM_cas:issn">1672-7681</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  The propagation and regulation of an immune response is driven by a network of effector and regulatory T (Treg) cells.  The interplay of effector T and Treg cells dets. the direction of the immune response towards inflammation or its resoln. in an autoimmune disease setting.  In autoimmune diseases, this interplay shifts the balance in favor of the development of autoreactive effector T cells, resulting in inflammatory pathol.  The objective of an effective therapeutic approach for autoimmune disease is to restore this balance.  In this review, we describe the characteristics and development of pathogenic T helper 1 (Th1) and Th17 cells and the beneficial Treg cells in autoimmune diseases and the crucial roles of the cytokine milieu in influencing the balance of these T-cell subsets.  Given the importance of cytokines, we discuss current immunotherapeutic strategies using cytokine or cytokine receptor antibodies for the treatment of autoimmune diseases.  Cellular & Mol. Immunol. (2010) 7, 182-189; doi:10.1038/cmi.2010.22; published online 19 Apr. 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV9rj_Z2r_lrVg90H21EOLACvtfcHk0lgPCYWLkk_x0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFSmtbo%253D&md5=a6b3de6660b7d410fef0fb9c35d3faa9</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fcmi.2010.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcmi.2010.22%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DThe%2520cytokine%2520milieu%2520in%2520the%2520interplay%2520of%2520pathogenic%2520Th1%252FTh17%2520cells%2520and%2520regulatory%2520T%2520cells%2520in%2520autoimmune%2520disease%26jtitle%3DCell.%2520Mol.%2520Immunol.%26date%3D2010%26volume%3D7%26spage%3D182%26epage%3D189%26doi%3D10.1038%2Fcmi.2010.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coverstone, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seibold, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, M. C.</span></span> <span> </span><span class="NLM_article-title">Diagnosis and management of T2-high asthma</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2019.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2019.11.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32037108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387gtVWqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=442-450&author=A.+M.+Coverstoneauthor=M.+A.+Seiboldauthor=M.+C.+Peters&title=Diagnosis+and+management+of+T2-high+asthma&doi=10.1016%2Fj.jaip.2019.11.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosis and Management of T2-High Asthma</span></div><div class="casAuthors">Coverstone Andrea M; Seibold Max A; Peters Michael C</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">442-450</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Type 2 (T2) inflammation plays a key role in the pathogenesis of asthma.  IL-4, IL-5, and IL-13, along with other inflammatory mediators, lead to increased cellular eosinophilic inflammation.  It is likely that around half of all patients with asthma have evidence of T2-high inflammation.  Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels, and airway gene expression markers are frequently used biomarkers of T2-high asthma.  Individuals with T2-high asthma tend to have several features of increased asthma severity, including reduced lung function and increased rates of asthma exacerbations, and T2-high patients demonstrate distinct pathologic features including increased airway remodeling and alterations in airway mucus production.  Several monoclonal antibodies are now available to treat individuals with T2-high asthma and these medications significantly reduce asthma exacerbation rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgQ7H1MpvaP9yzdcP07UmufW6udTcc2eYJC3b7WD_9lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387gtVWqsg%253D%253D&md5=8d3ac8cf7544b11293fdfb53651bd5e5</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2019.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2019.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DCoverstone%26aufirst%3DA.%2BM.%26aulast%3DSeibold%26aufirst%3DM.%2BA.%26aulast%3DPeters%26aufirst%3DM.%2BC.%26atitle%3DDiagnosis%2520and%2520management%2520of%2520T2-high%2520asthma%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2020%26volume%3D8%26spage%3D442%26epage%3D450%26doi%3D10.1016%2Fj.jaip.2019.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, E.</span></span> <span> </span><span class="NLM_article-title">Role of eosinophils in protective immunity against secondary nematode infections</span>. <i>Immunol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1080/25785826.2019.1697135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1080%2F25785826.2019.1697135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31794348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3MflvVKltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=148-155&author=K.+Yasudaauthor=E.+Kuroda&title=Role+of+eosinophils+in+protective+immunity+against+secondary+nematode+infections&doi=10.1080%2F25785826.2019.1697135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Role of eosinophils in protective immunity against secondary nematode infections</span></div><div class="casAuthors">Yasuda Koubun; Kuroda Etsushi</div><div class="citationInfo"><span class="NLM_cas:title">Immunological medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">148-155</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Infections with parasites, especially those involving nematodes that invade tissues, induce a strong Th2-type immune response, which increases immunoglobulin E and eosinophil levels in the blood and tissues.  Eosinophils are not effective against all possible helminth infections, but are known to be effective against nematode larvae.  In particular, when a host is re-infected by a species of nematode that it previously encountered, the activation of acquired immunity causes robust accumulation and activation of eosinophils that damages the nematode larvae.  Eosinophil production and activation processes are mainly induced by interleukin (IL)-5, which is produced by Th2 cells and group 2 innate lymphoid cells, and eosinophils have been shown to generally participate in host defense, inflammation, and immunomodulation.  Recently, several papers have reported host defense by non-antigen-specific immune activation, in which group 2 innate lymphoid cells and Th2 cells produce interleukin (IL)-5 and IL-13 in response to IL-33 stimulation.  This immune activation is produced by migrating larvae of a species that differs from the species previously encountered.  Eosinophils also play an important role in the eradication of migrating larvae.  Thus, eosinophils contribute to host defense in both antigen-specific and non-antigen-specific manners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpLfsw-fV3Jb0AGQpJZWpJfW6udTcc2eYJC3b7WD_9lbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MflvVKltw%253D%253D&md5=60e89a4decc49f37101eff4322369719</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1080%2F25785826.2019.1697135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F25785826.2019.1697135%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DK.%26aulast%3DKuroda%26aufirst%3DE.%26atitle%3DRole%2520of%2520eosinophils%2520in%2520protective%2520immunity%2520against%2520secondary%2520nematode%2520infections%26jtitle%3DImmunol.%2520Med.%26date%3D2019%26volume%3D42%26spage%3D148%26epage%3D155%26doi%3D10.1080%2F25785826.2019.1697135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starkl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marichal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, S. J.</span></span> <span> </span><span class="NLM_article-title">IgE and mast cells in host defense against parasites and venoms</span>. <i>Semin. Immunopathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1007/s00281-016-0565-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00281-016-0565-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27225312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28Xos1Wks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=581-603&author=K.+Mukaiauthor=M.+Tsaiauthor=P.+Starklauthor=T.+Marichalauthor=S.+J.+Galli&title=IgE+and+mast+cells+in+host+defense+against+parasites+and+venoms&doi=10.1007%2Fs00281-016-0565-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">IgE and mast cells in host defense against parasites and venoms</span></div><div class="casAuthors">Mukai, Kaori; Tsai, Mindy; Starkl, Philipp; Marichal, Thomas; Galli, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunopathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-603</span>CODEN:
                <span class="NLM_cas:coden">SIEMB7</span>;
        ISSN:<span class="NLM_cas:issn">1863-2297</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">IgE-dependent mast cell activation is a major effector mechanism underlying the pathol. assocd. with allergic disorders.  The most dramatic of these IgE-assocd. disorders is the fatal anaphylaxis which can occur in some people who have developed IgE antibodies to otherwise innocuous antigens, such as those contained in certain foods and medicines.  Why would such a highly "maladaptive" immune response develop in evolution and be retained to the present day.  Host defense against parasites has long been considered the only beneficial function that might be conferred by IgE and mast cells.  However, recent studies have provided evidence that, in addn. to participating in host resistance to certain parasites, mast cells and IgE are crit. components of innate (mast cells) and adaptive (mast cells and IgE) immune responses that can enhance host defense against the toxicity of certain arthropod and animal venoms, including enhancing the survival of mice injected with such venoms.  Yet, in some people, developing IgE antibodies to insect or snake venoms puts them at risk for having a potentially fatal anaphylactic reaction upon subsequent exposure to such venoms.  Delineating the mechanisms underlying beneficial vs. detrimental innate and adaptive immune responses assocd. with mast cell activation and IgE is likely to enhance our ability to identify potential therapeutic targets in such settings, not only for reducing the pathol. assocd. with allergic disorders but perhaps also for enhancing immune protection against pathogens and animal venoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_DsUxIO-PfbVg90H21EOLACvtfcHk0lgv5JgP0qomDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xos1Wks7w%253D&md5=f9c7da89f29257c5cbce6fb651c6a32e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1007%2Fs00281-016-0565-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00281-016-0565-1%26sid%3Dliteratum%253Aachs%26aulast%3DMukai%26aufirst%3DK.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DStarkl%26aufirst%3DP.%26aulast%3DMarichal%26aufirst%3DT.%26aulast%3DGalli%26aufirst%3DS.%2BJ.%26atitle%3DIgE%2520and%2520mast%2520cells%2520in%2520host%2520defense%2520against%2520parasites%2520and%2520venoms%26jtitle%3DSemin.%2520Immunopathol.%26date%3D2016%26volume%3D38%26spage%3D581%26epage%3D603%26doi%3D10.1007%2Fs00281-016-0565-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gour, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills-Karp, M.</span></span> <span> </span><span class="NLM_article-title">IL-4 and IL-13 signaling in allergic airway disease</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2015.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.cyto.2015.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26070934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsV2gtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=68-78&author=N.+Gourauthor=M.+Wills-Karp&title=IL-4+and+IL-13+signaling+in+allergic+airway+disease&doi=10.1016%2Fj.cyto.2015.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">IL-4 and IL-13 signaling in allergic airway disease</span></div><div class="casAuthors">Gour, Naina; Wills-Karp, Marsha</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-78</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aberrant prodn. of the prototypical type 2 cytokines, interleukin (IL)-4 and IL-13 has long been assocd. with the pathogenesis of allergic disorders.  Despite tremendous scientific inquiry, the similarities in their structure, and receptor usage have made it difficult to ascertain the distinct role that these two look-alike cytokines play in the onset and perpetuation of allergic inflammation.  However, recent discoveries of differences in receptor distribution, utilization/assembly and affinity between IL-4 and IL-13, along with the discovery of unique innate lymphoid 2 cells (ILC2) which preferentially produce IL-13, not IL-4, are beginning to shed light on these mysteries.  The purpose of this chapter is to review our current understanding of the distinct roles that IL-4 and IL-13 play in allergic inflammatory states and the utility of their modulation as potential therapeutic strategies for the treatment of allergic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSLyxVXCbZzLVg90H21EOLACvtfcHk0lgv5JgP0qomDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsV2gtL8%253D&md5=c5ea5d3c0debc413fb69fbad853bbe0d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2015.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2015.05.014%26sid%3Dliteratum%253Aachs%26aulast%3DGour%26aufirst%3DN.%26aulast%3DWills-Karp%26aufirst%3DM.%26atitle%3DIL-4%2520and%2520IL-13%2520signaling%2520in%2520allergic%2520airway%2520disease%26jtitle%3DCytokine%26date%3D2015%26volume%3D75%26spage%3D68%26epage%3D78%26doi%3D10.1016%2Fj.cyto.2015.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipps, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holguin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, P. G.</span></span> <span> </span><span class="NLM_article-title">T2-“Low” asthma: overview and management strategies</span>. <i>J. Allergy Clin. Immunol. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">463</span>, <span class="refDoi"> DOI: 10.1016/j.jaip.2019.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaip.2019.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32037109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387gtVWqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=452-463&author=A.+M.+Fitzpatrickauthor=B.+E.+Chippsauthor=F.+Holguinauthor=P.+G.+Woodruff&title=T2-%E2%80%9CLow%E2%80%9D+asthma%3A+overview+and+management+strategies&doi=10.1016%2Fj.jaip.2019.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">T2-"Low" Asthma: Overview and Management Strategies</span></div><div class="casAuthors">Fitzpatrick Anne M; Chipps Bradley E; Holguin Fernando; Woodruff Prescott G</div><div class="citationInfo"><span class="NLM_cas:title">The journal of allergy and clinical immunology. In practice</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">452-463</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although the term "asthma" has been applied to all patients with airway lability and variable chest symptoms for centuries, phenotypes of asthma with distinct clinical and molecular features that may warrant different treatment approaches are well recognized.  Patients with type 2 (T2)-"high" asthma are characterized by upregulation of T2 immune pathways (ie, IL-4 and IL-13 gene sets) and eosinophilic airway inflammation, whereas these features are absent in patients with T2-"low" asthma and may contribute to poor responsiveness to corticosteroid treatment.  This review details definitions and clinical features of T2-"low" asthma, potential mechanisms and metabolic aspects, pediatric considerations, and potential treatment approaches.  Priority research questions for T2-"low" asthma are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgQ7H1MpvaP3thwrmtH4OBfW6udTcc2ebeqBtWCqctTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387gtVWqsw%253D%253D&md5=07da4bef4a0b9b05f6ea9f71e5adb6b5</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1016%2Fj.jaip.2019.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaip.2019.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DFitzpatrick%26aufirst%3DA.%2BM.%26aulast%3DChipps%26aufirst%3DB.%2BE.%26aulast%3DHolguin%26aufirst%3DF.%26aulast%3DWoodruff%26aufirst%3DP.%2BG.%26atitle%3DT2-%25E2%2580%259CLow%25E2%2580%259D%2520asthma%253A%2520overview%2520and%2520management%2520strategies%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%2520Pract.%26date%3D2020%26volume%3D8%26spage%3D452%26epage%3D463%26doi%3D10.1016%2Fj.jaip.2019.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, S.</span></span> <span> </span><span class="NLM_article-title">The 3 major types of innate and adaptive cell-mediated effector immunity</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaci.2014.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25528359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=626-635&author=F.+Annunziatoauthor=C.+Romagnaniauthor=S.+Romagnani&title=The+3+major+types+of+innate+and+adaptive+cell-mediated+effector+immunity&doi=10.1016%2Fj.jaci.2014.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">The 3 major types of innate and adaptive cell-mediated effector immunity</span></div><div class="casAuthors">Annunziato, Francesco; Romagnani, Chiara; Romagnani, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The immune system has tailored its effector functions to optimally respond to distinct species of microbes.  Based on emerging knowledge on the different effector T-cell and innate lymphoid cell (ILC) lineages, it is clear that the innate and adaptive immune systems converge into 3 major kinds of cell-mediated effector immunity, which we propose to categorize as type 1, type 2, and type 3.  Type 1 immunity consists of T-bet+ IFN-γ-producing group 1 ILCs (ILC1 and natural killer cells), CD8+ cytotoxic T cells (TC1), and CD4+ TH1 cells, which protect against intracellular microbes through activation of mononuclear phagocytes.  Type 2 immunity consists of GATA-3+ ILC2s, TC2 cells, and TH2 cells producing IL-4, IL-5, and IL-13, which induce mast cell, basophil, and eosinophil activation, as well as IgE antibody prodn., thus protecting against helminthes and venoms.  Type 3 immunity is mediated by retinoic acid-related orphan receptor γt+ ILC3s, TC17 cells, and TH17 cells producing IL-17, IL-22, or both, which activate mononuclear phagocytes but also recruit neutrophils and induce epithelial antimicrobial responses, thus protecting against extracellular bacteria and fungi.  On the other hand, type 1 and 3 immunity mediate autoimmune diseases, whereas type 2 responses can cause allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOlI4X4Np67Vg90H21EOLACvtfcHk0ljR_LZJlMW0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D&md5=16371c1d39a427d5ea96f9237e7b4d5a</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziato%26aufirst%3DF.%26aulast%3DRomagnani%26aufirst%3DC.%26aulast%3DRomagnani%26aufirst%3DS.%26atitle%3DThe%25203%2520major%2520types%2520of%2520innate%2520and%2520adaptive%2520cell-mediated%2520effector%2520immunity%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D135%26spage%3D626%26epage%3D635%26doi%3D10.1016%2Fj.jaci.2014.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeganeh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movassagh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koziol-White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Alwan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. G.</span></span> <span> </span><span class="NLM_article-title">Emerging mediators of airway smooth muscle dysfunction in asthma</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pupt.2012.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22776693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2msr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=105-111&author=B.+Yeganehauthor=C.+Xiaauthor=H.+Movassaghauthor=C.+Koziol-Whiteauthor=Y.+Changauthor=L.+Al-Alwanauthor=J.+E.+Bourkeauthor=B.+G.+Oliver&title=Emerging+mediators+of+airway+smooth+muscle+dysfunction+in+asthma&doi=10.1016%2Fj.pupt.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging mediators of airway smooth muscle dysfunction in asthma</span></div><div class="casAuthors">Yeganeh, Behzad; Xia, Connie; Movassagh, Hesam; Koziol-White, Cynthia; Chang, Ying; Al-Alwan, Laila; Bourke, Jane E.; Oliver, Brian G. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-111</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Phenotypic changes in airway smooth muscle are integral to the pathophysiol. changes that constitute asthma - namely inflammation, airway wall remodelling and bronchial hyperresponsiveness.  In vitro and in vivo studies have shown that the proliferative, secretory and contractile functions of airway smooth muscle are dysfunctional in asthma.  These functions can be modulated by various mediators whose levels are altered in asthma, derived from inflammatory cells or produced by airway smooth muscle itself.  In this review, we describe the emerging roles of the CXC chemokines (GROs, IP-10), Th17-derived cytokines (IL-17, IL-22) and semaphorins, as well as the influence of viral infection on airway smooth muscle function, with a view to identifying new opportunities for therapeutic intervention in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptXSeQfvX02bVg90H21EOLACvtfcHk0ljR_LZJlMW0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2msr%252FO&md5=e9f9e93985656dbaaf818230701e1bb9</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DYeganeh%26aufirst%3DB.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DMovassagh%26aufirst%3DH.%26aulast%3DKoziol-White%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DAl-Alwan%26aufirst%3DL.%26aulast%3DBourke%26aufirst%3DJ.%2BE.%26aulast%3DOliver%26aufirst%3DB.%2BG.%26atitle%3DEmerging%2520mediators%2520of%2520airway%2520smooth%2520muscle%2520dysfunction%2520in%2520asthma%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D105%26epage%3D111%26doi%3D10.1016%2Fj.pupt.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kardas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daszyńska-Kardas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marynowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brza̧kalska, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panek, M.</span></span> <span> </span><span class="NLM_article-title">Role of Platelet-Derived Growth Factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3389%2Ffphar.2020.00047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32116722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslyksbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=47&author=G.+Kardasauthor=A.+Daszy%C5%84ska-Kardasauthor=M.+Marynowskiauthor=O.+Brza%CC%A7kalskaauthor=P.+Kunaauthor=M.+Panek&title=Role+of+Platelet-Derived+Growth+Factor+%28PDGF%29+in+asthma+as+an+immunoregulatory+factor+mediating+airway+remodeling+and+possible+pharmacological+target&doi=10.3389%2Ffphar.2020.00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Platelet-Derived Growth Factor (PDGF) in asthma as an immunoregulatory factor mediating airway remodeling and possible pharmacological target</span></div><div class="casAuthors">Kardas, Grzegorz; Ska-Kardas, Agnieszka Daszyn; Marynowski, Mateusz; Brzakalska, Oliwia; Kuna, Piotr; Panek, Michal</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Asthma is a chronic and heterogenic disease of the respiratory system, one of the most common lung diseases worldwide.  Theunderlying pathologies, which are chronic inflammatory process and airway remodeling (AR), are mediated by numerous cells and cytokines.  Particularly interesting in this field is the platelet-derived growth factor (PDGF), one of the members of the human growth factor family.  In this article, the authors analyze the available data on the role of PDGF in asthma in exptl. models and in human research.  PDGF is expressed in airway by various cells contributing to asthma pathogenesis-mast cells, eosinophils, and airway epithelial cells.  Research confirms the thesis that this factor is also secreted by these cells in the course of asthma.  The main effects of PDGF on bronchi are the proliferation of airway smooth muscle (ASM) cells, migration of ASM cells into the epithelium and enhanced collagen synthesis by lung fibroblasts.  The importance of AR in asthma is well recognized and new therapies should also aim to manage it, possibly targeting PDGFRs.  Further studies on new and already existing drugs, mediating the PDGF signaling and related to asthma are necessary.  Several promising drugs from the tyrosine kinase inhibitors group, including nilotinib, imatinib masitinib, and sunitinib, are currently being clin. tested and other mols. are likely to emerge in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWdWoYGwflCrVg90H21EOLACvtfcHk0ljR_LZJlMW0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslyksbvE&md5=0302627093d52b8b1fd5a2269734a423</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00047%26sid%3Dliteratum%253Aachs%26aulast%3DKardas%26aufirst%3DG.%26aulast%3DDaszy%25C5%2584ska-Kardas%26aufirst%3DA.%26aulast%3DMarynowski%26aufirst%3DM.%26aulast%3DBrza%25CC%25A7kalska%26aufirst%3DO.%26aulast%3DKuna%26aufirst%3DP.%26aulast%3DPanek%26aufirst%3DM.%26atitle%3DRole%2520of%2520Platelet-Derived%2520Growth%2520Factor%2520%2528PDGF%2529%2520in%2520asthma%2520as%2520an%2520immunoregulatory%2520factor%2520mediating%2520airway%2520remodeling%2520and%2520possible%2520pharmacological%2520target%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D47%26doi%3D10.3389%2Ffphar.2020.00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suganuma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aso, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span> <span> </span><span class="NLM_article-title">STIM1 regulates platelet-derived growth factor-induced migration and Ca<sup>2+</sup> influx in human airway smooth muscle cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e45056</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0045056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0045056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22984609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2jsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=N.+Suganumaauthor=S.+Itoauthor=H.+Asoauthor=M.+Kondoauthor=M.+Satoauthor=M.+Sokabeauthor=Y.+Hasegawa&title=STIM1+regulates+platelet-derived+growth+factor-induced+migration+and+Ca2%2B+influx+in+human+airway+smooth+muscle+cells&doi=10.1371%2Fjournal.pone.0045056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">STIM1 regulates platelet-derived growth factor-induced migration and Ca2+ influx in human airway smooth muscle cells</span></div><div class="casAuthors">Suganuma, Nobukazu; Ito, Satoru; Aso, Hiromichi; Kondo, Masashi; Sato, Mitsuo; Sokabe, Masahiro; Hasegawa, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e45056</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">It is suggested that migration of airway smooth muscle (ASM) cells plays an important role in the pathogenesis of airway remodeling in asthma.  Increases in intracellular Ca2+ concns. ([Ca2+]i) regulate most ASM cell functions related to asthma, such as contraction and proliferation.  Recently, STIM1 was identified as a sarcoplasmic reticulum (SR) Ca2+ sensor that activates Orai1, the Ca2+ channel responsible for store-operated Ca2+ entry (SOCE).  We investigated the role of STIM1 in [Ca2+]i and cell migration induced by platelet-derived growth factor (PDGF)-BB in human ASM cells.  Cell migration was assessed by a chemotaxis chamber assay.  Human ASM cells express STIM1, STIM2, and Orai1 mRNAs.  SOCE activated by thapsigargin, an inhibitor of SR Ca2+-ATPase, was significantly blocked by STIM1 siRNA and Orai1 siRNA but not by STIM2 siRNA.  PDGF-BB induced a transient increase in [Ca2+]i followed by sustained [Ca2+]ielevation.  Sustained increases in [Ca2+]i due to PDGF-BB were significantly inhibited by a Ca2+ chelating agent EGTA or by siRNA for STIM1 or Orai1.  The nos. of migrating cells were significantly increased by PDGF-BB treatment for 6 h.  Knockdown of STIM1 and Orai1 by siRNA transfection inhibited PDGF-induced cell migration.  Similarly, EGTA significantly inhibited PDGF-induced cell migration.  In contrast, transfection with siRNA for STIM2 did not inhibit the sustained elevation of [Ca2+]i or cell migration induced by PDGF-BB.  These results demonstrate that STIM1 and Orai1 are essential for PDGF-induced cell migration and Ca2+ influx in human ASM cells.  STIM1 could be an important mol. responsible for airway remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnKZDnzA5mKLVg90H21EOLACvtfcHk0ljR_LZJlMW0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2jsbnM&md5=dbe4b1d8c495416516eabdd1b748ec26</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0045056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0045056%26sid%3Dliteratum%253Aachs%26aulast%3DSuganuma%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DAso%26aufirst%3DH.%26aulast%3DKondo%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSokabe%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DY.%26atitle%3DSTIM1%2520regulates%2520platelet-derived%2520growth%2520factor-induced%2520migration%2520and%2520Ca2%252B%2520influx%2520in%2520human%2520airway%2520smooth%2520muscle%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0045056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fayon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbé, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marthan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, P.</span></span> <span> </span><span class="NLM_article-title">An age-wise comparison of human airway smooth muscle proliferative capacity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0122446</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0122446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0122446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25798916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslSjurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=M.+Fayonauthor=A.+Andrieuxauthor=I.+Baraauthor=M.+Rebolaauthor=A.+Labb%C3%A9author=R.+Marthanauthor=P.+Berger&title=An+age-wise+comparison+of+human+airway+smooth+muscle+proliferative+capacity&doi=10.1371%2Fjournal.pone.0122446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">An age-wise comparison of human airway smooth muscle proliferative capacity</span></div><div class="casAuthors">Fayon, Michael; Andrieux, Annick; Bara, Imane; Rebola, Muriel; Labbe, Andre; Marthan, Roger; Berger, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0122446/1-e0122446/13</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">We compared the proliferation of neonatal and adult airway smooth muscle cells (ASMC) with no/moderate lung disease, in glucose- (energy prodn. by glycolysis) or glucose-free medium (ATP prodn. from mitochondrial oxidative phosphorylations only), in response to 10% fetal calf serum (FCS) and PDGF-AA.  In the presence of glucose, cell counts were significantly greater in neonatal vs. adult ASMC.  Similarly, neonatal ASMC DNA synthesis in 10% FCS and PDGF-AA, and [Ca2+]i responses in the presence of histamine were significantly enhanced vs. adults.  In glucose-free medium, cell proliferation was preserved in neonatal cells, unlike in adult cells, with concomitant increased porin (an indicator of mitochondrial activity) protein expression.  Compared to adults, stimulated neonatal human ASMC are in a rapid and robust proliferative phase and have the capacity to respond disproportionately under abnormal environmental conditions, through increased mitochondrial biogenesis and altered calcium homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKqo2FjteU5bVg90H21EOLACvtfcHk0lgkUkmw-1uGcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslSjurfK&md5=bc093313045f83f0af92c0932d8bce05</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0122446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0122446%26sid%3Dliteratum%253Aachs%26aulast%3DFayon%26aufirst%3DM.%26aulast%3DAndrieux%26aufirst%3DA.%26aulast%3DBara%26aufirst%3DI.%26aulast%3DRebola%26aufirst%3DM.%26aulast%3DLabb%25C3%25A9%26aufirst%3DA.%26aulast%3DMarthan%26aufirst%3DR.%26aulast%3DBerger%26aufirst%3DP.%26atitle%3DAn%2520age-wise%2520comparison%2520of%2520human%2520airway%2520smooth%2520muscle%2520proliferative%2520capacity%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0122446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of mabuterol on proliferation of rat ASMCs induced by PDGF-BB via regulating [Ca<sup>2+</sup>]i and mitochondrial fission/fusion</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2019.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.cbi.2019.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31009640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVCntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2019&pages=63-72&author=Y.+Guauthor=X.+Yuauthor=X.+Liauthor=X.+Wangauthor=X.+Gaoauthor=M.+Wangauthor=S.+Wangauthor=X.+Liauthor=Y.+Zhang&title=Inhibitory+effect+of+mabuterol+on+proliferation+of+rat+ASMCs+induced+by+PDGF-BB+via+regulating+%5BCa2%2B%5Di+and+mitochondrial+fission%2Ffusion&doi=10.1016%2Fj.cbi.2019.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of mabuterol on proliferation of rat ASMCs induced by PDGF-BB via regulating [Ca2+]i and mitochondrial fission/fusion</span></div><div class="casAuthors">Gu, Yaru; Yu, Xitong; Li, Xiaoran; Wang, Xiaomin; Gao, Xiaoxiao; Wang, Miao; Wang, Siqi; Li, Xin; Zhang, Yuyang</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-72</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">This study is aimed to investigate whether Mabuterol (Mab) inhibits proliferation of airway smooth muscle cells (ASMCs) induced by platelet-derived growth factor BB (PDGF-BB) and how far it is related to mitochondrial fission/fusion and intracellular calcium if it comes into play.  The inhibitory effect of Mab on S phase of ASM cell cycle induced by PDGF-BB was analyzed by flow cytometry (FCM).  Fluo-3/AM, Ca2+ fluorescent probe, was used to detect Ca2+ fluorescence intensity by inverted microscope and flow cytometry.  The gene expression of Drp-1 and Mfn-2 was obsd. with Real time PCR and the proteins of Drp-1, Mfn-2, PCNA and cyclin D1 were assessed by Western Blot.  Mab and Mdivi-1 both suppressed the proliferation induced by PDGF-BB.  The results from inverted microscope and flow cytometry showed that Mab inhibited [Ca2+]i in rat ASMCs induced by PDGF-BB.  Cell cycle concept map illustrated that Mab significantly controlled the S phase of ASM cell cycle induced by PDGF-BB.  As a consequence, Real time PCR and Western blot revealed the fact that Mab decreased the expression of Drp-1 mRNA and protein, and promoted the expression of Mfn-2 mRNA and protein.  These findings suggested that Mab placed restrictions on the proliferation of rat ASMCs induced by PDGF-BB and the mechanism might be assocd. with the intracellular calcium inhibited and the mitochondrial fission/fusion regulated by Mab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOW4mOhYfzZ7Vg90H21EOLACvtfcHk0lgkUkmw-1uGcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVCntrY%253D&md5=f5c26169076409d868a83ebf1a91074e</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2019.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2019.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DInhibitory%2520effect%2520of%2520mabuterol%2520on%2520proliferation%2520of%2520rat%2520ASMCs%2520induced%2520by%2520PDGF-BB%2520via%2520regulating%2520%255BCa2%252B%255Di%2520and%2520mitochondrial%2520fission%252Ffusion%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2019%26volume%3D307%26spage%3D63%26epage%3D72%26doi%3D10.1016%2Fj.cbi.2019.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chachi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzahrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koziol-White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biddle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagadood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradding, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrani, Y.</span></span> <span> </span><span class="NLM_article-title">Increased β<sub>2</sub>-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1111/cei.13191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fcei.13191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30069878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFygtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2018&pages=253-258&author=L.+Chachiauthor=A.+Alzahraniauthor=C.+Koziol-Whiteauthor=M.+Biddleauthor=R.+Bagadoodauthor=R.+A.+Panettieriauthor=P.+Braddingauthor=Y.+Amrani&title=Increased+%CE%B22-adrenoceptor+phosphorylation+in+airway+smooth+muscle+in+severe+asthma%3A+possible+role+of+mast+cell-derived+growth+factors&doi=10.1111%2Fcei.13191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors</span></div><div class="casAuthors">Chachi, L.; Alzahrani, A.; Koziol-White, C.; Biddle, M.; Bagadood, R.; Panettieri, R. A., Jr; Bradding, P.; Amrani, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">194</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">253-258</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate whether growth factors produced by activated human lung mast cells (HLMCs) impair β2-adrenoceptor (β2-AR) function in human airway smooth muscle (ASM) cells.  Protein array anal. confirmed the presence of various growth factors, including transforming growth factor (TGF)-β1, in the supernatants of high-affinity IgE receptor (FceRI)-activated HLMCs which, when applied to ASM cells, impaired albuterol-induced cyclic adenosine monophosphate (cAMP) prodn., an effect that was prevented following neutralization of TGF-β1.  This blunted β2-AR response was reproduced by treating ASM cells with TGF-β1 or fibroblast growth factor (FGF)-2, which induced β2-AR phosphorylation at tyrosine residues Tyr141 and Tyr350, and significantly reduced the maximal bronchorelaxant responses to isoproterenol in human precision cut lung slices (PCLS).  Finally, ASM cells isolated from severe asthmatics displayed constitutive elevated β2-AR phosphorylation at both Tyr141 and Tyr350 and a reduced relaxant response to albuterol.  This study shows for the first time that abnormal β2-AR phosphorylation/function in ASM cells that is induced rapidly by HLMC-derived growth factors, is present constitutively in cells from severe asthmatics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWpczs6QMXB7Vg90H21EOLACvtfcHk0lgkUkmw-1uGcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFygtrvO&md5=a728fbeaa7fa32b984ae68c799ac91d8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1111%2Fcei.13191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.13191%26sid%3Dliteratum%253Aachs%26aulast%3DChachi%26aufirst%3DL.%26aulast%3DAlzahrani%26aufirst%3DA.%26aulast%3DKoziol-White%26aufirst%3DC.%26aulast%3DBiddle%26aufirst%3DM.%26aulast%3DBagadood%26aufirst%3DR.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26aulast%3DBradding%26aufirst%3DP.%26aulast%3DAmrani%26aufirst%3DY.%26atitle%3DIncreased%2520%25CE%25B22-adrenoceptor%2520phosphorylation%2520in%2520airway%2520smooth%2520muscle%2520in%2520severe%2520asthma%253A%2520possible%2520role%2520of%2520mast%2520cell-derived%2520growth%2520factors%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2018%26volume%3D194%26spage%3D253%26epage%3D258%26doi%3D10.1111%2Fcei.13191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagdonas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raudoniute, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzauskaite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldonyte, R.</span></span> <span> </span><span class="NLM_article-title">Novel aspects of pathogenesis and regeneration mechanisms in COPD</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">995</span>– <span class="NLM_lpage">1013</span>, <span class="refDoi"> DOI: 10.2147/COPD.S82518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S82518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26082624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC287jtlOlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=995-1013&author=E.+Bagdonasauthor=J.+Raudoniuteauthor=I.+Bruzauskaiteauthor=R.+Aldonyte&title=Novel+aspects+of+pathogenesis+and+regeneration+mechanisms+in+COPD&doi=10.2147%2FCOPD.S82518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Novel aspects of pathogenesis and regeneration mechanisms in COPD</span></div><div class="casAuthors">Bagdonas Edvardas; Raudoniute Jovile; Bruzauskaite Ieva; Aldonyte Ruta</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">995-1013</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD), a major cause of death and morbidity worldwide, is characterized by expiratory airflow limitation that is not fully reversible, deregulated chronic inflammation, and emphysematous destruction of the lungs.  Despite the fact that COPD is a steadily growing global healthcare problem, the conventional therapies remain palliative, and regenerative approaches for disease management are not available yet.  We aim to provide an overview of key reviews, experimental, and clinical studies addressing lung emphysema development and repair mechanisms published in the past decade.  Novel aspects discussed herein include integral revision of the literature focused on lung microflora changes in COPD, autoimmune component of the disease, and environmental risk factors other than cigarette smoke.  The time span of studies on COPD, including emphysema, chronic bronchitis, and asthmatic bronchitis, covers almost 200 years, and several crucial mechanisms of COPD pathogenesis are described and studied.  However, we still lack the holistic understanding of COPD development and the exact picture of the time-course and interplay of the events during stable, exacerbated, corticosteroid-treated COPD states, and transitions in-between.  Several generally recognized mechanisms will be discussed shortly herein, ie, unregulated inflammation, proteolysis/antiproteolysis imbalance, and destroyed repair mechanisms, while novel topics such as deviated microbiota, air pollutants-related damage, and autoimmune process within the lung tissue will be discussed more extensively.  Considerable influx of new data from the clinic, in vivo and in vitro studies stimulate to search for novel concise explanation and holistic understanding of COPD nowadays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzcle58pui0BpyrDyM_m9cfW6udTcc2eaupKbC82Onk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287jtlOlsg%253D%253D&md5=4d2ee72a1b2e76040284688435aaa355</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S82518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S82518%26sid%3Dliteratum%253Aachs%26aulast%3DBagdonas%26aufirst%3DE.%26aulast%3DRaudoniute%26aufirst%3DJ.%26aulast%3DBruzauskaite%26aufirst%3DI.%26aulast%3DAldonyte%26aufirst%3DR.%26atitle%3DNovel%2520aspects%2520of%2520pathogenesis%2520and%2520regeneration%2520mechanisms%2520in%2520COPD%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2015%26volume%3D10%26spage%3D995%26epage%3D1013%26doi%3D10.2147%2FCOPD.S82518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cançado, J. E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">The pathology of small airways disease in COPD: historical aspects and future directions</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1186/s12931-019-1017-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2Fs12931-019-1017-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30832670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3cbgtlSgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=49-59&author=A.+Highamauthor=A.+M.+Quinnauthor=J.+E.+D.+Can%C3%A7adoauthor=D.+Singh&title=The+pathology+of+small+airways+disease+in+COPD%3A+historical+aspects+and+future+directions&doi=10.1186%2Fs12931-019-1017-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The pathology of small airways disease in COPD: historical aspects and future directions</span></div><div class="casAuthors">Higham Andrew; Singh Dave; Quinn Anne Marie; Cancado Jose Eduardo D; Singh Dave</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Small airways disease (SAD) is a cardinal feature of chronic obstructive pulmonary disease (COPD) first recognized in the nineteenth century.  The diverse histopathological features associated with SAD underpin the heterogeneous nature of COPD.  Our understanding of the key molecular mechanisms which drive the pathological changes are not complete.  In this article we will provide a historical overview of key histopathological studies which have helped shape our understanding of SAD and discuss the hallmark features of airway remodelling, mucous plugging and inflammation.  We focus on the relationship between SAD and emphysema, SAD in the early stages of COPD, and the mechanisms which cause SAD progression, including bacterial colonization and exacerbations.  We discuss the need to specifically target SAD to attenuate the progression of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0GsNW0WmBGEcLvDNbOD4DfW6udTcc2eaupKbC82Onk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbgtlSgsA%253D%253D&md5=95a3c9495699eddfb9743814ffc40c25</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1186%2Fs12931-019-1017-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-019-1017-y%26sid%3Dliteratum%253Aachs%26aulast%3DHigham%26aufirst%3DA.%26aulast%3DQuinn%26aufirst%3DA.%2BM.%26aulast%3DCan%25C3%25A7ado%26aufirst%3DJ.%2BE.%2BD.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DThe%2520pathology%2520of%2520small%2520airways%2520disease%2520in%2520COPD%253A%2520historical%2520aspects%2520and%2520future%2520directions%26jtitle%3DRespir.%2520Res.%26date%3D2019%26volume%3D20%26spage%3D49%26epage%3D59%26doi%3D10.1186%2Fs12931-019-1017-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utokaparch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzatu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherniack, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciurba, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxson, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paré, P. D.</span></span> <span> </span><span class="NLM_article-title">The nature of small-airway obstruction in chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2645</span>– <span class="NLM_lpage">2653</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa032158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa032158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15215480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltFGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2645-2653&author=J.+C.+Hoggauthor=F.+Chuauthor=S.+Utokaparchauthor=R.+Woodsauthor=W.+M.+Elliottauthor=L.+Buzatuauthor=R.+M.+Cherniackauthor=R.+M.+Rogersauthor=F.+C.+Sciurbaauthor=H.+O.+Coxsonauthor=P.+D.+Par%C3%A9&title=The+nature+of+small-airway+obstruction+in+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa032158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">The nature of small-airway obstruction in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg, James C.; Chu, Fanny; Utokaparch, Soraya; Woods, Ryan; Elliott, W. Mark; Buzatu, Liliana; Cherniack, Ruben M.; Rogers, Robert M.; Sciurba, Frank C.; Coxson, Harvey O.; Pare, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2645-2653</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major public health problem assocd. with long-term exposure to toxic gases and particles.  We examd. the evolution of the pathol. effects of airway obstruction in patients with COPD.  METHODS: The small airways were assessed in surgically resected lung tissue from 159 patients -39 with stage 0 (at risk), 39 with stage 1, 22 with stage 2, 16 with stage 3, and 43 with stage 4 (very severe) COPD, according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).  RESULTS: The progression of COPD was strongly assocd. with an increase in the vol. of tissue in the wall (P<0.001) and the accumulation of inflammatory mucous exudates in the lumen (P<0.001) of the small airways.  The percentage of the airways that contained polymorphonuclear neutrophils (P<0.001), macrophages (P<0.001), CD4 cells (P=0.02), CD8 cells (P=0.038), B cells (P<0.001), and lymphoid aggregates contg. follicles (P=0.003) and the abs. vol. of B cells (P=0.03) and CD8 cells (P=0.02) also increased as COPD progressed.  CONCLUSIONS: Progression of COPD is assocd. with the accumulation of inflammatory mucous exudates in the lumen and infiltration of the wall by innate and adaptive inflammatory immune cells that form lymphoid follicles.  These changes are coupled to a repair or remodeling process that thickens the walls of these airways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0FQMblvr8K7Vg90H21EOLACvtfcHk0ljeVtZ5fTScAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltFGgur4%253D&md5=8445d6a31c9f1d8ccae5065a0dd04c65</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032158%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DUtokaparch%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DBuzatu%26aufirst%3DL.%26aulast%3DCherniack%26aufirst%3DR.%2BM.%26aulast%3DRogers%26aufirst%3DR.%2BM.%26aulast%3DSciurba%26aufirst%3DF.%2BC.%26aulast%3DCoxson%26aufirst%3DH.%2BO.%26aulast%3DPar%25C3%25A9%26aufirst%3DP.%2BD.%26atitle%3DThe%2520nature%2520of%2520small-airway%2520obstruction%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2645%26epage%3D2653%26doi%3D10.1056%2FNEJMoa032158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timens, W.</span></span> <span> </span><span class="NLM_article-title">The pathology of chronic obstructive pulmonary disease</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1146/annurev.pathol.4.110807.092145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1146%2Fannurev.pathol.4.110807.092145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18954287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1ahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=435-459&author=J.+C.+Hoggauthor=W.+Timens&title=The+pathology+of+chronic+obstructive+pulmonary+disease&doi=10.1146%2Fannurev.pathol.4.110807.092145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The pathology of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg, James C.; Timens, Wim</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">435-459</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The pathogenesis of chronic obstructive pulmonary disease (COPD) is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases.  Although tobacco smoking is the primary cause of this inhalation injury, many other environmental and occupational exposures contribute to the pathol. of COPD.  The immune inflammatory changes assocd. with COPD are linked to a tissue-repair and -remodeling process that increases mucus prodn. and causes emphysematous destruction of the gas-exchanging surface of the lung.  The common form of emphysema obsd. in smokers begins in the respiratory bronchioles near the thickened and narrowed small bronchioles that become the major site of obstruction in COPD.  The mechanism(s) that allow small airways to thicken in such close proximity to lung tissue undergoing emphysematous destruction remains a puzzle that needs to be solved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUfxYoGB-w1bVg90H21EOLACvtfcHk0lggGmVRlv6_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1ahsr0%253D&md5=e94a98c1e9426544621b833684ccb64c</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathol.4.110807.092145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathol.4.110807.092145%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26aulast%3DTimens%26aufirst%3DW.%26atitle%3DThe%2520pathology%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2009%26volume%3D4%26spage%3D435%26epage%3D459%26doi%3D10.1146%2Fannurev.pathol.4.110807.092145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Immunology of asthma and chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nri2254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnri2254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18274560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=183-192&author=P.+J.+Barnes&title=Immunology+of+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnri2254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive airway diseases that involve chronic inflammation of the respiratory tract, but the type of inflammation is markedly different between these diseases, with different patterns of inflammatory cells and mediators being involved.  As described in this Review, these inflammatory profiles are largely detd. by the involvement of different immune cells, which orchestrate the recruitment and activation of inflammatory cells that drive the distinct patterns of structural changes in these diseases.  However, it is now becoming clear that the distinction between these diseases becomes blurred in patients with severe asthma, in asthmatic subjects who smoke and during acute exacerbations.  This has important implications for the development of new therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKkJK_5vmv57Vg90H21EOLACvtfcHk0lggGmVRlv6_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D&md5=a1d09a214bbd87e31e0c714039077289</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnri2254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2254%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DImmunology%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D183%26epage%3D192%26doi%3D10.1038%2Fnri2254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Cellular and molecular mechanisms of asthma and COPD</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1541</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1042/CS20160487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1042%2FCS20160487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFalt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=1541-1558&author=P.+J.+Barnes&title=Cellular+and+molecular+mechanisms+of+asthma+and+COPD&doi=10.1042%2FCS20160487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular and molecular mechanisms of asthma and COPD</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1541-1558</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Asthma and chronic obstructive pulmonary disease (COPD) both cause airway obstruction and are assocd. with chronic inflammation of the airways.  However, the nature and sites of the inflammation differ between these diseases, resulting in different pathol., clin. manifestations and response to therapy.  In this review, the inflammatory and cellular mechanisms of asthma and COPD are compared and the differences in inflammatory cells and profile of inflammatory mediators are highlighted.  These differences account for the differences in clin. manifestations of asthma and COPD and their response to therapy.  Although asthma and COPD are usually distinct, there are some patients who show an overlap of features, which may be explained by the coincidence of two common diseases or distinct phenotypes of each disease.  It is important to better understand the underlying cellular and mol. mechanisms of asthma and COPD in order to develop new treatments in areas of unmet need, such as severe asthma, curative therapy for asthma and effective anti-inflammatory treatments for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohVzYWx9UyhLVg90H21EOLACvtfcHk0lggGmVRlv6_FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFalt7zP&md5=000dc9977a91274d17101e8c6af816a9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1042%2FCS20160487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20160487%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DCellular%2520and%2520molecular%2520mechanisms%2520of%2520asthma%2520and%2520COPD%26jtitle%3DClin.%2520Sci.%26date%3D2017%26volume%3D131%26spage%3D1541%26epage%3D1558%26doi%3D10.1042%2FCS20160487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maarsingh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bidan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brook, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuidhof, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldenburger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timens, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurs, H.</span></span> <span> </span><span class="NLM_article-title">Small airway hyperresponsiveness in COPD: relationship between structure and function in lung slices</span>. <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">L537</span>– <span class="NLM_lpage">L546</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00325.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1152%2Fajplung.00325.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30628486" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2019&pages=L537-L546&author=H.+Maarsinghauthor=C.+M.+Bidanauthor=B.+S.+Brookauthor=A.+B.+Zuidhofauthor=C.+Elzingaauthor=M.+Smitauthor=A.+Oldenburgerauthor=R.+Gosensauthor=W.+Timensauthor=H.+Meurs&title=Small+airway+hyperresponsiveness+in+COPD%3A+relationship+between+structure+and+function+in+lung+slices&doi=10.1152%2Fajplung.00325.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00325.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00325.2018%26sid%3Dliteratum%253Aachs%26aulast%3DMaarsingh%26aufirst%3DH.%26aulast%3DBidan%26aufirst%3DC.%2BM.%26aulast%3DBrook%26aufirst%3DB.%2BS.%26aulast%3DZuidhof%26aufirst%3DA.%2BB.%26aulast%3DElzinga%26aufirst%3DC.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DOldenburger%26aufirst%3DA.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DTimens%26aufirst%3DW.%26aulast%3DMeurs%26aufirst%3DH.%26atitle%3DSmall%2520airway%2520hyperresponsiveness%2520in%2520COPD%253A%2520relationship%2520between%2520structure%2520and%2520function%2520in%2520lung%2520slices%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2019%26volume%3D316%26spage%3DL537%26epage%3DL546%26doi%3D10.1152%2Fajplung.00325.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Similarities and differences in inflammatory mechanisms of asthma and COPD</span>. <i>Breathe</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1183/20734735.026410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1183%2F20734735.026410" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=229-238&author=P.+J.+Barnes&title=Similarities+and+differences+in+inflammatory+mechanisms+of+asthma+and+COPD&doi=10.1183%2F20734735.026410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1183%2F20734735.026410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F20734735.026410%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DSimilarities%2520and%2520differences%2520in%2520inflammatory%2520mechanisms%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBreathe%26date%3D2011%26volume%3D7%26spage%3D229%26epage%3D238%26doi%3D10.1183%2F20734735.026410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, N. L.</span></span> <span> </span><span class="NLM_article-title">Airway smooth muscle</span>. <i>Lung</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">373</span>, <span class="refDoi"> DOI: 10.1007/s004080000073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs004080000073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12040426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1ChtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2001&pages=333-373&author=N.+L.+Stephens&title=Airway+smooth+muscle&doi=10.1007%2Fs004080000073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Airway smooth muscle</span></div><div class="casAuthors">Stephens, N. L.</div><div class="citationInfo"><span class="NLM_cas:title">Lung</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">333-373</span>CODEN:
                <span class="NLM_cas:coden">LUNGD9</span>;
        ISSN:<span class="NLM_cas:issn">0341-2040</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag New York Inc.</span>)
        </div><div class="casAbstract">A review.  The greatest impetus to research in elucidating the fundamental biophysics and biochem. of airway smooth muscle (ASM) has undoubtedly been provided by the need to understand how these are altered in asthma.  Many of the biophys. and biochem. properties of this muscle have been reviewed before.  They resemble those of striated muscle; however, even though mech. properties are very similar, there are differences in biochem.  For example, in smooth muscle, calcium sensitive regulation of contraction is mediated by a calmodulin/myosin-light chain kinase/phosphatase system, not by the familiar troponin-tropomyosm system.  Thus, the mol. mechanisms to be investigated in understanding disorders of increased smooth muscle contraction, which occur in allergic bronchospasm, for example, may be quite different from those in striated muscle.  Much of the following material is based on studies of canine tracheal smooth muscle (TSM) because there is evidence that it serves as a model for ASM - at least with respect to contractility down to the sixth generation of airways.  Studies of isolated smooth muscle from smaller airways are few and are based mainly on studies of lung strips.  Since then, we have developed a bronchial smooth muscle prepn. (fifth generation) that allows precise study of those airways that are involved in allergic bronchospasm.  Considerable work has been carried out on ASM from a variety of animal models of asthma.  It should be pointed out that none of these reproduces the human disease exactly, and that they really should be identified as examples of nonspecific hyperreactivity.  Be that as it may, the nonspecificity found in human patients in vivo and in animals suggests that the primary cause of asthma may reside at the muscle cell level.  Whether it is the cell membrane, the excitation-contraction coupling app., or the contractile machinery that is primarily involved, is not yet known with certainty.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp14ppQxn5Y2rVg90H21EOLACvtfcHk0li6d9Azdjynug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1ChtLg%253D&md5=6a3adc2ebcf0ec2047802ac6b6173d36</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1007%2Fs004080000073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004080000073%26sid%3Dliteratum%253Aachs%26aulast%3DStephens%26aufirst%3DN.%2BL.%26atitle%3DAirway%2520smooth%2520muscle%26jtitle%3DLung%26date%3D2001%26volume%3D179%26spage%3D333%26epage%3D373%26doi%3D10.1007%2Fs004080000073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sommerville, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartshorne, D. J.</span></span> <span> </span><span class="NLM_article-title">Intracellular calcium and smooth muscle contraction</span>. <i>Cell Calcium</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">364</span>, <span class="refDoi"> DOI: 10.1016/0143-4160(86)90038-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2F0143-4160%2886%2990038-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=3545487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaL2sXotF2msQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1986&pages=353-364&author=L.+E.+Sommervilleauthor=D.+J.+Hartshorne&title=Intracellular+calcium+and+smooth+muscle+contraction&doi=10.1016%2F0143-4160%2886%2990038-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular calcium and smooth muscle contraction</span></div><div class="casAuthors">Sommerville, L. E.; Hartshorne, D. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Calcium</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">353-64</span>CODEN:
                <span class="NLM_cas:coden">CECADV</span>;
        ISSN:<span class="NLM_cas:issn">0143-4160</span>.
    </div><div class="casAbstract">A review, with 31 refs., on the regulation of intracellular Ca2+, its role in the contraction-relaxation cycle of smooth muscle, and a description of various Ca2+-dependent processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7iLzbGzdJE7Vg90H21EOLACvtfcHk0li6d9Azdjynug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXotF2msQ%253D%253D&md5=5fef50d63d0176ea4de10b82dc9f255f</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2F0143-4160%2886%2990038-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0143-4160%252886%252990038-2%26sid%3Dliteratum%253Aachs%26aulast%3DSommerville%26aufirst%3DL.%2BE.%26aulast%3DHartshorne%26aufirst%3DD.%2BJ.%26atitle%3DIntracellular%2520calcium%2520and%2520smooth%2520muscle%2520contraction%26jtitle%3DCell%2520Calcium%26date%3D1986%26volume%3D7%26spage%3D353%26epage%3D364%26doi%3D10.1016%2F0143-4160%2886%2990038-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Microdomain elements of airway smooth muscle in calcium regulation and cell proliferation</span>. <i>J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.26402/jpp.2018.2.01</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.26402%2Fjpp.2018.2.01" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVylt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=151-163&author=C.+Zhaoauthor=A.+Y.+Wuauthor=X.+Yuauthor=Y.+Guauthor=Y.+Luauthor=X.+Songauthor=N.+Anauthor=Y.+Zhang&title=Microdomain+elements+of+airway+smooth+muscle+in+calcium+regulation+and+cell+proliferation&doi=10.26402%2Fjpp.2018.2.01"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Microdomain elements of airway smooth muscle in calcium regulation and cell proliferation</span></div><div class="casAuthors">Zhao, C.; Woo, A. Y.-H.; Yu, X.; Gu, Y.; Lu, Y.; Song, X.; An, N.; Zhang, Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-163</span>CODEN:
                <span class="NLM_cas:coden">JPHPEI</span>;
        ISSN:<span class="NLM_cas:issn">0867-5910</span>.
    
            (<span class="NLM_cas:orgname">Polish Physiological Society</span>)
        </div><div class="casAbstract">Airway remodeling manifested by hyperplasia of airway smooth muscle cells (ASMCs) and other structural and functional changes is a pathol. condition in asthma not addressed by current treatment.  Ca2+ signaling is crucial for ASMC proliferation. lnositol-l,4,5-trisphosphate receptor (IP3R) and ryanodine receptor (RyR) mediate Ca2+ release from endoplasmic reticulum/sarcoplasmic reticulum (KR/SR).  Upon sensing the depletion of Ca2+ in ER/SR, stromal interaction mol. I (STIMI) aggregates and redistributes at the microdomain of ER/SR-plasma membrane (PM) and activates Orail a component of the store-operated Ca2+ (SOC) channels, to initiate Ca2+ influx.  The STIMI/Orail-mediated SOC entry is the main cause of a sustained intracellular calcium ([Ca2+]i) elevation, which is different from a transient rise of [Ca2+]i mediated by IP3R and RyR.  Extended-synaptotagmin 1 (E-Sytl) is recruited to the ER/SR-PM junction and anchors to the PM lipid phosphatidylinositol-4,5-bisphosphalc (PI(4,5)P2) in a SOC-dependent manner.  The subsequent strengthening of the ER/SR-PM connection by E-Sytl facilitates the phosphalidylinositol (PI) transfer protein, Nir2. to supplement PI, a PI(4,5)P2 substrate, for the generation of IP3 and the propagation of Ca2+ signaling.  Calcineurin and nuclear factor of activated T cells are the downstream signaling factors of elevated [Ca2+]i contributing to ASMC proliferation.  Mitochondrial Ca2+ uptake/efflux, mitochondrial fission/fusion and mitochondrial-ER/SR coupling also play important roles in modulating [Ca2+]i and ASMC proliferation.  Together, these pathways and mechanisms represent new therapeutic targets for airway remodeling.  The present review provides an overview of our current understanding of the mechanisms of ASMC proliferation involving Ca2+ and highlights potential directions to control airway remodeling in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdU1MqAH1E5LVg90H21EOLACvtfcHk0li6d9Azdjynug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVylt7o%253D&md5=14eaedcbd4e28f3ad16405ca14252d52</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.26402%2Fjpp.2018.2.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.26402%252Fjpp.2018.2.01%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DA.%2BY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DAn%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DMicrodomain%2520elements%2520of%2520airway%2520smooth%2520muscle%2520in%2520calcium%2520regulation%2520and%2520cell%2520proliferation%26jtitle%3DJ.%2520Physiol.%2520Pharmacol.%26date%3D2018%26volume%3D69%26spage%3D151%26epage%3D163%26doi%3D10.26402%2Fjpp.2018.2.01" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojo, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span> <span> </span><span class="NLM_article-title">cAMP regulation of airway smooth muscle function</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2012.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pupt.2012.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22634112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVaqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=112-120&author=C.+K.+Billingtonauthor=O.+O.+Ojoauthor=R.+B.+Pennauthor=S.+Ito&title=cAMP+regulation+of+airway+smooth+muscle+function&doi=10.1016%2Fj.pupt.2012.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP regulation of airway smooth muscle function</span></div><div class="casAuthors">Billington, Charlotte K.; Ojo, Oluwaseun O.; Penn, Raymond B.; Ito, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-120</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Agonists activating β2-adrenoceptors (β2ARs) on airway smooth muscle (ASM) are the drug of choice for rescue from acute bronchoconstriction in patients with both asthma and chronic obstructive pulmonary disease (COPD).  Moreover, the use of long-acting β-agonists combined with inhaled corticosteroids constitutes an important maintenance therapy for these diseases. β-Agonists are effective bronchodilators due primarily to their ability to antagonize ASM contraction.  The presumed cellular mechanism of action involves the generation of intracellular cAMP, which in turn can activate the effector mols. cAMP-dependent protein kinase (PKA) and Epac.  Other agents such as prostaglandin E2 and phosphodiesterase inhibitors that also increase intracellular cAMP levels in ASM, can also antagonize ASM contraction, and inhibit other ASM functions including proliferation and migration.  Therefore, β2ARs and cAMP are key players in combating the pathophysiol. of airway narrowing and remodeling.  However, limitations of β-agonist therapy due to drug tachyphylaxis related to β2AR desensitization, and recent findings regarding the manner in which β2ARs and cAMP signal, have raised new and interesting questions about these well-studied mols.  In this review we discuss current concepts regarding β2ARs and cAMP in the regulation of ASM cell functions and their therapeutic roles in asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq72EwTpkxB4bVg90H21EOLACvtfcHk0lhaijQL9RLyRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVaqu70%253D&md5=8a236a8da936fe58e40231b5613910f1</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DBillington%26aufirst%3DC.%2BK.%26aulast%3DOjo%26aufirst%3DO.%2BO.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DIto%26aufirst%3DS.%26atitle%3DcAMP%2520regulation%2520of%2520airway%2520smooth%2520muscle%2520function%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D112%26epage%3D120%26doi%3D10.1016%2Fj.pupt.2012.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, M. J.</span></span> <span> </span><span class="NLM_article-title">Airway smooth muscle relaxation results from a reduction in the frequency of Ca<sup>2+</sup> oscillations induced by a cAMP-mediated inhibition of the IP<sub>3</sub> receptor</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-7-34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2F1465-9921-7-34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16504084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD283mtl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=34-53&author=Y.+Baiauthor=M.+J.+Sanderson&title=Airway+smooth+muscle+relaxation+results+from+a+reduction+in+the+frequency+of+Ca2%2B+oscillations+induced+by+a+cAMP-mediated+inhibition+of+the+IP3+receptor&doi=10.1186%2F1465-9921-7-34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Airway smooth muscle relaxation results from a reduction in the frequency of Ca2+ oscillations induced by a cAMP-mediated inhibition of the IP3 receptor</span></div><div class="casAuthors">Bai Yan; Sanderson Michael J</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It has been shown that the contractile state of airway smooth muscle cells (SMCs) in response to agonists is determined by the frequency of Ca2+ oscillations occurring within the SMCs.  Therefore, we hypothesized that the relaxation of airway SMCs induced by agents that increase cAMP results from the down-regulation or slowing of the frequency of the Ca2+ oscillations.  METHODS:  The effects of isoproterenol (ISO), forskolin (FSK) and 8-bromo-cAMP on the relaxation and Ca2+ signaling of airway SMCs contracted with methacholine (MCh) was investigated in murine lung slices with phase-contrast and laser scanning microscopy.  RESULTS:  All three cAMP-elevating agents simultaneously induced a reduction in the frequency of Ca2+ oscillations within the SMCs and the relaxation of contracted airways.  The decrease in the Ca2+ oscillation frequency correlated with the extent of airway relaxation and was concentration-dependent.  The mechanism by which cAMP reduced the frequency of the Ca2+ oscillations was investigated.  Elevated cAMP did not affect the re-filling rate of the internal Ca2+ stores after emptying by repetitive exposure to 20 mM caffeine.  Neither did elevated cAMP limit the Ca2+ available to stimulate contraction because an elevation of intracellular Ca2+ concentration induced by exposure to a Ca2+ ionophore (ionomycin) or by photolysis of caged-Ca2+ did not reverse the effect of cAMP.  Similar results were obtained with iberiotoxin, a blocker of Ca2+-activated K+ channels, which would be expected to increase Ca2+ influx and contraction.  By contrast, the photolysis of caged-IP3 in the presence of agonist, to further elevate the intracellular IP3 concentration, reversed the slowing of the frequency of the Ca2+ oscillations and relaxation of the airway induced by FSK.  This result implied that the sensitivity of the IP3R to IP3 was reduced by FSK and this was supported by the reduced ability of IP3 to release Ca2+ in SMCs in the presence of FSK.  CONCLUSION:  These results indicate that the relaxant effect of cAMP-elevating agents on airway SMCs is achieved by decreasing the Ca2+ oscillation frequency by reducing internal Ca2+ release through IP3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS59KjxJhpCRpyrDyM_m9cfW6udTcc2eaKJkVs-46nebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283mtl2gtA%253D%253D&md5=039321875eea8ddb9337d9a8c7d78ebf</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-7-34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-7-34%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DY.%26aulast%3DSanderson%26aufirst%3DM.%2BJ.%26atitle%3DAirway%2520smooth%2520muscle%2520relaxation%2520results%2520from%2520a%2520reduction%2520in%2520the%2520frequency%2520of%2520Ca2%252B%2520oscillations%2520induced%2520by%2520a%2520cAMP-mediated%2520inhibition%2520of%2520the%2520IP3%2520receptor%26jtitle%3DRespir.%2520Res.%26date%3D2006%26volume%3D7%26spage%3D34%26epage%3D53%26doi%3D10.1186%2F1465-9921-7-34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aburima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wraith, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raslan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magwenzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseem, K. M.</span></span> <span> </span><span class="NLM_article-title">cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3533</span>– <span class="NLM_lpage">3545</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-03-487850</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1182%2Fblood-2013-03-487850" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24100445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVehsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=3533-3545&author=A.+Aburimaauthor=K.+S.+Wraithauthor=Z.+Raslanauthor=R.+Lawauthor=S.+Magwenziauthor=K.+M.+Naseem&title=cAMP+signaling+regulates+platelet+myosin+light+chain+%28MLC%29+phosphorylation+and+shape+change+through+targeting+the+RhoA-Rho+kinase-MLC+phosphatase+signaling+pathway&doi=10.1182%2Fblood-2013-03-487850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway</span></div><div class="casAuthors">Aburima, Ahmed; Wraith, Katie S.; Raslan, Zaher; Law, Robert; Magwenzi, Simbarashe; Naseem, Khalid M.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3533-3545</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Cyclic adenosine monophosphate (cAMP)-dependent signaling modulates platelet shape change through unknown mechanisms.  We examd. the effects of cAMP signaling on platelet contractile machinery.  Prostaglandin E1 (PGE1)-mediated inhibition of thrombin-stimulated shape change was accompanied by diminished phosphorylation of myosin light chain (MLC).  Since thrombin stimulates phospho-MLC through RhoA/Rho-assocd., coiled-coil contg. protein kinase (ROCK)-dependent inhibition of MLC phosphatase (MLCP), we examd. the effects of cAMP on this pathway.  Thrombin stimulated the membrane localization of RhoA and the formation of a signaling complex of RhoA/ROCK2/myosin phosphatase-targeting subunit 1 (MYPT1).  This resulted in ROCK-mediated phosphorylation of MYPT1 on threonine 853 (thr853), the disassocn. of the catalytic subunit protein phosphatase 1δ (PP1δ) from MYPT1 and inhibition of basal MLCP activity.  Treatment of platelets with PGE1 prevented thrombin-induced phospho-MYPT1-thr853 in a protein kinase A (PKA)-dependent manner.  Examn. of the mol. mechanisms revealed that PGE1 induced the phosphorylation of RhoA on serine188 through a pathway requiring cAMP and PKA.  This event inhibited the membrane relocalization of RhoA, prevented the assocn. of RhoA with ROCK2 and MYPT1, attenuated the dissocn. of PP1δ from MYPT1, and thereby restored basal MLCP activity leading to a decrease in phospho-MLC.  These data reveal a new mechanism by which the cAMP-PKA signaling pathway regulates platelet function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmssR0QJfsMLVg90H21EOLACvtfcHk0lhaijQL9RLyRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVehsr%252FJ&md5=b127548f10c62d5628bf61bd00a5bbe1</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-487850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-487850%26sid%3Dliteratum%253Aachs%26aulast%3DAburima%26aufirst%3DA.%26aulast%3DWraith%26aufirst%3DK.%2BS.%26aulast%3DRaslan%26aufirst%3DZ.%26aulast%3DLaw%26aufirst%3DR.%26aulast%3DMagwenzi%26aufirst%3DS.%26aulast%3DNaseem%26aufirst%3DK.%2BM.%26atitle%3DcAMP%2520signaling%2520regulates%2520platelet%2520myosin%2520light%2520chain%2520%2528MLC%2529%2520phosphorylation%2520and%2520shape%2520change%2520through%2520targeting%2520the%2520RhoA-Rho%2520kinase-MLC%2520phosphatase%2520signaling%2520pathway%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D3533%26epage%3D3545%26doi%3D10.1182%2Fblood-2013-03-487850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dekkers, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehlic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaagsma, J.</span></span> <span> </span><span class="NLM_article-title">Glucocorticosteroids and β<sub>2</sub>-adrenoceptor agonists synergize to inhibit airway smooth muscle remodeling</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.195867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.112.195867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22685341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlShu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=780-787&author=B.+G.+Dekkersauthor=A.+Pehlicauthor=R.+Marianiauthor=I.+S.+Bosauthor=H.+Meursauthor=J.+Zaagsma&title=Glucocorticosteroids+and+%CE%B22-adrenoceptor+agonists+synergize+to+inhibit+airway+smooth+muscle+remodeling&doi=10.1124%2Fjpet.112.195867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Glucocorticosteroids and β2-adrenoceptor agonists synergize to inhibit airway smooth muscle remodeling</span></div><div class="casAuthors">Dekkers, Bart G. J.; Pehlic, Adnan; Mariani, Raissa; Bos, I. Sophie T.; Meurs, Herman; Zaagsma, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">780-787</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Airway remodeling, including increased airway smooth muscle (ASM) mass and contractility, contributes to increased airway narrowing in asthma.  Increased ASM mass may be caused by exposure to mitogens, including platelet-derived growth factor (PDGF) and collagen type I, which induce a proliferative, hypocontractile ASM phenotype.  In contrast, prolonged exposure to insulin induces a hypercontractile phenotype.  Glucocorticosteroids and β2-adrenoceptor agonists synergize to increase glucocorticosteroid receptor translocation in ASM cells; however, the impact of this synergism on phenotype modulation is unknown.  Using bovine tracheal smooth muscle, we investigated the effects of the glucocorticosteroids fluticasone (10 nM), budesonide (30 nM), and dexamethasone (0.1-1 μM) and the combination of low concns. of fluticasone (3-100 pM) and fenoterol (10 nM) on ASM phenotype switching in response to PDGF (10 ng/mL), collagen type I (50 μg/mL), and insulin (1 μM).  All glucocorticosteroids inhibited PDGF- and collagen I-induced proliferation and hypocontractility, with the effects of collagen I being less susceptible to glucocorticosteroid action.  At 100-fold lower concns., fluticasone (100 pM) synergized with fenoterol to prevent PDGF- and collagen I-induced phenotype switching.  This inhibition of ASM phenotype switching was assocd. with a normalization of the PDGF-induced decrease in the cell cycle inhibitors p21WAF1/CIP1 and p57KIP2.  At this concn., fluticasone also prevented the insulin-induced hypercontractile phenotype.  At even lower concns., fluticasone (3 pM) synergized with fenoterol to inhibit this phenotype switch.  Collectively, these findings indicate that glucocorticosteroids and β2-agonits synergistically inhibit ASM phenotype switching, which may contribute to the increased effectiveness of combined treatment with glucocorticosteroids and β2-agonists in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1DsS1aZCh4bVg90H21EOLACvtfcHk0li5ZqRxrSnHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlShu7vK&md5=ccd8591382e1a47dcdeff1e473421b10</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.195867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.195867%26sid%3Dliteratum%253Aachs%26aulast%3DDekkers%26aufirst%3DB.%2BG.%26aulast%3DPehlic%26aufirst%3DA.%26aulast%3DMariani%26aufirst%3DR.%26aulast%3DBos%26aufirst%3DI.%2BS.%26aulast%3DMeurs%26aufirst%3DH.%26aulast%3DZaagsma%26aufirst%3DJ.%26atitle%3DGlucocorticosteroids%2520and%2520%25CE%25B22-adrenoceptor%2520agonists%2520synergize%2520to%2520inhibit%2520airway%2520smooth%2520muscle%2520remodeling%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D780%26epage%3D787%26doi%3D10.1124%2Fjpet.112.195867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncharova, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krymskaya, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2011-0217OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1165%2Frcmb.2011-0217OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22210825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=48-54&author=E.+A.+Goncharovaauthor=D.+A.+Goncharovauthor=H.+Zhaoauthor=R.+B.+Pennauthor=V.+P.+Krymskayaauthor=R.+A.+Panettieri&title=%CE%B22-adrenergic+receptor+agonists+modulate+human+airway+smooth+muscle+cell+migration+via+vasodilator-stimulated+phosphoprotein&doi=10.1165%2Frcmb.2011-0217OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic receptor agonists modulate human airway smooth muscle cell migration via vasodilator-stimulated phosphoprotein</span></div><div class="casAuthors">Goncharova, Elena A.; Goncharov, Dmitry A.; Zhao, Hengjiang; Penn, Raymond B.; Krymskaya, Vera P.; Panettieri, Reynold A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-54</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Severe asthma manifests as airway remodeling and irreversible airway obstruction, in part because of the proliferation and migration of human airway smooth muscle (HASM) cells.  We previously reported that cyclic adenosine monophosphate-mobilizing agents, including β2-adrenergic receptor (β2AR) agonists, which are mainstay of asthma therapy, and prostaglandin E2 (PGE2), inhibit the migration of HASM cells, although the mechanism for this migration remains unknown.  Vasodilator-stimulated phosphoprotein (VASP), an anticapping protein, modulates the formation of actin stress fibers during cell motility, and is neg. regulated by protein kinase A (PKA)-specific inhibitory phosphorylation at serine 157 (Ser157).  Here, we show that treatment with β2AR agonists and PGE2 induces the PKA-dependent phosphorylation of VASP and inhibits the migration of HASM cells.  The stable expression of PKA inhibitory peptide and the small interfering (si) RNA-induced depletion of VASP abolish the inhibitory effects of albuterol and PGE2 on the migration of HASM cells.  Importantly, prolonged treatment with albuterol prevents the agonist-induced phosphorylation of VASP at Ser157, and reverses the inhibitory effects of albuterol and formoterol, but not PGE2, on the basal and PDGF-induced migration of HASM cells.  Collectively, our data demonstrate that β2AR agonists selectively inhibit the migration of HASM cells via a β2AR/PKA/VASP signaling pathway, and that prolonged treatment with albuterol abolishes the inhibitory effect of β-agonists on the phosphorylation of VASP and migration of HASM cells because of β2AR desensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTmlB6JvyB8bVg90H21EOLACvtfcHk0li5ZqRxrSnHUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlWqtQ%253D%253D&md5=fb744bdc8cc4b0cb1784cb20abe7f89c</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2011-0217OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2011-0217OC%26sid%3Dliteratum%253Aachs%26aulast%3DGoncharova%26aufirst%3DE.%2BA.%26aulast%3DGoncharov%26aufirst%3DD.%2BA.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DKrymskaya%26aufirst%3DV.%2BP.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26atitle%3D%25CE%25B22-adrenergic%2520receptor%2520agonists%2520modulate%2520human%2520airway%2520smooth%2520muscle%2520cell%2520migration%2520via%2520vasodilator-stimulated%2520phosphoprotein%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2012%26volume%3D46%26spage%3D48%26epage%3D54%26doi%3D10.1165%2Frcmb.2011-0217OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theron, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steel, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintinger, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, C.</span></span> <span> </span><span class="NLM_article-title">The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">105420</span>, <span class="refDoi"> DOI: 10.1155/2014/105420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1155%2F2014%2F105420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24733958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2cnjslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=105420&author=R.+Andersonauthor=A.+J.+Theronauthor=H.+C.+Steelauthor=C.+Durandtauthor=G.+R.+Tintingerauthor=C.+Feldman&title=The+beta-2-adrenoreceptor+agonists%2C+formoterol+and+indacaterol%2C+but+not+salbutamol%2C+effectively+suppress+the+reactivity+of+human+neutrophils+in+vitro&doi=10.1155%2F2014%2F105420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro</span></div><div class="casAuthors">Anderson Ronald; Steel Helen C; Durandt Chrisna; Tintinger Gregory R; Theron Annette J; Feldman Charles</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of inflammation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2014</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105420</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The clinical relevance of the anti-inflammatory properties of beta-2 agonists remains contentious possibly due to differences in their molecular structures and agonist activities.  The current study has compared the effects of 3 different categories of β 2-agonists, namely, salbutamol (short-acting), formoterol (long-acting) and indacaterol (ultra-long-acting), at concentrations of 1-1000 nM, with human blood neutrophils in vitro.  Neutrophils were activated with either N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP, 1 μM) or platelet-activating factor (PAF, 200 nM) in the absence and presence of the β 2-agonists followed by measurement of the generation of reactive oxygen species and leukotriene B4, release of elastase, and expression of the β 2-integrin, CR3, using a combination of chemiluminescence, ELISA, colorimetric, and flow cytometric procedures respectively.  These were correlated with alterations in the concentrations of intracellular cyclic-AMP and cytosolic Ca(2+).  At the concentrations tested, formoterol and indacaterol caused equivalent, significant (P < 0.05 at 1-10 nM) dose-related inhibition of all of the pro-inflammatory activities tested, while salbutamol was much less effective (P < 0.05 at 100 nM and higher).  Suppression of neutrophil reactivity was accompanied by elevations in intracellular cAMP and accelerated clearance of Ca(2+) from the cytosol of activated neutrophils.  These findings demonstrate that β 2-agonists vary with respect to their suppressive effects on activated neutrophils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNHMVjMpinWNenUz0lpNqnfW6udTcc2ebhXOx6DHJLnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnjslGgsQ%253D%253D&md5=a7d502e5ec575f849715ab02083f67e7</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1155%2F2014%2F105420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F105420%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DR.%26aulast%3DTheron%26aufirst%3DA.%2BJ.%26aulast%3DSteel%26aufirst%3DH.%2BC.%26aulast%3DDurandt%26aufirst%3DC.%26aulast%3DTintinger%26aufirst%3DG.%2BR.%26aulast%3DFeldman%26aufirst%3DC.%26atitle%3DThe%2520beta-2-adrenoreceptor%2520agonists%252C%2520formoterol%2520and%2520indacaterol%252C%2520but%2520not%2520salbutamol%252C%2520effectively%2520suppress%2520the%2520reactivity%2520of%2520human%2520neutrophils%2520in%2520vitro%26jtitle%3DMediators%2520Inflammation%26date%3D2014%26volume%3D2014%26spage%3D105420%26doi%3D10.1155%2F2014%2F105420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamyel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnken-Uhlich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemann, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmedat, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meurs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller-Larsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racké, K.</span></span> <span> </span><span class="NLM_article-title">The β<sub>2</sub>-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1007/s00210-011-0655-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00210-011-0655-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21603974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2011&pages=133-145&author=F.+Lamyelauthor=M.+Warnken-Uhlichauthor=W.+K.+Seemannauthor=K.+Mohrauthor=E.+Kostenisauthor=A.+S.+Ahmedatauthor=M.+Smitauthor=R.+Gosensauthor=H.+Meursauthor=A.+Miller-Larssonauthor=K.+Rack%C3%A9&title=The+%CE%B22-subtype+of+adrenoceptors+mediates+inhibition+of+pro-fibrotic+events+in+human+lung+fibroblasts&doi=10.1007%2Fs00210-011-0655-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts</span></div><div class="casAuthors">Lamyel, F.; Warnken-Uhlich, M.; Seemann, W. K.; Mohr, K.; Kostenis, E.; Ahmedat, A. S.; Smit, M.; Gosens, R.; Meurs, H.; Miller-Larsson, A.; Racke, Kurt</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-145</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Fibrosis is part of airway remodelling obsd. in bronchial asthma and COPD.  Pro-fibrotic activity of lung fibroblasts may be suppressed by β-adrenoceptor activation.  We aimed, first, to characterize the expression pattern of β-adrenoceptor subtypes in human lung fibroblasts and, second, to probe β-adrenoceptor signaling with an emphasis on anti-fibrotic actions.  Using reverse transcription PCR, mRNA encoding β2-adrenoceptors was detected in MRC-5, HEL-299 and primary human lung fibroblasts, whereas transcripts for β1- and β3-adrenoceptors were not found.  Real-time measurement of dynamic mass redistribution in MRC-5 cells revealed β-agonist-induced Gs-signaling.  Proliferation of MRC-5 cells (detd. by [3H]-thymidine incorporation) was significantly inhibited by β-agonists including the β2-selective agonist formoterol (-logIC50, 10.2) and olodaterol (-logIC50, 10.6).  Formoterol's effect was insensitive to β1-antagonism (GCP 20712, 3 μM), but sensitive to β2-antagonism (ICI 118,551; apparent, pA 2, 9.6).  Collagen synthesis in MRC-5 cells (detd. by [3H]-proline incorporation) was inhibited by β-agonists including formoterol (-logIC50, 10.0) and olodaterol (-logIC50, 10.3) in a β2-blocker-sensitive manner. α-Smooth muscle actin, a marker of myo-fibroblast differentiation, was down-regulated at the mRNA and the protein level by about 50% following 24 and 48 h exposure to 1 nM formoterol, a maximally active concn.  In conclusion, human lung fibroblasts exclusively express β2-adrenoceptors and these mediate inhibition of various markers of pro-fibrotic cellular activity.  Under clin. conditions, anti-fibrotic actions may accompany the therapeutic effect of long-term β2-agonist treatment of bronchial asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcrrxy9mSlR7Vg90H21EOLACvtfcHk0lhYQ4Cfr_O_3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsFOksbc%253D&md5=f72d9809b80589d1a5dc921d1dc09971</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1007%2Fs00210-011-0655-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-011-0655-5%26sid%3Dliteratum%253Aachs%26aulast%3DLamyel%26aufirst%3DF.%26aulast%3DWarnken-Uhlich%26aufirst%3DM.%26aulast%3DSeemann%26aufirst%3DW.%2BK.%26aulast%3DMohr%26aufirst%3DK.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DAhmedat%26aufirst%3DA.%2BS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DGosens%26aufirst%3DR.%26aulast%3DMeurs%26aufirst%3DH.%26aulast%3DMiller-Larsson%26aufirst%3DA.%26aulast%3DRack%25C3%25A9%26aufirst%3DK.%26atitle%3DThe%2520%25CE%25B22-subtype%2520of%2520adrenoceptors%2520mediates%2520inhibition%2520of%2520pro-fibrotic%2520events%2520in%2520human%2520lung%2520fibroblasts%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2011%26volume%3D384%26spage%3D133%26epage%3D145%26doi%3D10.1007%2Fs00210-011-0655-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, J. G.</span></span> <span> </span><span class="NLM_article-title">The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1048</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2010.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20590599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1048-1061&author=J.+G.+Baker&title=The+selectivity+of+beta-adrenoceptor+agonists+at+human+beta1-%2C+beta2-+and+beta3-adrenoceptors&doi=10.1111%2Fj.1476-5381.2010.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors</span></div><div class="casAuthors">Baker, Jillian G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1061</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).  Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.  In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.  This study examd. the affinity and intrinsic efficacy of β-adrenoceptor agonists at the three human β-adrenoceptors to det. whether the current agonists are subtype selective because of affinity or intrinsic efficacy.  Stable clonal CHO-K1 cell lines, transfected with either the human β1, β2 or β3-adrenoceptor, were used, and whole-cell [3H]-CGP 12177 radioligand binding and [3H]-cAMP accumulation were measured.  Several agonists were highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2-adrenoceptor over the β1 or β3), while others (e.g. isoprenaline) had little affinity-selectivity.  However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.  Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype-selective intrinsic efficacy.  Several ligands appeared to activate two agonist conformations of the β1- and β3-adrenoceptors.  There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.  Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopuUPn04Hp7LVg90H21EOLACvtfcHk0lhYQ4Cfr_O_3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D&md5=daff8f97b1dfc4732135d3aa79e7de0f</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520selectivity%2520of%2520beta-adrenoceptor%2520agonists%2520at%2520human%2520beta1-%252C%2520beta2-%2520and%2520beta3-adrenoceptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1048%26epage%3D1061%26doi%3D10.1111%2Fj.1476-5381.2010.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newhouse, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCallum, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abboud, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paré, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesic-Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molfino, N. A.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1378/chest.110.3.595</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1378%2Fchest.110.3.595" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8797398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK2sXit1aksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=1996&pages=595-603&author=M.+T.+Newhouseauthor=K.+R.+Chapmanauthor=A.+L.+McCallumauthor=R.+T.+Abboudauthor=D.+M.+Bowieauthor=R.+V.+Hodderauthor=P.+D.+Par%C3%A9author=H.+Mesic-Fuchsauthor=N.+A.+Molfino&title=Cardiovascular+safety+of+high+doses+of+inhaled+fenoterol+and+albuterol+in+acute+severe+asthma&doi=10.1378%2Fchest.110.3.595"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma</span></div><div class="casAuthors">Newhouse, Michael T.; Chapman, Kenneth R.; Mccallum, Andrew L.; Abboud, Raja T.; Bowie, Dennis M.; Hodder, Richard V.; Pare, Peter D.; Mesic-Fuchs, Hilda; Molfino, Nestor A.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-603</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">It has been suggested that overuse of fenoterol metered-dose inhalers (MDIs) may increase the risk of death from asthma due to cardiac arrhythmias.  Our primary objective was to compare the cardiovascular safety of fenoterol and albuterol MDIs when administered in maximal bronchodilating or maximal tolerated doses to an abs. max. of 16 puffs, for the emergency department (ED) treatment of acute severe asthma.  Asthmatic patients presenting to the ED with acute severe asthma (FEV1 less than 50% of predicted) were enrolled in a multicenter, randomized, double-blind, parallel-group study.  Following baseline measurements, (medical history, phys. examn., detn. of serum potassium and serum theophylline levels, oximetry, 12-lead ECG, and spirometry), each patient received 4 puffs of either fenoterol, 200 μg per puff, or albuterol, 100 μg per puff, 1 puff every 30 s via an MDI attached to a holding chamber.  Addnl. doses of inhaled β2-agonist were administered by dose titrn., 2 puffs every 10 min to a maximal cumulative dose of 16 puffs of albuterol or fenoterol, side effects were intolerable to the patient, or an FEV1 plateau (ie, <10% improvement for 2 consecutive doses) occurred.  ECG was recorded continuously via Holter monitor, and respiratory rate, BP, dyspnea (Borg scale), and FEV1 were assessed after each dose.  128 Patients were randomized to receive fenoterol and 129 to receive albuterol.  Overall, fenoterol increased FEV1 160 mL more than albuterol.  The mean (SEM) FEV1 increase from baseline was 0.75±0.06 L in the fenoterol group and 0.59±0.06 L in the albuterol group (p<0.03).  Both β2-agonists caused a decrease in serum potassium level that was significantly greater in the fenoterol (0.23±0.04 mmol/L) than in the salbutamol (0.06±0.03 mmol/L) group (p=0.0002).  There was also a greater increase in the Q-Tc interval in the fenoterol group, 0.011±0.003 s compared with 0.003±0.003 s in the albuterol group (p<0.05).  Differences in hypokalemia and Q-Tc prolongation assocd. with fenoterol and albuterol were significantly different only after 8 puffs of fenoterol had been given.  32 Patients exhibited ventricular premature beats, 14 in the fenoterol group and 18 in the albuterol group.  There were 34 patients with episodes of supraventricular premature beats, 17 in each group.  No episodes of sustained ventricular tachycardia were detected in either group.  In adequately oxygenated patients, using dose titrn. of fenoterol, in a formulation of 200 μg per puff by MDI valved holding chamber and mask, to a total dose of 3,200 μg and salbutamol (100 μg per puff) to a total dose of 1,600 μg over 90 min, showed cardiovascular safety in acute severe asthma.  This was evidenced by absence of cardiovascular mortality or clin. significant arrhythmias in either group.  The 100% greater dose of fenoterol improved FEV1 significantly more than salbutamol and was assocd. with a relatively small but significantly greater prolongation of the Q-Tc interval and decrease in serum potassium level.  This study does not exclude the possibility that adverse cardiac events could occur with severe hypoxemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYexc5KH5JHrVg90H21EOLACvtfcHk0lhYQ4Cfr_O_3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXit1aksrk%253D&md5=f4be8fe2c00098efdb7f1eadb5450175</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1378%2Fchest.110.3.595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.110.3.595%26sid%3Dliteratum%253Aachs%26aulast%3DNewhouse%26aufirst%3DM.%2BT.%26aulast%3DChapman%26aufirst%3DK.%2BR.%26aulast%3DMcCallum%26aufirst%3DA.%2BL.%26aulast%3DAbboud%26aufirst%3DR.%2BT.%26aulast%3DBowie%26aufirst%3DD.%2BM.%26aulast%3DHodder%26aufirst%3DR.%2BV.%26aulast%3DPar%25C3%25A9%26aufirst%3DP.%2BD.%26aulast%3DMesic-Fuchs%26aufirst%3DH.%26aulast%3DMolfino%26aufirst%3DN.%2BA.%26atitle%3DCardiovascular%2520safety%2520of%2520high%2520doses%2520of%2520inhaled%2520fenoterol%2520and%2520albuterol%2520in%2520acute%2520severe%2520asthma%26jtitle%3DChest%26date%3D1996%26volume%3D110%26spage%3D595%26epage%3D603%26doi%3D10.1378%2Fchest.110.3.595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotvall, J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.160.1.9901063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm.160.1.9901063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10390407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1Mzit1akug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1999&pages=244-249&author=M.+Palmqvistauthor=T.+Ibsenauthor=A.+Mellenauthor=J.+Lotvall&title=Comparison+of+the+relative+efficacy+of+formoterol+and+salmeterol+in+asthmatic+patients&doi=10.1164%2Fajrccm.160.1.9901063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients</span></div><div class="casAuthors">Palmqvist M; Ibsen T; Mellen A; Lotvall J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">244-9</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a partial agonist on the beta2-receptor in comparison to formoterol.  In the present study we evaluated whether these pharmacological differences between salmeterol and formoterol also are applicable to asthmatic patients.  The protective effects by increasing cumulative doses of formoterol (12, 60, 120 micrograms) and salmeterol (50, 250, 500 micrograms) on methacholine-induced bronchoconstriction were evaluated in a double-blind, crossover, placebo-controlled design.  Patients were regularly treated with salbutamol 200 micrograms twice daily during the study period, to avoid variability in beta2-adrenoceptor tolerance.  S-potassium, heart rate corrected Q-T interval (Q-Tc), and tremor score were followed as measures of systemic effects.  Formoterol dose-dependently protected against methacholine responsiveness (4.6 doubling doses after 120 micrograms).  Salmeterol, however, showed a flatter dose-response curve, and a significantly weaker maximal protective effect (2.8 doubling doses after 250 micrograms).  Formoterol caused a significantly higher tremor score and a larger drop in S-potassium than salmeterol at the highest doses.  These data show that salmeterol is a partial agonist on the beta2-receptor in relation to formoterol in human airways in vivo.  Further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZ6w02B1-o54USrryheKE6fW6udTcc2eY3vPAU31M4e7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1Mzit1akug%253D%253D&md5=105e03de4d8b2a6742a5d4f7f9796d02</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.160.1.9901063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.160.1.9901063%26sid%3Dliteratum%253Aachs%26aulast%3DPalmqvist%26aufirst%3DM.%26aulast%3DIbsen%26aufirst%3DT.%26aulast%3DMellen%26aufirst%3DA.%26aulast%3DLotvall%26aufirst%3DJ.%26atitle%3DComparison%2520of%2520the%2520relative%2520efficacy%2520of%2520formoterol%2520and%2520salmeterol%2520in%2520asthmatic%2520patients%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D160%26spage%3D244%26epage%3D249%26doi%3D10.1164%2Fajrccm.160.1.9901063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span> <span> </span><span class="NLM_article-title">Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism</span>. <i>Curr. Opin. Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1097/MCP.0b013e328333def8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1097%2FMCP.0b013e328333def8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19887938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1MfhtFequw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1-5&author=N.+A.+Hananiaauthor=B.+F.+Dickeyauthor=R.+A.+Bond&title=Clinical+implications+of+the+intrinsic+efficacy+of+beta-adrenoceptor+drugs+in+asthma%3A+full%2C+partial+and+inverse+agonism&doi=10.1097%2FMCP.0b013e328333def8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism</span></div><div class="casAuthors">Hanania Nicola A; Dickey Burton F; Bond Richard A</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pulmonary medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE OF REVIEW:  beta2-Adrenoceptor (AR) agonists are the most effective bronchodilators known, and play important roles in every step of asthma therapy.  Intrinsic efficacy is an important pharmacological property that differentiates the clinical effects and safety profile of beta2-AR agonists.  We review the role of beta2-AR agonist intrinsic efficacy in asthma treatment focusing on recent literature.  RECENT FINDINGS:  In acute asthma, a full agonist (high intrinsic efficacy) offers a clinical advantage over a partial agonist (low intrinsic efficacy) but with the potential of inducing dose-dependent adverse effects.  The chronic use of beta2-AR agonists may be associated with several adverse outcomes including loss of asthma control and even increased mortality.  Recently, the role of beta-AR inverse agonists (beta-blockers) which have a negative intrinsic efficacy was studied.  Whereas contraindicated in acute asthma, preliminary data suggest that the chronic use of these agents may be associated with attenuation of airway hyper-responsiveness in patients with mild asthma.  Studies in a murine model of asthma suggest that such effects may be related to decreased airway inflammation and mucous metaplasia.  SUMMARY:  Rational choice among beta2-AR agonists in acute and chronic asthma should be influenced by differences in intrinsic efficacy among these agents.  In acute severe asthma, a full agonist offers a clinical advantage over a partial agonist.  Whereas the use of inverse agonists in the treatment of asthma is still experimental and needs further exploration in future trials, preliminary studies suggest that their chronic use is well tolerated and is associated with decreased airway hyper-responsiveness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMmy4TEGSezKx48Rj5GnGofW6udTcc2eY3vPAU31M4e7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfhtFequw%253D%253D&md5=a64dcac78ab7e558289c996b64036c94</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e328333def8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e328333def8%26sid%3Dliteratum%253Aachs%26aulast%3DHanania%26aufirst%3DN.%2BA.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DBond%26aufirst%3DR.%2BA.%26atitle%3DClinical%2520implications%2520of%2520the%2520intrinsic%2520efficacy%2520of%2520beta-adrenoceptor%2520drugs%2520in%2520asthma%253A%2520full%252C%2520partial%2520and%2520inverse%2520agonism%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1%26epage%3D5%26doi%3D10.1097%2FMCP.0b013e328333def8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Battram, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuenoud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton-Davies, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEvoy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological characterization of 5-[(<i>R</i>)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1<i>H</i>-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.098251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.098251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16434564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=762-770&author=C.+Battramauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=M.+R.+Dowlingauthor=R.+A.+Fairhurstauthor=D.+Farrauthor=J.+R.+Fozardauthor=J.+R.+Leighton-Daviesauthor=C.+A.+Lewisauthor=L.+McEvoyauthor=R.+J.+Turnerauthor=A.+Trifilieff&title=In+vitro+and+in+vivo+pharmacological+characterization+of+5-%5B%28R%29-2-%285%2C6-diethyl-indan-2-ylamino%29-1-hydroxy-ethyl%5D-8-hydroxy-1H-quinolin-2-one+%28indacaterol%29%2C+a+novel+inhaled+beta%282%29+adrenoceptor+agonist+with+a+24-h+duration+of+action&doi=10.1124%2Fjpet.105.098251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action</span></div><div class="casAuthors">Battram, Cliff; Charlton, Steven J.; Cuenoud, Bernard; Dowling, Mark R.; Fairhurst, Robin A.; Farr, David; Fozard, John R.; Leighton-Davies, Juliet R.; Lewis, Christine A.; McEvoy, Lorraine; Turner, Robert J.; Trifilieff, Alexandre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-770</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Here, we describe the preclin. pharmacol. profile of indacaterol, a novel, chirally pure inhaled β2 adrenoceptor agonist, in comparison with marketed drugs.  Indacaterol is close to a full agonist at the human β2 adrenoceptor (Emax = 73±1% of the maximal effect of isoprenaline; pEC50 = 8.06±0.02), whereas salmeterol displays only partial efficacy (38±1%).  The functional selectivity profile of indacaterol over β1 human adrenoceptors is similar to that of formoterol, whereas its β3 adrenoceptor selectivity profile is similar to that of formoterol and salbutamol.  In isolated superfused guinea pig trachea, indacaterol has a fast onset of action (30±4 min) similar to formoterol and salbutamol, and a long duration of action (529±99 min) comparable with salmeterol.  In the conscious guinea pig, when given intratracheally as a dry powder, indacaterol inhibits 5-hydroxytryptamine-induced bronchoconstriction for at least 24 h, whereas salmeterol, formoterol, and salbutamol have durations of action of 12, 4, and 2 h, resp.  When given via nebulization to anesthetized rhesus monkeys, all of the compds. dose-dependently inhibit methacholine-induced bronchoconstriction, although indacaterol produces the most prolonged bronchoprotective effect and induces the lowest increase in heart rate for a similar degree of antibronchoconstrictor activity.  In conclusion, the preclin. profile of indacaterol suggests that this compd. has a superior duration of action compatible with once-daily dosing in human, together with a fast onset of action and an improved cardiovascular safety profile over marketed inhaled β2 adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNpFkEE8xZvbVg90H21EOLACvtfcHk0ljGvbKOATSXhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamu70%253D&md5=0ea4e459100f0d3971d8a7f89c5de059</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.098251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.098251%26sid%3Dliteratum%253Aachs%26aulast%3DBattram%26aufirst%3DC.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DLeighton-Davies%26aufirst%3DJ.%2BR.%26aulast%3DLewis%26aufirst%3DC.%2BA.%26aulast%3DMcEvoy%26aufirst%3DL.%26aulast%3DTurner%26aufirst%3DR.%2BJ.%26aulast%3DTrifilieff%26aufirst%3DA.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520characterization%2520of%25205-%255B%2528R%2529-2-%25285%252C6-diethyl-indan-2-ylamino%2529-1-hydroxy-ethyl%255D-8-hydroxy-1H-quinolin-2-one%2520%2528indacaterol%2529%252C%2520a%2520novel%2520inhaled%2520beta%25282%2529%2520adrenoceptor%2520agonist%2520with%2520a%252024-h%2520duration%2520of%2520action%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D762%26epage%3D770%26doi%3D10.1124%2Fjpet.105.098251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist/β<sub>2</sub>-adrenoceptor agonist (MABA) molecule</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.pupt.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28729041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=1-10&author=M.+Apariciauthor=C.+Carcasonaauthor=I.+Ramosauthor=J.+L.+Monteroauthor=J.+L.+Ortizauthor=J.+Cortijoauthor=C.+Puigauthor=D.+Vilellaauthor=C.+Doeauthor=A.+Gavald%C3%A0author=M.+Miralpeix&title=Pharmacological+preclinical+characterization+of+LAS190792%2C+a+novel+inhaled+bifunctional+muscarinic+receptor+antagonist%2F%CE%B22-adrenoceptor+agonist+%28MABA%29+molecule&doi=10.1016%2Fj.pupt.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule</span></div><div class="casAuthors">Aparici, Monica; Carcasona, Carla; Ramos, Israel; Montero, Jose Luis; Ortiz, Jose Luis; Cortijo, Julio; Puig, Carlos; Vilella, Dolors; Doe, Chris; Gavalda, Amadeu; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases.  This study investigated the pharmacol. profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol.  LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays).  It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compds. (pEC50 in spontaneous tone isolated trachea: 9.6).  The relaxant potency of LAS190792 in elec. stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol slightly higher than batefenterol (pIC50 of 8.3 vs. 7.9 in human tissue).  LAS190792 exhibits a sustained duration of action in isolated tissue longer than that of batefenterol.  Nebulized LAS190792 inhibits acetylcholine-induced bronchoconstriction in dog with minimal cardiac effects and sustained bronchodilation (t1/2: 13.3 h).  In conclusion, these studies suggest that LAS190792 is a dual-acting muscarinic antagonist β2-adrenoceptor agonist that has the potential to be a next generation bronchodilator with long-lasting effects and wide safety margin in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4xsgKu0EdJ7Vg90H21EOLACvtfcHk0lgs_ZtETOZbUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ&md5=c4199d8a8fccd880ff64bb6a07bd8a1d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DOrtiz%26aufirst%3DJ.%2BL.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520preclinical%2520characterization%2520of%2520LAS190792%252C%2520a%2520novel%2520inhaled%2520bifunctional%2520muscarinic%2520receptor%2520antagonist%252F%25CE%25B22-adrenoceptor%2520agonist%2520%2528MABA%2529%2520molecule%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.pupt.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Blanco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Alba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β<sub>2</sub>-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>770</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.11.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.ejphar.2015.11.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26656755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSrs73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=770&publication_year=2016&pages=61-69&author=M.+Apariciauthor=A.+Gavald%C3%A0author=I.+Ramosauthor=C.+Carcasonaauthor=R.+Otalauthor=J.+A.+Fern%C3%A1ndez-Blancoauthor=J.+L.+Monteroauthor=V.+M.+Garc%C3%ADaauthor=R.+L%C3%B3pezauthor=J.+De+Albaauthor=C.+Doeauthor=C.+Puigauthor=D.+Vilellaauthor=M.+Miralpeix&title=In+vitro+and+in+vivo+preclinical+profile+of+abediterol+%28LAS100977%29%2C+an+inhaled+long-acting+%CE%B22-adrenoceptor+agonist%2C+compared+with+indacaterol%2C+olodaterol+and+vilanterol&doi=10.1016%2Fj.ejphar.2015.11.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol</span></div><div class="casAuthors">Aparici, Monica; Gavalda, Amadeu; Ramos, Israel; Carcasona, Carla; Otal, Raquel; Fernandez-Blanco, Joan Antoni; Montero, Jose Luis; Garcia, Vicente Marco; Lopez, Rosa; De Alba, Jorge; Doe, Christopher; Puig, Carlos; Vilella, Dolors; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">770</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61-69</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Abediterol is a novel long-acting β2-adrenoceptor agonist (LABA) currently in development for once-daily combination maintenance therapy of asthma and COPD.  This study investigated the preclin. profile of abediterol in terms of affinity, potency, selectivity, duration of action and cardiac effects in comparison to the marketed once-daily LABAs indacaterol, olodaterol and vilanterol.  Abediterol was the compd. with the highest in vitro potency for dog, guinea pig and human β2-adrenoceptors.  In elec. field stimulated guinea pig trachea, abediterol demonstrated 5-, 44- and 77-fold greater potency than olodaterol, indacaterol and vilanterol, resp.  In anesthetized guinea pigs, inhaled abediterol was also the most potent compd., with 5-20 times higher bronchoprotective potency than other once-daily LABAs against acetylcholine.  The bronchoprotective half-life of abediterol in guinea pigs was 36 h compared with 51 h for indacaterol, 47 h for olodaterol, and 18 h for vilanterol.  In anesthetized dogs, abediterol also inhibited acetylcholine-induced bronchoconstriction, with higher potency than olodaterol and vilanterol [ID40 (dose inhibiting bronchoconstriction by 40%) of 0.059 μg/kg, 0.180 μg/kg and 2.870 μg/kg, resp.].  In parallel, effects on heart rate in dogs were also measured.  Abediterol showed greater safety index (defined as the ratio of the maximal dose without effect on heart rate and the ID40) than olodaterol and vilanterol (10.5 vs. 4.9 and 2.4, resp.).  Taken together, these data suggest that abediterol offers potent bronchodilation and a sustained duration of action suited to once-daily dosing, plus a reduced potential for class-related cardiac side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoagjLQjotrprVg90H21EOLACvtfcHk0lgs_ZtETOZbUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSrs73F&md5=7da502fd0f03f119d53e91b3f4b8849f</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.11.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.11.053%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez-Blanco%26aufirst%3DJ.%2BA.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DV.%2BM.%26aulast%3DL%25C3%25B3pez%26aufirst%3DR.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520preclinical%2520profile%2520of%2520abediterol%2520%2528LAS100977%2529%252C%2520an%2520inhaled%2520long-acting%2520%25CE%25B22-adrenoceptor%2520agonist%252C%2520compared%2520with%2520indacaterol%252C%2520olodaterol%2520and%2520vilanterol%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D770%26spage%3D61%26epage%3D69%26doi%3D10.1016%2Fj.ejphar.2015.11.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, R. J.</span></span> <span> </span><span class="NLM_article-title">Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis</span>. <i>Clin. Rev. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1385/CRIAI:31:2:279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1385%2FCRIAI%3A31%3A2%3A279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17085800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD28nltVantw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2006&pages=279-288&author=R.+J.+Hancox&title=Concluding+remarks%3A+can+we+explain+the+association+of+beta-agonists+with+asthma+mortality%3F+A+hypothesis&doi=10.1385%2FCRIAI%3A31%3A2%3A279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis</span></div><div class="casAuthors">Hancox Robert J</div><div class="citationInfo"><span class="NLM_cas:title">Clinical reviews in allergy & immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">279-88</span>
        ISSN:<span class="NLM_cas:issn">1080-0549</span>.
    </div><div class="casAbstract">Beta-agonists have clearly demonstrated benefits for the treatment of both acute and chronic asthma.  Therefore, it is perhaps surprising that many of the articles in this issue have focused on concerns about their safety.  Much of this concern can be traced back to the "beta-agonist controversy"--the association of high-dose isoprenaline and fenoterol inhalers with asthma mortality in the 1960s and 1970s.  Although a causal link was never proven, lingering doubts about the safety of beta-agonists remain.  It is unclear whether a similar adverse effect is responsible for recently reported association of long-acting beta-agonists with asthma deaths.  No mechanism for the beta-agonist controversy was established, but the evidence presented in this collection of articles points to a number of contributing factors.  I suggest that a combination of these effects provides a plausible mechanism for the association of frequent beta-agonist use with asthma mortality.  Rebound bronchoconstriction and bronchial hyperresponsiveness occur on withdrawal of regular beta-agonist treatment.  Regular use of fenoterol is associated with a reduction in morning peak flow suggesting that the overnight interval between doses is sufficient to allow rebound bronchoconstriction.  This has not been observed with terbutaline or salbutamol, although rebound phenomena do occur when these drugs are withdrawn for slightly longer periods.  Regular use of beta-agonists also leads to tolerance to their bronchoprotective and bronchodilator effects.  Tolerance becomes more apparent with worsening bronchoconstriction.  In severe asthma, this could result in a poor response to emergency treatment.  The combination of rebound deterioration of asthma and a poor response to beta-agonist treatment resulting from tolerance could explain the increased mortality associated with fenoterol and isoprenaline.  Both effects are probably caused by downregulation of beta-receptors which occurs with all beta-agonists.  Long-acing beta-agonists cause a similar degree of tolerance to short-acting beta-agonists, but avoid the problem of overnight withdrawal.  Long-acting beta-agonists have also been shown to improve asthma control when taken in combination with inhaled corticosteroids.  The clinical significance of tolerance in this context remains to be determined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVM2NArfZ8ZdHxxy173TfNfW6udTcc2eZmIyA6vhR5Irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nltVantw%253D%253D&md5=75c7c2f008e49714b9e7991fbcdcf71c</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1385%2FCRIAI%3A31%3A2%3A279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FCRIAI%253A31%253A2%253A279%26sid%3Dliteratum%253Aachs%26aulast%3DHancox%26aufirst%3DR.%2BJ.%26atitle%3DConcluding%2520remarks%253A%2520can%2520we%2520explain%2520the%2520association%2520of%2520beta-agonists%2520with%2520asthma%2520mortality%253F%2520A%2520hypothesis%26jtitle%3DClin.%2520Rev.%2520Allergy%2520Immunol.%26date%3D2006%26volume%3D31%26spage%3D279%26epage%3D288%26doi%3D10.1385%2FCRIAI%3A31%3A2%3A279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Agonist efficacy and receptor desensitization: from partial truths to a fuller picture</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00352.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2009.00352.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19719779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=165-168&author=S.+J.+Charlton&title=Agonist+efficacy+and+receptor+desensitization%3A+from+partial+truths+to+a+fuller+picture&doi=10.1111%2Fj.1476-5381.2009.00352.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist efficacy and receptor desensitization: from partial truths to a fuller picture</span></div><div class="casAuthors">Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-168</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It has been demonstrated that the degree of agonist-induced desensitization of the β2-adrenoceptor is related to agonist efficacy (strength of signaling), whereby high-efficacy agonists (e.g., formoterol) cause more phosphorylation and internalization of the receptor than low-efficacy agonists (e.g., salmeterol).  These early studies, however, used a protocol where agonists were matched for receptor occupancy rather than functional effect.  In this issue of the BJP, Duringer and colleagues have extended these studies to compare the ability of agonists to cause desensitization at equi-effective (cAMP signaling) concns. rather than equal occupancy.  Their data and conclusions are quite different from those previously described.  After prolonged exposure, all the agonists caused a similar degree of desensitization, whereas a pulse protocol uncovered a greater loss of responsiveness with the low-efficacy ligands.  This is consistent with the notion that high-efficacy agonists have 'spare receptors', and are therefore less sensitive to loss of receptors through desensitization.  It also reflects experience in the clinic, where both formoterol and salmeterol show a similar early decline in bronchoprotection, after which their effects remain stable.  These findings challenge the notion that high-efficacy ligands always cause more functional desensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc6mA_BbjssbVg90H21EOLACvtfcHk0li8Iu-gzZHTFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmu7fO&md5=c8fcca272d976d4893fcb9cc0621613c</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00352.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00352.x%26sid%3Dliteratum%253Aachs%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DAgonist%2520efficacy%2520and%2520receptor%2520desensitization%253A%2520from%2520partial%2520truths%2520to%2520a%2520fuller%2520picture%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D165%26epage%3D168%26doi%3D10.1111%2Fj.1476-5381.2009.00352.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregorio, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masureel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Aguilar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiasen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S. C.</span></span> <span> </span><span class="NLM_article-title">Single-molecule analysis of ligand efficacy in β<sub>2</sub>AR-G-protein activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>547</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1038/nature22354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature22354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28607487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=547&publication_year=2017&pages=68-73&author=G.+G.+Gregorioauthor=M.+Masureelauthor=D.+Hilgerauthor=D.+S.+Terryauthor=M.+Juetteauthor=H.+Zhaoauthor=Z.+Zhouauthor=J.+M.+Perez-Aguilarauthor=M.+Haugeauthor=S.+Mathiasenauthor=J.+A.+Javitchauthor=H.+Weinsteinauthor=B.+K.+Kobilkaauthor=S.+C.+Blanchard&title=Single-molecule+analysis+of+ligand+efficacy+in+%CE%B22AR-G-protein+activation&doi=10.1038%2Fnature22354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Single-molecule analysis of ligand efficacy in β2AR-G-protein activation</span></div><div class="casAuthors">Gregorio, G. Glenn; Masureel, Matthieu; Hilger, Daniel; Terry, Daniel S.; Juette, Manuel; Zhao, Hong; Zhou, Zhou; Perez-Aguilar, Jose Manuel; Hauge, Maria; Mathiasen, Signe; Javitch, Jonathan A.; Weinstein, Harel; Kobilka, Brian K.; Blanchard, Scott C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">547</span>
        (<span class="NLM_cas:issue">7661</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptor (GPCR)-mediated signal transduction is central to human physiol. and disease intervention, yet the mol. mechanisms responsible for ligand-dependent signaling responses remain poorly understood.  In class A GPCRs, receptor activation and G-protein coupling entail outward movements of transmembrane helix 6 (TM6).  Here, using single-mol. fluorescence resonance energy transfer imaging, we examine TM6 movements in the β2 adrenergic receptor (β2AR) upon exposure to orthosteric ligands with different efficacies, in the absence and presence of the Gs heterotrimer.  We show that partial and full agonists differentially affect TM6 motions to regulate the rate at which GDP-bound β2AR-Gs complexes are formed and the efficiency of nucleotide exchange leading to Gs activation.  These data also reveal transient nucleotide-bound β2AR-Gs species that are distinct from known structures, and provide single-mol. perspectives on the allosteric link between ligand- and nucleotide-binding pockets that shed new light on the G-protein activation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqox1l7GNlNIbVg90H21EOLACvtfcHk0li8Iu-gzZHTFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb8%253D&md5=b7fc7f43e98bdf40611a7e7936b882af</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fnature22354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22354%26sid%3Dliteratum%253Aachs%26aulast%3DGregorio%26aufirst%3DG.%2BG.%26aulast%3DMasureel%26aufirst%3DM.%26aulast%3DHilger%26aufirst%3DD.%26aulast%3DTerry%26aufirst%3DD.%2BS.%26aulast%3DJuette%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DPerez-Aguilar%26aufirst%3DJ.%2BM.%26aulast%3DHauge%26aufirst%3DM.%26aulast%3DMathiasen%26aufirst%3DS.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DBlanchard%26aufirst%3DS.%2BC.%26atitle%3DSingle-molecule%2520analysis%2520of%2520ligand%2520efficacy%2520in%2520%25CE%25B22AR-G-protein%2520activation%26jtitle%3DNature%26date%3D2017%26volume%3D547%26spage%3D68%26epage%3D73%26doi%3D10.1038%2Fnature22354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masureel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Westhuizen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mildorf, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structural insights into binding specificity, efficacy and bias of a β<sub>2</sub>AR partial agonist</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1066</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0145-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41589-018-0145-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30327561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFCgsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1059-1066&author=M.+Masureelauthor=Y.+Zouauthor=L.+P.+Picardauthor=E.+van+der%0AWesthuizenauthor=J.+P.+Mahoneyauthor=J.+Rodriguesauthor=T.+J.+Mildorfauthor=R.+O.+Drorauthor=D.+E.+Shawauthor=M.+Bouvierauthor=E.+Pardonauthor=J.+Steyaertauthor=R.+K.+Sunaharaauthor=W.+I.+Weisauthor=C.+Zhangauthor=B.+K.+Kobilka&title=Structural+insights+into+binding+specificity%2C+efficacy+and+bias+of+a+%CE%B22AR+partial+agonist&doi=10.1038%2Fs41589-018-0145-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist</span></div><div class="casAuthors">Masureel, Matthieu; Zou, Yaozhong; Picard, Louis-Philippe; van der Westhuizen, Emma; Mahoney, Jacob P.; Rodrigues, Joao P. G. L. M.; Mildorf, Thomas J.; Dror, Ron O.; Shaw, David E.; Bouvier, Michel; Pardon, Els; Steyaert, Jan; Sunahara, Roger K.; Weis, William I.; Zhang, Cheng; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1059-1066</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Salmeterol is a partial agonist for the β2 adrenergic receptor (β2AR) and the first long-acting β2AR agonist to be widely used clin. for the treatment of asthma and chronic obstructive pulmonary disease.  Salmeterol's safety and mechanism of action have both been controversial.  To understand its unusual pharmacol. action and partial agonism, we obtained the crystal structure of salmeterol-bound β2AR in complex with an active-state-stabilizing nanobody.  The structure reveals the location of the salmeterol exosite, where sequence differences between β1AR and β2AR explain the high receptor-subtype selectivity.  A structural comparison with the β2AR bound to the full agonist epinephrine reveals differences in the hydrogen-bond network involving residues Ser2045.43 and Asn2936.55.  Mutagenesis and biophys. studies suggested that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G-protein activation and the limited β-arrestin recruitment for salmeterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7LnLZOttfbVg90H21EOLACvtfcHk0li8Iu-gzZHTFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFCgsrzF&md5=6ab1b302fde86f7c68ca9b8b86f91ae4</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0145-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0145-x%26sid%3Dliteratum%253Aachs%26aulast%3DMasureel%26aufirst%3DM.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DPicard%26aufirst%3DL.%2BP.%26aulast%3Dvan%2Bder%2BWesthuizen%26aufirst%3DE.%26aulast%3DMahoney%26aufirst%3DJ.%2BP.%26aulast%3DRodrigues%26aufirst%3DJ.%26aulast%3DMildorf%26aufirst%3DT.%2BJ.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructural%2520insights%2520into%2520binding%2520specificity%252C%2520efficacy%2520and%2520bias%2520of%2520a%2520%25CE%25B22AR%2520partial%2520agonist%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D1059%26epage%3D1066%26doi%3D10.1038%2Fs41589-018-0145-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurten, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainty, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panettieri, R. A.</span></span> <span> </span><span class="NLM_article-title">Formoterol and salmeterol induce a similar degree of β<sub>2</sub>-adrenoceptor tolerance in human small airways but via different mechanisms</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">521</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01257.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2011.01257.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21306583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslWqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=521-532&author=P.+R.+Cooperauthor=R.+C.+Kurtenauthor=J.+Zhangauthor=D.+J.+Nichollsauthor=I.+A.+Daintyauthor=R.+A.+Panettieri&title=Formoterol+and+salmeterol+induce+a+similar+degree+of+%CE%B22-adrenoceptor+tolerance+in+human+small+airways+but+via+different+mechanisms&doi=10.1111%2Fj.1476-5381.2011.01257.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms</span></div><div class="casAuthors">Cooper, P. R.; Kurten, R. C.; Zhang, J.; Nicholls, D. J.; Dainty, I. A.; Panettieri, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-532</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Steroids prevent and reverse salbutamol-induced β2-adrenoceptor tolerance in human small airways.  This study examines the effects of the long-acting β2 agonists (LABAs) formoterol and salmeterol, and the ability of budesonide to prevent desensitization.  Exptl. Approach Long-acting β2 agonists in the presence and absence of budesonide were incubated with human precision-cut lung slices contg. small airways.  Tolerance was deduced from measurements of reduced bronchodilator responses to isoprenaline and correlated with β2-adrenoceptor trafficking using a virally transduced, fluorescent-tagged receptor.  The ability of the LABAs to protect airways against muscarinic-induced contraction was also assessed.  Key Results Following a 12 h incubation, both formoterol and salmeterol attenuated isoprenaline-induced bronchodilation to a similar degree and these effects were not reversible by washing.  Pre-incubation with budesonide prevented the desensitization induced by formoterol, but not that induced by salmeterol.  Formoterol also protected the airways from carbachol-induced bronchoconstriction to a greater extent than salmeterol.  In the epithelial cells of small airways, incubation with formoterol promoted receptor internalization but this did not appear to occur following incubation with salmeterol.  Budesonide inhibited the formoterol-induced redn. in plasma membrane β2-adrenoceptor fluorescence.  Conclusions and Implications Although both formoterol and salmeterol attenuate isoprenaline-induced bronchodilation, they appear to induce β2-adrenoceptor tolerance via different mechanisms; formoterol, but not salmeterol, enhances receptor internalization.  Budesonide protection against β2-adrenoceptor tolerance was correlated with the retention of receptor fluorescence on the plasma membrane, thereby suggesting a mechanism by which steroids alter β2-adrenoceptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk0m7NQ1r6b7Vg90H21EOLACvtfcHk0lgMowRxaxcHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslWqtL8%253D&md5=70b04822185c042933594e9225e2f5f5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01257.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01257.x%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DP.%2BR.%26aulast%3DKurten%26aufirst%3DR.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DDainty%26aufirst%3DI.%2BA.%26aulast%3DPanettieri%26aufirst%3DR.%2BA.%26atitle%3DFormoterol%2520and%2520salmeterol%2520induce%2520a%2520similar%2520degree%2520of%2520%25CE%25B22-adrenoceptor%2520tolerance%2520in%2520human%2520small%2520airways%2520but%2520via%2520different%2520mechanisms%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D521%26epage%3D532%26doi%3D10.1111%2Fj.1476-5381.2011.01257.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millman, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godines, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span> <span> </span><span class="NLM_article-title">Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">254</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2006-0158OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1165%2Frcmb.2006-0158OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16980556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFWju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2007&pages=254-261&author=R.+H.+Mooreauthor=E.+E.+Millmanauthor=V.+Godinesauthor=N.+A.+Hananiaauthor=T.+M.+Tranauthor=H.+Pengauthor=B.+F.+Dickeyauthor=B.+J.+Knollauthor=R.+B.+Clark&title=Salmeterol+stimulation+dissociates+beta2-adrenergic+receptor+phosphorylation+and+internalization&doi=10.1165%2Frcmb.2006-0158OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol stimulation dissociates β2-adrenergic receptor phosphorylation and internalization</span></div><div class="casAuthors">Moore, Robert H.; Millman, Ellen E.; Godines, Veronica; Hanania, Nicola A.; Tran, Tuan M.; Peng, Hui; Dickey, Burton F.; Knoll, Brian J.; Clark, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">254-261</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease.  It differs from other β-agonists in that it has a very low intrinsic efficacy, esp. when compared with the other available long-acting β-agonist, formoterol.  Receptor desensitization and down-regulation was described with the chronic use of β-agonists.  This effect may not be the same with all β-agonists and may be related to their stabilization of altered receptor states.  The extreme hydrophobicity and high-affinity quasi-irreversible binding of salmeterol have rendered studies examg. the mechanisms by which it mediates receptor desensitization, down-regulation, and internalization difficult.  We detd. the capacity of salmeterol to induce β2AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degrdn., and β-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies.  Despite stimulating GRK-mediated phosphorylation of Ser355, 356 after 30 min and 18 h to an extent similar to that obsd. with agonists of high intrinsic efficacy, such as epinephrine and formoterol, salmeterol did not induce significant β2AR internalization or degrdn. and was incapable of stimulating the translocation of enhanced green fluorescent protein-β-arrestin2 chimera (EGFP-β-arrestin2) to the cell surface.  Salmeterol-induced receptor endocytosis was rescued, at least in part, by the overexpression of EGFP-β-arrestin2.  Our data indicate that salmeterol binding induces an active receptor state that is unable to recruit β-arrestin or undergo significant endocytosis or degrdn. despite stimulating considerable GRK-site phosphorylation.  Defects in these components of salmeterol-induced receptor desensitization may be important determinants of its sustained bronchodilation with chronic use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofK2ze86PqCbVg90H21EOLACvtfcHk0lgMowRxaxcHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFWju70%253D&md5=6f2f2d3e21a928c1439bf9239291880a</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2006-0158OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2006-0158OC%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DR.%2BH.%26aulast%3DMillman%26aufirst%3DE.%2BE.%26aulast%3DGodines%26aufirst%3DV.%26aulast%3DHanania%26aufirst%3DN.%2BA.%26aulast%3DTran%26aufirst%3DT.%2BM.%26aulast%3DPeng%26aufirst%3DH.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DKnoll%26aufirst%3DB.%2BJ.%26aulast%3DClark%26aufirst%3DR.%2BB.%26atitle%3DSalmeterol%2520stimulation%2520dissociates%2520beta2-adrenergic%2520receptor%2520phosphorylation%2520and%2520internalization%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2007%26volume%3D36%26spage%3D254%26epage%3D261%26doi%3D10.1165%2Frcmb.2006-0158OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gimenez, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baameur, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayttaden, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R. B.</span></span> <span> </span><span class="NLM_article-title">Salmeterol efficacy and bias in the activation and kinase-mediated desensitization of β<sub>2</sub>-adrenergic receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1124/mol.114.096800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fmol.114.096800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25784721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=954-964&author=L.+E.+Gimenezauthor=F.+Baameurauthor=S.+J.+Vayttadenauthor=R.+B.+Clark&title=Salmeterol+efficacy+and+bias+in+the+activation+and+kinase-mediated+desensitization+of+%CE%B22-adrenergic+receptors&doi=10.1124%2Fmol.114.096800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol efficacy and bias in the activation and kinase-mediated desensitization of β2-adrenergic receptors</span></div><div class="casAuthors">Gimenez, Luis E.; Baameur, Faiza; Vayttaden, Sharat J.; Clark, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">954-964</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Salmeterol is a long-acting β2-adrenergic receptor (β2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids.  Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the β2AR remains poorly understood.  In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-β2AR binding to arrestin and through kinetic studies of cAMP turnover.  First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to β2AR relative to isoproterenol.  The ratio of BRETISO/BRETSALM after 5-min stimulation was 20 and decreased to 5 after 35 min, reflecting a progressive decline in BRETISO and a stable BRETSALM.  Second, to assess salmeterol efficacy for functional desensitization, we examd. the kinetics of salmeterol-induced cAMP accumulation (0-30 min) in human airway smooth muscle cells in the presence and absence of phosphodiesterase inhibition.  Anal. of shaping of cAMP turnover for both agonists demonstrated significant salmeterol desensitization, although it was reduced relative to isoproterenol.  Using an isoproterenol rescue protocol after either short-term (10 min) or long-term (2 and 14 h) salmeterol pretreatments, we found that salmeterol progressively depressed isoproterenol stimulation but did not prevent subsequent rescue by isoproterenol and addnl. isoproterenol-mediated desensitization.  Our findings reveal a complex efficacy for functional desensitization, demonstrating that although salmeterol shows weak efficacy for adenylyl cyclase activation and G protein-coupled receptor kinase/arrestin-mediated desensitization, it acts as a strong agonist in highly amplified protein kinase A-mediated events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH_8J6eA1wobVg90H21EOLACvtfcHk0lgMowRxaxcHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wgtrs%253D&md5=f004d644d6ab5cd98e65b30c1f8c7764</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.096800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.096800%26sid%3Dliteratum%253Aachs%26aulast%3DGimenez%26aufirst%3DL.%2BE.%26aulast%3DBaameur%26aufirst%3DF.%26aulast%3DVayttaden%26aufirst%3DS.%2BJ.%26aulast%3DClark%26aufirst%3DR.%2BB.%26atitle%3DSalmeterol%2520efficacy%2520and%2520bias%2520in%2520the%2520activation%2520and%2520kinase-mediated%2520desensitization%2520of%2520%25CE%25B22-adrenergic%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D954%26epage%3D964%26doi%3D10.1124%2Fmol.114.096800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naline, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devillier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarosa, P.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub> agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings (Abstract)</span>. <i>Am. J. Respir. Crit. Care. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">A4443</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2010&pages=A4443&author=E.+Nalineauthor=A.+Ostermannauthor=P.+Devillierauthor=P.+Casarosa&title=%CE%B22+agonist+intrinsic+activity%3A+comparison+of+BI+1744+and+formoterol+in+different+functional+settings+%28Abstract%29&doi=10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443%26sid%3Dliteratum%253Aachs%26aulast%3DNaline%26aufirst%3DE.%26aulast%3DOstermann%26aufirst%3DA.%26aulast%3DDevillier%26aufirst%3DP.%26aulast%3DCasarosa%26aufirst%3DP.%26atitle%3D%25CE%25B22%2520agonist%2520intrinsic%2520activity%253A%2520comparison%2520of%2520BI%25201744%2520and%2520formoterol%2520in%2520different%2520functional%2520settings%2520%2528Abstract%2529%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care.%2520Med.%26date%3D2010%26volume%3D181%26spage%3DA4443%26doi%3D10.1164%2Fajrccm-conference.2010.181.1_MeetingAbstracts.A4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">β-Adrenergic receptor subtype signaling in heart: from bench to bedside</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1038/aps.2011.201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Faps.2011.201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22286918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1emt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=335-341&author=A.+Y.+Wooauthor=R.+P.+Xiao&title=%CE%B2-Adrenergic+receptor+subtype+signaling+in+heart%3A+from+bench+to+bedside&doi=10.1038%2Faps.2011.201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">β-Adrenergic receptor subtype signaling in heart: From bench to bedside</span></div><div class="casAuthors">Woo, Anthony Yiu Ho; Xiao, Rui-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-341</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  β-Adrenergic receptor (βAR) stimulation by the sympathetic nervous system or circulating catecholamines is broadly involved in peripheral blood circulation, metabolic regulation, muscle contraction, and central neural activities.  In the heart, acute βAR stimulation serves as the most powerful means to regulate cardiac output in response to a fight-or-flight situation, whereas chronic βAR stimulation plays an important role in physiol. and pathol. cardiac remodeling.  There are three βAR subtypes, β1AR, β2AR and β3AR, in cardiac myocytes.  Over the past two decades, we systematically investigated the mol. and cellular mechanisms underlying the different even opposite functional roles of β1AR and β2AR subtypes in regulating cardiac structure and function, with keen interest in the development of novel therapies based on our discoveries.  We have made three major discoveries, including (1) dual coupling of β2AR to Gs and Gi proteins in cardiomyocytes, (2) cardioprotection by β2AR signaling in improving cardiac function and myocyte viability, and (3) PKA-independent, CaMKII-mediated β1AR apoptotic and maladaptive remodeling signaling in the heart.  Based on these discoveries and salutary effects of β1AR blockade on patients with heart failure, we envision that activation of β2AR in combination with clin. used β1AR blockade should provide a safer and more effective therapy for the treatment of heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_BfdUo0idFbVg90H21EOLACvtfcHk0lh19DqIG_Zp1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1emt7c%253D&md5=5706be5ba5397bcede3e5ec0d3f41c9a</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.201%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3D%25CE%25B2-Adrenergic%2520receptor%2520subtype%2520signaling%2520in%2520heart%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2012%26volume%3D33%26spage%3D335%26epage%3D341%26doi%3D10.1038%2Faps.2011.201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapaidze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nivarthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devi, L. A.</span></span> <span> </span><span class="NLM_article-title">Oligomerization of opioid receptors with beta2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1073/pnas.98.1.343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.98.1.343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11134510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=343-348&author=B.+A.+Jordanauthor=N.+Trapaidzeauthor=I.+Gomesauthor=R.+Nivarthiauthor=L.+A.+Devi&title=Oligomerization+of+opioid+receptors+with+beta2-adrenergic+receptors%3A+a+role+in+trafficking+and+mitogen-activated+protein+kinase+activation&doi=10.1073%2Fpnas.98.1.343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Oligomerization of opioid receptors with β2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation</span></div><div class="casAuthors">Jordan, B. A.; Trapaidze, N.; Gomes, I.; Nivarthi, R.; Devi, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">343-348</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have recently joined the list of cell surface receptors that dimerize.  Dimerization has been shown to alter the ligand-binding, signaling, and trafficking properties of these receptors.  Recent studies have shown that GPCRs heterodimerize with closely related members, resulting in the modulation of their function.  In this study, the authors have attempted to det. whether members of GPCR superfamilies that couple to different families of G-proteins can assoc. and form oligomers.  The authors chose the β2 adrenergic receptor that couples to stimulatory G-proteins and δ & κ opioid receptors that couple to inhibitory G-proteins.  β2 And δ receptors undergo robust agonist-mediated endocytosis, whereas κ receptors do not.  The authors find that when coexpressed, β2 receptors can form heteromeric complexes with both δ and κ receptors.  This hetero-oligomerization does not significantly alter the ligand binding or coupling properties of the receptors.  However, it affects the trafficking properties of the receptors.  For example, the authors find that δ receptors, when coexpressed with β2 receptors, undergo isoproterenol-mediated endocytosis.  Conversely, β2 receptors in these cells undergo etorphine-mediated endocytosis.  However, β2 receptors, when coexpressed with κ receptors, undergo neither opioid- nor isoproterenol-mediated endocytosis.  Moreover, these cells exhibit a substantial decrease in the isoproterenol-induced phosphorylation of mitogen-activated protein kinases.  Taken together, these results provide direct evidence of heteromerization of GPCRs that couple to different types of G-proteins, which results in the modulation of receptor trafficking and signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5yHYduSV3bVg90H21EOLACvtfcHk0lh19DqIG_Zp1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslOnsw%253D%253D&md5=84062a961d1d645ef48d3114435ff60a</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1073%2Fpnas.98.1.343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.98.1.343%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DB.%2BA.%26aulast%3DTrapaidze%26aufirst%3DN.%26aulast%3DGomes%26aufirst%3DI.%26aulast%3DNivarthi%26aufirst%3DR.%26aulast%3DDevi%26aufirst%3DL.%2BA.%26atitle%3DOligomerization%2520of%2520opioid%2520receptors%2520with%2520beta2-adrenergic%2520receptors%253A%2520a%2520role%2520in%2520trafficking%2520and%2520mitogen-activated%2520protein%2520kinase%2520activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2001%26volume%3D98%26spage%3D343%26epage%3D348%26doi%3D10.1073%2Fpnas.98.1.343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span> <span> </span><span class="NLM_article-title">Biased receptor signaling in drug discovery</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1124/pr.118.016790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fpr.118.016790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30914442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvV2gtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=267-315&author=T.+Kenakin&title=Biased+receptor+signaling+in+drug+discovery&doi=10.1124%2Fpr.118.016790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Biased receptor signaling in drug discovery</span></div><div class="casAuthors">Kenakin, Terry</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-315</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  A great deal of exptl. evidence suggests that ligands can stabilize different receptor active states that go on to interact with cellular signaling proteins to form a range of different complexes in varying quantities.  In pleiotropically linked receptor systems, this leads to selective activation of some signaling pathways at the expense of others (biased signaling).  This article summarizes the current knowledge about the complex components of receptor systems, the evidence that biased signaling is used in natural physiol. to fine-tune signaling, and the current thoughts on how this mechanism may be applied to the design of better drugs.  Although this is a fairly newly discovered phenomenon, theor. and exptl. data suggest that it is a ubiquitous behavior of ligands and receptors and to be expected.  Biased signaling is simple to detect in vitro and there are numerous methods to quantify the effect with scales that can be used to optimize this activity in structure-activity medicinal chem. studies.  At present, the major hurdle in the application of this mechanism to therapeutics is the translation of in vitro bias to in vivo effect; this is because of the numerous factors that can modify measures of bias in natural physiol. systems.  In spite of this, biased signaling still has the potential to justify revisiting of receptor targets previously thought to be intractable and also furnishes the means to pursue targets previously thought to be forbidden due to deleterious physiol. (as these may be eliminated through biased signaling).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomawYtBX53pbVg90H21EOLACvtfcHk0lh19DqIG_Zp1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvV2gtL3E&md5=ddf8cb5adb1dc14783bfc82a308fc70d</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fpr.118.016790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.118.016790%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DBiased%2520receptor%2520signaling%2520in%2520drug%2520discovery%26jtitle%3DPharmacol.%2520Rev.%26date%3D2019%26volume%3D71%26spage%3D267%26epage%3D315%26doi%3D10.1124%2Fpr.118.016790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">β-Arrestin-biased ligands at seven-transmembrane receptors</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.tips.2007.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17644195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=416-422&author=J.+D.+Violinauthor=R.+J.+Lefkowitz&title=%CE%B2-Arrestin-biased+ligands+at+seven-transmembrane+receptors&doi=10.1016%2Fj.tips.2007.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-biased ligands at seven-transmembrane receptors</span></div><div class="casAuthors">Violin, Jonathan D.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">416-422</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Seven-transmembrane receptors (7TMRs), the most common mol. targets of modern drug therapy, are critically regulated by β-arrestins, which both inhibit classic G-protein signaling and initiate distinct β-arrestin signaling.  The interplay of G-protein and β-arrestin signals largely dets. the cellular consequences of 7TMR-targeted drugs.  Until recently, a drug's efficacy for β-arrestin recruitment was believed to be proportional to its efficacy for G-protein activities.  This paradigm restricts 7TMR drug effects to a linear spectrum of responses, ranging from inhibition of all responses to stimulation of all responses.  However, it is now clear that 'biased ligands' can selectively activate G-protein or β-arrestin functions and thus elicit novel biol. effects from even well-studied 7TMRs.  Here, we discuss the current state of β-arrestin-biased ligand research and the prospects for β-arrestin bias as a therapeutic target.  Consideration of ligand bias might have profound influences on the way scientists approach 7TMR-targeted drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ODUMAQK-WrVg90H21EOLACvtfcHk0li7CRNes4tN3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLc%253D&md5=3bd811aa19edfdc583e7e3c1266b4730</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3D%25CE%25B2-Arrestin-biased%2520ligands%2520at%2520seven-transmembrane%2520receptors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D416%26epage%3D422%26doi%3D10.1016%2Fj.tips.2007.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wisler, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">16657</span>– <span class="NLM_lpage">16662</span>, <span class="refDoi"> DOI: 10.1073/pnas.0707936104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.0707936104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17925438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Wmu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=16657-16662&author=J.+W.+Wislerauthor=S.+M.+DeWireauthor=E.+J.+Whalenauthor=J.+D.+Violinauthor=M.+T.+Drakeauthor=S.+Ahnauthor=S.+K.+Shenoyauthor=R.+J.+Lefkowitz&title=A+unique+mechanism+of+beta-blocker+action%3A+carvedilol+stimulates+beta-arrestin+signaling&doi=10.1073%2Fpnas.0707936104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling</span></div><div class="casAuthors">Wisler, James W.; Dewire, Scott M.; Whalen, Erin J.; Violin, Jonatan D.; Drake, Matthew T.; Ahn, Seungkirl; Shenoy, Sudha K.; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">16657-16662</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">For many years, β-adrenergic receptor antagonists (β-blockers or βAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction.  More recently, β-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different β-blockers varies widely in this condition.  One drug, carvedilol, a nonsubtype-selective βAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial.  Here, we report that among 16 clin. relevant βAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics.  We obsd. that in β2 adrenergic receptor (β2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating Gs-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of β-arrestin to the β2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant β2ART68F,Y132G,Y219A (β2ARTYY) and abolished by β-arrestin2 siRNA.  Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from Gs, is nonetheless able to stimulate β-arrestin-mediated signaling.  We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic β2AR ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo93wOR8ANKWbVg90H21EOLACvtfcHk0li7CRNes4tN3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Wmu7%252FJ&md5=cd03ae4a87363d9bca28b14dce173589</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0707936104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0707936104%26sid%3Dliteratum%253Aachs%26aulast%3DWisler%26aufirst%3DJ.%2BW.%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DWhalen%26aufirst%3DE.%2BJ.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DDrake%26aufirst%3DM.%2BT.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DA%2520unique%2520mechanism%2520of%2520beta-blocker%2520action%253A%2520carvedilol%2520stimulates%2520beta-arrestin%2520signaling%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D16657%26epage%3D16662%26doi%3D10.1073%2Fpnas.0707936104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of β-arrestin-biased β<sub>2</sub>-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1095</span>– <span class="NLM_lpage">1105</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0200-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41401-018-0200-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30643208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFSns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=1095-1105&author=A.+Y.+Wooauthor=X.+Y.+Geauthor=L.+Panauthor=G.+Xingauthor=Y.+M.+Moauthor=R.+J.+Xingauthor=X.+R.+Liauthor=Y.+Y.+Zhangauthor=I.+W.+Wainerauthor=M.+S.+Chengauthor=R.+P.+Xiao&title=Discovery+of+%CE%B2-arrestin-biased+%CE%B22-adrenoceptor+agonists+from+2-amino-2-phenylethanol+derivatives&doi=10.1038%2Fs41401-018-0200-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives</span></div><div class="casAuthors">Woo, Anthony Yiu-Ho; Ge, Xin-yue; Pan, Li; Xing, Gang; Mo, Yong-mei; Xing, Rui-juan; Li, Xiao-ran; Zhang, Yu-yang; Wainer, Irving W.; Cheng, Mao-sheng; Xiao, Rui-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1095-1105</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In the present study, we evaluated agonist bias for compds. developed along a drug discovery project of β2-adrenoceptor agonists.  About 150 compds., including derivs. of fenoterol, 2-amino-1-phenylethanol and 2-amino-2-phenylethanol, were obtained or synthesized, and initially screened for their β-adrenoceptor-mediated activities in the guinea pig tracheal smooth muscle relaxation assay or the cardiomyocyte contractility assay.  Nineteen bioactive compds. were further assessed using both the HTRF cAMP assay and the PathHunter β-arrestin assay.  Their concn.-response data in stimulating cAMP synthesis and β-arrestin recruitment were applied to the Black-Leff operational model for ligand bias quantitation.  As a result, three compds. (L-2, L-4, and L-12) with the core structure of 5-(1-amino-2-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one were identified as a new series of β-arrestin-biased β2-adrenoceptor agonists, whereas salmeterol was found to be Gs-biased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_MkV43cL0qrVg90H21EOLACvtfcHk0li7CRNes4tN3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFSns7k%253D&md5=be6a5c2ab300dce93cf24d237650e3a2</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0200-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0200-x%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DGe%26aufirst%3DX.%2BY.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DMo%26aufirst%3DY.%2BM.%26aulast%3DXing%26aufirst%3DR.%2BJ.%26aulast%3DLi%26aufirst%3DX.%2BR.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DCheng%26aufirst%3DM.%2BS.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26atitle%3DDiscovery%2520of%2520%25CE%25B2-arrestin-biased%2520%25CE%25B22-adrenoceptor%2520agonists%2520from%25202-amino-2-phenylethanol%2520derivatives%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D1095%26epage%3D1105%26doi%3D10.1038%2Fs41401-018-0200-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penn, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanania, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span> <span> </span><span class="NLM_article-title">New perspectives regarding β(2)-adrenoceptor ligands in the treatment of asthma</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01178.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2010.01178.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21175591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=18-28&author=J.+K.+Walkerauthor=R.+B.+Pennauthor=N.+A.+Hananiaauthor=B.+F.+Dickeyauthor=R.+A.+Bond&title=New+perspectives+regarding+%CE%B2%282%29-adrenoceptor+ligands+in+the+treatment+of+asthma&doi=10.1111%2Fj.1476-5381.2010.01178.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives regarding β2-adrenoceptor ligands in the treatment of asthma</span></div><div class="casAuthors">Walker, J. K. L.; Penn, R. B.; Hanania, N. A.; Dickey, B. F.; Bond, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">18-28</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  In the last 2 decades several significant changes were proposed in the receptor theory that describes how ligands can interact with G protein-coupled receptors (GPCRs).  Here we briefly summarize the evolution of receptor theory and detail recent prominent advances.  These include: (i) the existence of spontaneously active GPCRs that are capable of signaling even though they are unoccupied by any ligand; (ii) the discovery of ligands that can inactivate these spontaneously active receptors; (iii) the notion that a ligand may simultaneously activate more than one GPCR signaling pathway; and (iv) the notion that certain ligands may be able to preferentially direct receptor signaling to a specific pathway.  Because the data supporting these receptor theory ideas are derived primarily from studies using artificial expression systems, the physiol. relevance of these new paradigms remains in question.  As a potential example of how these new perspectives in receptor theory relate to drug actions and clin. outcomes, we discuss their relevance to the recent controversy regarding the chronic use of β2-adrenoceptor agonists in the treatment of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg2HtWkdeFhLVg90H21EOLACvtfcHk0ljmlAByfyc6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7c%253D&md5=3de8d518f635a1d1557abfdd92282adf</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01178.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01178.x%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DJ.%2BK.%26aulast%3DPenn%26aufirst%3DR.%2BB.%26aulast%3DHanania%26aufirst%3DN.%2BA.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DBond%26aufirst%3DR.%2BA.%26atitle%3DNew%2520perspectives%2520regarding%2520%25CE%25B2%25282%2529-adrenoceptor%2520ligands%2520in%2520the%2520treatment%2520of%2520asthma%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D18%26epage%3D28%26doi%3D10.1111%2Fj.1476-5381.2010.01178.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. K.</span></span> <span> </span><span class="NLM_article-title">Beta-arrestins and cell signaling</span>. <i>Annu. Rev. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1146/annurev.physiol.69.022405.154749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1146%2Fannurev.physiol.69.022405.154749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17305471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVaksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2007&pages=483-510&author=S.+M.+DeWireauthor=S.+Ahnauthor=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Beta-arrestins+and+cell+signaling&doi=10.1146%2Fannurev.physiol.69.022405.154749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">β-arrestins and cell signaling</span></div><div class="casAuthors">DeWire, Scott M.; Ahn, Seungkirl; Lefkowitz, Robert J.; Shenoy, Sudha K.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">483-510</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Upon their discovery, β-arrestins 1 and 2 were named for their capacity to sterically hinder the G protein coupling of agonist-activated seven-transmembrane receptors, ultimately resulting in receptor desensitization.  Surprisingly, recent evidence shows that β-arrestins can also function to activate signaling cascades independently of G protein activation.  By serving as multiprotein scaffolds, the β-arrestins bring elements of specific signaling pathways into close proximity.  β-Arrestin regulation has been demonstrated for an ever-increasing no. of signaling mols., including MAP kinases ERK, JNK, and p38 as well as Akt, PI3 kinase, and RhoA.  In addn., investigators are discovering new roles for β-arrestins in nuclear functions.  Here, the authors review the signaling capacities of these versatile adapter mols. and discuss the possible implications for cellular processes such as chemotaxis and apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeWSVCmd5eorVg90H21EOLACvtfcHk0ljmlAByfyc6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVaksLg%253D&md5=a49f06fb1de1e09593d89a8bbfa4c9f7</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1146%2Fannurev.physiol.69.022405.154749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.physiol.69.022405.154749%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DBeta-arrestins%2520and%2520cell%2520signaling%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2007%26volume%3D69%26spage%3D483%26epage%3D510%26doi%3D10.1146%2Fannurev.physiol.69.022405.154749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parameswaran, N.</span></span> <span> </span><span class="NLM_article-title">Multifaceted role of β-arrestins in inflammation and disease</span>. <i>Genes Immun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">513</span>, <span class="refDoi"> DOI: 10.1038/gene.2015.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fgene.2015.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26378652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKkt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=499-513&author=D.+Sharmaauthor=N.+Parameswaran&title=Multifaceted+role+of+%CE%B2-arrestins+in+inflammation+and+disease&doi=10.1038%2Fgene.2015.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted role of β-arrestins in inflammation and disease</span></div><div class="casAuthors">Sharma, D.; Parameswaran, N.</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Immunity</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">499-513</span>CODEN:
                <span class="NLM_cas:coden">GEIMA2</span>;
        ISSN:<span class="NLM_cas:issn">1466-4879</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Arrestins are intracellular scaffolding proteins known to regulate a range of biochem. processes including G protein-coupled receptor (GPCR) desensitization, signal attenuation, receptor turnover and downstream signaling cascades.  Their roles in regulation of signaling network have lately been extended to receptors outside of the GPCR family, demonstrating their roles as important scaffolding proteins in various physiol. processes including proliferation, differentiation and apoptosis.  Recent studies have demonstrated a crit. role for arrestins in immunol. processes including key functions in inflammatory signaling pathways.  In this review, we provide a comprehensive anal. of the different functions of the arrestin family of proteins esp. related to immunity and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoooGvJJETlv7Vg90H21EOLACvtfcHk0ljmlAByfyc6qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKkt7fO&md5=80d649be7dadb702defaf71e170af9b4</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fgene.2015.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgene.2015.37%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DD.%26aulast%3DParameswaran%26aufirst%3DN.%26atitle%3DMultifaceted%2520role%2520of%2520%25CE%25B2-arrestins%2520in%2520inflammation%2520and%2520disease%26jtitle%3DGenes%2520Immun.%26date%3D2015%26volume%3D16%26spage%3D499%26epage%3D513%26doi%3D10.1038%2Fgene.2015.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cullum, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, G. P.</span></span> <span> </span><span class="NLM_article-title">Salbutamol: a new, selective beta-adrenoceptive receptor stimulant</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1969.tb07975.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.1969.tb07975.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=5762037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaF1MXls1Slsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1969&pages=141-151&author=V.+A.+Cullumauthor=J.+B.+Farmerauthor=D.+Jackauthor=G.+P.+Levy&title=Salbutamol%3A+a+new%2C+selective+beta-adrenoceptive+receptor+stimulant&doi=10.1111%2Fj.1476-5381.1969.tb07975.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Salbutamol; an β-adrenoceptive receptor stimulant</span></div><div class="casAuthors">Cullum, Valerie A.; Farmer, John B.; Jack, David; Levy, G. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-51</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">Salbutamol is a β-adrenoceptive receptor stimulant.  Its pharmacol. actions are reduced or abolished by β-receptor antagonists.  In anesthetized animals, salbutamol, given i.v. was slightly less active than isoprenaline in preventing spasm of bronchial smooth muscle but was considerably less active as a cardiac stimulant and vasodepressor.  Its duration of action was about 2 to 3 times that of isoprenaline.  Salbutamol given by mouth or aerosol to conscious guinea pigs, greatly diminished bronchospasm caused by inhalation of acetylcholine.  By mouth, salbutamol was more active and had a longer duration than isoprenaline or orciprenaline without affecting heart rate.  By aerosol, salbutamol was approx. 10 times as active as isoprenaline and 100 times as active as orciprenaline.  Its duration of action was much longer than that of isoprenaline or orciprenaline.  Only isoprenaline produced an increase in heart rate by the aerosol route.  On isolated guinea pig trachea, salbutamol had about 1/10 the activity of isoprenaline and on isolated atria about 1/2000 the activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w5zQ-_X3cLVg90H21EOLACvtfcHk0lgxW_0B3yd56A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXls1Slsw%253D%253D&md5=5c012efa7d10ff3e73e1a45688df8706</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1969.tb07975.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1969.tb07975.x%26sid%3Dliteratum%253Aachs%26aulast%3DCullum%26aufirst%3DV.%2BA.%26aulast%3DFarmer%26aufirst%3DJ.%2BB.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DLevy%26aufirst%3DG.%2BP.%26atitle%3DSalbutamol%253A%2520a%2520new%252C%2520selective%2520beta-adrenoceptive%2520receptor%2520stimulant%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1969%26volume%3D35%26spage%3D141%26epage%3D151%26doi%3D10.1111%2Fj.1476-5381.1969.tb07975.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ball, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denyer, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunts, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nials, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, I. F.</span></span> <span> </span><span class="NLM_article-title">Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1991.tb12486.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.1991.tb12486.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1686740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK3MXmsVOrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1991&pages=665-671&author=D.+I.+Ballauthor=R.+T.+Brittainauthor=R.+A.+Colemanauthor=L.+H.+Denyerauthor=D.+Jackauthor=M.+Johnsonauthor=L.+H.+Luntsauthor=A.+T.+Nialsauthor=K.+E.+Sheldrickauthor=I.+F.+Skidmore&title=Salmeterol%2C+a+novel%2C+long-acting+beta+2-adrenoceptor+agonist%3A+characterization+of+pharmacological+activity+in+vitro+and+in+vivo&doi=10.1111%2Fj.1476-5381.1991.tb12486.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Salmeterol, a novel, long-acting β2-adrenoceptor agonist:  characterization of pharmacological activity in vitro and in vivo</span></div><div class="casAuthors">Ball, D. I.; Brittain, R. T.; Coleman, R. A.; Denyer, L. H.; Jack, D.; Johnson, M.; Lunts, L. H. C.; Nials, A. T.; Sheldrick, K. E.; Skidmore, I. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">665-71</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">Salmeterol, a novel, long-acting β-adrenoceptor agonist, has been compared with isoprenaline and salbutamol for activity in vitro on a range of β-adrenoceptor contg. prepns. from lab. animals and man, and in vivo for bronchodilator activity in the conscious guinea-pig.  The results indicate that salmeterol is a potent and selective β2-adrenoceptor agonist with a remarkably long duration of action in isolated superfused airways smooth muscle.  It also causes persistent bronchodilation in vivo, in the guinea-pig, when administered by the inhaled route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreiLxM-Bl_PLVg90H21EOLACvtfcHk0lgxW_0B3yd56A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsVOrtr4%253D&md5=15b5a132eca52fc209a0724d2e1d52b2</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1991.tb12486.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1991.tb12486.x%26sid%3Dliteratum%253Aachs%26aulast%3DBall%26aufirst%3DD.%2BI.%26aulast%3DBrittain%26aufirst%3DR.%2BT.%26aulast%3DColeman%26aufirst%3DR.%2BA.%26aulast%3DDenyer%26aufirst%3DL.%2BH.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLunts%26aufirst%3DL.%2BH.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DSheldrick%26aufirst%3DK.%2BE.%26aulast%3DSkidmore%26aufirst%3DI.%2BF.%26atitle%3DSalmeterol%252C%2520a%2520novel%252C%2520long-acting%2520beta%25202-adrenoceptor%2520agonist%253A%2520characterization%2520of%2520pharmacological%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1991%26volume%3D104%26spage%3D665%26epage%3D671%26doi%3D10.1111%2Fj.1476-5381.1991.tb12486.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span> <span> </span><span class="NLM_article-title">Beta2-adrenoceptors: mechanisms of action of beta2-agonists</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1053/prrv.2000.0102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1053%2Fprrv.2000.0102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16263481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=57-62&author=M.+Johnson&title=Beta2-adrenoceptors%3A+mechanisms+of+action+of+beta2-agonists&doi=10.1053%2Fprrv.2000.0102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Beta2-adrenoceptors: mechanisms of action of beta2-agonists</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-62</span>
        ISSN:<span class="NLM_cas:issn">1526-0542</span>.
    </div><div class="casAbstract">The human beta2-adrenoceptor is a member of the 7 transmembrane family of receptors.  It is encoded by a gene on chromosome 5 and is widely distributed in the respiratory tract.  Following beta2-adrenoceptor activation, intracellular signalling is mainly produced by inducing cyclic AMP.  This produces airway relaxation through phosphorylation of muscle regulatory proteins and modification of cellular Ca2+concentrations.  Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in asthmatic patients.  Beta-adrenoceptor desensitisation is associated with beta2-agonist activation and differs depending on the cell type.  It is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described which appear to alter the behaviour of the receptor, including the degree of downregulation and response to beta2-agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUowsFMb9kLcvLc4ARHEmzfW6udTcc2eYsjCREP6-Cg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mros1amtg%253D%253D&md5=18b08b6aa45ab53a8bf757299ad12dfe</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1053%2Fprrv.2000.0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fprrv.2000.0102%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DBeta2-adrenoceptors%253A%2520mechanisms%2520of%2520action%2520of%2520beta2-agonists%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2001%26volume%3D2%26spage%3D57%26epage%3D62%26doi%3D10.1053%2Fprrv.2000.0102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.088914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.088914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16051698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=839-848&author=A.+A.+Carterauthor=S.+J.+Hill&title=Characterization+of+isoprenaline-+and+salmeterol-stimulated+interactions+between+beta2-adrenoceptors+and+beta-arrestin+2+using+beta-galactosidase+complementation+in+C2C12+cells&doi=10.1124%2Fjpet.105.088914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of isoprenaline- and salmeterol-stimulated interactions between β2-adrenoceptors and β-arrestin 2 using β-galactosidase complementation in C2C12 cells</span></div><div class="casAuthors">Carter, Alison A.; Hill, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">839-848</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">β-Arrestin is an adaptor protein that has been shown to couple G protein-coupled receptors (GPCRs) to clathrin-coated pits and target them for subsequent internalization.  More recently, β-arrestin 2 has also been shown to be involved in the activation of mitogen-activated protein kinase cascades by G protein-coupled receptors independently of G protein activation.  Direct interactions between proteins can be monitored using enzyme complementation between two inactive deletion mutants of β-galactosidase (β-gal; Δα and Δω).  In the present study, we have used fusion proteins of the human β2-adrenoceptor (C-terminal β-gal Δα) and β-arrestin 2 (β-gal Δω) to study directly the pharmacol. of this interaction in C2C12 cells expressing the β2-adrenoceptor-β-gal Δα fusion protein at low physiol. levels (38.2±2.7 fmol · mg protein-1).  Isoprenaline, noradrenaline, and adrenaline (-log EC50 = 5.9, 5.5, and 5.7, resp.) stimulated an assocn. between the β2-adrenoceptor and β-arrestin 2 at much higher concns. than required for activation of cAMP accumulation (-log EC50 = 7.6, 6.3, and 7.7, resp.).  This was sensitive to inhibition by the β2-adrenoceptor antagonists propranolol, timolol, and ICI 118551.  Both salbutamol and terbutaline behaved as partial agonists of β-gal complementation.  Furthermore, the long-acting β2-agonist salmeterol (-log KD for inhibition of [3H]CGP12177 binding = 8.7) behaved as an antagonist of isoprenaline-stimulated β2-adrenoceptor-arrestin 2 interactions (-log KD = 8.0), whereas acting as a full agonist of cAMP accumulation in the same cells (-log EC50 = 9.2).  These data suggest that salmeterol can discriminate between receptor-Gs protein and receptor-arrestin 2 complexes (in terms of efficacy and affinity) in a way that is favorable for its long duration of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKqVIvFdANF7Vg90H21EOLACvtfcHk0lgUJkRLbAPZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtrzP&md5=2277ec0be759013249d80a32efc3baa8</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.088914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.088914%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DA.%2BA.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26atitle%3DCharacterization%2520of%2520isoprenaline-%2520and%2520salmeterol-stimulated%2520interactions%2520between%2520beta2-adrenoceptors%2520and%2520beta-arrestin%25202%2520using%2520beta-galactosidase%2520complementation%2520in%2520C2C12%2520cells%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D839%26epage%3D848%26doi%3D10.1124%2Fjpet.105.088914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facciolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>745</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2014.10.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.ejphar.2014.10.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25446566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVems7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=745&publication_year=2014&pages=135-143&author=M.+Cazzolaauthor=L.+Calzettaauthor=C.+P.+Pageauthor=P.+Roglianiauthor=F.+Faccioloauthor=A.+Gavald%C3%A0author=M.+G.+Matera&title=Pharmacological+characterization+of+the+interaction+between+aclidinium+bromide+and+formoterol+fumarate+on+human+isolated+bronchi&doi=10.1016%2Fj.ejphar.2014.10.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi</span></div><div class="casAuthors">Cazzola, Mario; Calzetta, Luigino; Page, Clive P.; Rogliani, Paola; Facciolo, Francesco; Gavalda, Amadeu; Matera, Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">745</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenoceptor agonists (LABAs) cause airway smooth muscle (ASM) relaxation via different signal transduction pathways, but there are limited data concerning the interaction between these two drug classes on human bronchi.  The aim of this study was to investigate the potential synergistic interaction between aclidinium bromide and formoterol fumarate on the relaxation of human ASM.  We evaluated the influence of aclidinium bromide and formoterol fumarate on the contractile response induced by acetylcholine or elec. field stimulation (EFS) on human isolated airways (segmental bronchi and bronchioles).  We analyzed the potential synergistic interaction between the compds. when administered in combination by using Bliss independence (BI) theory.  Both aclidinium bromide and formoterol fumarate completely relaxed segmental bronchi pre-contracted with acetylcholine (Emax: 97.5±2.6% and 96.4±1.1%; pEC50 8.5±0.1 and 8.8±0.1; resp.).  Formoterol fumarate, but not aclidinium bromide, abolished the contraction induced by acetylcholine in bronchioles (Emax: 68.1±4.5% and 99.0±5.6%; pEC50 7.9±0.3 and 8.4±0.3; resp.).  The BI anal. indicated synergistic interaction at low concns. in segmental bronchi (+18.4±2.7%; P<0.05 vs. expected effect) and from low to high concns. in bronchioles (+19.7±0.9%; P<0.05 vs. expected effect).  Low concns. of both drugs produced a synergistic relaxant interaction on isolated bronchi stimulated with EFS that was sustained for 6 h post-treatment (+55.1±9.4%; P<0.05 vs. expected effect).  These results suggest that combining aclidinium bromide plus formoterol fumarate provides synergistic benefit on ASM relaxation of both medium and small human airways, which may have major implications for the use of this combination in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Rc3myVw7grVg90H21EOLACvtfcHk0lgUJkRLbAPZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVems7fP&md5=9502fcec7e9db43321db554ede010227</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2014.10.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2014.10.025%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DPage%26aufirst%3DC.%2BP.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DFacciolo%26aufirst%3DF.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DPharmacological%2520characterization%2520of%2520the%2520interaction%2520between%2520aclidinium%2520bromide%2520and%2520formoterol%2520fumarate%2520on%2520human%2520isolated%2520bronchi%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D745%26spage%3D135%26epage%3D143%26doi%3D10.1016%2Fj.ejphar.2014.10.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span> <span> </span><span class="NLM_article-title">New beta-adrenoreceptor stimulants. Studies on 3-acylamino-4-hydroxy-alpha-(<i>N</i>-substitutedaminomethyl)benzyl alcohols</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1368</span>– <span class="NLM_lpage">1377</span>, <span class="refDoi"> DOI: 10.1248/cpb.25.1368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1248%2Fcpb.25.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaE2sXlsFWku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1977&pages=1368-1377&author=K.+Muraseauthor=T.+Maseauthor=H.+Idaauthor=K.+Takahashiauthor=M.+Murakami&title=New+beta-adrenoreceptor+stimulants.+Studies+on+3-acylamino-4-hydroxy-alpha-%28N-substitutedaminomethyl%29benzyl+alcohols&doi=10.1248%2Fcpb.25.1368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">New β-adrenoreceptor stimulants.  Studies on 3-acylamino-4-hydroxy-α-(N-substituted aminomethyl)benzyl alcohols</span></div><div class="casAuthors">Murase, Kiyoshi; Mase, Toshiyasu; Ida, Hisashi; Takahashi, Kozo; Murakami, Masuo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1368-77</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">The 2-bromoacetophenone I was converted to eighteen α-(aminomethyl)benzyl alcs. II (R = H, Me, substituted methyl; R1 = CHMe2, CMe3, substituted phenethyl, substituted 3-phenylpropyl, substituted 3-cyclohexylpropyl), which showed bronchodilator activity.  Thus, I was treated with benzylamines, reduced (NaBH4), reduced (Fe-HCl), N-acylated, and deprotected to yield the II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9MdnjCjnJDbVg90H21EOLACvtfcHk0lgUJkRLbAPZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXlsFWku7Y%253D&md5=f2290871cf292be610caf2f01486c1b3</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1248%2Fcpb.25.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.25.1368%26sid%3Dliteratum%253Aachs%26aulast%3DMurase%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DM.%26atitle%3DNew%2520beta-adrenoreceptor%2520stimulants.%2520Studies%2520on%25203-acylamino-4-hydroxy-alpha-%2528N-substitutedaminomethyl%2529benzyl%2520alcohols%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1977%26volume%3D25%26spage%3D1368%26epage%3D1377%26doi%3D10.1248%2Fcpb.25.1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murase, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mase, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, M.</span></span> <span> </span><span class="NLM_article-title">Absolute configurations of four isomers of 3-formamido-4-hydroxy-α-[[<i>N</i>-(<i>p</i>-methoxy-α-methylphenethyl)amino]methyl]benzyl alcohol, a potent β-adrenoreceptor stimulant</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1248/cpb.26.1123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1248%2Fcpb.26.1123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaE1cXltVOku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1978&pages=1123-1129&author=K.+Muraseauthor=T.+Maseauthor=H.+Idaauthor=K.+Takahashiauthor=M.+Murakami&title=Absolute+configurations+of+four+isomers+of+3-formamido-4-hydroxy-%CE%B1-%5B%5BN-%28p-methoxy-%CE%B1-methylphenethyl%29amino%5Dmethyl%5Dbenzyl+alcohol%2C+a+potent+%CE%B2-adrenoreceptor+stimulant&doi=10.1248%2Fcpb.26.1123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Absolute configurations of four isomers of 3-formamido-4-hydroxy-α-[[N-(p-methoxy-α-methylphenethyl)amino]methyl]benzyl alcohol, a potent β-adrenoreceptor stimulant</span></div><div class="casAuthors">Murase, Kiyoshi; Mase, Toshiyasu; Ida, Hisashi; Takahashi, Kozo; Murakami, Masuo</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1123-9</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    </div><div class="casAbstract">The configuration of 2 pairs of enantiomers of 3-formamido-4-hydroxy-α-[[N-(p-methoxy-α-methylphenethyl)amino]methyl]benzyl alc. were detd. by chem. correlation with those of N-(p-hydroxy-α-methylphenethyl)amine, whose configuration is known.  The bronchodilator activity of these compds. was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoViKC9EXgFM7Vg90H21EOLACvtfcHk0lgUJkRLbAPZ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXltVOku7g%253D&md5=992c7ed48a46f4772bfb93fa641e03f2</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1248%2Fcpb.26.1123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.26.1123%26sid%3Dliteratum%253Aachs%26aulast%3DMurase%26aufirst%3DK.%26aulast%3DMase%26aufirst%3DT.%26aulast%3DIda%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DM.%26atitle%3DAbsolute%2520configurations%2520of%2520four%2520isomers%2520of%25203-formamido-4-hydroxy-%25CE%25B1-%255B%255BN-%2528p-methoxy-%25CE%25B1-methylphenethyl%2529amino%255Dmethyl%255Dbenzyl%2520alcohol%252C%2520a%2520potent%2520%25CE%25B2-adrenoreceptor%2520stimulant%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1978%26volume%3D26%26spage%3D1123%26epage%3D1129%26doi%3D10.1248%2Fcpb.26.1123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baur, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuenoud, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fozard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeuillet-Ritzler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedaldi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trifilieff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss, D.</span></span> <span> </span><span class="NLM_article-title">The Identification of indacaterol as an ultra-long-acting inhaled β<sub>2</sub>-adrenoceptor agonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3684</span>, <span class="refDoi"> DOI: 10.1021/jm100068m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100068m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3675-3684&author=F.+Baurauthor=D.+Beattieauthor=D.+Beerauthor=D.+Bentleyauthor=M.+Bradleyauthor=I.+Bruceauthor=S.+J.+Charltonauthor=B.+Cuenoudauthor=R.+Ernstauthor=R.+A.+Fairhurstauthor=B.+Fallerauthor=D.+Farrauthor=T.+Kellerauthor=J.+R.+Fozardauthor=J.+Fullertonauthor=S.+Garmanauthor=J.+Hattoauthor=C.+Haydenauthor=H.+Heauthor=C.+Howesauthor=D.+Janusauthor=Z.+Jiangauthor=C.+Lewisauthor=F.+Loeuillet-Ritzlerauthor=H.+Moserauthor=J.+Reillyauthor=A.+Stewardauthor=D.+Sykesauthor=L.+Tedaldiauthor=A.+Trifilieffauthor=M.+Tweedauthor=S.+Watsonauthor=E.+Wisslerauthor=D.+Wyss&title=The+Identification+of+indacaterol+as+an+ultra-long-acting+inhaled+%CE%B22-adrenoceptor+agonist&doi=10.1021%2Fjm100068m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist</span></div><div class="casAuthors">Baur, Francois; Beattie, David; Beer, David; Bentley, David; Bradley, Michelle; Bruce, Ian; Charlton, Steven J.; Cuenoud, Bernard; Ernst, Roland; Fairhurst, Robin A.; Faller, Bernard; Farr, David; Keller, Thomas; Fozard, John R.; Fullerton, Joe; Garman, Sheila; Hatto, Julia; Hayden, Claire; He, Handan; Howes, Colin; Janus, Diana; Jiang, Zhengjin; Lewis, Christine; Loeuillet-Ritzler, Frederique; Moser, Heinz; Reilly, John; Steward, Alan; Sykes, David; Tedaldi, Lauren; Trifilieff, Alexandre; Tweed, Morris; Watson, Simon; Wissler, Elke; Wyss, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3675-3684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Following a lipophilicity-based hypothesis, an 8-hydroxyquinolinone 2-aminoindan derived series of β2-adrenoceptor agonists have been prepd. and evaluated for their potential as inhaled ultralong-acting bronchodilators.  Detn. of their activities at the human β2-adrenoceptor receptor showed sym. substitution of the 2-aminoindan moiety at the 5- and 6-positions delivered the targeted intermediate potency and intrinsic-efficacy profiles relative to a series of clin. ref. β2-adrenoceptor agonists.  Further assessment with an in vitro superfused elec. stimulated guinea-pig tracheal-strip assay established the onset and duration of action time courses, which could be rationalized by considering the lipophilicity, potency, and intrinsic efficacy of the compds.  From these studies the 5,6-diethylindan analog indacaterol was shown to possess a unique profile of combining a rapid onset of action with a long duration of action.  Further in vivo profiling of indacaterol supported the long duration of action and a wide therapeutic index following administration to the lung, which led to the compd. being selected as a development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDXzKlPrfGY7Vg90H21EOLACvtfcHk0lgFxe4sqrrwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtbs%253D&md5=3aadd254472ad850897fe8a8b7297bab</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm100068m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100068m%26sid%3Dliteratum%253Aachs%26aulast%3DBaur%26aufirst%3DF.%26aulast%3DBeattie%26aufirst%3DD.%26aulast%3DBeer%26aufirst%3DD.%26aulast%3DBentley%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCuenoud%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DR.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DFarr%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DT.%26aulast%3DFozard%26aufirst%3DJ.%2BR.%26aulast%3DFullerton%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DHatto%26aufirst%3DJ.%26aulast%3DHayden%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DHowes%26aufirst%3DC.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DLoeuillet-Ritzler%26aufirst%3DF.%26aulast%3DMoser%26aufirst%3DH.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSteward%26aufirst%3DA.%26aulast%3DSykes%26aufirst%3DD.%26aulast%3DTedaldi%26aufirst%3DL.%26aulast%3DTrifilieff%26aufirst%3DA.%26aulast%3DTweed%26aufirst%3DM.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DWissler%26aufirst%3DE.%26aulast%3DWyss%26aufirst%3DD.%26atitle%3DThe%2520Identification%2520of%2520indacaterol%2520as%2520an%2520ultra-long-acting%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3675%26epage%3D3684%26doi%3D10.1021%2Fjm100068m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gontovnick, L.</span></span> <span> </span><span class="NLM_article-title">Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1164/ajrccm/142.5.1147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm%2F142.5.1147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1978619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK3MXnsV2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=1990&pages=1147-1152&author=J.+L.+Maloauthor=A.+Cartierauthor=C.+Trudeauauthor=H.+Ghezzoauthor=L.+Gontovnick&title=Formoterol%2C+a+new+inhaled+beta-2+adrenergic+agonist%2C+has+a+longer+blocking+effect+than+albuterol+on+hyperventilation-induced+bronchoconstriction&doi=10.1164%2Fajrccm%2F142.5.1147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Formoterol, a new inhaled beta-2 adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction</span></div><div class="casAuthors">Malo, Jean Luc; Cartier, Andre; Trudeau, Carole; Ghezzo, Heberto; Gontovnick, Larry</div><div class="citationInfo"><span class="NLM_cas:title">American Review of Respiratory Disease</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-52</span>CODEN:
                <span class="NLM_cas:coden">ARDSBL</span>;
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">The duration of effect of inhaled formoterol (24 μg) was compared with that of a placebo and that of inhaled albuterol (200 μg) in 12 adult asthmatic subjects who underwent hyperventilation tests with cold dry air (-20 °) on 4 study days.  On the control day, they were subjected to four hyperventilation tests to ensure functional stability.  On the 3 remaining days, after a first hyperventilation test, they inhaled placebo, albuterol, or formoterol in randomized, double-blind fashion.  The hyperventilation test was repeated 1, 4, and 8 h and, if the blocking effect was still present, 12 and 24 h after the drug had been administered.  The dose of hyperventilation of cold air causing a 20% fall in FEV1 (PD20) was interpolated on the dose-response curve.  The magnitude of the blocking effect at each time interval on each study day was assessed by comparing the changes in PD20 from baseline with the within-day variability of PD20 (standardized change in PD20).  The acute bronchodilator effect was not significantly different as assessed 15 min (21% for albuterol and 18% for formoterol) and 1 h (20% for albuterol and 18% for formoterol) after administering the medication.  The duration of the blocking effect was more prolonged for formoterol (8.0 h) than for albuterol (3.0 h).  Two subjects still demonstrated the presence of a blocking effect 4 h after inhaling albuterol, whereas 11 subjects did after formoterol.  After 12 h, three subjects still demonstrated the presence of a blocking effect after inhaled formoterol.  Apparently, the protection against bronchoconstriction induced by hyperventilation of unconditioned air in asthmatic subjects is significantly more prolonged after formoterol than after albuterol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnEMo0rc9vqrVg90H21EOLACvtfcHk0lgFxe4sqrrwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXnsV2qtA%253D%253D&md5=c7ef2c88f10744f193f6f5c3852e2df4</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1164%2Fajrccm%2F142.5.1147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm%252F142.5.1147%26sid%3Dliteratum%253Aachs%26aulast%3DMalo%26aufirst%3DJ.%2BL.%26aulast%3DCartier%26aufirst%3DA.%26aulast%3DTrudeau%26aufirst%3DC.%26aulast%3DGhezzo%26aufirst%3DH.%26aulast%3DGontovnick%26aufirst%3DL.%26atitle%3DFormoterol%252C%2520a%2520new%2520inhaled%2520beta-2%2520adrenergic%2520agonist%252C%2520has%2520a%2520longer%2520blocking%2520effect%2520than%2520albuterol%2520on%2520hyperventilation-induced%2520bronchoconstriction%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1990%26volume%3D142%26spage%3D1147%26epage%3D1152%26doi%3D10.1164%2Fajrccm%2F142.5.1147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub>-adrenoceptor agonists: current and future direction</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01216.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1476-5381.2011.01216.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21232045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=4-17&author=M.+Cazzolaauthor=L.+Calzettaauthor=M.+G.+Matera&title=%CE%B22-adrenoceptor+agonists%3A+current+and+future+direction&doi=10.1111%2Fj.1476-5381.2011.01216.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">β2-adrenoceptor agonists: current and future direction</span></div><div class="casAuthors">Cazzola, Mario; Calzetta, Luigino; Matera, Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4-17</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Despite the passionate debate over the use of β2-adrenoceptor agonists in the treatment of airway disorders, these agents are still central in the symptomatic management of asthma and COPD.  A variety of β2-adrenoceptor agonists with long half-lives, also called ultra long-acting β2-adrenoceptor agonists (ultra-LABAs; indacaterol, olodaterol, vilanterol, carmoterol, LAS100977 and PF-610355) are currently under development with the hopes of achieving once-daily dosing.  It is likely that the once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clin. outcomes.  As combination therapy with an inhaled corticosteroid (ICS) and a LABA is important for treating patients suffering from asthma, and a combination with an inhaled long-acting antimuscarinic agent (LAMA) is important for treating COPD patients whose conditions are not sufficiently controlled by monotherapy with a β2-adrenoceptor agonist, some novel once-daily combinations of LABAs and ICSs or LAMAs are under development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-1Esjz92QG7Vg90H21EOLACvtfcHk0lhyNvvTs507iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Gjt7Y%253D&md5=670b1493bcf250c56425e50732b00c33</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01216.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01216.x%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3D%25CE%25B22-adrenoceptor%2520agonists%253A%2520current%2520and%2520future%2520direction%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D4%26epage%3D17%26doi%3D10.1111%2Fj.1476-5381.2011.01216.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoenke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouyssou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konetzki, I.</span></span> <span> </span><span class="NLM_article-title">Use of 5-hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-ones as β<sub>2</sub>-adrenoceptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6640</span>– <span class="NLM_lpage">6644</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19875286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6640-6644&author=C.+Hoenkeauthor=T.+Bouyssouauthor=C.+S.+Tautermannauthor=K.+Rudolfauthor=A.+Schnappauthor=I.+Konetzki&title=Use+of+5-hydroxy-4H-benzo%5B1%2C4%5Doxazin-3-ones+as+%CE%B22-adrenoceptor+agonists&doi=10.1016%2Fj.bmcl.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists</span></div><div class="casAuthors">Hoenke, Christoph; Bouyssou, Thierry; Tautermann, Christofer S.; Rudolf, Klaus; Schnapp, Andreas; Konetzki, Ingo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6640-6644</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novel β2-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described.  Systematic chem. variations at the phenethylamine residue of these compds. lead to the discovery of compd. 6m as potent, full agonist of the β2-adrenoceptor with a high β1/β2-selectivity.  Mol. modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the β2-receptor as putative explanation for the high obsd. selectivity.  Further, compd. 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzC12KHZPa17Vg90H21EOLACvtfcHk0lhyNvvTs507iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLbJ&md5=0d7f9187ea8842e3986cf7e67ce05696</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DUse%2520of%25205-hydroxy-4H-benzo%255B1%252C4%255Doxazin-3-ones%2520as%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6640%26epage%3D6644%26doi%3D10.1016%2Fj.bmcl.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouyssou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustenberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pestel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Büttner, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konetzki, I.</span></span> <span> </span><span class="NLM_article-title">Discovery of olodaterol, a novel inhaled β<sub>2</sub>-adrenoceptor agonist with a 24 h bronchodilatory efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1410</span>– <span class="NLM_lpage">1414</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2009.12.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20096576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1410-1414&author=T.+Bouyssouauthor=C.+Hoenkeauthor=K.+Rudolfauthor=P.+Lustenbergerauthor=S.+Pestelauthor=P.+Siegerauthor=R.+Lotzauthor=C.+Heineauthor=F.+H.+B%C3%BCttnerauthor=A.+Schnappauthor=I.+Konetzki&title=Discovery+of+olodaterol%2C+a+novel+inhaled+%CE%B22-adrenoceptor+agonist+with+a+24+h+bronchodilatory+efficacy&doi=10.1016%2Fj.bmcl.2009.12.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy</span></div><div class="casAuthors">Bouyssou, Thierry; Hoenke, Christoph; Rudolf, Klaus; Lustenberger, Philipp; Pestel, Sabine; Sieger, Peter; Lotz, Ralf; Heine, Claudia; Buettner, Frank H.; Schnapp, Andreas; Konetzki, Ingo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1410-1414</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Compd. 4p (I) was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human β2-adrenoceptor with a high β1/β2-selectivity.  A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection.  The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects.  Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h.  In summary, the preclin. profile of compd. (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq_OHb0Lpw87Vg90H21EOLACvtfcHk0lhyNvvTs507iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSmt7c%253D&md5=4527e1e074c1ee33eccc2d9f3293bdef</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DBouyssou%26aufirst%3DT.%26aulast%3DHoenke%26aufirst%3DC.%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DLustenberger%26aufirst%3DP.%26aulast%3DPestel%26aufirst%3DS.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DC.%26aulast%3DB%25C3%25BCttner%26aufirst%3DF.%2BH.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26atitle%3DDiscovery%2520of%2520olodaterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B22-adrenoceptor%2520agonist%2520with%2520a%252024%2520h%2520bronchodilatory%2520efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1410%26epage%3D1414%26doi%3D10.1016%2Fj.bmcl.2009.12.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggadike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchers, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsley, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li-Kwai-Cheung, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLay, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlin, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4522</span>– <span class="NLM_lpage">4530</span>, <span class="refDoi"> DOI: 10.1021/jm100326d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100326d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFKqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4522-4530&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+C.+Boxauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=A.+Emmonsauthor=A.+J.+Fordauthor=D.+S.+Holmesauthor=H.+Horsleyauthor=F.+Kerrauthor=A.+M.+Li-Kwai-Cheungauthor=B.+E.+Lookerauthor=I.+S.+Mannauthor=I.+M.+McLayauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=C.+E.+Smithauthor=P.+Tomlin&title=Synthesis+and+structure-activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+metabolic+inactivation%3A+an+antedrug+approach&doi=10.1021%2Fjm100326d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, Victoria J.; Bevan, Nicola J.; Biggadike, Keith; Box, Philip C.; Butchers, Peter R.; Coe, Diane M.; Conroy, Richard; Emmons, Amanda; Ford, Alison J.; Holmes, Duncan S.; Horsley, Helen; Kerr, Fern; Li-Kwai-Cheung, Anne-Marie; Looker, Brian E.; Mann, Inderjit S.; McLay, Iain M.; Morrison, Valerie S.; Mutch, Peter J.; Smith, Claire E.; Tomlin, Paula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4522-4530</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of saligenin β2 adrenoceptor agonist antedrugs having high clearance were prepd. by reacting a protected saligenin oxazolidinone with protected hydroxyethoxyalkoxyalkyl bromides, followed by removal of the hydroxy-protecting group, alkylation, and final deprotection.  The compds. were screened for β2, β1, and β3 agonist activity in CHO cells.  The onset and duration of action in vitro of selected compds. were assessed on isolated superfused guinea pig trachea.  I had high potency, selectivity, fast onset, and long duration of action in vitro and was found to have long duration in vivo, low oral bioavailability in the rat, and to be rapidly metabolized.  Cryst. salts of I (vilanterol) were identified that had suitable properties for inhaled administration.  A proposed binding mode for I to the β2-receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSi1eD2OieFbVg90H21EOLACvtfcHk0lhS_Xhv-AFk5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFKqt7o%253D&md5=3b59a1fdaba51d1688c14a3da96b4b4d</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fjm100326d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100326d%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DBox%26aufirst%3DP.%2BC.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEmmons%26aufirst%3DA.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DHolmes%26aufirst%3DD.%2BS.%26aulast%3DHorsley%26aufirst%3DH.%26aulast%3DKerr%26aufirst%3DF.%26aulast%3DLi-Kwai-Cheung%26aufirst%3DA.%2BM.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMann%26aufirst%3DI.%2BS.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26aulast%3DTomlin%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520metabolic%2520inactivation%253A%2520an%2520antedrug%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4522%26epage%3D4530%26doi%3D10.1021%2Fjm100326d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casarosa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devree, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thian, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konetzki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pautsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure of a nanobody-stabilized active state of the β<sub>2</sub> adrenoceptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1038/nature09648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature09648" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21228869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=175-180&author=S.+G.+Rasmussenauthor=H.+J.+Choiauthor=J.+J.+Fungauthor=E.+Pardonauthor=P.+Casarosaauthor=P.+S.+Chaeauthor=B.+T.+Devreeauthor=D.+M.+Rosenbaumauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=A.+Schnappauthor=I.+Konetzkiauthor=R.+K.+Sunaharaauthor=S.+H.+Gellmanauthor=A.+Pautschauthor=J.+Steyaertauthor=W.+I.+Weisauthor=B.+K.+Kobilka&title=Structure+of+a+nanobody-stabilized+active+state+of+the+%CE%B22+adrenoceptor&doi=10.1038%2Fnature09648"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a nanobody-stabilized active state of the β2 adrenoceptor</span></div><div class="casAuthors">Rasmussen, Soren G. F.; Choi, Hee-Jung; Fung, Juan Jose; Pardon, Els; Casarosa, Paola; Chae, Pil Seok; DeVree, Brian T.; Rosenbaum, Daniel M.; Thian, Foon Sun; Kobilka, Tong Sun; Schnapp, Andreas; Konetzki, Ingo; Sunahara, Roger K.; Gellman, Samuel H.; Pautsch, Alexander; Steyaert, Jan; Weis, William I.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7329</span>),
    <span class="NLM_cas:pages">175-180</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein coupled receptors (GPCRs) exhibit a spectrum of functional behaviors in response to natural and synthetic ligands.  Recent crystal structures provide insights into inactive states of several GPCRs.  Efforts to obtain an agonist-bound active-state GPCR structure have proven difficult due to the inherent instability of this state in the absence of a G protein.  We generated a camelid antibody fragment (nanobody) to the human β2 adrenergic receptor (β2AR) that exhibits G protein-like behavior, and obtained an agonist-bound, active-state crystal structure of the receptor-nanobody complex.  Comparison with the inactive β2AR structure reveals subtle changes in the binding pocket; however, these small changes are assocd. with an 11 Å outward movement of the cytoplasmic end of transmembrane segment 6, and rearrangements of transmembrane segments 5 and 7 that are remarkably similar to those obsd. in opsin, an active form of rhodopsin.  This structure provides insights into the process of agonist binding and activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqITZxHz6Vi77Vg90H21EOLACvtfcHk0lhS_Xhv-AFk5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvFartA%253D%253D&md5=3a1d3bac6d92c9d54cf1ddd14d56ab8c</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fnature09648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09648%26sid%3Dliteratum%253Aachs%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DFung%26aufirst%3DJ.%2BJ.%26aulast%3DPardon%26aufirst%3DE.%26aulast%3DCasarosa%26aufirst%3DP.%26aulast%3DChae%26aufirst%3DP.%2BS.%26aulast%3DDevree%26aufirst%3DB.%2BT.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DSchnapp%26aufirst%3DA.%26aulast%3DKonetzki%26aufirst%3DI.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DGellman%26aufirst%3DS.%2BH.%26aulast%3DPautsch%26aufirst%3DA.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructure%2520of%2520a%2520nanobody-stabilized%2520active%2520state%2520of%2520the%2520%25CE%25B22%2520adrenoceptor%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D175%26epage%3D180%26doi%3D10.1038%2Fnature09648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westfield, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripathi-Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oleskie, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dosey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klink, B. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidhu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penczek, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossiakoff, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, V. L.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiniotis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Visualization of arrestin recruitment by a G-protein-coupled receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1038/nature13430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature13430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25043026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGntb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2014&pages=218-222&author=A.+Shuklaauthor=G.+Westfieldauthor=K.+Xiaoauthor=R.+I.+Reisauthor=L.+Y.+Huangauthor=P.+Tripathi-Shuklaauthor=J.+Qianauthor=S.+Liauthor=A.+Blancauthor=A.+N.+Oleskieauthor=A.+M.+Doseyauthor=M.+Suauthor=C.+R.+Liangauthor=L.+L.+Guauthor=J.+M.+Shanauthor=X.+Chenauthor=R.+Hannaauthor=M.+Choiauthor=X.+J.+Yaoauthor=B.+U.+Klinkauthor=A.+W.+Kahsaiauthor=S.+S.+Sidhuauthor=S.+Koideauthor=P.+A.+Penczekauthor=A.+A.+Kossiakoffauthor=V.+L.+Woodsauthor=B.+K.+Kobilkaauthor=G.+Skiniotisauthor=R.+J.+Lefkowitz&title=Visualization+of+arrestin+recruitment+by+a+G-protein-coupled+receptor&doi=10.1038%2Fnature13430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Visualization of arrestin recruitment by a G-protein-coupled receptor</span></div><div class="casAuthors">Shukla, Arun K.; Westfield, Gerwin H.; Xiao, Kunhong; Reis, Rosana I.; Huang, Li-Yin; Tripathi-Shukla, Prachi; Qian, Jiang; Li, Sheng; Blanc, Adi; Oleskie, Austin N.; Dosey, Anne M.; Su, Min; Liang, Cui-Rong; Gu, Ling-Ling; Shan, Jin-Ming; Chen, Xin; Hanna, Rachel; Choi, Minjung; Yao, Xiao Jie; Klink, Bjoern U.; Kahsai, Alem W.; Sidhu, Sachdev S.; Koide, Shohei; Penczek, Pawel A.; Kossiakoff, Anthony A.; Woods Jr, Virgil L.; Kobilka, Brian K.; Skiniotis, Georgios; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">7513</span>),
    <span class="NLM_cas:pages">218-222</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) are critically regulated by β-arrestins, which not only desensitize G-protein signaling but also initiate a G-protein-independent wave of signaling.  A recent surge of structural data on a no. of GPCRs, including the β2 adrenergic receptor (β2AR)-G-protein complex, has provided novel insights into the structural basis of receptor activation.  However, complementary information has been lacking on the recruitment of β-arrestins to activated GPCRs, primarily owing to challenges in obtaining stable receptor-β-arrestin complexes for structural studies.  Here the authors devised a strategy for forming and purifying a functional human β2AR-β-arrestin-1 complex that allowed the authors to visualize its architecture by single-particle neg.-stain electron microscopy and to characterize the interactions between β2AR and β-arrestin 1 using hydrogen-deuterium exchange mass spectrometry (HDX-MS) and chem. crosslinking.  Electron microscopy two-dimensional avs. and three-dimensional reconstructions reveal bimodal binding of β-arrestin 1 to the β2AR, involving two sep. sets of interactions, one with the phosphorylated C-terminus of the receptor and the other with its seven-transmembrane core.  Areas of reduced HDX together with identification of crosslinked residues suggest engagement of the finger loop of β-arrestin 1 with the seven-transmembrane core of the receptor.  In contrast, focal areas of raised HDX levels indicate regions of increased dynamics in both the N and C domains of β-arrestin 1 when coupled to the β2AR.  A mol. model of the β2AR-β-arrestin signaling complex was made by docking activated β-arrestin 1 and β2AR crystal structures into the electron microscopy map densities with constraints provided by HDX-MS and crosslinking, allowing the authors to obtain valuable insights into the overall architecture of a receptor-arrestin complex.  The dynamic and structural information presented here provides a framework for better understanding the basis of GPCR regulation by arrestins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGW0zJyKs9qbVg90H21EOLACvtfcHk0ljp0qUq1KjkIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGntb%252FO&md5=c88e93c104ccb4ed30a1687cd9a54aca</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fnature13430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13430%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DA.%26aulast%3DWestfield%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DK.%26aulast%3DReis%26aufirst%3DR.%2BI.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DTripathi-Shukla%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DBlanc%26aufirst%3DA.%26aulast%3DOleskie%26aufirst%3DA.%2BN.%26aulast%3DDosey%26aufirst%3DA.%2BM.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DC.%2BR.%26aulast%3DGu%26aufirst%3DL.%2BL.%26aulast%3DShan%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHanna%26aufirst%3DR.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DX.%2BJ.%26aulast%3DKlink%26aufirst%3DB.%2BU.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DSidhu%26aufirst%3DS.%2BS.%26aulast%3DKoide%26aufirst%3DS.%26aulast%3DPenczek%26aufirst%3DP.%2BA.%26aulast%3DKossiakoff%26aufirst%3DA.%2BA.%26aulast%3DWoods%26aufirst%3DV.%2BL.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DSkiniotis%26aufirst%3DG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DVisualization%2520of%2520arrestin%2520recruitment%2520by%2520a%2520G-protein-coupled%2520receptor%26jtitle%3DNature%26date%3D2014%26volume%3D512%26spage%3D218%26epage%3D222%26doi%3D10.1038%2Fnature13430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">House, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovato, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a new intravenous β<sub>2</sub>-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1268</span>– <span class="NLM_lpage">1273</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2015.08.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2015.08.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26324315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC287nvFGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2015&pages=1268-1273&author=S.+L.+Houseauthor=K.+Matsudaauthor=G.+O%E2%80%99Brienauthor=M.+Makhayauthor=Y.+Iwakiauthor=I.+Fergusonauthor=L.+M.+Lovatoauthor=L.+M.+Lewis&title=Efficacy+of+a+new+intravenous+%CE%B22-adrenergic+agonist+%28bedoradrine%2C+MN-221%29+for+patients+with+an+acute+exacerbation+of+asthma&doi=10.1016%2Fj.rmed.2015.08.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma</span></div><div class="casAuthors">House Stacey L; Matsuda Kazuko; O'Brien Geoffrey; Makhay Malath; Iwaki Yuichi; Ferguson Ian; Lewis Lawrence M; Lovato Luis M</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1268-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Many patients with acute exacerbation of asthma are non-responders to inhaled β-adrenergic agonists.  The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy.  METHODS:  Patients (N = 167) received standard therapy and were randomized to either bedoradrine (1200 μg) or placebo.  Safety and efficacy parameters were monitored hourly for 3 h, followed by a 24-h follow-up visit and an 8-day follow-up phone call.  Change in %FEV1 from baseline to Hour 3 was the primary outcome.  Secondary outcome measures included change in %FEV1 at 1 and 2 h, change in dyspnea score at 1, 2, and 3 h, treatment failure rate, defined as a combination of hospitalization on the index visit or return to the emergency department within 1 week, and safety monitoring.  RESULTS:  There was no significant difference in %FEV1 at 3 h between the 2 groups.  The dyspnea scores were significantly improved for patients treated with bedoradrine compared to placebo (AUC0-2 hP < 0.005, AUC0-3 hP < 0.05).  The safety profile for those treated with bedoradrine was consistent with the known mechanism of action of β-adrenergic agonists, and included both cardiovascular and metabolic effects.  CONCLUSIONS:  Intravenous bedoradrine, in addition to standard therapy, did not significantly increase %FEV1 at 3 h, but it was associated with significantly improved dyspnea scores.  TRIAL REGISTRATION:  Clinicaltrials.gov; study name: MN-221-CL-007, registration number: NCT00838591; www.clinical trials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjVe9fFhSfDxKDYG3bNImrfW6udTcc2eYX5BqXXP0jO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nvFGhtQ%253D%253D&md5=a4c830e39b04b3997888c24ce7932f9d</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2015.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2015.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DHouse%26aufirst%3DS.%2BL.%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DG.%26aulast%3DMakhay%26aufirst%3DM.%26aulast%3DIwaki%26aufirst%3DY.%26aulast%3DFerguson%26aufirst%3DI.%26aulast%3DLovato%26aufirst%3DL.%2BM.%26aulast%3DLewis%26aufirst%3DL.%2BM.%26atitle%3DEfficacy%2520of%2520a%2520new%2520intravenous%2520%25CE%25B22-adrenergic%2520agonist%2520%2528bedoradrine%252C%2520MN-221%2529%2520for%2520patients%2520with%2520an%2520acute%2520exacerbation%2520of%2520asthma%26jtitle%3DRespir.%2520Med.%26date%3D2015%26volume%3D109%26spage%3D1268%26epage%3D1273%26doi%3D10.1016%2Fj.rmed.2015.08.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawarabayashi, T.</span></span> <span> </span><span class="NLM_article-title">Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant</span>. <i>J. Obstet. Gynaecol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1111/j.1447-0756.2008.01001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1447-0756.2008.01001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19527375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslOlsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=405-413&author=Y.+Inoueauthor=T.+Yoshizatoauthor=T.+Kawarabayashi&title=Investigation+of+beta%282%29-adrenoceptor+subtype+selectivity+and+organ+specificity+for+bedoradrine+%28KUR-1246%29%2C+a+novel+tocolytic+beta-adrenergic+receptor+stimulant&doi=10.1111%2Fj.1447-0756.2008.01001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of β2-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant</span></div><div class="casAuthors">Inoue, Yoshihito; Yoshizato, Toshiyuki; Kawarabayashi, Tatsuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Obstetrics and Gynaecology Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">JOGRFD</span>;
        ISSN:<span class="NLM_cas:issn">1341-8076</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the beta-adrenergic receptor (β-AR) selectivity, organ specificity and efficacy of delaying the onset of spontaneous delivery of bedoradrine (KUR-1246), a novel uterine relaxant.  β-AR selectivity was evaluated in terms of the amt. of cyclic adenosine monophosphate produced by bedoradrine, ritodrine and isoprenaline in Chinese hamster ovary cells expressing human β1-, β2-AR or β3-AR.  Inhibition of contractions of the atrium, trachea and proximal colon by bedoradrine were compared with those of the uterus in pregnant rats using an organ bath method.  Finally, the delaying effect of bedoradrine on spontaneous labor was evaluated by an in vivo study using term pregnant rats.  EC50 values of bedoradrine for cyclic adenosine monophosphate prodn. in Chinese hamster ovary cells via β1-, β2- and β3-AR were 2400 ± 30, 2.9 ± 0.10 and 363 ± 3 nmol/L, resp., indicating that bedoradrine had 832- and 126-fold higher selectivity for β2-AR than for β1- and β3-AR.  EC50 values of bedoradrine for the uterus, atrium, trachea and proximal colon were 1.01 ± 0.27, 2300 ± 356, 1610 ± 299 and 219 ± 23.5 nmol/L, resp.  Thus, bedoradrine was 2280-, 1590- and 217-fold more specific for the uterus than for the atrium, trachea and proximal colon, resp.  Bedoradrine delayed the spontaneous delivery of 21-day-pregnant rats in a dose-dependent manner.  Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice because it has better selectivity for β2-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqVMqHhJGTjLVg90H21EOLACvtfcHk0ljp0qUq1KjkIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslOlsbY%253D&md5=409d9853d2ce96be232af88d5f2bcc94</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1111%2Fj.1447-0756.2008.01001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1447-0756.2008.01001.x%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DYoshizato%26aufirst%3DT.%26aulast%3DKawarabayashi%26aufirst%3DT.%26atitle%3DInvestigation%2520of%2520beta%25282%2529-adrenoceptor%2520subtype%2520selectivity%2520and%2520organ%2520specificity%2520for%2520bedoradrine%2520%2528KUR-1246%2529%252C%2520a%2520novel%2520tocolytic%2520beta-adrenergic%2520receptor%2520stimulant%26jtitle%3DJ.%2520Obstet.%2520Gynaecol.%2520Res.%26date%3D2009%26volume%3D35%26spage%3D405%26epage%3D413%26doi%3D10.1111%2Fj.1447-0756.2008.01001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwaki, Y.</span></span> <span> </span><span class="NLM_article-title">Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion</span>. <i>J. Asthma</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1071</span>– <span class="NLM_lpage">1078</span>, <span class="refDoi"> DOI: 10.3109/02770903.2012.729631</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3109%2F02770903.2012.729631" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23094708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FnvVWhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=1071-1078&author=K.+Matsudaauthor=M.+Makhayauthor=K.+Johnsonauthor=Y.+Iwaki&title=Evaluation+of+bedoradrine+sulfate+%28MN-221%29%2C+a+novel%2C+highly+selective+beta2-adrenergic+receptor+agonist+for+the+treatment+of+asthma+via+intravenous+infusion&doi=10.3109%2F02770903.2012.729631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion</span></div><div class="casAuthors">Matsuda Kazuko; Makhay Malath; Johnson Kirk; Iwaki Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of asthma : official journal of the Association for the Care of Asthma</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1071-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The number of hospitalizations or deaths due to asthma, most of which result from acute exacerbations of asthma, has remained the same for the past 20 years.  MN-221 (bedoradrine sulfate) is a novel, highly selective beta2- (β2-) adrenergic agonist administered via intravenous (IV) infusion in development for the treatment for acute exacerbation of asthma.  OBJECTIVES:  Trial MN-221-CL-004 assessed the safety profile and preliminary efficacy of MN-221 in escalating doses in patients with stable mild-to-moderate asthma.  Study MN-221-CL-005 assessed the safety profile and preliminary efficacy of MN-221 in patients with stable moderate-to-severe asthma when given as a fixed dose over 1- or 2- hr infusion.  METHODS:  Two randomized, placebo-controlled clinical trials (n = 40) were performed to evaluate the pharmacokinetic (PK) and clinical effects of a novel, highly selective β2-agonist, MN-221, via IV infusion.  Safety evaluations included vital signs, adverse events (AEs), clinical laboratory parameters, and electrocardiogram results.  Efficacy evaluation included measurement of forced expiratory volume in 1 second (FEV) a1nd PK parameters were additionally monitored.  The study was reviewed and approved by the Institutional Review Board at each site.  RESULTS:  Adverse effects were mild or moderate and there were no serious AEs or deaths during the studies.  The most frequently reported AEs were tremor, hypokalemia, and headache.  There were no consistent dose-dependent effects of MN-221 on any safety parameters, with the exception of heart rate, which was not considered to be clinically significant and did not require any treatment.  Moderate hypokalemia occurred once in one subject in the MN-221-CL-004 study and twice in one subject in the MN-221-CL-005 study and were transient and returned to normal range following single oral potassium chloride treatments.  PK assessments indicated a linear response in MN-221 plasma concentrations for the doses evaluated.  Dose escalation results showed that mean changes in FEV1 from pre-infusion were significantly greater than placebo and an overall dose response was statistically significant (p < .0001).  Post-infusion FEV1 improvements appeared to plateau at the 30 μg/min dose level despite a higher peak plasma concentration at 60 μg/min.  Dose-rate escalation results demonstrated greater mean increases in change in FEV1 compared to the placebo group with the largest increase associated with the higher MN-221 dose rate and peak plasma concentration.  CONCLUSIONS:  The safety profile of MN-221 and evidence of dose- and plasma-concentration-related bronchodilation supports further clinical development and suggests the potential for clinical benefit without increased clinical risk, particularly for patients where inhaled or nebulized therapy is not adequate or possible.  Trial registry name and registration number:Name: MN-221-CL-005Number: NCT00679263.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcSwT0HwXjfpw7prLlxLOzfW6udTcc2eZCgfeRMBjH6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FnvVWhtQ%253D%253D&md5=b6e6845b35ed81ffca47b671279e8016</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.3109%2F02770903.2012.729631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02770903.2012.729631%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuda%26aufirst%3DK.%26aulast%3DMakhay%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DIwaki%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520bedoradrine%2520sulfate%2520%2528MN-221%2529%252C%2520a%2520novel%252C%2520highly%2520selective%2520beta2-adrenergic%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520asthma%2520via%2520intravenous%2520infusion%26jtitle%3DJ.%2520Asthma%26date%3D2012%26volume%3D49%26spage%3D1071%26epage%3D1078%26doi%3D10.3109%2F02770903.2012.729631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Angelats, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viñals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Alba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morcillo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beleta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.193284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.112.193284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22588259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2012&pages=497-509&author=M.+Apariciauthor=M.+G%C3%B3mez-Angelatsauthor=D.+Vilellaauthor=R.+Otalauthor=C.+Carcasonaauthor=M.+Vi%C3%B1alsauthor=I.+Ramosauthor=A.+Gavald%C3%A0author=J.+De+Albaauthor=J.+Grasauthor=J.+Cortijoauthor=E.+Morcilloauthor=C.+Puigauthor=H.+Ryderauthor=J.+Beletaauthor=M.+Miralpeix&title=Pharmacological+characterization+of+abediterol%2C+a+novel+inhaled+%CE%B2%282%29-adrenoceptor+agonist+with+long+duration+of+action+and+a+favorable+safety+profile+in+preclinical+models&doi=10.1124%2Fjpet.112.193284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of abediterol, a novel inhaled β2-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models</span></div><div class="casAuthors">Aparici, Monica; Gomez-Angelats, Mireia; Vilella, Dolors; Otal, Raquel; Carcasona, Carla; Vinals, Marisa; Ramos, Israel; Gavalda, Amadeu; De Alba, Jorge; Gras, Jordi; Cortijo, Julio; Morcillo, Esteban; Puig, Carlos; Ryder, Hamish; Beleta, Jorge; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Abediterol is a novel potent, long-acting inhaled β2-adrenoceptor agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.  Abediterol shows subnanomolar affinity for the human β2-adrenoceptor and a functional selectivity over β1-adrenoceptors higher than that of formoterol and indacaterol in both a cellular model with overexpressed human receptors and isolated guinea pig tissue.  Abediterol is a full agonist at the human β2-adrenoceptor (Emax = 91 ± 5% of the maximal effect of isoprenaline).  The potency and onset of action that abediterol shows in isolated human bronchi (EC50 = 1.9 ± 0.4 nM; t1/2 onset = 7-10 min) is not significantly different from that of formoterol, but its duration of action (t1/2 ∼ 690 min) is similar to that of indacaterol.  Nebulized abediterol inhibits acetylcholine-induced bronchoconstriction in guinea pigs in a concn.-dependent manner, with higher potency and longer duration of action (t1/2 = 36 h) than salmeterol (t1/2 = 6 h) and formoterol (t1/2 = 4 h) and similar duration of action to indacaterol up to 48 h.  In dogs, the bronchoprotective effect of abediterol is more sustained than that of salmeterol and indacaterol at doses without effects on heart rate, thus showing a greater safety margin (defined as the ratio of dose increasing heart rate by 5% and dose inhibiting bronchospasm by 50%) than salmeterol, formoterol, and indacaterol (5.6 vs. 3.3, 2.2, and 0.3, resp.).  In conclusion, our results suggest that abediterol has a preclin. profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsT0Jt09WvbVg90H21EOLACvtfcHk0lgdIumR1n172A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOru7vK&md5=a102a6455f01c296d2beda412fa527c0</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.193284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.193284%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez-Angelats%26aufirst%3DM.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DOtal%26aufirst%3DR.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DVi%25C3%25B1als%26aufirst%3DM.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DDe%2BAlba%26aufirst%3DJ.%26aulast%3DGras%26aufirst%3DJ.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DMorcillo%26aufirst%3DE.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DRyder%26aufirst%3DH.%26aulast%3DBeleta%26aufirst%3DJ.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520abediterol%252C%2520a%2520novel%2520inhaled%2520%25CE%25B2%25282%2529-adrenoceptor%2520agonist%2520with%2520long%2520duration%2520of%2520action%2520and%2520a%2520favorable%2520safety%2520profile%2520in%2520preclinical%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D342%26spage%3D497%26epage%3D509%26doi%3D10.1124%2Fjpet.112.193284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miquel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e00356</span> <span class="refDoi"> DOI: 10.1002/prp2.356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fprp2.356" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&author=J.+Beierauthor=R.+Fuhrauthor=B.+Seoaneauthor=E.+Massanaauthor=G.+de+Miquelauthor=H.+Pujolauthor=S.+Ruiz&title=Efficacy%2C+safety%2C+and+tolerability+of+once-daily+abediterol+in+patients+with+stable%2C+persistent+asthma%3A+a+Phase+II%2C+randomized%2C+7-day%2C+crossover+study&doi=10.1002%2Fprp2.356"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1002%2Fprp2.356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.356%26sid%3Dliteratum%253Aachs%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3DMassana%26aufirst%3DE.%26aulast%3Dde%2BMiquel%26aufirst%3DG.%26aulast%3DPujol%26aufirst%3DH.%26aulast%3DRuiz%26aufirst%3DS.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520once-daily%2520abediterol%2520in%2520patients%2520with%2520stable%252C%2520persistent%2520asthma%253A%2520a%2520Phase%2520II%252C%2520randomized%252C%25207-day%252C%2520crossover%2520study%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2017%26volume%3D5%26doi%3D10.1002%2Fprp2.356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seoane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astbury, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miquel, G.</span></span> <span> </span><span class="NLM_article-title">Abediterol, a novel long-acting β<sub>2</sub>-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD</span>. <i>BMC Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">102</span>, <span class="refDoi"> DOI: 10.1186/s12890-016-0266-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2Fs12890-016-0266-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27439370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkt1OgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=102&author=J.+Beierauthor=H.+Pujolauthor=B.+Seoaneauthor=E.+Jimenezauthor=C.+Astburyauthor=E.+Massanaauthor=S.+Ruizauthor=G.+de+Miquel&title=Abediterol%2C+a+novel+long-acting+%CE%B22-agonist%3A+bronchodilation%2C+safety%2C+tolerability+and+pharmacokinetic+results+from+a+single-dose%2C+dose-ranging%2C+active-comparator+study+in+patients+with+COPD&doi=10.1186%2Fs12890-016-0266-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD</span></div><div class="casAuthors">Beier, Jutta; Pujol, Helena; Seoane, Beatriz; Jimenez, Eulalia; Astbury, Carol; Massana, Eric; Ruiz, Sandrine; de Miquel, Gonzalo</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">102/1-102/13</span>CODEN:
                <span class="NLM_cas:coden">BPMMBB</span>;
        ISSN:<span class="NLM_cas:issn">1471-2466</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent.  This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD.  Methods: Seventy patients (aged <40 years, Global initiative for chronic Obstructive Lung Disease Stage II/III) were randomised (1:1:1:1:1:1) to single doses of abediterol 0.625, 2.5, 5 or 10 μg, indacaterol 150 μg or placebo.  Spirometry was performed up to 36 h post-dose.  Pharmacokinetics were assessed in a subset of patients (N = 20).  Safety and tolerability were evaluated throughout the study.  Results: Abediterol (all doses) significantly improved change from baseline in trough forced expiratory vol. in 1 s (FEV1) compared with placebo (0.102, 0.203, 0.233 and 0.259 L for abediterol 0.625, 2.5, 5 and 10 μg, resp.; all p < 0.0001; primary endpoint).  Abediterol 2.5, 5 and 10 μg significantly improved trough FEV1 compared with indacaterol 150 μg (0.092, 0.122 and 0.148 L, resp.; all p < 0.0001).  Improvements in bronchodilation were maintained at all time points post-dose vs. placebo (all abediterol doses) and from 15 or 30 min post-dose vs. indacaterol 150 μg with abediterol 2.5, 5 and 10 μg (all p < 0.05).  Abediterol had low systemic exposure; incidence of treatment-emergent adverse events was similar between treatment groups.  Conclusions: All doses of abediterol (0.625-10 μg) provided clin. and statistically significant, dose-dependent improvements in bronchodilation vs. placebo, and abediterol 2.5, 5 and 10 μg gave significant improvements vs. indacaterol.  All doses of abediterol were safe and well tolerated in patients with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppi04RHvhOi7Vg90H21EOLACvtfcHk0lirchp0U3q3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkt1OgsLk%253D&md5=212c479f94a86c177687661b09fcf5b6</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1186%2Fs12890-016-0266-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12890-016-0266-5%26sid%3Dliteratum%253Aachs%26aulast%3DBeier%26aufirst%3DJ.%26aulast%3DPujol%26aufirst%3DH.%26aulast%3DSeoane%26aufirst%3DB.%26aulast%3DJimenez%26aufirst%3DE.%26aulast%3DAstbury%26aufirst%3DC.%26aulast%3DMassana%26aufirst%3DE.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3Dde%2BMiquel%26aufirst%3DG.%26atitle%3DAbediterol%252C%2520a%2520novel%2520long-acting%2520%25CE%25B22-agonist%253A%2520bronchodilation%252C%2520safety%252C%2520tolerability%2520and%2520pharmacokinetic%2520results%2520from%2520a%2520single-dose%252C%2520dose-ranging%252C%2520active-comparator%2520study%2520in%2520patients%2520with%2520COPD%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2016%26volume%3D16%26spage%3D102%26doi%3D10.1186%2Fs12890-016-0266-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span> <span> </span><span class="NLM_article-title">Trachea relaxing effects and β<sub>2</sub>-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1248/bpb.26.323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1248%2Fbpb.26.323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12612441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=323-328&author=L.+L.+Ganauthor=M.+W.+Wangauthor=M.+S.+Chengauthor=L.+Pan&title=Trachea+relaxing+effects+and+%CE%B22-selectivity+of+SPFF%2C+a+newly+developed+bronchodilating+agent%2C+in+guinea+pigs+and+rabbits&doi=10.1248%2Fbpb.26.323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Trachea relaxing effects and β2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span></div><div class="casAuthors">Gan, Le-Ling; Wang, Min-Wei; Cheng, Mao-Sheng; Pan, Li</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">In this paper we evaluated the bronchodilator effects of SPFF [2-(4-amino-3-chloro-5-trifluomethyl-phenyl)- 2-tert-butylamino-ethanol chloride], a newly synthesized β2 adrenergic agonist in guinea pigs and rabbits, in comparison with other β2 adrenergic agonists, isoprenaline or salbutamol.  We studied in vitro the bronchodilator effects of SPFF and isoprenaline on isolated guinea pig trachea strips with or without the precontraction of bronchocontractors (acetylcholine and histamine).  The pos. chronotropic effects of SPFF and isoprenaline on isolated guinea pig left atria were also tested in vitro.  Potency values (pD2, pA2 or ED50) were detd. from the cumulative concn.-response curves.  The results showed that SPFF and isoprenaline dose-dependently relaxed the isolated guinea pig trachea strips and the pD2 values of both drugs were 7.66±0.68 and 8.79±0.19, resp.  Moreover, we confirmed that the bronchodilator effect of SPFF was due to the activation of β2 adrenoceptor because this effect was easily antagonized by ICI-118551 (pA2 8.90±0.01), a specific β2 adrenoceptor antagonist.  SPFF also dose-dependently relaxed the isolated guinea pig trachea strip precontraction with acetylcholine or histamine with ED50 values of 10.2±0.7 μM and 550±38.2 nM, resp.  Furthermore, the pos. chronotropic effect of SPFF on isolated guinea pig left atria (pD2 5.41±0.38) was much weaker than that of isoprenaline (pD2 8.75±0.24), which implied that SPFF was more selective to airway β2 adrenoceptor than isoprenaline; the β1/β2 selectivity assay also showed that SPFF was about 162 times more selective to β2 adrenoceptor than isoprenaline.  A radioligand binding expt. using guinea pig lung and cardiac ventricle as β2 and β1 adrenoceptor sources, resp., also demonstrated that SPFF possesses high affinity (27.3 nM) and selectivity (4.6 fold) to β2 adrenoceptors.  The protective effects of SPFF and salbutamol on bronchospasm induced by bronchoconstrictor aerosol in guinea pigs in vivo were investigated, and the Konzett and Rossler expt. in rabbits in vivo was also carried out.  SPFF significantly prolonged the latency time of histamine and acetylcholine induced asphyxiation collapse in guinea pigs: the ED50 value of SPFF i.g. was 0.32±0.05 mg·kg-1 in this expt.  Meanwhile, the ED50 values of salbutamol was 2.37±0.22, which meant that the bronchorelaxation effect of salbutamol was about 6 times less potent than that of SPFF.  The Konzett and Rossler expt. performed in anesthetized rabbit showed that intraduodenal administration of SPFF exerted action of longer duration than salbutamol.  From the results above we suggested that SPFF was a potent, long-acting bronchodilator with relatively higher β2 adrenoceptor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgmv60MqHPLVg90H21EOLACvtfcHk0lirchp0U3q3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D&md5=87227d7e445c13d7b74f1adf69cfaee9</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1248%2Fbpb.26.323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.26.323%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DM.%2BW.%26aulast%3DCheng%26aufirst%3DM.%2BS.%26aulast%3DPan%26aufirst%3DL.%26atitle%3DTrachea%2520relaxing%2520effects%2520and%2520%25CE%25B22-selectivity%2520of%2520SPFF%252C%2520a%2520newly%2520developed%2520bronchodilating%2520agent%252C%2520in%2520guinea%2520pigs%2520and%2520rabbits%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2003%26volume%3D26%26spage%3D323%26epage%3D328%26doi%3D10.1248%2Fbpb.26.323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span> <span> </span><span class="NLM_article-title">Randomized, multicenter clinical study of tratinterol hydrochloride tablets for the treatment of bronchial asthma</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1258</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2015.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.clinthera.2015.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25857594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsV2gtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2015&pages=1248-1258&author=L.+Kongauthor=J.+Liuauthor=G.+Guauthor=J.+Huoauthor=Z.+Maauthor=Y.+Shaoauthor=S.+Sunauthor=Y.+Yuanauthor=S.+Zhuauthor=C.+Yaoauthor=G.+Duauthor=M.+Chengauthor=J.+Kang&title=Randomized%2C+multicenter+clinical+study+of+tratinterol+hydrochloride+tablets+for+the+treatment+of+bronchial+asthma&doi=10.1016%2Fj.clinthera.2015.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, Multicenter Clinical Study of Tratinterol Hydrochloride Tablets for the Treatment of Bronchial Asthma</span></div><div class="casAuthors">Kong, Lingfei; Liu, Jiaming; Gu, Guozhong; Huo, Jianmin; Ma, Zhongsen; Shao, Yuxia; Sun, Shenghua; Yuan, Yuan; Zhu, Sainan; Yao, Chen; Du, Guijie; Cheng, Maosheng; Kang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1248-1258</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The aim of this study was to det. the efficacy and safety profile of tratinterol hydrochloride tablets in the treatment of bronchial asthma.  This multicenter, randomized, double-blind clin. research study was completed at 6 centers in the People's Republic of China from March 2009 to June 2010, and a randomized trial of procaterol hydrochloride tablets produced by Otsuka Pharmaceutical Co Ltd was conducted.  The study was approved by the Medical Ethics Committee of the First Hospital of China Medical University.  The clin. trial registration no. is 2007L04263.  A total of 223 patients were selected for this study, with 112 patients in the treatment group and 111 in the control group.  The lung function of the 2 groups after treatment significantly increased in all (P < 0.05); however, there was no significant difference in the changes between the 2 groups (P > 0.05).  The occurrence of related adverse events at varying degrees in the control group was higher than in the treatment group.  It is safe and effective to use tratinterol hydrochloride tablets to treat bronchial asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTP1rG3e18jLVg90H21EOLACvtfcHk0lirchp0U3q3fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsV2gtLc%253D&md5=bdfd80da5133573e5d0ede9a30559c75</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2015.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2015.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DG.%26aulast%3DHuo%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DJ.%26atitle%3DRandomized%252C%2520multicenter%2520clinical%2520study%2520of%2520tratinterol%2520hydrochloride%2520tablets%2520for%2520the%2520treatment%2520of%2520bronchial%2520asthma%26jtitle%3DClin.%2520Ther.%26date%3D2015%26volume%3D37%26spage%3D1248%26epage%3D1258%26doi%3D10.1016%2Fj.clinthera.2015.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span> <span> </span><span class="NLM_article-title">Assessment of a novel β<sub>2</sub>-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities</span>. <i>Toxicol. In Vitro</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1016/j.tiv.2011.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.tiv.2011.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21466844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2ntLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1033-1038&author=K.+Jiangauthor=K.+Liauthor=F.+Qinauthor=X.+Luauthor=F.+Li&title=Assessment+of+a+novel+%CE%B22-adrenoceptor+agonist%2C+trantinterol%2C+for+interference+with+human+liver+cytochrome+P450+enzymes+activities&doi=10.1016%2Fj.tiv.2011.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities</span></div><div class="casAuthors">Jiang, Kun; Li, Kunjie; Qin, Feng; Lu, Xiumei; Li, Famei</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology In Vitro</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1033-1038</span>CODEN:
                <span class="NLM_cas:coden">TIVIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0887-2333</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The effect of a novel β2-adrenoceptor agonist, trantinterol on the activities of cytochrome P 450 (CYP450) was investigated with human liver microsomes and human cryohepatocytes to assess the potential for drug-drug interactions.  The ability of trantinterol to inhibit CYP450 activities was evaluated in vitro in human liver microsomes.  Trantinterol did not inhibit CYP2C19, CYP2D6, and CYP3A4/5 (IC 50 > 100 μM).  It acted as a weak inhibitor of CYP1A2 and CYP2C9 with IC 50 of 70.8 and 81.9 μM, resp.  No time-dependent inhibitions were obsd. in the present research.  To evaluate CYP450 induction, human cryohepatocytes (n = 3) were used and treated once daily for 3 days with trantinterol (0.01, 0.1, and 1 ng/mL), after which CYP450 activities were measured.  At concn. of 0.01 ng/mL, which is close to the C max at maximal recommended doses (50 μg), trantinterol was about 8% as effective as omeprazole (CYP1A2 inducer) only with donor 2.  At concn. of 1 ng/mL, trantinterol was about 3.6% as effective as rifampin (CYP3A4/5 inducer).  These in vitro results indicated that, at pharmacol. relevant concns., trantinterol will not produce clin. significant CYP450 inhibition or induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6DwyZziP4hbVg90H21EOLACvtfcHk0lhAPO7CVi_lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2ntLs%253D&md5=fec5958fc693ae3d54cbcd8e25f02c70</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.tiv.2011.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tiv.2011.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DQin%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26atitle%3DAssessment%2520of%2520a%2520novel%2520%25CE%25B22-adrenoceptor%2520agonist%252C%2520trantinterol%252C%2520for%2520interference%2520with%2520human%2520liver%2520cytochrome%2520P450%2520enzymes%2520activities%26jtitle%3DToxicol.%2520In%2520Vitro%26date%3D2011%26volume%3D25%26spage%3D1033%26epage%3D1038%26doi%3D10.1016%2Fj.tiv.2011.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Procopiou, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggadike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchers, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edney, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLay, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteith, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutch, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2280</span>– <span class="NLM_lpage">2288</span>, <span class="refDoi"> DOI: 10.1021/jm801016j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801016j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1GlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2280-2288&author=P.+A.+Procopiouauthor=V.+J.+Barrettauthor=N.+J.+Bevanauthor=K.+Biggadikeauthor=P.+R.+Butchersauthor=D.+M.+Coeauthor=R.+Conroyauthor=D.+D.+Edneyauthor=R.+N.+Fieldauthor=A.+J.+Fordauthor=S.+B.+Guntripauthor=B.+E.+Lookerauthor=I.+M.+McLayauthor=M.+J.+Monteithauthor=V.+S.+Morrisonauthor=P.+J.+Mutchauthor=S.+A.+Richardsauthor=R.+Sasseauthor=C.+E.+Smith&title=Synthesis+and+structure-activity+relationships+of+long-acting+beta2+adrenergic+receptor+agonists+incorporating+arylsulfonamide+groups&doi=10.1021%2Fjm801016j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups</span></div><div class="casAuthors">Procopiou, Panayiotis A.; Barrett, Victoria J.; Bevan, Nicola J.; Biggadike, Keith; Butchers, Peter R.; Coe, Diane M.; Conroy, Richard; Edney, Dean D.; Field, Rita N.; Ford, Alison J.; Guntrip, Stephen B.; Looker, Brian E.; McLay, Iain M.; Monteith, Michael J.; Morrison, Valerie S.; Mutch, Peter J.; Richards, Stephen A.; Sasse, Rosemary; Smith, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2280-2288</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of saligenin alkoxyalkylphenylsulfonamide β2 adrenoceptor agonists were prepd. by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection.  The meta-substituted primary sulfonamide was more potent than the para- and the ortho-analogs.  Primary sulfonamides were more potent than the secondary and tertiary analogs.  The onset and duration of action in vitro of selected compds. was assessed on isolated superfused guinea pig trachea.  Sulfonamide I [X = (CH2)n, n = 4] had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus.  Furthermore, I was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation.  Cryst. salts of I were identified that had suitable properties for inhaled administration.  A proposed binding mode for I to the β2-receptor is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-aSFpSwy7zrVg90H21EOLACvtfcHk0lhAPO7CVi_lmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1GlsL8%253D&md5=b057a3592d919da24d7211a23bf214fb</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Fjm801016j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801016j%26sid%3Dliteratum%253Aachs%26aulast%3DProcopiou%26aufirst%3DP.%2BA.%26aulast%3DBarrett%26aufirst%3DV.%2BJ.%26aulast%3DBevan%26aufirst%3DN.%2BJ.%26aulast%3DBiggadike%26aufirst%3DK.%26aulast%3DButchers%26aufirst%3DP.%2BR.%26aulast%3DCoe%26aufirst%3DD.%2BM.%26aulast%3DConroy%26aufirst%3DR.%26aulast%3DEdney%26aufirst%3DD.%2BD.%26aulast%3DField%26aufirst%3DR.%2BN.%26aulast%3DFord%26aufirst%3DA.%2BJ.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DLooker%26aufirst%3DB.%2BE.%26aulast%3DMcLay%26aufirst%3DI.%2BM.%26aulast%3DMonteith%26aufirst%3DM.%2BJ.%26aulast%3DMorrison%26aufirst%3DV.%2BS.%26aulast%3DMutch%26aufirst%3DP.%2BJ.%26aulast%3DRichards%26aufirst%3DS.%2BA.%26aulast%3DSasse%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520long-acting%2520beta2%2520adrenergic%2520receptor%2520agonists%2520incorporating%2520arylsulfonamide%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2280%26epage%3D2288%26doi%3D10.1021%2Fjm801016j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span> <span> </span><span class="NLM_article-title">The discovery of adamantyl-derived, inhaled, long acting beta2-adrenoreceptor agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2008.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18226900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlajtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1280-1283&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=K.+Jamesauthor=R.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=M.+Trevethickauthor=R.+Webster&title=The+discovery+of+adamantyl-derived%2C+inhaled%2C+long+acting+beta2-adrenoreceptor+agonists&doi=10.1016%2Fj.bmcl.2008.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of adamantyl-derived, inhaled, long acting β2-adrenoreceptor agonists</span></div><div class="casAuthors">Brown, Alan D.; Bunnage, Mark E.; Glossop, Paul A.; James, Kim; Jones, Rhys; Lane, Charlotte A. L.; Lewthwaite, Russell A.; Mantell, Simon; Perros-Huguet, Christelle; Price, David A.; Trevethick, Mike; Webster, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1280-1283</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design and profile of a series of adamantyl-contg. long acting β2-adrenoreceptor agonists are described.  An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacol. profile when assessed using a guinea pig trachea tissue model.  A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8PigIxSWqNrVg90H21EOLACvtfcHk0lhtIHCLqccMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlajtrc%253D&md5=b483e4c9001fd184c934ea6f863187db</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DTrevethick%26aufirst%3DM.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520adamantyl-derived%252C%2520inhaled%252C%2520long%2520acting%2520beta2-adrenoreceptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1280%26epage%3D1283%26doi%3D10.1016%2Fj.bmcl.2008.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span> <span> </span><span class="NLM_article-title">The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6188</span>– <span class="NLM_lpage">6191</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.09.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmcl.2007.09.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17897826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=6188-6191&author=A.+D.+Brownauthor=M.+E.+Bunnageauthor=P.+A.+Glossopauthor=M.+Holbrookauthor=R.+D.+Jonesauthor=C.+A.+Laneauthor=R.+A.+Lewthwaiteauthor=S.+Mantellauthor=C.+Perros-Huguetauthor=D.+A.+Priceauthor=R.+Webster&title=The+discovery+of+indole-derived+long+acting+beta2-adrenoceptor+agonists+for+the+treatment+of+asthma+and+COPD&doi=10.1016%2Fj.bmcl.2007.09.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of indole-derived long acting β2-adrenoceptor agonists for the treatment of asthma and COPD</span></div><div class="casAuthors">Brown, Alan D.; Bunnage, Mark E.; Glossop, Paul A.; Holbrook, Mark; Jones, Rhys D.; Lane, Charlotte A. L.; Lewthwaite, Russell A.; Mantell, Simon; Perros-Huguet, Christelle; Price, David A.; Webster, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6188-6191</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The design and profile of a series of indole contg. long acting β2-adrenoceptor agonists is described.  Evaluation of these analogs using an in vitro guinea pig trachea tissue model demonstrates that analogs such as I within this series have salmeterol-like duration of action with potential for long duration of action in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrci7Y0aY4eybVg90H21EOLACvtfcHk0lhtIHCLqccMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOjt7zN&md5=4ae7111899e82d2506f88152171eec10</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.09.031%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DHolbrook%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DR.%2BD.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DMantell%26aufirst%3DS.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DWebster%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520indole-derived%2520long%2520acting%2520beta2-adrenoceptor%2520agonists%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520COPD%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D6188%26epage%3D6191%26doi%3D10.1016%2Fj.bmcl.2007.09.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunnage, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewthwaite, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeadon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros-Huguet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevethick, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeder, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, F. J.</span></span> <span> </span><span class="NLM_article-title">Inhalation by design: novel ultra-long-acting β<sub>2</sub>-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6640</span>– <span class="NLM_lpage">6652</span>, <span class="refDoi"> DOI: 10.1021/jm1005989</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1005989" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6640-6652&author=P.+A.+Glossopauthor=C.+A.+Laneauthor=D.+A.+Priceauthor=M.+E.+Bunnageauthor=R.+A.+Lewthwaiteauthor=K.+Jamesauthor=A.+D.+Brownauthor=M.+Yeadonauthor=C.+Perros-Huguetauthor=M.+A.+Trevethickauthor=N.+P.+Clarkeauthor=R.+Websterauthor=R.+M.+Jonesauthor=J.+L.+Burrowsauthor=N.+Feederauthor=S.+C.+Taylorauthor=F.+J.+Spence&title=Inhalation+by+design%3A+novel+ultra-long-acting+%CE%B22-adrenoreceptor+agonists+for+inhaled+once-daily+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease+that+utilize+a+sulfonamide+agonist+headgroup&doi=10.1021%2Fjm1005989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup</span></div><div class="casAuthors">Glossop, Paul A.; Lane, Charlotte A. L.; Price, David A.; Bunnage, Mark E.; Lewthwaite, Russell A.; James, Kim; Brown, Alan D.; Yeadon, Michael; Perros-Huguet, Christelle; Trevethick, Michael A.; Clarke, Nicholas P.; Webster, Robert; Jones, Rhys M.; Burrows, Jane L.; Feeder, Neil; Taylor, Stefan C. J.; Spence, Fiona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6640-6652</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of potent and selective sulfonamide derived β2-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease.  Analogs from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips.  The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state.  Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events.  Compd. 38 (PF-610355) is identified as a clin. candidate from this series, with in vivo duration of action studies confirming its potential for once-daily use in humans.  Compd. 38 is currently in advanced phase II clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGaBcfoYeu7Vg90H21EOLACvtfcHk0lhtIHCLqccMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2ktLjJ&md5=34cf266aa0f796ee5ec370369c726f6e</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1021%2Fjm1005989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1005989%26sid%3Dliteratum%253Aachs%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DLane%26aufirst%3DC.%2BA.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBunnage%26aufirst%3DM.%2BE.%26aulast%3DLewthwaite%26aufirst%3DR.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DA.%2BD.%26aulast%3DYeadon%26aufirst%3DM.%26aulast%3DPerros-Huguet%26aufirst%3DC.%26aulast%3DTrevethick%26aufirst%3DM.%2BA.%26aulast%3DClarke%26aufirst%3DN.%2BP.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BL.%26aulast%3DFeeder%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BC.%26aulast%3DSpence%26aufirst%3DF.%2BJ.%26atitle%3DInhalation%2520by%2520design%253A%2520novel%2520ultra-long-acting%2520%25CE%25B22-adrenoreceptor%2520agonists%2520for%2520inhaled%2520once-daily%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520that%2520utilize%2520a%2520sulfonamide%2520agonist%2520headgroup%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6640%26epage%3D6652%26doi%3D10.1021%2Fjm1005989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R.</span>; <span class="NLM_string-name">Huebner, H.</span>; <span class="NLM_string-name">Shonberg, J.</span></span> <span> </span><span class="NLM_article-title">Beta-2 Selective Adrenergic Receptor Agonists</span>. WO Patent <span class="NLM_patent">2019112913</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+Sunahara&author=H.+Huebner&author=J.+Shonberg&title=Beta-2+Selective+Adrenergic+Receptor+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSunahara%26aufirst%3DR.%26atitle%3DBeta-2%2520Selective%2520Adrenergic%2520Receptor%2520Agonists%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X. M.</span>; <span class="NLM_string-name">Zhou, W. J.</span>; <span class="NLM_string-name">Liu, Y. F.</span></span> <span> </span><span class="NLM_article-title">Beta2-Adrenergic Receptor Agonist in Rhizoma Curcumae and Application Thereof</span>. CN Patent <span class="NLM_patent">109806254</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.+M.+Liang&author=W.+J.+Zhou&author=Y.+F.+Liu&title=Beta2-Adrenergic+Receptor+Agonist+in+Rhizoma+Curcumae+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%2BM.%26atitle%3DBeta2-Adrenergic%2520Receptor%2520Agonist%2520in%2520Rhizoma%2520Curcumae%2520and%2520Application%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, L.</span>; <span class="NLM_string-name">Jin, T. Y.</span>; <span class="NLM_string-name">Shen, T.</span></span> <span> </span><span class="NLM_article-title">Beta2-AR Exciting and Anti-inflammatory Dual-function Alkaloid and Application Thereof</span>. CN Patent <span class="NLM_patent">107043371</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Xiang&author=T.+Y.+Jin&author=T.+Shen&title=Beta2-AR+Exciting+and+Anti-inflammatory+Dual-function+Alkaloid+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DL.%26atitle%3DBeta2-AR%2520Exciting%2520and%2520Anti-inflammatory%2520Dual-function%2520Alkaloid%2520and%2520Application%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of β<sub>2</sub>-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.ejmech.2018.04.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29751236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt12rs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2018&pages=424-435&author=X.+Geauthor=A.+Y.+Wooauthor=G.+Xingauthor=Y.+Luauthor=Y.+Moauthor=Y.+Zhaoauthor=Y.+Lanauthor=J.+Liauthor=H.+Yanauthor=L.+Panauthor=Y.+Zhangauthor=B.+Linauthor=M.+Cheng&title=Synthesis+and+biological+evaluation+of+%CE%B22-adrenoceptor+agonists+bearing+the+2-amino-2-phenylethanol+scaffold&doi=10.1016%2Fj.ejmech.2018.04.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of β2-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold</span></div><div class="casAuthors">Ge, Xinyue; Woo, Anthony Yiu-Ho; Xing, Gang; Lu, Yali; Mo, Yongmei; Zhao, Ying; Lan, Yi; Li, Jinyan; Yan, Haining; Pan, Li; Zhang, Yuyang; Lin, Bin; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">424-435</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new series of β-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold, compds. I [R = phenethyl, (1H-indol-3-yl)ethyl, 4-(4-phenylbutoxy)butyl, etc.] were synthesized.  Evaluation of the compds. using cell assays and an in-vitro guinea pig trachea relaxation assay showed that compd. I [R = 4-hydroxyphenethyl] had the best pharmacol. profile among all the evaluated compds.  The (S)-isomer of compd. I [R = 4-hydroxyphenethyl] was subsequently found to be the active enantiomer with a promising EC50 value of 1.26nM in stimulating β2-adrenoceptor-mediated cAMP accumulation and a substantially higher selectivity for the β2 than for the β1 subtype.  The putative binding mode of (S)-compd. I [R = 4-hydroxyphenethyl] revealed by mol. docking of the β2-adrenoceptor resembled that in agonist binding.  Taken together, these results showed that S isomer of compd. I [R = 4-hydroxyphenethyl] is a promising compd. worthy of further study for the development of β2-adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuxR7C_XJhsLVg90H21EOLACvtfcHk0li5ZbTdZwgNYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt12rs7k%253D&md5=e78c694306c275618485681f0994479c</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.041%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DX.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520%25CE%25B22-adrenoceptor%2520agonists%2520bearing%2520the%25202-amino-2-phenylethanol%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D152%26spage%3D424%26epage%3D435%26doi%3D10.1016%2Fj.ejmech.2018.04.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel β<sub>2</sub>-adrenoceptor agonists</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bioorg.2018.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29751321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFCksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2018&pages=155-162&author=X.+Geauthor=Y.+Moauthor=G.+Xingauthor=L.+Jiauthor=H.+Zhaoauthor=J.+Chenauthor=B.+Heauthor=X.+Chenauthor=R.+Xingauthor=X.+Liauthor=Y.+Zhaoauthor=J.+Liauthor=H.+Yanauthor=A.+Y.+Wooauthor=Y.+Zhangauthor=B.+Linauthor=L.+Panauthor=M.+Cheng&title=Synthesis%2C+biological+evaluation+and+molecular+modeling+of+2-amino-2-phenylethanol+derivatives+as+novel+%CE%B22-adrenoceptor+agonists&doi=10.1016%2Fj.bioorg.2018.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel β2-adrenoceptor agonists</span></div><div class="casAuthors">Ge, Xinyue; Mo, Yongmei; Xing, Gang; Ji, Lei; Zhao, Haiyan; Chen, Jianfang; He, Bin; Chen, Xuyao; Xing, Ruijuan; Li, Xiaoqiang; Zhao, Ying; Li, Jinyan; Yan, Haining; Woo, Anthony Yiu-Ho; Zhang, Yuyang; Lin, Bin; Pan, Li; Cheng, Maosheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-162</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of 2-amino-2-phenylethanol derivs. were developed as β2-adrenoceptor agonists.  Among them, 2-amino-3-fluoro-5-(2-hydroxy-1-(isopropylamino)ethyl)benzonitrile (compd. I) exhibited the highest activity (EC50 = 0.25 nM) in stimulating β2-adrenoceptor-mediated cellular cAMP prodn. with a 763.6-fold selectivity over the β1-adrenoceptor.  The (S)-isomer of I was subsequently found to be 8.5-fold more active than the (R)-isomer.  Mol. docking was performed to det. the putative binding modes of this new class of β2-adrenoceptor agonists.  Taken together, these data show that compd. I is a promising lead compd. worthy of further study for the development of β2-adrenoceptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUyGy6gy6FTLVg90H21EOLACvtfcHk0li5ZbTdZwgNYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFCksLo%253D&md5=ea0b1e2c81c2ef4f70abc61f0c0edc64</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DX.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXing%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%2520and%2520molecular%2520modeling%2520of%25202-amino-2-phenylethanol%2520derivatives%2520as%2520novel%2520%25CE%25B22-adrenoceptor%2520agonists%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D79%26spage%3D155%26epage%3D162%26doi%3D10.1016%2Fj.bioorg.2018.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wold, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=88-127&author=E.+A.+Woldauthor=J.+Chenauthor=K.+A.+Cunninghamauthor=J.+Zhou&title=Allosteric+modulation+of+class+A+GPCRs%3A+targets%2C+agents%2C+and+emerging+concepts&doi=10.1021%2Facs.jmedchem.8b00875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts</span></div><div class="casAuthors">Wold, Eric A.; Chen, Jianping; Cunningham, Kathryn A.; Zhou, Jia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs.  Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases.  GPCR allosteric modulation is an innovative targeting approach that broadens the available small mol. toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clin. trials.  Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development.  This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chem. approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7zBEGIhRgD7Vg90H21EOLACvtfcHk0lhYgyztC2kQfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2lsLbK&md5=c724b7cb534a9eb52c371961bb9c9b42</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00875%26sid%3Dliteratum%253Aachs%26aulast%3DWold%26aufirst%3DE.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%2BA.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DAllosteric%2520modulation%2520of%2520class%2520A%2520GPCRs%253A%2520targets%252C%2520agents%252C%2520and%2520emerging%2520concepts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D88%26epage%3D127%26doi%3D10.1021%2Facs.jmedchem.8b00875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strachan, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staus, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinnaeve, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamerdin, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassoni, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavino, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husemoen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Allosteric “beta-blocker” isolated from a DNA-encoded small molecule library</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1708</span>– <span class="NLM_lpage">1713</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620645114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.1620645114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28130548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=1708-1713&author=S.+Ahnauthor=A.+W.+Kahsaiauthor=B.+Paniauthor=Q.+T.+Wangauthor=S.+Zhaoauthor=A.+L.+Wallauthor=R.+T.+Strachanauthor=D.+P.+Stausauthor=L.+M.+Winglerauthor=L.+D.+Sunauthor=J.+Sinnaeveauthor=M.+Choiauthor=T.+Choauthor=T.+T.+Xuauthor=G.+M.+Hansenauthor=M.+B.+Burnettauthor=J.+E.+Lamerdinauthor=D.+L.+Bassoniauthor=B.+J.+Gavinoauthor=G.+Husemoenauthor=E.+K.+Olsenauthor=T.+Franchauthor=S.+Costanziauthor=X.+Chenauthor=R.+J.+Lefkowitz&title=Allosteric+%E2%80%9Cbeta-blocker%E2%80%9D+isolated+from+a+DNA-encoded+small+molecule+library&doi=10.1073%2Fpnas.1620645114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library</span></div><div class="casAuthors">Ahn, Seungkirl; Kahsai, Alem W.; Pani, Biswaranjan; Wang, Qin-Ting; Zhao, Shuai; Wall, Alissa L.; Strachan, Ryan T.; Staus, Dean P.; Wingler, Laura M.; Sun, Lillian D.; Sinnaeve, Justine; Choi, Minjung; Cho, Ted; Xu, Thomas T.; Hansen, Gwenn M.; Burnett, Michael B.; Lamerdin, Jane E.; Bassoni, Daniel L.; Gavino, Bryant J.; Husemoen, Gitte; Olsen, Eva K.; Franch, Thomas; Costanzi, Stefano; Chen, Xin; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1708-1713</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR) has been a model system for understanding regulatory mechanisms of G-protein-coupled receptor (GPCR) actions and plays a significant role in cardiovascular and pulmonary diseases.  Because all known β-adrenergic receptor drugs target the orthosteric binding site of the receptor, we set out to isolate allosteric ligands for this receptor by panning DNA-encoded small-mol. libraries comprising 190 million distinct compds. against purified human β2AR.  Here, we report the discovery of a small-mol. neg. allosteric modulator (antagonist), compd. 15 [([4-((2S)-3-(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide], exhibiting a unique chemotype and low micromolar affinity for the β2AR.  Binding of 15 to the receptor cooperatively enhances orthosteric inverse agonist binding while neg. modulating binding of orthosteric agonists.  Studies with a specific antibody that binds to an intracellular region of the β2AR suggest that 15 binds in proximity to the G-protein binding site on the cytosolic surface of the β2AR.  In cell-signaling studies, 15 inhibits cAMP prodn. through the β2AR, but not that mediated by other Gs-coupled receptors.  Compd. 15 also similarly inhibits β-arrestin recruitment to the activated β2AR.  This study presents an allosteric small-mol. ligand for the β2AR and introduces a broadly applicable method for screening DNA-encoded small-mol. libraries against purified GPCR targets.  Importantly, such an approach could facilitate the discovery of GPCR drugs with tailored allosteric effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE5o7Ib4LtSrVg90H21EOLACvtfcHk0lhYgyztC2kQfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kjsbs%253D&md5=c42863673c8b91fcb4a2c42c2b253ebc</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620645114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620645114%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%2BT.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWall%26aufirst%3DA.%2BL.%26aulast%3DStrachan%26aufirst%3DR.%2BT.%26aulast%3DStaus%26aufirst%3DD.%2BP.%26aulast%3DWingler%26aufirst%3DL.%2BM.%26aulast%3DSun%26aufirst%3DL.%2BD.%26aulast%3DSinnaeve%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DT.%2BT.%26aulast%3DHansen%26aufirst%3DG.%2BM.%26aulast%3DBurnett%26aufirst%3DM.%2BB.%26aulast%3DLamerdin%26aufirst%3DJ.%2BE.%26aulast%3DBassoni%26aufirst%3DD.%2BL.%26aulast%3DGavino%26aufirst%3DB.%2BJ.%26aulast%3DHusemoen%26aufirst%3DG.%26aulast%3DOlsen%26aufirst%3DE.%2BK.%26aulast%3DFranch%26aufirst%3DT.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DAllosteric%2520%25E2%2580%259Cbeta-blocker%25E2%2580%259D%2520isolated%2520from%2520a%2520DNA-encoded%2520small%2520molecule%2520library%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D1708%26epage%3D1713%26doi%3D10.1073%2Fpnas.1620645114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latorraca, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Mechanism of intracellular allosteric β<sub>2</sub>AR antagonist revealed by X-ray crystal structure</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>548</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1038/nature23652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fnature23652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28813418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=548&publication_year=2017&pages=480-484&author=X.+Liuauthor=S.+Ahnauthor=A.+W.+Kahsaiauthor=K.+C.+Mengauthor=N.+R.+Latorracaauthor=B.+Paniauthor=A.+J.+Venkatakrishnanauthor=A.+Masoudiauthor=W.+I.+Weisauthor=R.+O.+Drorauthor=X.+Chenauthor=R.+J.+Lefkowitzauthor=B.+K.+Kobilka&title=Mechanism+of+intracellular+allosteric+%CE%B22AR+antagonist+revealed+by+X-ray+crystal+structure&doi=10.1038%2Fnature23652"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure</span></div><div class="casAuthors">Liu, Xiangyu; Ahn, Seungkirl; Kahsai, Alem W.; Meng, Kai-Cheng; Latorraca, Naomi R.; Pani, Biswaranjan; Venkatakrishnan, A. J.; Masoudi, Ali; Weis, William I.; Dror, Ron O.; Chen, Xin; Lefkowitz, Robert J.; Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">548</span>
        (<span class="NLM_cas:issue">7668</span>),
    <span class="NLM_cas:pages">480-484</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptors (GPCRs) pose challenges for drug discovery efforts because of the high degree of structural homol. in the orthosteric pocket, particularly for GPCRs within a single subfamily, such as the nine adrenergic receptors.  Allosteric ligands may bind to less-conserved regions of these receptors and therefore are more likely to be selective.  Unlike orthosteric ligands, which tonically activate or inhibit signaling, allosteric ligands modulate physiol. responses to hormones and neurotransmitters, and may therefore have fewer adverse effects.  The majority of GPCR crystal structures published to date were obtained with receptors bound to orthosteric antagonists, and only a few structures bound to allosteric ligands have been reported.  Cmpd-15 (4-((2S)-3-(((S)-3-(3-bromophenyl)-1-(methylamino)-1-oxopropan-2-yl)amino)-2-(2-cyclohexyl-2-phenylacetamido)-3-oxopropyl)benzamide) is an allosteric modulator of the β2 adrenergic receptor (β2AR) that was recently isolated from a DNA-encoded small-mol. library.  Orthosteric β-adrenergic receptor antagonists, known as beta-blockers, are amongst the most prescribed drugs in the world and Cmpd-15 is the first allosteric beta-blocker.  Cmpd-15 exhibits neg. cooperativity with agonists and pos. cooperativity with inverse agonists.  Here the authors present the structure of the β2AR bound to a polyethylene glycol-carboxylic acid deriv. (Cmpd-15PA) of this modulator.  Cmpd-15PA binds to a pocket formed primarily by the cytoplasmic ends of transmembrane segments 1, 2, 6 and 7 as well as intracellular loop 1 and helix 8.  A comparison of this structure with inactive- and active-state structures of the β2AR reveals the mechanism by which Cmpd-15 modulates agonist binding affinity and signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi-_6yRhxeGLVg90H21EOLACvtfcHk0lhYgyztC2kQfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvI&md5=6e2bf28f5dec63976158fb226c10817e</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fnature23652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23652%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DMeng%26aufirst%3DK.%2BC.%26aulast%3DLatorraca%26aufirst%3DN.%2BR.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DVenkatakrishnan%26aufirst%3DA.%2BJ.%26aulast%3DMasoudi%26aufirst%3DA.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DMechanism%2520of%2520intracellular%2520allosteric%2520%25CE%25B22AR%2520antagonist%2520revealed%2520by%2520X-ray%2520crystal%2520structure%26jtitle%3DNature%26date%3D2017%26volume%3D548%26spage%3D480%26epage%3D484%26doi%3D10.1038%2Fnature23652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β<sub>2</sub>-adrenergic receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2320</span>– <span class="NLM_lpage">2330</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmc.2018.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29588128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVCit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2320-2330&author=K.+Mengauthor=P.+Shimauthor=Q.+Wangauthor=S.+Zhaoauthor=T.+Guauthor=A.+W.+Kahsaiauthor=S.+Ahnauthor=X.+Chen&title=Design%2C+synthesis%2C+and+functional+assessment+of+Cmpd-15+derivatives+as+negative+allosteric+modulators+for+the+%CE%B22-adrenergic+receptor&doi=10.1016%2Fj.bmc.2018.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β2-adrenergic receptor</span></div><div class="casAuthors">Meng, Kaicheng; Shim, Paul; Wang, Qingtin; Zhao, Shuai; Gu, Ting; Kahsai, Alem W.; Ahn, Seungkirl; Chen, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2320-2330</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2AR), a G protein-coupled receptor, is an important therapeutic target.  We recently described Cmpd-15, the first small mol. neg. allosteric modulator (NAM) for the β2AR.  Herein we report in details the design, synthesis and structure-activity relationships (SAR) of seven Cmpd-15 derivs.  Furthermore, we provide in a dose-response paradigm, the details of the effects of these derivs. in modulating agonist-induced β2AR activities (G-protein-mediated cAMP prodn. and β-arrestin recruitment to the receptor) as well as the binding affinity of an orthosteric agonist in radio-ligand competition binding assay.  Our results show that some modifications, including removal of the formamide group in the para-formamido phenylalanine region and bromine in the meta-bromobenzyl methylbenzamide region caused dramatic redn. in the functional activity of Cmpd-15.  These SAR results provide valuable insights into the mechanism of action of the NAM Cmpd-15 as well as the basis for future development of more potent and selective modulators for the β2AR based on the chem. scaffold of Cmpd-15.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBC1jsMFZPQbVg90H21EOLACvtfcHk0lhJLMWCJSKwpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVCit7Y%253D&md5=f6bf973f25925a6de055ae21cb1a646f</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DK.%26aulast%3DShim%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DT.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520functional%2520assessment%2520of%2520Cmpd-15%2520derivatives%2520as%2520negative%2520allosteric%2520modulators%2520for%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D2320%26epage%3D2330%26doi%3D10.1016%2Fj.bmc.2018.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husemoen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestergaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingler, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambarat, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simhal, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staus, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule positive allosteric modulators of the β<sub>2</sub>-adrenoceptor isolated from DNA-encoded libraries</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1124/mol.118.111948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fmol.118.111948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29769246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=850-861&author=S.+Ahnauthor=B.+Paniauthor=A.+W.+Kahsaiauthor=E.+K.+Olsenauthor=G.+Husemoenauthor=M.+Vestergaardauthor=L.+Jinauthor=S.+Zhaoauthor=L.+M.+Winglerauthor=P.+K.+Rambaratauthor=R.+K.+Simhalauthor=T.+T.+Xuauthor=L.+D.+Sunauthor=P.+J.+Shimauthor=D.+P.+Stausauthor=L.+Y.+Huangauthor=T.+Franchauthor=X.+Chenauthor=R.+J.+Lefkowitz&title=Small-molecule+positive+allosteric+modulators+of+the+%CE%B22-adrenoceptor+isolated+from+DNA-encoded+libraries&doi=10.1124%2Fmol.118.111948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule positive allosteric modulators of the β2-adrenoceptor isolated from DNA-encoded libraries</span></div><div class="casAuthors">Ahn, Seungkirl; Pani, Biswaranjan; Kahsai, Alem W.; Olsen, Eva K.; Husemoen, Gitte; Vestergaard, Mikkel; Jin, Lei; Zhao, Shuai; Wingler, Laura M.; Rambarat, Paula K.; Simhal, Rishabh K.; Xu, Thomas T.; Sun, Lillian D.; Shim, Paul J.; Staus, Dean P.; Huang, Li-Yin; Franch, Thomas; Chen, Xin; Lefkowitz, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">850-861</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Conventional drug discovery efforts at the β2-adrenoceptor (β2AR) have led to the development of ligands that bind almost exclusively to the receptor's hormone-binding orthosteric site.  However, targeting the largely unexplored and evolutionarily unique allosteric sites has potential for developing more specific drugs with fewer side effects than orthosteric ligands.  Using our recently developed approach for screening G protein-coupled receptors (GPCRs) with DNA-encoded small-mol. libraries, we have discovered and characterized the first β2AR smallmol. pos. allosteric modulators (PAMs)-compd. (Cmpd)-6 [(R)-N-(4-amino-1-(4-(tert-butyl)phenyl)-4-oxobutan- 2-yl)-5-(N-isopropyl-N-methylsulfamoyl)-2-((4-methoxyphenyl)- thio)benzamide] and its analogs.  We used purified human β2ARs, occupied by a high-affinity agonist, for the affinity-based screening of over 500 million distinct library compds., which yielded Cmpd-6.  It exhibits a low micro-molar affinity for the agonist-occupied β2AR and displays pos. cooperativity with orthosteric agonists, thereby enhancing their binding to the receptor and ability to stabilize its active state.  Cmpd-6 is cooperative with G protein and β-arrestin1 (a.k.a. arrestin2) to stabilize high-affinity, agonist-bound active states of the β2AR and potentiates downstream cAMP prodn. and receptor recruitment of β-arrestin2 (a.k.a. arrestin3).Cmpd-6 is specific for the β2AR compared with the closely related β1AR.  Structure- activity studies of select Cmpd-6 analogs defined the chem. groups that are crit. for its biol. activity.Wethus introduce the first smallmol. PAMs for the β2AR, which may serve as a lead mol. for the development of novel therapeutics.  The approach described in this work establishes a broadly applicable proof-of-concept strategy for affinity-based discovery of small-mol. allosteric compds. targeting unique conformational states of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoufq1o7mNfFLVg90H21EOLACvtfcHk0lhJLMWCJSKwpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgsr7O&md5=b50b8775c33f7ebe34560295f8b80720</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1124%2Fmol.118.111948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.118.111948%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DOlsen%26aufirst%3DE.%2BK.%26aulast%3DHusemoen%26aufirst%3DG.%26aulast%3DVestergaard%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWingler%26aufirst%3DL.%2BM.%26aulast%3DRambarat%26aufirst%3DP.%2BK.%26aulast%3DSimhal%26aufirst%3DR.%2BK.%26aulast%3DXu%26aufirst%3DT.%2BT.%26aulast%3DSun%26aufirst%3DL.%2BD.%26aulast%3DShim%26aufirst%3DP.%2BJ.%26aulast%3DStaus%26aufirst%3DD.%2BP.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DFranch%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DSmall-molecule%2520positive%2520allosteric%2520modulators%2520of%2520the%2520%25CE%25B22-adrenoceptor%2520isolated%2520from%2520DNA-encoded%2520libraries%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D94%26spage%3D850%26epage%3D861%26doi%3D10.1124%2Fmol.118.111948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahsai, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staus, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simhal, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambarat, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B.</span></span> <span> </span><span class="NLM_article-title">Mechanism of β<sub>2</sub>AR regulation by an intracellular positive allosteric modulator</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1126/science.aaw8981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1126%2Fscience.aaw8981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31249059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWjtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2019&pages=1283-1287&author=X.+Liuauthor=A.+Masoudiauthor=A.+W.+Kahsaiauthor=L.+Y.+Huangauthor=B.+Paniauthor=D.+P.+Stausauthor=P.+J.+Shimauthor=K.+Hirataauthor=R.+K.+Simhalauthor=A.+M.+Schwalbauthor=P.+K.+Rambaratauthor=S.+Ahnauthor=R.+J.+Lefkowitzauthor=B.+Kobilka&title=Mechanism+of+%CE%B22AR+regulation+by+an+intracellular+positive+allosteric+modulator&doi=10.1126%2Fscience.aaw8981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of β2AR regulation by an intracellular positive allosteric modulator</span></div><div class="casAuthors">Liu, Xiangyu; Masoudi, Ali; Kahsai, Alem W.; Huang, Li-Yin; Pani, Biswaranjan; Staus, Dean P.; Shim, Paul J.; Hirata, Kunio; Simhal, Rishabh K.; Schwalb, Allison M.; Rambarat, Paula K.; Ahn, Seungkirl; Lefkowitz, Robert J.; Kobilka, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">6447</span>),
    <span class="NLM_cas:pages">1283-1287</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Many drug discovery efforts focus on G protein-coupled receptors (GPCRs), a class of receptors that regulate many physiol. processes.  An exemplar is the β2-adrenergic receptor (β2AR), which is targeted by both blockers and agonists to treat cardiovascular and respiratory diseases.  Most GPCR drugs target the primary (orthosteric) ligand binding site, but binding at allosteric sites can modulate activation.  Because such allosteric sites are less conserved, they could possibly be targeted more specifically.  Liu et al. report the crystal structure of β2AR bound to both an orthosteric agonist and a pos. allosteric modulator that increases receptor activity.  The structure suggests why the modulator compd. is selective for β2AR over the closely related β1AR.  Furthermore, the structure reveals that the modulator acts by enhancing orthosteric agonist binding and stabilizing the active conformation of the receptor.  Science, this issue p.  1283.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqowDT5dSXkH7Vg90H21EOLACvtfcHk0lhJttQi4R6kNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWjtL3P&md5=17481f29b32a6bd0d10cc5bf7ca0ab61</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaw8981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaw8981%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMasoudi%26aufirst%3DA.%26aulast%3DKahsai%26aufirst%3DA.%2BW.%26aulast%3DHuang%26aufirst%3DL.%2BY.%26aulast%3DPani%26aufirst%3DB.%26aulast%3DStaus%26aufirst%3DD.%2BP.%26aulast%3DShim%26aufirst%3DP.%2BJ.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DSimhal%26aufirst%3DR.%2BK.%26aulast%3DSchwalb%26aufirst%3DA.%2BM.%26aulast%3DRambarat%26aufirst%3DP.%2BK.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DKobilka%26aufirst%3DB.%26atitle%3DMechanism%2520of%2520%25CE%25B22AR%2520regulation%2520by%2520an%2520intracellular%2520positive%2520allosteric%2520modulator%26jtitle%3DScience%26date%3D2019%26volume%3D364%26spage%3D1283%26epage%3D1287%26doi%3D10.1126%2Fscience.aaw8981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span> <span> </span><span class="NLM_article-title">Structural insights into adrenergic receptor function and pharmacology</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.tips.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21414670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFGrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=213-218&author=B.+K.+Kobilka&title=Structural+insights+into+adrenergic+receptor+function+and+pharmacology&doi=10.1016%2Fj.tips.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into adrenergic receptor function and pharmacology</span></div><div class="casAuthors">Kobilka, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">213-218</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  It has been over 50 years since Sir James Black developed the first beta adrenergic receptor (βAR) blocker to treat heart disease.  At that time, the concept of cell surface receptors was relatively new and not widely accepted, and most of the tools currently used to characterize plasma membrane receptors had not been developed.  There has been remarkable progress in receptor biol. since then, including the development of radioligand binding assays, the biochem. characterization of receptors as discrete membrane proteins, and the cloning of the first G-protein-coupled receptors (GPCRs), which led to the identification of other members of the large family of GPCRs.  More recently, progress in GPCR structural biol. has led to insights into the three-dimensional structures of βARs in both active and inactive states.  Despite all of this progress, the process of developing a drug for a particular GPCR target has become more complex, time-consuming and expensive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovKQolsPC6q7Vg90H21EOLACvtfcHk0lhJttQi4R6kNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFGrurw%253D&md5=a7d646e99b0d10b850ae0e41eae2c6cf</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26atitle%3DStructural%2520insights%2520into%2520adrenergic%2520receptor%2520function%2520and%2520pharmacology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D213%26epage%3D218%26doi%3D10.1016%2Fj.tips.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehler, E. L.</span></span> <span> </span><span class="NLM_article-title">Probing the structural determinants for the function of intracellular loop 2 in structurally cognate G-protein-coupled receptors</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">10691</span>– <span class="NLM_lpage">10701</span>, <span class="refDoi"> DOI: 10.1021/bi100580s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100580s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=10691-10701&author=J.+Shanauthor=H.+Weinsteinauthor=E.+L.+Mehler&title=Probing+the+structural+determinants+for+the+function+of+intracellular+loop+2+in+structurally+cognate+G-protein-coupled+receptors&doi=10.1021%2Fbi100580s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the structural determinants for function of intracellular loop 2 in structurally cognate G-protein-coupled receptors</span></div><div class="casAuthors">Shan, Jufang; Weinstein, Harel; Mehler, Ernest L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">10691-10701</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Intracellular loop 2 (IL2) in G-protein-coupled receptors (GPCRs) is functionally important, e.g., in binding to G-protein and β-arrestin.  Differences in secondary structure of IL2 in the crystal structures of the very similar β1- and β2-adrenergic receptors (β1AR and β2AR, resp.), i.e., an α-helix and an L-shaped strand, resp., emphasize the need to understand the structural basis for IL2 functionality.  We studied the properties of IL2 in the context of exptl. data using a Monte Carlo-based ab initio method.  The procedure was validated first by verifying that the IL2 structures in β1AR and β2AR crystals were correctly reproduced, even after conformational ensemble searches at >1200 K where most secondary structure had been lost.  We found that IL2 in β1AR and β2AR sampled each other's conformation but adopted different energetically preferred conformations, consistent with the crystal structures.  The results indicate a persistent contextual preference for the structure of IL2, which was conserved when the IL2 sequences were interchanged between the receptors.  We conclude that the protein environment, more than the IL2 sequence, regulates the IL2 structures.  We extended the approach to the mol. model of 5-HT2AR for which no crystal structure is available and found that IL2 is predominantly helical, similar to IL2 in β1AR.  Because the P3.57A mutation in IL2 had been shown to decrease β-arrestin binding and internalization, we predicted the effects of the mutation and found that it decreased the propensity of IL2 to form helix, identifying the helical IL2 as a component of the GPCR active form.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4OS3Ex6lMibVg90H21EOLACvtfcHk0lhJttQi4R6kNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOktrzN&md5=8a81ef781c97aa1d3885c4a81f68ca96</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Fbi100580s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100580s%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DJ.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DMehler%26aufirst%3DE.%2BL.%26atitle%3DProbing%2520the%2520structural%2520determinants%2520for%2520the%2520function%2520of%2520intracellular%2520loop%25202%2520in%2520structurally%2520cognate%2520G-protein-coupled%2520receptors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D10691%26epage%3D10701%26doi%3D10.1021%2Fbi100580s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaindl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stößel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matt, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunahara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">An allosteric modulator binds to a conformational hub in the β<sub>2</sub> adrenergic receptor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1038/s41589-020-0549-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1038%2Fs41589-020-0549-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32483378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVGmtbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=749-755&author=X.+Liuauthor=J.+Kaindlauthor=M.+Korczynskaauthor=A.+St%C3%B6%C3%9Felauthor=D.+Denglerauthor=M.+Stanekauthor=H.+H%C3%BCbnerauthor=M.+J.+Clarkauthor=J.+Mahoneyauthor=R.+A.+Mattauthor=X.+Xuauthor=K.+Hirataauthor=B.+K.+Shoichetauthor=R.+K.+Sunaharaauthor=B.+K.+Kobilkaauthor=P.+Gmeiner&title=An+allosteric+modulator+binds+to+a+conformational+hub+in+the+%CE%B22+adrenergic+receptor&doi=10.1038%2Fs41589-020-0549-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric modulator binds to a conformational hub in the β2 adrenergic receptor</span></div><div class="casAuthors">Liu, Xiangyu; Kaindl, Jonas; Korczynska, Magdalena; Stossel, Anne; Dengler, Daniela; Stanek, Markus; Hubner, Harald; Clark, Mary J.; Mahoney, Jake; Matt, Rachel Ann; Xu, Xinyu; Hirata, Kunio; Shoichet, Brian K.; Sunahara, Roger K.; Kobilka, Brian K.; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">749-755</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Most drugs acting on G-protein-coupled receptors target the orthosteric binding pocket where the native hormone or neurotransmitter binds.  There is much interest in finding allosteric ligands for these targets because they modulate physiol. signaling and promise to be more selective than orthosteric ligands.  Here we describe a newly developed allosteric modulator of the β2-adrenergic receptor (β2AR), AS408, that binds to the membrane-facing surface of transmembrane segments 3 and 5, as revealed by X-ray crystallog.  AS408 disrupts a water-mediated polar network involving E1223.41 and the backbone carbonyls of V2065.45 and S2075.46.  The AS408 binding site is adjacent to a previously identified mol. switch for β2AR activation formed by I3.40, P5.50 and F6.44.  The structure reveals how AS408 stabilizes the inactive conformation of this switch, thereby acting as a neg. allosteric modulator for agonists and pos. allosteric modulator for inverse agonists. [graphic not available: see fulltext].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKv03WK0jgMrVg90H21EOLACvtfcHk0lhfvRpL4OEPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVGmtbrE&md5=a53c31ae052c78d0b13cf3993c1f24f4</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1038%2Fs41589-020-0549-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-020-0549-2%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKaindl%26aufirst%3DJ.%26aulast%3DKorczynska%26aufirst%3DM.%26aulast%3DSt%25C3%25B6%25C3%259Fel%26aufirst%3DA.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DStanek%26aufirst%3DM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMahoney%26aufirst%3DJ.%26aulast%3DMatt%26aufirst%3DR.%2BA.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DSunahara%26aufirst%3DR.%2BK.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DAn%2520allosteric%2520modulator%2520binds%2520to%2520a%2520conformational%2520hub%2520in%2520the%2520%25CE%25B22%2520adrenergic%2520receptor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D16%26spage%3D749%26epage%3D755%26doi%3D10.1038%2Fs41589-020-0549-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suissa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boivin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habbick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cockroft, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNutt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buist, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, W. O.</span></span> <span> </span><span class="NLM_article-title">A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.149.3.8118625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm.149.3.8118625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8118625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2c7mtlCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=1994&pages=604-610&author=S.+Suissaauthor=P.+Ernstauthor=J.+F.+Boivinauthor=R.+I.+Horwitzauthor=B.+Habbickauthor=D.+Cockroftauthor=L.+Blaisauthor=M.+McNuttauthor=A.+S.+Buistauthor=W.+O.+Spitzer&title=A+cohort+analysis+of+excess+mortality+in+asthma+and+the+use+of+inhaled+beta-agonists&doi=10.1164%2Fajrccm.149.3.8118625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists</span></div><div class="casAuthors">Suissa S; Ernst P; Boivin J F; Horwitz R I; Habbick B; Cockroft D; Blais L; McNutt M; Buist A S; Spitzer W O</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">3 Pt 1</span>),
    <span class="NLM_cas:pages">604-10</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The association between the use of inhaled beta-agonists and the risk of death and near-death from asthma has previously been reported.  It was based on a nested case-control study of 129 cases and 655 control subjects selected from a cohort of 12,301 users of asthma drugs followed during the period 1980 through 1987.  In this paper we examine the question of asthma and non-asthma mortality using data from the entire cohort of 12,301 asthmatics.  There were 46 asthma and 134 non-asthma deaths in this cohort, for which there were 47,842 person-years of follow-up.  The overall rate of asthma death was 9.6 per 10,000 asthmatics per year.  This rate varied significantly according to the use of fenoterol, albuterol, or oral corticosteroids in the prior 12 months and the number of asthma hospitalizations in the prior 2 years.  The rate decreased significantly, by 0.6 asthma deaths per 10,000 asthmatics per year over the study period, after controlling for the effect of the four other risk factors.  It also increased significantly with the use of all beta-agonists, and more so for fenoterol than for albuterol, although this difference was partly explained by the dose inequivalence of the two drugs.  Change-point dose-response curves showed that the risk of asthma death began to escalate drastically at about 1.4 canisters (of 20,000 micrograms each) per month of inhaled beta-agonist, the recommended limit.  For non-asthma death, the overall rate of 28 deaths per 10,000 asthmatics per year was not related to the use of inhaled beta-agonists.(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEB3OT4wgRIn6oPH0mYWL1fW6udTcc2ebV_WuD5t95GLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7mtlCjtQ%253D%253D&md5=453201bfece5a719a3c4a27b33cf922e</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.149.3.8118625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.149.3.8118625%26sid%3Dliteratum%253Aachs%26aulast%3DSuissa%26aufirst%3DS.%26aulast%3DErnst%26aufirst%3DP.%26aulast%3DBoivin%26aufirst%3DJ.%2BF.%26aulast%3DHorwitz%26aufirst%3DR.%2BI.%26aulast%3DHabbick%26aufirst%3DB.%26aulast%3DCockroft%26aufirst%3DD.%26aulast%3DBlais%26aufirst%3DL.%26aulast%3DMcNutt%26aufirst%3DM.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DSpitzer%26aufirst%3DW.%2BO.%26atitle%3DA%2520cohort%2520analysis%2520of%2520excess%2520mortality%2520in%2520asthma%2520and%2520the%2520use%2520of%2520inhaled%2520beta-agonists%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1994%26volume%3D149%26spage%3D604%26epage%3D610%26doi%3D10.1164%2Fajrccm.149.3.8118625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, C.</span></span> <span> </span><span class="NLM_article-title">Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">S18</span>– <span class="NLM_lpage">S30</span>, <span class="refDoi"> DOI: 10.1016/S0091-6749(99)70270-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0091-6749%2899%2970270-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10452785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADyaK1MXmt12gurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1999&pages=S18-S30&author=R.+Beasleyauthor=N.+Pearceauthor=J.+Craneauthor=C.+Burgess&title=Beta-agonists%3A+what+is+the+evidence+that+their+use+increases+the+risk+of+asthma+morbidity+and+mortality%3F&doi=10.1016%2FS0091-6749%2899%2970270-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">β-Agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?</span></div><div class="casAuthors">Beasley, Richard; Pearce, Neil; Crane, Julian; Burgess, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">S18-S30</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">A review with 112 refs.  In this article, studies that have examd. the effects on morbidity and mortality of β-agonist drugs are reviewed.  With regard to morbidity, there is considerable evidence that the regular use of β-agonist drugs as a class could potentially lead to worsening asthma control because of the effects on bronchial hyperresponsiveness, the development of tolerance and reduced protection against provoking stimuli, an increased allergen load, and masking of the symptoms of deteriorating asthma.  Despite these effects, the short-acting β-agonist drugs albuterol and terbutaline and the long-acting β-agonist drugs salmeterol and formoterol have, in general, not been assocd. with a significant worsening of asthma control or an increased frequency of severe attacks.  In contrast, there is evidence that the regular use of isoproterenol and fenoterol may lead to worsening asthma control.  With regard to deaths, available evidence indicates that the high-dose prepns. of isoproterenol and fenoterol are assocd. with increased mortality and were the major causes of the epidemics of asthma mortality obsd. in some countries.  The increased risk of death assocd. with isoproterenol and fenoterol is probably the result of both long-term effects with their regular use leading to worsening asthma control and acute effects resulting from their overuse in the situation of a life-threatening attack of asthma.  In contrast, the use of the short-acting β-agonists albuterol and terbutaline is not assocd. with an increased risk of mortality.  Although this lack of risk may also apply to formoterol and salmeterol, in the absence of sufficient studies specifically addressing the risk of death, this remains uncertain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyyVEcerx0Z7Vg90H21EOLACvtfcHk0lhfvRpL4OEPZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmt12gurg%253D&md5=004aec75f1c23740fbddb8478c148f7b</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2FS0091-6749%2899%2970270-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-6749%252899%252970270-8%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DPearce%26aufirst%3DN.%26aulast%3DCrane%26aufirst%3DJ.%26aulast%3DBurgess%26aufirst%3DC.%26atitle%3DBeta-agonists%253A%2520what%2520is%2520the%2520evidence%2520that%2520their%2520use%2520increases%2520the%2520risk%2520of%2520asthma%2520morbidity%2520and%2520mortality%253F%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D1999%26volume%3D104%26spage%3DS18%26epage%3DS30%26doi%3D10.1016%2FS0091-6749%2899%2970270-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhamane, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, M.</span></span> <span> </span><span class="NLM_article-title">Short-acting β-agonist use and its ability to predict future asthma-related outcomes</span>. <i>Ann. Allergy, Asthma, Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1016/j.anai.2012.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.anai.2012.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23176877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslKqt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=403-407&author=R.+H.+Stanfordauthor=M.+B.+Shahauthor=A.+O.+D%E2%80%99Souzaauthor=A.+D.+Dhamaneauthor=M.+Schatz&title=Short-acting+%CE%B2-agonist+use+and+its+ability+to+predict+future+asthma-related+outcomes&doi=10.1016%2Fj.anai.2012.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Short-acting β-agonist use and its ability to predict future asthma-related outcomes</span></div><div class="casAuthors">Stanford, Richard H.; Shah, Manan B.; D'Souza, Anna O.; Dhamane, Amol D.; Schatz, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Allergy, Asthma, & Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">403-407</span>CODEN:
                <span class="NLM_cas:coden">ALAIF6</span>;
        ISSN:<span class="NLM_cas:issn">1081-1206</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Short-acting β-agonist (SABA) use is well established in predicting asthma events in adults.  However, this predictive ability has yet to be established in a pediatric population together with an assessment of amt. of use.  To identify the no. of SABA canisters that best predicts future asthma-related exacerbations and the optimal length of time for measurement of SABA use in pediatric and adult asthma patients.  Asthma patients were identified from a Medicaid and a com. insured database (Jan. 1, 2004, through Dec. 31, 2005, and Jan. 1, 2004, through June 30, 2006, resp.).  Following the date of first asthma medication, an assessment period (3, 6, or 12 mo) was used to measure SABA use.  Asthma-related exacerbations were identified in the subsequent 12-mo period.  Receiver operating characteristic curve analyses and logistic regression were used to select the crit. values of SABA use and optimal assessment periods and to conduct incremental anal., resp.  A total of 33,793 Medicaid and 101,437 com. patients met the study criteria.  Use of 3 or more SABA canisters during 12 mo was identified in both pediatric Medicaid and com. populations to best predict an increased risk of an asthma-related exacerbation.  For adults, use of 2 or more SABA canisters was found as the crit. value with shorter optimal assessment periods of 3 and 6 mo.  Each addnl. SABA canister resulted in an 8% to 14% and 14% to 18% increase in risk of an asthma-related exacerbation in children and adults, resp.  The study identified crit. values of SABA use that predict future asthma events.  Each addnl. SABA canister predicted increases in exacerbation risk in children and adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRMZ0Bl_iTYLVg90H21EOLACvtfcHk0ljgVrp7-oUghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslKqt7bO&md5=852546c4556c6b4b74c8c047a91565de</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2Fj.anai.2012.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.anai.2012.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DStanford%26aufirst%3DR.%2BH.%26aulast%3DShah%26aufirst%3DM.%2BB.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DA.%2BO.%26aulast%3DDhamane%26aufirst%3DA.%2BD.%26aulast%3DSchatz%26aufirst%3DM.%26atitle%3DShort-acting%2520%25CE%25B2-agonist%2520use%2520and%2520its%2520ability%2520to%2520predict%2520future%2520asthma-related%2520outcomes%26jtitle%3DAnn.%2520Allergy%252C%2520Asthma%252C%2520Immunol.%26date%3D2012%26volume%3D109%26spage%3D403%26epage%3D407%26doi%3D10.1016%2Fj.anai.2012.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span> <i>Pocket Guide for Asthma Management and Prevention
(for adults and
children older than 5 years), A Pocket Guide for Health Professionals</i>; <span class="NLM_publisher-name">Global Initiative for Asthma</span>, <span class="NLM_year">2018</span>; <a href="http://www.ginasthma.org" class="extLink">www.ginasthma.org</a> (accessed 2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pocket+Guide+for+Asthma+Management+and+Prevention%0A%28for+adults+and%0Achildren+older+than+5+years%29%2C+A+Pocket+Guide+for+Health+Professionals%3B+Global+Initiative+for+Asthma%2C+2018%3B+www.ginasthma.org+%28accessed+2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPocket%2520Guide%2520for%2520Asthma%2520Management%2520and%2520Prevention%250A%2528for%2520adults%2520and%250Achildren%2520older%2520than%25205%2520years%2529%252C%2520A%2520Pocket%2520Guide%2520for%2520Health%2520Professionals%26pub%3DGlobal%2520Initiative%2520for%2520Asthma%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span> <i>Global Strategy for Asthma
Management and Prevention</i>; <span class="NLM_publisher-name">Global Initiative
for Asthma</span>, <span class="NLM_year">2019</span> <a href="http://www.ginasthma.org" class="extLink">www.ginasthma.org</a> (accessed
2020-09-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Strategy+for+Asthma%0AManagement+and+Prevention%3B+Global+Initiative%0Afor+Asthma%2C+2019+www.ginasthma.org+%28accessed%0A2020-09-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Strategy%2520for%2520Asthma%250AManagement%2520and%2520Prevention%26pub%3DGlobal%2520Initiative%250Afor%2520Asthma%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddel, H. K.</span></span> <span> </span><span class="NLM_article-title">Inhaled combined budesonide-formoterol as needed in mild asthma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1865</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1715274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1715274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29768149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1865-1876&author=P.+M.+O%E2%80%99Byrneauthor=J.+M.+FitzGeraldauthor=E.+D.+Batemanauthor=P.+J.+Barnesauthor=N.+Zhongauthor=C.+Keenauthor=C.+Jorupauthor=R.+Lamarcaauthor=S.+Ivanovauthor=H.+K.+Reddel&title=Inhaled+combined+budesonide-formoterol+as+needed+in+mild+asthma&doi=10.1056%2FNEJMoa1715274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled combined budesonide-formoterol as needed in mild asthma</span></div><div class="casAuthors">O'Byrne, Paul M.; FitzGerald, J. Mark; Bateman, Eric D.; Barnes, Peter J.; Zhong, Nanshan; Keen, Christina; Jorup, Carin; Lamarca, Rosa; Ivanov, Stefan; Reddel, Helen K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1865-1876</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2-agonist may be an alternative to conventional treatment strategies. methods We conducted a 52-wk, double-blind trial involving patients 12 years of age or older with mild asthma.  Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed (budesonide-formoterol group), or twice-daily budesonide (200 μg) plus terbutaline used as needed (budesonide maintenance group).  The primary objective was to investigate the superiority of as-needed budesonide-formoterol to as-needed terbutaline with regard to electronically recorded weeks with well-controlled asthma. results A total of 3849 patients underwent randomization, and 3836 (1277 in the terbutaline group, 1277 in the budesonide-formoterol group, and 1282 in the budesonide maintenance group) were included in the full anal. and safety data sets.  With respect to the mean percentage of weeks with well-controlled asthma per patient, budesonide-formoterol was superior to terbutaline (34.4% vs. 31.1% of weeks; odds ratio, 1.14; 95% confidence interval [CI], 1.00 to 1.30; P = 0.046) but inferior to budesonide maintenance therapy (34.4% and 44.4%, resp.; odds ratio, 0.64; 95% CI, 0.57 to 0.73).  The annual rate of severe exacerbations was 0.20 with terbutaline, 0.07 with budesonide-formoterol, and 0.09 with budesonide maintenance therapy; the rate ratio was 0.36 (95% CI, 0.27 to 0.49) for budesonide-formoterol vs. terbutaline and 0.83 (95% CI, 0.59 to 1.16) for budesonide-formoterol vs. budesonide maintenance therapy.  The rate of adherence in the budesonide maintenance group was 78.9%.  The median metered daily dose of inhaled glucocorticoid in the budesonide-formoterol group (57 μg) was 17% of the dose in the budesonide maintenance group (340 μg). conclusions In patients with mild asthma, as-needed budesonide-formoterol provided superior asthma-symptom control to as-needed terbutaline, assessed according to electronically recorded weeks with well-controlled asthma, but was inferior to budesonide maintenance therapy.  Exacerbation rates with the two budesonide-contg. regimens were similar and were lower than the rate with terbutaline.  Budesonide-formoterol used as needed resulted in substantially lower glucocorticoid exposure than budesonide maintenance therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoikROAIrfIV7Vg90H21EOLACvtfcHk0ljgVrp7-oUghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nN&md5=ae850bc200c13d178131a8c77fcc826e</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1715274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1715274%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26aulast%3DFitzGerald%26aufirst%3DJ.%2BM.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DKeen%26aufirst%3DC.%26aulast%3DJorup%26aufirst%3DC.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DIvanov%26aufirst%3DS.%26aulast%3DReddel%26aufirst%3DH.%2BK.%26atitle%3DInhaled%2520combined%2520budesonide-formoterol%2520as%2520needed%2520in%2520mild%2520asthma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1865%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1715274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwek-Posluszna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FitzGerald, J. M.</span></span> <span> </span><span class="NLM_article-title">As-needed budesonide-formoterol versus maintenance budesonide in mild asthma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1887</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1715275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1715275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29768147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1877-1887&author=E.+D.+Batemanauthor=H.+K.+Reddelauthor=P.+M.+O%E2%80%99Byrneauthor=P.+J.+Barnesauthor=N.+Zhongauthor=C.+Keenauthor=C.+Jorupauthor=R.+Lamarcaauthor=A.+Siwek-Poslusznaauthor=J.+M.+FitzGerald&title=As-needed+budesonide-formoterol+versus+maintenance+budesonide+in+mild+asthma&doi=10.1056%2FNEJMoa1715275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">As-needed budesonide-formoterol versus maintenance budesonide in mild asthma</span></div><div class="casAuthors">Bateman, Eric D.; Reddel, Helen K.; O'Byrne, Paul M.; Barnes, Peter J.; Zhong, Nanshan; Keen, Christina; Jorup, Carin; Lamarca, Rosa; Siwek-Posluszna, Agnieszka; FitzGerald, J. Mark</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1877-1887</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Patients with mild asthma often rely on inhaled short-acting β2-agonists for symptom relief and have poor adherence to maintenance therapy.  Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk. methods We conducted a 52-wk, double-blind, multicenter trial involving patients 12 years of age or older who had mild asthma and were eligible for treatment with regular inhaled glucocorticoids.  Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 μg) plus terbutaline (0.5 mg) used as needed.  The primary anal. compared budesonide-formoterol used as needed with budesonide maintenance therapy with regard to the annualized rate of severe exacerbations, with a prespecified noninferiority limit of 1.2.  Symptoms were assessed according to scores on the Asthma Control Questionnaire-5 (ACQ-5) on a scale from 0 (no impairment) to 6 (max. impairment). results A total of 4215 patients underwent randomization, and 4176 (2089 in the budesonide-formoterol group and 2087 in the budesonide maintenance group) were included in the full anal. set.  Budesonide-formoterol used as needed was noninferior to budesonide maintenance therapy for severe exacerbations; the annualized rate of severe exacerbations was 0.11 (95% confidence interval [CI], 0.10 to 0.13) and 0.12 (95% CI, 0.10 to 0.14), resp. (rate ratio, 0.97; upper one-sided 95% confidence limit, 1.16).  The median daily metered dose of inhaled glucocorticoid was lower in the budesonide-formoterol group (66 μg) than in the budesonide maintenance group (267 μg).  The time to the first exacerbation was similar in the two groups (hazard ratio, 0.96; 95% CI, 0.78 to 1.17).  The change in ACQ-5 score showed a difference of 0.11 units (95% CI, 0.07 to 0.15) in favor of budesonide maintenance therapy. conclusions In patients with mild asthma, budesonide-formoterol used as needed was noninferior to twice-daily budesonide with respect to the rate of severe asthma exacerbations during 52 wk of treatment but was inferior in controlling symptoms.  Patients in the budesonide-formoterol group had approx. one quarter of the inhaled glucocorticoid exposure of those in the budesonide maintenance group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocos3eQcRO47Vg90H21EOLACvtfcHk0ljgVrp7-oUghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCrt7nI&md5=fde52ddd8f99e016bc5ec497949dbee5</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1715275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1715275%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DReddel%26aufirst%3DH.%2BK.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DP.%2BM.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DKeen%26aufirst%3DC.%26aulast%3DJorup%26aufirst%3DC.%26aulast%3DLamarca%26aufirst%3DR.%26aulast%3DSiwek-Posluszna%26aufirst%3DA.%26aulast%3DFitzGerald%26aufirst%3DJ.%2BM.%26atitle%3DAs-needed%2520budesonide-formoterol%2520versus%2520maintenance%2520budesonide%2520in%2520mild%2520asthma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1877%26epage%3D1887%26doi%3D10.1056%2FNEJMoa1715275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braithwaite, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebmeier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oldfield, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavord, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherall, M.</span></span> <span> </span><span class="NLM_article-title">Team controlled trial of budesonide-formoterol as needed for mild asthma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">2020</span>– <span class="NLM_lpage">2030</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901963</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1901963" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31112386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3M7otFWrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2020-2030&author=R.+Beasleyauthor=M.+Hollidayauthor=H.+K.+Reddelauthor=I.+Braithwaiteauthor=S.+Ebmeierauthor=R.+J.+Hancoxauthor=T.+Harrisonauthor=C.+Houghtonauthor=K.+Oldfieldauthor=A.+Papiauthor=I.+D.+Pavordauthor=M.+Williamsauthor=M.+Weatherall&title=Team+controlled+trial+of+budesonide-formoterol+as+needed+for+mild+asthma&doi=10.1056%2FNEJMoa1901963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma</span></div><div class="casAuthors">Beasley Richard; Holliday Mark; Reddel Helen K; Braithwaite Irene; Ebmeier Stefan; Hancox Robert J; Harrison Tim; Houghton Claire; Oldfield Karen; Papi Alberto; Pavord Ian D; Williams Mathew; Weatherall Mark</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2020-2030</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA.  The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.  METHODS:  We conducted a 52-week, randomized, open-label, parallel-group, controlled trial involving adults with mild asthma.  Patients were randomly assigned to one of three treatment groups: albuterol (100 μg, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 μg, one inhalation through a Turbuhaler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation through a Turbuhaler as needed) (budesonide-formoterol group).  Electronic monitoring of inhalers was used to measure medication use.  The primary outcome was the annualized rate of asthma exacerbations.  RESULTS:  The analysis included 668 of 675 patients who underwent randomization.  The annualized exacerbation rate in the budesonide-formoterol group was lower than that in the albuterol group (absolute rate, 0.195 vs. 0.400; relative rate, 0.49; 95% confidence interval [CI], 0.33 to 0.72; P<0.001) and did not differ significantly from the rate in the budesonide maintenance group (absolute rate, 0.195 in the budesonide-formoterol group vs. 0.175 in the budesonide maintenance group; relative rate, 1.12; 95% CI, 0.70 to 1.79; P = 0.65).  The number of severe exacerbations was lower in the budesonide-formoterol group than in both the albuterol group (9 vs. 23; relative risk, 0.40; 95% CI, 0.18 to 0.86) and the budesonide maintenance group (9 vs. 21; relative risk, 0.44; 95% CI, 0.20 to 0.96).  The mean (±SD) dose of inhaled budesonide was 107±109 μg per day in the budesonide-formoterol group and 222±113 μg per day in the budesonide maintenance group.  The incidence and type of adverse events reported were consistent with those in previous trials and with reports in clinical use.  CONCLUSIONS:  In an open-label trial involving adults with mild asthma, budesonide-formoterol used as needed was superior to albuterol used as needed for the prevention of asthma exacerbations. (Funded by AstraZeneca and the Health Research Council of New Zealand; Novel START Australian New Zealand Clinical Trials Registry number, ACTRN12615000999538.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEFz8wTkOF4Px2phytoz6_fW6udTcc2eY8cJ1DZ6M67bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7otFWrtQ%253D%253D&md5=9ce5c6e56d5952700f7fce528d3ac212</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901963%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DHolliday%26aufirst%3DM.%26aulast%3DReddel%26aufirst%3DH.%2BK.%26aulast%3DBraithwaite%26aufirst%3DI.%26aulast%3DEbmeier%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DR.%2BJ.%26aulast%3DHarrison%26aufirst%3DT.%26aulast%3DHoughton%26aufirst%3DC.%26aulast%3DOldfield%26aufirst%3DK.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DPavord%26aufirst%3DI.%2BD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DWeatherall%26aufirst%3DM.%26atitle%3DTeam%2520controlled%2520trial%2520of%2520budesonide-formoterol%2520as%2520needed%2520for%2520mild%2520asthma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26spage%3D2020%26epage%3D2030%26doi%3D10.1056%2FNEJMoa1901963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushey, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinchilli, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemanske, R. F.,  jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorkness, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauger, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szefler, S. J.</span></span> <span> </span><span class="NLM_article-title">Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">2583</span>– <span class="NLM_lpage">2593</span>, <span class="refDoi"> DOI: 10.1001/jama.285.20.2583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1001%2Fjama.285.20.2583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=11368732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlCisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2001&pages=2583-2593&author=S.+C.+Lazarusauthor=H.+A.+Bousheyauthor=J.+V.+Fahyauthor=V.+M.+Chinchilliauthor=R.+F.+Lemanskeauthor=C.+A.+Sorknessauthor=M.+Kraftauthor=J.+E.+Fishauthor=S.+P.+Petersauthor=T.+Craigauthor=J.+M.+Drazenauthor=J.+G.+Fordauthor=E.+Israelauthor=R.+J.+Martinauthor=E.+A.+Maugerauthor=S.+A.+Nachmanauthor=J.+D.+Spahnauthor=S.+J.+Szefler&title=Long-acting+beta2-agonist+monotherapy+vs+continued+therapy+with+inhaled+corticosteroids+in+patients+with+persistent+asthma%3A+a+randomized+controlled+trial&doi=10.1001%2Fjama.285.20.2583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting β2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: A randomized controlled trial</span></div><div class="casAuthors">Lazarus, Stephen C.; Boushey, Homer A.; Fahy, John V.; Chinchilli, Vernon M.; Lemanske, Robert F., Jr.; Sorkness, Christine A.; Kraft, Monica; Fish, James E.; Peters, Stephen P.; Craig, Timothy; Drazen, Jeffrey M.; Ford, Jean G.; Israel, Elliot; Martin, Richard J.; Mauger, Elizabeth A.; Nachman, Sami A.; Spahn, Joseph D.; Szefler, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2583-2593</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Long-acting β2-agonists are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs).  No evidence exists, however, to support their use as monotherapy in adults with persistent asthma.  Objective: To examine the effectiveness of salmeterol xinafoate, a long-acting β2-agonist, as replacement therapy in patients whose asthma is well controlled by low-dose triamcinolone acetonide, an ICS.  Design and Setting: A 28-wk, randomized, blinded, placebo-controlled, parallel group trial conducted at 6 National Institutes of Health-sponsored, university-based ambulatory care centers from Feb. 1997 to Jan. 1999.  Participants: One hundred sixty-four patients aged 12 through 65 yr with persistent asthma that was well controlled during a 6-wk run-in period of treatment with inhaled triamcinolone (400 μg twice per day).  Interventions: Patients were randomly assigned to continue triamcinolone therapy (400 μg twice per day; n=54) or switch to salmeterol (42 μg twice per day; n=54) or to placebo (n=56) for 16 wk, after which all patients received placebo for an addnl. 6-wk run-out period.  Main Outcome Measures: Change in morning and evening peak expiratory flow (PEF), forced expiratory vol. in 1 s (FEV1), self-assessed asthma symptom scores, rescue albuterol use, asthma-specific quality-of-life scores, treatment failure, asthma exacerbation, bronchial reactivity, and markers of airway inflammation, compared among the 3 treatment groups.  Results: During the 16-wk randomized treatment period, no significant differences between the salmeterol and triamcinolone groups were obsd. for conventional outcomes of clin. studies of asthma therapy-morning PEF, evening PEF, asthma symptom scores, rescue albuterol sulfate use, or quality of life.  Both active treatments were superior to placebo.  However, the salmeterol group had more treatment failures than the triamcinolone group (13/54 [24%] vs. 3/54 [6%]; P=.004), as well as more asthma exacerbations (11/54 [20%] vs. 4/54 [7%]; P=.04), greater increases in median (interquartile range) sputum eosinophils (2.4% [0.0% to 10.6%] vs -0.1% [-0.7% to 0.3%]; P<.001), eosinophil cationic protein (71 [-2 to 430] U/L vs -4 [-31 to 56] U/L; P=.005), and tryptase (3.1 [2.1 to 7.6] ng/mL vs. 0.0 [0.0 to 0.7] ng/mL; P<.001).  The duration of benefit when patients were switched from active treatment to placebo after 22 wk of randomized treatment was not significantly longer in the triamcinolone group than in the salmeterol group.  Conclusion: Patients with persistent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monotherapy without risk of clin. significant loss of asthma control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_y8kjAsnsarVg90H21EOLACvtfcHk0lgvEEcU9dif5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlCisr4%253D&md5=25fe79bc91f34a6edb2f245a78abfaec</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1001%2Fjama.285.20.2583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.285.20.2583%26sid%3Dliteratum%253Aachs%26aulast%3DLazarus%26aufirst%3DS.%2BC.%26aulast%3DBoushey%26aufirst%3DH.%2BA.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26aulast%3DChinchilli%26aufirst%3DV.%2BM.%26aulast%3DLemanske%26aufirst%3DR.%2BF.%26aulast%3DSorkness%26aufirst%3DC.%2BA.%26aulast%3DKraft%26aufirst%3DM.%26aulast%3DFish%26aufirst%3DJ.%2BE.%26aulast%3DPeters%26aufirst%3DS.%2BP.%26aulast%3DCraig%26aufirst%3DT.%26aulast%3DDrazen%26aufirst%3DJ.%2BM.%26aulast%3DFord%26aufirst%3DJ.%2BG.%26aulast%3DIsrael%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DR.%2BJ.%26aulast%3DMauger%26aufirst%3DE.%2BA.%26aulast%3DNachman%26aufirst%3DS.%2BA.%26aulast%3DSpahn%26aufirst%3DJ.%2BD.%26aulast%3DSzefler%26aufirst%3DS.%2BJ.%26atitle%3DLong-acting%2520beta2-agonist%2520monotherapy%2520vs%2520continued%2520therapy%2520with%2520inhaled%2520corticosteroids%2520in%2520patients%2520with%2520persistent%2520asthma%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJAMA%26date%3D2001%26volume%3D285%26spage%3D2583%26epage%3D2593%26doi%3D10.1001%2Fjama.285.20.2583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agache, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, R. A.</span></span> <span> </span><span class="NLM_article-title">SPIRO, Investigators. Serious asthma events with Mometasone furoate plus formoterol compared with Mometasone furoate</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1402</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2018.10.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jaci.2018.10.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30537475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2019&pages=1395-1402&author=C.+Weinsteinauthor=N.+Ryanauthor=T.+Shekarauthor=D.+Gatesauthor=S.+J.+Laneauthor=I.+Agacheauthor=R.+A.+Nathan&title=SPIRO%2C+Investigators.+Serious+asthma+events+with+Mometasone+furoate+plus+formoterol+compared+with+Mometasone+furoate&doi=10.1016%2Fj.jaci.2018.10.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate</span></div><div class="casAuthors">Weinstein, Cindy L. J.; Ryan, Nicholas; Shekar, Tulin; Gates, Davis; Lane, Stephen J.; Agache, Ioana; Nathan, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1395-1402</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The safety of long-acting β-agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.  We sought to det. whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes (SAOs) compared with mometasone furoate alone.  This clin. trial is registered as NCT01471340.  We conducted a 26-wk, randomized, double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of SAOs (adjudicated hospitalization, intubation, or death) compared with mometasone furoate alone.  The key efficacy end point was asthma exacerbation (composite of hospitalization of ≥24 h, emergency department visits of <24 h requiring systemic corticosteroids, or use of systemic corticosteroids for ≥3 consecutive days).  Among 11,729 patients (mometasone furoate-formoterol, n = 5,868; mometasone furoate, n = 5,861), a total of 81 SAOs, all asthma-related hospitalizations, were obsd. in 71 patients: 45 events from 39 patients receiving mometasone furoate-formoterol and 36 events from 32 patients receiving mometasone furoate.  The hazard ratio for the first SAO in the mometasone furoate-formoterol vs. mometasone furoate group was 1.22 (95% CI, 0.76-1.94; P = .411).  Asthma exacerbation occurred in 1,487 patients: 708 receiving mometasone furoate-formoterol and 779 receiving mometasone furoate.  The hazard ratio for the first asthma exacerbation in the mometasone furoate-formoterol vs. mometasone furoate group was 0.89 (95% CI, 0.80-0.98; P = .021).  The addn. of formoterol to mometasone furoate maintenance therapy did not increase the risk of serious asthma-related events and reduced the risk of asthma exacerbation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQaUZZeKYErVg90H21EOLACvtfcHk0lgKQRzH8NGV1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrt78%253D&md5=b2e9b2460c4e1bb51a563367666d25db</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2018.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2018.10.065%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DC.%26aulast%3DRyan%26aufirst%3DN.%26aulast%3DShekar%26aufirst%3DT.%26aulast%3DGates%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DS.%2BJ.%26aulast%3DAgache%26aufirst%3DI.%26aulast%3DNathan%26aufirst%3DR.%2BA.%26atitle%3DSPIRO%252C%2520Investigators.%2520Serious%2520asthma%2520events%2520with%2520Mometasone%2520furoate%2520plus%2520formoterol%2520compared%2520with%2520Mometasone%2520furoate%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2019%26volume%3D143%26spage%3D1395%26epage%3D1402%26doi%3D10.1016%2Fj.jaci.2018.10.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sears, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radner, F.</span></span> <span> </span><span class="NLM_article-title">Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1968</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2009.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2009.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19815402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1MjkvVSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=1960-1968&author=M.+R.+Searsauthor=F.+Radner&title=Safety+of+budesonide%2Fformoterol+maintenance+and+reliever+therapy+in+asthma+trials&doi=10.1016%2Fj.rmed.2009.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials</span></div><div class="casAuthors">Sears Malcolm R; Radner Finn</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1960-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The safety of long-acting beta(2)-agonists (LABAs) in asthma is debated.  This study examined the safety of the inhaled corticosteroid (ICS)/LABA combination budesonide/formoterol dry powder inhaler used as maintenance and reliever therapy versus combination treatments based on guideline recommendations.  METHODS:  Safety data from six double-blind, randomised clinical trials (RCTs) in asthma where budesonide/formoterol was used as maintenance and reliever therapy for at least 6 months were reviewed (N=14 346).  All-cause mortality and asthma-related serious adverse events (SAEs) (co-primary endpoints), overall and cardiac SAEs, and discontinuations due to adverse events (DAEs) were assessed.  Estimated Mantel-Haenszel (MH) relative risks (RR) with this regimen versus comparators were calculated.  RESULTS:  There was no increase in all-cause mortality with budesonide/formoterol maintenance and reliever therapy (four deaths [0.07%] versus nine [0.10%]; pooled MH RR 0.70, 95% confidence interval [CI] 0.21-2.30).  Asthma-related SAEs were reduced with budesonide/formoterol maintenance and reliever therapy: 41 (0.73%) versus 121 (1.38%); pooled MH RR 0.59, 95% CI 0.42-0.85.  All-cause and asthma-related DAEs were also reduced with budesonide/formoterol maintenance and reliever therapy: pooled MH RR 0.60 (95% CI 0.46-0.79) and 0.43 (0.28-0.68), respectively.  Overall and cardiac-related SAEs were comparable between treatment groups: pooled MH RR 0.96 (95% CI 0.82-1.14) and 1.26 (0.72-2.22), respectively.  CONCLUSION:  Budesonide/formoterol dry powder inhaler maintenance and reliever therapy was well tolerated in RCTs versus fixed-dose alternatives and not associated with increased risk of death or cardiac-related SAEs and DAEs, and asthma-related SAEs and DAEs were significantly reduced.  Given the limitations of RCTs, particularly exclusion of patients with co-morbidities, ongoing surveillance is appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQugFsuSveOoDDnmmyUf5qOfW6udTcc2eaSX1MX8_OD77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjkvVSmsw%253D%253D&md5=2cc2bb75b9a4e8d28518a9b49bc60744</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2009.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2009.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DSears%26aufirst%3DM.%2BR.%26aulast%3DRadner%26aufirst%3DF.%26atitle%3DSafety%2520of%2520budesonide%252Fformoterol%2520maintenance%2520and%2520reliever%2520therapy%2520in%2520asthma%2520trials%26jtitle%3DRespir.%2520Med.%26date%3D2009%26volume%3D103%26spage%3D1960%26epage%3D1968%26doi%3D10.1016%2Fj.rmed.2009.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weatherall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wijesinghe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span> <span> </span><span class="NLM_article-title">Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1136/thx.2009.116608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.2009.116608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20029037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1MfktVelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=39-43&author=M.+Weatherallauthor=M.+Wijesingheauthor=K.+Perrinauthor=M.+Harwoodauthor=R.+Beasley&title=Meta-analysis+of+the+risk+of+mortality+with+salmeterol+and+the+effect+of+concomitant+inhaled+corticosteroid+therapy&doi=10.1136%2Fthx.2009.116608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy</span></div><div class="casAuthors">Weatherall M; Wijesinghe M; Perrin K; Harwood M; Beasley R</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There is concern that long-acting beta agonist (LABA) drugs may increase the risk of asthma mortality.  METHODS:  A meta-analysis was conducted of asthma deaths in randomised controlled clinical trials from the GlaxoSmithKline database that compared salmeterol with a non-LABA comparator treatment in asthma.  The Peto one-step method was used to determine the risk overall (all studies) and in derived datasets based on inhaled corticosteroid (ICS) use.  RESULTS:  There were 35 asthma deaths in 215 studies with 106,575 subjects.  Two studies (SMART and SNS) contributed 30/35 (86%) asthma deaths, the overall findings largely reflecting the characteristics of these studies.  The odds ratio for risk of asthma mortality with salmeterol was 2.7 (95% CI 1.4 to 5.3).  In 54 placebo controlled studies the risk of death from asthma in patients not prescribed ICS was 7.3 (95% CI 1.8 to 29.4).  In 127 studies in which patients were prescribed ICS, the risk of asthma death was 2.1 (95% CI 0.6 to 7.9).  In 63 studies in which patients were randomised to receive the combination salmeterol/fluticasone propionate inhaler or ICS, there were no asthma deaths among 22,600 patients.  CONCLUSIONS:  Salmeterol monotherapy in asthma increases the risk of asthma mortality and this risk is reduced with concomitant ICS therapy.  There is no evidence that combination salmeterol/fluticasone propionate therapy is associated with an increased risk of asthma mortality, although this interpretation is limited by the low statistical power of available studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFULdOEbw9x0ewzGPswiWOfW6udTcc2eaSX1MX8_OD77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfktVelsg%253D%253D&md5=6be085a51b7c458c89db5103d67050b2</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1136%2Fthx.2009.116608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2009.116608%26sid%3Dliteratum%253Aachs%26aulast%3DWeatherall%26aufirst%3DM.%26aulast%3DWijesinghe%26aufirst%3DM.%26aulast%3DPerrin%26aufirst%3DK.%26aulast%3DHarwood%26aufirst%3DM.%26aulast%3DBeasley%26aufirst%3DR.%26atitle%3DMeta-analysis%2520of%2520the%2520risk%2520of%2520mortality%2520with%2520salmeterol%2520and%2520the%2520effect%2520of%2520concomitant%2520inhaled%2520corticosteroid%2520therapy%26jtitle%3DThorax%26date%3D2010%26volume%3D65%26spage%3D39%26epage%3D43%26doi%3D10.1136%2Fthx.2009.116608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stempel, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphiou, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeakey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prazma, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buaron, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascoe, S. J.</span></span> <span> </span><span class="NLM_article-title">AUSTRI, Investigators. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1822</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1511049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1511049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26949137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOltLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1822-1830&author=D.+A.+Stempelauthor=I.+H.+Raphiouauthor=K.+M.+Kralauthor=A.+M.+Yeakeyauthor=A.+H.+Emmettauthor=C.+M.+Prazmaauthor=K.+S.+Buaronauthor=S.+J.+Pascoe&title=AUSTRI%2C+Investigators.+Serious+asthma+events+with+fluticasone+plus+salmeterol+versus+fluticasone+alone&doi=10.1056%2FNEJMoa1511049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Serious asthma events with fluticasone plus salmeterol versus fluticasone alone</span></div><div class="casAuthors">Stempel, David A.; Raphiou, Ibrahim H.; Kral, Kenneth M.; Yeakey, Anne M.; Emmett, Amanda H.; Prazma, Charlene M.; Buaron, Kathleen S.; Pascoe, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1822-1830</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated.  In two large clin. trials, investigators found a potential risk of serious asthma-related events assocd. with LABAs.  This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.  METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 wk.  All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month.  Patients were excluded from the trial if they had a history of lifethreatening or unstable asthma.  The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization).  Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0.  The efficacy end point was the first severe asthma exacerbation.  RESULTS Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group.  The hazard ratio for a serious asthmarelated event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P = 0.003).  There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthmarelated intubation.  The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).  CONCLUSIONS Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone.  Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdtYh9KG12rVg90H21EOLACvtfcHk0lgKQRzH8NGV1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOltLbI&md5=2cea1dab41cda2e30c7ac9730a376422</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1511049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1511049%26sid%3Dliteratum%253Aachs%26aulast%3DStempel%26aufirst%3DD.%2BA.%26aulast%3DRaphiou%26aufirst%3DI.%2BH.%26aulast%3DKral%26aufirst%3DK.%2BM.%26aulast%3DYeakey%26aufirst%3DA.%2BM.%26aulast%3DEmmett%26aufirst%3DA.%2BH.%26aulast%3DPrazma%26aufirst%3DC.%2BM.%26aulast%3DBuaron%26aufirst%3DK.%2BS.%26aulast%3DPascoe%26aufirst%3DS.%2BJ.%26atitle%3DAUSTRI%252C%2520Investigators.%2520Serious%2520asthma%2520events%2520with%2520fluticasone%2520plus%2520salmeterol%2520versus%2520fluticasone%2520alone%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1822%26epage%3D1830%26doi%3D10.1056%2FNEJMoa1511049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleecker, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canonica, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fjallbrant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorup, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, U. J.</span></span> <span> </span><span class="NLM_article-title">Serious asthma events with budesonide plus formoterol vs. budesonide alone</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1511190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa1511190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27579635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=850-860&author=S.+P.+Petersauthor=E.+R.+Bleeckerauthor=G.+W.+Canonicaauthor=Y.+B.+Parkauthor=R.+Ramirezauthor=S.+Hollisauthor=H.+Fjallbrantauthor=C.+Jorupauthor=U.+J.+Martin&title=Serious+asthma+events+with+budesonide+plus+formoterol+vs.+budesonide+alone&doi=10.1056%2FNEJMoa1511190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Serious asthma events with budesonide plus formoterol vs. budesonide alone</span></div><div class="casAuthors">Peters, Stephen P.; Bleecker, Eugene R.; Canonica, Giorgio W.; Park, Yong B.; Ramirez, Ricardo; Hollis, Sally; Fjallbrant, Harald; Jorup, Carin; Martin, Ubaldo J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Concerns remain about the safety of adding long-acting β2-agonists to inhaled glucocorticoids for the treatment of asthma.  In a postmarketing safety study mandated by the Food and Drug Administration, we evaluated whether the addn. of formoterol to budesonide maintenance therapy increased the risk of serious asthma-related events in patients with asthma.  METHODS: In this multicenter, double-blind, 26-wk study, we randomly assigned patients, 12 years of age or older, who had persistent asthma, were receiving daily asthma medication, and had had one to four asthma exacerbations in the previous year to receive budesonide-formoterol or budesonide alone.  Patients with a history of life-threatening asthma were excluded.  The primary end point was the first serious asthma-related event (a composite of adjudicated death, intubation, and hospitalization), as assessed in a time-to-event anal.  The noninferiority of budesonide-formoterol to budesonide was defined as an upper limit of the 95% confidence interval for the risk of the primary safety end point of less than 2.0.  The primary efficacy end point was the first asthma exacerbation, as assessed in a time-to-event anal.  RESULTS: A total of 11,693 patients underwent randomization, of whom 5846 were assigned to receive budesonide-formoterol and 5847 to receive budesonide.  A serious asthma-related event occurred in 43 patients who were receiving budesonide-formoterol and in 40 patients who were receiving budesonide (hazard ratio, 1.07; 95% confidence interval [CI], 0.70 to 1.65); budesonide-formoterol was shown to be noninferior to budesonide alone.  There were two asthma-related deaths, both in the budesonide-formoterol group; one of these patients had undergone an asthma-related intubation.  The risk of an asthma exacerbation was 16.5% lower with budesonide-formoterol than with budesonide (hazard ratio, 0.84; 95% CI, 0.74 to 0.94; P = 0.002).  CONCLUSIONS: Among adolescents and adults with predominantly moderate-to-severe asthma, treatment with budesonide-formoterol was assocd. with a lower risk of asthma exacerbations than budesonide and a similar risk of serious asthma-related events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgH7g0WIHhpLVg90H21EOLACvtfcHk0lg5w0-vfYxtng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks73O&md5=bcc44d41a30ddb02a9b4d8b9ff172bd9</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1511190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1511190%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%2BP.%26aulast%3DBleecker%26aufirst%3DE.%2BR.%26aulast%3DCanonica%26aufirst%3DG.%2BW.%26aulast%3DPark%26aufirst%3DY.%2BB.%26aulast%3DRamirez%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DS.%26aulast%3DFjallbrant%26aufirst%3DH.%26aulast%3DJorup%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DU.%2BJ.%26atitle%3DSerious%2520asthma%2520events%2520with%2520budesonide%2520plus%2520formoterol%2520vs.%2520budesonide%2520alone%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D850%26epage%3D860%26doi%3D10.1056%2FNEJMoa1511190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iftikhar, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imtiaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brett, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrol, D. J.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of long acting beta agonist-inhaled corticosteroid combination products in adult patients with asthma: a systematic review</span>. <i>Lung</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1007/s00408-013-9525-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00408-013-9525-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24153452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFChsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2014&pages=47-54&author=I.+H.+Iftikharauthor=M.+Imtiazauthor=A.+S.+Brettauthor=D.+J.+Amrol&title=Cardiovascular+safety+of+long+acting+beta+agonist-inhaled+corticosteroid+combination+products+in+adult+patients+with+asthma%3A+a+systematic+review&doi=10.1007%2Fs00408-013-9525-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular Safety of Long Acting Beta Agonist-Inhaled Corticosteroid Combination Products in Adult Patients with Asthma: A Systematic Review</span></div><div class="casAuthors">Iftikhar, Imran H.; Imtiaz, Muhammad; Brett, Allan S.; Amrol, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Lung</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">LUNGD9</span>;
        ISSN:<span class="NLM_cas:issn">0341-2040</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Introduction Long-acting beta agonists and inhaled corticosteroids combination products (LABA-ICS) are widely used in the treatment of asthma.  However, there appears to be little data on their cardiovascular safety.  The purpose of this study was to conduct a systematic review of the available studies and trials on the cardiovascular safety of LABA-ICS in adults with asthma.  Methods Two independent reviewers screened citations from PubMed and National Clin. Trials registry to identify studies and trials on the cardiovascular effects of LABA-ICS in patients with asthma.  Results A total of 15 studies (with 17 cohorts on LABA-ICS to compare with a comparator or placebo) with 5,440 total study participants met the inclusion criteria.  Two studies on budesonide-formoterol and one on fluticasone-salmeterol reported treatment emergent cardiovascular adverse events, all of which were dysrhythmias.  For comparison, the pooled est. of the Peto odds ratio (0.72; 95 % confidence interval [CI] 0.17-3; p = 0.65) and the summary risk ratio (0.77; 95 % CI 0.26-2.3; p = 0.64) indicated a nonsignificant difference between LABA-ICS and comparator/placebo groups.  Conclusions Our systematic review found that few studies and trials reported treatment emergent cardiovascular adverse events with LABA-ICS.  However, the Peto odds ratio and risk ratio for these outcomes was statistically nonsignificant.  This suggests that LABA-ICS products may have a safe cardiovascular profile in asthma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRcznxY-xJ-bVg90H21EOLACvtfcHk0lg5w0-vfYxtng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFChsbk%253D&md5=cdc9962c341f1b101fd0a0c98e16c6e9</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1007%2Fs00408-013-9525-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00408-013-9525-x%26sid%3Dliteratum%253Aachs%26aulast%3DIftikhar%26aufirst%3DI.%2BH.%26aulast%3DImtiaz%26aufirst%3DM.%26aulast%3DBrett%26aufirst%3DA.%2BS.%26aulast%3DAmrol%26aufirst%3DD.%2BJ.%26atitle%3DCardiovascular%2520safety%2520of%2520long%2520acting%2520beta%2520agonist-inhaled%2520corticosteroid%2520combination%2520products%2520in%2520adult%2520patients%2520with%2520asthma%253A%2520a%2520systematic%2520review%26jtitle%3DLung%26date%3D2014%26volume%3D192%26spage%3D47%26epage%3D54%26doi%3D10.1007%2Fs00408-013-9525-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Maltzahn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naya, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T.</span></span> <span> </span><span class="NLM_article-title">Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2009.02320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1742-1241.2009.02320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20456215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2010&pages=619-627&author=S.+J.+Edwardsauthor=R.+von+Maltzahnauthor=I.+P.+Nayaauthor=T.+Harrison&title=Budesonide%2Fformoterol+for+maintenance+and+reliever+therapy+of+asthma%3A+a+meta+analysis+of+randomised+controlled+trials&doi=10.1111%2Fj.1742-1241.2009.02320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomized controlled trials</span></div><div class="casAuthors">Edwards, S. J.; von Maltzahn, R.; Naya, I. P.; Harrison, T.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">619-627</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1368-5031</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To compare the effectiveness of budesonide/formoterol (Symbicort) for Maintenance and Reliever Therapy (Symbicort SMART) Turbuhaler with twice daily inhaled corticosteroid (ICS) treatment, alone or in combination with a long-acting β2-agonist (LABA).  Meta anal. of randomized controlled trials (RCTs) using a fixed effects model.  RCTs were included if the comparator with budesonide/formoterol for maintenance and relief had the equiv., or up to fourfold higher, maintenance dose of ICS.  The primary outcome was the incidence of severe exacerbation (oral glucocorticosteroid treatment for ≥ 3 days, emergency visit and/or hospitalization).  Of the seven RCTs available six met the inclusion criteria.  Risk of severe exacerbations was significantly reduced: 41% vs. higher-dose budesonide alone [relative risk (RR) 0.59, 95% confidence interval (95% CI): 0.51-0.68, p < 0.00001]; 43% vs. equiv. dose budesonide/formoterol as maintenance twice daily (RR 0.57, 95% CI: 0.49-0.66, p < 0.00001); 24% vs. higher-dose salmeterol/fluticasone twice daily (RR 0.76, 95% CI: 0.64-0.90, p = 0.002); and 26% vs. higher-dose budesonide/formoterol twice daily (RR 0.74, 95% CI: 0.58-0.96, p = 0.02).  Significant heterogeneity was not detected in the primary analyses (p > 0.1).  Secondary analyses also demonstrated that budesonide/formoterol for maintenance and relief reduced the most severe exacerbations, resulting in less hospitalizations/accident and emergency visits than higher-dose budesonide, equiv. dose budesonide/formoterol and higher-dose salmeterol/fluticasone twice daily.  Budesonide/formoterol for maintenance and relief is significantly more effective at reducing severe exacerbations than higher-dose ICS alone, or in combination with a LABA.  This has important implications for treating uncontrolled patients at steps 2 and 3 of the joint BTS/SIGN guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzWH0iEN2dDLVg90H21EOLACvtfcHk0ljDryBN8FQukA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVertbg%253D&md5=50ff7372227b5a985639eed52ec43fd7</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2009.02320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2009.02320.x%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DS.%2BJ.%26aulast%3Dvon%2BMaltzahn%26aufirst%3DR.%26aulast%3DNaya%26aufirst%3DI.%2BP.%26aulast%3DHarrison%26aufirst%3DT.%26atitle%3DBudesonide%252Fformoterol%2520for%2520maintenance%2520and%2520reliever%2520therapy%2520of%2520asthma%253A%2520a%2520meta%2520analysis%2520of%2520randomised%2520controlled%2520trials%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2010%26volume%3D64%26spage%3D619%26epage%3D627%26doi%3D10.1111%2Fj.1742-1241.2009.02320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sobieraj, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeda, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarus, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. L.</span></span> <span> </span><span class="NLM_article-title">Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>319</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1496</span>, <span class="refDoi"> DOI: 10.1001/jama.2018.2769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1001%2Fjama.2018.2769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29554195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFKjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2018&pages=1485-1496&author=D.+M.+Sobierajauthor=E.+R.+Weedaauthor=E.+Nguyenauthor=C.+I.+Colemanauthor=C.+M.+Whiteauthor=S.+C.+Lazarusauthor=K.+V.+Blakeauthor=J.+E.+Langauthor=W.+L.+Baker&title=Association+of+inhaled+corticosteroids+and+long-acting+%CE%B2-agonists+as+controller+and+quick+relief+therapy+with+exacerbations+and+symptom+control+in+persistent+asthma%3A+A+systematic+review+and+meta-analysis&doi=10.1001%2Fjama.2018.2769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis</span></div><div class="casAuthors">Sobieraj, Diana M.; Weeda, Erin R.; Nguyen, Elaine; Coleman, Craig I.; White, C. Michael; Lazarus, Stephen C.; Blake, Kathryn V.; Lang, Jason E.; Baker, William L.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">319</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1485-1496</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Combined use of inhaled corticosteroids and long-acting β-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma.  Objective To conduct a systematic review and meta-anal. of the effects of SMART in patients with persistent asthma.  Data Sources and Study Selection The databases of MEDLINE via OVID, EMBASE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched from database inception through August 2016 and updated through Nov. 28, 2017.  Two reviewers selected randomized clin. trials or observational studies evaluating SMART vs inhaled corticosteroids with or without a LABA used as the controller therapy and short-acting β-agonists as the relief therapy for patients aged 5 years or older with persistent asthma and reporting on an outcome of interest.  Data Extn. and Synthesis Meta-analyses were conducted using a random-effects model to calc. risk ratios (RRs), risk differences (RDs), and mean differences with corresponding 95% CIs.  Citation screening, data abstraction, risk assessment, and strength of evidence grading were completed by 2 independent reviewers.  Main Outcomes and Measures Asthma exacerbations.  Results The analyses included 16 randomized clin. trials (N = 22748 patients), 15 of which evaluated SMART as a combination therapy with budesonide and formoterol in a dry-powder inhaler.  Among patients aged 12 years or older (n = 22524; mean age, 42 years; 14634 [65%] were female), SMART was assocd. with a reduced risk of asthma exacerbations compared with the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.68 [95% CI, 0.58 to 0.80]; RD, -6.4% [95% CI, -10.2% to -2.6%]) and a higher dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.77 [95% CI, 0.60 to 0.98]; RD, -2.8% [95% CI, -5.2% to -0.3%]).  Similar results were seen when SMART was compared with inhaled corticosteroids alone as the controller therapy.  Among patients aged 4 to 11 years (n = 341; median age, 8 [range, 4-11] years; 69 [31%] were female), SMART was assocd. with a reduced risk of asthma exacerbations compared with a higher dose of inhaled corticosteroids as the controller therapy (RR, 0.55 [95% CI, 0.32 to 0.94]; RD, -12.0% [95% CI, -22.5% to -1.5%]) or the same dose of inhaled corticosteroids and LABA as the controller therapy (RR, 0.38 [95% CI, 0.23 to 0.63]; RD, -23.2% [95% CI, -33.6% to -12.1%]).  Conclusions and Relevance In this meta-anal. of patients with persistent asthma, the use of single maintenance and reliever therapy compared with inhaled corticosteroids as the controller therapy (with or without a long-acting β-agonist) and short-acting β-agonists as the relief therapy was assocd. with a lower risk of asthma exacerbations.  Evidence for patients aged 4 to 11 years was limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWucPj8fg0pbVg90H21EOLACvtfcHk0ljDryBN8FQukA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFKjtL8%253D&md5=0b9e5aaa1ddd1f222f7b872071cb6ef0</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1001%2Fjama.2018.2769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2018.2769%26sid%3Dliteratum%253Aachs%26aulast%3DSobieraj%26aufirst%3DD.%2BM.%26aulast%3DWeeda%26aufirst%3DE.%2BR.%26aulast%3DNguyen%26aufirst%3DE.%26aulast%3DColeman%26aufirst%3DC.%2BI.%26aulast%3DWhite%26aufirst%3DC.%2BM.%26aulast%3DLazarus%26aufirst%3DS.%2BC.%26aulast%3DBlake%26aufirst%3DK.%2BV.%26aulast%3DLang%26aufirst%3DJ.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BL.%26atitle%3DAssociation%2520of%2520inhaled%2520corticosteroids%2520and%2520long-acting%2520%25CE%25B2-agonists%2520as%2520controller%2520and%2520quick%2520relief%2520therapy%2520with%2520exacerbations%2520and%2520symptom%2520control%2520in%2520persistent%2520asthma%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DJAMA%26date%3D2018%26volume%3D319%26spage%3D1485%26epage%3D1496%26doi%3D10.1001%2Fjama.2018.2769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kew, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavergames, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J. A. E.</span></span> <span> </span><span class="NLM_article-title">Long-acting beta2-agonists for chronic obstructive pulmonary disease</span>. <i>Cochrane. Db. Syst. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">CD001104</span>, <span class="refDoi"> DOI: 10.1002/14651858.CD010177.pub2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2F14651858.CD010177.pub2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=CD001104&author=K.+M.+Kewauthor=C.+Mavergamesauthor=J.+A.+E.+Walters&title=Long-acting+beta2-agonists+for+chronic+obstructive+pulmonary+disease&doi=10.1002%2F14651858.CD010177.pub2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1002%2F14651858.CD010177.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F14651858.CD010177.pub2%26sid%3Dliteratum%253Aachs%26aulast%3DKew%26aufirst%3DK.%2BM.%26aulast%3DMavergames%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DJ.%2BA.%2BE.%26atitle%3DLong-acting%2520beta2-agonists%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DCochrane.%2520Db.%2520Syst.%2520Rev.%26date%3D2013%26volume%3D3%26spage%3DCD001104%26doi%3D10.1002%2F14651858.CD010177.pub2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonikov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleasdale, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1136/thx.2009.125435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.2009.125435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20522841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3cvks1ensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2010&pages=473-479&author=R.+Dahlauthor=K.+F.+Chungauthor=R.+Buhlauthor=H.+Magnussenauthor=V.+Nonikovauthor=D.+Jackauthor=P.+Bleasdaleauthor=R.+Owenauthor=M.+Higginsauthor=B.+Kramer&title=Efficacy+of+a+new+once-daily+long-acting+inhaled+beta2-agonist+indacaterol+versus+twice-daily+formoterol+in+COPD&doi=10.1136%2Fthx.2009.125435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD</span></div><div class="casAuthors">Dahl Ronald; Chung Kian Fan; Buhl Roland; Magnussen Helgo; Nonikov Vladimir; Jack Damon; Bleasdale Patricia; Owen Roger; Higgins Mark; Kramer Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">473-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Indacaterol is a long-acting inhaled beta(2)-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD).  In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action.  This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year.  METHODS:  Patients with moderate to severe COPD were randomised to receive once-daily indacaterol 300 microg (n=437) or 600 microg (n=428), twice-daily formoterol 12 microg (n=435) or placebo (n=432) for 52 weeks in a double-blind double-dummy parallel group study.  The primary efficacy variable was forced expiratory volume in 1 s (FEV(1)) measured 24 h postdose after 12 weeks (indacaterol vs placebo).  Other outcomes included dyspnoea (transition dyspnoea index, TDI), use of as-needed salbutamol, symptom-based measures recorded on diary cards, exacerbations, health status (St George's Respiratory Questionnaire), BODE index (body mass index, obstruction, dyspnoea, exercise), safety and tolerability.  RESULTS:  Indacaterol increased 24 h postdose FEV(1) after 12 weeks by 170 ml (both doses) versus placebo and by 100 ml versus formoterol (all p<0.001).  These significant differences were maintained at 52 weeks.  Symptomatic outcomes were improved compared with placebo with all active treatments, and indacaterol was more effective than formoterol in improving TDI score and reducing the need for as-needed salbutamol.  Indacaterol was well tolerated and had a good overall safety profile, including minimal impact on QTc interval and systemic beta(2)-mediated events.  CONCLUSIONS:  Once-daily indacaterol is an effective 24 h bronchodilator that improves symptoms and health status and confers clinical improvements over a twice-daily 12 h LABA as a treatment for patients with moderate to severe COPD.  TRIAL REGISTRATION NUMBER:  NCT 00393458.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSW_IgXNgeCDUE-swuRqsHfW6udTcc2eY6qJNzVd5eMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvks1ensg%253D%253D&md5=e20b65f2a8c271ac399904f6ad65e38d</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1136%2Fthx.2009.125435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2009.125435%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DBuhl%26aufirst%3DR.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DNonikov%26aufirst%3DV.%26aulast%3DJack%26aufirst%3DD.%26aulast%3DBleasdale%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26atitle%3DEfficacy%2520of%2520a%2520new%2520once-daily%2520long-acting%2520inhaled%2520beta2-agonist%2520indacaterol%2520versus%2520twice-daily%2520formoterol%2520in%2520COPD%26jtitle%3DThorax%26date%3D2010%26volume%3D65%26spage%3D473%26epage%3D479%26doi%3D10.1136%2Fthx.2009.125435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizzichini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korducki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Salvo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paggiaro, P.</span></span> <span> </span><span class="NLM_article-title">Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.2147/COPD.S62502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S62502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25045258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yjtbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=697-714&author=A.+Kochauthor=E.+Pizzichiniauthor=A.+Hamiltonauthor=L.+Hartauthor=L.+Korduckiauthor=M.+C.+De+Salvoauthor=P.+Paggiaro&title=Lung+function+efficacy+and+symptomatic+benefit+of+olodaterol+once+daily+delivered+via+Respimat%C2%AE+versus+placebo+and+formoterol+twice+daily+in+patients+with+GOLD+2%E2%80%934+COPD%3A+results+from+two+replicate+48-week+studies&doi=10.2147%2FCOPD.S62502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies</span></div><div class="casAuthors">Koch, Andrea; Pizzichini, Emilio; Hamilton, Alan; Hart, Lorna; Korducki, Lawrence; De Salvo, Maria Cristina; Paggiaro, Pierluigi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">697-714, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Two replicate, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III studies investigated the long-term efficacy and safety of once-daily olodaterol via Respimat vs. placebo and formoterol over 48 wk in patients with moderate to very severe chronic obstructive pulmonary disease receiving usual-care background therapy.  Patients received once-daily olodaterol 5 or 10 μg, twice-daily formoterol 12 μg, or placebo.  Co-primary end points were forced expiratory vol. in 1 s (FEV1) area under the curve from 0-3 h response, FEV1 trough response, and Mahler transition dyspnea index total score after 24 wk; secondary end points included St George's Respiratory Questionnaire.  Overall, 904 (Study 1222.13) and 934 (Study 1222.14) patients received treatment.  Olodaterol significantly improved FEV1 area under the curve from 0-3 h vs. placebo in both studies (with olodaterol 5 μg, 0.151 L and 0.129 L; with olodaterol 10 μg, 0.165 L and 0.154 L; for all comparisons P<0.0001) and FEV1 trough responses vs. placebo (0.053-0.085 L; P<0.01), as did formoterol.  Primary anal. revealed no significant difference in transition dyspnea index focal score for any active treatment vs. placebo.  Post hoc anal. using pattern mixt. modeling (accounting for discontinuations) demonstrated statistical significance for olodaterol vs. placebo.  St George's Respiratory Questionnaire total score was significantly improved with olodaterol, but not formoterol, vs. placebo.  No safety signals were identified from adverse-event or other safety data.  Once-daily olodaterol 5 μg and 10 μg is efficacious in patients with moderate to very severe chronic obstructive pulmonary disease on usual-care maintenance therapy, with a satisfactory safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSeMaO_9_CM7Vg90H21EOLACvtfcHk0lhHGM88Gbhsbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yjtbrJ&md5=99c19c78088850263c442a017508dbbc</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S62502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S62502%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DPizzichini%26aufirst%3DE.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DHart%26aufirst%3DL.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DDe%2BSalvo%26aufirst%3DM.%2BC.%26aulast%3DPaggiaro%26aufirst%3DP.%26atitle%3DLung%2520function%2520efficacy%2520and%2520symptomatic%2520benefit%2520of%2520olodaterol%2520once%2520daily%2520delivered%2520via%2520Respimat%25C2%25AE%2520versus%2520placebo%2520and%2520formoterol%2520twice%2520daily%2520in%2520patients%2520with%2520GOLD%25202%25E2%2580%25934%2520COPD%253A%2520results%2520from%2520two%2520replicate%252048-week%2520studies%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2014%26volume%3D9%26spage%3D697%26epage%3D714%26doi%3D10.2147%2FCOPD.S62502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGarvey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewoehner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korducki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bothner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, G. T.</span></span> <span> </span><span class="NLM_article-title">One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: Results of a pre-specified pooled analysis</span>. <i>COPD</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.3109/15412555.2014.991864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3109%2F15412555.2014.991864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25692310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2MrmsVWitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=484-493&author=L.+McGarveyauthor=D.+Niewoehnerauthor=S.+Magderauthor=P.+Sachsauthor=K.+Tetzlaffauthor=A.+Hamiltonauthor=L.+Korduckiauthor=U.+Bothnerauthor=C.+Vogelmeierauthor=A.+Kochauthor=G.+T.+Ferguson&title=One-year+safety+of+olodaterol+once+daily+via+Respimat%C2%AE+in+patients+with+GOLD+2%E2%80%934+chronic+obstructive+pulmonary+disease%3A+Results+of+a+pre-specified+pooled+analysis&doi=10.3109%2F15412555.2014.991864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis</span></div><div class="casAuthors">McGarvey Lorcan; Niewoehner Dennis; Magder Sheldon; Sachs Paul; Tetzlaff Kay; Bothner Ulrich; Tetzlaff Kay; Hamilton Alan; Korducki Lawrence; Vogelmeier Claus; Koch Andrea; Ferguson Gary T</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">484-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies.  This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2-4) chronic obstructive pulmonary disease (COPD).  The studies compared olodaterol (5 or 10 μg) QD via Respimat®, formoterol 12 μg twice daily (BID) via Aerolizer® (1222.13 and 1222.14), and placebo for 48 weeks.  Patients continued receiving background maintenance therapy, with ∼60% receiving concomitant cardiovascular therapy and 25% having a history of concomitant cardiac disease.  Pre-specified analyses of pooled data assessed the adverse events (AEs) and serious AEs in the whole population, and in subgroups with cardiac disease, along with in-depth electrocardiogram and Holter monitoring.  In total, 3104 patients were included in the safety analysis: 876 received olodaterol 5 μg, 883 received olodaterol 10 μg, 885 received placebos, and 460 received formoterol 12 μg BID.  Overall incidence of on-treatment AEs (71.2%), serious AEs (16.1%), and deaths (1.7%) were balanced across treatment groups.  Respiratory and cardiovascular AEs, including major adverse cardiac events, were reported at similar frequencies in placebo and active treatment groups.  The safety profiles of both olodaterol 5 μg (marketed and registered dose) and 10 μg QD delivered via Respimat® are comparable to placebo and formoterol BID in this population, with no safety signals identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPzdDD_1opdjDnmmyUf5qOfW6udTcc2eY6qJNzVd5eMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrmsVWitw%253D%253D&md5=80568c046bb23f134c9edbc3a1be6d80</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.3109%2F15412555.2014.991864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15412555.2014.991864%26sid%3Dliteratum%253Aachs%26aulast%3DMcGarvey%26aufirst%3DL.%26aulast%3DNiewoehner%26aufirst%3DD.%26aulast%3DMagder%26aufirst%3DS.%26aulast%3DSachs%26aufirst%3DP.%26aulast%3DTetzlaff%26aufirst%3DK.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DKorducki%26aufirst%3DL.%26aulast%3DBothner%26aufirst%3DU.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DKoch%26aufirst%3DA.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26atitle%3DOne-year%2520safety%2520of%2520olodaterol%2520once%2520daily%2520via%2520Respimat%25C2%25AE%2520in%2520patients%2520with%2520GOLD%25202%25E2%2580%25934%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520Results%2520of%2520a%2520pre-specified%2520pooled%2520analysis%26jtitle%3DCOPD%26date%3D2015%26volume%3D12%26spage%3D484%26epage%3D493%26doi%3D10.3109%2F15412555.2014.991864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metaxas, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balis, E.</span></span> <span> </span><span class="NLM_article-title">The safety of indacaterol for the treatment of COPD</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1080/14740338.2018.1472233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1080%2F14740338.2018.1472233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29741108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptFCmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=637-642&author=E.+I.+Metaxasauthor=E.+Balis&title=The+safety+of+indacaterol+for+the+treatment+of+COPD&doi=10.1080%2F14740338.2018.1472233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">The safety of indacaterol for the treatment of COPD</span></div><div class="casAuthors">Metaxas, Evgenios I.; Balis, Evangelos</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">637-642</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Bronchodilators, namely long-acting inhaled β2-agonists and long-acting muscarinic antagonists, are the first-line medications for chronic obstructive pulmonary disease (COPD).  The safety of these medicines is of great concern since COPD patients usually have other co-morbidities such as cardio- and cerebrovascular diseases.: In this review we present information about the safety and the use of indacaterol in COPD.  Indacaterol is the first once-daily, long-acting inhaled β2-agonist approved for COPD.  We provide data about its mechanism of action as well as, pharmacodynamics and pharmacokynetics.  Moreover, we present the available literature data focused on the the safety of indacaterol.  Data from post-marketing studies are presented and also data from comparative reviews and meta-anal.: Indacaterol's safety is very favorable since in controlled trials it was similar to placebo.  Nevertheless, physicians must be alerted to use indacaterol only according to its approved indications They must be aware of the possible adverse events since side effects may appear when the medicine is used for a prolonged period of time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4xzs1hpJbXrVg90H21EOLACvtfcHk0li_yvnEU4ZTkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptFCmtr8%253D&md5=9d43f051c3a28d8f3019a8e9d417df87</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1080%2F14740338.2018.1472233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2018.1472233%26sid%3Dliteratum%253Aachs%26aulast%3DMetaxas%26aufirst%3DE.%2BI.%26aulast%3DBalis%26aufirst%3DE.%26atitle%3DThe%2520safety%2520of%2520indacaterol%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2018%26volume%3D17%26spage%3D637%26epage%3D642%26doi%3D10.1080%2F14740338.2018.1472233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melani, A. S.</span></span> <span> </span><span class="NLM_article-title">Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1611</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1518431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1080%2F14656566.2018.1518431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30311516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWiurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1603-1611&author=A.+S.+Melani&title=Olodaterol+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+narrative+review&doi=10.1080%2F14656566.2018.1518431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review</span></div><div class="casAuthors">Melani, Andrea S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1603-1611</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management.  Olodaterol 5 μg, a long-acting β2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy.: This article reviews the several trials that have assessed olodaterol as a COPD therapy.  It covers safety and tolerability data and provides the reader with an expert opinion on its use as a treatment for COPD.: Olodaterol improves lung function for 24 h and reduces rescue medication use.  It may also improve dyspnea, exercise tolerance, and health-related quality of life.  It is well tolerated with an acceptable cardiovascular and respiratory adverse event profile.  There is some evidence that olodaterol, as well as other LABAs, can reduce exacerbation frequency, but not FEV1 decline and death.  LABAs alone are indicated in group A/B COPD subjects.  Olodaterol and indacaterol are administered once-daily and may offer an adherence advantage over other LABAs with more frequent dosing schedules.  Co-administration of an olodaterol/tiotropium fixed dose combination in a single inhaler device is recommended as step-up in group A/B COPD subjects not sufficiently treated by olodaterol alone or as initial therapy in those with severe exertional dyspnea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroTyoaAt_l2LVg90H21EOLACvtfcHk0li_yvnEU4ZTkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWiurrM&md5=efbf7235b6be6130d17bddc2e4f283d8</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1518431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1518431%26sid%3Dliteratum%253Aachs%26aulast%3DMelani%26aufirst%3DA.%2BS.%26atitle%3DOlodaterol%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520narrative%2520review%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D1603%26epage%3D1611%26doi%3D10.1080%2F14656566.2018.1518431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">Ultra-LABAs for the treatment of asthma</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2019.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2019.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31425937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvpt1yrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=47-52&author=M.+Cazzolaauthor=P.+Roglianiauthor=M.+G.+Matera&title=Ultra-LABAs+for+the+treatment+of+asthma&doi=10.1016%2Fj.rmed.2019.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Ultra-LABAs for the treatment of asthma</span></div><div class="casAuthors">Cazzola Mario; Rogliani Paola; Matera Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The term ultra-LABA indicates once-daily β2-AR agonists (abediterol, indacaterol, olodaterol and vilanterol) that are single enantiomers of the (R)-configuration.  All have a near full-agonist profile at human β2-AR.  They can be prescribed in asthmatics only when associated with an with ICS, although further confirmations need to clarify what really these agents add if used in association to ICS and in what asthmatic patients this association may have more value.  They are also under development in triple inhalers that include an ultra-LABA, a LAMA and an ICS.  The once-daily posology might increase adherence in long-term treatment of asthma but superiority to twice-daily LABAs has not yet been fully demonstrated.  In any case, still no ultra-LABA can be recommended as preferred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTC0N4vCAp6RFwe7cAcrfPfW6udTcc2eYCkMUFI8oyELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvpt1yrtw%253D%253D&md5=e529d4d908bcbf44c1247eb8afbe1d94</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2019.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2019.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DUltra-LABAs%2520for%2520the%2520treatment%2520of%2520asthma%26jtitle%3DRespir.%2520Med.%26date%3D2019%26volume%3D156%26spage%3D47%26epage%3D52%26doi%3D10.1016%2Fj.rmed.2019.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hederer, B. M.</span></span> <span> </span><span class="NLM_article-title">Effect of once-daily indacaterol maleate/Mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial</span>. <i>BMJ. Open</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e006131</span> <span class="refDoi"> DOI: 10.1136/bmjopen-2014-006131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fbmjopen-2014-006131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25649209" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=R.+W.+Beasleyauthor=J.+F.+Donohueauthor=R.+Mehtaauthor=H.+S.+Nelsonauthor=M.+Clayauthor=A.+Motonauthor=H.+J.+Kimauthor=B.+M.+Hederer&title=Effect+of+once-daily+indacaterol+maleate%2FMometasone+furoate+on+exacerbation+risk+in+adolescent+and+adult+asthma%3A+a+double-blind+randomised+controlled+trial&doi=10.1136%2Fbmjopen-2014-006131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1136%2Fbmjopen-2014-006131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmjopen-2014-006131%26sid%3Dliteratum%253Aachs%26aulast%3DBeasley%26aufirst%3DR.%2BW.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DMehta%26aufirst%3DR.%26aulast%3DNelson%26aufirst%3DH.%2BS.%26aulast%3DClay%26aufirst%3DM.%26aulast%3DMoton%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DHederer%26aufirst%3DB.%2BM.%26atitle%3DEffect%2520of%2520once-daily%2520indacaterol%2520maleate%252FMometasone%2520furoate%2520on%2520exacerbation%2520risk%2520in%2520adolescent%2520and%2520adult%2520asthma%253A%2520a%2520double-blind%2520randomised%2520controlled%2520trial%26jtitle%3DBMJ.%2520Open%26date%3D2015%26volume%3D5%26doi%3D10.1136%2Fbmjopen-2014-006131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kornmann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucsi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolosa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satlin, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/Mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">105809</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2019.105809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2019.105809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=32056721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB387hvFOmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2020&pages=105809&author=O.+Kornmannauthor=J.+Mucsiauthor=N.+Kolosaauthor=L.+Bandelliauthor=B.+Senauthor=L.+C.+Satlinauthor=P.+D%E2%80%99Andrea&title=Efficacy+and+safety+of+inhaled+once-daily+low-dose+indacaterol+acetate%2FMometasone+furoate+in+patients+with+inadequately+controlled+asthma%3A+Phase+III+randomised+QUARTZ+study+findings&doi=10.1016%2Fj.rmed.2019.105809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings</span></div><div class="casAuthors">Kornmann Oliver; Mucsi Janos; Kolosa Nadezda; Bandelli Lorraine; Satlin Lisa C; D'Andrea Peter; Sen Biswajit</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105809</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Global initiative for asthma (GINA) 2019 recommends adding a long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma.  Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients.  OBJECTIVE:  This phase III QUARTZ was a multicentre, randomised, double-blind, double-dummy and parallel-group study to assess the efficacy and safety of low-dose IND/MF 150/80 μg once daily (o.d.) versus MF 200 μg o.d. in adult and adolescent patients with inadequately controlled asthma.  METHODS:  Eligible patients (n = 802) were randomised (1:1) to receive either low-dose IND/MF 150/80 μg o.d. via Breezhaler® or MF 200 μg o.d. via Twisthaler® for 12 weeks.  Primary endpoint was trough forced expiratory volume in 1 s (FEV1) and key secondary endpoint was Asthma Control Questionnaire (ACQ-7) treatment difference after 12-week treatment.  Other secondary endpoints included ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, evaluated over 12-week treatment.  Safety was also assessed including serious asthma outcomes.  RESULTS:  Low-dose IND/MF significantly improved trough FEV1 (least squares mean treatment difference [LSMTD]: 0.182 L; p < 0.001) and ACQ-7 (LSMTD: -0.218; p < 0.001) versus MF at Week 12.  Improvements in all other secondary endpoints favoured low-dose IND/MF.  Safety was comparable.  CONCLUSION:  These results support the use of low-dose IND/MF 150/80 μg o.d. as a potential therapy for adult and adolescent patients with inadequately controlled asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl2FEczvBfOXp3bfzSLaX5fW6udTcc2eZ3EwJRtNtBO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387hvFOmuw%253D%253D&md5=2a3bbf84f20315b661d940f8b8b3136d</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2019.105809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2019.105809%26sid%3Dliteratum%253Aachs%26aulast%3DKornmann%26aufirst%3DO.%26aulast%3DMucsi%26aufirst%3DJ.%26aulast%3DKolosa%26aufirst%3DN.%26aulast%3DBandelli%26aufirst%3DL.%26aulast%3DSen%26aufirst%3DB.%26aulast%3DSatlin%26aufirst%3DL.%2BC.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520inhaled%2520once-daily%2520low-dose%2520indacaterol%2520acetate%252FMometasone%2520furoate%2520in%2520patients%2520with%2520inadequately%2520controlled%2520asthma%253A%2520Phase%2520III%2520randomised%2520QUARTZ%2520study%2520findings%26jtitle%3DRespir.%2520Med.%26date%3D2020%26volume%3D161%26spage%3D105809%26doi%3D10.1016%2Fj.rmed.2019.105809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, S.</span></span> <span> </span><span class="NLM_article-title">Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2014.10.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2014.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25524507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2MzosVGrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2015&pages=44-53&author=J.+Linauthor=J.+Kangauthor=S.+H.+Leeauthor=C.+Wangauthor=X.+Zhouauthor=J.+Crawfordauthor=L.+Jacquesauthor=S.+Stone&title=Fluticasone+furoate%2Fvilanterol+200%2F25+mcg+in+Asian+asthma+patients%3A+a+randomized+trial&doi=10.1016%2Fj.rmed.2014.10.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial</span></div><div class="casAuthors">Lin Jiangtao; Kang Jian; Lee Sang Haak; Wang Changzheng; Zhou Xiangdong; Crawford Jodie; Jacques Loretta; Stone Sally</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study investigated the efficacy and safety of the inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) combination fluticasone furoate (FF)/vilanterol (VI) in Asian asthma patients.  METHODS:  A 12-week, double-blind, double-dummy, active-comparator, parallel-group, multicenter study. 309 Asian asthma patients (≥12 years, uncontrolled with high-strength ICS or mid-dose ICS/LABA) were randomized (1:1) and included in the intent-to-treat population; 155 received once-daily FF/VI 200/25 mcg and 154 received twice-daily fluticasone propionate (FP) 500 mcg.  The primary endpoint was change from baseline in daily evening peak expiratory flow (PEF) averaged over 12 weeks.  Secondary endpoints were mean change from baseline in % rescue-free 24-h periods, daily morning PEF, % symptom-free 24-h periods, and overall Asthma Quality of Life Questionnaire score.  Safety assessments were performed.  RESULTS:  For change from baseline in daily evening PEF, the adjusted mean treatment difference for FF/VI versus FP of 28.5 L/min (95% confidence interval [CI]: 20.1, 36.9) was clinically and statistically significant (p < 0.001).  For change from baseline in % rescue-free 24-h periods, the adjusted mean treatment difference (1.0%; 95% CI: -7.3, 9.2) was not statistically significant (p = 0.821).  Statistical significance could not be inferred for the remaining endpoints due to the statistical hierarchy employed.  Incidence of on-treatment adverse events was similar with FF/VI (26%; 3% treatment-related; n = 1 serious) and FP (27%; 3% treatment-related; n = 2 serious); none were fatal.  No further safety concerns were identified.  CONCLUSIONS:  FF/VI improved evening PEF over 12 weeks versus FP in Asian patients, with a similar safety profile.  The results are generally consistent with a global study comparing the same treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRz0GQkGQIPXENoizSOkG_FfW6udTcc2eZ3EwJRtNtBO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzosVGrug%253D%253D&md5=8c9a93fc2860a761d5dddf89f4d77860</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2014.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2014.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DCrawford%26aufirst%3DJ.%26aulast%3DJacques%26aufirst%3DL.%26aulast%3DStone%26aufirst%3DS.%26atitle%3DFluticasone%2520furoate%252Fvilanterol%2520200%252F25%2520mcg%2520in%2520Asian%2520asthma%2520patients%253A%2520a%2520randomized%2520trial%26jtitle%3DRespir.%2520Med.%26date%3D2015%26volume%3D109%26spage%3D44%26epage%3D53%26doi%3D10.1016%2Fj.rmed.2014.10.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devillier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boye, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachgo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antoun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grouin, J. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β<sub>2</sub>-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2018.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2018.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30053956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3c7islCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2018&pages=111-120&author=P.+Devillierauthor=M.+Humbertauthor=A.+Boyeauthor=W.+Zachgoauthor=L.+Jacquesauthor=C.+Nunnauthor=S.+Westauthor=A.+Nichollsauthor=Z.+Antounauthor=L.+Spinuauthor=J.+M.+Grouin&title=Efficacy+and+safety+of+once-daily+fluticasone+furoate%2Fvilanterol+%28FF%2FVI%29+versus+twice-daily+inhaled+corticosteroids%2Flong-acting+%CE%B22-agonists+%28ICS%2FLABA%29+in+patients+with+uncontrolled+asthma%3A+An+open-label%2C+randomized%2C+controlled+trial&doi=10.1016%2Fj.rmed.2018.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial</span></div><div class="casAuthors">Devillier Philippe; Humbert Marc; Boye Alain; Zachgo Wolfgang; Jacques Loretta; Nunn Carol; West Sarah; Nicholls Andy; Antoun Zeina; Spinu Luminita; Grouin Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-120</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  A variety of different fixed-dose combinations of inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) are available for the treatment of asthma.  The aim of this 24-week, open-label, multicenter, Phase IIIb randomized controlled trial was to evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI; 100/25 or 200/25 μg) compared with twice-daily fixed combinations of ICS/LABA (fluticasone propionate/salmeterol [FP/S] and budesonide/formoterol [BUD/F]) as maintenance therapy in patients with uncontrolled asthma treated with ICS alone.  METHODS:  Adult patients with documented physician-diagnosed asthma ≥1 year with an Asthma Control Test (ACT) score ≥15 and < 20 were included.  The primary study endpoint was change from baseline in ACT total score at Week 12.  RESULTS:  Overall, 423 patients were randomized to receive study medication in France and Germany.  The least-squares mean change (standard error) in ACT total score at Week 12 was 3.6 units with FF/VI and 2.8 with usual ICS/LABA, giving a treatment difference of 0.8 (95% confidence interval 0.1, 1.5; p = 0.033).  Non-inferiority of FF/VI to usual ICS/LABA was confirmed at Weeks 6, 18 and 24.  The observed safety profile for FF/VI in this study was in line with previous experience with FF/VI.  CONCLUSIONS:  These findings suggest that, in a tightly controlled randomized controlled trial setting, once-daily FF/VI provides similar asthma control over 24 weeks to usual, twice-daily ICS/LABA in patients with asthma that is uncontrolled on ICS alone.  FF/VI was well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvXcj8_Toz3e-MdeMhXAHkfW6udTcc2ebetS10xIODPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7islCktg%253D%253D&md5=f9751b062d629f25decd0aa65a35d3b7</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2018.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DDevillier%26aufirst%3DP.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DBoye%26aufirst%3DA.%26aulast%3DZachgo%26aufirst%3DW.%26aulast%3DJacques%26aufirst%3DL.%26aulast%3DNunn%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DNicholls%26aufirst%3DA.%26aulast%3DAntoun%26aufirst%3DZ.%26aulast%3DSpinu%26aufirst%3DL.%26aulast%3DGrouin%26aufirst%3DJ.%2BM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520fluticasone%2520furoate%252Fvilanterol%2520%2528FF%252FVI%2529%2520versus%2520twice-daily%2520inhaled%2520corticosteroids%252Flong-acting%2520%25CE%25B22-agonists%2520%2528ICS%252FLABA%2529%2520in%2520patients%2520with%2520uncontrolled%2520asthma%253A%2520An%2520open-label%252C%2520randomized%252C%2520controlled%2520trial%26jtitle%3DRespir.%2520Med.%26date%3D2018%26volume%3D141%26spage%3D111%26epage%3D120%26doi%3D10.1016%2Fj.rmed.2018.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donner, C. F.</span></span> <span> </span><span class="NLM_article-title">Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1610</span>, <span class="refDoi"> DOI: 10.2165/00003495-200565120-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2165%2F00003495-200565120-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16060696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=1595-1610&author=M.+Cazzolaauthor=M.+G.+Materaauthor=C.+F.+Donner&title=Inhaled+beta2-adrenoceptor+agonists%3A+cardiovascular+safety+in+patients+with+obstructive+lung+disease&doi=10.2165%2F00003495-200565120-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled β2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease</span></div><div class="casAuthors">Cazzola, Mario; Matera, Maria G.; Donner, Claudio F.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1595-1610</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Although large surveys have documented the favorable safety profile of β2-adrenoceptor agonists (β2-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality.  The coexistence of β1- and β2-adrenoceptors in the heart clearly indicates that β2-agonists do have some effect on the heart, even when they are highly selective.  It should also be taken into account that the β2-agonists utilized in clin. practice have differing selectivities and potencies.  β2-Agonist use has, in effect, been assocd. with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death.  Moreover, patients who have either asthma or chronic obstructive pulmonary disease may be at increased risk of cardiovascular complications because these diseases amplify the impact of these agents on the heart and, unfortunately, are a confounding factor when the impact of β2-agonists on the heart is evaluated.  Whatever the case may be, this effect is of particular concern for those patients with underlying cardiac conditions.  Therefore, β2-agonists must always be used with caution in patients with cardiopathies because these agents may ppt. the concomitant cardiac disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVXEAr6uqOorVg90H21EOLACvtfcHk0lhCo_JLtEnfsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKgtr%252FI&md5=fa894b87f871cb31b93be5b0c22d348f</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.2165%2F00003495-200565120-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200565120-00001%26sid%3Dliteratum%253Aachs%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DDonner%26aufirst%3DC.%2BF.%26atitle%3DInhaled%2520beta2-adrenoceptor%2520agonists%253A%2520cardiovascular%2520safety%2520in%2520patients%2520with%2520obstructive%2520lung%2520disease%26jtitle%3DDrugs%26date%3D2005%26volume%3D65%26spage%3D1595%26epage%3D1610%26doi%3D10.2165%2F00003495-200565120-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grove, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipworth, B. J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1136/thx.51.1.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.51.1.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8658370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK283msVCjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1996&pages=54-58&author=A.+Groveauthor=B.+J.+Lipworth&title=Evaluation+of+the+beta+2+adrenoceptor+agonist%2Fantagonist+activity+of+formoterol+and+salmeterol&doi=10.1136%2Fthx.51.1.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol</span></div><div class="casAuthors">Grove A; Lipworth B J</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-8</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Salmeterol and formoterol have a lower intrinsic activity at beta 2 receptors than isoprenaline in human bronchus in vitro.  The aim of the present study was to evaluate in vivo the beta 2 agonist/antagonist activity of salmeterol and formoterol at rest with low endogenous adrenergic tone, on exercise with raised endogenous adrenergic tone, and in the presence of fenoterol, an exogenous full beta 2 receptor agonist.  METHODS:  Eight normal subjects were randomised to receive single doses of placebo, salmeterol 300 micrograms, formoterol 72 micrograms, or propranolol 80 mg at weekly intervals. beta 2 adrenoceptor responses were evaluated at rest, at peak exercise, and after treatment with fenoterol 2.4 mg.  RESULTS:  At rest salmeterol and formoterol exhibited equivalent beta 2 agonist activity with regard to decrease in serum potassium levels and increase in finger tremor, with propranolol having no effect.  Salmeterol and formoterol, like propranolol, potentiated the hyperkalaemic delta response to exercise compared with placebo, consistent with beta 2 antagonism: (mean difference and 95% confidence interval (CI) compared with placebo) salmeterol 0.20 (0.02 to 0.38) mmol/l, formoterol 0.17 (0.00 to 0.34) mmol/l, propranolol 0.45 (0.08 to 0.82) mmol/l.  Propranolol blunted the heart rate delta response to exercise, consistent with beta 1 blockade, whilst salmeterol and formoterol had no effect.  Salmeterol and formoterol, like propranolol, attenuated the hypokalaemic, tremor, and heart rate delta responses to fenoterol compared with placebo, in keeping with beta 2 blockade: potassium, salmeterol 0.18 (0.0 to 0.36) mmol/l, formoterol 0.17 (-0.03 to 0.37) mmol/l, propranolol 0.80 (0.54 to 1.06) mmol/l; tremor, salmeterol -0.69 (-1.26 to -0.12) log units, formoterol -0.71 (-1.53 to 0.11) log units, propranolol -0.85 (-1.66 to -0.04) log units; heart rate, salmeterol -6 (-13 to 1) beats/min, formoterol -10 (-19 to -1) beats/min, propranolol -18 (-29 to -7) beats/min.  CONCLUSIONS:  At rest with low endogenous adrenergic tone salmeterol and formoterol showed equivalent beta 2 mediated agonist activity in terms of serum potassium and finger tremor responses.  In the presence of raised endogenous adrenergic tone at peak exercise and in the presence of fenoterol (an exogenous full beta 2 receptor agonist), salmeterol and formoterol, like propranolol, exhibited beta 2 receptor antagonism as evidenced by their attenuation of beta 2 receptor mediated responses.  The degree of beta 2 blockade with formoterol and salmeterol was comparable but less than with propranolol.  The relevance of these findings at extrapulmonary beta 2 receptors with regard to airway beta 2 responses remains unclear and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRdfzygottJpeRS7coPn-RtfW6udTcc2ebetS10xIODPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK283msVCjtA%253D%253D&md5=08e09a99435f754540436344fb60fe81</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1136%2Fthx.51.1.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.51.1.54%26sid%3Dliteratum%253Aachs%26aulast%3DGrove%26aufirst%3DA.%26aulast%3DLipworth%26aufirst%3DB.%2BJ.%26atitle%3DEvaluation%2520of%2520the%2520beta%25202%2520adrenoceptor%2520agonist%252Fantagonist%2520activity%2520of%2520formoterol%2520and%2520salmeterol%26jtitle%3DThorax%26date%3D1996%26volume%3D51%26spage%3D54%26epage%3D58%26doi%3D10.1136%2Fthx.51.1.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grove, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarlane, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipworth, B. J.</span></span> <span> </span><span class="NLM_article-title">Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1136/thx.50.2.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.50.2.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7701450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2M3hsF2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1995&pages=134-138&author=A.+Groveauthor=L.+C.+McFarlaneauthor=B.+J.+Lipworth&title=Expression+of+the+beta+2+adrenoceptor+partial+agonist%2Fantagonist+activity+of+salbutamol+in+states+of+low+and+high+adrenergic+tone&doi=10.1136%2Fthx.50.2.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone</span></div><div class="casAuthors">Grove A; McFarlane L C; Lipworth B J</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-8</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Salbutamol exhibits partial agonist/antagonist activity at airway beta 2 receptors in vitro in that it attenuates the bronchorelaxant effect of the full agonist isoprenaline.  The aim of the present study was to characterise the partial beta 2 agonist/antagonist activity of salbutamol in vivo during supine rest and exercise, in states of low and high adrenergic tone.  METHODS:  Eight normal subjects were randomised to receive single oral doses of salbutamol 2 mg, 4 mg, 8 mg (S2, S4, S8), placebo (PL), or propranolol 80 mg (PR).  The beta 2 adrenoceptor responses were evaluated after supine rest and subsequently in response to maximal exercise.  RESULTS:  Salbutamol demonstrated a dose-related increase in resting heart rate and tremor and a fall in serum potassium level consistent with beta 2 agonism.  On exercise, the hyperkalaemic response was augmented by propranolol compared with placebo consistent with beta 2 blockade: mean difference for delta response (95% CI) PR v PL was 0.60 (0.02 to 1.27) mmol/l.  This effect also occurred with salbutamol in a dose-related fashion: S8 v PL 0.33 (0.01 to 0.71) mmol/l, S8 v S2 0.31 (-0.02 to 0.61) mmol/l.  Whilst propranolol blunted exercise heart rate in keeping with beta 1 blockade, salbutamol had no effect.  Exercise produced an increase in lymphocyte beta 2 receptor binding density (Bmax) which was not affected by salbutamol.  Plasma levels of adrenaline and noradrenaline at peak exercise were also unaltered by salbutamol in comparison with placebo.  CONCLUSIONS:  In a state of low adrenergic tone at rest salbutamol produces effects consistent with beta 2 agonism.  In contrast, in a state of increased adrenergic tone during exercise salbutamol produced beta 2 selective antagonism as evidenced by its effects on exercise-induced hyperkalaemia (beta 2) but not on exercise-induced tachycardia (beta 1).  The effects of salbutamol on beta 2 receptor density do not explain its effects on exercise-induced hyperkalaemia since upregulation rather than downregulation was observed.  This in vivo phenomenon of partial beta 2 agonist/antagonist activity of salbutamol may be of relevance in the setting of acute asthma if adrenergic tone is increased.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL8_xqzNejzlUIs6wFK5xJfW6udTcc2eYiLt6uyIMTjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M3hsF2kug%253D%253D&md5=dfaa8d601a1176e09d477b93c8af0b10</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1136%2Fthx.50.2.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.50.2.134%26sid%3Dliteratum%253Aachs%26aulast%3DGrove%26aufirst%3DA.%26aulast%3DMcFarlane%26aufirst%3DL.%2BC.%26aulast%3DLipworth%26aufirst%3DB.%2BJ.%26atitle%3DExpression%2520of%2520the%2520beta%25202%2520adrenoceptor%2520partial%2520agonist%252Fantagonist%2520activity%2520of%2520salbutamol%2520in%2520states%2520of%2520low%2520and%2520high%2520adrenergic%2520tone%26jtitle%3DThorax%26date%3D1995%26volume%3D50%26spage%3D134%26epage%3D138%26doi%3D10.1136%2Fthx.50.2.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salpeter, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ormiston, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salpeter, E. E.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2309</span>– <span class="NLM_lpage">2321</span>, <span class="refDoi"> DOI: 10.1378/chest.125.6.2309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1378%2Fchest.125.6.2309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=15189956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslanurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2004&pages=2309-2321&author=S.+R.+Salpeterauthor=T.+M.+Ormistonauthor=E.+E.+Salpeter&title=Cardiovascular+effects+of+beta-agonists+in+patients+with+asthma+and+COPD%3A+a+meta-analysis&doi=10.1378%2Fchest.125.6.2309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects of β-agonists in patients with asthma and COPD: A meta-analysis</span></div><div class="casAuthors">Salpeter, Shelley R.; Ormiston, Thomas M.; Salpeter, Edwin E.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2309-2321</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">β-Adrenergic agonists exert physiol. effects that are the opposite of those of β-blockers.  β-Blockers are known to reduce morbidity and mortality in patients with cardiac disease.  β2-Agonist use in patients with obstructive airway disease has been assocd. with an increased risk for myocardial infarction, congestive heart failure, cardiac arrest, and acute cardiac death.  The aim of this study was to assess the cardiovascular safety of β2-agonist use in patients with obstructive airway disease, defined as asthma or COPD.  This was a meta-anal. of randomized placebo-controlled trials of β2-agonist treatment in patients with obstructive airway disease was performed, to evaluate the short-term effect on heart rate and potassium concns., and the long-term effect on adverse cardiovascular events.  Longer duration trials were included in the anal. if they reported at least one adverse event.  Adverse events included sinus and ventricular tachycardia, syncope, atrial fibrillation, congestive heart failure, myocardial infarction, cardiac arrest, or sudden death.  Thirteen single-dose trials and 20 longer duration trials were included in the study.  A single dose of β2-agonist increased the heart rate by 9.12 beats/min (95% confidence interval [CI], 5.32 to 12.92) and reduced the potassium concn. by 0.36 mmol/L (95% CI, 0.18 to 0.54), compared to placebo.  For trials lasting from 3 days to 1 yr, β2-agonist treatment significantly increased the risk for a cardiovascular event (relative risk [RR], 2.54; 95% CI, 1.59 to 4.05) compared to placebo.  The RR for sinus tachycardia alone was 3.06 (95% CI, 1.70 to 5.50), and for all other events it was 1.66 (95% CI, 0.76 to 3.6).  β2-Agonist use in patients with obstructive airway disease increases the risk for adverse cardiovascular events.  The initiation of treatment increases heart rate and reduces potassium concns. compared to placebo.  It could be through these mechanisms, and other effects of β-adrenergic stimulation, that β2-agonists may ppt. ischemia, congestive heart failure, arrhythmias, and sudden death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTACBJGKU-5rVg90H21EOLACvtfcHk0lhWe3vSLCQ3Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslanurY%253D&md5=12a2319a8b72dfdfd44afa8c9fbe6fe8</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1378%2Fchest.125.6.2309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.125.6.2309%26sid%3Dliteratum%253Aachs%26aulast%3DSalpeter%26aufirst%3DS.%2BR.%26aulast%3DOrmiston%26aufirst%3DT.%2BM.%26aulast%3DSalpeter%26aufirst%3DE.%2BE.%26atitle%3DCardiovascular%2520effects%2520of%2520beta-agonists%2520in%2520patients%2520with%2520asthma%2520and%2520COPD%253A%2520a%2520meta-analysis%26jtitle%3DChest%26date%3D2004%26volume%3D125%26spage%3D2309%26epage%3D2321%26doi%3D10.1378%2Fchest.125.6.2309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croxford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzavara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanbrook, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upshur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stukel, T. A.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease</span>. <i>JAMA. Int. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1185</span>, <span class="refDoi"> DOI: 10.1001/jamainternmed.2013.1016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1001%2Fjamainternmed.2013.1016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23689820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3snlt1Cmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2013&pages=1175-1185&author=A.+Gershonauthor=R.+Croxfordauthor=A.+Calzavaraauthor=T.+Toauthor=M.+B.+Stanbrookauthor=R.+Upshurauthor=T.+A.+Stukel&title=Cardiovascular+safety+of+inhaled+long-acting+bronchodilators+in+individuals+with+chronic+obstructive+pulmonary+disease&doi=10.1001%2Fjamainternmed.2013.1016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Gershon Andrea; Croxford Ruth; Calzavara Andrew; To Teresa; Stanbrook Matthew B; Upshur Ross; Stukel Therese A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA internal medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1175-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">IMPORTANCE:  Chronic obstructive pulmonary disease (COPD) is a common and deadly disease.  Long-acting inhaled β-agonists and anticholinergics, first-line medications for COPD, have been associated with increased risk of cardiovascular outcomes.  When choosing between the medications, patients and physicians would benefit from knowing which has the least risk.  OBJECTIVE:  To assess the association of these classes of medications with the risk of hospitalizations and emergency department visits for cardiovascular events.  DESIGN:  We conducted a nested case-control analysis of a retrospective cohort study.  We compared the risk of events between patients newly prescribed inhaled long-acting β-agonists and anticholinergics, after matching and adjusting for prognostic factors.  SETTING:  Health care databases from Ontario, the largest province of Canada, with a multicultural population of approximately 13 million.  PARTICIPANTS:  All individuals 66 years or older meeting a validated case definition of COPD, based on health administrative data, and treated for COPD from September 1, 2003, through March 31, 2009.  EXPOSURE:  New use of an inhaled long-acting β-agonist or long-acting anticholinergic.  MAIN OUTCOME AND MEASURES:  An emergency department visit or a hospitalization for a cardiovascular event.  RESULTS:  Of 191 005 eligible patients, 53 532 (28.0%) had a hospitalization or an emergency department visit for a cardiovascular event.  Newly prescribed long-acting inhaled β-agonists and anticholinergics were associated with a higher risk of an event compared with nonuse of those medications (respective adjusted odds ratios, 1.31 [95% CI, 1.12-1.52; P < .001] and 1.14 [1.01-1.28; P = .03]).  We found no significant difference in events between the 2 medications (adjusted odds ratio of long-acting inhaled β-agonists compared with anticholinergics, 1.15 [95% CI, 0.95-1.38; P = .16]).  CONCLUSIONS AND RELEVANCE:  Among older individuals with COPD, new use of long-acting β-agonists and anticholinergics is associated with similar increased risks of cardiovascular events.  Close monitoring of COPD patients requiring long-acting bronchodilators is needed regardless of drug class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsLI4Tm6tClnELvajU9pjPfW6udTcc2ebznq-cstGR1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snlt1Cmug%253D%253D&md5=51badbd39c783da3428d7b374d50fd06</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1001%2Fjamainternmed.2013.1016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamainternmed.2013.1016%26sid%3Dliteratum%253Aachs%26aulast%3DGershon%26aufirst%3DA.%26aulast%3DCroxford%26aufirst%3DR.%26aulast%3DCalzavara%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DT.%26aulast%3DStanbrook%26aufirst%3DM.%2BB.%26aulast%3DUpshur%26aufirst%3DR.%26aulast%3DStukel%26aufirst%3DT.%2BA.%26atitle%3DCardiovascular%2520safety%2520of%2520inhaled%2520long-acting%2520bronchodilators%2520in%2520individuals%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJAMA.%2520Int.%2520Med.%26date%3D2013%26volume%3D173%26spage%3D1175%26epage%3D1185%26doi%3D10.1001%2Fjamainternmed.2013.1016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipworth, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struthers, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDevitt, D. G.</span></span> <span> </span><span class="NLM_article-title">Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">586</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1164/ajrccm/140.3.586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1164%2Fajrccm%2F140.3.586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=2782734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref243/cit243&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaL1MzptFWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=1989&pages=586-592&author=B.+J.+Lipworthauthor=A.+D.+Struthersauthor=D.+G.+McDevitt&title=Tachyphylaxis+to+systemic+but+not+to+airway+responses+during+prolonged+therapy+with+high+dose+inhaled+salbutamol+in+asthmatics&doi=10.1164%2Fajrccm%2F140.3.586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit243R"><div class="casContent"><span class="casTitleNuber">243</span><div class="casTitle"><span class="NLM_cas:atitle">Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics</span></div><div class="casAuthors">Lipworth B J; Struthers A D; McDevitt D G</div><div class="citationInfo"><span class="NLM_cas:title">The American review of respiratory disease</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">586-92</span>
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses.  The purpose of the present study was to investigate whether tachyphylaxis occurs during prolonged treatment with high dose inhaled salbutamol.  Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design.  During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes.  At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).  Treatment had no significant effect on baseline values.  There were dose-dependent increases in FEV1 and FEF25-75 (p less than 0.001), and pretreatment with HDS did not displace the DRC to the right.  DRC for HR (p less than 0.001), K (p less than 0.001), and Glu (p less than 0.005) were attenuated after treatment with HDS compared with PI.  There were also differences between HDS and LDS for HR (p less than 0.001) and Glu (p less than 0.05) responses.  Frequency and severity of subjective adverse effects were also reduced after HDS: tremor (p less than 0.001), palpitations (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW3quDKyShfJVVjGoY74BafW6udTcc2ebznq-cstGR1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1MzptFWnsg%253D%253D&md5=b989ef6e14876814673f697742b0aa86</span></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=10.1164%2Fajrccm%2F140.3.586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm%252F140.3.586%26sid%3Dliteratum%253Aachs%26aulast%3DLipworth%26aufirst%3DB.%2BJ.%26aulast%3DStruthers%26aufirst%3DA.%2BD.%26aulast%3DMcDevitt%26aufirst%3DD.%2BG.%26atitle%3DTachyphylaxis%2520to%2520systemic%2520but%2520not%2520to%2520airway%2520responses%2520during%2520prolonged%2520therapy%2520with%2520high%2520dose%2520inhaled%2520salbutamol%2520in%2520asthmatics%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1989%26volume%3D140%26spage%3D586%26epage%3D592%26doi%3D10.1164%2Fajrccm%2F140.3.586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czaja, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiks, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Localio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmeier, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, W. G.</span></span> <span> </span><span class="NLM_article-title">Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias</span>. <i>Pharmacoepidemiol. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1002/pds.4562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fpds.4562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29806185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yjtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=815-822&author=A.+S.+Czajaauthor=M.+E.+Rossauthor=W.+Liuauthor=A.+G.+Fiksauthor=R.+Localioauthor=R.+C.+Wassermanauthor=R.+W.+Grundmeierauthor=W.+G.+Adams&title=Electronic+health+record+%28EHR%29+based+postmarketing+surveillance+of+adverse+events+associated+with+pediatric+off-label+medication+use%3A+A+case+study+of+short-acting+beta-2+agonists+and+arrhythmias&doi=10.1002%2Fpds.4562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: A case study of short-acting beta-2 agonists and arrhythmias</span></div><div class="casAuthors">Czaja, Angela S.; Ross, Michelle E.; Liu, Weiwei; Fiks, Alexander G.; Localio, Russell; Wasserman, Richard C.; Grundmeier, Robert W.; Adams, William G.; for the Comparative Effectiveness Research through Collaborative Electronic Reporting Consortium</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacoepidemiology and Drug Safety</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-822</span>CODEN:
                <span class="NLM_cas:coden">PDSAEA</span>;
        ISSN:<span class="NLM_cas:issn">1053-8569</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Use electronic health record (EHR) data to (1) est. the risk of arrhythmia assocd. with inhaled short-acting beta-2 agonists (SABA) in pediatric patients and (2) det. whether risk varied by on-label vs. off-label prescribing.  Retrospective cohort study of 335 041 children =18 years using EHR primary care data from 2 pediatric health systems (2011-2013).  A series of monthly pseudotrials were created, using propensity score methodol. to balance baseline characteristics between SABA-exposed (identified by prescription) and SABA-unexposed children.  Assocn. between SABA and subsequent arrhythmia for each health system was estd. through pooled logistic regression with sep. ests. for children initiating under and over 4 years old (off-label and on-label, resp.).  Eleven percent of the cohort received a SABA prescription, 57% occurred under the age of 4 years (off-label).  During the follow-up period, there were 283 first arrhythmia events, most commonly atrial tachyarrhythmias and premature ventricular/atrial contractions.  In 1 health system, adjusted risk for arrhythmia was increased among exposed children (OR 1.89, 95% CI 1.31-2.73) without evidence of interaction between label status and risk.  The abs. adjusted rate difference was 3.6/10 000 person-years of SABA exposure.  The assocn. between SABA exposure and arrhythmias was less strong in the second system (OR 1.26, 95% CI 0.30-5.33).  Using EHR data, we could est. the risk of a rare event assocd. with medication use and det. difference in risk related to on-label vs. off-label status.  These findings support the value of EHR-based data for postmarketing drug studies in the pediatric population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpmxC9v_NcmLVg90H21EOLACvtfcHk0lggAF6JqZn_GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yjtr3K&md5=fed2fab3464483fde08c8cef013fc55a</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1002%2Fpds.4562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpds.4562%26sid%3Dliteratum%253Aachs%26aulast%3DCzaja%26aufirst%3DA.%2BS.%26aulast%3DRoss%26aufirst%3DM.%2BE.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DFiks%26aufirst%3DA.%2BG.%26aulast%3DLocalio%26aufirst%3DR.%26aulast%3DWasserman%26aufirst%3DR.%2BC.%26aulast%3DGrundmeier%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DW.%2BG.%26atitle%3DElectronic%2520health%2520record%2520%2528EHR%2529%2520based%2520postmarketing%2520surveillance%2520of%2520adverse%2520events%2520associated%2520with%2520pediatric%2520off-label%2520medication%2520use%253A%2520A%2520case%2520study%2520of%2520short-acting%2520beta-2%2520agonists%2520and%2520arrhythmias%26jtitle%3DPharmacoepidemiol.%2520Drug%2520Saf.%26date%3D2018%26volume%3D27%26spage%3D815%26epage%3D822%26doi%3D10.1002%2Fpds.4562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warnier, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blom, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdowksi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souverein, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoes, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koster, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H. L.</span></span> <span> </span><span class="NLM_article-title">Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e65638</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0065638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0065638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23755262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFKhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+J.+Warnierauthor=M.+T.+Blomauthor=A.+Bardaiauthor=J.+Berdowksiauthor=P.+C.+Souvereinauthor=A.+W.+Hoesauthor=F.+H.+Ruttenauthor=A.+de+Boerauthor=R.+W.+Kosterauthor=M.+L.+De+Bruinauthor=H.+L.+Tan&title=Increased+risk+of+sudden+cardiac+arrest+in+obstructive+pulmonary+disease%3A+a+case-control+study&doi=10.1371%2Fjournal.pone.0065638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study</span></div><div class="casAuthors">Warnier, Miriam Jacoba; Blom, Marieke Tabo; Bardai, Abdennasser; Berdowksi, Jocelyn; Souverein, Patrick Cyriel; Hoes, Arno Wilhelmus; Rutten, Frans Hendrik; de Boer, Anthonius; Koster, Rudolph Willem; De Bruin, Marie Louise; Tan, Han Liong</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e65638</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: We aimed to det. whether (1) patients with obstructive pulmonary disease (OPD) have an increased risk of sudden cardiac arrest (SCA) due to ventricular tachycardia or fibrillation (VT/VF), and (2) the SCA risk is mediated by cardiovascular risk-profile and/or respiratory drug use.  Methods: A community-based case-control study was performed, with 1310 cases of SCA of the ARREST study and 5793 age, sex and SCA-date matched non-SCA controls from the PHARMO database.  Only incident SCA cases, age older than 40 years, that resulted from unequivocal cardiac causes with electro-cardiog. documentation of VT/VF were included.  Conditional logistic regression anal. was used to assess the assocn. between SCA and OPD.  Pre-specified subgroup analyses were performed regarding age, sex, cardiovascular risk-profile, disease severity and current use of respiratory drugs.  Results: A higher risk of SCA was obsd. in patients with OPD (n = 190 cases [15%], 622 controls [11%]) than in those without OPD (OR adjusted for cardiovascular risk-profile 1.4 [1.2-1.6]).  In OPD patients with a high cardiovascular risk-profile (OR 3.5 [2.7-4.4]) a higher risk of SCA was obsd. than in those with a low cardiovascular risk-profile (OR: 1.3 [0.9-1.9]).  The obsd. SCA risk was highest among OPD patients who received short-acting β2-adrenoreceptor agonists (SABA) or anticholinergics (AC) at the time of SCA (SABA OR: 3.9 [1.7-8.8], AC OR: 2.7 [1.5-4.8] compared to those without OPD).  Conclusions: OPD is assocd. with an increased obsd. risk of SCA.  The most increased risk was obsd. in patients with a high cardiovascular risk-profile, and in those who received SABA and, possibly, those who received AC at the time of SCA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLwFXsCsIhRLVg90H21EOLACvtfcHk0lgz14uHTLCNMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFKhtbs%253D&md5=0ffba9b00b7d96bc26220b3d422f2bea</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0065638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0065638%26sid%3Dliteratum%253Aachs%26aulast%3DWarnier%26aufirst%3DM.%2BJ.%26aulast%3DBlom%26aufirst%3DM.%2BT.%26aulast%3DBardai%26aufirst%3DA.%26aulast%3DBerdowksi%26aufirst%3DJ.%26aulast%3DSouverein%26aufirst%3DP.%2BC.%26aulast%3DHoes%26aufirst%3DA.%2BW.%26aulast%3DRutten%26aufirst%3DF.%2BH.%26aulast%3Dde%2BBoer%26aufirst%3DA.%26aulast%3DKoster%26aufirst%3DR.%2BW.%26aulast%3DDe%2BBruin%26aufirst%3DM.%2BL.%26aulast%3DTan%26aufirst%3DH.%2BL.%26atitle%3DIncreased%2520risk%2520of%2520sudden%2520cardiac%2520arrest%2520in%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520case-control%2520study%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0065638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouwels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klungel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leufkens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Staa, T.</span></span> <span> </span><span class="NLM_article-title">Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2007.03077.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fj.1365-2125.2007.03077.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18279472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref246/cit246&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Cgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=580-586&author=F.+de+Vriesauthor=S.+Pouwelsauthor=M.+Brackeauthor=J.+W.+Lammersauthor=O.+Klungelauthor=H.+Leufkensauthor=T.+van+Staa&title=Use+of+beta2+agonists+and+risk+of+acute+myocardial+infarction+in+patients+with+hypertension&doi=10.1111%2Fj.1365-2125.2007.03077.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit246R"><div class="casContent"><span class="casTitleNuber">246</span><div class="casTitle"><span class="NLM_cas:atitle">Use of β2 agonists and risk of acute myocardial infarction in patients with hypertension</span></div><div class="casAuthors">de Vries, Frank; Pouwels, Sander; Bracke, Madelon; Lammers, Jan-Willem; Klungel, Olaf; Leufkens, Hubert; van Staa, Tjeerd</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">580-586</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">AIM: Observational retrospective studies of the assocn. between use of β2 agonists and the risk of acute myocardial infarction (MI) have demonstrated conflicting results, particularly among first-time users.  The aim of this study was to examine the assocn. between β2 agonist use and first nonfatal acute MI.  METHODS: We conducted a case-control study (2476 cases) nested in a cohort of antihypertensive drug users in the Dutch PHARMO RLS database.  PHARMO RLS consists of drug dispensing linked to the national hospitalizations register.  Each case of nonfatal acute MI was matched with up to 12 control patients by gender, age and region.  Drug and disease history and the severity of the underlying respiratory disease were adjusted for.  RESULTS: Risk of acute MI was increased in current β2 agonist users [crude odds ratio (OR) 1.36, 95% confidence interval (CI) 1.15, 1.61].  However, this excess risk was reduced after adjustment for severity of asthma and chronic obstructive pulmonary disease (adjusted OR 1.18, 95% CI 0.93, 1.49).  The risk was highest in patients with ischemic heart disease and low cumulative dose of β2 agonists (adjusted OR 2.47, 95% CI 1.60, 3.82).  CONCLUSION: Most users of β2 agonists did not have an increased risk of acute MI.  Only patients with ischemic heart disease with low cumulative exposure to β2 agonists had an increased risk of acute MI.  It is likely that this increased risk was related to latent cardiovascular disease rather than to the direct effects of β2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB7p3aDcMwBbVg90H21EOLACvtfcHk0lgz14uHTLCNMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Cgsbs%253D&md5=e9a9df243c1b4f6b3f0c0f64460140b6</span></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2007.03077.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2007.03077.x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVries%26aufirst%3DF.%26aulast%3DPouwels%26aufirst%3DS.%26aulast%3DBracke%26aufirst%3DM.%26aulast%3DLammers%26aufirst%3DJ.%2BW.%26aulast%3DKlungel%26aufirst%3DO.%26aulast%3DLeufkens%26aufirst%3DH.%26aulast%3Dvan%2BStaa%26aufirst%3DT.%26atitle%3DUse%2520of%2520beta2%2520agonists%2520and%2520risk%2520of%2520acute%2520myocardial%2520infarction%2520in%2520patients%2520with%2520hypertension%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D65%26spage%3D580%26epage%3D586%26doi%3D10.1111%2Fj.1365-2125.2007.03077.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thottathil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zareba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. L.</span></span> <span> </span><span class="NLM_article-title">International Long QT Syndrome Investigative Group Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2008.05.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.amjcard.2008.05.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18805113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref247/cit247&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFektrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=871-874&author=P.+Thottathilauthor=J.+Acharyaauthor=A.+J.+Mossauthor=C.+Jonsauthor=S.+McNittauthor=I.+Goldenbergauthor=W.+Zarebaauthor=E.+Kaufmanauthor=M.+Qiauthor=J.+L.+Robinson&title=International+Long+QT+Syndrome+Investigative+Group+Risk+of+cardiac+events+in+patients+with+asthma+and+long-QT+syndrome+treated+with+beta%282%29+agonists&doi=10.1016%2Fj.amjcard.2008.05.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit247R"><div class="casContent"><span class="casTitleNuber">247</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of Cardiac Events in Patients With Asthma and Long-QT Syndrome Treated With Beta2 Agonists</span></div><div class="casAuthors">Thottathil, Princy; Acharya, Jay; Moss, Arthur J.; Jons, Christian; McNitt, Scott; Goldenberg, Ilan; Zareba, Wojciech; Kaufman, Elizabeth; Qi, Ming; Robinson, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">871-874</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The clin. course and risk factors assocd. with β2-agonist therapy for asthma have not been investigated previously in patients with the long-QT syndrome (LQTS).  The risk of a first LQTS-related cardiac event due to β2-agonist therapy was examd. in 3,287 patients enrolled in the International LQTS Registry with QTc ≥450 ms.  The Cox proportional hazards model was used to assess the independent contribution of clin. factors for first cardiac events (syncope, aborted cardiac arrest, or sudden death) from birth through age 40.  Time-dependent β2-agonist therapy for asthma was assocd. with an increased risk for cardiac events (hazard ratio [HR] = 2.00, 95% confidence interval 1.26 to 3.15, p = 0.003) after adjustment for relevant covariates including time-dependent β-blocker use, gender, QTc, and history of asthma.  This risk was augmented within the first year after the initiation of β2-agonist therapy (HR = 3.53, p = 0.006).  The combined use of β2-agonist therapy and anti-inflammatory steroids was assocd. with an elevated risk for cardiac events (HR = 3.66, p <0.01); β-blocker therapy was assocd. with a redn. in cardiac events in those using β2 agonists (HR = 0.14, p = 0.05).  In conclusion, β2-agonist therapy was assocd. with an increased risk for cardiac events in patients with asthma with LQTS, and this risk was diminished in patients receiving β blockers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEO9G66YprrVg90H21EOLACvtfcHk0lgz14uHTLCNMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFektrjL&md5=ec100c7cccd7921bc4171ecc7cba23e6</span></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2008.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2008.05.029%26sid%3Dliteratum%253Aachs%26aulast%3DThottathil%26aufirst%3DP.%26aulast%3DAcharya%26aufirst%3DJ.%26aulast%3DMoss%26aufirst%3DA.%2BJ.%26aulast%3DJons%26aufirst%3DC.%26aulast%3DMcNitt%26aufirst%3DS.%26aulast%3DGoldenberg%26aufirst%3DI.%26aulast%3DZareba%26aufirst%3DW.%26aulast%3DKaufman%26aufirst%3DE.%26aulast%3DQi%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DJ.%2BL.%26atitle%3DInternational%2520Long%2520QT%2520Syndrome%2520Investigative%2520Group%2520Risk%2520of%2520cardiac%2520events%2520in%2520patients%2520with%2520asthma%2520and%2520long-QT%2520syndrome%2520treated%2520with%2520beta%25282%2529%2520agonists%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2008%26volume%3D102%26spage%3D871%26epage%3D874%26doi%3D10.1016%2Fj.amjcard.2008.05.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, J. W.</span></span> <span> </span><span class="NLM_article-title">Can oral beta2 agonists cause heart failure?</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)79750-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2805%2979750-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9798578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1M%252Fht12hsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=1998&pages=1081-1082&author=J.+W.+Jenne&title=Can+oral+beta2+agonists+cause+heart+failure%3F&doi=10.1016%2FS0140-6736%2805%2979750-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Can oral beta2 agonists cause heart failure?</span></div><div class="casAuthors">Jenne J W</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">9134</span>),
    <span class="NLM_cas:pages">1081-2</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmOZZGvZAIlK2q3xNe7a7QfW6udTcc2eZbU-5CvwA2z7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252Fht12hsA%253D%253D&md5=bf46c30ad2a060ced3f246349bbce627</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2979750-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252979750-6%26sid%3Dliteratum%253Aachs%26aulast%3DJenne%26aufirst%3DJ.%2BW.%26atitle%3DCan%2520oral%2520beta2%2520agonists%2520cause%2520heart%2520failure%253F%26jtitle%3DLancet%26date%3D1998%26volume%3D352%26spage%3D1081%26epage%3D1082%26doi%3D10.1016%2FS0140-6736%2805%2979750-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemaitre, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siscovick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Psaty, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunathan, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitsel, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinmann, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span> <span> </span><span class="NLM_article-title">Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest</span>. <i>Am. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1016/S0002-9343(02)01384-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0002-9343%2802%2901384-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=12517359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref249/cit249&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVWh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2002&pages=711-716&author=R.+N.+Lemaitreauthor=D.+S.+Siscovickauthor=B.+M.+Psatyauthor=R.+M.+Pearceauthor=T.+E.+Raghunathanauthor=E.+A.+Whitselauthor=S.+A.+Weinmannauthor=G.+D.+Andersonauthor=D.+Lin&title=Inhaled+beta-2+adrenergic+receptor+agonists+and+primary+cardiac+arrest&doi=10.1016%2FS0002-9343%2802%2901384-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit249R"><div class="casContent"><span class="casTitleNuber">249</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest</span></div><div class="casAuthors">Lemaitre, Rozenn N.; Siscovick, David S.; Psaty, Bruce M.; Pearce, Rachel M.; Raghunathan, Trivellore E.; Whitsel, Eric A.; Weinmann, Sheila A.; Anderson, Gail D.; Lin, Danyu</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">AJMEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0002-9343</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">We sought to investigate if short-acting, inhaled β2-adrenergic receptor agonists were assocd. with higher risk of primary cardiac arrest in patients with asthma or chronic obstructive pulmonary disease (COPD).  We conducted a population-based study involving 454 patients enrolled in a health maintenance organization, aged 40 to 79 yr, who had asthma or COPD and who experienced primary cardiac arrest during 1980 to 1994.  We randomly selected 586 controls from strata of enrollees, defined by age, sex, calendar year, and prior heart disease.  Medication use was assessed from computerized pharmacy data, and risk factors from medical record review.  Use of inhaled β-agonists was assocd. with a twofold increased risk of primary cardiac arrest (odds ratio [OR] = 1.9; 95% confidence interval [CI]: 1.1 to 3.3) among patients with asthma, but not among those with COPD (OR = 1.3; 95% CI: 0.6 to 2.7), after adjustment for risk factors.  This assocn. was obsd. only with use of two or more canisters of metered-dose, inhaled β-agonists for 3 mo, and when inhaled steroids were not used.  These results support current guidelines recommending inhaled steroids as first-line asthma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqtIblsNz9-rVg90H21EOLACvtfcHk0lhkZfXgHU1KPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVWh&md5=bbc1f7add31a50438001f0c7e203b098</span></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=10.1016%2FS0002-9343%2802%2901384-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9343%252802%252901384-0%26sid%3Dliteratum%253Aachs%26aulast%3DLemaitre%26aufirst%3DR.%2BN.%26aulast%3DSiscovick%26aufirst%3DD.%2BS.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DPearce%26aufirst%3DR.%2BM.%26aulast%3DRaghunathan%26aufirst%3DT.%2BE.%26aulast%3DWhitsel%26aufirst%3DE.%2BA.%26aulast%3DWeinmann%26aufirst%3DS.%2BA.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DLin%26aufirst%3DD.%26atitle%3DInhaled%2520beta-2%2520adrenergic%2520receptor%2520agonists%2520and%2520primary%2520cardiac%2520arrest%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2002%26volume%3D113%26spage%3D711%26epage%3D716%26doi%3D10.1016%2FS0002-9343%2802%2901384-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warnier, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutten, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kors, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lammers, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoes, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, M. L.</span></span> <span> </span><span class="NLM_article-title">Cardiac arrhythmias in adult patients with asthma</span>. <i>J. Asthma</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.3109/02770903.2012.724132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.3109%2F02770903.2012.724132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=23013453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FgtlCjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2012&pages=942-946&author=M.+J.+Warnierauthor=F.+H.+Ruttenauthor=J.+A.+Korsauthor=J.+W.+Lammersauthor=A.+de+Boerauthor=A.+W.+Hoesauthor=M.+L.+de+Bruin&title=Cardiac+arrhythmias+in+adult+patients+with+asthma&doi=10.3109%2F02770903.2012.724132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac arrhythmias in adult patients with asthma</span></div><div class="casAuthors">Warnier Miriam J; Rutten Frans H; Kors Jan A; Lammers Jan Willem J; de Boer Anthonius; Hoes Arno W; de Bruin Marie L</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of asthma : official journal of the Association for the Care of Asthma</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The pathogenesis of cardiac arrhythmias in asthma patients has not been fully elucidated.  Adverse drug effects, particularly those of β2-mimetics, may play a role.  The aim of this study was to determine whether asthma is associated with the risk of cardiac arrhythmias and electrocardiographic characteristics of arrhythmogenicity (ECG) and to explore the role of β2-mimetics.  METHODS:  A cross-sectional study was conducted among 158 adult patients with a diagnosis of asthma and 6303 participants without asthma from the cohort of the Utrecht Health Project-an ongoing, longitudinal, primary care-based study.  All patients underwent extensive examinations, including resting 12-lead electrocardiogram (ECG) and pulmonary function tests.  The primary outcome was "any arrhythmia on the ECG" (including tachycardia, bradycardia, premature ventricular contraction (PVC), and atrial fibrillation or flutter).  Secondary outcomes were tachycardia, bradycardia, PVC, atrial fibrillation or flutter, mean heart rate, mean corrected QT (QTc) interval length, and prolonged QTc interval.  RESULTS:  Tachycardia and PVCs were more prevalent in patients with asthma (3% and 4%, respectively) than those without asthma (0.6%, p < .001; 2%, p = .03, respectively).  The prevalence of QTc interval prolongation was similar in participants with (2%) and without asthma (3%, odds ratio [OR]: 0.6 and 95% confidence interval [95% CI]: 0.2-2.0).  In 74 asthma patients, who received β2-mimetics, tachycardia and PVCs were more common (OR: 12.4 [95% CI: 4.7-32.8] and 3.7 [95% CI: 1.3-10.5], respectively).  CONCLUSIONS:  The adult patients with asthma more commonly show tachycardia and PVCs on the ECG than those without asthma.  The patients with asthma received β2-mimetics; the risk of tachycardia and PVCs is even more pronounced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPSOrd7VZ0PZagfuraLLzSfW6udTcc2eZsChhCMh5HS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FgtlCjsw%253D%253D&md5=08ee6eef1a338fe0d653e9f176d9493e</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.3109%2F02770903.2012.724132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02770903.2012.724132%26sid%3Dliteratum%253Aachs%26aulast%3DWarnier%26aufirst%3DM.%2BJ.%26aulast%3DRutten%26aufirst%3DF.%2BH.%26aulast%3DKors%26aufirst%3DJ.%2BA.%26aulast%3DLammers%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BBoer%26aufirst%3DA.%26aulast%3DHoes%26aufirst%3DA.%2BW.%26aulast%3Dde%2BBruin%26aufirst%3DM.%2BL.%26atitle%3DCardiac%2520arrhythmias%2520in%2520adult%2520patients%2520with%2520asthma%26jtitle%3DJ.%2520Asthma%26date%3D2012%26volume%3D49%26spage%3D942%26epage%3D946%26doi%3D10.3109%2F02770903.2012.724132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, W.</span></span> <span> </span><span class="NLM_article-title">Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.2147/COPD.S198288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S198288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31114181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref251/cit251&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGksrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=799-808&author=C.+Liauthor=W.+Chengauthor=J.+Guoauthor=W.+Guan&title=Relationship+of+inhaled+long-acting+bronchodilators+with+cardiovascular+outcomes+among+patients+with+stable+COPD%3A+a+meta-analysis+and+systematic+review+of+43+randomized+trials&doi=10.2147%2FCOPD.S198288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit251R"><div class="casContent"><span class="casTitleNuber">251</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials</span></div><div class="casAuthors">Li, Chenxi; Cheng, Wenke; Guo, Jin; Guan, Wei</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">799-808</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease (COPD).  Although previous studies have supported inhaled long-acting bronchodilators (ILABs) for overall cardiovascular safety, the risk of specific cardiovascular outcomes such as arrhythmia, heart failure and stroke is still unknown.  Materials and methods: We systematically searched from PubMed, the Embase database and the Cochrane Library for published studies on ILABs and COPD, from its inception to Nov. 10, 2018, with no language restrictions.  The RRs and corresponding 95% CIs were pooled to evaluate ILAB/placebo.  Results: Finally, 43 randomized controlled trials were included.  Compared with placebo, ILABs do not increase the risk of overall and specific cardiovascular adverse events (AEs); on the contrary, they can reduce the incidence of hypertension (RR 0.73, 95% CI 0.55-0.98; I219.9%; P= 0.221).  However, when stratified according to the specific agents of ILABs, olodaterol might reduce the risk of overall cardiovascular adverse events (OCAEs) (RR 0.65, 95% CI 0.49-0.88;I227.5%; P= 0.000), and the protective effect of lowing blood pressure disappeared.  Similarly, the use of inhaled LABA might increase the risk of cardiac failure (RR 1.71, 95% CI 1.04-2.84;I20%; P= 0.538), but this risk disappeared when stratified according to the specific agents of LABA.  Besides, formoterol might decrease the risk of cardiac ischemia (RR 0.53, 95% CI 0.32-0.91; I20%; P= 0.676).  Conclusions: Overall, the use of ILABs was not assocd. with overall cardiovascular AEs in patients with stable COPD.  When stratified according to the specific agents of LABA, olodaterol might reduce the risk of OCAE; and formoterol might decrease the risk of cardiac ischemia.  LABA might reduce the incidence of hypertension, but might increase the risk of heart failure.  Therefore, COPD patients with a history of heart failure should use it with caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdd357FBOMGbVg90H21EOLACvtfcHk0lhAmrMxgEXgHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGksrjJ&md5=2223f750c874a5bc4555cbf699947c14</span></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S198288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S198288%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DW.%26atitle%3DRelationship%2520of%2520inhaled%2520long-acting%2520bronchodilators%2520with%2520cardiovascular%2520outcomes%2520among%2520patients%2520with%2520stable%2520COPD%253A%2520a%2520meta-analysis%2520and%2520systematic%2520review%2520of%252043%2520randomized%2520trials%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2019%26volume%3D14%26spage%3D799%26epage%3D808%26doi%3D10.2147%2FCOPD.S198288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canepa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, G.</span></span> <span> </span><span class="NLM_article-title">Pulmonary and cardiac drugs: clinically relevant interactions</span>. <i>Herz</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1007/s00059-019-4834-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00059-019-4834-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31297545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3MzmsFGnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=517-521&author=H.+Olschewskiauthor=M.+Canepaauthor=G.+Kovacs&title=Pulmonary+and+cardiac+drugs%3A+clinically+relevant+interactions&doi=10.1007%2Fs00059-019-4834-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary and cardiac drugs: clinically relevant interactions</span></div><div class="casAuthors">Olschewski H; Kovacs G; Canepa M</div><div class="citationInfo"><span class="NLM_cas:title">Herz</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">517-521</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic heart and lung diseases are very common in the elderly population.  The combination of chronic heart failure and chronic obstructive pulmonary disease (COPD) is also common and, according to current guidelines, these patients should be treated for both diseases.  In patients with heart failure, beta-blockers are very important drugs because their use is associated with significantly improved morbidity and mortality.  These beneficial effects were documented in patients with and without COPD, although theoretically there is a risk for bronchoconstriction, particularly with non-beta1 selective blockers.  In COPD patients, long-acting sympathomimetics (LABA) improve lung function, dyspnea, and quality of life and their combination with a beta-blocker makes sense from a pharmacological and a clinical point of view, because any potential arrhythmogenic effects of the LABA will be ameliorated by the beta-blocker.  Inhaled tiotropium, a long-acting muscarinic antagonist (LAMA), has been extensively investigated and no safety concerns were reported in terms of cardiac adverse effects.  The same applies for the other approved LAMA preparations and LAMA-LABA combinations.  Severe COPD causes air-trapping with increasing pressures in the thorax, leading to limitations in blood return into the thorax from the periphery of the body.  This causes a decrease in stroke volume and cardiac index and is associated with dyspnea.  All these adverse effects can be ameliorated by potent anti-obstructive therapy as recently shown by means of a LABA-LAMA combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1kRjIWrnkV_xQvRxYU81tfW6udTcc2eZsChhCMh5HS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzmsFGnuw%253D%253D&md5=d4e83a7439ab1ecfae51bdbe1b297c15</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1007%2Fs00059-019-4834-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00059-019-4834-3%26sid%3Dliteratum%253Aachs%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DCanepa%26aufirst%3DM.%26aulast%3DKovacs%26aufirst%3DG.%26atitle%3DPulmonary%2520and%2520cardiac%2520drugs%253A%2520clinically%2520relevant%2520interactions%26jtitle%3DHerz%26date%3D2019%26volume%3D44%26spage%3D517%26epage%3D521%26doi%3D10.1007%2Fs00059-019-4834-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhund, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span> <span> </span><span class="NLM_article-title">Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1093/eurjhf/hfn013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Feurjhf%2Fhfn013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=19168510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref253/cit253&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FpsFGjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=130-139&author=N.+M.+Hawkinsauthor=M.+C.+Petrieauthor=P.+S.+Jhundauthor=G.+W.+Chalmersauthor=F.+G.+Dunnauthor=J.+J.+McMurray&title=Heart+failure+and+chronic+obstructive+pulmonary+disease%3A+diagnostic+pitfalls+and+epidemiology&doi=10.1093%2Feurjhf%2Fhfn013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit253R"><div class="casContent"><span class="casTitleNuber">253</span><div class="casTitle"><span class="NLM_cas:atitle">Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology</span></div><div class="casAuthors">Hawkins Nathaniel Mark; Petrie Mark C; Jhund Pardeep S; Chalmers George W; Dunn Francis G; McMurray John J V</div><div class="citationInfo"><span class="NLM_cas:title">European journal of heart failure</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-9</span>
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    </div><div class="casAbstract">Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are global epidemics incurring significant morbidity and mortality.  The combination presents many diagnostic challenges.  Clinical symptoms and signs frequently overlap.  Evaluation of cardiac and pulmonary function is often problematic and occasionally misleading.  Echocardiography and pulmonary function tests should be performed in every patient.  Careful interpretation is required to avoid misdiagnosis and inappropriate treatment.  Airflow obstruction, in particular, must be demonstrated when clinically euvolaemic.  Very high and very low concentrations of natriuretic peptides have high positive and negative predictive values for diagnosing HF in those with both conditions.  Intermediate values are less informative.  Both conditions are systemic disorders with overlapping pathophysiological processes.  In patients with HF, COPD is consistently an independent predictor of death and hospitalization.  However, the impact on ischaemic and arrhythmic events is unknown.  Greater collaboration is required between cardiologists and pulmonologists to better identify and manage concurrent HF and COPD.  The resulting symptomatic and prognostic benefits outweigh those attainable by treating either condition alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgpJDHp8VZjtXdcedVHT5tfW6udTcc2eZXz4XxW8aiHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FpsFGjtA%253D%253D&md5=2a3f91a114e394485b7d0e1499fcbba0</span></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfn013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfn013%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DN.%2BM.%26aulast%3DPetrie%26aufirst%3DM.%2BC.%26aulast%3DJhund%26aufirst%3DP.%2BS.%26aulast%3DChalmers%26aufirst%3DG.%2BW.%26aulast%3DDunn%26aufirst%3DF.%2BG.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26atitle%3DHeart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520diagnostic%2520pitfalls%2520and%2520epidemiology%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2009%26volume%3D11%26spage%3D130%26epage%3D139%26doi%3D10.1093%2Feurjhf%2Fhfn013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhund, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrand, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, J. J.</span></span> <span> </span><span class="NLM_article-title">Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2138</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2011.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jacc.2011.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21596228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXot1yjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2011&pages=2127-2138&author=N.+M.+Hawkinsauthor=M.+C.+Petrieauthor=M.+R.+Macdonaldauthor=P.+S.+Jhundauthor=L.+M.+Fabbriauthor=J.+Wikstrandauthor=J.+J.+McMurray&title=Heart+failure+and+chronic+obstructive+pulmonary+disease+the+quandary+of+Beta-blockers+and+Beta-agonists&doi=10.1016%2Fj.jacc.2011.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Heart failure and chronic obstructive pulmonary disease: The quandary of beta-blockers and beta-antagonists</span></div><div class="casAuthors">Hawkins, Nathaniel M.; Petrie, Mark C.; MacDonald, Michael R.; Jhund, Pardeep S.; Fabbri, Leonardo M.; Wikstrand, John; McMurray, John J. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2127-2138</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The combination of heart failure and chronic obstructive pulmonary disease presents many therapeutic challenges.  The cornerstones of therapy are beta-blockers and beta-agonists, resp.  Their pharmacol. effects are diametrically opposed, and each is purported to adversely affect the alternative condition.  The tolerability of beta-blockade in patients with mild and fixed airflow obstruction likely extends to those with more severe disease.  However, the evidence is rudimentary.  The long-term influence of beta-blockade on pulmonary function, symptoms, and quality of life is unclear.  Low-dose Initiation and gradual up-titrn. of cardioselective beta-blockers is currently recommended.  Robust clin. trials are needed to provide the answers that may finally allay physicians' mistrust of beta-blockers in patients with chronic obstructive pulmonary disease.  Beta-agonists are assocd. with incident heart failure in patients with pulmonary disease and with increased mortality and hospitalization In those with existing heart failure.  These purported adverse effects require further Investigation.  In the meantime, clinicians should consider carefully the etiol. of dyspnea and obtain objective evidence of airflow obstruction before prescribing beta-agonists to patients with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrdoZS5Xtv4bVg90H21EOLACvtfcHk0ljBABb6krXSsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXot1yjsLY%253D&md5=f654f84e3c9736760ef231ad0973e0bd</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2011.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2011.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DN.%2BM.%26aulast%3DPetrie%26aufirst%3DM.%2BC.%26aulast%3DMacdonald%26aufirst%3DM.%2BR.%26aulast%3DJhund%26aufirst%3DP.%2BS.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DWikstrand%26aufirst%3DJ.%26aulast%3DMcMurray%26aufirst%3DJ.%2BJ.%26atitle%3DHeart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%2520the%2520quandary%2520of%2520Beta-blockers%2520and%2520Beta-agonists%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2011%26volume%3D57%26spage%3D2127%26epage%3D2138%26doi%3D10.1016%2Fj.jacc.2011.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kubota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuse, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, W.</span></span> <span> </span><span class="NLM_article-title">Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.2147/COPD.S79942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S79942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25784798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2Mnls1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=515-523&author=Y.+Kubotaauthor=K.+Asaiauthor=E.+Furuseauthor=S.+Nakamuraauthor=K.+Muraiauthor=Y.+T.+Tsukadaauthor=W.+Shimizu&title=Impact+of+%CE%B2-blocker+selectivity+on+long-term+outcomes+in+congestive+heart+failure+patients+with+chronic+obstructive+pulmonary+disease&doi=10.2147%2FCOPD.S79942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Kubota Yoshiaki; Asai Kuniya; Furuse Erito; Nakamura Shunichi; Murai Koji; Tsukada Yayoi Tetsuou; Shimizu Wataru</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">515-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is present in approximately one-third of all congestive heart failure (CHF) patients, and is a key cause of underprescription and underdosing of β-blockers, largely owing to concerns about precipitating respiratory deterioration.  For these reasons, the aim of this study was to evaluate the impact of β-blockers on the long-term outcomes in CHF patients with COPD.  In addition, we compared the effects of two different β-blockers, carvedilol and bisoprolol.  METHODS:  The study was a retrospective, non-randomized, single center trial.  Acute decompensated HF patients with COPD were classified according to the oral drug used at discharge into β-blocker (n=86; carvedilol [n=52] or bisoprolol [n=34]) and non-β-blocker groups (n=46).  The primary endpoint was all-cause mortality between the β-blocker and non-β-blocker groups during a mean clinical follow-up of 33.9 months.  The secondary endpoints were the differences in all-cause mortality and the hospitalization rates for CHF and/or COPD exacerbation between patients receiving carvedilol and bisoprolol.  RESULTS:  The mortality rate was higher in patients without β-blockers compared with those taking β-blockers (log-rank P=0.039), and univariate analyses revealed that the use of β-blockers was the only factor significantly correlated with the mortality rate (hazard ratio: 0.41; 95% confidence interval: 0.17-0.99; P=0.047).  Moreover, the rate of CHF and/or COPD exacerbation was higher in patients treated with carvedilol compared with bisoprolol (log-rank P=0.033).  In the multivariate analysis, only a past history of COPD exacerbation significantly increased the risk of re-hospitalization due to CHF and/or COPD exacerbation (adjusted hazard ratio: 3.11; 95% confidence interval: 1.47-6.61; P=0.003).  CONCLUSION:  These findings support the recommendations to use β-blockers in HF patients with COPD.  Importantly, bisoprolol reduced the incidence of CHF and/or COPD exacerbation compared with carvedilol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvDoMDseirLGLFM_lbR1VmfW6udTcc2eZk0Jv_d3h6HLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mnls1Wguw%253D%253D&md5=8f868868e9b5287a7b33afc30ec7df11</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S79942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S79942%26sid%3Dliteratum%253Aachs%26aulast%3DKubota%26aufirst%3DY.%26aulast%3DAsai%26aufirst%3DK.%26aulast%3DFuruse%26aufirst%3DE.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DMurai%26aufirst%3DK.%26aulast%3DTsukada%26aufirst%3DY.%2BT.%26aulast%3DShimizu%26aufirst%3DW.%26atitle%3DImpact%2520of%2520%25CE%25B2-blocker%2520selectivity%2520on%2520long-term%2520outcomes%2520in%2520congestive%2520heart%2520failure%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2015%26volume%3D10%26spage%3D515%26epage%3D523%26doi%3D10.2147%2FCOPD.S79942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puente-Maestu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-González, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Márquez-Martín, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcos-Rodriguez, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Hermosa, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malo de Molina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobradillo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcázar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Conde, G.</span></span> <span> </span><span class="NLM_article-title">GEMEPOC, Group. Multicentric study on the beta-blocker use and relation with exacerbations in COPD</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2014.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.rmed.2014.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24635914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref256/cit256&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC2crktlWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2014&pages=737-744&author=L.+Puente-Maestuauthor=M.+Calleauthor=A.+Ortega-Gonz%C3%A1lezauthor=A.+Fusterauthor=C.+Gonz%C3%A1lezauthor=E.+M%C3%A1rquez-Mart%C3%ADnauthor=P.+J.+Marcos-Rodriguezauthor=C.+Caleroauthor=J.+L.+Rodr%C3%ADguez-Hermosaauthor=R.+Malo+de+Molinaauthor=M.+Aburtoauthor=P.+Sobradilloauthor=B.+Alc%C3%A1zarauthor=G.+Tirado-Conde&title=GEMEPOC%2C+Group.+Multicentric+study+on+the+beta-blocker+use+and+relation+with+exacerbations+in+COPD&doi=10.1016%2Fj.rmed.2014.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit256R"><div class="casContent"><span class="casTitleNuber">256</span><div class="casTitle"><span class="NLM_cas:atitle">Multicentric study on the beta-blocker use and relation with exacerbations in COPD</span></div><div class="casAuthors">Puente-Maestu Luis; Calle Myriam; Rodriguez-Hermosa Juan Luis; Ortega-Gonzalez Angel; Fuster Antonia; Gonzalez Cruz; Marquez-Martin Eduardo; Marcos-Rodriguez Pedro Jorge; Calero Carmen; Malo de Molina Rosa; Aburto Myriam; Sobradillo Patricia; Alcazar Bernardino; Tirado-Conde Gema</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">737-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart failure (CHF) or coronary artery disease (CAD).  In spite of the recommendation to use beta-blockers (BB) they are likely under-prescribed to patients with concurrent COPD and heart diseases.  To find out the prevalence of use of BB, 256 COPD patients were consecutively recruited by pulmonary physicians from 14 hospitals in 7 regions of Spain in their outpatient offices if they had a diagnosis of COPD, were not on long-term oxygen therapy, had CHF or CAD, and met the criteria for BB treatment.  In patients with indication 58% (95%CI, 52-64%) of the COPD patients and 97% of the non-COPD patients were on BB (p < 0.001).  In patients with COPD, several factors were independently related to at least one visit to the emergency room in the previous year such as use of BB, adjusted OR = 0.27 (95% CI 0.15-0.50), GOLD stage D, OR = 2.52 (1.40-4.53), baseline heart rate >70, OR 2.19 (1.24-3.86) use of long-acting beta2-agonists OR = 2.18 (1.29-3.68), previous episodes of left ventricular failure OR 2.27 (1.19-4.33) and diabetes, OR = 1.82 (1.08-3.38).  We conclude that, according to what is recommended by current guidelines, BB are still under-prescribed in COPD patients.  COPD patients with CHF or CAD using BB suffer fewer exacerbations and visits to the ER.  GOLD stage, use of long-acting beta2-agonists, baseline heart rate and comorbidities are also risk factors for exacerbations in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSyATmu1Y79DPx2phytoz6_fW6udTcc2eZk0Jv_d3h6HLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crktlWjtQ%253D%253D&md5=82f92c3e93a6e2fc4645bb0e6374b43b</span></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2014.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2014.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DPuente-Maestu%26aufirst%3DL.%26aulast%3DCalle%26aufirst%3DM.%26aulast%3DOrtega-Gonz%25C3%25A1lez%26aufirst%3DA.%26aulast%3DFuster%26aufirst%3DA.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DC.%26aulast%3DM%25C3%25A1rquez-Mart%25C3%25ADn%26aufirst%3DE.%26aulast%3DMarcos-Rodriguez%26aufirst%3DP.%2BJ.%26aulast%3DCalero%26aufirst%3DC.%26aulast%3DRodr%25C3%25ADguez-Hermosa%26aufirst%3DJ.%2BL.%26aulast%3DMalo%2Bde%2BMolina%26aufirst%3DR.%26aulast%3DAburto%26aufirst%3DM.%26aulast%3DSobradillo%26aufirst%3DP.%26aulast%3DAlc%25C3%25A1zar%26aufirst%3DB.%26aulast%3DTirado-Conde%26aufirst%3DG.%26atitle%3DGEMEPOC%252C%2520Group.%2520Multicentric%2520study%2520on%2520the%2520beta-blocker%2520use%2520and%2520relation%2520with%2520exacerbations%2520in%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2014%26volume%3D108%26spage%3D737%26epage%3D744%26doi%3D10.1016%2Fj.rmed.2014.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span> <span> </span><span class="NLM_article-title">The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2573</span>– <span class="NLM_lpage">2581</span>, <span class="refDoi"> DOI: 10.2147/COPD.S141694</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2147%2FCOPD.S141694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=28894360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref257/cit257&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVGhs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2573-2581&author=K.+M.+Liaoauthor=T.+Y.+Linauthor=Y.+B.+Huangauthor=C.+C.+Kuoauthor=C.+Y.+Chen&title=The+evaluation+of+%CE%B2-adrenoceptor+blocking+agents+in+patients+with+COPD+and+congestive+heart+failure%3A+a+nationwide+study&doi=10.2147%2FCOPD.S141694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit257R"><div class="casContent"><span class="casTitleNuber">257</span><div class="casTitle"><span class="NLM_cas:atitle">The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study</span></div><div class="casAuthors">Liao, Kuang-Ming; Lin, Tien-Yu; Huang, Yaw-Bin; Kuo, Chen-Chun; Chen, Chung-Yu</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2573-2581</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Objective: β-Blockers are safe and improve survival in patients with both congestive heart failure (CHF) and COPD.  However, the superiority of different types of β-blockers is still unclear among patients with CHF and COPD.  The assocn. between β-blockers and CHF exacerbation as well as COPD exacerbation remains unclear.  The objective of this study was to compare the outcome of different β-blockers in patients with concurrent CHF and COPD.  Patients and methods: We used the National Health Insurance Research Database in Taiwan to conduct a retrospective cohort study.  The inclusion criteria for CHF were patients who were < 20 years old and were diagnosed with CHF between Jan. 1, 2005 and Dec. 31, 2012.  COPD patients included those who had outpatient visit claims $ 2 times within 365 days or 1 claim for hospitalization with a COPD diagnosis.  A time-dependent Cox proportional hazards regression model was applied to evaluate the effectiveness of β-blockers in the study population.  Results: We identified 1,872 patients with concurrent CHF and COPD.  Only high-dose bisoprolol significantly reduced the risk of death and slightly decreased the hospitalization rate due to CHF exacerbation (death: adjusted hazard ratio [aHR] = 0.51, 95% confidence interval [CI] = 0.29-0.89; hospitalization rate due to CHF exacerbation: aHR = 0.48, 95% CI = 0.23-1.00).  No assocn. was obsd. between β-blocker use and COPD exacerbation.  Conclusion: In patients with concurrent CHF and COPD, β-blockers reduced mortality, CHF exacerbation, and the need for hospitalization.  Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKdmQgYj1G_bVg90H21EOLACvtfcHk0lgN2oZMAFnX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVGhs7w%253D&md5=1b156213d2f929145447050a3ca02aec</span></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S141694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S141694%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DK.%2BM.%26aulast%3DLin%26aufirst%3DT.%2BY.%26aulast%3DHuang%26aufirst%3DY.%2BB.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BY.%26atitle%3DThe%2520evaluation%2520of%2520%25CE%25B2-adrenoceptor%2520blocking%2520agents%2520in%2520patients%2520with%2520COPD%2520and%2520congestive%2520heart%2520failure%253A%2520a%2520nationwide%2520study%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2017%26volume%3D12%26spage%3D2573%26epage%3D2581%26doi%3D10.2147%2FCOPD.S141694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perng, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. J.</span></span> <span> </span><span class="NLM_article-title">Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>95</i></span>, <span class="NLM_elocation-id">e2427</span> <span class="refDoi"> DOI: 10.1097/MD.0000000000002427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1097%2FMD.0000000000002427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26844454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref258/cit258&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVWrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2016&author=V.+Y.+Suauthor=Y.+S.+Changauthor=Y.+W.+Huauthor=M.+H.+Hungauthor=S.+M.+Ouauthor=F.+Y.+Leeauthor=K.+T.+Chouauthor=K.+Y.+Yangauthor=D.+W.+Perngauthor=T.+J.+Chenauthor=C.+J.+Liu&title=Carvedilol%2C+bisoprolol%2C+and+metoprolol+use+in+patients+with+coexistent+heart+failure+and+chronic+obstructive+pulmonary+disease&doi=10.1097%2FMD.0000000000002427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit258R"><div class="casContent"><span class="casTitleNuber">258</span><div class="casTitle"><span class="NLM_cas:atitle">Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Su, Vincent Yi-Fong; Chang, Yu-Sheng; Hu, Yu-Wen; Hung, Man-Hsin; Ou, Shuo-Ming; Lee, Fa-Yauh; Chou, Kun-Ta; Yang, Kuang-Yao; Perng, Diahn-Warng; Chen, Tzeng-Ji; Liu, Chia-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e2427</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Beta (β)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs.  We aimed to evaluate the survival effects of β-blockers in patients with coexistent HF and COPD.  Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study.  Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled.  Doses of the 3 β-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extd.  The primary endpoint was cumulative survival.  Patients were followed until Dec. 31, 2009.  The study included 11,558 subjects, with a mean follow-up period of 4.07 years.  After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)=0.76, 95% confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95% CI=0.26-0.63, P<0.001] compared with nonusers, whereas no survival difference was obsd. for carvedilol or metoprolol.  Compared with patients with HF alone, this special HF+COPD cohort received significantly fewer targeted β-blockers (108.8 vs 137.3 defined daily doses (DDDs)/person-year, P<0.001) and bisoprolol (57.9 vs 70.8DDDs/person-year, P<0.001).  In patients with coexisting HF and COPD, this study demonstrated a dose-response survival benefit of bisoprolol use, but not of carvedilol or metoprolol use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHbBhP3bWqfrVg90H21EOLACvtfcHk0lgN2oZMAFnX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVWrtrY%253D&md5=3e17c450681e50493e9263fdd85c4a74</span></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=10.1097%2FMD.0000000000002427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0000000000002427%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DV.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BS.%26aulast%3DHu%26aufirst%3DY.%2BW.%26aulast%3DHung%26aufirst%3DM.%2BH.%26aulast%3DOu%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChou%26aufirst%3DK.%2BT.%26aulast%3DYang%26aufirst%3DK.%2BY.%26aulast%3DPerng%26aufirst%3DD.%2BW.%26aulast%3DChen%26aufirst%3DT.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%2BJ.%26atitle%3DCarvedilol%252C%2520bisoprolol%252C%2520and%2520metoprolol%2520use%2520in%2520patients%2520with%2520coexistent%2520heart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DMedicine%26date%3D2016%26volume%3D95%26doi%3D10.1097%2FMD.0000000000002427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoluabi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieske, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammar-Aouchiche, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesimer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuvim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, R. A.</span></span> <span> </span><span class="NLM_article-title">Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2007-0279RC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1165%2Frcmb.2007-0279RC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18096872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref259/cit259&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFejtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=256-262&author=L.+P.+Nguyenauthor=O.+Omoluabiauthor=S.+Parraauthor=J.+M.+Frieskeauthor=C.+Clementauthor=Z.+Ammar-Aouchicheauthor=S.+B.+Hoauthor=C.+Ehreauthor=M.+Kesimerauthor=B.+J.+Knollauthor=M.+J.+Tuvimauthor=B.+F.+Dickeyauthor=R.+A.+Bond&title=Chronic+exposure+to+beta-blockers+attenuates+inflammation+and+mucin+content+in+a+murine+asthma+model&doi=10.1165%2Frcmb.2007-0279RC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit259R"><div class="casContent"><span class="casTitleNuber">259</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model</span></div><div class="casAuthors">Nguyen, Long P.; Omoluabi, Ozozoma; Parra, Sergio; Frieske, Joanna M.; Clement, Cecilia; Ammar-Aouchiche, Zoulikha; Ho, Samuel B.; Ehre, Camille; Kesimer, Mehmet; Knoll, Brian J.; Tuvim, Michael J.; Dickey, Burton F.; Bond, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-262</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Single-dose administration of β-adrenoceptor agonists produces bronchodilation and inhibits airway hyperresponsiveness (AHR), and is the std. treatment for the acute relief of asthma.  However, chronic repetitive administration of β-adrenoceptor agonists may increase AHR, airway inflammation, and risk of death.  Based upon the paradigm shift that occurred with the use of β-blockers in congestive heart failure, we previously detd. that chronic administration of β-blockers decreased AHR in a murine model of asthma.  To elucidate the mechanisms for the beneficial effects of β-blockers, we examd. the effects of chronic administration of several β-adrenoceptor ligands in a murine model of allergic asthma.  Administration of β-blockers resulted in a redn. in total cell counts, eosinophils, and the cytokines IL-13, IL-10, IL-5, and TGF-β1 in bronchoalveolar lavage, and attenuated epithelial mucin content and morphol. changes.  The differences in mucin content also occurred if the β-blockers were administered only during the ovalbumin challenge phase, but administration of β-blockers for 7 days was not as effective as administration for 28 days.  These results indicate that in a murine model of asthma, chronic administration of β-blockers reduces inflammation and mucous metaplasia, cardinal features of asthma that may contribute to airflow obstruction and AHR.  Similar to heart failure, our results provide a second disease model in which beta-blockers producing an acutely detrimental effect may provide a therapeutically beneficial effect with chronic administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-NIQ8z1s2E7Vg90H21EOLACvtfcHk0liLg_JDVaeNsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFejtLg%253D&md5=0de7cd6897989d8a2154a3b7a6bfcc62</span></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2007-0279RC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2007-0279RC%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BP.%26aulast%3DOmoluabi%26aufirst%3DO.%26aulast%3DParra%26aufirst%3DS.%26aulast%3DFrieske%26aufirst%3DJ.%2BM.%26aulast%3DClement%26aufirst%3DC.%26aulast%3DAmmar-Aouchiche%26aufirst%3DZ.%26aulast%3DHo%26aufirst%3DS.%2BB.%26aulast%3DEhre%26aufirst%3DC.%26aulast%3DKesimer%26aufirst%3DM.%26aulast%3DKnoll%26aufirst%3DB.%2BJ.%26aulast%3DTuvim%26aufirst%3DM.%2BJ.%26aulast%3DDickey%26aufirst%3DB.%2BF.%26aulast%3DBond%26aufirst%3DR.%2BA.%26atitle%3DChronic%2520exposure%2520to%2520beta-blockers%2520attenuates%2520inflammation%2520and%2520mucin%2520content%2520in%2520a%2520murine%2520asthma%2520model%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2008%26volume%3D38%26spage%3D256%26epage%3D262%26doi%3D10.1165%2Frcmb.2007-0279RC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">Safety considerations with dual bronchodilator therapy in COPD: An update</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1007/s40264-016-0402-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs40264-016-0402-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26924197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFemsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2016&pages=501-508&author=M.+G.+Materaauthor=P.+Roglianiauthor=L.+Calzettaauthor=M.+Cazzola&title=Safety+considerations+with+dual+bronchodilator+therapy+in+COPD%3A+An+update&doi=10.1007%2Fs40264-016-0402-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update</span></div><div class="casAuthors">Matera, Maria Gabriella; Rogliani, Paola; Calzetta, Luigino; Cazzola, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">501-508</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Combining a long-acting β2-agonist (LABA) with a long-acting anti-muscarinic agent (LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have major implications for the use of LABA/LAMA combinations in the treatment of chronic obstructive pulmonary disease (COPD).  There are four different approved LAMA/LABA fixed-dose combinations (FDCs)-glycopyrronium/indacaterol, umeclidinium/vilanterol, tiotropium/olodaterol, and aclidinium/formoterol-and another, glycopyrronium/formoterol, that is still under clin. development.  Many pivotal trials have shown that all of these FDCs are more effective than monotherapies in inducing bronchodilation and do not amplify the possible adverse events (AEs) that are characteristic of LAMAs and LABAs when used as monotherapy.  Unfortunately, these clin. trials have included a very small and highly selected fraction of the COPD patient population.  Therefore, it is questionable whether such data can be extrapolated to a larger, 'real-life' population of patients with COPD, esp. given that COPD patients with co-morbidities are often excluded from clin. trials, COPD is a major risk factor for most cardiovascular diseases, and both LAMAs and LABAs have a high potential to impact cardiac activities.  All clin. trials have been conducted under widely varying conditions and, consequently, AE rates of a drug obsd. in a clin. trial cannot be directly compared with rates in the clin. trials of another drug and may not reflect the rates obsd. in practice.  Head-to-head studies comparing the different LAMA/LABA FDCs that will include the true patients that we meet in our everyday practice are absolutely essential if we wish to make a therapeutic choice that is not purely empirical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi6JckVyKkn7Vg90H21EOLACvtfcHk0liLg_JDVaeNsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFemsLY%253D&md5=065ba0fee9b13218e1f7e70f95644377</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1007%2Fs40264-016-0402-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-016-0402-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DSafety%2520considerations%2520with%2520dual%2520bronchodilator%2520therapy%2520in%2520COPD%253A%2520An%2520update%26jtitle%3DDrug%2520Saf.%26date%3D2016%26volume%3D39%26spage%3D501%26epage%3D508%26doi%3D10.1007%2Fs40264-016-0402-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mentz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiuzat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenfeld, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, C. M.</span></span> <span> </span><span class="NLM_article-title">Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2012.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.cardfail.2012.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=22555273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref261/cit261&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1yhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=413-422&author=R.+J.+Mentzauthor=M.+Fiuzatauthor=M.+Kraftauthor=J.+Lindenfeldauthor=C.+M.+O%E2%80%99Connor&title=Bronchodilators+in+heart+failure+patients+with+COPD%3A+is+it+time+for+a+clinical+trial%3F&doi=10.1016%2Fj.cardfail.2012.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit261R"><div class="casContent"><span class="casTitleNuber">261</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilators in Heart Failure Patients With COPD: Is It Time for a Clinical Trial?</span></div><div class="casAuthors">Mentz, Robert J.; Fiuzat, Mona; Kraft, Monica; Lindenfeld, Joann; O'Connor, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Chronic heart failure (HF) and chronic obstructive pulmonary disease (COPD) commonly coexist, and patients with both diseases fare worse than those with either disease alone.  Several factors may contribute to worse outcomes, including an increased burden of care related to greater disease complexity, an overlap of symptoms resulting in misapplication of therapy, and the adverse effects of treatment for one disease on the symptoms and outcomes related to the other.  For example, there are conflicting data about the cardiovascular risks of bronchodilators in HF patients who may experience worse outcomes with inhaled beta-2 agonists via arrhythmogenesis, ischemia, and/or attenuation of beta-blocker benefits.  In contrast, the long-acting anticholinergic class of bronchodilators has a more reassuring safety profile.  Anticholinergic bronchodilators may be the preferred first-line agents for COPD patients with comorbid HF, yet data supporting these recommendations are limited.  Therapeutic trials in COPD patients have generally excluded patients with significant HF and vice-versa.  This paper reviews bronchodilator therapy in HF and proposes a randomized trial designed to enroll patients with significant COPD and HF to det. the risks and/or benefits of adding a long-acting beta-2 agonist to patients currently taking a long-acting anticholinergic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryRfLGmY4wkbVg90H21EOLACvtfcHk0liLg_JDVaeNsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1yhsLs%253D&md5=74fb04c6a7a7517e5eefd9d97df38380</span></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2012.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2012.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DMentz%26aufirst%3DR.%2BJ.%26aulast%3DFiuzat%26aufirst%3DM.%26aulast%3DKraft%26aufirst%3DM.%26aulast%3DLindenfeld%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DC.%2BM.%26atitle%3DBronchodilators%2520in%2520heart%2520failure%2520patients%2520with%2520COPD%253A%2520is%2520it%2520time%2520for%2520a%2520clinical%2520trial%253F%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2012%26volume%3D18%26spage%3D413%26epage%3D422%26doi%3D10.1016%2Fj.cardfail.2012.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perng, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. Y.</span></span> <span> </span><span class="NLM_article-title">Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap</span>. <i>Aging</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3650</span>– <span class="NLM_lpage">3667</span>, <span class="refDoi"> DOI: 10.18632/aging.102004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.18632%2Faging.102004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=31175265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BB3cXis1egu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=3650-3667&author=V.+Y.+Suauthor=Y.+H.+Yangauthor=D.+W.+Perngauthor=Y.+H.+Tsaiauthor=K.+T.+Chouauthor=K.+C.+Suauthor=W.+J.+Suauthor=P.+C.+Chenauthor=K.+Y.+Yang&title=Real-world+effectiveness+of+medications+on+survival+in+patients+with+COPD-heart+failure+overlap&doi=10.18632%2Faging.102004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap</span></div><div class="casAuthors">Su, Vincent Yi-Fong; Yang, Yao-Hsu; Perng, Diahn-Warng; Tsai, Ying-Huang; Chou, Kun-Ta; Su, Kang-Cheng; Su, Wei-Juin; Chen, Pau-Chung; Yang, Kuang-Yao</div><div class="citationInfo"><span class="NLM_cas:title">Aging</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3650-3667</span>CODEN:
                <span class="NLM_cas:coden">AGINCN</span>;
        ISSN:<span class="NLM_cas:issn">1945-4589</span>.
    
            (<span class="NLM_cas:orgname">Impact Journals LLC</span>)
        </div><div class="casAbstract">The appropriate treatment for patients with coexistent chronic obstructive pulmonary disease (COPD) and heart failure (HF) remains unclear.  Data from the Taiwan National Health Insurance Research Database was used for this retrospective cohort study.  Patients diagnosed with both diseases between 1997 and 2012 were enrolled as the COPD-heart failure overlap cohort.  Patients were categorized as non-users and users of specific COPD and HF medications.  Medication prescriptions in each 3-mo and 1-yr period served as time-dependent covariates.  The primary endpoint was cumulative survival.  The validation study confirmed the accuracy of definitions of COPD (94.0% sensitivity) and HF (96.3% sensitivity).  The study included 275,436 patients with COPD-heart failure overlap, with a mean follow-up period of 9.32 years.  The COPD-heart failure overlap cohort had more medical service use and higher mortality than did the COPD alone cohort.  Use of inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations, long-acting muscarinic antagonist (LAMA), angiotensin receptor blockers (ARBs), β blockers, aldosterone antagonists, and statins reduced mortality risk compared with non-use.  Sensitivity and subgroup analyses confirmed the consistency and robustness of results.  ICS/LABA combinations, LAMA, ARBs, β blockers, aldosterone antagonists, and statins use was assocd. with a lower mortality risk in patients with COPD-heart failure overlap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaqdt2Xy-QOLVg90H21EOLACvtfcHk0lhpWR6JyxBc4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXis1egu7o%253D&md5=822c27f20bff228b901686736b9b07b8</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.18632%2Faging.102004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Faging.102004%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DV.%2BY.%26aulast%3DYang%26aufirst%3DY.%2BH.%26aulast%3DPerng%26aufirst%3DD.%2BW.%26aulast%3DTsai%26aufirst%3DY.%2BH.%26aulast%3DChou%26aufirst%3DK.%2BT.%26aulast%3DSu%26aufirst%3DK.%2BC.%26aulast%3DSu%26aufirst%3DW.%2BJ.%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DYang%26aufirst%3DK.%2BY.%26atitle%3DReal-world%2520effectiveness%2520of%2520medications%2520on%2520survival%2520in%2520patients%2520with%2520COPD-heart%2520failure%2520overlap%26jtitle%3DAging%26date%3D2019%26volume%3D11%26spage%3D3650%26epage%3D3667%26doi%3D10.18632%2Faging.102004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. S.</span></span> <span> </span><span class="NLM_article-title">Comparative cardiovascular and cerebrovascular safety of inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: A population-based cohort study</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1002/phar.1684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fphar.1684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26799347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOkurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=26-37&author=Y.+H.+Dongauthor=C.+H.+Changauthor=J.+J.+Gagneauthor=C.+L.+Hsuauthor=M.+S.+Lai&title=Comparative+cardiovascular+and+cerebrovascular+safety+of+inhaled+long-acting+bronchodilators+in+patients+with+chronic+obstructive+pulmonary+disease%3A+A+population-based+cohort+study&doi=10.1002%2Fphar.1684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study</span></div><div class="casAuthors">Dong, Yaa-Hui; Chang, Chia-Hsuin; Gagne, Joshua J.; Hsu, Chia-Lin; Lai, Mei-Shu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-37</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Study Objective : Inhaled long-acting bronchodilators are commonly used as maintenance therapy in chronic obstructive pulmonary disease (COPD).  We compared the risk of cardiovascular and cerebrovascular events among patients with COPD treated with inhaled long-acting bronchodilator monotherapy and combination therapy.  Design : Retrospective cohort study.  Settings : A population-based health care database from Taiwan.  Patients : Individuals with COPD who initiated long-acting muscarinic antagonists (LAMAs) alone, long-acting β-2 agonists (LABA) alone, and LABA and LAMA in combination between 2001 and 2010.  Measurements and Main Results : We used Cox regression models to compare a composite cardiovascular outcome, defined as hospitalization for acute myocardial infarction, congestive heart failure, and cerebrovascular diseases among the three treatment groups, adjusting for potential confounders.  Among a cohort of 3458 study-eligible patients, we identified 505 composite cardiovascular events during 10,590 patient-years of follow-up.  In the primary anal. which considered first exposure carried forward, LABA alone and LAMA alone were assocd. with similar risks of the composite outcome (hazard ratio [HR] 1.09; 95% confidence interval [CI] 0.87-1.37).  The HR comparing LABA and LAMA in combination with LAMA alone was 1.13 (95% CI 0.60-2.13) and to LABA alone was 1.03 (95% CI 0.55-1.92).  The secondary anal. in which we allowed patients to reenter the cohort upon treatment change yielded similar results, but with slightly higher HRs comparing LABA and LAMA in combination with LAMA alone (HR 1.26, 95% CI 0.74-2.15) and to LABA alone (HR 1.31, 95% CI 0.80-2.13).  Conclusions : Our results suggest similar cardiovascular and cerebrovascular safety of LABA and LAMA when agents are used alone.  Addnl. studies are needed to rule out potential risk assocd. with inhaled long-acting bronchodilator combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgoX9k0vml1bVg90H21EOLACvtfcHk0lhpWR6JyxBc4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOkurk%253D&md5=92474b5b0afb3a57d22a77ffa122b500</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.1002%2Fphar.1684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1684%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DY.%2BH.%26aulast%3DChang%26aufirst%3DC.%2BH.%26aulast%3DGagne%26aufirst%3DJ.%2BJ.%26aulast%3DHsu%26aufirst%3DC.%2BL.%26aulast%3DLai%26aufirst%3DM.%2BS.%26atitle%3DComparative%2520cardiovascular%2520and%2520cerebrovascular%2520safety%2520of%2520inhaled%2520long-acting%2520bronchodilators%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520A%2520population-based%2520cohort%2520study%26jtitle%3DPharmacotherapy%26date%3D2016%26volume%3D36%26spage%3D26%26epage%3D37%26doi%3D10.1002%2Fphar.1684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosentino, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landolfo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentivenga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinardi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposti, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miceli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borghi, C.</span></span> <span> </span><span class="NLM_article-title">Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study</span>. <i>BMC Cardiovasc. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12872-018-0986-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1186%2Fs12872-018-0986-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30651063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref264/cit264&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BB3cjit1Sitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=20-26&author=E.+R.+Cosentinoauthor=M.+Landolfoauthor=C.+Bentivengaauthor=L.+Spinardiauthor=D.+D.+Espostiauthor=A.+F.+Ciceroauthor=R.+Miceliauthor=V.+Buiauthor=E.+Berardiauthor=C.+Borghi&title=Morbidity+and+mortality+in+a+population+of+patients+affected+by+heart+failure+and+chronic+obstructive+pulmonary+disease%3A+an+observational+study&doi=10.1186%2Fs12872-018-0986-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit264R"><div class="casContent"><span class="casTitleNuber">264</span><div class="casTitle"><span class="NLM_cas:atitle">Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study</span></div><div class="casAuthors">Cosentino Eugenio Roberto; Landolfo Matteo; Bentivenga Crescenzio; Spinardi Luca; Esposti Daniela Degli; Cicero Arrigo Francesco; Miceli Rinaldo; Bui Virna; Borghi Claudio; Berardi Emanuela</div><div class="citationInfo"><span class="NLM_cas:title">BMC cardiovascular disorders</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) and heart failure (HF) often coexist.  Moreover, elderly patients suffering from HF have a higher incidence of COPD, which further complicates their clinical condition.  Indacaterol/glycopirronium has shown benefits in the treatment of COPD, with few cardiologic adverse effects.  We evaluated the safety and efficacy of this therapy in patients with history of HF.  METHODS:  We enrolled 56 patients with a history of HF (New York Heart Association [NYHA] classes II and III) and stable COPD.  We evaluated blood samples, clinical assessment, echocardiograms and basal spirometry at baseline and after 6 months of therapy with indacaterol/glycopirronium.  In addition, the number of re-hospitalizations during the treatment period was evaluated.  RESULTS:  The treatment was well tolerated.  Brain natriuretic peptide (BNP) levels were significantly reduced compared with baseline (p < 0.001) after 6 months of treatment, and a higher percentage of patients improved their clinical status compared with baseline (p < 0.001).  Minor changes were noted in the hemodynamic and metabolic parameters.  Significant improvements in the echocardiographic parameters were noted in HF with reduced ejection fraction (HFrEF) patients.  All respiratory parameters (forced expiratory volume in 1 s [FEV1], FEV1/forced vital capacity [FVC] ratio and COPD Assessment Test [CAT] scores) improved significantly (p < 0.001).  No hospitalizations owing to HF or COPD exacerbation occurred.  One patient died of respiratory failure.  CONCLUSION:  Indacaterol/glycopirronium was well-tolerated and effective in the treatment of COPD in this cohort of patients with a history of HF.  Further studies are needed to clarify whether this compound can have a direct role in improving overall cardiovascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxAmj6DAngMUkUaC_kzhvyfW6udTcc2eajTvnlspC6Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjit1Sitg%253D%253D&md5=9b7bc83c15be6c371b04f6af611fc068</span></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=10.1186%2Fs12872-018-0986-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12872-018-0986-y%26sid%3Dliteratum%253Aachs%26aulast%3DCosentino%26aufirst%3DE.%2BR.%26aulast%3DLandolfo%26aufirst%3DM.%26aulast%3DBentivenga%26aufirst%3DC.%26aulast%3DSpinardi%26aufirst%3DL.%26aulast%3DEsposti%26aufirst%3DD.%2BD.%26aulast%3DCicero%26aufirst%3DA.%2BF.%26aulast%3DMiceli%26aufirst%3DR.%26aulast%3DBui%26aufirst%3DV.%26aulast%3DBerardi%26aufirst%3DE.%26aulast%3DBorghi%26aufirst%3DC.%26atitle%3DMorbidity%2520and%2520mortality%2520in%2520a%2520population%2520of%2520patients%2520affected%2520by%2520heart%2520failure%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520an%2520observational%2520study%26jtitle%3DBMC%2520Cardiovasc.%2520Disord.%26date%3D2019%26volume%3D19%26spage%3D20%26epage%3D26%26doi%3D10.1186%2Fs12872-018-0986-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talan, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakatta, E. G.</span></span> <span> </span><span class="NLM_article-title">β<sub>2</sub> AR agonists in treatment of chronic heart failure: long path to translation</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">533</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2010.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2010.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20888833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref265/cit265&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=529-533&author=M.+I.+Talanauthor=I.+Ahmetauthor=R.+P.+Xiaoauthor=E.+G.+Lakatta&title=%CE%B22+AR+agonists+in+treatment+of+chronic+heart+failure%3A+long+path+to+translation&doi=10.1016%2Fj.yjmcc.2010.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit265R"><div class="casContent"><span class="casTitleNuber">265</span><div class="casTitle"><span class="NLM_cas:atitle">β2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation</span></div><div class="casAuthors">Talan, Mark I.; Ahmet, Ismayil; Xiao, Riu-Ping; Lakatta, Edward G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">529-533</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The main clin. manifestations of advanced chronic heart failure (CHF), e.g. in dilated cardiomyopathy (DCM), are reduced systolic and diastolic functions, increased arterial elastance and arterio-ventricular uncoupling, accompanied and exacerbated by an excessive sympathetic activation and extensive abnormalities in the βAR signaling.  Loss of cardiomyocytes due to apoptosis is one mechanism that undoubtedly contributes to cardiac remodeling and functional deterioration assocd. with dilated cardiomyopathy (DCM).  Research during the last decade on the single cardiomyocyte level strongly suggested that selective stimulation of β1 AR activates the proapoptotic signaling pathways, while selective stimulation of β2 AR is antiapoptotic, but its precise mechanisms remain to be elucidated.  Extensive research in the rat model of DCM following induction of myocardial infarction (MI) showed that prolonged treatment with of β2 AR agonist, fenoterol, in combination with a β1 AR blocker, metoprolol, is more effective than β1 AR blocker alone and as effective as β1 AR blocker with ACE inhibitor with respect to survival and cardiac remodeling.  This combined regimen of β2 AR agonists and a β1 AR blocker might be considered for clin. testing as alternative or adjunct therapy to currently acceptable CHF arsenal.  This article is part of a special issue entitled "Key Signaling Mols. in Hypertrophy and Heart Failure".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiDT4tTRCfEbVg90H21EOLACvtfcHk0ljx-qbyTdyiRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFymt7vE&md5=5f5c41410ca15d031d9bdb81e7332262</span></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2010.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2010.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DTalan%26aufirst%3DM.%2BI.%26aulast%3DAhmet%26aufirst%3DI.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DLakatta%26aufirst%3DE.%2BG.%26atitle%3D%25CE%25B22%2520AR%2520agonists%2520in%2520treatment%2520of%2520chronic%2520heart%2520failure%253A%2520long%2520path%2520to%2520translation%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2011%26volume%3D51%26spage%3D529%26epage%3D533%26doi%3D10.1016%2Fj.yjmcc.2010.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beasley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, R.</span></span> <span> </span><span class="NLM_article-title">Fenoterol and asthma mortality</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(89)92768-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2889%2992768-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1989&pages=1196-1197&author=N.+Pearceauthor=J.+Craneauthor=C.+Burgessauthor=R.+Beasleyauthor=R.+Jackson&title=Fenoterol+and+asthma+mortality&doi=10.1016%2FS0140-6736%2889%2992768-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2889%2992768-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252889%252992768-2%26sid%3Dliteratum%253Aachs%26aulast%3DPearce%26aufirst%3DN.%26aulast%3DCrane%26aufirst%3DJ.%26aulast%3DBurgess%26aufirst%3DC.%26aulast%3DBeasley%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DR.%26atitle%3DFenoterol%2520and%2520asthma%2520mortality%26jtitle%3DLancet%26date%3D1989%26volume%3D333%26spage%3D1196%26epage%3D1197%26doi%3D10.1016%2FS0140-6736%2889%2992768-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemantle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, R. D.</span></span> <span> </span><span class="NLM_article-title">Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1136/thx.53.7.558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1136%2Fthx.53.7.558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9797754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref267/cit267&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1M%252FhsVCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1998&pages=558-562&author=R.+M.+Martinauthor=N.+R.+Dunnauthor=S.+N.+Freemantleauthor=R.+D.+Mann&title=Risk+of+non-fatal+cardiac+failure+and+ischaemic+heart+disease+with+long+acting+beta+2+agonists&doi=10.1136%2Fthx.53.7.558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit267R"><div class="casContent"><span class="casTitleNuber">267</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists</span></div><div class="casAuthors">Martin R M; Dunn N R; Freemantle S N; Mann R D</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">558-62</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  The long term safety of beta agonists, particularly in patients with heart disease, has not been fully established.  METHODS:  This study accessed the results of three cohort studies involving: 12,294 patients receiving at least one prescription for nedocromil between November 1986 and September 1988; 15,407 patients prescribed salmeterol between December 1990 and May 1991; and 8098 patients prescribed bambuterol between February 1993 and December 1995.  Details of all dispensed prescriptions for these drugs prescribed by general practitioners in England soon after their launch were provided in confidence by the Prescription Pricing Authority.  Questionnaires were sent to the prescriber asking for details of events occurring after the first prescription (prescription event monitoring).  Rates and relative risks of non-fatal cardiac failure and ischaemic heart disease were calculated, comparing bambuterol and salmeterol with the reference drug nedocromil.  RESULTS:  The age and sex adjusted relative risk of non-fatal cardiac failure associated with bambuterol was 3.41 (95% confidence limits (CL) 1.99 to 5.86) when compared with nedocromil.  When salmeterol was compared with nedocromil the adjusted relative risk of non-fatal cardiac failure was 1.10 (95% CL 0.63 to 1.91).  The adjusted relative risk of non-fatal ischaemic heart disease was 1.23 (95% CL 0.73 to 2.08) and 1.07 (95% CL 0.69 to 1.66) for bambuterol and salmeterol, compared with nedocromil, respectively.  However, in the first month of exposure the adjusted relative risk of non-fatal ischaemic heart disease was 3.95 (95% CL 1.38 to 11.31) when bambuterol was compared with nedocromil.  CONCLUSIONS:  Caution should be exercised when prescribing long acting oral beta agonists to patients at risk of cardiac failure.  More definitive evidence would come from prospective randomised trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjVN-vZ51Twgwxfk_AGB-EfW6udTcc2ebw7TQ7-ydpqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FhsVCrug%253D%253D&md5=7a256ae746cee0c6f11a9ca0f593f0c7</span></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=10.1136%2Fthx.53.7.558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.53.7.558%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DR.%2BM.%26aulast%3DDunn%26aufirst%3DN.%2BR.%26aulast%3DFreemantle%26aufirst%3DS.%2BN.%26aulast%3DMann%26aufirst%3DR.%2BD.%26atitle%3DRisk%2520of%2520non-fatal%2520cardiac%2520failure%2520and%2520ischaemic%2520heart%2520disease%2520with%2520long%2520acting%2520beta%25202%2520agonists%26jtitle%3DThorax%26date%3D1998%26volume%3D53%26spage%3D558%26epage%3D562%26doi%3D10.1136%2Fthx.53.7.558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boushey, H. A.</span></span> <span> </span><span class="NLM_article-title">Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma</span>. <i>Clin. Chest. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">733</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=8565410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref268/cit268&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK287lslCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1995&pages=715-733&author=J.+V.+Fahyauthor=H.+A.+Boushey&title=Controversies+involving+inhaled+beta-agonists+and+inhaled+corticosteroids+in+the+treatment+of+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit268R"><div class="casContent"><span class="casTitleNuber">268</span><div class="casTitle"><span class="NLM_cas:atitle">Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma</span></div><div class="casAuthors">Fahy J V; Boushey H A</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">715-33</span>
        ISSN:<span class="NLM_cas:issn">0272-5231</span>.
    </div><div class="casAbstract">Controversy over the use of inhaled beta-agonists has dated almost from their introduction as a treatment for asthma.  Their effectiveness as bronchodilators is not disputed, but there is concern that they may worsen asthma control if used regularly and that excessive use may increase the risk of death from asthma.  Five years after the report from Sears and colleagues suggested that regular use of fenoterol worsens asthma control, we do not have definitive corroborative evidence that this effect of fenoterol is real or is shared by other members of the beta-agonist class.  It also remains disputed whether the documented association between excessive beta-agonist use and death from asthma is a causal or a spurious association.  Undisputed is the fact that excessive beta-agonist use by asthmatics indicates an increased risk of death from asthma and so indicates a need for clinicians to advise anti-inflammatory medications for these patients.  Happily, although there are legitimate concerns about the possible implications of the development of tolerance to the non-bronchodilating effects of beta-agonists, there is currently little evidence that treatment with conventional doses of the beta-agonists currently available in the United States, including salmeterol, is harmful to asthmatic patients.  The controversies over the use of inhaled corticosteroids revolve around the issue of whether the clinical benefit easily demonstrated with their short-term use is justified in the face of their possible long-term systemic toxicity.  Unsettled questions about their therapeutic use include whether dose dependence can be shown for the clinical benefits of inhaled corticosteroids, whether delay in initiating inhaled corticosteroid treatment reduces the benefit that can be achieved, and whether the benefits of even prolonged therapy are short-lasting.  The great unsettled question about their toxicity is whether systemic absorption of inhaled corticosteroids increases the risk of long-term systemic complications, like osteoporosis, cataracts, and growth inhibition.  Current evidence suggests that significant risk of such toxicity is not likely to be associated with the long-term use of the equivalent of 800 micrograms/d of beclomethasone in adults and 400 micrograms/d in children.  If higher doses are used to obtain greater clinical benefit, the answers to these questions may determine the place of new inhaled corticosteroids with high local potency and little systemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTz8BS3SeIq1LGbPKh4T9eAfW6udTcc2ebw7TQ7-ydpqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287lslCisA%253D%253D&md5=33bb168c325b079f87693448da308b1d</span></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26aulast%3DBoushey%26aufirst%3DH.%2BA.%26atitle%3DControversies%2520involving%2520inhaled%2520beta-agonists%2520and%2520inhaled%2520corticosteroids%2520in%2520the%2520treatment%2520of%2520asthma%26jtitle%3DClin.%2520Chest.%2520Med.%26date%3D1995%26volume%3D16%26spage%3D715%26epage%3D733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottosson, A.</span></span> <span> </span><span class="NLM_article-title">Beta2 agonists and heart failure</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1709</span>– <span class="NLM_lpage">1710</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)61488-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2FS0140-6736%2805%2961488-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=9853469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK1M%252FmvVemug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=1998&pages=1709-1710&author=B.+Lindmarkauthor=A.+Ottosson&title=Beta2+agonists+and+heart+failure&doi=10.1016%2FS0140-6736%2805%2961488-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Beta2 agonists and heart failure</span></div><div class="casAuthors">Lindmark B; Ottosson A</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">9141</span>),
    <span class="NLM_cas:pages">1709-10</span>
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTx90Qz_NU9YSjiVMCqkKxVfW6udTcc2eY9RJdVjz4Krrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FmvVemug%253D%253D&md5=6094e9e876ce6308fd8b6ba81ee0d05c</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2961488-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252961488-2%26sid%3Dliteratum%253Aachs%26aulast%3DLindmark%26aufirst%3DB.%26aulast%3DOttosson%26aufirst%3DA.%26atitle%3DBeta2%2520agonists%2520and%2520heart%2520failure%26jtitle%3DLancet%26date%3D1998%26volume%3D352%26spage%3D1709%26epage%3D1710%26doi%3D10.1016%2FS0140-6736%2805%2961488-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, E. H.</span></span> <span> </span><span class="NLM_article-title">Adverse effects of beta-agonists: are they clinically relevant?</span>. <i>Am. J. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1007/BF03256657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2FBF03256657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=14719995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsVymtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=287-297&author=M.+J.+Abramsonauthor=J.+Waltersauthor=E.+H.+Walters&title=Adverse+effects+of+beta-agonists%3A+are+they+clinically+relevant%3F&doi=10.1007%2FBF03256657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Adverse effects of β-agonists: Are they clinically relevant?</span></div><div class="casAuthors">Abramson, Michael J.; Walters, Julia; Walters, E. Haydn</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-297</span>CODEN:
                <span class="NLM_cas:coden">AJRMAG</span>;
        ISSN:<span class="NLM_cas:issn">1175-6365</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled β2-adrenoceptor agonists (β2-agonists) are the most commonly used asthma medications in many Western countries.  Minor adverse effects such as palpitations, tremor, headache and metabolic effects are predictable and dose related.  Time series studies suggested an assocn. between the relatively nonselective β-agonist fenoterol and asthma deaths.  Three case-control studies confirmed that among patients prescribed fenoterol, the risk of death was significantly elevated even after controlling for the severity of asthma.  The Saskatchewan study not only found an increased risk of death among patients dispensed fenoterol, but also suggested this might be a class effect of β2-agonists.  However, in subsequent studies, the long-acting β2-agonist salmeterol was not assocd. with increased asthma mortality.  In a case-control study blood albuterol (salbutamol) concns. were found to be 2.5 times higher among patients who died of asthma compared with controls.  It is speculated that such toxic concns. could cause tachyarrhythmias under conditions of hypoxia and hypokalemia.  The risk of asthma exacerbations and near-fatal attacks may also be increased among patients dispensed fenoterol, but this assocn. may be largely due to confounding by severity.  Although salmeterol does not appear to increase the risk of near-fatal attacks, there is a consistent assocn. with the use of nebulized β2-agonists.  Nebulized and oral β2-agonists are also assocd. with an increased risk of cardiovascular death, ischemic heart disease and cardiac failure.  Caution should be exercised when first prescribing a β-agonist for patients with cardiovascular disease.  A potential mechanism for adverse effects with regular use of β2-agonists is tachyphylaxis.  Tachyphylaxis to the bronchodilator effects of long-acting β2-agonists can occur, but has been consistently demonstrated only for formoterol (eformoterol) a full agonist, rather than salmeterol, a partial agonist.  Tachyphylaxis to protection against induced bronchospasm occurs with both full and partial β2-agonists, and probably within a matter of days at most.  Underlying airway responsiveness to directly acting bronchoconstricting agents is not increased when the bronchodilator effect of the regular β2-agonist has been allowed to wear off, although there may be an increase in responsiveness to indirectly acting agents.  While there has been speculation that underlying airway inflammation in asthma may be made worse by regular use of short-acting β2-agonists, in contradistinction, a no. of studies have shown that long-acting β2-agonists have pos. anti-inflammatory effects.  An Australian Cochrane Airways Group systematic review of the randomized, controlled trials of short-acting β-agonists found only minimal and clin. unimportant differences between regular use and use as needed.  Regular short-acting treatment was better than placebo.  However, a subsequent systematic review has found that regular use of long-acting β-agonists had significant advantages over regular use of short-acting β-agonists.  More studies and data are needed on the regular use of β2-agonists in patients not taking inhaled corticosteroids, and in potentially vulnerable groups, such as the elderly and those with particular genotypes for the β-receptor, who might be more prone to adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzI8kxaal7vbVg90H21EOLACvtfcHk0ljOxrd8C6Ws2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsVymtrs%253D&md5=3608930880ae780a5dfe226ceab816af</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1007%2FBF03256657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03256657%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DM.%2BJ.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DWalters%26aufirst%3DE.%2BH.%26atitle%3DAdverse%2520effects%2520of%2520beta-agonists%253A%2520are%2520they%2520clinically%2520relevant%253F%26jtitle%3DAm.%2520J.%2520Respir.%2520Med.%26date%3D2003%26volume%3D2%26spage%3D287%26epage%3D297%26doi%3D10.1007%2FBF03256657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maak, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClintock, D. E.</span></span> <span> </span><span class="NLM_article-title">Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?</span>. <i>J. Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1016/j.jemermed.2007.11.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.jemermed.2007.11.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18572345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref271/cit271&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADC%252BC3M7mvVaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2011&pages=135-145&author=C.+A.+Maakauthor=J.+A.+Tabasauthor=D.+E.+McClintock&title=Should+acute+treatment+with+inhaled+beta+agonists+be+withheld+from+patients+with+dyspnea+who+may+have+heart+failure%3F&doi=10.1016%2Fj.jemermed.2007.11.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit271R"><div class="casContent"><span class="casTitleNuber">271</span><div class="casTitle"><span class="NLM_cas:atitle">Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure?</span></div><div class="casAuthors">Maak Carley Ann; Tabas Jeffrey A; McClintock Dana E</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of emergency medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-45</span>
        ISSN:<span class="NLM_cas:issn">0736-4679</span>.
    </div><div class="casAbstract">In patients with dyspnea, prehospital and emergency providers make therapeutic decisions before a diagnosis is established.  Inhaled beta-2 agonists are frontline treatment for patients with dyspnea due to asthma or chronic obstructive pulmonary disease (COPD) exacerbations.  However, these agents have been associated with increased adverse events when administered chronically to heart failure patients.  Our goal was to determine the safety and efficacy of acute administration of inhaled beta-2 agonists to patients with heart failure.  MEDLINE and EMBASE searches were performed using the terms "beta agonists," "albuterol," "congestive heart failure," and "pulmonary edema." Bibliographies of relevant articles were searched.  Only studies addressing acute effects of beta-2 agonists were included for analysis.  Twenty-four studies comprising 434 patients were identified that addressed the acute delivery of beta-2 agonists in subjects with heart failure--five studies with inhaled administration and 19 with systemic administration.  No study directly evaluated the effects of inhaled beta-2 agonists to patients with acutely decompensated heart failure.  Treatment of heart failure patients with beta-2 agonists resulted in transient improvements in pulmonary function and cardiovascular hemodynamics.  Only one investigation reported an association between beta-2 agonist use and an increase in malignant dysrhythmias.  Investigations in animal models of heart failure and acute lung injury demonstrated resolution of pulmonary edema with beta agonist administration.  There is insufficient evidence to suggest that acute treatment with inhaled beta-2 agonists should be avoided in patients with dyspnea who may have heart failure.  Based on small studies and indirect evidence, administration of beta-2 agonists to patients with heart failure seems to improve pulmonary function, cardiovascular hemodynamics, and resorption of pulmonary edema.  Although an increase in adverse effects with the use of beta-2 agonists cannot be ruled out based on these data, there was no evidence of an increase in clinically significant dysrhythmias, especially when administered by inhalation.  Based on these findings, further study should focus on the clinical outcomes of patients with acutely decompensated heart failure who are treated with inhaled beta-2 agonist therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSfNcJfxKztMczK395ZObgVfW6udTcc2eZBqcCKtY1Opbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7mvVaqsg%253D%253D&md5=3c3bd536608c090eaee3c7ce8573bff4</span></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=10.1016%2Fj.jemermed.2007.11.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jemermed.2007.11.056%26sid%3Dliteratum%253Aachs%26aulast%3DMaak%26aufirst%3DC.%2BA.%26aulast%3DTabas%26aufirst%3DJ.%2BA.%26aulast%3DMcClintock%26aufirst%3DD.%2BE.%26atitle%3DShould%2520acute%2520treatment%2520with%2520inhaled%2520beta%2520agonists%2520be%2520withheld%2520from%2520patients%2520with%2520dyspnea%2520who%2520may%2520have%2520heart%2520failure%253F%26jtitle%3DJ.%2520Emerg.%2520Med.%26date%3D2011%26volume%3D40%26spage%3D135%26epage%3D145%26doi%3D10.1016%2Fj.jemermed.2007.11.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermingham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawkins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samsudin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, M.</span></span> <span> </span><span class="NLM_article-title">Are beta2-agonists responsible for increased mortality in heart failure?</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1093/eurjhf/hfr063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Feurjhf%2Fhfr063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21791542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref272/cit272&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Ohsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=885-891&author=M.+Berminghamauthor=E.+O%E2%80%99Callaghanauthor=I.+Dawkinsauthor=S.+Miwaauthor=S.+Samsudinauthor=K.+McDonaldauthor=M.+Ledwidge&title=Are+beta2-agonists+responsible+for+increased+mortality+in+heart+failure%3F&doi=10.1093%2Feurjhf%2Fhfr063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit272R"><div class="casContent"><span class="casTitleNuber">272</span><div class="casTitle"><span class="NLM_cas:atitle">Are beta2-agonists responsible for increased mortality in heart failure?</span></div><div class="casAuthors">Bermingham, Margaret; O'Callaghan, Eleanor; Dawkins, Ian; Miwa, Saki; Samsudin, Shazzarina; McDonald, Kenneth; Ledwidge, Mark</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-891</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Previous large-scale, retrospective studies have shown increased mortality in heart failure (HF) patients using β2-agonists (B2As).  We further examd. the relationship between B2A use and mortality in a well-characterized population by adjusting for natriuretic peptide levels as a measure of HF severity.  This was a retrospective cohort study of patients attending an HF Disease Management Program with mean follow-up of 2.9 ± 2.4 years.  Chart review confirmed B2A use, dose and duration of use, and documented pulmonary function evaluation.  The primary endpoint was the effect of B2A use compared with no B2A use on mortality using unadjusted and adjusted Kaplan-Meier survival curves.  Data were available for 1294 patients (age 70.6 ± 11.5 years) of whom 64% were male and 22.2% were taking B2As. β2-Agonist users were older, more likely to be male, to have smoked, to have chronic obstructive pulmonary disease (COPD) and asthma, and less likely to take beta-blockers.  Multivariable assocs. of mortality included: B-type natriuretic peptide (BNP), coronary artery disease, age, and beta-blocker use.  Unadjusted mortality rates for B2A users were found to be significantly higher than non-B2A users [hazard ratio (HR) 1.304, 95% confidence interval (CI) 1.030-1.652, P= 0.028].  However, when adjusted for age, sex, medication, co-morbidity, smoking, COPD, and BNP differences, overall mortality rates were similar [HR 1.043, 95% CI (0.771-1.412), P= 0.783].  Unlike previous reports, this retrospective evaluation of B2A therapy in HF patients shows no relationship with long-term mortality when adjusted for population differences including BNP.  Large, prospective studies are required to define the risk/benefit ratio of B2As in patients with heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQYtePql13bVg90H21EOLACvtfcHk0ljzzzyuJmuM2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Ohsbg%253D&md5=ee091530fb41e80ca20370504b7bddea</span></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfr063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfr063%26sid%3Dliteratum%253Aachs%26aulast%3DBermingham%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DE.%26aulast%3DDawkins%26aufirst%3DI.%26aulast%3DMiwa%26aufirst%3DS.%26aulast%3DSamsudin%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DK.%26aulast%3DLedwidge%26aufirst%3DM.%26atitle%3DAre%2520beta2-agonists%2520responsible%2520for%2520increased%2520mortality%2520in%2520heart%2520failure%253F%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2011%26volume%3D13%26spage%3D885%26epage%3D891%26doi%3D10.1093%2Feurjhf%2Fhfr063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sears, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. R.</span></span> <span> </span><span class="NLM_article-title">The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.2165/00002018-199411040-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.2165%2F00002018-199411040-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=7848546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A280%3ADyaK2M7ltFWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1994&pages=259-283&author=M.+R.+Searsauthor=D.+R.+Taylor&title=The+beta+2-agonist+controversy.+Observations%2C+explanations+and+relationship+to+asthma+epidemiology&doi=10.2165%2F00002018-199411040-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology</span></div><div class="casAuthors">Sears M R; Taylor D R</div><div class="citationInfo"><span class="NLM_cas:title">Drug safety</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-83</span>
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    </div><div class="casAbstract">Links between frequent use of inhaled beta 2-agonists and morbidity and mortality from asthma appear probable.  Two mortality epidemics followed the marketing of potent inhaled adrenergic agents.  Case-control studies in New Zealand linked mortality with prescription of fenoterol, especially in severe asthma.  A Saskatchewan case-control study confirmed an association of mortality with fenoterol, and also with frequent use of salbutamol (albuterol).  Cardiac effects of beta 2-agonists do not cause mortality, but frequent use of these agents may increase the chronic severity of asthma, hence increasing the number of asthmatic patients at risk of death in an acute attack.  Frequent use of beta 2-agonists may reduce lung function, increasing airway responsiveness, and impair control of asthma, despite use of inhaled corticosteroids.  Mechanisms for this effect may include tachyphylaxis to nonbronchodilator effects, increased responsiveness to allergen, interaction with corticosteroid receptors, altered mucociliary function, differential effects of enantiomers, and masking of symptoms by beta 2-agonist use.  The withdrawal of fenoterol from New Zealand in 1990 was associated with a substantial decline in morbidity and mortality.  Overall, the evidence suggests that frequent use of inhaled beta 2-agonists has a deleterious effect on the control of asthma.  Epidemics of mortality are explained by an increase in chronic severity of asthma following introduction of more potent beta 2-agonists.  While beta 2-agonists remain essential for relief of breakthrough symptoms, long term use, particularly with high doses of potent agents, appears to be detrimental.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj0afGi4QZEHwOGIfWJ7-GfW6udTcc2ea8e1VpSnNovLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7ltFWkuw%253D%253D&md5=c07fab0121f18ac42e7215ee63eb2963</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.2165%2F00002018-199411040-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-199411040-00005%26sid%3Dliteratum%253Aachs%26aulast%3DSears%26aufirst%3DM.%2BR.%26aulast%3DTaylor%26aufirst%3DD.%2BR.%26atitle%3DThe%2520beta%25202-agonist%2520controversy.%2520Observations%252C%2520explanations%2520and%2520relationship%2520to%2520asthma%2520epidemiology%26jtitle%3DDrug%2520Saf.%26date%3D1994%26volume%3D11%26spage%3D259%26epage%3D283%26doi%3D10.2165%2F00002018-199411040-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xydas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kherani, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutrie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oz, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.099432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.105.099432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16421285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref274/cit274&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFamtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=553-561&author=S.+Xydasauthor=A.+R.+Kheraniauthor=J.+S.+Changauthor=S.+Klotzauthor=I.+Hayauthor=C.+J.+Mutrieauthor=G.+W.+Mossauthor=A.+Guauthor=A.+R.+Schulmanauthor=D.+Gaoauthor=D.+Huauthor=E.+X.+Wuauthor=C.+Weiauthor=M.+C.+Ozauthor=J.+Wang&title=Beta%282%29-Adrenergic+stimulation+attenuates+left+ventricular+remodeling%2C+decreases+apoptosis%2C+and+improves+calcium+homeostasis+in+a+rodent+model+of+ischemic+cardiomyopathy&doi=10.1124%2Fjpet.105.099432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit274R"><div class="casContent"><span class="casTitleNuber">274</span><div class="casTitle"><span class="NLM_cas:atitle">β2-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy</span></div><div class="casAuthors">Xydas, Steve; Kherani, Aftab R.; Chang, Jonathan S.; Klotz, Stefan; Hay, Ilan; Mutrie, Christopher J.; Moss, Garrett W.; Gu, Anguo; Schulman, Allison R.; Gao, Daqing; Hu, Debora; Wu, Ed X.; Wei, Chiming; Oz, Mehmet C.; Wang, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">553-561</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The benefit of the β2-adrenergic agonist, clenbuterol, in left ventricular assist device patients with dilated cardiomyopathy has been reported, but its effect on ischemic heart failure (HF) is unknown.  We investigated whether clenbuterol improves left ventricular remodeling, myocardial apoptosis and has synergy with a β1 antagonist, metoprolol, in a model of ischemic HF.  Rats were randomized to: (1) HF only; (2) HF + clenbuterol; (3) HF + metoprolol; (4) HF + clenbuterol + metoprolol; and (5) rats with sham surgery.  HF was induced by left anterior descending artery (LAD) artery ligation and confirmed by decreased left ventricular fractional shortening, decreased max. left ventricular dP/dt (dP/dtmax), and elevated left ventricular end-diastolic pressure (LVEDP) compared with sham rats (p < 0.01).  After 9 wk of oral therapy, echocardiog., hemodynamic, and ex vivo end-diastolic pressure-vol. relation (EDPVR) measurements were obtained.  Immunohistochem. was performed for myocardial apoptosis and DNA damage markers.  Levels of calcium-handling proteins were assessed by Western blot anal.  Clenbuterol-treated HF rats had increased wt. gain and heart wts. vs. HF rats (p < 0.05).  EDPVR curves revealed a leftward shift in clenbuterol rats vs. metoprolol and HF rats (p < 0.05).  The metoprolol-treated group had a lower LVEDP and higher dP/dtmax vs. the HF group (p < 0.05).  Clenbuterol and metoprolol groups had decreased myocardial apoptosis and DNA damage markers and increased DNA repair markers vs. HF rats (all p < 0.01).  Protein levels of the ryanodine receptor and sarcoplasmic reticulum calcium-ATPase were improved in clenbuterol-, metoprolol-, and clenbuterol + metoprolol-treated groups vs. HF rats.  However, as a combination therapy, there were no synergistic effects of clenbuterol + metoprolol treatment.  We conclude that clenbuterol ameliorates EDPVR, apoptosis, and calcium homeostasis but does not have synergy with metoprolol in our model of ischemic HF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvFyOEGr-NYbVg90H21EOLACvtfcHk0li2HKqV2sVwWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFamtLc%253D&md5=0a9616c9347b3f44b6e48c22dde284f1</span></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.099432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.099432%26sid%3Dliteratum%253Aachs%26aulast%3DXydas%26aufirst%3DS.%26aulast%3DKherani%26aufirst%3DA.%2BR.%26aulast%3DChang%26aufirst%3DJ.%2BS.%26aulast%3DKlotz%26aufirst%3DS.%26aulast%3DHay%26aufirst%3DI.%26aulast%3DMutrie%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DG.%2BW.%26aulast%3DGu%26aufirst%3DA.%26aulast%3DSchulman%26aufirst%3DA.%2BR.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DE.%2BX.%26aulast%3DWei%26aufirst%3DC.%26aulast%3DOz%26aufirst%3DM.%2BC.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DBeta%25282%2529-Adrenergic%2520stimulation%2520attenuates%2520left%2520ventricular%2520remodeling%252C%2520decreases%2520apoptosis%252C%2520and%2520improves%2520calcium%2520homeostasis%2520in%2520a%2520rodent%2520model%2520of%2520ischemic%2520cardiomyopathy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D553%26epage%3D561%26doi%3D10.1124%2Fjpet.105.099432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soppa, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stagg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felkin, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlecka, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youssef, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C. M.</span></span> <span> </span><span class="NLM_article-title">Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvm106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1093%2Fcvr%2Fcvm106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18178572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref275/cit275&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=695-706&author=G.+K.+Soppaauthor=J.+Leeauthor=M.+A.+Staggauthor=L.+E.+Felkinauthor=P.+J.+Bartonauthor=U.+Siedleckaauthor=S.+Youssefauthor=M.+H.+Yacoubauthor=C.+M.+Terracciano&title=Role+and+possible+mechanisms+of+clenbuterol+in+enhancing+reverse+remodelling+during+mechanical+unloading+in+murine+heart+failure&doi=10.1093%2Fcvr%2Fcvm106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit275R"><div class="casContent"><span class="casTitleNuber">275</span><div class="casTitle"><span class="NLM_cas:atitle">Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure</span></div><div class="casAuthors">Soppa, Gopal K. R.; Lee, Joon; Stagg, Mark A.; Felkin, Leanne E.; Barton, Paul J. R.; Siedlecka, Urszula; Youssef, Samuel; Yacoub, Magdi H.; Terracciano, Cesare M. N.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">695-706</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Combined left ventricular assist device (LVAD) and pharmacol. therapy was proposed to favor myocardial recovery in patients with end-stage heart failure (HF).  Clenbuterol (Clen), a β2-adrenoceptor (β2-AR) agonist, was used as a part of this strategy.  In this study, we investigated the direct effects of clenbuterol on unloaded myocardium in HF.  Left coronary artery ligation or sham operation was performed in male Lewis rats.  After 4-6 wk, heterotopic abdominal transplantation of the failing hearts into normal recipients was performed to induce LV unloading (UN).  Recipient rats were treated with saline (Sal) or clenbuterol (2 mg/kg/day) via osmotic minipumps (HF + UN + Sal or HF + UN + Clen) for 7 days.  Non-transplanted HF animals were treated with Sal (Sham + Sal, HF + Sal) or clenbuterol (HF + Clen).  LV myocytes were isolated and studied using optical, fluorescence, and electrophysiol. techniques.  Clenbuterol treatment improved in vivo LV function measured with echocardiog. (LVEF (%): HF 35.9 ± 2 [16], HF + Clen 52.1 ± 1.4 [16]; P < 0.001; mean ± SEM [n]).  In combination with unloading, clenbuterol increased sarcomere shortening (amplitude (μm): HF + UN + Clen 0.1 ± 0.01 [50], HF + UN + Sal 0.07 ± 0.01 [38]; P < 0.001) by normalizing the depressed myofilament sensitivity to Ca2+ (slope of the linear relationship between Ca2+ transient and sarcomere shortening hysteresis loop during relaxation (μm/ratio unit): HF + UN + Clen 2.13 ± 0.2 [52], HF + UN + Sal 1.42 ± 0.13 [38]; P < 0.05).  Clenbuterol treatment of failing rat hearts, alone or in combination with mech. unloading, improves LV function at the whole-heart and cellular levels by affecting cell morphol., excitation-contraction coupling, and myofilament sensitivity to Ca.  This study supports the use of this drug in the strategy to enhance recovery in HF patients treated with LVADs and also begins to elucidate some of the possible cellular mechanisms responsible for the improvement in LV function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJTdOA2hkIrVg90H21EOLACvtfcHk0ljrgGgOfUEseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjvVaisro%253D&md5=c461f570994565ea289b2bb3a44745f4</span></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvm106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvm106%26sid%3Dliteratum%253Aachs%26aulast%3DSoppa%26aufirst%3DG.%2BK.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DStagg%26aufirst%3DM.%2BA.%26aulast%3DFelkin%26aufirst%3DL.%2BE.%26aulast%3DBarton%26aufirst%3DP.%2BJ.%26aulast%3DSiedlecka%26aufirst%3DU.%26aulast%3DYoussef%26aufirst%3DS.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26aulast%3DTerracciano%26aufirst%3DC.%2BM.%26atitle%3DRole%2520and%2520possible%2520mechanisms%2520of%2520clenbuterol%2520in%2520enhancing%2520reverse%2520remodelling%2520during%2520mechanical%2520unloading%2520in%2520murine%2520heart%2520failure%26jtitle%3DCardiovasc.%2520Res.%26date%3D2008%26volume%3D77%26spage%3D695%26epage%3D706%26doi%3D10.1093%2Fcvr%2Fcvm106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donniacuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gritti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martuscelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafaniello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span> <span> </span><span class="NLM_article-title">Effects of chronic treatment with the new ultra-long-acting β<sub>2</sub>-adrenoceptor agonist indacaterol alone or in combination with the β<sub>1</sub>-adrenoceptor blocker metoprolol on cardiac remodelling</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">3627</span>– <span class="NLM_lpage">3637</span>, <span class="refDoi"> DOI: 10.1111/bph.13148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1111%2Fbph.13148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25825265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=3627-3637&author=B.+Rinaldiauthor=M.+Donniacuoauthor=L.+Sodanoauthor=G.+Grittiauthor=E.+Martuscelliauthor=A.+Orlandiauthor=C.+Rafanielloauthor=F.+Rossiauthor=L.+Calzettaauthor=A.+Capuanoauthor=M.+G.+Matera&title=Effects+of+chronic+treatment+with+the+new+ultra-long-acting+%CE%B22-adrenoceptor+agonist+indacaterol+alone+or+in+combination+with+the+%CE%B21-adrenoceptor+blocker+metoprolol+on+cardiac+remodelling&doi=10.1111%2Fbph.13148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1-adrenoceptor blocker metoprolol on cardiac remodelling</span></div><div class="casAuthors">Rinaldi, Barbara; Donniacuo, Maria; Sodano, Loredana; Gritti, Giulia; Martuscelli, Eugenio; Orlandi, Augusto; Rafaniello, Concetta; Rossi, Francesco; Calzetta, Luigino; Capuano, Annalisa; Matera, Maria Gabriella</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3627-3637</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2-adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1-adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF).  Exptl. Approach : We investigated the effects of indacaterol and metoprolol, administered alone or in combination, on myocardial histol., β-adrenoceptor-mediated pathways, markers of remodelling and haemodynamic parameters in a rat model of HF.  Five groups of rats were assessed: sham-operated rats; HF rats; HF + indacaterol 0.3 mg·kg-1·day-1; HF + metoprolol 100 mg·kg-1·day-1; HF + metoprolol + indacaterol.  All pharmacol. treatments continued for 15 wk.  Key Results : Treatment with either indacaterol or metoprolol significantly reduced the infarct size in HF rats.  However, the combination of indacaterol and metoprolol reduced the infarct size even further, reduced both BP and heart rate, reversed the decrease in ejection fraction, normalized left ventricular systolic and diastolic internal diams., normalized the decreased β1 adrenoceptor mRNA expression as well as cardiac cAMP levels and reduced cardiac GPCR kinase 2 expression, compared with the untreated HF group.  Conclusion and Implications : The results of our study demonstrated an additive interaction between indacaterol and metoprolol in normalizing and reversing cardiac remodelling in our exptl. model of HF.  The translation of these findings to clin. practice might be of interest, as this combination of drugs could be safer and more effective in patients suffering from HF and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE1FPXeSofzrVg90H21EOLACvtfcHk0ljrgGgOfUEseA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurvP&md5=7a37f5752178bba96642432e43c25145</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1111%2Fbph.13148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13148%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi%26aufirst%3DB.%26aulast%3DDonniacuo%26aufirst%3DM.%26aulast%3DSodano%26aufirst%3DL.%26aulast%3DGritti%26aufirst%3DG.%26aulast%3DMartuscelli%26aufirst%3DE.%26aulast%3DOrlandi%26aufirst%3DA.%26aulast%3DRafaniello%26aufirst%3DC.%26aulast%3DRossi%26aufirst%3DF.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DCapuano%26aufirst%3DA.%26aulast%3DMatera%26aufirst%3DM.%2BG.%26atitle%3DEffects%2520of%2520chronic%2520treatment%2520with%2520the%2520new%2520ultra-long-acting%2520%25CE%25B22-adrenoceptor%2520agonist%2520indacaterol%2520alone%2520or%2520in%2520combination%2520with%2520the%2520%25CE%25B21-adrenoceptor%2520blocker%2520metoprolol%2520on%2520cardiac%2520remodelling%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D3627%26epage%3D3637%26doi%3D10.1111%2Fbph.13148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navaratnarajah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlecka, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doorn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soppa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukadia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, C. M.</span></span> <span> </span><span class="NLM_article-title">Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e92909</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0092909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1371%2Fjournal.pone.0092909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=25268495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref277/cit277&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKisb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+Navaratnarajahauthor=U.+Siedleckaauthor=M.+Ibrahimauthor=C.+van+Doornauthor=G.+Soppaauthor=A.+Gandhiauthor=A.+Shahauthor=P.+Kukadiaauthor=M.+H.+Yacoubauthor=C.+M.+Terracciano&title=Impact+of+combined+clenbuterol+and+metoprolol+therapy+on+reverse+remodelling+during+mechanical+unloading&doi=10.1371%2Fjournal.pone.0092909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit277R"><div class="casContent"><span class="casTitleNuber">277</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading</span></div><div class="casAuthors">Navaratnarajah, Manoraj; Siedlecka, Urszula; Ibrahim, Michael; van Doorn, Carin; Soppa, Gopal; Gandhi, Ajay; Shah, Adarsh; Kukadia, Punam; Yacoub, Magdi H.; Terracciano, Cesare M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e92909/1-e92909/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Clenbuterol (Cl), a β2 agonist, is assocd. with enhanced myocardial recovery during left ventricular assist device (LVAD) support, and exerts beneficial remodelling effects during mech. unloading (MU) in rodent heart failure (HF).  However, the specific effects of combined Cl+β1 blockade during MU are unknown.  Methods and Results: We studied the chronic effects 4 wk of β2-adrenoceptor (AR) stimulation via Cl 2 mg/kg/day alone, and in combination with β1-AR blockade using metoprolol Met, 250 mg/kg/day, on whole heart/cell structure, function and excitation-contraction (EC) coupling in failing induced by left coronary artery (LCA) ligation, and unloaded induced by heterotopic abdominal heart transplantation (HATx) failing rat hearts.  Combined Cl+Met therapy displayed favorable effects in HF: Met enhanced Cl's improvement in ejection fraction (EF) while preventing Cl-induced hypertrophy and tachycardia.  During MU combined therapy was less beneficial than either mono-therapy.  Met, not Cl, prevented MU-induced myocardial atrophy, with increased atrophy occurring during combined therapy.  MU-induced recovery of Ca2+ transient amplitude, speed of Ca2+ release and sarcoplasmic reticulum Ca2+ content was enhanced equally by Cl or Met mono-therapy, but these benefits, together with Cl's enhancement of sarcomeric contraction speed, and MU-induced recovery of Ca2+ spark frequency, disappeared during combined therapy.  Conclusions: Combined Cl+Met therapy shows superior functional effects to mono-therapy in rodent HF, but appears inferior to either mono-therapy in enhancing MU-induced recovery of EC coupling.  These results suggest that combined β2-AR simulation+β1-AR blockade therapy is likely to be a safe and beneficial therapeutic HF strategy, but is not as effective as mono-therapy in enhancing myocardial recovery during LVAD support.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8nJUR-yYfKrVg90H21EOLACvtfcHk0liEjzlnvlehVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKisb%252FO&md5=f759bc3c1fd013caba89e3ae6c772d8a</span></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0092909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0092909%26sid%3Dliteratum%253Aachs%26aulast%3DNavaratnarajah%26aufirst%3DM.%26aulast%3DSiedlecka%26aufirst%3DU.%26aulast%3DIbrahim%26aufirst%3DM.%26aulast%3Dvan%2BDoorn%26aufirst%3DC.%26aulast%3DSoppa%26aufirst%3DG.%26aulast%3DGandhi%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DKukadia%26aufirst%3DP.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26aulast%3DTerracciano%26aufirst%3DC.%2BM.%26atitle%3DImpact%2520of%2520combined%2520clenbuterol%2520and%2520metoprolol%2520therapy%2520on%2520reverse%2520remodelling%2520during%2520mechanical%2520unloading%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0092909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref278"><div class="reference"><strong class="refLabel"><a href="#ref278" class="rightTabRefNumLink">278</a></strong><div class="NLM_citation" id="rightTab-cit278"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, Y. N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obokata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koepp, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbe, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlaug, B. A.</span></span> <span> </span><span class="NLM_article-title">The β-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.118.313832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.118.313832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30582447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref278/cit278&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=306-314&author=Y.+N.+V.+Reddyauthor=M.+Obokataauthor=K.+E.+Koeppauthor=A.+C.+Egbeauthor=B.+Wileyauthor=B.+A.+Borlaug&title=The+%CE%B2-adrenergic+agonist+albuterol+improves+pulmonary+vascular+reserve+in+heart+failure+with+preserved+ejection+fraction&doi=10.1161%2FCIRCRESAHA.118.313832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit278R"><div class="casContent"><span class="casTitleNuber">278</span><div class="casTitle"><span class="NLM_cas:atitle">The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial</span></div><div class="casAuthors">Reddy, Yogesh N. V.; Obokata, Masaru; Koepp, Katlyn E.; Egbe, Alexander C.; Wiley, Brandon; Borlaug, Barry A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">306-314</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction (HFpEF).  Interventions that enhance pulmonary vasodilation might be beneficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion.  I.v. β-agonists reduce pulmonary vascular resistance but are not suitable for chronic use.  Objective: We hypothesized that the inhaled β-adrenergic agonist albuterol would improve pulmonary vasodilation during exercise in patients with HFpEF, without increasing left heart filling pressures.  Methods and results: We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjects with HFpEF using high-fidelity micromanometer catheters and expired gas anal.  The primary end point was pulmonary vascular resistance during exercise.  Subjects with HFpEF (n=30) underwent resting and exercise hemodynamic assessment and were then randomized 1:1 to inhaled, nebulized albuterol or placebo.  Rest and exercise hemodynamic testing was then repeated.  Albuterol improved the primary end point of exercise pulmonary vascular resistance as compared with placebo (-0.6±0.5 vs. +0.1±0.7 WU; P=0.003).  Albuterol enhanced cardiac output reserve and right ventricular pulmonary artery coupling, reduced right atrial and pulmonary artery pressures, improved pulmonary artery compliance, and enhanced left ventricular transmural distending pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures.  Conclusions: Albuterol improves pulmonary vascular reserve in patients with HFpEF without worsening left heart congestion.  Further study is warranted to evaluate the chronic efficacy of β-agonists in HFpEF and other forms of pulmonary hypertension.  Clin. trial registration: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT02885636.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTq9INpvOF7rVg90H21EOLACvtfcHk0liEjzlnvlehVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVagtrk%253D&md5=db1df4e7fd23405bb3319fc830aa563c</span></div><a href="/servlet/linkout?suffix=cit278&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.118.313832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.118.313832%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DY.%2BN.%2BV.%26aulast%3DObokata%26aufirst%3DM.%26aulast%3DKoepp%26aufirst%3DK.%2BE.%26aulast%3DEgbe%26aufirst%3DA.%2BC.%26aulast%3DWiley%26aufirst%3DB.%26aulast%3DBorlaug%26aufirst%3DB.%2BA.%26atitle%3DThe%2520%25CE%25B2-adrenergic%2520agonist%2520albuterol%2520improves%2520pulmonary%2520vascular%2520reserve%2520in%2520heart%2520failure%2520with%2520preserved%2520ejection%2520fraction%26jtitle%3DCirc.%2520Res.%26date%3D2019%26volume%3D124%26spage%3D306%26epage%3D314%26doi%3D10.1161%2FCIRCRESAHA.118.313832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref279"><div class="reference"><strong class="refLabel"><a href="#ref279" class="rightTabRefNumLink">279</a></strong><div class="NLM_citation" id="rightTab-cit279"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birks, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tansley, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaghani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span> <span> </span><span class="NLM_article-title">Left ventricular assist device and drug therapy for the reversal of heart failure</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1873</span>– <span class="NLM_lpage">1884</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa053063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1056%2FNEJMoa053063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17079761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref279/cit279&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKjurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1873-1884&author=E.+J.+Birksauthor=P.+D.+Tansleyauthor=J.+Hardyauthor=R.+S.+Georgeauthor=C.+T.+Bowlesauthor=M.+Burkeauthor=N.+R.+Bannerauthor=A.+Khaghaniauthor=M.+H.+Yacoub&title=Left+ventricular+assist+device+and+drug+therapy+for+the+reversal+of+heart+failure&doi=10.1056%2FNEJMoa053063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit279R"><div class="casContent"><span class="casTitleNuber">279</span><div class="casTitle"><span class="NLM_cas:atitle">Left ventricular assist device and drug therapy for the reversal of heart failure</span></div><div class="casAuthors">Birks, Emma J.; Tansley, Patrick D.; Hardy, James; George, Robert S.; Bowles, Christopher T.; Burke, Margaret; Banner, Nicholas R.; Khaghani, Asghar; Yacoub, Magdi H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1873-1884</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In patients with severe heart failure, prolonged unloading of the myocardium with the use of a left ventricular assist device has been reported to lead to myocardial recovery in small nos. of patients for varying periods of time.  Increasing the frequency and durability of myocardial recovery could reduce or postpone the need for subsequent heart transplantation.  We enrolled 15 patients with severe heart failure due to nonischemic cardiomyopathy and with no histol. evidence of active myocarditis.  All had markedly reduced cardiac output and were receiving inotropes.  The patients underwent implantation of left ventricular assist devices and were treated with lisinopril, carvedilol, spironolactone, and losartan to enhance reverse remodeling.  Once regression of left ventricular enlargement had been achieved, the β2-adrenergic-receptor agonist clenbuterol was administered to prevent myocardial atrophy.  Eleven of the 15 patients had sufficient myocardial recovery to undergo explantation of the left ventricular assist device a mean (±SD) of 320±186 days after implantation of the device.  On patient died of intractable arrhythmias 24 h after explantation; another died of carcinoma of the lung 27 mo after explantation.  The cumulative rate of freedom from recurrent heart failure among the surviving patients was 100% and 88.9% 1 and 4 years after explantation, resp.  The quality of life as assessed by the Minnesota Living with Heart Failure Questionnaire score at 3 years was nearly normal.  Fifty-nine months after explantation, the mean left ventricular ejection fraction was 64 ± 12%, the mean left ventricular end-diastolic diam. was 59.4 ± 12.1 mm, the mean left ventricular end-systolic diam. was 42.5 ± 13.2 mm, and the mean maximal oxygen uptake with exercise was 26.3 ± 6.0 mL per kg of body wt. per min.  In this single-center study, we found that sustained reversal of severe heart failure secondary to nonischemic cardiomyopathy could be achieved in selected patients with the use of a left ventricular assist device and a specific pharmacol. regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYG88vSSSsTLVg90H21EOLACvtfcHk0liEjzlnvlehVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKjurfJ&md5=a5a8a6489d6727dfe1011ab12367bd5f</span></div><a href="/servlet/linkout?suffix=cit279&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa053063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa053063%26sid%3Dliteratum%253Aachs%26aulast%3DBirks%26aufirst%3DE.%2BJ.%26aulast%3DTansley%26aufirst%3DP.%2BD.%26aulast%3DHardy%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BS.%26aulast%3DBowles%26aufirst%3DC.%2BT.%26aulast%3DBurke%26aufirst%3DM.%26aulast%3DBanner%26aufirst%3DN.%2BR.%26aulast%3DKhaghani%26aufirst%3DA.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26atitle%3DLeft%2520ventricular%2520assist%2520device%2520and%2520drug%2520therapy%2520for%2520the%2520reversal%2520of%2520heart%2520failure%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1873%26epage%3D1884%26doi%3D10.1056%2FNEJMoa053063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref280"><div class="reference"><strong class="refLabel"><a href="#ref280" class="rightTabRefNumLink">280</a></strong><div class="NLM_citation" id="rightTab-cit280"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birks, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahrami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amrani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyfus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaghani, A.</span></span> <span> </span><span class="NLM_article-title">Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.109.933960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCULATIONAHA.109.933960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=21242487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref280/cit280&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=381-390&author=E.+J.+Birksauthor=R.+S.+Georgeauthor=M.+Hedgerauthor=T.+Bahramiauthor=P.+Wiltonauthor=C.+T.+Bowlesauthor=C.+Webbauthor=R.+Bougardauthor=M.+Amraniauthor=M.+H.+Yacoubauthor=G.+Dreyfusauthor=A.+Khaghani&title=Reversal+of+severe+heart+failure+with+a+continuous-flow+left+ventricular+assist+device+and+pharmacological+therapy%3A+a+prospective+study&doi=10.1161%2FCIRCULATIONAHA.109.933960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit280R"><div class="casContent"><span class="casTitleNuber">280</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy: A Prospective Study</span></div><div class="casAuthors">Birks, Emma J.; George, Robert S.; Hedger, Mike; Bahrami, Toufan; Wilton, Penny; Bowles, Christopher T.; Webb, Carole; Bougard, Robert; Amrani, Mohammed; Yacoub, Magdi H.; Dreyfus, Gilles; Khaghani, Asghar</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-390</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We have previously shown that a specific combination of drug therapy and left ventricular assist device unloading results in significant myocardial recovery, sufficient to allow pump removal, in two thirds of patients with dilated cardiomyopathy receiving a Heartmate I pulsatile device.  However, this protocol has not been used with nonpulsatile devices.  We report the results of a prospective study of 20 patients who received a combination of angiotensin-converting enzymes, β-blockers, angiotensin II inhibitors, and aldosterone antagonists followed by the β2-agonist clenbuterol and were regularly tested (echocardiograms, exercise tests, catheterizations) with the pump at low speed.  Before left ventricular assist device insertion, patient age was 35.2 ± 12.6 years (16 male patients), patients were on 2.0 ± 0.9 inotropes, 7 (35%) had an intra-aortic balloon pump, 2 were hemofiltered, 2 were ventilated, 3 had a prior Levitronix device, and 1 had extracorporeal membrane oxygenation.  Cardiac index was 1.39 ± 0.43 L/min-1/m-2, pulmonary capillary wedge pressure was 31.5 ± 5.7 mm Hg, and heart failure history was 3.4 ± 3.5 years.  One patient was lost to follow-up and died after 240 days of support.  Of the remaining 19 patients, 12 (63.2%) were explanted after 286 ± 97 days.  8 Had symptomatic heart failure for ≤6 mo and 4 for >6 mo (48 to 132 mo).  Before explantation, at low flow for 15 min, ejection fraction was 70 ± 7%, left ventricular end-diastolic diam. was 48.6 ± 5.7 mm, left ventricular end-systolic diam. was 32.3 ± 5.7 mm, mVO2 was 21.6 ± 4 mL/kg-1/min-1, pulmonary capillary wedge pressure was 5.9 ± 4.6 mm Hg, and cardiac index was 3.6 ± 0.6 L/min-1/m-2.  Estd. survival without heart failure recurrence was 83.3% at 1 and 3 years.  After a 430.7 ± 337.1-day follow-up, surviving explants had an ejection fraction of 58.1 ± 13.8%, left ventricular end-diastolic diam. of 59.0 ± 9.3 mm, left ventricular end-systolic diam. of 42.0 ± 10.7 mm, and mVO2 of 22.6 ± 5.3 mL/kg-1/min-1.  Reversal of end-stage heart failure secondary to nonischemic cardiomyopathy can be achieved in a substantial proportion of patients with nonpulsatile flow through the use of a combination of mech. and pharmacol. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8zpEU_f3KtLVg90H21EOLACvtfcHk0liWjc8r5Q2AXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSqtb8%253D&md5=b6bcfeb3b6ae77275f1702dfde8c5f60</span></div><a href="/servlet/linkout?suffix=cit280&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.109.933960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.109.933960%26sid%3Dliteratum%253Aachs%26aulast%3DBirks%26aufirst%3DE.%2BJ.%26aulast%3DGeorge%26aufirst%3DR.%2BS.%26aulast%3DHedger%26aufirst%3DM.%26aulast%3DBahrami%26aufirst%3DT.%26aulast%3DWilton%26aufirst%3DP.%26aulast%3DBowles%26aufirst%3DC.%2BT.%26aulast%3DWebb%26aufirst%3DC.%26aulast%3DBougard%26aufirst%3DR.%26aulast%3DAmrani%26aufirst%3DM.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26aulast%3DDreyfus%26aufirst%3DG.%26aulast%3DKhaghani%26aufirst%3DA.%26atitle%3DReversal%2520of%2520severe%2520heart%2520failure%2520with%2520a%2520continuous-flow%2520left%2520ventricular%2520assist%2520device%2520and%2520pharmacological%2520therapy%253A%2520a%2520prospective%2520study%26jtitle%3DCirculation%26date%3D2011%26volume%3D123%26spage%3D381%26epage%3D390%26doi%3D10.1161%2FCIRCULATIONAHA.109.933960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref281"><div class="reference"><strong class="refLabel"><a href="#ref281" class="rightTabRefNumLink">281</a></strong><div class="NLM_citation" id="rightTab-cit281"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berzetei-Gurske, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozocas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abernethy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2903</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.1021/jm070030d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070030d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref281/cit281&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1yktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2903-2915&author=K.+Jozwiakauthor=C.+Khalidauthor=M.+J.+Tangaauthor=I.+Berzetei-Gurskeauthor=L.+Jimenezauthor=J.+A.+Kozocasauthor=A.+Wooauthor=W.+Zhuauthor=R.+P.+Xiaoauthor=D.+R.+Abernethyauthor=I.+W.+Wainer&title=Comparative+molecular+field+analysis+of+the+binding+of+the+stereoisomers+of+fenoterol+and+fenoterol+derivatives+to+the+beta2+adrenergic+receptor&doi=10.1021%2Fjm070030d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit281R"><div class="casContent"><span class="casTitleNuber">281</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Molecular Field Analysis of the Binding of the Stereoisomers of Fenoterol and Fenoterol Derivatives to the β2 Adrenergic Receptor</span></div><div class="casAuthors">Jozwiak, Krzysztof; Khalid, Chakir; Tanga, Mary J.; Berzetei-Gurske, Ilona; Jimenez, Lucita; Kozocas, Joseph A.; Woo, Anthony; Zhu, Weizhong; Xiao, Rui-Ping; Abernethy, Darrell R.; Wainer, Irving W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2903-2915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereoisomers of fenoterol and six fenoterol derivs. have been synthesized and their binding affinities for the β2 adrenergic receptor (Kiβ2-AR), the subtype selectivity relative to the β1-AR (Kiβ1-AR/Kiβ2-AR) and their functional activities were detd.  Of the 26 compds. synthesized in the study, submicromolar binding affinities were obsd. for (R,R)-fenoterol, the (R,R)-isomer of the p-methoxy, and (R,R)- and (R,S)-isomers of 1-naphthyl derivs. and all of these compds. were active at submicromolar concns. in cardiomyocyte contractility tests.  The Kiβ1-AR/Kiβ2-AR ratios were >40 for (R,R)-fenoterol and the (R,R)-p-methoxy and (R,S)-1-naphthyl derivs. and 14 for the (R,R)-1-naphthyl deriv.  The binding data was analyzed using comparative mol. field anal. (CoMFA), and the resulting model indicated that the fenoterol derivs. interacted with two sep. binding sites and one steric restricted site on the pseudo-receptor and that the chirality of the second stereogenic center affected Kiβ2 and subtype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvfopNTVaQLVg90H21EOLACvtfcHk0liWjc8r5Q2AXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1yktL4%253D&md5=592e198e4cd90179f12f7a638e740fbe</span></div><a href="/servlet/linkout?suffix=cit281&amp;dbid=16384&amp;doi=10.1021%2Fjm070030d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070030d%26sid%3Dliteratum%253Aachs%26aulast%3DJozwiak%26aufirst%3DK.%26aulast%3DKhalid%26aufirst%3DC.%26aulast%3DTanga%26aufirst%3DM.%2BJ.%26aulast%3DBerzetei-Gurske%26aufirst%3DI.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DKozocas%26aufirst%3DJ.%2BA.%26aulast%3DWoo%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DAbernethy%26aufirst%3DD.%2BR.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DComparative%2520molecular%2520field%2520analysis%2520of%2520the%2520binding%2520of%2520the%2520stereoisomers%2520of%2520fenoterol%2520and%2520fenoterol%2520derivatives%2520to%2520the%2520beta2%2520adrenergic%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2903%26epage%3D2915%26doi%3D10.1021%2Fjm070030d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref282"><div class="reference"><strong class="refLabel"><a href="#ref282" class="rightTabRefNumLink">282</a></strong><div class="NLM_citation" id="rightTab-cit282"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beigi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakir, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abernethy, D. R.</span></span> <span> </span><span class="NLM_article-title">Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol</span>. <i>Chirality</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1002/chir.20317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1002%2Fchir.20317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=16917835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref282/cit282&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFenurfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=822-827&author=F.+Beigiauthor=C.+Bertucciauthor=W.+Zhuauthor=K.+Chakirauthor=I.+W.+Wainerauthor=R.+P.+Xiaoauthor=D.+R.+Abernethy&title=Enantioselective+separation+and+online+affinity+chromatographic+characterization+of+R%2CR-+and+S%2CS-fenoterol&doi=10.1002%2Fchir.20317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit282R"><div class="casContent"><span class="casTitleNuber">282</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective separation and online affinity chromatographic characterization of R,R- and S,S-fenoterol</span></div><div class="casAuthors">Beigi, Farideh; Bertucci, Carlo; Zhu, Weizhong; Chakir, Khalid; Wainer, Irving W.; Xiao, Rui-Ping; Abernethy, Darrell R.</div><div class="citationInfo"><span class="NLM_cas:title">Chirality</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">822-827</span>CODEN:
                <span class="NLM_cas:coden">CHRLEP</span>;
        ISSN:<span class="NLM_cas:issn">0899-0042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Rac-fenoterol is a β2-adrenoceptor agonist (β2-AR) used in the treatment of asthma.  It has 2 chiral centers and is marketed as a racemic mixt. of R,R'- and S,S'-fenoterol (R-F and S-F).  Here we report the sepn. of the R-F and S-F enantiomers and the evaluation of their binding to and activation of the β2-AR.  R-F and S-F were sepd. from the enantiomeric mixt. by chiral chromatog. and abs. configuration detd. by CD.  β2-AR binding was evaluated using frontal affinity chromatog. with a stationary phase contg. immobilized membranes from HEK-293 cells that express human β2-AR and std. membrane binding studies using the same membranes.  The effect of R-F and S-F on cardiomyocyte contractility was also investigated using freshly isolated adult rat cardiomyocytes.  Chiral chromatog. of rac-fenoterol yielded sepd. peaks with an enantioselectivity factor of 1.21.  The less retained peak was assigned the abs. configuration of S-F and the more retained peak R-F.  Frontal chromatog. using membrane-bound β2-AR as the stationary phase and rac-3H-fenoterol as a marker ligand showed that addn. of increasing concns. of R-F to the mobile phase produced concn.-dependent decreases in rac-3H-fenoterol retention, while similar addn. of S-F produced no change in rac-3H-fenoterol retention.  The calcd. dissocn. const. of R-F was 472 nM and the no. of available binding sites 176 pmol/column, which was consistent with the results from the membrane binding study 460 nM (R-F) and 109,000 nM (S-F).  In the cardiomyocytes, R-F increased max. contractile response from 265% to 306% of resting cell length and reduced EC50 from -7.0 to -7.1 log[M], while S-F had no significant effect.  Previous studies have shown that rac-fenoterol acts as an apparent β2-AR/Gs selective agonist and fully restores diminished β2-AR contractile response in cardiomyocytes from failing hearts of spontaneously hypertensive rats (SHR).  Here we report the sepn. of the enantiomers of rac-fenoterol and that R-F is the active component of rac-fenoterol.  Further evaluation of R-F will det. if it has enhanced selectivity and specificity for β2-AR/Gs activation and if it can be used in the treatment of congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0_YQuoc6id7Vg90H21EOLACvtfcHk0liud0PiZR7xsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFenurfL&md5=5aeb8818ee644cddb1f5fff740c70529</span></div><a href="/servlet/linkout?suffix=cit282&amp;dbid=16384&amp;doi=10.1002%2Fchir.20317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchir.20317%26sid%3Dliteratum%253Aachs%26aulast%3DBeigi%26aufirst%3DF.%26aulast%3DBertucci%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChakir%26aufirst%3DK.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DAbernethy%26aufirst%3DD.%2BR.%26atitle%3DEnantioselective%2520separation%2520and%2520online%2520affinity%2520chromatographic%2520characterization%2520of%2520R%252CR-%2520and%2520S%252CS-fenoterol%26jtitle%3DChirality%26date%3D2006%26volume%3D18%26spage%3D822%26epage%3D827%26doi%3D10.1002%2Fchir.20317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref283"><div class="reference"><strong class="refLabel"><a href="#ref283" class="rightTabRefNumLink">283</a></strong><div class="NLM_citation" id="rightTab-cit283"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plazinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span> <span> </span><span class="NLM_article-title">Molecular interactions between fenoterol stereoisomers and derivatives and the β<sub>2</sub>-adrenergic receptor binding site studied by docking and molecular dynamics simulations</span>. <i>J. Mol. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4919</span>– <span class="NLM_lpage">4930</span>, <span class="refDoi"> DOI: 10.1007/s00894-013-1981-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1007%2Fs00894-013-1981-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24043542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref283/cit283&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOktrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4919-4930&author=A.+Plazinskaauthor=M.+Kolinskiauthor=I.+W.+Wainerauthor=K.+Jozwiak&title=Molecular+interactions+between+fenoterol+stereoisomers+and+derivatives+and+the+%CE%B22-adrenergic+receptor+binding+site+studied+by+docking+and+molecular+dynamics+simulations&doi=10.1007%2Fs00894-013-1981-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit283R"><div class="casContent"><span class="casTitleNuber">283</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular interactions between fenoterol stereoisomers and derivatives and the β2-adrenergic receptor binding site studied by docking and molecular dynamics simulations</span></div><div class="casAuthors">Plazinska, Anita; Kolinski, Michal; Wainer, Irving W.; Jozwiak, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4919-4930</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The β2 adrenergic receptor (β2-AR) has become a model system for studying the ligand recognition process and mechanism of the G protein coupled receptors activation.  In the present study stereoisomers of fenoterol and some of its derivs. (N = 94 mols.) were used as mol. probes to identify differences in stereo-recognition interactions between β2-AR and structurally similar agonists.  The present study aimed at detg. the 3D mol. models of the fenoterol deriv.-β2-AR complexes.  Mol. models of β2-AR have been developed by using the crystal structure of the human β2-AR T4 lysozyme fusion protein with bound (S)-carazolol (PDB ID: 2RH1) and more recently reported structure of a nanobody-stabilized active state of the β2-AR with the bound full agonist BI-167107 (PDB ID: 3P0G).  The docking procedure allowed us to study the similarities and differences in the recognition binding site(s) for tested ligands.  The agonist mols. occupied the same binding region, between TM III, TM V, TM VI and TM VII.  The residues identified by us during docking procedure (Ser203, Ser207, Asp113, Lys305, Asn312, Tyr308, Asp192) were exptl. indicated in functional and biophys. studies as being very important for the agonist-receptor interactions.  Moreover, the addnl. space, an extension of the orthosteric pocket, was identified and described.  Furthermore, the mol. dynamics simulations were used to study the mol. mechanism of interaction between ligands ((R,R')- and (S,S')-fenoterol) and β2-AR.  Our research offers new insights into the ligand stereoselective interaction with one of the most important GPCR member.  This study may also facilitate the design of improved selective medications, which can be used to treat, prevent and control heart failure symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-6xhaMGVD6rVg90H21EOLACvtfcHk0liud0PiZR7xsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOktrbL&md5=bb3cf560cbe53be858f605e9d47b6f32</span></div><a href="/servlet/linkout?suffix=cit283&amp;dbid=16384&amp;doi=10.1007%2Fs00894-013-1981-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00894-013-1981-y%26sid%3Dliteratum%253Aachs%26aulast%3DPlazinska%26aufirst%3DA.%26aulast%3DKolinski%26aufirst%3DM.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DJozwiak%26aufirst%3DK.%26atitle%3DMolecular%2520interactions%2520between%2520fenoterol%2520stereoisomers%2520and%2520derivatives%2520and%2520the%2520%25CE%25B22-adrenergic%2520receptor%2520binding%2520site%2520studied%2520by%2520docking%2520and%2520molecular%2520dynamics%2520simulations%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2013%26volume%3D19%26spage%3D4919%26epage%3D4930%26doi%3D10.1007%2Fs00894-013-1981-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref284"><div class="reference"><strong class="refLabel"><a href="#ref284" class="rightTabRefNumLink">284</a></strong><div class="NLM_citation" id="rightTab-cit284"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanga, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozocas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plazinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">736</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.11.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmc.2009.11.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=20036561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref284/cit284&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1yquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=728-736&author=K.+Jozwiakauthor=A.+Y.+Wooauthor=M.+J.+Tangaauthor=L.+Tollauthor=L.+Jimenezauthor=J.+A.+Kozocasauthor=A.+Plazinskaauthor=R.+P.+Xiaoauthor=I.+W.+Wainer&title=Comparative+molecular+field+analysis+of+fenoterol+derivatives%3A+A+platform+towards+highly+selective+and+effective+beta%282%29-adrenergic+receptor+agonists&doi=10.1016%2Fj.bmc.2009.11.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit284R"><div class="casContent"><span class="casTitleNuber">284</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists</span></div><div class="casAuthors">Jozwiak, Krzysztof; Woo, Anthony Yiu-Ho; Tanga, Mary J.; Toll, Lawrence; Jimenez, Lucita; Kozocas, Joseph A.; Plazinska, Anita; Xiao, Rui-Ping; Wainer, Irving W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">728-736</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of the study was to use a previously developed CoMFA model to design a series of new structures of high selectivity and efficacy towards the β2-adrenergic receptor.  Out of 21 computationally designed structures 6 compds. were synthesized and characterized for β2-AR binding affinities, subtype selectivities and functional activities.  The best compd. was found to be (R,R)-4-methoxy-1-naphthylfenoterol (I) with K iβ2-AR = 0.28 μm, K iβ1-AR/K iβ2-AR = 573, EC50cAMP = 3.9 nm, EC50cardio = 16 nm.  The CoMFA model appeared to be an effective predictor of the cardiomocyte contractility of the studied compds. which are targeted for use in congestive heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn5_GNVS8ftLVg90H21EOLACvtfcHk0liud0PiZR7xsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1yquw%253D%253D&md5=76b1252884c8e6f73e13d8fe44ddd0d1</span></div><a href="/servlet/linkout?suffix=cit284&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.11.062%26sid%3Dliteratum%253Aachs%26aulast%3DJozwiak%26aufirst%3DK.%26aulast%3DWoo%26aufirst%3DA.%2BY.%26aulast%3DTanga%26aufirst%3DM.%2BJ.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DKozocas%26aufirst%3DJ.%2BA.%26aulast%3DPlazinska%26aufirst%3DA.%26aulast%3DXiao%26aufirst%3DR.%2BP.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DComparative%2520molecular%2520field%2520analysis%2520of%2520fenoterol%2520derivatives%253A%2520A%2520platform%2520towards%2520highly%2520selective%2520and%2520effective%2520beta%25282%2529-adrenergic%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D728%26epage%3D736%26doi%3D10.1016%2Fj.bmc.2009.11.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref285"><div class="reference"><strong class="refLabel"><a href="#ref285" class="rightTabRefNumLink">285</a></strong><div class="NLM_citation" id="rightTab-cit285"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plazinska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pajak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozocas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span> <span> </span><span class="NLM_article-title">Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β<sub>2</sub>-adrenergic receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.bmc.2013.11.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24326276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref285/cit285&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=234-246&author=A.+Plazinskaauthor=K.+Pajakauthor=E.+Rutkowskaauthor=L.+Jimenezauthor=J.+Kozocasauthor=G.+Koolpeauthor=M.+Tangaauthor=L.+Tollauthor=I.+W.+Wainerauthor=K.+Jozwiak&title=Comparative+molecular+field+analysis+of+fenoterol+derivatives+interacting+with+an+agonist-stabilized+form+of+the+%CE%B22-adrenergic+receptor&doi=10.1016%2Fj.bmc.2013.11.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit285R"><div class="casContent"><span class="casTitleNuber">285</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β2-adrenergic receptor</span></div><div class="casAuthors">Plazinska, Anita; Pajak, Karolina; Rutkowska, Ewelina; Jimenez, Lucita; Kozocas, Joseph; Koolpe, Gary; Tanga, Mary; Toll, Lawrence; Wainer, Irving W.; Jozwiak, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-246</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The β2-adrenergic receptor (β2-AR) agonist [3H]-(R,R')-methoxyfenoterol was employed as the marker ligand in displacement studies measuring the binding affinities (Ki values) of the stereoisomers of a series of 4'-methoxyfenoterol analogs in which the length of the alkyl substituent at α' position was varied from 0 to 3 carbon atoms.  The binding affinities of the compds. were addnl. detd. using the inverse agonist [3H]-CGP-12177 as the marker ligand and the ability of the compds. to stimulate cAMP accumulation, measured as EC50 values, were detd. in HEK293 cells expressing the β2-AR.  The data indicate that the highest binding affinities and functional activities were produced by Me and Et substituents at the α' position.  The results also indicate that the Ki values obtained using [3H]-(R,R')-methoxyfenoterol as the marker ligand modeled the EC50 values obtained from cAMP stimulation better than the data obtained using [3H]-CGP-12177 as the marker ligand.  The data from this study was combined with data from previous studies and processed using the Comparative Mol. Field Anal. approach to produce a CoMFA model reflecting the binding to the β2-AR conformation probed by [3H]-(R,R')-4'-methoxyfenoterol.  The CoMFA model of the agonist-stabilized β2-AR suggests that the binding of the fenoterol analogs to an agonist-stabilized conformation of the β2-AR is governed to a greater extend by steric effects than binding to the [3H]-CGP-12177-stabilized conformation(s) in which electrostatic interactions play a more predominate role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9MLvvJg7wibVg90H21EOLACvtfcHk0lht96JISAD-bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOhtbrM&md5=c1e879cea178fce6e8a355415762937b</span></div><a href="/servlet/linkout?suffix=cit285&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DPlazinska%26aufirst%3DA.%26aulast%3DPajak%26aufirst%3DK.%26aulast%3DRutkowska%26aufirst%3DE.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DKozocas%26aufirst%3DJ.%26aulast%3DKoolpe%26aufirst%3DG.%26aulast%3DTanga%26aufirst%3DM.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DJozwiak%26aufirst%3DK.%26atitle%3DComparative%2520molecular%2520field%2520analysis%2520of%2520fenoterol%2520derivatives%2520interacting%2520with%2520an%2520agonist-stabilized%2520form%2520of%2520the%2520%25CE%25B22-adrenergic%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D234%26epage%3D246%26doi%3D10.1016%2Fj.bmc.2013.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref286"><div class="reference"><strong class="refLabel"><a href="#ref286" class="rightTabRefNumLink">286</a></strong><div class="NLM_citation" id="rightTab-cit286"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">Beta-arrestin-mediated signaling in the heart</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1725</span>– <span class="NLM_lpage">1729</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-08-0734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1253%2Fcircj.CJ-08-0734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=18838825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref286/cit286&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWltrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2008&pages=1725-1729&author=P.+A.+Patelauthor=D.+G.+Tilleyauthor=H.+A.+Rockman&title=Beta-arrestin-mediated+signaling+in+the+heart&doi=10.1253%2Fcircj.CJ-08-0734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit286R"><div class="casContent"><span class="casTitleNuber">286</span><div class="casTitle"><span class="NLM_cas:atitle">Beta-arrestin-mediated signaling in the heart</span></div><div class="casAuthors">Patel, Priyesh A.; Tilley, Douglas G.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1725-1729</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">A review.  Beta-arrestin is a multifunctional adapter protein well known for its role in G-protein-coupled receptor (GPCR) desensitization.  Exciting new evidence indicates that β-arrestin is also a signaling mol. capable of initiating its own G-protein-independent signaling at GPCRs.  One of the best-studied β-arrestin signaling pathways is the one involving β-arrestin-dependent activation of a mitogen-activated protein kinase cascade, the extracellular regulated kinase (ERK).  ERK signaling, which is classically activated by agonist stimulation of the epidermal growth factor receptor (EGFR), can be activated by a no. of GPCRs in a β-arrestin-dependent manner.  Recent work in animal models of heart failure suggests that β-arrestin-dependent activation of EGFR/ERK signaling by the β-1-adrenergic receptor, and possibly the angiotensin II Type 1A receptor, are cardioprotective.  Hence, a new model of signaling at cardiac GPCRs has emerged and implicates classical G-protein-mediated signaling with promoting harmful remodeling in heart failure, while concurrently linking β-arrestin-dependent, G-protein-independent signaling with cardioprotective effects.  Based on this paradigm, a new class of drugs could be identified, termed "biased ligands", which simultaneously block harmful G-protein signaling, while also promoting cardioprotective β-arrestin-dependent signaling, leading to a potential breakthrough in the treatment of chronic cardiac disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiYFy2SSoVrVg90H21EOLACvtfcHk0lht96JISAD-bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWltrnE&md5=bf09d9169bf26cba22d2234198a24033</span></div><a href="/servlet/linkout?suffix=cit286&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-08-0734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-08-0734%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BA.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3DBeta-arrestin-mediated%2520signaling%2520in%2520the%2520heart%26jtitle%3DCirc.%2520J.%26date%3D2008%26volume%3D72%26spage%3D1725%26epage%3D1729%26doi%3D10.1253%2Fcircj.CJ-08-0734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref287"><div class="reference"><strong class="refLabel"><a href="#ref287" class="rightTabRefNumLink">287</a></strong><div class="NLM_citation" id="rightTab-cit287"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naga Prasad, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barki-Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Corvoisier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-mediated β<sub>1</sub>-adrenergic receptor transactivation of the EGFR confers cardioprotection</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2445</span>– <span class="NLM_lpage">2458</span>, <span class="refDoi"> DOI: 10.1172/JCI31901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1172%2FJCI31901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=17786238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref287/cit287&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCms7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2445-2458&author=T.+Nomaauthor=A.+Lemaireauthor=S.+V.+Naga+Prasadauthor=L.+Barki-Harringtonauthor=D.+G.+Tilleyauthor=J.+Chenauthor=P.+Le+Corvoisierauthor=J.+D.+Violinauthor=H.+Weiauthor=R.+J.+Lefkowitzauthor=H.+A.+Rockman&title=%CE%B2-arrestin-mediated+%CE%B21-adrenergic+receptor+transactivation+of+the+EGFR+confers+cardioprotection&doi=10.1172%2FJCI31901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit287R"><div class="casContent"><span class="casTitleNuber">287</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection</span></div><div class="casAuthors">Noma, Takahisa; Lemaire, Anthony; Prasad, Sathyamangla V. Naga; Barki-Harrington, Liza; Tilley, Douglas G.; Chen, Juhsien; Le Corvoisier, Philippe; Violin, Jonathan D.; Wei, Huijun; Lefkowitz, Robert J.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2445-2458</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Deleterious effects on the heart from chronic stimulation of β-adrenergic receptors (βARs), members of the 7 transmembrane receptor family, have classically been shown to result from Gs-dependent adenylyl cyclase activation.  Here, we identify a new signaling mechanism using both in vitro and in vivo systems whereby β-arrestins mediate β1AR signaling to the EGFR.  This β-arrestin-dependent transactivation of the EGFR, which is independent of G protein activation, requires the G protein-coupled receptor kinases 5 and 6.  In mice undergoing chronic sympathetic stimulation, this novel signaling pathway is shown to promote activation of cardioprotective pathways that counteract the effects of catecholamine toxicity.  These findings suggest that drugs that act as classical antagonists for G protein signaling, but also stimulate signaling via β-arrestin-mediated cytoprotective pathways, would represent a novel class of agents that could be developed for multiple members of the 7 transmembrane receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvSYQwqS-dwbVg90H21EOLACvtfcHk0lht96JISAD-bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCms7vP&md5=721bdd41511d9cf6836d86bdd7bf64da</span></div><a href="/servlet/linkout?suffix=cit287&amp;dbid=16384&amp;doi=10.1172%2FJCI31901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31901%26sid%3Dliteratum%253Aachs%26aulast%3DNoma%26aufirst%3DT.%26aulast%3DLemaire%26aufirst%3DA.%26aulast%3DNaga%2BPrasad%26aufirst%3DS.%2BV.%26aulast%3DBarki-Harrington%26aufirst%3DL.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLe%2BCorvoisier%26aufirst%3DP.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-arrestin-mediated%2520%25CE%25B21-adrenergic%2520receptor%2520transactivation%2520of%2520the%2520EGFR%2520confers%2520cardioprotection%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D2445%26epage%3D2458%26doi%3D10.1172%2FJCI31901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref288"><div class="reference"><strong class="refLabel"><a href="#ref288" class="rightTabRefNumLink">288</a></strong><div class="NLM_citation" id="rightTab-cit288"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynham, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pironti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockman, H. A.</span></span> <span> </span><span class="NLM_article-title">β-arrestin1-biased β<sub>1</sub>-adrenergic receptor signaling regulates microRNA processing</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.114.302766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1161%2FCIRCRESAHA.114.302766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=24334028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref288/cit288&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=833-844&author=I.+M.+Kimauthor=Y.+Wangauthor=K.+M.+Parkauthor=Y.+Tangauthor=J.+P.+Teohauthor=J.+Vinsonauthor=C.+J.+Traynhamauthor=G.+Pirontiauthor=L.+Maoauthor=H.+Suauthor=J.+A.+Johnsonauthor=W.+J.+Kochauthor=H.+A.+Rockman&title=%CE%B2-arrestin1-biased+%CE%B21-adrenergic+receptor+signaling+regulates+microRNA+processing&doi=10.1161%2FCIRCRESAHA.114.302766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit288R"><div class="casContent"><span class="casTitleNuber">288</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin1-Biased β1-Adrenergic Receptor Signaling Regulates MicroRNA Processing</span></div><div class="casAuthors">Kim, Il-man; Wang, Yongchao; Park, Kyoung-mi; Tang, Yaoping; Teoh, Jian-peng; Vinson, Joseph; Traynham, Christopher J.; Pironti, Gianluigi; Mao, Lan; Su, Huabo; Johnson, John A.; Koch, Walter J.; Rockman, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Rationale: MicroRNAs (miRs) are small, noncoding RNAs that function to post-transcriptionally regulate gene expression.  First transcribed as long primary miR transcripts (pri-miRs), they are enzymically processed in the nucleus by Drosha into hairpin intermediate miRs (pre-miRs) and further processed in the cytoplasm by Dicer into mature miRs where they regulate cellular processes after activation by a variety of signals such as those stimulated by β-adrenergic receptors (βARs).  Initially discovered to desensitize βAR signaling, β-arrestins are now appreciated to transduce multiple effector pathways independent of G-protein-mediated second messenger accumulation, a concept known as biased signaling.  We previously showed that the β-arrestin-biased βAR agonist, carvedilol, activates cellular pathways in the heart.  Objective: Here, we tested whether carvedilol could activate β-arrestin-mediated miR maturation, thereby providing a novel potential mechanism for its cardioprotective effects.  Methods and results: In human cells and mouse hearts, carvedilol upregulates a subset of mature and pre-miRs, but not their pri-miRs, in β1AR-, G-protein-coupled receptor kinase 5/6-, and β-arrestin1-dependent manner.  Mechanistically, β-arrestin1 regulates miR processing by forming a nuclear complex with hnRNPA1 and Drosha on pri-miRs.  Conclusions: Our findings indicate a novel function for β1AR-mediated β-arrestin1 signaling activated by carvedilol in miR biogenesis, which may be linked, in part, to its mechanism for cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohMPKnya33VrVg90H21EOLACvtfcHk0lhn6PlP-XmUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSiu7g%253D&md5=a2025fbbc31d0e0b609639e4b57b1b46</span></div><a href="/servlet/linkout?suffix=cit288&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.114.302766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.114.302766%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DK.%2BM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DVinson%26aufirst%3DJ.%26aulast%3DTraynham%26aufirst%3DC.%2BJ.%26aulast%3DPironti%26aufirst%3DG.%26aulast%3DMao%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DRockman%26aufirst%3DH.%2BA.%26atitle%3D%25CE%25B2-arrestin1-biased%2520%25CE%25B21-adrenergic%2520receptor%2520signaling%2520regulates%2520microRNA%2520processing%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D114%26spage%3D833%26epage%3D844%26doi%3D10.1161%2FCIRCRESAHA.114.302766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref289"><div class="reference"><strong class="refLabel"><a href="#ref289" class="rightTabRefNumLink">289</a></strong><div class="NLM_citation" id="rightTab-cit289"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aonuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weintraub, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2018.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1016%2Fj.yjmcc.2018.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=29627294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref289/cit289&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=225-236&author=J.+P.+Teohauthor=A.+S.+Bayoumiauthor=T.+Aonumaauthor=Y.+Xuauthor=J.+A.+Johnsonauthor=H.+Suauthor=N.+L.+Weintraubauthor=Y.+Tangauthor=I.+M.+Kim&title=%CE%B2-arrestin-biased+agonism+of+%CE%B2-adrenergic+receptor+regulates+Dicer-mediated+microRNA+maturation+to+promote+cardioprotective+signaling&doi=10.1016%2Fj.yjmcc.2018.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit289R"><div class="casContent"><span class="casTitleNuber">289</span><div class="casTitle"><span class="NLM_cas:atitle">β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling</span></div><div class="casAuthors">Teoh, Jian-Peng; Bayoumi, Ahmed S.; Aonuma, Tatsuya; Xu, Yanyan; Johnson, John A.; Su, Huabo; Weintraub, Neal L.; Tang, Yaoliang; Kim, Il-Man</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">225-236</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">MicroRNAs (miRs) are small, non-coding RNAs that function to post-transcriptionally regulate target genes.  First transcribed as primary miR transcripts (pri-miRs), they are enzymically processed by Drosha into premature miRs (pre-miRs) and further cleaved by Dicer into mature miRs.  Initially discovered to desensitize β-adrenergic receptor (βAR) signaling, β-arrestins are now well-appreciated to modulate multiple pathways independent of G protein signaling, a concept known as biased signaling.  Using the β-arrestin-biased βAR ligand carvedilol, we previously showed that β-arrestin1 (not β-arrestin2)-biased β1AR (not β2AR) cardioprotective signaling stimulates Drosha-mediated processing of six miRs by forming a multi-protein nuclear complex, which includes β-arrestin1, the Drosha microprocessor complex and a single-stranded RNA binding protein hnRNPA1.  Here, we investigate whether β-arrestin-mediated βAR signaling induced by carvedilol could regulate Dicer-mediated miR maturation in the cytoplasm and whether this novel mechanism promotes cardioprotective signaling.  In mouse hearts, carvedilol indeed upregulates three mature miRs, but not their pre-miRs and pri-miRs, in a β-arrestin 1- or 2-dependent manner.  Interestingly, carvedilol-mediated activation of miR-466g or miR-532-5p, and miR-674 is dependent on β2ARs and β1ARs, resp.  Mechanistically, β-arrestin 1 or 2 regulates maturation of three newly identified βAR/β-arrestin-responsive miRs (β-miRs) by assocg. with the Dicer maturation RNase III enzyme on three pre-miRs of β-miRs.  Myocardial cell approaches uncover that despite their distinct roles in different cell types, β-miRs act as gatekeepers of cardiac cell functions by repressing deleterious targets.  Our findings indicate a novel role for βAR-mediated β-arrestin signaling activated by carvedilol in Dicer-mediated miR maturation, which may be linked to its protective mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6Fs7pDRFpCLVg90H21EOLACvtfcHk0lhn6PlP-XmUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslOisr8%253D&md5=22b9cdc76d97176d2f2a4c287302cabe</span></div><a href="/servlet/linkout?suffix=cit289&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2018.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2018.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DBayoumi%26aufirst%3DA.%2BS.%26aulast%3DAonuma%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DWeintraub%26aufirst%3DN.%2BL.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DI.%2BM.%26atitle%3D%25CE%25B2-arrestin-biased%2520agonism%2520of%2520%25CE%25B2-adrenergic%2520receptor%2520regulates%2520Dicer-mediated%2520microRNA%2520maturation%2520to%2520promote%2520cardioprotective%2520signaling%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2018%26volume%3D118%26spage%3D225%26epage%3D236%26doi%3D10.1016%2Fj.yjmcc.2018.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref290"><div class="reference"><strong class="refLabel"><a href="#ref290" class="rightTabRefNumLink">290</a></strong><div class="NLM_citation" id="rightTab-cit290"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynham, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benovic, J. L.</span></span> <span> </span><span class="NLM_article-title">β-arrestin-biased signaling through the β<sub>2</sub>-adrenergic receptor promotes cardiomyocyte contraction</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E4107</span>– <span class="NLM_lpage">E4116</span>, <span class="refDoi"> DOI: 10.1073/pnas.1606267113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1073%2Fpnas.1606267113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref290/cit290&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=27354517" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E4107-E4116&author=R.+Carrauthor=J.+Schillingauthor=J.+Songauthor=R.+L.+Carterauthor=Y.+Duauthor=S.+M.+Yooauthor=C.+J.+Traynhamauthor=W.+J.+Kochauthor=J.+Y.+Cheungauthor=D.+G.+Tilleyauthor=J.+L.+Benovic&title=%CE%B2-arrestin-biased+signaling+through+the+%CE%B22-adrenergic+receptor+promotes+cardiomyocyte+contraction&doi=10.1073%2Fpnas.1606267113"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit290&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1606267113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1606267113%26sid%3Dliteratum%253Aachs%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DSchilling%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DR.%2BL.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DYoo%26aufirst%3DS.%2BM.%26aulast%3DTraynham%26aufirst%3DC.%2BJ.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DCheung%26aufirst%3DJ.%2BY.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26atitle%3D%25CE%25B2-arrestin-biased%2520signaling%2520through%2520the%2520%25CE%25B22-adrenergic%2520receptor%2520promotes%2520cardiomyocyte%2520contraction%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3DE4107%26epage%3DE4116%26doi%3D10.1073%2Fpnas.1606267113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref291"><div class="reference"><strong class="refLabel"><a href="#ref291" class="rightTabRefNumLink">291</a></strong><div class="NLM_citation" id="rightTab-cit291"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grisanti, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lucia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benovic, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilley, D. G.</span></span> <span> </span><span class="NLM_article-title">Pepducin-mediated cardioprotection via β-arrestin-biased β<sub>2</sub>-adrenergic receptor-specific signaling</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4664</span>– <span class="NLM_lpage">4678</span>, <span class="refDoi"> DOI: 10.7150/thno.26619</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.7150%2Fthno.26619" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=30279730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref291/cit291&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1egtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=4664-4678&author=L.+A.+Grisantiauthor=T.+P.+Thomasauthor=R.+L.+Carterauthor=C.+de+Luciaauthor=E.+Gaoauthor=W.+J.+Kochauthor=J.+L.+Benovicauthor=D.+G.+Tilley&title=Pepducin-mediated+cardioprotection+via+%CE%B2-arrestin-biased+%CE%B22-adrenergic+receptor-specific+signaling&doi=10.7150%2Fthno.26619"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit291R"><div class="casContent"><span class="casTitleNuber">291</span><div class="casTitle"><span class="NLM_cas:atitle">Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling</span></div><div class="casAuthors">Grisanti, Laurel A.; Thomas, Toby P.; Carter, Rhonda L.; de Lucia, Claudio; Gao, Erhe; Koch, Walter J.; Benovic, Jeffrey L.; Tilley, Douglas G.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4664-4678</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Reperfusion as a therapeutic intervention for acute myocardial infarction-induced cardiac injury itself induces further cardiomyocyte death. β-arrestin (βarr)-biased β-adrenergic receptor (βAR) activation promotes survival signaling responses in vitro; thus, we hypothesize that this pathway can mitigate cardiomyocyte death at the time of reperfusion to better preserve function.  However, a lack of efficacious βarr-biased orthosteric small mols. has prevented investigation into whether this pathway relays protection against ischemic injury in vivo.  We recently demonstrated that the pepducin ICL1-9, a small lipidated peptide fragment designed from the first intracellular loop of β2AR, allosterically engaged pro-survival signaling cascades in a βarr-dependent manner in vitro.  Thus, in this study we tested whether ICL1-9 relays cardioprotection against ischemia/reperfusion (I/R)-induced injury in vivo.  Methods: Wild-type (WT) C57BL/6, β2AR knockout (KO), βarr1KO and βarr2KO mice received intracardiac injections of either ICL1-9 or a scrambled control pepducin (Scr) at the time of ischemia (30 min) followed by reperfusion for either 24 h, to assess infarct size and cardiomyocyte death, or 4 wk, to monitor the impact of ICL1-9 on long-term cardiac structure and function.  Neonatal rat ventricular myocytes (NRVM) were used to assess the impact of ICL1-9 vs. Scr pepducin on cardiomyocyte survival and mitochondrial superoxide formation in response to either serum deprivation or hypoxia/reoxygenation (H/R) in vitro and to investigate the assocd. mechanism(s).  Results: Intramyocardial injection of ICL1-9 at the time of I/R reduced infarct size, cardiomyocyte death and improved cardiac function in a β2AR- and βarr-dependent manner, which led to improved contractile function early and less fibrotic remodeling over time.  Mechanistically, ICL1-9 attenuated mitochondrial superoxide prodn. and promoted cardiomyocyte survival in a RhoA/ROCK-dependent manner.  RhoA activation could be detected in cardiomyocytes and whole heart up to 24 h post-treatment, demonstrating the stability of ICL1-9 effects on βarr-dependent β2AR signaling.  Conclusion: Pepducin-based allosteric modulation of βarr-dependent β2AR signaling represents a novel therapeutic approach to reduce reperfusion-induced cardiac injury and relay long-term cardiac remodeling benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxBwJQYSCJrVg90H21EOLACvtfcHk0lj_f27e41lbKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1egtbg%253D&md5=b86c36731becdcc3f4fc5c2e053b87ef</span></div><a href="/servlet/linkout?suffix=cit291&amp;dbid=16384&amp;doi=10.7150%2Fthno.26619&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.26619%26sid%3Dliteratum%253Aachs%26aulast%3DGrisanti%26aufirst%3DL.%2BA.%26aulast%3DThomas%26aufirst%3DT.%2BP.%26aulast%3DCarter%26aufirst%3DR.%2BL.%26aulast%3Dde%2BLucia%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DE.%26aulast%3DKoch%26aufirst%3DW.%2BJ.%26aulast%3DBenovic%26aufirst%3DJ.%2BL.%26aulast%3DTilley%26aufirst%3DD.%2BG.%26atitle%3DPepducin-mediated%2520cardioprotection%2520via%2520%25CE%25B2-arrestin-biased%2520%25CE%25B22-adrenergic%2520receptor-specific%2520signaling%26jtitle%3DTheranostics%26date%3D2018%26volume%3D8%26spage%3D4664%26epage%3D4678%26doi%3D10.7150%2Fthno.26619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref292"><div class="reference"><strong class="refLabel"><a href="#ref292" class="rightTabRefNumLink">292</a></strong><div class="NLM_citation" id="rightTab-cit292"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Littmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göttle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinartz, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kälble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span> <span> </span><span class="NLM_article-title">Recruitment of β-arrestin 1 and 2 to the β<sub>2</sub>-adrenoceptor: analysis of 65 ligands</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.227959</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=10.1124%2Fjpet.115.227959" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=26306764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref292/cit292&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=183-190&author=T.+Littmannauthor=M.+G%C3%B6ttleauthor=M.+T.+Reinartzauthor=S.+K%C3%A4lbleauthor=I.+W.+Wainerauthor=T.+Ozawaauthor=R.+Seifert&title=Recruitment+of+%CE%B2-arrestin+1+and+2+to+the+%CE%B22-adrenoceptor%3A+analysis+of+65+ligands&doi=10.1124%2Fjpet.115.227959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit292R"><div class="casContent"><span class="casTitleNuber">292</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands</span></div><div class="casAuthors">Littmann, Timo; Goettle, Martin; Reinartz, Michael T.; Kaelble, Solveig; Wainer, Irving W.; Ozawa, Takeaki; Seifert, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Beyond canonical signaling via Gαs and cAMP, the concept of functional selectivity at β2-adrenoceptors (β2ARs) describes the ability of adrenergic drugs to stabilize ligand-specific receptor conformations to initiate further signaling cascades comprising addnl. G-protein classes or β-arrestins (βarr).  A set of 65 adrenergic ligands including 40 agonists and 25 antagonists in either racemic or enantiopure forms was used for βarr recruitment expts. based on a split-luciferase assay in a cellular system expressing β2AR.  Many agonists showed only (weak) partial agonism regarding βarr recruitment.  Potencies and/or efficacies increased depending on the no. of chirality centers in (R) configuration; no (S)-configured distomer was more effective at inducing βarr recruitment other than the eutomer. βarr2 was recruited more effectively than βarr1.  The anal. of antagonists revealed no significant effects on βarr recruitment.  Several agonists showed preference for activation of Gαs GTPase relative to βarr recruitment, and no βarr-biased ligand was identified.  In conclusion: (1) agonists show strong bias for Gαs activation relative to βarr recruitment; (2) agonists recruit βarr1 and βarr2 with subtle differences; and (3) there is no evidence for βarr recruitment by antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBFkWzU6mIbbVg90H21EOLACvtfcHk0liTA_3T4pfm-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsrs%253D&md5=3eb8449a84369867dad25f211b6b6b90</span></div><a href="/servlet/linkout?suffix=cit292&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227959%26sid%3Dliteratum%253Aachs%26aulast%3DLittmann%26aufirst%3DT.%26aulast%3DG%25C3%25B6ttle%26aufirst%3DM.%26aulast%3DReinartz%26aufirst%3DM.%2BT.%26aulast%3DK%25C3%25A4lble%26aufirst%3DS.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DSeifert%26aufirst%3DR.%26atitle%3DRecruitment%2520of%2520%25CE%25B2-arrestin%25201%2520and%25202%2520to%2520the%2520%25CE%25B22-adrenoceptor%253A%2520analysis%2520of%252065%2520ligands%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D183%26epage%3D190%26doi%3D10.1124%2Fjpet.115.227959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01195&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01195%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01195" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997aeea9813c9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
